,ticker,content
0,MRK,stock market take breather monday digest friday earning fuel rally give back precious little nasdaq composite be fraction hold friday surge fall dow jone industrial average volume fall nasdaq nyse sign institutional investor choose
1,MRK,nasdaq composite hold solid gain afternoon trading friday help strong earning tech bellwether amazon com amzn alphabet googl microsoft msft nasdaq be picked dow jone industrial average lag rise weigh weakness share merck mrk chevron cvx slump respectively earning blue chip index have plenty strong gainer well apple aapl microsoft intel intc show gain range wall street like look intel earning report also come bullish guidance stock market today amazon gap buy point earning sale easily top expectation share soar alphabet meanwhile gap reclaim buy point rise more microsoft sail ahead be already well extend prior entry financial silicon valley base svb financial sivb gap lengthy consolidation buy point share jump company report third straight quarter accelerate earning sale growth ibd align technology algn be big winner nearly maker invisalign brace report rise quarterly profit third straight quarter accelerate sale growth meanwhile try logmein logm fade badly afternoon trading share pop early gain fade less still hold conventional entry triple digit earning sale growth recent quarters be result company acquisition citrix system ctxs goto family product related option trading play apple facebook earning amazon hit time high score numerous price target invest stock market simple routine
2,MRK,day dominate big name technology stock nasdaq composite roar record high nasdaq close gain largest component include alphabet googl amazon com amzn microsoft msft intel intc rally earning report stock also have home climb also hit new high dow jone industrial average lag increase merck mrk earning report chevron cvx cut capital spending plan slide drag dow technology heavyweight amazon apple aapl facebook fb alphabet clear buy point solidify breakout many other top rate stock also be breaking humana hum break cup handle base close buy point ibd take cup handle breakout be just good stock clear cup handle read more former investor corner column be news specifically humana health insurer february drop merger aetna aet wall street journal report friday be talk be acquire cvs health cvs news seem affect other medical stock hospital drug wholesaler medical supply company be mainly lower wellcare health plan wcg health insurer rise buy point flat base company report earning tuesday market open resm rmd break flat base sailing entry more triple usual volume resm specialize product respiratory disorder beat profit expectation quarterly earning cent share rise sale share surge granite construction gva surge cup handle buy point big turnover material heavy construction company beat profit estimate solar energy stock also lead market first solar fslr soar third quarter result crushed estimate first solar sale jump adjust earning share be year wti crude oil future jump barrel retail sector be lag penney jcp share sell huge volume time lows department store chain warn much bigger loss slash full year profit forecast related microsoft spike record high september quarter be retail stock be crash today
3,MRK,stock scrape mixed start friday trainload influential company report mix third quarter result tech sector rally early lead nasdaq composite jump positive earning news amazon com amzn microsoft msft alphabet googl dow jone industrial average limp start gate dow name microsoft intel intc rally merck mrk chevron cvx fall apiece swung boost techs well first solar fslr tenet healthcare thc gauge also moved higher dive expedia expe decline mattel mat result be shortage dramatic move friday premarket session fang stock name amazon open higher stomp third quarter expectation revenue earning line move lift share flat base buy point google parent alphabet shot ahead report earning be revenue gain well analyst expectation growth traffic acquisition cost slow prior quarter gain put share back buy range flat base buy point report also muster early strength apple aapl rise facebook fb gain nearly ibd stock align technology algn spiked premarket trade maker invisalign clear brace report big beat sale earning line share earning revenue gain share be extend august rebound week support first solar flash higher very big third quarter earning revenue beat boost full year earning guidance well consensus view gain drive share buy range buy point flat base downside retailer penney jcp dive warning third quarter loss be much wider expect economy grow clip third quarter accord initial estimate commerce department be slightly gdp growth second quarter well economist consensus expectation gain inflation be also pick steam gdp price index better double second quarter gain well forecast increase university michigan be expect weigh final tally october consumer sentiment et baker hughe bhge report weekly rig count census et asia market hammer powerful session nikkei tokyo thump advance leave index seventh straight weekly gain hong kong hang seng index climb europe market rolled uneven gain afternoon trade cac paris frankfurt dax hold gain london ftse struggle flat trade related nasdaq future road tech earning fang stock signal buy big picture dow keep lead fed factor unsettle stock marketwith yellen be market pick next fed chief
4,MRK,tech heavy nasdaq composite roar back friday big earning report amazon amzn alphabet googl microsoft msft ibd late thursday powershare qqq trust qqq rally record high spdr spy add spdr dow jone industrial average dium edge higher stock market today alphabet gap amazon microsoft soar positive quarterly result amazon blast past buy point late stage base apple aapl joined tech rally rise take buy point cup handle report strong demand upcoming iphone facebook fb also surge past flat base entry be trading buy range chevron cvx merck mrk weigh dow jone industrial drop more apiece sector play tech bank semiconductor lead upside retail homebuilder health fund lag spdr retail xrt sank nearly component stock penney jcp plunge disappointing earning forecast gold oil fund be mostly higher respective underlie commodity price utility have be outperform tech stock pull back sector rotation continue stock market shift defensive sector have be occur market remain record high utility select sector spdr xlu be build right side flat base buy point be entry etf climb august prior flat base start current pattern year old fund be biggest utility etfs asset track utility select sector be make company produce distribute transmit electricity natural gas xlu biggest holding oct be nextera energy nee duke energy duk southern co so dominion energy performance be trail broader market year year date return oct accord morningstar direct vs gain xlu see average annual return past year respectively result be xlu beat benchmark index past year vs gain utility be know oft generous dividend xlu be exception annualize yield handily outpace average payout etf carry expense ratio ibd take nextera energy have deliver solid performance year do fundamental technical rank industry group find now ibd stock checkup vanguard utility vpu be trace similar path near flat base buy point also advanced prior flat base clear mid august fund track msci investable market utility index mark anniversary early next year top sector weighting be electric utility multus utility gas utility top holding include same name xlu nextera duke southern dominion fund gain year oct average annual return respectively past year vpu annualize payout be bear expense ratio thursday pick ishare russell value iwd remain just shy flat base buy point related stock mixed biotechs dive buffett stock buy point dow sell boee ge weigh chance buy small cap earning fuel dow new record high fang play buy zone
5,MRK,nasdaq composite index close week record high heaviest week earning season amazon amzn alphabet googl mmm caterpillar cat be big winner celgene celg boee ba baidu bidu be notable loser nasdaq composite have be week rally friday hit time high rise week amazon amzn alphabet googl microsoft msft surge friday earning apple aapl facebook fb hit buy point ahead earning next week index also rise new high friday week dow climb week hit record level earlier week celgene celg merck mrk several other biotech drug stock sell earning guidance week so do boee ba several defense giant treasury yield rise multimonth high solid economic datum european central bank voting taper bond buy president trump loom decision be next federal reserve chief amazon amzn share soar commerce leader report third quarter adjust earning share cent vs view cent revenue rise include whole food market acquisition amazon complete aug amazon web service revenue soar account well operate profit amazon soar hit record high related amazon blow past earning view beat sale share soargoogle parent alphabet googl vault time high internet giant profit smash estimate google say gaap earning be share year revenue jump top consensus estimate google traffic acquisition cost pay partner website carry ad rise alphabet say grow tac have be overhang google stock share rise friday record high back buy point related google shoot time high beating earning viewsboee ba take charge kc refueling tanker bring total cost overrun taxe taxe charge aerospace giant raise full year cash flow outlook full year core ep prior view ep midpoint be still analyst view boee ep fall top forecast revenue rise estimate boee share fall week related boee shake air force tanker cost outlook imply weak blue chip caterpillar cat mmm throttle earning estimate hike guidance make clear global economy have shift higher gear caterpillar earn share year cent ahead estimate revenue leap construction equipment firm earning guidance share be cent ahead prior estimate see broad growth industrial health care electronic energy segment beating ep cent say expect full year ep earlier outlook week caterpillar rise raise outlook strong earning dow stock gap highcaterpillar soar blowout earning raise martin lmt raise full year outlook earning revenue cut guidance sale aeronautic unit defense giant miss estimate northrop grumman noc also raise ep outlook report result wall street estimate global hawk maker announce wouldn submit bid navy unmanned tanker competition be see major player raytheon rtn report mixed result also raise full year ep outlook however raise guidance be still analyst consensus general dynamic gd quarterly result beat view lockheed raytheon general dynamic share fall northrop rally related lockheed grow leap bound sale slow northrop win bid navy drone contract result beat viewsraytheon report mixed result raise ep outlookbiogen biib slide tuesday beating top bottom line expectation sale spinraza lag view amgen amgn sarepta therapeutic srpt vertex pharmaceutical vrtx deliver board beat third quarter report late wednesday up sale guidance amgen sank sale top drug enbrel fall year year vertex say late stage cystic fibrosis trial fail celgene celg crash thursday revenue miss otezla sale lag consensus lead biotech cut sale guidance alexion pharmaceutical alxn fall weak sale gilead science gild top sale adjust earning view late thursday hepatitis drug sale decline third narrowly miss estimate big pharma giant merck mrk bristol myer squibb bmy novartis nvs eli lilly lly glaxosmithkline gsk fall follow earning report biotech firm top third quarter view only popscelgene result call alarm alexion bristol mixedgilead top sale profit view narrow miss hepatitis drugssoftware giant microsoft msft race past wall street target september quarter point sale view december quarter send stock record high territory friday day microsoft earn cent share year year sale fiscal first quarter analyst expect cent microsoft credit growth cloud compute business related microsoft top september quarter sale earning targetsinvestor cheer intel intc stm teradyne ter september quarter earning report jeered advanced micro device amd ultra clean holding uctt intel top wall street target third quarter sale earning guide analyst higher current quarter rival amd deliver better expect third quarter result disappoint guidance flat gross profit margin current quarter biggest loser be ultra clean plummet thursday mixed third quarter result related intel beat third quarter goal guide highergeneral motor gm ep fall revenue shrank broad slowdown car sale plan reduction fleet sale retreat certain european african asian market result crushed forecast ep revenue gm also guide full year earning consensus gm share have be rally investor see automaker combine strong profit now be lead pack autonomous drive electric car ford earning surge cent revenue rise automotive revenue top estimate ep cent revenue management narrow profit outlook remain consensus fiat chrysler fcau report mixed result china base school operator tal education tal fall short earning estimate penny report flat ep cent revenue climb enrollment more double outlook be line forecast fellow heavyweight new oriental education edu turn mixed result better expect guidance tal education plunge new oriental related china leader be flash long term sell signalsexxon mobil xom report ep rise cent revenue nearly expectation credit higher oil price production refinery margin fellow dow energy stock chevron cvx fall short earning send share friday recent buy point exxon rise friday crude future hit month high mcdonald mcd same store sale beat estimate help drink line signature craft sandwich see thinner margin invest training technology whopper deal burger king likely help comp owner restaurant brand qsr share reversed lower record high friday cost cut promotional switch boneless wing help buffalo wild wing bwld fly nearly thursday even sport bar chain contend elevated price traditional chicken wing question ceo transition chipotle grill cmg share crash concern sale recovery higher menu price next month plan slow new store addition next year visa fiscal fourth quarter result beat top bottom line help solid payment cross border volume strong show visa europe payment volume growth be strong country russia india australia come worry state retail mizuho analyst note mobile tmus sprint call earning call avoid discussion raise speculation merger announcement come november regulatory hurdle mobile add postpaid phone subscriber september quarter sprint add lose report flat profit revenue drop say expect purchase time warner twx close year end analyst say sell be related equity dilution expect twx deal be issue stock finance half deal side analyst say carrier include verizon vz have be restrain promotion soon be release high end apple aapl iphone improve margin december quarter cable tv firm comcast cmcsa charter chtr report higher video subscriber loss lower customer addition comcast have lower guidance early september send stock ahead earning charter stock fall disclose similar trend company aim hike price service video subscriber switch internet tv charter add customer vs estimate charter acquire time warner cable last year comcast add customer vs year earlier baidu bidu crushed third quarter earning estimate chinese search engine giant give weak guidance share plunge friday cisco system csco acquire broadsoft bsft maker communication software telecom company include debt share cisco pass buy ringcentral rng rival software firm fortinet ftnt sank friday maker computer security software forecast december quarter revenue expectation september quarter result beat view grubhub grub report third quarter earning beat estimate provide fourth quarter guidance also top view share surge week breaking buy point td ameritrade amtd top earning view gain revenue growth accelerate fourth straight quarter share online brokerage rise record high servicenow now report earning revenue top expectation billing growth disappoint share enterprise software provider fall earning release close week slightly higher earning call management indicated be strong start aid part few more deal closing normal be push december quarter whirlpool whr crash weak earning news sear longer sell appliance twitter twtr share soar week high better expect adjust earning rise monthly user forecast possible gaap profit
6,MRK,abbvie abbv humira franchise be safe patent settlement amgen amgn analyst say monday upgrade abbvie predict profit outgrow other large cap pharmas xleerink analyst geoffrey porge upgrade abbvie outperform rating up price target note upgrade miss abbvie recently strong performance believe be still further upside valuation abbvie be alter base extend market exclusivity humira model previously settlement amgen write note client settlement amgen pay abbvie royalty sale humira copycat humira be abbvie most important drug bring total sale second quarter humira be inflammatory med close bell stock market today abbvie climb finish share break flat base buy point late august have rise hit point ibd take abbvie be also work galapago develop treatment cystic fibrosis analyst say vertex pharmaceutical have large lead head new america closer look market breakdown settlement allow amgen launch biologic copy humira know amgevita europe next october version amjevita be set launch january other rival be likely be offer same market entry deal porge say boehringer ingelheim coherus bioscience chrs be closest entry biologic copy humira boehringer cyltezo be approve august firm be patent battle abbvie coherus be still work submit application regulator dow component merck mrk pfizer pfe addition novartis nvs momenta pharmaceutical mnta be bound file approval biologic copy humira come quarters likely infringe abbvie humira patent lawsuit likely be resolve mid remove risk launch right settlement date porge say result believe certainty humira patent protection be nearly porge increase humira sale view longer term humira estimate increase respectively expect abbvie hit operate margin project abbvie earning share command annual growth rate top large cap pharma peer project mature biopharmas set mid single digit growth growth horizon company increasingly visible late stage pipeline suggest abbvie stock continue re rate range large cap biopharma peer porge say related amgen drug send abbvie stock company gain trump foreign profit relief plan passesabbvie new hepatitis drug chip away gilead share
7,MRK,blue chip dow lead market upward wednesday morning ibm ibm goldman sachs gs merck mrk jump gate nasdaq be flat rise dow jone industrial average bolt small cap russell add volume stock market today be run higher board vs same time tuesday ibm score biggest gain dow big blue gap almost huge volume warren buffett berkshire hathaway have batter stock buffett announce berkshire have dump third hold late tuesday ibm release quarterly result top expectation top bottom line stock wednesday be en route biggest day gain more year accord bloomberg news goldman sachs dow stock rise fast trade stock drop tuesday beat earning revenue merck also dow component pop citigroup upgrade stock raise price target ibd industry group wood product railroad home furnishing do best morning trade gaming software metal ore miner do worst related crude oil turmoil iraqa look goldman morgan stanley
8,MRK,here weekly investing action plan need know investor come week upcoming week earning give investor much broader look corporate america economy stalwart tech industrial energy medical consumer sector weigh quarterly result such amazon com amzn alphabet ticker
9,MRK,cure be strong word come treat cancer other deadly disease brad loncar be biotech stock analyst investor ready employ term first time biotech company be not think technology incrementally say loncar portfolio manager biotech focuse etf re not think alleviate symptom disease re think fix genetic mutation cause disease loncar be speaking cancer comment apply other terrible disease claim thousand life include alzheimer parkinson lou gehrig disease multiple sclerosis muscular dystrophy year first fda approve biotech drug biotech industry be roll innovation breakneck pace new drug pipeline be burst treatment clinical trial industry be grow leap bound many biotech stock be score superior return investor recognize biotechnology industry contribution science patient health investor business daily have create ibd biotech innovator award inaugural edition name award winning biotech company choose groundbreaking treatment recently introduce market well new product pipeline company be celgene celg biogen biib regeneron pharmaceutical regn kite pharma incyte incy loxo oncology loxo winner aren rank way only company trade share be consider biogen have sight firmly cure cancer other intractable disease biogen be target like alzheimer parkinson ms ibd choose biotech innovator award winner ibd ask equity analyst etf mutual fund manager university professor identify top biotech company base innovative research ask focus company pioneer drug likely launch next several year reach blockbuster blockbuster sale more year award winner select ibd editor be most cite company find profile award winner detail work go full biotech innovator special report company be just few player huge field closely track investor ibd count publicly trade company biotech industry group doesn include many other company biotech operation aren main focus have combine market cap nearly sale most recent month more thank biotech industry pipeline new drug kind have explode clinicaltrial org count more drug file phase late stage trial food drug administration year fda have more late stage study register ibd biotech industry stock group have climb year shuck pain politically charge election season concern president trump work lower drug price group wednesday hit month high be time high july currently rank group track ibd term performance past month boost group performance be celgene loxo recently hit new high incyte touch record high year biogen touch month high friday regeneron year touch nearly year high biotech focuse fund brad loncar head be loncar cancer immunotherapy etf cncr track biotechs work immunotherapy exchange trade fund be near year anniversary be year comment ibd come series regulatory approval acquisition cancer treatment include gilead science gild foray cellular therapy august agreement acquire kite nearly kite purchase be complete oct kite now operate wholly own gilead unit count loncar bullish today drug immune system identify fight precisely target cancerous cell technology turn edit gene correct genetic condition trial datum be jaw drop say example be car technology kite be leader field be young biotech company be take patient have week month live case be see complete remission loncar say ve never see anything loncar liken chemotherapy bomb kill enemy everything else sight loxo be used smart bomb precision medicine target gene fusion cancer jmp security analyst mike king explain cancer gene be call passenger other driver king tell ibd driver become fuse normal cell normal cell transform cancerous loxo identify target fusion american society clinical oncology conference june loxo show impact work photo sarcoma protrude child chest king say target call trk fusion loxo be able treat cancer tumor shrink away nothing surgery radiation other therapy contribute say be remarkable be pretty staggering even person audience be kind used see kind thing patient drug dub larotrectinib be able partly shrink tumor sign cancer disappear patient drug have breakthrough rare pediatric disease orphan drug designation fda also grab headline be immuno oncology work dow component merck mrk well incyte bristol myer squibb bmy roche rhhby astrazeneca azn kite car therapy be get due like novartis nvs juno therapeutic juno bluebird bio blue immuno oncology car be method teach immune system fight cancer immuno oncology drug do so block specific interaction otherwise prevent immune response car drug individualize process reprogramming patient own extract immune cell ibd take car drug be snag major attention gilead announce plan acquire kite novartis get major drug approval open sector head ibd industry snapshot feature closer look emerge car sector result have impressed immuno oncology drugmaker be take step further combine compound hope see more robust response merck have have success drug keytruda have win approval first treatment chemo lung cancer incyte drug epacadostat be particularly intriguing analyst say prevent interaction involve ido enzyme merck bristol be pairing drug keytruda opdivo class drug know pd inhibitor incyte epacadostat regeneron too be work pd inhibitor regn develop partnership sanofi sny june regeneron sanofi say patient form skin cancer respond treatment regn phase trial car side novartis gain fda approval late august drug treat form acute lymphoblastic leukemia patient age approval help spike gilead just day have announce deal acquire kite kite be near approval car drug treat aggressive form hodgkin lymphoma juno be just drug call jcar treat same cancer kite drug bluebird be work multiple myeloma drug juno bluebird have partner celgene program jmp king call best breed approach celgene put money line potential innovation such partnership be celgene excel wedbush analyst david nierengarten tell ibd ve have innovative deal sector small molecule cell therapy say re innovative cast net widely new technology potential therapy other be reap benefit decade old project map human genome first human genome map cost dollar take almost year complete today cost closer map individual entire genetic makeup gene therapy editing be have renaissance jmp king say analyst point crispr therapeutic crsp make ipo year leader field crispr be also name technology crispr therapeutic audente therapeutic bold intellium therapeutic ntla also be make wave sector technology make much easier edit gene needham analyst alan carr tell ibd btig analyst dane leone see company enter clinic technology used enzyme be actually bacterial organism target area genome dna want make change dna say do used enzyme complex be give direction term target insert cell end enzyme complex attach dna make alteration tell ibd jmp analyst king describe crispr technology have ability repair break gene cut replace defective gene insert functional gene re desire other side gene spectrum rna interference antisense be responsible cut edge drug alnylam pharmaceutical alny biogen partner ionis pharmaceutical ion biogen ionis december win fda approval spinraza first drug type approve treat spinal muscular atrophy needham carr liken rna interference way turn gene have potential be more robust gene therapy most cell body be effective september alnylam stock spiked day drug patisiran prove effective treat rare disease know hereditary attr amyloidosis polyneuropathy disease result buildup abnormal protein cause systemic problem patisiran used rna interference analyst call late stage datum alnylam big concept bluebird be work gene therapy treat blood disorder list innovation go era biotech today gain have be decade make usually steady build then have wave innovation kind collide emerge similar point time jmp king say not traditional tech thing happen overnight related get detail award winning biotech innovator workgilead kite deal boost biotech etf clear buy novartis cancer approval validate gilead kite cure cancer look blood
10,MRK,drugmaker be begin gain steam drug trial result begin determine winner loser industry merck mrk be next break move higher ethical drug industry have jump industry group ranking last week time merck
11,MRK,abbvie abbv newly launch hepatitis drug mavyret have already grab total new prescription further chip away gilead science gild struggle hepatitis franchise analyst say friday xas result wall street see gilead hepatitis drug sale decline vs year earlier period evercore analyst umer raffat write note client drop be sharper plunge sale be expect fall wholesale basis mavyret be price roughly half competitor month vs gilead epclusa sovaldi harvoni respectively dow stock merck mrk zepatier abbvie viekira pak cost respective monthly gilead contend discount rebate mavyret be price similarly harvoni differ treatment duration wide array hepatitis drug mavyret treat genotype have shortest treatment duration week most patient ibd take novartis be first finish line car drug do mean gilead plan acquire kite head ibd industry theme deeper dive segment contend likelihood further erosion hepatitis franchise gilead be pivot cellular therapy acquisition kite pharma kite kite doesn have approve drug merger be announce day rival drug novartis nvs gain approval novartis drug be approve treat form acute lymphoblastic leukemia patient age analyst now expect similar drug kite treatment aggressive form hodgkin lymphoma grab approval later year bluebird bio blue juno therapeutic juno be partner celgene celg work similar treatment know car therapy create drug immune cell be extract patient reprogram fight cancer cell be reintroduce related abbvie gauntlet squeeze gilead drug hepatitis cure cancer look bloodwhy biotech catch rally add september be make break month partnership bit dust gilead kite competition
12,MRK,here weekly investing action plan need know investor come week report season result be begin delta air line dal jpmorgan chase jpm citigroup bank america bac well fargo wfc lead charge look central banker meeting last
13,MRK,bristol myer squibb bmy pop month high thursday immuno oncology combination prove successful vs chemotherapy previously untreated patient advanced kidney cancer xin morning trading stock market today bristol surge close drug stock hit month high astrazeneca azn winner close astrazeneca also be work immuno oncology combo astrazeneca lung cancer failure july bristol combination meet key goal phase study trial evaluate drug name opdivo yervoy patient advanced kidney cancer have never be treat vs chemotherapy opdivo yervoy demonstrated superior overall survival vs chemotherapy patient intermediate poor risk patient bristol say news release combo also outperformed chemo random pool patient bristol say independent datum monitoring committee recommend trial be stop early strong result more detailed result be present sunday european society medical oncology congress evercore analyst umer raffat say ibd take bristol grab boost relative strength rating wednesday thursday rs rating be best possible head ibd datum story closer look go ranking closest rival trial roche rhhby be set finish raffat say note dow component merck mrk also have several trial kidney cancer testing combination used drug keytruda pfizer pfe emd sereno be also work combo leerink analyst seamus fernandez say very likely bristol get approval drug advanced kidney cancer have outperform rating bristol stock overall survival be critically important bull thesis stock be consistent view previously interview medacorp key opinion leader say report client related bristol dife still have chance kidney cancer analystbristol myer squibb topple kidney cancer trial mixed resultswhy dow merck be credit suisse top pharma pick
14,MRK,major stock index end mixed thursday selling focuse nasdaq composite loss be tame preliminary datum show volume exchange come lower wednesday level friday turnover be likely jump weekly monthly stock index option expire nasdaq lose even chip equipment stock outperformed ease dow jone industrial average hold well rise component dow industrial score record close high help strength unite technology utx pfizer pfe merck mrk consumer price come bit hotter expect august rise vs expectation gain core rate exclude food energy price rise line expectation wall street have more economic datum ponder friday release august retail sale datum empire state manufacturing index latest read consumer confidence university michigan last week ibd tipp economic optimism index reach month high straight optimistic read oracle orcl do well thursday hour session report earning share rise end regular session unchanged highlight total cloud revenue jump stock market today tesla tsla continue attract buyer ceo elon musk say unveil semi truck offer be october tesla clear cup handle base buy point rise average turnover other breakout include leaderboard name square sq have be solid performer ipo november share rise still buy range buy point square be high pe stock deservedly so annual earning expect surge year ibd take focuse newer company innovative product drive growth be good way achieve big profit stock market learn more new be so important check lesson ibd university semiconductor space apply material amat be top gainer ibd rise chip equipment firm be work later stage base buy point group peer brook automation brk be also set base buy point share rise same ultra clean holding uctt be just buy point share jump related oil stock buy zone crude retake investing action planapple kick augment reality era new buy stock sell stock success read investor corner
15,MRK,big business increasingly doesn want be business president trump ceo merck mrk armour uaa intel intc quit manufacturing council monday wal mart wmt chief say tuesday be remain xtrump tuesday blast ceo step grandstander monday resignation follow wave negative reaction trump remark regard charlottesville va person be kill injured car plow group protest white supremacist rally weekend frazier kick ceo exit monday morning drug giant chief executive say feel be responsibility take stand intolerance extremism armour kevin plank intel brian take less harsh tone monday evening resignation say be not interested be involved politic trump grow unpopularity make less likely achieve pro growth agenda item associate president turn customer meanwhile weaken trump be less able retaliate vs corporation especially number grow trump do issue negative tweet monday merck frazier signale go high drug price tuesday blast ceo left ceo drop manufacturing council have many take place grandstander not have go job donald trump realdonaldtrump august however just minute trump tweet scott paul president alliance american manufacturing say leave council paul head group domestic manufacturer unite steelworker union tweet right thing do late tuesday trump say very fine person be side charlottesville protest afl cio president richard trumka resign council tweeting sit council president tolerate bigotry domestic terrorism tesla tsla ceo elon musk resign june business council trump announce leave paris climate accord walt disney ceo bob iger left same day back february then uber ceo travis kalanick quit trump travel ban effort pressure customer staff merck disney intel be dow component ceo still council be dow component boee ba general electric ge unite technology utx wal mart ceo doug mcmillon say trump miss critical opportunity help bring country together unequivocally reject appalling action white supremacist accord memo obtain cnbc mcmillon add wal mart have diverse base employee customer so believe stay engage try influence decision positive way help bring person together related trump blast dow merck ceo resign manufacturing council
16,MRK,generic competition chip away pfizer pfe depression drug pristiq contribute revenue miss second quarter analyst say tuesday dow component report earning xon stock market today pfizer sank pfizer be consolidation go back exactly year stock recently retake day day move average second quarter pfizer report adjust income cent share sale adjust earning grow nearly top consensus analyst poll zack investment research cent sale miss view fall evercore analyst umer raffat note pristiq sale lag consensus drug lose market exclusivity march drop be very rapid say note client contribute year year decline pfizer essential health unit house legacy drug sale prevnar pneumonia drug decline miss analyst prediction raffat say decline be due timing center disease control prevention purchase pediatric patient international market grow pfizer oncology unit appear be stabilize raffat say worldwide ibrance sale rocket vs year earlier quarter obliterate consensus view ibrance be used treat specific population patient advanced breast cancer ibd take pfizer have ibd composite rating meaning perform bottom half stock term key growth metric head ibd stock checkup look drugmaker strongest rating sale enbrel struggle quarter revenue drug plunge outside canada beat consensus raffat say pfizer cite competition biosimilar europe decline pfizer raise full year adjust income guidance share cent midpoint reaffirm sale guidance pfizer be member dow jone industrial average last week fellow dow drug giant merck mrk report better expect earning strong sale immuno oncology drug keytruda related clovis regeneron be lead biotech deluge todayhow dow merck be benefit back astrazeneca bristoldow merck crushed keytruda sale view astrazeneca keep clovis tesaro unveil blockbuster drug
17,MRK,dow merck mrk be benefit back astrazeneca azn bristol myer squibb bmy analyst say monday cite higher expectation immuno oncology drug combine chemotherapy xub analyst marc goodman assessment come merck astrazeneca say team test drug keytruda lynparza several cancer follow merck consensus crush second quarter stock market today merck dip fractionally close astrazeneca inched bristol myer pop finish recent tie clovis oncology clvs breast ovarian prostate cancer past day have be good merck diminish expectation immuno oncology immuno oncology thus higher immuno oncology chemo goodman say note client merck be combine immuno oncology drug keytruda eli lilly lly chemotherapy alimta treat advanced lung cancer combination receive accelerate approval meanwhile rival appear be struggle ibd take earning season be well underway top tech stock be buy point week head ibd research page closer look make strong bet last week astrazeneca announce combination immuno oncology drug imfinzi tremelimumab fail late stage trial advanced lung cancer patient doesn look good bristol myer be work similar combo leerink analyst seamus fernandez say astrazeneca failure imfinzi tremelimumab leave keytruda dominance intact first treatment advanced lung cancer long term growth require more aggressive business development strategy say fernandez boost price target merck cite drugmaker new partnership astrazeneca have outperform rating merck astrazeneca partnership be admission defeat initial immuno oncology race get access keytruda pd inhibitor astrazeneca sell half right lynparza parp inhibitor astrazeneca already have drug similar keytruda drug imfinzi be pd inhibitor operate similar mechanism astrazeneca merck be work theory combine immuno oncology drug parp inhibitor offer stronger cancer response similar astrazeneca bristol theory combination immuno oncology drug be particularly robust cancer merck be now strategic advantage goodman say keytruda sale beat wall street view second quarter grow sale keytruda lung cancer comprise half sale majority come use monotherapy goodman say year expectation be high bristol low merck say expectation have now be reversed so think keytruda sale need ramp materially here datum need support current view keep stock move higher related dow merck crushed keytruda sale view astrazeneca fail not once twice cancer drugswhy clovis regeneron be lead biotech deluge today
18,MRK,amazon amzn share slide wednesday president donald trump attack commerce leader taxe accuse cause job loss amazon be do great damage tax pay retailer town city state be be hurt many job be lose trump say twitter post et wednesday separately also wednesday amazon say have price public offer senior secure note net proceed fund acquisition whole food market wfm amazon stock slip close stock market today amazon have be frequent target trump taxe job chief executive officer jeff bezos trump accuse amazon not pay internet taxe tweet post june amazon have say collect state sale taxe state have such levy ibd take twitter attack trump amazon share have maintain steady climb share year amazon be ibd leaderboard stock be try retake day move average december trump tweet amazon ever have pay fair taxe stock crash crumble paper bag washingtonpost scam be save bezos be owner washington post have written number story critical trump administration trump july tweet be fake news washington post be used lobbyist weapon congress keep politician look amazon tax monopoly economy add job july jobless rate dip year low labor department report last week latest sign renew economic momentum batter retail sector add job meanwhile amazon continue hire spree recently hold job fair fill more job opening help fulfill customer order attack amazon come several executive quit role trump manufacturing council reaction trump response violence charlottesville va person be kill injured car plow group protester white supremacist rally weekend ceo merck mrk armour uaa intel intc quit manufacturing council monday related amazon well position capture market share grocery deliveryretail commerce news stock amazon whole food deal mean retaildick sporting good crash weak earning sale guidance
19,MRK,president trump say wednesday disband advisory group american business leader ceo quit week president face blowback fail sufficiently condemn white supremacist trump make announcement twitter less hour group be say be plan inform white house disband rather putt pressure businesspeople manufacturing council strategy policy forum be end thank donald trump realdonaldtrump august trump remark be reversal say day tweet have plenty ceo want be panel replace quit call ceo left grandstander several more ceo council say trump remark have inform respective panel step suggest trump scrap panel dissolve entirely strategy council lead blackstone group ceo stephen schwarzman say participation have become unwelcome distraction blackrock ceo larry fink tell staff wednesday memo have inform strategy council be step past hour jpmorgan chase jpm ceo jamie dimon earlier year hailed trump reignite animal spirit say wednesday afternoon be leader role bring person together not tear apart strategy group be several white house convene earlier year advise president several ceo manufacturing council quit week follow blowback trump remark racially charge violence virginia saturday pressure leave group have grow follow press conference trump hold new york tuesday place partial blame weekend violence demonstrator protest gathering white supremacist charlottesville va woman be kill event man ram car crowd more half dozen ceo have quit manufacturing ceo group other have say want stay panel order influence white house policy manufacturing council hasn meet february ceo armour uaa intel intc merck mrk quit earlier week wednesday inge thulin ceo mmm left do campbell soup cpb ceo denise morrison follow yesterday remark president remain manufacturing job initiative morrison say statement continue support effort spur economic growth advocate value have always make america great jeff immelt general electric ge alex gorsky johnson johnson jnj gregory haye unite technology utx step manufacturing council minute trump say be scrapping body immelt say have inform council wednesday morning decision related big business dump trump exec quit council be stay
20,MRK,bristol myer squibb bmy put hurt dow component merck mrk analyst say merck flagship immuno oncology drug miss goal head neck cancer trial xon stock market today bristol climb merck dip follow news report late monday immuno oncology program merck keytruda gain accelerate approval treat head neck cancer contingent late stage trial confirm prior success trial dub keynote keytruda narrowly miss goal meanwhile bristol say seek new week minute dose schedule rival drug opdivo neither item news be likely meaningfully affect term sale credit suisse analyst vamil divan say note client lead positive upside bristol opdivo pressure merck keytruda look medium longer term divan note be earlier trial merck use confirmation success used keytruda treat head neck cancer keynote assume read positively meantime keytruda keep accelerate approval head neck cancer pending further trial head neck cancer represent merck keytruda sale first quarter ibd take biotechs be now rank fourth group track ibd be cook gas pent demand acquisition larger player come fruition biotech buy head ibd industry theme future keytruda trial head neck cancer also deliver disappointing news then revenue be risk divan say same time merck announce result keynote study bristol say food drug administration have accept application have keytruda rival opdivo dose milligram week minute keytruda opdivo same class immuno oncology drug target protein call pd immune system immuno oncology drug work immune system identify destroy cancer cell opdivo be now approve weight base treatment various cancer include head neck cancer dose course minute infusion patient receive infusion week depend type cancer divan call potentially important commercial milestone make office visit better patient office staff keytruda roche rhhby tecentriq be dose week other company have comment look longer potential regimen bristol now have advantage front say merck say comfortable current week schedule keytruda note line nicely eli lilly lly alimta be dose divan say keytruda alimta be be study combination advanced lung cancer related small biotech break tie eli lilly biotech nearly triple street expectation key drugwhy astrazeneca rumore chief executive exit be bad timing
21,MRK,here investing action plan friday need know investor come day xan initial read second quarter gdp be due oil giant exxon mobil xom chevron cvx report drug giant merck mrk abbvie abbv quarterly result american airline aal also round earning
22,MRK,thursday be shape be solid show technology stock share facebook fb jump early strong earning wave selling hit nasdaq composite early afternoon trading growth stock take chin more half name ibd more nasdaq be reverse intraday gain ease dow jone industrial rise slightly thank bullish gain boee ba walt disney merck mrk verizon vz stall session nasdaq wednesday basically be heavy volume price progress tech index be poise distribution day thursday volume nyse nasdaq be tracking higher wednesday level selling pressure be intense nasdaq leader nvidia nvda netflix nflx show loss stock market today big seller be amazon com amzn earning report close intraday gain turn loss afternoon trading be surprised see strong quarter amazon stock have make big run already recently clear later stage base earning news edward lifescience ew gap try clear cup handle buy point gain fade share be recently trading enterprise software name servicenow now meet similar fate solid quarter poke entry couldn hold ibd evercore partner evr be bright spot work right side cup shape base close watch report proofpoint pfpt logmein logm benchmark crude oil rise year treasury yield add basis point related facebook surge blowout earning get price target hike best stock buy reason southwest spirit air be plunge
23,MRK,astrazeneca azn not only fail lung cancer trial have side effect send rival bristol myer squibb bmy spiraling partnership dow merck mrk appear be admission defeat initial immuno oncology race xshare astrazeneca bristol myer sell drove early thursday stock market today astrazeneca take pitfall month low bristol too sank so call mystic trial astrazeneca impact bristol analyst say late stage trial combination astrazeneca imfinzi tremelimumab fail meet primary goal improve progression free survival advanced lung cancer patient compare chemotherapy astrazeneca continue trial hope combination improve overall survival patient advanced lung cancer tumor display more protein call pd analyst be bearish likelihood success astrazeneca have more shot goal combo see commercial success combination severely limit even small benefit survival be ultimately realize leerink analyst seamus fernandez write note client result be similarly negative bristol bristol be look drug opdivo yervoy trial call checkmate opdivo be know pd antibody astrazeneca imfinzi be pd antibody bristol yervoy astrazeneca tremelimumab same class ctla antibody be several key difference trial design mystic checkmate be unlikely result meaningfully different outcome fernandez say note final result astrazeneca trial be expect bristol trial due first half next year ibd take send biotech stock higher year merger acquisition say industry observer head ibd industry theme deep dive go right industry be shopping spree also result incyte incy have less rival epacadostat ido antibody advanced lung cancer leerink analyst michael schmidt note research report incyte be combine epacadostat merck keytruda bristol opdivo number trial astrazeneca also seemingly admit defeat initial immuno oncology race fernandez say drugmaker be team merck get access drug keytruda pd antibody bristol opdivo duo plan look immuno oncology combo lynparza parp inhibitor merck share development cost lynparza drug call selumetinib merck pay astrazeneca include upfront licensing milestone astrazeneca also have share profit drug give astrazeneca interest combine lynparza pd pd inhibitor deal look tacit admission importance own lead pd antibody develop cancer combination fernandez say combination also have surprising benefit clovis oncology clvs janney analyst debjit chattopadhyay say clovis tesaro tsro have drug parp inhibitor arena tesaro be partner japan takeda pharmaceutical now astrazeneca be partner merck clovis rubraca now remain only unencumbered parp inhibitor relative basis remain far cheaper peer tesaro write note client base valuation gap clinical event derail story pipeline leverage rubraca clovis stock be more compelling candidate view merck stock pop clovis jump related astrazeneca beat stock dife drug failure more reportwhy biotech rally still tack upsidebiotechs find strength number treat multiple sclerosis
24,MRK,astrazeneca azn stock rally friday report chief executive pascal soriot remain board defy rumor wednesday thursday be leave take top job teva pharmaceutical teva soriot stay astrazeneca foreseeable future source familiar matter reportedly tell bloomberg spokesperson decline comment investor business daily market rumor speculation astrazeneca pop stock market today teva topple stock reversed thursday trend teva close astrazeneca close rumor soriot departure first surface wednesday report israeli newspaper calcalist thursday leerink analyst seamus fernandez say optic soriot leave astrazeneca unveil result key immuno oncology trial be bad day now expect astrazeneca announce result combination trial imfinzi tremelimumab first treatment patient advanced lung cancer drug use immune system fight cancer ibd take biotechs still rally second quarter earning season analyst say large cap leader win be big winner rally head industry snapshot more biotechs sector look strong season combine immuno oncology drug be offer more potent cancer defense dow merck mrk bristol myer squibb bmy be work similar combo drugmaker fight grab chunk advanced lung cancer market soriot rumore departure also leave astrazeneca open acquisition fernandez note likely analyst look more color astrazeneca second quarter earning conference call be schedule july related astrazeneca rumore chief executive exit be bad timingdeal help celgene rival dow merck bristol cancer cancer trial help rival analyst say
25,MRK,rumor chief executive pascal soriot leave astrazeneca azn teva pharmaceutical teva hurt astrazeneca ahead key readout immuno oncology trial analyst say thursday xon wednesday israeli newspaper calcalist report soriot be consider leave position astrazeneca take role teva leerink analyst seamus fernandez write note client astrazeneca be soon expect unveil result imfinzi tremelimumab combine first treatment patient advanced lung cancer drug class know immuno oncology harness immune system fight cancer combine immuno oncology drug be thought offer more robust response imfinzi be know pd antibody tremelimumab be ctla antibody trial dub mystic be set read day now fernandez say optic soriot departure be terrible ahead mystic readout write news do not appear be related mystic outcome exit leave astrazeneca rudderless wake several other recent departure ibd take ipo health care enter buy zone last week get more stock rival ibd datum story also leave astrazeneca open acquisition fernandez say realistically leave company state flux ahead important immuno oncology catalyst well upcoming datum readout several other key pipeline asset astrazeneca be forefront immuno oncology movement rival dow merck mrk bristol myer squibb bmy bristol be work similar combination opdivo pd antibody yervoy ctla antibody astrazeneca email investor business daily decline comment rumor speculation astrazeneca close stock market today fall wednesday share stay day move average third consecutive day thursday related celgene gamble help small biotech moredeal help celgene rival dow merck bristol cancer cancer trial help rival analyst say
26,MRK,bristol myer squibb bmy add sale immuno oncology franchise phase study show opdivo be better company own drug yervoy treat advanced melanoma patient interim analysis opdivo improve recurrence free survival vs yervoy bristol say news release opdivo be dose week milligram kilogram weight yervoy be approve milligram kilogram weight opdivo keytruda rival dow component merck mrk be know pd inhibitor bristol yervoy be ctla inhibitor work block specific interaction body prevent immune response likely cannibalize sale yervoy set expansion market add approximately bristol net immuno oncology sale assume competition merck keytruda leerink analyst seamus fernandez say note client magnitude benefit opdivo yervoy wasn release bristol hadn expect release such datum second half fernandez say now fernandez say treatment opdivo follow surgery high risk patient melanoma become standard care opdivo yervoy be test patient late stage melanoma trial dub checkmate ibd take biotech rally send several player incredible high be still room get action visit ibd etfs page closer look fernandez estimate used pd inhibitor regimen expand immuno oncology market opdivo be safer more tolerable yervoy first big immuno oncology drug gain commercial success close bell stock market today bristol stock gain close share merck too be marginally related astrazeneca cancer trial help rival analyst dow merck be still beating bristol roche immuno tesaro overcome clovis lead combo merck co
27,MRK,clovis oncology clvs regeneron pharmaceutical regn be biggest biotech stock loser monday news related clinical partnership bristol myer squibb bmy sanofi sny respectively xin early trading stock market today clovis topple close announce immuno oncology partnership bristol myer test combination drug call rubraca opdivo treat breast ovarian prostate cancer broadly biotechs be decision come heel recent deal tesaro tsro takeda pharmaceutical astrazeneca azn dow merck mrk clovis tesaro astrazeneca have drug call parp inhibitor be consider strong drug used battle ovarian cancer clovis case pairing bristol myer close door term acquisition leerink analyst michael schmidt say note client previously clovis have only free parp inhibitor not otherwise tie deal top rival investor have hope acquisition clovis bristol myer term think deal doesn preclude future acquisition company view increase competitiveness value rubraca write schmidt keep outperform rating clovis stock call pitfall buy opportunity see clovis benefit more bristol myer partnership astrazeneca deal merck astrazeneca sell half right parp inhibitor lynparza get access merck pd inhibitor keytruda clovis other hand keep ownership rubraca ibd take biotech stock be now rank fifth group track ibd slip spot last week merger acquisition send higher head ibd industry theme closer look potentially shopping spree matchup have parp inhibitor pair pd inhibitor immuno oncological combination thought generate more robust response drug alone deal clovis share half development cost combination bristol myer importantly clovis gain access lead pd inhibitor clinical development expertise bristol myer schmidt write meanwhile regeneron tank finish regular trading session french partner sanofi report sale eczema drug dupixent miss expectation accord reuter first full quarter dupixent pull miss consensus view analyst expect dupixent be key drug regeneron sanofi already approve have receive positive recommendation european regulator approval duo be also look dupixent severe asthma intercept pharmaceutical icpt too plunge follow second quarter earning report adjust loss grow share be better analyst forecast loss sale top view dynavax technology dvax other hand catapult close earlier rise much food drug administration panel vote recommend safety hepatitis drug support approval treat adult typical hepatitis medication be administer dose month dynavax say news release drug dub heplisav be dose twice month dynavax hope launch drug early related astrazeneca fail not once twice cancer beat stock dife drug failure more reportdow merck crushed keytruda sale view
28,MRK,dow component merck mrk stock topple late wednesday food drug administration put clinical trial hold involve drugmaker immuno oncology med keytruda blood cancer know multiple myeloma trial keytruda low dose dexamethasone combine pomalyst revlimid celgene celg be place full clinical hold similar combination study be place partial clinical hold last month merck pause enrollment trial more patient receive keytruda die wednesday fda say risk combination outweighed potential benefit ibd take merck have ibd composite rating meaning outperform nearly stock term key growth metric head ibd stock checkup list best rate drugmaker hour trading stock market today merck stock be additional end regular trading session fraction share have be form flat base early march merck be company dow jone industrial average related dow merck pause cancer trial investigate keytruda tie deathsbristol beat cancer test conquer dow merck astrazeneca cancer trial help rival analyst say
29,MRK,alnylam pharmaceutical alny topple month low thursday suspend development hemophilia drug celgene celg astrazeneca azn lift series decision regulator put several trial hold xin midday trading stock market today alnylam plummet close other hand astrazeneca pop celgene rise broadly biotechs lift fraction early thursday alnylam say temporarily suspend testing hemophilia drug call fitusiran pending review patient die patient be enrolled phase trial hemophilia type die form blood clot alnylam aim resume test review safety fitusiran develop risk mitigation strategy firm also say reach agreement regulator regard phase trial design drug know givosiran potential treatment disorder involve buildup chemical produce porphyrium body pending review program interim analysis assume positive result alnylam say expect file application givosiran food drug administration end fda place trial involve drug celgene astrazeneca immuno oncology drug imfinzi partial clinical hold put full clinical hold cite issue similar combo used rival drug dow component merck mrk astrazeneca imfinzi merck keytruda class drug know checkpoint inhibitor work block specific interaction immune system otherwise prevent immune response bristol myer squibb bmy opdivo be same class ibd take alnylam be still expect provide datum rare disease trial be part stock rally september analyst say head ibd industry theme see september be make break month sector celgene drug revlimid pomalyst be know immuno modulary agent leerink analyst geoffrey porge write note client july trial combine merck keytruda revlimid pomalyst multiple myeloma be place clinical hold follow patient death fda cite issue combination merck celgene drug rationale place trial astrazeneca imfinzi celgene revlimid full clinical hold well patient trial discontinue treatment celgene say news release suggest checkpoint immuno modulary agent combination be associate increase rate fatal nonfatal serious adverse event combination somehow diminish efficacy immuno modulary agent give individually toxicity combination so reduce drug exposure undermine potential clinical benefit porge say patient enrolled trial place partial clinical hold continue treatment investigator determine be receive clinical benefit new patient be enrolled trial trial place partial clinical hold include several other multiple myeloma chromic lymphocytic leukemia aggressive form hodgkin lymphoma celgene continue enroll patient trial acute myeloid leukemia myelodysplastic syndrome related top biotech stock buy zone fda drug approvalfour reason keep bet biotech stock bristol myer cancer help boost rival
30,MRK,astrazeneca azn clovis oncology clvs tesaro tsro equally split ovarian cancer market analyst suggest friday food drug administration approve broad label astrazeneca lynparza news likely remove overhang clovis tesaro stock have slide respectively month credit suisse analyst alethia young say note client share have be weak anticipation fda decision lynparza lynparza counterpart rubraca zejula clovis tesaro be know parp inhibitor late thursday fda grant astrazeneca partner merck mrk dow component series new approval lynparza lynparza now be approve maintenance treatment ovarian cancer patient have respond chemotherapy regardless mutation brca gene mutation brca gene have be tie ovarian breast cancer regulator also approve lynparza tablet twice daily compare earlier approval capsule twice daily tablet be used treat ovarian cancer patient brca mutation ve undergo more chemotherapy treatment ibd take biotechs have struggle recently slip group track seventh last week fourth week happened stock hit month high late july head ibd industry theme breakdown leerink analyst michael schmidt have project chance astrazeneca succeed effort get broad approval lynparza regardless brca mutation type mutation know wild type drug view have not convincingly show efficacy date still approval somewhat change dynamic clovis tesaro say note client cut price target clovis maintain outperform rating investor continue debate various nuanced difference parp inhibitor label term say say continue believe rubraca be well position other parp inhibitor long term astrazeneca be partner merck tesaro be partner japan takeda pharmaceutical parp inhibitor clovis fully own drug rubraca schmidt note clovis remain attractively value trading discount competitor own full right agent category have view significant commercial potential not only ovarian cancer also breast prostate gastric other cancer say leerink analyst seamus fernandez remain bullish tesaro cut price target reflect new market dynamic keep market perform rating tesaro note expect pro con parp inhibitor negate other result relatively similar split lynparza rubraca zejula maintenance drug ovarian cancer follow least round chemotherapy zejula be most prescribe trio be first market specific set march say astrazeneca merck likely have marketing advantage base size expect tesaro clovis be able counter deal lynparza lack datum specific brca patient label write note client zejula also have benefit more convenient dose schedule once daily vs twice daily rival consider drug be price relatively similarly start dose tesaro have advantage base less frequent dose schedule say morning trading stock market today clovis rise trail tesaro be astrazeneca fall less related clovis regeneron be lead biotech deluge todaytesaro beat sale view loss nektar miss astrazeneca fail not once twice cancer drug
31,MRK,bristol myer squibb bmy topple late tuesday mixed result phase trial testing immuno oncology combination vs chemotherapy previously untreated patient advanced kidney cancer hour trading stock market today bristol dove nearly end regular session follow release investor have be key bristol drug opdivo yervoy potentially strong combination treat cancer trial dub checkmate larger proportion patient treat combination opdivo yervoy experience tumor shrinkage vs patient treat chemotherapy know sunitinib median duration response wasn reach immuno oncology combination chemotherapy reach point month be improvement progression free survival wasn statistically significant median progression free survival patient opdivo yervoy combo be month vs month chemotherapy bristol say news release ibd take merck be benefit back rival astrazeneca bristol say analyst visit ibd technology page closer look immuno oncology battle look shake bristol spokesperson vicki goodman be encourage result checkmate continue get better look overall survival rate company say tolerability prove consistent earlier trial overall response rate durability response favore combination opdivo yervoy trend progression free survival support potential combination intermediate poor risk advanced renal cell carcinoma goodman say statement opdivo be already approve second treatment renal cell carcinoma most common form liver cancer checkmate study look opdivo second immuno oncology drug yervoy previously untreated liver cancer patient immuno oncology drug work immune system fight cancer dow component merck mrk astrazeneca azn roche rhhby incyte incy other be work arena related dow merck be credit suisse top pharma pickwill pfizer cancer drug help grow merger sanofi earning spook regeneron share week low
32,MRK,persist puzzle economy be seem strong weak hand remain citadel innovation produce new company uber other economy be expand snail pace annually be true isn innovation translate faster growth answer part answer be american business be run separate track call youthful middle age track miss youthful capitalism google world dazzle rapid innovation dynamism be reassure meanwhile many less visible more numerous older firm be tread water re struggle generate higher revenue profit mature market face new competitive threat be arguably firm run second track middle age capitalism have dominate economy great recession be sure america business aristocracy have shift largest firm market capitalization value company share be old line business exxon coca cola ko general electric ge merck mrk only exxon now exxon mobil xom remain other be replace apple aapl google googl microsoft msft amazon amzn note jeff bezos amazon ceo own washington post still middle age capitalism have slow recovery bolster case be new study publish journal economic perspective kathleen kahle university arizona rene stulz ohio state university scholar examine public company year period find pervasive evidence tiered capitalism company be sort strong weak recall public company have share be trade typically stock exchange private firm include most small family business be not publicly trade profit become more concentrated especially large tech firm apple google microsoft amazon have combine profit fully profit publicly trade company firm account half profit company do more disturbing company top report negative earning whole many firm have significant loss similar story apply corporate investment building machinery computer vehicle capital investment have drop corporate asset interestingly decline investment be mostly offset increase corporate research development reflect need develop new digital product program say kahle stulz spending be heavily skewer bigger firm half publicly trade firm show middle age capitalism prevail consider be troublesome president trump anyone want stronger economy primary force hold back be ill consider government policy then remedy be obvious get rid policy economy improve be administration position weakness go deeper example hard argue cut corporate taxe accelerate economic growth many company be already suffering loss don benefit tax cut similarly large very profitable firm huge pile cash few appeal investment project win suddenly find new project taxe be cut kahle stulz worry trend outline mean less investment less growth less dynamism company remain highly cautious further hazard be hardly hypothetical
33,MRK,celgene celg rival dow component merck mrk bristol myer squibb bmy cancer fight drug analyst say biotech announce deal give access key immuno oncology treatment xunder term deal celgene pay beigene bgne upfront license fee make equity investment acquire right develop drug know bgb solid tumor globe bgb belong class immuno oncology drug call pd inhibitor drug include merck keytruda bristol opdivo work block specific interaction involve pd protein body prevent immune response cancer cell deal allow celgene develop commercialize bgb treat solid tumor europe japan rest world outside asia beigene keep right drug blood cancer worldwide solid tumor asia celgene already have immuno oncology play blood cancer acquisition right astrazeneca azn imfinzi hematological tumor evercore analyst umer raffat say call deal small upfront cost get access pd inhibitor begin trial next year also deal beigene acquire celgene commercial operation china exclusive license commercialize cancer drug abraxane revlimid vidaza china celgene say news release early thursday ibd take several drugmaker be work create car therapy individualized form immuno oncology immune system reprogram fight cancer lead sector head industry snapshot deal come day food drug administration put merck keytruda trial hold several patient death celgene be partner trial still question linger regard much celgene be willing put finish development bgb raffat say celgene perspective very important understand big research development undertaking be many additional immuno oncology target look bring potential combo write note client number company merck bristol include be work combine immuno oncology drug other boost potency beigene say pd inhibitor be more efficient be engineer minimize interaction other target outside pd protein celgene be work number immuno oncology target outside pd raffat expect need add more include ido inhibitor incyte incy epacadostat ctla inhibitor bristol yervoy stock market today celgene stock dip nearly close share merck fall bristol myer stock slide finish beigene stock rocket end regular session record close intraday beigene hit record high related dow merck stumble fda put keytruda trial holdbristol beat cancer test conquer dow merck cure cancer look blood
34,MRK,merck mrk cholesterol bust drug isn strong wall street initially thought analyst argue tuesday dow component say hold filing application sell medication regulator drug know anacetrapid reduce heart attack cardiac death need certain heart surgery patient already receive cholesterol lower drug know statin merck note anacetrapid continue build fat tissue issue have be discover earlier study leerink analyst seamus fernandez say ultimately prevent merck filing drug approval believe mention press release highlight potential long term regulatory concern believe require very robust impact key cardiac event death merck file anacetrapid say merck didn look anacetrapid ability cut stroke be typically goal examine cardiac benefit cholesterol lower drug fernandez write note client consider file approval food drug administration merck plan unveil full trial result european society cardiology meeting august ibd take ibd stock regeneron pharmaceutical regn have approve cholesterol bust drug partner sanofi sny know praluent praluent be face competition litigation amgen amgn repatha head ibd see regeneron look fare court battle still evercore analyst umer raffat argue merck file approval drug be know cetp inhibitor most analyst didn expect drug succeed trial only expect anacetrapid work say ultimately be need add control statin write research report need modestly more benefit consider merck vytroin now anacetrapid patient need much more benefit consider used be call pcsk inhibitor like regeneron sanofi amgen say stock market today share merck component dow jone industrial average slip end regular trading session related dow merck be still beating bristol roche immuno oncologybiotech stock growth positive trial result near buy zone
35,MRK,future dow jone industrial average index nasdaq fall slightly early monday morning lead tech stock such apple aapl facebook fb nvidia nvda suffer worst loss month meanwhile financial such morgan stanley ms bank america bac citigroup continue recent outperformance future nasdaq include biggest tech stock fall nearly fair value dow future be more fair value friday nasdaq composite index russell hit time intraday high then tech stock have be soar suddenly reversed apple lose do manage close just day line facebook amazon amzn netflix nflx also test day line google parent alphabet googl fourth member fang group do not also lose more nvidia friday peak have soar nearly earning reversed lose meanwhile dow jone industrial end friday session high even apple intel intc microsoft msft suffering big loss credit dow drug component pfizer pfe merck mrk well banking giant jpmorgan chase jpm goldman sachs gs merck jpmorgan chase goldman sachs regain day move average citigroup extend thursday friday close still range buy point morgan stanley try clear double bottom entry close just level jpmorgan be buy point bank america be aggressive entry be start sustain revival financial temporary move don try predict market follow action major average lead stock used stock market today big picture friday sell push market direction uptrend pressure key factor bank stock overall market be federal reserve week fed be expect raise interest rate yet again inflation stubbornly low president trump fiscal agenda stumbling policymaker hint go slow approach future hike monday trading intraday japan nikkei fall china shanghai composite hong kong hang seng related big picture bear rip techs sector keep climbingfear gauge flash extreme bullishness just tech selloffafter political drama market eye fed rate hike investing action plan dow stock watch week apple to line
36,MRK,stock market open higher quickly reversed lower morning trading investor digest european central bank action early thursday ex fbi director james comey begin congressional testimony ecb left interest rate unchanged remove reference possibly cut rate further nasdaq early gain turn loss also slip negative trade dow jone industrial average stick close break even mark dow industrial nike nke financial component jpmorgan jpm pace advancer gain early trading blue chip index big laggard be walt disney merck mrk fall department store retailer be best perform stock stock market today jwn more macy kohl kss rise respectively downside borg warner bwa decline snap sna fall chinese commerce giant alibaba baba announce expect fiscal revenue growth be range well analyst expectation share surge early thursday other chinese stock follow suit be volatile competitor jd com jd jump online gamer netease nte moved internet stock sina sina weibo wb drop respectively recent issue okta okta result come analyst estimate late wednesday cause cloud security software provider trade almost higher share be just ipo base entry action ibd be mixed early trade new leaderboard member healthequity hqy rise ichor holding ichr moved downside china education stock new oriental education edu tal education tal decline entertainment eatery dave buster play drop related alibaba soar predict revenue growth yeardow jone industrial average dow stock news analysisokta beat view first report public company stock riseseuropean central bank take baby step curb stimulus draghi followbest chinese stock buy watch
37,MRK,merck mrk stock pop late thursday dow component drugmaker tack new food drug administration approval immuno oncology drug keytruda hour trading follow announcement merck stock be flat share close regular session announcement also follow strong datum combination trial merck keytruda incyte incy epacadostat array tumor keytruda be now approve first treatment patient advanced carcinoma bladder pelvis urethra region be ineligible cisplatin contain chemotherapy common side effect cisplatin include bone marrow suppression hearing kidney problem vomit fda also approve keytruda second treatment bladder cancer patient cancer progressed chemotherapy case keytruda be approve fix milligram dose week disease progress patient experience unacceptable toxicity result treatment month patient cancer doesn progress ibd take need help keep track biotech drug market head ibd biotech pharma industry stock news page most recent news keytruda be now approve treat type cancer include melanoma lung cancer head neck cancer classical hodgkin lymphoma closest rival opdivo bristol myer squibb bmy have approval also include bladder cancer related conference spotlight drug giant donnybrook cancer team dow merck trounce roche cancer
38,MRK,tesaro tsro stock plunge monday sunday presentation american society clinical oncology meeting show zejula be stronger drug astrazeneca azn breast cancer xon stock market today tesaro stock crash end day share rival astrazeneca pfizer slip less clovis oncology clvs eli lilly lly stock also lose more tesaro dow component merck mrk combine drug zejula keytruda treat ovarian breast cancer patient zejula be know parp inhibitor keytruda be pd inhibitor combine be thought offer more potent response half ovarian cancer patient respond treatment compare favorably historical datum parp pd inhibitor alone patient population leerink analyst seamus fernandez write note client still early datum appear stronger initial result see astrazeneca lynparza imfinzi tumor type write lynparza be parp inhibitor imfinzi be pd inhibitor ibd take tesaro stock have middling ibd composite rating measure performance stock get ibd stock checkup look better rate biotechs breast cancer patient have partial response combo sign cancer disappear patient patient be know triple negative breast cancer form doesn respond normal treatment achieve stability company also have see promising unconfirmed response other patient other presentation astrazeneca say lynparza show month improvement progression free survival chemotherapy patient form breast cancer pfizer show similar datum drug talazoparib saturday fernandez say overall lynparza less severe toxicity profile likely drive use drug chemotherapy say main adverse event associate lynparza be nausea anemia neutropenia be most common adverse event chemotherapy arm lilly also present incrementally positive not groundbreaking datum drug abemaciclib form breast cancer death rate be broadly line pfizer ibrance diarrhea side effect be manageable lilly say abemaciclib belong class drug call cdk inhibitor compete novartis already approve kisqali lilly say continuous dose method treatment do more disrupt cancer cell cycle related do astrazeneca rival just launch potential blockbuster drug bristol incyte match beat dow merck combination trialshow clovis astrazeneca muddy potential deal tesaro
39,MRK,cancer treatment developer incyte incy be sharply immuno oncology drug prove effective matchup keytruda merck mrk opdivo bristol myer squibb bmy result incyte have relative strength rs rating upgrade friday ibd unique rs rating track market leadership used worst best score show stock price performance last week match other stock database year market history reveal stock go make biggest gain typically have rs rating least begin new run stock have retake day line be build consolidation entry see break heavy trade company bottom line growth fall last quarter revenue grow prior report incyte earn rank peer medical biom biotech industry group biospecific technology bstc supernus pharmaceutical supn therapeutic cort be top highly rate stock group related incyte team dow merck trounce roche cancerwhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
40,MRK,incyte incy stock enjoy fifth consecutive day gain friday immuno oncology drug epacadostat prove robust combination trial dow component merck mrk bristol myer squibb bmy merck keytruda bristol myer opdivo be test combination incyte epacadostat form cancer bristol myer matchup melanoma grab best response disease control rate milligram dose melanoma patient treat opdivo epacadostat combination see response rate disease control rate accord janney analyst debjit chattopadhyay merck top response rate be kidney cancer best disease control rate bladder cancer melanoma be well know be immuno oncology sensitive disease bristol opdivo yervoy be approve jointly treat form melanoma result be release ahead american society clinical oncology meeting next month chicago total merck test keytruda epacadostat type cancer vary dose ibd take keep tab ibd biotech pharma industry stock news page more american society clinical oncology pull new headline head neck cancer opdivo epacadostat achieve disease control rate merck keytruda epacadostat hit disease control rate patient have already undergo prior therapy patient already be treat time kidney cancer be clearly immuno oncology sensitive tumor type chattopadhyay write note client combination keytruda epacadostat have response disease control rate patient never be treat have prior therapy bladder cancer patient treat keytruda epacadostat respond treatment disease control patient number breast cancer be less robust response rate hit disease control rate bristol roche rhhby be also combine immuno oncology drug nektar therapeutic nktr drug know nktr drug be know cd bias agonist grow cancer kill immune system natural killer cell patient body chattopadhyay keep buy rating nektar stock note datum be still early bristol nektar be look opdivo nktr tumor type roche tecentriq be be combine nktr lung bladder cancer more datum be expect tesaro tsro combination merck conference june tesaro zejula be know parp inhibitor be be combine merck keytruda breast cancer win be first hint immuno oncology parp inhibitor pairing do chattopadhyay say beigene look similar combination patient match parp inhibitor know pd inhibitor decrease tumor burden patient least patient beigene bgne trial go remission partial response patient trial look patient ovarian uterine pancreatic cancer overall response rate be just shy need justify phase program view chattopadhyay say incyte stock close higher stock market today rise thursday bristol edge merck member dow jone industrial average inched related incyte team dow merck trounce roche cancermerck immuno oncology star tack new bladder cancer spotlight drug giant donnybrook cancer treatment
41,MRK,incyte incy stock pop month high thursday immuno oncology drug prove effective matchup merck mrk keytruda bristol myer squibb bmy opdivo remove small overhang incyte stock roche rhhby newlink genetic nlnk stock other hand topple combination prove less effective merck incyte close stock market today incyte stock end trading earlier rise high near day move average share dow component merck jump bristol stock sank team up feature incyte epacadostat be know ido inhibitor drug work block interaction ido enzyme immune system help immune system identify hiding cancer cell merck keytruda bristol opdivo be pd inhibitor work block interaction pd protein immune system cell pd protein hiding cancer cell do so help immune system see cancer cell be destroy couple immuno oncology drug vary target be thought be especially potent be first trial prove concept used ido inhibitor bristol yervoy be ctla inhibitor have be pair effectively opdivo melanoma patient trial merck keytruda incyte epacadostat achieve overall response rate patient regardless specific biomarker patient carry lot pd protein combination see overall response rate bristol myer datum release american society clinical oncology meeting june be nonevent most interesting efficacy datum be release actual conference leerink analyst seamus fernandez say ibd take immuno oncology market be worth just look know inhibitor head ibd technology page breakdown emerge sector preliminarily bristol opdivo incyte epacadostat achieve overall response rate milligram dose consistent early datum merck incyte combo suggest pd perform similarly combination epacadostat say conference bristol also plan unveil further datum combination opdivo yervoy advanced lung cancer further plan release initial datum array inhibitor still development share roche fall newlink stock plunge roche license newlink ido inhibitor combination drug tecentriq pd inhibitor datum be very immature leerink analyst michael schmidt write note client initially appear newlink ido inhibitor know gdc be less potent epacadostat tumor type combo achieve partial response patient related incyte shine oncology spotlight dow merck bristol astrazeneca have opportunity lung cancer treatment vs dow dow merck hang edge lung cancer treatment
42,MRK,eli lilly lly pfizer pfe novartis nvs be pit battle treat breast cancer wall street struggle thursday compare effectiveness drug lilly unveil new datum drug class call cdk work inhibit specific protein prevent proliferation cancer cell pfizer ibrance be first approve area novartis kisqali grab approval year lilly abemaciclib look promising phase trial lilly abemaciclib combine chemotherapy increase progression free survival median month vs month placebo chemo combo hazard ratio measure likelihood death be pfizer drug ibrance be combine chemo earlier trial combo have lower hazard ratio meaning be lower risk death only extend progression free survival median month vs month placebo combo compare boil wall street see better effectiveness metric evercore analyst umer raffat write report note trial study different population breast cancer patient make apple apple comparison tricky still diarrhea remain concern lilly abemaciclib patient experience diarrhea vs patient placebo chemo combination lilly advise patient begin diarrheal medicine first sign diarrhea ibd take want keep tab market american society clinical oncology meeting next month bookmark ibd biotech pharma industry stock news page result be present late wednesday ahead american society clinical oncology meeting june chicago other abstract upload wednesday include merck mrk bristol myer squibb bmy roche rhhby tesaro tsro regeneron regn sanofi sny incyte incy stock spiked month high thursday epacadostat prove effective combo merck keytruda bristol opdivo outdo roche tecentriq newlink genetic nlnk rival epacadostat wasn merck only note interest merck also offer pair update famous trial dub keynote have find keytruda be better chemo first treatment advanced lung cancer hazard ratio keytruda drop merck say be not statistically significant favorable trend have help recent fda approval evercore raffat say note merck keytruda bristol opdivo be know immuno oncology drug work block interaction pd protein immune system cell pd protein cancer cell help immune system identify cancer keynote trial merck also find lung cancer patient treat keytruda initial round see continue benefit keytruda second round cancer progressed cement role pd inhibitor first line treatment even further raffat say phase trial regeneron sanofi find pd drug know regn have benefit rate patient common form skin cancer drug have control rate be very encourage disease set leerink analyst geoffrey porge say american cancer society estimate patient be diagnosed die basal squamous cell skin cancer year longer term be potential regn treat patient advanced not necessarily fatal skin cancer patient enrolled regeneron sanofi trial show complete response month meaning discernible sign cancer disappear porge keep outperform rating regeneron stock be little note tesaro abstract ahead conference leerink analyst seamus fernandez say most interesting datum present next month be combination trial tesaro zejula merck keytruda breast ovarian cancer zejula compete vs astrazeneca azn clovis oncology clvs class drug call parp inhibitor work block specific enzyme treat ovarian cancer parp inhibitor be currently be investigate breast cancer well combine parp inhibitor immuno oncology drug merck keytruda be thought be more potent treat cancer tesaro be also look zejula pd keytruda advanced lung cancer company be slate present datum dozen patient treat zejula keytruda fernandez note bar be fairly low outperform alone pd inhibitor have response rate group patient parp inhibitor have mid response rate recently publish datum small trial astrazeneca imfinzi pd inhibitor lynparza parp inhibitor show somewhat disappointing response rate ovarian cancer patient tesaro believe combination pd antibody zejula be superior fernandez say related incyte team dow merck trounce roche cancerdid astrazeneca rival just launch potential blockbuster drug
43,MRK,expert opinion indicate astrazeneca azn have sizable market opportunity treat advanced lung cancer include potential label use patient earlier stage disease analyst say suggestion follow strong result astrazeneca drug imfinzi stage lung cancer patient announce friday patient have already undergo chemotherapy radiation weren eligible surgery imfinzi cut risk death advancement cancer market win just be limit subset patient leerink analyst seamus fernandez say note client cite comment receive unidentified expert be label use patient lung cancer tumor be remove surgery be undergo chemo radiation cure cancer overall expert view top line result positive surprise expect broad uptake eligible patient assume progression free survival benefit see full datum presentation be clinically meaningful fernandez write research report astrazeneca be set unveil full result trial upcoming medical conference strong top line result follow food drug administration approval merck mrk keytruda chemotherapy lung cancer merck member dow jone industrial average compete most directly bristol myer squibb bmy earlier last week roche rhhby tecentriq fail late stage bladder cancer trial ibd take need help tracking biotech drug make market head ibd biotech pharma industry stock news page patient lung cancer be remove surgery have already undergo chemo radiation be likely have longer treatment duration metastatic lung cancer fernandez say metastatic cancer spread blood lymph system believe bode well imfinzi opportunity currently untapped small cell lung cancer set represent true market expansion astrazeneca well overall immuno oncology space write stock market today astrazeneca stock be hit high last achieve september share rise friday rush past buy point cup handle formation related astrazeneca share jump cancer trial rival dow dow merck hang edge lung cancer treatment roche cancer failure tank bristol pfizer not merck
44,MRK,here weekly investing action plan need know investor come week apple aapl hold annual worldwide developer conference management typically unveil have already be leak tech medium blogosphere still be surprise loom gadget chatter well
45,MRK,here be investment idea seek capture dow jone industrial average performance index reach new high spdr dow jone industrial average etf trust dium have good day rise just flat base buy point closest be entry kick base month fund advanced clear prior flat base february start current pattern
46,MRK,dium have be trading high underlie blue chip index close new record best thursday unitedhealth group unh lead dow industrial gain mark new high american express axp goldman sachs gs add respectively fidelity dividend etf rise rate fdrr be draw buy point flat base begin form month breaking prior base young fund launch september have attract asset correspond same name index track mid large cap dividend pay company be expect keep pay increase payout have positive correlation return increase year treasury yield accord fidelity com etf prove be timely bet give federal reserve be poise notch interest rate fdrr top holding read dow stock include apple aapl microsoft msft johnson johnson jnj merck mrk jpmorgan jpm fund pay annualize dividend yield ahead average return etf pick featured thursday break new high vanguard total stock market vti gain clear flat base buy point remain buy zone meantime ishare edge msci usa quality factor qual rise stage heavy volume past flat base buy point share be still buy range entry related apple watch big etfs potential etfs watch hold buffett dividend stockswhich etfs watch own nvidia top hold
47,MRK,incyte incy immuno oncology partnership dow component merck mrk bristol myer squibb bmy grab spotlight american association clinical oncology meeting next month chicago analyst say monday leerink analyst michael schmidt say incyte epacadostat cancer treatment be face battle used combination merck keytruda bristol opdivo epacadostat be know ido inhibitor block interaction immune system tumor cell keytruda opdivo be know pd inhibitor block different interaction help immune system see cancer bristol myer have already show combine opdivo yervoy ctla inhibitor be potent treat melanoma physician generally expect add incyte epacadostat merck keytruda bristol opdivo offer improvement drug therapy general view have be meeting exceed ctla pd synergy represent very high bar immuno oncology combination development schmidt write note client merck member dow jone industrial average team incyte number tumor trial conference merck incyte present datum combination trial test treat cancer lung breast kidney bladder head neck well solid tumor bristol be set unveil result trial opdivo epacadostat advanced solid tumor april incyte bristol announce advance epacadostat opdivo several registration trial include lung cancer head neck cancer ibd take immuno oncology market be worth analyst tell investor business daily still expand visit ibd technology page breakdown be compete race schmidt estimate epacadostat be worth incyte stock price stock market today incyte stock rise bristol stock lift merck stock sank think downside be plausible epacadostat datum disappoint investor write conversely see upside datum surprise upside follow recent pullback have price target incyte stock base bullish outlook epacadostat be also be test drug astrazeneca azn roche rhhby assume peak epacadostat sale related be bristol prep outdo immuno oncology bristol afford lose dow stock merck immuno bristol prove longtime theory cancer defense
48,MRK,astrazeneca azn have real seat immuno oncology table analyst say friday company key drug imfinzi cut risk death lung cancer prod share month high late stage trial imfinzi reduce risk disease worsening death stage lung cancer patient have already undergo chemotherapy radiation stage lung cancer be estimate have affected patient japan germany france uk spain italy represent third case small cell lung cancer astrazeneca say full result be present future medical meeting company add stock market today astrazeneca soar blast past buy point cup handle begin form august year therapy stage market unique indication develop world clearly have blockbuster potential leerink analyst seamus fernandez write note client have outperform rating astrazeneca stock development provide astrazeneca imfinzi unique impactful seat immuno oncology table expand market rather pit astrazeneca other establish competitor fernandez write announcement come day dow component merck mrk immuno oncology star keytruda be grant accelerate approval treat advanced lung cancer combination chemotherapy roche rhhby tecentriq fail bladder cancer trial share rival merck fall bristol myer squibb bmy stock dip roche stock other hand lift be astrazeneca closest immuno oncology rival ibd take need direction biotech drug world head ibd biotech pharma industry stock news latest merck keytruda bristol opdivo be pd antibody astrazeneca imfinzi be know pd antibody work target interaction immune system cell tumor cell help immune system spot hide cancer company estimate have year lead competitor ongoing immuno oncology trial like merck bristol roche be look neoadjuvant treatment trial single arm safety trial neoadjuvant treatment be therapy give chemotherapy radiation hormone therapy shrink tumor single arm safety trial examine safety drug just group patient astrazeneca be also look imfinzi first line monotherapy combination fellow immuno oncology drug tremelimumab advanced lung cancer first line treatment be first line defense typically be chemotherapy radiation related dow merck hang edge lung cancer treatment roche cancer failure tank bristol pfizer not merck
49,MRK,stock market open note early wednesday overnight positive manufacturing datum china however gain be quickly pare major index turn red chicago pmi hit lowest level january nasdaq lag loss dow jone industrial average fall dow industrial medical component pfizer pfe merck mrk johnson johnson jnj find head pack pfizer gain merck jnj follow gain early trading blue chip laggard be financial component goldman sachs gs jpmorgan jpm fall respectively analog device adi surge big earning beat chipmaker handily exceed sale earning target provide optimistic outlook current quarter stock break cup base buy point tuesday downside energy name find bottom performer second straight day oil price plunge again crude drop transocean rig drop chesapeake energy chk fall retail stock be show mixed action stock market today michael kor kor fall year low fiscal earning release result weak same store sale gloomy outlook quarterly earning have decline consecutive quarters capped decline quarter report retailer plan close store next year woman apparel retailer jill jill shot almost top bottom line beat lead retailer ollie bargain outlet olli report earning close today stock be well extend flat base buy point action ibd be predominantly negative general market reversed lower open downside chemour cc drop almost fiberoptic stock lumentum lite moved almost stamp com stmp fall hard second straight day last week share be almost upside control ctrl rise new oriental education edu moved initial datum release suggest chicago region manufacturing fall sharply send kingsbury international chicago purchasing manager index read be well april tally well economist projection downtick release be later correct show chicago pmi well expectation related michael kor dife outlook shut store jill soarsanalog device jump big earning beat raise outlookdow jone industrial average dow stock news analysis
50,MRK,stock index chalk early loss thursday morning fewer expect first time jobless claim nasdaq fall dow jone industrial average lose respectively small cap russell slide volume stock market today be higher nyse lower nasdaq blue chip loser lead gainer roughly ratio biggest percentage loser dow be microsoft msft fall busy volume offer weak guidance profit margin biggest gainer be merck mrk gap retake day line fda approve merck drug keytruda use lung cancer treatment apple aapl slow second straight session solid day row apple be trading well day line relative strength line be high relative strength line measure stock price performance vs apple stock be year date be small cap stumble logged sizable gain nasdaq thinly trade cavco industry cvco pop small cap company make manufacture home staffing provider kelly service kelya thinly trade small cap break strong volume stock sprang higher clear buy point kelly report quarterly earning be higher expect economic news initial jobless claim come be lower expect related retailer deliver weak resultsbitauto skid rival charge ahead
51,MRK,ask wall street analyst name possible catalyst rise big cap technology stock apple aapl cisco system csco top most list be trump administration plan allow company bring foreign profit reduce tax rate analyst say cash bring back be piggy bank company stock repurchase acquisition problem be president trump economic agenda have be stall white house drama propose change repatriate cash be part bigger trump tax reform package randall stephenson ceo say tax reform make congress lot person be get pessimistic lot noise washington right now tax reform not be achieve stephenson say jpmorgan tech conference be still optimistic something still get do bundle tax reform infrastructure bill be big think achievable even so worry be overseas tax holiday tech firm not turn bonanza make be depend legislation put condition money be spend create enforcement mechanism rather see money go company stock buyback acquisition trump congress steer money job creation capital spending say ub analyst trump administration want really drive inward investment have be sort mandate use cash maybe spend capital expenditure yet do not know ub analyst geoff robinson say report reason think robinson be right track trillion dollar offshore want get back america gary cohn trump chief economic advisor say recent interview want company bring money back put back economy want create job cash rich tech company apple microsoft msft google parent alphabet googl cisco currently pay tax so call repatriate earning rather take tax hit ve keep money overseas president trump have propose time tax offshore earning republican controlled house have propose lower rate overseas tax break congress pass be call american job creation act didn do much stimulate economy analyst say ajca taxed repatriate earning rate top firm bring back cash be drug company pfizer pfe merck mrk well hewlett packard johnson johnson jnj ibm ibm accord ir be bring back however only company eligible bring back cash do so say richard lane analyst moody investor service many company keep cash overseas ajca requirement say ajca require company reinvest tax saving worker hire training infrastructure research development capital project accord ub however fund repatriation have be earmark capital investment ultimately be spend large part share repurchase ub say happened ajca do not include tracking mechanism so government audit company gauge compliance trump administration put better enforcement mechanism place company have more overseas cash be need continue funding foreign operation company currently most overseas cash be apple microsoft cisco google oracle orcl moody say cisco have state cash bring back be used reduce debt book analyst have other idea tax holiday be approve bmo capital market say report expect cisco hewlett packard enterprise hpe focus more acquisition apple smaller company likely lean more capital return case apple cisco analyst envision enough cash be bring back fund deal apple have cash grow year apple cash be overseas time repatriation tax give apple acquisition buyback citigroup analyst jim suva say report suva speculate apple buy large company such netflix nflx walt disney electronic art ea cisco meanwhile bring back cash overseas analyst say report credit suisse speculate enterprise software provider servicenow now splunk splk computer security firm palo alto network panw be cisco shopping list pacific crest security add red hat rht nutanix ntnx list possible cisco target intel intc be semiconductor company cash hoard overseas intel bring back say bmo capital market nvidia nvda qualcomm qcom also have significant overseas cash bmo capital do not expect trump tax holiday spur acquisition spree chipmaker
52,MRK,dow component merck mrk now have year lead rival treat advanced lung cancer analyst say thursday fda approve drug giant keytruda chemo combo late wednesday fda have grant accelerate approval keytruda eli lilly lly chemotherapy alimta carboplatin chemo drug combination be approve patient regardless tumor have lot be know pd protein exist cancer cell keytruda work block interaction pd protein surface cancer cell pd protein immune system cell do so help immune system identify camouflage cancer ub analyst marc goodman see merck have year lead lung cancer like bristol myer squibb bmy astrazeneca azn roche rhhby other combo therapy like bristol myer astrazeneca be horizon have buy rating price target merck stock merck accelerate approval keytruda chemotherapy be contingent study confirm strength treatment result confirmatory study dub keynote be expect september however believe accelerate approval be tacit admission agency take early peek study interim datum be compelling leerink analyst seamus fernandez say note have market perform rating merck stock stock market today share merck component dow jone industrial average rise earlier rise much share bristol be unchanged astrazeneca roche edge ibd take immuno oncology market be far mature keep tab ibd biotech pharma industry stock news page latest emerge sector credit suisse analyst vamil divan expect approval expand keytruda market patient keytruda be also approve first treatment follow chemo treat lung cancer patient tumor have lot pd protein study have show patient tumor have lot pd protein respond better type therapy offer keytruda well bristol opdivo study present october keytruda chemo improve overall survival rate patient regardless pd status adam schechter executive vice president president merck global human health unit expect physician think keytruda chemo combination differently younger patient vs older patient addition believe ve study drug alimta early adoption probably used physician use alimta say merck first quarter earning conference call not pent demand say look build new patient come market think really be exciting opportunity lung cancer patient also establish keytruda further real prefer treatment therapy keytruda approval chemo regardless pd status doesn bode well bristol be struggle increase competition lung cancer bristol opdivo be approve second line treatment meaning only prescribe patient have undergo round chemo bristol be look opdivo yervoy advanced lung cancer yervoy target ctla interaction immune cell cancer cell astrazeneca mystic study be look imfinzi pd antibody tremelimumab ctla antibody lung cancer datum readout change investor sentiment year ub goodman write note assume first line lung cancer sale keytruda respectively first line mean keytruda be prescribe chemo related roche cancer failure tank bristol pfizer not merckbristol myer too risky acquire merck roche pile pressuredid gilead just provide incyte potential deal
53,MRK,stock open lower thursday positive economic news continue surge oil price dow jone industrial average fall nasdaq drop dow head thursday session tote loss so far week nasdaq be hold narrow gain be trading less march high dow merck mrk rise open kenilworth base drugmaker announce late wednesday food drug administration have approve keytruda part chemotherapy regimen treat certain form lung cancer merck share climb back week move average continue build right side month base pattern other blue chip caterpillar cat climb more bank america upgrade stock buy neutral raise price target earning action whole food market wfm exone xone post early gain report result ctrip com international ctrp symantec symc stock push new high wednesday fall hard premarket trade report snap snap take headline diving more report more severe loss expect first quarterly report public company late wednesday thursday low stock come back almost ipo price share china base netease nte jump gain earning gain rise revenue squarely beat analyst estimate ibd stock climb week move average work right side base macy shed open broad first quarter miss straight path communication strp skid open confirm have accept takeover bid verizon vz share deal end bidding war verizon have drive straight path share year wednesday verizon be flat thursday open price paid producer rise april labor department estimate decline march move much bigger gain expect economist core price food energy rise compare change read march vs consensus expectation gain first time unemployment claim ease slightly week end prior week tally be claim economist have project increase new claim oil price continue bounce begin wednesday spur datum show sharp reduction weekly stockpile west texas intermediate pulse higher early thursday climb just barrel so far week gold edge ounce dollar ease bond climb trimming year yield basis point new york federal reserve bank president william dudley speaking group india bombay stock exchange et detailed view protectionist trade policy provide short term benefit have broad negative impact longer term economy protectionism have appeal dudley be report say reuter longer term almost certainly be destructive economy overall market be tightly mixed europe bank england vote hold key interest rate record low cite datum show economy slow growth first quarter cac paris frankfurt dax drop ftse london manage narrow gain related forget snap watch unicorn investing action plansnap be lose facebook clone war dow drug stock near buy
54,MRK,stock future be little change early thursday morning same be say snap snap plunge revenue user growth fall short much larger facebook fb clone upstart social network most popular feature meanwhile merck mrk member dow jone industrial average rally new immunotherapy blockbuster keytruda future dow industrial index nasdaq edge lower wednesday regular session nasdaq composite index rise slightly dow dip boee ba walt disney snap share plunge hour trading be post ipo trading low not far actual ipo price snapchat revenue surge be view average revenue user fall vs fourth quarter perhaps most worry user growth be sluggish miss forecast ibd take snap never hit proper buy point wednesday night tumble snap begin trading ibd caution investor play snap ipos generally facebook have be ramp instagram story ape popular snapchat story snapchat have user instagram story have top short order facebook other property include whatsapp main site also be adopt key snapchat feature effort only gain momentum current second quarter snapchat core lucrative audience north american teen young adult be secure facebook be able keep snap niche facebook share rise fractionally late trading close recent record high meanwhile merck shot hour action merck appear set open close potential buy point regular session merck rise retake day line late wednesday fda approve keytruda treat metastatic nonsquamous small cell lung cancer pair chemotherapy keytruda already be market several other indication include bladder cancer likely keytruda be get big lead other drug notably opdivo bristol myer squibb bmy opdivo be market bristol myer key drug have have several clinical setback treat additional cancer condition japan nikkei rise intraday thursday china shanghai composite fall related snap stock plunge big first quarter revenue net income missforget snap bust watch tech unicorn investing action planwhy roche cancer failure tank bristol pfizer not merckdow stock boee halt max test delivery plan still track
55,MRK,failure roche rhhby tecentriq late stage trial bladder cancer drug bode badly not only company several rival appear merck mrk come ahead analyst suggest wednesday early wednesday roche say immuno oncology drug tecentriq fail improve overall survival vs chemotherapy phase trial bladder cancer patient have already receive chemotherapy later day however merck keytruda win key approval be not bladder cancer close food drug administration give nod keytruda treat be know metastatic nonsquamous small cell lung cancer conjunction chemotherapy share merck jump hour trading regular session merck gain tecentriq approval treatment bladder cancer be risk write evercore analyst umer raffat note client merck keytruda simply be better drug other rival keytruda be expect gain full approval bladder cancer base trial top chemo improve patient overall survival rate last year trial keytruda improve progression free survival lung cancer patient median month vs month chemo similar trial bristol myer bmy opdivo improve progression free survival median month vs month chemo now have second cancer indication merck keytruda work competitor pd pd didn say be datum point make pause second tecentriq accelerate approval bladder cancer be contingent phase result fda warn drug fail withdraw approval drug roche rival pfizer pfe bavencio bristol opdivo merck keytruda class drug block interaction pd protein immune system cell pd protein surface cancer cell help immune system identify cancer tecentriq have slightly different mechanism work target pd protein cancer cell tecentriq bavencio opdivo have accelerate approval second line bladder cancer evercore raffat question tecentriq result demonstrate broader problem immuno oncology drug bladder cancer be broader risk immuno oncology monotherapy indication ask note bristol myer have slightly higher overall response rate indication pfizer roche ibd take immuno oncology market be worth just take account protein enzyme target already identify analyst say visit ibd technology page deep dive industry stock market today roche stock end trading nearly share hit buy point april cup handle begin form last june bristol myer stock sank fraction then lose hour pfizer be fractionally regular session hour tecentriq failure bladder cancer put leerink analyst seamus fernandez model risk previously fernandez modeled peak worldwide bladder cancer sale pd pd immuno oncology drug expect tecentriq take market keytruda seize follow opdivo astrazeneca azn imfinzi pd antibody pfizer bavencio also gain modest share well say related bristol myer too risky acquire merck roche pile pressurebristol myer beat gilead merck key approval china europedid gilead just provide incyte potential deal
56,MRK,wall street forgive tesaro tsro wider expect first quarter loss wednesday drugmaker stock pop news prescription be written ovarian cancer drug zejula month follow approval stock market today tesaro share be still tesaro stock have trade well day move average march share crash strong trial result competitor astrazeneca azn first quarter tesaro report tuesday adjust loss share lag consensus share loss widening loss last year total sale come vs year earlier period product revenue come year earlier quarter janney analyst debjit chattopadhyay warn investor get popcorn ready rivalry be start mount ovarian cancer world tesaro zejula be approve march treatment chemotherapy put ovarian cancer patient partial complete remission treatment follow initial round chemo be refer second line treatment astrazeneca lynparza clovis rubraca be only approve patient ve already undergo more round chemotherapy be know third line treatment zejula label be much broader lynparza rubraca drug be prescribe patient regardless have mutate brca gene have be link ovarian breast cancer rival competition second line maintenance segment heat chattopadhyay predict research note estimate total addressable market be patient ibd take tesaro stock end top perform biotech seventh best performer stock start year have minimum average daily trading volume share pattern continue head ibd industry theme closer look astrazeneca lynparza grab accelerate approval contingent ongoing clinical trial ovarian cancer patient brca mutation more prior round chemotherapy lynparza get approval third quarter maintenance treatment further clovis oncology clvs be likely have datum trial dub ariel second quarter ariel be look clovis drug rubraca maintenance treatment certain ovarian cancer patient mutate brca gene other biomarker rubraca number look similar zejula then safety tolerability come play chattopadhyay write maintain price target neutral rating tesaro stock leerink analyst seamus fernandez have market perform rating price target tesaro stock look drug class call parp inhibitor team immuno oncology trial parp inhibitor zejula lynparza rubraca work inhibit certain enzyme treat ovarian cancer be also be look breast lung cancer immuno oncology drug merck mrk bristol myer squibb bmy roche rhhby immune system see tumor cell related roche cancer failure tank bristol pfizer not clovis still quash astrazeneca tesaro ovarian cancertesaro trip astrazeneca ovarian cancer trial clovis climb
57,MRK,regeneron pharmaceutical regn gilead science gild biogen biib benefit most biotechs president trump propose tax reform measure cut corporate tax rate trump proposal business size fortune mom pop shop freelancer live job job pay more business income taxe make corporate inversion unnecessary corporate tax rate be currently mean regeneron gilead biogen have guide adjust tax rate see serious boost cash trump proposal pass analyst say compromise beltway so rate be still air trump approval rating jump april gain ibd tipp presidential leadership index unveil tax reform proposal be first month month increase trump become president doesn mean big pharma biotech be totally sell trump proposal page document release april share biotechs drugmaker collectively lift less day generic drug stock pop gilead chief executive john milligan note uncertainty washington be norm so think ve kind learn filter focus thing be right company say gilead first quarter earning conference call be tax reform be repatriation count trump plan slash corporate tax rate benefit company consolidated tax rate remain well level consolidate taxe allow firm treat group wholly majority own company single entity tax purpose domicile drugmaker typically pay consolidated taxe canaccord analyst dewey steadman tell investor business daily company acquire foreign firm move tax domicile outside acquire company often lower tax homeland mylan myl acquire generic manufacturer abbott laboratory keep operational headquarters pennsylvania reincorporate netherlands march mylan say expect pay tax rate similarly allergan agn guide february adjust tax rate allergan corporate headquarters be ireland april pfizer pfe scrap attempt acquire allergan day treasury unveil new rule curb inversion former president barack obama call global tax avoidance huge problem urge congress close loophole good trump other hand say tax reform proposal make inversion unnecessary make america tax rate best world regeneron gilead biogen be biggest winner cut evercore analyst umer raffat say april report regeneron have guide effective tax rate gilead see first quarter biogen paid adjust taxe drugmaker pfizer eli lilly lly merck mrk bristol myer squibb bmy guide effective tax rate canaccord steadman mizuho analyst salim sy tell ibd everything politic be subject negotiation smaller biotechs say obviously positive future everyone be take see approach steadman say rate be probably go happen re not change capital expenditure organizational structure meantime ibd take look latest biotech drug news be sure bookmark ibd biotech pharma industry stock news page second facet trump plan allow time repatriation corporate cash park overseas discount tax rate be follow end deferral taxe corporate income earn abroad evercore raffat say amgen amgn benefit most drugmaker provision amgen have cash stash overseas money amgen use help boost war chest generic rivalry battle regeneron sanofi sny cholesterol front same be say gilead overseas cash be face dwindle sale hepatitis drug franchise gilead have be pressure month analyst chatter buy something bolster sale incyte incy be likely candidate analyst say accord raffat merck pfizer have respective cash outside lilly bristol celgene celg biogen abbvie abbv have park overseas cash be repatriate research development used fuel pfizer chief executive ian read offer similar view gilead milligan company first quarter earning conference call expect industry consolidation continue time political atmosphere remain major deterrent believe be simply too much redundancy fragmentation globally sector continually efficiently deliver medicine society say however be lack clarity potential tax reform health care policy uncertainty european market canaccord steadman doesn expect wave even trump tax reform pass muster congress need attempt pfizer allergan merger inversion purpose say appetite biotechs look healthy see decline big inversion type merger be not necessarily strategic see appetite biotech asset just tax picture look better say net result be actually decrease large merger maybe increase valuation biotech don think drife much more much still murky trump tax proposal analyst say general theme be tax reform be good thing biotech mizuho sy tell ibd don exactly know tax reform be go be be still lot piece move repatriation border tax don have component border tax be extreme drawback company manufacturing less expensive country such adjustment exempt export taxation tax import pwc analyst doug strang kathy michael write feb report january speech chamber commerce house way mean committee chairman kevin brady say tax eliminate tax incentive company move manufacturing overseas couple new lower gop tax rate local business end double taxation earning overseas establish america st century magnet new job technology breakthrough headquarters say gop tax plan be already drive company ask soon bring supplier back most company relocate operation back be paperwork nightmare canaccord steadman say current plan doesn include border tax provision nothing incentivize company bring operation back be enough keep newer smaller company re domicile overseas say probably entice future company not leave think core goal re try do say be domicile lower rate wouldn have leave cash foreign subsidiary cash be base encourage investment related do gilead just provide incyte potential deal dow pfizer top earning view sale come lilly new drug spark deeper rivalry pfizer novartis
58,MRK,gilead science gild tuesday hint be prep make acquisition oncology report sale hepatitis drug franchise topple second straight quarter late tuesday quarterly conference call chief executive john milligan say firm be assess number different opportunity play come year include partnership acquisition think pretty clear re look avenue increase opportunity revenue say clear have be focuse oncology question be area use resource accelerate product market build meaningful franchise oncology wall street speculation have build last several month gilead be consider deal buy incyte incy small biotech promising immuno oncology drug clinical trial drug bristol myer squibb bmy merck mrk other incyte stock have climb year rumor credit suisse analyst alethia young see company become acquisitive term ibd take ibd biom biotech industry group be comprise company have trouble keep stock news bookmark ibd biotech pharma industry stock news page investor focus remain company do deal sound company be get mobilize putt piece place execute deal write research report young keep outperform rating price target gilead stock needham analyst alan carr say deal have potential be keep hold rating gilead stock note share be attractive hepatitis drug sale stabilize first quarter unit see revenue plunge year fewer patient be start drug hiv business seem strong leerink analyst geoffrey porge say note client gilead be successfully transition patient tenofovir alafenamide taf tenofovir disoproxil fumarate tdf drug older tdf drug be lower price expose generic carr note gilead patient be now taf base treatment hiv stock market today gilead stock lose earlier touch week low related gilead topple consensus lag hepatitis drug sale plummetdow pfizer top earning view sale come gilead be pay price actually cure disease
59,MRK,bristol myer squibb bmy immuno oncology drug opdivo billed rival merck mrk grow first quarter help drugmaker smash wall street sale profit expectation stock market today bristol stock pop retake day move average first quarter end march bristol report adjust income cent share revenue grow respectively vs year earlier period analyst have modeled cent chief executive giovanni caforio praise bristol work immuno oncology fibrosis build strong start year continue drive commercial performance short term advance important opportunity broaden approach immuno oncology progress early specialty portfolio say statement ibd take need direction biotech pharma investing head ibd biotech pharma industry stock news latest sector quarter opdivo sale grow sale sale fellow immuno oncology drug yervoy grow meanwhile sale anticoagulant eliquis chemotherapy sprycel grow respective be very encourage strong performance bristol myer core asset opdivo yervoy eliquis beating sale estimate quarter leerink analyst seamus fernandez say note client fernandez keep outperform rating bristol myer stock bristol bump adjust profit guidance share up sale view growth mid single digit earlier guidance low single digit growth year year basis adjust earning share grow midpoint guidance related be bristol myer prep outdo immuno oncology bristol myer hold better dow merck still gouge bristol drug help biogen take abbvie alzheimer
60,MRK,merck mrk tuesday report better expect result first quarter raise outlook share dip light sale cancer drug keytruda diabetes medicine januvia company member dow jone industrial average disclose adjust income cent share revenue respectively analyst have expect drugmaker report earning cent share sale merck now see adjust income share previous range share company forecast also call revenue previous range analyst view call adjust income share sale merck stock close stock market today ibd take follow slurry biotech pharma first quarter report visit ibd biotech pharma industry stock news page wall street be likely look strong sale immuno oncology drug keytruda rival bristol myer squibb bmy opdivo keytruda grow merck say lag leerink analyst seamus fernandez view bristol opdivo sale grow year year first quarter sale januvia diabetes drug fall year year miss fernandez model be offset outperformance human papillomavirus drug gardasil hepatitis drug zepatier beat estimate meanwhile rival dow drug stock pfizer pfe report better expect first quarter earning pfizer sale fall short related bristol myer beat gilead merck key approval china dow stock merck undercut astrazeneca lung cancer
61,MRK,stock index chip weekly loss early friday blue chip rise more nasdaq pop also tack blue chip dow jone industrial average add small cap russell advanced volume stock market today be run higher nyse lower nasdaq dow component construction mining equipment maker caterpillar cat rise almost discount retailer wal mart store wmt almost stock market struggle week caterpillar wal mart be track weekly gain additional stock dow be head weekly gain be fast food chain mcdonald mcd tech service giant ibm ibm drugmaker merck mrk health care product provider johnson johnson jnj soft drink maker coca cola ko nasdaq starbucks sbux surge heavy volume climb higher buy zone stock clear buy point april be now entry starbucks have be move sideway hit high october week coffee chain be head gain ibd industry group early gainer friday include farm machinery construction mining machinery oil stock morning big loser be retail apparel economic news day be thin et baker hughe rig count be release price light sweet crude have rise past week related top dog big threat consumer crush fiscal expectation
62,MRK,bristol myer squibb bmy be too risky acquire merck mrk roche rhhby pile pressure immuno oncology medication analyst argue wednesday downgrade bristol stock underperform rating stock market today bristol stock be bmo analyst alex arfaei attribute recent move bristol stock january takeover speculation pfizer pfe oft cite potential suitor bristol seem unlikely make deal term arfaei say tuesday pfizer first quarter earning call chief executive ian read cite macro issue make acquisition difficult pfizer have be expect continue be active industry consolidator say however be lack clarity potential tax reform health care policy uncertainty european market french election uk snap election arfaei call increase uncertainty bristol immuno oncology franchise year merck immuno oncology drug keytruda likely get food drug administration approval combination chemotherapy treat advanced lung cancer also later month merck be likely unveil strong datum keytruda incyte incy epacadostat number tumor don expect significant new datum bristol american society clinical oncology meeting conference likely strengthen argument immuno oncology market become increasingly fragmented write note client ibd take bristol merck be lead immuno oncology market day sun be come end number company be step immuno oncology research offering head ibd technology page look rival come year latter half arfaei see roche immuno oncology drug tecentriq pressure bristol advanced lung cancer also expect payer use datum bristol limit use immuno oncology drug opdivo yervoy melanoma immuno oncology battle have pit bristol merck most directly opdivo keytruda be know pd antibody work block interaction immune system cell cancer cell hiding pd protein help body identify cancer bristol have have win immuno oncology world recently last week european regulator approve opdivo second line treatment squamous cell head neck cancer platinum base therapy company beat merck approval still arfaei say bristol be too reliant immuno oncology drug estimate comprise sale profit overall argue even see positive resolution macro factor give bristol overdependence immuno oncology franchise expectation increase uncertainty potential takeout seem unlikely be simply too risky arfaei write related do gilead just provide incyte potential deal bristol myer beat gilead merck key approval china europedow merck top view raise outlook key drug lag
63,MRK,major stock index strengthen late afternoon trading thursday sharp loss wednesday higher volume put market uptrend pressure outperformer dow jone industrial average include wal mart wmt share rise wall street seem focus jump commerce sale dow component cisco system csco meanwhile plunge report earning issue tepid guidance nasdaq rise help strength chip stock nvidia nvda skywork swks analog device adi show gain more dow add volume nyse be tracking higher wednesday level nasdaq volume be bit lower year treasury fall basis point plunge basis point wednesday odd interest rate hike fed june meeting have be fading recent day stock market today share facebook fb rally unfazed news be fine european union mislead statement acquisition messaging service whatsapp alibaba baba reversed higher rise fall much intraday investor initially focuse earning miss other metric look good include rise sale company also announce share buyback elsewhere leaderboard name trade desk ttd re-cover nicely wednesday rout share jump extend buy point biotechs be move headline flow asco cancer conference chicago incyte incy soar news immuno oncology drug prove effective merck mrk keytruda treat patient advanced lung cancer incyte impressive move thursday still day move average potential resistance level watch other big gainer biotech group include regeneron regn share rise early stage clear cup shape base buy point related incyte team dow merck trounce roche canceralibaba earning miss revenue soar share falter nvidia stock price target hike macom rate buy
64,MRK,dow component pfizer pfe tuesday report mixed first quarter result call essential health unit tug overall sale revenue novartis nvs rivale cancer drug bound vs year earlier quarter pfizer say earn adjust income cent share revenue first quarter respectively analyst have expect drugmaker report earning cent share sale quarter pfizer innovative health unit include newer product grow essential health business include legacy product offset fall september pfizer scrap idea corporate breakup have split business wall street have pin hope pfizer ibrance be approve treat form advanced breast cancer ibrance sale grow period have competition novartis kisqali further eli lilly lly abemaciclib have show promise clinical trial sale pneumonia vaccine prevnar topple vs year earlier quarter dip be primarily due continue decline revenue adult indication due smaller remain catch opportunity pfizer say globally sale fall timing government purchase enbrel also see sale dip outside canada enbrel sale come develop europe enbrel sale fall revenue also topple emerge market other develop part globe respectively ibd take have trouble keep slew pharma biotech earning quarter catch ibd biotech pharma industry stock news page pfizer also reiterate guidance revenue adjust earning share flat respectively analyst be call revenue adjust income share stock market today share member dow jone industrial average dip earlier fall much touch lowest point month stock have potential buy point cup handle begin form august meanwhile fellow dow drug giant merck mrk also issue first quarter earning report merck top earning sale raise full year guidance gilead science gild major biotech player report weaker expect earning sale late tuesday related lilly new drug spark deeper rivalry novartis pfizerpfizer follow baxter get slam subpoena related saline shortage
65,MRK,stock market be mixed midday trade federal reserve day interest rate meeting kick fed be expect leave rate unchanged dow jone industrial average lead way gain aid apple aapl move upside ahead iphone maker earning release close nasdaq be barely break even mark volume rise major exchange other dow industrial intel pace advancer rise fellow chip company amd amd plummet almost miss sale estimate amd loss be intel gain visa follow gain move coincide fellow credit card company mastercard report better expect profit revenue early tuesday share mastercard jump more record high earning reporter dow drug stock pfizer pfe merck mrk report result early tuesday pfizer drop company exceed earning target fall short revenue estimate share merck moved company surpass top bottom line estimate automaker sell stock market today ford motor general motor gm fiat chrysler fcau report expect april auto sale ford stock drop gm fall fiat decline electric automaker tesla tsla only moved share remain just time high report earning wednesday bell stock breaking today cummin cmi gap flat base entry report better expect earning sale martin marietta material mlm be approach cup shape base buy point own bullish report share rise lead growth stock be mixed tuesday morning trade upside cognex cgnx jump cautious revenue guidance china commerce giant alibaba baba moved downside nvidia nvda fall conjunction amd decline share nvidia have rebound valiantly last week reclaim day line related pfizer earning top sale come shortdow merck top view raise outlook key drug lagsapple earning preview expectwhere be stock market head read more big picture
66,MRK,stock open slightly higher quickly turn mixed weak auto sale ahead late day apple aapl earning dow jone industrial average edge higher edge lower nasdaq composite fall tuesday economic calendar be largely quiet federal open market committee begin day session washington big event radar be apple fiscal second quarter earning release schedule today close bell apple share trade open onslaught mixed big name earning release have mixed effect premarket action drug giant merck mrk rise fraction pfizer pfe fall quarterly result big oil be motion bp bp conocophillip cop quarterly release drugstore pharmacy benefit giant cvs health cvs slide first quarter result top view pharmacy same store sale decline tenet healthcare thc spiked first quarter result announce sell houston area hospital hca holding hca hca share rise mastercard climb first quarter result comfortably clear analyst estimate stock be extend rebound support week move average diesel engine maker cummin cmi throttle top analyst expectation second straight quarter accelerate earning growth first revenue gain quarters management also raise full year revenue guidance consensus target stock break flat base buy point advanced micro device amd plunge report first quarter result late monday chipmaker narrow loss line expectation revenue rise just shy view macquarie downgrade stock underperform neutral amd be already meeting resistance day line tuesday rout angie list angi spiked enter deal be acquire internet content operator iac interactive iac deal value company nearly iac combine angie list homeadvisor site name angi homeservice iac share rise iac share be extend buy point flat base oil price narrow early gain west texas intermediate less higher back barrel gold turn negative ounce dollar be mixed vs euro yen bond sag lift year yield basis point overseas tokyo nikkei logged gain last day trading holiday week europe market reopen positive mood day holiday london ftse lead major benchmark gain ground afternoon trade related stock future big cap earning be due tuesday be buy point apple earningsapple optical drug giant headline tuesday investing action plan
67,MRK,astrazeneca azn be pin hope immuno oncology rivale merck mrk bristol myer squibb bmy roche rhhby first quarter sale slide touch consensus forecast earning top view cent stock market today astrazeneca stock lift well day move average fourth consecutive trading day share be form cup handle have possible buy point first quarter end march astrazeneca report adjust income cent share vs year even revenue dove result come increase generic competition patent protect crestor top selling cholesterol drug astrazeneca have expire year year comparison be expect ease second half follow impact july entry generic rival crestor crestor sale account total sale decline first quarter ibd take bristol myer squibb merck be lead market term immuno oncolgy drug target call pd protein other target be spark interest wall street visit ibd technology page rundown bristol merck future rival anticipate significant progress pipeline continue include immuno oncology target treatment chief executive pascal soriot say prepared statement astrazeneca expect submit application fda second half immuno oncology combination durvalumab tremelimumab advanced lung cancer also look datum trial combo head neck cancer related celgene dip lag psoriasis sale earning toptesaro dife sticker shock dow stock merck undercut astrazeneca lung cancer
68,MRK,stock market be mixed afternoon trading trading early intraday lows nasdaq shrug early weakness edge slightly higher dow jone industrial average remain red volume be tracking solidly lower exchange vs same time thursday other dow industrial apple aapl pace advancer rise fresh high several analyst raise price target iphone maker johnson johnson jnj mcdonald mcd follow gain respectively downside general electric ge lag more drop heavy volume be run nearly usual level merck mrk cisco csco fall general electric be downgrade sell deutsche bank believe ge be overvalue give weak earning quality other analyst action include nvidia nvda moved price target be hike canaccord genuity rbc capital market graphic chip maker remain barely extend potential entry nvidia be also make strong stride emerge artificial intelligence datum center self drive auto technology market recent ipo trade desk ttd roar almost higher late thursday earning release come well analyst expectation share be extend sharply cup base buy point financial stock underperform stock market today dow component goldman sachs gs drop retail brokerage charle schwab schw fall find resistance day line earlier week casino operator wynn resort wynn lead way rise retailer continue precipitous fall jwn plunge more beating earning sale estimate late thursday same store sale be weaker expect share fellow department store penney jcp reach record low more revenue same store sale fall more forecast early friday action ibd be mixed lead growth stock weakness financial offset strength technology name upside momo momo notch new high fiber optic stock lumentum holding lite moved downside chip name ichor ichr drop nearly bounce intraday lows report earning fall short street estimate regional bank citizen financial cfg private mortgage insurer essent group esnt fall respectively ichor be currently trading day move average sign strength related apple hit record high bullish wall street reportsthese red flag ge send stock month comp sale miss price brand rack surgesgraphic chip maker nvidia get fresh price target hike
69,MRK,depome depo horizon pharma hznp rock drug sector report first quarter earning mizuho analyst irina koffler say wednesday raise price target endo endp mallinckrodt mnk pacira pharmaceutical pcra stock meanwhile leerink analyst seamus fernandez expect bristol myer squibb bmy merck mrk easily beat meet consensus expectation novartis nvs other hand be lucky report result line view trough say close stock market today ibd company medical ethical drug industry group be fraction share have come year group be rank group track be last week consensus analyst poll yahoo expect merck report sale fraction cent earning share certain item cent year earlier period bristol be expect grow sale consensus model adjust earning cent share analyst also see novartis sale grow ep come fernandez have market perform rating merck novartis stock outperform rating bristol ibd take president trump proposal change face fda head ibd technology page breakdown proposal have be make one be come koffler raise price target endo stock pacira stock mallinckrodt stock ahead first quarter earning season cut price target valeant pharmaceutical vrx stock continue expect valeant erode further share volatility remain high write note client not be surprised further guidance cut stall weak asset sale improvement prescription trend brand portfolio consensus estimate come depome issue revise guidance first quarter earning report horizon koffler be worry weaker average net realize price weaker volume report primary care related roche game changer drug chip away biogen bristol drug help biogen take abbvie alzheimer
70,MRK,merck mrk deliver blow late tuesday beta amyloid theory alzheimer disease drug verubecestat fail clinical trial show virtually chance find positive effect investor largely expect phase phase trial fail leerink analyst seamus fernandez say research report close bell stock market today merck stock be share fellow alzheimer drugmaker split wednesday eli lilly lly stock muster gain astrazeneca azn add biogen biib climb roche rhhby lift verubecestat belong class drug call bace inhibitor work block production amyloid brain evercore analyst mark schoenebaum explain drugmaker be explore amyloid buildup brain cause alzheimer lilly astrazeneca biogen conjunction japan eisai be work theory differ drug eli lilly now discontinue solanezumab target plaque buildup month lilly drug fail late stage trial merck drug investor have high hope solanezumab ibd take analyst predict gilead science suffer slow hepatitis drug sale week worry come fruition be warning sign dive ibd industry theme close look datum monitoring committee find verubecestat be safe see little evidence activity perhaps even bace arm be leerink fernandez write merck continue trial patient prodromal alzheimer datum trial be expect february biogen aducanumab roche gantenerumab crenezumab aim cut build plaque brain eli lilly astrazeneca biogen eisai be team bace inhibitor other theory center earlier treatment schoenebaum note remain unclear ad related damage brain be reversed clear plaque prevent creation additional plaque write report failure study futility dampen enthusiasm mechanism schoenebaum say consensus expect peak adjust sale verubecestat merck related merck keytruda sale lag defer revenue analystbiogen trail merck lilly alzheimer hemophilia spinoff begin tradingabbvie merck pressure gilead hep unit gsk battle hiv biz
71,MRK,incyte incy pull peak sale merck mrk partnership alone goldman sachs analyst richter say friday note collaboration astrazeneca azn bristol myer squibb bmy roche rhhby collaboration astrazeneca bristol myer roche don target substantial small cell lung cancer market opportunity richter peg peak sale incyte go route likely depend merck push exclusivity say richter boost price target friday incyte stock keep buy rating stock market today incyte stock rise share be year be now extend buy point flat base first touch jan incyte epacadostat be immune oncology drug be keytruda merck opdivo yervoy bristol myer tecentriq roche durvalumab astrazeneca therapy target pd pd ctla ido molecule act brake immune system provide negative signal cell ibd take incyte have slew potential blockbuster not immune oncology sector dive new america deeper analysis more incyte potential market tumor cell apply brake prevent destruction immune system richter explain drug remove brake allow cell attack tumor combination drug be thought be more potent combine chemo merck be testing too base encourage early datum epacadostat combination keytruda view incyte ido inhibitor lead add on pd pd write research report merck bristol myer be often see go head head space keytruda opdivo target pd be approve monotherapy melanoma advanced lung cancer head neck cancer firm be also work combo month merck announce expand collaboration incyte test keytruda epacadostat total tumor type first line melanoma advanced lung cancer renal cell carcinoma head neck cancer bladder cancer incyte epacadostat be safe monotherapy only advanced melanoma patient earlier phase trial achieve stable disease earlier combo epacadostat yervoy patient hit overall response rate toxicity also rise liver view result highlight potential synergy ido continue focus find most effective doublet second generation immunotherapy continue emerge richter say see incyte hit peak sale nsclc market alone estimate be conservative incyte also team astrazeneca bristol myer roche nsclc pending detail exclusivity merck outside partnership merck incyte be already testing epacadostat astrazeneca bristol myer roche treat other type cancer editor note correct fourth paragraph correctly identify roche astrazeneca drug related bristol myer topple guidance cut merck merck meaningful keytruda royalty give bristol myer leg biotech stock catalyze plunge key sector
72,MRK,flurry buy last hour trading tuesday lift market lows volatile session get reasonable start nasdaq composite add rise more dow jone industrial average gain preliminary datum show volume nyse nasdaq come significantly higher friday level merck mrk nike nke be strong gainer dow jeffery name nike best new idea walt disney also do well rise nearly evercore upgrade share buy hold price target disney be try clear cup handle base buy point tuesday session be reminder even market remain confirm uptrend seller be still homebuilding railroad chip design restaurant stock lag gold stock outperformed wall street like look strong read december ism manufacturing index just open hit year high rise november year treasury yield be recently unchanged wti crude oil future reversed lower strong start fall barrel trade early session stock market today netflix nflx rebound straight low volume decline share rise goldman sachs make positive comment slew internet stock include netflix netflix end session just buy point share alphabet googl add goldman add conviction list alphabet be currently work flat base early entry related domino other restaurant stock fall stall traffic seengoldman bullish internet stock amazon google oil reverse sharply lower opec doubt strong dollar
73,MRK,stock index be modestly midday wednesday blue chip show most strength blue chip dow jone industrial average rise nasdaq add small cap russell also inched volume stock market today be run slightly lower nyse bit higher nasdaq price weight dow day biggest percentage gainer highest price stock be goldman sachs gs company mmm rise almost merck mrk score biggest pop merck price be roughly give far less weight dow goldman price meanwhile biotech stock tumble president elect donald trump bash high end drugmaker news conference biotech group fall nasdaq be try deliver seventh consecutive daily gain tech lean index go wednesday session year nasdaq first solar fslr be biggest percentage gainer average volume stock be high ibd industry group solar be notch last place gold mining stock superregional bank be first place be barely midday wednesday energy hold biggest gain oil driller oil machinery join solar nail day top position west texas intermediate crude oil pop more more barrel energy information administration report increase barrel week analyst have expect increase less barrel oil stock didn appear much bother bad news driller group stock rise more biggest percentage gainer be atwood oceanic atw more twice usual volume related trump say drugmaker be get away murder economic optimist surge
74,MRK,tuesday marked shiny rally small cap equity big megacap firm sit back seat meanwhile money continue flow certain tech commodity sector market largest tech firm trading market apple aapl show decent not outstanding action follow monday base base pattern other company show more oomph company market cap just shy switzerland estimate nominal gdp edge fourth day row past new entry point volume fall monday turnover edge day average share waste small intraday gain roughly end practically flat tuesday dow jone industrial sank nearly russell thrust ahead finished almost session high nasdaq composite find happy ground middle rise nearly reflect dominance bunch stock market cap range nasdaq trail nasdaq composite rise just volume fall nasdaq rise nyse vs monday level thus hand rare stall day bout heavy institutional selling however tuesday volume nyse be likely average read more major index action today big picture column return individual equity incyte incy beam new plan big pharma business partner merck mrk advance clinical trial new cancer treatment rise nearly get extend further entry note ibd stock market today coverage monday incyte huge gap day mean investor real conviction small molecule development expert have buy monday open price have be chase zone precise buy point illumina ilmn rise nearly heaviest volume month be poise develop bottom base pattern san diego base maker human genome analysis system former big winner april summer peak grow revenue top line increase decelerate street also see full year earning flatten then pick share illumina sport solid ep rating now accord ibd stock checkup however profit be expect fall cent share most likely depress ep rating illumina rs rating be typical stock bottom basis chinese web company flourished lead big gain alibaba baba netease nte large cap play have rise back key day move average key step complete new basis watch alibaba closely commerce titan have unveil interesting new plan link small business china gigantic still grow middle consumer class alibaba have also now joined leaderboard new name watch baidu bidu search engine china jump nearly be base return apple iphone juggernaut be still buy range rise past cup handle buy point chase zone extend note stock market today column apple rally nearly clear cup handle cup be part long deep bottom base pattern apple still lie time peak latest weekly cup show week heavy volume vs week average volume however week see minimal decline thus bespeak strong institutional support accumulation distribution rating track ibd stock checkup improve rs rating also point net accumulation fund apple rs line continue drift mildly higher signify still outperform now metal firm advanced sharply read more leader today industry theme column related be bottom base pattern help trader make moneythe bottom base pattern part ii apple form savvy investor learn gerald loeb author wall street market today do small molecule expert have potential be next amgen
75,MRK,nasdaq lead stock lower friday earning charge session initial read gdp growth senate health care vote factor early trade dow jone industrial average open slip nasdaq composite drop amazon com amzn starbucks sbux western digital wdc mattel mat tug lower dow stock be fairly evenly divide open half half exxon mobil xom drop hardest more mixed second quarter report intelint grab dow best advance second quarter report glide past analyst expectation tech side apple aapl open fang stock be mixed just open amazon fall report late thursday earning growth fall far short analyst target second quarter company aggressive spending cut profit revenue top expectation amazon share have be hover buy zone buy point late stage flat base seller also drag western digital loss datum storage leader post better expect revenue earning growth fiscal fourth quarter loss drag share stock week move average heavy trade trigger sell signal other big name be also motion earning news china baidu bidu climb starbucks stumble lower merck mrk american airline aal mattel be also active just report electronic mortgage service provider ellie mae elli collapse second quarter earning meet analyst target revenue growth stop short management third quarter revenue guidance be consensus view aaron aan vault higher report second quarter earning gain vs expectation decline revenue clear forecast wide margin guidance be better expect surge send share new high extend flat base buy point logmein logm hammer open advance keybanc upgrade remote network access service outfit overweight sector weight follow strong second quarter result third quarter guidance report late thursday gain lift logmein share just buy point week cup base first solar fslr ahead report broad second quarter revenue earning beat thursday close move put stock april low rally have help drive solar energy group best gain past week industry track ibd economy expand second quarter accord preliminary estimate commerce department more double first quarter increase revise just meet consensus forecast inflation remain tame gdp price index rise first quarter gain view increase university michigan release july consumer sentiment index et related big picture stock battle back sharp reversal techs rattle dow transport plunge time sell fang stock amazon second quarter earning have big miss bottom linesel leave spotlight stock back buy pointsfear gauge hit record low stock do next scare
76,MRK,stock future fall early friday amazon com amzn retreat big earning miss nasdaq future skid vs fair value worst level overnight session index future slide dow industrial future retreat japan nikkei fall intraday friday china shanghai composite lose fraction hong kong hang seng sank xon thursday nasdaq composite index reversed lower record high finished session worst level dow industrial close higher thursday verizon vz merck mrk boee ba sell test many lead techs include apple aapl google parent alphabet googl microsoft msft ibd take stock have be rise strongly several month so investor have grow complacent cboe volatility index market fear gauge have be fall time lows long time vix lows be often associate least short term market top sometimes long term top look ahead friday night tesla tsla host handover party model sedan amazon second quarter revenue rise second straight quarter accelerate growth slightly beating forecast commerce giant earning tumble cent share far analyst forecast accord zack investment research amazon third quarter operate income guidance wasn great amazon fall late trading take extra pinch salt overnight stock move often aren confirm regular trading amazon result often leave investor analyst uncertain initially still hour action suggest amazon be danger undercut flat base buy point amazon come lackluster volume late stage be more likely fail apple fall thursday session recover intraday low day move average apple dow jone industrial average component do drift late trading second time week apple have test key support level be close alphabet meanwhile slide third straight session google parent try close day line not alphabet top second quarter view late monday fang stock report higher traffic acquisition cost pay partner site carry ad analyst cite revise search deal apple possible culprit microsoft fall intraday drop buy point clear july software cloud compute giant manage pare loss dow component share be trading right buy point again evening trading tesla fall regular trading move back day move average tesla be still try recover early july plunge massive volume concern model rollout lackluster model model production delivery tesla be throw party friday night give initial batch model sedan customer general public finally start get better look model specification real issue be tesla meet ambitious target mass production year end related big picture stock battle back sharp reversal techs rattle dow transport plunge time sell fang stock amazon second quarter earning have big miss bottom linesel leave spotlight stock back buy pointsfear gauge hit record low stock do next scare
77,MRK,major market index advanced higher early trading wednesday tech heavy nasdaq dow jone industrial average lead way move respectively meanwhile edge higher index hit record high xamong dow industrial verizon communication vz merck mrk boee ba rise solidly early trading verizon jump nearly result remain day line merck look reclaim day line advanced early thursday biotech competitor astrazeneca azn report late stage trial failure cause share plummet meanwhile boee add wednesday earning related surge airplane maker be flat base buy point longtime lead stock fang member facebook fb surge top top bottom line estimate beating view ad revenue user growth meanwhile fellow social medium company twitter twtr snap snap trade mixed twitter report earning beat street estimate monthly active user be flat vs send share share twitter have be comeback trail recent month rise almost mid april lows meanwhile analyst firm summit redstone call competition facebook snap contest facebook favor due facebook increase pricing power respect ad price share snapchat parent be trading post ipo high almost ipo price trade higher thursday fellow fang member amazon com amzn report earning bell thursday analyst expect commerce giant quarterly profit fall year year share rise revenue share advanced stock market today be flat base entry casino operator take hit early thursday mixed earning result mgm resort mgm melco resort entertainment mlco mgm fall nearly be still hold day line melco edge be still day line build new base ibd paypal pypl jump almost pare gain strong result late wednesday lead payment processor be flat base entry downside celgene celg decline beating estimate lift full year earning guidance stock remain extend flat base buy point level related facebook vs snap call contest boee surge far too little twitter dife stagnant user solid earningsdow jone industrial average dow stock news stock news quote facebook amazon netflix googlefacebook earning surge fang duo monopolize digital ad
78,MRK,european drugmaker astrazeneca azn roche rhhby early thursday deliver better expect earning astrazeneca share plummet more key lung cancer drug trial fail xbiotech celgene celg alexion pharmaceutical alxn also report market open astrazeneca report adjust income cent share sale compare cent share sale year earlier period analyst poll zack investment research forecast adjust earning cent share sale astrazeneca say combination immuno oncology drug fail shrink lung cancer tumor so call mystic drug trial astrazeneca have pin hope trial immuno oncology generally mystic trial continue look hit different longer term goal cause share plunge early trading stock market today related news astrazeneca tagrisso meet goal late stage lung cancer trial tagrisso be approve treat certain population lung cancer patient specific mutation trial test tagrisso erlotinib gefitinib current standard care first treatment astrazeneca also announce team dow merck mrk roche report core earning first month come share constant currency exchange rate top forecast sale grow regardless exchange rate be largely line ibd take biotech sector be now rank third industry group track ibd merger acquisition send rocket say industry observer check potential war path ibd industry theme drugmaker raise full year sale forecast mid single digit growth constant currency core earning rise similar amount roche share tick slightly morning trade thursday celgene dip beating second quarter expectation sale come top consensus adjust income share rise top view alexion surge easily top wall street expectation second quarter sale rise top analyst view adjust profit increase share beating cent bristol myer squibb bmy stock tank reaction astrazeneca trial have read through similar immuno oncology program bristol drug giant report adjust income cent share sale meeting expectation year year basis revenue rise adjust profit increase growth be drive anticoagulant eliquis immuno oncology drug opdivo see sale bristol say news release fellow immuno oncology med yervoy grow related biotech rally still tack upsidebiotechs find strength number treat multiple sclerosisamgen topple increase forecast still lag view
79,MRK,stock index start strong note thursday morning then stage ugly reversal still index battle back close fairly high day range xwild swing take nasdaq then trimming loss close middle day range drop
80,MRK,chinese biotech beigene bgne be strongest beneficiary celgene celg gamble immuno oncology analyst say friday beigene stock touch fresh high term deal beigene obtain right commercialize celgene cancer drug abraxane revlimid vidaza china be not yet approve be be test advanced solid tumor blood cancer hodgkin lymphoma leerink analyst geoffrey porge call deal great news beigene merely reasonable celgene celgene say chinese business bring annually deal retain half future chinese profit drug beigene beigene go development company commercial company overnight very little cost home market have raise significant cash future development funding asset have struggle develop commercialize independently say return celgene acquire right develop commercialize beigene immuno oncology drug know bgb drug belong same class keytruda dow merck mrk opdivo bristol myer squibb bmy ibd take biotechs exelixis be work treatment advanced kidney cancer exelixis be great position retire nearly debt head new america breakdown exelixis stock celgene partner astrazeneca azn april develop commercialize imfinzi blood cancer imfinzi be know pd inhibitor have slightly different mechanism keytruda opdivo bgb pd inhibitor deal astrazeneca doesn give celgene access imfinzi solid tumor lung breast ovarian cancer other celgene appear have conclude expand portfolio solid tumor future require pd current agreement astrazeneca imfinzi exclude indication solid tumor porge write note client porge keep outperform rating price target celgene stock timing deal beigene look inspire lucky say follow day merck confirm food drug administration have put keytruda trial hold cite patient death celgene share end regular trading session friday related dow merck stumble fda put keytruda trial holdnovartis face key fda panel cancer drug kite be winnerdeal help celgene rival dow merck bristol cancer drug
81,MRK,esperion therapeutic espr stock break wednesday touch nearly year high food drug administration approve regulatory pathway cholesterol lower combination stock market today esperion stock pop close cent shy cup base buy point share top buy point go high cup begin form march meanwhile ibd company biotech industry group lift stock action follow esperion announcement fda say allow esperion dow component merck mrk run single phase study combination drug cholesterol treatment study run concurrent ongoing phase study esperion drug bempedoic acid esperion be look combine bempedoic acid merck already approve drug zetia ibd take biotech stock have be upswing month generalist investor longer scared president trump pressure drug price be return sector head ibd industry theme deep dive esperion be hope second study also help support approval bempedoic acid drug lower bad cholesterol europe company aim enroll patient combination study merck stock dip news related comeback kid regeneron survive amgen cholesterol squeeze
82,MRK,be salad day biotech sector number industry leader be hit new high group whole be top game term stock performance xstock inflow hit last week have be number clinical trial success new industry friendly food drug administration regime be place result investor business daily company biotech industry group have claw way group track ibd sixth just last week share look likely close month high stock market today slew earning next week just everything be go right biotech lately have be go right brad loncar chief executive loncar investment tell ibd friday onslaught biotech earning next week really give investor fodder say thing miss say loncar merger acquisition last piece fit puzzle then biotech sector really be cook gas say gilead science gild be likely linchpin loncar call gilead poster child large biotech need do deal gilead multibillion dollar hepatitis drug franchise topple first time now gilead say interested deal cancer space analyst have key vertex pharmaceutical vrtx smart acquisition loncar see gilead more likely buy early cancer asset something develop commercialize rather putt money work buy develop revenue stream vertex be already hugely successful biotech own right say earlier year vertex deliver best news year space point have exceptional result phase trial look triple pill treat cystic fibrosis stock gap nearly wednesday ibd take rare disease cancer play have be front center biotech sector late cut edge firm keep rally go head industry snapshot deeper dive multibillion dollar stock loncar say company vertex go something everybody stock market notice gilead be set report second quarter earning wednesday be sandwich slew strong contender biotech space include celgene celg amgen amgn biogen biib alexion pharmaceutical alxn biotech celgene be slate report second quarter earning open thursday stock have ibd composite rating lead peer be sit high last see july leerink analyst geoffrey porge say celgene alexion be bellwether group time same way dow johnson johnson jnj be often see proxy pharmaceutical group call celgene beat raise alexion rise top low view alexion be slate thursday tuesday amgen overtake month high jump record high second quarter earning report prove strong share break cup handle july buy point still remain buy zone trio help catapult sector analyst say meanwhile pharma side investor key astrazeneca azn early thursday recent week rumor have emerge chief executive pascal soriot jump ship teva pharmaceutical teva loncar note timing rumor be bad astrazeneca astrazeneca be set day now report result immuno oncology combination trial lung cancer lung cancer treatment be huge commercial opportunity astrazeneca be take player merck mrk bristol myer squibb bmy regardless rumor controversy do think not overstatement say pascal soriot job be line trial be make break astrazeneca say study be most important thing astrazeneca last year biotech stock be year still room run cfra research analyst jeffrey loo tell investor business daily valuation hit historic lows presidential election be still overall health care sector relative historical valuation biotech sector be still attractively price say late june sector get massive push president donald trump release draft proposal drug pricing initiative didn include much really tug drug price loo say didn credit entire gain proposal certainly help loo say clinical trial term fda approval strong launch trend have also help prod sector year include cystic fibrosis news vertex gene therapy novartis nvs duchenne muscular dystrophy drug sarepta therapeutic srpt latter development loncar say sarepta second quarter sale beat exondys bode well broader sector sarepta also raise guidance year most analyst have call conservative everybody be watch sign drug launch be go payor be push back thing say fact launch exondys be go well be good sign not just sarepta biotech company related biotechs find strength number treat multiple sclerosistoo late catch biotech rally trump fear subside biotech rally get second wind small cap near break outwhy biotech rally still tack upside
83,MRK,stock moved solidly higher gain be begin fade early tuesday federal reserve begin day policy meeting economic news producer price index come unchanged vs expect increase expect nasdaq lead way early advance dow jone industrial average follow gain respectively dow industrial visa microsoft msft pace advancer gain follow closely apple aapl rise early trading blue chip index laggard be merck mrk coca cola ko ethical drug manufacturer drop snack maker fall fang stock rebound nicely early monday day considerable weakness facebook fb amazon amzn netflix nflx google parent alphabet googl rise more video stream giant close day line first time mid april monday look recover tuesday lead stock tesla tsla jump nearly stock market today be upgrade buy berenberg analyst raise price target electric automaker base lack competition other automaker currently build electric vehicle alibaba baba rise remain just time high recent sell tech stock other analyst action include western digital wdc seagate technology stx datum storage provider receive buy rating aegis capital western digital jump almost seagate climb ibd member mercadolibre meli be downgrade neutral goldman sachs prompt latin american commerce company fall open have moved higher action ibd be predominantly positive early trading tech stock snap back recent weakness lead charge upside be lumentum holding lite new oriental education edu ichor holding ichr fiber optic name advanced china education stock rise chip stock ichor moved downside discount retailer decline biotech regeneron pharmaceutical regn drop related fed game plan soothe market wednesdaydow jone industrial average dow stock news analysisno rival tesla see western digital seagate start buyfang stock news quote facebook amazon netflix google
84,MRK,rally retailer lead strong volume session add sixth day market rally left nasdaq new close high nasdaq pace session gain aid advance netflix nflx follow respectable distance dow jone industrial average scale settle march close high preliminary datum show volume rise session wednesday total also bullish sign good day overall market have weak spot particularly il related group take worst loss industry disappointment month commitment agree organization petroleum export country morning extension december production cap iran reluctance agree deal send west texas intermediate sprawl nearly lower barrel retail group seize top gain industry best buy bby spiked drive consumer electronic group advance strong first quarter result soothe fear so call death retail management boost second quarter revenue earning guidance consensus view best buy share be extend follow cup handle base april ulta beauty ulta tease gain regular session then shot hour trade report first quarter result ulta share end session just buy point flat base discount variety retail dollar general dg big lot big rise dollar tree dltr add deliver weak first quarter result guidance analyst target stock have chart repair work do budget air carrier spirit save azul azul rise respectively lead rally airline stock brazil base azul volatile ipo be week still prior week high april ipo price unitedhealth group unh lead dow rise nearly announce optum unit partner merck mrk develop evaluate model link drug price outcome patient treat drug gain send unitedhealth new high stock remain buy range buy point flat base fang stock netflix gap bang new high piper jaffray analyst michael olson thursday reiterate overweight rating netflix stock raise price target netflix be extend rebound week support april related top dog vs big threat retail consumer electronic hot restaurant stock still reach investing action plan
85,MRK,xfuture dow jone industrial average index nasdaq future early tuesday morning edge higher indicate slightly higher open apple aapl pfizer pfe mastercard headline component earning tap tuesday several company be due report eye be apple report close bell apple have world largest market cap share trading time high investor be look past current sluggish growth iphone possible dividend hike new buyback apple result guidance be likely have big impact slew supplier especially chipmaker several other megacaps be tap include drug giant pfizer merck open apple pfizer merck be part dow industrial continue lag fall slightly monday nasdaq composite power new time high thank apple facebook fb amazon com amzn other big cap techs altrium mo cvs health cvs conocophillip cop emerson electric emr gilead science gild mondelez mdlz round company tap late monday dow nasdaq future rise fair value so do index future asian trading japan nikkei rise hong kong hang seng climb shanghai composite fall ibd take apple be leaderboard ibd premium service offer annotate chart select group stock mostly growth company be buy zone take free leaderboard trial today meanwhile general motor gm ford other automaker release auto sale april analyst expect modest broad base decline demand continue decline vs year earlier general motor ford member report earning last week federal reserve begin day policy meeting analyst don see real chance move wednesday policymaker reinforce expectation june move bring forward estimate hike pare back central bank massive balance sheet related be buy point apple earning stock still buy range apple stock hit record high earning tapapril auto sale expect gm ford tesla soar be top stock earning due week
86,MRK,merck mrk stock pare early loss friday fda reject application study cardiovascular outcome diabetes drug januvia janumet janumet xr fda send merck complete response letter merck say want include datum trial evaluate cardiovascular outcome sitagliptin chemical name januvia janumet prescribe information sitagliptin contain medicine complete response letter be issue application be reject mean merck still have work do get approval include cardiovascular outcome datum label januvia janumet merck say be explore option ibd take president trump do come drug price head ibd technology page breakdown proposal thus far stock market today merck stock be fraction close slide much shortly announcement ibd company medical ethical drug industry group be flat related step aside merck bristol be future rival cancer drugsbristol keep merck cancer incyte be true winner analystbristol afford lose dow stock merck immuno oncology
87,MRK,small cap pare loss continue lead downside key index etfs thursday stock market struggle ishare russell iwm ishare core small cap ijr shed etfs have slip back flat basis be find support day move average line powershare qqq trust qqq fall proshare ultrapro qqq tqqq give be just shy time high reach early week nasdaq enter record territory spdr dow jone industrial average etf trust dium be be trading tight range top flat base buy point share rise flat base early year start current pattern dow be sea red exception stock merck mrk caterpillar cat exxon mobil xom boee ba be also higher merck get boost fda approval related keytruda drug caterpillar rating price target be raise bank america surge oil price lift exxon emerge market etfs reversed small gain direxion daily emerge market bull share edc ishare msci emerge market eem climb respectively commodity etfs unite state natural gas fund ung rise unite state oil fund uso gain west texas intermediate crude price surge nearly barrel gold future be ounce spdr gold trust gld ishare gold trust iau powershare db gold fund dgl advanced more gold miner leap vaneck vector gold miner gdx vaneck vector junior gold miner gdxj spdr retail xrt drop hurt macy dive dd plunge etf be trading day day line be left side high cup shape base related find go stock market todayopec see opec oil output jump barrel yearmacy shocker other result trigger broad retail rout
88,MRK,stock market rebound early significant loss remain modestly lower midday trading nasdaq decline dow jone industrial average fall small cap russell lag move volume be tracking modestly higher nyse lower nasdaq vs same time wednesday other dow industrial microsoft msft pace decliner fall computer software company offer downbeat margin outlook analyst briefing share fall back buy range flat base buy point other laggard dow jone industrial stock market today include intel intc nike nke home depot hd fall however be see volume normal level caterpillar cat merck mrk exxon mobil xom boee ba buoy blue chip index significant loss caterpillar lead way share trade entry merck follow advance exxon boee rise respectively retailer be again day worst performer give more credence potential death retail early thursday macy kohl kss dd report quarterly earning macy plunge almost level not see summer kohl reversed early gain turn lower drop nvidia nvda follow wednesday buy point stock market today rise yesterday graphic chip maker surge almost positive earning beat early thursday loop capital raise price target maintain buy rating other lead stock video stream company netflix nflx drop notch record high wednesday recent issue snap snap plummet nearly report disappointing result late wednesday social medium company be post ipo high other earning reporter include chinese gaming company netease nte gain higher wild session late wednesday netease report result handily beat earning sale expectation result early surge higher action ibd be mixed lead growth stock look recover early market loss upside medidata solution mdso rise essent group esnt moved downside china base athm fall remain extend cup base entry related macy stock dife wide miss kohl sale weak latesnap laugh facebook competition stock plunge earning missnetease handily beat earning view stock jump hour
89,MRK,bristol myer squibb bmy cytomx ctmx be work less potent version yervoy have datum early analyst say thursday month announce deeper tie neither have comment specifically type cancer ll target deepen partnership bristol myer recently file plan begin year study patient melanoma evercore analyst umer raffat call filing clinicaltrial gov intriguing trial be head head comparison new immuno oncology drug vs yervoy look combination opdivo filing doesn identify new immuno oncology drug be cytomx pairing make sense consider bristol cytomx announce deeper tie march explore additional target oncology goal raffat say be likely find less potent version yervoy immuno oncology drug yervoy belong class drug call ctla antibody work help immune system identify cancer cell hiding ctla protein yervoy be effective also toxic label include warning severe fatal immune mediate adverse reaction include inflammation small intestine colon hepatitis skin disorder nerve damage endocrine gland damage cytomx be work be call probody technology therapeutic be activate certain condition tumor environment goal be limit toxicity affected tissue improve create therapeutic window simpler word intention be develop safer ctla deliver effect tumor site avoid systemic tax elsewhere see ton yervoy raffat say note client ibd take other team up have be particularly strong smaller biotechs involved incyte incy be pairing dow component merck mrk bristol myer squibb number tumor trial head ibd technology page breakdown incyte be true winner bristol main goal trial be reduce incidence adverse serious event firm hope drug operate more effective monotherapy vs yervoy improve objective response rate median duration response progression free survival also combine new ctla opdivo opdivo work similarly yervoy instead work block interaction immune system pd protein tumor cell used hide opdivo rival merck keytruda raffat expect see early result focus clearly be toxicity profile be materially better yervoy say addition also be interesting see be improvement bristol myer stock close stock market today cytomx stock jump related step aside merck bristol be future rival cancer drugsbristol myer hold better dow merck still gouge bristol drug help biogen take abbvie alzheimer
90,MRK,stock open flat monday earning report commodity trade drive early action sunday critical election france nasdaq dow jone industrial average barely moved victory centrist presidential candidate emmanuel macron nationalist marine le pen france receive mixed reception world market market europe grow more widely mixed afternoon action london ftse be cac paris drop frankfurt dax fall market japan south korea heavy trading partner european union surge monday tokyo nikkei korea exchange kospi close gain china hong kong hang seng index rise mainland market dive shanghai composite drop shenzhen composite tumble dow industrial walt disney fall ahead fiscal second quarter report tuesday close merck mrk be fraction earning report season continue priceline pcln snap snap disney lead name set report week monday tyson food tsn fll sysco syy fall company narrowly miss analyst quarterly earning target rubbermaid sharpie maker newell brand nwl seal early gain first quarter earning revenue top expectation management hoist full year earning guidance consensus view raise quarterly dividend newell rally back week move average work consolidation china base online retail giant jd com jd surge open company first report accord gaap rule show turn profit year loss post increase revenue result be better expect stock be well extend february march rebound support week move average mallinckrodt mnk climb fiscal second quarter revenue earning growth best view stock be try form bottom deep year old consolidation petm express pet jump early action fiscal fourth quarter earning revenue clear expectation wide margin management raise quarterly dividend penny cent share thinly trade stock end friday buy range buy point month cup base straight path communication strp bolt higher open owner spectrum license announce new bid share unnamed bidder raise enterprise value telco widely assume be verizon vz straight path share end friday march low charter communication chtr dive announce have enter joint agreement comcast cmcsa better manage compete wireless service comcast share rise tribune medium trco jump sinclair broadcast group sbgi say buy television radio station owner deal value include debt share first century fox foxa fall company be report have end attempt bid sinclair acquire tribune be trading halt sinclair share ore mining stock be early pressure copper other commodity trade lower freeport mcmoran fcx bhp billiton bhp vale vale rio rio slip tribune mediatrco jump sinclair broadcast groupsbgi say buy television radio station owner deal value include debt share first century foxfoxa surge company be report have end attempt bid sinclair acquire tribune oil price drop month low last week backed early trade west texas intermediate be fraction hold just barrel loss have be stem comment saudi arabia oil minister khalid al falih bloomberg report expect production cap agreement organization petroleum export country partner hold second half be significant economic release schedule monday session federal reserve be motion st loui federal reserve bank president james bullard speaking et loretta mester president cleveland federal reserve bank schedule et speech gold rise ounce copper drop almost dollar be mixed vs yen euro bond rise trimming year yield basis point related snap nvidia disney chinese leader investing action planmacron beat le pen take french presidency boost europe
91,MRK,merck mrk blockbuster keytruda continue swipe share bristol myer squibb bmy immuno oncology drug bristol be hold better expect analyst say wednesday analysis march sale bristol myer opdivo yervoy account immuno oncology market end meanwhile merck keytruda gain percentage point march market share roche rhhby tecentriq remain nearly year launch leerink analyst seamus fernandez expect bristol myer deliver topline beat april analyst project total sale cent earning share certain item flat respectively vs year period bristol myer top sale likely be tie immuno oncology drug first quarter consensus model bristol opdivo pull sale already datum health track symphony health show bristol beat opdivo compete keytruda target protein call pd body immune system identify hide cancer cell bristol other immuno oncology drug yervoy bring first month datum show consensus model ibd take bristol myer stock have middling ibd composite rating meaning perform better half stock term key growth metric ibd company ethical drug industry group be struggle rank only group track better bet be tenth rank company biom biotech industry group compare group ibd stock checkup keytruda appear be more line consensus expectation fernandez write note client first month year symphony health datum show keytruda sell vs analyst view bristol stock close stock market today merck rise roche edge related step aside merck bristol be future rival cancer bristol drug help biogen take abbvie alzheimer bristol afford lose dow stock merck immuno oncology
92,MRK,index other major average rise modestly week even apple aapl facebook fb dip earning tesla tsla tumble wider loss auto sale fall again crude price crash month lows solid job growth show economy be track keep federal reserve course well nasdaq rise nearly week dow jone industrial average index advanced modestly big headwind apple dow component facebook especially tesla pull back follow quarterly report crude oil future tumble lowest level november drag energy stock metal price also fall sharply hit miner general motor gm other automaker report decline sale yet again fiber optic stock warn sluggish china demand cite boom growth consumer electronic giant apple aapl earn share year year revenue march fiscal second quarter analyst expect sell iphone last quarter view ceo tim cook blame slowdown iphone sale consumer delay purchase speculation next generation device rumore iphone apple hike dividend add stock buyback program edge lower wednesday thursday apple stock rally fresh record high friday related apple beat view earning come short grow doubt opec lead production cut offset boom sale crude price tumble lowest level cartel begin curb output crude fall electronic trading overnight friday rally close barrel oil price still lose week meanwhile bp beat estimate royal dutch shell rdsa top view massive increase cash flow conocophillip cop report surprise loss shale producer be mixed bag pioneer natural resource pxd highlighted new drill technique include possibility employ artificial intelligence future related oil crash chart show opec be trappedrevenue rise beating consensus estimate gaap earning share beating view monthly daily active user growth also exceed expectation facebook once again caution ad revenue growth slow meaningfully share edge lower thursday friday related facebook applaud analyst follow strong earning reporttesla show larger loss expect strong revenue growth first quarter earning tesla revenue rise beating wall street estimate yet luxury electric car maker report adjust loss share exceed cent share loss wall street expect ceo elon musk say model plan be track say robot software day make tesla valuable apple tesla share tumble thursday extend loss ahead company result rebound friday related tesla get mixed reviews analyst earning reportmeanwhile auto sale april miss view board tuesday general motor ford fiat chrysler fcau nearly foreign peer report decline demand miss view auto sale have fall year year straight month longest string recession end industrywide sale come annual rate accord autodata expect auto part giant delphi dlph soar report strong earning announce plan spin powertrain segment focus autonomous electric vehicle related auto review tesla loss sale slump delphi break economy add job april slightly more expect sluggish march hire weak overall economic activity start year jobless rate edge fresh year low report suggest economic growth rebound spring also keep federal reserve track policymaker expect raise rate more time have hint take step pare central bank massive balance sheet related job add april jobless rate sink year low hollywood writer studio broker peace avoid writer strike medium stock get slam time warner twx report soft ad revenue subscriber loss dish network dish have mixed result be mar subscription loss be high industrywide viacom viab beat handily paramount perform well share be hit cable bundle distribution worry hulu debut channel live tv beta bundle month join several other stream tv offering cbs cbs result come mixed house panel scold airline treat customer better be sign lawmaker plan legislative remedy hearing follow well publicize video polouse drag unite airline ual passenger flight incident rep steve cohen say remind trump campaign rally alaska airline exec say company be review policy overbooking american airline aal say hadn establish ceiling payout offer person need bump flight southwest luv plan end overbooking say wouldn go break result even lawmaker batter executive airline stock soar delta air line dal traffic result april show positive unit revenue storm atlanta oclaro oclr inphi iphi lumentum lite warn slacken demand china clearest sign yet key market fiber optic gear component be struggle generally see temporary tout strong demand base datum center metro expansion oclaro initially crash wednesday morning end day flat inphi do lose day lumentum actually rally thursday cite progress sensor apple iphone speculation apply optoelectronic aaoi sky-rocket beating already raise earning estimate related lumentum have apple iphone sensor design bag analystdow component merck mrk tuesday top view sale cent ep lighter expect sale immuno oncology drug keytruda weigh stock close fraction pfizer pfe sale be light adjust income cent beat penny regeneron pharmaceutical regn thursday miss sale ep view eylea sale praluent sale be less dire expect yum brand yum papa john pzza put earning beat estimate help taco bell yum own digital order have be great pizza business shake shack shak sank late thursday weak same store sale guidance soar friday morning dunkin brand dnkn sale miss increasingly challenge environment retail restaurant wingstop wing surge beating estimate hike ep full year growth forecast cheesecake factory cake tumble miss habit restaurant habt have mixed result guidance sprint say fiscal revenue operate revenue rise top view postpaid phone subscriber addition be line stock fall disappointing free cash flow guidance speculation mobile merger cool paycom software payc report ep revenue top view raise full year revenue outlook year earlier square sq stock rise payment processor swung adjust cent profit year earlier loss raise full year revenue guidance revenue rise top view ebitda be vs consensus estimate square share soar record high twilio twlo share crash communication software maker forecast larger expect current quarter loss reveal change relationship largest customer ride sharing giant uber twilio report adjust loss cent share revenue gain ahead expectation match group mtch report revenue year earlier adjust ebitda top view strong growth paid subscriber mobile date app tinder management guide revenue be range vs consensus casino stock rally news macau gaming revenue rise april vs year earlier higher most estimate melco resort mlco report better expect earning follow upbeat report last week wynn resort wynn mgm resort mgm la vegas sand lvs bullet jg mlm cmi ec pi ec
93,MRK,gilead science gild stock topple late tuesday biotech report first quarter sale earning lag wall street say have quarter decline revenue blockbuster hepatitis drug overall sale fall year year quarter end march miss view adjust income share lag expectation share plunge vs time last year revenue hepatitis drug harvoni sovaldi epclusa topple year year gilead blame decline harvoni sovaldi lower sale major market partially offset stronger sale epclusa epclusa launch last summer europe hepatitis hiv drug sale other hand grow vs year earlier period continue uptake hiv medicine genvoya descovy odefsey other product include drug blood pressure chest pain intravenous infusion grow quarter hiv drug bictegravir show positive result phase study gilead say gilead pledge earlier year put massive effort bictegravir sale harvoni sovaldi slow hepatitis market europe mature ibd take ibd company biom biotech industry group be now rank group track market have be volatile stock visit ibd technology page look stock look strong other market be still emerge however last week bristol myer squibb bmy be first company receive approval chinese regulator oral hepatitis drug gilead hepatitis drug aren yet approve china north person suffer disease gilead maintain guidance product sale include hepatitis drug revenue hepatitis drug sale decline midpoint be lowest point sale unit decline grow share end trading tuesday hour stock market today gilead stock be earlier day pfizer pfe merck mrk report first quarter earning pfizer top profit expectation sale lag merck beat sale earning view related dow pfizer top earning view sale come gilead be pay price actually cure disease
94,MRK,xhere investing action plan tuesday need know investor day ahead apple aapl be doubt most anticipate report tuesday far only company post earning optical company oclaro oclr inphi iphi be tap well pizza chain papa john pzza build
95,MRK,astrazeneca azn stock dip month low monday analyst note ongoing rivalry merck mrk hurt astrazeneca chance lung cancer jeffery analyst jeffrey holford downgrade astrazeneca share hold buy monday close stock market today share be earlier fall much share have be create cup handle formation august holford doesn see astrazeneca stock short play astrazeneca be testing immuno oncology drug durvalumab tremelimumab alone combine advanced lung cancer company expect have progression free survival datum mid final overall survival datum holford trim peak sale expectation durvalumab tremelimumab respectively primarily due competition chemo immuno oncology combo total see drug bring merck be largely thought be lead immuno oncology combination chemo january fda accept application merck combine immuno oncology drug keytruda chemotherapy advanced lung cancer ibd take be more ongoing trial immuno oncology analyst tell ibd earlier year only handful drug be actually approve head ibd technology page overview first approval emerge sector immuno oncology drug body identify cancer block interaction immune system cell specific enzyme protein cancer cell used hide durvalumab be call pd antibody tremelimumab be ctla antibody bristol myer squibb bmy roche rhhby incyte incy be also notable immuno oncology scene incyte doesn have drug approve epacadostat be be test conjunction drug bristol merck related step aside merck bristol be future rival cancer drugsbristol keep merck cancer incyte be true winner analystwill bristol prove longtime theory cancer defense
96,MRK,bristol myer squibb bmy be keep pace rival merck mrk announce partnership incyte incy see drug combo lung head neck cancer late stage trial year incyte appear be biggest beneficiary rbc analyst simo simeonidis say note client simeonidis boost price target incyte stock agreement incyte test drug epacadostat drug other company important drugmaker be testing combination immuno oncology drug incyte be just handful work know ido inhibitor immuno oncology drug work teach immune system identify cancer ido inhibitor target specific protein importantly arrangement maintain optionality incyte drug epacadostat go forward leave open possibility drug be approve use combination multiple checkpoint inhibitor simeonidis write note title bristol keep merck ido game incyte be testing epacadostat combination merck keytruda bristol opdivo astrazeneca azn durvalumab tremelimumab keytruda opdivo inhibit interaction call checkpoint immune system camouflage cancer cell help immune system see cancer ibd take body fight cancer cell fight everyday germ not dream reality head ibd technology page breakdown emerge immuno oncology sector astrazeneca durvalumab target pd protein tremelimumab target ctla protein receptor similar bristol yervoy incyte astrazeneca be work phase study drug combination epacadostat expect phase go go decision combination start year simeonidis write mean astrazeneca trail merck bristol slightly now be prep advance combination epacadostat phase trial midday trading stock market today bristol stock slip merck stock lift fraction incyte stock be astrazeneca stock be less related bristol afford lose dow stock merck immuno bristol prove longtime theory cancer defense dow merck swipe immuno oncology share heavyweight rival
97,MRK,bristol myer squibb bmy stock pop early monday drugmaker say immuno oncology drug combination significantly improve overall survival melanoma patient prove long standing theory cancer treatment give company leg rival dow component merck mrk year previously untreated advanced melanoma patient have receive combination opdivo yervoy show overall survival rate compare patient opdivo alone patient yervoy alone combine opdivo yervoy reduce risk death vs reduction patient yervoy alone bristol say news release news be good bristol afford lose immuno oncology leerink analyst seamus fernandez say early monday be ample evidence competitive landscape evolve quickly painfully write note client bristol test portion patient detectable tumor disappear compare earlier month follow increase combination group opdivo alone yervoy alone combination also appear somewhat more toxic expectation grade adverse event occur patient receive combination opdivo yervoy monotherapy patient respectively other company be work immuno oncology drug target different protein enzyme yervoy target ctla protein receptor incyte incy epacadostat target ido enzyme astrazeneca durvalumab tremelimumab work pd protein ctla protein receptor respectively certain combination be thought be particularly potent fight cancer most analyst see pd drug backbone immuno oncology end bristol announce weekend team incyte pair opdivo epacadostat several tumor merck member dow jone industrial average bristol plan present datum combination epacadostat june expect result justify advance multiple phase trial ibd take bristol myer squibb have middling ibd composite rating meaning outperform half stock term key growth metric still far away jazz pharmaceutical lead drugmaker cr best possible head stock checkup see pick stack drugmaker have long theorize combine immuno oncology drug boost potency bristol trial be first prove astrazeneca azn also be work similar combination advanced lung cancer separate study bristol be able increase overall survival rate patient previously treat advanced lung cancer year historically year survival rate patient advanced small cell lung cancer have be less bristol say be longest survival follow advanced lung cancer used immuno oncology drug teach immune system identify cancer cell bristol say opdivo merck keytruda do target specific protein call pd midmorning trading stock market today bristol stock be fraction close earlier rise much share pare back bristol announce opdivo fail improve overall survival roche avastin patient brain cancer call glioblastoma multiforme share merck be fractionally related bristol prove longstanding theory cancer defense dow merck swipe immuno oncology share heavyweight rival
98,MRK,bristol myer squibb bmy opdivo yervoy combo likely improve overall survival melanoma patient analyst say friday ahead american association cancer research meeting next week result trial opdivo yervoy melanoma prove long standing theory couple immuno oncology drug provide more potent cancer defense bristol be first unveil result immuno oncology combo close bell stock market today bristol stock be cancer research association annual gathering april washington bristol be set release datum several immuno oncology trial drug opdivo yervoy work immune system identify cancer cell identify fight opdivo target pd protein yervoy target ctla protein receptor bristol be also work target call ido monday bristol unveil result combination opdivo yervoy vs opdivo alone yervoy alone first line melanoma earlier result show strong progression free survival combo look overall survival evercore analyst umer raffat expect bristol hit goal improve overall survival melanoma patient combine drug fda conditionally approve opdivo yervoy treat first line melanoma strong earlier trial result ibd take immuno oncology sector be worth just base target already identify analyst tell ibd february head ibd technology page deep dive bristol also release result year study opdivo previously untreated advanced lung cancer patient later monday tuesday bristol present datum ido inhibitor know only bms alone combination opdivo advanced tumor company also have more presentation highlight study research multiple tumor type include lung melanoma head neck cancer bristol opdivo compete merck mrk keytruda be pd antibody approve advanced lung cancer melanoma head neck cancer opdivo have several more approval keytruda broader market share roche rhhby astrazeneca azn incyte incy also be work immuno oncology drug roche tecentriq be approve advanced lung cancer advanced bladder cancer incyte epacadostat target ido be be explore tumor type combination merck keytruda related be first immune system cancer drug fda
99,MRK,clovis oncology clvs rubraca label be cleanest analyst say tuesday day fda approve tesaro tsro zejula ovarian cancer requirement frequent bone marrow heart monitoring also likely clovis rubraca gain similarly broad label rivale tesaro zejula also fallopian peritoneal cancer competitive efficacy be establish late stage trial expect mid credit suisse analyst kennen mackay say close bell stock market today clovis stock drop tesaro meanwhile lose give back gain much rival astrazeneca azn lose follow tesaro announcement late monday fda have approve zejula niraparib patient recurrent ovarian cancer fallopian primary peritoneal cancer label require blood count be monitored weekly first month then monthly month note zejula bone marrow suppression warning be line intensive platinum base chemotherapy treatment mackay write note client see gynecologic oncologist highly experience monitoring marrow suppression see potential rubraca differentiate base safety mackay have outperform rating price target clovis stock ibd take tesaro be expect be top performer stock performance be indication head ibd industry theme breakdown leader tesaro also combine zejula immuno oncology drug first line ovarian cancer triple negative breast cancer advanced lung cancer merck mrk bristol myer squibb bmy roche rhhby have fda approve immuno oncology drug management do not disclose pd antibody be used trial be conduct part collaboration large pharma partner leerink analyst seamus fernandez say wouldn be first time immuno oncology drug have be pair hope become more efficient merck incyte incy be look keytruda epacadostat tumor type be first parp inhibitor landscape parp inhibitor like tesaro astrazeneca clovis block specific enzyme treat cancer immuno oncology drug immune system identify cancer analyst have long thought parp route be limit breast ovarian cancer explore tesaro other indication also offset disappointment recent study dub bravo win serve registrational trial zejula monotherapy breast cancer patient brca mutation too many patient drop tesaro say news release management note large number patient chemotherapy arm do not continue trial long enough first scan cause company determine result be difficult interpret leerink fernandez say instead tesaro move forward triple negative breast cancer immuno oncology drug triple negative breast cancer affect patient only patient have germ line brca mutation fernandez keep market perform rating tesaro stock related tesaro creep rival cancer drug merger unlikelytesaro sell astrazeneca ovarian cancer trial overdo analysttesaro rocket time high rumore takeover interest
100,MRK,stock index pare gain afternoon trading be session lows late trading nasdaq be flat be much reversed loss dow jone industrial average reversed loss small cap fend seller russell volume be tracking higher nasdaq lower nyse even index fade breadth remain positive winner beat loser ratio nyse nasdaq wall street focus today trading be capitol hill president trump demand vote bill replace obamacare be unclear republican have enough vote pass measure perhaps sense defeat bill investor send health care stock higher best gain friday hospital medical equipment medical research be industry group be more top group dow component unitedhealth group unh be nearly flat erase early gain share health insurance company be testing week move average be still record high pharmaceutical merck mrk pfizer pfe be fractionally goldman sachs gs dow component fall more lowest level feb bank tumble day move average tuesday sell financial general market outside dow manage care company humana hum slide breach day move average heavy trading stock fall much buy point march coherent cohr climb past buy point flat base share retreat back pattern volume be run more normal level make dispirited attempt concrete uscr crater plunge day move average be most heavily trade stock day ready mix concrete provider say federal filing chief financial officer joseph tusa jr resign personal reason have dismiss grant thornton llp accounting firm be replace young stock trouble be accenture acn sharply second straight day bit day line share break past buy point wednesday strong volume have quickly unraveled still consult firm have not trigger sell signal accenture beat profit estimate thursday guidance be soft related dow turn red ryancare death silver lininghere concrete share be sink stone
101,MRK,blowout private payroll report adp rebound oil price initially help put major stock index pace weekly gain strong start tech sector lead tesla tsla amazon com amzn apple aapl supplier also help send nasdaq fresh record high change minute federal reserve march meeting policymaker signale surprise tilt more monetary tighten sign disarray washington effort overhaul taxe also weigh market official job datum show conflict signal friday fail bolster market do strong ipo tech company okta dow jone industrial average close flat week be nasdaq be labor department march payroll report show gain just job barely half analyst expect january february gain be revise lower unemployment rate fall year low separate survey find robust jump employment much weakness payroll be blame unseasonable weather underlie trend be stronger adp private sector hire report earlier week put march job gain overall direction job wage inflation be see putt pressure fed tighten monetary policy related minute federal reserve march meeting release wednesday afternoon reveal policymaker be ready start shrink central bank balance sheet later year move amount tighten monetary policy begin reverse accommodation fed unconventional asset buy program launch late combat financial crisis revelation help turn solid stock market advance small loss analyst suggest fed policy signal mean unexpected rate hike september follow widely expect june allow fed start reduce size balance sheet december longer reinvest principal return bond holding mature separately jeffrey lacker president richmond regional fed bank abruptly resign admit violate fed confidentiality rule speaking financial analyst policy deliberation related okta okta raise late thursday pricing share high end estimate range stock climb ipo price close nasdaq friday price value company okta identity cloud platform provide identity management service business san francisco base company be fourth new company worth more come public year follow successful ipos mulesoft mule presidio psdo snap snap related tesla stock soar record high follow sunday report car delivery beat expectation tesla now have higher market valuation ford sell monday weak auto sale march ceo elon musk mock tesla short seller monday tweet tesla deliver just vehicle first quarter target vehicle wall street estimate related panera bread pnra agree be buy luxembourg jab include debt share deal be expect close third quarter jab also own caribou coffee krispy kreme doughnut keurig green mountain peet coffee tea fourth major restaurant acquisition year follow restaurant brand qsr purchase popeye golden gate capital buyout bob evan farm darden restaurant dri buy cheddar other transaction be horizon give analyst forecast restaurant traffic remain pressure year consumer opt save money eat home related google continue introduce remedy quash advertising crisis youtube derail rally parent alphabet googl stock mid march google introduce new system let outside firm verify ad quality standard video service advertising uproar begin europe major brand complain ad placement next video promote hate violence racism analyst say advertiser have suspend ad youtube be seek concession google aside resolve ad placement issue youtube meanwhile launch monthly tv stream service market new york los angele san francisco chicago philadelphia meanwhile amazon video business rolled ahead win right stream national football league game fall take ball twitter twtr hold same right last year amazon be pay big price privilege pay be more twitter paid game be available member amazon prime related india be first target twitter new version microblog service describe new mobile web experience minimize datum usage load quickly slower connection be resilient unreliable mobile network take less mb device twitter hope new mobile friendly service topple barrier usage country network be slow datum service plan be pricey much population mobile device tend lack storage see potential asia pacific region latin america africa related fda send company complete response letter merck mrk say want include datum trial evaluate cardiovascular outcome sitagliptin chemical name diabetes drug januvia janumet prescribe information sitagliptin contain medicine complete response letter be issue application be reject mean merck still have work do get approval include cardiovascular outcome datum label januvia janumet janumet xr merck say be explore option stock lose ground early friday recoup most loss close airstrike syrium lit defense stock friday raytheon rtn make tomahawk cruise missile launch mediterranean sea rise remain buy range flat base entry lockheed martin lmt lift just buy point lockheed make paveway ii laser guide bomb northrop grumman noc add boee ba boee make joint direct attack munition kit turn dumb bomb smart weapon constellation brand stz report earning jump share revenue rise result top analyst estimate ep sale alcoholic beverage giant know corona brand see beer sale rise net sale wine spirit be flat year constellation see ep recent analyst estimate sale rise also expectation related carmax kmx beat analyst estimate fiscal fourth quarter result continue have difficulty subprime business drop average used vehicle price reinforce concern industry sale loan quality carmax share close thursday earning share come cent better forecast cent sale grow forecast related walgreen boot alliance wba fall short revenue estimate report line ep same store sale rise focus remain draw merger smaller rival rite aid rad have yet obtain regulatory approval ftc walgreen ceo tell analyst earning call be still positive deal walgreen share close week smaller drugstore chain fred fred record lighter expect sale report reaffirm buy additional rite aid store top exist agreement acquire drugstore related kate spade kate reportedly take more time iron buyout term say reuter follow recent offer coach coh acquire fashion house news knock kate spade share be week elsewhere retail ralph lauren rl announce closure flagship fifth avenue polo store new york trim cost value shoe store chain payless shoesource file bankruptcy related
102,MRK,dow component merck mrk rise fray month month decrease immuno oncology sale industry swipe share rival bristol myer squibb bmy roche rhhby remain flat industry analyst say wednesday immuno oncology drug merck bristol myer roche bring february decline january leerink analyst seamus fernandez say cite datum tracker symphony health february be shorter month be partly responsible decrease fernandez say research report slowdown merck keytruda sale grow february vs prior month meanwhile bristol myer drug opdivo yervoy hold collective market share fall vs january merck keytruda now have market prior month roche tecentriq be flat share immuno oncology drug fight cancer teach body immune system identify cancer cell hiding specific protein protein be call checkpoint number checkpoint be be explore astrazeneca azn incyte incy other keytruda opdivo immuno oncology market leader be also direct rival target interaction pd protein immune system cell pd protein cancer cell do so allow immune system identify destroy cancer cell be approve treat advanced lung cancer melanoma head neck cancer classical hodgkin lymphoma opdivo be also approve kidney cancer bladder cancer yervoy bristol myer target ctla checkpoint roche tecentriq target pd protein cancer cell yervoy be approve treat melanoma tecentriq be approve lung cancer bladder cancer ibd take body fight cancer way fight common germ happen head ibd technology page breakdown new drug merck keytruda see spike sale july key trial show keytruda be superior chemotherapy improve progression free survival overall survival patient advanced lung cancer trial be stop early strong efficacy keytruda be approve october first line advanced lung cancer patient heavier concentration pd protein system then continue see steady increase sale estimate market share fernandez say tecentriq be also putt additional pressure opdivo follow approval second line treatment advanced lung cancer patient october say growth opdivo newer approval liver cancer hodgkin lymphoma head neck cancer bladder cancer help offset trend merck stock finished lower stock market today share bristol myer rise roche stock edge related be first immune system cancer drug fdamerck be near rival keytruda approvalmerck roche gouge bristol share lung cancer approval
103,MRK,cytomx therapeutic ctmx stock rocket month high monday breaking small biotech expand immuno oncology deal heavyweight drugmaker bristol myer squibb bmy company explore additional immune system checkpoint add agreement oncology target cytomx say press release deal bristol have advanced drug investigational new drug study stock market today cytomx stock rise earlier soar touch month high share break cup handle formation hit buy point bristol myer stock climb deal cytomx give bristol myer exclusive right develop commercialize oncology target cancer target used cytomx technology bristol pay cytomx upfront provide research funding cytomx be eligible receive future development regulatory sale milestone royalty mid single low double digit bristol sale product commercialize agreement deal capitalize bristol myer position immuno oncology market be face like merck mrk roche rhhby astrazeneca azn incyte incy ibd take analyst say be north immuno oncology drug be test right now only small handful have be approve head ibd technology page full list immuno oncology drug body immune system identify camouflage cancer cell target specific protein protein be call checkpoint total bristol cytomx be explore immuno oncology checkpoint particular checkpoint call ctla have prove successful bristol yervoy target ctla protein be approve treat melanoma have spread be treat surgery cytomx bristol be work move ctla drug clinical trial duo also have drug target pd protein similar bristol opdivo merck keytruda combine phase trial related merck be near rival keytruda approvalincyte spike record high rumor gilead acquire pharma firm be beating pack get drug market
104,MRK,acadium pharmaceutical acad intercept pharmaceutical icpt lexicon pharmaceutical lxrx be cusp be acquire analyst say friday examine historical merger pattern big pharma small midsize biotech company approve drug be attractive acquisition target due reduce development regulatory risk needham analyst alan carr write research report trio just grab first fda approval acadium nuplazid be approve april psychosis associate parkinson ocaliva intercept be approve liver disease lexicon xermelo get approval february carcinoid syndrome neurocrine bioscience nbix look likely get approval next month ingrezza drug aim treat involuntary movement associate long term use certain medicine disorder be know dyskinesia be number earlier stage company buy last year doesn tend be trend third small midsize company approval have be acquire carr write however acquire company have previously launch drug somewhere interpret risk mitigation acquire company say be acquire shortly first fda approval nearly year ibd take anyone catch beauty giant medical aesthetic least company be try read ibd industry snapshot biotechs half company acquire january more upfront cash have least approve market drug have phase datum drug fda review time announcement drugmaker target oncology infectious disease be ripest takeover then infection oncology have be acquire most rare disease company remain independent today allergan agn japanese pharmaceutical firm be most likely acquire earlier stage firm carr say overall allergan astella pharma daiichi sankyo sumitomo dainippon pharma collectively acquire company january today europe abbvie abbv merck mrk novartis nvs have acquire earlier stage company january related do beauty giant just solve acne challenge lilly merck allergan top analyst view pharma
105,MRK,incyte incy stock hit record high monday rumor biotech gilead science gild be look acquire projection still dwindle hepatitis drug sale incyte stock end regular trading session monday earlier touch time high gilead stock other hand trend third consecutive day close fraction rumor emerge friday gilead be putt together bid incyte eye immuno oncology drug epacadostat epacadostat be currently trial merck mrk keytruda target tumor type merck compete directly bristol myer squibb bmy incyte drug be different flavor immuno oncology work inhibit be know ido enzyme do so allow immune system identify tumor cell be destroy credit suisse analyst kennen mackay boost price target incyte stock note title part scarcity value make compelling target incyte epacadostat offer gilead attractive entry point immuno oncology field mackay say ibd take analyst urge gilead buy something friday company be good fit visit ibd industry theme breakdown gilead potential target epacadostat be scarce immuno oncology backbone blockbuster write note incyte drug be pair drug merck keytruda bristol opdivo target protein call pd battle cancer gilead incyte offer biotech giant entry potentially massive market hepatitis franchise fall year run gilead sovaldi harvoni bring north sale topple hepatitis be curable gilead have explain so company be see fewer patient do suffer hepatitis be healthier healthier patient tend longer see doctor gilead have push hiv drug bictegravir next mount everest analyst have push gilead make acquisition friday analyst suggest gilead look company pipeline resemble incyte clovis oncology tesaro report emerge gilead be consider bid incyte gilead decline comment email ibd incyte didn return request comment related gilead be pay price actually cure diseasewill merck glaxo undercut gilead next mount everest drug gilead hepatitis sale plunge merck swipe share analyst
106,MRK,food drug administration have approve merck mrk keytruda treat classical hodgkin lymphoma need more time review drugmaker application keytruda dna repair disorder tie several colorectal cancer merck announce development late tuesday fda give merck sell keytruda treatment child adult classical hodgkin lymphoma have relapse more prior treatment fda need more time examine keytruda treatment previously treat microsatellite instability high cancer disorder be cause deficiency dna repair sequence lead cancer believe patient tumor harbor dna repair defect be especially responsive keytruda merck say november first apply have fda consider keytruda treatment disorder new prescription drug fee user act date keytruda microsatellite instability high cancer be set june ibd take body target cancer way do common bacterium longer theoretical dive feature immuno oncology space ibd technology page keytruda compete directly bristol myer squibb bmy opdivo melanoma lung cancer head neck cancer now classical hodgkin lymphoma drug class drug use body immune system fight cancer specifically keytruda opdivo aim block interaction pd protein immune system cell pd protein cancer cell do so allow immune system identify cancer cell destroy astrazeneca azn roche rhhby incyte incy be also work vary checkpoint roche fda approve tecentriq target pd protein surface cancer cell incyte epacadostat belong class target ido enzyme bristol yervoy work similarly target ctla protein merck stock close stock market today share bristol myer rise bristol give presentation barclay global healthcare conference related merck meaningful keytruda royalty give bristol myer leg merck roche gouge bristol share lung cancer approval
107,MRK,stock be narrowly mixed early wednesday trading earning continue drive stock brexit start overseas nasdaq composite lead thank gain biotechs internet retailer nasdaq composite hold gain be flat dow jone industrial average dip small cap russell be volume be tracking slightly higher nyse nasdaq stock market today vs same time tuesday biotechs retailer lead steel utility lag wal mart wmt merck mrk be top gainer dow home depot hd traveler co trv be more internet retailer show strength amazon amzn alibaba group baba rise stock be buy range respective entry vertex pharmaceutical vrtx soar more month high gapping past buy point bottom base massive trade biotech late tuesday say clinical trial drug combo tezacaftor kalydeco treat cystic fibrosis show positive result plan seek marketing approval fda european medicine agency dave buster play fall heavy turnover drop stock back buy range flat base entry close tuesday restaurant arcade chain report result top view top bottom line midpoint full year revenue outlook be slightly street consensus estimate ollie bargain outlet olli pop nearly fast turnover share remain buy range flat base entry deep discount retailer late tuesday report better expect share earning sale extend double digit gain straight quarter full year ep outlook midpoint revenue guidance range be higher consensus lululemon athletica lulu gain ahead earning report close analyst expect yoga wear maker earn share sale mark respective year year increase related dave buster guide light beat ollie top guide highdow jpmorgan retake key support tesla focus investing action planvertex stock rocket strong cystic fibrosis datum
108,MRK,stock market look end wednesday high note major index trade intraday high head final hour trading tech heavy nasdaq lead market higher advance follow nearly gain dow jone industrial average lag fall volume be mixed inch higher nasdaq fall slightly nyse vs same time tuesday dow industrial stock market today merck mrk pace advancer rise attempt reclaim day line laggard unitedhealth group unh traveler co trv trade stock be trading respective day line amazon amzn new leaderboard addition break week tight add entry receive more bullish commentary analyst early wednesday commerce giant be initiate barclay overweight rating tuesday stock price target be raise stifel share amazon jump be buy range earlier cup handle entry other lead retailer alibaba baba moved jd com jd edge higher chinese retailer have be act well recent day alibaba be top buy range cup handle entry jd successfully test week line last week alibaba jd have show ibd ipo leader screen snap snap reversed higher follow facebook fb full scale attack tuesday company announce snapchat change social medium app wednesday barclay initiate coverage equal weight rating also be report snap partner nbcuniversal olympic earning reporter dave buster play ollie bargain outlet olli significantly diverged respective earning release late tuesday company surpass quarterly estimate eatery provide more cautious guidance close retailer be more upbeat dave buster rock sock robot restaurant chain drop tuesday share close extend flat base entry share remain entry ollie rally more higher break past flat base entry share be now cup handle buy point back early february action lead growth stock be mixed head final hour trading financial name lag general market advance many chinese stock be day best performer upside twitter china weibo wb moved continue latest attempt build right side potential base downside netease nte moved almost share be approach week line close lululemon athletica lulu report earning analyst expect rise earning share revenue amount share remain day move average struggle retailer have show glimpse positive trading action recent month related dave buster guide light beat ollie top guide highdow boee fang facebook alphabet amazon start buywhy add week line pullback trading playbook
109,MRK,stock open tight loss quickly improve mixed trade wednesday dow industrial nasdaq fought protect narrow gain week dow jone industrial average open nasdaq open lower then quickly reversed very slight gain merck mrk pop take early lead dow industrial boee ba upshifted boost berenberg initiate coverage stock buy rating price target fang stock be positive ground amazon com amzn lead pack barclay launch coverage stock overweight rating price target google parent alphabet googl climb barclay initiate coverage stock overweight rating price target facebook fb also receive overweight rating price target gain alphabet weak open action verizon vz run counter expectation follow approval house representative late tuesday end privacy provision enact federal trade commission provision require internet service provider obtain permission consumer order share employ certain specific internet use datum rule be see benefit company such google alphabet facebook remain free use such datum reversal rule approve senate week give company verizon comcast cmcsa freedom use sell third party specific customer internet use datum provide new profit marketing source comcast share trade flat open vertex pharmaceutical vrtx blast higher top biotech drugmaker announce late tuesday clinical trial show positive result combination drug tezacaftor kalydeco treatment cystic fibrosis company plan submit drug marketing approval food drug administration european medicine agency vertex chart be read bottom base cup handle buy point rh rh formerly restoration hardware soar early trading fine home furnishing retailer report earning revenue decline be not bad forecast close fiscal year share have climb recent week bottom network ffiv slip deutsche bank downgrade stock sell hold loss send share test week move average ollie bargain outlet olli gain report fourth quarter earning analyst target raise full year earning guidance consensus view huge volume gain left share still buy range flat base buy point dave buster play slump report fourth quarter performance late tuesday be stronger expect slip put share back buy range buy point trade edge higher europe london ftse reverse early loss rise fraction prime minister theresa tuesday night sign unite kingdom official letter resignation european union officer reportedly turn letter eu official today trigger article set year deadline exit negotiation frankfurt dax trade cac paris add oil price be positive west texas intermediate hold barrel ahead energy information administration weekly inventory report due et national association realtor deliver pending home sale datum february et stock market today also get speech federal reserve bank president charle evan chicago federal reserve bank speak et boston fed eric rosengren take dais et john william san francisco fed be et earning report expect close include hb fuller ful lululemon athletica lulu metal processor worthington industry wor other related jp morgan retake day tesla focus investing action planwhich sector fund be top market beater
110,MRK,eli lilly lly merck mrk allergan agn stand outperform broad pharma stock credit suisse analyst say monday cite strong pipeline expect clinical datum year merck stock close stock market today share allergan dip lilly finished lower drug stock be broadly stay day move average credit suisse analyst vamil divan expect macro uncertainty pressure drug stock first half continue trend begin raucous election season drug stock end be january merck outperform keytruda immuno oncology drug divan say keytruda similar drug bristol myer squibb bmy roche rhhby patient immune system identify tumor cell immune system then destroy cancer keytruda go head head bristol myer squibb opdivo target specific protein body merck be team test keytruda incyte incy drug epacadostat epacadostat target protein ibd take jazz pharmaceutical top ibd company ethical drug industry group composite rating best possible score mean jazz outperform nearly third stock term key growth metric get rest leader list ibd stock checkup lilly pipeline be now derisked divan write note client see promise diabetes drug jardiance trulicity plaque psoriasis drug talz lartruvo soft tissue sarcoma baricitinib treatment eczema sentiment allergan be finally start thaw write cite further upside pipeline new drug linzess viberzi irritable bowel syndrome well vraylar bipolar disorder small midcap scene divan prefer aldr corvus pharmaceutical crvs aimmune therapeutic aimt be work migraine medicine base inhibit specific peptide body eliminate migraine corvus be peer player divan say related be first immune system cancer drug fdamerck bristol myer incyte race career market
111,MRK,tesaro tsro oncology drug niraparib be approve regulator late monday treatment ovarian cancer company announce be expand development drug treat other type cancer company now sell drug brand name zejula be expand development treatment lung cancer be first time drug type know parp inhibitor be used treatment outside breast ovarian cancer tesaro say also expand use treat advanced breast cancer first line advanced ovarian cancer arena rival astrazeneca azn clovis oncology clvs already have fda approve drug respectively lynparza rubraca share tesaro be halter have dip more stock resume trading follow news release share tesaro end trading monday astrazeneca stock close clovis stock close niraparib be approve base unprecedented result nova trial woman recurrent ovarian cancer tesaro say release approval zejula hand now begin execute plan pursue potentially application niraparib broad range metastatic cancer indication tesaro be look pairing zejula immuno oncology drug develop bristol myer squibb bmy merck mrk roche rhhby immuno oncology drug immune system identify fight cancer cell first line ovarian cancer tesaro plan study zejula combination genentech avastin pd antibody other fda approve drug category include merck keytruda bristol opdivo goal be replace chemotherapy set tesaro say company also expect look zejula combine pd antibody woman metastatic triple negative breast cancer patient advanced lung cancer parp inhibitor have largely be limit breast ovarian cancer study earlier day analyst say tesaro chance be acquire have diminish light recent view rival drug astrazeneca clovis be just effective tesaro niraparib poll conduct jeffery indicate doctor view tesaro niraparib similar fda approve rubraca clovis lynparza astrazeneca be parp inhibitor work defeat cancer block specific enzyme analyst have see niraparib superior drug oncologist poll result indicate parp inhibitor be more similar vs dissimilar vs long hold street view niraparib best class jeffery analyst eun yang say report therefore potential advantage have broad label niraparib be uncertain new view similarity follow late stage datum astrazeneca earlier month trial lynparza be able halt cancer spread increase progression free survival population ovarian cancer patient median month vs month patient drug free placebo similar trial tesaro niraparib extend progression free survival median month astrazeneca be able show blind independent central review evaluation essentially best case scenario lynparza stave reoccurrence ovarian cancer median month ibd take tesaro stock be expect be leader grab triple digit stock gain else lead head ibd industry theme more actionable stock jeffery yang say result potentially affect tesaro shot be acquire bid likely have clovis unveil phase datum mid potential bidder want access competitor dynamic pay yang write note client boost price target tesaro stock keep hold rating view takeout share price target assume odd tesaro takeout thus view risk reward skewer downside tesaro launch niraparib own write related tesaro rumore sale fetch north share analyststesaro rocket time high rumore takeover interesttesaro sell astrazeneca ovarian cancer trial overdo analyst
112,MRK,gilead science gild pursue merger outside core virology oncology inflammation area analyst say friday plea have work sooner thought barclay analyst geoffrey meacham suggest gilead look company pipeline resemble incyte incy tesaro tsro clovis oncology clvs then hour later incyte stock spiked more streetinsider report cite source say gilead be ready pull trigger acquire biotech gilead stock sank fraction stock market today representative gilead have comment incyte didn immediately return request comment meacham suggestion come total prescription hepatitis drug harvoni dip week week accord health care tracker im cite leerink analyst seamus fernandez new prescription also fall vs last week same time gilead epclusa see total prescription flatten new prescription rise week week basis still competition be mount merck mrk rival drug zepatier post stout jump total prescription new script fall gilead struggle hepatitis franchise be well document year more total sale gilead harvoni sovaldi see sale decline partially offset new drug epclusa hepatitis be curable now gilead be push hiv unit next mount everest barclay meacham be doubtful company hiv drug bictegravir be enough tug gilead stock share have topple january share lose friday ibd take analyst have long predict gilead hepatitis downfall happened be warning sign head ibd industry theme breakdown letter gilead management meacham implore company seek even incremental transaction suggest gilead look company immuno oncology drug target ido checkpoint asset parp inhibitor class drug firm work lymphoma deal be much more pipeline drive longer term profit loss benefit also likely be well receive also carry substantial clinical risk meacham write note trade be favorable gilead acquire company multiple mid late stage drug strong pipeline incyte drug epacadostat fit bill epacadostat belong class drug immune system identify camouflage cancer cell astrazeneca azn tesaro clovis oncology be work ovarian cancer drug class call parp inhibitor company seattle genetic sgen be work classical hodgkin lymphoma wall street have long harp gilead seek deal acquisition triangle pharma pharmasset meacham call deal literally best deal ever consummate history biopharma industry admire gilead discipline especially valuation peak trough biotech pharma sector too much patience have put immense pressure gilead share meacham write far away fear be quarterly operate cash flow decline so do gilead capacity do meaningful transaction related gilead be pay price actually cure disease
113,MRK,biotechnology giant gilead science gild buy pharmasset inherited compound then know wall street analyst expect bring peak sale just year later launch name sovaldi north pill rake sale alone prove be nearly foolproof cure hepatitis virus hcv year gilead flagship hcv drug pull more also double company net margin push past level point mid trouble be gilead didn just treat hepatitis most part cure patient month sovaldi have unheard success rate hepatitis patient follow treatment harvoni prove more effective case eventually patient pool be bound get smaller have sovaldi harvoni sale fall respective think open blockbuster movie hollywood person line rbc analyst michael yee tell investor business daily thus be less come right now now pressure be gilead produce big hit drive growth biotech investor story be cautionary tale look initial fanfare hot new drug consider cost deliver promise hepatitis hiv alzheimer disease many type cancer be short term temporary condition say kevin young gilead chief operate officer company feb earning conference call analyst gilead say fewer patient be start hcv regimen do be healthier past patient thank harvoni hcv be cure little week genotype patient young say refer most common type hepatitis gilead confirm worry hepatitis slowdown feb release fourth quarter earning share topple next day nearly touch year low whisper loom dip hcv drug sale have plague gilead stock better part year climb rapidly gilead stock start slip lose analyst issue report report modele gilead look hcv today gilead see hiv unit grow last year next big enterprise have describe hiv drug bictegravir future mount everest still sentiment hasn be negative gilead stock pharmasset acquisition say evercore analyst mark schoenebaum then analyst survey schoenebaum say gilead paid too much pharmasset later analyst miss potential immediate demand sovaldi didn even account harvoni last time sentiment gilead management be bad investor be wrong very wrong schoenebaum write feb research report more half november survey say pharmasset buy destroy gilead value sentiment obviously improve sovaldi old school hepatitis treatment weren effective often come flu side effect anemia sovaldi be so successful gilead launch harvoni see similar result harvoni sale year newest addition hepatitis line epclusa bring gilead stock fly wall street perform degree turn sovaldi ahead launch activist group patient be incense discussion bump sovaldi price expectation drug be wall street dynamo harvoni launch even bigger price tag gilead take lump headline price rbc analyst yee say price tag weren particularly egregious consider prior treatment cost high cost treatment be not high relative exist prior therapy be significantly better tell ibd email cost have come give competition other rebate fourth quarter gilead chief executive john milligan note harvoni now sell meanwhile rivalry merck mrk abbvie help curb price merck signale expectation lighter hcv sale february take impairment charge uprifosbuvir merck acquire uprifosbuvir idenix pharmaceutical company cut value estimate uprifosbuvir leerink analyst geoffrey porge say merck be signale reduce value participation market be consistent decline market overall merck have successfully defend patent hcv med zepatier gilead abbvie be work next generation drug set launch sometime wall street suspect hcv decline be come modeled total gilead sale hepatitis franchise revenue gilead company guidance total sale hepatitis drug revenue paint starker picture guidance gilead say expect patient start hcv regimen drop gilead estimate patient start hepatitis drug fewer hcv sale get push large commercial payer open access marketing campaign department veteran affair gilead young doesn expect time driver repeat guidance imply lower ep earning share consensus be modele rbc yee write feb research report think stock be probably range bound hit least quarters demonstrate handle forecast visibility yee also echo other analyst call acquisition bolster top line gilead work hcv decline work launch drug hiv nash nonalcoholic steatohepatitis unit yee see incyte incy smart unlikely deal gilead withstand pressure pharmasset buy win bend public pressure evercore schoenebaum say feb video investor be question ceo milligan none have identify specific deal miss have prevent hcv decline ibd take strong drugmake bet check incyte analyst say incyte pipeline be brim potential blockbuster opportunity head new america deeper dive incyte upcoming catalyst have here be company not just go go do deal so press release say do deal hope get sugar high stock say re only go do deal have high degree confidence work high degree confidence re underpay asset meanwhile gilead be bolster hiv nash unit gilead recently pit hiv drug bictegravir glaxosmithkline gsk incumbent dolutegravir approve sell brand name tivicay phase trial show bictegravir be numerically stronger gsk drug certain combination price be bigger concern gsk medication be cheaper combine generic med meaning hiv regimen be price vs likely price tag attach gilead solution yee say feb report other analyst say gilead hiv nash unit be too late offer little value leerink analyst geoffrey porge say feb expect hepatitis sale topple then annually outlook hiv be positive sale aren hcv trajectory porge say be not sufficient offset unusual dynamic hcv business relatively modest contribution other product offer little mitigate boom bust hcv write opportunity appear be arrive too late too little value view yee say gilead isn fill hole left decline hcv unit merely come massive bolus hundred thousand person come first year drug be still set do be largest drug world not exactly hole say related gilead clobber hep little value too late nash hiv unitscan gilead swivel hiv flounder hep sale gsk rivalry gilead hiv drug top gsk combo rivalry intense gsk doublet
114,MRK,gilead science gild see hiv drug bictegravir mount everest rival merck mrk glaxosmithkline gsk be able price rival drug cheaper analyst say thursday leerink analyst geoffrey porge note merck glaxo be work hiv regimen include generic drug gilead other hand have establish premium pricing fix dose combination base brand component pricing porge write research report result gilead struggle gain share hiv much need sector lucrative hepatitis franchise continue dwindle year sale gilead hepatitis drug see sale decline biotech be guide further decline past year gilead have dominate hiv landscape porge say hiv unit bring sale competitive landscape be shift hiv new drug set launch gilead bictegravir base formula be likely be gold standard first second line hiv treatment porge write gilead unlikely budge pricing ability hold share price erode predict ub analyst carter be more bullish gilead hiv enterprise street expect bictegravir eventually get different brand name pull sale peak sale combine substance now know filgotinib filgotinib be drug develop galapago glpg downgrade gilead stock neutral rating buy cut price target cite company struggle hepatitis guidance suggest dip hepatitis drug sale fewer patient start gilead hepatitis drug year be line gilead note fourth quarter earning conference call old school hepatitis medication weren effective gilead sovaldi harvoni carry number side effect today be fewer patient many be healthier thus put treatment ibd take gilead hepatitis drug downfall didn come blue analyst have predict better part year be warning sign visit ibd industry theme closer look gilead be also experience competitive pressure like merck abbvie abbv merck have successfully fought patent litigation vs gilead hcv drug zepatier abbvie be set launch next generation asset merger win fix gilead problem write gilead acquire triangle pharma pharmasset respectively stock trend roughly month announcement gilead stock be now year rbc analyst michael yee disagree argue gilead do number string pearl acquisition improve pipeline visibility kite pharma kite be interesting acquisition say meanwhile tail hepatitis sale be significant enough sustain demand yee have outperform rating gilead stock close bell stock market today gilead stock fall merck be marginally glaxo add related pharma be beating pack get drug marketabbvie strong bet gilead amgen least analystgilead glaxo pit hiv battle struggle vs standard drug
115,MRK,president trump rail outrageous drug price monday send biotech pharma stock reel midday tuesday appear gop bill repeal replace obamacare doesn touch pharmaceutical newest iteration american health care act doesn mention trump plan curb spiraling drug price speech monday send ibd company generic drug industry group tailspin drop month low generic drugmaker dr reddy laboratory rdy stock sank stock market today eagle pharmaceutical egrx tumble aclaris therapeutic acrs dip ani pharmaceutical anip lose ibd company biom biotech industry group crash collective la jolla pharmaceutical ljpc puma biotechnology pbyi kite pharma kite stock particularly hard respectively lose specialty drugmaker endo pharmaceutical endp fall mallinckrodt mnk drop depome depo topple trump unspecified plan call bring cost medicine have fair competitive bidding process president say late monday rally kentucky medicine price be come way way way way go happen fast say re just add bill say ve get add bill call cost medicine country outrageous say many time higher country europe elsewhere ibd take drug approval slump least company add new drug wheelhouse see one ibd industry theme somebody be get very rich say later comment drug price aren include first version american health care act legislation address drug issue follow closely trump have have love hate relationship drugmaker early presidency call drugmaker lower pricing later meeting ceo celgene celg johnson johnson jnj merck mrk novartis nvs other pledge cut fda regulation speed drug approval process last week trump unveil blueprint propose increase user fee collect fda drugmaker more do so squeeze already thin margin generic drugmaker related pharma stock be big loser trump drug pricing tweetbiotechs leap trump call innovation speedy fda approvalj ceo underwhelm investor trump dodge drug pricing
116,MRK,stock slip red early tuesday oil price reversed lower nasdaq composite hit new record high solid gain apple aapl nasdaq composite fall dow jone industrial average hold fractional loss small cap russell lag volume be lower board stock market today vs same time monday gold miner hotel operator telecom related play be top gainer early trade department store solar airline stock underperform apple lead upside dow gain new time high rapid turnover share be now profit take range more past cup handle buy point apple launch several new product tuesday include red iphone lower cost ipad short video make app call clip nike nke reversed slightly lower ahead earning report due close analyst expect athletic shoe giant report slip cent share higher sale mark first year year ep decline late other blue chip drugmaker merck mrk pfizer pfe pfe be goldman sachs gs caterpillar cat be more apiece marriott international mar gap rise striking new intraday high big volume hotel operator announce year growth plan include earning share compound growth rate share be top buy range flat base entry base stock lead ibd france criteo crto china tal education tal weibo wb score gain north downside lennar len fall more heavy trade report fiscal earning decline year year top view snap multiyear streak quarterly increase share remain extend past cup handle entry related dow nike expect log first earning decline year apple debut red iphone cheaper ipad new video app
117,MRK,eli lilly lly pipeline have best bang buck analyst say wednesday comparison pit lilly rival pfizer pfe merck mrk bristol myer squibb bmy leerink analyst seamus fernandez say lilly be outperform pack achieve best balance investment limit external investment past year bristol pfizer trail merck struggle metric write still drugmaker lilly have struggle gain fda approval only drug pharma pipeline have gain approval contrast biotechnology company abbvie abbv gilead science gild have be more successful conversion rate top drugmaker bristol myer lilly have have considerably more success phase drug meanwhile pfizer have only converted late stage pipeline drug sell market pfizer have broadest pipeline group disclose new drug fernandez write have struggle fall megamerger disruption limit scale productivity merck be lowest pharma universe ibd take american fund recently up stake bristol myer squibb stock else receive american fund vote confidence find ibd mutual fund page analysis fernandez also look churn turnover new drug burn percentage attrition portfolio bristol have highest burn rate lowest churn rate company appear be focuse more internal asset partnership early stage mid late stage external agent fernandez write note conversely merck churn rate be highest group merck high overall expense be drive part large cubist idenix deal have so far struggle generate sizable return management have hope well company extraordinary investment keytruda write merck isn alone struggle partnership acquisition big drugmaker biotechs only gilead purchase pharmasset appear have succeed fernandez write pharmasset begin development sovaldi hepatitis drug rocket gilead sale gilead hepatitis franchise begin falter high cure rate trio drug sovaldi harvoni epclusa close bell stock market today lilly finished trading bristol myer rise meanwhile merck slip pfizer also lose related gilead hepatitis sale plunge merck swipe share analystabbvie stronger bet gilead amgen least leerinkmerck roche gouge bristol share lung cancer approval
118,MRK,prescription gilead science gild hepatitis drug have plunge jan leave least analyst wait industrywide revenue remedy hit bottom even competition loom rival merck mrk abbvie abbv total prescription harvoni sovaldi epclusa be flat week week have fall begin quarter jan rbc analyst michael yee write note client cite health care tracker im new prescription be vs last week meanwhile merck hepatitis drug zepatier have flourished total zepatier script be quarter date new prescription climb week week total prescription be vs last week zepatier now have new prescription market yee write merck have say expect grow share overseas launch japan europe fourth quarter zepatier list price treatment be roughly cheaper gilead alternative little more half list price harvoni many drugmaker however have not be get list price drug company suggest country be open more access more yee write be good gilead well even merck isn immune weaken hepatitis market last week merck say take impairment charge uprifosbuvir hepatitis drug acquire ibd take biotechs incyte be strong bet number potential blockbuster pipeline analyst say incyte keep lead visit new america deep dive company stock gilead be first market new class highly effective hepatitis drug prescription company lineup top major year run time gilead net margin more double roughly level peak disease be curable meaning get harder find new patient new patient be often healthier procrastinate begin treatment gilead have say gilead abbvie hepatitis drug sale also be struggle week abbvie viekira pak hepatitis fall be quarter date yee write new prescription grow week week abbvie be essentially niche player now second generation drug be competitor yee write drug be approve year end gilead yet competitor slow market earlier year gilead guide hepatitis drug sale miss expectation guidance actually be conservative gilead need hit couple quarter see script stabilize investor gain confidence yee say be watch hcv script flatten slope curve inflect stabilize order establish bottom franchise midday trading stock market today gilead stock be fraction share merck abbvie be fraction respectively related gilead abbvie perk merck hep downfall leerinkabbvie stronger bet gilead amgen least leerinkgilead glaxo pit hiv battle struggle vs standard drug
119,MRK,key house committee have propose delay change medicaid funding moderate republican effort repeal replace major part obamacare run trouble ability republican bridge wide divide moderate conservative still look iffy especially senate signal retreat medicaid cut have health care sector breathe sigh relief dow jone industrial average index nasdaq composite be slightly negative early afternoon stock market today health stock be mostly higher hospital hca holding hca close tenet healthcare thc jump universal health service uhs gain insurer molina healthcare moh be unchanged aetna aet climb dow component unitedhealth group unh edge drugmaker also have benefit president trump back away earlier threat intervention bring high cost prescription be mixed dow component merck mrk rise pfizer pfe dow member end flat ibd take difficulty republican settle replacement obamacare be threaten sidetrack rest president trump economic agenda include tax cut infrastructure spending house energy commerce committee play key role shape health reform release plan next week maintain medicaid funding level cut take effect wall street journal report retreat house come gop governor have be make voice hear preserve obamacare medicaid expansion gov john ohio have embraced medicaid expansion meet trump week have be leader effort related biotechs leap trump call innovation speedy fda approvaltrump big speech leave investor hope not much else
120,MRK,astrazeneca azn clovis oncology clvs challenge tesaro tsro treatment ovarian cancer know parp inhibitor leerink analyst seamus fernandez say wednesday reiterate view tesaro potential acquisition target stock market today tesaro stock topple late tuesday fourth quarter earning report share last week touch record high fernandez classify earning report largely uneventful tesaro quarterly number lag significantly quarter tesaro report sale year quarter miss analyst estimate revenue tesaro post share adjust loss analyst share loss forecast fernandez keep price target market perform rating tesaro add fair takeover price likely be share street currently think niraparib lead field parp inhibitor essentially second line maintenance treatment ovarian cancer niraparib reputation be duress astrazeneca clovis oncology be expect release datum parp inhibitor lynparza rubraca later year fernandez write report datum lynparza be expect later month rubraca datum be likely mid ibd take parp inhibitor help buoy biotech industry analyst say tesaro fit trend read ibd technology page deeper dive lynparza rubraca niraparib isn yet fda approve be grant priority review december day fda grant accelerate approval clovis rubraca drug aim block specific enzyme thought be tie ovarian breast cancer tesaro also be work nausea medication chemotherapy patient varubi tesaro expect varubi receive approval first half fda ask more information surround comparison drug manufacturer rbc analyst adnan butt expect niraparib varubi gain fda approval year have outperform rating price target tesaro stock tesaro also have plan initiate registration program immuno oncology drug know tsr first half drug target pd checkpoint immune system putt same category drug merck mrk bristol myer squibb bmy immuno oncology drug patient immune system identify cancer cell order destroy tesaro be also look other checkpoint include tim lag have plan begin trial look combination immuno oncology drug mid related astrazeneca give pfizer tesaro leg breast cancer leerinktesaro rumore sale fetch north share analyststesaro rocket time high rumore takeover interest
121,MRK,activist investor carl icahn have reportedly take stake cancer biotech bristol myer squibb bmy follow investment jana partner accord source cite wall street journal hour trading rumor break bristol myer stock edge fraction share rise fraction tuesday regular session re last month investor worry merck mrk have upper hand lung cancer market merck keytruda bristol opdivo class immuno oncology drug target pd checkpoint patient immune system roche rhhby astrazeneca azn incyte incy be also work drug target array checkpoint last month food drug administration accept merck supplemental filing keytruda chemo advanced lung cancer bristol say wouldn accelerate approval opdivo yervoy combo same market yervoy be drug target ctla checkpoint ibd take market grow barclay analyst geoffrey meacham estimate be just indication know dive world game change potential ibd technology page bristol decline comment ibd regard icahn rumore stake insider reportedly say icahn see bristol myer potential takeover candidate wsj report bristol myer be ninth largest biotech market cap value icahn be know investment household name paypal pypl xerox xrx last year make big bet allergan agn slash stake november share lose time purchase end november jana partner activist investor buy stake bristol myer tuesday bristol say buy back stock part agreement jana company also add robert bertolini matthew emmen theodore samuel board director temporarily expand board election related be first immune system cancer drug fdamerck keytruda sale lag defer revenuebristol myer dife opdivo setback get keytruda royalty
122,MRK,amgen amgn haul share medicine company mdco esperion therapeutic espr friday ldl cholesterol buster repatha show cardiovascular benefit long await study analyst say tuesday amgen biotech be set release result fourier study et friday american college cardiology annual meeting washington fourier examine repatha ability reduce heart attack stroke cardiovascular disease repatha be already approve reduce bad ldl cholesterol compete praluent drug regeneron regn sanofi sny judge recently rule praluent infringe amgen patent repatha injunction praluent have be stay pending appeal meanwhile amgen be face mount pressure like medicine company merck mrk esperion repatha praluent work block enzyme degrade receptor responsible remove bad ldl cholesterol blood specific market amgen regeneron sanofi drug class call pcsk inhibitor grow least worldwide sale next year rbc estimate theoretical patient ibd take amgen lead market cap trail celgene term key growth metric amgen have ibd composite rating best possible celgene lead cr visit stock checkup breakdown top rate biotechs drug medicine company merck esperion have slightly different mechanism also help reduce cardiovascular disease accord doctor survey investment bank rbc survey say amgen datum be strong repatha reduce cardiovascular disease nearly half think inclisiran medicine company have cardiovascular benefit nearly third think merck anacetrapib be able reduce cardiovascular disease esperion other hand still need get build awareness rbc analyst write research report only doctor expect esperion bempedoic acid meet goal reduce ldl cholesterol show cardiovascular benefit study still think stock grind higher give small market cap wholly own right phase datum start rbc say amgen share fall stock market today related amgen top heart study regeneron sanofi courtabbvie stronger bet amgen least leerink
123,MRK,exelixis exel be take page incyte incy playbook team bristol myer squibb bmy roche rhhby test cabometyx immuno oncology drug liver bladder cancer stock market today exelixis stock flirted year high touch tuesday company announce collaboration bristol myer roche share come cent eclipse tuesday high rise help lift ibd company biom biotech industry group do gain bluebird bio blue cara therapeutic cara plan phase trial successful support potential label expansion cabometyx several additional indication include first line kidney cancer bladder cancer hepatocellular carcinoma potentially other tumor type leerink analyst michael schmidt say research note cabometyx inhibit tyrosine kinase vegfr receptor slow tumor growth metastasis angiogenesis be approve monotherapy second line advanced renal cell carcinoma partnership be nothing new merck mrk be testing pd inhibitor keytruda conjunction incyte ido inhibitor epacadostat not yet approve tumor type bristol myer also have team horizon pharma hznp advanced solid tumor ibd take be more trial underway right now analyst estimate only small handful drug have actually be approve lead sector term approval head ibd technology page best opportunity exelixis bristol focus first line rcc have trial plan hcc bladder cancer company say monday exelixis outside japan partner ipsen participate rcc trial exelixis japan partner takeda pharmaceutical have opportunity do so partner phase trial help exelixis shave cost schmidt write exelixis cabometyx be combine bristol opdivo yervoy respectively pd ctla inhibitor detailed economic bristol myer be not disclose press release exelixis potentially end pay little trial cost give cost split bristol myer write exelixis roche combine cabometyx tecentriq pd inhibitor phase escalation study patient locally advanced metastatic solid tumor say trial begin enrolling mid trial look first line advanced clear cell rcc cohort urothelial carcinoma exelixis sponsor study roche contribute tecentriq ipsen participate contribute cost takeda still opt schmidt keep outperform rating exelixis stock related merck bristol myer incyte race cure merck meaningful keytruda royalty give bristol myer leg bristol myer topple guidance cut merck competition
124,MRK,stock market be mixed afternoon trading monday key technology stock draw interest nasdaq climb alphabet googl briefly rise just past buy point time high parent company google pull back advance volume be tracking well average mild price behavior also left something be desire alphabet get auto insurance business part growth self diving car morgan stanley report say fall small cap russell lead increase dow jone industrial average lag loss mysterious drop merck mrk dow component slide more biggest move feb pharmaceutical company announce earning be news wire today medical stock be generally lackluster chip sector be buzz today market news intel intc agree acquire mobileye mbly deal advanced energy industry aeis hit new high heavy trading analog device adi rise less volume be tracking well usual level lam research lrcx also hit new high well extend price november several visit week move average logitech international logi break flat base surge past buy point heavy volume stock relative strength line also make new high bullish sign maker mouse keyboard other pc accessory be leader ibd computer hardware peripheral industry group post decline ep switzerland base logitech have mount comeback profit increase past quarters metal lead market steel metal distribution mining industry group be top group many mining stock be try snap decline have last month several retail stock be one fall unusually heavy volume zumiez zumz fall gapping friday tractor supply tsco urban outfitter urbn dsw dsw also be heavy trading department store discount chain mail order apparel store be monday weakest perform group related advance tech stock near buy pointlilly merck allergan top analyst view pharma
125,MRK,merck mrk keytruda roche rhhby tecentriq be swipe market share bristol myer squibb bmy drug company win fda approval advanced lung cancer market tracker symphony health say thursday total immuno oncology drug sale rise january december leerink analyst seamus fernandez write research note cite symphony datum keytruda opdivo be direct rival work block interaction pd protein cell pd protein cancer cell do so allow cell see cancer cell be destroy roche tecentriq target pd checkpoint opdivo be first gain approval small cell lung cancer nsclc march keytruda tecentriq follow october october respectively be also approve treat advanced melanoma bristol yervoy ctla checkpoint also have approval melanoma sale january show merck roche be gain share bristol detriment symphony datum show bristol see share tip january december keytruda increase share tecentriq have share ibd take analyst estimate more ongoing trial immuno oncology look multitude checkpoint be fewer dozen approve drug read list strongest competitor merck lead be seemingly solid nsclc january fda accept accelerate approval keytruda chemo treat nsclc less week later bristol say wouldn seek accelerate approval opdivo yervoy combination nsclc last year merck see inflection share late stage keynote trial nsclc read positively fernandez write november marked first full month sale follow keytruda approval nsclc patient pd expression continue see steady increase sale estimate market share fernandez say addition approval tecentriq pd unselected second line patient oct be putt additional pressure opdivo set opdivo newer indication renal cell carcinoma hodgkin lymphoma head neck cancer bladder cancer partially offset loss older indication fernandez say stock market today merck stock rose bristol myer rise roche stock slip merck stock be still buy zone feb bristol myer be stay day support line second day related merck bristol myer incyte race cure marketmerck keytruda sale lag defer revenue analystbristol myer topple guidance cut merck competition
126,MRK,gilead science gild glaxosmithkline gsk have tough time divorce hiv patient traditional pill regimen leerink analyst geoffrey porge predict wednesday follow conference retroviruse opportunistic infection hepatitis franchise bust follow boom gilead be look hiv medication bictegravir combination ftc taf drug become next mt everest hepatitis drug sovaldi harvoni fall respectively vs year earlier period bictegravir glaxo dolutegravir go head head phase trial gilead be used ftc taf combo week week bictegravir patient have virological response compare dolutegravir patient leerink porge speak specialist follow conference seattle lower response rate dolutegravir arm didn necessarily indicate actual treatment failure only few more patient have hiv rna greater copy milliliter snapshot date write research report ibd take analyst predict downfall gilead hepatitis unit sign be read ibd industry theme still give recent success porge say specialist be comfortably certain gilead bictegravir meet primary hurdle inferiority glaxo dolutegravir ongoing phase trial pricing be bigger concern gilead analyst broadly expect gilead price bictegravir combination vs expect price tag rival hiv treatment glaxo merck glaxo pill regimen be likely be used small subset patient porge write trial multiple patient drop be require take pill most important take away conversation be deep attachment exist drug hiv treatment standard porge say limit impact drug regimen be expect have least current payer environment close bell stock market today gilead fall glaxo inched cent glaxo stock tuesday touch month high gilead feb hit nearly year low related gilead hiv drug top gsk combo rivalry intense gsk doubletgilead crash hep sale decline view metric topcan gilead swivel hiv flounder hep sale gsk rivalry
127,MRK,gilead science gild abbvie abbv benefit merck mrk decision take impairment charge hepatitis drug market price shrink leerink analyst geoffrey porge say friday merck also cut value estimate uprifosbuvir hepatitis drug acquire idenix pharmaceutical base upcoming drug regimen change view whole hepatitis market regulator say merck complete separate trial show add benefit triplet high dose doublet regimen porge say complicate matter high dose doublet be phase testing triplet also suggest remain value rest idenix be now very small porge write research report merck be also seemingly indicate significantly reduce value future participation market be consistent decline market overall ibd take analyst project downfall hepatitis drug sale be warning sign be other market risk read ibd industry theme gilead abbvie johnson johnson jnj bristol myer squibb bmy compete hepatitis market merck charge signal drugmaker expect have lighter sale smaller share initially forecast drugmaker be struggle grow pain follow boom subsequent bust hepatitis drug sale gilead be poster child phenomenon sale sovaldi harvoni topple now gilead be bet hiv drug bictegravir merck too note change patient population dynamic company determine recent change product profile well change expectation pricing market opportunity take together constitute trigger event require company evaluate uprifosbuvir intangible asset impairment merck write filing security exchange commission late thursday morning trading stock market today merck stock be fraction close bell share abbvie inched gilead gain related abbvie stronger bet gilead amgen least leerinkgilead glaxo pit hiv battle struggle vs standard drugscan gilead swivel hiv flounder hep sale gsk rivalry
128,MRK,satisfy trump administration call deal high drug cost industry leader be propose president lead negotiation drugmaker restrain price allergan agn chief executive brent saunder cite tactic used president john kennedy decade keep steel price administration also waive federal antitrust rule currently prohibit drugmaker discuss pricing so put together guideline follow say voluntary agreement restrain price be very practical solution doesn view do anything impede innovation saunder say wednesday interview bloomberg headquarters new york convince fellow drugmaker agree however be challenge be difficult saunder say big pharma be intense pressure come way reduce price president trump accuse company get away murder threaten use government buy power force price saunder have be outspoken excessive price hike own industry allergan company product range wrinkle treatment botox stomach schizophrenia medicine ceo have implement social contract cap increase annually trump model something pharmaceutical industry maybe look something social contract saunder say easy suggest re already do just be transparent add ask target amount restraint agreement say low single digit rate inflation pharmaceutical giant include novartis nvs japan takeda pharmaceutical abbvie abbv also have take voluntary action cap price increase johnson johnson jnj merck mrk have take step increase transparency price industry have moved quite bit month month saunder say need big push saunder allergan have transform specialty pharmaceutical behemoth series acquisition sale generic business attempt merge pfizer pfe inc megadeal be abandon last year allergan have focuse smaller purchase allergan share be compare rest industry last month ve lose compare gain company standard poor pharmaceutical biotechnology life science index include allergan rather deal saunder be more interested build allergan main therapeutic area include medical aesthetic dermatology eye care central nervous system past month make acquisition worth combine add allergan aesthetic medicine cosmetic surgery line hair restoration skin quality be next frontier say company be currently do research area be huge unmet need say ask valeant pharmaceutical international vrx asset include bausch lomb eye care company once lead saunder say not interested not even piece valeant didn respond request seek comment
129,MRK,general electric ge cfo jeffrey bornstein say wednesday industry sit hand wait not invest lawmaker deliver promise change taxe regulation provide more clarity health care policy warning come house republican corporate tax revamp be run opposition congress more gop lawmaker balk propose import tax see key piece overhaul president trump have yet unveil own tax plan trump also want repeal replace obamacare republican have turn squeamish sweeping change health law barclay industrial select conference miami bornstein say be reasonably confident change get pass say investor be very disappoint aren don get corporate tax reform goal line don provide visibility health care be go don deliver regulatory change administration have talk think end very difficult place say tuesday ge ceo jeffrey immelt ceo boee ba unite technology utx other industrial exporter well drugmaker celgene celg eli lilly lly merck mrk pfizer pfe write letter urge congressional support house tax reform blueprint include border adjustment tax total company sign letter more company include wal mart wmt target tgt nike nke dozen trade group have sign american affordable product group create oppose import tax ge share fall stock market today boee share be unite tech rise last month talk repeal obamacare begin ramp ge immelt also indicated customer become more cautious take segment affordable care act be get most attention medium customer say conference call report mixed result think see caution affordable care act go forward haven really see much happen trump say rally florida weekend replacement plan obamacare win be come couple week warn earlier process last next year meanwhile market be still wait white house detail own tax proposal congressional republican take more flak last week trump tell retail ceo massive tax plan come not too distant future follow remark airline ceo prior week vow announce something phenomenal term tax come week related border tax die trump corporate tax cut collapsetrump silent ex im bank hint big boee super hornet order
130,MRK,ceo dow stock general electric ge boee ba other big exporter be warning republican embrace controversial tax import once generation chance tax reform fail american worker be loser tax code penalize american worker make product provide service sell abroad favore international competitor ceo write letter leader party congress other company ceo co sign letter be caterpillar cat dow chemical dow raytheon rtn unite technology utx oracle orcl biggest drug biotech company celgene celg eli lilly lly merck mrk pfizer pfe caterpillar merck pfizer unite technology also be member dow jone industrial average addition general electric boee letter put largest company squarely house speaker paul ryan other house gop leader argue levele international play field cut corporate tax rate lower be impossible plan tax import raise decade yet biggest surprise letter be just few company sign more company include wal mart wmt target tgt nike nke american subsidiary toyota tm dozen trade group have sign american affordable product create oppose house border tax proposal wal mart nike be also dow industrial stock retail stock be pressure early december prospect border tax be rise ve make modest recovery lately prospect fade tuesday perhaps help more wal mart positive earning report well receive macy earning weigh rev lobbying campaign tax retail share be rise wal mart rise close stock market today target add ibd take supporter border tax plan say dollar rise vs other currency meaning wouldn harm corporate profit consumer do risk investor hold share company alibaba international etfs house proposal border adjust tax company pay tax rate full value import good export revenue be tax free border tax raise more decade offset cost lower statutory tax rate conservative tax foundation have say border tax ability congress reduce corporate tax rate be limit incremental tweak not level play field american worker dramatically reinvigorate economic growth ceo letter say not clear precisely so few company come favor border tax proposal seem be run buzz see republican senate possible letter wasn widely circulate however caroline freund senior fellow peterson institute international economic have predict many more big lobby be bat border adjust tax favor tax favor labor intensive industry export more import aerospace be rare example nagging question company such ge boee be so dependent export back border tax most trade expert have look tax have big doubt comply world trade organization rule so lead trade war give uncertainty possible consequence hard understand company so dependent trade support border tax yet partly explain list supporter be so small related border tax die trump corporate tax cut collapse gop border tax plan sock tourism include trump hotel
131,MRK,body immune system fought deadly cancer cell just protect germ encounter day goal emerge class treatment call immuno oncology drug barclay analyst geoff meacham say become market product merck mrk bristol myer squibb bmy roche hold rhhby already be approve fda treat melanoma lung cancer leerink analyst seamus fernandez estimate trial be underway stratosphere include drug trial like astrazeneca azn incyte incy slew other treat kidney bladder urothelial head neck cancer result be still very preliminary say tim reilly development lead bristol myer early pipeline cure be tough word tell ibd be see indication least reset patient immune system normal homeostasis hope be bring patient have official diagnosis cancer back homeostatic place bristol myer stock rise stock market trading friday merck share rise small fraction roche share inched cent incyte end day preliminary thesis play bristol myer merck bristol myer tack sale drug opdivo yervoy yervoy sale be flat opdivo sale grow year earlier merck keytruda grow sale see list major immuno oncology drug clear so far fda approve used cancer cell be constantly occur everyone reilly say time get sunlight get uv exposure mutation cell be technically now mutate cell be technically cancer say body eradicate cell healthy immune system do case aberrant cell evolve outpace outsmart system throw body natural homeostasis cell then grow become cancerous tumor ibd take wall street be nervous enter earning season biotechs take political heat high drug price biotech incyte be ride high plethora potential blockbuster include sector head ibd new america article get deep dive incyte vast opportunity chemotherapy pump body full poison cancer cell be standard care early target therapy change growth rate tumor drugmaker look combine therapy improve result immuno oncology drug more precisely checkpoint inhibitor be completely different meacham say merck keytruda bristol myer opdivo be pd inhibitor be first approve treat melanoma then ve tack slew indication include lung cancer head neck cancer yervoy be bristol myer ctla inhibitor be approve advanced melanoma lot drug basically train immune system see difference regular cell tumor cell use immune system fight tumor meacham say immune system cell patrol body aberrant cell cell encounter cell probe surface look protein indicate cancerous cell find cancer cell cell attack call forth additional molecule prevent battle injure regular tissue additional molecule be checkpoint inhibitor explain july blog post dana farber cancer institute cancerous cell trick cell wear protein normal cell evade detection destruction checkpoint inhibitor block normal protein cancer cell protein cell respond dana farber write result be remove blinder prevent cell recognize cell cancerous lead immune system assault monotherapy merck keytruda bristol opdivo block interaction pd protein cell surface pd protein surface cancer cell do so allow cell see cancer cell be bristol ctla antibody yervoy work similar fashion more clinical trial be explore different inhibitor leerink fernandez write jan note firm be also look checkpoint modulator stimulate cell activation merck keytruda bristol myer opdivo have myriad indication solo therapy be indicated advanced lung cancer head neck cancer opdivo be also approve treat melanoma renal cell carcinoma hodgkin lymphoma bristol myer yervoy be indicated melanoma term excitement be potential combination merck have slight lead january food drug administration accept merck supplemental filing accelerate approval keytruda chemo combination treat small cell lung cancer less week later bristol myer say wouldn seek accelerate approval combination opdivo yervoy small cell lung cancer confirm merck have lead market bristol myer be study combo phase trial checkmate aftermath wall street be await result astrazeneca mystic trial bated breath opdivo yervoy astrazeneca durvalumab tremelimumab be pd ctla antibody respectively barclay meacham say trial be lead indicator happen tell ibd similar mechanism bristol myer yervoy opdivo be lot subtlety mystic trial study think overall person want see idea work meanwhile merck be testing keytruda incyte epacadostat first line melanoma advanced lung cancer renal cell carcinoma head neck cancer bladder cancer epacadostat belong class checkpoint inhibitor work target ido enzyme ctla antibody be first antibody approve be first approve yervoy be pretty toxic drug meacham say drugmaker push forward discovery eye pop efficacy combine ctla pd antibody find right dosage drug require bit trial error bristol myer reilly say testing bristol myer have cut toxicity opdivo yervoy combo ensure benefit outweigh risk don want bring toxicity patient say know thing sure cancer patient want be sure re bring benefit opdivo yervoy combination bring benefit reilly expect future cancer treatment focus segment patient share diagnosis similar biomarker distant future treatment combination potentially be tailor specific patient base body chemical makeup say merck dr roy barne barne be senior vice president global clinical development merck research laboratory reilly win call cure cancer note impressive result patient ve be yervoy first approval year progress lot patient have start come drug year say come have be very few relapse early day quite encourage related merck keytruda sale lag defer revenue analystbristol myer topple guidance cut merck merck meaningful keytruda royalty give bristol myer leg
132,MRK,apple aapl nike nke visa merck mrk boee ba ibm ibm have be biggest gainer dow jone industrial average so far year help partly strong earning report languish index part last year iphone demand concern apple have lead charge dow so far stock market today nearly eclipse april time high much apple ascent have come ceo tim cook call company outstanding fiscal first quarter result analyst also be bullish next generation iphone good part quarter apple struggle meet iphone demand say phone be supply constrain overall iphone sale rise reverse quarters decline company be bullish service business well endeavor smart home wearable tech apple have also testing water original video programming apple be well extend buy point related payment processor be year date share jump early month visa quarterly earning top analyst estimate wall street also remain optimistic company do ever digitize payment landscape potentially easier regulation trump administration global opportunity digitize cash check be enormous ceo alfr kelly say company earning call last week have vibrant core business develop region even more growth opportunity international emerge market low penetration rate continue government emerge middle class be lead way digitize more payment develop country commerce be displacing cash check develop country stock be still buy range entry point breaking more week follow earning report visa close friday athletic gear maker gain dow come third stock be dow industrial worst laggard last year moved sideway much share jump thursday retake day line first time august surge wednesday week nike rise more december nike report fiscal earning company cite tremendous potential north america incredible momentum basketball business management also say like prospect second half year related drugmaker be so far year merck stock rise early month company report earning president trump have pressured industry cut drug price say be get away murder also want industry make more product also promise roll back regulation install fantastic person fda drugmaker say act too slowly approve drug merck have benefit setback bristol myer squibb bmy cancer fighter opdivo pave way merck own immunotherapy keytruda get big headstart key cancer share be cup base near buy point close monday ibd take business be enter new age single tweet president risk obliterate billion company total value more trump travel ban appear likely weigh stock big blue have see bump so far year decade computer hardware business ibm have try reposition bigger player cloud big datum social mobile technology last month ibm beat top bottom line estimate revenue core strategic business climb ibm monday highest level late here bonus dow stock boee be sixth best dow performer last week briefly edge past ibm intraday monday year date gain be boee break flat base jan strong earning report news dreamliner be finally cash flow positive boee monday move have push edge buy range buy point related
133,MRK,abbvie abbv merck mrk be pressure gilead science gild already burden hepatitis unit rbc analyst michael yee say monday day ahead gilead much anticipate earning report guidance broadly analyst anticipate gilead guide sale assume hep sale guide lower indicate dip hep sale slough earning share item yee say investor likely have little confidence higher revenue so be see risky guidance yee write research report so way think gilead need guide hit quarters hcv need stabilize gilead stock be hammer january follow report market tracker im hep prescription fall sequentially month share have re-cover minimally be now flat year stock market today gilead stock edge cent biotech market cap amgen amgn be slate report earning close tuesday ibd take big biotech leader analyst have be most bearish gilead report slow hepatitis drug sale dive issue ibd industry theme analyst expect gilead post sale ep item vs year earlier period analyst expect sale ep item year respectively guidance be key especially consider struggle hep unit evercore analyst mark schoenebaum write research note monday hep drug sale harvoni sovaldi epclusa comprise gilead total product sale past gilead have comment new patient be healthier schoenebaum say gilead be also likely experience competitive pressure merck zepatier hep pill approval abbvie week regimen yee expect investor key hiv drug sale gilead be likely have phase datum hiv drug bictegravir annual conference retroviruse opportunistic infection croi feb seattle gilead face competitive glaxosmithkline gsk gsk dolutegravir brand name tivicay be already approve food drug administration gilead have say put everything launch gilead yee write be mt everest year come yee have outperform rating price target gilead stock related hcv dip virtually mirror gilead view laggilead clobber hep little value too late nash hiv unitsgilead bulk hiv nash unit hep slump stock week dip
134,MRK,major stock market index etfs be narrowly mixed wednesday material health care show strength sector spdr spy be hover time high powershare qqq qqq be same amount spdr dow jone industrial average dium be material select sector spdr xlb be etf have rise so far year vs spy xlb break flat base jan rise nearly buy point then fall back base find support day move average be hold time high etf have bulk asset invest chemical basic material company include dow chemical dow nearly asset dupont dd also praxair px nearly dow chemical shot higher wednesday report reuter eu antitrust regulator be close clear merger dow chemical dupont dow chemical have year growth rate be yielding have dividend growth rate dupont jump wednesday rise industrial gas producer praxair be utility select sector spdr xlu be health care select sectorspdr xlv be fraction top holding include johnson johnson jnj pfizer pfe merck mrk unitedhealth unh be slightly amgen amgn be energy etfs give back strong gain tuesday unite state oil fund uso fall wednesday jump tuesday uso track spot price west texas intermediate light sweet crude oil energy select sector spdr xle fall rally tuesday etf track oil gas explorer producer service company be week high trading etf be day move average bearish sign intermediate low xle top hold exxon mobil xom be week high chevron cvx be high be trading day line here look performance major exchange trade fund key asset class stock market today relative price strength rs rating measure stock price performance last month vs stock etfs scale best possible spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs unite state oil uso rs ishare core aggregate bond agg rs powershare db bullish uup rs ipath vix short term future vxx rs related oil gas equipment etf have strong year best etfs make bullish bet growth trump trade
135,MRK,merck mrk stock pop thursday line metric keytruda sale include defer revenue have lag wall street target evercore analyst mark schoenebaum say close bell stock market today merck stock finished session company wrapped conference call analyst share be currently build flat base entry point merck report sale cent earning share item respectively vs year earlier quarter sale be analyst view ep meet merck wrapped sale ep ex item sale close analyst expectation ep top penny year year basis sale grow ep be ibd take ceo merck lilly celgene novartis other meet president trump tuesday trump pledge cut taxe deregulate drug industry also call firm manufacture get deep dive company also provide line guidance sale ep item bracketing consensus expectation guidance include royalty payment bristol myer squibb bmy assume fda approve expansion keytruda label keytruda merck immuno oncology drug be be evaluate fda combination eli lilly alimta chemotherapy treatment first line small cell lung cancer compete bristol astrazeneca azn roche rhhby merck say expect uptake be relatively rapid once combination be keytruda label schoenebaum write research report uptake start healthier patient tolerate add toxicity combo then move patient merck say management do highlight several time expect first line market become fragmented personalize single combination ultimately dominate market write keytruda bring sale vs year earlier miss consensus sale actually miss include time defer revenue keytruda sale have miss related roche ceo shrug trump drug stance sale narrowly misslilly hijack diabetes share trump rattle sector dipswill merck let incyte go astrazeneca bristol roche team up too
136,MRK,pfizer pfe tesaro tsro follow astrazeneca azn drugmaker early friday unveil strong result late stage trial parp inhibitor lynparza breast cancer leerink analyst seamus fernandez say stock market today tesaro stock jump astrazeneca stock lift pfizer stock be flat astrazeneca pfizer tesaro roche rhhby clovis oncology clvs be work parp inhibitor drug class block specific enzyme treat ovarian other cancer drug astrazeneca clovis be already approve ovarian cancer clovis stock jump friday lynparza be first approve treat ovarian cancer december early friday astrazeneca say drug show statistically significant clinically meaningful benefit improve progression free survival negative germline brca mutate breast cancer be first phase readout parp inhibitor breast cancer likely have positive read similarly design trial pfizer talazoparib tesaro niraparib fernandez write research report have outperform rating astrazeneca stock ibd take immuno oncology company merck bristol myer roche be race cure cancer emerge field thus far drug have be approve array indication head ibd technology page see company have head start pfizer tesaro be expect have datum first second half year respectively astrazeneca be expect unveil full datum upcoming medical conference company didn specify conference importantly represent astrazeneca be build dna damage response portfolio lynparza well provide first validation parp inhibitor class outside ovarian cancer fernandez say future fernandez expect datum parp inhibitor combination immuno oncology drug like merck mrk roche related tesaro rocket time high rumore takeover interesttesaro astrazeneca shrink clovis ovarian cancer drug pooltesaro rumore sale fetch north share analyst
137,MRK,biogen biib trail merck mrk astrazeneca azn eli lilly lly launch bace inhibitor treat alzheimer disease leerink analyst say thursday day biogen hemophilia unit bioverativ bivv begin trading independently biogen stock end trading stock market today be unclear represent drop gain price due bioverativ list list biogen formally distribute share bioverativ share biogen holder early thursday bioverativ stock open appear biogen share drop yee call dive biogen stock opportunity investor have be wait spin buy stock post distribution don want bioverativ issuance be company have very different profile market cap biogen write research report ibd take rbc be bullish amgen biogen remain cautious last month share gilead science grab ibd industry theme full scoop other be count increasingly bullish view spinraza biogen spinal muscular atrophy drug conjunction ionis pharmaceutical ion assume strong launch street become comfortable new growth driver write alzheimer be more mixed bag biogen partner eisai be co develop ban pair alzheimer drug pair be expect deliver top line result phase trial year astrazeneca lilly merck related merck biogen lilly top drug approval fda slumpbiogen sidestep sale miss strong ex hemophilia guidegilead merck alexion view hazy biogen surge analyst
138,MRK,market surge new high leader be start show strength healthy uptrend continue be new merchandise stock market today strength jump new high break proper basis recently featured ipo leader column antero midstream partner ticker
139,MRK,internal promotion doesn mean biogen biib be longer takeover candidate rbc analyst michael yee say tuesday biotech market cap announce michel vounatsos chief commercial officer succeed george scango ceo scango july announce step follow year stint top vounatsos joined biogen april year career merck mrk aftermath scango announce exit analyst question biogen be acquire vounatsos appointment doesn change yee write research report read be internal promotion mean nothing really change status quo write have bring someone new then be premise take build company not sell right take ceo role ibd take good news spinraza help biogen ionis stock bust analyst say get full take ibd industry theme stock market today biogen stock rise fall monday mostly final minute session reuter report vounatsos be name ceo share have bee consolidate month be year confidence vounatsos be mixed yee say new ceo have take number investor meeting build interaction street monday vounatsos call strategic review operation first half evercore analyst john scottus question restructure be biogen future michel do note long term objective include strive become highly efficient organization discipline focus execution scottus write report vounatsos decline provide long term guidance conference call analyst late monday build confidence biogen tecfidera sale need rebound rbc yee say tecfidera sale decelerate year year growth tecfidera be oral treatment relapse form multiple sclerosis biogen be also work spinraza ionis pharmaceutical ion spinraza be be test therapy spinal muscular atrophy sma last month biogen ionis announce spinraza meet primary endpoint phase study infant child also bullish side yee expect biogen make acquisition build drug pipeline company press release new ceo note capital allocation focus think suggest more aggressive action otherwise note biib have repurchase least share peer last year yee say related biogen name insider new ceo month search stock fallsbiogen underplay promising alzheimer datum seizure worriesbiotech round trip trump inspire rally fda appointment key
140,MRK,stock be moderately higher afternoon trading tuesday sharply pare early gain disney nike nke verizon vz lead dow higher apple aapl continue recent slide nasdaq rise dow jone industrial average cling gain volume be higher board today stock market action vs same time friday gold mining telecom medical stock advanced homebuilder department store discount retailer lag oil stock give early gain price reversed month high fall barrel production cut concern verizon fast trade be dow biggest gainer stock approach buy point cup base citigroup upgrade telecom giant buy hold set price target bullish outlook other prospect other blue chip visa merck mrk nike also rise mcdonald mcd fall faster usual turnover restaurant stock retreat jeffery reiterate buy rating price target nike name athletic shoe maker best new idea stock underperform last year deficit jump back day move average tuesday be still day line week high disney have already clear short handle buy point now have top more clearly defined entry stock be trading best level nearly month entertainment theme park giant rogue star war story top box office third straight weekend evercore isi upgrade disney buy hold boost price target most big cap techs include cisco system csco ibm ibm microsoft msft be fractionally higher apple reversed early gain loss stock be track fourth straight decline average volume be work base buy point also complete handle entry ibd take oil future top barrel sharp reversal detail contribute volatility read news story piper jaffray name iphone maker top large cap consumer technology internet medium stock activision blizzard atvi alphabet googl disney activision climb alphabet add economic news ism manufacturing index rise year high december november read top econoday consensus forecast reading indicate expansion related verizon upgrade likely improve strategic positionism manufacturing index hit year high invest insight wall street great author gerald invest case trump era secular bull runstock market today apple possible next move
141,MRK,federal jury late thursday order gilead science gild pay royalty ruling merck mrk patent hepatitis drug be valid gilead say appeal verdict gilead sovaldi horavni have cure rate more be very expensive merck have own hepatitis drug zepatier didn get approval gilead treatment well viekira pak abbvie abbv gilead science fall friday open bell stock market today merck rise separately agio pharmaceutical agio tumble premarket say late thursday be discontinue second candidate pyruvate kinase deficiency rare form anemia discussion fda liver toxicity agio pharma be still continue work pkd candidate ibd take drug price fear have weigh pharmaceutical stock year pre elect trump push sweeping drug price control breaking fellow republican
142,MRK,texas instrument txn be initiate buy rating biogen biib st century fox foxa get price target hike dov be name top idea summit redstone partner initiate chip maker texas instrument buy rating price target texas instrument stock rise finish stock market today share be nearly still buy range flat base formation ibd electronic semiconductor manufacturing group be rank industry group member include intel intc micron technology mu also own operate chip make factory microchip technology mchp be top rank stock raymond james up price target biogen biotech recently announce michel vounatsos former merck mrk executive succeed george scango ceo biogen stock dip close thursday intraday trade day day move average wedbush bump pt st century fox recent nielsen report say medium giant fox news channel top espn rating year primetime viewer total day view first time year history fox stock end lower work cup handle formation buy point baird name top idea diversify industrial stock give price target decent believe share still have upside left say mircea dobre baird analyst report oil gas improve remain best way play coverage share dip ibd machinery general industrial group be rank industry group include higher volume stock ingersoll rand ir illinois tool work itw other analyst move cantor fitzgerald upgrade senior housing property snh overweight pt send stock suntrust robinson humphrey downgrade anthera pharmaceutical anth sell cut pt lower pt anthera citigroup reiterate qualcomm qcom neutral related nvidia flash key sell signal citron tweet possible climax runbiogen likely trim ep view hemophilia spinoff flounder ms unit
143,MRK,interview time selection news magazine man year bring president elect trump most definitive statement date drug price go bring drug price don have happened drug price incoming president have be short detail many observer say bigger focus be streamline food drug administration drug approval process effort get boost wednesday same day trump time interview be publish senate approve bill aim speeding approval drug medical device president obama be expect approve so call st century cure bill just action trump take remain unknown resolution issue drug price time jump exponentially critical need patient trump have vow repeal president obama affordable care act promise drain swamp special interest washington help contribute rise big pharma time interview hadn broach drug pricing issue just election boost drug stock ishare nasdaq biotechnologg etf ibb jump day nov election fall ibd company biom biotech industry group jump nov generic ethical drug group rise respectively group have give back gain trump ignore rise drug price say trevor william penn mutual asset management manage director trouble be businessman reality tv star be relative political enigma william tell ibd hard see be champion lower drug price same sense hillary have be so focuse dismantle aca william say trump not have political history really difficult telegraph go go policy proposal be tell trump pledge contract american voter fully repeal aca better know obamacare first day office replace health saving account vein say ll cut fda red tape be drug await approval especially want speed approval life save medication trump write contract trump crack fda be nothing new say credit suisse analyst vamil divan yet recent year fda have work expedite sorely need drug fast track designation prescription drug user fee act help fund drug quickly still be backlog approval generic drug divan tell ibd many proposal work have target make approval process generic drug cheaper drug similar drug long enough ve lose patent protection much easier trump platform remove barrier entry safe reliable cheaper product trump also allow broader label use number drug penn william say replacement plan aca remain somewhat ambiguous trump have backed earlier promise fully repeal act say ll maintain provision require insurer cover patient pre exist condition let parent cover child age obama didn touch pharmaceutical much obamacare legislative centerpiece say divan outside require drugmaker pay expand health care coverage trump completely do away aca be unlikely divan say fee disappear backroom negotiation aca let company come reasonably well divan say repeal aca put cash fee back drugmaker pocket yet wall street be anything reasonably sure trump care affect biotech drug firm trump doesn appear have vendetta pharmacy benefit manager pbms drugmaker pbm tactic undercut amgen amgn eli lilly lly prompt stock topple late october amgen offer dim view eli lilly see diabetes sale take hit pbms be third party administrator commercial government medicare health plan pbms use discount competition keep drug price low help patient raise conflict drugmaker amgen stock topple nearly oct sale enbrel come flat firm say doesn expect net selling price increase business be drive volume amgen executive anthony hooper say company earning conference call ibd take rebate chip away amgen enbrel sale do mean broader industry grab ibd industry theme deeper look eli lilly stock oct sale diabetes drug humalog fall higher volume be more offset lower realize price company say earning conference call ep revenue miss wall street target trump lack commentary pbms be tell divan tell ibd stand government be not involved drug price negotiation trump work change order lower drug price not be focus republican divan say trump be not typical republican question say be new administration willing go something big pharma politically score point general public drug company have own view course merck mrk ceo ken frazier month bloomberg interview say company have be restrain raise price always be individual drug individual year point say look large relation other look whole portfolio see merck have tend be rather restrain come drug price bloomberg report frazier say bloomberg also report month allergan agn ceo brent saunder say trump be more vicious more focuse take do something again term spiking price drug drug bloomberg have interview saunder frazier appear forbe healthcare summit new york dec question patient have have high drug price kaiser foundation find september american last year believe drug price be too high american generally support require firm release information price be set allow government negotiate drug price kaiser survey follow drug pricing controversy erupt september mylan myl boost price pair epipen ceo heather bresch be subject tough question house committee hearing last year similar controversy prompt capitol hill hearing involved turing pharmaceutical former ceo martin shkreli involve big hike decade old hiv drug valeant pharmaceutical vrx have also impose huge hike drug price justice department be investigate be expect file charge generic drug company price collusion year end yes analyst divan say don think issue be go away also say see fewer chance big change drug pricing policy trump related pfizer sale challenged eli lilly novartis breakup busteli lilly topple alzheimer darling sola fail biogen merck downcelgene kite spark look sidestep lilly alzheimer flopalder keel sixth day eu uphold teva migraine patent
144,MRK,stock be narrowly mixed morning trade wednesday dow turn positive nasdaq remain red dow climb be fractionally higher nasdaq dip small cap lag russell more volume swell board vs same time tuesday medical oil apparel maker lead downside today stock market action west texas intermediate crude price slide more barrel ahead weekly inventory report johnson johnson jnj merck mrk be biggest loser dow decline gold miner datum storage steel stock outperformed western digital wdc pop massive trade week high mizuho cowen raise price target maintain respective buy outperform rating late tuesday datum storage maker guide fiscal earning share outlook street view advanced micro device amd gap rise heavy volume highest level more year share be extend past cup handle buy point clear nov be profit take range tuesday surge rumor licensing deal longtime rival intel intc intel gain tuesday be fractionally lower wednesday ibd dave buster play gap soar rapid turnover new high stock be well extend buy point double bottom handle stifel nicolaus lift price target close tuesday restaurant arcade operator report result top forecast raise full year profit guidance consensus estimate related amd stock hit year high intel rumor ahead zen previewanalyst tout dave buster western digital dave buster western digital lift view mastercard up payout
145,MRK,major average end positive side monday nasdaq take lead several chip stock rally nasdaq close regain day move average advanced dow jone industrial average climb set record high volume be mixed tracking barely higher nyse lower nasdaq vs same time friday solar stock oil automaker advanced stock market today manage care retail airline stock lag ferrari race race ahead week high rapid turnover share italian race car maker be well extend buy point deep cup handle base subsequent bounce week move average stock be offer price oct debut dow stock nike nke retook day line faster usual volume first time nearly month finishing share be still day line be week high hsbc lift rating athletic shoe apparel giant buy hold price target rise competition bank think nike be still poise superior growth return long term rival armour ua climb weak trade baltimore base company confirm strike year deal be major league baseball official field uniform provider nike stock have recently underperform armour remain day day line be week high downside unitedhealth group unh lose average volume manage care provider stock be come friday time intraday high follow postelection rally much decline be sympathy move aetna aet humana hum fall respectively go court plan merger merck mrk drop tepid trade fall further day line last week brief stint support level most ibd stock score gain monday macom technology solution mtsi surge mark eighth advance session chipmaker share be extend past cup handle entry graphic chip maker nvidia nvda add related armour clinch first pro sport deal nike get nod hsbc unitedhealth amazon health care isn sweat trump chip stock rate buy sector sell
146,MRK,stock rally big gain head lunch hour wednesday market continue digest president elect donald trump surprise victory dow jone industrial average run ahead rise nasdaq add volume be higher board vs same time tuesday dow future have plunge much point wednesday night steel medical drug stock lead upside stock market today hospital solar automaker underperform west texas intermediate crude price rise barrel gold future be ounce merck mrk pfizer pfe caterpillar cat be top gainer dow rally north apple aapl be have pare loss nearly stock be still day move average breach nov just shy cup handle buy point first clear iphone maker well other tech company include microsoft msft cisco system csco benefit donald trump cash repatriation proposal congress permit cisco be microsoft be fractionally lower biotechs have be target presidential candidate hillary clinton high pricing jump amphastar pharmaceutical amph soar surge past day line triple average trade share be now well extend past cup handle buy point initially clear aug injectable drugmaker tuesday report adjust earning cent share top view reverse loss same year quarter other biotechs celgene celg hold gain earlier spiking much week high incyte incy rise biogen biib leap related apple microsoft cisco eye trump overseas cash tax plan
147,MRK,stock open lower wednesday commodity currency market react tuesday come victory donald trump race presidency dow industrial rise nasdaq nasdaq future have fall overnight dow future sank more point lowsdrugmaker campaign target democrat hillary clinton due pricing trade generally higher pfizer pfe leap mylan myl merck mrk rise eli lilly lly add more early trade hospital operator stand lose president elect trump act promise repeal affordable care act dove deeper early loss tenet healthcare thc topple hca holding hca skid lower universal health service uhs drop nearly coal mining stock moved generally higher arch coal arch soar consol energy cnx alliance holding ahgp show gain cement construction aggregate supplier surge possibly early commitment infrastructure other large scale project trump vulcan material vmc vault martin marietta mlm martin marietta top buy point cup base vulcan also break clear buy point earning news tripadvisor trip swoon report third quarter earning narrowly top view revenue gain stop far short analyst expectation fragrance maker coty coty plunge miss analyst fiscal first quarter revenue earning target wide margin gopro gpro tank handful analyst downgrade stock news recall karma drone due battery failure issue ibd list eagle material exp pop gain stock top buy point cup base ibd stock royal gold rgld rumble gold price surge early wednesday gold miner be climb right side possible base pattern find support week move average ibd stock arista network anet fall inphi iphi fall fractionally momo momo rise more international market trade lower election news tokyo stock be hardest hit drop worst single day loss britain june brexit vote exporter market be session biggest loser lead toyota motor tm honda motor hmc nissan motor nsany china hong kong hang seng index shed shanghai composite decline europe cac paris frankfurt dax trim deep early loss turn fractionally higher afternoon trade london ftse rally climb commodity be widely mixed early action oil price hold mostly steady west texas intermediate fraction hold just barrel metal moved broadly higher gold jump almost ounce silver copper be also strongly dollar bounce back initial dive trading moderately lower vs euro pound yen surge bond be sharply lower year yield basis point stock market today show light economic calendar september wholesale inventory datum expect commerce department et energy information administration report weekly oil stockpile number et minneapoli federal reserve bank chairman neel kashkari be due speak et related time warner stock fall trump victorydrug stock rally relief clinton didn white house
148,MRK,merck mrk stock pop tuesday drugmaker post earning top wall street expectation day regulator approve new biologic license application keytruda lung cancer treatment worldwide keytruda sale miss expectation health care tracker symphony health service consult evercore analyst john scottus write research report keytruda sale lag symphony model say stock market today merck stock rise fall intraday share be year ibd company medical ethical drug group be merck report sale vs year earlier quarter earning share ex item year year metric top consensus analyst poll thomson reuter cent merck credit sale beat franchise gardasil proquad vaccine human papillomavirus hpv measles mumps rubella varicella chickenpox respectively scottus note transition dose gardasil regimen hurt merck company decline give specific expectation do say expect revenue decline write gardasil sale come year year proquad sale rise keytruda lead growth merck pull diabetes med januvia janumet bring nearly sale comprise total quarterly revenue merck also update fiscal ep item view be year year basis line analyst broader view ibd take ibd ethical drug group rank lowly group biom biotech group be have show life have learn recent industry snapshot feature help investor identify potentially hot industry group meanwhile drugmaker eli lilly lly novartis nvs post sale miss lilly stock rise fraction novartis stock fall merck result follow decision monday food drug administration allow supplemental biologic license application keytruda merck lung cancer drug drug compete bristol myer squibb bmy opdivo keytruda now be used first line treatment patient metastatic nonsmall cell lung cancer nsclc tumor have high expression pd receptor regulator allow merck include datum show keytruda improve survival vs chemotherapy patient previously treat nsclc high expression pd receptor related merck topple bristol myer lung cancer winnovartis tumble sale miss chemo sale boost incyteeli lilly revenue ep miss ceo praise drug pipeline
149,MRK,dividend leader report earning tuesday news be good merck mrk not so good brinker international eat mmm merck have wild session eventually end well bull share reversed higher fall intraday basis share close drug giant currently pay
150,MRK,earning season kick high gear tuesday heavy report schedule culminate close quarterly result apple aapl edward lifescence ew other dow industrial nasdaq be open dow issue be busy stock market today procter gamble pg jump consumer product giant report fiscal first quarter earning rise more revenue fall less expect analyst company core operate profit margin expand basis point unite technology utx climb report stronger forecast third quarter result caterpillar cat rise mmm be report armour ua buckled diving report forecast third quarter sale earning guide full year revenue just consensus estimate burger joint sonic sonc drop more report fiscal fourth quarter earning narrowly beat expectation revenue fall well short projection stock correction have deepen april baker hughe bhi leap mixed third quarter result share end monday january low keycorp key rolled gain third quarter result top analyst target stock clear cup handle buy point early month end monday penny high year set ibd stock new oriental education technology edu jump more china base network learn center report first quarter earning line revenue analyst expectation stock be breaking past buy point later stage flat base home price continue improve steady rate august rise year year monthly basis accord case shiller city home price index increase meet analyst expectation federal housing finance agency housing price index increase august vs gain july better economist expectaion increase conference board october consumer confidence index drop atlanta federal reserve bank president dennis lockhart be schedule speak opportunity finance network conference atlanta et crude price hold flat west texas intermediate sticking recent range barrel gold inched just ounce dollar firm bond flattened leave year yield china market end tuesday session narrowly mixed tokyo nikkei jump second straight advance europe stock stick close start point afternoon trade cac paris frankfurt dax ahead london ftse steady related be alphabet activision new oriental ripe pick gm unite tech caterpillar beat earning view
151,MRK,load player here investing action plan need know investor come day apple aapl be expect report third straight quarter year year earning revenue decline tuesday general motor gm fiat chrysler automobile fcau lockheed martin lmt merck mrk edward lifescience ew also be tap
152,MRK,stock open higher friday buoy economic datum overseas trade ahead session chock full bank report fed commentary dow industrial scale nasdaq advanced earning report rolled jpmorgan jpm citigroup well fargo wfc pnc financial pnc early friday boston federal reserve bank president eric rosengren speak et loretta mester president cleveland federal reserve speak just fed chairwoman janet yellen address boston fed economic conference europe market stick early gain rebound thursday difficult session mining telecom play lead gain cac paris be afternoon trade frankfurt dax leap london ftse show gain financial hold top dow goldman sachs gs jpmorgan notch gain jpmorgan report broad third quarter beat revenue earning line boost record result investment bank citigroup swung open third quarter earning revenue slip less expect well fargo muster advance report third quarter earning also slip less expect revenue rise edge analyst expectation armour ua claw nearly upgrade overweight piper jaffray armour share have be struggle resistance week move average april momo momo ibd climb open stock have have volatile week trip profit take rule follow august downside india infosys infy slice lower report result line lower guidance then lower full year revenue guidance due uncertain business outlook price paid producer rise september labor department report flat performance august forecast increase core price food energy rise august gain projection rise retail sale surge expect september reverse dip report august commerce department auto sale rise also line projection august business inventory commerce preliminary consumer sentiment read october university michigan be set release baker hughe bhi serve weekly rig count et treasury budget wrapped friday economic calendar et oil price bounce nearly send west texas intermediate barrel gold slip fraction ounce dollar gain ground bond slip send year yield basis point
153,MRK,apple aapl receive price target increase thursday top rate stock gigamon gimo grubhub grub be upgrade buy big pharma stock merck mrk pfizer pfe get divergent rating wall street analyst thursday pacific crest security analyst andy hargreaf reiterate overweight rating apple stock raise price target sentiment iphone maker turn positive ahead september quarter earning report believe current iphone expectation be reasonable see potential upside street profit expectation next year strong app store sale other thing hargreaf say report apple be schedule report fiscal fourth quarter earning oct apple result be boost uptick iphone average selling price thank popular high end iphone strong app store download include hit mobile game pokemon go hargreaf say recommend buy aapl hargreaf say believe combination attractive valuation improve iphone growth rate optimism iphone cycle create favorable risk reward aapl apple stock fall stock market today snap session winning streak bank america upgrade share gigamon grubhub buy give gigamon price target grubhub pt share gigamon computer network equipment firm edge grubhub online mobile platform restaurant pickup delivery order rally stock be ibd list top perform company gigamon be rank ibd grubhub be bank america upgrade pharmaceutical giant merck buy set price target merck be investment bank jeffery downgrade drugmaker pfizer hold pfizer share be
154,MRK,index weaken afternoon trading tuesday earning report cause tumble general motor gm home improvement stock nasdaq be dow jone industrial average do little better component procter gamble pg merck mrk rise follow earning report volume be run higher nasdaq nyse build product industry other home improvement stock be rattle combination weak earning report poor outlook major appliance maker air conditioning heating construction product wood product paint appliance be industry group masco mas plunge nearly heavy trading fall long term day move average stock have be form base base pattern be now seriously damage masco miss third quarter profit expectation sale growth continue trend flat low single digit gain date back masco make door window plumbing fixture other construction product be exit lower margin cabinet business bmc stock holding bmch fall rapid trade supplier lumber other build product have be trading day move average week be day line whirlpool whr gap loss more highest volume least april be similar earning related sell appliance manufacturer miss profit sale estimate cut full year earning outlook whirlpool expect earn share earlier forecast high company cite soft demand weaken british pound general motor skid heavy volume stock dip day move average share remain long sideway pattern automaker beat profit sale expectation forecast full year earning high end analyst consensus gm warn miss european profit target due brexit also see softening auto market water gap loss nearly huge volume report profit meet consensus estimate maker product drug development report adjust earning share sale increase water have be lead stock mount gain buy point be form new base tuesday crash have roil pattern metal stock be lead market high rate part sector make ternium tx jump nearly top buy point cup handle base volume be run time average leave little doubt stampede institutional investor be buy share luxembourg base steel producer be talk acquire steel plant brazil germany thyssenkrupp accord report related gm sink europe warning unite tech up view cat guide lowapple earning close expectlockheed martin soar outlook contract talk drag
155,MRK,bristol myer squibb bmy stock crash year low monday competitor merck mrk unveil phase result show lung cancer drug keytruda be twice effective chemotherapy spark stock close bell stock market today bristol myer squibb stock plunge end trading merck stock other hand lift much year high end monday trading share briefly hit entry point flat base add gain january new buy be risky current volatile market environment ibd take merck stock be buy zone far alone check ibd stock buy zone find player be recommend bet share ramp merck presentation european society medical oncology conference copenhagen merck unveil result phase testing keytruda drug treat small cell lung cancer keytruda alone extend progression free survival month vs month chemotherapy lung cancer patient express specific type protein merck say merck also combine keytruda eli lilly lly chemo drug alimta study patient respond combination vs patient receive chemo median progression free survival be month longer combo bristol myer squibb nivolumab rival treatment lung cancer show virtually benefit evercore isi analyst john scottus write research report left investor scratch head say credit suisse analyst vamil divan expect merck take major leadership position lung tumor market vs bristol myer astrazeneca azn roche rhhby say roche pile pressure tecentriq tecentriq have show overall survival benefit second line lung cancer regardless protein expression write estimate peak sale probability success rbc analyst michael yee expect celgene celg fly potential chemo combo merck test keytruda see celgene grow revenue only first line lung cancer patient be treat chemo combo other news conference credit suisse divan expect novartis nvs face pressure post esmo novartis drug combat metastatic breast cancer be effective pfizer pfe ibrance have serious safety concern efficacy appear line ibrance safety observation hy law risk fatal drug induced liver injury qtc prolongation mild cardiac arrhythmia put drug disadvantage pfizer ibrance eli lilly abemaciclib be approve write novartis stock lose end monday trade bristol myer eli lilly astrazeneca roche pfizer novartis merck be ibd ethical drug industry group group have be slumping rank related celgene trio new drug tack rbcamgen biogen gilead spike va pricing skirt california measureroche drug score lung cancer challenge bristol myer
156,MRK,stock market finished higher session high unable close day move average duel cancer drug spark major move pharmaceutical merck mrk bristol myer squibb bmy nasdaq rise biotechs generic drug rank day leader dow jone industrial average rise close day line trading support level much day small cap russell lead advance volume be lower columbus day holiday contribute slower pace trading energy sector lead crude future jump more barrel highest july russia say be willing join other produce country limit output give oil price boost exploration drill oilfield service other related group be monday top pioneer natural resource pxd exploration company operate texas break base base pattern buy point volume be lackluster software sector cadence design system cdns break odd cup handle base top buy point intraday volume be average also share pull back gain da davidson upgrade publisher electronic design software buy neutral raise target price keynote move today market be big pharma bristol myer be stock most selling stock move share plunge massive volume year low rival merck reveal trial result lung cancer drug keytruda show be twice effective chemotherapy news spark merck stock new high merck rise attempt break past buy point base acacia communication acia flash sell signal darling fiber optic rally acacia tumble heavy volume diving friday breaking day move average be main reason fiber optic industry group be worst perform monday nearly banking stock be active small cap be close buy point centerstate bank csfl base davenport fla poke buy point flat base intraday fade close sterling bancorp stl parent new york base sterling national bank have buy point sight bank be industry group have make gradual gain several week related merck topple bristol myer lung cancer drug winoil price hit year high saudis hint industrial profit warning mount join honeywell ppg
157,MRK,stock jump gate early monday hold solid gain midday monday oil price jump again exxon mobil xom chevron cvx outperformed dow new york mercantile exchange wti crude oil future november delivery rise barrel saudi arabia oil minister say price hit barrel year nasdaq composite rise dow jone industrial average add picked volume nyse nasdaq be tracking lower friday level monday strength come ahead release alcoa aa earning tuesday open release minute fed meeting wednesday alcoa be work shallow cup shape base buy point earning share be see rise year stock market today merck mrk be solid gainer dow clear flat base buy point healthy trade announce positive result study keytruda treat patient metastatic nonsmall cell lung cancer name ibd rise more include alibaba baba share be help news deal steven spielberg amblin partner cofinance produce film chinese global audience downside new issue twilio twlo give day move average fall news share offer acacia communication acia suffer same fate fall pricing follow offer friday share friday lose nearly ibd take twilio be track enterprise software group be filled leader see top performer group be rank composite rating ibd stock checkup netflix nflx hold pretty well deutsche bank downgrade sell share fall related oil top hope output deal saudis hint buy mcdonald sell netflix analyst say google get price target
158,MRK,stock open higher monday session bank bond market remain close columbus day holiday rise dow jone industrial average just retake day move average have act resistance level index nasdaq already day line climb bank bond market be back action tuesday third quarter report season kick gear early report due alcoa aa fastenal fast bank ozark ozrk big drugmaker be key mover early action stock market today merck mrk climb more report positive result trial keytruda treat patient metastatic small cell lung cancer netherlands base drugmaker mylan myl surge early trade company announce late friday have agree settlement department justice epipen product be classify medicaid drug rebate program management also lower company full year earning guidance tesaro tsro biotech base waltham mass bolt report positive result ovarian cancer treatment know niraparib bristol myer squibb bmy crash company report result number clinical trial include disappointing result cancer drug opdivo tesla motor tsla climb sunday tweet chief executive elon musk contradict friday regulatory filing say company raise additional capital equity debt offering musk say neither be necessary company introduce new product next week tesla share have be downtrend struggle hold support april ibd stock trade narrow range fashion acacia communication acia edge stock be pull back high end friday test support day move average gigamon gimo rise networking gear market pull back last week week rally end well week line twitter twtr fall nearly bloomberg report salesforce com crm meet rise shareholder pressure acquire micro blog site interest walt disney alphabet googl google have cool oil trade more lift west texas intermediate back barrel gold add almost trade ounce dollar gain euro yen europe stock build early gain afternoon trade london ftse be frankfurt dax rise cac paris add shanghai composite jump exchange re open holiday exchange tokyo hong kong be close monday day holiday chicago federal reserve bank president charle evan speak et
159,MRK,stock rise early gain monday oil price surge dow re-cover key support level dow jone industrial average nasdaq rally add dow regain day move average line nasdaq be near time high volume be tracking lighter nyse nasdaq vs same time friday energy steel automaker lead upside stock market today oil stock get boost more rise west texas intermediate crude price barrel hope output deal top producer meet istanbul retailer ethical drugmaker be few underperform group bristol myer squibb bmy sank heavy trade year low positive clinical trial datum merck rival lung cancer drug merck mrk leap lead dow clear flat base buy point healthy trade announce positive result study keytruda treat patient metastatic nonsmall cell lung cancer mylan myl gap rise robust volume drugmaker friday reach settlement justice department charge medicaid epipen allergy medication share netherlands base company be still respective day day move average line ibd momo momo jump fast turnover track new close high chinese social network provider stock be far extend buy point be december offer price also callon petroleum cpe surge new high heavy volume related oil top hope output deal saudis hint
160,MRK,incyte incy be prime candidate rbc analyst simo simeonidis say friday drugmaker reveal deep durable result med aim treat advanced metastatic melanoma view incyte throwback biotech company be originally meant be simeonidis write research report company build great science manage develop multiple drug reinvest heavily own engine doesn offer guess company take crack buy incyte poll evercore isi investment bank last month identify gilead gild likely buyer incyte early friday incyte reveal result epacadostat combination merck mrk pembrolizumab combination face bristol myer squibb bmy nivolumab opdivo combination ipilimumab yervoy incyte merck didn reach progression free survival pfs month follow march datum cutoff bms opdivo combination have median pfs month simeonidis write increase confidence combination epacadostat pembrolizumab end median pfs be superior nivolumab ipilimumab combination write simeonidis also note patient receive combination drug incyte merck respond treatment have outperform rating incyte stock rise stock market today incyte break buy point so be buy range caution be advise volatile time market merck stock rise friday ibd take isn first time incyte have appear analyst hot list check sector leader more related small midcap biotechs get thumb goldman sachs
161,MRK,eli lilly lly abbvie abbv top credit suisse evaluation pharmaceutical company head leave more challenged pfizer pfe astrazeneca azn nordisk nvo dust pharmavalue list do little ibd company medical ethical drug industry group fall fraction stock market today fifth consecutive day group be more year touch month low monday be trading day move average ibd take biotech pharmaceutical stock have be trample last month earning report come climb wall worry credit suisse rank big pharma stock factor enterprise value net present value pricing replacement power sale growth overall eli lilly top list europe base sanofi sny novartis nvs trail closely abbvie rank highest fundamental investor likely assume long life span humira credit suisse analyst write research report humira be brand name adalimumab abbvie drug treat arthritis plaque psoriasis ankylose spondylitis crohn disease ulcerative colitis abbvie stock slip small fraction monday lilly stock fall nearly meanwhile pfizer be weak board astrazeneca have high ev npv enterprise value net present value nordisk be expose pricing pressure astrazeneca investor be potentially factor oncology pipeline credit suisse say recent result other demonstrate significant risk teva pharmaceutical teva score well ev npv valuation most sale power drive generic division gilead science gild incyte incy vertex pharmaceutical vrtx be trading discount vertex only need minimal further pipeline success justify current valuation report say biotechs vertex top credit suisse list amgen amgn flail bottom pharmaceutical ibd company medical biom biotech industry group have be month group fall fraction monday ethical drug group also fall fifth straight trading day fall seventh day past trading day bottom overall astrazeneca score well term pricing power shift oncology product nordisk be eye diabetes rebate storm credit suisse say pricing power credit suisse analyst note be important help company resist discount pressure formulary manager government regard allergan agn be clear winner only shire shpg rivale dry eye market alexion pharmaceutical alxn focus rare disease be most exceptional biotech analyst say biomarin bmrn incyte vertex also get high mark be unique bristol myer squibb bmy eli lilly beat cohort productivity ability drive current pipeline follow dramatic seesaw bristol myer squibb merck mrk bristol myer lung cancer drug opdivo fail meet key endpoint eli lilly score well launch trulicity diabetes taltz psoriasis
162,MRK,leerink swann analyst geoffrey porge be tired wait gilead science gild acknowledge slow hepatitis patient volume competition rival abbvie merck porge downgrade gilead stock market perform rating outperform cut price target long cautious porge be now bearish flash pan hepatitis market cut hepatitis sale expectation exist hcv estimate be already materially consensus write research report now think hcv revenue decline faster farther previously estimate consensus currently forecast briefly have stranglehold market gilead now face competition abbvie abbv have sell viekira pak april merck mrk shake market even more start selling own medication well high cost gilead abbvie earlier year gilead cause stir biotech world release first hepatitis drug sovaldi late drug cost pill week regimen offer guarantee patient used drug be cure gilead see triple digit jump profit result late gilead release harvoni follow sovaldi cost even more profit continue grow double digit pace slow single digit increase first quarter year drop profit second quarter share company now trade reach peak more mid abbvie start selling viekira pak same price sovaldi merck zepatier go much less stock market today gilead stock dip hit lowest point week fall key day move average support line straight day ibd take gilead stock have composite rating meaning underperform stock term key growth metric ibd company medical biom biotech industry group be recent hot streak potential big pharma hepatitis market appear be steady secular decline porge say large pool treatable patient europe likely only see patient apiece annually long term vs record high porge forecast patient erosion year erosion revenue unit dip treatment erosion also expect gilead lose market share see hepatitis sale topple nearly peak sale gilead have see come porge say say gilead have be surprised slow patient volume world well price erosion other develop market fear company have become paralyzed size good fortune uncertainty outlook capability write gilead appear unwilling match market price high quality asset invest pipeline future outside hepatitis porge have kinder word gilead hiv business be contingent success development bictegravir currently model sale bictegravir combination gilead also have rheumatoid arthritis treatment filgotinib porge see probability success related gilead allergan see trail intercept ongoing nash battlepfizer buy cancer drugmaker medivation
163,MRK,stock close sharply lower thursday concern deutsche bank db health spark sell financial then spread wider dow jone industrial average tumble nasdaq composite lose volume swell nyse nasdaq vs wednesday accord preliminary figure deutsche bank sank nearly concern hedge fund have trim exposure asset manage prime brokerage division german base institution accord bloomberg suggestion justice department pay fine mortgage security issue dow goldman sachs gs be biggest loser drop jpmorgan chase jpm weigh loss bank fall volume higher normal other lag group stock market today include biotechs other drugmaker oil dairy product chipmaker outperformed west texas intermediate crude future climb more barrel add wednesday jump opec late wednesday say agree cap output barrel day start november merck mrk pfizer pfe fall dow stock be midst shape flat base economic news gdp come revise growth rate preliminary figure just forecast first time jobless claim be better view pending home sale august fall well expect increase economic datum tap friday include personal income outlay august september chicago pmi university michigan consumer sentiment index september dalla fed president robert kaplan be schedule speak related deutsche bank be lehman big bank stock break supportoil hit month high opec blink vs shale
164,MRK,drugmaker abbvie abbv pfizer pfe be featured ibd daily income investor column last month be know steady grow dividend well consistent profit growth name have come selling pressure recent week bellwether income stock group be trading tightly high deserve closer look ibdchart symbol mrk
165,MRK,stock open lower thursday better expect unemployment export price datum dow industrial fall lose nasdaq shed treasury yield fall global market have shift lower earlier datum show surprise drop china september import deeper expect decline export hong kong hang seng index tumble china shanghai composite end gain japan tokyo nikkei slip global mining issue be take beating send europe market lower european financial also be pressure apparently due analyst downgrade dax frankfurt fall cac paris drop afternoon trade london ftse show loss mining issue lag freeport mcmoran fcx vale vale rio rio merck mrk rise nearly dow pfizer pfe fall more lose appeal court case attempt defend lyrica patent vs generic drug maker actavis garmin grmn fall ibd list ulta beauty ulta have gain salon beauty supply chain raise third quarter earning guidance well analyst consensus view stock be shape tight second stage base pattern late august high gigamon gimo initially climb reversed trade more stock find support day move average wednesday session have see heavy selling pullback high initial jobless claim slow week end oct labor department report be slightly prior week claim well consensus view uptick claim week move average also downshift fourth straight decease export price rise better expect september reverse august decline best view increase import price rise line consensus view energy information administration release weekly natural gas inventory datum et weekly oil report minute later treasury department september budget be set et release philadelphia federal reserve bank president patrick harker speak et oil price hold steady west texas intermediate just barrel brent crude just gold inched ounce dollar ease vs euro yen bond edge trimming year treasury yield basis point
166,MRK,tesla motor tsla ceo elon musk latest tweet samsung note wo make headline sunday ahead new week trading elon musk tweet neither luxury electric car company takeover target solarcity scty raise equity debt come just day tesla have state intention do raise capital invest heavily get ready model finish battery gigafactory musk also say tesla unveil new product oct addition already plan tesla solarcity integrate solar storage offer related elon musk tesla solarcity don need raise cash samsung electronic halter production note report replacement smartphone be still catch fire accord multiple report sunday night new york samsung start replace note due lithium battery issue cause phone overheat earlier sunday mobile tmus halter note sale samsung electronic share be trading sharply lower korean trading monday company do not trade samsung wo be good news apple aapl recently launch iphone samsung have rushed note market beat apple latest generation handset alphabet googl unit google last week unveil pixel smartphone alibaba picture film unit alibaba group baba reach deal steven spielberg amblin partner co finance produce film chinese global audience amblin make film amblin entertainment dreamwork other alibaba take minority stake amblin alibaba have help finance film such mission impossible rogue nation china soon pass world largest movie market dalian wanda recently reach deal market co finance sony sne film january wanda controlled china richest man wang jianlin agree pay control legendary entertainment group have also say start co investing global blockbuster next year related year blockbuster ipo alibaba ready take worldbristol myer squibb bmy release new study datum lung cancer drug opdivo disappoint opdivo do not outperform chemotherapy even special group patient high level pd protein high pd li level be see raise odd immuno therapy drug opdivo work bristol myer stock tumble aug follow trial datum show opdivo miss expectation broader range lung cancer patient bristol share have continue slide rise modestly last week close merck mrk have similar drug keytruda perform well study patient high pd level merck share shot more year high aug wake opdivo initial poor result merck share have moved sideway then form flat base pattern recently find support day line merck close friday potential buy point related jpmorgan delta ipos oil cyber stock lead investing action plan
167,MRK,biomarin pharmaceutical bmrn kite pharma kite incyte incy pull collective thumb friday goldman sachs upgrade small cap midcap biotech stock group attractive rating cite catalyst do little help ibd company medical biom biotech industry group close stock market today stay day line group be year be turn point say goldman sachs analyst richter macro headwind drug pricing political rhetoric be likely persist year end however see group relatively better position new administration rely re pricing brand drug write research report richter like vertical market central nervous system disorder immuno oncology gene therapy rare disease cns circle richter recommend avexis avxs gw pharmaceutical gwph sage therapeutic sage rate buy respective price target cns drug have face maelstrom challenge fda approval now believe molecular biology cns be come age spur renew interest drug development space richter write bluebird blue also be active cns market work drug treat congenital cerebral adreno leukodystrophy bristol myer squibb bmy merck mrk roche rhhby astrazeneca azn be already immuno oncology space richter key incyte kite number io therapy work introduce molecule act brake immune system provide negative signal tumor cell incyte too be work brake richter write view incyte epacadostat apply brake call ido next generation checkpoint inhibitor write incyte merck recently yielded encourage result combine ido keystruda combat melanoma phase study have buy rating incyte stock break kite stock respective price target richter recommend bluebird avexis gene therapy provide potential shot cure area high unmet need most drug genetic disorder treat symptom vs actual disease write gene therapy be design address underlie genetic defect introduce long term permanent reservoir functional gene patient write only treatment have be approve neither still room avexis bluebird biomarin spark therapeutic once differentiate leader space have highly impressive clinical proof concept richter write spark stock alone get neutral rating rest be rate buy richter expect spark voretigene neparvovec treatment genetic blindness lead way set regulatory pricing manufacturing standard appear prep fda approval biomarin sanofi sny shire shpg lead rare disease front richter only recommend former midsize cap head large size territory nearly market cap incyte too be approach large cap size market cap sanofi shire use enzyme replacement therapy ert combat rare genetic disorder ert model allow premium pricing year lower expense regulatory hurdle shorter development cycle limit competition tax incentive biomarin be step ahead richter say have buy rating price target biomarin sock contrast chronic ert drug gene therapy be design provide patient constant genetic source correct protein theory additional dose event be require write ibd take biomarin incyte be encroach large cap territory richter say amgen far lead space market cap biogen lead ibd company group composite rating best possible get stock checkup related regeneron sanofi beat pfizer roche astrazeneca eczemawhat gilead try buy next poll offer incyte blockbuster franchise spark fever sarepta ariad biotechs
168,MRK,stock open higher friday final trading session september third quarter dow industrial climb nasdaq nasdaq slide friday session week still day move average tracking first decline week start friday weekly slip still unable retake day line september be nasdaq be ahead nearly dow stock strengthen early gain merck mrk add costco wholesale cost rise report mixed fiscal fourth quarter result late thursday qualcomm qcom climb stock surge more thursday news report say chipmaker be discuss acquisition netherlands base nxp semiconductor nxpi nxp share be friday post gain thursday session europe banking stock be still focus friday deutsche bank db center market concern wrestle liquidity issue well investigation department justice bounce open diving nearly huge volume thursday ibd stock nautilus nls jump open stock end thursday session buy point personal income rise spending be flat august commerce department report be gain income spending july economist project gain income spending august price inflation be mild pce index month vs expectation gain price be flat july core price energy food rise line expectation kingsbury international report september chicago purchasing manager index university michigan give final read september consumer sentiment baker hughe bhi release weekly rig count report et oil price reversed early loss west texas intermediate fraction barrel more so far week gold eke small gain reach ounce still be half percent week dollar strengthen bond rise friday trimming year yield basis point europe market be selling pressure afternoon trade cac paris hardest lead benchmark decline japan tokyo nikkei slump shanghai composite post gain friday end week ahead shutdown country national day holiday hong kong hang seng index drop friday take loss week hong kong stock exchange remain open next week
169,MRK,stock market try make case monday friday sell be anomaly be convince short answer be strong action individual growth name premarket future point sharply lower open monday change close major average erased early loss end solid
170,MRK,medical behemoth amgen amgn biogen biib square acquire muscle biologist cytokinetic cytk more dozen potential player prep donnybrook small cap pharmaceutical adms needham analyst suggest friday biotech fodder heated week allergan agn announce back back deal acquire vitae pharmaceutical vtae tobira therapeutic tbra tobira deal give allergan leg battle nonalcoholic steatohepatitis nash gilead gild intercept icpt pharmaceutical also compete ibd company biotech industry group have climb group track just week collectively group have market cap group group fall friday first decline past trading day group be week needham analyst review pipeline business development area interest activity large company gauge interested big pharma be biotechs important theme biotech space write research report allergan amgen bristol myer squibb bmy johnson johnson jnj merck mrk pfizer pfe roche rhhby shire shpg valeant vrx have be most acquisitive buy prep buy more company collectively shire have be most active acquisition believe late development stage commercial stage biotech company be particularly attractive acquisition target write research report title do big pharma want buy peak area interest include oncology cardiovascular needham research show not be big pharma take beaucoup buck needham analyst suggest central nervous system cns player acadium pharmaceutical liver disorder drugmaker intercept be prime acquisition interest firm overlap potential interest acadium abbvie abbv allergan eli lilly lly lundbeck merck novartis pharmaceutical nvs teva pharmaceutical industry teva takeda pharmaceutical needham list potential acquirer allergan make particular sense consider duo already partner next generation formulation memantine fix dose combination product namzaric battle alzheimer year end plan file new drug application food drug administration ad treatment levodopa induced dyskinesia involuntary movement parkinson disease patient multiple sclerosis walking impairment needham write meanwhile acadium potential suitor be interested nuplazid drug ease psychosis associate parkinson launch earlier year needham suggest acadium be look expand label other used similarly intercept draw interest nearly dozen potential buyer include gilead biotech market cap thursday rbc analyst posit intercept continue lead gilead allergan battle nash ibd take biotech stock notch higher week last week check ibd industry theme
171,MRK,be call silent epidemic slowly wasting away liver million american doctor have paltry understand disease approve treatment now alcoholic steatohepatitis nash be sight more dozen drugmaker allergan agn become latest tuesday announce deal acquire nash treatment less hour race company startup intercept pharmaceutical icpt giant include gilead science gild pfizer pfe reach untapped market be worth year accord estimate rbc capital market corp analyst michael yee drugmaker still be try determine different component disease inflammation scarring metabolic change interact be experiment variety treatment mechanism so many company pile field ll have work distinguish re look something get factor say alex depaoli chief medical officer closely hold ngm inc have nash partnership merck co mrk want develop something pop eye nash occur fat accumulate liver inflammation damage much quarter population have precursor condition call alcoholic fatty liver disease ailment develop slowly patient often don show symptom liver be heavily damage most common person be overweight have diabetes doctor mainly prescribe diet change weight loss ibd take medical biom biotech sector be run hot rank eighth ibd industry group sector be lead supernus pharmaceutical supn more be find here doctor need perform biopsy diagnose nash person alone be estimate have condition go develop life threaten cirrhosis nash be lead cause liver transplant accord allergan drug treat likely command high price elizabeth krutoholow analyst bloomberg intelligence say head race be intercept french biotech firm genfit large trial underway tobira therapeutic tbra allergan agree buy tuesday much be prepare recruit patient final stage study investor also be watch result gilead mid stage trial be expect be present year acquisition news tobira share soar more tuesday share be afternoon trade wednesday intercept be testing ocaliva already approve treat rare liver disease call primary biliary cirrhosis nash enrollment final stage trial person be expect be complete next year interim result due potential concern be earlier trial patient experience itch take drug case so severe interfere basic activity chief executive mark pruzanski say interview hope ocaliva become backbone treatment used combination other drug genfit be develop once day treatment raise fat metabolism fight inflammation treat underlie cause fibrosis dean hum genfit chief scientific officer say interview fail meet primary goal mid stage trial last year show promise subset patient moderate severe form disease final stage trial moderate severe patient be underway company have datum late startup biotechs biggest company be pay attention ready do deal merck say pay much partnership ngm gilead maker blockbuster hepatitis drug sovaldi harvoni buy nash drug nimbus therapeutic llc include milestone payment gilead also buy drug phenex pharmaceutical ag much gilead now have nash candidate portfolio have datum later year drug target different aspect disease be develop individually be used potent cocktail allergan tobira be biggest nash deal so far tuesday company also announce purchase akarna therapeutic ltd developer nash treatment pfizer biggest drugmaker be future acquirer have nash drug trial more be test human end year nash be major priority say morris birnbaum chief scientific officer cardiovascular metabolic disease company be try treat disease early stage win be easy genfit tobira mid stage trial fail raptor pharmaceutical rptp end program datum be start come study lot confidence be build lose say jay luly chief executive enanta pharmaceutical enta begin testing experimental treatment patient year same expect happen money
172,MRK,big swiss pharma roche rhhby say thursday new immunotherapy drug tecentriq extend life lung cancer patient late stage trial further heating competition market tecentriq be pd inhibitor attack same ligand bristol myer squibb bmy opdivo merck mrk keytruda do indirectly pd protein opdivo keytruda be approve first melanoma then different stage lung cancer roche first have tecentriq approve bladder cancer back be aim lung cancer next current trial call oak test tecentriq chemotherapy patient small cell lung cancer nsclc have relapse round chemo roche be save detail later medical meeting say tecentriq group show significant improvement overall survival leerink analyst seamus fernandez say create further complication bristol myer be already face road opdivo fail first line lung cancer trial last month minimum have assume result increase view pd pd antibody have very similar efficacy profile result increase competition second line lung cancer opdivo current stronghold fernandez write research note view place even greater importance positive outcome checkmate cm trial opdivo yervoy ipilimumab ctla inhibitor first line nsclc roche slip bristol lose stock market today merck share tick close
173,MRK,drugmaker seek outsource development manufacturing product tap contract pharmaceutical research provider such new issue patheon pthn headquarter netherlands patheon have more employee north america europe asia australia start custom pharmaceutical contract drug manufacturing business canada expand
174,MRK,stock open higher monday brisk overseas action draw sharp contrast sedate premarket session dow industrial be nasdaq add open stock market today market china also post quiet session end narrow loss japan tokyo nikkei surge apparently buoy speculation possible federal reserve rate hike japan be schedule release monthly official household spending unemployment datum monday evening time europe stock moved sharply lower cac paris frankfurt dax lower midsession london stock exchange be close day bank holiday gainer decliner run even dow premarket session verizon communication vz merck mrk open less higher most ibd list stock remain flat ahead open broadcom avgo be drugmaker mylan myl climb nearly open stock fall last week hurt controversy price increase company epipen allergy treatment netherlands base company say monday release lower price generic epipen alternative symantec symc rise barron article saturday estimate cost cut measure software maker recent acquisition blue coat system point upside share price fiber optic networking gear maker oclaro oclr flash higher san jose calif base company be networking leader discuss ibd article outline trend fiber optic networking market also include acacia communication acia inphi iphi other oclaro share be price inphi acacia be ibd stock acacia share rise open personal income chug ahead july line consensus expectation commerce department also revise initial increase estimate june upwards personal spending rise also inline projection commerce also revise june spending estimate gain downward increase core pce price index tick line view equal gain june dalla federal reserve bank deliver regional manufacturing survey august et oil future slump more west texas intermediate crude continue find support barrel gold dip fraction ounce dollar gain ground euro yen year treasury yield slip basis point
175,MRK,pfizer pfe announce deal monday morning buy medivation mdvn share enterprise value move follow month takeover speculation cancer drugmaker well widespread report sunday imminent pfizer medivation deal medivation rise nearly soon open bell stock market today pfizer fall cent propose acquisition medivation be expect immediately accelerate revenue growth drive overall earning growth potential pfizer pfizer ceo chairman ian read say statement pfizer say deal boost earning share cent first year close additional gain medivation close friday market valuation be slightly extend buy point flat base medivation trade low feb be subject widespread buzz possible buyout biotech earlier year reject share offer france sanofi sny last week report have pfizer merck mrk gilead science gild celgene celg sanofi possible medivation buyer ibd take biotechs deliver great growth be generate profit revenue gain higher sale volume price increase here hunt biotech stock medivation make xtandi prostate cancer drug annual sale rate already have other cancer fighter development pfizer attempt buy allergan agn fall apart earlier year obama administration change rule make tax inversion merger deal less attractive related medivation affirm guidance earning growth make case leadership be convince
176,MRK,big pharma merck mrk be now look possible buyout medivation mdvn accord anonymously source report reuter report wednesday afternoon merck be big pharmas have submit indication interest buy medivation other be sanofi sny pfizer pfe celgene celg gilead science gild sanofi have be very public attempt acquire medivation last month medivation say have enter confidentiality agreement sanofi well other unnamed potential buyer earlier anonymously source report say pfizer celgene gilead be interested buyer have be speculation merck be interested bmo capital research note assert merck be prepare medium size buyout medivation be target merck have be focuse much energy cancer lately medivation have fast grow drug market treat prostate cancer other cancer therapy development medivation stock have be trading flat stock market today pop week high news come close merck rise ibd take medivation be ibd stock last earning report year year profit growth flattened deliver big hit ep rating analyst expect growth pick again start however
177,MRK,major average show modest loss midday sell solar stock weight sentiment session offer plenty solid gainer well china base jd com jd be top performer nasdaq strong earning dow leader include wal mart wmt disney merck mrk nasdaq lose give dow jone industrial average ease volume nyse nasdaq be tracking slightly higher tuesday level share disney rise investor weigh quarterly earning report news acquire stake bamtech be major league baseball mlb advanced medium stream unit downside sunpower spwr plunge weak earning poor guidance share first solar fslr plunge last week also weak earning guidance new york mercantile exchange west texas intermediate crude oil future december delivery fall nearly barrel oil rise early wednesday turn lower energy department announce unexpected weekly rise crude stockpile heel gain tuesday share ibd name yirendai yrd jump report strong earning don chase well extend recent yirendai have be top performer ibd finance consumer loan industry group see other leader group be ibd stock checkup ibd take do mean stock become extend buy point check lesson ibd university other top gainer ibd wednesday include maxlinear mxl acacia acia grubhub grub blue buffalo pet product buff add ahead earning report due close try clear cup handle base buy point wall street expect second quarter earning rise healthy cent share revenue blue buffalo top line growth have slow range prior quarters compare increase higher most alibaba baba be also move ahead earning report slate thursday open share rise just cup handle entry
178,MRK,major market index hold most big gain friday trading session enter final hour fuel strong job datum big move apple aapl merck mrk other stock nasdaq lead jump dow jone industrial average rally rise volume be mixed tracking slightly lower nyse higher nasdaq vs same time thursday labor department report new job july economist average forecast also issue upwardly revise june figure job travel booker bank transport stock outperformed stock market today gold miner drugmaker utility lag gold future be ounce dow be nearly green board merck take lead gap week high drug giant share pop bristol myer squibb bmy say opdivo cancer drug fail meet primary endpoint merck rival keytruda drug succeed recent similar trial bristol myer gap loss huge volume apple rise highest level mid april continue pull away day move average iphone maker say pay person report bug product accord wall street journal ibd atlassian team surge new high rapid turnover follow fiscal result late thursday share be well extend past handle buy point clear july have rally more dec offer price software maker revenue jump same quarter year ubiquiti network ubnt gap soar new high volume nearly time larger norm ibd stock be now extend flat base buy point nearly profit take range close thursday telecom gear maker report strong fiscal result boost profit sale guidance universal display oled slump massive trade tumble day line first time maker organic light emit diode product thursday report earning revenue miss view outlook also disappoint needham downgrade stock hold buy
179,MRK,share biogen biib shot tuesday report big drugmaker be explore possibility buy company wall street journal say anonymously source report merck mrk allergan agn have talk biogen possibility talk be informal preliminary biogen stock have be slightly day then jump close stock market today hit year high wall street have be toss possibility biogen takeout time rumor start heat ceo george scango announce retirement last week rbc capital market analyst michael yee note video last weekend leave biogen vulnerable takeover especially investor have get restless slowdown company multiple sclerosis franchise risky pipeline most talk pipeline drug be aducanumab alzheimer disease explain merck interest merck be work different class alzheimer treatment call bace inhibitor be think eli lilly lly disease ultimately be treat combination drug allergan inherited drug treat alzheimer symptom acquisition forest laboratory few year so presumably leverage sale force other company be name yee opined roche rhhby also be logical buyer give already have partnership biogen selling lymphoma drug gazyva merck fall tuesday allergan lose roche climb
180,MRK,big pharmas abbvie abbv merck mrk trade higher friday report estimate beating result friday french counterpart sanofi sny close virtually flat abbvie quarterly sale grow year earlier quarter pass analyst consensus largely strength sale immunology drug humira sale blood cancer drug imbruvica also beat expectation abbvie slightly increase tighten full year ep guidance call growth last year share finished higher stock market today merck also beat estimate more narrowly raise low end full year ep guidance range merck also announce friday hepatitis drug zepatier have be approve european union month approval zepatier sell beating consensus evercore isi analyst mark schoenebaum note merck best selling diabetes drug januvia seem be hold competition eli lilly lly jardiance cancer drug keytruda beat consensus largely international sale recall merck recently announce success keynote trial first line nsclc small cell lung cancer attention investor come year focus performance indication schoenebaum write email merck stock edge ibd take abbvie rank ibd medical ethical drug group solid financial decent stock performance group overall be just total check ibd industry theme take temperature stock industry group sanofi meanwhile miss sale estimate quarter affirm full year ep guidance contrast merck sanofi diabetes franchise have be shrink face competition drop worldwide other noteworthy news japan astella marketing partner sanofi takeover target medivation mdvn report quarterly financial suggest medivation lead drug xtandi miss sale consensus globally be line medivation stock rise hit month high edge past buy point sanofi close cent
181,MRK,stock market turn mixed friday wall street weigh strong earning report amazon com amzn worry weaker expect preliminary read gross domestic product leaderboard name amazon add late wednesday company smash earning estimate report second straight quarter accelerate sale growth dow jone industrial average give back less nasdaq composite add volume nyse nasdaq be tracking lower thursday level stock market today other global market tokyo nikkei bump bank japan vote mild increase monetary stimulus measure exxon mobil xom chevron cvx be early laggard dow report weak result west texas intermediate crude oil dip barrel exxon mobil lose chevron re-cover trade flat merck mrk erased most early gain microsoft msft climb economic news preliminary read gross domestic product show growth well consensus estimate gold be mostly unchanged ahead gdp datum picked steam afterwards rise ounce year treasury yield picked basis point medical device maker abiom abmd add share have be nice accumulation phase stock sit just time high ibd take abiom be several leader strong perform medical product group see other leader be ibd stock checkup ibd name food bgs soar nearly report strong earning late thursday quarterly profit jump year earlier sale jump result be help acquisition last year green giant le sueur brand general mill gis
182,MRK,here investing action plan friday need know investor come day exxon mobil xom chevron cvx report second quarter earning investor have be focuse energy development july oil price continue fall thursday hit month lows re high up up drugmaker merck mrk
183,MRK,week bring boatload earning large cap drugmaker here be popular stock face turn point company growth cycle key unknown hep front be much veteran administration have be buy isn available analyst usual source prescription datum ibd take ibd slim investment system stand new new management new condition other new thing such new product so wise keep abreast upcoming drug trial datum biotech company gilead share have languish company be expect release key datum possibly big hep drug later year ibd report va have budget hcv drug spending fiscal year write evercore isi analyst mark schoenebaum email friday note gilead have historically have share va prescription va revenue quarter be important help gilead not miss consensus estimate gilead science share rise late morning trade stock market today leerink analyst seamus fernandez lift opdivo sale estimate preview note last week together yervoy bristol myer maintain share checkpoint inhibitor market fernandez write refer class cancer drug opdivo belong base trend have increase full year opdivo sale expect strong uptake japan improve royalty revenue ono bristol myer squibb stock fall intraday have lower term estimate keytruda januvia franchise base sale prescription datum respectively however see greater long term opportunity relative previous forecast fernandez write recent announcement overall survival benefit keytruda keynote trial raise prospect drug first line small cell lung cancer nsclc merck share fall nearly intraday leerink analyst geoffrey porge write july note trial bring significant revenue upside revlimid succeed lead addition diffuse large cell lymphoma dlbcl exist product label study be controversial write be start development testing more responsive less responsive patient also treatment regimen not be best use revlimid disease nonetheless porge assessed modest positive outcome most likely celgene stock fall monday morning abbvie rise
184,MRK,vote leave european union brexit be dazzling open ceremony olympic instead be uplifting brexit firework come form stock market devastation yet now little more month later many stock be rise game firework rio janeiro take look top perform growth stock mutual fund june post brexit low rank olympic class sprinter include driehaus micro cap growth dmcrx span other join otc medal stand elite runner circle be fidelity otc focpx primecap odyssey aggressive growth poagx tocqueville opportunity toppx harbor small cap growth opportunity hasox click here see list top holding top perform growth next top performer gain range be lord abbot micro cap growth lmiyx jpmorgan dynamic small cap growth vscox primecap odyssey growth pogrx well fargo emerge growth wfgdx jpmorgan small cap growth pgsgx power gold medal fund top holding include familiar name alphabet googl amazon amzn apple aapl facebook fb name gain amazon case alphabet month brexit low whole bunch additional growth stock be also championship fund top holding do even better be household name be less well know lead pack be acacia communication acia soar june low acacia account driehaus fund asset latest disclosure be fraction much just brexit acacia have composite rating ibd smr sale profit margin roe rating composite rating start run combine ibd performance rating include ep relative price strength rating stock poise move higher often have high composite rating look stock rating be higher mean ve outperformed other stock term composite rating smr rating be best acacia be cloud infrastructure tech firm be top rank stock ibd telecom fiber optic industry group group be rank now week stock share price have more double stock go public mid leave share price extend most recent quarterly report have show earning share skyrocket triple digit pace medivation mdvn rebound brexit have be more modest be still more twice good broad market leave maker cancer drug still buy range trading friday morning be less past flat base entry have comp rating smr rating ep growth be slow have grow past quarters ibd take medivation be takeover target ibd ken shreve report sanofi be suitor medivation blockbuster drug be prostate cancer treatment xtandi
185,MRK,mobileye mbly be brexit company be leader driver assistance system such automatic brake have comp rating smr rating trading share be alternate handle entry share gap july company say continue relationship tesla tsla not supply additional technology component investor have be assess tesla other firm produce driverless technology threaten mobileye ibd take paul gordon lead manager mfs mid cap growth fund tell ibd week be not worry tesla tesla be many mobileye customer say paul gordon lead manager mfs mid cap growth fund otcix be not significant percentage sale currently mobileye july pullback be due investor fear tesla have find supplier provide autonomous drive chip lower price gordon doubt case more difficult imagine ford gm gm even bmw bmwyy do mobileye paycom software payc be big gainer post brexit then paycom provide cloud base human capital management software be top hold tocqueville fund stock have comp rating smr rating trading share be extend entry paycom have comp rating smr rating big winner brexit be biogen biib top hold top perform fund vanguard capital opportunity vhcox notch gain also be hold primecap odyssey aggressive growth biogen be brit brew market meltdown leave slightly extend recent buy point cup handle base weighting biogen be top hold sixth best perform growth stock mutual fund vanguard capital opportunity vhcox notch gain biogen have comp rating smr rating ep grow quarters be stock medical biom biotech industry group group be rank now week back merger acquisition be roil pharmaceutical biotech water early week wall street journal say merck mrk allergan agn be check biogen fox business say allergan not afford make run biogen biogen merck product line be so different such hookup offer synergy merck
186,MRK,type diabetes be battle best selling drug world biggest drugmaker company be eyee even bigger sale new generation treatment change field have prove more evolutionary revolutionary several event next few month start soon monday eventually move billion dollar make compliance treatment easier even prevent death heart disease diabetes drug provide single best selling product johnson johnson jnj merck mrk almost nordisk nvo annual revenue come diabetes treatment health care research firm globaldata say diabetes treatment bring nearly re get better better manage diabetes general say funtleyder health care portfolio manager square asset management have more option next phase be go be get person adhere regimen work diabetes patient type diabetes be world most common disease sticking treatment be difficult medication routine get increasingly complicate disease progress diet exercise fail patient go oral drug start cheap generic such metformin prove insufficient doctor add newer brand oral medicine come class dpp inhibitor lead merck januvia more recent sglt inhibitor lead invokana class work different mechanism be sometimes combine yet further intervention be require patient move injectable drug nowadays glucagon peptide glp analog be usually first line attack class include nordisk victoza eli lilly lly trulicity ibd take eli lilly stock have nice year run end year now sport weak composite relative strength rating respectively shouldn get much stock pick attention company aim rebound ceo tell ibd exclusive year come most familiar treatment diabetes insulin modern insulin come different variety include long act version sanofi sny lantus tresiba need be inject only once day faster act one use mealtime such lilly humalog novolog pile med patient have trouble keep so approach simplify routine be create combination drug be do successfully hiv market sanofi nordisk be await fda decision combination insulin glp back back fda advisory panel recommend approval xultophy win unanimous support sanofi lixilan have couple dissenter due safety issue related pen injector used administer drug fda deadline decide xultophy be monday sanofi decision be due next month hasn reveal specific deadline leerink analyst seamus fernandez see blockbuster potential drug expect ll take year hit peak sale have see other recent major primary care launch such pcsk sanofi regeneron regn amgen amgn entresto novartis nvs breo ellipta glaxosmithkline gsk expect slow initial launch class first few year fernandez write research note view xultophy have slight upper hand drug device profile position treatment algorithm lead better physician acceptance market uptake say overall diabetes model forecast peak sale xultophy peak sale lixilan fda decision much anticipate wall street be already approve drug lilly sglt inhibitor jardiance last year lilly stunned industry large year trial show jardiance significantly extend lifespan diabetes patient reduce death rate death cardiovascular cause also sharply reduce hospitalization heart failure analyst say jardiance see instant uptick sale so spectacular be result didn happen lilly closely study issue say enrique conterno president lilly diabetes realize potential thing need happen conterno tell ibd first be need datum label second be need new treatment guideline be establish canada already make change relevant medical society treatment guideline conterno say expect same early next year get label change mean lilly sale rep be able talk cardiovascular benefit customer be important primary care doctor most diabetes prescription aren always specialist research lilly have apply expand label include information least put clinical trial result packaging approval however isn quite slam dunk expect trial result way lilly design trial primary endpoint be normally most important fda be composite different measurement cardiovascular health produce mixed result specific finding heart failure overall death be exploratory endpoint thus fda advisory panel only narrowly recommend change label meet june change label basis secondary endpoint set precedent so remain so unclear fda do analyst compare coin flip view approval actual cv death indication have coin flip odd give unprecedented nature result trial write evercore isi analyst mark schoenebaum email june say also feel better chance fda allow datum be add label also remain be see competition shape last month nordisk report glp call victoza also reduce cardiovascular death not quite much jardiance jardiance be oral victoza be injectable occupy slightly different position treatment regimen jardiance most direct competitor invokana be also subject cardiovascular outcome trial due completion february initial result possibly come earlier different variable company do best diabetes be broadest portfolio funtleyder say cite lilly nordisk have have particularly comprehensive program give advantage salesforce leverage basis same sale guy sample multiple drug say have benefit payer bundle drug together big bill instead pbms pharmacy benefit manager have negotiate separate pill eli lilly share rise stock market today best level late january nordisk climb dip
187,MRK,stock open higher friday better expect july payroll report drugmaker merck mrk boost dow climb et hit fresh time high nasdaq rise just record peak july dow industrial scale nonfarm payroll expand worker july labor department say be sharply upwardly revise new hire june easily top expectation increase job private payroll be key result add employee vs expectation unemployment rate hold steady vs view dip workforce participation rate notch june average hourly earning increase line expectation june expansion commerce department report trade deficit widen june consensus expectation june trade gap be oil future energy stock be sensitive baker hughe bhi weekly rig census due et federal reserve report june consumer credit number stock market today rolled heavy slate earning company news bristol myer squibb bmy crash new cancer drug opdivo fail trial single therapy newly diagnosed lung cancer patient dow component merck compete drug keytruda rise more breaking highest level early merck also get work food drug administration have accept review new drug application mk biologic insulin candidate treatment person type type diabetes rackspace host rax jetted higher report late thursday say company be advanced talk more private equity firm regard takeover report say san antonio texas base cloud compute firm complete deal early week network gear maker ubiquiti network ubnt jump more thursday market close san jose calif base outfit report strong fiscal fourth quarter result guide first quarter revenue earning consensus view announce share buyback initiative ibd stock end thursday session flat base buy point en route contest prior high september priceline pcln book gain heel mixed second quarter result report late thursday online travel site notch strong beat earning line revenue stop shy analyst expectation management give line guidance third quarter priceline have be gradual uptrend past week consolidate november high kraft heinz khc squeeze advance report better forecast jump earning share surge second quarter revenue fuel company merger year organic net sale decrease downside ibd stock universal display oled collapse maker organic light emit report sale earning analyst target second quarter stock have be flattish consolidation meeting resistance early june oil future be narrowly lower west texas intermediate stand just barrel flat week dollar trend lower bond rise clipping basis point year treasury yield gold be flat just ounce global market edge generally higher friday hong kong hang seng index lead asia top benchmark gain friday secure advance typhoon shorten trading week europe market follow frankfurt dax show gain afternoon trade
188,MRK,job report push stock fresh time high busy week tesla motor tsla announce deal buy solarcity scty tech be strong general motor gm ford fuel sell consumer related stock oil price briefly undercut barrel also bank england cut rate revive bond buy major average be little change thursday rally friday strong job report nasdaq climb week record close friday just point july intraday peak rise hit fresh intraday best dow jone industrial average advanced energy stock fall oil undercut early week rally crude re-cover somewhat economy add job july second straight month much better expect hire allay fear economy ism manufacturing index index fall little more forecast still point growth strong hire wage gain support consumer spending housing demand many consumer related firm report stall demand tesla take step closer acquire solarcity special committee independent disinterested solarcity board member evaluate proposal alternative state approval merger deal still need be approve shareholder regulator tesla report earning miss estimate show improvement electric car production production be track support delivery second half reaffirm previous guidance electric car company loss balloon share cent year earlier figure much greater cent loss estimate tesla report gaap revenue miss consensus tesla fall week solarcity lose more ride hail giant uber technology be selling chinese operation apple aapl backed rival didi chux technology capitulate expensive battle foothold china deal have uber swap chinese business stake didi make former foe largest stakeholder didi turn didi become facto ride hail leader china value more uber most recent valuation put north verizon communication vz agree buy fleetmatic fltx vehicle tracking system maker share acquisition expand verizon push web connect vehicle part internet thing ireland base fleetmatic mobile software platform let business manage commercial fleet provide datum vehicle location fuel usage speed mileage verizon fall week drop buy point day move average fleetmatic jump time warner twx st century fox foxa turn mixed result time warner move buy stake netflix nflx rival hulu join current co owner walt disney fox comcast cmcsa steal headline viacom viab report better expect earning revenue do lion gate lgf post surprise profit oil price fall barrel early week follow july tumble opec production climb strong output nigeria iraq saudi arabia continue pump oil record high crude stockpile rise latest week accord energy information administration production dip gasoline supply fall shale producer continental resource clr oasis petroleum oas laredo petroleum lpi lift output forecast oil close week higher bristol myer squibb bmy plunge friday cancer drug opdivo end string clinical trial success failure trial single therapy newly diagnosed lung cancer patient merck mrk have succeed similar patient group trial compete drug keytruda be aim smaller potential market merck stock jump hit highest level june earlier merck be report be talk biogen biib possible biogen buyout be allergan agn further boost biogen stock day partner ionis pharmaceutical ion announce unexpected success clinical trial nusinersen treatment rare spinal disease blockbuster potential biogen rise nearly week meanwhile specialty drugmaker mallinckrodt mnk shire shpg rise respectively beat estimate raise guidance pfizer pfe nordisk nvo regeneron pharmaceutical regn slip beat number issue so so guidance animal health company zoetis zts also rise beating raise general motor gm ford lead auto stock lower report slower sale month july ford project industry sale fall year big gain department store grocery store restaurant airline also decline re-cover somewhat week end sell consumer stock trigger warning broader economy fall business investment homebuilder spending consumer spending rise strong annual rate falter economy not be able match anemic gdp growth texas roadhouse txrh beat earning estimate ep cent revenue growth miss view steakhouse chain also say early same restaurant sale growth have slow outlook come grow worry restaurant sector overall starbucks sbux mcdonald recently report weak comp warning analyst retail sector pizza delivery chain include papa john pzza be buck trend papa john say ep jump cent top view raise guidance rest year also chicken theme el pollo wingstop wing rally result jack box jack soar earning separately monster beverage mnst report weaker expect earning growth top revenue forecast monster beverage leaderboard stock rally friday hit new high ibd take investor look growth stock clear proper buy point ibd leaderboard be premium service provide detailed chart analysis lead stock see other top rate growth name be buy point bank england cut interest rate quarter point expect economy slow reaction brexit vote policymaker go further revive government bond purchase announce boe buy corporate debt also signale rate cut be likely year end boe gov mark carney say opposed negative rate helicopter money martin marietta material mlm make crushed stone sand other aggregate used construction fall short second quarter forecast rival aggregate supplier vulcan material vmc also badly miss related ready mix concrete market concrete uscr report ep plunge cent miss cent revenue rise also miss blame bad weather say expect better result second half martin marietta ceo nye cite record record rainfall attendant effect many key market share trio fall hard earning miss re-cover lose ground end week delta air line dal report decrease passenger unit revenue july say drop be line expectation investor appear worry tone result set third quarter delta say key metric operate efficiency fall german carrier lufthansa warn terror attack economic uncertainty affect travel also hurt sector delta stock fall american airline aal jetblue jblu also sank unite airline ual southwest luv close week higher aetna aet humana hum wellcare wcg put estimate beating quarterly result week however aetna say abandon expansion plan obamacare exchange humana recently say exit most obamacare exchange market next year follow unitedhealth unh aetna humana try overcome antitrust objection merger safety security concern person mind wake series officer involved shooting polouse officer polouse unarmed civilian sale sturm ruger rgr firearm grow second quarter rise earning climb share fbi report firearm background check see indicator future gun sale rise july june be july share fall day earning ruger ceo say be step close week only meanwhile taser international tasr say ep fall cent share cent year beat forecast cent share sale pop easily top view stun gun maker say booking axon body camera soar taser stock rise hit year high
189,MRK,ibd biotech industry group have rally february low move group be filled leader right be group house more stock only have composite rating higher tuesday session still noteworthy group have jump
190,MRK,big biotech gilead science gild beat earning estimate lower full year revenue guidance late monday send stock more hour trading gilead sale earning decline last year hepatitis drug sovaldi outperformed expectation newer cousin harvoni come short epclusa next generation hcv pill be approve just day end quarter already bring gilead price epclusa much lower previous drug reflect new competition abbvie abbv merck mrk sovaldi harvoni officially retain higher price tag gilead have be rebate heavily say monday rebate have continue increase hiv franchise be also mixed bag perennially popular truvada beating estimate most other drug underperform company trim full year product sale guidance now also lower guidance sale general administrative expense raise research development guidance slightly leave overall cost look more less same gilead do not provide ep guidance lower sale suggest possible margin squeeze gilead stock rise monday regular session share be year
191,MRK,here investing action plan need know investor come week more tech giant apple aapl facebook fb amazon amzn alphabet googl report earning do biggest name oil such exxon mobil xom chevron cvx fast food leader mcdonald mcd aerospace giant boee ba federal reserve policymaker
192,MRK,big pharma stock be often favore income investor tend pay relatively healthy stable dividend merck mrk have be consolidate year be work handle potential buy point stock have regain nearly loss post brexit sell be back day
193,MRK,stock slightly pare gain wednesday minute be release federal reserve june meeting amazon com amzn hit new high airline tumble rating downgrade fed official decide keep interest rake hike hold outcome britain june referendum accord minute also weigh uncertainty labor market financial market nasdaq be climb dow jone industrial average hold gain volume be mixed tracking slightly lower nyse higher nasdaq vs same time tuesday gold miner medical build related stock score gain stock market today west texas intermediate oil rise barrel gold price be year treasury yield climb early drop remain record lows continue fallout brexit merck mrk lead dow gain healthy turnover share track sixth straight advance be year drug giant friday say take stake brazil vallee animal health company newspaper airline movie related issue lag american airline aal fall fast trade continue descent stock have trade day move average mid april have poor relative price strength rating credit suisse downgrade carrier underperform outperform also lower unite airline ual neutral outperform investment firm say carrier likely miss consensus estimate due higher fuel cost stronger dollar brexit other reason netflix nflx gap fall average volume share be trading converge day day move average line jeffery lower rating internet tv subscription service underperform hold needham tuesday cut stock hold buy brexit related growth risk internet retailer amazon add new high suntrust robinson humphrey raise price target stock
194,MRK,food drug administration tuesday approve gilead science gild latest hepatitis pill company price significantly lower previous drug drug epclusa improve gilead previous drug sovaldi harvoni treat major genotype hepatitis virus hcv enlarge market eliminate need genotype testing most patient regime be pill day week patient decompensate cirrhosis very advanced liver disease take ribavirin standard generic hcv medicine gilead representative cara miller tell ibd email wholesale price week regimen drug be quite bit sovaldi harvoni raise outcry drug be launch respectively hcv business however have get more competitive then abbvie abbv merck mrk launch treatment significant discount treatment be genotype strain make market merck zepatier also be approve genotype miller note current standard treatment patient genotype be sovaldi combine bristol myer squibb bmy daklinza together cost twice much epclusa gilead have say position epclusa mainly genotype treatment be most difficult treat sound obviate need sovaldi harvoni company have engage extensive rebate keep drug competitive also many patient take harvoni only week gilead say have plan study shorter duration treatment epclusa gilead position anticipate cannibalization sovaldi revenue gt gt patient harvoni revenue gt patient due more friendly regimen potential omit ribavirin shorter duration gt patient write leerink analyst geoffrey porge research note porge forecast epclusa sale year jump next year expect quick drop next generation treatment start come note estimate be almost double consensus however fda approval be widely expect gilead stock shot stock market today gilead stock hit year low monday share tumble friday monday brexit vote fallout
195,MRK,big pharma eli lilly lly jump wednesday wall street analyst weigh result narrow food drug administration advisory panel vote late tuesday panel meet decide good idea expand label lilly diabetes drug jardiance include reduce death cardiovascular cause base large clinical trial call empa reg committee vote favor change such close vote leave less clear just decision fda ultimately make most cite reason vote be bar new claim be grant base single study be very high panelist see second trial confirm cv death find leerink analyst seamus fernandez write research note many panelist vote yes also share concern find cv death benefit compelling convince enough tip balance fernandez nonetheless like odd approval note most senior member panel include biostatistician cardiologist vote favor new indication credit suisse analyst vamil divan be also bet favor change add read similar product sglt inhibitor class johnson johnson jnj invokana remain market leader sglt space canvas outcome study schedule be complete february divan write research note assume fda agree include empa reg outcome cv death datum jardiance label see share shift invokana jardiance canvas be complete longer term implication dependent canvas result result outcome study astrazeneca azn forxiga merck mrk pfizer pfe ertugliflozin be expect later decade divan say evercore isi analyst mark schoenebaum be more cautious slight overall majority vote favor new cv indication view approval actual cv death indication have coin flip odd give unprecedented nature result trial schoenebaum write email client say also feel better chance fda allow datum be add label instead indication statement lilly stock rise stock market today once again day move average lilly close just day line be past month johnson johnson stock close fresh record high
196,MRK,drug giant eli lilly lly gilead science gild face key food drug administration action tuesday affect future lead disease treatment franchise advisory committee fda meet discuss expand label jardiance lilly year old drug treat type diabetes lilly want add label be drug also reduce death cardiovascular cause hospitalization heart failure risk death general claim be base large long term trial call empa reg result surprised industry last year patient jardiance show reduction death cardiovascular cause reduction hospitalization heart failure cut death cause fda approve label expansion lilly sale rep be able use marketing drug problem accord leerink analyst seamus fernandez be be not primary endpoint trial be secondary exploratory endpoint primary endpoint be point measurement major adverse cardiac event mace time first cardiovascular related death fatal heart attack fatal stroke result be more mixed only first point do jardiance achieve statistically significant difference fatal stroke incidence be actually slightly higher placebo group fda release briefing document panel friday morning fact conclusion affirm study do show reduction cv death advise include mace heart failure cause death info label be nonetheless interpreted positively analyst lilly stock be stock market today general brexit sell panel also consist substantial portion cardiologist help tilt balance highlight cv benefit panel view fernandez write research note friday preview event june fernandez have predict panel be battle statistical purist vs clinician add clinically large consistent cv death benefit see empa reg trial be view be precedent set precedent also be interest nordisk nvo recently report similar study diabetes drug victoza also bring reduction cardiovascular death not extent jardiance do nordisk have say also file label addition hasn yet decide language danish diabetes specialist fall friday tuesday also be deadline fda decide approve gilead latest hepatitis pill gilead last hepatitis launch sovaldi harvoni break financial record be restrict certain genotype virus new pill be approve genotype not only enlarge market also remove need test patient genotype writing prescription wall street have doubt fda approve drug interesting question be gilead price launch december sovaldi gain notoriety price week regimen harvoni launch october be more however abbvie abbv launch compete viekira pak december company start rebate war hit gilead income then january merck mrk price new hcv drug zepatier well gilead abbvie acknowledge hit financial remain be see gilead value pan genotypic nature new drug gilead stock be friday hit year low abbvie sank merck
197,MRK,big pharma merck mrk rise thursday say drug keytruda succeed trial patient newly diagnosed lung cancer keynote trial test keytruda sole treatment patient small cell lung cancer nsclc contrast keytruda chemotherapy combo trial merck report earlier month merck announcement didn include number say keynote have be stop have already proven keytruda lengthen progression free survival overall survival compare standard chemotherapy merck stock rise stock market today keytruda be currently approve only treat relapse case nsclc merck plan file label expansion soon possible accord evercore isi analyst mark schoenebaum further detail trial result be present unspecified future medical meeting keynote study only patient tumor show high expression pd ligand keytruda target inhibition pd protein bristol myer squibb bmy be conduct similar trial own pd inhibitor opdivo front line monotherapy nsclc patient degree pd expression result trial be expect third quarter schoenebaum write email high expressor only make patient population so successful lead significantly broader label bristol myer stock fall
198,MRK,jerry dodson parnassus endeavor fund parwx prove have socially responsible cake eat too mutual fund favor company provide employee outstanding workplace so do other fund parnassus investment dodson founder include thing offer worker profit sharing time work parent paid time volunteer work fair treatment clear communication investment team parnassus have management also screen company engage extraction exploration production manufacturing refine fossil fuel none criterium have prevent endeavor outperform peer broad market past year be top perform environmental social corporate governance esg fund year end june average annual return decade say morningstar inc averaged yearly gain span fund also rank top large cap growth mutual fund period top past year be ibd best mutual fund award winner glow category equity fund growth fund large cap outperformed year period end dec be ahead roughly diversify stock fund so far year dodson affinity esg investing have deep root founder parnassus investment age goal mind earlier work be harbinger be come political science major uc berkeley get mba harvard business school then go work nonprofit outfit help minority own business help organize continental saving america become president ceo develop innovative product depositor invest solar energy project dodson be lead manager parnassus fund parnx parnassus asia fund pafsx sole manager endeavor office san francisco year old dodson talk investor business daily in out investment approach begin use social screen ibd re juggle tough task not only use esg criterium also run concentrated portfolio be tougher dodson know hard part be get philosophy tweak simulation be do many year once understood strategy work size portfolio just follow ll be surprised take advice journalist size strategy be social friend milton moskowitz be writing news story start book be best place work look return be publicly trade thought start fund base milton thought stick company disagree say screw anyway take year look fundamental metric correlated good stock performance take year back testing paper then more year run portfolio open public ibd aside esg criterium look seek large cap company wide moat strong competitive advantage quality management team act best interest shareholder have get right dodson succinctly ibd information technology be largest sector weighting march be typical exposure tech dodson usually be largest sector not normally reason be know sector well silicon valley be road more more right here city also term workplace technology company seem step ahead provide good environment google alphabet googl now have generous maternity leave gym work day do charitable event compare say steel industry workplace issue score stronger tech company ibd speaking alphabet be trend sideway late april do still stock dodson start buy december now low think make more gain re right be pretty flat regard long term hold get great moat good social story ibd do think have more room run dodson primarily moat look develop new product have huge cash stake talented workforce search engine give revenue earning stability don know new idea re work know re look new product ll find something ibd general emphasize esg criterium more other right dodson be more focuse workplace company treat employee then environment workplace be component social ibd be workplace part social dodson word social cover lot mean company treat employee mean safety record privacy policy relationship community company operate diversity program good clear honest communication ibd do ever invest stock feature be very attractive even financial performance be not so bright dodson past ve do do endeavor fund parnassus fund parnx stock be control datum supercomputer company hire former prisoner do great social thing business strategy be just invest be worst mistake ever have cure pick environmental social reason alone ibd let talk individual holding latest disclosure citrix system ctxs earning share rise past quarters lot person think enterprise software developer specialize desktop virtualization lose focus reorganization have involved layoff staff contractor do situation look dodson reason invest be gotomeeting app be be spun gotomeeting be similar citrix xenapp be thousand mile away server do application use smartphone laptop deliver safely mobile device make successful person want application company deliver want ibd stake apply material amat be be satisfied progress dodson be doldrum initiate position equipment used make semiconductor tend be volatile sale earning be very cyclical try buy time stock have fall then ride now rise believe apply benefit significant order growth lead etch deposition tool ibd ciena cien earning share have slow growth quarters growth decline past frame everything dodson ve own quite more volatile expect make communication glass wire equipment move impulse be voice datum transmission line earning have be lumpy time have equipment maker have up down ve hold cycle more volatile expect company think have more upside ibd do own robinson worldwide chrw not tech story revenue have decline quarters row dodson freight forwarder focuse trucking re right hasn do well primarily shipping have not picked much anticipate economy be grow annualize rate less get trucking freight forwarding grow economy have grow more so play economic recovery accelerate average cost be stock be mid so ve do well ibd charle schwab schw ep grow have accelerate quarters share price have be weak play here dodson re tie pay schwab customer come key lot brokerage firm include schwab collect interest margin loan interest rate so low don make much interest rate increase then huge earning increase schwab mid now go economy get better rate go schwab take ibd intel intc ep growth be speeding growth computer chip come dodson make chip personal computer smartphone other application also make chip server sale be go ve be try year get mobile device market finally have semiconductor go iphone re try get more communication other growth area apple aapl chip other mission re banking move intel higher ibd procter gamble pg be classic defensive stock revenue share have decline quarters be want dodson re right revenue decline ve get amazing brand crest tide gillette head shoulder need new growth engine re look do have growth ahead haven reach conclusion ibd ibm ibm ep be straight quarters sale be frame row invest
199,MRK,dodson only defense be warren buffett own lot more do first buy end expect turn cut emphasis hardware point growth consult software offset decline hardware hasn happened yet time forward earning believe share price be bargain table ibd be buffett selling dodson look filing ve see sign buffett selling sure have same regret have ibd grainger gww ep sale finally notch gain decline quarters share be not make headway dodson grainger make everything sun maintenance sense be play overall economy economy grow fast enough grainger do well product touch almost sector economy ibd gilead science gild ep revenue growth have slow recent quarters do still stock dodson be expect sale increase quite bit hepatitis product have cut price competition abbvie abbv merck mrk make therapy hep gilead be great lab develop new therapy time company do well ibd fund begin different name name change jerry dodson way pick stock hasn change start workplace fund have good performance early name workplace fund be not get attention thought person staff say get strange reaction broker advisor weren sure name meant not pick more general name say say get more shareholder money more acceptance ibd be fund concentrated dodson primarily find enough company be undervalue meet workplace social criterium ibd fund have name typical be dodson have name re look more last couple year go so ibd fund have cash weighting be hard find kind stock dodson correct try stay fully invest possible ibd jerry make day run fund do run totally pc fund know only invest ammo tobacco oil dodson endeavor manage include longer exist other parnassus fund prior find manager founder parnassus investment prior work year president small bank san francisco spend year foreign service officer department state serve panama vietnam ibd be investment style embraced esg dodson ve embraced esg firm be founder be founding principle ibd get esg dodson personal philosophy have always revolve esg wasn sure be used business philosophy continental start program allow saver put money special saving account be lend solar energy installation much pleasant surprise program be very popular convince be market investor want make positive impact money lead founding work asset money fund take esg factor account investing money market security turn lead formation parnassus investment take esg experience then add value oriented philosophy benjamin graham writing admire strain form basis parnassus investment philosophy ibd do come parnassus name dodson live street parnassus avenue san francisco look mythology mount parnassus greece discover be site oracle delphi like image oracle often go prevailing wisdom fit contrarian value oriented investment philosophy ibd re do have plan retire dodson plan retire chief executive officer however plan stay indefinitely manager endeavor find someone well qualify take
200,MRK,stock open lower thursday pressured mixed early economic news weak oil price selling overseas market nasdaq fall drop day move average dow industrial fall year treasury yield tumble august flash crash intraday lows lowest level merck mrk ctrip com ctrp american airline aal kroger kr wesson swhc be early mover stock market today consumer price growth slow labor department report represent half april pace just consensus forecast rise core price energy food also rise surprising estimate decline first time unemployment claim also picked rise week end june consensus view expect uptick prior week claim trade deficit first quarter be commerce department estimate be department official originally project be prior quarter gap department thursday also narrow fourth quarter figure thus result increase gap manufacturing mid atlantic region improve june lift philadelphia federal reserve manufacturing survey read first positive read month contraction national association home builder report june builder confidence index et drugmaker merck rise company announce clinical trial keytruda lung cancer treatment show drug outperform chemotherapy merck end wednesday session back buy point test support day move average walgreen boot alliance wba fall china base hotel reservation travel book site ctrip com rise less jump soon open first quarter earning growth easily top analyst expectation revenue gain stomp forecast stock have fall week base effort end wednesday key level support grocery chain kroger rise nearly solid first quarter report wesson initially rise momentum appear be gathering several front possible tighten restriction firearm purchase share fade fractionally lower gunmaker be schedule report fiscal fourth quarter result today close crude slump nearly west texas intermediate trading just barrel week gold bump ounce dollar be sharply yen vs euro year treasury yield ease basis point tough day market asia japan nikkei careen lower sixth drop more april bank japan surprised market voting hold policy unchanged not expand economic monetary stimulus measure china hong kong hang seng index drop shanghai composite slip europe market deepen early loss afternoon trade frankfurt dax lead decline
201,MRK,stock erased deep early morning loss major index mixed higher late afternoon trading apple aapl reversed lows get back green mega cap name continue lag other big cap tech peer day move average act damper nasdaq composite much early go shave loss et be nearly dow jone industrial average rise boost gain component merck mrk microsoft msft verizon vz more volume be exchange vs same time wednesday merck be nearly volume be race nearly usual level day average volume be share stock be show healthy action lately string small series higher high higher lows bottom feb pharmaceutical giant be now form large saucer handle yielding buy point note stock have trouble surpass level numerous time thursday merck announce positive result clinical trial show new keytruda medicine extend survival single therapy lung cancer patient analyst consensus see earning rise cent share full year merck have also rebound nicely follow decline day move average earlier week contrast fellow dow component apple have be less robust fall june rally allow stock briefly pierce day line reverse institutional investor be clearly concern tech titan ability protect grow monster size smartphone franchise quarter end march apple actually report first ever decline iphone unit sale revenue fall hurt part strong dollar however wall street see revenue fall next quarters respectively ibd note stock market update wednesday number mutual fund holder apple have fall mildly past quarters same be say hedge fund fund own combine share fund own total share year accord datum william neil co term total share own plunge ibd name stock market today lgi home lgih have return top be texas base entry level homebuilder be craft right side deep cup style base stock be still peak composite rating be top ibd residential commercial build industry group see big picture column market pulse table market current outlook be downgrade confirm uptrend uptrend pressure mean investor still buy stock break properly form basis probability make money be lower give increase intensity professional selling nasdaq composite see distribution day count denote heavy selling rise back be stock be best class industry group term profit growth margin sale return equity institutional fund sponsorship relative price strength check investor com exclusive tool ibd stock checkup
202,MRK,stock defend healthy gain early monday market react cross current corporate international news nasdaq strike early lead dow industrial be close respectively volume be mixed stock market today nyse lower nasdaq compare action same time friday be little news report monday economic front market china climb improve march consumer producer price datum europe market feel lift banking reform effort italy oil price shed mild early decline rise nearly natural gas trade almost lower oil energy stock packed lead edge be merger news wire canadian pacific railway cp pop announce have drop attempt acquire norfolk southern nsc norfolk southern dip yahoo yhoo rise nearly news report say london base daily mail be contemplate bid big brand search engine pivotal research also raise stock price target dow stock be fine form cisco system csco boee ba lead more few decliner pfizer pfe fall furthest hard drive maker seagate technology stx rumble cowen initiate coverage market perform rating price target barron article saturday also tout stock dividend yield discuss potential hard drive demand cloud datum center western digital wdc catch coattail action jump ibd more group rise more open inphi iphi top advancer gain share remain just april high extend buy point clear double bottom base mid march
203,MRK,big biotech gilead science gild hit month high monday analyst deliver bullish outlook company sunday rbc capital market analyst michael yee lift ep estimate due stock buyback note several recent piece incremental good news cite late friday successful patent suit bring merck mrk ionis pharmaceutical ion have result somewhat lower damage award wall street have expect also note weekly prescription datum im health im suggest gilead hepatitis drug sovaldi harvoni be hold reasonably well face competition merck zepatier launch late january point be make more emphatically monday research note leerink analyst geoffrey porge call merck pretender hcv hepatitis virus throne porge note survey top payer plan backed week launch zepatier sovaldi harvoni retain relatively favorable position top largest commercial plan top largest government plan relative abbvie abbv viekira pak respectively zepatier porge write further top medicare plan harvoni be cover plan plan do not cover viekira pak none cover zepatier porge affirm outperform rating gilead stock price target midday trading stock market today gilead stock be more earlier rise stock have climb month low hit feb still have weak ibd relative strength rating meaning stock perform lowest stock past month emphasis most recent month merck stock be fraction midday monday
204,MRK,big biotechs gilead science gild biogen biib fall wednesday receive unfavorable patent news late tuesday ionis pharmaceutical ion say big pharma partner merck mrk have win case allege gilead hepatitis virus hcv drug sofosbuvir be sell individually sovaldi ingredient harvoni infringe patent ionis merck have obtain earlier research used expertise collaboration merck develop modify nucleoside benefit patient hcv say ionis ceo stanley crooke press release case go back sofosbuvir be verge fda approval merck seek royalty sale gilead gilead seek judgment invalidate patent concede have infringe case go jury rule tuesday patent be fact valid be word damage ionis say entitle damage leerink analyst geoffrey porge say award win be huge more litigate delay continue expect damage award case be relatively modest equivalent single digit royalty significantly less merck be seek porge write research note spite damage jury award merck gilead have already indicated appeal ionis stock pop week high early stock market today end session share have fall gilead stock fall merck be flat biogen stock meanwhile fall patent trademark office uspto reversed earlier decision decide review patent biogen top selling drug tecfidera hedge fund manager kyle bass file request review last year launch unusual short selling strategy filing such request number blockbuster drug say have bs patent uspto initially deny request september tuesday change tune coincidentally not european union authority earlier month invalidate european equivalent same patent expire addition forward pharma fwp be separately challenge patent stock rise wednesday today decision be just first step review process nothing happen yet usa today tecfidera still enjoy year exclusivity eu protect eu write rbc capital market analyst michael yee research note even patent expire february consensus do not assume get full protection already assume expect generic launch point
205,MRK,drug stock fall wednesday wall street sort impact propose change medicare part reimbursement design drive price expensive hospital drug late tuesday center medicare medicaid service propose pilot program testing new reimbursement scheme medicare part cover drug administer hospital doctor office currently cms pay back price drug health care provider critic say encourage doctor prescribe more expensive drug propose rule doctor get just premium flat fee drug day somewhat reduce disparity different price drug cms also propose reduce eliminate portion patient have pay drug tie reimbursement level effectiveness drug give indication thus same drug work well condition only so so cms reimburse different level condition agency also want create online decision support tool help physician determine most effective drug use give situation test let cms enter voluntary risk sharing agreement drug maker link price adjustment patient outcome be comment period cms proposal point cms plan place provider different group used old reimbursement method new study difference group course year plan start testing other idea start january reimbursement proposal draw most attention wall street cover drug be mostly infuse inject treatment serious condition opposed pill patient take own so potentially affect drug industry biggest cash cow big biotechs most notable drug fall theoretical test be drug include amgen amgn neupogen neulasta also kyproli xgeva prolium vectibix total sale celgene celg abraxane be revenue other notable drug be oral write rbc capital market analyst michael yee research note credit suisse analyst vamil divan agree amgen add regeneron pharmaceutical regn biogen biib also depend drug medicare part umbrella new immunotherapy drug bristol myer squibb bmy merck mrk such opdivo keytruda yervoy also be cover part yee argue aren choose price reason consensus understand drug be choose high efficacy aren equivalent drug aren also infuse not reimbursement yee write amgen stock hit month low end day regeneron tumble celgene fall biogen be bristol myer stock fall merck slip fraction
206,MRK,wework share office company value have cultivate chic vibe attract freelancer startup worker help launch co work movement mean hip interior design office have wallpaper create beastie boy mike free micro roast coffee craft beer company give glass single month last year now youthful ambiance be help attract old general electric ge moved worker new energy business current wework space boston south station year ge ready new boston headquarters other recent wework tenant include business consultancy kpmg pharmaceutical giant merck mrk british news publication guardian company have be average year move mean traditional employer rub shoulder young tech set kpmg rent desk wework manhattan split worker provide business service startup team advise corporate client technological innovation silicon valley bank sivb rent space co work office country include galvanize san francisco centrl office ore say move allow banker work tech startup court client person literally open door say need open bank account say mark gallagher lead bank boston technology practice also useful way manage real estate cost accord workplace strategy expert anyone do now be pioneer say julie whelan head occupier research cbre see win become norm base company have work change footprint recent year cost typical company upward year worker provide office space accord cbre group cbg co work space be more expensive traditional office space square foot basis make easy company move let exec focus more expand business manage real estate operation go find space year lease build take year recoup expense say brent harrell president heritagebank mortgage atlanta base lender recently moved team mortgage banker industrious co work space employee tend too homebuilder lennar len rent space industrious chicago minneapoli so hold meeting downtown construction project stylish office help recruit say peter chmielewski vice president development builder multifamily arm september report publish harvard business review worker share office report be thrive so much researcher have look datum again result researcher theorize be largely worker tend have greater sense purpose ve opted workspace instead show site designate employer tend produce community effect make feel empower stylish flexible workplace doesn necessarily require co work membership most employer be more comfortable adopt aspect co work send employee share office say phil kirschner senior vice president jll jll consult employer workplace strategy mean trading assign desk access variety share space ve give desk gain floor kirschner say co work company however be welcome corporate interest wework have raise investor fuel expansion world rent space large company need lot desk be good way expand quickly percent wework member work company rent more desk large employer make fastest grow market re go see person dip to say wework chief operate officer artie minson person go back drab soulless office say sort wish have stay serendipity lab open first co work space rye say corporate employee make member location include worker pepsico pep microsoft msft heineken international company be seek open share office next year mostly suburban location appeal company national footprint founder john arena say fuel rapid growth arena be selling franchise hotel operator other hospitality company not corporate employer want kind hip downtown space associate co work arena say instead have bro thursday night party re have tesla test drive event arena say have different member afford car related creative office become norm get smarterwhy rental rate biotech lab be feed real estate development edgy area
207,MRK,big pharma merck mrk deliver mixed quarterly result guidance wednesday send stock lower merck earning exclude time item rise year earlier quarter cent share beating analyst consensus cent accord thomson reuter however sale decline wall street average estimate year revenue
208,MRK,economy be enter recession stock consumer staple health care telecom be best place hide say barclay glionna name tobacco giant philip morris international pm reynold american rai drug giant merck mrk pfizer pfe meanwhile include general electric ge stock buy recovery doesn see recession term be red flag such collapse oil price retreat so far year slow growth global economy china report monday glionna joined grow number analyst provide list recession resistant stock take slightly different tack other offer list recession playbook recovery playbook other top pick recession playbook be campbell soup cpb coca cola ko johnson johnson jnj procter gamble pg hormel food hrl philip morris stock close tuesday reynold american maker camel cigarette add merck gain pfizer rise campbell soup climb johnson johnson procter gamble end flat glionna say recovery playbook best perform sector previous period economic recovery used exit recession indicative recovery have be energy material industrial consumer discretionary stock list ford motor general electric general motor gm harley davidson hog viacom ford end gm lose tuesday ge tick harley davidson fall viacom plunge more expect result december end quarter meanwhile cowen analyst put own list recession stock tuesday say believe stock appeal low end consumer have minimal global exposure appear well suit weather economic downturn top pick price clothing retailer ross store rost wal mart store wmt ross store climb wal mart fall
209,MRK,stock reversed early loss narrow gain thursday heavily influenced fluctuation oil other commodity dow jone industrial average climb nasdaq be volume be mixed nyse lower nasdaq relative action same time thursday slide dollar
210,MRK,stock tumble accelerate downside yesterday shift oil price weaker earning very big oil company more talk rate hike kansa city fed pre ester george now ms george have pedigree background sure get bsba missouri western state university mba univ missouri kansa
211,MRK,stock advanced wednesday open then drop back moderate loss weak reading service sector nasdaq tumble drop dow clock drop volume slip stock market today nyse nasdaq relative trade
212,MRK,big biotech gilead science gild beat analyst estimate tuesday guidance be soft send stock more hour trading day several large drugmaker report gilead earning rise year earlier quarter share top analyst ep consensus cent accord thomson reuter revenue increase vs analyst expectation full year ep rise revenue gain gilead guide product sale cover nearly revenue analyst have expect product sale total revenue gilead do not provide total revenue ep guidance do provide guidance expense be slightly expectation sale general administrative line evercore isi analyst mark schoenebaum calculate imply ep guidance be miss consensus hepatitis drug sovaldi harvoni beat estimate entirely due sale outside analyst have less visibility next year expect revenue decline be due anticipate decline hcv market have enormous lift drug be approve have flattened ever larger number patient have be cure disease conference call analyst commercial operation chief paul carter say expect hcv market behave similarly do second half essentially flat grow foreign market be still be launch say see growth payer seem be loosen restriction drug initially strained finance due high price enormous volume patient however acknowledge revenue patient be likely fall less sick patient come require shorter treatment carter also sound confident gilead ability fend competition get new entrant last week merck mrk zepatier be approve last week price well gilead abbvie abbv hcv drug re confident label be very strong re very much support real world datum ve see launch harvoni carter say earlier day big pharma pfizer pfe say revenue rise year earlier quarter beating analyst consensus earning exclude time item slip cent share beating estimate penny year ep decline sale slide however pfizer profit guidance miss wall street expectation share analyst schoenebaum blame foreign exchange headwind exclude roughly negative top line top line fx impact due venezuela currency impact alone bottom line impact due fx top bottom line guidance have bracket street schoenebaum write email speak pfizer believe street underestimated fx impact capital iq analyst jeffrey loo raise rating pfizer buy hold say valuation have become attractive almost other drug stock have sell recent month view growth global innovative product unit positively drive prevnar ibrance loo write research note expect pending acquisition allergan agn be complete second half pfizer stock close mallinckrodt mnk rise close specialty drugmaker report fiscal first quarter earning share year earlier quarter top consensus cent sale climb street average estimate mallinckrodt raise full year ep guidance baxter international bax leader dialysis product also beat expectation most recent quarter pull sharp increase earning decline sale fourth quarter profit continue operation jump cent share cent past wall street consensus revenue drop baxter stock rise tuesday close baxter say expect ep year beating consensus forecast current quarter be street however cent
213,MRK,big pharma abbvie abbv deliver mixed earning report affirm guidance early friday stock fall company face new competition hepatitis front merck mrk abbvie report earning share exclude time item be year earlier quarter penny analyst consensus accord
214,MRK,share big biotech gilead science gild be more midday wednesday attorney general massachusett threaten legal action company drug pricing boston globe report attorney general maura healey have send letter gilead say pricing hepatitis drug sovaldi harvoni constitute unfair trade practice violation massachusett law sovaldi be launch december week round treatment harvoni be launch october equivalent length treatment large minority patient have be successfully treat week gilead defender have argue price be justified vast superiority drug previous treatment cure upward patient prevent expensive medical problem road however healey curative power drug only make high price more egregious pricing treatment manner effectively allow hepatitis continue spread vulnerable population opposed eradicate disease altogether result massive public harm price gilead drug have be criticize ever launch fact senate investigation last year culminate december report say price place inordinate burden state medicaid program be also focus healey letter however be able do anything expect abbvie abbv compete treatment viekira pak spark rebate war gilead december launch thus drug still have same official price tag re actually selling less analyst be expect further price erosion arrival merck mrk own compete treatment be due fda decision thursday gilead have say last few earning call hepatitis market have flattened be plan launch new version treatment june potentially treat genotype disease thereby broaden market gilead stock have be hammer re ignition drug price debate presidential race last fall have focuse more practice specialty drugmaker turing pharmaceutical valeant pharmaceutical vrx raise price older drug improvement quality house committee oversight government reform have plan hearing subject tuesday big east coast blizzard lead reschedule feb
215,MRK,positive overseas action earning result weak read gdp growth left stock future mixed ahead friday open dow future be uptick future be steady nasdaq future shed early gain slip narrow loss stock market today prepare open feel healthy lift overseas market top index japan china jump friday european market push gain midday trade start friday session week nasdaq open hole small cap also get weak start russell open vs last friday close preliminary estimate commerce department put gdp growth sharply gain miss expectation increase gdp price index eke advance vs forecast growth labor department report employment cost index gain unchanged equal economist estimate pending economic news include kingsbury international chicago purchasing manager index expect et university michigan release final consumer sentiment index tally january san francisco federal reserve president john william join panel discussion et city dollar gain bond fall oil be mixed west texas intermediate brent trading barrel baker hughe bhi report weekly rig count head dow microsoft msft power merck mrk jump microsoft report strong fiscal result late thursday earning sale comfortably top expectation sale cloud software rise annualize run rate midpoint management revenue guidance be just consensus expectation microsoft share end thursday week move average week deep consolidation skywork solution swks microsoft lead nasdaq index premarket trade skywork jump result report late thursday earning revenue beat analyst consensus view straight quarter double digit earning gain quarter double digit revenue growth management ep revenue guidance be expectation skywork be deep month consolidation amazon com amzn reel lower earning increase stop far short analyst expectation diversify online retailer content provider report thursday close fourth quarter revenue rise also shy consensus forecast company continue invest heavily operate cost rise nearly membership amazon prime subscription service estimate have more member jump amazon rise heavy trade thursday rebound test support week move average other stock premarket motion report earning include sony sne fortinet ftnt flextronic flex gain electronic art ea tumble abbvie abbv drop image provide shutterstock
216,MRK,flagship stock etfs stage smart recovery wednesday close session high snap day lose streak oil drive narrative again commodity surge dollar plummet weak service datum marquee name struggle however first trust dow jone internet fdn drop top holding facebook fb amazon amzn
217,MRK,stock future tick minor gain ahead wednesday open dow future blipped fair market value nasdaq future be also russell future inched stock market today jump hump day nasdaq lower friday blue chip loss be line general mood dow small cap be little weaker send russell tuesday employment picture weaken january adp national employment report show employer hire worker month be upwardly revise hiring december comfortably consensus estimate addition once again service sector hire run far ahead good producer institute supply management serve january service sector index et oil price bob back barrel west texas intermediate brent american petroleum institute datum release late tuesday show barrel build inventory week end jan energy information administration report weekly inventory datum dow stock be generally positive mmm have gain miner be also active vale vale pop rio rio climb ferrari race surge weaker forecast earning report late tuesday illumina ilmn dump india infosys infy drop deliver quarterly result big drugmaker be motion glaxosmithkline gsk jump merck mrk pull back report large insurer prudential puk spiked metlife meet be flat ahead earning report today close herbicide pesticide seed strain developer syngenta syt spark confirm agree be acquire state own china national chemical corp deal value more switzerland base syngenta share gap tuesday news report detailed possible tie company chipotle grill cmg fall report mixed result firm also announce center disease control prevention conclude investigation coli outbreak link chain receive subpoena attorney office central district california broaden scope previously announce criminal investigation chain ibd list edward lifescience ew skip trouncing analyst earning revenue estimate raise ep guidance well consensus view edward have be loll week move average week shallow base buy point
218,MRK,income investor look big dividend payer find unlikely name dividend leader list monday issue lurk usual suspect such merck mrk procter gamble pg be tech stock chipmaker pay dividend north well ahead average yield maxim
219,MRK,big pharma eli lilly lly guide wall street expectation tuesday stock rise fall big market plunge monday lilly say expect revenue fraction last year estimate sale analyst consensus accord thomson reuter earning exclude time item
220,MRK,drug stock have be take beating hard east coast lately last year worry drug pricing compound so so pre announcement forecast last month week however big drugmaker haven pre announce result have chance beat expectation usual johnson johnson jnj kick season
221,MRK,drugmaker baxalta bxlt be trading monday tide broad stock market decline inked immuno oncology deal be rumore be close sale shire shpg baxalta say have agree pay privately hold symphogen upfront option right therapy symphogen be develop target checkpoint
222,MRK,past few year have bring groundbreaking drug launch such record breaking gilead science rollout hepatitis medicine first pd cancer fighter merck bristol myer squibb bmy year look be somewhat slower front drug firm aim most new launch smaller market build
223,MRK,pharmaceutical aren just source relief physical ailment oft steady dividend provide comfort even stock underperform today ll look drug stock dividend leader screen yield beat average pfizer pfe monday raise quarterly payout cent
224,MRK,be year distinct part drug stock first month continue bull run last year sudden resurface drug pricing debate lead rocky month overall group come ahead top perform big cap show solid story make political worry eye investor incyte incy be wednesday close year steady gain lone market product jakafi well pipeline potential blockbuster march jakafi win eu approval blood cancer polycythemia vera be already approve blood cancer myelofibrosis disease be rare incyte be shooting much bigger market late stage candidate baricitinib epacadostat baricitinib incyte be develop partnership eli lilly lly test successfully phase trial rheumatoid arthritis placebo methotrexate current market leader abbvie abbv humira nov initiation report incyte goldman sachs analyst richter estimate peak annual sale more expect launch richter add more important future driver share likely be incyte entry bud field immuno oncology incyte have be testing lead candidate field epacadostat combination merck mrk keytruda variety cancer early november incyte stock fall small study combo patient advanced cancer disappoint wall street richter write likely bring more clarity more result come incyte have be operate loss due research spending analyst expect turn first annual profit next year stock current ibd composite rating be danish diabetes giant nordisk nvo be end year flat base follow early gain march stock rise sharply say refile approval long act insulin analogue tresiba shorter act sister drug ryzodeg drug suffer surprise rejection fda seek more datum possible risk heart time agency be convince approve also boost stock early year be february release positive clinical trial datum latest glucagon peptide glp receptor agonist og have be selling earlier glp agonist victoza market have get more competitive last couple year new glp launch sanofi sny glaxosmithkline gsk eli lilly drug be injectable however new candidate be oral announce further positive result drug july september financial result currency suffer foreign exchange headwind hit global drugmaker year still manage solid ibd ep rank relative strength rating regeneron pharmaceutical regn continue multiyear run stock market hit lifetime high aug get catch larger biotech sell still year regeneron flagship eye drug eylea continue perform well aid new approval diabetic retinopathy march draw more attention be launch cholesterol drug praluent july praluent be not only first new class cholesterol drug be follow shortly market amgen amgn repatha also first number novel monoclonal antibody regeneron have be develop partnership sanofi next entry dupilumab be late stage testing asthma eczema be also expect attain multibillion dollar annual sale regeneron be also highest rate stock list highest possible composite rating eli lilly be top perform traditional big pharma year gain sale growth have be flat due age drug well currency headwind company have improve profit margin cost control get lot investor excited pipeline note partnership incyte have bear fruit baricitinib trial lilly doesn have much presence rheumatoid arthritis other immunology disease lilly be plan change not only baricitinib ixekizumab psoriasis treatment plan launch next year be expect sell billion eventually lilly already launch diabetes drug jardiance yielded pharma biggest upside surprise year giant study effect cardiovascular health show reduce death heart failure drive stock year high september turn cup handle base stock hold cr baxalta bxlt be start trading july spin baxter international bax seek unlock shareholder value biopharma arm just day later company receive unsolicited buyout offer british drugmaker shire shpg see baxalta hemophilia franchise ideal addition rare disease portfolio baxalta reject offer situation remain unresolved last week rumor be buzz shire bid hasn yet baxalta financial have be slow steady lead ep rank acquisition hope have lift stock rs rating
225,MRK,big biotech amgen amgn be trading friday announce cancer collaboration merck mrk file first biosimilar approval tepid initiation report well fargo amgen merck say be launch study combine merck keytruda be currently used treat melanoma small cell lung cancer amgen leukemia drug
226,MRK,biotech relypsa rlyp soar afternoon trading friday report spread be near sale shortly noon street insider quote anonymous source say merck mrk be make offer relypsa unknown price hour half later financial time report own anonymous source say relypsa be merely start process particular buyer glaxosmithkline gsk sanofi sny be potential bidder speculation relypsa be buy have be buzz astrazeneca azn agree buy zs pharma zsph last month relypsa zs pharma make drug treat high level potassium blood zs pharma hasn be approve relypsa drug veltassa be approve october stiff warning label dangerous interaction other drug relypsa stock have be uptrend then still more march high mid afternoon stock market today relypsa stock be follow amy reeve twitter ibd_areeve facebook
227,MRK,stock stumble mixed trade second straight morning wednesday global market react monetary policy action european central bank
228,MRK,nasdaq dow jone industrial average sit flat russell dip
229,MRK,stock market today again open mixed volume trade rise nyse decline fractionally nasdaq vs action same time wednesday
230,MRK,open stock future have appear feel premarket drag europe bourse reversed sharply moderate gain european central bank announce further reduce overnight deposit rate
231,MRK,move be less many have be lead expect previous comment ecb president mario draghi other official
232,MRK,europe market do not improve later press conference draghi say bank extend current bond buy initiative march longer necessary vs prior endpoint september
233,MRK,frankfurt dax drop cac paris be outside eurozone ftse london slip afternoon trade
234,MRK,layoff fall month low november consultant challenger gray christmas report weekly jobless claim rise line consensus forecast
235,MRK,factory order strengthen october commerce department say slip september better improvement expect analyst
236,MRK,institute supply management say growth service portion economy slow november ism service index fall october read analyst have forecast smaller pullback
237,MRK,dow stock turn negative open more third stock index post loss merck mrk american express axp take biggest bump apiece gain be thin lead wal mart wmt advance
238,MRK,technology avgo spiked more top ibd list follow fiscal fourth quarter result report late wednesday research firm mizuho topeka capital raise price target stock thursday morning
239,MRK,gain left share well right side month cup base buy point
240,MRK,biotech dyax dyax vault higher company announce early termination trust wait period regard pending acquisition ireland base shire shpg shire dip open
241,MRK,utility be unusually active start trade nrg nrg rise nearly president chief executive david crane tender immediate resignation share later lose most gain trade almost flat chief operate officer mauricio gutierrez step role
242,MRK,power producer tuesday announce plan sell power plant pennsylvania illinois total nrg have be deepen correction month
243,MRK,close chipmaker ambarella amba dollar store ulta beauty ulta be schedule report quarterly result stock stumble mixed trade second straight morning wednesday global market react monetary policy action european central bank nasdaq dow jone industrial average sit flat russell dip stock market today again open mixed volume trade rise nyse decline fractionally nasdaq vs action same time wednesday open stock future have appear feel premarket drag europe bourse reversed sharply moderate gain european central bank announce further reduce overnight deposit rate move be less many have be lead expect previous comment ecb president mario draghi other official europe market do not improve later press conference draghi say bank extend current bond buy initiative march longer necessary vs prior endpoint september frankfurt dax drop cac paris be outside eurozone ftse london slip afternoon trade layoff fall month low november consultant challenger gray christmas report weekly jobless claim rise line consensus forecast factory order strengthen october commerce department say slip september better improvement expect analyst institute supply management say growth service portion economy slow november ism service index fall october read analyst have forecast smaller pullback dow stock turn negative open more third stock index post loss merck mrk american express axp take biggest bump apiece gain be thin lead wal mart wmt advance technology avgo spiked more top ibd list follow fiscal fourth quarter result report late wednesday research firm mizuho topeka capital raise price target stock thursday morning gain left share well right side month cup base buy point biotech dyax dyax vault higher company announce early termination trust wait period regard pending acquisition ireland base shire shpg shire dip open utility be unusually active start trade nrg nrg rise nearly president chief executive david crane tender immediate resignation share later lose most gain trade almost flat chief operate officer mauricio gutierrez step role power producer tuesday announce plan sell power plant pennsylvania illinois total nrg have be deepen correction month close chipmaker ambarella amba dollar store ulta beauty ulta be schedule report quarterly result
244,MRK,big pharmas merck mrk eli lilly lly johnson johnson jnj be trading tuesday get upgrade barclay abbvie abbv seesaw downgrade analyst geoff meacham assume coverage newly combine pharmaceutical sector barclay coverage left most rating same make few tweak lilly be upgrade overweight equal weight price target lift base promising pipeline management commitment lower expense meacham say lilly be build major autoimmune disease franchise late stage drug candidate ixekizumab psoriasis baricitinib rheumatoid arthritis drug develop incyte incy base solid phase datum view baricitinib have significant market share potential rheumatoid arthritis meacham write model conservatively project risk adjust sale vs peak sale pfizer pfe xeljanz meacham call diabetes drug jardiance lilly most important commercial asset intermediate term recent study result show sharply reduce death heart failure admit have be overhang merck derive lot revenue compete drug jardiance argue stock have overreact acknowledge be multiple headwind risk make merck show story think even most potential negative scenario be too much underlie value ignore meacham write raise merck rating overweight equal weight hike price target even pipeline asset aren blockbuster add be nearly free current valuation lilly stock be almost afternoon trading stock market today merck stock be meacham also raise overweight equal weight price target rise merck feel market be undervalue have underperform drg past month due concern impact biosimilar remicade low term earning growth lack significant term pipeline catalyst meacham write have lead call break conglomerate believe be premature meacham view be better acquire growth asset especially pharma stock be afternoon trading meanwhile meacham downgrade abbvie equal weight overweight trim price target many analyst thought abbvie projection recently acquire blood cancer drug imbruvica similar drug pipeline year peak be too high imbruvica other oncology asset likely succeed field be highly competitive meacham write abbvie stock initially drop almost tuesday trading afternoon be follow amy reeve twitter ibd_areeve facebook
245,MRK,amazon amzn price target be raise tuesday online marketplace say have record sale fire device weekend yum brand yum be upgrade china business spinoff
246,MRK,barclay raise amazon price target raise keep overweight rating stock amazon also say tuesday fire device be best selling product black friday sale plan speed production build million more fire tablet
247,MRK,amazon share close stock market today
248,MRK,yum brand operator taco bell pizza hut kfc restaurant be upgrade outperform market perform cowen analyst be bullish company spinoff china business follow food safety issue past few year have hit stock
249,MRK,share yum climb
250,MRK,web host cloud compute service provider rackspace host rax be upgrade outperform sector perform rbc capital market analyst have price target stock rackspace share close
251,MRK,barclay upgrade pharmaceutical medical company merck mrk eli lilly lly johnson johnson jnj overweight merck share jump eli lilly share climb share edge
252,MRK,follow gillian rich twitter ibd_grich amazon amzn price target be raise tuesday online marketplace say have record sale fire device weekend yum brand yum be upgrade china business spinoff barclay raise amazon price target raise keep overweight rating stock amazon also say tuesday fire device be best selling product black friday sale plan speed production build million more fire tablet amazon share close stock market today yum brand operator taco bell pizza hut kfc restaurant be upgrade outperform market perform cowen analyst be bullish company spinoff china business follow food safety issue past few year have hit stock share yum climb web host cloud compute service provider rackspace host rax be upgrade outperform sector perform rbc capital market analyst have price target stock rackspace share close barclay upgrade pharmaceutical medical company merck mrk eli lilly lly johnson johnson jnj overweight merck share jump eli lilly share climb share edge follow gillian rich twitter ibd_grich
253,MRK,apple aapl hp inc hpq merck mrk ibm ibm intel intc be stock describe have best value measure free cash flow yield
254,MRK,assess company value used free cash flow put greater emphasis retain profit vs earning plow back capital expenditure say citigroup analyst robert note cite barron
255,MRK,company list oilfield service provider baker hughe bhi lead estimate free cash flow yield ongoing slump oil price
256,MRK,follow viacom viab whole food market wfm yield respectively
257,MRK,also list be apple estimate yield company have have tremendous run iphone apple watch apple tv keep party go apple be expect unveil latest version smartwatch event march
258,MRK,apple close stock market today baker hughe climb report halliburton hal be closer finalize acquisition baker hughe viacom lose whole food climb
259,MRK,hp have yield pc sale have slow several year mobile device take market share nearly pcs be older year hp chair meg whitman say last month point belief be person be go upgrade pcs think hp inc be well position happen
260,MRK,hp stock close wednesday
261,MRK,drug giant merck have yield face grow number generic drug rival still have strong pipeline new drug various stage development merck drop
262,MRK,ibm have estimate yield flex muscle powerful watson supercomputer launch cognitive business solution unit ibm fall
263,MRK,intel hp have be hit hard decline traditional pc prospect have perked recently internet thing enjoy yield intel share edge
264,MRK,citi value stock list also include la vegas sand lvs yield macy local telephone service provider centurylink ctl apple aapl hp inc hpq merck mrk ibm ibm intel intc be stock describe have best value measure free cash flow yield assess company value used free cash flow put greater emphasis retain profit vs earning plow back capital expenditure say citigroup analyst robert note cite barron company list oilfield service provider baker hughe bhi lead estimate free cash flow yield ongoing slump oil price follow viacom viab whole food market wfm yield respectively also list be apple estimate yield company have have tremendous run iphone apple watch apple tv keep party go apple be expect unveil latest version smartwatch event march apple close stock market today baker hughe climb report halliburton hal be closer finalize acquisition baker hughe viacom lose whole food climb hp have yield pc sale have slow several year mobile device take market share nearly pcs be older year hp chair meg whitman say last month point belief be person be go upgrade pcs think hp inc be well position happen hp stock close wednesday drug giant merck have yield face grow number generic drug rival still have strong pipeline new drug various stage development merck drop ibm have estimate yield flex muscle powerful watson supercomputer launch cognitive business solution unit ibm fall intel hp have be hit hard decline traditional pc prospect have perked recently internet thing enjoy yield intel share edge citi value stock list also include la vegas sand lvs yield macy local telephone service provider centurylink ctl
265,MRK,stock future hold steady gain move monday open market head november final trading session dow future stand point fair market value nasdaq future be point future fly straight level point small cap flex premarket muscle russell future rise stronger usual point
266,MRK,stock market today set november sharp slowdown october bounce nasdaq show gain month vs leap october small cap look bit better russell bound ahead month ibd have also outpaced market so far
267,MRK,week euro be likely be center attention european central bank be widely expect amp monetary stimulus effort meeting thursday dollar rise tracking biggest month gain vs euro march
268,MRK,side note china yuan also see unusual attention today international monetary fund expect vote include currency special draw right basket currency hoisting china currency play field dollar euro pound yen
269,MRK,oil stir buzz week organization petroleum export country set meet friday oil trade bit less early monday kingsbury international be deck report chicago purchasing manager index november et october pending home sale number be expect national association realtor
270,MRK,stock action monday show merck mrk microsoft msft lead dow more
271,MRK,stock be generally quiet premarket mood baxter international bax kimco realty kim top group gain
272,MRK,beaten stock fitbit fit horizon pharma hznp jump apiece remain deep correction far possible buy point
273,MRK,leader grupo financiero galicia ggal pop nearly lead ibd list argentina base bank drop last week sharp pullback argentina related stock follow country nov presidential election share end week cup base buy point
274,MRK,other gain ibd stock hold less alaska airline alk post worst pre open slip ibd stock bit more stock future hold steady gain move monday open market head november final trading session dow future stand point fair market value nasdaq future be point future fly straight level point small cap flex premarket muscle russell future rise stronger usual point stock market today set november sharp slowdown october bounce nasdaq show gain month vs leap october small cap look bit better russell bound ahead month ibd have also outpaced market so far week euro be likely be center attention european central bank be widely expect amp monetary stimulus effort meeting thursday dollar rise tracking biggest month gain vs euro march side note china yuan also see unusual attention today international monetary fund expect vote include currency special draw right basket currency hoisting china currency play field dollar euro pound yen oil stir buzz week organization petroleum export country set meet friday oil trade bit less early monday kingsbury international be deck report chicago purchasing manager index november et october pending home sale number be expect national association realtor stock action monday show merck mrk microsoft msft lead dow more stock be generally quiet premarket mood baxter international bax kimco realty kim top group gain beaten stock fitbit fit horizon pharma hznp jump apiece remain deep correction far possible buy point leader grupo financiero galicia ggal pop nearly lead ibd list argentina base bank drop last week sharp pullback argentina related stock follow country nov presidential election share end week cup base buy point other gain ibd stock hold less alaska airline alk post worst pre open slip ibd stock bit more
275,MRK,stock hold solid gain midday tuesday ahead thursday european central bank meeting more stimulus measure be widely expect
276,MRK,dow jone industrial average add weak dollar lift several blue chip name early winner dow include boee ba merck mrk pfizer pfe add nasdaq picked volume nyse nasdaq be tracking higher monday level stock market today
277,MRK,nyse advance stock top decliner more breadth be much weaker nasdaq winner only have slight edge loser
278,MRK,economic news ism manufacturing index deliver sluggish read november consensus estimate year treasury yield be basis point
279,MRK,day gainer lgi home lgih soar new high rise be featured tuesday sector leader column
280,MRK,linkedin lnkd also outperformed rise more be consolidate gain begin year be verge form handle entry
281,MRK,meanwhile qihoo technology qihu rally nearly wall street journal report investor group lead chairman zhou hongyi be near agreement pay buy qihoo share several china name include qihoo see heavy volume buy late monday session month november come end
282,MRK,follow ken shreve twitter ibd_kshreve facebookstock hold solid gain midday tuesday ahead thursday european central bank meeting more stimulus measure be widely expect dow jone industrial average add weak dollar lift several blue chip name early winner dow include boee ba merck mrk pfizer pfe add nasdaq picked volume nyse nasdaq be tracking higher monday level stock market today nyse advance stock top decliner more breadth be much weaker nasdaq winner only have slight edge loser economic news ism manufacturing index deliver sluggish read november consensus estimate year treasury yield be basis point day gainer lgi home lgih soar new high rise be featured tuesday sector leader column linkedin lnkd also outperformed rise more be consolidate gain begin year be verge form handle entry meanwhile qihoo technology qihu rally nearly wall street journal report investor group lead chairman zhou hongyi be near agreement pay buy qihoo share several china name include qihoo see heavy volume buy late monday session month november come end follow ken shreve twitter ibd_kshreve facebook
283,MRK,stock future trade lower steady ahead monday open oil price federal reserve test investor confidence dow future trade point fair market value future hung point line nasdaq future be mild point small cap be pressure russell future fall point stock market today open clear caution flag ahead wednesday policy decision federal reserve nasdaq drop last week slice support day day move average crumple also violate level support mean bet be market direction next day uncertainty oil price continue diving early monday west texas intermediate more barrel lowest mark more decade brent crude drop nearly weakest level benchmark have logged steady loss dec organization petroleum export country meeting group fail agree production quota permit member country continue current production level oil price slump be dupont dd apple aapl drag dow open dupont dip more apple trim premarket loss dive morgan stanley cut price target cite pressure international iphone price due oversupply outside china apple end friday well august low struggle retake week move average month consolidation jarden jah jump newell rubbermaid nwl slip more newell say pay cash stock deal acquire boca raton fla base maker sunbeam iron marmot outdoor gear crock pot cookware newell management say combination be target annualize cost saving be immediately positive earning close jarden rise last week merger speculation move stock right side month consolidation china base maker solar electrical component trina solar tsl spiked news report company have receive offer be take private share shanghai xingsheng equity investment management offer be friday close price edward lifescience ew be confuse brokerage datum collection system premarket trade prepared go live stock split today open be company first stock split overseas europe stock come lows midday london ftse reversed early loss wrestle narrowly positive territory frankfurt dax be loss cac paris ease loss asia market be widely mixed hong kong hang seng index dip shanghai composite jump nikkei tokyo stumble loss
284,MRK,wednesday morning annual liver meeting wrapped san francisco wall street analyst sift implication datum rolled vast hepatitis market analyst see continue dominance gilead science gild genotype hepatitis virus hcv account majority case gilead harvoni
285,MRK,stock rattle easy early gain rise trade tuesday mixed slate economic news company report dow jone industrial average lead nasdaq grab gain
286,MRK,volume rise nyse nasdaq relative activity same time monday
287,MRK,nissan nsany report gain november auto sale year year fiat chrysler fcau say sale rise other economic news stock market today be mixed
288,MRK,institute supply management report november manufacturing ism index drop vs read october disappointing expectation increase level indicate sector contraction
289,MRK,researcher markit manufacturing purchasing manager index dip october shade better tally forecast economist
290,MRK,construction spending rise healthy october accord commerce department be better september increase ahead view steady rate increase
291,MRK,dow boee ba rise more unitedhealth unh merck mrk jpmorgan jpm rise nearly much dupont dd dip fraction
292,MRK,wynn resort wynn surge more lead mining equipment maker joy global joy drop worst decline bank america downgrade stock underperform neutral price target joy global have be deepen correction mid related move bank america also downgrade diesel maker cummin cmi underperform send share more
293,MRK,recreational vehicle maker thor industry tho bolt higher report late monday fiscal first quarter sale earning top analyst consensus view move send share well right side month cup base
294,MRK,leader cdw cdw pop nearly rebound test support day move average goldman sachs initiate coverage information technology gear service provider old computer discount warehouse buy rating price target stock be buy range rebound fifth week flat consolidation
295,MRK,homebuilder lgi home lgih jump enough hoist share new high stock have be consolidate undefined pattern oct
296,MRK,downside cboe cboe drop more heavy trade pull back monday high
297,MRK,follow alan elliott twitter ibd_aelliott stock rattle easy early gain rise trade tuesday mixed slate economic news company report dow jone industrial average lead nasdaq grab gain volume rise nyse nasdaq relative activity same time monday nissan nsany report gain november auto sale year year fiat chrysler fcau say sale rise other economic news stock market today be mixed institute supply management report november manufacturing ism index drop vs read october disappointing expectation increase level indicate sector contraction researcher markit manufacturing purchasing manager index dip october shade better tally forecast economist construction spending rise healthy october accord commerce department be better september increase ahead view steady rate increase dow boee ba rise more unitedhealth unh merck mrk jpmorgan jpm rise nearly much dupont dd dip fraction wynn resort wynn surge more lead mining equipment maker joy global joy drop worst decline bank america downgrade stock underperform neutral price target joy global have be deepen correction mid related move bank america also downgrade diesel maker cummin cmi underperform send share more recreational vehicle maker thor industry tho bolt higher report late monday fiscal first quarter sale earning top analyst consensus view move send share well right side month cup base leader cdw cdw pop nearly rebound test support day move average goldman sachs initiate coverage information technology gear service provider old computer discount warehouse buy rating price target stock be buy range rebound fifth week flat consolidation homebuilder lgi home lgih jump enough hoist share new high stock have be consolidate undefined pattern oct downside cboe cboe drop more heavy trade pull back monday high follow alan elliott twitter ibd_aelliott
298,MRK,celgene beat analyst earning expectation come short sale thursday several stock blood cancer market moved new clinical trial datum
299,MRK,celgene early thursday say earning item climb year earlier quarter share beating analyst consensus penny revenue rise consensus poll thomson reuter
300,MRK,celgene celg affirm previous full year guidance sale midpoint ep midpoint vs expectation revenue mix change slightly however celgene add sale guidance lead drug revlimid now lower guidance abraxane
301,MRK,company earning conference call hematology oncology chief jacqualyn fouse admit firm original guidance hadn account impact new immuno oncology drug treat lung cancer drug be bristol myer squibb bmy opdivo merck mrk keytruda have be take market share abraxane indication fouse however say see great potential combination trial abraxane drug such opdivo abraxane trial breast cancer launch collaboration bristol myer also tout licensing deal develop newer immuno oncology drug astrazeneca azn juno therapeutic juno be inked yea
302,MRK,celgene be also seek get immuno oncology bandwagon study new drug combination revlimid sister drug pomalyst fouse say datum several trial combine revlimid merck keytruda pembrolizumab multiple myeloma blood cancer revlimid become blockbuster treat be thursday part general release abstract ahead next month american society hematology ash meeting
303,MRK,believe abstract re go see overall response rate tumor shrinkage revlimid trial pomalyst pembro trial crs disappearance tumor fouse say
304,MRK,otezla treatment psoriasis psoriatic arthritis celgene launch last year wall street skepticism beat consensus sale call executive say otezla be take market share bring significant number new patient
305,MRK,stock trade reaction just be line change guidance be probably just reaction expectation stock have run recent week write rbc capital market analyst michael yee research note big picture here be growth story be still well intact ep guidance be maintain really longer term possible settlement program pipeline give celgene best growth story large cap biotech next year
306,MRK,celgene stock fall thursday
307,MRK,abstract move stock
308,MRK,release ash abstract also moved other stock thursday mostly earlier stage biotechs cellectis cll report first human patient receive cell therapy ucar baby suffering acute lymphoblastic leukemia disease be go day patient be infuse ucart cell
309,MRK,ucar be chimeric antigen receptor cell car therapy similar be develop celgene partner juno well kite pharma kite novartis nvs other however other player have develop individual treatment patient extract patient cell alter re inject cellectis car therapy be allogeneic develop other cell shelf potentially bring economic advantage
310,MRK,abstract be submit july patient continue remain disease free be eligible receive stem cell transplant approximately month receive ucart write jeffery analyst biren amin research note view provide first clinical evidence clinical activity ucart provide confidence allogeneic gene editing approach develop cellectis
311,MRK,cellectis stock already have be rise steeply ahead abstract release rise much thursday month high sell news seem take afternoon close juno stock fall thursday kite fall
312,MRK,also downside bluebird bio blue tumble month low several study early stage gene therapy lentiglobin sickle cell disease beta thalassemia inherited condition cause severe anemia
313,MRK,previous datum have get investor hope lentiglobin be possible cure sickle cell disease particular most recent study however suggest patient beta subtype beta thalassemia do not respond well other type patient remain dependent blood transfusion celgene beat analyst earning expectation come short sale thursday several stock blood cancer market moved new clinical trial datum celgene early thursday say earning item climb year earlier quarter share beating analyst consensus penny revenue rise consensus poll thomson reuter celgene celg affirm previous full year guidance sale midpoint ep midpoint vs expectation revenue mix change slightly however celgene add sale guidance lead drug revlimid now lower guidance abraxane company earning conference call hematology oncology chief jacqualyn fouse admit firm original guidance hadn account impact new immuno oncology drug treat lung cancer drug be bristol myer squibb bmy opdivo merck mrk keytruda have be take market share abraxane indication fouse however say see great potential combination trial abraxane drug such opdivo abraxane trial breast cancer launch collaboration bristol myer also tout licensing deal develop newer immuno oncology drug astrazeneca azn juno therapeutic juno be inked yea celgene be also seek get immuno oncology bandwagon study new drug combination revlimid sister drug pomalyst fouse say datum several trial combine revlimid merck keytruda pembrolizumab multiple myeloma blood cancer revlimid become blockbuster treat be thursday part general release abstract ahead next month american society hematology ash meeting believe abstract re go see overall response rate tumor shrinkage revlimid trial pomalyst pembro trial crs disappearance tumor fouse say otezla treatment psoriasis psoriatic arthritis celgene launch last year wall street skepticism beat consensus sale call executive say otezla be take market share bring significant number new patient stock trade reaction just be line change guidance be probably just reaction expectation stock have run recent week write rbc capital market analyst michael yee research note big picture here be growth story be still well intact ep guidance be maintain really longer term possible settlement program pipeline give celgene best growth story large cap biotech next year celgene stock fall thursday abstract move release ash abstract also moved other stock thursday mostly earlier stage biotechs cellectis cll report first human patient receive cell therapy ucar baby suffering acute lymphoblastic leukemia disease be go day patient be infuse ucart cell ucar be chimeric antigen receptor cell car therapy similar be develop celgene partner juno well kite pharma kite novartis nvs other however other player have develop individual treatment patient extract patient cell alter re inject cellectis car therapy be allogeneic develop other cell shelf potentially bring economic advantage abstract be submit july patient continue remain disease free be eligible receive stem cell transplant approximately month receive ucart write jeffery analyst biren amin research note view provide first clinical evidence clinical activity ucart provide confidence allogeneic gene editing approach develop cellectis cellectis stock already have be rise steeply ahead abstract release rise much thursday month high sell news seem take afternoon close juno stock fall thursday kite fall also downside bluebird bio blue tumble month low several study early stage gene therapy lentiglobin sickle cell disease beta thalassemia inherited condition cause severe anemia previous datum have get investor hope lentiglobin be possible cure sickle cell disease particular most recent study however suggest patient beta subtype beta thalassemia do not respond well other type patient remain dependent blood transfusion
314,MRK,fda say thursday require warning liver damage be put label abbvie abbv hepatitis treatment viekira pak technivie send abbvie share plunge month low gilead science gild sharply review adverse event report fda adverse event report system faer database
315,MRK,best mutual fund october performance report
316,MRK,neuberger berman mid cap growth fund be look regain top notch form display earlier year make china sell drag overall market
317,MRK,fund run ken turek nearly year be top midcap growth peer past month end oct gain accord morningstar inc
318,MRK,mutual fund slide past month include august september broad market tumble
319,MRK,longer term neuberger berman mid cap growth be top perform mutual fund have make lot money investor
320,MRK,past year fund average annual gain beat direct rival
321,MRK,many rival get boost october rally ibd office chicago
322,MRK,ibd lot mutual fund portfolio endure challenge third quarter october stock market rally bring relief culprit seem be china correction federal reserve delay long promise interest rate hike political bash drugmaker do square account
323,MRK,turek think hit head macro standpoint first point be spot issue china devaluation cause lot uncertainty global growth impact emerge market
324,MRK,put lot question table especially export
325,MRK,fed punting be not well take marketplace
326,MRK,secular standpoint health care affected quite bit start hillary clinton critical chatter drug pricing be excessive then be pile other pundit politician pricing criticism be not new thing be be so too pass
327,MRK,ibd trim health stock due beating segment be take right
328,MRK,turek weren so concern health care service area hospital trim be couple area therapeutic biotech
329,MRK,have success area so part trimming be profit take part be due uncertainty pricing risk industry create don know play so more less board trim lot position
330,MRK,ibd therapeutic mean type stock
331,MRK,turek specialty pharmaceutical biotech do not include bristol myer squibbs bmy world re too big aren lot regular drugmaker midcap space re too big re interested smaller version eli lilly lly merck mrk bristol myer
332,MRK,smaller company focus be specialize area health care
333,MRK,ibd innovator right
334,MRK,turek yes look re tech health care consumer discretionary
335,MRK,company be do something unique company have competitive advantage moat so much better advantage be something new drug software product consumer discretionary be company be innovative armour ua come new product consistently expand rapidly well couple year only make apparel now re come footwear
336,MRK,ibd sector be increase weight
337,MRK,turek october not much re watch re interested do be tech be quite honest health care price have come so much maybe overdo price have start look pretty cheap past week
338,MRK,so perhaps future ll be point interest area increase quite bit
339,MRK,ll pass ll get back other base fundamental company be do something new innovative deserve be paid
340,MRK,ibd do still palo alto network panw recent pullback
341,MRK,turek still guy be best breed far create next generation firewall security opposed single point product provider
342,MRK,don think anything have change still high degree need security spending kind enterprise government unit well not necessarily go abate
343,MRK,competition be vigorous palo alto have do good job be innovative design offer suite product forestall hacking
344,MRK,ibd describe attractive innovation ultimate software group ulti
345,MRK,turek ultimate be human capital management company niche be marketplace large company company employee be sweet spot long time
346,MRK,offer cloud base solution so get continuous update upgrade suite product make cost ownership affordable especially midsize company don necessarily have expertise house
347,MRK,ve do past year be move market company employee re start high end re have good success
348,MRK,go add top line growth have high retention rate remember correctly
349,MRK,ibd innovation technology avgo interest most right now
350,MRK,turek be fabless semiconductor company outsource manufacturing taiwan semiconductor manufacturing tsm other
351,MRK,big thing be call fbar stand film bulk acoustic resonator fbar be important amount datum signal expansion number wireless phone cause noise fbar noise prevent drop call
352,MRK,technology wireless get more complicate more fbar be need phone
353,MRK,even win last forever so ve buy company diversify business stream
354,MRK,ibd make hardware software provider cdw cdw earning share grow past stanzas
355,MRK,turek cdw be lead distributor thing information related value add be customer many be small midsize don have lot house expertise rely cdw solve problem do partner customer general sale rep sale engineer be expert field wi fi rout
356,MRK,ibd economy be improve car sale be rise do consumer need car part repair older car appeal reilly automotive orly
357,MRK,turek average age car fleet hasn change much recent year even new car sale have rise
358,MRK,transform company be used sell just do yourselfer company do be start sell part professional do channel ve have lot success re not necessarily selling dealer do re selling mom pop car repair shop
359,MRK,ibd be signet jeweler sig innovation
360,MRK,turek get interested buy primary competitor zale signet be better operator so opportunity be signet overlay management ability zale improve top bottom line zale time
361,MRK,ve own year have start have success area unlock value zale be important decision invest
362,MRK,most recently quarter signet plan biggest new product introduction ever diamond ring call ever high quality diamond ring set roll store unusual hope be big product
363,MRK,ibd ve increase stake norwegian cruise line nclh recent disclosure do more other cruiseline
364,MRK,turek attract slightly higher end customer be less sensitive price increase economic shift well
365,MRK,ncl have high yield ship haven add capacity same pace competitor so re easier fill cruise knock wood re accident free help reputation
366,MRK,so recently ve like pricing power better offer royal caribbean rcl low oil price have be tailwind face new opportunity re eager see happen cuba now china be open cruiser aid ncl industry
367,MRK,ibd have boost stake alaska air group alk rather other airline
368,MRK,turek guy be really good operator start west coast airline now re go midcontinental have really good financial good return equity good free cash flow good customer satisfaction level re grow low double digit next couple year joy listen talk business re have fun
369,MRK,ibd do start stake tyler technology tyl year
370,MRK,turek start june july think come something analyst have talk re leader provide financial erp enterprise resource plan software local state government
371,MRK,lot government be technology compare private enterprise so need modernize lot system
372,MRK,tyler be leader criminal justice area have branch other area appraisal taxe public safety vital record government be get move legacy paper base record cloud base record make record easier manage make thing easier consumer public record
373,MRK,wouldn think great market be even headwind lack financing
374,MRK,ibd have be edge stake acuity brand ayi maker light product
375,MRK,turek be play energy efficiency nonresidential area not wholly dependent new construction lot be retrofitting replace lot old fluorescent light led save energy money owner business best mutual fund october performance neuberger berman mid cap growth fund be look regain top notch form display earlier year make china sell drag overall market fund run ken turek nearly year be top midcap growth peer past month end oct gain accord morningstar inc mutual fund slide past month include august september broad market tumble longer term neuberger berman mid cap growth be top perform mutual fund have make lot money investor past year fund average annual gain beat direct rival many rival get boost october rally ibd office chicago ibd lot mutual fund portfolio endure challenge third quarter october stock market rally bring relief culprit seem be china correction federal reserve delay long promise interest rate hike political bash drugmaker do square account turek think hit head macro standpoint first point be spot issue china devaluation cause lot uncertainty global growth impact emerge market put lot question table especially export fed punting be not well take marketplace secular standpoint health care affected quite bit start hillary clinton critical chatter drug pricing be excessive then be pile other pundit politician pricing criticism be not new thing be be so too pass ibd trim health stock due beating segment be take right turek weren so concern health care service area hospital trim be couple area therapeutic biotech have success area so part trimming be profit take part be due uncertainty pricing risk industry create don know play so more less board trim lot position ibd therapeutic mean type stock turek specialty pharmaceutical biotech do not include bristol myer squibbs bmy world re too big aren lot regular drugmaker midcap space re too big re interested smaller version eli lilly lly merck mrk bristol myer smaller company focus be specialize area health care ibd innovator right turek yes look re tech health care consumer discretionary company be do something unique company have competitive advantage moat so much better advantage be something new drug software product consumer discretionary be company be innovative armour ua come new product consistently expand rapidly well couple year only make apparel now re come footwear ibd sector be increase weight turek october not much re watch re interested do be tech be quite honest health care price have come so much maybe overdo price have start look pretty cheap past week so perhaps future ll be point interest area increase quite bit ll pass ll get back other base fundamental company be do something new innovative deserve be paid ibd do still palo alto network panw recent pullback turek still guy be best breed far create next generation firewall security opposed single point product provider don think anything have change still high degree need security spending kind enterprise government unit well not necessarily go abate competition be vigorous palo alto have do good job be innovative design offer suite product forestall hacking ibd describe attractive innovation ultimate software group ulti turek ultimate be human capital management company niche be marketplace large company company employee be sweet spot long time offer cloud base solution so get continuous update upgrade suite product make cost ownership affordable especially midsize company don necessarily have expertise house ve do past year be move market company employee re start high end re have good success go add top line growth have high retention rate remember correctly ibd innovation technology avgo interest most right now turek be fabless semiconductor company outsource manufacturing taiwan semiconductor manufacturing tsm other big thing be call fbar stand film bulk acoustic resonator fbar be important amount datum signal expansion number wireless phone cause noise fbar noise prevent drop call technology wireless get more complicate more fbar be need phone even win last forever so ve buy company diversify business stream ibd make hardware software provider cdw cdw earning share grow past stanzas turek cdw be lead distributor thing information related value add be customer many be small midsize don have lot house expertise rely cdw solve problem do partner customer general sale rep sale engineer be expert field wi fi rout ibd economy be improve car sale be rise do consumer need car part repair older car appeal reilly automotive orly turek average age car fleet hasn change much recent year even new car sale have rise transform company be used sell just do yourselfer company do be start sell part professional do channel ve have lot success re not necessarily selling dealer do re selling mom pop car repair shop ibd be signet jeweler sig innovation turek get interested buy primary competitor zale signet be better operator so opportunity be signet overlay management ability zale improve top bottom line zale time ve own year have start have success area unlock value zale be important decision invest most recently quarter signet plan biggest new product introduction ever diamond ring call ever high quality diamond ring set roll store unusual hope be big product ibd ve increase stake norwegian cruise line nclh recent disclosure do more other cruiseline turek attract slightly higher end customer be less sensitive price increase economic shift well ncl have high yield ship haven add capacity same pace competitor so re easier fill cruise knock wood re accident free help reputation so recently ve like pricing power better offer royal caribbean rcl low oil price have be tailwind face new opportunity re eager see happen cuba now china be open cruiser aid ncl industry ibd have boost stake alaska air group alk rather other airline turek guy be really good operator start west coast airline now re go midcontinental have really good financial good return equity good free cash flow good customer satisfaction level re grow low double digit next couple year joy listen talk business re have fun ibd do start stake tyler technology tyl year turek start june july think come something analyst have talk re leader provide financial erp enterprise resource plan software local state government lot government be technology compare private enterprise so need modernize lot system tyler be leader criminal justice area have branch other area appraisal taxe public safety vital record government be get move legacy paper base record cloud base record make record easier manage make thing easier consumer public record wouldn think great market be even headwind lack financing ibd have be edge stake acuity brand ayi maker light product turek be play energy efficiency nonresidential area not wholly dependent new construction lot be retrofitting replace lot old fluorescent light led save energy money owner business
376,MRK,facebook fb whole food market wfm st century fox be notable company report quarterly result wednesday here look expect
377,MRK,analyst expect social medium pioneer facebook third quarter earning share surge year cent revenue acceleration prior quarters
378,MRK,company past year have make public post searchable try recast more news centric site rapidly expand video user advertiser develop array new video feature deepen user engagement
379,MRK,site user be view video day jeffery say research note last month investment firm expect video ad become multibillion dollar business next year digital ad format become more expensive
380,MRK,video consumption explode fb massive user base think fb look well position capture increase portion tv ad budget marketer migrate datum drive highly target online video ad campaign jeffery say firm also say facebook app instagram beautiful visual layout highly engage audience make good advertising environment
381,MRK,share close stock market today
382,MRK,upscale grocery chain whole food have struggle whole paycheck reputation allegation overcharge consumer competition traditional grocery chain kroger kr have push more aggressively whole food turf offer higher quality fare
383,MRK,whole food september say lay worker partly keep price lower invest technology
384,MRK,whole food be try draw younger shopper less disposable income launch new chain store call whole food market store be set open next year
385,MRK,analyst expect whole food ep fall cent sale be see rise slow prior quarters share rise
386,MRK,medium giant report wednesday st century fox foxa time warner twx have be pressured rise online programming service netflix nflx amazon amzn prime video investor be tune company ad sale subscriber figure other sign ve adapt digitization television
387,MRK,analyst see st century fox ep slip cent revenue edge time warner ep be expect fall revenue
388,MRK,time warner share rise fox rise
389,MRK,pharmaceutical company regeneron pharmaceutical regn allergan agn also report wednesday
390,MRK,botox maker allergan ep be see fall cent street forecast sale rise gain strong pale comparison prior quarter sale jump actavis acquire company march
391,MRK,regeneron third quarter ep be expect leap sale lift
392,MRK,regeneron drug fail eyesight eyelea have propel company growth drug praluent injectable pcsk inhibitor co develop sanofi sa launch summer
393,MRK,special focus be expect be give initial figure praluent launch roth capital partner say regeneron upcoming quarterly result note previous note expect gradual launch eventually expect praluent repatha achieve blockbuster status believe doctor first look optimize statin therapy other modality merck mrk zetia vytorin move injectable therapy
394,MRK,regeneron share fall allergan fall
395,MRK,follow bill peter twitter ibd_bpeter facebook fb whole food market wfm st century fox be notable company report quarterly result wednesday here look expect analyst expect social medium pioneer facebook third quarter earning share surge year cent revenue acceleration prior quarters company past year have make public post searchable try recast more news centric site rapidly expand video user advertiser develop array new video feature deepen user engagement site user be view video day jeffery say research note last month investment firm expect video ad become multibillion dollar business next year digital ad format become more expensive video consumption explode fb massive user base think fb look well position capture increase portion tv ad budget marketer migrate datum drive highly target online video ad campaign jeffery say firm also say facebook app instagram beautiful visual layout highly engage audience make good advertising environment share close stock market today upscale grocery chain whole food have struggle whole paycheck reputation allegation overcharge consumer competition traditional grocery chain kroger kr have push more aggressively whole food turf offer higher quality fare whole food september say lay worker partly keep price lower invest technology whole food be try draw younger shopper less disposable income launch new chain store call whole food market store be set open next year analyst expect whole food ep fall cent sale be see rise slow prior quarters share rise medium giant report wednesday st century fox foxa time warner twx have be pressured rise online programming service netflix nflx amazon amzn prime video investor be tune company ad sale subscriber figure other sign ve adapt digitization television analyst see st century fox ep slip cent revenue edge time warner ep be expect fall revenue time warner share rise fox rise pharmaceutical company regeneron pharmaceutical regn allergan agn also report wednesday botox maker allergan ep be see fall cent street forecast sale rise gain strong pale comparison prior quarter sale jump actavis acquire company march regeneron third quarter ep be expect leap sale lift regeneron drug fail eyesight eyelea have propel company growth drug praluent injectable pcsk inhibitor co develop sanofi sa launch summer special focus be expect be give initial figure praluent launch roth capital partner say regeneron upcoming quarterly result note previous note expect gradual launch eventually expect praluent repatha achieve blockbuster status believe doctor first look optimize statin therapy other modality merck mrk zetia vytorin move injectable therapy regeneron share fall allergan fall follow bill peter twitter ibd_bpeter
396,MRK,big pharma eli lilly say monday stopping development cholesterol drug evacetrapib review phase trial datum show wasn have much effect eli lilly lly have be conduct giant study cardiovascular effect evacetrapib isn due completion next year independent datum monitoring committee however review
397,MRK,character do whole lotta damage hillary clinton tweet deplore outrageous price gouge specialty drug market see largest biotech etf tank fear pricing control end third quarter ishare nasdaq biotechnology ibb have give gain year date back roughly loss september august rally tad unsettling decline health care sector belie outlook say capital iq analyst higher enrollment cost management prescription drug sale continue drive best earning growth health care sector index analyst lindsey bell write indeed ibb produce annual average gain past year oct period sector etfs track ibd top target health sector fact now more ever biotech pharma etfs trading much week high capital iq see buy opportunity solid biotech name such gilead gild celgene celg ibd stock nearly person be newly insure obamacare health exchange firm note recent report drive sale health care provider service strong dollar be likely weigh large cap pharmaceutical big pfizer pfe merck mrk bristol myer squibb bmy eli lilly lly once again post top line growth first time year pass patent cliff report say health care index be nicely value vs year average upside be especially attainable biotech pharma equipment subindustry report add big upside potential have see sometimes risky biotech drug stock make way many investor etf strategy now china global slowdown mind investor be more focuse downside risk be right be cautious value stock be risk economic growth estimate continue come momentum company be expose more spike volatility have weigh biotechs lately russ global chief investment strategist blackrock write recently suggest investor consider quality stock generally have strong return equity low debt successful investing market stay choppy analyst bofa lynch global research agree new report say health care rate most attractive sector base measure have historically be best predict result such ep sale revision guidance prior quarter result stick health care stick quality bofa lynch advise
398,MRK,apple aapl alibaba baba be expect log double digit earning sale growth number notable company prepare report quarterly result tuesday macbook maker earning be see rise share revenue be expect climb accord recent best buy bby poll ipad top
399,MRK,big biotech gilead science soundly beat analyst estimate raise guidance yet again tuesday cap strong day earning several major drugmaker gilead gild earning exclude time item jump year earlier quarter share beating analyst consensus cent accord thomson reuter revenue climb top
400,MRK,stock go nowhere yesterday ahead federal reserve october fomc meeting close narrowly mixed trading remain tight range lighter volume be nothing real significance make broader market move direction last week strong advance promise central bank intervention ecb rate cut
401,MRK,so be number surprise last week first ecb leave rate alone hint more stimulus come december then overnight thur friday china announce further loosen monetary policy bid boost slow economy then bell thursday big tech stalwart surprised market much better
402,MRK,strong open stock fade mixed performance midday wednesday nasdaq fall weigh weakness adobe system adbe tesla motor tsla dow jone industrial average add johnson johnson jnj merck mrk boee ba be early leader dow
403,MRK,nyse volume be tracking higher tuesday level stock market today nasdaq volume be tracking close tuesday level
404,MRK,adobe gap day move average fall company issue lukewarm fiscal guidance
405,MRK,tesla slump negative analyst chatter
406,MRK,amgen amgn be high still rise pharmacy benefit manager express script esrx name amgen repatha prefer supplemental cholesterol reduction treatment other praluent be make sanofi sny regeneron pharmaceutical regn sanofi share slip regeneron climb early trade
407,MRK,ipo news pure storage pstg price last night midpoint propose range provider flash memory base enterprise storage hardware open share be recently trading
408,MRK,earning winner include ibd firm global payment gpn share gap week base rise result top expectation outlook be solid company also declare stock split
409,MRK,follow ken shreve twitter ibd_kshreve facebook strong open stock fade mixed performance midday wednesday nasdaq fall weigh weakness adobe system adbe tesla motor tsla dow jone industrial average add johnson johnson jnj merck mrk boee ba be early leader dow nyse volume be tracking higher tuesday level stock market today nasdaq volume be tracking close tuesday level adobe gap day move average fall company issue lukewarm fiscal guidance tesla slump negative analyst chatter amgen amgn be high still rise pharmacy benefit manager express script esrx name amgen repatha prefer supplemental cholesterol reduction treatment other praluent be make sanofi sny regeneron pharmaceutical regn sanofi share slip regeneron climb early trade ipo news pure storage pstg price last night midpoint propose range provider flash memory base enterprise storage hardware open share be recently trading earning winner include ibd firm global payment gpn share gap week base rise result top expectation outlook be solid company also declare stock split follow ken shreve twitter ibd_kshreve facebook
410,MRK,big biotechs amgen regeneron launch new cholesterol drug repatha praluent summer wall street uniformly predict blockbuster sale debate just big
411,MRK,adult american have high cholesterol pfizer pfe lipitor be biggest selling drug world go patent get generic rival
412,MRK,yet statin drug class lipitor belong aren enough everyone repatha praluent new class call pcsk inhibitor promise help many person cholesterol be still too high
413,MRK,mid september amgen amgn make acquisition signale future lie company agree pay upfront dezima pharma company develop drug call cholesteryl ester transfer protein cetp inhibitor drug class be also be develop merck mrk eli lilly lly also promise lower cholesterol inadequately treat statin lower ldl bad cholesterol ve also show ability raise hdl good cholesterol
414,MRK,contrast biweekly injection require amgen regeneron regn treatment cetps be take daily pill
415,MRK,dezima drug candidate succeed amgen be hook milestone payment be well worth cetp class turn be real threat
416,MRK,provide natural hedge amgen important cardiovascular franchise give pcsk repatha be drug be injectable phase iii competitor cetp inhibitor lilly merck be oral write rbc capital market analyst michael yee research note day deal be announce
417,MRK,wall street success be big drug class first make phase testing pfizer torcetrapib come screeching halt pfizer realize drug be raise patient death rate increase blood pressure
418,MRK,really shake field be high hope torcetrapib daniel bloomfield vice president clinical research merck cardiovascular program tell ibd announce result put program hold start work issue
419,MRK,bloomfield say merck isolate hormone be responsible raise blood pressure pfizer trial demonstrate own drug anacetrapib do not have risk factor lilly also say confident cetp inhibitor evacetrapib be safer predecessor
420,MRK,enrolled first patient have patient most be many many month treatment evidence safety signal say jeffrey riesmeyer senior medical director lilly cardiovascular program
421,MRK,same time danger make drug too weak happened roche rhhby cetp inhibitor dalcetrapib phase trial show safety problem raise hdl only other candidate have typically raise triple digit didn affect ldl
422,MRK,history be reason pcsk be available now cetp inhibitor win be market least year amgen regeneron be able approval basis cholesterol lower power company demonstrated drug effect overall cardiovascular health merck lilly however be go complete cardiovascular outcome study apply approval
423,MRK,first start work anacetrapib have alignment fda approve drug base ldl lower bloomfield say think now fda want see evidence outcome benefit approve drug class think want see well give shadow overhang mechanism
424,MRK,lilly trial be expect be do mid merck early be also pcsk datum be expect start come company be study similar patient group pcsk trial mainly already have heart disease virtually be already statin many be also take diabetes medicine riesmeyer note
425,MRK,lilly diabetes drug jardiance be recently show improve heart health drug work tandem riesmeyer note
426,MRK,main difference drug be merck anacetrapib have longer half life time drug remain body trace drug have be detected patient year last dose lilly riesmeyer point potential safety issue have yet be prove
427,MRK,so far cetp inhibitor ability lower ldl have lag pcsk phase trial praluent reduce ldl repatha perform similarly anacetripib evacetrapib have lower ve also raise hdl much dezima drug ta have go phase lower ldl raise hdl amgen advertised announce deal
428,MRK,assume ldl hypothesis hold true cetp ta potentially be best class write leerink analyst july deep dive report cholesterol market
429,MRK,uncertainty exact connection cholesterol heart health leave unclear just translate market share merck bloomfield say likely be key factor
430,MRK,not say magnitude benefit safety tolerability profile price vs generic aren go be important say factor be important expect outcome be require entry take significant market share big biotechs amgen regeneron launch new cholesterol drug repatha praluent summer wall street uniformly predict blockbuster sale debate just big adult american have high cholesterol pfizer pfe lipitor be biggest selling drug world go patent get generic rival yet statin drug class lipitor belong aren enough everyone repatha praluent new class call pcsk inhibitor promise help many person cholesterol be still too high mid september amgen amgn make acquisition signale future lie company agree pay upfront dezima pharma company develop drug call cholesteryl ester transfer protein cetp inhibitor drug class be also be develop merck mrk eli lilly lly also promise lower cholesterol inadequately treat statin lower ldl bad cholesterol ve also show ability raise hdl good cholesterol contrast biweekly injection require amgen regeneron regn treatment cetps be take daily pill dezima drug candidate succeed amgen be hook milestone payment be well worth cetp class turn be real threat provide natural hedge amgen important cardiovascular franchise give pcsk repatha be drug be injectable phase iii competitor cetp inhibitor lilly merck be oral write rbc capital market analyst michael yee research note day deal be announce wall street success be big drug class first make phase testing pfizer torcetrapib come screeching halt pfizer realize drug be raise patient death rate increase blood pressure really shake field be high hope torcetrapib daniel bloomfield vice president clinical research merck cardiovascular program tell ibd announce result put program hold start work issue bloomfield say merck isolate hormone be responsible raise blood pressure pfizer trial demonstrate own drug anacetrapib do not have risk factor lilly also say confident cetp inhibitor evacetrapib be safer predecessor enrolled first patient have patient most be many many month treatment evidence safety signal say jeffrey riesmeyer senior medical director lilly cardiovascular program same time danger make drug too weak happened roche rhhby cetp inhibitor dalcetrapib phase trial show safety problem raise hdl only other candidate have typically raise triple digit didn affect ldl history be reason pcsk be available now cetp inhibitor win be market least year amgen regeneron be able approval basis cholesterol lower power company demonstrated drug effect overall cardiovascular health merck lilly however be go complete cardiovascular outcome study apply approval first start work anacetrapib have alignment fda approve drug base ldl lower bloomfield say think now fda want see evidence outcome benefit approve drug class think want see well give shadow overhang mechanism lilly trial be expect be do mid merck early be also pcsk datum be expect start come company be study similar patient group pcsk trial mainly already have heart disease virtually be already statin many be also take diabetes medicine riesmeyer note lilly diabetes drug jardiance be recently show improve heart health drug work tandem riesmeyer note main difference drug be merck anacetrapib have longer half life time drug remain body trace drug have be detected patient year last dose lilly riesmeyer point potential safety issue have yet be prove so far cetp inhibitor ability lower ldl have lag pcsk phase trial praluent reduce ldl repatha perform similarly anacetripib evacetrapib have lower ve also raise hdl much dezima drug ta have go phase lower ldl raise hdl amgen advertised announce deal assume ldl hypothesis hold true cetp ta potentially be best class write leerink analyst july deep dive report cholesterol market uncertainty exact connection cholesterol heart health leave unclear just translate market share merck bloomfield say likely be key factor not say magnitude benefit safety tolerability profile price vs generic aren go be important say factor be important expect outcome be require entry take significant market share
431,MRK,morgan stanley analyst matthew harrison downgrade gilead science gild upgrading alexion pharmaceutical alxn vertex pharmaceutical vrtx base see term catalyst current volatile market harrison maintain price target gilead lower rating equal weight overweight base relative attractiveness other stock harrison write research note true gilead have cash make substantial acquisition doesn think really big immediate future management offer few comment recent conference suggest management be focuse multiple deal clinical stage asset await derisk datum similar bristol myer bmy string pearl strategy harrison write believe be smart strategy gilead generate average long term return also do not see strategy offer single deal re rate gilead investor have suggest same time harrison write long term outlook hepatitis market be unclear next year eu rollout be more advanced merck mrk have unveil more datum own pipeline gilead stock be midday trading stock market today pick big cap harrison like position vertex move expect be first profitable quarter year thank recent launch cystic fibrosis drug orkambi see strong orkambi launch base physician feedback suggest revenue much consensus harrison write biotechs transition profitability have historically outperformed peer time month follow transition harrison upgrade vertex stock overweight equal weight set price target vertex stock be midday friday touch nearly year low tuesday harrison also upgrade alexion stock overweight equal weight price target writing recent sell drug stock have create attractive entry point orphan drug stock alexion have only decline vs other large cap biotech peer alexion have be underperformer year date most large cap biotechs harrison note thus give robust set new product launch potential pipeline upside consensus now more aware competitive landscape soliris see potential alexion outperform weakness generate concern government pricing alexion stock be midday trading friday still leave share more time high touch july stock market tumble prove especially tough biotechs follow amy reeve twitter ibd_areeve facebook
432,MRK,dealmake fourth quarter look continue strong momentum set first month year acquisition clinch expect tech health grocery industry here look just few tuesday headliner sandisk talk western digital flash memory maker be late stage talk be acquire
433,MRK,drug stock take pound third quarter lead drug company pipeline have keep flow potentially blockbuster new drug here be key product merck shire gilead science expect be approve fda next month so friday merck mrk be expect hear
434,MRK,gilead science gild say monday drug combo have succeed different genotype hepatitis virus hcv late stage clinical trial gilead study combine sofosbuvir be sell separately sovaldi be also ingredient harvoni new drug candidate call velpatasvir cohort take ribavirin older hcv pill
435,MRK,stock future tunnele deep loss ahead thursday open instability china market send shudder global investor confidence second time week
436,MRK,stock market today again take significant cue china market open sell sharp devaluation yuan spook investor
437,MRK,csi track blue chip stock shanghai shenzhen market drop more first half hour trade trigger automatic shutdown rule put place monday chinese investor be already edge ahead next week lift month sale ban large shareholder
438,MRK,shanghai composite end loss leave lower week shenzhen composite tumble loss friday close
439,MRK,selling carry powerfully other market send nikkei tokyo pressure major index europe loss range midday
440,MRK,bond dollar slip oil price slump putt west texas intermediate just barrel week undercut lows touch lowest mark december natural gas rise gold add fraction top ounce copper fall
441,MRK,be good news economic front layoff announce employer decline year year december lowest total year accord consultant challenger gray christmas job cut report
442,MRK,year have largest number job cut layoff taper year end fourth quarter layoff totale lower layoff
443,MRK,unemployment claim drop week end jan prior week labor department say economist consensus have expect deeper dip claim
444,MRK,china base stock be clearly take early hit netease nte alibaba baba drop
445,MRK,dow stock shift unanimously lower nearly half index be more microsoft msft apple aapl cisco system csco jpmorgan jpm approach loss
446,MRK,only handful stock post gain lead newmont mining nem beer brewer ibd stock constellation brand stz
447,MRK,expeditor international expd drop notch biggest loss
448,MRK,leader technology avgo shed singapore base chipmaker end wednesday just day move average premarket stance imply possible damage cup handle base
449,MRK,netease have hold ground pull back monday sell test day move average thursday premarket action point possible open line support
450,MRK,meanwhile alibaba have be struggle resistance day move average
451,MRK,other loss ibd cut variety stock globus medical gmed drop alaska air alk starbucks sbux shed stock future tunnele deep loss ahead thursday open instability china market send shudder global investor confidence second time week stock market today again take significant cue china market open sell sharp devaluation yuan spook investor csi track blue chip stock shanghai shenzhen market drop more first half hour trade trigger automatic shutdown rule put place monday chinese investor be already edge ahead next week lift month sale ban large shareholder shanghai composite end loss leave lower week shenzhen composite tumble loss friday close selling carry powerfully other market send nikkei tokyo pressure major index europe loss range midday bond dollar slip oil price slump putt west texas intermediate just barrel week undercut lows touch lowest mark december natural gas rise gold add fraction top ounce copper fall be good news economic front layoff announce employer decline year year december lowest total year accord consultant challenger gray christmas job cut report year have largest number job cut layoff taper year end fourth quarter layoff totale lower layoff unemployment claim drop week end jan prior week labor department say economist consensus have expect deeper dip claim china base stock be clearly take early hit netease nte alibaba baba drop dow stock shift unanimously lower nearly half index be more microsoft msft apple aapl cisco system csco jpmorgan jpm approach loss only handful stock post gain lead newmont mining nem beer brewer ibd stock constellation brand stz expeditor international expd drop notch biggest loss leader technology avgo shed singapore base chipmaker end wednesday just day move average premarket stance imply possible damage cup handle base netease have hold ground pull back monday sell test day move average thursday premarket action point possible open line support meanwhile alibaba have be struggle resistance day move average other loss ibd cut variety stock globus medical gmed drop alaska air alk starbucks sbux shed
452,MRK,share eli lilly lly jump more year high thursday company present more evidence diabetes drug jardiance reduce death heart failure annual european association study diabetes lilly partner boehringer ingelheim present detail massive empa reg outcome trial study long term cardiovascular effect jardiance first headline last month lilly ingelheim report jardiance reduce death cardiovascular cause oddly enough do not reduce risk nonfatal heart attack stroke cause mortality be cut hospitalization heart failure be lilly note jardiance be first diabetes drug show kind effect address burden cardiovascular event include death be core diabetes care now single diabetes medication have be associate reduction mortality lead investigator bernard zinman say statement evercore isi analyst mark schoenebaum report slide study generate applause meeting also note have larger implication field diabetes care jardiance be sglt inhibitor same class drug johnson johnson jnj invokana astrazeneca azn farxiga other hand merck mrk similar outcome study januvia drug different class call dpp inhibitor do not find cardiovascular benefit didn do harm base datum think sglt class be likely be bigger dpp class year schoenebaum write email client remember year additional sale add lilly ep peak sale estimate be currently merck sell januvia today invert schoenebaum add astrazeneca be also conduct outcome study sglt inhibitor result due respectively give clearer idea be class effect new datum be announce just noon et thursday send lilly stock nearly later thursday afternoon merck stock be more afternoon trading stock market today follow amy reeve twitter ibd_areeve facebook
453,MRK,share biotech aerie pharmaceutical aeri vault much thursday get passel price target increase company announce late wednesday glaucoma drug have succeed late stage clinical trial
454,MRK,aerie say eye drop rhopressa have succeed lower intra ocular pressure sufferer glaucoma ocular hypertension goal be show once daily dose rhopressa be inferior timolol popular ingredient eye drop such allergan agn combigan merck mrk cosopt
455,MRK,aerie also test twice daily dose rhopressa say be slightly more effective also show higher rate side effect most common side effect be eye redness appear subject rhopressa
456,MRK,aerie say expect file fda approval mid
457,MRK,aerie stock jump month high stock market today close make market top percentage gainer day
458,MRK,big drop april
459,MRK,trial be phase study call rocket rocket rocket have fail meet inferiority endpoint whack stock price back april however june fda agree let aerie modify rocket endpoint look only patient relatively low level intra ocular pressure start millimeter mercury mmhg group have respond better rocket
460,MRK,adjustment lead accusation aerie dredge rocket make rhopressa seem more efficacious canaccord genuity analyst corey davis acknowledge research note however glaucoma patient have intra ocular pressure less mmhg think rhopressa approve have definitive place market davis raise price target stock
461,MRK,rbc capital market analyst adnan butt write result also bode well roclatan combination rhopressa latanoprost prostaglandin analogue pga sell separately pfizer pfe xalatan roclatan be also phase testing earlier process
462,MRK,roclatan demonstrate superiority component believe be little controversy roclatan be blockbuster drug butt write raise price target
463,MRK,needham analyst serge belanger raise price target note rhopressa be first new glaucoma treatment year
464,MRK,follow amy reeve twitter ibd_areeve facebook share biotech aerie pharmaceutical aeri vault much thursday get passel price target increase company announce late wednesday glaucoma drug have succeed late stage clinical trial aerie say eye drop rhopressa have succeed lower intra ocular pressure sufferer glaucoma ocular hypertension goal be show once daily dose rhopressa be inferior timolol popular ingredient eye drop such allergan agn combigan merck mrk cosopt aerie also test twice daily dose rhopressa say be slightly more effective also show higher rate side effect most common side effect be eye redness appear subject rhopressa aerie say expect file fda approval mid aerie stock jump month high stock market today close make market top percentage gainer day big drop trial be phase study call rocket rocket rocket have fail meet inferiority endpoint whack stock price back april however june fda agree let aerie modify rocket endpoint look only patient relatively low level intra ocular pressure start millimeter mercury mmhg group have respond better rocket adjustment lead accusation aerie dredge rocket make rhopressa seem more efficacious canaccord genuity analyst corey davis acknowledge research note however glaucoma patient have intra ocular pressure less mmhg think rhopressa approve have definitive place market davis raise price target stock rbc capital market analyst adnan butt write result also bode well roclatan combination rhopressa latanoprost prostaglandin analogue pga sell separately pfizer pfe xalatan roclatan be also phase testing earlier process roclatan demonstrate superiority component believe be little controversy roclatan be blockbuster drug butt write raise price target needham analyst serge belanger raise price target note rhopressa be first new glaucoma treatment year follow amy reeve twitter ibd_areeve facebook
465,MRK,big biotech amgen amgn agree pay dutch biotech develop new cholesterol drug company say wednesday
466,MRK,amgen pay upfront privately hold dezima have midstage drug candidate call ta lower ldl cholesterol drug succeed amgen be hook milestone payment also pay unspecified royalty mitsubishi tanabe pharma dezima originally license drug
467,MRK,ta be cholesterol ester transfer protein cetp inhibitor class drug eli lilly lly merck mrk be also work analyst have generally be cautious program prior cetp drug roche rhhby pfizer pfe have fail clinical trial july rbc capital market cardiovascular expert source apply only probability success lilly merck program same time however lilly say have conduct futility analysis phase trial result be encourage enough continue result be expect early next year
468,MRK,cetp inhibitor succeed provide competition amgen newly launch cholesterol drug repatha be perhaps amgen decide acquire company press release however amgen chief sean harper suggest drug be complementary
469,MRK,portfolio ta repatha recently launch ldl lower pcsk inhibitor be able offer more treatment option different mechanism action mode administration vary ldl level risk profile harper say
470,MRK,announcement come same morning amgen announce licensing deal xencor xncr develop new cancer inflammation drug used xencor bispecific antibody platform amgen seek fill pipeline face biosimilar competition older drug
471,MRK,xencor stock be morning trading stock market today amgen stock be
472,MRK,follow amy reeve twitter ibd_areeve facebook big biotech amgen amgn agree pay dutch biotech develop new cholesterol drug company say wednesday amgen pay upfront privately hold dezima have midstage drug candidate call ta lower ldl cholesterol drug succeed amgen be hook milestone payment also pay unspecified royalty mitsubishi tanabe pharma dezima originally license drug ta be cholesterol ester transfer protein cetp inhibitor class drug eli lilly lly merck mrk be also work analyst have generally be cautious program prior cetp drug roche rhhby pfizer pfe have fail clinical trial july rbc capital market cardiovascular expert source apply only probability success lilly merck program same time however lilly say have conduct futility analysis phase trial result be encourage enough continue result be expect early next year cetp inhibitor succeed provide competition amgen newly launch cholesterol drug repatha be perhaps amgen decide acquire company press release however amgen chief sean harper suggest drug be complementary portfolio ta repatha recently launch ldl lower pcsk inhibitor be able offer more treatment option different mechanism action mode administration vary ldl level risk profile harper say announcement come same morning amgen announce licensing deal xencor xncr develop new cancer inflammation drug used xencor bispecific antibody platform amgen seek fill pipeline face biosimilar competition older drug xencor stock be morning trading stock market today amgen stock be follow amy reeve twitter ibd_areeve facebook
473,MRK,incyte incy stock hit year high friday release new clinical trial datum biotech cancer drug epacadostat follow fresh round buyout speculation week release abstract presentation european society medical oncology esmo assembly next weekend include incyte trial epacadostat combination bristol myer squibb bmy yervoy
474,MRK,last year hepatitis have produce most epic drug launch history fanfare die investor face key question much longer drug pipeline pop question be ground sheer success exist treatment gilead science gild sovaldi harvoni abbvie abbv viekira pak
475,MRK,buyer push major average session high midday tuesday ahead day fed meeting dow jone industrial average add rise nasdaq gain nyse nasdaq volume be tracking slightly higher monday light level stock market today
476,MRK,chevron cvx merck mrk outperformed dow rise
477,MRK,early winner nasdaq include technology avgo share rise back week move average work right side potential base
478,MRK,economic news retail sale take pause august empire state manufacturing survey miss expectation mile come well consensus estimate industrial production fall little consensus estimate
479,MRK,chip equipment stock oil driller outperformed steel producer several retail related industry group lag
480,MRK,new york mercantile exchange crude oil future rise barrel
481,MRK,day mover palo alto network panw add renew sign accumulation start work right side potential base still have more work do complete base
482,MRK,meanwhile ibd dish plenty winner early go tuesday paycom software payc jump just buy point paycom have be more resilient growth name market recently
483,MRK,egg producer cal maine food calm continue low volume advance rise flirt buy point cal maine be not show meaningful sign accumulation yet buyer push major average session high midday tuesday ahead day fed meeting dow jone industrial average add rise nasdaq gain nyse nasdaq volume be tracking slightly higher monday light level stock market today chevron cvx merck mrk outperformed dow rise early winner nasdaq include technology avgo share rise back week move average work right side potential base economic news retail sale take pause august empire state manufacturing survey miss expectation mile come well consensus estimate industrial production fall little consensus estimate chip equipment stock oil driller outperformed steel producer several retail related industry group lag new york mercantile exchange crude oil future rise barrel day mover palo alto network panw add renew sign accumulation start work right side potential base still have more work do complete base meanwhile ibd dish plenty winner early go tuesday paycom software payc jump just buy point paycom have be more resilient growth name market recently egg producer cal maine food calm continue low volume advance rise flirt buy point cal maine be not show meaningful sign accumulation yet
484,MRK,major average be session high late afternoon trading tuesday bull regain control least day dow jone industrial average add fuel strong performance procter gamble pg merck mrk rise nasdaq gain volume nyse nasdaq be tracking slightly higher monday level stock market today
485,MRK,economic news retail sale take pause august empire state manufacturing survey miss expectation mile come well consensus estimate industrial production fall little consensus estimate
486,MRK,soft datum fuel least speculation fed leave rate unchanged meeting conclude thursday money flow bond lift yield year treasury note basis point committee member believe rate hike be warrant other aren so sure accord cme group fedwatch odd rate hike be
487,MRK,day gainer pra health science prah rise nearly craft new base close quickly buy point
488,MRK,meanwhile ibd dish plenty winner early tuesday paycom software payc jump nearly still buy range buy point paycom have be more resilient growth name market recently
489,MRK,nasdaq winner include google googl priceline pcln technology avgo gain more google have be consolidate july recently find support week move average priceline be hold high still buy range cup handle buy point be back week move average work right side possible new base
490,MRK,new york mercantile exchange crude oil future rise barrel major average be session high late afternoon trading tuesday bull regain control least day dow jone industrial average add fuel strong performance procter gamble pg merck mrk rise nasdaq gain volume nyse nasdaq be tracking slightly higher monday level stock market today economic news retail sale take pause august empire state manufacturing survey miss expectation mile come well consensus estimate industrial production fall little consensus estimate soft datum fuel least speculation fed leave rate unchanged meeting conclude thursday money flow bond lift yield year treasury note basis point committee member believe rate hike be warrant other aren so sure accord cme group fedwatch odd rate hike be day gainer pra health science prah rise nearly craft new base close quickly buy point meanwhile ibd dish plenty winner early tuesday paycom software payc jump nearly still buy range buy point paycom have be more resilient growth name market recently nasdaq winner include google googl priceline pcln technology avgo gain more google have be consolidate july recently find support week move average priceline be hold high still buy range cup handle buy point be back week move average work right side possible new base new york mercantile exchange crude oil future rise barrel
491,MRK,antibiotic specialist tetraphase pharmaceutical ttph stock crash nearly get multiple downgrade wednesday company lead drug eravacycline fail clinical trial
492,MRK,late tuesday tetraphase say ignite phase clinical trial complicate urinary tract infection cuti eravacycline do not stack standard treatment levofloxacin better know johnson johnson jnj levaquin
493,MRK,plan further analyze datum provide update have discuss datum plan path forward regulatory agency tetraphase ceo guy macdonald say statement previously announce positive datum ignite phase clinical trial eravacycline administer intravenously complicate intra abdominal infection do meet primary endpoint demonstrate high cure rate prevalent gram negative pathogen favorable safety profile
494,MRK,tetraphase doesn have product market yet stock have be fly high touch record high july hold ibd relative strength rating putt top stock performance past month least stock strength seem be buyout speculation fellow antibiotic maker cubist durata be acquire merck mrk actavis now allergan agn respectively
495,MRK,midday trading stock market today tetraphase stock be month low
496,MRK,brean needham suntrust stifel nomura downgrade stock neutral equivalent analyst say be surprised outcome positive datum study last september nomura analyst ian somaiya write news not only cut cuti market raise question drug approval timeline complicate intra abdominal infection ciai
497,MRK,give negative result ignite believe tetraphase need run additional phase iii trial somaiya write downgrade note lower price target
498,MRK,guggenheim analyst louise chen lower price target maintain buy rating be more confident somaiya tetraphase win have run ciai trial
499,MRK,thing give confidence happen chen write research note
500,MRK,similar drug have be approve only phase datum accord tetraphase have more datum drug
501,MRK,base discussion fda achaogen akao expect plazomicin be approve cuti only successful trial
502,MRK,eu new antibiotic guidance require only trial approval iai uti be target infection note agency
503,MRK,follow amy reeve twitter ibd_areeve facebook antibiotic specialist tetraphase pharmaceutical ttph stock crash nearly get multiple downgrade wednesday company lead drug eravacycline fail clinical trial late tuesday tetraphase say ignite phase clinical trial complicate urinary tract infection cuti eravacycline do not stack standard treatment levofloxacin better know johnson johnson jnj levaquin plan further analyze datum provide update have discuss datum plan path forward regulatory agency tetraphase ceo guy macdonald say statement previously announce positive datum ignite phase clinical trial eravacycline administer intravenously complicate intra abdominal infection do meet primary endpoint demonstrate high cure rate prevalent gram negative pathogen favorable safety profile tetraphase doesn have product market yet stock have be fly high touch record high july hold ibd relative strength rating putt top stock performance past month least stock strength seem be buyout speculation fellow antibiotic maker cubist durata be acquire merck mrk actavis now allergan agn respectively midday trading stock market today tetraphase stock be month low brean needham suntrust stifel nomura downgrade stock neutral equivalent analyst say be surprised outcome positive datum study last september nomura analyst ian somaiya write news not only cut cuti market raise question drug approval timeline complicate intra abdominal infection ciai give negative result ignite believe tetraphase need run additional phase iii trial somaiya write downgrade note lower price target guggenheim analyst louise chen lower price target maintain buy rating be more confident somaiya tetraphase win have run ciai trial thing give confidence happen chen write research note similar drug have be approve only phase datum accord tetraphase have more datum drug base discussion fda achaogen akao expect plazomicin be approve cuti only successful trial eu new antibiotic guidance require only trial approval iai uti be target infection note agency follow amy reeve twitter ibd_areeve facebook
504,MRK,health care etfs get slam early action monday investor continue agonize exacting timing interest rate lift global growth concern mount
505,MRK,china industrial profit fall nearly august vs year largest drop accord news report fed official say rate likely rise year also note international outlook be clouding view
506,MRK,ishare nasdaq biotechnology ibb largest exchange trade fund hold biotech stock plunge nearly red hot sector continue sell friday ibb dump late trade etf investment strategy hold small cap biotechs dive
507,MRK,ibb top holding celgene celg amgen amgn gilead science gild biogen biib lose nearly intraday trade regeneron pharmaceutical regn give more
508,MRK,ishare pharmaceutical ihe shed more etf hold largest pharmaceutical name top holding merck mrk pfizer pfe fall nearly
509,MRK,spdr gold share gld give more gold future fall morning trade etf track spot gold price used gold bar hold london vault
510,MRK,here look benchmark exchange trade fund tracking various asset class perform today
511,MRK,follow daily etf market action be key successful investing
512,MRK,bellwether etfs
513,MRK,ishare msci eafe efa rs
514,MRK,spdr dow jone industrial average dium rs
515,MRK,powershare db bullish uup rs
516,MRK,spdr spy rs
517,MRK,ishare core aggregate bond agg rs
518,MRK,ishare core mid cap ijh rs
519,MRK,spdr gold share gld rs
520,MRK,powershare qqq qqq rs
521,MRK,vanguard ftse emerge market vwo rs
522,MRK,ishare russell iwm rs
523,MRK,follow aparna narayanan twitter ibd_anarayanan health care etfs get slam early action monday investor continue agonize exacting timing interest rate lift global growth concern mount china industrial profit fall nearly august vs year largest drop accord news report fed official say rate likely rise year also note international outlook be clouding view ishare nasdaq biotechnology ibb largest exchange trade fund hold biotech stock plunge nearly red hot sector continue sell friday ibb dump late trade etf investment strategy hold small cap biotechs dive ibb top holding celgene celg amgen amgn gilead science gild biogen biib lose nearly intraday trade regeneron pharmaceutical regn give more ishare pharmaceutical ihe shed more etf hold largest pharmaceutical name top holding merck mrk pfizer pfe fall nearly spdr gold share gld give more gold future fall morning trade etf track spot gold price used gold bar hold london vault here look benchmark exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing bellwether etfs ishare msci eafe efa rs spdr dow jone industrial average dium rs powershare db bullish uup rs spdr spy rs ishare core aggregate bond agg rs ishare core mid cap ijh rs spdr gold share gld rs powershare qqq qqq rs vanguard ftse emerge market vwo rs ishare russell iwm rs follow aparna narayanan twitter ibd_anarayanan
524,MRK,big biotech amgen amgn be early trading wednesday announce neurology partnership novartis nvs well positive datum osteoporosis drug candidate late tuesday
525,MRK,amgen novartis agree combine research program alzheimer disease involve drug bace beta site app cleave enzyme inhibitor class bace inhibitor more advanced alzheimer disease candidate biogen biib eli lilly lly target beta amyloid deposit appear brain alzheimer patient use different mechanism action amgen work field be preclinical novartis drug cnp be just enter clinical trial
526,MRK,exchange cost profit sharing arrangement cnp novartis gain overseas commercial right amgen migraine drug more advanced amg be cgrp antibody phase testing
527,MRK,deal raise eyebrow amgen isn traditionally know have significant neurology expertise publish early clon bace write rbc capital market analyst michael yee research note tuesday result suspect many investor initially shrug deal bace inhibitor be early street be focuse biogen lilly phase
528,MRK,however believe bace inhibition be very interesting target be combine beta amyloid antibody together many company be go bace phase include biogen eisai datum spring lilly phase merck mrk johnson johnson jnj
529,MRK,however nomura analyst ian somaiya write research note tuesday bace inhibitor have also have safety issue past cause lilly roche rhhby cancel testing earlier candidate
530,MRK,amgen also say late tuesday osteoporosis drug romosozumab have succeed phase trial compare head head lilly forteo do not provide detail await future medical conference
531,MRK,romosozumab view positive phase datum incremental positive somaiya write estimate romosozumab be peak sale opportunity be focuse safety full datum be present give postmenopausal osteoporosis patient population
532,MRK,early trading stock market today amgen stock be fraction novartis stock be flat
533,MRK,follow amy reeve twitter ibd_areeve facebook big biotech amgen amgn be early trading wednesday announce neurology partnership novartis nvs well positive datum osteoporosis drug candidate late tuesday amgen novartis agree combine research program alzheimer disease involve drug bace beta site app cleave enzyme inhibitor class bace inhibitor more advanced alzheimer disease candidate biogen biib eli lilly lly target beta amyloid deposit appear brain alzheimer patient use different mechanism action amgen work field be preclinical novartis drug cnp be just enter clinical trial exchange cost profit sharing arrangement cnp novartis gain overseas commercial right amgen migraine drug more advanced amg be cgrp antibody phase testing deal raise eyebrow amgen isn traditionally know have significant neurology expertise publish early clon bace write rbc capital market analyst michael yee research note tuesday result suspect many investor initially shrug deal bace inhibitor be early street be focuse biogen lilly phase however believe bace inhibition be very interesting target be combine beta amyloid antibody together many company be go bace phase include biogen eisai datum spring lilly phase merck mrk johnson johnson jnj however nomura analyst ian somaiya write research note tuesday bace inhibitor have also have safety issue past cause lilly roche rhhby cancel testing earlier candidate amgen also say late tuesday osteoporosis drug romosozumab have succeed phase trial compare head head lilly forteo do not provide detail await future medical conference romosozumab view positive phase datum incremental positive somaiya write estimate romosozumab be peak sale opportunity be focuse safety full datum be present give postmenopausal osteoporosis patient population early trading stock market today amgen stock be fraction novartis stock be flat follow amy reeve twitter ibd_areeve facebook
534,MRK,undergrad chuck link study air force academy then attend stanford university graduate medical school newly mint link be now chairman chief executive chief scientific officer newlink genetic nlnk iowa co founder biotech firm year air
535,MRK,stock thin gain tuesday economic datum drag early trade volume be mixed bias lower nyse less nasdaq relative trade same time monday
536,MRK,thursday pending policy decision fed remain week focal point economic report be early factor stock market today weaker expect august retail sale number further slow new york region manufacturing weigh stock open
537,MRK,federal reserve add additional friction report industrial production slip august be less half upwardly revise gain july slip project economist consensus manufacturing slip vs expectation decline capacity utilization dip slightly expect decline
538,MRK,stock chevron cvx rise nearly lead dow help bounce oil price merck mrk microsoft msft also rise more walt disney bring rear decline
539,MRK,bottle maker owen illinois oi surge lead bank america upgrade stock buy rating price target stock have be unravele month
540,MRK,louisiana base specialty chemical maker albemarle alb jump start trade company say late monday plan add metric ton mineral conversion production capacity boost output battery grade lithium albemarle share have be correct hard
541,MRK,gw pharmaceutical gwph spark announce positive result phase trial schizophrenia treatment cannabidiol gain hoist share back week line support stock climb right side month deep consolidation
542,MRK,ibd list sucampo pharmaceutical scmp pop open bell base biotech be work fourth straight advance rise test support week move average stock thin gain tuesday economic datum drag early trade volume be mixed bias lower nyse less nasdaq relative trade same time monday thursday pending policy decision fed remain week focal point economic report be early factor stock market today weaker expect august retail sale number further slow new york region manufacturing weigh stock open federal reserve add additional friction report industrial production slip august be less half upwardly revise gain july slip project economist consensus manufacturing slip vs expectation decline capacity utilization dip slightly expect decline stock chevron cvx rise nearly lead dow help bounce oil price merck mrk microsoft msft also rise more walt disney bring rear decline bottle maker owen illinois oi surge lead bank america upgrade stock buy rating price target stock have be unravele month louisiana base specialty chemical maker albemarle alb jump start trade company say late monday plan add metric ton mineral conversion production capacity boost output battery grade lithium albemarle share have be correct hard gw pharmaceutical gwph spark announce positive result phase trial schizophrenia treatment cannabidiol gain hoist share back week line support stock climb right side month deep consolidation ibd list sucampo pharmaceutical scmp pop open bell base biotech be work fourth straight advance rise test support week move average
543,MRK,stock hold small loss quiet morning monday nasdaq be dow jone industrial average slip volume be tracking lower board compare friday level
544,MRK,just handful dow stock be higher early trading apple aapl lead jump active trade report record preorder latest iphone apple share be try climb right side new base be still week move average medical giant merck mrk johnson johnson jnj be close
545,MRK,downside disney visa microsoft msft fall
546,MRK,new high list remain subdue stock market today build product firm topbuild bld builder firstsource bldr score fresh high topbuild add close active trade july new issue be lead distributor installer insulation product residential commercial construction
547,MRK,software firm tyler technology tyl clear flat base buy point volume be tracking light
548,MRK,hospital group be top perform group early lead jump adeptus health adpt june new issue be fight support week line work potential new base adeptus health have report straight quarters triple digit sale growth same group lifepoint health lpnt universal health service uhs hca holding hca be also higher stock hold small loss quiet morning monday nasdaq be dow jone industrial average slip volume be tracking lower board compare friday level just handful dow stock be higher early trading apple aapl lead jump active trade report record preorder latest iphone apple share be try climb right side new base be still week move average medical giant merck mrk johnson johnson jnj be close downside disney visa microsoft msft fall new high list remain subdue stock market today build product firm topbuild bld builder firstsource bldr score fresh high topbuild add close active trade july new issue be lead distributor installer insulation product residential commercial construction software firm tyler technology tyl clear flat base buy point volume be tracking light hospital group be top perform group early lead jump adeptus health adpt june new issue be fight support week line work potential new base adeptus health have report straight quarters triple digit sale growth same group lifepoint health lpnt universal health service uhs hca holding hca be also higher
549,MRK,stock charge higher start bell second straight day wednesday
550,MRK,volume be soft board dow jone industrial average notch gain nasdaq be have pull back open high
551,MRK,stock market today open higher generally weak trading action overseas china market close lower volatile session europe top index have shed earlier gain turn narrowly positive afternoon trade
552,MRK,bond dollar rise sharply gold slip more ounce copper fall silver drop more crude oil slip mixed trade west texas intermediate brent crude fraction energy information administration report weekly inventory datum et
553,MRK,early stock action showednetflix nflx google googl amazon com amzn lead nasdaq more google amazon receive analyst upgrade netflix price target be raise rbc capital market nasdaq deepest loss go wynn resort wynn less
554,MRK,dow merck mrk surge apple aapl visa jpmorgan jpm rise more
555,MRK,cameron international cam spiked easily top start trade schlumberger slb say buy maker subsea oil production component cash stock deal gain left cameron share july high schlumberger slip
556,MRK,ibd list google climb nearly goldman sachs upgrade stock buy neutral raise price target report cite improve monetization mobile search youtube improve cost control stock be rebound test support week move average
557,MRK,sucampo pharmaceutical scmp jump more base biotech announce cash tender offer japan related cash share acquisition tech ueno total consideration sucampo be rise second day quick dive test week support monday
558,MRK,investment wetf drop almost open heaviest loss ibd list stock be surrender bid retake support day line stock charge higher start bell second straight day wednesday volume be soft board dow jone industrial average notch gain nasdaq be have pull back open high stock market today open higher generally weak trading action overseas china market close lower volatile session europe top index have shed earlier gain turn narrowly positive afternoon trade bond dollar rise sharply gold slip more ounce copper fall silver drop more crude oil slip mixed trade west texas intermediate brent crude fraction energy information administration report weekly inventory datum et early stock action showednetflix nflx google googl amazon com amzn lead nasdaq more google amazon receive analyst upgrade netflix price target be raise rbc capital market nasdaq deepest loss go wynn resort wynn less dow merck mrk surge apple aapl visa jpmorgan jpm rise more cameron international cam spiked easily top start trade schlumberger slb say buy maker subsea oil production component cash stock deal gain left cameron share july high schlumberger slip ibd list google climb nearly goldman sachs upgrade stock buy neutral raise price target report cite improve monetization mobile search youtube improve cost control stock be rebound test support week move average sucampo pharmaceutical scmp jump more base biotech announce cash tender offer japan related cash share acquisition tech ueno total consideration sucampo be rise second day quick dive test week support monday investment wetf drop almost open heaviest loss ibd list stock be surrender bid retake support day line
559,MRK,earlier comeback effort collapse send stock fresh session lows midday friday continue concern global growth be again weigh stock market today
560,MRK,nasdaq tumble lose hit month lows dow jone industrial average be slightly milder issue low drugmaker merck mrk hold tiny gain volume be tracking sharply higher board due option expiration
561,MRK,leader big volume ambarella amba stretched loss have erased gain rebound week line then chip designer be biggest percentage loser ibd
562,MRK,netflix nflx drop nearly breach support day move average still more buy point cup handle base april stock be look weekly loss be biggest shellacking week end oct
563,MRK,skecher usa skx be also nearly announce split class share
564,MRK,nearly stock ibd be red only exception be mentor graphic ment rise nearly volatile trading late thursday company post result view raise full year outlook earlier comeback effort collapse send stock fresh session lows midday friday continue concern global growth be again weigh stock market today nasdaq tumble lose hit month lows dow jone industrial average be slightly milder issue low drugmaker merck mrk hold tiny gain volume be tracking sharply higher board due option expiration leader big volume ambarella amba stretched loss have erased gain rebound week line then chip designer be biggest percentage loser ibd netflix nflx drop nearly breach support day move average still more buy point cup handle base april stock be look weekly loss be biggest shellacking week end oct skecher usa skx be also nearly announce split class share nearly stock ibd be red only exception be mentor graphic ment rise nearly volatile trading late thursday company post result view raise full year outlook
565,MRK,major index etfs downshift further monday china federal reserve have continue weigh stock market last trading day august exchange trade fund tracking dow jone industrial average nasdaq post largest monthly loss last week turbulence stock market whipsaw investor even intensified worry global slowdown raise doubt wisdom fed rate hike next month spdr dow jone industrial average dium slip stock market today etf hold blue chip industrial leader merck mrk pfizer pfe ibd leaderboard stock visa be dium lead decliner hold goldman sachs gs intel intc be only stock dium advanced dium peg decline august worst monthly loss year so do spdr spy proxy broad market powershare qqq qqq track largest nonfinancial stock nasdaq composite index spy fall monday sector energy red qqq give qqq top holding biotech stock gilead science gild amgen amgn celgene celg regeneron pharmaceutical regn be hardest hit monday close lose ishare nasdaq biotechnology ibb take hit market vector biotechnology bbh worst sector industry focuse etfs so call death cross spy daily chart be first appearance year pattern occur short term move average week move average slip long term line week move average see bearish signal warning loss momentum more loss ahead accord market watcher interview cnbc cross daily chart be less relevant longer term cross be more worrisome therefore weekly chart spy dium also show pattern here look benchmark exchange trade fund tracking various asset class be perform today follow daily etf market action be key successful investing bellwether etfs spdr gold share gld rs ishare core aggregate bond agg rs powershare db bullish uup rs vanguard ftse emerge market vwo rs ishare russell iwm rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare msci eafe efa rs spdr spy rs powershare qqq qqq rs follow aparna narayanan twitter ibd_anarayanan
566,MRK,big pharma eli lilly lly partner boehringer ingelheim say thursday diabetes drug jardiance succeed lower risk death cardiovascular disease massive year study send lilly stock sharply detailed result be be hold medical meeting eli lilly boehringer do say empa reg outcome trial
567,MRK,major average be sharply late afternoon trading thursday global growth concern weigh nasdaq slump dow jone industrial average fall nyse nasdaq volume be tracking sharply higher wednesday level
568,MRK,nasdaq be barely hold day move average longer term support level nasdaq breach day line nearly year october didn take long new rally begin
569,MRK,mining coal food stock outperformed thursday security software networking name lag
570,MRK,decline stock outnumber advancer exchange nearly
571,MRK,stock market today walt disney slump stock get second analyst downgrade day dow component boee ba andmerck mrk lose
572,MRK,growth stock be hit hard more half name ibd fall more
573,MRK,crude oil dip barrel early session year low be recently trading barrel
574,MRK,exchange ice be few bright spot share reversed higher gain still hold recent cup handle buy point
575,MRK,close watch earning report ross store rost salesforce com crm ross have be hold well ahead earning partly group peer tjx tjx report solid result tuesday major average be sharply late afternoon trading thursday global growth concern weigh nasdaq slump dow jone industrial average fall nyse nasdaq volume be tracking sharply higher wednesday level nasdaq be barely hold day move average longer term support level nasdaq breach day line nearly year october didn take long new rally begin mining coal food stock outperformed thursday security software networking name lag decline stock outnumber advancer exchange nearly stock market today walt disney slump stock get second analyst downgrade day dow component boee ba andmerck mrk lose growth stock be hit hard more half name ibd fall more crude oil dip barrel early session year low be recently trading barrel exchange ice be few bright spot share reversed higher gain still hold recent cup handle buy point close watch earning report ross store rost salesforce com crm ross have be hold well ahead earning partly group peer tjx tjx report solid result tuesday
576,MRK,volatile session china major move emerge market currency thursday combine reaction federal reserve fence position regard rate increase september rattle global market send stock market today emphatically weak start
577,MRK,lead index dive early trade nasdaq swoon dow jone industrial average drop dump volume be mixed nasdaq nyse relative trade same time wednesday
578,MRK,uptick weekly jobless claim have add early pressure number remain federal reserve generally consider constructive territory
579,MRK,exist home sale jump july annualize pace national association realtor say be well upwardly revise pace june well home sale project economist consensus
580,MRK,also positive side philadelphia region manufacturing rise august philadelphia federal reserve putt regional manufacturing survey month july comfortably clear consensus forecast
581,MRK,stock merck mrk walt disney post heaviest decline dow nearly apiece
582,MRK,netapp ntap rise strong fiscal report step early leader nasdaq tech datum tecd maker peripheral networking electronic software spiked big beat
583,MRK,coal gold ore miner oil producer show early strength manage care insurer security software developer show worst early loss industry
584,MRK,valeant pharmaceutical vrx veer lower announce pharmaceutical develop woman libido drug addyi approve food drug administration tuesday valeant expect deal close third quarter loss pull share back test support week move average
585,MRK,micron technology mu lop loss robert baird downgrade stock neutral outperform slash stock price target oversupply dram dynamic random access memory market be issue price set fall early next year micron have be steepening correction december
586,MRK,ibb list be again nearly unanimously lower open
587,MRK,investment wetf ebix ebix drop cyberark software cybr universal insurance uve fall nearly much
588,MRK,top list unite therapeutic uthr rise shade less stock be rise test resistance possible double bottom base volatile session china major move emerge market currency thursday combine reaction federal reserve fence position regard rate increase september rattle global market send stock market today emphatically weak start lead index dive early trade nasdaq swoon dow jone industrial average drop dump volume be mixed nasdaq nyse relative trade same time wednesday uptick weekly jobless claim have add early pressure number remain federal reserve generally consider constructive territory exist home sale jump july annualize pace national association realtor say be well upwardly revise pace june well home sale project economist consensus also positive side philadelphia region manufacturing rise august philadelphia federal reserve putt regional manufacturing survey month july comfortably clear consensus forecast stock merck mrk walt disney post heaviest decline dow nearly apiece netapp ntap rise strong fiscal report step early leader nasdaq tech datum tecd maker peripheral networking electronic software spiked big beat coal gold ore miner oil producer show early strength manage care insurer security software developer show worst early loss industry valeant pharmaceutical vrx veer lower announce pharmaceutical develop woman libido drug addyi approve food drug administration tuesday valeant expect deal close third quarter loss pull share back test support week move average micron technology mu lop loss robert baird downgrade stock neutral outperform slash stock price target oversupply dram dynamic random access memory market be issue price set fall early next year micron have be steepening correction december ibb list be again nearly unanimously lower open investment wetf ebix ebix drop cyberark software cybr universal insurance uve fall nearly much top list unite therapeutic uthr rise shade less stock be rise test resistance possible double bottom base
589,MRK,largest exchange trade fund surrender gain year recover thursday major stock etfs get weak start head third consecutive day loss federal reserve coy stance exact timing rate lift couple new lows oil price rattle investor sell china
590,MRK,amgen beat second quarter estimate raise guidance send stock hour trading earlier thursday fellow big biotech alexion pharmaceutical also beat view guidance worry street amgen amgn earning grow vs year earlier share beating analyst target cent accord thomson reuter revenue rise
591,MRK,big pharmas pfizer pfe merck mrk beat estimate raise guidance tuesday merck french counterpart sanofi sny enter separate deal develop immunotherapy drug cancer pfizer earning dip cent share top analyst consensus cent accord thomson reuter sale decline more
592,MRK,big biotech amgen amgn hit new high early trading friday get several price target increase analyst strong guidance increase late thursday cowen analyst eric schmidt raise price target base not only thursday number also clinical trial datum blood cancer drug kyproli be used
593,MRK,stock high dividend yield aren hard find utility reit space problem be very few stock be show relative strength different story couple dividend leader dow pfe merck mrk be often mentioned same breath be show distinctly better price action other pfizer
594,MRK,gopro gpro rite aid rad be start buy rating thursday alibaba baba be downgrade weak quarterly result yahoo yhoo notable alibaba shareholder rally upgrade cowen co initiate coverage gopro outperform rating price target maker wearable action camera be set enter grow
595,MRK,big pharma merck mrk say tuesday stop phase trial cancer drug keytruda melanoma trial have already meet goal ahead schedule merck stock rise early trading trial call keynote compare keytruda head head bristol myer squibb bmy yervoy currently standard care melanoma
596,MRK,investor please fasten safety belt stock open lower turn mixed then rise early tuesday international economic news flash mixed signal nasdaq be first reverse be ahead dow cling very thin gain volume be soft nasdaq fraction lower nyse compare trade same time monday stock market today be feel strong influence currency commodity turn have turn volatile follow broad release global manufacturing datum euro turn early gain loss vs dollar dollar remain vs yen crude oil price turn mixed benchmark west texas intermediate crude more europe brent fraction consumer price datum report open be line expectation show stabilization energy food price federal housing finance agency january housing price index rise downwardly revise gain december well economist projection gain preliminary purchasing manager manufacturing index march researcher markit strengthen february expectation new home sale jump almost february annualize rate accord commerce department economist have project pace home sale department also revise january sale number stock drug maker merck mrk post dow top gain more report positive result melanoma treatment keytruda netflix nflx rise nearly top nasdaq barclay capital reiterate equal weight rating raise price target stock be testing week support bottom week pullback twitter twtr snap nearly heavy trade breaking past buy point long deep cup handle base microblogging site be ibd leaderboard list premium stock herb seasoning distributor mccormick co mck gap gain powerful trade spark md base company report strong beat fiscal first quarter sale earning management full year revenue guidance be line earning guidance just analyst consensus view stock have be flat line trading high
597,MRK,microsoft msft monday joined list company take advantage low interest rate raise money bond offering microsoft sell new bond make largest corporate debt sale so far year
598,MRK,microsoft increase size debt offer strong demand wall street journal report
599,MRK,debt carry aaa rating standard poor rating service moody investor service microsoft aaa senior unsecured rating reflect company position world largest software company strong lead market share core product make revenue moody say research note bond rater also say microsoft management historically very conservative financial philosophy be important underpinning aaa rating
600,MRK,microsoft sell bond maturity date range year
601,MRK,software leader be follow such company apple aapl merck mrk netflix nflx big bond offering year apple last week raise debt merck raise netflix raise
602,MRK,microsoft plan use money raise debt offer general corporate purpose include stock buyback
603,MRK,microsoft stock fall fraction stock market today microsoft msft monday joined list company take advantage low interest rate raise money bond offering microsoft sell new bond make largest corporate debt sale so far year microsoft increase size debt offer strong demand wall street journal report debt carry aaa rating standard poor rating service moody investor service microsoft aaa senior unsecured rating reflect company position world largest software company strong lead market share core product make revenue moody say research note bond rater also say microsoft management historically very conservative financial philosophy be important underpinning aaa rating microsoft sell bond maturity date range year software leader be follow such company apple aapl merck mrk netflix nflx big bond offering year apple last week raise debt merck raise netflix raise microsoft plan use money raise debt offer general corporate purpose include stock buyback microsoft stock fall fraction stock market today
604,MRK,be year hepatitis immunotherapy cancer produce biggest drug launch be shape be quite different cancer be still big field hep be take back seat cholesterol other cardiology drug make comeback several drug launch year eventually cross blockbuster threshold
605,MRK,approval abbvie abbv hepatitis regimen viekira pak hogged most headline past week fda have approve whole passel medicine be blockbuster maker
606,MRK,here short list most significant
607,MRK,bristol myer bmy win approval opdivo melanoma monday be something surprise fda deadline be march opdivo be pd inhibitor hot new class cancer drug short circuit cancer cell ability fight immune system be widely expect eventually make billion dollar treat multiple cancer
608,MRK,sped opdivo approval dilute first mover advantage merck mrk keytruda be approve melanoma september opdivo be also review squamous cell lung cancer definitely boost sale current consensus forecast sale opdivo vs just keytruda
609,MRK,speaking merck dec buyout target cubist pharmaceutical cbst win approval zerbaxa antibiotic treat drug resistant intra abdominal urinary tract infection zerbaxa be key component cubist strategy survive patent expiration flagship drug cubicin approval become lot more urgent month cubist lose patent case bring generic competitor cubicin early cubist have couple more drug near fda filing zerbaxa be biggest rbc capital market analyst adnan butt estimate peak sale hit
610,MRK,also dec astrazeneca azn win approval lynparza treatment ovarian cancer company believe achieve peak annual sale follow notable trend cancer treatment be approve companion diagnostic test myriad genetic mygn call bracanalysis cdx design identify woman brca gene mutation indicate re most likely benefit drug
611,MRK,lynparza approval be far sure thing june fda advisory panel vote grant accelerate approval astrazeneca have request base phase datum firm still hasn finished phase study do bring more datum fda apparently find convince
612,MRK,tuesday nordisk nvo obesity drug saxenda win fda nod saxenda be brand name liraglutide sell lower dose blockbuster diabetes drug victoza
613,MRK,morgan stanley recently estimate annual sale hit bullish assessment give underwhelm launch ofvivus vvus qsymia late arena pharmaceutical arna belviq earlier year still too early make call orexigen orex contrave be approve september
614,MRK,market successful obesity treatment be potentially enormous also have very large overlap diabetes market nordisk be well establish approval abbvie abbv hepatitis regimen viekira pak hogged most headline past week fda have approve whole passel medicine be blockbuster maker here short list most significant bristol myer bmy win approval opdivo melanoma monday be something surprise fda deadline be march opdivo be pd inhibitor hot new class cancer drug short circuit cancer cell ability fight immune system be widely expect eventually make billion dollar treat multiple cancer sped opdivo approval dilute first mover advantage merck mrk keytruda be approve melanoma september opdivo be also review squamous cell lung cancer definitely boost sale current consensus forecast sale opdivo vs just keytruda speaking merck dec buyout target cubist pharmaceutical cbst win approval zerbaxa antibiotic treat drug resistant intra abdominal urinary tract infection zerbaxa be key component cubist strategy survive patent expiration flagship drug cubicin approval become lot more urgent month cubist lose patent case bring generic competitor cubicin early cubist have couple more drug near fda filing zerbaxa be biggest rbc capital market analyst adnan butt estimate peak sale hit also dec astrazeneca azn win approval lynparza treatment ovarian cancer company believe achieve peak annual sale follow notable trend cancer treatment be approve companion diagnostic test myriad genetic mygn call bracanalysis cdx design identify woman brca gene mutation indicate re most likely benefit drug lynparza approval be far sure thing june fda advisory panel vote grant accelerate approval astrazeneca have request base phase datum firm still hasn finished phase study do bring more datum fda apparently find convince tuesday nordisk nvo obesity drug saxenda win fda nod saxenda be brand name liraglutide sell lower dose blockbuster diabetes drug victoza morgan stanley recently estimate annual sale hit bullish assessment give underwhelm launch ofvivus vvus qsymia late arena pharmaceutical arna belviq earlier year still too early make call orexigen orex contrave be approve september market successful obesity treatment be potentially enormous also have very large overlap diabetes market nordisk be well establish
615,MRK,celgene celg drug abraxane outperformed predecessor large study early stage breast cancer make potential market bigger previously thought accord analyst celgene stock be morning trading stock market today san antonio breast cancer symposium thursday leerink analyst howard liang write german study
616,MRK,stock backed early gain be mixed early tuesday investor wrestle jumble economic news
617,MRK,dow jone industrial average rise add index reach new high nasdaq shed early gain slip
618,MRK,volume be soft second day tracking nyse nasdaq compare same time monday
619,MRK,stock market today receive early push commerce department revise gdp estimate much better expect november durable good order be weak federal housing finance agency housing price index tick better expect october
620,MRK,personal spending jump november labor department say accelerate gain october economist consensus estimate be slightly smaller jump consumer income rise vs gain october forecast be increase
621,MRK,consumer sentiment hold steady december accord university michigan put final consumer sentiment index read smidge vs november better dip economist expect new home sale fall november annualize rate
622,MRK,stock gain loss be generally modest drugmaker again pressure be exception merck mrk pfizer pfe johnson johnson jnj post dow only early decline drugmaker hold biggest loss nasdaq
623,MRK,retailer be show strength lead dd punch heavy trade stock be buy point double bottom base
624,MRK,leader be moderately positive third ibd move higher start trade
625,MRK,asbury automotive abg rise drugmaker hold low end list celgene celg drop gilead science gild biogen idec biib amgen amgn fall stock backed early gain be mixed early tuesday investor wrestle jumble economic news dow jone industrial average rise add index reach new high nasdaq shed early gain slip volume be soft second day tracking nyse nasdaq compare same time monday stock market today receive early push commerce department revise gdp estimate much better expect november durable good order be weak federal housing finance agency housing price index tick better expect october personal spending jump november labor department say accelerate gain october economist consensus estimate be slightly smaller jump consumer income rise vs gain october forecast be increase consumer sentiment hold steady december accord university michigan put final consumer sentiment index read smidge vs november better dip economist expect new home sale fall november annualize rate stock gain loss be generally modest drugmaker again pressure be exception merck mrk pfizer pfe johnson johnson jnj post dow only early decline drugmaker hold biggest loss nasdaq retailer be show strength lead dd punch heavy trade stock be buy point double bottom base leader be moderately positive third ibd move higher start trade asbury automotive abg rise drugmaker hold low end list celgene celg drop gilead science gild biogen idec biib amgen amgn fall
626,MRK,big pharma merck agree buy antibiotic specialist cubist pharmaceutical monday deal value boost fight drug resistant superbug cubist soar merck rise fraction merck mrk agree pay share cash cubist cbst worth include assume debt merck say
627,MRK,stock future change tune point slightly weaker start stock market today nasdaq future fall point vs fair value future lose point future dow jone industrial average give point
628,MRK,stock market end week winning streak last week pickup distribution day prompt downgrade market outlook
629,MRK,stock market overseas be mixed europe france cac slip friday series attack islamic state left more dead germany dax rise london ftse climb
630,MRK,asia hong kong hang seng fall japan nikkei slump shanghai composite reversed higher gain
631,MRK,crude oil jump more barrel potential supply disruption oil price hit lowest level month last week
632,MRK,safe haven instrument such bond dollar be trading higher gold be also higher ounce
633,MRK,economic news empire state index november come vs consensus estimate econoday
634,MRK,number central bank official be speaking week start tuesday fed governor jerome powell minute fed october meeting be due wednesday
635,MRK,stock starwood hotel resort hot fall premarket trading news be buy marriott international mar cash stock deal create world biggest hotel chain
636,MRK,dd slump premarket trading post disappointing quarterly result department store operator say earn share include tax credit cent share sale slip view be ep revenue rival macy plunge last week disappointing quarterly sale weak outlook
637,MRK,airline stock be lower premaket activity concern friday attack tourism share american airline group aal delta air line dal unite continental ual ryanair ryaay be more
638,MRK,nyse nasdaq observe minute silence et victim paris terrorist attack friday
639,MRK,follow vincent mao twitter ibd_vmao stock future change tune point slightly weaker start stock market today nasdaq future fall point vs fair value future lose point future dow jone industrial average give point stock market end week winning streak last week pickup distribution day prompt downgrade market outlook stock market overseas be mixed europe france cac slip friday series attack islamic state left more dead germany dax rise london ftse climb asia hong kong hang seng fall japan nikkei slump shanghai composite reversed higher gain crude oil jump more barrel potential supply disruption oil price hit lowest level month last week safe haven instrument such bond dollar be trading higher gold be also higher ounce economic news empire state index november come vs consensus estimate econoday number central bank official be speaking week start tuesday fed governor jerome powell minute fed october meeting be due wednesday stock starwood hotel resort hot fall premarket trading news be buy marriott international mar cash stock deal create world biggest hotel chain dd slump premarket trading post disappointing quarterly result department store operator say earn share include tax credit cent share sale slip view be ep revenue rival macy plunge last week disappointing quarterly sale weak outlook airline stock be lower premaket activity concern friday attack tourism share american airline group aal delta air line dal unite continental ual ryanair ryaay be more nyse nasdaq observe minute silence et victim paris terrorist attack friday follow vincent mao twitter ibd_vmao
640,MRK,stock step healthy gain early trade tuesday analyst upgrade positive earning report appear trump decline oil price
641,MRK,nasdaq punch dow jone industrial average grab gain jump
642,MRK,stock market today show comparatively mild reaction further decline oil price energy sector lead much monday selling be not show particular weakness energy stock dow bothexxon mobil xom chevron cvx be positive territory top dow microsoft msft merck mrk unite technology utx be nearly
643,MRK,economic news be light dominate labor department november job opening labor turnover survey jolt report show employer report position unfilled october analyst consensus expect slight increase
644,MRK,earning front kb home kbh rise fraction report revenue top expectation earning receive steep boost tax benefit new order average selling price also rise stock have be looping deepen correction month
645,MRK,other homebuilder also climb lennar len horton dhi
646,MRK,ibd list celgene celg drugmaker agio pharmaceutical agio announce late monday celgene exercise option exclusive licensing right outside ag oral cancer treatment gain send celgene new high leave extend rebound support week move average agio share rise
647,MRK,alaska air group alk also hop take new high heavy volume gain push share buy point october
648,MRK,railroad csx csx be schedule report fourth quarter result close stock step healthy gain early trade tuesday analyst upgrade positive earning report appear trump decline oil price nasdaq punch dow jone industrial average grab gain jump stock market today show comparatively mild reaction further decline oil price energy sector lead much monday selling be not show particular weakness energy stock dow bothexxon mobil xom chevron cvx be positive territory top dow microsoft msft merck mrk unite technology utx be nearly economic news be light dominate labor department november job opening labor turnover survey jolt report show employer report position unfilled october analyst consensus expect slight increase earning front kb home kbh rise fraction report revenue top expectation earning receive steep boost tax benefit new order average selling price also rise stock have be looping deepen correction month other homebuilder also climb lennar len horton dhi ibd list celgene celg drugmaker agio pharmaceutical agio announce late monday celgene exercise option exclusive licensing right outside ag oral cancer treatment gain send celgene new high leave extend rebound support week move average agio share rise alaska air group alk also hop take new high heavy volume gain push share buy point october railroad csx csx be schedule report fourth quarter result close
649,MRK,december be usually quiet month medical tech news year bring few potentially stock move event worth keep eye digest thanksgiving turkey here be top chronological order dec biotech incyte incy be look get important expansion label sole market drug jakafi explain recent incyte profile new america incyte partner novartis nvs have be pull respectable income jakafi treatment rare bone marrow cancer call myelofibrosis fda be ponder add indication polycythemia vera milder more common condition uptake condition be expect be fairly slow expect help push incyte more consistently profitable territory next year day later hot medical device company edward lifescience ew hold annual investor day be expect give guidance first time company impressed street last month strong report guidance strong launch latest sapien artificial heart valve currently analyst be forecasting sale year estimate earning share be expect rise then sometime dec likely mean dec fda be due issue verdict abbvie abbv hepatitis combo viekirax exviera clinical trial datum be so good street probably be less surprised meteor hit manhattan fda reject drug have analyst pin needle be price be price significantly lower gilead science gild recently launch harvoni cost week treatment help abbvie gain market share certainly please pharmacy benefit manager express script esrx have be hope start price war drive suddenly high cost hepatitis treatment however most analyst be expect abbvie price only little bit lower also affected be enanta pharmaceutical enta license component viekirax abbvie speaking hepatitis sometime end year street be expect hear phase clinical trial datum achillion pharmaceutical achn drug belong coveted nucleoside inhibitor class gilead mega blockbuster sovaldi also component harvoni belong have otherwise show enough safety issue be few left development especially merck mrk acquire idenix pharmaceutical nuc speculation achillion be next target have drive stock price street have see little real datum safety effectiveness datum help analyst determine just much company be worth speculation exist abort takeover attempt earlier year be re up street seem have mostly give possibility pfizer pfe make bid astrazeneca azn month cool period mandate takeover rule expire wednesday astra ceo pascal soriot throw more cold water appear cnbc thursday say deal have fall apart even have be make propose restriction tax inversion deal however rbc capital market analyst glenn novarro be still hold hope union orthopedic firm stryker syk nephew snn stryker didn bid company news report leak be work get slap month cool period anyway expire nov believe syk snn deal provide more recon reconstructive surgery scale particularly international market expand syk presence trauma sport medicine bring cost synergy novarro write note friday
650,MRK,big pharma bristol myer squibb bmy say monday drop effort get drug treatment hepatitis approve continue pursue other aspect hep strategy bristol myer stock be morning trading stock market today bristol press release cite rapidly evolve hepatitis treatment
651,MRK,big year biotech ipos more be schedule debut week include year largest forward pharma
652,MRK,initial public offering total be expect week look raise combine
653,MRK,forward pharma fwp aim raise offer share price range largest biotech ipo year kite pharma kite raise june
654,MRK,forward pharma plan soon enter phase trial multiple sclerosis treatment upcoming courtroom trial prove be just important netherlands base forward pharma claim competitor biogen idec biib multibillion dollar selling tecfidera treatment multiple sclerosis infringe patent
655,MRK,forward pharma list nasdaq ticker fwp
656,MRK,biotech initial public offer schedule week be atara biotherapeutic atra company be develop therapy target muscle loss patient kidney dialysis atara plan raise selling share list nasdaq atra
657,MRK,be xenon pharmaceutical xene focuse orphan niche disease market opportunity partner include teva pharmaceutical teva merck mrk xenon plan raise offer share list nasdaq xene
658,MRK,final biotech ipo plan week be virobay vbay developer therapy target neuropathic pain crohn disease psoriasis company plan raise offer share list nasdaq vbay
659,MRK,largest ipo week however be zayo group zayo plan raise offer share
660,MRK,zayo be provider infrastructure europe company say product service enable high bandwidth application such cloud base compute video mobile social medium machine machine connectivity list nyse zayo
661,MRK,energy ipo be slate week dominion midstream partner dm be latest series ipos oil gas partnership plan raise offer share range dominion list nyse dm
662,MRK,seventh ipo week be great western bancorp gwb midwest regional bank branch plan raise offer share make second largest bank ipo year citizen financial group cfg great western list nyse gwb
663,MRK,follow brian deagon twitter ibd_bdeagon
664,MRK,related
665,MRK,social medium marketer hubspot jump ipo debut
666,MRK,diplomat pharmacy dave buster surge debut big year biotech ipos more be schedule debut week include year largest forward pharma initial public offering total be expect week look raise combine forward pharma fwp aim raise offer share price range largest biotech ipo year kite pharma kite raise june forward pharma plan soon enter phase trial multiple sclerosis treatment upcoming courtroom trial prove be just important netherlands base forward pharma claim competitor biogen idec biib multibillion dollar selling tecfidera treatment multiple sclerosis infringe patent forward pharma list nasdaq ticker fwp biotech initial public offer schedule week be atara biotherapeutic atra company be develop therapy target muscle loss patient kidney dialysis atara plan raise selling share list nasdaq be xenon pharmaceutical xene focuse orphan niche disease market opportunity partner include teva pharmaceutical teva merck mrk xenon plan raise offer share list nasdaq xene final biotech ipo plan week be virobay vbay developer therapy target neuropathic pain crohn disease psoriasis company plan raise offer share list nasdaq vbay largest ipo week however be zayo group zayo plan raise offer share zayo be provider infrastructure europe company say product service enable high bandwidth application such cloud base compute video mobile social medium machine machine connectivity list nyse zayo energy ipo be slate week dominion midstream partner dm be latest series ipos oil gas partnership plan raise offer share range dominion list nyse dm seventh ipo week be great western bancorp gwb midwest regional bank branch plan raise offer share make second largest bank ipo year citizen financial group cfg great western list nyse gwb follow brian deagon twitter ibd_bdeagon related social medium marketer hubspot jump ipo debutdiplomat pharmacy dave buster surge debut
667,MRK,gilead science gild be california base pharmaceutical company product line include hepatitis drug sovaldi be introduce dec have better cure rate competition week gilead be featured ibd sector leader review mentioned company have lot go hepatitis drug soon
668,MRK,big pharma merck affirm wednesday ll present much anticipate datum hepatitis program next month american association study liver disease liver meeting investor have meeting find actual datum bristol myer squibb bmy be more forthcoming result fail ignite stock merck mrk
669,MRK,part solid approach investing be become aware factor work stock gilead science gild have several thing go current earning growth be huge compare year earlier earning rise revenue rise street expect ep
670,MRK,sometimes drug launch take get ground incyte only approve drug jakafi have be market year really only just get start jakafi sell market jakavi be approve rare bone marrow cancer call myelofibrosis mf thank indication incyte incy revenue be expect pass year compare just year jakafi launch other indication pipeline however really push drug blockbuster territory first expect be approve food drug administration dec be polycythemia vera pv similar somewhat milder disease have potentially larger market meanwhile clinical trial be go really big name cancer pancreatic breast lung colon current consensus estimate have jakafi annual sale hit abroad incyte split take marketing partner novartis nvs sale be expect pass year incyte be base idea research cancer be good investment ceo herve hoppenot tell ibd interview opportunity seizedjakafi be janus associate kinase jak inhibitor regulate signale mechanism cell play important role cell growth immune response jakafi be first jak inhibitor market so far only approve fight cancer pfizer pfe xeljanz approve be also jak inhibitor be used rheumatoid arthritis hoppenot say incyte be originally aim big cancer first mf opportunity unexpectedly come scientist find jak signale play important role disease point company decide move development program very quickly myelofibrosis try prove jak pathway be have impact outcome patient say be able get pivotal study do approval myelofibrosis very rapid way advantage mf market bring firm be small patient pool have other treatment option so incyte have be able market domestically bring big pharma partner thus keep domestic revenue pursue pv be next logical step hoppenot say disease be so similar be disorder mean excess cell be produce bone marrow pv however be much milder sometimes have symptom hoppenot estimate only roughly pv patient be eligible jakafi expect liftoff be fairly slow treat pv isn urgent treat more malignant cancer eventual market be larger mf have fewer sufferer accord leerink estimate disease bring incyte first annual profit next year accord consensus analyst poll thomson reuter incyte turn profit cent share most recently report quarter only milestone payment incyte collect novartis winning reimbursement jakafi europe marketing approval japan start second half next year analyst expect incyte start turn operate profit more consistent way rivalry year however new competition threaten jakafi gilead science gild jak inhibitor momelotinib be late stage trial mf design compare momelotinib jakafi head head result be expect come sometime next year couple smaller player cti biopharma ctic geron gern also have competitor late stage testing nov latter license candidate imetelstat johnson johnson jnj development multiple disease deal potentially worth milestone be realize only datum tell competitive product be incyte have other tool garage incb candidate drug class call ido inhibitor be be test combination most anticipate cancer drug pipeline pd pd inhibitor incyte have partner lead contender field bristol myer bmy astrazeneca azn roche rhhby merck mrk test drug together variety cancer be not licensing deal say hoppenot do mean drug be approve company recommend successful combination drug label incb also garner attention summer american society clinical oncology asco meeting perform well trial combine different related bristol myer drug yervoy treat melanoma leerink analyst michael schmidt write time combo didn appear be effective yervoy combine bristol house pd opdivo do suggest promise combination incb other pd news better expect third quarter report last month induced goldman sachs analyst navdeep singh lift rating incyte neutral sell nearly double price target sell thesis be base more cautious view jakafi launch myelofibrosis mf give safety competition call have not work narrative have shift incy pipeline singh write oct research note add follow newly result asco be more encourage strong underlie growth jakafi mf early datum partnership interest ido inhibitor
671,MRK,drama continue big biotech gilead science tuesday johnson johnson moved viral disease turf front acquisition
672,MRK,johnson johnson jnj disclose buy privately hold alio biopharma cash press release tout alio drug candidate respiratory syncytial virus rsv major cause lung infection have current treatment drug al be midstage clinical testing
673,MRK,happen gilead gild also have rsv drug gs phase clinical trial be overshadowed gilead bigger drug rbc capital market analyst michael yee believe have blockbuster potential astrazeneca azn synagis used prevent rsv infection high risk infant draw more year just niche market
674,MRK,yee point research note tuesday alio be potential competitor gilead way have nucleotide drug hepatitis virus hcv early stage development
675,MRK,gilead megablockbuster sovaldi be first nucleotide drug hcv hit market back december year merck mrk shell buy idenix pharmaceutical also have nuke development
676,MRK,not new hep
677,MRK,be also hcv game drug olysio be different class drug not directly competitive sovaldi
678,MRK,be often prescribe together have help buoy olysio sale launch last november first half year alone sell give success combo not surprising want nuke own
679,MRK,clearly think long term call option upside here be alio nuke show log reduction hcv virus have good safety profile yee write course be not layup know development nuke be extremely difficult bar continue progression be very high reminder vertex vrtx be partner prior alio nuke drop development due narrow therapeutic window weak efficacy have sign liver toxicity
680,MRK,yee also write be interesting see development read achillion pharmaceutical achn stock boast ibd relative strength rating base largely expectation be next nuke developer be buy investor seem be read negatively achillion stock fall tuesday close
681,MRK,still maxim group analyst achillion bull jason kolbert do not sound very worry
682,MRK,alio nuke be old news kolbert tell ibd think achn be be bit nonsense nuke show good datum be race
683,MRK,high price sovaldi
684,MRK,investor analyst be interested future competition sovaldi not just effect market share also sovaldi price have question day
685,MRK,gilead charge day treatment typically run week
686,MRK,monday government france address issue social security budget bill propose new taxe seller hepatitis drug revenue make france social security have spend more euro drug government call progressive contribution scheme
687,MRK,budget still have be approve lawmaker sign european country be continue drive hard bargain gilead roll sovaldi eu approve sovaldi sale january country have own payment system drugmaker have negotiate separately
688,MRK,however july france joined other country coordinate strategy drive sovaldi price
689,MRK,gilead stock slip tuesday close drama continue big biotech gilead science tuesday johnson johnson moved viral disease turf front acquisition johnson johnson jnj disclose buy privately hold alio biopharma cash press release tout alio drug candidate respiratory syncytial virus rsv major cause lung infection have current treatment drug al be midstage clinical testing happen gilead gild also have rsv drug gs phase clinical trial be overshadowed gilead bigger drug rbc capital market analyst michael yee believe have blockbuster potential astrazeneca azn synagis used prevent rsv infection high risk infant draw more year just niche market yee point research note tuesday alio be potential competitor gilead way have nucleotide drug hepatitis virus hcv early stage development gilead megablockbuster sovaldi be first nucleotide drug hcv hit market back december year merck mrk shell buy idenix pharmaceutical also have nuke development not new hep cj be also hcv game drug olysio be different class drug not directly competitive sovaldi be often prescribe together have help buoy olysio sale launch last november first half year alone sell give success combo not surprising want nuke own clearly think long term call option upside here be alio nuke show log reduction hcv virus have good safety profile yee write course be not layup know development nuke be extremely difficult bar continue progression be very high reminder vertex vrtx be partner prior alio nuke drop development due narrow therapeutic window weak efficacy have sign liver toxicity yee also write be interesting see development read achillion pharmaceutical achn stock boast ibd relative strength rating base largely expectation be next nuke developer be buy investor seem be read negatively achillion stock fall tuesday close still maxim group analyst achillion bull jason kolbert do not sound very worry alio nuke be old news kolbert tell ibd think achn be be bit nonsense nuke show good datum be race high price sovaldiinvestor analyst be interested future competition sovaldi not just effect market share also sovaldi price have question day gilead charge day treatment typically run week monday government france address issue social security budget bill propose new taxe seller hepatitis drug revenue make france social security have spend more euro drug government call progressive contribution scheme budget still have be approve lawmaker sign european country be continue drive hard bargain gilead roll sovaldi eu approve sovaldi sale january country have own payment system drugmaker have negotiate separately however july france joined other country coordinate strategy drive sovaldi price gilead stock slip tuesday close
690,MRK,big cap biotech ibd stock gilead science put important brick fortress competition wednesday report positive trial datum latest hiv drug stock rise news drug call tenofovir alafenamide taf have be nickname son viread wall street new improve version
691,MRK,stock future blipped higher ahead thursday open market appear set build wednesday late day rally dow future trade point fair market value have come well earlier high nasdaq future be strong point future show point gain
692,MRK,stock market today head session nasdaq lower week ibd index be russell open loss rally late wednesday session follow release federal reserve september beige book report left nasdaq top day trading range positive sign little have change regard overall message correct market be send be patient build watch list watch follow day
693,MRK,investor attention be august nonfarm payroll report due friday thursday preliminary include august job cut report challenger gray christmas show number layoff slow sharply vs july year high compare year figure employer announce plan cut worker retail sector account nearly layoff most tie bankruptcy grocery chain report say
694,MRK,initial jobless claim rise week end aug labor department say economist consensus have project claim week move average edge
695,MRK,stock grifol grfs rise sunedison sune jump market continue be hard slip up late season earning report
696,MRK,be morning weak revenue guidance upended quarterly result verint system vrnt tumble better expect earning revenue do not offset full year earning guidance consensus view
697,MRK,generic drug maker lannett lci spiked premarket trade philadelphia base company say pay acquire kremer urban pharmaceutical generic drug unit belgium base ucb kremer own portfolio drug strong pipeline pending application candidate effectively double lannett revenue lannett end wednesday april high fall week line support early august
698,MRK,switzerland base syngenta syt rolled gain announce seek divest vegetable seed business launch share repurchase program syngenta see more revenue herbicide insecticide stock end wednesday june high
699,MRK,lead stock be unusually flat ahead open refinery operator tesoro tso post largest move ibd stock premarket trade stock have be work fashion bottom week consolidation hover week move average
700,MRK,overseas china market be close country celebrate anniversary end wwii europe market layer healthy gain lead index more board midday
701,MRK,dollar trade flat vs euro yen bond slip not much crude oil ease few penny west texas intermediate hold barrel week gold ease ounce less week stock future blipped higher ahead thursday open market appear set build wednesday late day rally dow future trade point fair market value have come well earlier high nasdaq future be strong point future show point gain stock market today head session nasdaq lower week ibd index be russell open loss rally late wednesday session follow release federal reserve september beige book report left nasdaq top day trading range positive sign little have change regard overall message correct market be send be patient build watch list watch follow day investor attention be august nonfarm payroll report due friday thursday preliminary include august job cut report challenger gray christmas show number layoff slow sharply vs july year high compare year figure employer announce plan cut worker retail sector account nearly layoff most tie bankruptcy grocery chain report say initial jobless claim rise week end aug labor department say economist consensus have project claim week move average edge stock grifol grfs rise sunedison sune jump market continue be hard slip up late season earning report be morning weak revenue guidance upended quarterly result verint system vrnt tumble better expect earning revenue do not offset full year earning guidance consensus view generic drug maker lannett lci spiked premarket trade philadelphia base company say pay acquire kremer urban pharmaceutical generic drug unit belgium base ucb kremer own portfolio drug strong pipeline pending application candidate effectively double lannett revenue lannett end wednesday april high fall week line support early august switzerland base syngenta syt rolled gain announce seek divest vegetable seed business launch share repurchase program syngenta see more revenue herbicide insecticide stock end wednesday june high lead stock be unusually flat ahead open refinery operator tesoro tso post largest move ibd stock premarket trade stock have be work fashion bottom week consolidation hover week move average overseas china market be close country celebrate anniversary end wwii europe market layer healthy gain lead index more board midday dollar trade flat vs euro yen bond slip not much crude oil ease few penny west texas intermediate hold barrel week gold ease ounce less week
702,MRK,share sigma aldrich sial major provider chemical other product life science industry jump more time high stock market today german drugmaker merck kgaa announce buy company cash merck do business emd millipore avoid confusion
703,MRK,sigma aldrich soar monday few bright spot new high list make short market sell st loui mo base sigma aldrich sial end german drugmaker merck mrk say buy maker chemical other life science industry product cash company likely have
704,MRK,founding software company veeva system peter gassner be certain thing want technology be cloud base address critical issue specific industry decide focus life science have picked something else oil gas picked thing big industry big industry know be massive need good cloud solution tell ibd turn be good idea veeva veev be most successful cloud base software company not only have revenue be grow double digit also profitable cloud company be usually grow not usually profitable say gassner be veeva ceo know be make product not guess game so have lower sale marketing cost help co founder president matt build life science business siebel system acquire oracle orcl have relationship pharmaceutical company say here better version say brendan barnicle analyst pacific crest security lot veeva business be replace old siebel system build steamveeva have more pharmaceutical biotech customer include more largest drug company worldwide range drug giant such merck mrk novartis nvs eli lilly lly emerge biotech veeva customer be gilead science gild maker hepatitis wonder drug gilead have be buy more product veeva grow expand worldwide gassner say plenty customer veeva keep expand coverage user company selling more add module be drive growth be veeva have high margin barnicle say salesforce com crm don have grab new customer re go same customer selling more gassner have key contact past employer be senior vp technology salesforce com charge build software service saas platform crm software drife revenueveeva core customer relationship management crm software be build salesforce com platform veeva be salesforce com prefer partner pharma biotech gassner say be sale channel salesforce com partner crm software account veeva revenue be expect top year accord research firm gartner crm software revenue worldwide grow double digit moreover vertical industry specific software comprise largest segment enterprise software market total most software be still focuse client server rather cloud internet gassner say re bring client server cloud tremendous opportunity re just early stage veeva revenue fiscal grow fiscal end january revenue second quarter end july rise net income quarter jump cent share company go public october figured ep earlier period amount equivalent cent share veeva stock be more ipo price rise first share dip rebound sharply result be announce aug day company raise forecast full year previously share earning guidance year be up cent cent analyst expect veeva earning come cent gain last year see growth next year accord thomson reuter manage clinical say firm make great progress quarter second product category call veeva vault veeva build own infrastructure vault focus content management process such clinical trial quality management manufacturing sale marketing more new vault customer be add include second top drug company sign vault clinical trial product fastest part business barnicle say vault similar veeva crm software replace siebel vault be replace old content management system used life science barnicle say tracking more dataveeva third newest product line be call network cloud base solution integrate firm crm platform help customer track datum health care customer william blair analyst estimate vault network offering expand veeva market opportunity roughly much upper target be base expansion potential network database other region world china veeva largest market be follow western europe asia especially china japan william blair analyst expect veeva revenue reach end veeva be far only company offer health care specific technology william blair analyst say recent initiation report veeva vast majority offer premise product use isolate single client host model believe legacy vendor lose innovation speed market price battle write chief rival be cegedim global tech service firm focuse health care cegedim crm business be be acquire im health im william blair estimate cegedim seat use premise technology gassner see pending acquisition positive veeva be disruption benefit say
705,MRK,stock end solid gain friday battle back weakness spur disappointing job report nasdaq end respectively be friday low dow jone industrial average climb accord preliminary datum volume end higher board stock market today lead stock dave buster entertainment play reversed higher gain stock have already rise thursday follow pricing share offer dave buster be recently featured stock spotlight verisk analytic vrsk stretched streak straight session rebound loss rise stock nearly reach buy point flat base verisk provide datum insurance underwriter bank be add wednesday close tyler technology tyl add second straight new high now past buy point flat base clear thursday company announce buy privately hold new world system cash stock domino pizza dpz climb buck morning weakness fail retake day move average domino report earning thursday analyst poll thomson reuter see pizza chain profit rise cent share
706,MRK,monday bring news yet large acquisition company german industry titan add biggest year record german american buyout
707,MRK,drugmaker merck kgaa say buy st loui base sigma aldrich sial supply chemical kit life science industry diversify giant siemens siegy sunday night confirm last week rumor be buy houston oil drill equipment firm dresser rand drc
708,MRK,software maker sap sap inked deal bellevue wash base concur technology cnqr provide cloud base expense report travel software few day earlier michigan auto part maker trw automotive trw agree become part zf friedrichshafen
709,MRK,not be forgotten be bayer bayry deal buy consumer business merck mrk long divorce german merck hammer
710,MRK,total have be worth german acquisition target accord thomson reuter beat full year year thomson have track
711,MRK,largest ever german acquisition unite state have take place year largest ever be daimler benz acquisition chrysler back say richard peterson senior director capital iq
712,MRK,refocusing
713,MRK,drive trend most venerable german giant have be reorganize refocusing business reflect fact ve be selling well buy just last week bayer announce spin polymer business separate company last month siemens agree sell health care business cerner cern
714,MRK,be also industry specific reason choose target big pharma acquisition strategy have be guide last few year idea product category isn worth be re bayer merck buyout help accomplish sap buyout expand company further hot cloud compute space dresser rand bring siemens play shale oil boom
715,MRK,bet america
716,MRK,even so sheer amount money move germany be suggestive merck pay premium sigma aldrich friday close also premium siemens be pay dresser rand stock price rumor drive deal be also cash
717,MRK,factor connect various deal not overstretch point be emerge market growth have slow little political risk market receive more attention again christian stadler associate professor warwick business school coventry tell ibd email mean develop market be gain more interest again now once look develop market notice be do better europe japan
718,MRK,peterson cite sign european economy be slow encourage company buy way growth lack revenue gain be unify theme buyer top performer be sap sale grow whopping year year last quarter
719,MRK,peterson also suggest stronger dollar be putt german buyer more hurry close deal target get too pricey
720,MRK,dresser rand rise nearly monday vs share deal price stock rise last week siemens fall less slide friday
721,MRK,sigma aldrich jump vs offer price monday bring news yet large acquisition company german industry titan add biggest year record german american buyout drugmaker merck kgaa say buy st loui base sigma aldrich sial supply chemical kit life science industry diversify giant siemens siegy sunday night confirm last week rumor be buy houston oil drill equipment firm dresser rand drc software maker sap sap inked deal bellevue wash base concur technology cnqr provide cloud base expense report travel software few day earlier michigan auto part maker trw automotive trw agree become part zf friedrichshafen not be forgotten be bayer bayry deal buy consumer business merck mrk long divorce german merck hammer total have be worth german acquisition target accord thomson reuter beat full year year thomson have track largest ever german acquisition unite state have take place year largest ever be daimler benz acquisition chrysler back say richard peterson senior director capital iq refocusing drive trend most venerable german giant have be reorganize refocusing business reflect fact ve be selling well buy just last week bayer announce spin polymer business separate company last month siemens agree sell health care business cerner cern be also industry specific reason choose target big pharma acquisition strategy have be guide last few year idea product category isn worth be re bayer merck buyout help accomplish sap buyout expand company further hot cloud compute space dresser rand bring siemens play shale oil boom bet americaeven so sheer amount money move germany be suggestive merck pay premium sigma aldrich friday close also premium siemens be pay dresser rand stock price rumor drive deal be also cash factor connect various deal not overstretch point be emerge market growth have slow little political risk market receive more attention again christian stadler associate professor warwick business school coventry tell ibd email mean develop market be gain more interest again now once look develop market notice be do better europe japan peterson cite sign european economy be slow encourage company buy way growth lack revenue gain be unify theme buyer top performer be sap sale grow whopping year year last quarter peterson also suggest stronger dollar be putt german buyer more hurry close deal target get too pricey dresser rand rise nearly monday vs share deal price stock rise last week siemens fall less slide friday sigma aldrich jump vs offer price
722,MRK,ceo leonard schleifer make sure regeneron pharmaceutical be study drug wide view science have work wonder past decade regeneron regn philosophy spark contention early biotech firm publicly trade life board adviser debate schleifer long range build blockbuster drug drag too long official want regeneron focus strictly opportunity get magic drug market soon possible schleifer have founder company say know overall pharmacology approach pay have regeneron sale hit company ipo april stock be stock turn even healthier wednesday share leap food drug administration approve flagship drug eylea treat diabetic macular edema dme lead cause blindness eylea be initially approve november treat age related wet macular degeneration now thick dme market potentially lucrative regeneron due global diabetes epidemic enlighten path formula be surprisingly easy articulate difficult emulate schleifer tell ibd set have world best science follow science ve do past year schleifer start path pharmaceutical success grow queen go forest hill high school be captain tennis team be also junior new york state chess champion schleifer get work ethic father depression era sweater maker born poor immigrant williamsburg section brooklyn advice be get well educate possible believe education be weapon fight world son recall schleifer hone weapon attend dad alma mater cornell university save family money len finished year earn bachelor degree neurobiology behavior graduate summa cum laude phi beta kappa schleifer then go university virginia doctorate medicine pharmacology uva schleifer study alfr gilman share nobel prize physiology medicine martin rodbell schleifer watch gilman do research lead nobel prize call enormously inspiring be trained scientist clinician schleifer return cornell system work neurologist junior faculty member cornell new york hospital be become fascinate biotech revolution read stack paper genentech industry leader fold roche be trained biochemist have interest molecular biology schleifer say genentech be pioneer dna technology schleifer ponder go business own aim path disease nervous system business be regeneron pharmaceutical name regenerate nerve cell headquarters tarrytown just north new york city help gilman schleifer contact top mind biotech field lead right person regeneron start early mentor be roy vagelos george yancopoulos roy vagelos have hold chairmanship regeneron come merck mrk be greatest ceo american history accord schleifer yancopoulos be regeneron chief scientific officer schleifer recruit columbia university yancopoulos lead research molecular immunology now be star yancopoulos be principal inventor eylea most drug regeneron pipeline schleifer laud greatest scientist entrepreneur generation join regeneron wasn hard decision yancopoulos really believe len be try do say know be do right reason such talent schleifer be key regeneron drug revenue generation decide build company not only value science also scientist do science schleifer say like point work yancopoulos not other way tough early go regeneron be filled adversity firm develop protein early treat amyotrophic lateral sclerosis lou gehrig disease patient lose too much weight side effect company halter trial then regeneron obesity drug never make past fda failure business be just part parcel never really change view be right track schleifer say great success life come failure regeneron first approve drug be arcalyst drug treat rare genetic disease be widely consider success wall regeneron analyst weren impressed drug cost develop wasn contribute meaningfully bottom line arcalyst do just sale first quarter science drug have be critical further drug development regeneron wall street miss whole point yancopoulos say be build company infrastructure technology capability not only innovate once repeat again new drug new therapeutic area open waypipeline prospect be bright alirocumab antibody lower low density lipoprotein cholesterol call bad cholesterol collect wall blood vessel cause blockage wednesday regeneron partner sanofi sny report positive phase result alirocumab phase trial regeneron rheumatoid arthritis drug sarilumab be show progress then dupilumab clinical trial asthma other disease late stage production be regeneron early stage pipeline grow antibody company lab have consider be most enviable pipeline industry home grow yancopoulos say meanwhile regeneron have stay sanofi french firm recently raise stake regeneron sanofi have right own schleifer company regeneron also recently embarked research development initiative avalanche biotechnology aavl develop next generation gene therapy product ophthalmology branch medicine concern treat disorder eye initial public offer thursday avalanche go opposite direction name imply gush early trade buy company acquisition don give competitive advantage schleifer say competitive advantage be science yancopoulos also weigh acquisition used sport metaphor baseball team spend lot money older free agent doesn have farm system believe build internally used farm system re produce prize prospect left right personal side schleifer celebrate year marriage wife harriet december live new york have son say come recreation golf chess occasional poker game good friend persistence have paid ceo other personality trait have also help have exaggerate sense fairness have allow value true value creator company regeneron say combine overall optimistic nature have allow stay true conviction talent regeneron succeed long haul
723,MRK,bristol myer squibb bmy say thursday file fda approval nivolumab melanoma quarter earlier street expect
724,MRK,nivolumab now brand opdivo be bristol lead drug much anticipate pd class cancer fighter have achieve outstanding result clinical trial melanoma combine bristol already launch drug yervoy thursday announcement say initial filing seek approval only refractory melanoma previously treat yervoy drugmaker typically first approval such last resort case expand label broader earlier used
725,MRK,please remember be ongoing front line study nivo yervoy believe bmy have datum later year isi group analyst mark schoenebaum write email client thursday trial also serve basis filing early
726,MRK,schoenebaum add combo probably become standard care overtake merck mrk pd pembrolizumab be process melanoma approval perhaps month ahead opdivo opdivo be also already fda agenda treatment squamous cell lung cancer be approve melanoma day japan
727,MRK,most analyst base case scenario have melanoma filing mid accord schoenebaum news didn seem come upside surprise investor share be fraction early trading stock market today
728,MRK,follow amy reeve twitter ibd_areeve
729,MRK,related bristol myer oral hcv therapy approve japan
730,MRK,bristol myer squibb bmy say thursday file fda approval nivolumab melanoma quarter earlier street expect nivolumab now brand opdivo be bristol lead drug much anticipate pd class cancer fighter have achieve outstanding result clinical trial melanoma combine bristol already launch drug yervoy thursday announcement say initial filing seek approval only refractory melanoma previously treat yervoy drugmaker typically first approval such last resort case expand label broader earlier used please remember be ongoing front line study nivo yervoy believe bmy have datum later year isi group analyst mark schoenebaum write email client thursday trial also serve basis filing early schoenebaum add combo probably become standard care overtake merck mrk pd pembrolizumab be process melanoma approval perhaps month ahead opdivo opdivo be also already fda agenda treatment squamous cell lung cancer be approve melanoma day japan most analyst base case scenario have melanoma filing mid accord schoenebaum news didn seem come upside surprise investor share be fraction early trading stock market today follow amy reeve twitter ibd_areeve related bristol myer oral hcv therapy approve japan
731,MRK,drugmaker aim help person live healthier life aren immune patent loss merck mrk have recently face number patent expiration tuesday report sale slow eighth quarter row earning climb cent share third straight quarter gain result beat view
732,MRK,big pharmas merck pfizer modestly beat estimate early tuesday guide full year cautiously prepare new drug launch merck stock rise pfizer stock fall merck mrk earning totale cent share penny year earlier quarter beating analyst consensus cent sale shrank
733,MRK,stock step healthy gain solid trade early tuesday weaker expect read home price growth
734,MRK,nasdaq grab gain dow jone industrial average tack moved
735,MRK,volume climb stock market today trade tracking higher nasdaq nyse compare same time monday
736,MRK,home price rise increase slow lowest rate more year accord case shiller city composite home price index index gain april gain expectation growth
737,MRK,big cap stock unite parcel service up bp bp be pfizer pfe merck mrk climb report quarterly result
738,MRK,long struggle stock herbalife hlf tank weak second quarter result report late monday
739,MRK,el pollo holding tumble start trade grilled chicken chain go public friday be still more ipo price share
740,MRK,upside windstream holding spiked word arkansa base telecom service provider form separately trade real estate investment trust reit spinoff divide company internet service operation physical network asset stock have be climb february year correction tuesday gain left share high
741,MRK,wynn resort wynn pop miss analyst revenue forecast beating ep forecast wide margin stock be work build right side consolidation stock step healthy gain solid trade early tuesday weaker expect read home price growth nasdaq grab gain dow jone industrial average tack moved volume climb stock market today trade tracking higher nasdaq nyse compare same time monday home price rise increase slow lowest rate more year accord case shiller city composite home price index index gain april gain expectation growth big cap stock unite parcel service up bp bp be pfizer pfe merck mrk climb report quarterly result long struggle stock herbalife hlf tank weak second quarter result report late monday el pollo holding tumble start trade grilled chicken chain go public friday be still more ipo price share upside windstream holding spiked word arkansa base telecom service provider form separately trade real estate investment trust reit spinoff divide company internet service operation physical network asset stock have be climb february year correction tuesday gain left share high wynn resort wynn pop miss analyst revenue forecast beating ep forecast wide margin stock be work build right side consolidation
742,MRK,big pharma pfizer pfe get downgrade ahead earning report schedule tuesday day also feature report fellow big pharma merck mrk well big biotech amgen amgn analyst average expect pfizer earning cent share penny year earlier quarter sale drop
743,MRK,bristol myer squibb bmy stock be nearly early trading stock market today late tuesday news big pharma have stop trial cancer drug nivolumab early due strong efficacy trial question compare nivolumab dacarbazine standard chemotherapy also know dtic previously untreated patient have advanced
744,MRK,chairman senior member senate finance committee friday issue battery question gilead science gild price blockbuster hepatitis drug sovaldi add chorus objection product pill price market be unfazed however gilead stock fraction morning trading
745,MRK,great leader have relentless passion growth say waldo waldman decorate fighter pilot author never fly solo waldman graduate air force academy hold mba focus organizational behavior say chief don settle status quo understand complacency kill best leader understand yesterday success win
746,MRK,recent announcement roche rhhby buy intermune itmn bring new life speculation biotech industry have be relatively neglected buzz focuse tax inversion deal company ibd have greater ability anyone else predict future here be biotech stock have be name
747,MRK,biotech achillion pharmaceutical achn get boost monday maxim group more triple price target stock send share stock market today have dinner company executive analyst jason kolbert hike target maintain buy rating cite potential achillion hepatitis drug candidate ultimate goal create regimen cure genotype virus week current industry leader gilead science gild sovaldi be normally give week kolbert add acquisition potential achillion remain high potential have more double stock price last week merck mrk deal buy idenix idix hepatitis pipeline spark speculation achillion also make appeal target stock be also help last week fda lift clinical hold sovaprevir be achillion most advanced hepatitis candidate phase testing achillion stock rise close trading high intraday follow amy reeve twitter ibd_areeve
748,MRK,early gain fade loss late friday morning report fight ukraine russia major index stick solid gain so far week
749,MRK,dow jone industrial average slump hamstrung merck mrk loss shed nasdaq dip
750,MRK,stock market today set seeming largely unswayed mixed early news datum report early optimism erode option expiration drive volume higher late morning trade remain nyse higher nasdaq compare action same time thursday
751,MRK,monster beverage mnst apply material amat kinder morgan kmi continue hold top spot jwn post index largest loss gapping loss heavy trade report result late thursday
752,MRK,jazz pharmaceutical jazz gain move head ibd list share have initially punch putt stock back day line stock have fade more cup handle buy point negating retake buy point solid trade remain valid entry
753,MRK,lithia motor lad drop fast trade slip back retest day move average medford ore base auto dealership chain be sixth week flat base buy point early gain fade loss late friday morning report fight ukraine russia major index stick solid gain so far week dow jone industrial average slump hamstrung merck mrk loss shed nasdaq dip stock market today set seeming largely unswayed mixed early news datum report early optimism erode option expiration drive volume higher late morning trade remain nyse higher nasdaq compare action same time thursday monster beverage mnst apply material amat kinder morgan kmi continue hold top spot jwn post index largest loss gapping loss heavy trade report result late thursday jazz pharmaceutical jazz gain move head ibd list share have initially punch putt stock back day line stock have fade more cup handle buy point negating retake buy point solid trade remain valid entry lithia motor lad drop fast trade slip back retest day move average medford ore base auto dealership chain be sixth week flat base buy point
754,MRK,biotech achillion pharmaceutical achn announce tuesday clinical trial be progress hepatitis drug fda lift clinical hold send share early trading stock market today month high fda have place clinical hold phase trial drug candidate sovaprevir last july cite potentially dangerous
755,MRK,hot biotech stock achillion pharmaceutical achn be midday trading stock market today analyst find more support prospect buyout candidate baird brian skorney note merck mrk official tender offer statement friday indicated be bidder idenix pharmaceutical idix accept merck bid last week skorney view mean somebody still prowl nucleoside hepatitis drug achillion have company draw many similarity idenix asset perspective have only unpartnered nuc left development make attractive target write research note friday skorney also write achillion prospect develop oral hep cure be dim pipeline have be slow various issue even gilead science gild abbvie abbv steam ahead own regimen maintain outperform rating set price target reflect more modest expectation maxim target set earlier week average price target stock be accord thomson follow amy reeve twitter ibd_areeve
756,MRK,stock future be positive not much ahead wednesday open
757,MRK,dow future hold point fair market value nasdaq future be ahead point future cling advance small cap lag russell index point
758,MRK,stock market today be ears federal open market committee wrapped day meeting policy announcement afternoon consensus appear expect further taper change target interest rate
759,MRK,day other economic news be relatively thin current account deficit expand first quarter vs revise deficit fourth quarter balance measure transaction other country rise gdp vs
760,MRK,heavyweight headline do little stir stock premarket trade
761,MRK,amazon com amzn rise less ahead press event schedule seattle today company be expect introduce smartphone partnership share be fraction open amazon have be scoop deep consolidation january
762,MRK,german chemical pharmaceutical giant bayer bayry be flat report have sign loan acquire consumer care business new jersey base merck mrk merck share be also unmoved
763,MRK,adobe system adbe bolt higher surprise increase fiscal second quarter earning maker software program include photoshop acrobat reader end tuesday buy point month cup base
764,MRK,furniture maker la boy lzb drop narrowly top fiscal fourth quarter earning expectation stopping short estimate revenue line stock have be unable climb key level support start right side month base
765,MRK,overseas china market finished lower second day tokyo nikkei gain still work take back ground lose monday session datum show sharp drop export europe stock be narrowly higher midday
766,MRK,dollar ease euro strengthen vs yen oil continue bob barrel natural gas be firm british thermal unit gold trade flat stock future be positive not much ahead wednesday open dow future hold point fair market value nasdaq future be ahead point future cling advance small cap lag russell index point stock market today be ears federal open market committee wrapped day meeting policy announcement afternoon consensus appear expect further taper change target interest rate day other economic news be relatively thin current account deficit expand first quarter vs revise deficit fourth quarter balance measure transaction other country rise gdp vs heavyweight headline do little stir stock premarket trade amazon com amzn rise less ahead press event schedule seattle today company be expect introduce smartphone partnership share be fraction open amazon have be scoop deep consolidation january german chemical pharmaceutical giant bayer bayry be flat report have sign loan acquire consumer care business new jersey base merck mrk merck share be also unmoved adobe system adbe bolt higher surprise increase fiscal second quarter earning maker software program include photoshop acrobat reader end tuesday buy point month cup base furniture maker la boy lzb drop narrowly top fiscal fourth quarter earning expectation stopping short estimate revenue line stock have be unable climb key level support start right side month base overseas china market finished lower second day tokyo nikkei gain still work take back ground lose monday session datum show sharp drop export europe stock be narrowly higher midday dollar ease euro strengthen vs yen oil continue bob barrel natural gas be firm british thermal unit gold trade flat
767,MRK,israeli specialty drug giant teva pharmaceutical industry teva say tuesday agree buy privately hold labrys biologic gain migraine drug expect be blockbuster teva agree pay upfront labrys milestone payment labrys drug lbr work way approval process lbr midstage
768,MRK,even re not biotech pharma investor ve probably catch earful news lately virus call hepatitis last december record breaking launch gilead science gild wonder drug sovaldi controversy price tag merck mrk recent buyout formerly neglected biotech idenix pharmaceutical idix
769,MRK,bristol myer squibb bmy report stellar result clinical trial advanced melanoma monday stock fall more stock market today wall street digest weekend filled cancer news annual american society clinical oncology asco meeting chicago bristol report year survival rate patient take immuno oncology
770,MRK,merck mrk seek add potential new blockbuster drug disease fight arsenal take cancer hepatitis monday drugmaker present result phase trial pembrolizumab cancer treatment american society clinical oncology meeting chicago study show patient advanced melanoma have spread elsewhere
771,MRK,dow jone component merck mrk jump month high monday strong datum cancer drug keytruda melanoma share nektar therapeutic nktr go free fall combination bristol myer squibb bmy stock market today merck pop close outperform broader dow jone industrial average be bristol fall finish share pharmaceutical company broadly lift fraction merck follow keytruda treat patient several year pair test cancer didn worsen progress melanoma patient complete year treatment cancer drug metric be take median month follow get newsletter deliver inbox more info product service privacy policy term usegeorgina long co medical director melanoma institute australia note keytruda have already show bristol yervoy advanced melanoma patient cancer drug also show persistent tumor ability follow test say written statement re now see ongoing effectiveness patient complete protocol specify year keytruda treatment well additional tumor activity patient progress first course treatment complete second course treatment say study call keynote merck look keytruda bristol yervoy melanoma drug median follow month overall survival rate be keytruda treat patient drop receive yervoy overall keytruda patient respond treatment vs yervoy patient merck say news release never receive treatment year overall survival rate be treat keytruda yervoy respectively tumor shrink keytruda treat patient yervoy treat patient test call keynote look melanoma patient median follow month include continue receive keytruda overall response rate be patient never be treat estimate year overall survival rate be patient never treat group melanoma study keytruda prove safe study merck test keytruda patient previously treat form lung cancer overall response rate be improve patient tumor have more protein call pd new datum keytruda small cell lung cancer underscore merck be pursue broad clinical development program type lung cancer cheng vice president oncology clinical research merck research laboratory say statement response also appear durable nearly quarters patient continue respond month longer merck say news release median cancer didn worsen progress month month cancer didn worsen patient respectively nektar tank cancer drug combine bristol show drop effectiveness later part study bristol nektar combine drug nktr opdivo respectively patient stage melanoma regimen shrink tumor never treat patient stage melanoma effectiveness drop second part study drug opdivo likely work better patient have more protein call pd study patient protein still respond regimen response rate patient protein be better jmp analyst konstantino aprilakis boost price target loxo oncology loxo firm present datum caner drug saturday be far expectation respect effectiveness safety phase study loxo initially pop share dip recent action loxo study cancer involve mutation ret gene be know ret fusion positive cancer loxo drug loxo have overall response rate improve response rate unveil mid view effectiveness datum present loxo exceedingly impressive well own expectation street aprilakis say note further safety profile present be clean be anticipate give remarkable therapeutic effect report related chart read basic buy point mark time real invest stock free new apps aim basic sell stock
772,MRK,dow stock lead monday early action earning news medical datum release factor open trade dow jone industrial average climb nasdaq composite future open merck mrk loxo oncology loxo be big early mover iqiyi iq baozun bzun step early gain china base stock palo alto network panw dell technology dvmt advanced report quarterly result asian stock market book strong gain monday japan tokyo nikkei pop feel uplift friday payroll report dip yen boost export stock hong kong hang seng index muscle also ride positive sentiment market also climb weekend stalemate china trade negotiation china base stock trading iqiyi jump early action netflix video stream service spun baidu march surge more friday gain left share extend pair ipo basis march ipo price get newsletter deliver inbox more info product service privacy policy term useibd stock baozun add open trade week advance left commerce technology provider extend be buy point clear third stage cup base baidu lead nasdaq gain ibd leaderboard name alibaba group holding baba nothced gain alibaba remain buy range double bottom base buy point merck power lead dow company sunday release datum show immuno oncology drug keytruda help patient advanced lung cancer live longer chemotherapy loxo oncology bolt higher monday premarket trade stamford conn base drug maker report saturday experimental cancer drug loxo shrink tumor nearly patient specific genetic mutation merck loxo be many company present trial datum american society clinical oncology annual meeting chicago ibd stock palo alto jump early action security software leader report forecast fiscal third quarter earning revenue palo alto have pre announce revenue booking result late friday also say former softbank sftby president nikesh arora replace mark mclaughlin chairman effective june mclaughlin move vice chairman role dell technology swung investor dig first quarter report stock be sit week advance buy point cup base september ipo apple aapl amazon com amzn microsoft msft gain monday open score new close high friday apple lead group gain google parent alphabet googl rise stock post strong volume gain thursday friday end buy point month double bottom base relative strength line be likely be key indicator here hover just new high last week see move new high ahead stock economic calendar get slow roll monday april factory order datum be due commerce department et service purchasing manager index be set release tuesday first quarter cost productivity number be tap wednesday also ibd stock be buy range nowfang stock apple strengthen be buy now ibd stock day chinese internet giant power buy big picture stock open strong never look back
773,MRK,kris bakowski be diagnosed alzheimer disease georgia resident feel relieve finally put name fog be slowly envelop brain even be viable alzheimer treatment month forget own phone number have trouble colleague name mapping route home work become chore day find alone mall recollection be get biopharma company believe be able help soon analyst say biogen biib be first crack code disease modify alzheimer treatment slow disease progression indeed biogen tokyo base eisai announce late thursday phase test alzheimer drug slow progression disease month news send biogen stock soar more point friday novartis nvs roche rhhby amgen amgn other also be develop potential alzheimer drug number development stage biotech company victory be not certain number big pharma company include merck mrk eli lilly lly johnson johnson jnj have be road abandon plan alzheimer treatment least expert see success next decade wouldn come too soon bakowski other alzheimer patient get newsletter deliver inbox more info product service privacy policy term usebakowski now have be blog alzheimer experience year blog post alzheimer association describe month testing lead diagnosis subsequent relief hopeful cure son lifetime family isn so optimistic husband liken titanic ship be sink son be go survive wasn write son reflect be mother be death row innocent crime potential alzheimer market be massive estimate american be live alzheimer other form dementia way intervene alzheimer association expect cost care person disease hit today dollar be estimate bakowski many expert be hopeful privately hold proclara bioscience be cadre biotech company aim develop alzheimer treatment chief medical officer david michelson call field pretty vibrant michelson have hold position merck lilly say steady drumbeat bad news alzheimer treatment reflect not so much failure affect specific target brain issue such side effect specific test recently speak webinar host endpoint news lot really tremendous work ongoing enable new approach be become possible generate promising new target say be actually very hopeful optimistic next year hold research alzheimer several drug have be approve treat dementia alzheimer type include eisai namenda allergan agn treat symptom alzheimer disease neither cure disease elliot goldstein chief executive promis neurosciences count type treatment hand none slow progression disease tell investor business daily promis be also work alzheimer treatment trade toronto stock exchange doesn have sale earning yet goldstein previously work novartis be also develop alzheimer drug biogen strongest hope be drug now dub aducanumab goldstein predict drug come market aducanumab have high potential approval have show small improvement decline patient alzheimer symptom say biogen do not respond request comment article visit ibd stock checkup see biogen rate now key fundamental technical metric total biogen have potential alzheimer treatment pipeline aducanumab be farthest late stage study likely have datum analyst say biogen eisai thursday announcement involved drug know ban test involved patient diagnosed early alzheimer company say drug antibody achieve statistical significance key predefined endpoint evaluate effectiveness month biogen stock jump close have surge intraday high gain point still messy field biogen stock plunge valentine day year add new patient ongoing study aducanumab move catch investor guard also week merck scrap late stage alzheimer treatment study risk look likely outweigh benefit be volatile area canaccord analyst sumant kulkarni tell investor business daily have be very spectacular failure past component investor think next work help stock point view then again say nothing else have work past trouble alzheimer treatment research be scientist aren exactly sure cause disease prevailing theory ty disease buildup toxic plaque brain happen protein call beta amyloid structurally change beta amyloid be sticky clump together become plaque pharmaceutical company be look approach beta amyloid essentially boil remove prevent bace inhibitor work prevent buildup monoclonal antibody biogen aducanumab aim remove promis goldstein note adverse event also be sidestep alzheimer treatment come side effect know amyloid related imaging abnormality aria refer swell brain goldstein say promis alzheimer treatment set begin clinical study doesn cause mizuho analyst salim sy say possible help patient get past aria common idiom industry be don get aria be really treat plaque tell ibd then trouble determine study be design well proclara michelson say first evidence show drug engage intend target beta amyloid second patient be proven actually have alzheimer third study be big appropriate duration turn look back history aren many study many drug have be study way really fulfill element say argue only study have hit design goal be merck now fail bace inhibitor know verubecestat biogen aducanumab february merck scrap study alzheimer treatment patient prodromal very early stage alzheimer disease year earlier say same drug have virtually chance find positive effect patient mild moderate form disease meanwhile field be thin stop midstage test bace inhibitor group patient liver safety concern january pfizer pfe stop research alzheimer parkinson disease lilly alzheimer treatment failure late be acutely painful company monoclonal antibody call solanezumab lose late stage study last study be patient mild form alzheimer promis alzheimer treatment bound several toxic misfold protein cause alzheimer goldstein say function theory be other target alzheimer disease outside beta amyloid drug be also testing theory tangle protein call tau be root cause privately hold unite neurosciences hope come vaccine alzheimer goal be use drug treatment early alzheimer preventive measure physician administer drug too late rescue brain unite neurosciences chief medical officer ajay verma tell investor business daily verma background be biogen direct development drug include aducanumab be merck novartis verma expect aducanumab get approval several sell side analyst model likelihood aducanumab appease food drug administration verma see possibility aducanumab be expensive be first treatment slow progression alzheimer disease think challenge be be solution just rich say verma ultimately expect solution treat alzheimer disease lie combination drug be key treat cancer hiv cardiovascular disease metabolic disease high cholesterol say intervention number alzheimer patient triple james hendrix say endpoint news webinar hendrix be director global science initiative alzheimer association need better therapy need sooner rather later hendrix say alzheimer treatment study be tricky unite neurosciences verma say barrier blood brain make get drug brain difficult animal model aren particularly predictive study run long period time further complicate matter science isn sure stage be best treat reason be center approval rate fda alzheimer treatment accord paper present hendrix industry average be research be improve hendrix say scientist be aware potential impact beta amyloid tau well number approach target different stage end be enough alzheimer treatment just delay begin disease several year say be possible delay onset die something else say also stock market forecast next month build long term profit stock take gain robotic surgery revolution be just get term retirement investing strategy etfsnew option strategy limit risk earning
774,MRK,tech stock small cap stock be driver seat midday friday stock market digest strong job growth june well start tariff chinese import early gainer nasdaq include biogen biib share biotech giant soar company report positive phase trial datum alzheimer drug nasdaq composite lead way russell small cap index add rise dow jone industrial average picked mcdonald mcd merck mrk walgreen boot alliance wba lead blue chip index gain more stock market rally be fuel part better expect job growth june economy create job top consensus estimate unemployment rate rise stock market result today tech service company mantech international mant jump nearly help positive comment suntrust robinson humphrey semiconductor space advanced micro device amd be top gainer marketsmith growth more still buy range conventional entry netflix nflx be heavy volume gainer netflix be member leaderboard be best perform fang stock friday facebook fb also do well heel big price target hike thursday btig ibd name rise more include lululemon athletica lulu share be nearly bank america raise price target get instant access more trading idea exclusive stock list ibd proprietary rating only also jpmorgan citigroup well fargo kick earning season investing action planbreakout watch ipo growth near buy zonea trade tariff start bite canada top apparel stock hold
775,MRK,start stock dow jone industrial average djia now include america largest company wide range industry include apple aapl exxon mobil xom intel intc nike nke goldman sachs gs general electric ge have be only remain original dow stock be just replace walgreen boot alliance wba conjunction nasdaq composite dow jone index dow stock serve bellwether general market american economy help investor gauge current environment future outlook bookmark page ongoing coverage dow stock benchmark index scroll see list component stock dow jone industrial average index get newsletter deliver inbox more info product service privacy policy term useclick symbol get latest news stock quote company get instant access more trading idea exclusive stock list ibd proprietary rating only related best stock buy stock be ibd big cap
776,MRK,rumore buyout drugmaker tesaro tsro swiss drugmaker roche rhhby send share tesaro soar wednesday make little sense strategic standpoint analyst say rbc analyst kennen mackay see combination unlikely give see lack compelling strategic rationale tesaro make ovarian cancer drug call zejula compete rival drug astrazeneca azn clovis oncology clvs mackay note tesaro guidance zejula sale be trouble rivalry grow ovarian cancer drug sale expect tesaro lower full year outlook make potential acquirer hesitant say report client spanish intereconomia com say late tuesday roche be interested acquire tesaro announce plan buy foundation medicine fmi site report roche announce acquisition tesaro next few day get newsletter deliver inbox more info product service privacy policy term useat close bell stock market today tesaro stock rocket stock pop much earlier trading roche lift same time biotech stock rise less further tesaro already have ongoing collaboration dow jone component merck mrk treat form breast cancer ovarian cancer also partner johnson johnson jnj develop zejula treat prostate cancer roche other hand be collaborate roche rival clovis treat gynecological tumor clovis make ovarian cancer drug call rubraca duo be testing rubraca roche immuno oncology drug call tecentriq roche focus develop acquire best class molecule see rubraca line effectiveness superior safety vs zejula potentially better fit context strategy zejula mackay say tesaro too already have partnership zejula market outside detract value acquire global pharmaceutical company roche flip side roche tesaro do have ongoing clinical collaboration look roche tecentriq zejula bladder cancer researcher be also combine zejula roche drug avastin form ovarian cancer related do spot major market top easy look heavy basic sell stocklooking next nvidia start simple routine
777,MRK,stock higher wednesday open telecom entertainment stock continue respond tuesday district court ruling allow time warner twx merge sector affected ruling market set hold pattern ahead afternoon policy announcement federal reserve st century fox fox lead early advancer time warner discovery communication disca cbs cbs also make strong related move comcast cmcsa block hrb post heaviest early decline dow jone industrial fought hold fractional gain nasdaq composite gain almost federal judge washington late tuesday throw justice department effort block acquisition time warner judge say doj case echo promise make donald trump presidential campaign be too weak consider appeal ruling throw open door broad range restructure telecom entertainment name struggle adapt competition bring netflix nflx facebook fb alphabet googl google other huge new medium venue update story other market coverage visit stock news today meanwhile disney inched disney inked deal december acquire bulk st century fox comcast also want asset investor anticipate bidding war now time warner deal have go response comcast drop fox vault higher result st century fox discovery communication post largest premarket gain nasdaq issue fox time warner cbs lead block dive bottom disappointing quarterly result comcast hold next largest decline comcast be worst performer nasdaq stock premarket trade dow intel intc goldman sachs gs set early lead apiece merck mrk tick higher food drug administration agree priority review possibly expand permissible age range merck human papillomavirus vaccine gardasil merck share be buy range buy point bottom base fang stock tech leader netflix jump ibd leaderboard stock be extend flat base follow ibd list twitter twtr again swung early lead open stock be work fourth straight weekly gain clear buy point cup handle base share be more place stock profit take zone pivotal software pvtl blast higher send april ipo take new high pivotal report tuesday close fiscal first quarter revenue blast past analyst expectation loss be less forecast san francisco base company also hoist second quarter earning revenue guidance estimate stock be extend clear ipo base june end tuesday april ipo share korn ferry international kfy jetted ahead follow fiscal fourth quarter report staffing service firm result top analyst expectation particularly revenue line management issue strong first quarter earning revenue guidance announce rebrand plan collect company sub brand single name share be extend clear flat base march china base bitauto holding bita jump online auto shopping marketing service turn first quarter earning slightly consensus target revenue top view wide margin stock end tuesday april low attempt climb right side deep month consolidation block careen lower accounting firm report fiscal fourth quarter sale earning comfortably analyst target full year revenue guidance be just consensus expectation however company say discount pricing affect top line performance stock have be climb right side month base bank financial stock other interest rate sensitive portion market kick action late wednesday session depend outcome federal reserve policy announcement come et press conference begin market have most part baked expectation quarter point rate hike putt fed target hint fed strategy include more rate increase remainder year cause adjustment shift tone late session oil price also factor wednesday action pending result weekly datum due energy information administration et weekly datum american petroleum institute tuesday show lighter anticipate barrel decrease oil inventory vs forecast barrel decline gasoline supply unexpectedly rise barrel west texas intermediate future trade lower ahead open dip just barrel related big picture stock index hit record high buy time warner court ruling ignite comcast disney big be time warner ruling even stock be rallyingat time warner ruling set big medium stockstesla help nasdaq gain twitter lead growth stock shinewhen buy starbucks shake shack value pyramid
778,MRK,astrazeneca azn eli lilly lly become latest tuesday series pharmaceutical company scrap study potential alzheimer disease treatment appear unlikely work drugmaker discontinue phase study drug call lanabecestat independent datum monitoring committee predict lanabecestat miss goal study early alzheimer disease mild alzheimer dementia complexity alzheimer disease pose most difficult medical challenge time lilly research lab president daniel skovronsky say written statement be grateful contribution study participant family lanabecestat belong class drug call bace inhibitor work prevent buildup substance call beta amyloid plaque brain researcher believe toxic substance be center alzheimer disease get newsletter deliver inbox more info product service privacy policy term useastrazeneca lilly be far only pharmaceutical company frustrated pursuit alzheimer disease treatment dow jone component merck mrk end study drug verubecestat mild moderate early alzheimer disease earlier year fellow dow jone stock pfizer pfe abandon research treatment alzheimer parkinson disease johnson johnson jnj stop study bace inhibitor patient late stage alzheimer disease liver worry lilly stock crash drug miss goal phase study lilly study drug solanezumab patient mild alzheimer disease market be increasingly look biogen be work monoclonal antibody drug know aducanumab work remove beta amyloid plaque brain analyst expect biogen have datum key study lilly say tuesday doesn expect significant cost associate decision end study potential alzheimer disease treatment reaffirm guidance midterm guidance remainder decade be commit ensure finding be used inform further research alzheimer community give importance find treatment disease say astrazeneca spokesperson menela pangalos statement stock market today lilly sank fraction close share be consolidate buy point astrazeneca lose collectively share pharmaceutical company be flat related invest stock free new apps aim buy stock ahead earning report be inflation do matter fed
779,MRK,share dow jone component merck mrk pop early wednesday drugmaker say regimen used blockbuster drug keytruda improve survival lung cancer treatment stock market today merck share climb close stock easily outperformed dow jone industrial average sank fraction share other pharmaceutical company be lift nearly merck test keytruda chemotherapy patient lung cancer have spread other body part patient never receive treatment regimen outperformed chemo alone improve overall survival progression free survival lung cancer treatment first line treatment keytruda combination traditional chemotherapy have now demonstrated improve survival benefit compare chemotherapy alone metastatic lung cancer patient squamous histology merck research laboratory president roger perlmutter say prepared statement get newsletter deliver inbox more info product service privacy policy term company have already submit application food drug administration approval lung cancer treatment also plan unveil further datum american society clinical oncology annual meeting next month merck be just several lead pharmaceutical company used immuno oncology treat cancer immuno oncology medicine immune system fight cancer bristol myer squibb bmy roche rhhby be also field related much volume look stock long term retirement investing strategy etfsstill rule stock investor always cut loss short
780,MRK,glaxosmithkline gsk potential blockbuster shingle vaccine have encourage start first quarter chief executive emma walmsley say wednesday glaxo stock topple broader revenue profit lag vaccine call shingrix gain approval october adult age older analytic firm clarivate analytic list shingrix dozen drug launch year be expect become blockbuster next year quarter shingrix sale be british pound roughly analyst have call just pound reuter say drug be see rivale merck mrk zostavax be strong focuse commercial execution encourage start most recent new product launch shingrix chronic obstructive pulmonary disease drug trelegy hiv drug juluca walmsley say prepared statement get free access ibd digital april
781,MRK,get premium stock list pass fail stock rating more start total sale adjust profit lag expectation glaxo share fall stock market today glaxo fall close earlier share touch week low trading cup formation buy point first quarter glaxo report adjust income cent share sale just north adjust profit lag expectation cent sale grow year earlier period miss view glaxo note be significant currency impact quarter pharmaceutical sale be currency vaccine sale come consumer health care unit bring roughly glaxo be now look see generic version asthma inhaler advair gain approval firm guide full year earning growth constant currency basis otherwise glaxo see earning flat related chart read basic buy point mark time real invest stock free new apps aim buy stock ahead earning report
782,MRK,regeneron pharmaceutical regn experimental cancer drug look legit treat form lung cancer analyst say thursday meaning soon rival dow jone merck mrk bristol myer squibb bmy be work cancer drug call pd checkpoint immuno oncology drug immune system identify fight tumor cell merck bristol already have drug approve call keytruda opdivo respectively regeneron appear be hot tail early stage study regeneron test drug cemiplimab previously treat patient call small cell lung cancer overall tumor shrank patient have disease control regeneron unveil datum late wednesday ahead american society clinical oncology annual meeting june piper jaffray analyst christopher raymond call datum biggest surprise meeting cemiplimab have long be also run immuno oncology space get newsletter deliver inbox more info product service privacy policy term use compare well overall response rate approve pd keytruda opdivo high teen say note grant be small number do think investor take interest today action stock market today regeneron climb close merck dip bristol add leerink analyst geoffrey porge note overall response rate cemiplimab specific group patient be line rate keytruda opdivo phase study cemiplimab also look safe patient result generate small cohort be encourage sign cemiplimab have potential compete toe toe establish product market say report client rbc analyst kennen mackay be less surprised regeneron success cemiplimab small cell lung cancer proof concept come expect say note biotech company test cemiplimab small group patient study support cemiplimab potential have line potentially better effectiveness leader keytruda opdivo mackay add regeneron be also testing cemiplimab phase phase study patient advanced form skin cancer call cutaneous squamous cell carcinoma overall response well duration response improve update datum vs time last year leerink porge say believe cemiplimab be well track receive expedite approval previously overlooked indication use carve least initial niche competitive pd pd cancer drug field say porge see likelihood regeneron gain approval cemiplimab advanced type skin cancer expect sale cemiplimab use peak sale keep price target regeneron stock food drug administration review cemiplimab cutaneous squamous cell carcinoma october review date help regeneron partner sanofi sny be first market rbc mackay say related much money do need start investing start here find best stock buy be inflation do matter fed
783,MRK,retail stock outperformed monday technology stock weren far fang stock apple aapl amazon com amzn netflix nflx hit new high nasdaq composite score time close high close dow jone industrial average nasdaq composite rise add small cap lag russell
784,MRK,dow jone industrial average lead stock market advance early monday social medium giant facebook fb fall new york time report datum sharing agreement update story other market coverage visit stock news today dow jone industrial average rise tech heavy nasdaq follow gain respectively dow stock merck mrk pace gainer advance morning trade company report positive result keytruda drug melanoma trial stock be stage strong rebound strongly day line recent test company report earning palo alto network panw reversed lower fall morning trade monday cybersecurity firm report better expect fiscal earning appoint new chairman chief executive share remain well extend cup base buy point be hold day move average line get newsletter deliver inbox more info product service privacy policy term close top software stock coupa software coup lead hsa provider healthequity hqy release earning result analyst expect ipo leader coupa lose cent share revenue share be barely extend flat base entry accord marketsmith chart analysis stock moved stock relative strength line be approach fresh high healthequity be expect report ep cent revenue share be modestly extend flat base buy point share fall early monday fang stock facebook decline new york time report company make agreement least device maker provide access user personal information share be buy range buy point top top growth stock chinese stock yy yy moved work way right side potential base formation share remain week high day streak downside viper energy partner vnom faltered second straight day monday share be key day line analyst stifel nicolaus downgrade energy stock buy hold meanwhile micron technology mu fall share be last day cup shape entry stock trigger loss cut sell rule related apple big show broadcom earning lead investing action planibd stock day chinese internet giant power buy zonethese top stock elite screen be buy range nowthese top stock buy zone include fang facebookdow jone industrial average dow stock news analysis
785,MRK,dow jone future rise modestly monday morning future nasdaq future apple aapl today begin worldwide developer conference palo alto neworks panw healthequity hqy coupa software coup report quarterly earning meanwhile merck mrk loxo oncology loxo report positive cancer drug datum weekend annual asco meeting nasdaq composite end last week multus month high clear recent sideway trend dow jone test day line last week remain range apple be world most valuable company be top component dow jone index nasdaq composite apple be slightly extend recent be coupa software palo alto network healthequity loxo oncology be well extend have relative strength line track stock performance vs index record high merck be try bounce back year low dow jone future advanced vs fair value future rise nasdaq future be fair value get newsletter deliver inbox more info product service privacy policy term usecommerce secretary wilbur ross conclude day trade talk beij sunday little progress china warn win buy more good have tentatively agree do last month president donald trump commit not impose new tariff chinese good trump administration surprised chinese official continue move forward plan slap tariff chinese product mostly tech telecom gear china have warn ll retaliate dollar dollar last week trump administration impose steel aluminum tariff european union canada mexico quickly announce retaliatory duty good apple unveil augment reality software well new operate system mobile macs analyst think apple tout low end phone cheaper homepod smart speaker apple rise friday back just chase zone buy point apple stock also have form week tight pattern stock move exist holder choose add more share apple stock hasn fared well wwdc week apple wwdc share fall apple stock fall wwdc wwdc share rise open monday stock market trading suggest possible buy opportunity week tight late friday cybersecurity company report fiscal third quarter revenue rise billing climb analyst have expect revenue palo alto network also name nikesh arora new ceo chairman effective june succeed mark mclaughlin be vice chairman arora be president softbank previous be chief business officer google googl search giant enjoy explosive growth palo alto network stock rise early monday share be well extend earlier year company now release third quarter result stock market open monday have previously plan report close analyst expect earning share rise cent better expect revenue suggest palo alto top ep view company have top view least cent last quarters nation second largest health saving account custodian announce earning late monday analyst expect revenue rise ep cent healthequity stock be modestly extend base base formation clear early coupa cloud base software help business control spending analyst expect share loss widen cent vs cent year earlier revenue climb share close friday slightly extend buy point coupa stock be mini consolidation week stock climb early monday dow jone drug giant merck biotech loxo oncology be many company present trial datum american society clinical oncology annual meeting chicago merck release datum show immuno oncology drug keytruda help patient advanced lung cancer live longer chemotherapy keytruda have stand vs bristol myer squibb bmy drug opdivo well other rival treatment monday merck report keytruda do well melanoma trial loxo oncology say experimental cancer drug shrank tumor patient specific genetic mutation merck share have rebound year low early april be still well week high loxo oncology be well extend earlier year merck stock rise premarket loxo shot also ibd stock be buy range nowfang stock apple strengthen be buy now ibd stock day chinese internet giant power buy big picture stock open strong never look back
786,MRK,biogen biib benefit fear miss rally close pivotal datum alzheimer disease treatment aducanumab analyst say week upgrade stock canaccord analyst sumant kulkarni update biogen buy rating hold trim price target new price target be base conservative expectation sale spinal muscular drug spinraza say report client acknowledge call be early especially multiple sclerosis spinraza dynamic play come quarters say say potential stock benefit fear miss rally more datum point crop biogen high stake alzheimer disease pipeline stock market today biogen slip close biogen stock be consolidate buy point share other biotech company collectively lift get newsletter deliver inbox more info product service privacy policy term usebiogen be work number alzheimer disease treatment include aducanumab drug partner eisai call ban aducanumab datum isn expect meanwhile investor aren hopeful datum month study ban third quarter month study ban have impact expectation aducanumab say so far aducanumab have show promise kulkarni see chance aducanumab get approval treat alzheimer disease note stock tend be volatile alzheimer news aducanumab have be largely devoid scare thus far kulkarni say february biogen increase size study aducanumab patient send biogen share diving same time dow jone component merck mrk scrap study alzheimer disease treatment still alzheimer disease market be large enough biogen benefit fear miss case positive emerge say kulkarni see multiple sclerosis drug sale accounting biogen total revenue risk segment include rivalry roche rhhby drug ocrevus biogen get royalty sale drug pricing concern risk headwind still remain note biogen prescription share least appear have be stabilize say continue monitor trend closely be also mindful be too early ascertain effect initiative such value base pricing multiple sclerosis be often cite expensive condition treat general frequency price increase drug have slow twice year once annually further generic like teva pharmaceutical teva eventually take share now however biogen look safe multiple sclerosis patient tend stick brand medicine don seem see doctor often kulkarni say sale spinal muscular atrophy drug spinraza be choppy load dose schedule patient receive load dose quick succession move maintenance dose month mean sale patient peter move maintenance dose be view investor be generally catch surprise fast launch be now somewhat more pessimistic product give most recent quarterly performance say further novartis nvs compete now have acquire spinal muscular atrophy player avexis related much volume look stock long term retirement investing strategy etfsstill rule stock investor cut loss short
787,MRK,drug treatment bristol myer squibb bmy merck mrk design battle lung cancer top expectation recent test company say monday bristol share plunge merck combination prove be stronger firm test drug harness patient immune system fight cancer regimen be study patient common form advanced lung cancer patient have never be treat cancer have spread regimen bristol immuno oncology drug opdivo yervoy cut risk cancer progression death compare chemotherapy merck regimen however used combination keytruda chemotherapy reduce risk death stock market today bristol tank close merck other hand lift company unveil result american association cancer research annual meeting chicago get newsletter deliver inbox more info product service privacy policy term usebristol focuse patient least mutation cancer know high tumor mutational burden tmb patient high tmb cancer didn worsen year treat regimen just chemotherapy treat patient have same result test also look much protein call pd be patient tumor bristol opdivo merck keytruda class drug call pd inhibitor researcher believe drug work better patient tumor have lot pd protein bristol note investigator find progression free survival benefit patient regardless pd status merck also find overall survival progression free survival benefit regimen much protein patient tumor have overall patient respond bristol regimen ahead report chemotherapy patient year treatment patient opdivo yervoy be still respond therapy vs just patient treat chemo lead investigator matthew hellmann note study call checkmate be first combine pair immuno oncology drug lung cancer patient high tmb result demonstrated opdivo yervoy provide frequent deep durable response compare chemotherapy patient small cell lung cancer have high tmb say prepared statement investigator see severe life threaten side effect patient treat regimen vs chemotherapy patient merck focuse patient tumor have high medium level pd protein tumor investigator see improvement overall survival progression free survival regardless patient pd status median month follow keytruda chemotherapy reduce risk death vs chemo alone patient treat chemo alone live median month patient receive keytruda chemo regimen live long enough median overall survival couldn be determine treat regimen have reduction risk cancer worsening death vs chemotherapy alone receive keytruda regimen live median month cancer progress compare month chemo alone year treatment receive combination be alive cancer have not worsen just chemotherapy treat patient have same result overall patient respond keytruda chemo regimen compare chemo investigator note serious life threaten side effect patient receive keytruda chemotherapy regimen vs treat chemo alone be adverse event cause merck note roger perlmutter president merck research laboratory expect result change treatment plan lung cancer result trial have potential change treatment paradigm patient squamous small cell lung cancer first line set include patient tumor be pd negative be untested say written statement related long term retirement investing strategy etfsnew option strategy limit risk buy stock ahead earning report
788,MRK,share dow jone component merck mrk pop tuesday upgrade lung cancer treatment trounce rival regimen bristol myer squibb bmy morgan stanley analyst david risinger now expect merck take lion share first line lung cancer market first medication used treatment diagnosis largest cancer market drugmaker merck be currently run oncology clinical trial risinger write note client keytruda additional cancer be used combination chemotherapy be adopt earlier line therapy monday merck bristol layer result study testing immuno oncology drug small cell lung cancer merck combine keytruda chemotherapy reduce risk death untreated lung cancer patient bristol drug opdivo yervoy together cut risk cancer progression death similar group patient compare chemo alone get newsletter deliver inbox more info product service privacy policy term useon stock market today merck gain close earlier share rise much touch high last see first week february bristol dip close risinger boost price target merck also upgrade stock overweight equal weight rating expect keytruda bring sale grow keytruda be set sustain lead first line lung cancer say merck regimen keytruda chemo reduce risk death more half result be consistent patient regardless level pd protein tumor amount pd be thought predict well drug work bristol test drug patient tumor have more mutation biomarker call high tumor mutational burden tmb risinger note early result bristol show drug have overall survival rate bristol survival figure improve longer follow think be unlikely match merck impressive result say related look best stock buy watch start herenew option strategy limit risk buy stock ahead earning report
789,MRK,do novartis nvs amgen amgn merck mrk pfizer pfe celgene celg gilead science gild baxter international bax eli lilly lly have common have licensing other business relationship ligand pharmaceutical lgnd ligand be recently add ibd list top growth stock be lead biotech stock
790,MRK,ligand pharmaceutical lgnd stock break tuesday touch record high defy broader downturn see biotech company stock dip collective fraction close bell stock market today ligand stock gain close share break cup base buy point stock have remain black past trading day meanwhile share biotech company close analyst be bullish ligand have licensing deal biotech company pharmaceutical company bigger client include novartis nvs amgen amgn celgene celg gilead science gild also work dow jone component pfizer pfe merck mrk get newsletter deliver inbox more info product service privacy policy term useligand be ibd top grow stock firm acquire early stage technology necessary drug development then license platform other pharmaceutical company stock have ibd composite rating best possible meaning perform top stock term key growth metric ligand stock lead biotech group ahead supernus pharmaceutical supn also have cr first quarter ligand crushed expectation top guidance view currently analyst have buy rating ligand stock accord marketbeat com have sell rating share be second time ligand stock have break month share hit entry flat base march related much volume look stock long term retirement investing strategy basic analyze stock cup handle
791,MRK,sale merck mrk powerhouse cancer drug keytruda soar triple digit first quarter share dow jone component dip tuesday lower expect total revenue stock market today merck dip close fellow dow stock pfizer pfe also report mixed quarter early tuesday share fall finish cfra analyst jeffrey loo remain bullish merck chance grow keytruda sale study call keynote combination keytruda chemotherapy reduce risk death lung cancer patient seemingly outperform rival regimen bristol myer squibb bmy datum trial cut risk death be impressive view loo say note client merck first quarter earning announcement boost price target merck keep hold rating get newsletter deliver inbox more info product service privacy policy term investor weren excited merck first quarter sale grow yet miss consensus poll zack investment research adjust profit advanced beat cent keytruda sale be grow year year nearly sequentially loo have forecast revenue keytruda sale other big ticket item include diabetes drug januvia janumet grow gardasil gardasil vaccine human papillomavirus latter bring represent growth cholesterol drug include zetia vytorin decline merck blame loss exclusivity zetia vytorin respectively merck guide adjust earning share midpoint beat analyst prediction sale be expect come midpoint sale outlook top analyst view related do spot major market top easy look heavy next nvidia start simple routinewhat be inflation do matter fed
792,MRK,stock close higher monday gain more end much reduce close bell market continue seek consistent direction nasdaq composite be much close higher cut gain more fourths end higher selling picked final minute trading dow jone industrial average climb merck mrk have largest percentage gain dow company keytruda drug extend life lung cancer patient late stage trial drug be already approve treat lung cancer patient merck share jump back day move average have long way go buy point appear volume fall compare friday total accord early computation decline stock outnumber advancer modestly nyse winner lead nasdaq get newsletter deliver inbox more info product service privacy policy term major index remain day move average be tentative bottom hold april lows russell be bell small cap benchmark meet resistance day move average last week monday rally be surprising early strength trade row china have not abate be new geopolitical worry president trump tweet imbalance auto tariff china tension middle east increase israel attack military base syrium follow news syrium used chemical weapon rebel trump suggest retaliate biotechs rise more group headline heavy day industry novartis nvs offer acquire avexis avxs ionis pharmaceutical ion be team astrazeneca azn liver disease treatment celgene celg be rumore be interested buy agio pharmaceutical agio avexis soar more agio jump other stock be little change chip stock also lead thank analyst comment evercore isi raise price target intel intc chip gear firm lam research lrcx call micron technology mu bargain current price micron share last week trigger round trip sell signal erase gain buy point double bottom base be now slightly day move average show support be critical keep stock fall further intel stock be try find support day move average lam trigger sell rule entry stock be compromise related jpmorgan citigroup earning tap be bank stock long term issuecrop chemical giant stock soar doj see approve bayer dealintel lam research get price target hike chip stock deem oversoldpalo alto vs apple not break support be sell signal
793,MRK,do lead pharmaceutical stock merck mrk abiom abmd abbvie abbv astrazeneca azn biogen biib have common be client medical software stock ipo veeva system veev lead mutual fund manager have take note veeva impressive client roster well company strong fundamental veeva have be
794,MRK,president trump offer plan friday reduce price costly ethical drug speech spur generally positive reaction pharmaceutical related industry biotech group be day top industry track ibd rise generic drugmaker rally group ethical drug stock bound drugstore be manage care wholesale drug supply meanwhile major equity index play small ball most friday session finished week smart gain ibd upgrade stock market current outlook uptrend resume thursday nasdaq composite rushed higher week lift apple aapl also post second straight weekly gain iphone giant halter session winning streak still close bullish week more top jump prior week unusually heavy volume recent rally have hoist apple much past new proper buy point very mild week double bottom base read latest update stock market action go stock market today landing page nasdaq composite edge lower inched nearly higher dow jone industrial average rally thank gain point more big pharma component merck mrk pfizer pfe unitedhealth group unh dow jone industrial component also rise merck be still try clear stubborn upside resistance long term day move average relative price strength rating mean merck be outperform only company ibd database past month small cap tick higher index be now more jan strong corporate earning more sign modest inflation valuation equity vs bond still offer reason be bullish stock rest year even compare earning yield yield baa corporate bond not year treasury bond stock market still look attractively value leo grohowski chief investment officer asset management giant bny mellon wealth management tell ibd interview not invest snapshot view look month even cool economy see year yield lower yield benchmark treasury year bond continue hover critical level finishing day grohowski forecast yield end year back apple megacap turnaround tech play be now trading roughly ideal buy point double bottom base try buy share more past correct entry so avoid get prematurely shake even large cap leader be prone testing even fall briefly point strong upward thrust price apple fundamental continue shine earning climb vs year level past quarters street see fiscal profit rise share mark slight acceleration growth apple be now almost clear first stage cup handle base entry jan ibd pharmaceutical play rejoin list premier growth stock supernus pharmaceutical supn blast higher volume jump nearly quadruple usual level straight session stock be now extend past correct buy point month cuplike base base supernus form roughly week downward slant handle lighter trade handle base represent final shakeout weak holder week huge expert treatment epilepsy adhd post leap first quarter earning cent share crush consensus estimate nearly sale increase quarterly record ipg photonic ipgp industrial laser maker oil gas play wildhorse resource development wrd also joined ibd recent session please follow saito chung twitter ibd_dchung additional commentary top growth stock breakout sell signal financial market related other stock be new ibd top growth screen check herelooking next nvidia follow simple easy way check ibd rating apple go here
795,MRK,eli lilly lly be try leapfrog dow jone stock merck mrk bristol myer squibb bmy acquisition cancer immunotherapy biotech armo bioscience armo industry observer say thursday drugmaker lilly be late game cancer immunotherapy brad loncar tell investor business daily loncar run several biotech stock index include cancer immunotherapy sector index contain armo loncar cancer immunotherapy exchange trade fund pop thursday leader be merck bristol myer squibb roche rhhby say re company have completely miss boat want play area have do something try leapfrog competition early thursday lilly make first big move cancer immunotherapy space area medicine drug immune system fight cancer lilly say pay share armo cash deal get newsletter deliver inbox more info product service privacy policy term usearmo share rocket close lilly stock rise fellow drug stock merck bristol rise less roche have failure early day colon cancer dip lilly expect deal close end second quarter armo late stage biotech go public january quickly pop be hot initial public offer loncar say note price early thursday indicate investor expect bid leerink analyst chang note acquisition price be premium armo close price wednesday initiate coverage stock outperform rating price target earlier year thursday downgrade armo market perform deal confirm investment thesis armo view read positively other emerge immuno oncology stock say be unclear other bidder emerge give short close date acquisition make sense pharmaceutical stock lilly try assert cancer immunotherapy space loncar say armo lead drug call pegilodecakin be know cytokine boost strength drug know pd inhibitor merck keytruda bristol opdivo earlier year bristol validate cytokine drug call nktr pay upfront partner nektar therapeutic nktr deal hit record upfront payment biotech loncar say now little surprise armo be be take loncar have consistently predict be big year biotech deal merger takeout year kick news celgene celg plan buy juno therapeutic sanofi sny bid bioverativ bivv ablynx ablx deal armo be little different say think have happened be middle terrible bear market say other hand be also good example large company eli lilly many have not be forefront innovation re have buy still lilly isn alone trail position cancer immunotherapy roche astrazeneca azn pfizer pfe have immuno oncology drug remain merck bristol be level own say cancer immunotherapy space desperately need good news say earlier year incyte incy drug know ido inhibitor fail late stage combination merck keytruda melanoma incyte pain extend other cancer immunotherapy stock background volatility remain cancer immunotherapy space loncar say key say be be different piece technology armo drug be different incyte drug know epacadostat news item set person mood say everybody be immunotherapy think overrate then deal happen cause opposite reaction have emerge technology go be roller coaster related chart read basic buy point mark time real tame volatile swing trade half positionlook next nvidia start simple routine
796,MRK,exelixis exel tank month low thursday combination drug big pharma giant roche rhhby fail late stage study hard treat colon cancer patient regimen test exelixis drug cotellic roche drug tecentriq patient hard treat form colon cancer have advanced spread cancer have progressed be intolerant prior chemotherapy regimen combination prove safe miss mark exelixis roche aim improve overall survival compare drug call regorafenib bayer bayry sell regorafenib stivarga colon cancer drug pre treat patient failure be yet roche cancer immunotherapy industry observer brad loncar tell investor business daily loncar run several biotech index tecentriq be similar rival drug merck mrk bristol myer squibb bmy get newsletter deliver inbox more info product service privacy policy term use be disappointing space maybe roche need do something creative get back lead position say reference eli lilly lly decision earlier day buy armo bioscience armo stock market today exelixis topple close earlier share plunge much roche dip broadly share biotech company lose pharmaceutical stock pop rbc analyst kennen mackay remain bullish exelixis cut price target keep outperform rating exelixis also make cabometyx kidney cancer drug expect be worth failure study call imblaze doesn change bullish cabo centric thesis exelixis mackay say note client be surprise earlier stage datum regimen cotellic single drug be strong say still even combination not much downside say cabometyx be approve kidney cancer food drug administration be also consider treatment liver cancer re buyer dip anticipate cabo growth well ahead street expectation say mackay believe street be mis modele cabometyx see total cabometyx sale kidney cancer vs street view piper jaffray analyst edward tenthoff be similarly bullish keep overweight rating exelixis reduce price target note failure colon cancer doesn impact study cotellic tecentriq roche zelboraf melanoma related do spot major market top easy look heavy basic sell stocksell take profit hold here be several guideline follow
797,MRK,eli lilly lly top street first quarter estimate tuesday unexpected strength diabetes drug early impact chemotherapy tie dow jone component merck mrk sale psoriasis drug taltz key growth product osteoporosis drug forteo lag expectation wholesale retail buy pattern lilly say press release still firm boost guidance first quarter beat evercore analyst umer raffat characterize good quarter lilly early trading stock market today lilly share tick close get newsletter deliver inbox more info product service privacy policy term first quarter lilly report adjust profit share sale rise respective metric top consensus analyst poll zack investment research adjust income share sale year lilly raise adjust earning forecast share revenue analyst expect adjust earning share sale late monday food drug administration advisory panel dealt lilly partner incyte incy setback panel opposed approve new rheumatoid arthritis drug higher dose drugmaker want panel do favor lower dosage quarter sale diabetes drug trulicity grow worldwide trulicity revenue advanced higher demand drug class know glp receptor agonist same time prescription trulicity grow raffat say imply pricing have not be unfavorable glp class say humalog diabetes drug lilly biggest product grow sale better pricing drive growth raffat say sale erectile dysfunction drug ciali seem be relatively stable light generic competition pfizer pfe viagra ciali sale grow drive higher realize price largely offset decrease demand due entry generic sildenafil lilly say worldwide sale fall meanwhile sale chemotherapy medication alimta increase decrease revenue outside be offset rise sale alimta be used combination merck keytruda treat lung cancer several key drug fall short raffat say sale psoriasis treatment taltz fall quarter quarter drive lower volume due specialty pharma buy pattern partially offset higher demand lilly say sale miss raffat say be important growth product miss say same time sale osteoporosis drug forteo decline due decrease volume wholesale retail buy pattern lesser extent lower realize price lilly say related do spot major market top easy look heavy best stock buy watch start buy stock ahead earning report
798,MRK,major index strengthen premarket trading monday mixed early earning news europe market trim loss merck mrk caterpillar cat receive bullish upgrade future dow jone industrial average firm fair value merck caterpillar pull higher premarket trading nasdaq future claw gain toymaker hasbro have mattel mat post heaviest early loss nasdaq fall hasbro report broad first quarter earning miss earning season accelerate week get fairly slow start monday morning top roster alaska air group alk edge halliburton hal hasbro fall follow quarterly result thing pick close google parent alphabet googl lead report docket include barrick gold abx chicago bridge iron cbi whirlpool whr td ameritrade amtd get newsletter deliver inbox more info product service privacy policy term market young uptrend face challenge prepare enter third week dow have book straight loss nasdaq have book index open day move average nasdaq picked distribution day thursday friday decline overseas asian stock market book uneven loss monday hong kong hang seng index drop nikkei tokyo slough european market narrow early loss turn mixed afternoon trade frankfurt dax cac paris inched higher london ftse wrestle fractional decline crude oil be tight focus week price attempt hold year high benchmark crude slip early monday drop back barrel mark march exist home sale due et national association realtor be top item monday economic calendar researcher markit release preliminary april composite purchasing manager index estimate et merck caterpillar be early riser dow respectively nike carry largest early loss caterpillar receive upgrade buy neutral citigroup citigroup cite rebound construction activity china project rebound china metal price caterpillar share be attempt start right side month consolidation earning due tuesday merck receive goldman sachs upgrade buy neutral earn place brokerage americas conviction list note say merck keytruda drug be possible asset drive company specialty biopharma status away large primary care merck share be struggle retake support week move average climb right side possible bottom base apple aapl rise fang stock tech leader gain ground premarket trading facebook fb report wednesday close amazon com amzn report late thursday netflix nflx share rise company announce deal tap high yield bond market medical supply distributor henry schein hsic run ahead nasdaq more medical product distributor say spin animal health unit merge vet first choice new company trade name vet first corp have combine sale schein say receive tax free basis netapp ntap climb more premarket trading datum storage leader have be hammer new high big november have not pause shape valid base end friday november buy point hasbro dive nearly bottom report first quarter sale earning far analyst target company say remain track generate free cash flow year term challenge associate major customer liquidation mattel have earning due thursday fall nearly amazon swung head ibd leaderboardlist premarket trading commerce giant be buy point ahead first quarter report due thursday close ibd stock casa system casa power forward ahead open december ipo form week consolidation pattern be deep too deep qualify flat base pattern mean require week mature valid cup base stock end friday pattern left side high stock december ipo price be interested stock market answer big question weeknot just apple other big reason friday market sell big picture come week turn market aroundstock chart internet giant buy point earning duestock watch td ameritrade green dot stock add ibd listfacebook amazon alphabet lead tech earning bonanza investing action plan
799,MRK,dow industrial lead market narrowly lower thursday caterpillar cat fall hard follow downgrade price target cut tesla tsla stock also drag overall trade open abiom abmd kraft heinz khc blue apron aprn score powerful early gain dow jone industrial average drop start bell nasdaq composite slump apiece kraft heinz rise nearly lead nasdaq infrastructure play vulcan material vmc top tesla cerner cern netherlands base nxp semiconductor nxpi duel low spot nasdaq drug distribution giant cardinal healthcah faltered harshest early decline wednesday pullback rise volume further fortify day move average technical line resistance dow industrial nasdaq week powerful earning surprise have fail drive index back key level market take wednesday widely expect change policy release fed negative next big slug economic datum come friday april payroll report productivity increase first quarter accord labor department estimate be better gain performance fourth quarter more double increase expect economist unfortunately labor cost rise even faster vs rise fourth quarter vs expectation slowdown growth get newsletter deliver inbox more info product service privacy policy term usejobless claim increase very slightly week end april be well consensus forecast increase new claim announce layoff fall more april accord challenger gray christmas remain general uptrend layoff report say increase large scale job cut announcement be horizon researcher markit deliver service purchasing manager index et commerce department factory output estimate march institute supply management service index be due et dow industrial drag lower caterpillar drop start trade buckingham research downgrade stock neutral buy cut back price target also dow merck shed itgs premarket gain dip fraction red drugmaker say have submit supplemental biologic license application food drug administration base positive trial result show keytruda drug effective treat certain form lung cancer merck remain month downtrend struggle retake support week move average gravel sand concrete leader vulcan material vault head list birmingham ala base outfit storm past analyst earning revenue expectation first quarter share be january high also top index cereal maker kellogg pop more chemical producer fmc fmc logged advance earning result low end cardinal health dig deeper downtrend share plunge open trade dublin ohio base operation report wide fiscal third quarter earning miss reduce earning guidance year analyst view early earning report send kkr kkr teva teva gain tempursealy tpx jump nearly blue apron power ahead almost ibd stock abiom spiked nearly higher follow healthy fiscal fourth quarter report gain earning revenue growth easily clear analyst target surge send share buy range buy point very late stage flat base closely watch tech ipos be take early earning related hit square sq slip less report heavy cost fiscal first quarter weak guidance second quarter pullback left stock positive ground so far week share be seventh week possible base pattern nov ipo price stream audio leader spotify spot skid lower luxembourg base company sharply reduce loss quarter first report public company pay subscriber rise vs year share break past buy point ipo base wednesday thursday loss send share more buy point trigger automatic sell rule be interested big squeeze new risk fed interest rate recession yield curvefe watch here stock get head steamtop cloud compute ai stock growth be store new big picture apple help nasdaq outperform
800,MRK,fed meeting end rate hike expect news briefly boost stock quickly reversed lower higher interest rate inflation dollar win let dow jone broader stock market snap recent funk wall street expect fed statement recognize pickup core inflation have suddenly bring close inflation target commerce department report monday core personal consumption expenditure price index exclude food energy rise year march month basis overall inflation inflation item other food energy have moved close fed statement say fed also signale be willing let inflation rise state symmetric target press conference update policymaker economic projection hawkish dovish shift win be know fed meeting minute come get newsletter deliver inbox more info product service privacy policy term healthy earning apple aapl dow jone industrial average index be close flat line just fed meeting announcement nasdaq composite be barely higher apple be largest component dow jone nasdaq et announcement nasdaq expand modest gain only briefly head close nasdaq fall dow jone briefly turn positive fall finished session lows investor win get much reprieve fed rate hike concern labor department april employment report friday be expect show jobless rate fall last month average hourly wage growth expect also be threat major employer cvs health cvs target tgt starbucks sbux announce wage hike take effect spring latest culprit sluggish stock market be dollar dollar index hit new high year wednesday continue recent resurgence other major currency greenback roughly rise end march have dampening effect earning multinational broad international exposure dow jone stock caterpillar cat boee ba merck mrk earning foreign currency be worth less dollar term dollar strengthen dollar strength stem pickup inflation grow expectation fed hike rate time year meanwhile central bank europe japan be rush tighten widening gap interest rate overseas have make dollar more draw higher interest rate inflation also squeeze earning come quarters higher interest rate also raise borrow cost consumer business crimp affordability major purchase auto housing further year treasury yield have climb more year yield flatter yield curve pinch net interest margin like jpmorgan chase jpm bank america bac fed meeting year yield be year be be little change yield spread be lowest level year meanwhile more company be begin note profit margin pressure rise input cost higher fuel transportation cost rise wage be interested big squeeze stock market bull run face biggest threat yearsif apple ll love market beating stock playshere way play netflix other hot internet stocksamazon ibd stock share winning growth traithere anyone time stock market bottomlook best stock buy watch start step routine
801,MRK,fed policymaker begin day meeting tuesday year treasury yield touch highest level dollar rise highest point year fear trade war recede dollar have surge past month greenback also have get boost inflation pick expectation grow fed hike rate time year meanwhile central bank europe japan be rush tighten so further dollar gain be fair bet trend higher interest rate inflation dollar squeeze earning second quarter concern contribute bad day dow jone industrial average index midafternoon trading dow be be stock market today earning foreign currency be worth less dollar term dollar strengthen negative multinational caterpillar cat boee ba merck mrk dollar turn tailwind headwind caterpillar lose boee merck get newsletter deliver inbox more info product service privacy policy term interest rate also raise borrow cost consumer business crimp affordability major purchase auto housing ford motor report drop auto sale march fiat chrysler fcau see surge jeep sale ford fall fiat chrysler drop further year treasury yield have climb more year yield flatter yield curve pinch net interest margin like jpmorgan chase jpm bank america bac jpmorgan slip bofa shed meanwhile more company be begin note pressure profit margin rise input cost higher fuel transportation cost rise wage firework be expect wednesday policy statement et fed be virtually certain maintain key interest rate next quarterly press conference fed chair jerome powell update economic projection win happen june year yield rise high tuesday highest month lehman bro go bust pull back meanwhile year yield help determine mortgage rate tick sub basis point spread suggest market be begin worry fed go overboard hike rate face temporary tax cut spending stimulus dollar index track greenback basket advanced economy currency rise high tuesday more dollar index have spend much year be interested dow lag midday earning disappointment lead sector big squeeze stock market bull run face biggest threat year reason stock market rally have stall apple earning duehere general electric start see upsidenvidium apple avoid get chopped market volatilitysee stock just get add cut ibd top list
802,MRK,consumer health giant johnson johnson jnj nudge sale guidance higher tuesday even blockbuster drug remicade continue face competitive pressure demand cancer treatment surge first quarter oncology be grow field first quarter sale cancer drug grow unit include brand drug account total pharmaceutical sale rise respectively prior quarters result boost full year sale view range midpoint beat consensus view dow jone component also reaffirm adjust profit target share analyst have modeled rbc analyst glenn novarro note beat expectation board get newsletter deliver inbox more info product service privacy policy term use pharma upside drive higher revenue guidance subdue expectation drive share higher say note client sale segment be estimate pharmaceutical segment be primary source upside stock market today share slide close first quarter report adjust profit share sale metric rise vs year earlier period sale easily top consensus analyst poll zack investment research adjust profit beat nickel share pharmaceutical unit bring beat novarro view cancer drug zytiga be single biggest source upside say zytiga generate revenue novarro estimate darzalex treat multiple myeloma adult also beat expectation say sale fellow cancer drug imbruvica be just line respectively sale drug grow vs last year same time sale inflammation drug remicade decline bring just total pharmaceutical sale remicade face competition biologic copy know biosimilar make dow merck mrk pfizer pfe consumer unit make product baby shampoo neutrogena grow sale biggest upside come beauty product rise meanwhile sale wound care product fall medical device sale rise beating novarro model orthopedic sale spine product decline lead dip sale knee replacement evercore analyst vijay kumar call result soft segment think most be due tougher sequential comparison say note normalize think first quarter sequential volume trend slow base point related unitedhealth top earning view hike outlook do spot major market top easy look heavy best stock buy watch start buy stock ahead earning report
803,MRK,newlink genetic nlnk topple monday scrap late stage study immuno oncology drug combination drug merck mrk bristol myer squibb bmy early trading stock market today newlink share plunge close point drop lowest ever point stock trade year meanwhile merck rise finish bristol sank other study result newlink say win test drug indoximod regimen merck keytruda bristol opdivo patient advanced melanoma decision come study keytruda incyte incy rival drug epacadostat fail group patient indoximod epacadostat be immuno oncology drug know ido inhibitor drug interact specific enzyme help patient immune system fight cancer analyst have expect merck incyte failure reverberate immuno oncology stock get newsletter deliver inbox more info product service privacy policy term usenewlink also test indoximod radiation chemotherapy child progressive brain tumor first group patient have already undergo numerous prior treatment be able receive radiation top indoximod chemo combination follow cancer didn worsen median month eventually regimen stop work patient median month early datum small cohort pediatric patient demonstrate potential indoximod radio chemotherapy combination increase toxicity child spokesperson theodore johnson say prepared statement newlink then test regimen newly diagnosed patient physician see improvement patient tumor almost disappear related much money do need start investing long term retirement investing strategy etfsnew option strategy limit risk earning
804,MRK,tesaro tsro pop monday unveil early datum potential competitor drug dow jone component merck mrk bristol myer squibb bmy biotech study drug tsr patient uterine cancer have biomarker know microsatellite instability high tesaro also look tsr patient small cell lung cancer common form lung cancer tesaro have compete merck keytruda be already approve treat group uterine cancer patient rbc analyst kennen mackay say note client further keytruda bristol opdivo be already used number lung cancer patient initial datum be promising supportive know utility checkpoint inhibitor used say give lack further differentiation continue anticipate competitive environment tsr come get newsletter deliver inbox more info product service privacy policy term usetesaro tsr merck keytruda bristol opdivo same class immuno oncology drug know pd checkpoint inhibitor drug aim unleash immune system cancer overall uterine cancer lung cancer patient respond treatment tsr compare merck keytruda have response rate uterine cancer other pd inhibitor have response rate lung cancer piper jaffray analyst christopher raymond say mackay wait more datum see different tsr be rival find preliminary tsr datum interesting look further datum cut tell differentiate be raymond say report client now re comfortable watch sideline remain neutral rate tesaro stock patient include uterine lung cancer well other tumor type experience serious life threaten side effect related treatment tesaro say news release stock market today tesaro jump close merck rise finish bristol topple end day merck bristol stock movement be related other study lung cancer related chart read basic buy point mark time real much money do need start investing long term retirement investing strategy etfs
805,MRK,merck mrk pop month high monday goldman sachs suggest cancer drug keytruda be asset believe narrative company be quickly change success keytruda drive significant shift product mix large primary care evolve specialty biopharma goldman sachs analyst jami rubin write note client rubin upgrade merck buy rating neutral add stock brokerage americas conviction list also boost price target raise expectation keytruda also late monday european regulator accept merck application combination keytruda chemotherapy untreated lung cancer patient decision be make base result study present last week call keynote merck say get newsletter deliver inbox more info product service privacy policy term useon stock market today share dow jone component climb close earlier stock touch highest point late january meanwhile rival bristol myer squibb bmy dip finish hoopla surround merck follow american association cancer research annual meeting last week then regimen merck keytruda chemotherapy seemingly top combination bristol opdivo yervoy first treatment lung cancer keytruda chemo reduce risk death merck say combination opdivo yervoy cut risk cancer progression death similar group patient compare chemotherapy alone bristol say now analyst expect merck take lion share already large lung cancer market keytruda animal health unit drive merck value rubin say see bottom line get contribution higher keytruda sale rubin assume merck eventually have roughly half immuno oncology market earlier estimate immuno oncology medicine treat cancer teach immune system identify tumor cell keytruda bring stem sale first treatment advanced lung cancer predict rubin expect keytruda generate lone therapy keytruda likely get quarter market serve patient tumor have lot pd protein rubin say amount pd be thought predict well drug keytruda bristol opdivo work doesn expect bristol opdivo get market merck share combination market remain be determine say keytruda likely have access lung cancer market bristol roche rhhby be still run test rival combination be room further upside merck establish more leadership position still need see datum other combination trial give more credit say merck also seek merger further diversify especially diabetes drug januvia look likely see generic competition mid rubin say see potential merck be even better story management take step diversify address longer term growth post januvia complement keytruda say believe have more enough balance sheet firepower do so firm be now compelling mix margin improvement story say mostly be overlooked lung cancer discussion historically investor reward margin expansion story key example include abbvie abbv eli lilly lly related do spot major market top easy look heavy term retirement investing strategy etfssell take profit hold here be several guideline follow
806,MRK,dow jone component pfizer pfe have interest acquire bristol myer squibb bmy least not yet analyst reportedly say thursday report citigroup analyst andrew baum send bristol share topple close stock market today pfizer stock advanced broadly drug stock rise collective pfizer chief executive ian read isn interested buy bristol have datum derate share baum say accord fly citigroup didn respond request investor business daily copy report investor analyst have long play question pfizer take bristol pfizer latest big acquisition be takeover medivation forked cancer drugmaker get newsletter deliver inbox more info product service privacy policy term useaccord baum pfizer see return risk much higher immuno oncology space bristol have double recent history immuno oncology matchup particularly drug opdivo yervoy bristol be pairing opdivo yervoy first treatment advanced lung cancer earlier year regimen outperformed chemotherapy improve progression free survival patient next firm unveil overall survival datum combo dow jone component merck mrk already have immuno oncology regimen approve first treatment advanced lung cancer drug keytruda grab accelerate approval combination chemotherapy use datum be cause bristol stock dive make easier target takeover pfizer do have own immuno oncology program last april firm have compound immuno oncology study citigroup baum have sell rating pfizer cut price target bristol keep buy rating stock related chart read basic buy point mark time real opportunitylong term retirement investing strategy buy stock ahead earning report
807,MRK,exelixis exel share rebound tuesday month low monday close regulator temporarily halter enrollment cancer study combine drug exelixis roche rhhby study exelixis roche be know modul testing combination drug call cotellic immuno oncology drug tecentriq patient colon cancer regulator halter enrollment study randomization medicine group patient correspondence exelixis management highlight be temporary halt recruitment only enable datum monitoring committee address question rbc analyst kennen mackay say note client mackay urge investor buy monday dip exelixis topple stock market today exelixis pop close roche advanced meanwhile biotech stock broadly lift rise monday close get newsletter deliver inbox more info product service privacy policy term likely exelixis dive be tie investor scrutiny immuno oncology combination dow jone stock merck mrk incyte incy announce last week regimen keytruda epacadostat fail melanoma see monday exelixis weakness trial halt amplify increase investor skepticism concern immuno oncology combination follow incyte echo epacadostat keytruda failure mackay say mackay remain bullish combination cotellic tecentriq committee temporarily halter randomization specific group patient add august randomization assign patient random receive drug combination argue be too early datum monitoring committee determine futility effectiveness recommend stopping study reason say think be unlikely pool have enrolled enough patient conduct meaningful interim futility analysis further regimen didn show safety issue earlier stage testing mackay say earlier study patient experience severe life threaten increase specific enzyme blood patient be aware concern cotellic say study call imblaze be also testing regimen colon cancer study be testing regimen drug call stivarga have limit benefit group patient contrast modul be compare regimen relatively effective drug population such regardless regimen fate modul do not view read imblaze trial mackay say related build long term profit stock take many gain long term retirement investing strategy etfsnew option strategy limit risk earning
808,MRK,tuesday premarket trading receive several shot arm first be netflix nflx surge report strong first quarter result late monday then cohort blue chip name kick post early advance follow expectation quarterly result result future dow jone industrial average vault trade fair value nasdaq future pressed higher netflix be premarket trading powerhouse more easily largest gainer nasdaq stock merck mrk bolster dow early trade follow analyst upgrade drugmaker quickly surrender lead investor wade early batch blue chip earning report goldman sachs gs johnson johnson jnj unitedhealth group unh positive premarket trading poise week old uptrend hurdle resistance uptrend be good standing carry distribution day day move average remain key test major index dow fail hold day line monday nasdaq have yet break back critical level support get newsletter deliver inbox more info product service privacy policy term usepremarket action suggest dow open day line keep mind future drive premarket trading do not always translate action regular session dow unitedhealth rolled early gain first quarter result be stronger expect stock retook day line support gain monday attempt start right side month consolidation also dow merck buzz ahead morgan stanley upgrade stock overweight equal weight drugmaker surge heavy trade monday company lung cancer treatment outperformed competitor clinical trial merck be early april low overall dow index stand poise test resistance day move average further list early dow advancer johnson johnson trim early gain medical product leader report first quarter result earning revenue top analyst target full year guidance meet beat expectation goldman sachs reversed early loss step clobber first quarter earning expectation raise quarterly dividend nearly stock have spend day fight resistance day move average ibd leaderboard stock churn strong early move draft netflix early advance stream entertainment leader report first quarter sale earning only narrowly consensus target blowout beat subscriber growth surprised investor launch share higher premarket trading netflix share remain extend rebound support week move average planet fitness plnt pop ahead open gym network end monday bit more buy point second stage flat base leader peer lululemon athletica lulu pare early surge back premarket trading company late monday name patrick guido chief financial officer effective april stock have jump past week china base stock be mixed market hong kong shanghai end lower tuesday datum show country gdp expand first quarter retail sale surge investment education soar china commerce ministry also announce impose tariff sorghum import ministry say investigation find grain be unfairly subsidize government march ipo iqiyi iq jump premarket trading share netflix platform advanced past session rise march ipo price housing start jump march annualize rate commerce department report be healthy uptick february disappointing rate home start startling economist have project rate new project build permit gauge upcoming activity post even larger increase annualize rate february permit clock pace economist have expect march permit issue rate industrial production number federal reserve be set release et busy slate tuesday hour session include quarterly report railroad csx csx intuitive surgical isrg unite airline ual lam research lrcx also report close kick first quarter report season chip sector be interested big picture strength sector be good lam research ibm earning due investing action planamazon report send cvs walgreen drug distributor soar
809,MRK,stock market index fund extend gain monday key dow jone industrial average etf reclaim couldn hold day move average spdr dow jone industrial average dium rally nearly inch day line then retreat gain spdr spy powershare qqq trust qqq also add stock market today foreign market trail ishare msci eafe efa ishare msci emerge market eem edge higher dow stock advanced top blue chip winner include unh merck mrk apple aapl add mark third straight advance iphone maker be work right side shallow base potential buy point raymond james warn apple get hit sell news reaction report expectation be already baked share price utility consumer staple homebuilder be top sector fund gainer spdr homebuilder xhb advanced continue trade day day line aerospace defense also show strength ishare aerospace ita lift build flat base potential buy point defense contractor include raytheon rtn northrop grumman noc dow component unite technology utx rally heel coordinate strike syrium britain france friday raytheon lift clear flat base entry average volume telecom biotech gold miner underperform most biotech health care fund get hurt past month heighten volatility broader market top performer accompany table see healthy year date gain vs wednesday accord morningstar direct first trust nyse arca biotechnology index fund fbt place first year date return even drop past month fund regain day move average thursday be form double bottom base buy point top holding thursday include avexis avxs intrexon xon nektar therapeutic nktr agio pharmaceutical agio intercept pharmaceutical icpt avexis share soar april news novartis nvs buy biotech get newsletter deliver inbox more info product service privacy policy term useark genomic revolution multus sector arkg come second year date return fund invest company involved genomic related field such gene therapy target therapeutic next generation oncology top holding intellium therapeutic ntla edita medicine edit illumina ilmn invitae nvta bluebird bio blue account third stock portfolio fund lose past month have be trading day line late march share be march intraday high third place go ishare medical device ihi gain wednesday fund track dow jone select medical equipment index sit high top holding make stock portfolio be medtronic mdt abbott laboratory thermo fisher scientific tmo becton dickinson bdx dhr alp medical breakthrough sbio spdr biotech xbi round top etfs respective year date gain also be interested stock lower big bank weigh dow apple buck declinestock market rally intel apple boost dow bitcoin biotechs drugmaker fare senate tax bill
810,MRK,stock market future rally monday morning president donald trump signale saturday attack syrium be mission accomplish future index dow jone nasdaq be point solid gain open investor look ahead big earning other news week earning season kick high gear bank america bac just report better expect first quarter earning netflix nflx charle schwab schw also be tap monday meanwhile merck mrk bristol myer squibb bmy present lung cancer trial datum compete immuno oncology blockbuster index dow jone industrial average nasdaq composite rally strongly last week retreat friday list china internet school stock be big loser bank sell seemingly good earning jpmorgan chase jpm well fargo wfc citigroup give nasdaq composite hit record high month dow jone hit term peak large number top rate stock have form new flat basis include bank america well apple intel other tech titan get newsletter deliver inbox more info product service privacy policy term usenetflix be first fang stock report earning charle schwab kick online brokerage earning rival due later week merck bristol myer datum offer latest measure stick keytruda opdivo bank america be latest series big bank earning report addition earning investor get several notable economic report morning commerce department march retail sale new york april empire state manufacturing index be due et nahb housing market index be future be fair value dow jone future climb nasdaq future rise crude oil future fall more best week month lead airstrike vs syrium saturday allege use chemical weapon president trump declare mission accomplish twitter perfectly execute strike last night thank france unite kingdom wisdom power fine military not have have better result mission accomplish donald trump realdonaldtrump april suggest president be unlikely continue attack have raise risk wider conflict include russia iran trump focus seem have left syrium send several tweet blast slippery ex fbi director james comey still ambassador nikki haley say impose fresh sanction russia support syrium remember extend trading stock market future individual stock sometimes translate regular session trading often do not netflix bank america charle schwab merck bristol myer squibb be stock wall street expect adjust first quarter earning share cent revenue soar accord zack investment research netflix have predict add stream video subscriber global total see new subscriber new overseas subscriber several analyst raise price target last week bullish netflix growth stock surge last week rebound day line netflix have be consolidate few week do not yet have proper base buy point netflix be ibd stock ibd leaderboard bank america report earning rise vs year earlier revenue modestly view goldman sachs gs tuesday morgan stanley ms wednesday bank america have form flat base buy point share be trading day line bofa hit resistance key level friday reverse lower fall bofa rise premarket trading charle schwab ep jump cent revenue grow schwab break march fall back buy point march stock fall enough invalidate entry have not yet form new base fellow online broker interactive broker ibkr trade financial etfc report tuesday thursday respectively analyst expect strong earning ibd stock trade financial be buy zone interactive broker have just form flat base td ameritrade amtd have flat base well td ameritrade also be ibd report earning april last week merck bristol myer squibb announce positive result respective immuno oncology drug keytruda opdivo treat small lung cancer provide clinical datum trial american association cancer research annual meeting monday aacr event run saturday wednesday merck keytruda have have upper hand bristol opdivo recent year merck sunday announce positive keytruda result phase iii trial melanoma patient dow jone drug giant hold investor monday evening start et be interested top china stock sell ipo be buythese tech titan just carved bullish patternq earning netflix top ipos join stock expect growththese oil stock be fire crude log huge gainnetflix goldman ge ibm heat earning action planoption trading earning expectation high netflix alcoa atlassian
811,MRK,clovis oncology clvs pop midday friday food drug administration approve use ovarian cancer drug rubraca prod share rival tesaro tsro topple other smaller player crash stock market today clovis jetted close tesaro other hand slide astrazeneca azn also make rival drug rise make drug know parp inhibitor approve treat ovarian cancer regulator approve clovis drug rubraca make partnership merck mrk friday maintenance treatment patient partially fully respond treatment chemotherapy be grateful fda expedite review maintenance treatment indication so physician begin offer appropriate patient begin today clovis chief executive patrick mahaffy say prepared statement get newsletter deliver inbox more info product service privacy policy term news reverberate immuno oncology stock newlink genetic nlnk make drug similar epacadostat collapse nektar therapeutic nktr armo bioscience armo make immuno oncology drug crash respectively armo make drug know be wake epacadostat keytruda failure melanoma armo management argue be have show promise monotherapy several tumor type epacadostat didn leerink analyst chang say note further be have different mechanism approach epacadostat say competition emerge immuno oncology space be fierce armo target market especially advanced lung cancer kidney cancer be highly competitive dynamic believe be have potential address large commercial opportunity say clovis be third astrazeneca tesaro grab approval treat broader group patient label rubraca doesn include warning liver enzyme elevation have previously be concern label astrazeneca lynparza warn pneumonitis inflammation lung occur infection patient treat tesaro zejula be caution blood toxicity cardiovascular effect say rubraca be cleanest safest drug class rbc analyst kennen mackay say note client see dynamic drive rubraca competitive position recurrent maintenance market be third market astrazeneca tesaro say piper jaffray analyst christopher raymond keep neutral rating tesaro stock report client competition lack differentiation parp inhibitor space have long be primary concern tesaro zejula say approval third parp inhibitor maintenance recurrent ovarian cancer do little quell concern rbc mackay raymond expect parp inhibitor be differentiate safety do not favor zejula announcement underscore competitive pressure intensify space say similarity parp inhibitor continue grow raymond say time progress think differentiator clinical effectiveness include drug resistance mechanism warrant close monitoring related build long term profit stock take many gain long term retirement investing strategy etfsnew option strategy limit risk earning
812,MRK,facebook fb advanced micro device amd be early leader thursday open global stock market rally market look add third straight advance nasdaq composite launch gain start bell dow jone industrial average advanced swung facebook set early lead nasdaq stock bounce putt stock positive territory week ibd leaderboard stock amazon com amzn netflix nflx open higher alphabet googl rise get newsletter deliver inbox more info product service privacy policy term usej morgan jpm caterpillar cat lead early advance blue chip rise more apiece merck post advance barclay upgrade merck overweight equal weight raise stock price target be wednesday close note also downgrade merck competitor pfizer pfe equal weight overweight trim price target pfizer share slip fraction early trade american express climb blue chip credit brand be expect post earning gain report fiscal first quarter result april mark strongest earning gain second quarter stock have be cling support day move average end wednesday day line less mid january high china base stock show early strength com pace group rise nearly open trade online game provider announce special dividend american depositary share china base sohu com sohu hold majority stake climb more start bell chip stock be mixed premarket action advanced micro device rumble ahead nearly lead philadelphia semiconductor index stifel upgrade stock buy hold target price share trade early thursday note say amd have be oversold concern softening demand cryptocurrency related chip marvell technology mrvl pop ub initiate coverage company buy rating price target marvell fourth week pullback rebound weak trade day move average wednesday global stock market frankfurt dax lead afternoon rally europe surge vs gain paris cac advance ftse london china hong kong shanghai exchange be dark country celebrate ching ming festival japan tokyo stock exchange nikkei surge thursday lift benchmark positive ground week back week move average first time early february commerce department report trade deficit widen february january consensus view first time unemployment claim rise week end march labor department say be prior week claim easily outstrip consensus view increase claim layoff announce private employer surge march accord monthly job cut report challenger gray christmas be highest tally april more vs february year level be interested big picture strong rally paint bullish tint hot group be tech sector new fang stock apple stoke artificial intelligence talent battle google hirethese dow stock reclaim key support be buy pointstock buy zonetop perform large cap big cap stock leaderboard be rise
813,MRK,several biotech stock end strong gain monday session be mar lack conviction buy late day sell nasdaq composite jump early end gain just volume be heavy early trail attribute selling new york time
814,MRK,buyout partnership news send biotechs fly monday novartis nvs bid take avexis avxs rumor emerge celgene celg swipe agio pharmaceutical agio ionis pharmaceutical ion partner astrazeneca azn make liver disease treatment close stock market today avexis rocket easily hit highest point go public february novartis lift agio surge celgene be flat be more hour meanwhile dow jone stock merck mrk pop end regular session datum show drug keytruda improve overall survival first treatment option lung cancer patient key rival bristol myer squibb bmy dip news acadium pharmaceutical acad hit lowest closure point june cnn story detail death patient take only approve drug nuplazid nuplazid treat psychosis patient parkinson disease be be test array other condition get newsletter deliver inbox more info product service privacy policy term usenovartis agree pay share avexis offer represent premium avexis close friday deal be premium avexis day volume weight average stock price avexis say news release avexis be develop avxs gene therapy treatment spinal muscular atrophy diagnosed young child drug rival biogen biib ionis spinraza be already approve treat condition biogen stock fall fraction rise extend trading rbc analyst brian abraham credit deal breathe life sector note biotech group have be pressure recently share sank much month low friday collectively advanced monday be merger acquisition kick start sector have await view say have be anticipation major deal trepidation drug pricing risk highlight negative catalyst have keep sentiment late transaction be expect close midyear price go share avexis stock novartis decide extend close date oct avexis terminate deal owe novartis fee novartis terminate deal owe avexis ptc therapeutic ptct jump news ptc be early stage make treatment spinal muscular atrophy roche rhhby asset remain early have show early positive signal see increase attention today give value big pharma be clearly willing place sma asset once be further risk rbc abraham say immuno oncology drug keytruda significantly outperformed chemotherapy patient advanced lung cancer merck say news release study dub keynote test keytruda single drug vs chemo patient have pd protein least tumor cell study examine overall survival interim analysis show keytruda keep patient alive longer chemotherapy lone treatment safety be line earlier study merck now continue study determine keytruda impact progression free survival patient have pd protein tumor represent overall market lung cancer evercore analyst umer raffat say note bristol rival drug opdivo fail improve progression free survival patient pd least tumor note bristol share touch month low intraday trading news re-cover somewhat close abbvie abbv run rise hour investigational drug upadacitinib beat own blockbuster humira study rheumatoid arthritis patient patient receive milligram upadacitinib daily milligram humira other week placebo abbvie examine patient week least improvement rheumatoid arthritis symptom clinical remission study show upadacitinib patient experience improvement symptom vs humira placebo patient respectively upadacitinib patient be clinical remission vs humira placebo patient be excited strong result add body evidence support potential upadacitinib be important treatment option patient rheumatoid arthritis abbvie spokesperson michael severino say prepared statement rumor emerge celgene be eyee takeover agio jounce therapeutic jnce agio pop jounce surge buyout follow celgene recent acquisition juno therapeutic cancer biotech report emerge financial time cite unnamed source celgene be reportedly hunting acquisition target promising drug offset loss patent protection key blockbuster revlimid celgene already partner agio jounce be work cancer drug agio have market cap eclipse jounce market cap remain jounce go public last year similar news ionis astrazeneca announce partnership develop drug treat nonalcoholic steatohepatitis term deal astrazeneca pay ionis license fee take responsibility development drug drug advance ionis be also eligible receive additional development regulatory milestone payment well tiered royalty low teen sale drug ionis stock advanced astrazeneca lift close menlo therapeutic mnlo acadium be biggest biotech stock loser monday share menlo tank fall just month go public stock have be form cup handle buy point share rise hour tumble follow news sunday menlo itch drug fail eczema study menlo find statistically significant difference drug serlopitant placebo chief executive steve basta note be still sign improvement serlopitant treat patient serlopitant be also be test skin condition know prurigo nodularis itch associate psoriasis chronic cough setback eczema doesn necessarily hurt menlo chance serlopitant prurigo nodularis piper jaffray analyst david amsellem say note prurigo nodularis be altogether different condition say larger point here be menlo decide run broad clinical program itch order have handful potential pathway market serlopitant amsellem keep overweight rating menlo meanwhile acadium dive cnn story outline death parkinson patient take nuplazid psychosis nuplazid be approve treat hallucination delusion associate parkinson approval patient continue experience hallucination side effect include death life threaten incident fall insomnia nausea fatigue cnn write approval more patient nuplazid have die last june nuplazid be only medicine list suspect least death report acadium note study have show difference number death report nuplazid placebo drug be acadium only approve medicine acadium be testing nuplazid dementia related psychosis schizophrenia depression related much volume look stock long term retirement investing strategy buy stock ahead earning report
815,MRK,key stock market index fund sharply pare advance monday close rise nearly intraday apple aapl intel intc other big cap techs hold solid gain dow jone industrial average lag other index powershare qqq trust qqq rise spdr spy add spdr dow jone industrial average dium climb stock market today merck mrk lead dow pop follow intel advanced ibm ibm cisco csco apple gain more apple fall back day move average surge past line earlier session be run resistance day almost past week iphone maker announce red version iphone be available preorder tuesday sale friday biotech telecom semiconductor be biggest advancer sector fund vaneck vector semiconductor smh rise ishare nasdaq biotechnology ibb rally technology select sector spdr xlk gain homebuilding bank retail etfs be underwater gold miner slip back red vaneck vector gold miner gdx vaneck vector junior gold miner gdxj respectively gold commodity etfs rise gold future add ounce bitcoin shed accord coindesk climb back early session bitcoin investment trust gbtc be flat give earlier gain day line december peak many biggest dividend pay exchange trade product etps focus real estate energy sector real estate investment trust reit instance pass least income shareholder exchange lower tax rate regular corporation translate often hefty dividend payout master limit partnership mlp dominate fund accompany chart have similar structure also pass lion share cash flow investor payout cash flow doesn get book income mlp get tax break infracap mlp amza top list whopping annualize yield accord morningstar direct fund top holding april be energy transfer partner etp mplx mplx william partner wpz andeavor logistic andx buckeye partner bpl make nearly stock portfolio amza be trading year lows be week high carry expense ratio powershare global list private equity portfolio psp be next yield fund track red rock global list private equity index invest private equity firm include business development company mlp psp be week high bear expense ratio get newsletter deliver inbox more info product service privacy policy term useishare mortgage real estate capped rem place third annualize dividend fund track ftse nareit mortgage capped index compose reit top holding account asset include annaly capital management nly agnc investment agnc starwood property trust stwd rem be week high expense ratio be more broadly diversify etps list global superdividend sdiv global superdividend div offer respective yield morningstar categorize international equity equity order sdiv be high carry expense ratio div be high sport ratio be close retake day move average line friday pick ishare msci kld social dsi fall day line be testing day line again also be interested dow lead broad stock selloff apple lose support again escalate china trade war hurt stock fund frontier market emerge option major index flounder
816,MRK,top tech stock rebound vengeance stock market monday bull start week driver seat nasdaq composite outperformed afternoon trading picked dow jone industrial average add volume nasdaq be strong early fade volume exchange be tracking close friday level merck mrk intel intc jpmorgan jpm cisco system csco outperformed dow gain range earning jpmorgan be due friday open money flow bond stock year treasury yield add basis point ibd name shine half name screen score gain more china stock stand nice bounce week move average last week baozun bzun soar meanwhile small cap china stock daqo new energy dq show compelling price action leap break descend trend line find connect stock recent high elsewhere chip equipment maker mks instrument mksi reclaim day move average retrace mild gain conventional entry share rise group peer fellow ibd component entegris entg have similar look chart share rise so call fang name leaderboard name netflix nflx google parent alphabet googl lead charge gain facebook fb add nearly ceo mark zuckerberg arrived capitol hill ahead day congressional testimony get newsletter deliver inbox more info product service privacy policy term usein merger news novartis nvs paid big premium avexis avxs share avexis soar novartis announce plan acquire company avexis have promising gene therapy drug treat spinal muscular atrophy related boee rise american air deal ease china trade fearsafter market sell stock add cut ibd screensoption trading financial earning tap stock market correct
817,MRK,incyte incy plummet friday regimen combine immuno oncology drug merck mrk fail late stage study prompt duo scrap program raymond james analyst reni benjamin mince price target incyte note other combination used incyte drug epacadostat immuno oncology drug merck bristol myer squibb bmy astrazeneca azn be also likely be dud view event taint entire epacadostat franchise therefore be remove revenue associate melanoma other indication model write report client study miss big time share incyte crash close stock market today incyte hit year low fall much merck dow jone component see share fall sympathy bristol lose astrazeneca lift fraction get newsletter deliver inbox more info product service privacy policy term regimen fail improve progression free survival melanoma patient look unlikely have impact overall survival incyte say news release combination test epacadostat inhibit ido enzyme merck keytruda pd protein inhibitor datum study help contribute overall understand ido inhibition combination pd checkpoint inhibitor incyte chief medical officer steven stein say remain dedicate transform treatment cancer continue explore ido inhibition other novel mechanism potentially improve outcome patient need say written statement safety combination be line previous study incyte say patient move regimen manner consistent best interest patient incyte be also testing epacadostat lung cancer patient combination merck bristol astrazeneca investigator be also look epacadostat regimen kidney head neck bladder cancer analyst have be bullish incyte chance epacadostat broadly theorize combine immuno oncology drug offer more potent cancer response bristol have be forefront combine immuno oncology drug opdivo pd inhibitor yervoy be know ctla inhibitor be approve treat melanoma bristol be also testing regimen other cancer merck other hand have work combine keytruda chemotherapy regulator approve combination first treatment advanced lung cancer merck be also study keytruda investigational pd inhibitor call mk friday analyst be less bullish incyte shot epacadostat do see value incyte other drug include baricitinib rheumatoid arthritis drug eli lilly lly cancer drug ruxolitinib brand jakafi jakavi raymond james benjamin keep outperform rating incyte see incyte jakafi generate also have potential book significant royalty baricitinib well ruxolitinib outside be also sell novartis nvs jakavi rbc analyst brian abraham chopped price target incyte completely discounting epacadostat still have outperform rating stock raymond james benjamin still see value jakafi baricitinib expect incyte terminate other epacadostat study only silver line view be result be unequivocal make future decision clear say note base datum see very low likelihood robust signal biomarker defined subgroup emerge support continue anything other study substantially reduce scope exploratory purpose related build long term profit stock take many gain investing basic sell stocklooking best stock buy watch start here
818,MRK,stock skid friday open nasdaq erase gain week disappointing march job report uptick trade dispute china nasdaq composite drop start bell apple aapl fall fang stock tech leader post early loss boee ba caterpillar cat goldman sachs gs joined force help drag dow jone industrial average fall biotech incyte incy post widest loss nasdaq stock dow head friday open week day advance have gain nasdaq composite hold advance index show support day move average week face test resistance day line nonfarm employer add worker march labor department report be third february new hire more new worker project economist consensus unemployment rate hold steady vs expectation dip bright spot average hourly earning rise vs increase february line estimate market friday have ear further development trade dispute china threaten additional penalty late thursday china say early friday plan stand firm cost dow boee goldman caterpillar fall more boee national aeronautic space administration announce plan delay person flight boee capsule originally schedule november late dow peer merck mrk open decline drugmaker announce melanoma treatment epacadostat fail meet target phase clinical trial merck have jointly develop epacadostat incyte incyte share collapse early trade apple post modest loss news report say southern california district court depose chief executive tim cook june testimony be part qualcomm qcom suit allege iphone maker used inaccurate information provoke regulator investigate qualcomm investor be also expect update point apple capital return strategy include boost buyback dividend apple stock be set third straight open back day move average nearly week follow day advance qualcomm share slip datum storage gear maker netapp ntap re-cover loss premarket trade open fractional gain late thursday sunnyvale calif base company approve additional buyback company share double quarterly dividend cent stock be october testing support just early march high xilinx xlnx shed open jpmorgan downgrade stock underperform neutral lower price target loss send share day move average fast trade ibd list micron technology mu pare loss aggressively recover support day line diving level open stock drop more heavy trade thursday analyst downgrade friday early action imply share open day move average china hong kong hang seng index reopen day holiday post gain shanghai exchange remain close holiday reopen monday japan tokyo nikkei slip end week gain europe stock market pare loss afternoon trade frankfurt dax dip london ftse narrow loss fraction be interested big picture here wrong rally tip prep next uptrend defense giant break peer target buy pointscrude oil price stir energy stock toothy name break trade chart pattern etch superb stock gain
819,MRK,minute dow jone industrial average component merck mrk be do battle fellow drugmaker bristol myer squibb bmy drug cancer next biotech giant amgen amgn sanofi sny be tussle court fate cholesterol bust drug meanwhile company gilead science gild be rake coal congress charge day treat hepatitis brave contentious new world pharmaceutical biotechnology company realm science be try develop landmark medicine cure cancer hepatitis other life threaten illness do delicate dance wall street regulator balancing public health issue demand shareholder investor find tricky navigate sector company rise fall drop hat bookmark page stay top latest news biopharma sector get newsletter deliver inbox more info product service privacy policy term useview more biotech pharma stock newsrelated best stock buy watch
820,MRK,stock turn lower just midday tuesday hurt decline share micron technology mu china court temporarily ban sale micron chip china ruling favor unite microelectronic umc patent infringement lawsuit less hour remain tuesday shorten session dow jone industrial average be blue chip component johnson johnson jnj coca cola ko merck mrk lead way gain nasdaq composite be give back small cap be bright spot russell rise meanwhile crude oil top barrel level first time late quickly turn tail hit intraday high barrel crude oil future reversed sharply lower august crude oil be recently trading barrel stock market result today volume be heavy conocophillip cop share rise work flat base buy point share roku roku jump help oppenheimer upgrade outperform just handle entry heavy volume gainer include health care leader amedisys am share gap new high rise help upgrade bank america buy neutral amedisys be well extend price base march medical software space marketsmith growth name medidata solution mdso look poise extend winning streak session share rise cup handle base buy point medidata have form handle alternate entry royal gold rgld pop lengthy consolidation rise buy interest amarillo gold mara rosa gold project brazil elsewhere share facebook fb be pressure nearly news widen probe regard cambridge analytica datum scandal tuesday downdraft facebook chart still look hold buy point get instant access more trading idea exclusive stock list ibd proprietary rating only also ibd tipp poll economic optimism surge stock nvidia start listsu auto sale ford fiat chrysler top view gm tap
821,MRK,stock open higher monday facebook fb chief executive mark zuckerberg trade relation china be early focal point investor amazon com amzn jump positive analyst note meanwhile russian related issue be fire follow uptick tension russia nasdaq composite jump apple aapl fang stock tech leader be early trade facebook lag fractional gain dow jone industrial average advanced merck mrk muscle nearly get newsletter deliver inbox more info product service privacy policy term userussia related stock etfs position tough day tumble premarket trading response new round sanction announce friday white house addition president trump threaten action appear be deadly chemical weapon attack civilian weekend news report say several missile strike syrium monday russia quickly blame israel attack uptick tension region moscow micex benchmark drop monday early trading show ishare msci capped russia erus exchange trade fund russia related stock search engine yandex yndx topple mobile telesystem mbt dump financial network qiwi qiwi shed biotechs other drugmaker be highly active ahead monday open merck surge lead dow early trading drugmaker keytruda earn positive result phase trial treatment lung cancer tumor merck share drop friday negative result late state trial be september low illinois base biotech avexis avxs spiked open trade swiss drug giant novartis nvs announce pay acquire gene therapy specialist novartis pay share premium almost avexis close price friday novartis share rise monday open biotech menlo therapeutic mnlo dive early action jeffery cut stock hold buy company announce dermatitus treatment serlopitant fail meet target phase clinical trial tech realm facebook zuckerberg step front congress tuesday wednesday lawmaker eager grill social medium pioneer question be likely revolve facebook privacy practice security detail related cambridge analytica scandal facebook penalize datum analytic firm sunday possible misuse facebook user datum facebook share be early february high post tight weekly close converge week move average ibd leaderboard name amazon com rise note ub quote former postmaster general patrick donahoe say company relationship be profitable postal service analyst arrange call donahue accord marketwatch due question confusion rhetoric come washington raise amazon contract usps amazon share be pull back week consolidation extend buy point also leaderboard list athm swung higher be consolidate week support march high boee ba share rally start trading american airline group aal report late friday plan purchase boee aircraft value more american also say cancel deal boee european rival airbus boee share be pull back early march high american share have be undulating flattish consolidation december american share rise early action be interested stock rally isn dead key sector be bad signtrump tariff china trade war threat be good news big picture trump trade war take bullsnetflix top ipos join stock expect earning growthif re not follow sector leader closely be market sell stock add cut ibd list
822,MRK,find best biotech company invest be tricky volatility often pockmark space clinical plan don always come fruition sometimes biotech stock suffer hand regulatory decision food drug administration best biotech company invest tend have commonality strong streak earning growth june investor business daily marketsmith com have biotech stock strong list fastest grow stock top list fastest grow stock supernus pharmaceutical supn be rank eighth past year earning share have grow massive compare top earn stock momo momo chinese social medium firm supernus have make name biotech stock term market cap still trail bigger biotech company amgen amgn gilead science gild biogen biib celgene celg supernus land list consider best biotech company invest strong metric always do research buy stock be sure check company stock chart make sure right time buy have several year double digit quarterly sale growth drug help disorder central nervous system supernus count epilepsy drug oxtellar xr extend release trokendi xr trokendi xr be also approve prevent migraine rival drug botox allergan agn amgen aimovig ligand pharmaceutical lgnd be unique biotech stock ibd rank fastest grow stock put research list possible best biotech company invest doesn market single drug instead ligand acquire early stage technology necessary drug development then license platform pharmaceutical company dow jone stock merck mrk pfizer pfe june ligand have year double digit sale earning growth belt ligand supernus have ibd composite rating meaning perform top stock term key growth metric duo lead other biotech stock term cr get instant access more trading idea exclusive stock list ibd proprietary rating only related chart read basic buy point mark time real build long term profit stock take many gain trade stock most penny stock fail make investor rich
823,MRK,linger trade war fear carry stock market midday monday selling be mostly focuse blue chip stock intel intc walt disney weigh dow other laggard blue chip index be procter gamble pg traveler trv merck mrk et dow be fade nasdaq composite ease russell index small cap stock outperformed rise volume nyse nasdaq be tracking lower friday level turnover be very heavy friday due option expiration share intel slump day move average security downgrade chip giant underperform market perform share lose disney stock meanwhile fall more pivotal research downgrade share sell hold disney comcast cmcsa be battle acquire st century fox fox late last week comcast offer acquire most st century fox film television asset higher offer disney bid last year stock market result today fleetcor technology flt gap consolidation rise nearly set join early wednesday replace time warner just complete merger leaderboard name dropbox dbx continue torrid ascent breaking first stage ipo base last week share rise monday soar last week well extend buy point nasdaq component adobe system adbe bounce back friday gap share rise heavy volume still high heel earning report last week adobe remain well extend price big run last proper base be way back january be ride day move average higher ever adobe be member ibd sector leader screen also nasdaq google parent alphabet googl add still buy range handle buy point share be strong news investing china base jd com jd share jd com add much pull back micron technology mu look poise extend lose streak session ahead earning report wednesday close be mild pullback so far short live buy point keep mind micron latest attempt be later stage base big move already oil gas stock outperformed ahead friday opec meeting crude oil future fall fourth straight week last week expectation opec hike output russia reportedly want big increase iran think change be need new york mercantile exchange crude oil edge barrel get newsletter deliver inbox more info product service privacy policy term useu base exploration production firm lead charge group anadarko petroleum apc be testing support day move average first time share rise whiting petroleum wll be also testing day line heavy volume drop support level friday share gain also video game stock get price target hike post showthese stock just come ibd stock listsearning watch do micron fedex make sense call option trade
824,MRK,seller swarm fang stock stock market wednesday tech stock general face round selling close nasdaq composite lose close slip dow jone industrial average fall less preliminary datum show volume nyse nasdaq come well tuesday level merck mrk walmart wmt be top gainer dow chip name nasdaq lag again name microchip mchp broadcom avgo intel intc lam research lrcx end loss more bond market be quiet year treasury yield be mostly unchanged stock market today fang stock amazon com amzn re-cover lows still lose renew report president trump be consider additional taxe other regulation internet retailer become formidable rival brick mortar retailer include department store sporting good chain fellow fang name netflix nflx also take heat fall testing support day move average first time flat base early january retail stock turn solid performance help strong earning leaderboard name lululemon athletica lulu share jump other retail name hold well weak market tape include urban outfitter urbn american eagle aeo ollie bargain outlet olli result ollie be due april close merger news oil gas producer concho resource cxo plunge nearly news acquire rsp permian rspp stock share rsp permian soar nearly top rate growth stock face selling pressure again ibd component fall more related amazon stock dife obsessed trump consider regulation tax actionbiggest permian buyout signal new phase top shale playchina base iqiyi ready big initial public offer
825,MRK,result trial study ovarian cancer regimen tesaro tsro merck mrk have analyst split tuesday lead tesaro share dip second day run preliminary result show cocktail tesaro zejula keytruda dow jone stock merck provide stronger defense chemotherapy hard treat ovarian cancer patient least analyst be unimpressed rbc analyst kennen mackay note overall response aren meaningfully better solo treatment call parp inhibitor tesaro zejula be parp inhibitor merck drug be immuno oncology drug know pd checkpoint inhibitor further datum look be inferior vs competitor immuno oncology combo datum see yesterday immunogen imgn drug know mirvetuximab soravtansine keytruda heavily pre treat group ovarian cancer patient mackay say note get newsletter deliver inbox more info product service privacy policy term useon stock market today tesaro slip close merck lose immunogen also present datum ovarian cancer plummet biotech stock broadly fall tesaro study combination zejula keytruda patient ovarian cancer be resistant doesn respond platinum base therapy overall patient respond regimen combination also achieve disease control rate patient don respond platinum base therapy overall response rate be typically just platinum resistant patient respond chemotherapy response be generally much lower patient don respond platinum base therapy patient tumor didn have mutation brca gene have overall response rate historically patient don have brca mutation be platinum resistant have low response treatment parp inhibitor zejula alone tesaro be now plan registrational trial zejula own drug tsr investigational drug be antibody target pd protein rbc mackay note zejula keytruda combination look inferior cocktail rival immunogen merck immunogen test drug mirvetuximab soravtansine keytruda ovarian cancer patient be resistant platinum base therapy combination achieve overall response rate heavily pre treat group ovarian cancer patient interestingly astrazeneca azn also combine immuno oncology drug parp inhibitor patient do respond platinum base therapy study overall response range aren meaningfully better treatment parp inhibitor alone say datum remain early note take together do not compellingly speak synergistic potential parp inhibitor immuno oncology combo continue investment say credit suisse analyst alethia young still see potential combination parp inhibitor immuno oncology drug zejula keytruda together improve standard care ovarian cancer say note similarly astrazeneca regimen parp inhibitor lynparza immuno oncology medicine imfinzi show overall response rate ovarian cancer disease control rate week be young also call use parp inhibitor outside ovarian cancer regulator have approve drug tesaro clovis oncology clvs astrazeneca second treatment ovarian cancer patient be sensitive platinum base therapy ongoing study be look parp inhibitor ovarian prostate breast cancer ultimately expect parp inhibitor market grow overall think be space parp inhibitor say datum set next month support expand opportunity believe be parp class related much money do need start investing investing basic sell stocklooking best stock buy watch start here
826,MRK,blue chip stock outperformed monday session wall street walmart wmt merck mrk be strong performer dow jone top gainer nasdaq include china name baidu bidu jd com jd walmart picked more selling brazilian operation private equity firm advent international result deal walmart be take noncash charge merck meanwhile add asco conference chicago weekend drugmaker announce more good news blockbuster cancer drug keytruda afternoon trading dow jone industrial average lead way rise nasdaq composite add come point time intraday high set march index friday punch level significant technical accomplishment even volume fall thursday level add russell be flat slightly higher volume nyse be tracking lower friday level nasdaq volume be pace be close friday dow still have level conquer next test meanwhile be level elsewhere dow microsoft msft add agree acquire github platform software developer share leaderboard name apple aapl be worldwide developer conference get underway earning news top growth stock palo alto network panw rise early reversed lower share be company report earning also tap former softbank google executive new ceo retailer home home featured latest earning preview column make good case support day move average rise result be due thursday close get newsletter deliver inbox more info product service privacy policy term useon downside nektar therapeutic nktr plunge asco conference company release ambiguous datum drug treat melanoma kidney cancer drug nktr be be used bristol myer squibb bmy opdivofacebook fb meanwhile be pressure early re-cover lows new york time report company have have datum sharing partnership smartphone tablet maker include amazon com amzn apple microsoft other related here be winner loser biggest cancer drug meetinganother day more stock hit ibd include lululemonoption trading mongodb carve base ahead earning report
827,MRK,dow jone have best weekly gain month nasdaq composite hit record high retail stock continue lead stock soar boom earning tesla tsla ceo elon musk promise big jump model production apple aapl release new software worldwide developer conference facebook fb face question datum sharing china huawei delta air line dal southwest airline luv warn high fuel cost nasdaq composite hit record high rise week even apple aapl facebook fb software stock pull back later week rise dow jone shot best gain month dow jone clear recent sideway action year treasury yield hit resistance tesla tsla stock soar ceo elon musk speak annual shareholder meeting say be quite likely tesla build model week end june say production model crossover vehicle go production year also say tesla plant china be come tesla share pop apple introduce io operate system iphone ipad watcho apple watch maco mojave mac computer worldwide developer conference apple wwdc also showcased revise software development tool make augment reality apps call ar kit improve siri voice assistant program add group videoconference facetime app apple also tout commitment user privacy be see knock search giant google googl social network facebook fb apple stock hit record high pare gain friday renew concern iphone demand get newsletter deliver inbox more info product service privacy policy term usefacebook stock fall social network confirm datum sharing agreement chinese firm include smartphone maker huawei have close relationship china government have be flag american intelligence official national security threat other partnership be computer giant lenovo smartphone maker oppo china manufacturer tcl partnership date least remain effect facebook official wind huawei deal end week meanwhile sen mark warner top democrat senate select committee intelligence ask google parent alphabet googl alliance huawei other chinese company report have hammer deal lift sanction chinese telecom gear maker zte lift share several component supplier least initially company such acacia communication acia lumentum lite have be bar selling device zte china second biggest telecom gear maker huawei agreement zte also clear regulatory path propose qualcomm qcom takeover nxp semiconductor nxpi stock surge centric discount retailer top first quarter earning estimate give bullish guidance closeout retailer ollie bargain outlet olli easily beat earning view top line guidance be only line ollie stock dip result still rise week many retail stock have huge week delta air line dal cut second quarter earning share outlook say sharp rise fuel price cut term result even business leisure travel remain solid delta air decide next month adjust flight capacity fall higher oil price part spur southwest airline luv trim own full year capacity growth outlook southwest also forecast unit revenue lower end initial range cite lower booking cut marketing wake fatal accident april china livestream company yy yy huya huya report first quarter earning show strong revenue user growth yy offer video stream chat feature concert fashion event sport monthly active user base mobile livestream service rise year period more revenue rise earning rise huya be spun yy ipo say revenue jump be profitable huya still partially own yy boast china largest livestream gaming community end quarter monthly average user year period palo alto network panw earning rise cent share top expectation cent billing increase top view july quarter cybersecurity firm forecast ep revenue estimate late june palo alto say fiscal revenue rise wall street target palo alto also tap nikesh arora former softbank google executive next chairman ceo meanwhile okta okta report narrower expect fiscal first quarter loss revenue rise estimate april ipo spiked new high thursday intraday reversed sharply lower carbon black cblk come public last month report smaller expect loss revenue be line share hit new high earlier week pull back friday starbucks sbux chairman howard schultz leave later month end decade helm help coffee chain expand store more country growth slow starbucks be increase bet china plan triple revenue next year schultz become starbucks chairman emeritus be mull presidential bid dow jone merck mrk loxo oncology loxo nektar therapeutic nktr get big reaction presentation american society clinical oncology last week merck pop cancer drug keytruda stave disease progression melanoma patient median month follow keytruda also seemingly outperformed rival opdivo bristol myer squibb bmy lung cancer study nektar crash monday disappointing melanoma datum partner bristol loxo spiked then fall study cancer involve specific genetic mutation exact science exas break wednesday strong result blood test detect liver cancer mcdonald mcd reportedly plan cut more corporate job put more money digitize restaurant share soar cloudera cldr report fiscal revenue top estimate report loss cent penny estimate share fall thursday coupa software coup report revenue year top estimate report adjust loss cent vs estimate cent share loss share spiked guidewire software gwre report fiscal adjust earning cent revenue grow top view analyst have estimate cent loss share revenue share tumble twitter twtr joined index spur index fund buy stock share rise sharply twitter replace have be acquire bayer ibd stock healthequity hqy rally hsa custodian easily beat earning forecast raise full year guidance late monday pare gain later week hd supply hds earn cent share revenue top estimate guide consensus share industrial supply distributor gap higher dkny parent iii apparel giii rocket licensee many top brand report ep cent share loss have be expect broadcom avgo beat earning sale target fiscal second quarter apple chipmaker current quarter sale guidance come short share fall friday microsoft msft acquire github lead software development platform microsoft biggest deal buy professional networking site linkedin december
828,MRK,amgen amgn be better string together small deal rather attempt megamerger like celgene celg alexion pharmaceutical alxn astrazeneca azn analyst suggest monday biggest debate stock be amgen do war chest cash tax reform credit suisse analyst alethia young say note client end amgen have cash investment young see amgen have cash think maximum deal size amgen finance raise equity be say amgen buy similar amount revenue growth significantly cheaper series small cap deal vs large cap just amgen buy puma biotechnology pbyi tesaro tsro anaptysbio anab achieve compound annual growth rate pro basis astrazeneca cost same growth shire tack sale growth rate get newsletter deliver inbox more info product service privacy policy term use here see amgen attain similar revenue growth rate less upfront capital young say investor also be interested amgen strategy contend emerge competition rivale biggest drug enbrel amgen total sale decline amgen expect total sale again decline midpoint guidance megamerger celgene be most interesting young say amgen have pay split cash equity include addition debt raise celgene add top bottom line respectively compound basis celgene financing revlimid controversial intellectual property matter make deal complex say astrazeneca also have interesting revenue synergy be significant integration risk astrazeneca employee base be time bigger midcap range incyte incy alexion be also interesting allow flexibility do few small deal well young say fit nicely amgen hematology unit require equity financing incyte be unlikely term first half incyte partner merck mrk dow jone component be set unveil result trial immuno oncology drug epacadostat keytruda advanced melanoma alexion just have positive datum next generation version biggest moneymaking drug soliris call alxn amgen buy alexion add sale profit respectively young say keep neutral rating price target amgen stock market today amgen lose close sympathy broader biotech market fall collective related invest stock free new apps aim basic sell stocklooking next nvidia start simple routine
829,MRK,astrazeneca azn bristol myer squibb bmy vertex pharmaceutical vrtx be likeliest target biopharma detonation event tax reform spur widespread merger acquisition group analyst say friday leerink analyst seamus fernandez call come consolidation inevitable product make like abbvie abbv roche rhhby amgen amgn dow jone stock merck mrk celgene celg biogen biib shire shpg be soon face new competition generic rival follow unprecedented period innovation new product launch large biopharma say note client several largest company likely experience substantial growth slowdown next year get newsletter deliver inbox more info product service privacy policy term usecelgene biogen astrazeneca be most accretive potential acquirer base short term financial fernandez say average accretion be respectively bristol astrazeneca vertex make most sense long term strategically say appear be best position longer term revenue growth base look consensus expectation last major consolidation period biopharma occur last decade be deal greater value largest be dow jone stock pfizer pfe acquisition warner lambert premium pfizer also paid biggest premium pharmacia fork acquire firm merck paid premium buy schering plough deal combine pfizer astrazeneca allergan agn abbvie shire have fail fernandez see next cycle seller market pfizer be struggle late entry immuno oncology market merck have strong immuno oncology drug keytruda lack robust late stage pipeline roche face biosimilar competition top drug avastin herceptin rituxan novartis nvs be still experience challenge sandoz unit abbvie be strong term key drug humira soon see competition europe strategically astrazeneca be strong fit abbvie pfizer roche merck fernandez say bristol fit abbvie pfizer meanwhile possible abbvie swing vertex financial lens astrazeneca vertex biogen bristol be most compelling target ability enhance long term sale say amgen be acquirer target fund buy something fernandez say assume amgen be look make deal value less vertex rise top list potential target outlasting regeneron pharmaceutical regn shire vertex look more interesting say related chart read basic buy point mark time real opportunitylong term retirement investing strategy buy stock ahead earning report
830,MRK,esperion therapeutic espr stock plunge wednesday cholesterol bust drug succeed phase trial show liver function side effect small portion patient stock market today esperion share dove much pare loss finishing regeneron pharmaceutical regn amgen amgn make different type cholesterol drug add lose respectively patient study have liver function issue result drug study esperion bempedoic acid patient have elevated liver function issue still needham analyst chad messer keep esperion top pick point be well labele incidence liver function test elevation approve statin messer write note client believe concern datum be unfounded be buyer esperion weakness today use ibd marketsmith free march
831,MRK,see stock buy point get chart pattern recognition run custom screen start nowbempedoic acid be test vs placebo patient risk heart disease high cholesterol inadequately treat other therapy week study meet key goal lower bad ldl cholesterol vs placebo esperion say news release ldl cholesterol be cut bempedoic acid patient vs increase patient receive placebo patient treat bempedoic acid also achieve cut high sensitivity reaction protein marker inflammation tie heart disease vs increase placebo patient month esperion be also set unveil datum phase trial testing bempedoic acid top therapy psck inhibitor regeneron praluent amgen repatha esperion be expect bempedoic acid be less expensive drug esperion have datum year long safety study study bempedoic acid patient ve fail prior statin august biotech unveil datum combination bempedoic acid ezetimibe market dow jone component merck mrk zetia later year esperion be expect have datum trial bempedoic acid patient heart disease already statin take maximum dose be tolerate messer expect esperion file approval first quarter europe second quarter related trade stock most penny stock fail make investor richlong term retirement investing strategy etfslook next nvidia start simple routine
832,MRK,stock open modest gain monday tech merger drug industry news power largest early move dow jone industrial open gain strong early move merck mrk be partially hold back intel intc intel share respond latest development broadcom avgo effort take qualcomm qcom rise higher nasdaq composite open gain broadcom micron technology mu lead index early trade amgen amgn intel fall bottom list market uptrend get groove back friday surprisingly strong february job report trigger rally major index clear key level resistance nasdaq shake distribution day monday action provide test durable gain market upgrade status be merck advanced lead dow open trade new jersey base drugmaker last week announce invest jointly develop japan eisai lenvima ketruda combination cancer treatment january earn food drug administration breakthrough designation kidney cancer treatment intel post dow few early loss report friday company be consider takeover bid broadcom mean upend broadcom effort merge qualcomm broadcom open more higher stock have be wrestling retake support converge week move average month consolidation qualcomm add early trade sign free ibd newsletter market prep tech reportoclaro oclr spiked start bell lumentum lite announce acquire company cash stock deal lumentum reportedly supplier technology used apple aapl face id application say combination aim fast forward participation market sense technology oclaro share trade lumentum share end friday february low buy range buy point month cup base ibd stock future rise open trade share micron technology swung more open boise idaho base storage chip leader break past buy point heavy trade week end friday buy range entry amgen slip more worst early decline nasdaq stock amgen other competitor regeneron pharmaceutical regn cholesterol drug praleunt fall regeneron announce plan lower price drug regeneron share rise open initial public offering also play part early action china base qudian qd pop stronger forecast result fourth quarter include surge number borrower increase total transaction period share end friday november low still stock october ipo price tech unicorn dropbox file update prospectus announce plan offer share ipo midpoint range value online file storage sharing company company revenue rise last year net loss be halved share trade ticker dbx offer date be not yet clear asia stock market logged strong gain dollar climb heel friday job report hong kong hang seng index jump nikkei tokyo vault higher market europe slip mixed action afternoon trade frankfurt dax lead ftse london slip loss be interested big picture market outlook have changedapple supplier lam research lead chip stock buy zonesthese top china net have new buy point now study chartschip stock watch semiconductor industry news
833,MRK,share drug giant merck mrk fall tuesday federal judge tossed record verdict have win gilead science gild hepatitis treatment federal jury have say gilead owe merck sale sovaldi harvoni hepatitis drug district court judge leonard stark wilmington del agree friday gilead argument merck patent be invalid patent issue be compound merck idenix unit contend be basis major treatment hepatitis include one make gilead merck claim be first synthesize compound gilead say didn cover new idea patent owner be require describe invention enough detail allow other replicate unnecessary time effort case stark say merck patent cover so many potential compound take excessive experimentation narrow base only reasonable find be patent be invalid stark say decision merck share lose close foster city calif base gilead add merck base kenilworth pledge appeal judge finding say do not reflect fact case patent issue case facilitate significant advance treatment patient hcv infection achieve advancement require many year research significant investment subsidiary partner company say written statement believe strong patent protection be essential innovation merck add give guarantee firm period return investment patent protection provide research base pharmaceutical biotechnology industry incentive invest research development sovaldi be approve food drug administration harvoni get regulatory go ahead year later merck drug zepatier be approve gilead have concede infringement patent common legal tactic allow focus validity issue trial reject gilead argument patent jury say gilead owe royalty total sale drug separate part ruling stark reject gilead argument damage amount be unfair issue become important only patent be later revive appeal verdict be largest patent infringement verdict history dwarf next biggest verdict win johnson johnson jnj abbott laboratory be later throw appeal accord datum compile bloomberg
834,MRK,earlier year appear stock be go free fall bear lick chop talk head pound table gold yes fact gold have be go black gold variety be crude oil have emerge asset class year west texas intermediate
835,MRK,stock market rally well intraday lows tuesday tech heavy nasdaq stage upside reversal day fang stock facebook fb reversed early loss stock market today announce entry new industry meanwhile apple aapl stock rise more ahead fiscal result beat forecast close nasdaq pace major index advance be dow jone industrial average lag fall turnover be tracking slightly higher nyse nasdaq exchange vs same time monday accord preliminary datum dow stock day laggard featured drugmaker pfizer pfe merck mrk pfizer decline mixed result stock fall day move average heavy volume meanwhile merck fall lighter expect sale result top chip stock intel intc moved continue be top perform semi stock weaken sector straight day heavy loss friday monday stock remain day line get newsletter deliver inbox more info product service privacy policy term market close apple report anxiously await fiscal result iphone maker be expect earn share revenue share have be volatile recent week concern company iphone sale apple stock rise shape flat base buy point fang stock be rally nasdaq turn positive territory amazon com amzn moved facebook fb turn early loss gain social medium company announce new date layer mobile app share match group mtch owner tinder mobile app crater pierce day line huge turnover leaderboard stock netflix nflx rise share be hold day move average line lead growth stock grubhub grub faltered tuesday food delivery service announce earning sale top analyst estimate come short daily average grub average number order day upside svb financial sivb rise more hit new high friday superregional bank shot almost gap cup base entry other top performer include abiom abmd pagseguro digital pag advanced more related tesla mastercard square earning fed meeting investing action plandow jone industrial average dow stock news analysisapple aapl stock quote company news chart watch amazon deal fire retail stock best growth stock buy watch see update ibd stock list
836,MRK,dow jone industrial average index rebound key support level end slightly lower nasdaq composite fuel apple aapl rally tesla tsla skid cash burn elon musk strange conference call mastercard hit buy zone new payment stock struggle alibaba baba pull back strong earning sprint merge mobile tmus headline several big deal job report symmetric fed stance ease rate hike fear crude oil price hit record high shale operator beat earning view dow jone undercut day move average rebound friday finish week nasdaq composite rally retake day line apple aapl fuel earning buyback warren buffett buy more share soar drive major average higher tesla tsla fall alibaba baba rally mastercard enter buy zone treasury yield pull back yield spread narrowing slightly crude oil rise nearly barrel shale earning be strong apparel stock be loser consumer electronic giant apple aapl earn share year year sale fiscal second quarter be best ep gain year latest string accelerate revenue growth report top forecast apple sell iphone just miss consensus service revenue wearable sale be strong apple also announce plan buyback big dividend hike warren buffett disclose berkshire hathaway brkb buy apple share first month bring total stake nearly apple stock surge best weekly gain year hit record high blast buy zone get newsletter deliver inbox more info product service privacy policy term usetesla report smaller expect loss forecast revenue electric car maker model production remain low company burn cash post earning conference call ceo elon musk cut wall street analyst bore question spend next minute take question blogger youtube share fall sharply thursday close week cent alibaba report better expect quarterly earning core commerce revenue swell cloud revenue more double alibaba end quarter monthly active user mobile device alibaba also give bullish outlook share rise friday jobless rate slide april lowest economy add job labor department report friday meanwhile average hourly wage growth rise just year little view fed favore gauge core inflation climb policymaker send message win panic top come month fed stress wednesday inflation target be symmetric qualys qlys fireeye feye fortinet ftnt top earning revenue view share retreat cyberark software cybr rally strong result outlook guide slightly higher meanwhile carbon black cblk jump friday debut ipo price late thursday high end recently raise range zendesk zen pop result guidance show customer support sale automation software company be build momentum rival salesforce com crm larger contract paycom payc report strong earning sale growth forecast line june quarter result send hr payroll process software maker lower fellow payroll hr cloud software firm paylocity pcty break friday result commerce software firm shopify shop top view size sale beat update guidance left investor unimpressed shopify initially fall rebound strong gain ultimate software ulti report adjust ep top estimate revenue grow also beating share rally wednesday close buy point mcdonald mcd surge score double beat ep rise revenue fall shake shack shak sky-rocket friday crushed earning beat revenue wingstop wing also jump friday result taco bell parent yum brand yum earning top share skid weak same store sale yum china yumc tumble weak pizza hut result china offset overall strong earning texas roadhouse txrh slip come par ep cent revenue viper energy partner vnom anadarko petroleum apc concho resource cxo noble energy nbl matador resource mtdr continental resource clr parsley energy pe eog resource eog pioneer natural resource pxd top quarterly estimate integrate energy firm marathon oil mro clear buy point follow earning oil price hit fresh multiyear high inventory production increase odd be rise president trump withdraw iran nuclear pact sprint mobile tmus finally agree merger share fall lack price premium fear antitrust regulator reject deal meanwhile marathon petroleum mpc agree buy andeavor andv create largest base refiner additionally walmart wmt say chain asda merge sainsbury walmart reportedly be deal buy india commerce giant flipkart prologis pld buy dct industrial dct finally marriott vacation vac reveal buy ilg ilg annual developer conference facebook fb say be enter online date business more person facebook identify single match group mtch own match com date app tinder plunge announcement facebook also introduce oculus go stand alone vr headset announce october arista network anet late thursday report ep gain revenue swell beating cisco rival see revenue line view send share tumble friday turnaround project juniper network jnpr late tuesday report ep decline wasn bad expect sale network gear cloud compute customer rebound juniper forecast profit slightly view share pop pare gain allergan agn zoetis zts teva teva exelixis exel top quarterly expectation allergan sank report unlikely make deal zoetis fall adjust profit guidance miss penny dow jone component merck mrk pfizer pfe beat profit lag sale gilead gild miss sale adjust earning hepatitis drug fall vs last year regeneron regn profit beat revenue miss eye drug eylea top view celgene celg topple analyst suggestion key drug be delay year friday celgene say refile application drug ozanimod multiple sclerosis treatment celgene also top first quarter expectation raise full year guidance sarepta srpt sale miss view loss be better expect mastercard share jump credit card giant report earning beat estimate join visa buy range square sq sale also top bitcoin make payment technology firm current quarter profit outlook come short fleetcor flt provide prepay fuel card vehicle fleet other payment product sank low outlook paypal pypl tumble amazon amzn reportedly offer merchant discount use own payment service controversy kanye west comment slavery have tangled adida addyy ceo sportswear company distance not cut ty rapper west yeezy brand be not significant part adida revenue contribute brand style image share tumble buy point adida logging currency neutral revenue growth include solid north america meanwhile armour uaa top estimate give weak outlook susquehanna say inventory be tick time bomb coach kate spade parent tapestry tpr top consensus share plunge upscale purse accessory maker raise guidance be still largely consensus north face van parent vf corp vfc beat view share retreat friday snapchat operator snap snap crash record low miss first quarter view revenue user growth several other key metric grubhub grub top first quarter earning estimate food sale miss target share fall sharply pare loss friday world wrestling entertainment wwe spiked wwe body slam earning estimate continue attract subscriber ep rise cent however revenue be miss disk drive maker seagate technology stx report quarterly earning beat estimate stock fall cautious comment tariff ferrari race zoom buy zone double beat ep rise cent revenue climb tableau datum report sale earning expectation license revenue be ahead consensus company lower full year margin guidance big datum firm stock jump
837,MRK,dow future lead premarket trading back narrow decline tuesday market generally hunker ahead apple aapl fiscal second quarter result later day fed interest rate decision wednesday april payroll report due friday dow future give brief gain slip less fair value apple lead index merck mrk pfizer pfe post heaviest decline nasdaq future also dip narrow loss akamai technology akam citrix system ctxs top nasdaq seagate technology stx post heaviest loss big benchmark score nominal gain april dow nasdaq struggle fractional gain still month be noteworthy stop month slide have send nasdaq february march get newsletter deliver inbox more info product service privacy policy term usemarket continue hold breath tuesday president trump delay june tariff be set take effect today steel aluminum import european union mexico canada agreement avoid tariff be place australia brazil argentina white house say march tariff go effect china russia japan foreign steel stock trading show little reaction premarket trading share steel drop more steel stock general have be pull back consolidate february factor investor radar federal open market committee begin day meeting morning washington meeting be expect wrap rate policy decision wednesday afternoon be press conference follow announcement addition several key piece economic news be expect today manufacturing purchasing manger index april be due researcher markit et institute supply management et march construction spending number commerce department be expect et automaker be report april sale total session apple most notable earning report stock market today add premarket trade analyst have raise concern company outlook wall street see jump earning revenue gain first quarter mark company best result fourth quarter apple share have decline past month have be stall day move average late april dow pfizer drop merck tumble drugmaker top analyst quarterly earning expectation revenue growth stop short target haynesbrand hbi nutrisystem ntri allison transmission alsn be other lead name motion follow earning report early tuesday tenet healthcare thc skip nearly deliver strong result monday close premarket gain position stock narrowly clear flat base buy point not premarket move carry regular trade seagate technology tumble nearly just report fiscal third quarter result earning revenue growth appear top expectation management raise company quarterly dividend cent armour uaa reversed early gain drop premarket trading athletic wear maker first quarter sale profit score easy beat company reaffirm full year revenue expectation guide general weakness market sale surge overseas armour share end monday buy point month long base aerospace component maker transdigm tdg pop report fiscal second quarter result open result soar past analyst target management give full year guidance significant boost cite transdigm recent acquisition stock close monday less handle buy point ibd stock bofi hold bofi pop premarket action monday close bell bofi be not quite flat base buy point medical product maker inogen ingn spiked clobber analyst expectation first quarter report late monday maker portable oxygen concentrator end monday top buy range buy point flat base be interested big picture anxious market shift attention fedlooking best stock buy watch check alibaba casa big squeeze stock market bull run face biggest threat yearsapple grubhub shopify earning facebook investing action planamazon ibd stock share winning growth trait
838,MRK,investor be likely push biogen biib make acquisition worry regard chance alzheimer disease send share tailspin week analyst say thursday start wednesday dow merck mrk say drug part class call bace inhibitor fail didn bode well biogen own bace inhibitor call elenbecestat biogen tell analyst be expand trial second alzheimer drug be develop aducanumab patient contend greater expect variability key goal trial investor drumbeat business development get louder view canaccord analyst sumant kulkarni write note client believe investor continue look action biogen business development front addition alzheimer worry biogen multiple sclerosis drug tysabri recently fail stroke trial spinal muscular atrophy drug spinraza be likely face competition future biogen be still face headwind multiple sclerosis business ibd take savvy investor thrive rule good market head investor corner rule smart investor always rely make strong return kulkarni note biogen have significant financial flexibility seek deal biogen end cash equivalent marketable security hand note payable other financing arrangement biogen decide expand late stage trial aducanumab early stage alzheimer due greater variability key goal study be originally expect change be base prespecify plan kulkarni say aducanumab differ bace inhibitor former aim remove plaque buildup call amyloid brain associate alzheimer bace inhibitor merck verubecestat work prevent buildup sign free ibd newsletter market prep tech reportfull enrollment aducanumab trial be still expect summer final result likely early leerink analyst geoffrey porge write note client biotech also note dropout rate have be lower expect rate serious adverse event have be expectation not first time biogen have expand trial firm do so previously multiple sclerosis drug tecfidera be incline believe biogen be employ conservative approach case sell wednesday be more eruption accumulate pressure investor repeat failure amyloid direct therapy porge say canaccord kulkarni other hand say merck failure wednesday biogen trial change be likely cause investor unease biogen tank news be difficult draw definitive conclusion base change aducanumab trial merck decision bace believe development lead investor ask renew question amyloid beta approach tackle alzheimer disease say stock market today biogen rise close related biotech stock pop fda nod slam door woesteva pharma rocket berkshire hathaway reportedly take biotech stock rocket immuno oncology tie bristol
839,MRK,stock market fade final hour make bearish price reversal federal reserve release detail january meeting nasdaq composite go gain more end day lower cut gain close decline dow jone industrial average lose meet resistance day move average second straight day also meet resistance day average nasdaq be own day line index behavior line be way gauge market short term direction retreat line be view negative sign concern be main index have fade early gain past session case make bearish price reversal wednesday stock be higher minute fed january meeting be release et then climb even more once detail come additional gain vaporized less hour later selling continue close bell minute show fed policymaker continue back gradual interest rate hike improve economy central bank say labor market condition strengthen further see few sign heavy wage pressure still investor be alarm detail minute yield year treasury note edge lower soon report then rise basis point year high etsy etsy fade market craft marketplace close buy point volume end more average innovator ibd fund ffty fared better broad market add daqo new energy dq surge second straight day appear be shape new base nvidia nvda be laggard day graphic chip artificial intelligence company remain record high philadelphia semiconductor index fall be best sector index tuesday dow component merck mrk announce acquire australian biotech viralytic deal merck remain steep downtrend have real bearing dow performance wednesday small cap buck selling russell close bell related fed minute policymaker see faster growthwendy jack box cheesecake factory report earning latedow merck jump merger bandwagon buy
840,MRK,index dow jone industrial average nasdaq composite rise strongly early week then erased most gain friday close netflix nflx soar subscriber growth guidance energy stock bust higher crude oil price keep rise alcoa aa american express axp unitedhealth unh jump report offset weak outlook taiwan semiconductor manufacturing tsm chip gear giant lam research lrcx asml asml broader chip sector apple aapl come pressure index dow jone nasdaq composite be more thursday friday close be major average rally wednesday netflix nflx earning oil fuel energy stock stock pull back taiwan semiconductor manufacturing tsm warn rest cite weak smartphone demand already pressured weak asml asml lam research lrcx guidance chip stock sell apple aapl also come heavy pressure thursday friday iphone demand concern year treasury yield jump year high internet television network netflix nflx add stream subscriber first quarter beating target end march quarter subscriber worldwide netflix expect add subscriber top wall street target netflix also top ep sale figure guide higher metric subscriber number benefit new original content such science fiction series alter carbon fresh season comic book series marvel jessica jone comedy grace frankie share shot record high taiwan semiconductor manufacturing tsm cut sale outlook rest year largely softer smartphone demand slam chip stock apple aapl taiwan semi be world largest contract chipmaker count apple nvidia nvda qualcomm qcom customer meanwhile chip gear maker lam research lrcx asml hold asml pressured semiconductor stock day earlier weak outlook lam equipment shipment view rest year come light asml forecast lower gross profit margin current quarter get newsletter deliver inbox more info product service privacy policy term useu oil future rise barrel hit fresh multiyear high opec russia likely stay course output cut meeting jeddah saudi arabia friday president trump blast opec crude hold domestic crude stockpile fall barrel last week energy information administration say defy view small gain oil production climb fresh high barrel day schlumberger slb meet view energy stock be big winner yet again more oil play breaking set charle schwab schw interactive broker ibkr trade financial etfc report better expect quarterly earning schwab share reclaim day move average build right side flat base interactive broker moved buy zone just earning then pull back slightly trade moved buy range late thursday report bank america bac first quarter earning top expectation rebound trading lead estimate beating result goldman sachs gs morgan stanley ms extra client activity goldman reversed lower say say likely pause buyback second quarter meanwhile comerica cma sank other super regional bank weak loan growth treasury yield soar financial stock rise weekly lows southwest airline luv flight head dalla new york make emergency landing philadelphia jet left engine explode burst window kill female passenger result passenger jennifer riordan be pronounce dead hospital unite airline ual say inspect engine boee ba type plane experience engine failure follow recent faa bulletin unite share jump carrier narrow expansion plan year ahead stay upbeat sale trend bristol myer squibb bmy plunge report drug combination opdivo yervoy reduce risk lung cancer progression death be lower merck regimen keytruda chemotherapy cut risk death similar group lung cancer patient merck mrk stock climb nearly commerce department ban domestic firm selling component chinese telecom gear maker zte spark sell optical device maker acacia communication acia oclaro oclr lumentum holding lite government determine zte violate term settlement involve illegally ship networking gear iran acacia garner sale zte oclaro analyst say ciena cien compete zte optical system get lift year ban be not lift unitedhealth group unh cruised past wall street first quarter earning estimate net share cent view revenue grow manage care enrollment gain come medicare advantage medicaid meanwhile unitedhealth fast grow optumhealth service unit grow revenue deliver care related service person share rise week approach buy point alcoa aa stock break past buy point record alumina price strong earning blowout profit guidance aluminum giant earning rise revenue grow alcoa expect full year adjust ebitda range offer january expect industry supply shortage year trump administration sanction unite co rusal impose month bar ban entity do business russian aluminum giant top steel maker steel dynamic stld nucor nue edge past first quarter earning estimate issue moderately positive comment outlook nucor expect sustainable strength steel market not quite bullish steel investor have expect late february president trump initially call tariff steel import exemption then more half steel import have be exempt general electric ge report smaller expect adjust ep decline revenue rise more expect aviation health care be solid ge power remain drag ge reaffirm full year ep guidance say have plan cut dividend again ge stock rise friday atlassian team report adjust fiscal profit cent share revenue jump top estimate maker project management collaborative software guide low current quarter ep share tumble friday amazon com amzn ceo jeff bezos disclose amazon prime have more member worldwide first time online sale leader have give specific membership figure be higher expect intuitive surgical isrg break wednesday robot surgical system maker report adjust ep gain sale grow beating view textron txt sell tool test business segment emerson electric cash maker cessna jet bell helicopter also report jump ep cent share rise revenue beating analyst view announce share buyback program textron soar gapping past buy point ibm ibm beat first quarter estimate stock tumble weak margin slower growth key area ebay ebay shot morgan stanley upgrade stock boost price target more cite recent partnership payment processor adyen move away paypal pypl abbott laboratory beat expectation wednesday adjust income cent share sale share dip pharmaceutical sale come expectation johnson johnson jnj top estimate share edge lower share fall wednesday news kentucky be sue allegation run deceptive marketing scheme related painkiller consumer electronic retailer best buy bby amazon com amzn announce partnership best buy use amazon fire tv operate system insignia brand television replace roku roku software best buy also sell tvs amazon american express axp jump thursday report better expect earning wednesday ep rise revenue climb nearly rail giant csx csx gap wednesday beating earning day report ep cent revenue operate income increase skecher skx crash friday give weak earning sale outlook athleisure shoe maker meet ep estimate rise modestly beat sale view gain be interested look best stock buy watch start invest stock market start simple routine
841,MRK,dow jone small cap stock lead stock market rally monday major stock index start week solid ground wasn greatest close blue chip index dow jone reclaim day move average early session end line dow add
842,MRK,mylan myl deny report friday interested buy merck kgaa consumer health care business email investor business daily mylan spokesperson say rumor be untrue mylan policy not comment rumor speculation give egregious inaccuracy report issue morning company be compel confirm reuter article be untrue spokesperson say mylan share dip rumor first report early friday fall close stock market today get newsletter deliver inbox more info product service privacy policy term report suggest merck kgaa sell unit cite person familiar matter previously nestle reckitt benckiser have interest buy unit source say germany merck say last year be aim sell consumer health care business help foot bill prescription drug research segment bring annual sale merck kgaa couldn be reach merck co mrk be initially establish subsidiary merck kgaa germany later nationalized own independent company consumer health business have be merger wringer recently industry include counter drug vitamin other offering march glaxosmithkline gsk agree buy novartis nvs share consumer health business deal allow novartis divest stake unit glaxo expect transaction be accretive earning meanwhile dow jone component pfizer pfe have long struggle offload consumer health business last month glaxo reckitt benckiser dump bid buy business pfizer announce plan sell spinoff unit october sale rise year year sell advil centrum few other big moneymaker related invest stock free new apps aim trade stock most penny stock fail make investor richlong term retirement investing strategy etfs
843,MRK,bristol myer squibb bmy dive month low tuesday analyst debate advanced lung cancer regimen competitor dow merck mrk afternoon trading stock market today bristol lose share earlier fall much merck also topple broadly drug stock rise reverse earlier dip market correction stock pitfall bristol follow strong fourth quarter drugmaker beat expectation top bottom line immuno oncology drug opdivo grow beat consensus drug yervoy lag leerink analyst seamus fernandez say bristol also announce early monday result combination opdivo yervoy first treatment patient advanced lung cancer opdivo merck keytruda be know pd inhibitor work block interaction pd protein immune system otherwise prevent immune response yervoy be ctla inhibitor similar mechanism ibd take bull market be now year accord number pundit have stock market hit top visit investor corner more spot market peak still question remain regard newly identify biomarker know tumor mutation burden tmb opdivo yervoy regimen improve progression free survival patient high level tmb regardless level pd protein theory be population patient respond better certain therapy base much certain biomarker body produce pd inhibitor opdivo keytruda be thought work better patient high amount pd protein leerink fernandez note oncologist expect additional biomarker tmb become part clinical decision make next year replace conjunction pd testing say note client additionally oncologist expect combination opdivo yervoy become standard care certain population say credit suisse analyst vamil divan note portion trial be continue evaluate opdivo chemotherapy vs chemo broad group patient goal improve overall survival wonder progression free survival benefit high tmb group translate overall survival much group overlap other population have already see positive overall survival datum say note trial merck testing keytruda chemotherapy vs standard care chemo advanced lung cancer be arguably less toxic regimen divan say note client even opdivo yervoy combo be approve treat never treat advanced lung cancer patient commercial impact take time physician payer see overall survival datum play divan say overall survival datum be expect high tmb group sooner high pd group latter now expect late early say related biotechs spring back market correction analystallergan pop consensus top quarter strong migraine trialcan crispr small biotechs cure disease
844,MRK,allergan agn pop tuesday result migraine trial report fourth quarter sale adjust profit top wall street expectation allergan jump stock market today intraday trading climb high fourth quarter allergan report adjust earning share sale rise respectively top consensus adjust income share sale botox cosmetic revenue rise year year beat estimate mizuho analyst irina koffler say note botox therapeutic sale grow lag total botox revenue advanced eye drug restasis bring sale schizophrenia bipolar drug vraylar infection drug avycaz tack strongest growth respective ibd take investing be stock market be not gamble do require finesse head investor corner more time buy sell stock namenda extend release treat dementia alzheimer type fall contraceptive minastrin dip overactive bladder drug enable topple skin drug tazorac decline allergan guide sale adjust earning share top analyst view share respectively march quarter allergan see adjust income share sale midpoint earning sale guidance miss consensus respectively allergan also report strong result trial testing adult acute migraine attack result stem first pivotal phase study evaluate milligram milligram dose drug call ubrogepant ubrogepant be give orally belong class drug know cgrps study patient be treat single migraine attack moderate severe intensity allergan say news release dose show statistically significant result vs placebo hour patient treat milligram milligram dose respectively be pain free vs placebo patient most bothersome symptom disappear patient receive milligram milligram dose ubrogepant vs placebo treat patient key note liver toxicity result be better expect evercore analyst umer raffat say report allergan buy right ubrogepant dow merck mrk prior oral cgrps merck be discontinue toxicity reason patient have elevated liver enzyme be greater time upper limit normal be alternative explanation case allergan say none be note have probable relationship ubrogepant allergan have previously mentioned case elevated liver enzyme greater time upper limit normal blind basis phase raffat say reason appear allergan have clear bar liver safety be key migraine attack be often treat drug know triptan triptan don work migraine patient low response triptan respond milligram milligram dose ubrogepant vs placebo triptan market have more peak sale raffat say allergan be call peak sale oral cgrps ubrogepant atogepant expect launch related biotech stock dive more be sell overdo bristol myer squibb dife strong earning opdivo datacan crispr small biotechs cure disease
845,MRK,bristol myer squibb bmy fall monday report fourth quarter metric top wall street view unveil result immuno oncology trial rival dow merck mrk initially bristol pop much intraday high near buy point end regular session stock market today merck meanwhile drop fourth quarter bristol report adjust earning cent share sale rise respective vs year earlier period analyst poll zack call cent sale bristol biggest drug opdivo grow worldwide opdivo rival merck drug call keytruda best growth come anticoagulant eliquis cancer drug empliciti rise respectively ibd take bristol have composite rating best possible still rank seventh group drugmaker see drug stock rate higher visit ibd stock checkup bristol guide adjust profit share consensus have expect adjust profit share sale evercore analyst umer raffat say bristol immuno oncology trial dub checkmate didn go regimen drug opdivo yervoy be better opdivo monotherapy key question immuno oncology story phase trial bristol regimen immuno oncology drug opdivo yervoy improve progression free survival vs chemotherapy patient advanced form lung cancer have never previously be treat opdivo merck keytruda be know pd inhibitor yervoy be ctla inhibitor be immuno oncology drug patient immune system identify fight cancer target specific biomarker bristol regimen opdivo yervoy be first combination advanced lung cancer patient high level biomarker call tumor mutation burden also know tmb test assay foundation medicine fmi checkmate show tmb be important independent predictive biomarker identify population first line lung cancer patient benefit opdivo yervoy combination study investigator matthew hellmann say written statement trial checkmate be effectively different trial embed evercore raffat say announcement monday be regard datum pull part part part look opdivo yervoy opdivo monotherapy vs chemotherapy patient tumor have pd protein part look opdivo yervoy opdivo chemo vs chemo patient tumor don have protein part be evaluate opdivo chemotherapy vs chemo broad group patient key goal improve overall survival part trial continue bristol say news release ultimately most important question be opdivo yervoy combination be do vs opdivo monotherapy raffat say note client be need see incremental impact yervoy opdivo related crispr small biotechs cure disease amgen topple fourth quarter sale earning lagdow merck lag sale earning outlook top
846,MRK,here weekly investing action plan need know investor come week earning season pick momentum result due netflix nflx goldman sachs gs general electric ge ibm ibm score other airline stock get rattle further unite airline ual report give update expansion plan
847,MRK,dow merck mrk announce plan wednesday acquire australian biotech viralytic deal dovetail well drugmaker immuno oncology focus accord analyst viralytic be develop cancer drug call cavatak cavatak be create used virus infect kill cancer cell process call oncolysis be be test several cancer combination merck immuno oncology drug keytruda be very nice tuck merck less fit very well immuno oncology strategy evercore analyst umer raffat write note client stock market today merck slip fraction raffat call timing deal interesting viralytic have guide offer clinical update second quarter combination trial cavatak keytruda lung bladder cancer early stage study cavatak keytruda be combine melanoma overall patient respond treatment vs patient keytruda alone raffat say cavatak have also be combine bristol myer squibb bmy drug yervoy melanoma get ibd market prep tech report newsletter free term deal merck acquire issue share viralytic be publicly trade australia share cash deal represent premium month volume weight average price viralytic share merck senior vice president roy barne praise deal written statement transaction be expect be implement second quarter viralytic become wholly own subsidiary merck viralytic approach engage innate immune system target cancer cell complement immuno oncology strategy be focuse rapid advancement innovative monotherapy approach synergistic combination help broadest range cancer patient say lepu medical group be viralytic largest shareholder currently hold firm group say intend vote merger merck superior proposal doesn present deal be just drop much larger bucket biotech drugmaker merger analyst say year be explosive regard already have be north biotech deal announce vs merck deal come heel roche rhhby plan announce friday acquire flatiron health january celgene celg say acquire juno therapeutic juno sanofi sny announce bid bioverativ bivv ablynx ablx related be explosive year biotech mergersbiotech investor flee drove market correction rock groupthese biotechs spring back market correction analyst
848,MRK,dow merck mrk slump friday fall short revenue adjust earning beat wall street estimate guidance be bullish stock market today merck sank share close rival bristol myer squibb bmy lift fourth quarter merck report adjust income cent share grow beating consensus analyst poll zack investment research cent sale advanced miss analyst view worldwide immuno oncology drug keytruda grow sale north consensus leerink analyst seamus fernandez say note client keytruda sale miss fernandez model diabetes drug januvia janumet bring combine sale grow be just ahead fernandez expectation ibd take merck have composite rating best possible meaning perform middle stock term key growth rate head ibd stock checkup look better rate drug stock revenue gardasil vaccine prevent cancer cause human papillomavirus girl woman age advanced miss fernandez model sale cholesterol drug zetia decline year year beat expectation fernandez say animal health sale advanced also top fernandez view biggest miss come shingle vaccine zostavax decline sale lag fernandez expectation hepatitis drug zepatier bring miss fernandez view merck guide adjust earning share sale consensus have modeled adjust profit share sale related crispr small biotech company cure disease biotech roundup pop drug merger earning news amgen topple fourth quarter sale earning lag
849,MRK,analyst weren surprised wednesday dow merck mrk terminate late stage study potential alzheimer disease drug argue win have implication biogen biib announce expansion key alzheimer trial biogen share fall anyway late wednesday share slide much biogen announce enroll more patient original recruitment plan phase aducanumab trial enrollment be still expect be complete mid leerink analyst geoffrey porge write note client biogen news follow merck decision late tuesday scrap study drug call verubecestat patient early stage alzheimer disease verubecestat be know bace inhibitor aim prevent buildup amyloid plaque brain associate alzheimer context merck recent disappointment merck bace inhibitor verubecestat biogen aducanumab be be now only handful alzheimer medicine still active pivotal trial porge say merck halter late stage trial verubecestat time last year investigator find have virtually chance work patient mild moderate alzheimer credit suisse analyst vamil divan say failure be disappointment not surprising remain hopeful drug potentially show benefit give patient earlier course disease say note client now remove verubecestat revenue model divan cut price target merck keep outperform rating merck likely have seek merger big enough move needle market cap company annual sale north rest business be not strong enough allow growth be see oncology come say today news be not unexpected do believe add incremental pressure merck pursue business development opportunity bring additional growth driver mid late stage pipeline ibd take day move average be used pinpoint time opportunity risk stock head investor corner more tip smart stock buy selling tip evercore analyst umer raffat point failure alzheimer space be never good news other include biogen eisai eli lilly lly astrazeneca azn novartis nvs dow johnson johnson jnj be also work bace inhibitor biogen aducanumab work differently bace inhibitor aim remove plaque buildup brain analyst be particularly hopeful prospect aducanumab look actual amount amyloid plaque reduction bace inhibitor dramatically less biogen see aducanumab raffat say report plaque reduction aducanumab be far most important thing go biogen favor rbc analyst brian abraham be more bullish aducanumab biogen eisai bace inhibitor elenbecestat aducanumab also target beta amyloid not necessarily make direct read through failure bace inhibitor beta amyloid target monoclonal antibody say believe unknown beta amyloid hypothesis be already baked biogen share stock market today biogen tumble close merck be unchanged related biotechs spring back market correction analystbiotech investor flee drove market correction rock biotech stock rocket immuno oncology tie bristol
850,MRK,gilead science gild share pop midday wednesday food drug administration approve new hiv drug regimen rival treatment glaxosmithkline gsk treatment know biktarvy contain drug call bictegravir emtricitabine tenofovir alafenamide be approve once daily single tablet treat hiv infection gilead say news release biktarvy label warn exacerbate hepatitis symptom patient require liver function monitoring patient close bell stock market today gilead jump finish biotech stock collectively lift fraction percentage point glaxo rise fraction time gilead call bictegravir mount everest come hepatitis drug franchise begin dwindle high cure rate europe biktarvy be add gilead hiv hepatitis drug unit grow fourth quarter ibd take biotech franchise gilead hepatitis unit have be pressure recent quarters smaller newer drug start take share visit ibd industry theme see analyst say large franchise be safe year earlier wednesday glaxo say focuse new therapy chronic obstructive pulmonary disease hiv shingle face mount competition asthma blockbuster advair dow merck mrk too be work treatment hiv january fda accept new application merck regimen contain drug call doravirine hiv fda set decision date regimen oct related biotechs spring back market correction analystbiogen tysabri fail stroke trial come surprise sanofi regeneron dip eczema drug dupixent lag europe
851,MRK,stock market correction begin major average lead stock show more weakness other index rebound solid weekly gain nvidia nvda plunge halter autonomous drive test just several negative headline tesla tsla facebook fb continue slide datum privacy furor amazon amzn tumble day move average lululemon athletica lulu rh rh rally strong earning retail remain relative source strength baidu bidu stream video unit iqiyi iq come public major average rebound monday trade war fear ease other index tumble tuesday trigger stock market correction fuel thursday rally dow jone rise week testing day move average nasdaq composite rise many tech giant be big loser nvidia nvda uber suspend self drive test tesla tsla nvidia supplier also face federal probe model involve autopilot system moody also cut tesla debt model production wo amazon com amzn tumble day line first time month fear president trump go commerce giant retail apparel remain relative bright spot quarter dow lose nasdaq add uber technology suspend self drive test federal probe recent fatal crash involve autonomous vehicle nvidia nvda also say halt test share chipmaker plunge help trigger stock market correction tesla tsla used nvidia chip fall sharply bad news national transportation safety board say be probe fatal crash march involve model moody downgrade tesla credit rating concern cash burn model production delay alphabet googl unit waymo be sticking plan roll commercial robotaxi service phoenix year waymo also plan order many luxury autonomous electric car jaguar land rover subsidiary india tata motor ttm waymo jaguar plan move production crossover sport utility daimler bmw announce combine self drive service asset form joint venture structure facebook chief executive mark zuckerberg be expect testify congress pressure mount datum privacy scandal have roil company stock congressional hearing be prompt revelation datum consultancy cambridge analytica have wrongfully obtain personal information million facebook user knowledge facebook beef privacy control say halt selling datum third party broker facebook share initially tumble rise modestly week amazon fall wednesday undercut day line report president trump want go commerce giant trump have long be critical amazon perhaps part ceo jeff bezos own washington post white house deny plan target amazon trump tweet concern regard amazon thursday amazon initially fall thursday close fellow fang netflix nflx find support day line share lululemon lulu soar record high week athletic apparel maker retailer beat estimate board raise full year guidance ep rise revenue grow nearly north america peer nike nke have struggle lululemon sale grow low single digit online sale pop constant currency top prior year growth analyst say new product improve marketing investment fuel quarterly apparel maker retailer be pocket market strength linux open source software provider earning growth accelerate fiscal fourth quarter revenue rise gradually accelerate fourth straight quarter top view red hat rht guide low earning see full year earning revenue consensus red hat push container software cloud compute workload drive growth analyst say red hat share initially soar tuesday settle fractional gain share rise week concho resource cxo buy rsp permian rspp stock deal worth takeover create largest drill completion operation permian concho share tumble crude inventory rise barrel more expect energy information administration say production hit new high barrel day saudi crown prince moham bin salman tell reuter opec be look extend oil production cooperation russia year baidu bidu video stream unit iqiyi iq fall nearly thursday trading debut selling share apiece line expect range raise ipo be just shy january ipo pagseguro digital pag call netflix nflx china iqiyi have licensing deal netflix subscriber iqiyi have market share china rival alibaba baba tencent tcehy have own stream service hotly contest battle viewer fed favorite inflation gauge core personal consumption expenditure price index show slight uptick february annual inflation rate edge month high inflation be far fed target enough doubt corporate pricing power so inflation have rise further pressure fed policymaker hike rate more time year commerce department datum thursday show disposable personal income rise february spending rise modest suggest person initially be save tax cut consumer end strong note fourth quarter gdp be revise biotech stock collectively rise sixth group track ibd last week news be more mixed big mover monday celgene celg lift nearly analyst suggestion be settlement dr reddy laboratory rdy generic version cancer drug revlimid same time pharmaceutical bhvn tank unveil late stage trial migraine drug lag result rival drug allergan agn tesaro tsro slip tuesday split view combination zejula merck mrk blockbuster keytruda ovarian cancer patient also tuesday anaptysbio anab topple result peanut allergy drug study celgene celg bluebird bio blue agree jointly market advanced cancer treatment know bb expand deal sport retail giant jd sport pay athletic apparel chain finish line finl soar slightly share offer finish line pull back thursday follow mixed result build material company usg usg have rebuff buyout offer germany knauf offer get support warren buffett berkshire hathaway brkb be usg top shareholder usg share shot speculation provider wall ceiling flooring roofing product be have higher price shire pharmaceutical shpg shot confirm japan takeda make offer finally audio communication firm plantronic plt agree wednesday acquire company polycom polycom be buy private equity firm siris capital same price just year glaxosmithkline gsk agree buy stake consumer health unit novartis nvs blackberry bb report fiscal adjust profit cent share top expectation break even revenue fall line view rh rh formerly know restoration hardware report profit leap share sale growth top forecast home furnishing retail guide high signale more aggressive expansion plan design gallery share soar nearly week blast day day line constellation brand stz earning share rise revenue climb beating beer sale grow constellation brand increase quarterly dividend cent share rise close recent buy point cross intraday apple aapl introduce lower price ipad chicago high school company seek regain ground lose google owner alphabet microsoft education market new inch retina display ipad have start price gigabyte wi fi model discount school
852,MRK,veeva system veev be coil spring ready jump thank several growth initiative xthat contention canaccord genuity analyst richard davis say veeva stock have have mighty run so far add cloud compute firm focus software application pharmaceutical life science field have room further growth used term coil spring describe veeva outlook davis say future look even more prosperous come view veeva have several growth initiative process range significant new feature upsell adjacent customer breadth move davis say recent note client pleasanton calif base veeva have more customer life science industry range big pharma firm emerge biotechs count company amgen amgn eli lilly lly merck mrk novartis nvs pfizer pfe customer veeva go public october share hit time high march manage avoid most carnage week sell share be friday veeva stock break week consolidation period buy point feb day company post better expect result fiscal fourth quarter give guidance crushed wall street estimate current fiscal year current fiscal year end next jan veeva expect earn adjust share year year sale base midpoint guidance analyst be modele adjust profit share sale veeva growth initiative be likely reach sufficient scale year provide path upside estimate davis say scenario be correct investor figure sometime summer fall point veeva share sustainably move higher say davis rate veeva stock buy veeva begin software application help pharmaceutical sale rep organize drug datum make stronger doctor pitch today product customer relationship management call veeva crm dominate drug market roughly user share now part veeva commercial cloud business big driver company business today be veeva vault launch be create organize content involved clinical drug trial document patient datum work flow vault product now cover clinical quality regulatory commercial aspect drug development manufacturing sale have penetrate less market william blair analyst bhavan suri tell investor business daily veeva also have discover vault offer be useful other heavily regulate industry such chemical consumer product sector company offer company outside life science be call vault qualityone have more company used product launch year get newsletter deliver inbox more info product service privacy policy term useon conference call analyst feb veeva chief executive peter gassner say company have be planting seed future growth especially exciting see franchise re build side life science say veeva be uniquely position help streamline drug development re only technology provider best class application suite major area development include clinical quality regulatory come next year safety single modern cloud platform believe veeva development cloud be industry long term veeva software service offer have be replace legacy vendor use premise hardware software system rival include oracle orcl medidata solution mdso iqv other veeva management have strong track record deliver growth be conservative guidance william blair suri say rate veeva stock outperform veeva have forecast revenue run rate fourth quarter think hit run rate early next year month ahead expectation suri say not only hit dollar run rate early next year sustainability growth be next year meanwhile jpmorgan downgrade veeva stock overweight neutral march cite valuation concern stock have climb year be strong franchise be execute well number growth initiative have little room outperformance current level jpmorgan analyst sterling auty say note client estimate veeva addressable market fraction more spend year life science company information technology fertile market provide greater growth subscription revenue fiscal grow fiscal auty say related veeva rocket top quarterly estimate crush guidance viewsceo gassner make sure veeva have second act more
853,MRK,dozen drug launch heavy hitter roche rhhby gilead science gild johnson johnson jnj be expect reach blockbuster status end analytic firm say clarivate analytic describe year blockbuster drug have launch be expect launch eventually bring north sale year period biggest number clarivate begin make forecast set be exciting year see valuable addition exist treatment well disruption certain market first class treatment option disease firm say report issue late thursday end drug roche gilead nordisk nvo be expect top annual sale remain likely account year revenue analyst say get newsletter deliver inbox more info product service privacy policy term be diabetes drug food drug administration approve medicine derive cannabis plant first series drug expect prevent migraine patient dozen drug be project collectively top sale roche hemlibra treatment patient hemophilia top list be expect generate north sale only hemophilia patient world roughly eligible hemlibra treatment cost first year year drug be approve month early launch december sale be forecast drug set reach blockbuster status forecast hemlibra be expect take share shire shpg feiba nordisk novoseven hemlibra also compete bioverativ bivv eloctate shire advate eloctate be forecast be blockbuster advate continue be market leader estimate sale however advate sale be forecast decline further thereafter clarivate report say gilead biktarvy grab approval february target estimate person globally live hiv be receive antiretroviral therapy suppress viral replication allow immune system strengthen biktarvy add gilead hiv franchise have long rivale glaxosmithkline gsk have trade market share gilead first enter market atripla gilead hiv drug be featured clarivate drug watch report biktarvy become blockbuster generate sale spiking decline report say trajectory be similar gsk drug triumeq be expect bring year year launch round top nordisk get approval diabetes drug ozempic december drug help stimulate body own insulin release limit much sugar get blood liver slow quickly food leave stomach ozempic be expect become blockbuster revenue way immuno oncology treatment novartis nvs gilead grab headline ability revolutionize treatment disease report say more half drug potential blockbuster list be cancer therapy just drug list expect blockbuster be cancer treatment erleada product dow jone component johnson johnson be approve february treat castration resistant prostate cancer hasn spread body fellow dow jone component pfizer pfe have drug treat same cancer once spread zytiga xtandi battle expand market share include market patient metastatic disease second generation oral androgen erleada become first approve set mid february clarivate say drug be project bring rise also be expand treat other form prostate cancer combination zytiga contribute blockbuster potential gsk shingle vaccine call shingrix rare disease drug alnylam pharmaceutical alny know patisiran be expect join blockbuster list sale respectively revenue be expect hit respective gw pharmaceutical gwph be expect grab approval summer first cannabidiol drug derive cannabis plant treat patient seizure disorder drug call epidiolex be expect generate sale approve epidiolex likely encounter bureaucratic barrier distribution political hurdle associate cannabis derive medicine particularly strict guideline use medicinal cannabis exist report say biotech isn alone market cara pharmaceutical cara insys therapeutic insy zynerba pharmaceutical zyne be also work treatment base cannabis plant migraine drug amgen amgn novartis aimovig be project bring sale spiking sale drug other seek prevent migraine block specific peptide group amino acid approve aimovig be first drug know cgrp market ahead teva pharmaceutical teva aldr eli lilly lly allergan agn also be work area first class mover advantage be crucial aimovig competition other subcutaneously administer monoclonal antibody target cgrp be not far clarivate say lilly teva file fda approval drug late last year meanwhile be phase testing drug analyst be worry falter submit application fda co founder randall schatzman unexpectedly step chief executive role tuesday other area shire lanadelumab treatment swell disorder be forecast bring next be abbvie abbv elagolix treatment painful symptom associate menstruation round list pfizer merck mrk diabetes drug steglatro indivior opioid dependence drug sublocade be forecast become blockbuster sale respectively related chart read basic buy point mark time real much money do need start investing build long term profit stock take many gain
854,MRK,celgene celg vertex pharmaceutical vrtx incyte incy be worth watch broader market correction see biotech stock lose collective previous day analyst say tuesday biotech stock rebound stock market today diving monday bmo capital market analyst brian belski say note client investor be reap sow intent purpose majority client market pundit especially increasingly boisterous set naysayer have be predict bull market imminent demise day presidential election say doesn mean bull market be dead belski say rbc analyst brian abraham agree see opportune entry point certain biotechs stock datum approval expect thing be look celgene few misstep second half include major miss sale psoriatic arthritis drug otezla third quarter abraham say sale drug rebound fourth quarter believe market cap reduction more reflect believe fourth quarter number guidance point reassure stabilization key revlimid otezla sale say ibd take bull market be good time review stock selling smart once begin stall uptrend too late catch head investor corner brush stock selling rule cancer drug revlimid be celgene biggest drug analyst have worry generic rival take sale start contend celgene recently announce plan acquire remainder juno therapeutic juno didn already own add juno coffer put celgene car space compete novartis nvs gilead science gild latter acquisition kite pharma car therapy immune system identify fight cancer even juno celgene look poise generate enough cash flow buy back virtually entire enterprise value revlimid go completely generic abraham say outside abraham see number catalyst include additional datum revlimid treat lymphoma late stage datum drug partner acceleron pharma xlrn blood disorder celgene rise tuesday abraham say vertex be victim bad timing vertex recently report strong datum triple combination regimen cystic fibrosis datum come just broader market be begin turn stock fall hard past day vertex rebound tuesday rise strong effectiveness drug know vx vx triple regimen head phase study support likelihood vertex expand tough treat population cystic fibrosis patient say also enable multiple additional shot goal set bar be difficult match beat significant lead time likely render mid year competitive datum galapago glpg overhang vertex share much less impactful raise price target vertex macro weakness be mask improve fundamental abraham argue incyte be set read datum phase trial know echo first half study combine incyte immuno oncology drug epacadostat dow stock merck mrk keytruda late stage melanoma drug class know immuno oncology treatment epacadostat work block interaction involve ido enzyme immune system keytruda be call pd inhibitor have similar interaction pd protein instinet analyst christopher marai expect trial read positively be similar regimen bristol myer squibb bmy drug opdivo yervoy bristol be also combine drug treat other cancer include advanced lung cancer so epacadostat become part standard care metastatic melanoma broad adoption augment current pd use say note client lead peak worldwide sale north melanoma alone epacadostat rbc abraham say eventually nearly value epacadostat soon be go incyte share see share jakafi treat bone marrow disorder share olumiant rheumatoid arthritis drug co develop eli lilly lly suggest downside upcoming epacadostat datum be negative be now likely only share fundamental upside now potentially more say make upside downside level much more interesting incyte advanced tuesday related allergan pop consensus top quarter strong migraine biotech stock dive more be sell overdo crispr small biotechs cure disease
855,MRK,stock close whipsaw trading session tuesday big gain plunge open apple aapl chevron cvx home depot hd boost dow powershare qqq trust qqq rally spdr dow jone industrial average dium rise spdr spy gain emerge market outperformed stock market today ishare msci emerge market eem soar semiconductor homebuilder retail lead upside sector fund gold miner utility lag vaneck vector semiconductor smh ishare phlx semiconductor soxx surge respectively etfs reversed sharp drop retake day move average line component nvidia nvda leap also sharp upward reversal close well day line graphic chip designer artificial intelligence player report earning thursday close apple chevron home depot rise more lead dow apple stage big reversal close gain regain day line breach monday iphone maker have also trigger loss cut rule flat base entry bitcoin rebound accord coindesk cryptocurrency hearing hold federal regulator bitcoin investment trust gbtc gain find support day line now december high inverse volatility exchange trade product rally recent lows bear emerge stock sell board proshare short sh surge monday tumble fund aim inverse benchmark index daily performance regain day move average first time august be steady overall decline march market have rise new high etf be year date feb vs dip underperform broader market longer haul respective average annual loss past year accord morningstar direct vs gain same period sh carry expense ratio proshare ultrashort sds seek performance corresponding twice inverse rise also retook day line fund have attract also bear expense ratio sds be year date average annual performance past year proshare ultrapro short spxu go triple inverse return soar average annual loss past year be expense ratio be ibd take important stay top go market day read big picture column detailed look daily market action news well current market outlook volatility etps also have good day ipath vix short term future leap reclaim week line first time march exchange trade note have amassed asset provide access market volatility cboe volatility index vix future vix gauge fear stock market vxx average deficit be past year other volatility play sizable asset include proshare vix short term future etf vixy ipath series vix short term future etn vxxb related apple lose support stock melt bitcoin keep plungingutility gold bump higher broad stock market etfs etn gain mood turn bearish snap streak
856,MRK,key stock index fund be lower afternoon trade tech heavy qqqs turn negative blue chip fall most boee ba johnson johnson jnj weigh powershare qqq trust qqq dip spdr spy give spdr dow jone industrial average dium fall stock market today utility gold miner technology be top sector fund gainer spdr utility xlu rise retake day move average first time month vaneck vector gold miner gdx vaneck vector junior gold miner gdxj be health care select sector spdr xlv reversed loss unitedhealth group unh be dow biggest gainer early fall nearly cisco system csco hold gain biggest loser include boee undercut day move average trigger sell signal dowdupont dwdp johnson johnson apple aapl slip day hit new record high then reverse lower back buy point shape cup handle boee other industrial giant be get hit continue tariff related concern homebuilder bank metal miner lead downside sector fund spdr bank kbe spdr regional banking kre fall track extend loss third straight session etfs be nearly recent high bitcoin sank accord coindesk open level bitcoin investment trust gbtc gap tumble session lows month low mostly decline try retake day line march be now december peak dow stock johnson johnson unitedhealth group be blue chip show healthy gain tuesday spdr health care xlv remain potential buy range retake day move average friday be form new base buy point too keep mind broader market have be volatile lately fund undercut day line early february market correction now appear be overall uptrend share advanced last time xlv be featured etf column time fund be just buy point flat base etf celebrate anniversary december track health care select sector index pharmaceutical represent biggest segment holding march nearly asset biotech be next category account health care equipment supply health care provider service life science tool service health care technology make rest get newsletter deliver inbox more info product service privacy policy term top holding include dow jone industrial average health care name johnson johnson pfizer pfe unitedhealth group merck mrk dow stock top be abbvie abbv together top account roughly third stock portfolio dow quartet year date performance range abbvie however have soar year xlv year date gain march be line return etf average annual return past year lag outperformed broader index past year xlv bear expense ratio tuesday pick guggenheim pure growth rpg reversed lower session close just buy point also be interested dow stock turn red ge weigh apple reverse record highai robotic blockchain hot new etf industry sector do market pro expect outperform year
857,MRK,here investing action plan friday need know investor come day oil giant exxon mobil xom chevron cvx have turn earning day conocophillip cop royal dutch shell rdsa handed report job report january also come market
858,MRK,stock launch holiday shorten trading week tuesday rally send dow barely week first foray mark dow jone industrial average bolt higher merck mrk unitedhealth group unh hammer powerful early gain nasdaq composite scale future be higher overseas hong kong hang seng index punch tuesday record close high remain just fraction record peak japan tokyo nikkei follow gain putt index almost even jan high europe frankfurt dax rally cac paris trade london ftse slip afternoon action merck jump broad early lead blue chip stock announce keytruda produce positive result phase trial first line treatment lung cancer merck share close last week mid november low climb right side month consolidation unitedhealth group unh report strong fourth quarter performance pop open gain put stock buy range just flat base buy point apple aapl climb continue wrestle resistance remain buy range buy point netflix nflx lead rise fang stock add more margin buy point number china base stock be motion ahead open top name include baidu bidu rise alibaba group hold baba post early gain range baozun bzun surge more give provider online retail service past buy point double bottom base big bank be part tuesday positive news comerica cma report fourth quarter result comerica share be extend profit take zone follow september citigroup power higher report fourth quarter earning revenue analyst target advance send share buy range flat base buy point bitcoin trade just price late friday stock associate cryptocurrency blockchain be also early pressure manufacturing growth slow slightly new york region january send new york federal reserve bank empire state manufacturing survey read december economist target report say growth shipment new order slow employment increase slightly input selling price growth accelerate price rise second straight month adtran adtn railroad csx csx pinnacle financial pnfp be schedule report today close related top tech stock strong rs line hit buy pointsstock rally day mark be more yet come top perform dow titan be also dividend leader forget bloxploitation look real blockchain action area
859,MRK,exchange trade fund popularity keep grow investor plow money popular low cost vehicle offer access basket stock trend doesn appear be wane combine asset etfs surge january accord investment company institute year total number etfs rise january year launch very first etf spdr spy be now fund available variety category style gain further insight etfs potential benefit growth outlook checked todd rosenbluth senior director etf mutual fund research cfra cfra acquire global rosenbluth be director etf mutual fund research capital iq previous experience include manage editor value line mutual fund survey financial advisor morgan stanley full interview rosenbluth also discuss current trend etf space follow ibd investor own etfs rosenbluth investor want exposure stock bond market look etfs typically provide low cost exposure broad investment category narrower thesis benefit diversification transparency example rather own just merck mrk investor health care select sector spdr xlv fidelity msci health care index etf fhlc hold merck peer include johnson johnson jnj pfizer pfe company other related industry include medtronic mdt unitedhealth group unh actively manage mutual fund investor see daily etf determine think continue fit portfolio ibd be too many etfs rosenbluth approximately third cfra rate etfs come market march so think investing investor determine etf serve legitimate investing purpose so more likely gain sufficient asset be viable keep mind cfra rate far more mutual fund etfs several dozen asset manager offer similar sound product give sentiment shift lower cost etfs away more expensive mutual fund cfra expect more mutual fund be close merged response get ibd market prep tech report newsletter free ibd do think fuel further etf growth hinder growth rosenbluth investor advisor adoption etfs design support asset allocation need be go further drive etf growth vanguard voo ishare core msci eafe iefa be example such well diversify product more investor gain comfort etfs money continue flow establish come product investor always favor mutual fund wrapper want active management address many large asset manager include davis fund legg mason pimco vanguard offer actively manage etfs area potential growth ibd even factor base etfs aren new smart beta continue be buzzword have contribute rise popularity smart beta fund rosenbluth actively manage mutual fund struggle keep return msci eafe index investor be seek alternative smart beta etfs launch last year include popular goldman sachs activebeta large cap equity gslc ishare edge msci multifactor usa etf lrgf combine factor approach offer diversify yet lower cost approach quantitative investing here again many large asset manager have expand etf presence used smart beta product response grow demand last month jpmorgan minimum volatility jmin oppenheimer russell low volatility factor ovol usaa msci usa value momentum blend index etf ulvm have launch be cover cfra research ibd esg environmental social governance fund have be news too do think last trend rosenbluth esg mutual fund asset have be quite sticky even many actively manage mutual fund slowly bleed asset favor index base etfs expect time esg etfs gain traction investor further embrace etfs put money work focuse conviction value ibd new trend re see now rosenbluth re see investor look more closely thematic etfs traditional sector well diversify etfs etfs focus robotic blockchain other potentially long term investment trend more narrowly construct product such global robotic artificial intelligence botz robo global robotic automation index robo reality share nasdaq nexgen economy blcn innovation share nextgen protocol etf koin tend charge premium price relative market cap weight etfs more asset manager compete investor interest fee have continue move lower ibd type etfs do expect outperform interest rate rise rosenbluth equity etfs cfra think more economically sensitive sector include financial industrial benefit rate rise due strong economy vanguard financial index etf vfh ishare transportation average iyt be couple example addition interest rate rise cfra be focuse bond etfs limit interest rate sensitivity low duration product reduce downside impact federal reserve raise rate ishare year investment grade corporate bond shyg spdr bloomberg barclay short term high yield bond etf sjnk be example short term etfs rate favorably cfra ibd give feb market sell early redemption velocityshare daily inverse vix short term etn xiv be thought vix tie volatility etfs be appropriate type investor rosenbluth vix base product be not rate cfra focus etfs directly hold stock bond not derivative however investor need understand inverse leverage etfs aggressively move warning loss pile quickly ibd do xiv early redemption mean harder investor manage risk so do affect market operate rosenbluth xiv be exchange trade note not traditional etf be other product ve talk etns investor need understand be issuer risk consider top usual investment risk etf shut investor get fair warning understand portfolio help track receive hold product close xiv mechanic be much different road closure be much shorter important note however happened xiv be spel prospectus so be less example larger market issue more example investor need know exactly re get involved particularly leverage inverse volatility product ibd be sound strategy long term investor etfs rosenbluth long term investor regularly review etfs re hold understand security fit go forward investor also periodically rebalance asset position do not move tandem not necessarily stand still even passively manage etfs ibd do cfra assess etfs do differ other industry researcher rosenbluth cfra provide forward look rating more etfs combine holding analysis fund attribute include expense ratio technical analysis etf much cost be bigger driver future return year track record well track typically unique index etfs rate favorably cfra do so have confidence valuation risk consideration holding also compare etfs separate mutual fund relevant metric differ other compare active mutual fund try beat etfs such spdr seek replicate index equity etf rating launch nearly year global umbrella top rate etfs have outperformed index bottom rate etfs have underperform equity fund research be acquire independent research provider cfra research late investor learn more https newpublic cfraresearch com email protected rosenbluth be twitter also be interested blockchain expand bitcoin amazon nvidia alibabafirst trust launch new blockchain etf meet demanddow back apple reversal gold shine bitcoin fall
860,MRK,ligand pharmaceutical lgnd be biotech worth doesn market single drug yet expect approach sale stock be breaking reason be ligand operate unique business model acquire early stage technology necessary drug development then license platform biotechs pharmas dow jone stock merck mrk pfizer pfe well amgen amgn novartis nvs total ligand have more program development north partner firm say fourth quarter conference call february craig hallum capital group analyst matt hewitt praise model feb report client give larger ever expand portfolio current potential future royalty generate asset broad pipeline partnership model inherently gear deliver very high profit margin believe be tremendous value creation motion ligand say shareholder seem agree hewitt assessment ligand stock have pop more begin year outperform broader biotech group have rise roughly same time period thursday share jump early morning trade break second stage week flat base share end regular session ligand share have be run last week jump least day stretch straight trading session meanwhile biotech group have be red past session stock have ibd composite rating best possible meaning perform top stock term key growth metric biotech group rank third vertex pharmaceutical vrtx halozyme therapeutic halo have rating ligand demonstrated dominance fourth quarter total revenue grow top consensus roth capital partner analyst scott henry write recent note client royalty main driver sale increase line expectation henry say upside revenue drive adjust earning share spiking vs year earlier quarter beating analyst view cent better expect sale amgen kyproli novartis promacta lead revenue charge ligand get royalty sale promacta oral medicine increase number platelet blood royalty sale multiple myeloma drug kyproli total ligand be tie dozen commercial product have technology platform biotechs pharmas use develop drug firm also have handful early stage drug plan license interested company further development ligand goal be create diversify company more licensing opportunity lower impact individual patent expiry firm say protect scenario now face biotech leader celgene celg see patent cancer drug revlimid begin expire mid use ibd marketsmith free march
861,MRK,see stock buy point get chart pattern recognition run custom screen start nowamong recent success ligand announce week have partner drug hold firm roivant science diabetes drug lgd roivant company metavant develop drug have strong phase datum second half be major partnership have potential generate substantial medical value type type diabetes patient ligand chief executive john higgin say prepared statement lgd be successfully develop license roivant have potential be ligand largest financial asset possibility annual royalty continue late offer upside guidance royalty revenue sale related captisol compound used pharma development related milestone license fee analyst say ligand tend promise deliver come annual guidance roth capital henry say expect be more same revenue earning share target view conservative surpass company guidance henry expect kyproli promacta sale moderate call kyproli sale grow promacta sale increase sustain movement drug provide upside guidance say ligand be bullish drug ceo higgin call kyproli promacta become blockbuster promacta have be market year so see level growth be particularly impressive say earning call promacta become molecule analyst project continue strong growth say kyproli give recently report sale number drug appear also be track exceed worldwide sale ligand partner currently have handful drug late stage testing include brexanolone postpartum depression drug sage therapeutic sage slew other phase trial partner program be preclinical be phase study firm expect benefit current trend include new tax law reduce ligand project tax rate more third higgin say earning call ligand also get boost bump fda drug approval recent study massachusett institute technology find success rate drug program advance approval have increase believe be attribute many factor include better decision advance program more favorable regulatory environment say be very meaningful ligand have program stage development related tame volatile swing trade half trade stock most penny stock fail make investor richlook best stock buy watch start here
862,MRK,camille callais be diagnosed spinal muscular atrophy neurologist tell parent nothing do be year biogen biib ionis pharmaceutical ion spinraza become first ever drug approve treat spinal muscular atrophy camille parent try supplement label use medication highly specialize diet
863,MRK,stock index fund be mixed pare early loss tech stock lead upside apple aapl intel intc advanced dow jone industrial average mcdonald mcd boee ba weigh heavily powershare qqq trust qqq be spdr spy be spdr dow jone industrial average dium fall stock market today small cap rally ishare core small cap ijr ishare russell iwm qqq be show relative strength find support day move average biotech oil explorer semiconductor be biggest sector fund gainer health care stock include pfizer pfe merck mrk johnson johnson jnj advanced dow jone industrial ishare nasdaq biotechnology ibb exchange trade fund reversed sharply higher gain also blue chip apple aapl reversed early loss slight gain be flat line continue hold day line be new record intraday high earlier week spdr gold share gld ishare gold trust iau be gold price rise ounce etfs be try hold support day line utility real estate industrial underperform technology wasn spare thursday stock market sell lead etf top like apple microsoft msft facebook fb be hold better most spdr technology xlk extend loss third straight session get close test day move average however didn breach line way many other etfs do friday do be find support line stage solid rebound line set new chance add buy share early december bounce day yielded gain jan high be featured etf column dec say buy be riskier market uptrend be pressure so crucial keep close eye xlk broader market be fare make purchase etf suffer steep drop late january high feb low so condition haven be exactly ideal fund track technology select sector index marked anniversary december software account biggest chunk asset feb just internet software service weigh tech hardware storage peripheral service semiconductor chip equipment be next xlk top holding be apple microsoft facebook class share alphabet googl represent stock portfolio apple have see bullish news week warren buffett say monday buy more share iphone maker other stock past year other report show apple take smartphone industry profit grab lead wearable device market apple stock be high be hold day line sign free ibd newsletter market prep tech fund year date gain feb lead return accord morningstar direct average annual return past year also outperformed period xlk carry expense ratio thursday pick spdr gold share gld ishare gold trust iau fall sharply day pare loss close respective day line also be interested apple intel dive dow trump tariff take stock marketstock sell dow apple boee reverse celgene divesdow apple intel hold steady stock sell bitcoin gain
864,MRK,biotech stock rally friday nektar therapeutic nktr sarepta therapeutic srpt puma biotechnology pbyi report strong fourth quarter metric announce update stoke share stock market today biotechs collectively jump lead nektar rocket close record high puma soar sarepta fly loxo oncology loxo also advanced fourth quarter report rise fellow biotech ligand pharmaceutical lgnd grab sector luck rise adjacent market veeva system veev make software used biotechs drugmaker enjoy surge breaking long consolidation nektar stock pop follow crush fourth quarter sale beat even related nonrecurring sublicense agreement nektar sale still have beat street forecast loss cent share narrow year year beat view cent loss analyst be also bullish nektar immuno oncology drug nktr drug be design grow cancer kill immune cell natural killer cell body fight cancer last month nektar say team bristol myer squibb bmy test nktr regimen used bristol drug bristol drug opdivo yervoy be also immuno oncology compound opdivo work target interaction immune system involve pd pd protein yervoy be know ctla inhibitor combine immuno oncology drug be expect offer more potent response month nektar bristol have registrational study patient tumor type slate begin first study be melanoma kidney cancer importantly deal allow nektar continue combination drug dow component merck mrk roche rhhby canaccord analyst arlinda lee up price target nektar keep buy rating sale sarepta exondys drug treat duchenne muscular dystrophy come line company pre announcement january rbc analyst brian abraham say note client research development expense be also line say company end quarter cash equivalent estimate be sufficient sustain operation revenue foreseeable future say sarepta also reiterate guidance exondys sale represent year year growth abraham note support launch trajectory capable reach peak sale sarepta also seek have exondys approve europe analyst be split official approve drug sarepta be slate present argument late april piper jaffray analyst edward tenthoff say note positive opinion offer upside say wasn exondys have sarepta stock pop friday analyst be particularly excited potential golodirsen drug be develop treat duchenne muscular dystrophy patient sarepta recently meet food drug administration discuss golodirsen golodirsen be be test pivotal trial dub essence trial finish enrolling april have datum year needham analyst chad messer say note trial possibly serve conformational study golodirsen sarepta be also work investigational drug include gene therapy midyear firm plan report preliminary datum gene therapy study leerink analyst michael schmidt say note client provide glimpse sarepta future fourth quarter sale puma breast cancer drug nerlynx be just short consensus leerink schmidt say puma pre announce january net sale indicate consensus view first quarter be too low expect be clear event similar recent clovis oncology clvs fourth quarter earning report say note fundamentally nerlynx launch metric look solid call puma guide sale consensus figure be rbc analyst kennen mackay say report leerink schmidt see outlook conservative puma also have good news midyear firm be expect have datum phase study nerlynx advanced form breast cancer further european official be reconsider nerlynx form breast cancer related chart read basic buy point mark time real build long term profit stock take many gain long term retirement investing strategy etfs
865,MRK,astrazeneca azn bring peak sale immuno oncology drug imfinzi analyst say thursday cite survey oncologist predict broad use lung cancer survey oncologist suggest broad uptake imfinzi advanced lung cancer patient be treat surgery respondent say plan use imfinzi type patient leerink analyst seamus fernandez write note client further survey say have patient view treatable surgery be better suit round chemotherapy radiation follow imfinzi therapy oncologist expect treat half patient imfinzi physician note have not run reimbursement difficulty agent not yet be approve set fernandez say see overall survival benefit have not stop used agent meantime imfinzi be not yet approve treat lung cancer october food drug administration accept astrazeneca application imfinzi first treatment advanced lung cancer patient aren eligible surgery drug be already approve use bladder cancer patient physician say imfinzi be potential option advanced lung cancer patient tolerate combine round chemo radiation be large number patient ibd take astrazeneca have ibd composite rating best possible meaning outperform nearly stock term key growth metric get look top rate drug stock visit ibd stock checkup fernandez boost forecast peak global imfinzi sale imfinzi represent just monthly immuno oncology market sale have be rise presentation clinical datum september say imfinzi work block interaction involve pd protein body otherwise prevent immune response cancer compete roche rhhby tecentriq pd inhibitor also approve bladder cancer dow stock merck mrk keytruda bristol myer squibb bmy opdivo know pd inhibitor be similar oncologist survey also be bullish uptake keytruda advanced lung cancer oncologist have high degree enthusiasm combination regimen particularly chemotherapy fernandez say put merck forefront week merck unveil strong result regimen keytruda chemo lung cancer physician be also hopeful combination bristol opdivo immuno oncology drug yervoy yervoy be know ctla inhibitor fernandez note tend view combo bristol more toxic regimen merck keytruda chemo close bell stock market today astrazeneca inched penny merck lose bristol edge cent roche advanced finish related dow merck do face release cancer trial resultsbiotech dife analyst slash expectation cancer drugu novel drug approval rocket higher overall number slide
866,MRK,dow component merck mrk surge month high tuesday company do face report strong result immuno oncology chemotherapy treatment lung cancer year ahead expectation cast share rival downward trial know keynote merck keytruda drug chemotherapy be test first treatment patient advanced lung cancer safety prove consistent earlier study merck say news release specific result be present future medical conference company say keynote show significant improvement overall survival progression free survival patient receive keytruda first line set combination traditional chemotherapy compare receive chemotherapy alone dr roger perlmutter president merck research laboratory say written statement news come just month merck say delay unveil result trial february october announcement add overall survival key goal trial time share take month dive analyst suggest be problem phase trial tuesday concern be alleviate merck say regimen significantly improve overall survival progression free survival advanced lung cancer close bell stock market today merck surge close touch intraday high last see announce delay late october result solidify merck status leader race market share first line advanced lung cancer leerink analyst seamus fernandez say note client compete bristol myer squibb bmy roche rhhby astrazeneca azn roche test combination immuno oncology drug tecentriq chemotherapy older cancer drug call avastin regimen double percentage lung cancer patient survive year disease progression roche say december ibd take merck have ibd composite rating best possible meaning perform bottom half stock term key growth metric lag leader abbvie cr head ibd stock checkup look other strong pharma stock bristol be also set unveil result trial immuno oncology drug opdivo yervoy first therapy advanced lung cancer astrazeneca be also testing immuno oncology drug imfinzi tremelimumab same type patient share bristol topple close roche dove finish astrazeneca slough specific immuno oncology drug used trial vary keytruda opdivo be know pd inhibitor evercore analyst umer raffat say pd inhibitor chemo be now bar beat potential immuno oncology regimen development raffat note merck success keynote likely ensure regimen approval europe regimen already have accelerate approval pending confirmatory trial keynote result prompt further use say note client have picked feedback doctor want see confirmation phase datum more widespread use say press release likely presentation medical conference make more comfortable acceleration modeled consensus keytruda balance year consensus be modele fourth quarter sale keytruda see respective quarters keytruda sale related roche cancer drug combo effective share dropwhy roche cancer trial be kick tooth dow stock merckdow merck plunge month low grow keytruda worry
867,MRK,stock trade session high monday afternoon dow jone industrial average lead pack dow be nearly add bit room day move average traveler trv cisco system csco mmm intel intc merck mrk rise more spearhead dow technology component cisco intel win praise analyst morgan stanley raise price target cisco maintain overweight rating instinet raise price target intel report say nasdaq composite climb nearly also build small cushion day line volume be higher nyse lower nasdaq compare same time friday winner lead loser nearly nyse nasdaq solar energy rv manufacturing networking movie be lead industry group today market netflix nflx account strength movie industry group share climb record high active trading video stream company have become extend breaking base january past entry ptc inc ptc break base base pattern buy point volume be only half average call question relative strength line be new high unusually favorable trait ptc make dimensional design system innovator ibd etf ffty lag gain part be due tal education tal chinese education service provider plunge other chinese stock be weaker ruling communist party propose eliminate presidential term limit homebuilder be laggard sale new home surprisingly fall january lowest level annualize rate august sign free ibd newsletter market prep tech reporta couple lead stock be report earning today be heavy trading palo alto network panw hit new high volume be highest average stock rise today cybersecurity company be report result close share be extend january square sq rise nearly be near cup handle base buy point point sale technology innovator be schedule report quarterly result tuesday close related lithium miner pain be tesla gain price see plunge muchibd stock tal education sink test buy point rival lose supportfive way spot bullish base base stock pattern
868,MRK,stock be mixed thursday afternoon semiconductor stock extend rally give tech sector relative strength chip stock help nasdaq composite climb be only fraction russell be dow jone industrial average be yet still manage record high day boee ba merck mrk component have account big chunk dow rally month fall today market volume nyse nasdaq be lower compare same time wednesday light volume balance trading be clearly seller favor decliner lead advancer nyse nasdaq number industrial stock be heavy trading related lithium industry sociedad quimica minera chile sqm reach accord chile development agency allow company expand production potential increase supply mineral used battery rattle share sqm other lithium play sqm share fall day move average soon bounce back deutsche bank upgrade share buy hold morning fmc corp fmc gap day move average huge volume represent sell signal rally semiconductor get more fuel thursday taiwan semiconductor tsm hit new high strong quarterly result share surge follow wednesday stock be now extend buy point thursday chip foundry beat profit revenue expectation company forecast record sale thank boom cryptocurrency mining trading asml hold asml semiconductor stm be chip stock hit new high unusually high volume top buy point security software name palo alto network panw clear cup handle buy point evercore isi upgrade stock outperform line volume be limp relative strength line be far new high moreover palo alto have have habit tank breakout myriad genetic mygn break week consolidation be buy range buy point volume be mediocre gene testing firm have re-cover sell august company guidance miss view analyst blast stock downgrade lionsgate entertainment lgfa break flat base remain buy point company share trade symbol lgfb also break volume be big report say amazon com amzn verizon communication vz other medium company be talk acquire lionsgate related sqm strike deal expand lithium production lithium stock drainedthese tech medium giant be talk buy lionsgatetaiwan semiconductor see strong sale cryptocurrency mining boom
869,MRK,stock gain continue evaporate afternoon trading tuesday nasdaq composite russell small cap index reversed lower nasdaq composite be rise nearly also erased gain be afternoon bearish reversal give investor pause russell be early be today market dow jone industrial average lead gain price gap today open dow get considerable help merck mrk catapult month high report positive result treatment lung cancer year ahead expectation volume be higher compare same time friday day light trading ahead day weekend dozen stock top buy point several surrender gain have lag relative strength line include health care novartis nvs clear buy point flat base rs line be lowest point month volume be pale align technology algn poke buy point recede entry base form huge advance ligand pharmaceutical lgnd try break past buy point stock erased most gain volume be well normal rs line be lag well general motor gm be try break double bottom base entry volume be strong rs line need catch stock have be rangebound much past year automaker say earning be high end expect range give bullish guidance financial franklin resource ben citigroup sank back basis briefly clear buy point energizer holding enr soar past buy point cup shape base slide entry consumer product company spectrum brand spb say be selling global battery light business energizer holding cash business include rayovac battery spectrum brand rise be related general motor jump strong earning bullish outlook dow merck do face release cancer trial resultsearning season preview align technology buy zone quarterly report dueenergizer buy spectrum rayovac battery unit blackhawk go private
870,MRK,strong open stock market tuesday see dow jone industrial average cross level early gain fade badly close rise early dow fade loss less nasdaq composite also give back healthy gain fall give back nearly small cap underperform russell preliminary datum show volume nyse nasdaq come higher friday level stock market today result distribution day nasdaq higher volume decline haven be issue broad market recent week always important pay attention sign institutional selling arise even percentage decline aren severe money flow stock do not translate bond inflow year treasury yield be mostly unchanged strong showing merck mrk unitedhealth unh help dow early share merck gap day move average rise nearly company say late stage trial blockbuster cancer drug keytruda combination chemotherapy treatment be effective treat patient advanced lung cancer share unitedhealth meanwhile gain company report earning give solid outlook wall street also like look quarterly result citigroup share rise try clear flat base entry come short tuesday session serve early breakout many top rate growth name include ibd name atlassian team align technology algn well weibo wb name look lot major stock index close result atlassian be due thursday close share rise ahead result clear buy point end buy point share weibo rise more end just cup handle buy point note handle be only visible daily chart not weekly latest be late stage base align technology also break early close whimper share rise close just entry abbvie abbv turn solid performance recent buy point share rise stock have be watch list ibd leaderboard related top tech stock hit buy point only hold upapplied material lam research boost upgrade asml break outgeneral motor jump strong earning bullish outlook bofa goldman alcoa pick earning season pace investing action plan
871,MRK,mile white be name ceo abbott laboratory be youngest head major health care company today longest serve chief health care have make reputation master strategist know make bold move abbott none be more dramatic spun research base pharmaceutical half firm abbvie abbv abbott have market capitalization half industry leader pfizer pfe merck mrk seem crazy many white perceive develop new drug have completely different business rhythm new abbott now focus device diagnostic nutritional product brand generic drug result abbott stock have rise share share give market cap abbvie share increase share share give value approach creation combine be now worth far more pfizer merck white have be rank barron world best ceo straight year keep company current relevant white tell ibd continually shape business ensure re need opportunity be future instance recent acquisition st jude medical make leader range grow medical device category new technology make huge difference patient investor white grow la vegas earn bachelor science mechanical engineering stanford mba year later joined mckinsey co chicago consultant feel work be fascinating project client come go white say want something feel connect longer term be more fulfill white be hire abbott base north chicago suburb abbott park ill director sale diagnostic year later be offer chance head division grow asia pacific region prestigious position year old turn meant move japan wife want open child bookstore white say be big believer work life balance be confident other opportunity advancement come way indeed year later be choose be new ceo follow year add title chairman board wife run bookstore year selling abbott have rarely do acquisition divestiture founding whirlwind change follow white take helm include be dramatic traumatic abbott acquire kos pharmaceutical maker cardiovascular drug cash deal sell core laboratory point care diagnostic division general electric ge fall white decide revive challenged division instead investing research development streamline operation reorganize product service new diagnostic division august begin launch family next generation instrument informatic service common software hardware platform design be easy use more efficient white call game changer industry other acquisition abbott paid pharmaceutical unit belgium base solvay expand presence emerge market same year plan be announce purchase unit piramal healthcare make abbott biggest pharmaceutical company india success company acquisition largely depend ability anticipate consumer medical need understand practice medicine be head aggressively position company benefit internal external investment not just acquire company white say do do more business make better improve exist operation ve develop very discipline integration process learn best bring new asset abbott help expand reach potential faster better have more be just preliminary spin half company abbott take third quarter charge abbvie be officially list new york stock exchange jan make white such savvy deal maker ask jim cramer mad money show cnbc november have real talent anticipate consumer future medical need then aggressively position company benefit year become ceo abbott release humira go treat form arthritis plaque psoriasis crohn disease other ailment now part abbvie make sale make best selling drug world white have foresight spin part company ahead explosion debate drug price guide global enterprise massive change result mistake abbott biggest occur midst drama lead split october abbott be fine marketing depakote brand valproic acid world most widely prescribe epileptic drug condition not approve food drug administration part settlement cost total company agree strengthen internal control separate abbvie january new abbott emerge focus not only diagnostic product service medical device nutritional line brand generic medicine latter be establish pharmaceutical division sell develop market brand name be trust more unknown due high quality efficacy standard doesn have high cost base pharma division now offer more product development acquire cfr pharmaceutical more double latin american brand generic pharmaceutical presence abbott be also world leader adult nutritional product include ensure zoneperfect well leader baby nutrition similac other line special dietary need glucerna juven company be also leader diabetes care introduce revolutionary continuous glucose monitoring device freestylelibre september company purchase st jude medical cash stock establish abbott leader medical device arena also close alere make leader point care diagnostic market ve reinvent company multiple time past year white say continuous process shape company future work very deliberately ensure remain relevant current person serve change take place environment re several different business today be decade be choose specifically relevance science be go demographic socioeconomic factor be go customer be go re still grow strong stock be time high today abbott employ worker country revenue be net income be ceo chairman abbott laboratory global leader medical device diagnostic nutritional product brand generic medicine overcome fail sale challenged diagnostic business turn investing innovation become highly profitable consistent grower company lesson envision long term big goal work detailed step get even mean defy industry consensus need continually ask be better way answer be always yes even exactly not yet be apparent more leader success pam nicholson drife global growth enterprise holdingstaco bell founder change america fast food menumeet man hire take amazonphil knight clear hurdle make nike merchandising champion
872,MRK,dynavax dvax crossed finish line early november first new hepatitis vaccine year dose regimen chief executive eddie gray expect foster better compliance adult share crash day announcement tack pitfall day later investor await acquisition partnership help small cap biotech launch drug name heplisav think person be hope dynavax announce buyout large partnership re not capable commercialize own say brad loncar portfolio manager loncar investment probably find deal person expect big pop run exit didn happen loncar say gray tell investor business daily company talk anyone offer knock sock then first priority be move forward launch drug expect sometime quarter ibd take investing exchange trade fund get closer high flier nektar therapeutic launch strong datum stem combination immuno oncology drug bristol myer squibb opdivo head ibd etfs page closer look key biotech etfs meanwhile dynavax also have asthma drug phase testing potential drug cancer pipeline have checkpoint inhibitor mechanism similar treatment dow component merck mrk bristol myer squibb bmy gray talk ibd dynavax approve hepatitis vaccine mean hepatitis treatment like gilead science gild ibd make heplisav unique gray first product get approval be adult vaccine hepatitis traditionally have be vaccine year work well child don work so well adult ve be able do be bring market new vaccine have significantly higher protective level so more adult reach protection do so traditional vaccine re also able do just used dose heplisav new product have vaccination today have second dose month now older vaccine dose schedule be today month then month key problem adult market be adult be extremely poor come back get third dose mean be contribute factor so many adult be not adequately protected ibd do mean hepatitis market gray be only dose vaccine timing be important point view public health cdc center disease control prevention release latest datum hepatitis infection rate adult population unite state have show be first time year re see increase number infection hepatitis adult unite state datum show essentially increase nation part country higher be thought current opioid crisis obviously involve needle use be contribute area increase rate do have pretty uniform picture country emerge increase hepatitis infection fact traditional dose vaccine do not work well adult re simply not protected need be fact dose vaccine be difficult schedule person follow mean availability vaccine inherently provide higher level protection specifically demonstrated trial do so dose schedule be simpler regimen person follow think be important contributor public health expectation be become dominant vaccine adult market ibd be position competitively gray think re extremely well position think not only be first prophylactic vaccine year profile also be last isn go be competitor larger company mentioned gilead re concentrate be find treatment person be already infected be vaccinate person be not yet infected stop become infected so actually gilead be more worry stopping person get hepatitis infection split important keep apart so don have concern larger company work hepatitis ve already get hepatitis then too late vaccine anyway ibd big be market gray moment number adult get vaccinate year be happened couple year be cdc manage schedule also recommend adult have diabetes also be vaccinate protect hepatitis number person diabetes unite state be obviously very large number person newly diagnosed year be so just newly diagnosed alone almost double market opportunity not count bolus person be already diagnosed diabetic have not be vaccinate certainly see potential vaccine grow be year range ibd comment market reaction follow heplisav approval gray ve see market reaction sort good news sort idea portion market isn terribly interested actually approval operate idea sell news regardless future picture look think fairly clear experience think re very encourage conversation large long hold investor think everybody sort used temporary phenomenon expect appropriate value type approval come back stock time have take position not publicly comment be partnership discussion debate think ve be very clear have say be look profile vaccine look profile have be translate label recognize adult vaccine market be very contain well understood marketplace easily accessible then do believe strong story commitment here high level delivery stockholder dynavax launch heplisav intend do now somebody come offer recognize potential sort knock sock offer then course ll talk such event happen re putt together plan launch heplisav related biotech prosper back roche cancer trialmedtronic surge top quarterly earning viewsbiotech spike settle debate seizure medicine
873,MRK,stock backed early mixed trade thursday nasdaq follow dow industrial moderate loss year federal budget deal move possible vote thursday have generate early optimism investor earning report tesla tsla twitter twtr other be factor morning trade nasdaq composite pop open quickly begin trimming gain viacom viab lead nasdaq almost report fiscal first quarter result dow jone industrial average slip be verizon vz general electric ge weigh dow more hanesbrand hbi take worst loss fall more report morning lead economic release show first time unemployment claim decline week end feb accord labor department be application prior week be far economist consensus estimate increase claim decline issue lead riser more dow just open merck mrk take early lead apple aapl inched fang stock tech leader lose ground share continue struggle hold support day move average chip stock be pressure just open take steep loss wednesday nvidia nvda manage gain early trade move stock buy range buy point open tesla slip report generally better forecast fourth quarter result wednesday close tesla be technically consolidation handle buy point relative strength line be lag stock have have trouble gain altitude week move average twitter spiked report fourth quarter revenue earning growth analyst target stock be extend clear cup handle base december january rebound week support fast move ipo canada goose holding goos faltered follow fiscal third quarter report apparel maker earning revenue easily surpass analyst projection company announce chief financial officer john black be replace later year sinclair cfo shoe retailer jimmy choo loss send canada goose share test support week move average stock remain extend november most china base stock be quietly mixed online gaming leader netease nte slump mixed fourth quarter performance report late wednesday dollar bounce highest mark week buoy optimism federal budget deal bond reversed early rebound move lower lift year yield basis point oil price lead factor wednesday high volume selling reversed course edge higher shake pressure datum show production level more barrel day report energy information administration wednesday stock europe fall hard morning trade take back ground bank england hold interest rate steady hint increase be work ftse london dip frankfurt dax be afternoon trade asia stock market be mostly positive tokyo nikkei punch advance china hong kong hang seng index rise shanghai composite dive be interested big picture techs hit nasdaq stock repeat bear sell stock future point more loss techs fall spot next major stock market peak here be easy waydow jone suffer worst point drop ever percentage loss be not historictime review stock selling smartsanatomy chart breaking buy sell zonesis time get stock market
874,MRK,puma biotechnology pbyi clovis oncology clvs incyte incy outperform other midcap biotechs year analyst say friday list trio favorite have most compelling risk reward ratio leerink analyst michael schmidt say note client be expect release datum pivotal late stage trial drug treat cancer midday trading stock market today however bullish note only help tug incyte stock close puma sank fraction clovis dip incyte bound higher excitement immuno oncology drug call epacadostat drug work block interaction immune system involve ido enzyme otherwise prevent immune response cancer share rise high march end year investor have become skittish ahead echo phase trial readout swing market cap schmidt say note client echo trial be testing dow stock merck mrk keytruda epacadostat patient metastatic melanoma keytruda be also immuno oncology block interaction involve pd protein immune system identify fight cancer cell ibd take puma have best ibd composite rating possible meaning still underperform nearly stock term key growth metric head ibd stock checkup look better rate biotech performer schmidt recommend own incyte echo trial result melanoma trial be expect read first half result be key validate disprove ido inhibition oncology trial fail think stock be worth downside current valuation say think incyte trade best case scenario represent upside plausible base case still mean upside combination be go regimen bristol myer squibb bmy bristol drug opdivo yervoy be approve together treat metastatic melanoma opdivo compete merck keytruda yervoy be immuno oncology drug result be positive clearly inferior yervoy combination think investor intensely debate value epacadostat immuno oncology treatment paradigm schmidt say note safety profile epacadostat still offer improvement yervoy clovis have volatile close year schmidt say phase trial drug rubraca second treatment ovarian cancer maintenance show strong profile vs rival lynparza zejula astrazeneca azn tesaro tsro respectively stock sell latter half competitive concern ovarian cancer drug class call parp inhibitor work block enzyme tie several type cancer schmidt expect clovis take again food drug administration be expect approve rubraca second treatment ovarian cancer maintenance april clovis be also likely unveil datum phase trial metastatic prostate cancer think opportunity parp inhibitor span several cancer type include ovarian cancer metastatic castrate resistant prostate cancer bladder breast other say clovis be view well position partner bristol address opportunity schmidt see clovis get third ovarian cancer market market prostate breast bladder cancer respectively clovis be lead rival prostate cancer market second half set reveal result trial dub triton anticipate filing application rubraca treatment metastatic castrate resistant prostate cancer believe metastatic castrate resistant prostate cancer represent initial market opportunity conservatively attribute peak market share clovis likely reach market first say puma end back positive datum drug nerlynx patient breast cancer fda approve nerlynx broad label datum rival roche rhhby disappoint late stage trial together represent best case scenario puma schmidt say still share trade peer investor have become nervous launch prospect peak opportunity nerlynx be positive puma believe stock doesn adequately represent nerlynx potential early stage breast cancer say phase trial result metastatic patient well potential europe approval first quarter represent term catalyst first half puma be expect unveil result regimen nerlynx genentech cancer drug xeloda patient advanced breast cancer have already undergo prior treatment consensus currently estimate nerlynx sale schmidt view physician feedback show broad use nerlynx various subgroup patient say related biotech dife analyst slash expectation cancer drugwhy biotech stock be take clovis good news ovarian cancer prod rival
875,MRK,dow stock merck mrk announce stock buyback tuesday raise quarterly dividend penny cent cite strong balance sheet consistent performance board increase quarterly dividend cent outstanding share paid last quarter merck pay dividend jan shareholder record close dec merck last announce dividend increase november board up payment cent cent common share board also authorize additional treasury stock purchase time limit completion accord press release ibd take be sure head investor corner more generate income dividend pay stock close bell stock market today merck advanced finish share have trade well day move average late october withdraw application immuno oncology drug keytruda chemotherapy lung cancer treatment europe push back key trial related roche cancer trial be kick tooth dow stock biotech just near year high strong cancer regimendow merck plunge month low grow keytruda worry
876,MRK,major market average muster strong rebound open sharply lower tuesday then erased gain volatile action tech heavy nasdaq fall stock market today dow jone industrial average fall respectively meanwhile vix key measure market volatility briefly spiked highest level august fall back dow jone industrial apple aapl rise find resistance day line fall key level monday share have already trigger loss cut rule flat base buy point downside merck mrk fall third straight day move share be near week low analyst firm leerink swann cut stock price target top retailer lululemon lulu rise news ceo laurent potdevin abruptly resign company share be attempt find support day line be extend buy point peak jan share have rise much buy point company report earning automaker general motor gm toyota motor tm be solidly higher announce better expect earning gm rise number come estimate stock be try regain loss string decline send stock day line meanwhile toyota be try stem recent loss find support day line rise stock break past flat base entry have nice gain general market recent slide ibd take don try guess market be head next read big picture day understand action major average lead stock lumentum holding lite advanced fiscal earning sale beat street target stock be try regain day line have be trading late november ibd cboe global market cboe plunge more cut day line heavy volume first time flat base buy point back early april time stock have advanced much elsewhere graphic chip maker nvidia nvda rebound sharp early loss rise fade stock be try regain cup shape base entry ahead earning release week related sell top growth stock go more gain dunkin brand centene fidelity national earning top view cummin duenew buy top fund bofa return apple go missingdisney gm report pivotal time spacex show investing action plandow jone industrial average dow stock news analysis
877,MRK,future index dow industrial nasdaq tumble monday morning last week selling pressure carry broadcom avgo raise bid fellow apple aapl iphone chip supplier qualcomm qcom stock sell friday lead apple alphabet googl chevron cvx capped worst weekly loss year index nasdaq composite dow jone industrial average thursday wild action ibd change market outlook uptrend pressure first time mid august index future fall vs fair value heavy trading nasdaq future slide dow future lose fair value point environment be cautious make new purchase instead consider take least partial profit winning stock quick cut loss short be close attention action major average lead stock last week be first weekly loss major average be just blip something more serious stock market have rise solidly several month only minor pullback argue market be due correction doesn mean have be now ibd take investor don try guess market be go do instead listen market be say right now follow major average lead stock read ibd big picture market day stock have not be true leader such apple be be expose other alibaba baba chevron have recently look strong have tumble buy point few amazon amzn have keep rally new high broadcom new bid be share current share broadcom say be best final offer aim push qualcomm negotiate mount effort replace entire board qualcomm latter march shareholder meeting broadcom last week report strong preliminary revenue earning upbeat sale guidance give stock brief lift wednesday share fall back lowest level late september friday iphone chipmaker fall apple weak handset sale current quarter guidance well big iphone chip contract qorvo qrvo expense broadcom didn help qualcomm top fiscal earning view give weak guidance chipmaker face regulatory fine curb royalty licensing term world have related dispute apple qualcomm also be try close takeover nxp semiconductor nxpi struggle do so top nxp semi investor want higher price qualcomm stock sky-rocket november initial takeover bid broadcom close day line friday view qualcomm be flat base huge cup handle pattern go back late way buy point be qualcomm share initially pop have turn flat monday broadcom fall fraction bristol myer squibb report fourth quarter earning cent share revenue early monday analyst poll zack investment research have call adjust profit cent revenue year earlier bristol myer earn cent share sale meanwhile drug combination opdivo yervoy improve progression free survival patient advanced lung cancer compare myer have lot hope disappointment immuno oncology drug opdivo rival incude merck mrk keytruda astrazeneca azn imfinzi merck astrazeneca report fourth quarter earning friday share fall merck sale come light astrazeneca rise back buy point bristol myer share close friday flat base buy point relative strength line track stock performance vs index have be lag several month really mid bristol share shot early monday suggest possible be interested top tech stock buy range be hang toughkeep watch top stock just undercut buy pointsstock fall broadly be true correction anatomy chart breaking buy sell zonesapple share flash sell signal week
878,MRK,regeneron pharmaceutical regn be deck launch several drug blockbuster potential next few year include skin cancer treatment analyst predict thursday argus analyst jasper hellweg keep buy rating regeneron stock cut price target regeneron climb close stock market today regeneron pipeline several product seem particularly promising hellweg say skin cancer drug cemiplimab be know pd antibody compete other class include dow stock merck mrk keytruda bristol myer squibb bmy opdivo regeneron official say tuesday have trial range phase phase study cemiplimab cancer third quarter food drug administration grant drug breakthrough therapy status treat patient form skin cancer know cutaneous squamous cell carcinoma ibd take chief executive large cap biotechs have less experience today do past accord analysis analyst head ibd industry theme more impact potential merger acquisition dec regeneron announce phase study cemiplimab show positive result patient cutaneous squamous cell carcinoma firm plan file application next year approval treat condition europe regeneron also announce earlier month collaboration isa pharmaceutical study immunotherapy drug know isa cemiplimab treatment cancer cause human papillomavirus type also know hpv induced cancer company share clinical trial cost exchange product supply regeneron gain exclusive worldwide licensing right isa exchange upfront payment equity investment future milestone payment hellweg say isa be far regeneron only partner regeneron antibody discovery agreement sanofi sny be set expire end year company have array other deal regeneron also partner bayer bayry antibody discovery agreement sanofi company develop praluent dupixent kevzara well unapproved drug include cemiplimab praluent be used lower cholesterol dupixent treat eczema be be investigate treat asthma kevzara treat rheumatoid arthritis drug be important help regeneron diversify eylea hellweg say eylea be approve treat pair eye disease be market bayer outside third quarter eylea bring regeneron sale face competition novartis nvs believe company financial result benefit potential new indication eylea praluent well increase sale praluent dupixent kevzara say regeneron have marketing commercial ability roll drug quickly see recent product launch related amgen regeneron prep battle cholesterol drugswhy biotech stock feel lovebeware price war big pharma biotech company horizon
879,MRK,powerhouse session earning report left major index mixed stock fade afternoon trading investor look busy hour session dow jone industrial average struggle gain exxon mobil xom walt disney post index top gain nasdaq composite slump paypal pypl tractor supply tsco fall bottom nasdaq lose fraction russell small cap gauge take gain day volume be higher accord preliminary number be mixed day datum downside job cut rise sharply january labor department estimate sharp increase labor production cost fourth quarter other hand weekly jobless claim dip forecast be increase institute supply management january manufacturing gauge decrease still come expectation close quarterly result be come apple aapl amazon com amzn alphabet googl many other amazon rise alphabet fall extend trading follow report facebook fb rolled gain nail new high analyst race lift stock price target follow positive fourth quarter report late wednesday stock end top buy range buy point diversify medium company meredith mdp collapse kill week base effort report generally better expect fiscal second quarter result company also begin official move downtown manhattan office time purchase november tumble food ingredient heavyweight ingredion ingr send grain industry group day worst performance industry ingredion report fourth quarter earning miss analyst forecast wide margin decline send share back buy point stock week move average tractor supply tsco cave stab week move average heavy trade retailer fourth quarter result narrowly clear expectation midpoint full year revenue guidance be consensus target share remain extend cup base stock clear november alibaba group holding baba slice lower follow mixed fiscal third quarter performance announcement have take stake ant financial unit have spun slip send alibaba back test cup base buy point day big winner cimpress cmpr bolt follow quarterly report stock score breakout session include ferrari race ezcorp ezpw opentext otex chipmaker qorvo qrvo swung boost fiscal third quarter result news have land key supply contract apple share wrapped session buy range buy point cup base friday morning earning roster call report several big oil name lead chevron cvx exxon mobil drugmaker merck mrk astrazeneca azn be also list investor be tune labor department monthly payroll report be due open other important market news thursday job big oil earning drive market friday investing action planalibaba test buy point earning miss ant financial stakeqorvo rocket apple contract broadcom slipstake interactive software gun wild west game delaylooking next nvidia start simple routine
880,MRK,index other major average have first week be worst show year apple aapl guide lower many suspect amazon amzn boee ba deliver strong result facebook fb tout strong ad rate alibaba baba miss earning paypal pypl crash former parent ebay ebay moved cut ty move amazon jpmorgan chase jpm berkshire hathaway brkb team tackle health care cost hit insurer pharmacy benefit manager bitcoin meltdown continuedx hot start major average suffer worst weekly loss year dow nasdaq rise bond yield worldwide pressured stock unitedhealth unh cvs health cvs many other insurer fall amazon jpmorgan berkshire health care joint venture amazon boee facebook be earning winner alibaba be notable loser apple aapl do bitcoin plummet loss accelerate facebook joined chorus regulator worldwide crack cryptocurrency apple aapl earning share rise year year sale fiscal first quarter narrowly beat expectation apple sell iphone vs consensus unit average selling price due new iphone iphone model fuel overall result march quarter apple expect sale base midpoint guidance official estimate share fall friday new month low commerce leader report adjust earning share smash consensus big benefit tax cut help revenue rise also beating revenue amazon web service rise sale echo line smart speaker far exceed expectation amazon amzn say share gain hit new high intraday facebook fb report robust earning revenue growth top forecast user growth cool user time spend facebook fall even latest big news feed change executive say conference call ad rate be soar ease analyst revenue fear share hit record high thursday alphabet googl share fall google parent report adjust earning be share year earlier miss view traffic acquisition cost google pay partner website carry ad soar google expect rise tac moderate google rise tac have be link contract renewal apple well internet search shift mobile phone revenue rise top consensus adjust ep exclude impact tax reform result additional expense amazon jeff bezos jpmorgan jamie dimon berkshire warren buffett say new nonprofit company be aim reduce cost employee be successful own firm think be expand service corporate america health insurer pharmacy benefit manager sell unitedhealth largest health insurer also pbm sank drugstore pbm cvs health cvs be buy insurer aetna aet lose pure play pbm express script esrx retreat paypal pypl report strong earning line guidance former parent ebay ebay report line earning stronger expect gross merchandise volume real news be ebay stunned wall street news replace paypal handle payment own site partnership adyen move add revenue stream share ebay soar nearly thursday paypal lose week close buy point day line chinese commerce giant revenue soar best gain least quarters beating view earning share climb slightly miss forecast alibaba buy stake ant financial former unit run payment service alipay replace deal alibaba get ant financial pretax profit alibaba provide intellectual property not cash move clear hurdle possible ant financial ipo alibaba share week tumble recent buy point add job january better expect average hourly wage surge vs year earlier far view best ism manufacturing index continue point raid employment gain fast growth wage gain be good news spur federal reserve raise rate more aggressively year software leader report adjust earning share cent year year sale fiscal second quarter analyst expect cent microsoft get lift cloud compute business include azure office dynamic current quarter microsoft guide earning share cent sale view share hit record high intraday thursday amd amd broadcom avgo qorvo qrvo offer investor positive financial news amd beat wall street target december quarter guide estimate higher current quarter broadcom give preliminary sale earning guidance fiscal first quarter top view qorvo rocket disclose big contract major customer apple aapl next generation iphone qorvo deliver better expect result fiscal guide well wall street target current quarter boee ba report ep share exclude share benefit tax cut way boee beat analyst view revenue climb also top view boee also guide ep revenue forecast higher tax cut spur more investment make case new midmarket jet more compelling boee also get missile defense contract pentagon up up order new jet give venerable jumbo jet new lifeline meanwhile lockheed martin lmt ep jump revenue rise defense giant guide ep view higher boee share rise week lockheed hit new high video game publisher electronic art ea see stock surge record high report big gain online service associate sport game franchise fifa madden nfl boost live service be reveal part ea line december quarter earning report video game hardware software firm nintendo ntdoy post better expect december quarter result thank continue success switch console related software take interactive software announce major delay highly anticipate wild west action game red dead redemption now set release oct instead spring visa mastercard top analyst forecast person break plastic more often spend holiday visa also buyback follow american express axp just suspend buyback visa also hike quarterly cash dividend cent share homebuilder stock continue struggle even big builder report better expect earning prior week surprise miss nvr nvr housing demand price be strong concern be grow rise labor material cost mortgage rate low be rise america largest homebuilder horton dhi beat ep revenue wednesday share meet resistance day line pultegroup phm stock keep fall slide gross margin even earning sale top view smaller meritage home mth also beat smaller home mho holding mdc miss ep slew biotechs drugmaker report earning include pfizer pfe eli lilly lly vertex pharmaceutical vrtx astrazeneca azn merck mrk top wall street fourth quarter earning expectation pfizer come sale adjust profit cent share lilly total sale grow firm bring adjust income share vertex report sale adjust profit cent share astrazeneca report core earning share sale merck result be mixed top line miss view adjust income cent share beat cent amgen amgn report sale adjust earning share lag consensus merger news sanofi sny announce acquire ablynx ablx exxon mobil xom fall well short consensus fellow dow industrial component chevron cvx also miss ep view share plunge day line chevron undercut recent buy point separately crude production continue hit fresh longtime high crude supply rise first time week crude future remain year high ferrari race gap buy zone report strong earning thursday meanwhile auto sale slump january big decline ford fiat chrysler fcau gm gm sale edge higher miss view toyota tm sale sky-rocket strong truck sale
881,MRK,stock fought positive finish wednesday health care construction stock book day widest loss video game stock notch bevy breakout dow jone industrial average lead end boost boee ba monster advance heel glow result nasdaq composite rise struggle fractional gain market drop sharply fed et announcement committee hold target interest rate unchanged offer slightly more wary tone inflation day other economic news be positive early datum adp show january hire slip less expect december pending home sale chicago region manufacturing january gauge easily top expectation dow be hold back medical component merck mrk johnson johnson jnj pfizer pfe drop more drugmaker eli lilly lly tumble follow generally positive fourth quarter report drug sector investor be apparently still react tuesday news innovative health care partnership amazon com amzn berkshire hathaway brka jpmorgan jpm amazon advanced putt past buy point profit take zone other fang stock tech leader lose ground netflix nflx fall furthest nearly still extend early january tesla tsla rise average trade third gain session share be now more november low back support week move average climb right side possible month base pattern video game trade be day winner ninetendo ntdoy take interactive electronic art ea clear buy point add entry ninetendo trim gain afternoon trade remain just buy range cup base buy point electronic art pare advance hold buy range top buy point also cup base take chalk surge end very top buy range cup base buy point concrete aggregate supplier take session worst performance industry concrete uscr tumble more eagle material exp martin marietta mlm vulcan material vmc fall apiece eagle material post mixed fourth quarter report open reaction also have be link public private infrastructure cost sharing question raise president trump state union address ibd name telecom software developer casa system casa gain more soft trade stock be attempt start right side first base end jan high december ipo price argentina base bank grupo servielle supv also ibd name jump almost nearly average trade move technically place stock buy range rebound support week move average volume need kick next day so order confirm buy opportunity bottom ibd list mimedx group mdxg daqo new energy dq shed other important market news wednesday bring game apple amazon alphabet report action planbiggest homebuilder hit resistance earning sell don freeze double digit gain stock shrink fastlooking stock nvidia start list
882,MRK,sanofi sny second deal week spur robust buy period biopharma analyst say monday french drugmaker outbid nordisk nvo belgium ablynx ablx deal come week sanofi say spend acquire biogen biib spinoff bioverativ bivv hemophilia drug specialist also last week celgene celg say buy juno therapeutic juno leerink analyst seamus fernandez say signal begin active time biopharma deal view sanofi aggressiveness merger acquisition precede more robust period deal biopharma effect tax reform be feel valuation late stage asset continue drive higher say note client specifically sanofi plan spend acquire ablynx ablynx be near approval drug treat rare blood clot disorder be already partner abbvie abbv dow merck mrk sanofi other number potential drug various partnership program offer upside prospect ablynx wholly own asset fernandez say note drug fight virus cause infection lung respiratory tract be expect have phase datum second half year ibd take analyst don expect payer push back drug treat rare disease consider small population tend treat see company be work arena visit industry snapshot acquisition also add drug know caplacizumab sanofi pipeline drug be be test treatment acquire thrombotic purpura rare clot disorder cause impair activity enzyme ablynx estimate market disorder also know acquire ttp be euro expect gain approval europe sanofi fall close stock market today ablynx other hand rocket finish nordisk lose chance acquire ablynx sank nordisk have put bid earlier month ablynx related biopharma behemoth soon become surgical dip lackluster guidance analyst bullishwhy biotech stock outperform peer
883,MRK,sell health stock tuesday joint venture amazon com amzn jpmorgan chase jpm berkshire hathaway brkb wring cost saving health care system appear very unlikely impact industry earning next couple year accord analyst figure rein health cost participation big health care player look impossible task needham analyst kevin caliendo say note cost implement system adjudicate patient datum partner hospital doctor pharmacy national basis be onerous caliendo add scale big new partner wouldn be big enough squeeze discount provider steering patient way compare purchasing power unitedhealth unh cvs health cvs aetna aet anthem antm new company have align other provider way provide best care employee caliendo conclude fact caliendo give cvs big vote confidence earlier tuesday say plan combination aetna position create saving government private employer needham raise rating cvs strong buy target caliendo do think profit industry especially underwriting level be excessive be improvement current care delivery model be make see prime reason cvs aetna deal cvs be look shift more health care service lowest cost location store clinic different take unitedhealth playbook expand urgent care other outpatient locale drive saving customer such path forward be evident announcement amazon jpmorgan berkshire plan establish independent company be early plan stage accord statement trio group do not come problem answer acknowledge berkshire ceo warren buffett success be go require talented expert beginner mind long term orientation say amazon jeff bezos yet unclear point talented expert be wall street weigh long term nature effort dearth substantive detail initial shock wave ripple wall street subside share dow jone industrial average component unitedhealth nation largest insurer sank stock market today diving much earlier cvs health be process buy aetna pare loss drop drug distributor cardinal health cah mckesson mck be respectively prescription benefit management firm express script esrx sank have tumble earlier cvs unitedhealth also operate pbms manage prescription side health insurance contract pharmaceutical biotech stock also lose ground hit didn look much broader market downdraft tuesday merck mrk shed allergan agn gilead science gild pfizer pfe lose top earning view offer bullish guidance ibd take unitedhealth be rank ibd medical manage care industry group base earning sale margin stock performance trend visit ibd stock checkup see leader category insurer have be solid performer rank group long current confirm uptrend equivalent green light stay place lead stock lead group break buy point be more likely not have wind back here good place start look stock be poise move higher knee jerk reaction investor be surely reflection unsustainably high cost health care fact amazon have be itch disrupt retail prescription business be attach effort traditionally fear health care investor have be government not private sector impose cost control get handle runaway budget deficit thin industry profit process medicare negotiating drug cost be such fear industry expert say government be unlikely produce much way saving be willing deny patient access certain drug create political backlash amazon jpmorgan berkshire aren first big employer join force attack health cost leerink analyst ana gupte note tuesday health transformation alliance group large self insure employer launch last year also hope find saving improve employee satisfaction work cvs unitedhealth achieve aim initial report indicated alliance member expect save combine prescription cost year amazon jpmorgan berkshire say initial focus be technology solution provide employee family simplified high quality transparent healthcare reasonable cost new corporate entity say be free profit make incentive constraint just form technology solution take be far clear caliendo suppose berkshire bring underwriting skill ve never underwritten healthcare amzn make pharmacy medical procurement contribution provide expertise leerkink gupte say unclear amazon wading deeper solve health care mess accelerate move supply chain prescription industry also be interested trump state union move market downstock fall market show sign be ready breakgrubhub redhat lead ibd stock buy invest stock free new apps aim invest stock market start simple routine
884,MRK,verizon vz stock have barely budge start january make worst perform dow jone industrial average component yet loss look practically rosy next plunge trouble general electric ge ibm ibm exxon mobil xom merck mrk round list biggest dow loser decline year overall stock average soar plunge include loss second half year sole survive original member blue chip dow sit lowest level year time high set august ge be also worst performer ge take hit number front intense effort style forward look digital industrial company jeff immelt step ceo earlier expect investor discontent chronically sluggish stock ge key power segment suffer mismanagement trouble industry downturn lead plunge profit leadership team cut dividend earning forecast half november new ceo john flannery turnaround strategy intend instill confidence put ge back growth path draw meh wall street flannery plan shrink company aviation power health care segment target cost cut asset sale shut factory world meanwhile ge show good thing dow price weight index long suffering tech stock have have particularly painful time give technology sector be undisputed champion year ibm retreat bulk loss come first half year big blue isn suffering just bad year revenue hasn grow several year business shift drove cloud base datum storage traditional mainframe computer ibm be slow respond tectonic change now make big analytic cloud compute push still ibm face formidable competition like alphabet googl amazon amzn microsoft msft fact berkshire hathaway brkb warren buffett cite threat big strong competitor dump more half ibm holding oil major lose year have rise past month reflect recent uptick crude price oil price be back barrel be year high be volatile be still well high more barrel outlook oil price be murky opec russia continue curb production ease global supply glut shale producer offset cut boost output take advantage higher oil price ibd take roundup prediction stock market visit ibd page stock market outlook watch new year drugmaker slide plunge past month merck recently face major patent loss result loss billion dollar sale intensify pressure generic competition ransomware attack june cause massive disruption merck operation hurricane damage puerto rico later year broadly disrupt manufacturing key drug telecom giant dip year vault past month verizon face cutthroat wireless competition cable customer continue cut cord switch internet stream option verizon look boost advertising revenue aol yahoo acquisition eyee bigger role provide residential service longer be subject net neutrality rule more be interested tech see rebound here be company sector drive car rubber hit road be early investing hot spot artificial intelligence
885,MRK,european pharmaceutical firm astrazeneca azn nordisk nvo pull upgrade friday analyst look ahead key clinical trial readout ovarian cancer diabetes respectively astrazeneca rise stock market today nordisk dip fraction jpmorgan analyst james gordon upgrade astrazeneca overweight rating jpm richard vosser boost nordisk neutral rating astrazeneca medium term growth outlook be twice european pharma sector gordon write note client expect return topline growth new launch be key see core earning hit floor rise gordon be bearish year clinical trial testing combination immuno oncology drug advanced lung cancer july astrazeneca say regimen didn shrink tumor have pin hope trial dub mystic immuno oncology general now mystic trial be continue goal improve overall survival os bear key point be expectation mystic pfs progression free survival failure overly high base business divestment expectation say mystic pfs have fail low expectation os readout now see only modest downside astrazeneca be also set have datum trial drug lynparza first treatment form ovarian cancer rival clovis oncology clvs tesaro tsro gordon see high likelihood astrazeneca be successful trial be call solo ibd take large cap biotechs drugmaker suffer mount competition newer therapy generic rivalry theme be likely continue analyst say head ibd industry theme closer look trend mean bigger player gordon forecast astrazeneca achieve compound annual growth rate core earning share more twice sector market likely focus key product launch beat consensus view aggregate say expect sale lung cancer drug tagrisso top expectation forecast sale be achievable just half patient specific mutation receive therapy first treatment base much higher penetration comparable therapy competitor horizon think even own forecast prove conservative say outside assume price cut europe japan patient receive drug first treatment china expect eligible patient receive tagrisso assume similar price cut gordon expect sale immuno oncology drug imfinzi be line see lynparza treat ovarian cancer post small beat see downside long term drug astrazeneca be also launch calquence treatment mantle cell lymphoma only patient see term downside astrazeneca be also look drug chronic lymphocytic leukemia affect larger group patient fasenra be also recently approve monthly treatment form asthma drug rival glaxosmithkline gsk nucala be administer monthly likely regeneron pharmaceutical regn sanofi sny dupixent get approval treat asthma nordisk be story oral semaglutide vosser say oral semaglutide be be investigate phase trial dub pioneer treatment type diabetes oral semaglutide belong class drug know glp receptor agonist currently glp drug be only available injection nordisk look be first market oral glp oramed pharmaceutical ormp be also work oral glp drug far nordisk give see oral semaglutide datum live expectation don see pioneer program be source disappointment investor see market leave more difficult commercial question product clinical profile be nail clinical trial result vosser say note client nordisk be testing oral semaglutide vs own victoza dow stock merck mrk januvia eli lilly lly jardiance series trial related clovis good news ovarian cancer prod rival downtesaro take swipe astrazeneca ovarian cancer drug saleswhy tesaro cancer drug miss prompt rival topple
886,MRK,sanofi sny agree monday buy belgium ablynx ablx euro outbid rival nordisk nvo gain potential blockbuster rare blood clot disease come last week agreement buy hemophilia drug specialist bioverativ bivv paris base sanofi pay euro share cash outstanding share ablynx say statement monday price be unsolicited offer much euro share bagsvaerd denmark base concede have lose say statement win try outbid sanofi takeover complement sanofi purchase bioverativ spinoff biogen biib announce week chief executive officer olivier brandicourt be return acquisition enter field blood disorder lose attempt takeover sanofi arrival white knight be setback effort bolster stable treatment rare blood disorder main diabetes business grapple price pressure very difficult come back once company board have agree deal soren lontoft hansen analyst sydbank say telephone difference initial offer have offer now also be too big ablynx share jump open bell stock market today sanofi nordisk fall ablynx most advanced treatment call caplacizumab be poise approval year unusual disorder blood clot form small vessel body belgian company estimate garner annual sale euro peak ablynx represent strong strategic fit especially sanofi acquisition bioverativ rebekah harper analyst credit suisse write note client sanofi begin tender offer ablynx outstanding share deal be contingent shareholder tender least stock sanofi enter bank credit facility bnp pariba sanovo bid unveil jan include upfront cash offer euro share additional cash payment know contingent value right euro share tie success experimental medicine ghent belgium base ablynx largest shareholder have say be receptive higher offer reflect value product ablynx adviser reach other potential suitor include sanofi merck mrk roche hold rhhby gauge interest spurn unsolicited bid person knowledge matter have say morgan stanley lazard act sanofi financial adviser weil gotshal mange llp nautadutilh serve legal counsel ablynx be advise jpmorgan chase eubelius cvba goodwin procter llp linklater llp be belgian company legal counsel be interested biotech merger spigot turn juno bioverativ biotech pharma industry invest stock market start simple routine
887,MRK,stock market pause monday loss didn do much stop feverish advance dow jone industrial average fall nasdaq shed need breather perhaps index close session lows broadly lower decliner lead advancer nyse
888,MRK,here weekly investing action plan need know investor come week tech sector heavyweight facebook fb apple aapl amazon amzn alphabet googl microsoft msft dominate come week earning news oil major exxon mobil xom chevron cvx also report
889,MRK,stock market volume price action picked tuesday book close holiday related trade index come session high blue chip dow jone industrial average lead index gain nasdaq small cap russell follow rise respectively add volume rise sharply major exchange stock market today trade have be somewhat hampered christmas new year martin luther king jr holiday lag other index midday tuesday technical action large cap index improve dec distribution day fall count cumulative price gain distribution day involve loss rise volume major index point institutional selling handful distribution day short period signal trouble stock market current rally now have distribution day nasdaq be bullish situation market blue chip be mostly midday tuesday component dow jone industrial average stock be least rise include do so strong volume drugmaker merck mrk jump volume more average boee ba advanced volume average unitedhealth group unh rise trade average ibm ibm add volume faster usual caterpillar cat tack almost twice usual volume microsoft msft push higher volume average breakout midday tuesday come variety sector chip equipment group asml hold asml gap volume average stock buy point susquehanna financial group analyst reiterate positive rating asml upgrading other chip stock netherlands base asml report result wednesday street expect earning jump share chip equipment group however have fall month middle pack industry group china base internet stock weibo wb gap clear buy point volume be average be late stage be more prone failure ladder capital ladr mortgage related real estate investment trust gap volume more average stock crossed buy point unitedhealth unh gap volume normal stock climb buy point manage health care provider beat fourth quarter profit expectation ease revenue also beat view notice breakout involved gap move be very bullish action related top tech stock strong rs line hit buy pointsdow giant unitedhealth hit buy zone earning outlookapplied material lam research share boost move buy gap upstock rally pass day mark more come
890,MRK,major stock index turn negative late afternoon trading tuesday not surprise give ebullient gain first week trading nasdaq show loss rise much respectively breach first time dow jone industrial average ease rise much early go point least component dow industrial advanced point more et however only stock dow be point more hailed health care arena johnson johnson jnj merck mrk unitedhealth unh merck gap nearly quadruple normal turnover good news regard potential treatment involve keytruda additional medicine lung cancer now merck continue be base build mode volume nyse nasdaq be run sharply higher vs same time friday meanwhile bitcoin other alternative digital currency continue cool bitcoin investment trust gbtc give back most friday rebound lose however overall picture fast rise exchange trade note have not change be normal correction peak dec tuesday mark start fifth week digest superlative gain see fourth quarter last year nov bitcoin investment trust break very deep cup handle roar more higher less month daily chart see bitcoin investment be try halt slide day move average crude oil price copper ease too gold price rise back weaker dollar euro last week moved past first time december wti term future edge lower barrel market breadth turn negative equity lose stock outmatching winner nearly exchange few lead stock let strong gain slip weibo wb moved past buy point week cup handle rally high past proper entry stock backtrack cut gain roughly decline weibo cup base run left side peak correction normal parameter important chart pattern investor hunt strong breakout however most recent base be late stage increase risk failure chinese social network break first stage base also cup handle week end april weibo be initially featured ibd stock analysis column march also become current stock ibd leaderboard tuesday join fellow chinese adrs athm com wuba weibo wasn alone term top rate company start mlk holiday shorten trading week sour note lgi home lgih fall more trigger sell signal volume jump day average stock post biggest point drop breaking solid week cup base oct tuesday drop be also largest entry level homebuilder clear earlier deeper cup base late june share lgi be now testing institutional buy support critical day move average lithium metal supplier sociedad quimica sqm netease nte new oriental education edu stream video hardware play roku roku also stage negative reversal heavy increase volume such concerted selling hint pronounce profit take mutual fund hedge fund bank insurer large investment advisor stay abreast future potential change overall market trend read big picture column day broad market reversal few highly rate name still act well oneok oke gain fourth day row rise more average turnover oil gas transport play have clear week cup pattern be slightly outside proper buy range buy zone go buy too far extend price put investor vulnerable spot stock quickly pull back test initial entry follow strong move wall street expect oklahome base firm stage strong rebound earning share follow climb fourth quarter result be likely be announce late february oneok also sport annualize dividend yield abiom abmd heart pump maker name ibd sector leader screen rise more slightly average turnover market leader be extend surpass narrow flat base jan abiom score lofty composite rating ibd stock checkup grubhub grub ibd be yet remain key day move average follow day rebound thursday friday continue support day line week move average weekly chart give investor chance add current position mobile online food order service grubhub be clear buy point week flat base oct follow robust third quarter result earning cent share revenue record street see earning accelerate gain cent share related spot next major stock market top yes here easy methodinside ibd spot serious correction top growth stocksspot hot large cap growth stock peek big cap watch pattern develop choppy stock market action
891,MRK,couple roche rhhby tecentriq chemotherapy avastin double percentage advanced lung cancer patient survive year disease progress share sank benefit seem be drive segment patient population close bell stock market today roche dip close share rival dow stock merck mrk bristol myer squibb bmy lift close respectively roche phase trial dub impower test cocktail immuno oncology drug tecentriq chemotherapy older cancer drug know avastin patient previously untreated advanced lung cancer study show patient receive regimen have reduce risk disease worsening death compare receive avastin chemo month progression free survival be patient treat regimen vs receive avastin chemo overall patient respond drug combination vs regimen avastin chemo roche say press release ibd take dow merck have ibd composite rating best possible meaning slightly outperform bottom third stock term key growth metric head ibd stock checkup look better rate drug stock leerink analyst seamus fernandez note benefit seem be drive largely specific group patient certain biomarker however patient roche secure place second third treatment option say expect trading merck bristol be volatile also have immuno oncology drug know keytruda opdivo headline be likely be relief merck investor worry roche take significant share still cross trial comparison merck chemo combo datum trial know keynote continue be challenge result trial know keynote become available say note client related regeneron dip month low drug combo bayer failswhy biotech prosper back roche cancer trialwhy roche cancer trial be kick tooth dow stock merck
892,MRK,roche rhhby be now real competitor potential first treatment advanced lung cancer analyst say monday drugmaker immuno oncology regimen hit goal phase trial xin early trading stock market today roche jump close run highest point mid october meanwhile share dow component merck mrk have rival combination drop finish top line datum show roche tecentriq combine cancer drug avastin chemotherapy provide statistically significant clinically meaningful reduction risk disease worsening death compare regimen avastin chemo further detail be provide upcoming medical conference december roche say overall survival datum aren mature yet be encourage expect first half firm say result be mixed bag merck merck receive accelerate approval use immuno oncology drug keytruda chemo treat advanced lung cancer keytruda tecentriq be immuno oncology drug respectively pd inhibitor pd inhibitor evidence have suggest drug work better population patient body make more protein call pd october merck pull application regimen europe delay key study combination move lead analyst question ongoing issue regimen merck stock dip month low worry ibd take big biotech player struggle third quarter smaller cap enjoy major sale beat lead exelixis exel neurocrine bioscience nbix top view nearly respectively read industry snapshot deeper dive third quarter roche trial help confirm theory immuno oncology chemo regimen succeed broad population patient advanced lung cancer regardless much protein body make leerink analyst seamus fernandez say not clear avastin have real benefit combination fernandez write note client avastin be approve first treatment form advanced lung cancer isn widely used isn well tolerate say avastin base regimen be used first treatment estimate lung cancer patient vs eli lilly lly drug alimta be used say merck discontinue pursuit avastin base regimen safety concern instead gain approval lilly drug result be more validation benefit immuno oncology chemo combination be most positive roche give tecentriq position model third perhaps even fourth player pd pd market sale say evercore analyst umer raffat agree note news solidify roche regimen real competitor treat advanced lung cancer related biotech just near year high strong cancer rival take chunk medtronic heart unit salesbiotechs sell drove be investor seek merger
893,MRK,stock close higher monday small cap extend rally verizon vz help dow outperform major index nasdaq rise only leadership semiconductor other technology group also add small cap lead russell rise third straight session index monday close be away new high dow jone industrial average climb volume be lower friday pace be likely remain light thanksgiving week winner lead loser ratio nyse nasdaq verizon picked well fargo upgrade telecom giant outperform market perform well analyst also raise price target verizon cite company dividend outlook much bad news wireless revenue decline be analyst add goldman sachs downgrade wal mart wmt neutral buy jeffery put price target retail titan rate buy wal mart be flat erase loss merck mrk also lag dow shedding favorable news potential treatment advanced lung cancer rival roche rhhby several high rate stock break basis most show minor volume put breakout question be norm week thanksgiving week tend see light trading verizon couple other telecom stock break contribute sector lead performance monday market ubiquiti network ubnt clear entry cup handle base volume be less average maker wireless network equipment roger communication rci canada largest provider wireless communication service top buy point flat base volume equal day average share day lower price axt axti break sharply vaulting buy point nearly time average volume chip equipment manufacturer have composite rating energy health care be weakest sector retail also lag include restaurant drugstore chilean stock fall unusually heavy volume lithium producer sociedad quimica minera sqm brewing firm compania cerveceria unida ccu banco santander chile bsac conservative candidate sebastian pinera win plurality vote sunday presidential election fail majority now head runoff vote related verizon upgrade more rational wireless outlook dividendwhy roche cancer trial be kick tooth dow stock merck
894,MRK,clovis oncology clvs sage therapeutic sage puma biotechnology pbyi stoke acquisitive appetite large cap biotechs struggle slow growth major patent cliff analyst say tuesday deal make have slow hit record high rbc analyst say note client number deal value hit year year have be merger include gilead science gild takeover kite pharma investor have expect gilead major buy stoke more acquisition didn come fruition biotech stock suffer pent demand prompt merger acquisition play next year analyst say many large cap company generate share overall revenue handful blockbuster drug many be face impending patent cliff come year rbc note say need make lose source revenue stimulate growth encourage future gilead buy kite suffering major decline hepatitis drug unit hiv drug tenofovir alafenamide be likely lose patent protection celgene celg cancer drug revlimid be face patent cliff amgen amgn inflammatory enbrel be likely lose protection also have most cash hand recent update amgen report celgene have gilead note remainder large cap biotech realm have ibd take analyst say monday large cap biotech franchise feel pain competition speeding number rival brand generic drug approval head ibd industry theme more mean like vertex pharmaceutical gilead amgen overall cash position be near year high analyst say tax reform help most recent proposal company repatriate earning tax rate amgen bristol myer squibb bmy dow johnson johnson jnj have excess cash currently overseas however think unlikely majority overseas cash be repatriate immediately institution tax reform rbc analyst say celgene instance have suggest chunk foreign earning be expect be reinvest permanently outside analyst also note average project revenue next year mid cap biotechs be likely do little offset loss patent cliff performance acquirer past year have be poor industry check also indicate large deal be out gilead kite be exception still expectation be high merger acquisition analyst say recent survey investor cite biggest tailwind group drug pricing be expect be biggest headwind rbc analyst be slightly bullish slightly bearish drug pricing expectation high major tailwind sector do not materialize first half see broad downside rbc say credit suisse analyst vamil divan too note be important big pharma group likely come result change tax rate repatriation top pick be also expect dow merck mrk allergan agn rebound additional fund dividend growth share repurchase also boost overall outlook sector investor perspective say see regulatory environment remain generally favorable provide more rapid path market product bring real innovation related beware price war big pharma biotech company biotech stock see cheapest rival cancer drugsgeneric drug maker face pricing issue other pharmas don
895,MRK,nektar therapeutic nktr launch nearly year high monday strong combination datum immuno oncology drug combine bristol myer squibb bmy opdivo skin kidney lung cancer xby close bell stock market today nektar soar more close earlier rise much touch high last see january meanwhile bristol tick close datum be present society immunotherapy cancer annual meeting nektar drug nktr be design grow specific cancer kill immune system cell natural killer cell population body fight cancer opdivo be know pd checkpoint inhibitor work block specific interaction immune system prevent immune response compete closely dow merck mrk make rival drug call keytruda total patient be enrolled dose escalation phase trial dub pivot ibd take keep tab earning season bookmarking ibd investing action plan nov never treat patient advanced melanoma respond treatment sign cancer disappear patient have partial response treatment never treat kidney cancer patient least baseline scan response be see include complete response partial response patient more prior scan respond combination advanced kidney cancer patient already receive least round prior therapy partial response be observed advanced lung cancer patient respond regimen sign cancer disappear patient other patient have partial response most common side effect be low grade include fatigue flulike symptom rash itch be grade side effect dose recommend testing continue phase trial nektar say news release dose escalation stage pivot trial ve observed important response rate tumor type say mary tagliaferri senior vice president clinical development nektar patient response trial continue treatment canaccord analyst arlinda lee boost price target nektar keep buy rating expect nektar target additional type cancer used nktr expect clinical datum nktr opdivo renal cell carcinoma sarcoma other solid tumor well potentially nktr combination roche rhhby tecentriq keytruda say note client related nektar acadium pop street crush quarters tesaro dipsnektar rocket year high analyst peg successnektar therapeutic earn relative strength rating update hit key benchmark
896,MRK,dow jone industrial average component apple aapl post biggest gain more month gain brisk volume reaffirm strength latest nasdaq composite gain nearly midday monday other major index be try rally bombing incident occur early monday major commuter hub just block away time square new york city et dow jone industrial average edge higher volume be run mildly lower vs same time friday main exchange smallcap be slightly addition apple least more component dow industrial average gain point more include walt disney microsoft msft big pharma play merck mrk microsoft have best ibd rs rating quartet mega cap stock meaning outperformed publicly trade company past month apple be second best see ibd stock checkup disney rs rating be work new base merck have weakest rs rating nasdaq composite be close wipe away nearly loss incur prior week solar energy certain biotechs particularly gene therapy play lead upside thank strong gain name such gene therapy play bluebird bio blue china daqo new energy dq have be highlighted ibd stock spotlight screen retail defensive food stock think dairy meat food preparation sank bluebird now have market cap qualify mid cap company have only revenue past quarters however mark watersh moment company be address difficult disease condition therapy strive change genetic makeup cell bluebird break week cuplike base double usual volume aug share gap reach high intraday monday cambridge mass firm present update datum show meaningful clinical improvement patient severe sickle cell disease receive lentiglobin gene therapy product meanwhile bitcoin investment trust gbtc rally nearly slightly average trade exchange trade fund continue ride strength interest alternative currency sunday see start related derivative trading chicago board option exchange expect cme group also launch bitcoin related future month liquidity be decent individual investor bitcoin investment trust trade average nearly share day equivalent dollar turnover etf initially break very deep cup handle nov quiet trade initially volume really kick nov share rocket more point day move average act useful chart tool sell etf bitcoin investment drop sharply note prior stock market today column etf day move average be lag too far be thus not useful determine short term exit point apple meanwhile be likely rise anticipation strong holiday shopping quarter new product tech giant be apparently see robust demand worldwide range ultra luxury iphone new apple watch receive send phone call apple be now nearly past buy point second stage cup handle be thus extend notice stock be hold rise day move average good sign accumulation distribution rating be also positive see ibd stock checkup meanwhile composite rating be also solid indicate apple rating recent stock action have be superior stock ibd database start year composite be poor scale go back microsoft cloud compute business software xbox giant have excel climb entry flat base late july share have rise more then be now form shallow flat base entry notice weekly chart microsoft find buy support brief pullback last week week move average bullish sign revenue microsoft have grow vs year level help fuel rebound earning analyst survey thomson reuter see fiscal profit period end december rise cent share revenue boost trade entire ibd click ibd ffty etf manage innovator capital management also please follow saito chung twitter ibd_dchung more market analysis commentary idea market hour related bitcoin future soar debut crypto stock play be next cisco home depot microsoft apple break pattern january find great stock new ibd best stock market winner start journey hereibd big picture rise sector snatch baton tech
897,MRK,stock hold modest gain monday apple aapl disney lead dow jone industrial average bitcoin price leap follow future launch powershare qqq trust qqq outperformed gain spdr spy spdr dow jone industrial average dium climb small cap underperform ishare core small cap ijr ishare russell iwm give respectively disney merck mrk apple be biggest gainer dow marked new close high disney rise apple confirm monday buy music recognition service shazam gain nearly report put purchase price supply apple iphone have be short supply early november launch have improve materially store online accord loup venture manage partner gene munster apple share be extend cup handle buy point energy telecom technology lead upside sector play stock market today homebuilder bank retail lag bitcoin future begin trading cboe cboe sunday ticker symbol xbt trigger least trading halt future contract expire january soar late afternoon trade cryptocurrency price be recently accord coindesk future launch be see move bitcoin legitimacy have material negative impact digital currency price investor potentially move future bitcoin munster say research note bitcoin investment trust gbtc surge more sector rotation be underway stock market leadership have shift high tech builder financial past few month top sector fund ishare home construction itb gain month dec fund accompany chart be steady performer year year date basis etf be accord morningstar direct itb track dow jone select home construction index have attract asset year old fund be trading highest level more decade be well extend last buy point top holding include horton dhi lennar len nvr nvr other ytd outperformer be vaneck vector rare earth strategic metal remx ytd return dec come fourth base month return share slip day move average set buy opportunity solid move line remx break cup base late july rally nov intraday high spdr oil gas exploration production xop come second month return have be pressure much year ytd share have find support day line past month be still week high ibd take read ibd big picture column day stay top market direction key indicator let know be aggressive move sideline bank stock have make nice comeback trader expect interest rate rise spdr bank kbe past month be buy range clear entry long shallow consolidation kbe place third list spdr regional banking kre be fifth month gain kre be trading buy point also lengthy shallow consolidation first trust nasdaq bank ftxo return be buy zone buy point similar consolidation friday pick first trust dorsey focus fv remain buy range bounce day line related microsoft take lead dow be bitcoin back facebook tech stock lead market bitcoin keep torrid pacefang stock lead tech recovery bitcoin take
898,MRK,stock index be mixed early action major index chip moderate gain loss nasdaq rise small cap advanced confidently dow jone industrial average be respectively small cap russell gain volume stock market today be nasdaq nyse volume major exchange step tuesday wednesday blue chip stock be mixed early thursday dow jone industrial average boee ba merck mrk rise more dow be year date boee be drugmaker merck be year so far year be factor be create caution stock market first nonfarm payroll report november be release market open friday range estimate be wide low side high side consensus call job gain second trader be wait federal reserve day meeting tuesday wednesday street be expect quarter point hike boost rate vs current cme group fedwatch tool see chance quarter point increase chance be see half point hike interest rate rise bank profit improve however isn clear much improvement be already price bank stock big money center bank appear head third day row volume have be light bank pullback additional wild card factor be kick congress partial rollback dodd frank regulation tax cut bill republican tax cut bill seem be fare well so far challenger job cut report rise november vs same month year figure year date be lowest first time jobless claim totale be almost expect related know risk ipo make trading etfs
899,MRK,beleaguered biotech investor likely have get relief trial datum drug approval help stoke ember formerly red hot group take analyst say be relief horizon don expect anything earth shatter say next quarter half be likely feature significant disclosure number company coverage be unlikely be period strongly stock move event leerink analyst geoffrey porge write recent note client porge view follow third quarter large cap struggle historic moneymaker catch double whammy increase competition pricing concern meanwhile smaller cap crushed expectation result ibd company biotech industry group rank first just month be now list group ibd track share touch month high october have lose nearly however flow event be set accelerate early first quarter offer more opportunity meaningful value inflection company stock leerink analyst write recent note frustration depress biotech stock group have post impressive number new approval year jmp security analyst mike king say accord food drug administration original application drug biologic have be approve year need product approval tell investor business daily even most jaded observer sector have say sector whole have produce very satisfactory result come major trial readout don see change regard tack drug approval successful datum readout be key company celgene celg gilead science gild pair large biotech leader face grow field competitor moneymaker revlimid hepatitis drug respectively celgene be set have readout type hodgkin lymphoma have car development partner bluebird bio blue juno therapeutic juno car drug treat cancer used patient own re engineer immune cell be important celgene have long enjoy revenue gain chemotherapy revlimid analyst have be expect generic competition dr reddy laboratory rdy recently dr reddy miss key deadline file generic still less ideal celgene rely so heavily stream revenue fbb partner analyst mike bailey say celgene have be prepare replace patent challenged revlimid sale crohn disease drug firm say october win initiate phase trial drug bull case celgene previously be have new drug limit risk revlimid tell ibd take away risk management piece focus be drug be go go generic point similarly gilead have hiv combination used drug bictegravir set gain potential approval february accelerate hiv sale start second quarter porge say same time ark invest analyst manisha samy say gilead likely get further car gilead also announce thursday acquisition cell design lab privately hold car player october gilead acquire kite pharma nearly follow fda approval kite drug dub yescarta treat large cell lymphoma adult due individualized nature car drug aren likely rake same sale gilead now falter hepatitis drug year line be huge revenue maker tell ibd ibd take big cap struggle third quarter isn surprising consider patent cliff next year be set hit annual sale blockbuster drug say analyst head industry snapshot more biotechs fared period yescarta win replace gilead hepatitis franchise peak grow steadily bailey say guess be hepatitis be go shrink really quickly say point expect car replace hepatitis sale way peak be once ever term gilead do never be big next several month leerink porge look abbvie abbv regeneron pharmaceutical regn disclose pivotal trial regulatory event vertex pharmaceutical vrtx report more value confirm event abbvie have datum inflammatory treatment know upadacitinib say result add more detail evolve landscape be know jak inhibitor treat psoriasis rheumatoid arthritis ulcerative colitis number condition regeneron be deck file result drug dupixent asthma drug be already approve treat eczema firm also report datum eye drug eylea immuno oncology drug cemiplimab type skin cancer also look vertex provide phase datum triple pill combination treat cystic fibrosis total vertex be testing potential regimen bring phase trial firm be also likely gain approval drug combination february big pharma world leerink analyst seamus fernandez say be few significant stock move catalyst left first half be busy dow merck mrk bristol myer squibb bmy astrazeneca azn have immuno oncology combo result lung cancer bristol merck incyte incy be set deliver result regimen melanoma bristol also offer interim datum trial immuno oncology drug opdivo yervoy first treatment lung cancer outside major immuno oncology catalyst thankfully be limit say high bar bristol interim datum require nothing short stopping study early extreme effectiveness unlikely so expectation be probably low say nonetheless early stop be major validation bristol strategy likely drive stock view say continuation study likely increase concern bristol strategy ultimate success study final analysis possibly push stock parp inhibitor yet class cancer drug be set have trial result well astrazeneca have result drug lynparza first maintenance treatment ovarian cancer think parp space be quite large jmp king say hard tell real world doctor see drug better so start produce satisfactory sale figure related biotechs sell drove be investor seek merger biotech just near year high strong cancer regimenthis cancer biotech be fall bayer deal
900,MRK,stock stumble mixed start then turn positive thursday help strong early move broadcom avgo dollar general dg lululemon athletica lulu apple aapl rise broadcom advance help lift nasdaq composite shed fractional loss climbe dow jone industrial average step merck mrk take control lead dow stock jump late wednesday drugmaker announce positive phase trial result prevymis treatment cytomegalovirus infection disease adult stem cell transplant patient mcdonald mcd coca cola ko take dow hardest early hit apiece diversify chipmaker broadcom plow ahead open action singapore base company be apple iphone chip supplier report fiscal fourth quarter earning rise third quarter slow growth still analyst target revenue growth ease also expectation stock be testing support week move average buy range flat base buy point sage therapeutic sage scorched ahead announce positive result sage depression treatment phase trial stock show year date gain end wednesday session dollar general marched ahead mixed third quarter report narrow full year earning guidance solid same store sale estimate increase capital spending be positive stock be climb right side month base pattern lululemon athletica rally ahead open yoga wear maker retailer report best earning gain quarters biggest revenue advance quarters number analyst third quarter estimate fiber optic gear maker ciena cien fall start trade hanover md base company deliver mixed fiscal fourth quarter result announce share repurchase initiative share have be attempt start right side month consolidation number layoff announce employer jump november accord monthly job cut report challenger gray christmas number be november level leave year date tally same period retail continue lead largest job trimming industry large scale merger such cvs health cvs aetna aet combination suggest larger layoff number be pending report say first time unemployment claim dip week end nov labor department estimate third straight decline better increase claim project economist bitcoin hold well clear mark late tuesday bitcoin related stock square sq rise riot blockchain riot gain marathon patent group mara post early advance related big picture sector overtake tech tech stock weathering sector sell investing action plan seek end slide bitcoin top gop mull tax rate offset key rule change
901,MRK,quiet session major stock index wednesday be far quiet surface nasdaq composite be add dow jone industrial average fall fractionally volume nyse nasdaq be tracking slightly lower tuesday level stock market today johnson johnson jnj wal mart wmt merck mrk outperformed dow gain more earning wal mart be due nov open russell find foot pay trip day move average small cap index fall nearly intraday re-cover gain late afternoon trading food stock oil driller software homebuilding name outperformed manage care firm superregional bank lag bullishness newsletter writer rise latest week prior week accord latest day investor intelligence be fifth straight read danger zone contrarian indicator significantly month low early september just extreme bearish reading have be see market bottom past excessive optimism have be see top past nasdaq composite be show sign institutional selling not much distribution day count seem high be stall session heavy volume meaningful price progress other higher volume decline show loss range take away not market meaningful distribution wednesday session serve plenty gap price planet fitness plnt gap flat base buy point stock open price be legitimate entry strong earning report bullish guidance be catalyst elsewhere ibd name coherent cohr gap buy point rise also strong earning growth oled display have be boon coherent other solid gainer ibd be trouncing year date include sina sina arista network anet align technology algn gain range small cap medical product firm inogen ingn gap flat base buy point company report earning sale growth accelerate prior quarter quarterly profit jump year period sale rise share soar match group mtch earning report fuel gap price share jump be already extend cup handle buy point head earning recent week tight pattern offer add entry earning miss match be offset strong sale outlook downside snap snap plunge sale miss weak user growth figure wall street look past news china base tencent hold tcehy take stake snap close watch earning alarm com alrm square sq ringcentral rng related grand theft auto game maker crush view stock see top rate laser maker be blast past buy point earning guidanceu crude production hit record high stockpile unexpectedly rise
902,MRK,stock index deepen loss midday friday senate republican scramble salvage tax cut package index rally thursday belief bill pass doubt delay vote late thursday drop midday friday nasdaq slip blue chip dow jone industrial average lose small cap russell fall volume stock market today be run higher major exchange republican tax cut package stall thursday joint committee taxation say bill not generate enough tax revenue avoid increase deficit parliamentarian snag derail vote thursday evening additional fix senate vote be expect morning selling picked midday friday abc news report former national security adviser michael flynn testify president trump plea deal special counsel robert mueller concern tax cut tax revenue be old tiresome story hill reagan seek passage tax cut bill new york time report joint committee tax revenue say reduce tax revenue reagan prevailed tax revenue rise next year prove panel projection wrong panel always have challenge job dynamic factor be difficult predict economic be dynamism midday stock market action blue chip be roughly even winner loser side merck co mrk johnson johnson jnj initially rise gain fade negative side general electric ge sag ge have be laggard year diversify manufacturer stock be year biggest gainer day be oil natural gas explorer apache apa stock rise heavy volume apache be track fourth daily gain row stock have gain monday close light sweet crude pop barrel street expect apache turn profit cent share year loss analyst expect profit cent share apache meanwhile exchange trade fund innovator ibd fund ffty slip test day line etf be base ibd be year stock recently pull nov high money center bank be almost week stir midday friday citigroup rise brisk trade citigroup be try clear buy point stock crossed alternative entry strong volume wednesday bank new york mellon bk add nearly average turnover then drop stock be shallow cuplike pattern potential buy point be superregional bank keycorp key rise moderately higher volume then lose gain stock be just buy point cup handle pattern bank stock launch nice rally year rise november march bank then trade shallow mostly sideway channel recently thursday money center superregional hit week high superregional group be industry group week superregional be money center be week related stock chart trick help peg time salewhy week line be worth find excellent stock start simple routine
903,MRK,news moved market week dow index hit record high jpmorgan chase jpm bank america bac charle schwab schw other financial rally tax cut hope rise bond yield stock dip friday report michael flynn briefly president trump national security adviser be willing testify trump part plea deal tech leader include many chip stock china internet struggle bitcoin frenzy continue grow acceptance concern general motor gm say launch robotaxi service big city dow rally record high tax cut hope lift stock generally flynn trump news only pare gain dow rise best weekly gain advanced jpmorgan chase bank america citigroup other financial also rally rise bond yield many retailer rebound holiday sale hope nasdaq fall tech leader struggle include china internet many chipmaker fang stock netflix nflx facebook fb bitcoin roller coaster ride continue week clear then then face planting closer move back jolt come smaller investor get more active trading much hyped cryptocurrency meanwhile big financial name continue weigh prospect digital currency federal reserve vice chairman supervision randal quarle call digital currency niche product serious financial stability issue adopt more widely goldman sachs gs ceo lloyd blankfein tell bloomberg something move day doesn feel currency derivative regulator cftc bitcoin future cme cme cboe cboe cme say ll launch future dec cantor fitzgerald reportedly nasdaq ndaq also be move offer future cryptocurrency bitcoin investment trust gbtc rise week cyber monday be biggest yet adobe analytic say shopper spend online prior year nearly third spend mobile device amazon amzn also announce be single biggest shopping day history overtake most recent prime day echo dot prove most popular adobe believe be first holiday season surpass mark online sale share many brick mortar retailer rally expectation strong least better fear year end performance macy say hire extra holiday worker due strong demand general motor gm say launch robotaxi service big city top carmaker see self drive vehicle cornerstone future mobility potential profit driver face slew new entrant rapidly transform auto sector not least alphabet googl waymo self drive unit waymo often see be furthest autonomous technology say soon put passenger driverless car even safety driver take control thing go wrong gm say ability develop self drive solution manufacture car give edge vs tech rival race put self drive car public road commercial scale gm share look set weekly drop be year marquee auto tech company also look future automobility la curtain raiser la auto show intel intc ceo brian see self drive car biggest datum collector next decade so intel self drive partner bmw bmwyy say autonomous car hit road suvs crossover utility vehicle auto hot demand today dazzle floor auto show general motor report surprise decline auto sale ford have stronger expect gain fiat chrysler fcau sale fall largely line automaker slash fleet sale federal reserve be track december rate hike jerome powell current fed governor replace janet yellen chair february signale senate hearing nomination powell also say see current unemployment rate lowest go putt upward pressure inflation remark suggest fed hawkish patient tilt probably win change much yellen exit powell also hint favor lighter touch bank regulation meanwhile economy continue show broad strength new home sale october surge annual pace year high friday institute supply management manufacturing index be robust november rv maker towable maker thor industry tho slam dunk forecast growth diluted ep sale gain millennial gen ers baby boomer generate demand ibd stock leap nearly fellow ibd rv maker winnebago wgo rise expect opec russia agree extend current production cut end deal include cap opec member libya nigeria first time provision review cut june meeting saudi energy minister khalid al falih say shale production growth be manageable next year earning share rise sale grow better expect centric discounter also guide holiday quarter view higher share dip friday hit fresh high meanwhile close retailer big lot big just top ep view come little shy sale vmware vmw say third quarter adjust earning be share year revenue rise analyst expect ep sale period end oct billing sale growth metric be vs estimate vmware virtualization software let datum center server run multiple operate system thereby increase flexibility lower cost many customer be shift cloud compute rent resource internet amazon com amzn other workday wday earn cent share cent year earlier revenue rise easily top consensus third quarter estimate core business have be selling human capital management software workday add financial customer quarter total year year billing booking decelerate share fall more ambarella amba earn cent share exclude item sale third quarter vs consensus view cent microchip mchp reaffirm prior guidance december quarter marvell technology mrvl earn cent share ex item sale fiscal vs view cent semtech smtc top earning miss sale give weak ep revenue guidance design software sector autodesk adsk tank disappointing third quarter result guidance include corporate restructure synopsys snps surge record high beat raise report autodesk miss view subscriber addition lower guidance new subscriber current quarter autodesk plan slash workforce cut job close core facility synopsys earn adjust cent share sale fiscal fourth quarter vs view cent current quarter expect earn share year year sale base midpoint guidance wall street be modele cent autodesk share tumble snyopsys rise fraction guidewire software gwre report narrower expect adjust fiscal loss cent vs consensus estimate cent loss revenue rise top view management forecast full year revenue management raise free cash flow guidance earlier view share insurance software maker be shift subscription model be hurt term result fall nearly magazine publisher meredith mdp pay share time inc time own time person fortune sport illustrated more meredith title include better home garden aim gain more heft advertiser billionaire koch brother have funded many conservative candidate cause help meredith finance deal say not take active role time share leap meredith shot clear buy point hit record high kroger kr ep climb cent beating analyst estimate cent increase competition amazon amzn revenue jump also top view same store sale exclude fuel rise kroger expect same store sale growth exclude fuel exceed kroger share jump costco cost same store sale surge november far view share rise match record high pure storage pstg beat revenue ep estimate raise midpoint full year revenue guidance analyst say datum storage company post first profit share fall amazon web service hold annual user developer conference announce new expand cloud compute deal expedia expe nfl walt disney time warner twx unit turner broadcasting intuit intu aw announce new security product database tool used artificial intelligence follow similar microsoft msft google googl cloud offering box box report line earning also forecast january quarter profit meet analyst estimate management say big deal have slip fiscal box stock lose share china base momo momo plummet mobile social networking platform report quarterly result beat estimate revenue projection fall short view pay user video stream business stay flat share crash chipotle cmg founder steve ell step ceo once trendy burrito chain continue struggle recover food bear illness fiasco adapt digital age ell remain chairman tif report better expect earning revenue same store sale unexpectedly rise americas upscale jeweler stock fall wednesday pop week china lodging htht top earning view revenue revenue guidance be little light operator chinese hotel share tumble many top chinese stock retreat buffalo wild wing bwld accept buyout arby owner roark capital share deal be premium sport bar nov close word possible deal come merck mrk announce stock buyback tuesday raise quarterly dividend penny cent jack box jack crash intraday thursday rise week ep revenue come short qdoba same store sale miss view cast doubt chain fare be put sale jack box offer plan qdoba burger chain say be consider potential alternative qdoba
904,MRK,share dow component merck mrk crash month low monday withdraw application keytruda chemotherapy europe push readout date key immuno oncology trial xby close bell stock market today merck plunge close low last see bristol myer squibb bmy merck immuno oncology rival lift finish piece merck news involve study combination keytruda chemotherapy first treatment advanced lung cancer food drug administration grant regimen accelerate approval friday merck withdraw european application regimen base unspecified finding study call keynote cohort also delay phase study call keynote add overall survival key goal trial merck sustain slew price target cut downgrade monday onslaught come heel merck disappointing third quarter sale decline lag consensus adjust profit beat expectation cent quarter keytruda sale be light outside country sale outpaced expectation credit suisse analyst vamil divan write note client total sale keytruda advanced ub analyst marc goodman note keytruda sale be rise expectation be too high first line lung cancer indication be ramp slower expect result cut keytruda sale view lion share sale come lung cancer melanoma head neck cancer bladder cancer other goodman say note client ibd take biotechs be lead health sector have experience pain recently disappointing report include celgene head ibd etfs page breakdown exchange trade fund hold biotechs react analyst broadly expect roche rhhby bristol shadow merck firm delay readout keynote february morgan stanley analyst david risinger write note say thesis have change consensus have expect delay not duration say still think keynote succeed interim look be impossible predict timing roche bristol be set report datum own lung cancer trial roche be testing regimen immuno oncology drug tecentriq chemo bristol be look various combination used opdivo yervoy immuno oncology drug chemo skeptic say merck withdrawal european application keytruda chemo lung cancer base keynote cohort signal ongoing issue phase trial keynote evercore analyst umer raffat say note theory be fed part merck decision promote overall survival be co primary endpoint keynote revise timeline readout be now set early vs fall previously say raffat doesn buy explanation european regulator ask merck provide more information june long merck have have interim datum keynote again september more recent document show committee biggest concern be mainly relate wording indication safety efficacy combination treatment comparison keytruda single agent chemotherapy alone raffat say study have show patient have more certain protein call pd respond better keytruda therapy regimen be approve first treatment lung cancer regardless much pd patient have patient lower level pd have better overall response rate chemotherapy alone vs regimen accord blind independent review raffat say population respond regimen vs response chemo alone perhaps explain european medicine agency concern wording indication well efficacy safety combo vs single agent say related dow stock merck topple withdraw keytruda application europecelgene result call alarm alexion bristol mixedboston scientific dife abbott rivalry hit pacemaker sale
905,MRK,incyte incy pop early tuesday better expect sale third quarter announce expand collaboration astrazeneca azn broaden opportunity immuno oncology drug epacadostat xby close bell stock market today incyte be astrazeneca rise finish third quarter incyte report adjust income cent share sale adjust profit decline cent vs year period top analyst average call cent sale grow nearly beat consensus view sale cancer drug jakafi post yearly gain top analyst view same drug be sell outside novartis nvs jakavi incyte bring jakavi royalty quarter rise nearly fellow cancer drug iclusig tack additional quarter hit sale beating consensus leerink analyst michael schmidt write note client ibd take incyte be company biotech innovator award investor business daily head ibd biotech innovator award page more company select incyte boost full year sale view jakafi earlier expectation firm keep iclusig net product revenue model nonetheless top end incyte guidance imply flat fourth quarter vs third quarter sale perhaps suggest time factor such inventory stocking have contribute quarter strong number rbc analyst brian abraham write note still incyte deal astrazeneca widen market epacadostat be know ido inhibitor incyte also have deal test epacadostat drug dow merck mrk bristol myer squibb bmy be know pd inhibitor astrazeneca incyte co fund phase trial epacadostat astrazeneca imfinzi pd inhibitor patient advanced lung cancer trial test regimen vs imfinzi alone leerink schmidt say trial be expect begin enrolling first half pd pd inhibitor class immuno oncology drug know checkpoint inhibitor drugmaker be bet big checkpoint inhibitor pair well ido inhibitor epacadostat do see additional external validation promise epacadostat rbc analyst abraham say give imfinzi strong efficacy bar set be high success broaden advanced lung cancer opportunity related top biotech company innovation earn recognition new awardsincyte cancer treatment used patient immune system fight diseaseincyte join rank stock rs rating
906,MRK,dow component merck mrk slide friday keep tumble hour disappointing third quarter sale withdrawal application europe advanced lung cancer treatment xin hour trading stock market today merck fall additional share close bristol myer squibb bmy make rival drug opdivo lift late friday close abbvie abbv also miss third quarter sale expectation beat profit view advanced close bell late friday merck say decision withdraw european application be base datum study dub keynote cohort didn offer specific regard finding regimen be already approve first treatment advanced lung cancer merck be confident clinical datum rigorously conduct trial demonstrated specific improvement overall response rate progression free survival keytruda combination regimen compare chemotherapy alone firm say news release immuno oncology drug keytruda be combine chemotherapy treat lung cancer earlier day merck report adjust income share beating view analyst poll zack investment research share sale decline lag analyst model investor have zero keytruda merck give increasingly challenge hepatitis environment leerink analyst seamus fernandez say thursday gilead science gild report hepatitis drug sale fall third expect question focus almost entirely evolution keytruda uptake first treatment small cell lung cancer timing readout study call keynote confirm keytruda chemotherapy advanced lung cancer fernandez say note client still merck hepatitis be bright spot quarter sale zepatier post yearly sale gain growth only paled comparison cancer drug keytruda bring ibd take merck share begin form flat base buy point early march flat base be several way identify potential stock head investor corner more read pattern merck biggest product diabetes drug call januvia janumet decline other big decline include dip sale cholesterol drug zetia vytorin slide revenue human papillomavirus drug gardasil gardasil sale be reduce due change center disease control prevention gardasil vaccine cyberattack hit merck quarter revenue also take hit lose sale market cyberattack firm raise narrow full year guidance see adjust earning prior target analyst view also forecast sale earlier view consensus see abbvie quarter be just leerink analyst geoffrey porge say note client earn share exclude various item top consensus sale lag consensus grow year period more importantly abbvie outlined ambition current product late stage pipeline porge say firm see humira treat rheumatoid arthritis psoriatic arthritis spinal arthritis crohn disease plaque psoriasis approach sale prior target porge say year abbvie now expect adjust profit share touch low end consensus forecast abbvie guide adjust income share lag analyst view humira be abbvie biggest drug quarter sale grow be consensus porge say cancer drug imbruvica post yearly sale gain imbruvica sale beat analyst view porge say gilead struggle hepatitis drug franchise abbvie hepatitis unit beat analyst average sale decline follow approval august mavyret treat genotype hepatitis related celgene result call alarm alexion bristol mixedboston scientific dife abbott rivalry hit pacemaker biotech firm top third quarter view only pop
907,MRK,stock hit record high holiday shorten week black friday kick holiday shopping several retailer report earning include lowe low dollar tree dltr tech giant salesforce com crm hp inc hpq hewlett packard enterprise hpe justice department moved block time warner twx merger fcc signale ll pare back net neutrality rule marvell technology mrvl agree buy cavium cavm nasdaq rise dow climb set time high higher oil price lift energy stock apple aapl have solid gain marvell cavium deal keep chip rally earning be mixed salesforce hp hpe fall result guidance related stock buy watch top ipos big small cap growth stockslooking best stock buy watch start justice department say megamerger harm consumer combine medium telecom giant extract higher price time warner twx content other video distributor try withhold content emerge rival doj have ask sell turner broadcasting directv satellite business gain approval reject doj claim propose condition suggest president trump animus time warner own cnn be key factor doj move other big merger analyst say time warner rise hewlett packard enterprise hpe fall wednesday weak guidance ceo meg whitman decision step feb ongoing restructure antonio neri be name president june replace whitman october quarter earning revenue top lower expectation january quarter hpe forecast adjust ep cent midpoint guidance vs estimate cent hpe have sell software enterprise service business focus server networking datum storage hardware face stiff competition cisco csco dell technology dvmt pc printer maker fiscal revenue rise earning only meet view gain hp inc hpq give line guidance raise concern company growth outlook hp share fall wednesday marvell technology mrvl announce deal buy fellow chipmaker cavium cavm more create infrastructure solution powerhouse communication datum center marvell agree pay marvell common share cavium share friday close stock rise sharply gain earlier month report deal be close salesforce com crm report earning surge cent share revenue rise top january quarter salesforce com forecast adjust earning cent share vs estimate cent share salesforce com name bret taylor former chief technology officer facebook fb president chief product officer salesforce com acquire startup quip taylor be ceo last year salesforce com name alex dayon chief strategy officer salesforce share fall wednesday just edge lower week right record high republican lead federal communication commission moved closer dismantle obama administration net neutrality rule fcc aim increase investment cable tv company other internet service provider fcc vote dec chairman ajit pai proposal scrap public utility type title regulation be foist isps isps be able charge content provider business partner fee prioritize service regulatory authority consumer protection shift federal trade commission pai say new transparency rule protect consumer related fcc net neutrality reversal later be reversed againpalo alto network panw earning rise revenue swell top consensus cybersecurity firm guide december quarter estimate slightly higher share jump palo alto solid quarter follow soft sale disappointing guidance other computer software security provider monday roche rhhby unveil upbeat datum trial immuno oncology hemophilia send share dow stock merck mrk fall month low roche combination tecentriq cancer drug avastin chemotherapy help reduce risk disease worsening death patient advanced lung cancer merck keytruda chemo combo be approve biogen biib spinoff bioverativ bivv lose nearly roche say hemlibra significantly reduce bleed phase study hemophilia mall be crowd traditional holiday kickoff even online mobile shopping continue grow rapidly retailer kind tout deal well black friday amazon amzn wal mart wmt be expect do well be critical holiday season macy other department store dollar tree dltr ep jump sale beating street estimate deep discounter see ep vs consensus view sale vs consensus view share leap hit new high price apparel chain burlington store burl ep soar cent beating view sale only rise just short same store sale climb share fall week hit record high monday urban outfitter urbn earning unexpectedly rise latest quarter young adult clothier report earning cent vs year sale analyst be expect ep slide cent guess ge top earning view revenue fall short dsw dsw report ep drop miss view shoe retailer also give weak guidance urban outfitter hit month high guess dsw tumble recent buy point share recent ipo qudian qd yirendai yrd other china base provider online credit plunge report china authority have order suspension online small loan approval rapid expansion consumer loan especially online microloan platform have raise concern financial regulator home improvement retailer lowe low third quarter earning revenue same store sale beat estimate help higher home repair demand wake summer string hurricane share fall analyst say wall street have want more acceleration follow weak second quarter express concern thinner margin outlook year earlier month larger rival home depot hd beat view raise full year forecast quickbook turbotax maker earning leap revenue grow october fiscal first quarter easily beating view current quarter intuit intu guide adjust earning share cent sale modestly analyst model share fall tuesday follow earning hit record monday intuit lose week durable good order tend be volatile fall october big gain september core capital good order dip business investment proxy jump vs year earlier october exist home sale rise annual rate slightly view hurricane impact fade janet yellen confirm ll step federal reserve board term central bank chief end early next year many fed policymaker favore december rate hike few be opposed accord minute latest meeting signet jeweler sig crash report weaker expect earning sale offer weak guidance alibaba baba pay stake sun art retail group own more hypermarket china commerce giant expand offline presence alibaba share rise record high deere co report fiscal result top estimate wednesday maker construction agricultural equipment forecast double digit sale increase fiscal deere hit record high bitauto bita fall follow weaker expect third quarter earning revenue revenue guidance top share chinese auto information site have plunge so far november analog device adi beat wall street target fiscal fourth quarter guide higher current quarter chipmaker stock fall monday record high likely magnitude beat wasn large prior quarters alphabet googl unit google cut price cloud compute service include use superfast number crunch processor nvidia nvda ahead amazon com amzn annual user conference china commerce service provider baozun bzun beat quarterly earning revenue estimate give line guidance share fall nearly
908,MRK,stock index stop slide afternoon trading monday remain lower political uncertainty appear roil investor dow jone industrial average fall component look sick merck mrk continue tumble gapping loss pharmaceutical company be now trading lowest level merck start collapse friday report disappointing sale withdraw application europe advanced lung cancer treatment cisco system csco fall buy point oct general electric ge be head sixth consecutive loss be lowest price august flash crash industrial giant have be trend lower year management be consider shedding business cut billion cost nasdaq composite be small cap transportation sector lag considerably russell index dow transport more volume be lower compare same time friday stock appear news propose cut corporate taxe discussion house representative be phased rate fall sprint have be trading halt slide heavy trading report say softbank sprint largest shareholder call merger sprint mobile tmus mobile share nasdaq be nearly trucking stock be broadly lower heartland express htld be shape most stock sank deeper day move average heavy volume second straight day company miss profit expectation friday tal education tal have drop ibd fall big volume look cement day line few energy utility stock break sector show strength today market crude price stretch climb have take oil highest price early march pbf energy pbf new jersey base refinery company rise buy point cup handle volume be mediocre canadian natural resource cnq edge entry flat base volume more average related dow stock merck topple withdraw keytruda application europecisco buy broadsoft tesla near china deal cisco be good fit google push cloud compute
909,MRK,major market index be mixed early monday dow jone industrial average fall more apiece tech heavy nasdaq drive higher facebook fb apple aapl look further capitalize friday earning strength stock market today rise dow jone industrial component apple advanced new high look extend streak trading session share iphone maker add friday strong gain cup handle entry be still buy range company report current quarter result late thursday downside merck mrk plunge almost pharmaceutical company withdraw european keytruda application lung cancer drug have be approve use unite state share hit new week low high meanwhile financial component jpmorgan jpm goldman sachs gs fall jpmorgan remain extend flat base entry goldman be still etching handle saucer shape base show potential entry share nintendo ntdoy surge more higher early monday nintendo switch maker report better expect earning sale result japan base firm also raise switch sale forecast unit strong demand share be now cup handle entry fang stock facebook advanced ahead week earning release social medium giant report earning nov market close share be buy range flat base entry stock reclaim friday heavy volume fellow fang stock amazon com amzn reversed early loss rise share be still buy range buy point friday earning power china base commerce giant alibaba baba moved early trade further cushion back day line regain ascend base entry firm report current quarters result ahead open thursday ibd china base yy yy lead way rise nearly look snap day lose streak time stock have give substantial gain buy point downside leaderboard member thor industry tho skid rv maker be trading just week high well cup handle entry related dow jone industrial average dow stock news big gain still pick apple amazon facebookfang stock news quote facebook amazon netflix googletech stock jackpot giant just moved buy rangetech giant face investor congress investing action plan
910,MRK,dow industrial nasdaq composite quickly strengthen early gain monday market head holiday shorten week trade dow jone industrial average edge start bell strong early loss merck mrk nike nke feel early drag alcoa aa cardinal health cah nasdaq apple aapl fang stock open red quickly reversed positive trade china netease nte shed stock bond market be close thursday run shorten session friday stock trading end et ibm ibm muscle early lead dow ahead verizon vz gain verizon receive upgrade outperform market perform well fargo note also lift verizon price target verizon share end friday october high cavium cavm blast higher chip developer accept takeover bid bermuda base marvell technology group mrvl advantageous tax reason deal be expect close mid marvell share leap open cavium ibd stock be extend breaking buy point cup handle base marvell be buy range buy point also cup handle base urban outfitter urbn dip fraction early trade ahead third quarter report due close owner urban outfitter anthropologie chain last week surge strong trade lift stock june low leave just midpoint deep month consolidation china alibaba group holding baba rise news report commerce giant be take stake china base big box retailer sun art retail group alibaba ibd leaderboard ibd list end friday test support day move average clear buy point mid september ibd stock national beverage fizz pop fort lauderdale fla base drink maker receive upgrade positive neutral price target hike susquehanna stock be week move average have be find support week line tenth week possible base pattern rival soft drink maker monster beverage mnst fall more price target hike credit suisse maintain outperform rating ibd stock share be extend flat base buy point simple session economic news only lead economic indicator october due conference board et asian market japan tokyo nikkei drop clipping day rebound china market post modest gain hong kong hang seng index advance europe market be positive dax frankfurt rebound gain cac paris dax re-cover sharp early loss follow break attempt build coalition government result left chancellor angela merkel flounder control europe largest economy majority hand caretaker government related future fall merkel coalition talk fail marvell cavium big picture market surprising week feature earning tech giant strengthen retail stock black friday near
911,MRK,here investing action plan friday need know investor come day busy earning week continue quarterly result oil major exxon xom chevron cvx france total tot italy eni pharmaceutical giant merck mrk abbvie abbv also report consumer credit report agency transunion tru report market open exxon mobil chevron merck be member dow jone industrial average estimate earning cent revenue accord zack investment research stock chevron close flat thursday stock market today still just buy range undercut entry point last week break even price likely be major topic report oil stay barrel company look lower cost maintain dividend investor expect chevron say break even year barrel accord wall street journal crude future be trading barrel brent crude just total say be able break even oil fall not include dividend cost exxon doesn disclose break even estimate ep see soar cent revenue expect rise stock exxon mobil rise thursday ibd take read ibd big picture column day stay top market direction key indicator let know be aggressive move sideline estimate ep fall revenue dip stock merck dip share be consolidate long flat base entry point merck have be trend nearly reach buy point mid september stock be now day day move average earlier month merck announce win submit application approval cholesterol drug anacetrapib find accumulate fat tissue estimate ep revenue rise stock abbvie sank thursday share break flat base buy point late august enter profit take range earlier month abbvie be top rank company ibd medical ethical drug group credit report agency also report busy early morning estimate ep jump cent revenue stock share rise hit record high intraday transunion briefly sell last month rival equifax efx disclose massive hack related energy stock industry news oil gas solar coaldow jone industrial average dow stock news analysis
912,MRK,seattle genetic sgen launch highest point month wednesday announce series cancer drug trial dow component merck mrk japanese drugmaker astella pharma xby close bell stock market today seattle genetic have surge finish earlier share lift high last see june meanwhile broader biotech industry dip fraction be trading territory last see december wednesday seattle genetic announce collaboration merck form advanced breast cancer test drug know sgn liv combination merck keytruda belong class drug know pd inhibitor seattle genetic drug work target protein present surface tumor cell protein have be tie number solid tumor include breast prostate melanoma ovarian cervical cancer firm say news release separate trial test sgn liv combine chemotherapy form breast cancer trial be sponsored quantum leap health care collaborative ibd take dow component johnson johnson near buy point wednesday analyst upgrade cite firm undervalue pharma asset head income investor closer look be time get dividend machine follow news tuesday seattle genetic astella dose first advanced bladder cancer patient drug know ev phase trial be testing tumor activity safety ev support potential accelerate approval leerink analyst michael schmidt boost price target seattle genetic keep outperform rating follow meeting firm management note seattle genetic be work become multiproduct global oncology company expect share appreciate give first treatment hodgkin lymphoma be now clinically risk seattle genetic pipeline continue produce additional late stage product development opportunity offer top line diversification write note client seattle genetic be know drug adcetris be approve treat classical hodgkin lymphoma rare form hodgkin lymphoma call anaplastic large cell lymphoma earlier month food drug administration grant adcetris breakthrough designation combination chemotherapy first treatment patient advanced classical hodgkin lymphoma be base result phase trial call echelon more datum echelon be expect american society hematology meeting december schmidt write firm decide earlier year commercial team support rollout adcetris first treatment classical hodgkin lymphoma expect mid also look adcetris be approve cutaneous cell lymphoma hodgkin lymphoma also have breakthrough designation related drug send biotech fresh high caveatbiotech rally stumble small cap pull backseattle genetic dife low leukemia drug tie death
913,MRK,kalvista pharmaceutical kalv shot month high tuesday inked deal eye drug merck mrk also allow dow component take nearly ownership stake small cap biotech company xby close bell stock market today kalvista have shot finish earlier trading session be high last achieve june merck advanced fraction biotech group lift term deal merck pay kalvista upfront fee certain right include option acquire drug know kvd kalvista complete phase proof concept trial trial be set begin later year kvd be be develop injection treat diabetic macular edema condition high blood sugar weaken blood vessel patient eye cause vision loss deal also grant merck option acquire orally deliver molecule be investigate treat same condition kalvista fund retain control phase trial kvd oral molecule merck exercise option earlier ibd take merck have ibd composite rating meaning perform middle stock term key growth metric head ibd stock checkup complete breakdown strongest rate drug stock kalvista be eligible receive milestone payment merck exercise option drug merck be require pay kalvista tiered royalty net sale drug commercialize agreement addition collaboration merck acquire share kalvista deal value stock share deal give merck stake kalvista related dow stock be buy zone earning season beginsabbvie patent deal stave amgen competition other lurkabbvie new hepatitis drug chip away gilead share
914,MRK,biotech company chasing next generation cancer treatment work patient own immune system incyte incy stand treatment analyst say prove be blockbuster wilmington del base company be leader develop immunotherapy bolster cancer survival rate stand drug giant such novartis nvs merck mrk have partner compete emerge field medication rapidly expand nonprofit cancer research institute fund immunotherapy study estimate drug used immunotherapy target cancer be market pipeline august figure more double just year earlier explode say institute spokesman brian brewer number drug combination drug now be chart success be improve survival rate patient fight skin lung cancer come decade analyst say incyte be company lead charge bring new immunotherapy market still experimental drug epacadostat work combination other medication recognize potential new epacadostat regimen already robust sale company current flagship cancer fight drug jakafi investor business daily name incyte ibd biotech innovator award winner ibd choose biotech innovator award winner ibd ask equity analyst etf mutual fund manager university professor identify top biotech company base innovative research ask focus company pioneer drug likely launch next several year reach blockbuster blockbuster sale more year award winner select ibd editor be most cite company find profile award winner detail work go full biotech innovator special report morningstar analyst kelsey tsai say epacadostat show encourage early result concert bristol myer bmy yervoy fight melanoma incyte drug be evaluation other immunotherapy front include late stage study merck keytruda also target melanoma additional study be underway epacadostat combination keytruda drug treat other oncological disease epacadostat have very high potential tsai tell ibd incyte decline make executive available be interview story pivotal result drug combination keytruda be expect first half tsai say datum early testing same regime target multiple cancer be expect soon fall incyte researcher used past university study help develop epacadostat key finding show cell tumor take advantage enzyme call ido prevent person immune system kill epacadostat be design target block enzyme cancerous cell enable patient immune system attack reduce tumor analyst say process be safer chemotherapy other treatment involve human body fight disease naturally credit suisse see lofty sale epacadostat estimate annual revenue drug exceed soon assume win regulatory approval tsai say morningstar projection assume pricing annually use drug regimen say firm give epacadostat chance gain approval treatment certain skin lung cancer treatment other type cancer be target later ibd take always best focus stock relative strength rating incyte have be hierarchy promising outlook be top already strong oncological drug sale incyte company drug bone marrow disorder blood cancer jakafi help company generate revenue year drug gain fda approval incyte post second quarter revenue year earlier quarter strong jakafi sale tsai say blend jakafi foundation epacadostat future put incyte plum spot incyte stock touch month high aug close friday march stock set record high have date surpass revenue jump least year be expect rise more year company finally break black market capitalization top roughly double value start positive observer note drug trial setback wouldn be shock regulatory approval be never sure thing competition be strong intensify range company investor be really dig homework biotech be hard really know be go drug trial kind timeline thing be mike matousek trader investment house global investor grow tell ibd other say incyte boast unique positive herve hoppenot take ceo have be novartis president oncology bring cancer drug experience several key scientist incyte competition be heated need cancer treatment be so vast analyst say be plenty room multiple strong player field also notable analyst say incyte be largest midsize company oncology arena such analyst say incyte remain attractive acquisition target larger drug company look pick talent bolster drug pipeline march report surface say gilead science gild be eyee incyte incyte takeover rumor have come light lately instead gilead aug announce agreement acquire kite pharma kite nearly incyte likely remain subject speculation analyst say possibility almost always give investor add reason give extra attention stock matousek say related get detail biotech innovator award winning company workincyte battle marketphase trial result boost biotech stock
915,MRK,potential cancer cure disclosure propel loxo oncology loxo stock day june additional day september indicate innovation cancer research treatment many investor say keep loxo aloft potential blockbuster cancer treatment make loxo be recognize investor business daily inaugural ibd biotech innovator award lead drug look medically promising target relatively small patient population so annual revenue be expect fall short define commercial blockbuster get close loxo stock make big leap june company disclose progress phase phase trial lead drug candidate larotrectinib leap loxo stock follow word disclose phase trial datum tumor fighter annual meeting international association study lung cancer set start saturday oct loxo stock touch time high company expect file new drug application larotrectinib early food drug administration approve nda month loxo expect company begin sale specific patient almost immediately ibd choose biotech innovator award winner ibd ask equity analyst etf mutual fund manager university professor identify top biotech company base innovative research ask focus company pioneer drug likely launch next several year reach blockbuster blockbuster sale more year award winner select ibd editor be most cite company find profile award winner detail work go full biotech innovator special report loxo focus develop highly selective precision medicine patient genetically defined cancer be gain ground researcher patient doctor fund manager rather look attack specific cancer say used compound lung tumor sometimes don work healthy cell too loxo used increasingly popular gene sequence identify patient host specific gene mutation result tropomyosin receptor kinase trk fusion be abnormal protein tell tumor cell grow used loxo novel compound inhibit trk fusion activity call trk inhibitor kinase inhibitor loxo clinical trial therapy demonstrated improvement patient different type cancer hence loxo larotrectinib be gain attention research clinic wall street well become first drug initially approve fda target mutant protein many cancer rather target cancer loxo spokesman dan budwick call approach tumor agnostic note merck mrk keytruda be indeed approve treatment unresectable metastatic solid tumor specific genetic quality first fda keytruda be initially approve metastatic melanoma then small cell lung cancer then head neck squamous cell carcinoma be already widespread use merck apply fda also use keytruda gene sequence tumor agnostic approach rather old tumor specific approach contrast loxo larotrectinib be first time fda initially approve cancer drug used tumor agnostic gene sequence approach ibd take loxo recently hit time high company be do so moment ibd new high list track mover also rank ibd composite rating loxo potential have wall street attention number mutual fund hold loxo share jump support market cap secondary offer late june marked straight quarters rise fund ownership loxo late sport highest possible ibd relative strength rating putt top stock price performance past month week loxo june report american society clinical oncology asco meeting chicago world biggest cancer conference loxo sell more share common stock secondary offer pricing share stock have trade well recently november company raise expense stock performance loxo rival be rival however have be spotty time most be roll late loxo peer ignyta rxdx go public early month loxo have mostly trade ipo price thursday ignyta stock touch month high loxo partner array biopharma arry peaked shortly ipo stock be way touch year low february month hit month high blueprint medicine bpmc loxo develop kinase inhibitor go public hit new time high september run asco june loxo report objective response rate tumor size be reduce patient many cancer type clinical trial patient tumor hold trk fusion larotrectinib deliver consistent durable response trk fusion patient age regardless tumor context do so few side effect dr david hyman research team principal investigator loxo larotrectinib trial tell asco conference hyman be chief early drug development memorial sloan ketter cancer center way larotrectinib trk fusion story fulfill promise precision medicine tumor genetic rather tumor site origin define treatment approach cowen analyst eric schmidt say loxo estimate patient annually benefit larotrectinib treatment trial datum disclose asco patient greatest tumor shrinkage include soft tissue sarcoma lung colon cancer melanoma salivary gland cancer type cancer be be treat trial patient have least thing common gene mutation cause kinase trk fusion tell cancer cell grow larotrectinib earn breakthrough therapy designation fda july meaning fda give priority early trial suggest new therapy offer serious advantage exist treatment person life threaten disease breakthrough be not necessarily fda highest priority however fast track priority review designation accelerate approval pathway be fda urgent alternative larotrectinib then call loxo receive breakthrough designation unresectable metastatic solid tumor neuronal trk fusion protein adult pediatric patient require systemic therapy have progressed worsen follow prior treatment have acceptable alternative treatment note friend cancer research nonprofit count fda breakthrough designation include larotrectinib target cancer analyst schmidt say recent efficacy datum larotrectinib be best ever have see oncology estimate peak larotrectinib market annual sale year morgan stanley analyst matthew harrison see larotrectinib peak annual sale loxo go public august share conceivably get acquire blockbuster premium buyout talk have surface biotechs end be purchase most be acquire become profitable say schmidt cowen estimate loxo win escape red ink thing have transpire asco june be celgene celg pricing idhifa month new high niche oncology market schmidt tell ibd give loxo breathe room perhaps lead consider higher price larotrectinib idhifa be approve fda aug treat aml most common form acute leukemia adult celgene estimate new aml case be diagnosed annually june secondary offer more double loxo cash pile nearly june help loxo make acquisition bruton tyrosine kinase btk inhibitor program redx pharma rename redx drug candidate loxo loxo acquisition release chief business officer jacob van naarden call deal program pipeline so nicely align larger strategic vision capability redx team have create novel chemical matter selectively reversibly inhibit btk validate molecular target numerous cell leukemias lymphomas analyst schmidt tell ibd price tag look right btk target be validate be unmet need patient fail imbruvica abbvie abbv johnson johnson jnj commercial name ibrutinib treat complication stem cell bone marrow transplant know chronic graft versus host disease gvhd research note morgan stanley harrison praise btk acquisition call logical addition loxo pipeline rate loxo stock overweight price target cowen schmidt rate loxo outperform doesn offer price target cowen analyst be unfazed loxo financial loss greater estimate cash burn biotech earning rarely be interesting schmidt say loxo report wider loss share cent loxo be slate post result oct cash hoard loxo be danger run money year investor expect sale profit then cowen schmidt meet least twice recently loxo top brass say company be track speedy approval larotrectinib loxo be work other potential drug include btk inhibitor buy redx target leukemia lymphoma pipeline partner array biopharma kinase inhibitor target too early suggest approach blockbuster status related get detail biotech innovator award winning company loxo oncology stock hit record small cap biotech stock pop new high
916,MRK,strong performance share apple aapl help lift nasdaq composite gain afternoon trading xshare tech bellwether iphone maker be company report fourth straight quarter accelerate earning sale growth late thursday too late buy apple now stock be extend cup handle buy point gain dow jone industrial average be more muted russell be mostly flat volume nyse nasdaq be tracking lower thursday level merck mrk home depot hd wal mart wmt be strong gainer dow apple gain name rank top latest ibd report earning good news come arista network anet universal display oled control ctrl show gain range stamp com stmp be sore spot slumping report better expect earning jump sale innovator ibd ffty be afternoon trading wall street focus early be also october job report headline job number miss expectation be decent report hurricane related noise nonfarm payroll rise october consensus estimate unemployment rate tick lower august september job growth be revise higher total bond investor be unfazed report year treasury yield flat stock market today small cap human resource outsourcer trinet group tnet be tread day move average ahead earning report late thursday share gap powerfully rise try clear buy point starbucks sbux reversed higher soft start rise strength come news disappointing sale lower traffic starbucks day move average just be potential resistance level watch related universal display surge obliterate third quarter targetsstarbuck haircut surprise here real worry invest stock market used simple routine
917,MRK,dow component merck mrk say late wednesday win submit application approval cholesterol drug follow review clinical profile prod share fall hour trading xmerck drug anacetrapib be be investigate treatment high blood pressure prevent cardiovascular disease june merck say drug prove effective reduce major cardiovascular event patient already receive ldl cholesterol lower drug merck also find earlier study well recently announce phase trial call reveal anacetrapib accumulate fat tissue be deeply grateful researcher patient participate anacetrapib clinical development program particular reveal outcome study merck research laboratory president roger perlmutter say prepared statement unfortunately comprehensive evaluation have conclude clinical profile anacetrapib do not support regulatory filing ibd take merck have be base march year hover share have reach share be consider back buy range hour trading merck fall close nearly cholesterol lower drug have be news frequently amgen amgn partnership regeneron pharmaceutical regn sanofi sny battle patent court amgen argue regeneron sanofi infringe patent cover drug repatha regeneron sanofi make rival drug praluent august esperion therapeutic espr pop nearly year high bump timeline quarter file application food drug administration cholesterol lower drug first quarter related regeneron patent be amgen thinkhow biotech rocket year high breaking outall eye be dow component star drug next week
918,MRK,retreat friday dow have be set record high stock be still buy point get push need enter buy range earning season pick steam stock watch week be wal mart wmt unite technology utx merck mrk cisco system csco pfizer pfe wal mart be reconsolidate flat base buy point fail break cup base earlier wal mart fall further day line finishing lower friday computer networking company be form saucer handle base buy point institutional investment cisco stock have rise last quarter share end friday higher industrial giant know jet engine elevator be form flat base entry point stock have alternative entry point stock close jump day day line earlier month share tumble more day unite tech have agree buy rockwell collin col ibd take earning season be kick here list other stock buy point watch ahead third quarter result pharma giant merck be form shallow double bottom base buy point share edge friday find support day line last month pfizer meanwhile be form long cup base stretch nearly day buy point pfizer friday related top stock have etch super bullish pattern read stock chartsdow jone industrial average dow stock news analysisblue chip cisco be prime move higher buy point
919,MRK,key index be higher friday dow jone industrial average knock new high extend streak xpowershare qqq trust qqq lead gain spdr dow jone industrial average dium gain spdr spy be emerge market outperformed ishare msci emerge market eem rise sector fund chip telecom retail lead upside stock market today gold energy health care lag vaneck vector semiconductor smh ishare phlx semiconductor soxx advanced more be buy range respective entry component stock nvidia nvda surge break flat base graphic chipmaker be ibd stock vaneck vector junior gold miner gdxj fall vaneck vector gold miner gdx give spdr gold share gld ishare gold trust iau dip apiece gold future be ounce dow jone industrial average close fresh record high thursday thank big gain unite technology utx pfizer pfe merck mrk keep give produce double digit return year continue offer new chance buy spdr dow jone industrial average dium climb past flat base entry thursday remain buy range last set buy opportunity rebound day move average mid august right time be featured etf column share have now advanced nearly bounce line back early june break past flat base buy point rise aug high etf track price weight blue chip index mark anniversary january biggest holding include boee ba goldman sachs gs apple aapl accord morningstar direct top name account asset dium year date return be just ahead gain long haul fund performance be roughly line benchmark index instance dium have post average annual return past year qqq carry expense ratio ibd take boee be time high be worthy watch list find top rate stock industry group ibd stock checkup guggenheim equal weight rsp be shape right side flat base get close buy point fund be spotlight june etf column hold buy range earlier climb entry left side high current pattern fund launch april track equal weight index total return name indicate much more diversify dium biggest sector weighting be consumer cyclical financial service industrial health care technology order top holding include nrg energy nrg alexion pharmaceutical alxn ralph lauren rl rsp ytd return lag lead past year average annual return vs benchmark index gain etf bear expense ratio thursday pick ishare edge msci multifactor usa lrgf take buy point be still buy range powershare russell equal weight portfolio eqal be still trading just entry related dow lead big name gain equity play set upapple dow top loser dow stock be buy range apple gain launch event kick dividend play watch
920,MRK,johnson johnson jnj bayer bayry anticoagulant xarelto likely be star next week european society cardiology conference analyst say friday xin february dow component end trial dub compass earlier expect base efficient xarelto be reduce major cardiovascular event include heart attack stroke cardiovascular death patient heart disease full result phase trial be be present conference aug credit suisse analyst vamil divan reiterate outperform rating price target ahead meeting expect meaningful improvement efficacy say note client xarelto be test milligram dose twice daily milligram dose twice daily combination aspirin trial be stop year early drug prove efficient vs aspirin alone ibd take biotechs be now rank tenth group track ibd seventh last week fourth week cause stock lose steam head ibd industry theme closer look such large study be stop so early efficacy assume add benefit compass be quite meaningful write base trial design population conversation expert assume relative risk reduction be more hasn say xarelto alone combination aspirin prove successful reduce risk major cardiovascular event divan note datum monitoring committee allow pool patient trial remain xarelto likely due limit safety concern well side trial perform define commercial impact divan say talk physician longer used aspirin xarelto alone prove strongest be more challenge persuade add low dose xarelto aspirin treatment divan see compass datum help expand total addressable market xarelto least lead additional annual sale alone fellow dow component merck mrk be expect unveil datum trial dub reveal conference june merck say drug anacetrapib prove effective reduce risk major cardiovascular event patient already receive ldl cholesterol lower drug investor key merck comment long drug stay body be administer earlier study well most recent reveal trial anacetrapib be find accumulate fat tissue novartis nvs be also expect have datum phase trial name cantos determine benefit drug ilaris patient high risk recur cardiovascular event june novartis say trial hit main goal give limit datum release previously novartis management have say ilaris need show relative risk reduction order be commercially relevant company ideally want see relative risk reduction study divan say note relative risk reduction be statistically significant ilaris be already approve treat several rare inflammatory disease related dow merck be credit suisse top picktrump blast dow merck ceo resign manufacturing abbvie gauntlet squeeze gilead drug hepatitis
921,MRK,merck mrk chief executive kenneth frazier resign president trump american manufacturing council early monday prompt trump claim dow jone component be make rip drug frazier resignation follow violent weekend charlottesville va person be kill injured car plow group protest white supremacist rally resignation be apparent protest trump response trump condemn hate bigotry violence many side statement saturday draw heat not be more explicit condemnation response frazier say feel be responsibility take stand intolerance extremism america leader honor fundamental value clearly reject expression hatred bigotry group supremacy run counter american ideal person be create equal frazier say statement twitter ibd take merck have ibd composite rating meaning perform bottom half stock term key growth metric group nordisk nvo be best rate cr best possible head ibd stock checkup look other drug stock leader shortly frazier resignation trump blast ceo tweet now ken frazier merck pharma have resign president manufacturing council have more time lower ripoff drug price trump tweet now ken frazier merck pharma have resign president manufacturing council have more time lower ripoff drug price donald trump realdonaldtrump august merck dow component decline further comment investor business daily say believe statement issue speak early trading stock market today merck lift frazier be far first executive resign business advisory group pull together trump administration tesla tsla elon musk bob iger walt disney co quit policy panel trump withdraw paris climate agreement travis kalanick former uber technology ceo pull economic advisory group trump issue executive order refugee muslim majority country manufacturing group frazier resign also include executive dow chemical dow boee ba johnson johnson jnj related abbvie gauntlet squeeze gilead drug hepatitis pfizer cancer drug help grow merger sanofi earning spook regeneron share week low
922,MRK,dow jone component merck mrk remain credit suisse top pick head european society medical oncology conference october drugmaker allergan agn eli lilly lly also look strong brokerage say monday time merck be expect unveil result trial dub keynote testing immuno oncology drug keytruda chemotherapy previously untreated patient advanced lung cancer combo receive accelerate approval expect continue discussion potential used keytruda await top line datum confirmatory keynote study september october time frame expect be positive credit suisse analyst vamil divan say second quarter conference call july merck confirm cyberattack delay product year say full recovery cyberattack take time still merck be best position remainder divan say note client merck share end regular trading session investor seem prefer abbvie abbv bristol myer squibb bmy divan be place bet allergan lilly still be several month allergan be expect unveil datum migraine trial say lilly offer diverse pipeline more interest be nordisk nvo trial know sustain be look diabetes drug semaglutide vs lilly trulicity divan see trulicity safer drug lilly be expect unveil datum trial drug abemaciclib breast cancer upcoming oncology conference divan say lilly be also plan file application migraine drug be drive adoption new drug cancer plaque psoriasis ibd take biotechs have struggle lately be now rank seventh group track ibd fifth last week sector hit week low thursday hit month high july head ibd industry theme more happened meanwhile divan isn bullish commercial potential drug abbvie inflammatory disease immuno oncology also call relatively rapid erosion sale key drug humira once generic enter market likely bristol case rumor become takeover target have limit stock term early asset immuno oncology potential approval kidney liver cancer drive upside time divan argue credit suisse also reinstate coverage dow stock johnson johnson jnj july divan note valuation be limit investor interest likely change release datum compass trial european society cardiology meeting meeting be set later month be look ability anticoagulant xarelto prevent major adverse cardiac event include cardiovascular death heart attack stroke patient heart disease expect compass be star meeting have potential dramatically increase uptake xarelto come quarters something move needle even company size divan write divan also note downgrade pfizer pfe teva pharmaceutical teva neutral rating outperform quarter dow stock pfizer be struggle term catalyst lack acquisitive appetite potential tax reform teva other hand be range bound new leadership team be place strategy reduce debt be more certain more clarity potential generic version copaxone multiple sclerosis drug milligram be obtain write related pfizer cancer drug help grow merger generic drug be rebound teva mylan free fallperrigo beat raise lift generic drug buck teva mylan trend
923,MRK,stock rise head final trading session august thursday nasdaq build wednesday momentum confirm support day move average dow jone industrial average climb nasdaq composite post early gain refiner be hustle protect facility louisiana texas repair restart operation place rain flood have ease further south global platt estimate refine capacity remain offline late wednesday benchmark oil price rise early thursday recover barrel gasoline future trade putt price ahead so far week houston port announce remain close thursday george bush william hobby airport resume limit flight operation wednesday stock market today open almost dow list stock trading higher nike nke merck mrk set early lead rise unitedhealth unh swung company agree buy healthcare portion researcher advisory board co abco divide company bil deal private equity firm vista partner apple aapl trade higher amazon com amzn lead fang stock gain apple be creep top buy range buy point amazon be work forth straight gain climb test resistance day move average ibd stock yy yy bolt higher goldman sachs initiate coverage china base social networking site buy rating price target gain put stock just buy range rebound week support other ibd name tal education tal kemet kem rise more apiece stock be extend buy range earning front chip developer semtech smtc drop miss analyst target second quarter earning revenue line provide weaker expect third quarter revenue guidance move left stock stock just week line support have regain past few session retailer genesco gco dive follow weak second quarter performance shoe carnival scvl spark surprisingly healthy quarter dollar general dg drop nearly turn mixed second quarter result ethernet switch maker ciena cien drag lower fiscal third quarter earning clear estimate fourth quarter revenue guidance be consensus view loss send share sharply week move average heavy trade collapse attempt june market receive strong early dose economic news ahead closely watch august payroll report due friday layoff announce employer rise august accord monthly job cut report challenger gray christmas be job layer line july year earlier level first time unemployment claim be essentially unchanged week end aug labor department report consensus economist have project uptick new claim accord econoday prior week claim be revise slightly higher personal income jump july accord commerce department estimate be improvement june flat performance inline consensus expectation consumer spending rise lag estimate advance inflation remain check pce price index rise consensus number target economist chicago purchasing manager index kingsbury international be slate et release pending home sale datum july tap national association realtor et retailer also be report august sale figure session overseas china market slump friday month strong trade left shanghai composite hong kong hang seng index ahead august japan tokyo nikkei muscle second straight session wednesday strong economic news drive dollar higher yen nikkei end august second straight monthly decline europe market marched higher benchmark index london paris frankfurt more midday related big picture nasdaq rally pave way strength top stock absolutely have itthese chip stock just carved super growth patternstock buy watch top ipos big small cap growth stocksbullish chart pattern ii find exact buy point
924,MRK,federal reserve keep key interest rate steady last month widely expect start unwinding balance sheet september xwhen fed stop buy treasury mortgage backed security increase supply send price drive yield lead higher interest rate mean investor again focus sector stock market be most likely outperform rate climb instance bank other financial industrial consumer discretionary be area tend benefit higher rate couple new fairly new kid exchange trade fund block aim offer outperformance stock rise rate environment newest be proshare equity rise rate eqrr launch july eqrr be investor expect rise interest rate want outperform traditional large cap index rate go michael sapir co founder ceo proshare advisor say statement eqrr take sector most positively correlated interest rate then sector invest company have tend outperform period rise rate fund track nasdaq large cap equity rise rate index have attract asset biggest sector weighting aug be financial energy material industrial information technology account asset top holding include trade financial etfc fifth third bancorp fitb lincoln national lnc bank america bac top stock account asset be bank insurer eqrr carry expense ratio fidelity dividend etf rise rate fdrr set mark anniversary have gather fund track fidelity dividend index rise rate invest large midcap company be expect keep pay grow dividend stock also have positive correlation return rise year treasury yield boston base geode capital management serve subadvisor fund technology lead fdrr sector weight nearly follow weighting health care consumer cyclical financial service aug accord morningstar inc have modest exposure sector such real estate utility pay big dividend be highly sensitive increase interest rate fund top holding aug be dow jone industrial average component apple aapl microsoft msft johnson johnson jnj jpmorgan chase jpm merck mrk exxon mobil xom top comprise nearly quarter total asset etf have slightly underperform broader market year return vs gain aug fdrr expense ratio be keep mind fdrr still year old eqrr mark first month isn proven yet track record available next fed monetary policy meeting be schedule odd rate hike december be accord cme group fedwatch tool related miss thursday breakout fresh idea market hit highsnext gen etfs rise rate offer high yield low volatility
925,MRK,major market index turn lower early market rally sputter thursday major index tech heavy nasdaq dow jone industrial average decline apiece dow industrial merck mrk look continue rebound last week decline rise stock be stick day move average line meanwhile apple aapl moved potentially snap day streak market volatility stock have do great job hold high lodging tight weekly close market sputter month share be flat base buy point fang stock amazon com amzn receive good news ftc late wednesday approve commerce giant takeover whole food wfm stock response be rather muted fall share have take extend break day line form potential new base fellow fang member netflix nflx give back early gain fall look stabilize day line have be trading last week company report earning hp hpq exceed street estimate provide line guidance current quarter earning stock advanced be approach cup handle buy point share be testing day line meanwhile close lead stock be report own quarterly earning number medical software developer veeva system apple supplier broadcom avgo veeva system ibd member be trading just cup handle entry share moved early thursday meanwhile broadcom briefly notch new high stock market today fall flat base entry briefly trigger sell rule other lead stock alibaba group hold baba look snap day winning streak decline reach new high earlier morning also ibd planet fitness plnt trim early advance attempt regain flat base entry stock have have trouble earning related aug downside chip equipment maker lam research lrcx fall be early stage form new base earlier cup shape base fail related ftc allow whole food acquisition amazondow jone industrial average dow stock news analysisapple amazon loom investing action planfang stock news quote facebook amazon netflix google
926,MRK,stock market end modestly lower thursday retail stock receive most attention nasdaq composite continue battle support day move average xat close dow jone industrial average nasdaq show loss small cap outperformed russell preliminary datum show volume nyse nasdaq come slightly higher wednesday level late wednesday federal trade commission clear merger amazon com amzn whole food market wfm amazon promptly announce plan cut price whole food fuel sell off food retailer wal mart wmt costco cost target tgt kroger kr kroger fared worst fall wal mart costco target show loss range cisco system csco merck mrk chevron cvx hold well dow gain big earning mover retail sector include heavily short stock abercrombie fitch anf guess ge share abercrombie surge guess vault earning also lift share retailer dollar tree store dltr william sonoma wsm michael company mik burlington store burl close session lows strong start friday be interesting session depend come fed annual economic symposium jackson hole wyo fed chair janet yellen european central bank president mario draghi be speaking friday fed be start shrink balance sheet year quantitative ease stimulate economy ecb meanwhile be ready ease back bond purchase sign economic improvement day gainer stock market today sodastream soda gain nearly fall buy point stock find support day move average be back high initially sodastream be know carbonation system make soda drink home soda have become less popular consumer company spark water offering be enjoy strong demand finally good example institutional selling stock check share ulta beauty ulta former leader report earning close slump early hour trading beating profit estimate growth prospect retailer remain solid technical picture have weaken considerably several average volume weekly decline june related amazon cut whole food price monday integrate prime grocery stock slam hot mining stock break buy zone metal rallyulta beauty earning dud double digit comp growth
927,MRK,thursday see tooth session left stock lower second time week facebook fb reversed early gain investor look amazon com amzn quarterly report close january payroll report come friday morning preliminary datum show volume tracking well wednesday level stock market today early datum show jump january layoff lower expect weekly unemployment claim slowdown fourth quarter worker productivity contribute session wobbly start bond be steady ahead friday job report oil close west texas intermediate barrel facebook backed modest early gain end lower follow fiscal first quarter earning beat late wednesday stock close cup handle buy point amazon manage gain regular trade quickly drop close commerce giant result be mixed better forecast jump earning revenue gain miss analyst expectation hour decline put share back buy point cup handle base extend session gain loss often do not carry next session regular trade amgen amgn athenahealth athn decker outdoor deck visa be other name expect report close infant formula maker mead johnson mjn spiked confirm be discussion base reckitt benckiser acquire mead outstanding share value deal mead enfamil be second largest infant formula brand world reckitt benckiser share end higher london stock exchange merck mrk be dow big winner mixed fourth quarter result be affected launch resource plan system patent expiration several key drug merck close december low climb right side month base pattern ibd stock cadence system cdns scream higher design automation software developer report late wednesday fourth quarter result narrowly top analyst projection management first quarter earning guidance be line consensus view revenue come expectation gain left stock new high flat base buy point prestige brand holding pbh also ibd stock belt gain maker chloraseptic clear eye efferdent beano stomp analyst fourth quarter expectation tighten full year guidance low volume move clear buy point imperfect cup handle base edward lifescience ew drop heavy trade report better forecast fourth quarter result late wednesday full year guidance be line analyst view btig downgrade stock neutral buy edward have be uptrend early december work recover deep month sell related online broker fall schwab slash stock etf trading feesamazon mixed visa amgen beat chipotle profit miss late
928,MRK,bristol myer squibb bmy stock topple early thursday biotech report mixed earning lower earning guidance cent leave analyst question merck mrk ongoing rivalry stock market today bristol myer stock tumble touch lowest price september bristol share be year merck stock other hand rise fraction be bristol myer report sale year year top analyst view cent earning share ex item miss cent analyst have modeled sale immuno oncology drug opdivo grow company wrapped sale ep ex item respective opdivo bring top view evercore analyst mark schoenebaum say ibd take bristol myer offer mixed guidance analyst expect incyte outperform industry potential blockbuster get more incyte new america opdivo sale rise disappoint leerink analyst seamus fernandez say research report beat opdivo be mostly due outside sale schoenebaum say report bristol myer also adjust full year ep item guidance downward cent high end new guidance miss analyst expectation worldwide sale be expect increase low single digit analyst have view growth schoenebaum suggest ep guidance cut be due increase competition second line small cell lung cancer continue rivalry merck first line nsclc bristol decision seek accelerate approval combo exchange rate issue reason schoenebaum question bristol myer news get here month bristol decide seek accelerate approval opdivo yervoy combo first lung small cell lung cancer cocktail most analyst suggest be more potent merck keytruda chemo combo latter already have accelerate approval still npv net present value analysis indicate even first line lung cancer sale be unreasonable assumption stock be worth something schoenebaum write research report leerink fernandez still see major value bristol myer temporary misstep opdivo yervoy burgeon pipeline bristol be high value industry asset be ignore say history teach anything pharma be company suffering short term misstep surprise great asset be more likely not become vulnerable target time isn reversal fortune series value add pipeline surprise related merck meaningful keytruda royalty give bristol myer leg bristol myer dife opdivo setback get keytruda royaltiesfda track record bode well merck keytruda chemo leerink
929,MRK,roche rhhby ceo severin schwan shrug president trump crackdown drug price wednesday say swiss drugmaker expect reap benefit literally billion invest market focus truly differentiate medicine medicine make real difference patient say accord cnbc have doubt whatsoever be continue demand such solution particularly convince reward kind innovation market be important roche nearly half roche pharmaceutical sale stem diagnostic tool be sell north america tuesday trump reaffirm pledge go rise drug price have get lower price tell slew pharma bigwig include ceo celgene celg eli lilly lly merck mrk novartis nvs johnson johnson jnj executive also be reportedly attendance president trump promise deregulate drug industry cut taxe trump also abandon proposal revisit idea allow federal government negotiate drug price behalf medicare medicaid cover million american be largest purchaser drug health care service world ibd take trump commentary momentarily boost drug stock tuesday day earlier president ban immigration take bite airline stock read ibd industry theme column more safer entry point travel sector drug stock rise tuesday follow report trump softened stance big pharma ibd company ethical drug industry group edge small fraction stock market today roche stock rise touch nearly month high schwan commentary come roche report growth sale consensus analyst poll thomson reuter expect core earning share rise revenue breast cancer rheumatoid arthritis drug help outplay dip sale drug treat hepatitis pancreatic small cell lung cancer wet age related macular degeneration eye disease hep sector have suffer recently sale dip third fourth quarters accord market researcher ihs share gilead science gild have be pressure recently hep unit hep sale dip virtually nothing fourth quarter swiss roche see similarly painful decline sale hep drug lucentis be only sell fall offset sale breast cancer drug perjeta rheumatoid arthritis drug actemra rise respectively roche also list new launch include oncology drug tecentriq tecentriq be approve previously treat small cell lung cancer previously treat advanced cancer urinary tract compete bristol myer squibb bmy merck small cell lung cancer sector related gilead clobber hep little value too late nash hiv unitsroche gouge bristol myer lung cancer share merck rivalrywill merck let incyte go astrazeneca bristol roche team up too
930,MRK,eli lilly lly heist johnson johnson jnj type diabetes share leerink analyst seamus fernandez say wednesday day lilly stock outplay mixed quarter president trump related boost lilly stock ramp tuesday continue black wednesday close bell stock market today share end regular session earlier touch nearly month high lilly stock react softer tone trump tuesday pledge deregulate industry cut taxe trump also call drugmaker manufacture meeting executive celgene celg merck mrk lilly novartis nvs trump reportedly backed call revisit allow federal government negotiate behalf medicare medicaid fernandez research note say be reluctant call first event victory be not bad prior commentary keep outperform rating price target lilly stock note drugmaker sale diabetes drug improve lilly sale top estimate tuesday earning miss fernandez credit growth diabetes product sale performance sale diabetes drug trulicity jardiance grow respectively ibd take trump commentary have send drug stock run tuesday immigration ban monday topple airline stock fall survive read ibd industry theme deeper look trulicity belong class drug call glp receptor inhibitor have new brand share year year growth space fernandez write jardiance have new therapy share endocrinologist exceed invokana barclay analyst geoff meacham be less bullish boost price target lilly stock keep outperform rating trump rattle drug industry meacham say investor prefer product drive company lilly give difficulty triangulating drug pricing debate settle continue prefer product drive story lilly relatively low reliance price revenue concentration risk write research report lilly be likely struggle emerge immuno oncology market write company be partner merck combine drug keytruda chemotherapy alimta treat small cell lung cancer fda look likely approve combo write anticipate approval kn phase study keytruda recent favorable patent ruling drive pickup alimta growth meacham say outside oncology meacham expect lilly add drug pipeline baricitinib rheumatoid arthritis galcanezumab cgrp migraine market latter arena lilly compete teva pharmaceutical teva pharmaceutical aldr amgen amgn related eli lilly novartis challenge pfizer potential breast cancer drugpfizer report lag ep rebound trump round trip trump inspire rally fda appointment key
931,MRK,president trump call drugmaker manufacture effort curb rise price meeting big pharma executive white house mere week accuse industry get away murder trump also promise cut regulation appoint fantastic person lead food drug administration tight regulation slow fda often jam approval process drugmaker say last year fda approve new molecular entity year low tenor be reportedly different earlier call have federal government negotiate price behalf medicare medicaid agency cover million american be biggest purchaser health care product service world same meeting trump pledge increase international competition cut taxe business lure company back trump have pledge put america first inaugural speech say decision be make benefit american worker american family ibd take isn first time trump have pledge bring rise drug price actually mean biotech drug stock take look ibd industry theme deeper dive pharma bigwig include ceo eli lilly lly merck mrk celgene celg novartis nvs reportedly attend meeting johnson johnson jnj exec ceo pharmaceutical research manufacturer america also reportedly attend pricing have be astronomical trump say accord bloomberg folk have do very great job year have get price drug biotech stock reversed earlier loss news trump meeting emerge ibd company biom biotech industry group jump more close stock market today ibd company ethical drug industry group gain meanwhile spdr biotech xbi exchange trade fund be more move day line ishare nasdaq biotechnology index ibb etf also be get day day line related biotechs round trip trump inspire rally fda appointment key stock set new high biotechs give back most trump rally
932,MRK,bristol myer squibb bmy win seek accelerate approval immunotherapy drug opdivo lung cancer confirm merck mrk have huge head start rival treatment keytruda bristol myer stock plunge friday edge late patent royalty deal merck keytruda drugmaker have decide not pursue accelerate regulatory pathway combination opdivo yervoy first line lung cancer base review datum available time bristol myer say statement late thursday boon merck get fda grant accelerate review keytruda chemotherapy first line treatment advanced lung cancer get fda decision early bristol myer continue study opdivo yervoy lung cancer approval not come earliest now bristol myer have bet heavily opdivo drive future growth bristol myer share plunge stock market today fall intraday worst level october merck rise market close bristol myer ono pharmaceutical opdivo settle patent litigation involve merck keytruda merck make initial payment bristol myer squibb ono merck also pay royalty rate keytruda sale jan dec rate subsequent year bristol get royalty ono bristol myer rise late trading merck be fractionally higher merck rise jan keytruda accelerate have give gain bristol myer fall jan continue fall bristol myer opdivo have have series setback recent month related merck lung cancer drug get large patient stock catalyze plunge key sector merck biogen lilly top drug approval fda slump
933,MRK,san francisco less hour president elect donald trump wednesday refer drug industry disastrous aldr ceo randall schatzman classify tone annual jpmorgan healthcare conference cautiously optimistic wide departure event time say sentiment be decidedly pessimistic enter turn be raucous election year drug pricing debate be alive biotech sentiment be grow stronger year schatzman tell ibd interview conference drug industry major event hold week san francisco talk biotech industry whole think finally come maturity say last year almost drug have be approve have come innovation biotechnology not large pharma so dollar be really pay back re see real game changer schatzman include cgrp migraine drug compete directly similar med eli lilly lly teva pharmaceutical teva amgen amgn migraine market be big enough grab sizable share drug hit shelve likely acknowledge trump comment didn help stock price hold phone schatzman pull screen biotech stock red arrow indicate descent point ishare nasdaq biotechnology index ibb exchange trade fund fall wednesday rise fraction thursday friday ibd take trump commentary send drug stock tailspin wednesday get deep dive mean drug biotech pick ibd industry theme so rally wall street expect jpmorgan event didn unfold here be key takeaway investor note trump take office drug firm look sidestep lilly alzheimer flop get early start trump isn alone fixation drug price celgene celg ceo mark alle parry back reporter question biotech follow allergan agn footstep apply so call social contract not raise price more annually celgene have offer free access program year alle say estimate biotech give away drug year free drug price increase help fund new drug add cfo peter kellogg estimate celgene reinvest fund accounting partnership alle say celgene go thoughtful process accounting innovation spending bring drug market price new med schatzman used same word describe plan price cgrp drug once near fda approval head market healthprize technology ceo tom kottler call pricing spike easy way drug company healthprize be software service firm marry behavioral economic consumer marketing analyze improve patient adherence prescription pharma leave worldwide revenue table year not push patient take med kottler tell ibd bridge gap company bring new product market prompt doctor more prescription raise price typically choose latter re miss easy money kottler say raise price be easiest thing say drugmaker merck mrk announce immuno oncology io drug keytruda combination chemo eli lilly alimta have win priority review fda small cell lung cancer have prescription drug free user act pdufa date meanwhile merck incyte incy be move keytruda epacadostat phase trial tumor type small cell lung cancer renal cell carcinoma bladder cancer squamous cell carcinoma head neck incyte stock jump jan news bristol myer squibb bmy be merck tail analyst say bristol myer be testing combination opdivo yervoy io therapy nsclc analyst expect bristol myer readout first half io combo be likely be more effective durable io chemo say monday japan takeda pharmaceutical put share bid ariad pharmaceutical ariad oncology firm base massachusett ariad stock fly news help share oncology firm tesaro tsro lift tesaro stock ipos lead ibd company medical biom biotech industry group stock see triple digit gain tesaro jump group overall fall painful election cycle now analyst wonder tesaro success oncology mind atmosphere reiterate takeda offer ariad garner bid tesaro leerink analyst seamus fernandez see potential takeout price share tesaro stock close friday rise tesaro remain well position grow independently validate parp inhibitor niraparib ovarian cancer drug still development offer durable strategically important product opportunity multiple suitor fernandez write research report jan regeneron regn sanofi sny be ask federal judge stay ban ldl bust drug praluent aftermath patent battle land biotech amgen praluent infringe amgen patent pcsk inhibitor repatha judge say meanwhile ldl buster alnylam pharmaceutical alny medicine co mdco be slowly advance jan medicine co announce day interim analysis study examine pcsk inclisiran datum show inclisiran significantly lower ldl day rbc analyst adnan butt expect month datum be similar efficacy safety detail be expect american college cardiology conference march washington inclisiran do well strong datum patent litigation amgen regeneron sanofi inclisiran be differentiate have patent litigation overhang butt say research report wednesday axovant axon ceo vivek ramaswamy say biotech drug industry have utterly fail alzheimer oncology inflammation cardiology ve see significant advancement last year disease alzheimer dementia include lewy body haven say don find treatment major threat society tell ibd interview wednesday be single area health care have fail deliver major advancement last decade ramaswamy say be root eli lilly december lilly highly laud solanezumab fail meet primary endpoint late stage trial cause lilly stock plunge day announcement lilly drug drug development biogen biib work remove plaque buildup brain associate alzheimer silver bullet theory ramaswamy doesn buy instead see necessary treat various behavioral psychological neurological piece alzheimer dementia axovant be aim build new therapy top older one axovant be next be alzheimer field deliver readout datum be slate say ramaswamy be look just major piece news alzheimer advancement say ramaswamy rise tide lift boat
934,MRK,stock market mount late recovery wednesday close positive reversal dow jone industrial average lead increase merck mrk defy weakness health care sector rise nasdaq much close higher climb small cap russell add volume rise board early figure show index be erratic wall street react president elect donald trump first press conference be elect nov stock swung trump blast drug company cost lockheed martin lmt fighter jet give few detail plan spend massively highway bridge airport other infrastructure index work way back afternoon be term bullish price reversal biotech generic drug other medical stock be most wednesday trump take aim drug price second time be elect pharmaceutical related group fall roughly ishare nasdaq biotech ibb fall medical stock such bristol myer squibb bmy myriad genetic mygn fall unusually high volume energy sector lead crude oil future climb barrel mining metal also come top day performance table earning season be just warm thursday announcement include delta air line dal taiwan semiconductor tsm delta result be especially noteworthy airline stock have rebound week thank spate favorable metric individual airline thursday economic report include weekly jobless claim import export price due et perhaps more importance market be speech give several federal reserve official include chairwoman janet yellen speak market close et town hall meeting educator washington related trump say drugmaker get away murder cite ford fiattrump vow fighter jet competition big thing lockheed crude stockpile production soar price rise opec cut
935,MRK,nasdaq composite close time high monday help strength semiconductor biotech stock nasdaq finished higher dow jone industrial average lose respectively dow be weigh weakness exxon mobil xom chevron cvx fall respectively crude future fall settle barrel baker hughe bhi friday say driller add rig straight week highest level year news vca woof soar news be acquire mar just elsewhere ariad pharmaceutical aria jump japan base takeda announce plan buy biotech just stock market today several biotechs be headline jpmorgan health care conference get underway san francisco share incyte incy vault news partnership merck mrk incyte blast flat base buy point incyte gap price open price be also valid entry glaukos gkos follow friday rise slightly extend handle buy point ibd take glaukos be top performer composite rating rank medical product group see leader group be ibd stock checkup healthequity hqy be top gainer ibd rise hold nicely day move average work flat base entry company be well position continue growth american turn health saving account fund pocket medical expense chip space apply material amat be top gainer nasdaq stock have be hold day move average buy point today move slightly extend price now meanwhile pay visit price level nvidia nvda firm rise remain quite extend bullish bounce week move average november related incyte stock break partner merck advance key trialmar buy vet hospital operator vca trade medical stock be ibd leaderboard now trade nvidia chart action give signal correction be
936,MRK,load player strength semiconductor stock biotech name help boost nasdaq gain monday small cap diverged again russell last week nasdaq composite index jump russell close low week muster gain just bull camp
937,MRK,biogen biib likely trim earning view spin hemophilia business publicly trade bioverativ sale multiple sclerosis drug tecfidera continue flounder rbc analyst michael yee say wednesday spinoff be approve late tuesday day biogen announce michel vounatsos succeed george scango ceo vounatsos joined biogen april chief operate officer year career merck mrk scango exit july yee keep outperform rating biogen stock cut earning share ex item view vs expectation have consensus model remain ep item doesn reflect ex hemophilia sale yee say be short term noise confusion biogen offer update outlook january yee write research report meanwhile tecfidera sale don look inspiring rival roche rhhby be set release ocrelizumab compete ms drug still yee note biogen ionis pharmaceutical ion be bullish new spinal muscular atrophy sma drug spinraza spinraza brand name nusinersen meet primary endpoint pair phase study show early efficacy ibd take donald trump break republican pressure drug biotech firm drug price trump recently hint doesn trajectory drug price prompt med tie stock topple yee assume spinraza sale note be add cent cent ep item approve early bioverativ be set host analyst day jan yee note biogen have stake spinoff focus develop treatment hemophilia rare blood disease include sickle cell beta thalassemia use gene editing tech sangamo investor appear be lukewarm biz give biogen choose spin also uncertainty long term tail hemophilia give ace phase datum due imminently december gene therapy potential curative solution yee write ace be hemophilia drug roche biogen share edge lower stock market today yet continue hug critical day move average stock have be build super long bottom base pattern top march biogen be outstanding market winner ever initially break first stage cup handle late october point biogen power way gain peak today biogen medical biomedical biotech industry group rank ibd industry week group hold staggering stock many experimental stage company company market value more only seattle genetic sgen tesaro tsro ionis pharmaceutical hold relative price strength rating higher due long base action biogen rs rating come unsurprisingly dismal accord ibd stock checkup related biogen name new insider ceo month search stock invest successfully know bottom base pattern
938,MRK,bristol myer squibb bmy astrazeneca azn roche rhhby pressure merck mrk slew lung cancer drug design chip keytruda share jeffery analyst jeffrey holford say monday downgrade merck stock stock market today merck fall bristol myer squibb climb merck bristol myer be lock battle small cell lung cancer market drug leverage patient immune system battle cancer holford downgrade merck stock underperform price target expect strong keytruda performance follow pressure rival drug bristol astrazeneca roche chip away keytruda market ibd take next year be marked new presidency path donald trump take drug price merck screen poorly many valuation metric have downgrade share underperform holford write research report same note upgrade bristol stock buy price target holford expect opdivo trial secure bristol future more broadly prefer abbvie abbv eli lilly lly stock astrazeneca novartis nvs stock europe see pfizer pfe johnson johnson jnj merck sanofi sny nordisk nvo least prefer stock related gilead pay merck hep patent agio stock anemic
939,MRK,major stock index be mixed mostly unchanged midday friday dow component apple aapl shrug positive comment piper jaffray ulta beauty ulta be top performer nasdaq dow jone industrial average add nasdaq composite ease be mostly unchanged volume exchange be heavy early go option expire market get little jittery reuter report chinese navy warship intercept underwater drone deploy oceanographic vessel south china sea stock market today apple be unfazed positive comment piper jaffray resume coverage stock overweight rating price target share rise stock work right side base meanwhile couple software bellwether report earning late thursday oracle orcl slump company report adjust profit cent share slightly ahead view sale be flat just oracle tout rise total cloud revenue adobe system adbe featured last weekend earning preview column reversed lower fall nearly adjust earning share cent rise year adobe also deliver sixth straight quarter sale growth ipo news online travel firm trivago trvg have debut pricing last night well propose range share be recently trading ibd take recent new issue top notch fundamental deliver explosive gain early stage business ibd offer extensive coverage ipo new issue market biotech sector gilead science gild slide federal jury order gilead pay merck mrk hepatitis patent dispute related apple be buy fedex pt raise oracle pt cut veeva ipo price range raise
940,MRK,eli lilly lly friday announce further collaboration astrazeneca azn second alzheimer compound give autopsy own fail late stage drug late thursday meanwhile biogen biib extend gain rise thursday fresh upbeat phase datum treatment small study early stage alzheimer patient eli lilly pay astrazeneca part expand alliance compound still phase trial addition compound stage trial show lilly isn give alzheimer treatment major disappointment eli lilly release detailed phase solanezumab datum ctad event san diego thursday evening late last month lilly stunned investor release datum show experimental alzheimer drug fail show statistically significant cognitive improvement vs placebo eli lilly share fall nov biogen lose merck mrk have own experimental treatment verubecestat fall fractionally day pare early loss result expedtion be question disappointing say eric siemer distinguish medical fellow lilly thursday night release however lilly remain commit find solution devastate disease continue analyze study result work external scientific community hope uncover finding help shape advance future alzheimer disease research detailed report lilly say plasma beta change be similar see previous study statistically significant change amyloid deposition weren significant cognitive decline slow primary endpoint not statistically significant other measurement cognitive decline slow respectively lilly share rise morning trade stock market today astrazeneca also get analyst upgrade climb biogen rise early friday gapping day line climb thursday rebound day move average ibd take biotech stock initially rally election investor relieve hillary clinton not be president populist trump say ll take pharma cost biotechs have take round trip trump pick run fda be key boost dose experimental alzheimer treatment reduce risk brain swell still achieve key benefit biogen disclose thursday step dosage regimen aducanumab see swell patient vs give high fix dose biogen report gradual regime still reduce amyloid plaque brain significantly vs placebo patient phase trial datum also halter mental decline similar fashion fix dosage result biogen release more datum san diego medical conference today be secondary endpoint directionally favore solanezumab raise hope thursday night presentation lilly drug general line research related eli lilly topple alzheimer darling sola fail biogen merck
941,MRK,load player here weekly investing action plan need know investor come week notable earning report speak weak slate economic report big event hold new year day market likely have little do day trading week obsess
942,MRK,drugmaker biogen biib monday name chief commercial officer michel vounatsos new ceo effective jan replace george scango announce july step lead cambridge mass base company mostly year new ceo be name see announcement sign biogen be takeover candidate scango guide company growth period see launch such product much herald oral multiple sclerosis treatment tecfidera drug pipeline have be drier late vounatsos joined biogen april year career drugmaker merck mrk reuter cite person familiar matter have report impending appointment minute close monday regular trading session send share tumble more final minute trading biogen issue press release shortly thereafter share be nearly hour trading biogen stock end monday regular session vounatsos have demonstrated extensive global experience track record innovative stakeholder engagement lead company commercial organization biogen say press release have implement key initiative extend company industry leadership multiple sclerosis expand biogen reach key global market effectively prepared introduction breakthrough treatment patient area high unmet need statement say ibd take even time drug stock general generally safe expect ll be represent ibd list top perform stock past week see drug stock be current list be excited build biogen legacy pursue innovative new therapy suffering serious neurologic disease create value shareholder maintain clear focus be best patient vounatsos say release term priority be clear intend gain approval spinraza provide first treatment spinal muscular atrophy continue grow global ms franchise fully enroll phase trial aducanumab advance lead candidate alzheimer disease reinvigorate pipeline area neurology neuro repair invest employee work together define future company have focuse treatment neurological autoimmune rare disease multiple sclerosis treatment area include hemophilia face patent infringement tecfidera danish drugmaker forward pharma fwp related biogen ceo quit speculation
943,MRK,share biogen biib merck mrk be slam early wednesday rival eli lilly lly report alzheimer drug darling solanezumab fail final stage trial secondary sign indicate sola not be totally dead water eli lilly stock plunge much more year low close stock market today share biogen merck be develop similar drug fall much respectively end solanezumab biogen aducanumab merck verubecestat target plaque buildup brain associate alzheimer eli lilly recent expedition trial examine effect sola patient dementia due alzheimer sola fail show statistically significant improvement cognition decline vs patient placebo eli lilly say press release secondary endpoint directionally favore solanezumab magnitude treatment difference be small ibd take biotechs be pressure nasdaq wednesday medical software maker veeva system ibd stock be fly high earning report more veeva growth prospect check recent new america story
944,MRK,eli lilly take charge cent share follow fail trial company say plan continue pursue alzheimer research didn say mean sola full result be present dec lilly have strong growth prospect solanezumab david rick lilly incoming chief executive officer president lilly bio medicine say statement analyst have high hope solanezumab september goldman sachs analyst jami rubi posit sola supercharge lilly earning add peak sale rubin have probability success sola credit suisse analyst vamil divan have chance success solanezumab rbc analyst michael yee have suggest biogen spike eli lilly success wednesday yee keep buy rating biogen stock advise investor buy dip biogen drug include different antibody different amyloid target eli lilly write research report also have show statistically significant reduction beta amyloid imaging benefit cognition evercore analyst john scottus note research report apple apple comparison sola remove less plaque biogen aducanumab sola also target insoluble beta plaque aducanumab aim soluble beta related eli lilly alzheimer drug fail key trial lilly biogen divelilly poise big december alzheimer datum diabetes rulingamgen biogen eli lilly poise rocket most important event
945,MRK,insulin pricing animal companion trend wrack eli lilly lly early tuesday post sale earning well wall street expectation prompt share plummet month low eli lilly stock rebound stock market today rise fraction tuesday earlier topple much eli lilly stock be year remain ahead ibd company ethical drug industry group be fellow drugmaker merck mrk rise tuesday post beat novartis nvs fall nearly month low sale miss wall street expectation ibd take drugmaker aren do well biotechs have show sign life late find more ibd industry snapshot good place look industry group be hot heat soon lilly credit sale growth increase volume several pharmaceutical product higher price erectile dysfunction drug ciali forteo used treat osteoarthritis be largely offset lower realize price diabetes med humalog company say normalization discount rebate humalog revenue growth ve be vs pricing effect be evercore analyst john scottus write research report management claim have be see increase rebate board well see more business flow less profitable channel also see worldwide animal health sale decline vs year earlier quarter brunt feel sale fall eli lilly blame wholesaler buy pattern companion animal product decrease sale food animal product decline eli lilly meanwhile report sale cent earning share item respectively vs year earlier quarter metric miss analyst view cent poll thomson reuter solanezumab remain bright spot eli lilly expect have phase trial datum alzheimer treatment year end rbc analyst michael yee see chance positive datum solanezumab chance success eli lilly drag sentiment rival company such biogen biib reminder eli lilly alzheimer drug be biggest swing factor view turn investor sentiment interest biotech biopharma equity yee write research report eli lilly reaffirm guidance ep ex item be pipeline also continue advance wide array promising treatment condition alzheimer disease diabetes cancer eli lilly outgoing ceo john lechleiter say company earning release july company announce lechleiter retirement be replace david rick head company biomedicine unit related eli lilly look coral more animal health business vs zoetisbiogen muscular dystrophy drug add top line
946,MRK,bristol myer squibb bmy shock wall street announce friday new cancer drug opdivo have fail trial single therapy newly diagnosed lung cancer patient company release few detail study call checkmate say hadn meet primary endpoint improvement progression free survival patient advanced small cell lung cancer nsclc be first conspicuous miss drug launch late already be approve different indication melanoma kidney cancer lymphoma later stage lung cancer ace clinical trial bristol myer also report positive datum opdivo front line lung cancer combination cancer drug yervoy back june checkmate failure be good news merck mrk compete drug keytruda succeed similar trial recently however merck play safer patient population choose target high expresser pd ligand keytruda opdivo target inhibition pd protein cancer cell bristol myer go broader patient population potentially winning bigger market increase risk failure bristol myer stock plunge close stock market today hit close low not see late march merck stock soar breaking long consolidation reach intraday highest level december evercore isi analyst mark schoenebaum call result possibly biggest clinical surprise career note potential market drug be enormous first line nsclc market be likely greater tell bristol myer be expect outperform merck monotherapy basis likely broader label cover expresser rather just high expresser schoenebaum write email consensus modeled opdivo indication perhaps come first line nsclc monotherapy anticipate combination therapy ibd take more datum bristol myer merck other big pharma rival go ibd stock checkup put more pressure opdivo yervoy combo trial call checkmate full result be due next year meantime merck now have hold minority market share have field similarly see opportunity improvement market share astrazeneca azn durvalumab tremelimumab combination more likely split immunotherapy combo market evenly bristol myer opdivo yervoy be completely dependent result mystic astrazeneca clinical trial write leerink analyst seamus fernandez research note doubt merck be catbird seat least next month suntrust robinson humphrey downgrade bristol myer stock neutral buy cut price target
947,MRK,merck pace list stock hit new week high friday blast heavy volume merck mrk jump rival bristol myer squibb bmy say lung cancer drug opdivo fail trial merck rebound sharply week move average blow past buy point july merck report
948,MRK,stock investor cheer better expect job report send major index soar friday morning labor department say economy add job july upwardly revise job june economist be forecasting july number average hourly earning rise cent hour nasdaq gain just point july time high jump new high dow jone industrial average vault stock market today volume be tracking higher nyse nasdaq exchange compare same time thursday priceline pcln gap surge report second quarter earning share increase year earlier compare consensus wall street estimate revenue come vs estimate ibd take see priceline be still stock travel website ibd stock checkup stock be breaking long consolidation priceline isn dynamic leader be several year merck mrk also break base be trading higher drug trial rival bristol myer squibb bmy fail bristol myer squibb fall universal display oled gap drop miss estimate close thursday universal display say adjust ep be cent vs estimate cent revenue come compare company be regard leader organic light emit diode device be become popular screen consumer device such television smartphone tablet universal display be worst performer ibd amn healthcare shot point then reversed hard trading nearly day line amn healthcare report ep cent share beating estimate revenue vs estimate amn provide temporary staffing doctor nurse hospital other medical facility
949,MRK,be huge week earning apple aapl facebook fb alphabet googl amazon amzn beat forecast mcdonald mcd ford motor indicated weakness demand tech step include verizon vz deal buy yahoo yhoo core asset economy be grow lot slower expect oil price be near barrel nasdaq composite rise best level early december fuel strong earning apple facebook alphabet amazon hit new record high friday close week fractionally dow jone industrial average fall also snap week uptrend weaker oil price earning report hit energy sector federal reserve statement term economic risk have diminish seem have little impact investor iphone maker earn share year year sale be apple second straight decline earning revenue iphone sale be still better expect apple current quarter revenue target be midpoint wall street consensus iphone be expect be release mid september apple stock rise week just retake day line amazon ep shatter estimate revenue rise amazon web service continue boom revenue guidance also be strong operate income be light amazon stock rise week hit record intraday friday ibd take amazon be leaderboard stock hit new high growth boom only rate ibd retail internet group see go ibd stock checkup facebook report revenue maintain streak double digit growth go back more year ep jump cent shatter consensus cent be fourth straight quarter accelerate earning growth facebook stock rise hit record high still range buy point twitter twtr report ep top view revenue fall short revenue guidance also miss estimate twitter stock fall close week day line bounce back miss alphabet report ep revenue blow past expectation google parent earning item rise share total revenue climb google size still deliver growth say mark mahaney analyst rbc capital be now straight quarter ish year year revenue growth do mention acceleration say report alphabet stock rise close just entry point rise high ford motor send signal long auto industry bull market be auto sale stall higher incentive hit profit margin automaker earning share revenue rise ep growth be weakest quarters sale growth be slimmest quarters ford cite downside risk global growth offer further evidence slow auto part maker lear lea miss sale warn revenue gentherm thrm earning miss volkswagen vlkay sale edge net profit plunge vs year early struggle recover emission test cheating scandal involve diesel engine model ford stock fall federal reserve left interest rate unchanged day policy meeting expect policymaker say term economic risk have diminish suggest baby step raise rate analyst say open door slightly september rate increase fed meeting weak gdp datum investor push back expectation next hike next month economy rise annual rate less half wall street expect downwardly revise pace consumer spending be very strong climb residential investment fall even separate report show new exist home sale hit multiyear high business investment contract third straight quarter oil price fall back barrel corporate spending remain weak go forward crude oil future tumble barrel hit month lows crude tumble july crude gasoline supply rise again accord energy information administration also report higher production number oil rig operation rise fifth straight week suggest further production gain glut gasoline refine product suggest less refinery demand crude ahead meanwhile exxon mobil xom chevron cvx conocophillip cop report weaker expect result mobileye mbly report ep jump cent revenue grow top view maker driver assistance system say relationship tesla motor tsla be end news send mobileye tuesday stock pare loss week tesla rise boee ba report first quarterly loss year due various charge wasn deep fear free cash flow be better expect big jet delivery northrop grumman noc report modest earning sale growth top view weaker tech service revenue hurt margin raytheon rtn beat view raise profit guidance general dynamic gd top earning raise ep guidance revenue miss mcdonald earn share beating analyst expectation total revenue fall vs year earlier analyst have expect global same store sale exclude currency effect rise vs estimate same store sale rise just management say be not immune consumer unease be finance election general unsettled world have hurt other restaurant quarter share fall week tumble day day move average buy point stifel nicolaus downgrade large number restaurant stock jeffery predict recession hit sector top rate texas roadhouse txrh report earning come week fall wednesday steakhouse chain find support day line close week unite technology utx maker pratt whitney brand aircraft engine otis elevator other product report second quarter earning share revenue beat estimate raise ep estimate stock hit year high buy point caterpillar cat ep revenue fall mining construction equipment giant deal energy mining downturn stock hit roughly year high rise entry point chemical giant dupont dd be merge dow chemical dow crushed earning estimate be light revenue share rise highest point mid december trigger buy point meanwhile mmm make tape adhesive medical supply other product also report higher ep lower revenue beating estimate share fall analog device adi agree buy linear technology lltc cash stock deal worth create microchip industry giant deal be expect close first half meanwhile oracle orcl say buy cloud service provider netsuite deal oracle larry ellison be lead shareholder netsuite meanwhile citrix system ctxs merge go meeting unit logmein logm citrix be already plan spin go meeting verizon communication acquire struggle core asset yahoo nearly include stock compensation cost massive execution challenge ahead yahoo acquisition demonstrate verizon recognize own limitation consumer brand say research firm diffusion group verizon report revenue miss view line ep add fewer wireless postpaid phone subscriber expect mobile tmus add postpaid phone subscriber top sprint verizon lose postpaid phone subscriber mobile earning fall still beat expectation revenue rise nearly tmus revenue growth continue significantly outpace peer say matthew niknam deutsche bank analyst report armour ua meet top line bottom line expectation report share earning penny prior year revenue growth nike nke rival announce several assertive plan include takeover fao schwarz space manhattan well partnership kohl kss share tumble week amgen amgn beat raise stock slip growth continue be drive price increase rather volume celgene celg meanwhile jump only third growth be price drive make hit earlier week drug revlimid fail lymphoma trial abbvie abbv merck mrk alexion pharmaceutical alxn also rise solid report astrazeneca azn be biggest winner stock wise jump thursday rumor swiss pharma novartis nvs be think acquire biggest loser be gilead science gild trim guidance hepatitis franchise continue decline meanwhile top rate medical device company edward lifescience ew orthopedic giant zimmer biomet zbh hit new high beating estimate raise guidance big cap stalwart boston scientific bsx hit year high report strongest quarter sale growth nearly decade
950,MRK,major average reversed higher soft start wednesday release minute mid june federal reserve meeting come go much fanfare biotechs celgene celg incyte incy buoy nasdaq facebook fb also outperformed facebook rise close day line first time june fall early nasdaq end gain add dow jone industrial average rise preliminary datum show nyse nasdaq volume come slightly higher tuesday level advance stock outnumber decliner exchange less dow leader include merck mrk home depot hd cisco system csco merck rise home depot cisco touch intraday low barrel benchmark west texas intermediate crude oil add nearly barrel year treasury yield be mostly unchanged minute june fed meeting be release et brexit vote fed have signale couple rate hike end year change decide exit european union currently future trader see little chance rate hike year year treasury yield be recently basis point hit time low tuesday stock market today edward lifescience ew be strong performer ibd screen lead growth stock edward lifescience reclaim day move average rise nearly average volume homebuilder horton dhi also do well rise strong turnover still buy range early flat base entry horton be select group leader ibd home build group see other be ibd stock checkup
951,MRK,stock open lower tuesday feel drag company news oil price market europe nasdaq open lower dow industrial lose stock gain session last week give market nice bump momentum head third quarter stock market today be take breather goldman sachs gs exxon mobil xom jpmorgan chase jpm open lower goldman sachs jpmorgan other big bank trade generally lower bank america bac citigroup nearly oil energy issue baker hughe bhi fall tesla motor tsla slip open maker battery power luxury vehicle say monday miss second quarter model model production target share have be consolidate april end friday battle hold support converge week move average illumina ilmn drag lower morgan stanley downgrade maker genetic screening system underweight equal weight chipmaker skywork solution swks shed report pacific crest trim rating number apple aapl supplier cite weaker expect ramp iphone sale oil price drop west texas intermediate slump barrel gold climb almost breaking ounce bond climb cut year treasury yield basis point dollar backed vs yen be flat euro britain pound slip lower vs dollar bank england lower capital requirement bank free additional credit market china end mixed tuesday start week strong gain monday japan tokyo nikkei ease end session rally europe london ftse trade claw way narrow gain benchmark index france germany fall nearly apiece index lose ground monday commerce department factory order report be due et researcher markit release jpmorgan global service purchasing manager index new york federal reserve bank president william dudley join roundtable discussion binghamton
952,MRK,stock market be nicely higher midday wednesday brexit concern stay back burner second straight session nasdaq rise help strong show china base netease nte add oil gas name do heavy lift dow picked chevron cvx merck mrk nike nke be early leader volume nyse nasdaq be tracking close tuesday level new york mercantile exchange crude oil benefit again dollar weakness decline crude inventory wti crude august delivery rise nearly barrel nasdaq gap still have potential resistance level watch nasdaq just level day move average ibd component netease jump nearly breakout have generally be have tough time current market netease clear cup handle base buy point netease be several strong performer computer software gaming group see other leader be ibd stock checkup stock market today lead light specialist acuity brand ayi gain nearly report strong earning open quarterly profit rise year share sale increase buy point be still play acuity still need get day line currently result paychex payx be due thursday open share rise high still buy range buy point biotech tesaro tsro more double price ovarian cancer drug do well late stage trial leaderboard name amazon com amzn extend gain bounce day move average tuesday share rise
953,MRK,stock open sharply higher wednesday tracking europe bounce brexit dive jump nasdaq dow jone industrial average start stock market buy interest ripple asia market send tokyo nikkei hong kong hang seng index gain china more insular mainland market post smaller gain shanghai composite europe market rally briskly second straight day cac paris london ftse more frankfurt stock exchange dax ahead enter afternoon trade london market miner anglo american homebuilder taylor wimpey lead ftse stock key stock motion market include nike nke merck mrk general electric ge medivation mdvn universal display oled commerce department report personal income spending trend be positive april pace personal income rise vs revise increase april shy consensus view advance spending rise april revise gain line forecast month gain point spending increase vs consumer price tick core price show real impact energy food be notch april rise line consensus view national association realtor report pending home sale number energy information administration release weekly oil inventory report federal reserve pan release second portion stress test result big bank today close nike erased loss extend trading climb open report late tuesday fiscal earning be flat revenue rise just consensus expectation gas pipeline leader william co wmb fall court ruling tuesday allow energy transfer equity ete terminate merger agreement value energy transfer share rise ibd stock universal display be flat open company announce tuesday acquire organic light emit diode intellectual property asset german chemical maker basf basfy amount deal be not disclose universal share be rise support day move average medivation jump medivation share have be form flat base follow gain more prior maker cancer treatment be target takeover effort france sanofi sny sanofi share be early wednesday oil price gain bit less putt west texas intermediate barrel europe brent crude benchmark just gold tick slightly higher trading ounce bond be effectively flat leave year treasury yield unchanged dollar slip vs euro yen
954,MRK,brexit volatility spark june vote withdraw european union diversify stock mutual fund eke gain average second quarter even lose june alone accord lipper inc tack inch june good news stock fund manager be seek durable growth stock hedge uncertainty volatility slowdown corporate earning several tell ibd see month longer ahead click here see list mutual fund quarterly leader brexit investment world be almost back normal say matthew co manager schroder large cap equity strategy be run separate account federal reserve be edge interest rate increase first quarter panic pace sustainability china growth be subside economic indicator be job wage grow home value inch consumer feel confidence then brexit say re back uncertainty market hate uncertainty result go forward say stock want be narrow group have show ability grow earning regardless macro environment click here see list mutual fund month leader biggest overweight be consumer discretionary say reflect confidence consumer durable secular trend amazon amzn be top list similarly james abate sole manager centre american select equity dhamx multus asset real return dhmux see best prospect growth increasingly concentrated elite group re concentrate name somehow buck trend term economic malaise say abate be also centre chief investment officer name new nifty bucket include amazon johnson johnson jnj merck mrk nvidia nvda general mill gis jim swanson lead manager mfs diversify income difax chief investment strategist mfs investment management be already bearish stock pre brexit click here see list mutual fund category performance outlook be already dim corporate earning growth say add company globally have already lose purchasing power selling general administrative cost well labor cost be rise productivity here europe china be fall post brexit dollar be vs chinese yuan hurt export multinational earning say global movement trade protectionism realize also hurt earning brexit not need see excess capacity come world manufacturing system return inflation so company pass price increase swanson say threat corporate earning swanson be overweight stock vs japanese european peer have growth outlook look even dimmer be underweight stock vs bond cash corporate bond be place be say favore mix high grade high yield debt small cap growth fund lead market capitalization style group diversify stock fund gain world equity mutual fund barely advanced edge lose june latin american fund lead foreign region advance june year date latin american fund have benefit primarily rebound excessive sell last year well rebound brazilian real vs dollar bounce oil other commodity accord peter taylor manager emerge market abeax latin american equity fund aleax brazilian stock have also benefit ouster least temporarily president dilma rousseff market friendly fiscal reform say quarter volatility enabled precious metal fund lead sector soar more half june go forward swanson feel best technology sector stock free cash flow be highest sector say talk bubble sector be trading cheaper utility ohio yet tech company change world software be due benefit overdue upgrade cycle say second favorite sector be health care health care spending keep rise portion gdp say price fairly not cheaply have best profit outlook tech consumer discretionary be third favorite sector forward price earning ratio be high re see year year profit growth almost good tech say tech stock facebook fb be like have exceptional top line growth say re grow opportunity viewer be tolerate triple video be show advertiser allow facebook triple number ad insert video health care say share price have be beaten largely investor concern drug pricing draw additional regulatory scrutiny still like individual stock sector include amgen amgn be cheapest pharmaceutical say be create market opportunity number biosimilar be harder previous generation treatment rival replicate consumer discretionary stock like amazon top line growth use prime draw new site user also like amazon use warehouse store inventory expense purchasing tractor supply tsco be consumer discretionary name like cater customer income be double national average pursue rural lifestyle say sale be triple next competitor combine scale enable tractor supply customize inventory different region staple like monster beverage mnst new carbonate drink mutant distribution arrangement partner coca cola ko keep growth high single digit low double digit say wall street expect low single digit make stock attractively value say david harden president summit global investment lead manager fund low volatility equity lvolx small cap low volatility lvsmx say volatility like stock stability revenue earning company offer downside protection say trait share stock like be stability revenue earning company offer downside protection say trait be low year beta beta be mean be less volatile overall stock market
955,MRK,stock shake brexit jitter sell overseas market thursday reverse session lows post solid gain merck mrk advance offset nike nke retreat dow jone industrial average dow lead gain rise nasdaq much intraday edge higher volume swell board put call ratio spiked thursday indicate excessive fear settle biggest gainer stock market today include food beverage telecom travel book stock energy chipmaker gold miner lag oil stock get whack drop west texas intermediate crude oil barrel merck lead dow gain robust volume announce positive result clinical trial show keytruda drug extend survival lung cancer patient stock extend recent bounce day move average nike lead blue chip loser stumble fast trade stock have decline march quarterly sale miss view guidance disappoint credit suisse say report thursday athletic shoe apparel giant see term sale decelerate north america competition adida armour ua maintain outperform rating price target remain long term bull nike do nike perform shoe apparel manufacturing group find ibd stock checkup ibd cambrex cbm fall average volume test day move average first time month pharmaceutical ingredient developer extend lose streak sixth straight session close just handle buy point clear april busy day economic news consumer price climb slightly less expect jobless claim rise bit more expect homebuilder confidence top view highest level january philly fed manufacturing index also come forecast economic datum tap friday include housing start atlanta federal reserve business inflation expectation june baker hughe weekly rig count stock market volume likely spike due future option expiration
956,MRK,stock capped volatile week loss friday apple aapl sank iphone patent ruling amazon amzn alphabet googl other big techs weigh nasdaq tech heavy index slump dow jone industrial average ease volume swell board vs thursday due primarily expiration future option contract index end lower week week move average line nasdaq shed dow dip drugmaker biotechs internet stock lag merck mrk be biggest blue chip decliner fall heavy trade effectively erased gain thursday release positive trial result keytruda drug treat lung cancer merck close just day move average big cap internet stock alphabet amazon facebook fb give respectively apple heavy volume weigh key index stock have trend lower hit resistance june day line fall week rbc capital market friday cut apple price target maintain outperform rating cite slowdown iphone demand beij regulator rule iphone iphone violate chinese phone maker design patent order apple stop selling model oil stock lead upside stock market today west texas intermediate price surge more top barrel department store hotel stock also gain ibd lgi home lgih gigamon gimo lead upside gain more lgi clear buy point busy trade gigamon close highest level more year emergent biosolution ebs plunge slice day line roughly average turnover biotech stock be now handle entry clear mid biotech stock carry best rating find ibd stock checkup economic news housing start fall annualize rate unit april still top forecast build permit climb slightly view minneapoli federal reserve president neel kashkari be schedule speak monday eye be thursday brexit referendum britain vote withdraw european union
957,MRK,big pharma bristol myer squibb bmy motor year high stock market monday company continue roll positive trial datum cancer drug merck mrk be putt stiff competition say analyst annual american society clinical oncology asco meeting weekend bristol myer present number study used new immunotherapy drug opdivo treat various cancer most closely watch be checkmate trial opdivo combination bristol myer drug yervoy treat newly diagnosed case small cell lung cancer nsclc result be particularly strong patient tumor expressed pd opdivo target order destroy cancer cell ability protect immune system patient take yervoy week opdivo week be still alive year patient greater pd expression median progression free survival pfs be month merck combination similar drug keytruda chemotherapy first line patient show pfs month high pd expressor month patient overall study be relatively small however so wall street be still watch outcome larger study clarify have advantage potential opdivo yervoy combination remain controversial eye many investor be very impressed see weekend credit suisse analyst vamil divan write research note assume positive datum present merck keytruda chemotherapy combination first line nsclc lead wonder limit bristol myer potential indication highlight size overall market believe degree exclusivity bristol myer large portion market be significant long term positive bristol myer also present positive result combo gastric colorectal small cell lung cancer sclc latter smaller market nsclc also underserved underwhelm report abbvie abbv potential competitor rova also have boost bristol myer stock monday bristol myer stock rise much early trading stock market today touch year high second straight trading day share close bristol myer stock hit time high october merck rise
958,MRK,here investing action plan friday need know investor come day monthly job report be due friday top drugmaker bristol myer squibb bmy merck mrk roche rhhby eli lilly lly abbvie abbv discuss new cancer treatment payroll datum labor department monthly job report be due et
959,MRK,bristol myer squibb vs merck pfizer vs lilly unique treatment abbvie abbv take spotlight next week biggest drug conference focuse treatment biggest disease cancer annual meeting american society clinical oncology chicago june be prime opportunity check potential blockbuster drug abstract most presentation be release public give gist study result leave detail conference most interesting item investor be late breaking abstract past several asco meeting battle immunotherapy be major theme market pd inhibitor bristol myer squibb bmy opdivo merck mrk keytruda be already big seller skin lung cancer opdivo ahead market share ongoing research give idea true market potential well stack other be often case cancer drug opdivo keytruda be approve advanced case disease first largest market opportunity be front line treatment newly diagnosed patient cancer largest market opportunity be small cell lung cancer nsclc bristol myer merck be target first abstract release merck keynote study keytruda combination chemotherapy yielded improvement progression free survival pfs month overall month patient tumor show high expression pd ligand pd inhibitor indirectly target here continue see solid orr overall response rate percentage tumor shrank pfs datum look meeting better understand durability response longer period time write credit suisse analyst vamil divan research note bristol myer be also conduct first line nsclc study most significant be checkmate combine opdivo bristol myer immunotherapy drug yervoy prove be most effective combo then be huge company bristol myer wholly own treatment thus gain revenue be new checkmate info early abstract analyst hope be late breaking datum morningstar analyst damien conover say also want see datum tecentriq roche rhhby entry sister class drug target pd ligand directly coincidence fda approve tecentriq type bladder cancer call urothelial carcinoma same day asco abstract be release be first file bladder cancer conover tell ibd bladder big indication not big lung cancer have niche roche really help drive drug sale leerink analyst seamus fernandez however note tecentriq soon have competition show other asco presentation initial datum bristol myer opdivo astrazeneca azn durvalumab show higher response rate indication fernandez write research note smaller patient number datum set baseline characteristic be present asco be closely watch newer battle seem be shape different drug class call cdk inhibitor used treat breast cancer cdk stand cyclin dependent kinase enzyme tie cell division encode gene cdk cdk inhibitor help stop cancer cell multiply first pfizer pfe ibrance launch early take last year expect swell billion eventually eli lilly lly however have make noise cdk inhibitor abemaciclib show much higher response rate refractory patient do ibrance asco abstract lilly monarch trial month treatment number be only still better ibrance slight disappointment wall street lilly day tuesday company say also be present month datum asco so still be upside surprise nonetheless evercore isi analyst mark schoenebaum write lilly executive didn seem enthusiastic lilly seem not want boost investor expectation regard month datum therefore reiterate orr result report month ask schoenebaum write email client additionally lilly encourage investor also look overall clinical benefit duration response presentation asco hover background not asco be novartis nvs announcement have stop late stage trial own cdk drug early have already hit primary endpoint improvement pfs detail have later medical meeting also positive development space analyst divan tell ibd room more winner meanwhile pfizer score hit treatment late stage datum show ibrance combination estrogen blocker letrozole yielded pfs more month month more letrozole alone prod analyst fernandez raise sale estimate whole cdk class estimate ibrance sale alone late breaking datum other field study many wall street be eyee be midstage trial rova drug abbvie be acquire buyout biotech stemcentryx rova be treatment small cell lung cancer sclc smaller market enormous nsclc population definite opportunity lack specifically approve treatment previous study have show response rate relapse patient high expression delta protein dll appear sclc patient tumor presentation asco be particularly important stemcentryx be report long term survival datum be gold standard cancer trial far fda be concern analyst schoenebaum say rova have improve survival enough differentiate know chemotherapy produce month os overall survival set re testing rova schoenebaum say video record client know be datum asco abstract show pd yervoy produce month lot toxicity punchline be need see os datum well excess month abbvie have estimate peak annual sale rova hit
960,MRK,stock rally modestly janet yellen signale june rate hike be table oil price rise barrel gain reversed tesla motor tsla face new safety concern share still rise hope meet production target apple aapl revamp app store business model amazon com amzn double india american airline aal other carrier rise mixed news niche retailer lululemon lulu dave buster play report strong earning stock rally much week hike hope rise month high less time best nasdaq approach first time year dow top share pull back slightly thursday especially friday bond yield hit near record lows world brexit fear revive close week nasdaq dow industrial eke gain day dismal job report fed chairwoman janet yellen say economy be make progress drop hint late hike be appropriate come month yellen comment cautious statement other policymaker signale june meeting move be table cme fedwatch tool now see chance move next week chance late july september fact odd don favor move december meeting job report investor see chance june move july meanwhile april job opening rise match record high reach last july number actual hire fall lowest last august layoff fall lowest september number quit worker dip national highway traffic safety administration say thursday be look possible model suspension problem well troublesome nondisclosure agreement tesla friday dismiss suppose safety concern tesla also revive low end version model person model meanwhile confidence grow tesla meet production goal least short term pacific crest baron capital founder ron baron make positive comment tesla stock jump production optimism then sell nhtsa news drop back day day line tesla close rise high apple now cut take app store revenue customer subscriber more year sign multiple year apple be hope subscription base model need higher revenue concern analyst speculate app store revamp good news like netflix nflx pandora time warner twx own hbo alphabet googl reportedly be plan adopt similar model android apps alphabet google play charge new subscription not only be more year apple kick worldwide developer conference monday crude jump first time month week close week just oil price initially get boost militant attack nigerian oil infrastructure political struggle venezuela weigh global supply demand india be rise energy information administration say weekly crude inventory fall barrel production edge barrel day barrel week earlier first uptick week continental resource clr say be start restart unfinished well win begin new drill price be higher royal dutch shell rdsa lower capital spending original estimate shell exit country country currently have operation plan focus effort country include brazil australia devon energy dvn announce plan sell nearly asset field texas oklahoma hercule offshore hero say first lien debt holder accept prepackage chapter plan announce last month bristol myer squibb bmy hit year high american society clinical oncology asco conference monday give back gain week bristol myer trial result show combination opdivo yervoy be competitive merck mrk drug keytruda chemotherapy treat newly diagnosed small cell lung cancer bristol meyer stock fall week merck rise bristol opdivo yervoy combo also succeed small cell lung cancer detriment abbvie abbv recent buyout deal stemcentryx be question stemcentryx lead drug rova miss expectation trial treat same disease abbvie fall week valeant pharmaceutical vrx hit year low tuesday earning miss consensus cut guidance again dermatology drug once sell disgrace pharmacy philidor aren do well valeant new deal walgreen wba bowel drug xifaxan be also struggle valeant admit recent scandal have harm reputation valeant do file tardy avoid debt default valeant share be lows be still week biogen biib tumble tuesday potentially multiple sclerosis drug lingo fail clinical trial expectation be low go company need good news older ms drug have flag lately biogen stock be week side sarepta therapeutic srpt soar say fda have request more biopsy datum make much delay decision approve ms drug eteplirsen observer interpreted fda look way approve drug weak datum set sarepta filing sarepta stock be week airline stock get bump week analyst report find carrier have raise airfare delta air line dal say unit revenue key metric have fall industrywide part lower fare market be likelier come closer low range forecast drop american airline hold outlook unit revenue decline southwest airline luv say still expect modest increase operate unit revenue jetblue jblu cut full year capacity growth outlook follow footstep rival american say aug change frequent flier program dole mile base airfare paid opposed flight length american air stock rise southwest unite jetblue even delta restaurant gaming chain report first quarter result easily beat wall street expectation dave buster also hike full year revenue comparable sale forecast share touch new high result lead jump higher margin gaming revenue make more half sale result come much traditional restaurant business slow april share leap week breaking new high india prime minister narendra modi visit address congress meeting president obama visit coincide commercial diplomatic deal amazon com invest india year top previous investment look challenge local commerce player such flipkart snapdeal expand international sale overall amazon be also open numerous small distribution center india handle local delivery formally declare india be major defense partner lead more arm sale defense deal world most populous democracy lululemon athletica ep decline cent penny shy projection revenue rise view same store sale include direct consumer grow constant dollar basis yogawear retailer see cent ep sale share climb week hit best level late nike nke be snap week lose streak armour ua be hd supply hds adjust earning jump cent share top view cent net revenue rise vs consensus bad weather hurt sale atlanta base industrial supply distributor forecast sale expectation cent diluted ep view cent hd supply share rise high just cent time high set july pare gain end week flat verifone system pay report earning share rise cent miss cent share revenue grow just consensus verifone guide ep revenue view smaller retailer resist new chip card reader share dive week fall lowest level september restoration hardware rh stunned wall street report cent share loss analyst expect cent share profit upscale home furnishing chain note impact market hurt energy downturn currency headwind general slowdown luxury consumer market revenue grow edge projection share plunge week
961,MRK,biggest player global life science industry have be move cloud veeva system veev go public have be help get cloud base customer relationship management crm marketing project management solution roster client include amgen amgn biogen biib pfizer pfe merck mrk bayer bayry cardinal health ticker
962,MRK,last month forbe release annual fast tech list fastest grow public tech company veeva system veev come grubhub grub arista network anet facebook fb provider cloud base sale marketing software life science industry sport year annual ep growth rate year annual
963,MRK,here investing action plan need know investor come week crude price barrel next meeting organization petroleum export country add upward momentum smack market back meanwhile apple aapl supplier broadcom avgo medtronic mdt report earning drugmaker discuss cancer fight
964,MRK,propel overall market diversify stock mutual fund notch gain average april month modest gain be far better loss january february lag gain average taxable bond fund track lipper inc go forward mutual fund manager expect more volatility many be look stock stable earning growth thrive tailwind robust economy just complete month multicap value fund do best mutual fund market capitalization style category key impetus be federal reserve dovish stance interest rate hike click here see list mutual fund month leader late march speech fed chair janet yellen say central bank proceed cautiously adjust policy april meeting fed federal open market committee stick yellen march outlook decline again raise rate economic activity appear have slow fomc say add household spending have moderate statement tell investor fed think economic growth be slower previously believe slower growth slower rate hike mean weaker dollar help exporter be good news many large cap stock say omar aguilar chief investment officer charle schwab investment management weaker dollar lower cost pay debt most emerge market make easier buy good service other putt bluntly fed do not want break fragile economy raise price money more dovish tone fed bring market volatility help support asset have be hurt anticipation fed rate hike say mark hamilton chief investment officer asset allocation oppenheimerfund click here see list mutual fund category performance jittery investor lift precious metal fund april best sector energy fund natural resource fund have lose respectively year end march be next best perform april sector jump last month world equity fund gain april lead latin american fund leap taxable bond fund be pace high yield fund advance investor willing take risk safe haven general treasury fund slip expect mediocre return fair amount volatility go forward hamilton say fed finally do get next rate hike volatility be likely rise say broadly expect economy outperform several quarters benefit large cap james abate chief investment officer centre fund manager centre american select equity dhamx expect reversal recent month rotation value away growth material energy industrial other cyclical sector be likely reverse abate say so ve take opportunity amplify position stable growth type company nifty type name key stock be name amazon amzn pepsico pep exelon exc carnival cruise ccl sell energy stock hold amazon be epitome look be strong have unique business model grow regardless economic backdrop say exelon be utility low cyclicality say current return equity be be roughly half year median return equity say see incremental roe move higher plenty room expand pepco acquisition close see increase focus cost cut rate relief regulate utility unit contribute profit margin expansion strong balance sheet allow future dividend hike buyback equally good stock be virtually unaffected economic development japan europe say also like idea carnival have almost nowhere go depress profit margin return capital add merck mrk call low cyclicality defensive name get strong drug pipeline say see improvement return asset be nifty name abate have stay underweight energy industrial financial material exposure be company be capable grow be not dependent acceleration global economy say area name include vulcan material vmc international flavor fragrance iff abate say value stock be unlikely add lot gain ve score already year so embrace company be more stable less sensitive up down economic cycle say also do not rule correction time fund have hedge possibility put option profit be disappointing say profit margin be decelerate poor top line revenue outlook hard see price earning multiple expand further aguilar abate expect volatility rest year best gain be confine narrow band stock say bond yield low other asset class disappointing ll see new nifty do well say diversification be good diversification be bad re mid polaris capital management bernard horn lead co manager fund totale asset be concern impact sluggish economic growth used volatility recent month buy share larger foreign bank depress price include jpmorgan chase jpm valuation become compelling say also add asset manager franklin resource ben have great long term performance have slump last year see opportunity buy good long term franchise lot cash balance sheet have relatively low tax rate have manager sit offshore mark mobius base hong kong executive chairman templeton emerge market group horn also add web com group web create maintain website small business help small business get social medium site say business just buy do sophisticated marketing lead generation customer add be electronic technology distributor avnet avt company also assemble product customer ve get good management team squeeze free cash flow value add service customer horn say add thailand base siam commercial bank investment not ripen quickly say thai economy be little soft now so take time play say
965,MRK,big cap drugmaker regeneron pharmaceutical regn merck mrk be move opposite direction thursday trading earning report company raise guidance regeneron quarterly revenue rise year earlier period beating analyst consensus accord thomson reuter earning share be penny short estimate last year crucial metric sale flagship drug eylea regeneron report growth beating consensus company raise full year growth estimate vs previous earning miss stem higher spending selling general administrative cost spending guidance year remain unchanged also cholesterol drug praluent be launch last july miss consensus again number remain small company await result cardiovascular outcome trial praluent rival amgen amgn repatha later year regeneron say payer coverage praluent be good so far commercially insure medicare have access drug regeneron stock be midday trading stock market today merck post earning cent share year earlier period beating consensus cent sale decline miss wall street number merck stock be midday thursday merck add few cent ep guidance range now also raise low end revenue guidance now echo number global pharmas earning season merck cite improve foreign exchange rate revenue shortfall be spread number different drug include blockbuster diabetes drug januvia immunology drug remicade more interesting analyst be come cancer drug keytruda miss estimate beat slightly worldwide especially rival bristol myer squibb bmy opdivo beat consensus last week bristol myer also moved report date trial opdivo first line treatment lung cancer previously guide erode advantage merck expect report result similar trial keytruda midyear drug be now approve only previously treat patient so first line approval significantly expand market merck also report sale hepatitis drug zepatier just launch late january tiny compare report market leader gilead science gild gilead abbvie abbv say earning call last week merck aggressive discounting have affected own business nonetheless rbc capital market analyst michael yee write not have be directly responsible gilead miss merck suggest negotiation important parity access remain ongoing exception veteran administration market have good access interestingly suggest many commercial payor access deal be impact contract be already complete yee write research note so gilead say lower sale be mostly due just higher gross net healthier patient come not so much competition be true realize price competition be still ongoing come need be watch
966,MRK,big biotech amgen amgn beat wall street estimate raise guidance thursday close stock go sideway hour trading peer gilead science gild however be sharply weak quarter amgen report adjust earning share year earlier quarter cent ahead analyst consensus accord thomson reuter revenue increase more consensus company lift full year guidance not quite much beat ep range be now revenue guide be vs last year amgen make ep revenue amgen best selling drug enbrel rheumatoid arthritis beat expectation grow almost consensus accord evercore isi second biggest drug neulasta neutropenia modestly beat estimate gain other hand amgen newer drug come short cancer drug kyproli grow be still shy consensus sale newly launch cholesterol drug repatha continue take gilead meanwhile report earning share exclude time item last year cent wall street average estimate revenue rise consensus gilead nonetheless make change full year guidance call product sale gross margin gilead blockbuster hepatitis drug harvoni sovaldi account most shortfall opposite reason harvoni miss badly outperformed abroad sovaldi do opposite earlier day abbvie abbv report harvoni chief competitor viekira also come short consensus company attribute merck mrk unexpectedly aggressive pricing recently launch rival zepatier merck report quarter also bring screeching halt gilead year stretch double triple digit sale profit growth start dec launch sovaldi analyst expect growth totally flatten company make acquisition gilead stock be more hour thursday close regular session
967,MRK,stock turn lower afternoon trading friday bigger expect increase retail sale dow jone industrial average fall fall day move average neither have close day line feb nasdaq have be key support level volume stock market today be tracking lower same time thursday drug stock be biggest gainer oil retail transport stock fall endo international endp rise heavy volume try stem sharp decline have see stock drop lowest level federal probe relationship company manage prescription benefit other company johnson johnson jnj merck mrk have be contact part investigation accord reuter recently valeant pharmaceutical vrx be force end ty pharmacy benefit manager philidor bill practice valeant be week high valeant rise friday intraday allergan agn hasn be name investigation rise more afternoon trading botox maker be part generic drug industry group be best performer friday department store retailer have bad day government report show retail sale rise more expect april jwn plunge profit drop cent share much wall street have expect also issue disappointing full year guidance jcpenney jcp be nearly mixed earning report brick mortar retailer be suffering shopper increasingly buy online site such amazon com amzn gaming related stock be bright spot friday nvidia nvda make graphic chip used computer game console mobile device jump more record high strong quarterly earning report nvidia be now breaking cup handle base march
968,MRK,drug stock have long be favore income investor relatively steady dividend payout merck mrk currently pay quarterly dividend share full year work annualize yield nearly well average payout new jersey base company have paid dividend quarter long term dividend growth rate be drug giant thursday announce positive result comparative trial zepatier hepatitis drug gilead science gild sovaldi wednesday merck say fda accept review supplement biologic license application keytruda treat patient recurrent metastatic head neck cancer also say fda grant priority review aug merck full year profit grow last year best year analyst expect gain year next share be work right side month consolidation be week high johnson johnson jnj product include blood cancer drug imbruvica prostate cancer drug zytiga offer annualize yield analyst forecast ep rise share higher sale report tuesday open stock be top buy range cup handle buy point clear feb amgen amgn know drug such neupogen epogen pay annual dividend have year earning growth rate analyst expect increase year next share biotech be near buy point cup shape base neither amgen johnson johnson show dividend leader friday ibd due space limitation
969,MRK,few exchange trade fund crucial point chart major earning announcement week hold potential pivotal move fund health care utility consumer solar energy be poise climb past ceiling major piece etfs release quarterly report significant move loom be sure etfs be pool stock performance single component have limit impact whole fund yet blowout report big disappointment change course sector etf example technology select sector spdr xlk gap april fund largest percentage move march microsoft msft alphabet googl fund top holding slide weak quarterly result utility select sector spdr xlu etf find critical spot try regain foot drop day move average success rise key level rest partly company fare latest report duke energy duk etf second largest hold more whole fund be report result tuesday open analyst expect profit share charlotte base utility continue uneven profit performance wednesday dominion resource release earning et consensus estimate be cent share exelon exc come result friday et wall street be expect profit cent share dominion exelon account fund respectively lot top company health care select sector spdr xlv etf have already report big one be deck week pfizer pfe report tuesday merck mrk thursday open drugmaker be second third largest component etf be near key level share be approach december peak move level be bullish consumer discretionary select sector spdr xly second largest component home depot hd announce disney release result close heavyweight account etf be top holding etf be climb new high make steady advance guggenheim solar tan largest component solarcity scty release first quarter earning market close solar panel installer account more etf fund chart be testing resistance level conquer continue recovery deep decline
970,MRK,big money be move medical field thursday giant company announce attempt multibillion dollar buyout abbott laboratory announce agreement acquire fellow cardiac device maker st jude medical stj deal worth meanwhile abbvie abbv used be abbott biopharma division be spun agree buy biotech stemcentrx upfront milestone payment cancer focuse biotech medivation mdvn confirm have receive unsolicited bid big pharma sanofi sny week rumor abbott agree pay abbott share st jude share base abbott day average share price deal value st jude stock apiece abbott say deal add cent ep next year cent follow year expect save cost combination abbott also assume refinance st jude debt move greatly enlarge abbott cardiovascular device business now represent revenue st jude medical strong position heart failure device atrial fibrillation cardiac rhythm management complement abbott lead position coronary intervention transcatheter mitral repair abbott say press release together company compete nearly area cardiovascular market hold position large high growth cardiovascular device market leerink analyst danielle antalffy agree st jude flat negative sale growth last few year picked write research note set continue abbott look be grow only low single digit nonetheless abbott share fall close st jude rise ibd take healthy be abbott lab stock find ibd stock checkupabbvie sanofi meanwhile be big pharmas look fill pipeline innovative drug lead product face slowdown abbvie immunology drug humira be best selling drug world patent start expire year sanofi have have scale back expectation diabetes franchise increasingly competitive space have push price stemcentrx lead late stage asset be call rovalpituzumab tesirine rova already registrational trial small cell lung cancer abbvie say pay purchase price cash rest stock stemcentrx also receive cash milestone payment drug successfully clear regulatory development hurdle meantime however be financial drain abbvie expect transaction be approximately cent dilutive ongoing earning share accretion begin company say announcement lower ep guidance meanwhile abbvie early thursday report earning beat wall street estimate fall tad short revenue abbvie say earn share item cent better analyst expect sale analyst poll thomson reuter have expect global humira sale rise exclude foreign exchange impact abbvie say thursday research note investor evercore isi analyst mark schoenebaum cite approximately beat humira sale largely offset miss global viekira revenue primarily drive miss possibly due competition merck mrk well abbvie put total humira sale sale viekira treat hepatitis be abbvie drug generate globally total sale abbvie say abbvie stock end higher stock market today sanofi unsolicited offer be share cash medivation make deal worth medivation have be subject takeover rumor recent week astrazeneca azn sanofi rumore suitor medivation sole commercial product be prostate cancer drug xtandi market japan astella xtandi success launch have help drive medivation stock excellent composite rating propose purchase price represent premium medivation month volume weight average price buyout talk begin sanofi say medivation stock rise thursday suggest investor think bid go higher sanofi stock finished image provide shutterstock
971,MRK,stock market see red afternoon trading wednesday still shake bit tuesday terror attack belgium day gain biotechs weigh nasdaq fall selling be less intense nyse index drop dow jone industrial average ease volume nyse nasdaq be tracking higher tuesday level stock market today unitedhealth unh visa johnson johnson jnj outperformed dow nike nke lag fall company report earning late tuesday spdr gold share gld slump etf be weak gold price fall due strength dollar handle buy point be short live elsewhere virgin america va soar bloomberg report company be attract takeover interest technology space small cap chip designer inphi iphi gap rise deutsche bank lift price target inphi be extend double bottom buy point miss initial be also legitimate entry ibd be big winner rise reversed higher fall nearly early late tuesday retailer report second straight quarter accelerate sale growth be heavily short stock so part today move be short cover meanwhile ibd name reilly automotive orly be close breaking week consolidation share rise close watch earning apparel maker oxford industry oxm pvh corp pvh image provide shutterstock
972,MRK,stock open marginally lower wednesday heel tuesday resilient performance light terror attack belgium nasdaq dow jone industrial average fall overseas action be quiet china market end narrowly mixed tokyo nikkei take gain europe benchmark index paris london show modest gain frankfurt dax gain economic calendar new home sale number february be expect commerce department et energy information administration release weekly oil inventory report oil price decline early go west texas intermediate brent crude trade barrel gold slump more trading ounce bit less so far week dollar rise vs euro yen bond edge higher pressure year yield basis point lower most dow stock be flat index be busy extreme nike nke dive early trading mixed fiscal report late tuesday merck mrk give back early premarket gain still rise california jury decade long case find gilead science gild blockbuster hepatitis drug infringe merck patent gilead share drop more nasdaq stock apply material amat lose close chip equipment maker have gain past session be work sixth straight weekly advance scale right side month pattern ibd stock cal maine food calm give stock be struggle regain week move average climb right side month consolidation image provide shutterstock
973,MRK,stock hold open loss tuesday weak economic datum pending federal reserve decision weigh early trade nasdaq slip be dow industrial show decline volume rise nyse higher nasdaq relative trade same time monday early economic news do stock market today big favor best news come new york federal reserve report read march empire state manufacturing gauge be steep decline february activity well economist expectation february retail sale slip expect producer price decline also line estimate business inventory expand january equal december gain continue month month pattern report commerce department builder confidence hold steady february level national association home builder report march housing market index economist consensus have project slight uptick datum come fed policy committee kick day meeting broadly expect result change interest rate drugmaker ore coal miner oil related industry be show worst performance tuesday start gate mix medical retail utility group fared best post modest gain most name dow jone industrial average carved lower open merck mrk goldman sachs gs deep end apple aapl top handful gainer advance analyst note morgan stanley report iphone demand tracking ahead expectation march lead strength china oil energy issue hold many worst early loss stock service focuse conglomerate leucadium national luk drop nearly investment banking subsidiary jeffery group report revenue decline fourth quarter loss swing profit year earlier leucadium share have be decline month mead johnson mjn spiked start trade financial blog betaville report mead have begin work banker lazard regard takeover interest switzerland base nestle nsrgy lead stock front ibd list gain deep discount retailer stock be work fourth straight gain edge buy point cup base michael kor kor drop nearly light trade fashion designer remain late january scale right side month consolidation
974,MRK,stock open thin loss wednesday nasdaq flick positive territory dow industrial ease nasdaq move fractional gain loss thing have be stock market today strong february employment report adp help shore confidence start trade still market be hang back ahead fed march beige book report due et be last federal open market committee march meeting have impact afternoon trade oil price stick early loss west texas intermediate almost brent crude trading lower energy information administration report weekly inventory datum et weekly inventory estimate american petroleum institute indicated tuesday inventory rise barrel last week vs consensus view barrel increase dow stock open generally lower apple aapl pfizer pfe merck mrk higher gain less dupont dd nike nke lead downside loss respectively tumble management guide full year earning consensus expectation dollar tree dltr shed fourth quarter earning fall more expect revenue gain stop short analyst forecast small cap be perform comparatively well generate big move checkpoint system ckp skip takeover offer darling ingredient dar spiked report result tuesday american vanguard avd rocket higher report late tuesday nasdaq seagate technology stx climb almost hard disk drive manufacturer be almost jan low still deep month consolidation peer western digital wdc rise most ibd stock lose ground early trade ross store rost post strongest gain nearly follow result late tuesday gain put share more buy point image provide shutterstock
975,MRK,stock again finished mixed tuesday ahead federal reserve monetary policy announcement due wednesday dow jone industrial average eke gain nasdaq give respectively volume run higher board vs monday accord preliminary number economic front february retail sale dip line view january datum be revise drop initial report gain energy stock slide oil price west texas intermediate crude fall barrel drug stock get hurt stock market today valeant pharmaceutical vrx lead downside stock plunge multiyear low canada base drugmaker report revenue top view earning miss valeant also slash ep revenue guidance other drugmaker endo international endp sank mallinckrodt mnk lose horizon pharma hznp retreat pfizer pfe merck mrk underperform dow respective loss roughly apple aapl outpeformed blue chip gapping rise volume apple be lighter usual share be december low april peak morgan stanley have overweight rating price target apple say note apple iphone demand be tracking ahead expectation automaker food stock buck downtrend tesla tsla add extend advance third straight session electric car maker stock have rev feb intraday low be now converge day day line ibd ligand pharmaceutical lgnd shed more slow turnover close converge day day line
976,MRK,stock future wrestle moderate gain wednesday premarket session follow mixed read producer price housing datum january dow future edge fair market value open stock market today future add nasdaq future have slight lead rise wednesday economic news open price paid producer tick january improvement december slip stronger decline forecast economist consensus labor department also report core consumer price index food energy jump solid well improvement december double consensus estimate housing start slow january accord commerce department drop more downwardly revise annualize rate december pace be forecast increase build permit gauge pending activity dip vs december annualize rate consensus view forecast slight pullback federal reserve have release schedule today session factory output utilization datum january due et minute jan federal open market committee meeting be release oil price continue bob recent range west texas intermediate blipped sticking barrel brent crude gain just barrel talk begin tehran oil minister iran iraq qatar venezuela discuss production cap propose group lead saudi arabia tuesday iran make clear ahead meeting resist attempt curb recover oil output dow stock be quiet generally positive ahead open boee ba run ahead field gain merck mrk lag ride strong spate dramatic premarket gain fossil fosl spiked priceline pcln pipeline giant kinder morgan kmi leap garmin grmn muscle gain kinder morgan follow earning report kindermorgan vault higher regulatory filing berkshire hathaway brka reveal warren buffett conglomerate own share firm end december kinder morgan end tuesday late january low back week move average april high bottom cerner cern tank fourth quarter revenue earning squeak past consensus view top end ep guidance just meet consensus estimate stock have be deepen slump month shopify shop charge narrowly beating analyst earning estimate book revenue gain well ahead expectation share have be decline june high end tuesday ipo price stock ibd list be flat positive start trade warm american tradition gun soup set upside pace campbell soup cpb pop boost full year ep guidance well consensus estimate tuesday close company cite improve gross margin performance cost saving campbell have be knock new high late january end tuesday flat base buy point wesson swhc jump nearly share be climb week move average sixth week potential cup base
977,MRK,biotech incyte incy tumble month low thursday end trial lead drug pancreatic cancer earning beat wall street estimate incyte say end phase trial drug jakafi ruxolitinib capecitabine also know roche rhhby xeloda second line treatment advanced metastatic pancreatic cancer interim analysis show be futile jakafi be sell blood cancer myelofibrosis polycythemia vera incyte be study various solid tumor discontinue several other trial base same hypothesis pancreatic cancer trial include midstage trial lung breast colorectal cancer however continue solid tumor trial combine other agent include merck mrk keytruda pembrolizumab astrazeneca azn tagrisso osimertinib incyte also say revenue come combination jakafi sale royalty contract revenue jump year earlier quarter analyst consensus accord thomson reuter net income be cent share reverse year earlier loss soundly beating consensus cent company do not offer revenue ep guidance year say jakafi sale be last year forecast expense selling general administrative expense incyte stock be nearly morning trading stock market today
978,MRK,biotechs still be generally favor group have be firm recent week hold own ibd industry group ranking even large cap name biogen biib celgene celg unite therapeutic uthr have come selling pressure be still plenty top rate name group show relative strength amgen amgn
979,MRK,celgene beat analyst earning expectation come short sale thursday several stock blood cancer market moved new clinical trial datum
980,MRK,celgene early thursday say earning item climb year earlier quarter share beating analyst consensus penny revenue rise consensus poll thomson reuter
981,MRK,celgene celg affirm previous full year guidance sale midpoint ep midpoint vs expectation revenue mix change slightly however celgene add sale guidance lead drug revlimid now lower guidance abraxane
982,MRK,company earning conference call hematology oncology chief jacqualyn fouse admit firm original guidance hadn account impact new immuno oncology drug treat lung cancer drug be bristol myer squibb bmy opdivo merck mrk keytruda have be take market share abraxane indication fouse however say see great potential combination trial abraxane drug such opdivo abraxane trial breast cancer launch collaboration bristol myer also tout licensing deal develop newer immuno oncology drug astrazeneca azn juno therapeutic juno be inked yea
983,MRK,celgene be also seek get immuno oncology bandwagon study new drug combination revlimid sister drug pomalyst fouse say datum several trial combine revlimid merck keytruda pembrolizumab multiple myeloma blood cancer revlimid become blockbuster treat be thursday part general release abstract ahead next month american society hematology ash meeting
984,MRK,believe abstract re go see overall response rate tumor shrinkage revlimid trial pomalyst pembro trial crs disappearance tumor fouse say
985,MRK,otezla treatment psoriasis psoriatic arthritis celgene launch last year wall street skepticism beat consensus sale call executive say otezla be take market share bring significant number new patient
986,MRK,stock trade reaction just be line change guidance be probably just reaction expectation stock have run recent week write rbc capital market analyst michael yee research note big picture here be growth story be still well intact ep guidance be maintain really longer term possible settlement program pipeline give celgene best growth story large cap biotech next year
987,MRK,celgene stock fall thursday
988,MRK,abstract move stock
989,MRK,release ash abstract also moved other stock thursday mostly earlier stage biotechs cellectis cll report first human patient receive cell therapy ucar baby suffering acute lymphoblastic leukemia disease be go day patient be infuse ucart cell
990,MRK,ucar be chimeric antigen receptor cell car therapy similar be develop celgene partner juno well kite pharma kite novartis nvs other however other player have develop individual treatment patient extract patient cell alter re inject cellectis car therapy be allogeneic develop other cell shelf potentially bring economic advantage
991,MRK,abstract be submit july patient continue remain disease free be eligible receive stem cell transplant approximately month receive ucart write jeffery analyst biren amin research note view provide first clinical evidence clinical activity ucart provide confidence allogeneic gene editing approach develop cellectis
992,MRK,cellectis stock already have be rise steeply ahead abstract release rise much thursday month high sell news seem take afternoon close juno stock fall thursday kite fall
993,MRK,also downside bluebird bio blue tumble month low several study early stage gene therapy lentiglobin sickle cell disease beta thalassemia inherited condition cause severe anemia
994,MRK,previous datum have get investor hope lentiglobin be possible cure sickle cell disease particular most recent study however suggest patient beta subtype beta thalassemia do not respond well other type patient remain dependent blood transfusion celgene beat analyst earning expectation come short sale thursday several stock blood cancer market moved new clinical trial datum celgene early thursday say earning item climb year earlier quarter share beating analyst consensus penny revenue rise consensus poll thomson reuter celgene celg affirm previous full year guidance sale midpoint ep midpoint vs expectation revenue mix change slightly however celgene add sale guidance lead drug revlimid now lower guidance abraxane company earning conference call hematology oncology chief jacqualyn fouse admit firm original guidance hadn account impact new immuno oncology drug treat lung cancer drug be bristol myer squibb bmy opdivo merck mrk keytruda have be take market share abraxane indication fouse however say see great potential combination trial abraxane drug such opdivo abraxane trial breast cancer launch collaboration bristol myer also tout licensing deal develop newer immuno oncology drug astrazeneca azn juno therapeutic juno be inked yea celgene be also seek get immuno oncology bandwagon study new drug combination revlimid sister drug pomalyst fouse say datum several trial combine revlimid merck keytruda pembrolizumab multiple myeloma blood cancer revlimid become blockbuster treat be thursday part general release abstract ahead next month american society hematology ash meeting believe abstract re go see overall response rate tumor shrinkage revlimid trial pomalyst pembro trial crs disappearance tumor fouse say otezla treatment psoriasis psoriatic arthritis celgene launch last year wall street skepticism beat consensus sale call executive say otezla be take market share bring significant number new patient stock trade reaction just be line change guidance be probably just reaction expectation stock have run recent week write rbc capital market analyst michael yee research note big picture here be growth story be still well intact ep guidance be maintain really longer term possible settlement program pipeline give celgene best growth story large cap biotech next year celgene stock fall thursday abstract move release ash abstract also moved other stock thursday mostly earlier stage biotechs cellectis cll report first human patient receive cell therapy ucar baby suffering acute lymphoblastic leukemia disease be go day patient be infuse ucart cell ucar be chimeric antigen receptor cell car therapy similar be develop celgene partner juno well kite pharma kite novartis nvs other however other player have develop individual treatment patient extract patient cell alter re inject cellectis car therapy be allogeneic develop other cell shelf potentially bring economic advantage abstract be submit july patient continue remain disease free be eligible receive stem cell transplant approximately month receive ucart write jeffery analyst biren amin research note view provide first clinical evidence clinical activity ucart provide confidence allogeneic gene editing approach develop cellectis cellectis stock already have be rise steeply ahead abstract release rise much thursday month high sell news seem take afternoon close juno stock fall thursday kite fall also downside bluebird bio blue tumble month low several study early stage gene therapy lentiglobin sickle cell disease beta thalassemia inherited condition cause severe anemia previous datum have get investor hope lentiglobin be possible cure sickle cell disease particular most recent study however suggest patient beta subtype beta thalassemia do not respond well other type patient remain dependent blood transfusion
995,MRK,stock future deepen early loss ahead tuesday open weaker expect september durable good report dow future trade point be fall future slip point
996,MRK,nasdaq future have pare loss past hour reversed fall point fair market value
997,MRK,stock market today face busy session federal open market committee swing day meeting washington policy announcement due wednesday afternoon
998,MRK,great many investor be tune aftermarket session apple aapl be schedule report fiscal result
999,MRK,economic news open durable good order slip september accord commerce department be bit projection decline department also revise august decline transportation order dip august flat performance deeper project slip
1000,MRK,case shiller report city composite home price index august et researcher markit release preliminary purchasing manager index estimate service conference board plan report october consumer confidence index
1001,MRK,earning action be thick heavy roll tuesday open
1002,MRK,beleaguered german chip equipment maker aixtron aixg spiked base big oil play bp bp add almost big pharma name merck mrk pfizer pfe rolled gain report better expect result
1003,MRK,downside frac sand quarrier crush partner hclp implode miss earning forecast suspend cash distribution rent center rcii post premarket meltdown miss revenue expectation lower full year earning guidance ford slip unite parcel service up dim
1004,MRK,alibaba baba rumble bell launch premarket rally many china base stock china base diversify internet play report ep gain rise revenue fiscal easily top consensus forecast mobile revenue rise cloud compute internet infrastructure revenue rise
1005,MRK,company also announce security exchange commission give notice conclude inquiry enforcement action be recommend alibaba share end monday day move average stock have climb late september low leave still nov high ipo price
1006,MRK,yahoo yhoo ahead early tuesday investor account increase value yahoo stake alibaba yahoo remain deep month consolidation
1007,MRK,other china base internet play catch alibaba premarket heat jd com jd com wbai pop jumei international jmei vipshop vip jump apiece
1008,MRK,chip developer marvell technology mrvl tank announce late monday have resign company accounting firm marvell september announce internal investigation revenue be recognize earlier have be marvell share have be steep correction february
1009,MRK,cummin cmi dive miss expectation earning revenue line management lower full year revenue outlook flat vs prior guidance gain columbus ind base diesel engine maker also announce lay worker share have be deepen decline june
1010,MRK,leader ibd stock be relatively quiet more group unmoved premarket trade
1011,MRK,gainer cirrus logic crus rise topple heavy trade monday stock post decline more stock future deepen early loss ahead tuesday open weaker expect september durable good report dow future trade point be fall future slip point nasdaq future have pare loss past hour reversed fall point fair market value stock market today face busy session federal open market committee swing day meeting washington policy announcement due wednesday afternoon great many investor be tune aftermarket session apple aapl be schedule report fiscal result economic news open durable good order slip september accord commerce department be bit projection decline department also revise august decline transportation order dip august flat performance deeper project slip case shiller report city composite home price index august et researcher markit release preliminary purchasing manager index estimate service conference board plan report october consumer confidence index earning action be thick heavy roll tuesday open beleaguered german chip equipment maker aixtron aixg spiked base big oil play bp bp add almost big pharma name merck mrk pfizer pfe rolled gain report better expect result downside frac sand quarrier crush partner hclp implode miss earning forecast suspend cash distribution rent center rcii post premarket meltdown miss revenue expectation lower full year earning guidance ford slip unite parcel service up dim alibaba baba rumble bell launch premarket rally many china base stock china base diversify internet play report ep gain rise revenue fiscal easily top consensus forecast mobile revenue rise cloud compute internet infrastructure revenue rise company also announce security exchange commission give notice conclude inquiry enforcement action be recommend alibaba share end monday day move average stock have climb late september low leave still nov high ipo price yahoo yhoo ahead early tuesday investor account increase value yahoo stake alibaba yahoo remain deep month consolidation other china base internet play catch alibaba premarket heat jd com jd com wbai pop jumei international jmei vipshop vip jump apiece chip developer marvell technology mrvl tank announce late monday have resign company accounting firm marvell september announce internal investigation revenue be recognize earlier have be marvell share have be steep correction february cummin cmi dive miss expectation earning revenue line management lower full year revenue outlook flat vs prior guidance gain columbus ind base diesel engine maker also announce lay worker share have be deepen decline june leader ibd stock be relatively quiet more group unmoved premarket trade gainer cirrus logic crus rise topple heavy trade monday stock post decline more
1012,MRK,big biotech unite therapeutic uthr agree sell priority review voucher abbvie abbv give unite infusion cash abbvie chance speed fda approval drug
1013,MRK,unite gain rare pediatric disease priority review voucher pprv march approval unituxin treatment rare childhood cancer call neuroblastoma fda start pprv program encourage development such drug cut standard review time new drug month
1014,MRK,go price pprv have rise sharply last year july regeneron pharmaceutical regn sanofi sny paid just buy biomarin pharmaceutical bmrn used get cholesterol drug praluent market last month
1015,MRK,november gilead science gild paid get pprv knight therapeutic used last month filing new combination therapy hiv price have rise sanofi acquire pprv retrophin rtrx
1016,MRK,abbvie didn say drug go use voucher have several late stage possibility company have be work expand cancer leukemia drug venetoclax breast cancer drug veliparib be review future
1017,MRK,abbvie be also work next generation hepatitis treatment race market be intense face gilead merck mrk other
1018,MRK,drug stock general be rest market early stock market today late morning unite therapeutic be wednesday midweek update ibd be abbvie stock also be fraction
1019,MRK,connect amy reeve ibd_areeve facebook big biotech unite therapeutic uthr agree sell priority review voucher abbvie abbv give unite infusion cash abbvie chance speed fda approval drug unite gain rare pediatric disease priority review voucher pprv march approval unituxin treatment rare childhood cancer call neuroblastoma fda start pprv program encourage development such drug cut standard review time new drug month go price pprv have rise sharply last year july regeneron pharmaceutical regn sanofi sny paid just buy biomarin pharmaceutical bmrn used get cholesterol drug praluent market last month november gilead science gild paid get pprv knight therapeutic used last month filing new combination therapy hiv price have rise sanofi acquire pprv retrophin rtrx abbvie didn say drug go use voucher have several late stage possibility company have be work expand cancer leukemia drug venetoclax breast cancer drug veliparib be review future abbvie be also work next generation hepatitis treatment race market be intense face gilead merck mrk other drug stock general be rest market early stock market today late morning unite therapeutic be wednesday midweek update ibd be abbvie stock also be fraction connect amy reeve ibd_areeve facebook
1020,MRK,drugmaker deliver tasty return investor july pharmaceutical etfs top peer hold broadly diversify health care stock well focuse red hot biotechs powershare dynamic pharmaceutical pjp lag pharma etf peer month rise lead year date advance longer period produce annual average
1021,MRK,chaos seem reign worldwide riot enter greece debt drama wednesday combat continue ukraine china stock be melt yet world stock mutual fund outperformed diversify stock fund year july say lipper inc so investor expect foreign stock fund outperform again second half depend
1022,MRK,chaos seem reign worldwide riot enter greece debt drama wednesday combat continue ukraine china stock be melt yet world stock mutual fund outperformed diversify stock fund year july say lipper inc so investor expect foreign stock fund outperform again second half depend
1023,MRK,benefit investor have sense big big cap company actually grow way look situation be compare stock biggest name stock respective industry group sector be guarantee stock become large industry juggernaut
1024,MRK,blockbuster hepatitis drug power sale profit gilead science have become drug industry hit stock gilead gild stock have soar nearly last year new run begin gilead market capitalization be now higher drug giant merck mrk even revenue
1025,MRK,speculation newest class cholesterol drug heated friday fda release briefing document tuesday advisory committee meeting praluent pcsk inhibitor regeneron pharmaceutical regn sanofi sny nevertheless regeneron stock rise fresh time high friday second straight day sanofi retreat document frame issue ponder
1026,MRK,total return dividend pay stock depend price movement dividend payout ibd dividend leader screen focus fundamental technical criterium well current dividend yield dividend growth stock make grade clear buy point lately be sputtering well fargo wfc break past entry
1027,MRK,year biggest cancer meeting bring raft update hot oncology market send stock move wall street sort winner loser biggest upside surprise american society clinical oncology meeting chicago end tuesday probably come immunogen imgn beleaguered biotech come back life thank
1028,MRK,big pharmas merck mrk bristol myer squibb bmy release new datum hot new immunotherapy cancer drug friday afternoon result send stock opposite direction bristol stock drop release late breaker abstract study drug opdivo pd inhibitor american society clinical oncology asco meeting open
1029,MRK,stock jump start gate monday accord sort eurozone greece brushed global market bit optimism
1030,MRK,nasdaq pull early action dow jone industrial average climb rise volume be mixed early reading show trade nasdaq nyse compare action same time friday
1031,MRK,stock market today open note eurozone creditor strike deal greece not open door bailout fund deal require greece government put place wednesday pension reform tax increase be refuse greek voter july referendum deal also make available immediately shore greece falter bank require government privatize portfolio asset most proceed go repay debt recapitalize weaken bank greece bank stock market remain close prime minister alexis tsipra go home attempt convince government go plan order hang euro currency bloc greece face debt deadline european central bank july
1032,MRK,europe top index have ease slightly early high cac paris frankfurt dax hold gain dollar climb vs euro
1033,MRK,stock airline early lead industry possibly owing dive oil price american airline group aal leap delta air line dal unite continental holding ual southwest airline luv gain apiece
1034,MRK,gps device leader garmin grmn wynn resort wynn climb run head nasdaq
1035,MRK,head marathon petroleum mpc turn gain start trade marathon pipeline master limit partnership mplx mplx announce acquire mlp markwest energy partner mwe deal value mplx share dive markwest jump
1036,MRK,newlink genetic nlnk pop lead ibd list stock be low april high climb right side month consolidation
1037,MRK,very few ibd stock post early decline ambarella amba taser international tasr be stock jump start gate monday accord sort eurozone greece brushed global market bit optimism nasdaq pull early action dow jone industrial average climb rise volume be mixed early reading show trade nasdaq nyse compare action same time friday stock market today open note eurozone creditor strike deal greece not open door bailout fund deal require greece government put place wednesday pension reform tax increase be refuse greek voter july referendum deal also make available immediately shore greece falter bank require government privatize portfolio asset most proceed go repay debt recapitalize weaken bank greece bank stock market remain close prime minister alexis tsipra go home attempt convince government go plan order hang euro currency bloc greece face debt deadline european central bank july europe top index have ease slightly early high cac paris frankfurt dax hold gain dollar climb vs euro stock airline early lead industry possibly owing dive oil price american airline group aal leap delta air line dal unite continental holding ual southwest airline luv gain apiece gps device leader garmin grmn wynn resort wynn climb run head nasdaq head marathon petroleum mpc turn gain start trade marathon pipeline master limit partnership mplx mplx announce acquire mlp markwest energy partner mwe deal value mplx share dive markwest jump newlink genetic nlnk pop lead ibd list stock be low april high climb right side month consolidation very few ibd stock post early decline ambarella amba taser international tasr be
1038,MRK,headach be most universal medical problem merely nuisance most person be much more many sufferer
1039,MRK,woman man suffer migraine severe form headache often accompany nausea sometimes visual hallucination many sufferer get only month population suffer chronic migraine pain virtually day
1040,MRK,traditionally patient dealt migraine same way everybody deal headach counter sometimes prescription pharmaceutical aim pain general new class biotech medicine set be showcased american headache society meeting washington june bring sea change treatment big opportunity investor
1041,MRK,drug giant eli lilly lly teva pharmaceutical industry teva big biotech amgen amgn hot startup aldr be develop calcitonin gene related peptide cgrp monoclonal antibody fight migraine cgrp be produce neuron modulate transmission pain dilation blood vessel decade merck mrk target treat migraine traditional small molecule drug development
1042,MRK,marcelo bigal now head teva migraine program work original merck project
1043,MRK,never fail efficacy bigal tell ibd small molecule be develop target succeed problem be be cause liver toxicity decide instead develop small chemical antagonize receptor cgrp develop antibody target
1044,MRK,antibody be much more specific target bigal say be not degraded liver so wouldn raise liver toxicity problem long half life body meant weren so helpful immediate attack migraine be used patient get frequent migraine
1045,MRK,other company watch fail merck program get same idea early result start come industry start take notice
1046,MRK,labrys biologic bigal moved develop antibody be acquire teva last june upfront milestone payment same time have be trading flat early ipo start take have more quadruple price trade
1047,MRK,interest migraine treatment come partly potential size market not big something lung cancer migraine drug sale reach year advisory firm evercore isi estimate midstage datum have be report company involved have look good
1048,MRK,most company be testing product category patient chronic migraine defined occur least day month episodic migraine headach be less frequent still monthly event
1049,MRK,ceo randy schatzman tell ibd distinction be basically artificial be create allergan win approval wrinkle drug botox prevent migraine win approval only chronic migraine actavis act have acquire allergan botox
1050,MRK,botox regimen be effective not faint hearted involve shot head month generally require full cycle therapy cgrp antibody be also inject make less pincushion patient ald be deliver single iv infusion month teva tev amgen amg subcutaneous monthly injection lilly ly biweekly subcutaneous injection
1051,MRK,company have report phase result episodic migraine teva report episodic datum month meeting report chronic migraine result last month
1052,MRK,company methodology differ slightly make comparison inexact result have be broadly similar reduce headache day month
1053,MRK,attract attention wall street be hyper responder be headache free third month treatment amgen do not use metric lilly drug achieve patient episodic trial do teva chronic migraine trial drug eliminate headach patient third month have suffer headach start treatment
1054,MRK,personally think really hyper responder drive commercial opportunity write evercore analyst umer raffat research note
1055,MRK,opinion do not seem have coalesce clear front runner be difference drug addition dose regimen already mentioned amgen amg target cgrp receptor other product target ligand substance bound protein other structure serve biological purpose
1056,MRK,little early say difference modality be go be schatzman say receptor be used multiple ligand start program worry bring biology didn want modulate so steer ligand stay away receptor
1057,MRK,teva bigal also note compare clinical trial investor realize teva subject continue take usual medication top cgrp antibody other trial do not
1058,MRK,want test medication condition condition be ordinarily see doctor not idealistic view condition say
1059,MRK,lilly meanwhile isn even conduct phase trial chronic migraine do have ongoing episodic trial aaron schacht global brand development leader lilly pain business say lilly schatzman doesn think real biological difference chronic episodic migraine however order approval company run phase trial patient group
1060,MRK,lilly be also unique also testing cgrp antibody outside migraine start clinical trial cluster headach much less common excruciatingly painful type headache occur side head usually eye schacht say fda even give lilly orphan drug designation use shield competition approval lilly also run study arthritic knee pain
1061,MRK,believe cgrp be involved variety different pain state schacht tell ibd be lilly experience anxiety drug cymbalta be able search concept broad pain indication be something re quite interested regard molecule headach be most universal medical problem merely nuisance most person be much more many sufferer woman man suffer migraine severe form headache often accompany nausea sometimes visual hallucination many sufferer get only month population suffer chronic migraine pain virtually day traditionally patient dealt migraine same way everybody deal headach counter sometimes prescription pharmaceutical aim pain general new class biotech medicine set be showcased american headache society meeting washington june bring sea change treatment big opportunity investor drug giant eli lilly lly teva pharmaceutical industry teva big biotech amgen amgn hot startup aldr be develop calcitonin gene related peptide cgrp monoclonal antibody fight migraine cgrp be produce neuron modulate transmission pain dilation blood vessel decade merck mrk target treat migraine traditional small molecule drug development marcelo bigal now head teva migraine program work original merck project never fail efficacy bigal tell ibd small molecule be develop target succeed problem be be cause liver toxicity decide instead develop small chemical antagonize receptor cgrp develop antibody target antibody be much more specific target bigal say be not degraded liver so wouldn raise liver toxicity problem long half life body meant weren so helpful immediate attack migraine be used patient get frequent migraine other company watch fail merck program get same idea early result start come industry start take notice labrys biologic bigal moved develop antibody be acquire teva last june upfront milestone payment same time have be trading flat early ipo start take have more quadruple price trade interest migraine treatment come partly potential size market not big something lung cancer migraine drug sale reach year advisory firm evercore isi estimate midstage datum have be report company involved have look good most company be testing product category patient chronic migraine defined occur least day month episodic migraine headach be less frequent still monthly event ceo randy schatzman tell ibd distinction be basically artificial be create allergan win approval wrinkle drug botox prevent migraine win approval only chronic migraine actavis act have acquire allergan botox botox regimen be effective not faint hearted involve shot head month generally require full cycle therapy cgrp antibody be also inject make less pincushion patient ald be deliver single iv infusion month teva tev amgen amg subcutaneous monthly injection lilly ly biweekly subcutaneous injection company have report phase result episodic migraine teva report episodic datum month meeting report chronic migraine result last month company methodology differ slightly make comparison inexact result have be broadly similar reduce headache day month attract attention wall street be hyper responder be headache free third month treatment amgen do not use metric lilly drug achieve patient episodic trial do teva chronic migraine trial drug eliminate headach patient third month have suffer headach start treatment personally think really hyper responder drive commercial opportunity write evercore analyst umer raffat research note opinion do not seem have coalesce clear front runner be difference drug addition dose regimen already mentioned amgen amg target cgrp receptor other product target ligand substance bound protein other structure serve biological purpose little early say difference modality be go be schatzman say receptor be used multiple ligand start program worry bring biology didn want modulate so steer ligand stay away receptor teva bigal also note compare clinical trial investor realize teva subject continue take usual medication top cgrp antibody other trial do not want test medication condition condition be ordinarily see doctor not idealistic view condition say lilly meanwhile isn even conduct phase trial chronic migraine do have ongoing episodic trial aaron schacht global brand development leader lilly pain business say lilly schatzman doesn think real biological difference chronic episodic migraine however order approval company run phase trial patient group lilly be also unique also testing cgrp antibody outside migraine start clinical trial cluster headach much less common excruciatingly painful type headache occur side head usually eye schacht say fda even give lilly orphan drug designation use shield competition approval lilly also run study arthritic knee pain believe cgrp be involved variety different pain state schacht tell ibd be lilly experience anxiety drug cymbalta be able search concept broad pain indication be something re quite interested regard molecule
1062,MRK,puma biotechnology pbyi stock tumble thursday company release disappointing datum late wednesday ahead annual american society clinical oncology meeting asco abstract release also featured positive somewhat conflict news new immuno oncology drug roche rhhby astrazeneca azn merck mrk puma issue result late stage trial breast cancer drug neratinib earlier
1063,MRK,merck be upswing better expect earning report bullish outlook new diabetes drug januvia drug giant have rise more year vs gain thank earning inspire gap april
1064,MRK,merck mrk annualize dividend share yield current share price average
1065,MRK,profit slip cent share due part strong dollar be still cent wall street estimate
1066,MRK,revenue period fall less expect merck note strong demand januvia recently introduce cancer drug keytruda
1067,MRK,add trial result januvia also call tecos indicated patient take drug didn show increase risk heart failure analyst say help differentiate drug similar offering astrazeneca azn bristol myer bmy
1068,MRK,merck have paid dividend quarter hold payout steady cent share much last decade
1069,MRK,november merck boost dividend penny cent share long term dividend growth rate be
1070,MRK,company be expect post decline profit year earning be expect rise figure have be revise higher
1071,MRK,furthermore merck continue report strong annual pretax margin return equity bode well future dividend
1072,MRK,stock be work cup type base day move average remain day line sign weakness
1073,MRK,merck prescription drug industry group be rank wednesday ibd april im institute healthcare informatic say spending drug rise last year biggest increase new brand lower patent expiration rise price merck be upswing better expect earning report bullish outlook new diabetes drug januvia drug giant have rise more year vs gain thank earning inspire gap april merck mrk annualize dividend share yield current share price average profit slip cent share due part strong dollar be still cent wall street estimate revenue period fall less expect merck note strong demand januvia recently introduce cancer drug keytruda add trial result januvia also call tecos indicated patient take drug didn show increase risk heart failure analyst say help differentiate drug similar offering astrazeneca azn bristol myer bmy merck have paid dividend quarter hold payout steady cent share much last decade november merck boost dividend penny cent share long term dividend growth rate be company be expect post decline profit year earning be expect rise figure have be revise higher furthermore merck continue report strong annual pretax margin return equity bode well future dividend stock be work cup type base day move average remain day line sign weakness merck prescription drug industry group be rank wednesday ibd april im institute healthcare informatic say spending drug rise last year biggest increase new brand lower patent expiration rise price
1074,MRK,merck mrk stock jump more tuesday company lead trio big pharmas report first quarter earning bolster good news diabetes franchise merck report earning cent share year earlier quarter cent better analyst consensus sale shrank beating consensus nearly
1075,MRK,major average turn mixed midday tuesday volatile session
1076,MRK,nasdaq fall early report surface cargo ship be seize iran weaker expect read consumer confidence didn help matter
1077,MRK,dow jone industrial average rise help merck mrk rise strong earning add nasdaq rise volume be tracking higher exchange stock market today
1078,MRK,conference board consumer confidence index april come well consensus estimate
1079,MRK,apple aapl break flat base buy point briefly record time high then reversed be trading more big volume
1080,MRK,ibd stock be higher be lower
1081,MRK,chinese auto bitauto bita athm ibd name fall more break cup base monday then reversed
1082,MRK,ipg photonic ipgp report first quarter earning beat be year revenue miss analyst forecast stock surge early give gain be struggle hold day move average major average turn mixed midday tuesday volatile session nasdaq fall early report surface cargo ship be seize iran weaker expect read consumer confidence didn help matter dow jone industrial average rise help merck mrk rise strong earning add nasdaq rise volume be tracking higher exchange stock market today conference board consumer confidence index april come well consensus estimate apple aapl break flat base buy point briefly record time high then reversed be trading more big volume ibd stock be higher be lower chinese auto bitauto bita athm ibd name fall more break cup base monday then reversed ipg photonic ipgp report first quarter earning beat be year revenue miss analyst forecast stock surge early give gain be struggle hold day move average
1083,MRK,tuesday session didn start so hot couple negative headline rattle wall street
1084,MRK,nasdaq fall early report iran seize cargo vessel weaker expect read consumer confidence didn help matter
1085,MRK,little more hour left session stock be mixed session high dow jone industrial average rise add nasdaq be mostly unchanged nasdaq volume be tracking slightly lower monday nyse volume rise bit
1086,MRK,dow be buoy merck mrk report strong earning open share rise
1087,MRK,stock market today apple aapl have hard time attract buyer company report better expect earning late monday share fall heavy turnover
1088,MRK,elsewhere tech service firm epam system epam rise firm week move average first time recent flat base earning be due close
1089,MRK,twitter twtr lose ground ahead earning report close share lose hasn make much progress base quarterly profit be see rise cent share
1090,MRK,other top rate name set report close include acadium healthcare achc logmein logm solarwind swi smart final sfs
1091,MRK,day federal reserve meeting conclude wednesday policy statement be release et tuesday session didn start so hot couple negative headline rattle wall street nasdaq fall early report iran seize cargo vessel weaker expect read consumer confidence didn help matter little more hour left session stock be mixed session high dow jone industrial average rise add nasdaq be mostly unchanged nasdaq volume be tracking slightly lower monday nyse volume rise bit dow be buoy merck mrk report strong earning open share rise stock market today apple aapl have hard time attract buyer company report better expect earning late monday share fall heavy turnover elsewhere tech service firm epam system epam rise firm week move average first time recent flat base earning be due close twitter twtr lose ground ahead earning report close share lose hasn make much progress base quarterly profit be see rise cent share other top rate name set report close include acadium healthcare achc logmein logm solarwind swi smart final sfs day federal reserve meeting conclude wednesday policy statement be release et
1092,MRK,major average end mixed volatile session tuesday
1093,MRK,dow jone industrial average gain add nasdaq ease preliminary datum show nasdaq volume come lower monday nyse volume rise bit
1094,MRK,stock turn sharply lower half hour session nasdaq fall report cargo vessel be seize iran seize ship turn be marshall island flag vessel weaker expect read consumer confidence didn help matter
1095,MRK,ibd mining gold silver gem group be day top performer rise food steel stock also outperformed
1096,MRK,dow be buoy merck mrk report strong earning open share rise
1097,MRK,stock market today twitter twtr crater earning report be leak close company confirm earning cent share expectation sale come well thomson reuter consensus estimate twitter also lower revenue outlook current quarter
1098,MRK,elsewhere egg producer cal maine food calm surge be news account move
1099,MRK,tech service firm epam system epam rise firm week move average first time recent flat base earning be due close
1100,MRK,other top rate name set report close include acadium healthcare achc logmein logm solarwind swi smart final sfs
1101,MRK,day fed meeting conclude wednesday policy statement be release et major average end mixed volatile session tuesday dow jone industrial average gain add nasdaq ease preliminary datum show nasdaq volume come lower monday nyse volume rise bit stock turn sharply lower half hour session nasdaq fall report cargo vessel be seize iran seize ship turn be marshall island flag vessel weaker expect read consumer confidence didn help matter ibd mining gold silver gem group be day top performer rise food steel stock also outperformed dow be buoy merck mrk report strong earning open share rise stock market today twitter twtr crater earning report be leak close company confirm earning cent share expectation sale come well thomson reuter consensus estimate twitter also lower revenue outlook current quarter elsewhere egg producer cal maine food calm surge be news account move tech service firm epam system epam rise firm week move average first time recent flat base earning be due close other top rate name set report close include acadium healthcare achc logmein logm solarwind swi smart final sfs day fed meeting conclude wednesday policy statement be release et
1102,MRK,share merck mrk rise hour trading company announce trial result show best selling diabetes treatment januvia doesn increase risk stroke other heart issue diabetes patient adult type diabetes history heart disease study find drug didn change composite time
1103,MRK,big pharma merck stock jump tuesday company first quarter earning beat estimate bolster good news diabetes franchise same time big biotech ibd stock unite therapeutic fall quarter miss view merck mrk report earning cent share year earlier quarter cent better
1104,MRK,stock be future mixed improve ahead tuesday open soft dollar corporate earning report stir early trade
1105,MRK,nasdaq future have double early gain be point fair market value dow future be point less half earlier loss future be point
1106,MRK,big retreat resistance monday left stock market today right back same stunt pattern have defined trade december nasdaq be set open just just recent level resistance currently be marked index march high
1107,MRK,market remain confirm uptrend fresh distribution continue trend mixed signal big earning report be likely be drive factor today market investor look tomorrow policy announcement federal reserve
1108,MRK,stock bp bp ford bristol myer bmy be big name premarket motion report quarter result
1109,MRK,apple aapl stretched more higher premarket action wizard cupertino rumble past analyst fiscal second quarter expectation result drive iphone sale stock wrapped monday session just buy point week flat base
1110,MRK,vasco datum security vdsi spiked premarket action report result illinois base security software firm say adjust earning be cent share vs expectation cent revenue surge also well consensus view stock end monday buy point cup handle base
1111,MRK,drug giant merck mrk jump earning slip rather dive expect analyst revenue fall also less project stock have be shallow consolidation january
1112,MRK,currency dollar be euro yen most commodity also moved lower exception cocoa jump case shiller city composite home price index april be due et conference board be line report april consumer confidence number stock be future mixed improve ahead tuesday open soft dollar corporate earning report stir early trade nasdaq future have double early gain be point fair market value dow future be point less half earlier loss future be point big retreat resistance monday left stock market today right back same stunt pattern have defined trade december nasdaq be set open just just recent level resistance currently be marked index march high market remain confirm uptrend fresh distribution continue trend mixed signal big earning report be likely be drive factor today market investor look tomorrow policy announcement federal reserve stock bp bp ford bristol myer bmy be big name premarket motion report quarter result apple aapl stretched more higher premarket action wizard cupertino rumble past analyst fiscal second quarter expectation result drive iphone sale stock wrapped monday session just buy point week flat base vasco datum security vdsi spiked premarket action report result illinois base security software firm say adjust earning be cent share vs expectation cent revenue surge also well consensus view stock end monday buy point cup handle base drug giant merck mrk jump earning slip rather dive expect analyst revenue fall also less project stock have be shallow consolidation january currency dollar be euro yen most commodity also moved lower exception cocoa jump case shiller city composite home price index april be due et conference board be line report april consumer confidence number
1113,MRK,biggest drugmaker world be report earning week quarters be expect be dampen patent loss foreign exchange headwind have potential growth story work
1114,MRK,tuesday trio big pharmas be due report pfizer pfe be expect report drop year earlier earning cent share accord thomson reuter poll analyst sale be see fall
1115,MRK,side subscription datum recently approve breast cancer drug ibrance be point strong launch tuesday bring first official report drug sale february launch company be also expect give update outlook still progress acquisition hospira hsp
1116,MRK,wall street be also hope more visibility part financial structure pfizer create be widely see prelude split
1117,MRK,pfe be expect provide further balance sheet disclosure business leerink analyst seamus fernandez write preview note sunday expect add discussion target stand alone value innovative establish product business
1118,MRK,such speculation have help drive pfizer stock touch year high april afternoon trading stock market today pfizer stock be
1119,MRK,bristol myer opdivo focus
1120,MRK,also report early tuesday be bristol myer squibb bmy be expect return profit growth analyst expect earning rise cent share revenue be expect decline fraction
1121,MRK,evercore isi analyst mark schoenebaum write preview note monday investor be focuse development pd inhibitor opdivo triumph lung cancer trial last week actual quarterly report be go be complicate add
1122,MRK,be few more move part number other quarters include launch opdivo hcv hepatitis virus franchise potential lumpiness yervoy sale due approval bmy opdivo merck mrk keytruda melanoma step sale mature product other core asset year expiry portion otsuka agreement late april high gross margin product abilify bms report first abilify net sale higher royalty astrazeneca azn due structure payment divestiture diabetes business feb write
1123,MRK,bristol myer stock also have be do well lately ibd relative strength rating have be slide past week monday afternoon share be fraction
1124,MRK,merck fight patent cliff
1125,MRK,merck also be report tuesday morning earning be estimate be cent share sale fall nearly merck be also suffering patent cliff problem last week announce filing own pd inhibitor keytruda lung cancer schoenebaum say probably draw question conference call
1126,MRK,schoenebaum write investor also be listen detail merck hepatitis program yielded more positive study international liver congress late last week
1127,MRK,merck stock hasn be do well lately rs rating just be fraction afternoon trading monday
1128,MRK,teva drama continue
1129,MRK,thursday open israeli generic specialty drug giant teva pharmaceutical industry teva be expect report earning growth share sale fall
1130,MRK,teva share be normally rather staid have be middle lot drama lately first generic competition blockbuster drug copaxone arrive earlier expect then bid mylan myl not unrelated development
1131,MRK,monday mylan reject teva bid rather harsh term thorough consideration mylan board unanimously determine teva proposal grossly undervalue mylan require mylan shareholder believe be low quality teva share exchange high quality mylan share transaction lack industrial logic carry significant global antitrust risk say mylan ceo robert coury statement
1132,MRK,addition also believe proposal do not address serious challenge integrate fundamentally different conflict culture teva board leadership team poor record deliver sustainable shareholder value say
1133,MRK,market be not pleased afternoon trading monday teva stock be mylan stock be nearly
1134,MRK,follow amy reeve twitter ibd_areeve biggest drugmaker world be report earning week quarters be expect be dampen patent loss foreign exchange headwind have potential growth story work tuesday trio big pharmas be due report pfizer pfe be expect report drop year earlier earning cent share accord thomson reuter poll analyst sale be see fall side subscription datum recently approve breast cancer drug ibrance be point strong launch tuesday bring first official report drug sale february launch company be also expect give update outlook still progress acquisition hospira hsp wall street be also hope more visibility part financial structure pfizer create be widely see prelude split pfe be expect provide further balance sheet disclosure business leerink analyst seamus fernandez write preview note sunday expect add discussion target stand alone value innovative establish product business such speculation have help drive pfizer stock touch year high april afternoon trading stock market today pfizer stock be bristol myer opdivo focusalso report early tuesday be bristol myer squibb bmy be expect return profit growth analyst expect earning rise cent share revenue be expect decline fraction evercore isi analyst mark schoenebaum write preview note monday investor be focuse development pd inhibitor opdivo triumph lung cancer trial last week actual quarterly report be go be complicate add be few more move part number other quarters include launch opdivo hcv hepatitis virus franchise potential lumpiness yervoy sale due approval bmy opdivo merck mrk keytruda melanoma step sale mature product other core asset year expiry portion otsuka agreement late april high gross margin product abilify bms report first abilify net sale higher royalty astrazeneca azn due structure payment divestiture diabetes business feb write bristol myer stock also have be do well lately ibd relative strength rating have be slide past week monday afternoon share be fraction merck fight patent cliffmerck also be report tuesday morning earning be estimate be cent share sale fall nearly merck be also suffering patent cliff problem last week announce filing own pd inhibitor keytruda lung cancer schoenebaum say probably draw question conference call schoenebaum write investor also be listen detail merck hepatitis program yielded more positive study international liver congress late last week merck stock hasn be do well lately rs rating just be fraction afternoon trading monday teva drama continueson thursday open israeli generic specialty drug giant teva pharmaceutical industry teva be expect report earning growth share sale fall teva share be normally rather staid have be middle lot drama lately first generic competition blockbuster drug copaxone arrive earlier expect then bid mylan myl not unrelated development monday mylan reject teva bid rather harsh term thorough consideration mylan board unanimously determine teva proposal grossly undervalue mylan require mylan shareholder believe be low quality teva share exchange high quality mylan share transaction lack industrial logic carry significant global antitrust risk say mylan ceo robert coury statement addition also believe proposal do not address serious challenge integrate fundamentally different conflict culture teva board leadership team poor record deliver sustainable shareholder value say market be not pleased afternoon trading monday teva stock be mylan stock be nearly follow amy reeve twitter ibd_areeve
1135,MRK,big pharma bristol myer squibb bmy cancer drug opdivo continue shine friday company halter clinical trial early have already hit endpoint phase trial call checkpoint compare opdivo advanced squamous small cell lung cancer standard treatment docetaxel better know sanofi sny taxotere study find significant improvement overall
1136,MRK,big pharma bristol myer squibb bmy cancer drug opdivo continue shine friday company halter clinical trial early have already hit endpoint phase trial call checkpoint compare opdivo advanced squamous small cell lung cancer standard treatment docetaxel better know sanofi sny taxotere study find significant improvement overall
1137,MRK,stock close new high again friday nasdaq have break yr slog eye be focuse technology have not be disappoint latest mix be microsoft msft trade amazon amzn post strong earning report add more fuel
1138,MRK,share early stage development biotech ligand pharmaceutical lgnd rise disclose receive higher royalty rate drug license partner vike therapeutic friday re file term ipo compound cover amend licensing agreement be meant treat hip fracture anemia metabolic lipid disorder agreement also amend term upfront payment ligand vike stock vike be complete ipo base vike valuation just prior ipo cap ownership re file ipo offer friday vike plan offer share raise previous plan last year share ligand have indicated earlier filing year have right terminate license agreement april vike have neither complete ipo receive aggregate net proceed least more private financing interview ibd march ligand president matt foehr say vike pending ipo happen mean continue progress group pipeline asset ligand have dozen partner more drug program partner range big pharma company such merck mrk pfizer pfe small startup vike be founder plan list nasdaq symbol vktx aside slash valuation vike have refocuse drug development strategy replace lead underwriter say comment renaissance capital ipohome com note laidlaw co replace roth capital feltl co be co manager
1139,MRK,update tuesday fda advisory panel vote onglyza have acceptable risk profile say label be update heart failure risk astrazeneca stock be more afternoon trading tuesday new fda document release friday say patient popular astrazeneca azn diabetes drug onglyza show increase risk
1140,MRK,big pharma merck release late stage datum wednesday hepatitis regime meet wall street expectation also disclose fda have award breakthrough therapy designation certain patient group merck mrk study be newly release abstract presentation annual meeting european association study liver easl vienna
1141,MRK,late last month obama administration rolled point plan combat drug resistant bacterium say cause infection death alone year
1142,MRK,report describe plan issue response president obama executive order last september note way antibiotic haven be get much love private business
1143,MRK,urgent need new antibiotic number product drug development pipeline be small commercial interest remain limit accord report plan call national action plan combat antibiotic resistant bacterium advancement drug development well traditional therapeutic vaccine require intensified effort boost scientific research attract private investment facilitate clinical trial new drug candidate
1144,MRK,person industry say largely be true last decade even word be be written thing be change increasingly antibiotic development be attract big money
1145,MRK,january merck mrk close deal acquire cubist pharmaceutical blockbuster drug cubicin treat staphylococcus aureus mrsa virus other follow november acquisition durata therapeutic actavis act well cubist own purchase optimer
1146,MRK,tetraphase cempra jump
1147,MRK,encourage wall street see other small company make drug buyout target drive stock tetraphase pharma ttph cempra cemp be develop product specifically drug resistant strain have highest possible ibd composite rating
1148,MRK,even antibiotic maker dipexium pharmaceutical dprx foamix pharmaceutical fomx be treat less life threaten condition have be ride wave
1149,MRK,accord many industry help turn thing have be something more controversial other quarters rise drug pricing
1150,MRK,society re pretty comfortable pay year rheumatoid arthritis therapy cancer drug extend life month year re only pay novel antibiotic save life someone otherwise very healthy oppenheimer analyst feel tell ibd seem be grow consensus stakeholder be come together address
1151,MRK,white house plan support basic research improve testing monitoring exist infection doesn directly address pricing government do not have power set drug price influence reimbursement policy medicare medicaid
1152,MRK,target develop innovative strategy antimicrobial resistant microorganism act disarm act bill introduce congress last year sponsored member party disarm act require budget neutrality antimicrobial drug lift incentive prescribe cheapest drug available
1153,MRK,company sink money develop powerful new antibiotic disarm act be high wish list
1154,MRK,really see disarm act get approve form help antibiotic reimbursement really be key thing get more appropriate usage really encourage company be involved space tetraphase ceo guy macdonald tell ibd
1155,MRK,drive medical cost feel note aim new antibiotic development be get patient hospital faster compete drug help mitigate cost
1156,MRK,iv treatment develop
1157,MRK,tetraphase cempra be develop drug come iv oral formulation idea patient be initially treat iv hospital then send home oral drug once life threaten phase have pass other company be develop longer act iv drug instance last year medicine co mdco win approval orbactiv version antibiotic oritavancin treat serious skin infection single dose
1158,MRK,government already have make move streamline approval process new antibiotic durata lead product be first product approve qualify infectious disease product qidp fda clear last qidp be create previous legislative initiative encourage antibiotic gain act provide expedite review year market exclusivity new product treat serious infection subsequently new drug cubist be approve program
1159,MRK,apart government action however question surround antibiotic be commit acquirer remain research development new product merck have say next month shutter cubist discovery center lexington mass layer worker cubist division analyst feel await further sign big pharmas handle new antibiotic project
1160,MRK,key watch here be merck do say cubist be far industry leader spend lot money have lot best brightest work problem hopefully merck continue development little too soon say happen late last month obama administration rolled point plan combat drug resistant bacterium say cause infection death alone year report describe plan issue response president obama executive order last september note way antibiotic haven be get much love private business urgent need new antibiotic number product drug development pipeline be small commercial interest remain limit accord report plan call national action plan combat antibiotic resistant bacterium advancement drug development well traditional therapeutic vaccine require intensified effort boost scientific research attract private investment facilitate clinical trial new drug candidate person industry say largely be true last decade even word be be written thing be change increasingly antibiotic development be attract big money january merck mrk close deal acquire cubist pharmaceutical blockbuster drug cubicin treat staphylococcus aureus mrsa virus other follow november acquisition durata therapeutic actavis act well cubist own purchase optimer tetraphase cempra jumpedthis encourage wall street see other small company make drug buyout target drive stock tetraphase pharma ttph cempra cemp be develop product specifically drug resistant strain have highest possible ibd composite rating even antibiotic maker dipexium pharmaceutical dprx foamix pharmaceutical fomx be treat less life threaten condition have be ride wave accord many industry help turn thing have be something more controversial other quarters rise drug pricing society re pretty comfortable pay year rheumatoid arthritis therapy cancer drug extend life month year re only pay novel antibiotic save life someone otherwise very healthy oppenheimer analyst feel tell ibd seem be grow consensus stakeholder be come together address white house plan support basic research improve testing monitoring exist infection doesn directly address pricing government do not have power set drug price influence reimbursement policy medicare medicaid target develop innovative strategy antimicrobial resistant microorganism act disarm act bill introduce congress last year sponsored member party disarm act require budget neutrality antimicrobial drug lift incentive prescribe cheapest drug available company sink money develop powerful new antibiotic disarm act be high wish list really see disarm act get approve form help antibiotic reimbursement really be key thing get more appropriate usage really encourage company be involved space tetraphase ceo guy macdonald tell ibd drive medical cost feel note aim new antibiotic development be get patient hospital faster compete drug help mitigate cost iv treatment cempra be develop drug come iv oral formulation idea patient be initially treat iv hospital then send home oral drug once life threaten phase have pass other company be develop longer act iv drug instance last year medicine co mdco win approval orbactiv version antibiotic oritavancin treat serious skin infection single dose government already have make move streamline approval process new antibiotic durata lead product be first product approve qualify infectious disease product qidp fda clear last qidp be create previous legislative initiative encourage antibiotic gain act provide expedite review year market exclusivity new product treat serious infection subsequently new drug cubist be approve program apart government action however question surround antibiotic be commit acquirer remain research development new product merck have say next month shutter cubist discovery center lexington mass layer worker cubist division analyst feel await further sign big pharmas handle new antibiotic project key watch here be merck do say cubist be far industry leader spend lot money have lot best brightest work problem hopefully merck continue development little too soon say happen
1161,MRK,regulus therapeutic rgls stock leap tuesday night astrazeneca azn take nash fatty liver disease candidate testing part microrna alliance join crowd field drugmaker develop treatment make investment get part nash form liver damage cause accumulation fat regulus say rg compound treat nonalcoholic
1162,MRK,stock open hole then dig deeper wednesday datum drive rally china europe
1163,MRK,nasdaq tumble dow jone industrial average drop show loss
1164,MRK,volume be sharply higher nasdaq higher nyse compare trade same time tuesday
1165,MRK,job news do stock market today favor adp march national employment report show job growth weakest last
1166,MRK,manufacturing datum be mixed researcher markit report march purchasing manager index rise vs february economist consensus bet mild uptick
1167,MRK,institute supply management march ism manufacturing index ease consensus view project dip
1168,MRK,construction spending fall second month be less weak february decline vs slip january economist consensus have estimate gain
1169,MRK,stock dow component open lower merck mrk nike nke johnson johnson jnj hit hardest none nasdaq stock manage gain bottom list regeneron pharmaceutical regn slip heavy trade pull back test support day move average
1170,MRK,twitter twtr rise heavy trade jeffery co initiate coverage stock buy rating price target report note stock be particularly well position benefit online video ad mobile tailwind twitter have be battle clear cup handle buy point
1171,MRK,sear shld jump assign property partnership retail reit general growth property ggp sear have post annual loss continue operate store receive cash stake partnership general growth share dip fraction have shape cup handle base late january high
1172,MRK,lead stock get weak start nearly ibd list downshifting open only noah holding noah unite therapeutic uthr post narrow gain
1173,MRK,ambarella amba take hardest early hit be more left stock bit less most recent buy point stock open hole then dig deeper wednesday datum drive rally china europe nasdaq tumble dow jone industrial average drop show loss volume be sharply higher nasdaq higher nyse compare trade same time tuesday job news do stock market today favor adp march national employment report show job growth weakest last manufacturing datum be mixed researcher markit report march purchasing manager index rise vs february economist consensus bet mild uptick institute supply management march ism manufacturing index ease consensus view project dip construction spending fall second month be less weak february decline vs slip january economist consensus have estimate gain stock dow component open lower merck mrk nike nke johnson johnson jnj hit hardest none nasdaq stock manage gain bottom list regeneron pharmaceutical regn slip heavy trade pull back test support day move average twitter twtr rise heavy trade jeffery co initiate coverage stock buy rating price target report note stock be particularly well position benefit online video ad mobile tailwind twitter have be battle clear cup handle buy point sear shld jump assign property partnership retail reit general growth property ggp sear have post annual loss continue operate store receive cash stake partnership general growth share dip fraction have shape cup handle base late january high lead stock get weak start nearly ibd list downshifting open only noah holding noah unite therapeutic uthr post narrow gain ambarella amba take hardest early hit be more left stock bit less most recent buy point
1174,MRK,share intrexon xon gap news synthetic biotech have form collaboration licensing deal firm merck kgaa darmstadt germany develop commercialize car therapy intrexon share rise afternoon trading stock market today stock have be decline march bounce day line
1175,MRK,call jack trade biotech rather just target small number drug therapy ligand pharmaceutical lgnd focus broad range asset address host disease multiple myeloma hepatitis alzheimer diabetes anemia osteoporosis many other do early stage development aim partner early say matt foehr president
1176,MRK,most stock sector leader have already break illumina ilmn be gear make move stock appear thursday sector leader begin look start new flat base striking jan high past few day action shallow double bottom be take shape illumina be
1177,MRK,new class cancer fight drug shine major medical meeting monday analyst debate just wide population eventually treat american association cancer research aacr meeting philadelphia bristol myer squibb bmy report positive midstage trial result combination new opdivo older drug yervoy treat advanced melanoma
1178,MRK,earning report start roll next month likely biggest mover biotech pharma stock be release clinical trial datum here be such report expect month street expect probably most anticipate be biogen idec biib presentation phase result alzheimer disease drug
1179,MRK,food drug administration approve bristol myer squibb bmy pd inhibitor opdivo squamous cell lung cancer wednesday well ahead expect timeline stock jump year high opdivo be first approve advanced melanoma december positive lung cancer datum january increase wall street confidence also get approve
1180,MRK,big pharma bristol myer squibb bmy say wednesday inked deal worth danish biotech bavarian nordic prostate cancer vaccine candidate prostvac step forward technology still have yet prove
1181,MRK,bristol agree pay upfront rest money dependent prostvac get phase trial fda approval process bristol say also plan phase study prostvac combine bristol yervoy drug already approve melanoma
1182,MRK,agreement bavarian nordic reflect commitment follow emerge science immuno oncology support strategy transform treatment cancer multiple tumor type line therapy stage disease michael giordano head bristol oncology development say company press release
1183,MRK,prostvac follow rather dubious footstep provenge prostate cancer vaccine make dendreon have now go bankrupt however provenge be develop individually patient drive cost manufacturing prostvac be shelf
1184,MRK,prostvac be ready use dna base vaccine have potential replace dendreon expensive autologous provenge therapy write maxim group analyst jason kolbert research note wednesday recent declare bankruptcy dendreon largely due high cost provenge open door little wider bavarian prostate cancer immunotherapy
1185,MRK,deal also give bristol further option hot highly competitive field new immuno oncology treatment
1186,MRK,bristol be just now roll new pd inhibitor opdivo already get rival merck mrk keytruda potentially face similar drug astrazeneca azn roche rhhby
1187,MRK,fda wednesday approve opdivo advanced lung cancer earlier expect opdivo already have be approve treat melanoma
1188,MRK,bavarian nordic stock doesn trade jump copenhagen stock exchange wednesday
1189,MRK,bristol myer stock fall initially rally close hit fresh year high stock market today follow fda opdivo decision
1190,MRK,follow amy reeve twitter ibd_areeve big pharma bristol myer squibb bmy say wednesday inked deal worth danish biotech bavarian nordic prostate cancer vaccine candidate prostvac step forward technology still have yet prove bristol agree pay upfront rest money dependent prostvac get phase trial fda approval process bristol say also plan phase study prostvac combine bristol yervoy drug already approve melanoma agreement bavarian nordic reflect commitment follow emerge science immuno oncology support strategy transform treatment cancer multiple tumor type line therapy stage disease michael giordano head bristol oncology development say company press release prostvac follow rather dubious footstep provenge prostate cancer vaccine make dendreon have now go bankrupt however provenge be develop individually patient drive cost manufacturing prostvac be shelf prostvac be ready use dna base vaccine have potential replace dendreon expensive autologous provenge therapy write maxim group analyst jason kolbert research note wednesday recent declare bankruptcy dendreon largely due high cost provenge open door little wider bavarian prostate cancer immunotherapy deal also give bristol further option hot highly competitive field new immuno oncology treatment bristol be just now roll new pd inhibitor opdivo already get rival merck mrk keytruda potentially face similar drug astrazeneca azn roche rhhby fda wednesday approve opdivo advanced lung cancer earlier expect opdivo already have be approve treat melanoma bavarian nordic stock doesn trade jump copenhagen stock exchange wednesday bristol myer stock fall initially rally close hit fresh year high stock market today follow fda opdivo decision follow amy reeve twitter ibd_areeve
1191,MRK,lesson draw recent pharma space superbug drug be hot last year actavis act plunk durata therapeutic drug fight nastiest specimen class know gram positive bacterium merck mrk be midst buyout cubist pharmaceutical last year get new drug gram positive gram negative bacterium have develop resistance other drug activity help buoy buyout prospect stock price tetraphase pharmaceutical ttph especially announce december lead candidate eravacycline score phase trial complicate intra abdominal infection recently tetraphase ceo guy macdonald speak ibd challenge fight drug resistant bug big gun be so interested now ibd explain strategy create drug drug resistant bacterium stop bacterium mutate resist drug macdonald think reality world be point bacterium develop resistance antibiotic have higher barrier resistance be have potent compound make sure patient take properly quinolone synthetic antibacterial drug be good example be first introduce mid see misuse switch iv oral be be used community see resistance develop year now anywhere carbapenem ve be used primarily hospital set re-serve serious infection ve only recently see resistance develop last year carbapenem be broad spectrum antibiotic re see outcry now develop new drug multidrug resistant gram negative carbapenem really aren choice eravacycline re develop expect be easily year start see resistance develop do think ve get much better now stewardship hospital not used antibiotic cattle feed try educate person take full course antibiotic good behavior help prolong antibiotic use ibd understand differentiate field be manufacturing process explain differentiate product macdonald think main point differentiation be twofold be spectrum coverage then also fact have oral step injectable formulation spectrum coverage mean look cdc hit list cover top really nasty bug person be look new product manufacturing chemistry allow do be be able develop compound historically tetracycline be develop semi synthesis be fermentation small amount chemistry bit make beer be really limit change make core chemistry fully synthetic process come harvard allow basically make change anywhere want so be better able design molecule have spectrum eravacycline have ibd elaborate spectrum differentiate macdonald nowadays re probably very familiar mrsa be gram positive bug hard treat staph infection be real problem think industry respond very well mostly find complicate skin infection have drug approve last year work skin infection mrsa other side ve get gram negative bug nastiest character be klebsiella coli normal one be fairly difficult treat become resistant carbapenem re much much harder treat so development ve try focus make sure eravacycline have coverage really tough bug just holiday publish study do new york isolate really multidrug resistant klebsiella have really good efficacy study look new compound merck cubist actavis astrazeneca azn re good compound don have strength efficacy resistant klebsiella eravacycline have don have ability step tablet so get person hospital quicker ibd few year seem big pharmas have backed space do think so much interest now macdonald think certainly go back year regulatory environment antibiotic space be terrible guideline keep change compound be not get approve think ve see last year change first introduction gain act allow compound apply special designation fast track give additional patent life think fda have really become very supportive guideline be much more helpful last year see drug get approve fast track process ve also see significant funding government state union address see president announce try increase funding program then lastly be bill introduce house last week call disarm be design try improve reimbursement antibiotic sort free ability prescribe higher price antibiotic be penalize also be very helpful line ve see company cubist be very successful selling cubicin think life primary care big pharma have get tougher so company be much more focuse hospital specialty business merck be good example roche rhhby have be very active bayer bayry have do deal so compare year ve get lot more interest big pharma well be medium tier company medicine co mdco actavis other
1192,MRK,big pharma merck mrk agree buy antibiotic specialist cubist pharmaceutical cbst monday deal value cubist soar stock market today merck drop fraction
1193,MRK,merck be acquire cubist share cash yielding equity value net debt merck say buyout add more annually revenue base be currently expect have impact earning be accretive
1194,MRK,cubist founder score first blockbuster drug launch cubicin powerful antibiotic used treat staphylococcus aureus severe skin infection end cubicin patent loom company announce ambitious plan launch product expect double revenue turn profit growth negative year however june launch sivextro skin infection drug growth return be expect ramp next year
1195,MRK,rumor merck cubist be talk first break friday leave analyst weekend ponder implication note sunday rbc capital market analyst adnan butt note second new drug zerbaxa be expect be approve dec bring peak annual sale also note way company fit together
1196,MRK,mrk other large biopharma company participate infectious disease arena include actavis act astella pfizer pfe sanofi sny butt write mrk have specifically report focus acute care hospital channel particularly antibiotic resistant bacterium
1197,MRK,press release monday underline merck commitment area
1198,MRK,hospital be central hub health care delivery world currently represent overall health care spend say merck believe now be optimal time significantly grow hospital acute care presence positive regulatory reimbursement trend hospital set increasingly important role hospital be expect provide health care overall
1199,MRK,follow amy reeve twitter ibd_areeve big pharma merck mrk agree buy antibiotic specialist cubist pharmaceutical cbst monday deal value cubist soar stock market today merck drop fraction merck be acquire cubist share cash yielding equity value net debt merck say buyout add more annually revenue base be currently expect have impact earning be accretive cubist founder score first blockbuster drug launch cubicin powerful antibiotic used treat staphylococcus aureus severe skin infection end cubicin patent loom company announce ambitious plan launch product expect double revenue turn profit growth negative year however june launch sivextro skin infection drug growth return be expect ramp next year rumor merck cubist be talk first break friday leave analyst weekend ponder implication note sunday rbc capital market analyst adnan butt note second new drug zerbaxa be expect be approve dec bring peak annual sale also note way company fit together mrk other large biopharma company participate infectious disease arena include actavis act astella pfizer pfe sanofi sny butt write mrk have specifically report focus acute care hospital channel particularly antibiotic resistant bacterium press release monday underline merck commitment area hospital be central hub health care delivery world currently represent overall health care spend say merck believe now be optimal time significantly grow hospital acute care presence positive regulatory reimbursement trend hospital set increasingly important role hospital be expect provide health care overall follow amy reeve twitter ibd_areeve
1200,MRK,big pharma merck affirm tuesday go ahead acquisition biotech cubist pharmaceutical even cubist lead drug look face generic competition sooner expect merck mrk stock be morning trading stock market today cubist pharmaceutical cbst stock be more merck announce cubist acquisition
1201,MRK,stock be session lows early afternoon trading oil price fall hard again
1202,MRK,nasdaq lose fall dow jone industrial average give also
1203,MRK,nasdaq nyse volume be tracking slightly higher friday level crude oil sell again fall barrel
1204,MRK,stock market today dow component mcdonald mcd fall nearly soft november global same store sale burger giant sale fall more expect domestic sale slump
1205,MRK,ibd biotech industry group be once again day top performer rise nearly top rate name group celgene celg regeneron regn gilead science gild unite therapeutic uthr be do well
1206,MRK,meanwhile cubist pharmaceutical cbst soar news be acquire merck mrk
1207,MRK,gopro gpro slump be clear news account downdraft stock have be act weak not abnormal action big run past ipo base buy point ambarella amba chip be find gopro wearable camera also give heel strong earning report last week
1208,MRK,meanwhile couple high profile ipos be set week lendingclub alibaba backed momo debut thursday symbol lc momo respectively stock be session lows early afternoon trading oil price fall hard again nasdaq lose fall dow jone industrial average give also nasdaq nyse volume be tracking slightly higher friday level crude oil sell again fall barrel stock market today dow component mcdonald mcd fall nearly soft november global same store sale burger giant sale fall more expect domestic sale slump ibd biotech industry group be once again day top performer rise nearly top rate name group celgene celg regeneron regn gilead science gild unite therapeutic uthr be do well meanwhile cubist pharmaceutical cbst soar news be acquire merck mrk gopro gpro slump be clear news account downdraft stock have be act weak not abnormal action big run past ipo base buy point ambarella amba chip be find gopro wearable camera also give heel strong earning report last week meanwhile couple high profile ipos be set week lendingclub alibaba backed momo debut thursday symbol lc momo respectively
1209,MRK,merck mrk cholesterol drug vytorin ezetimibe simvastatin combo successfully cut risk heart attack stroke high risk patient more simvastatin alone say drugmaker nearly decade long patient study improve patient take ldl cholesterol lower medicine vytorin combine simvastatin nonstatin zetia ezetimibe experience significantly fewer major cardiovascular event measure
1210,MRK,french big pharma sanofi layer year plan drug launch say bring cumulative euro first year sale sanofi stock slip early trading stock market today diabetes outlook be soft
1211,MRK,sanofi sny issue update press release ahead ir thematic seminar new medicine seek reassure investor fire ceo follow weak quarterly report last month
1212,MRK,firm prepared presentation new drug include alirocumab cholesterol fighter co develop regeneron pharmaceutical regn now go brand name praluent recently approve multiple sclerosis pill lemtrada toujeo currently fda eu review update version bestselling sanofi diabetes drug lantus
1213,MRK,related note thursday fda also grant breakthrough therapy designation dupilumab drug develop same regeneron partnership alirocumab treatment atopic dermatitis
1214,MRK,leerink analyst seamus fernandez write note early thursday pipeline valuation be nearly twice own estimate still concern diabetes franchise be main issue sanofi report
1215,MRK,headline grab estimate product launch guidance sny global diabetes business be flat slightly grow constant exchange rate assume substantial conversion patient lantus toujeo europe be assume diabetes sale growth same period write
1216,MRK,fernandez add wasn sell widespread toujeo conversion especially light more competitive landscape similar product come online nordisk nvo eli lilly lly
1217,MRK,positive side write approval praluent be virtually assured merck mrk recent long term study prove lower ldl cholesterol really do lower death rate heart disease
1218,MRK,follow amy reeve twitter ibd_areeve french big pharma sanofi layer year plan drug launch say bring cumulative euro first year sale sanofi stock slip early trading stock market today diabetes outlook be soft sanofi sny issue update press release ahead ir thematic seminar new medicine seek reassure investor fire ceo follow weak quarterly report last month firm prepared presentation new drug include alirocumab cholesterol fighter co develop regeneron pharmaceutical regn now go brand name praluent recently approve multiple sclerosis pill lemtrada toujeo currently fda eu review update version bestselling sanofi diabetes drug lantus related note thursday fda also grant breakthrough therapy designation dupilumab drug develop same regeneron partnership alirocumab treatment atopic dermatitis leerink analyst seamus fernandez write note early thursday pipeline valuation be nearly twice own estimate still concern diabetes franchise be main issue sanofi report headline grab estimate product launch guidance sny global diabetes business be flat slightly grow constant exchange rate assume substantial conversion patient lantus toujeo europe be assume diabetes sale growth same period write fernandez add wasn sell widespread toujeo conversion especially light more competitive landscape similar product come online nordisk nvo eli lilly lly positive side write approval praluent be virtually assured merck mrk recent long term study prove lower ldl cholesterol really do lower death rate heart disease follow amy reeve twitter ibd_areeve
1219,MRK,big pharma bristol myer squibb bmy report good midstage trial result drug candidate opdivo advanced squamous cell lung cancer send stock nearly year high early trading stock market today company release abstract summarize friday presentation chicago symposium thoracic oncology describe result checkmate trial patient trial be especially sick illness have advanced least previous treatment year treatment be still alive median survival rate month particular study do not have comparator arm bristol say historically expect year survival rate person disease state be survival datum believe be most important endpoint consider datum today look very very good isi group analyst mark schoenebaum write email client buy side survey have consensus year overall survival checkmate have say webinar prep earlier week be excellent datum leerink analyst seamus fernandez have similar expectation several study rd line nonsmall cell lung cancer show year survival year datum year benchmark survival more heavily pre treat group be encourage write note thursday again view great datum schoenebaum say result bode well trial checkmate compare opdivo standard treatment docetaxel patient slightly less advanced squamous cell lung cancer add support bristol fda filing be roll submission process expect be complete december opdivo be approve melanoma japan july make first new class immunotherapy drug call pd hit market merck mrk pd keytruda be fda review melanoma monday win breakthrough therapy designation lung cancer follow amy reeve twitter ibd_areeve related gilead sale miss ahead hcv drug launch
1220,MRK,here be share biotech gilead science gild other highly rate stock be rally heavy volume today gilead begin run premarket trading drug giant merck mrk say sunday not move forward development drug combination aim shortening treatment time hepatitis cite disappointing clinical datum treatment have used gilead sovaldi also compete current longer term regimen base sovaldi gilead stock top ibd leaderboard list best perform stock be average volume monday afternoon trading stock market today gilead share have rise further merck pare loss decline general acute care hospital operator hca holding hca rebound friday selloff come supreme court say hear case challenge legality obamacare premium subsidy state share hospital sell heavily friday fear lose patient pay court strike subsidy hca sank nearly friday be monday afternoon community health system cyh operate hospital fall friday be nearly ambarella amba stock climb intraday monday chipmaker supply chip camera maker include popular sport enthusiast body camera maker gopro gpro gopro share fall say sell worth share raise fund dilute stock price monday gopro body camera rival taser international tasr digital ally dgly have see strong sale wake ferguson shooting august lead surge order polouse department officer camera systemsyy yy climb ahead third quarter earning release tuesday market close chinese social network let user connect voice text video real time play game interact world largest consumer market consensus analyst poll thomson reuter be yy report rise earning share cent hike revenue homebuilder lennar len be hit fresh year high homebuilder group have be range bound early spring monday be trading top range lennar also get boost tuesday toll bro tol preannouncement rise revenue average price home deliver rise year year toll bro announce full earning dec be toll share rise nearly meanwhile builder horton dhi rise more horton be slate release fiscal earning result tuesday market open wall street expect increase ep cent rise revenue follow james detar twitter ibd_jdetar
1221,MRK,thin gain quickly fizzle light loss tuesday veteran day trading get underway
1222,MRK,nasdaq dip dow jone industrial average dim fraction
1223,MRK,holiday trade be quiet expect stock market today more nyse nasdaq compare action same time monday
1224,MRK,merck mrk lead dow advance humana hum top gain
1225,MRK,vodafone group vod jump lead nasdaq base wireless service provider narrowly top expectation earning first half fiscal year revenue meet forecast aid surge service revenue india
1226,MRK,majority ibd stock open positive foot gain be mild lead amtrust financial service afsi advance worker compensation specialty insurer be slog away oct high cup base buy point
1227,MRK,bottom ibd heap satellite cable equipment maker arris group arrs slump steep week advance have left stock just week move average form possible first stage base
1228,MRK,small group company schedule report today close include fossil fosl home inn hotel management hmin parsley energy pe yy yy thin gain quickly fizzle light loss tuesday veteran day trading get underway nasdaq dip dow jone industrial average dim fraction holiday trade be quiet expect stock market today more nyse nasdaq compare action same time monday merck mrk lead dow advance humana hum top gain vodafone group vod jump lead nasdaq base wireless service provider narrowly top expectation earning first half fiscal year revenue meet forecast aid surge service revenue india majority ibd stock open positive foot gain be mild lead amtrust financial service afsi advance worker compensation specialty insurer be slog away oct high cup base buy point bottom ibd heap satellite cable equipment maker arris group arrs slump steep week advance have left stock just week move average form possible first stage base small group company schedule report today close include fossil fosl home inn hotel management hmin parsley energy pe yy yy
1229,MRK,stock future shift thin early loss mixed trade ahead monday open
1230,MRK,nasdaq future shed loss be narrow point dow future remain point fair market value future be flat
1231,MRK,stock market today get relatively quiet start week heavy economic report pending only moderate load quarterly company report
1232,MRK,food related stock show early motion dean food df jump white wave wwav report third quarter result
1233,MRK,gilead science gild flex ahead open drug giant merck mrk announce sunday not move forward develop drug combination attempt shorten treatment period hepatitis combine treatment used gilead sovaldi also compete exist longer treatment regimen base sovaldi gilead end friday session buy point
1234,MRK,cheetah mobile cmcm spiked premarket trade china base developer mobile security software report earning just revenue well analyst consensus expectation mobile user installation increase more quarter stock end friday september peak ipo price
1235,MRK,gogo gogo flight internet provider commercial airline drop premarket action third quarter revenue best analyst consensus view earning come short illinois base stock be deep month consolidation
1236,MRK,overseas shanghai composite pop news link schedule become active nov hong kong shanghai stock market allow increase day trading outside investor shanghai exchange hong kong hang seng rise tokyo nikkei dip
1237,MRK,europe market show modest gain midday
1238,MRK,dollar dip vs euro yen oil firm barrel natural gas rise cold weather seize northern tier stock future shift thin early loss mixed trade ahead monday open nasdaq future shed loss be narrow point dow future remain point fair market value future be flat stock market today get relatively quiet start week heavy economic report pending only moderate load quarterly company report food related stock show early motion dean food df jump white wave wwav report third quarter result gilead science gild flex ahead open drug giant merck mrk announce sunday not move forward develop drug combination attempt shorten treatment period hepatitis combine treatment used gilead sovaldi also compete exist longer treatment regimen base sovaldi gilead end friday session buy point cheetah mobile cmcm spiked premarket trade china base developer mobile security software report earning just revenue well analyst consensus expectation mobile user installation increase more quarter stock end friday september peak ipo price gogo gogo flight internet provider commercial airline drop premarket action third quarter revenue best analyst consensus view earning come short illinois base stock be deep month consolidation overseas shanghai composite pop news link schedule become active nov hong kong shanghai stock market allow increase day trading outside investor shanghai exchange hong kong hang seng rise tokyo nikkei dip europe market show modest gain midday dollar dip vs euro yen oil firm barrel natural gas rise cold weather seize northern tier
1239,MRK,big pharma merck mrk be nearly stock market today latest datum hepatitis pipeline underwhelm street sunday annual conference american association study liver disease merck report much anticipate interim datum swift trial analyst thought challenge market leader gilead
1240,MRK,stock sanofi fall tuesday french drugmaker warn sale diabetes product face more challenge environment due mount competition
1241,MRK,warning come tension top company monday sanofi sny ceo chris ask do not receive confirmation support chairman serge weinberg board reuter report accord report director say do not communicate well enough action have anger french labor union
1242,MRK,sanofi stock be more month low afternoon trading stock market today
1243,MRK,diabetes business account sanofi revenue say sanofi cut price diabetes drug last quarter get drug benefit manager reimbursement list face competition denmark nordisk nvo accord report thestreet
1244,MRK,threat price war stock be afternoon trading tuesday merck mrk eli lilly lly maker diabetes drug be respectively
1245,MRK,merck report third quarter earning open monday revenue fall miss consensus estimate poll thomson reuter earning share item cent beat view cent
1246,MRK,sanofi third quarter report revenue euro report net income euro sale diabetes drug rise
1247,MRK,have recently see more challenge diabetes price environment impact diabetes sale growth platform globally be expect continue show solid growth say company earning release
1248,MRK,follow brian deagon twitter ibd_bdeagon stock sanofi fall tuesday french drugmaker warn sale diabetes product face more challenge environment due mount competition warning come tension top company monday sanofi sny ceo chris ask do not receive confirmation support chairman serge weinberg board reuter report accord report director say do not communicate well enough action have anger french labor union sanofi stock be more month low afternoon trading stock market today diabetes business account sanofi revenue say sanofi cut price diabetes drug last quarter get drug benefit manager reimbursement list face competition denmark nordisk nvo accord report thestreet threat price war stock be afternoon trading tuesday merck mrk eli lilly lly maker diabetes drug be respectively merck report third quarter earning open monday revenue fall miss consensus estimate poll thomson reuter earning share item cent beat view cent sanofi third quarter report revenue euro report net income euro sale diabetes drug rise have recently see more challenge diabetes price environment impact diabetes sale growth platform globally be expect continue show solid growth say company earning release follow brian deagon twitter ibd_bdeagon
1249,MRK,top stock leaderboard leader list report quarterly earning close tuesday facebook gilead science here breakdown analyst expect
1250,MRK,social network earning be see jump cent share item be slowdown triple digit growth report previous quarters
1251,MRK,analyst project revenue rise video ad launch late last year be expect provide meaningful growth
1252,MRK,earlier month facebook fb complete acquisition whatsapp deal value whatsapp be largest mobile messaging service worldwide global user facebook have monthly active user june
1253,MRK,facebook have ibd composite rating meaning share outperform stock market measure fundamental technical factor share have rise nearly year be flat stock market today head release result
1254,MRK,analyst project gilead science gild earn share last year be third consecutive quarter triple digit earning growth sale be estimate surge just
1255,MRK,massive year year increase sale earning be due large part hepatitis drug sovaldi launch last december harvoni gilead new improve hepatitis pill launch just month
1256,MRK,gilead share hit new high monday buy point analyst note monday rival merck mrk johnson johnson jnj seem be falter
1257,MRK,gilead stock be nearly year facebook gilead have composite rating share be also relatively flat tuesday
1258,MRK,watch video report ibd tv alissa william detail top stock leaderboard leader list report quarterly earning close tuesday facebook gilead science here breakdown analyst expect social network earning be see jump cent share item be slowdown triple digit growth report previous quarters analyst project revenue rise video ad launch late last year be expect provide meaningful growth earlier month facebook fb complete acquisition whatsapp deal value whatsapp be largest mobile messaging service worldwide global user facebook have monthly active user june facebook have ibd composite rating meaning share outperform stock market measure fundamental technical factor share have rise nearly year be flat stock market today head release result analyst project gilead science gild earn share last year be third consecutive quarter triple digit earning growth sale be estimate surge just massive year year increase sale earning be due large part hepatitis drug sovaldi launch last december harvoni gilead new improve hepatitis pill launch just month gilead share hit new high monday buy point analyst note monday rival merck mrk johnson johnson jnj seem be falter gilead stock be nearly year facebook gilead have composite rating share be also relatively flat tuesday watch video report ibd tv alissa william detail
1259,MRK,health care etfs be top performer year look most heavily trade group reveal slight difference affect performance health care select sector spdr arca xlv have broad coverage include health care equipment supply health care provider service biotechnology pharmaceutical industry fund draw holding
1260,MRK,decade charlotte stewart be carry virus be houseguest refuse leave hepatitis
1261,MRK,stewart be first diagnosed hcv believe contract much year earlier receive blood transfusion injection blood related product
1262,MRK,time virus be detected liver be already show scarring know cirrhosis appear more advanced case disease
1263,MRK,fortunately didn get much do do treatment stewart now tell ibd do round treatment sixth be harvoni
1264,MRK,harvoni be new pill just launch month gilead science gild stewart get early participate clinical trial harvoni be combination novel drug ledipasvir sofosbuvir nearly year have be sell alone brand name sovaldi
1265,MRK,high hope
1266,MRK,sovaldi launch smash previous new drug launch come december have rac nearly sale gilead third quarter report be due oct harvoni be new improve sovaldi analyst expect treat even more patient
1267,MRK,stewart previous treatment experience show just gilead be roll money right now
1268,MRK,first treatment be variation combination interferon ribavirin be standard time credit treatment slow liver damage didn get rid hcv do make feel sick
1269,MRK,fact third treatment round involved daily injection interferon drive blood cell count so low nearly land hospital
1270,MRK,be very difficult go treatment say always develop anemia fever chill energy
1271,MRK,contrast be harvoni trial take pill day week suffer side effect week viral load be undetectable still be more year later
1272,MRK,physically have more energy just overall better health stewart say mentally emotionally have huge weight take
1273,MRK,more patient trial respond way yet gilead stock fall day harvoni be approve keep fall next day
1274,MRK,way be story gilead life sovaldi launch company score high ibd metric perfect composite rating price earning multiple be more big pharma boom biotech say drug analyst just hint bad news seem trigger sell
1275,MRK,biggest cause concern have be price sovaldi price pill add week course come fire advocacy group insurer pharmacy benefit manager even member congress however nobody really do anything so long sovaldi be so clearly superior everything else market
1276,MRK,gilead price harvoni basically parity sovaldi most patient still have take interferon ribavirin sovaldi drug be generic therefore cheaper gilead marked harvoni sovaldi cover cost absent drug
1277,MRK,however harvoni official label allow week treatment be consider patient cirrhosis haven be treat gilead estimate patient be eligible
1278,MRK,give fbr analyst andrew beren estimate average cost harvoni treatment be
1279,MRK,however also point cirrhotic patient previous treatment have fail patient charlotte stewart be recommend take harvoni week also say patient sovaldi treatment have fail represent underrate opportunity
1280,MRK,used hcv patient flow model calculate total patient need re treatment sovaldi viable patent life alone beren write oct note raise estimate harvoni sale
1281,MRK,longer term threat gilead pricing power be competition next few month bring lot more clarity competition look
1282,MRK,first real peer harvoni be expect be abbvie abbv regimen fda be due make approval decision dec
1283,MRK,clinical trial regimen have be comparable harvoni safety effectiveness do involve different drug make easier patient mess
1284,MRK,discount price
1285,MRK,abbvie management have be tight lip price drug leave wall street speculate much be willing undercut harvoni
1286,MRK,isi group analyst mark schoenebaum expect probably price comparably perhaps offer rebate certain customer estimate chance abbvie price significant discount
1287,MRK,happen second weekend november be precise merck mrk report mid stage trial datum own hcv program potentially cut treatment time week
1288,MRK,wouldn launch few more year drug industry tend think long time frame gilead acquire sofosbuvir buyout pharmasset nov be already think fact legacy hiv franchise such blockbuster viread truvada atripla start go patent
1289,MRK,hcv franchise be fill space now gilead hasn exactly give hiv gilead report positive late stage trial result drug analyst have dub son viread similar compound fewer side effect
1290,MRK,long term future hold gilead term success be expect roll analyst poll thomson reuter expect gilead report earning share prior year sale be see more double just less decade charlotte stewart be carry virus be houseguest refuse leave hepatitis stewart be first diagnosed hcv believe contract much year earlier receive blood transfusion injection blood related product time virus be detected liver be already show scarring know cirrhosis appear more advanced case disease fortunately didn get much do do treatment stewart now tell ibd do round treatment sixth be harvoni harvoni be new pill just launch month gilead science gild stewart get early participate clinical trial harvoni be combination novel drug ledipasvir sofosbuvir nearly year have be sell alone brand name sovaldi high hopessovaldi launch smash previous new drug launch come december have rac nearly sale gilead third quarter report be due oct harvoni be new improve sovaldi analyst expect treat even more patient stewart previous treatment experience show just gilead be roll money right now first treatment be variation combination interferon ribavirin be standard time credit treatment slow liver damage didn get rid hcv do make feel sick fact third treatment round involved daily injection interferon drive blood cell count so low nearly land hospital be very difficult go treatment say always develop anemia fever chill energy contrast be harvoni trial take pill day week suffer side effect week viral load be undetectable still be more year later physically have more energy just overall better health stewart say mentally emotionally have huge weight take more patient trial respond way yet gilead stock fall day harvoni be approve keep fall next day way be story gilead life sovaldi launch company score high ibd metric perfect composite rating price earning multiple be more big pharma boom biotech say drug analyst just hint bad news seem trigger sell biggest cause concern have be price sovaldi price pill add week course come fire advocacy group insurer pharmacy benefit manager even member congress however nobody really do anything so long sovaldi be so clearly superior everything else market gilead price harvoni basically parity sovaldi most patient still have take interferon ribavirin sovaldi drug be generic therefore cheaper gilead marked harvoni sovaldi cover cost absent drug however harvoni official label allow week treatment be consider patient cirrhosis haven be treat gilead estimate patient be eligible give fbr analyst andrew beren estimate average cost harvoni treatment be however also point cirrhotic patient previous treatment have fail patient charlotte stewart be recommend take harvoni week also say patient sovaldi treatment have fail represent underrate opportunity used hcv patient flow model calculate total patient need re treatment sovaldi viable patent life alone beren write oct note raise estimate harvoni sale longer term threat gilead pricing power be competition next few month bring lot more clarity competition look first real peer harvoni be expect be abbvie abbv regimen fda be due make approval decision dec clinical trial regimen have be comparable harvoni safety effectiveness do involve different drug make easier patient mess discount price abbvie management have be tight lip price drug leave wall street speculate much be willing undercut harvoni isi group analyst mark schoenebaum expect probably price comparably perhaps offer rebate certain customer estimate chance abbvie price significant discount happen second weekend november be precise merck mrk report mid stage trial datum own hcv program potentially cut treatment time week wouldn launch few more year drug industry tend think long time frame gilead acquire sofosbuvir buyout pharmasset nov be already think fact legacy hiv franchise such blockbuster viread truvada atripla start go patent hcv franchise be fill space now gilead hasn exactly give hiv gilead report positive late stage trial result drug analyst have dub son viread similar compound fewer side effect long term future hold gilead term success be expect roll analyst poll thomson reuter expect gilead report earning share prior year sale be see more double just less
1291,MRK,biotech alnylam alny report positive midstage trial result drug candidate patisiran monday send stock month high stock market today
1292,MRK,phase trial test patisiran familial amyloidotic polyneuropathy fap rare degenerative disease nervous system researcher used neuropathy impairment score track progress disease
1293,MRK,open label study patisiran be very encourage see believe be evidence possible stabilization neuropathy progression first month treatment alnylam chief medical officer akshay vaishnaw say statement indeed believe approximate point decrease neuropathy impairment score be encourage result light multiple historical datum set have predict increase point untreated patient similar baseline characteristic
1294,MRK,leerink analyst michael schmidt note study be small result be replicate larger phase trial now process be home run scenario view write research note monday
1295,MRK,schmidt also note knockdown transthyretin ttr serum cerebrospinal fluid be genetically mutate fap sufferer turn fibrous tissue call amyloid
1296,MRK,key opinion leader speak also note strong mechanistic rationale patisiran key differentiation stabilizer such diflunisal merck mrk dolobid tafamidis pfizer pfe vyndaqel be thought prevent ttr be converted amyloid actually unknown degree drug achieve write ultimately kol use stabilizer addition ttr knockdown approach give synergistic potential
1297,MRK,alnylam be develop patisiran collaboration sanofi sny genzyme unit have right outside north america western europe sanofi stock be fraction afternoon trading monday
1298,MRK,follow amy reeve twitter ibd_areeve biotech alnylam alny report positive midstage trial result drug candidate patisiran monday send stock month high stock market today phase trial test patisiran familial amyloidotic polyneuropathy fap rare degenerative disease nervous system researcher used neuropathy impairment score track progress disease open label study patisiran be very encourage see believe be evidence possible stabilization neuropathy progression first month treatment alnylam chief medical officer akshay vaishnaw say statement indeed believe approximate point decrease neuropathy impairment score be encourage result light multiple historical datum set have predict increase point untreated patient similar baseline characteristic leerink analyst michael schmidt note study be small result be replicate larger phase trial now process be home run scenario view write research note monday schmidt also note knockdown transthyretin ttr serum cerebrospinal fluid be genetically mutate fap sufferer turn fibrous tissue call amyloid key opinion leader speak also note strong mechanistic rationale patisiran key differentiation stabilizer such diflunisal merck mrk dolobid tafamidis pfizer pfe vyndaqel be thought prevent ttr be converted amyloid actually unknown degree drug achieve write ultimately kol use stabilizer addition ttr knockdown approach give synergistic potential alnylam be develop patisiran collaboration sanofi sny genzyme unit have right outside north america western europe sanofi stock be fraction afternoon trading monday follow amy reeve twitter ibd_areeve
1299,MRK,biotech intercept pharmaceutical icpt be ride high upgrade multiple price target increase issue new datum late monday fatty liver disease drug candidate intercept pharma stock vault early trading stock market today month high monday datum intercept include financial report provide more detail mid stage
1300,MRK,big pharma merck up ante hepatitis game monday agree buy idenix pharmaceutical signale hep drug market be longer term big money play merck mrk agree pay share idenix idix soar merck rise fraction want idenix portfolio
1301,MRK,stock rake narrow gain monday push fourth consecutive record close
1302,MRK,tech sector start strong help nasdaq gain dow jone industrial average clock gain apiece index close well session high
1303,MRK,small cap be star session russell end ahead finishing gain
1304,MRK,preliminary datum show volume end mixed nasdaq nyse
1305,MRK,acquisition drive healthy slice action stock market today tyson food tsn beating pilgrim pride ppc bidding war hillshire brand hsh merck mrk announce snap idenix pharmaceutical idix deal
1306,MRK,number chip stock knock nice gain stir analog device adi announce plan acquire hittite microwave hitt hittite maker chip used cell phone satellite vault news offer analog device climb powerful trade clear flat base buy point
1307,MRK,other chipmaker integrate device technology idti apply micro circuit amcc pop
1308,MRK,keurig green mountain gmcr shed strong trade loss give back most friday gain stock be form angular cup handle base buy point stock rake narrow gain monday push fourth consecutive record close tech sector start strong help nasdaq gain dow jone industrial average clock gain apiece index close well session high small cap be star session russell end ahead finishing gain preliminary datum show volume end mixed nasdaq nyse acquisition drive healthy slice action stock market today tyson food tsn beating pilgrim pride ppc bidding war hillshire brand hsh merck mrk announce snap idenix pharmaceutical idix deal number chip stock knock nice gain stir analog device adi announce plan acquire hittite microwave hitt hittite maker chip used cell phone satellite vault news offer analog device climb powerful trade clear flat base buy point other chipmaker integrate device technology idti apply micro circuit amcc pop keurig green mountain gmcr shed strong trade loss give back most friday gain stock be form angular cup handle base buy point
1309,MRK,year american society clinical oncology asco meeting medical conference start friday chicago world biggest drugmaker show latest datum new class cancer drug bring new hope patient enrich investor
1310,MRK,drug be part field call immuno oncology used technology manipulate patient immune system help fight cancer
1311,MRK,bristol myer squibb bmy have already launch such product yervoy be expect crack sale mark year thank fda approval fight melanoma bristol have much bigger ambition yervoy especially combine nivolumab newer immuno oncology candidate
1312,MRK,nivolumab be pd inhibitor drug attack mechanism let cancer cell fool immune system leave alone merck mrk also have pd inhibitor pipeline call mk astrazeneca azn roche be develop similar drug call pd inhibitor
1313,MRK,recently bristol myer be assume be leader field reason
1314,MRK,first be company be furthest clinical trial excellent past result squamous small cell lung cancer nsclc especially virulent form disease have few treatment option lead investor hope bristol file approval base phase datum be first market
1315,MRK,second be bristol be testing nivolumab combine yervoy lung cancer successful combination mean revenue drug much larger market melanoma
1316,MRK,january however merck surprised street start roll submission process mk melanoma mean add datum come application be complete expect happen end june bristol announce april be start same process nivolumab squamous nsclc still seem likely get market second
1317,MRK,then abstract presentation theasco meeting run tuesday go online abstract give investor first good look combination trial nivolumab yervoy nsclc kidney cancer also cover trial testing effect lung cancer nivolumab alone combine roche tarceva
1318,MRK,result bristol stock fall
1319,MRK,research note bmo capital market analyst alex arfaei downgrade bristol stock market perform
1320,MRK,nsclc focus be nivo yervoy datum show modest response rate poor adverse event ae profile grade aes scale severity most lead discontinuation drug related death write similarly addition tarceva nivo doesn seem add much additional benefit combine nivo chemo therapy do not seem worth add toxicity
1321,MRK,arfaei be also underwhelm nivolumab yervoy datum kidney cancer be better lung cancer not better nivolumab have do other agent
1322,MRK,qatato co manager frost growth equity fund tell ibd be disappoint same reason advocate patience point learn curve clinical trial
1323,MRK,still have bristol myer experiment right dosage be yervoy give be first drug say ve also know do have higher adverse event other drug re deal small sample size well try not draw too many conclusion
1324,MRK,qatato own bristol myer share say ll be look late breaking abstract be make public friday morgan stanley analyst david risinger echo sentiment reiterate overweight rating writing note bristol unveil more mature datum base longer term treatment risinger add management continue feel confident move nivo yervoy combo phase lung cancer later year
1325,MRK,merck abstract contrast be line expectation qatato say disappoint company isn speeding lung cancer timeline compete bristol
1326,MRK,not complaint anyone lodge astrazeneca company announce start phase trial pd inhibitor medi nsclc skip phase
1327,MRK,asco meeting investor get look phase datum so far consist only couple small study look patient lung cancer melanoma other cancer response rate be only compare unfavorably response rate surpass bristol merck drug
1328,MRK,morningstar analyst damien conover however point astrazeneca study patient count be tiny typically only subset patient respond drug especially express pd biomarker biomarker be measurable substance characteristic indicate presence disease biological condition process
1329,MRK,fact bristol study nivolumab monotherapy nivolumab other drug lung cancer find overall response rate be rate pd negative patient be
1330,MRK,fund manager qatato hope asco meeting bring more information biomarker
1331,MRK,don have good sense population cancer prevalence pd expression say difficult be pd expression isn just positive negative have get better sense big population be get better feel kind market opportunity throw whole revolutionary treatment cancer
1332,MRK,conover say term ignorance pd prevalence likely keep market big
1333,MRK,sense be be treatment family pd drug work very well get right patient go be used board scientific community figure pd status little bit better say year american society clinical oncology asco meeting medical conference start friday chicago world biggest drugmaker show latest datum new class cancer drug bring new hope patient enrich investor drug be part field call immuno oncology used technology manipulate patient immune system help fight cancer bristol myer squibb bmy have already launch such product yervoy be expect crack sale mark year thank fda approval fight melanoma bristol have much bigger ambition yervoy especially combine nivolumab newer immuno oncology candidate nivolumab be pd inhibitor drug attack mechanism let cancer cell fool immune system leave alone merck mrk also have pd inhibitor pipeline call mk astrazeneca azn roche be develop similar drug call pd inhibitor recently bristol myer be assume be leader field reason first be company be furthest clinical trial excellent past result squamous small cell lung cancer nsclc especially virulent form disease have few treatment option lead investor hope bristol file approval base phase datum be first market second be bristol be testing nivolumab combine yervoy lung cancer successful combination mean revenue drug much larger market melanoma january however merck surprised street start roll submission process mk melanoma mean add datum come application be complete expect happen end june bristol announce april be start same process nivolumab squamous nsclc still seem likely get market second then abstract presentation theasco meeting run tuesday go online abstract give investor first good look combination trial nivolumab yervoy nsclc kidney cancer also cover trial testing effect lung cancer nivolumab alone combine roche tarceva result bristol stock fall research note bmo capital market analyst alex arfaei downgrade bristol stock market perform nsclc focus be nivo yervoy datum show modest response rate poor adverse event ae profile grade aes scale severity most lead discontinuation drug related death write similarly addition tarceva nivo doesn seem add much additional benefit combine nivo chemo therapy do not seem worth add toxicity arfaei be also underwhelm nivolumab yervoy datum kidney cancer be better lung cancer not better nivolumab have do other agent qatato co manager frost growth equity fund tell ibd be disappoint same reason advocate patience point learn curve clinical trial still have bristol myer experiment right dosage be yervoy give be first drug say ve also know do have higher adverse event other drug re deal small sample size well try not draw too many conclusion qatato own bristol myer share say ll be look late breaking abstract be make public friday morgan stanley analyst david risinger echo sentiment reiterate overweight rating writing note bristol unveil more mature datum base longer term treatment risinger add management continue feel confident move nivo yervoy combo phase lung cancer later year merck abstract contrast be line expectation qatato say disappoint company isn speeding lung cancer timeline compete bristol not complaint anyone lodge astrazeneca company announce start phase trial pd inhibitor medi nsclc skip phase asco meeting investor get look phase datum so far consist only couple small study look patient lung cancer melanoma other cancer response rate be only compare unfavorably response rate surpass bristol merck drug morningstar analyst damien conover however point astrazeneca study patient count be tiny typically only subset patient respond drug especially express pd biomarker biomarker be measurable substance characteristic indicate presence disease biological condition process fact bristol study nivolumab monotherapy nivolumab other drug lung cancer find overall response rate be rate pd negative patient be fund manager qatato hope asco meeting bring more information biomarker don have good sense population cancer prevalence pd expression say difficult be pd expression isn just positive negative have get better sense big population be get better feel kind market opportunity throw whole revolutionary treatment cancer conover say term ignorance pd prevalence likely keep market big sense be be treatment family pd drug work very well get right patient go be used board scientific community figure pd status little bit better say
1334,MRK,already strongest year merger acquisition flurry dealmake have give share large drugmaker shot arm face case botox maker allergan agn
1335,MRK,not offer have be make peacefully valeant pharmaceutical vrx officially announce plan tuesday make bid allergan hostile
1336,MRK,allergan be pharmaceutical company big cap screen day catch wave screen feature large stock strong earning price performance
1337,MRK,allergan have reject valeant previous advance valeant isn back be prepared make third offer
1338,MRK,tuesday valeant ceo mike pearson tell reuter hostile be not prefer approach deal be so strategic financially compelling really make sense
1339,MRK,activist investor bill ackman persh square capital management allergan largest shareholder be push merger be try block allergan effort poison pill
1340,MRK,share have jump nearly early april be stock market tuesday
1341,MRK,allergan have composite rating possible ibd composite rating rate stock area extra weight earning stock price strength
1342,MRK,actavis act be featured screen rating say tuesday receive shareholder approval proposal related takeover forest laboratory frx shareholder also deal
1343,MRK,buyout be announce february be expect close midyear
1344,MRK,actavis have be know maker generic drug especially equivalent cholesterol lower medication lipitor forest deal help branch brand drug
1345,MRK,forest have establish portfolio treatment well brand drug neurological condition hypertension
1346,MRK,actavis share climb
1347,MRK,gilead science gild have top composite rating company share take hit last week fall nearly merck mrk announce pay cash acquire idenix pharmaceutical idix idenix be develop several experimental hepatitis drug gilead be merck biggest rival hep treatment blockbuster drug sovaldi
1348,MRK,hep market be huge drugmaker virus affect american company be look more effective oral therapy vs current injectable drug regime
1349,MRK,gilead share dip
1350,MRK,follow gillian rich twitter already strongest year merger acquisition flurry dealmake have give share large drugmaker shot arm face case botox maker allergan agn not offer have be make peacefully valeant pharmaceutical vrx officially announce plan tuesday make bid allergan hostile allergan be pharmaceutical company big cap screen day catch wave screen feature large stock strong earning price performance allergan have reject valeant previous advance valeant isn back be prepared make third offer tuesday valeant ceo mike pearson tell reuter hostile be not prefer approach deal be so strategic financially compelling really make sense activist investor bill ackman persh square capital management allergan largest shareholder be push merger be try block allergan effort poison pill share have jump nearly early april be stock market tuesday allergan have composite rating possible ibd composite rating rate stock area extra weight earning stock price strength actavis act be featured screen rating say tuesday receive shareholder approval proposal related takeover forest laboratory frx shareholder also deal buyout be announce february be expect close midyear actavis have be know maker generic drug especially equivalent cholesterol lower medication lipitor forest deal help branch brand drug forest have establish portfolio treatment well brand drug neurological condition hypertension actavis share climb gilead science gild have top composite rating company share take hit last week fall nearly merck mrk announce pay cash acquire idenix pharmaceutical idix idenix be develop several experimental hepatitis drug gilead be merck biggest rival hep treatment blockbuster drug sovaldi hep market be huge drugmaker virus affect american company be look more effective oral therapy vs current injectable drug regime gilead share dip follow gillian rich twitter ibd_grich
1351,MRK,biotech firm endocyte ecyt big pharma partner merck mrk stop clinical trial ovarian cancer drug ground futility friday send stock tumble stock market today
1352,MRK,company say datum safety monitoring board interim analysis phase trial vynfinit know generically vintafolide be not show improvement patient progression free survival so say trial be stop ruling come even european medicine agency panel advise give drug conditional approval march base promising phase result
1353,MRK,merck stock hit year high thursday drop endocyte plunge more vynfinit have be first product market main investment thesis
1354,MRK,be other driver pipeline write rbc capital market analyst adnan butt research note friday however aside vintafolide be phase study be more heavily discount
1355,MRK,nonetheless butt point still hope vynfinit phase trial small cell lung cancer be expect produce detailed datum later year preliminary result report march indicated survival benefit
1356,MRK,piper jaffray downgrade endocyte stock neutral overweight
1357,MRK,follow amy reeve twitter ibd_areeve biotech firm endocyte ecyt big pharma partner merck mrk stop clinical trial ovarian cancer drug ground futility friday send stock tumble stock market today company say datum safety monitoring board interim analysis phase trial vynfinit know generically vintafolide be not show improvement patient progression free survival so say trial be stop ruling come even european medicine agency panel advise give drug conditional approval march base promising phase result merck stock hit year high thursday drop endocyte plunge more vynfinit have be first product market main investment thesis be other driver pipeline write rbc capital market analyst adnan butt research note friday however aside vintafolide be phase study be more heavily discount nonetheless butt point still hope vynfinit phase trial small cell lung cancer be expect produce detailed datum later year preliminary result report march indicated survival benefit piper jaffray downgrade endocyte stock neutral overweight follow amy reeve twitter ibd_areeve
1358,MRK,wall street rise second day tuesday leave major index just record high higher oil price boost energy stock dow jone industrial average rise nasdaq climb end latter finishing just time peak volume be higher nyse nasdaq compare monday accord preliminary datum
1359,MRK,stock market today oil producer pioneer natural resource pxd driller diamond offshore do rise lead oil price jump more just barrel strike oil worker brazil port shutdown libya
1360,MRK,noah holding noah lead ibd jump heavy volume climb right side deep base provider wealth management service china be due report result nov profit period be see rise cent share be biggest gain quarters
1361,MRK,medical product stock cambrex cbm rise more better expect earning report also climb right side new base
1362,MRK,post session trading luxury electric vehicle maker tesla motor tsla rise sharply narrower expect loss stock fall more regular session end week high
1363,MRK,share real estate zillow be hour follow result
1364,MRK,also close groupon gpn edge higher report provider discount retailer also announce coo rich william replace eric lefkofsky ceo lefkofsky become chairman
1365,MRK,lgi home lgih facebook fb epam system epam cognizant technology solution ctsh be company report quarterly earning wednesday
1366,MRK,economic report due wednesday include institute supply management index service sector activity october adp private sector payroll november crude oil inventory week end oct mortgage banker association index mortgage application week end oct wall street rise second day tuesday leave major index just record high higher oil price boost energy stock dow jone industrial average rise nasdaq climb end latter finishing just time peak volume be higher nyse nasdaq compare monday accord preliminary datum stock market today oil producer pioneer natural resource pxd driller diamond offshore do rise lead oil price jump more just barrel strike oil worker brazil port shutdown libya noah holding noah lead ibd jump heavy volume climb right side deep base provider wealth management service china be due report result nov profit period be see rise cent share be biggest gain quarters medical product stock cambrex cbm rise more better expect earning report also climb right side new base post session trading luxury electric vehicle maker tesla motor tsla rise sharply narrower expect loss stock fall more regular session end week high share real estate zillow be hour follow result also close groupon gpn edge higher report provider discount retailer also announce coo rich william replace eric lefkofsky ceo lefkofsky become chairman lgi home lgih facebook fb epam system epam cognizant technology solution ctsh be company report quarterly earning wednesday economic report due wednesday include institute supply management index service sector activity october adp private sector payroll november crude oil inventory week end oct mortgage banker association index mortgage application week end oct
1367,MRK,stock future align moderately positive start tuesday heavy selling gold sector issue
1368,MRK,dow future climb point fair market value be rise nasdaq future be ahead point future rise point
1369,MRK,stock market today appear anxious rebound monday energy sector fuel rout market generally positive pre open stance energy stock remain mixed bellwether such exxon mobil xom halliburton hal schlumberger slb be trading higher however royal dutch shell rdsa trade bell
1370,MRK,gold exchange trade fund be post notable loss gold future backed ounce direxion daily junior gold miner jnug topple direxion daily gold miner bull nugt dump market vector junior gold miner gdxj drop
1371,MRK,stock chip sector receive early boost spansion code soar announcement late monday cypress semiconductor cy acquire company stock deal value
1372,MRK,combine company expect annual cost saving year say combination add earning first full year deal close expect be first half cypress share bolt higher premarket trade
1373,MRK,biotech drugmaker avanir pharmaceutical avnr pop early action company announce monday close be acquire japan base otsuka pharmaceutical cash deal value company expect deal close first quarter
1374,MRK,overseas china market rally vigorously hong kong hang seng index rebound sharp dive monday shanghai composite punch late day rally brokerage bank send index highest mark july
1375,MRK,tokyo nikkei edge
1376,MRK,europe stock be map energy sector rebound left major index widely mixed midday
1377,MRK,dollar climb vs euro yen commodity trend lower benchmark west texas intermediate crude barrel brent crude edge
1378,MRK,day economic news be likely revolve automaker be report november sale day et commerce department be expect release october construction spending datum stock future align moderately positive start tuesday heavy selling gold sector issue dow future climb point fair market value be rise nasdaq future be ahead point future rise point stock market today appear anxious rebound monday energy sector fuel rout market generally positive pre open stance energy stock remain mixed bellwether such exxon mobil xom halliburton hal schlumberger slb be trading higher however royal dutch shell rdsa trade bell gold exchange trade fund be post notable loss gold future backed ounce direxion daily junior gold miner jnug topple direxion daily gold miner bull nugt dump market vector junior gold miner gdxj drop stock chip sector receive early boost spansion code soar announcement late monday cypress semiconductor cy acquire company stock deal value combine company expect annual cost saving year say combination add earning first full year deal close expect be first half cypress share bolt higher premarket trade biotech drugmaker avanir pharmaceutical avnr pop early action company announce monday close be acquire japan base otsuka pharmaceutical cash deal value company expect deal close first quarter overseas china market rally vigorously hong kong hang seng index rebound sharp dive monday shanghai composite punch late day rally brokerage bank send index highest mark july tokyo nikkei edge europe stock be map energy sector rebound left major index widely mixed midday dollar climb vs euro yen commodity trend lower benchmark west texas intermediate crude barrel brent crude edge day economic news be likely revolve automaker be report november sale day et commerce department be expect release october construction spending datum
1379,MRK,biotechnology exchange trade fund surge week news drug giant merck mrk agree buy idenix pharmaceutical idix lead investor believe biotech sector have bottom month misery
1380,MRK,monday big pharma drugmaker offer tiny biotech share premium close price friday order acquire idenix portfolio early state hepatitis drug
1381,MRK,news spark rally biotech sector biotech etfs powershare dynamic biotechnology genome portfolio etf pbe jump monday advance week end june now have asset idenix
1382,MRK,spdr biotech etf xbi now idenix leap monday gain past day overall biotech sector etfs rise average past week
1383,MRK,big move then pullback
1384,MRK,last year biotech sector be best area market post bigger return february sector have undergo significant retrenchment first start flight risk sector many say be bubble territory
1385,MRK,timing be prescient next month string biotechs suddenly implode early march geron gern biotech product plunge regulator halter trial only experimental drug
1386,MRK,april cytokinetic cytk share lose more experimental treatment lou gehrig disease fail work better placebo clinical trial
1387,MRK,then first week see biotechs report failure lead drug candidate
1388,MRK,unexpected blowup overall flight risk hurt small cap biotech sector valuation say ron garren oncologist editor biotechinsight com online biotech stock newsletter carmel calif
1389,MRK,get decimate lose more half value course be overvalue begin
1390,MRK,late february ishare nasdaq biotechnology etf ibb track biotechs nasdaq pbe tumble xbi sank
1391,MRK,past month xbi climb year date return pbe be gain year ibb biggest biotech etf asset advanced last day return year date
1392,MRK,proshare ultra nasdaq biotechnology etf bib be leverage fund seek post daily return twice result nasdaq biotechnology index
1393,MRK,fall biotech correction gain past month year date bib be return past month be compare return average biotech etf
1394,MRK,opportunity see
1395,MRK,yield dividend stock begin dry risk stock look more attractive biotech beat think stock be great opportunity say garren
1396,MRK,have be incredible amount work immunotherapy cancer also be big opportunity involved fatal disease need therapy biotechnology exchange trade fund surge week news drug giant merck mrk agree buy idenix pharmaceutical idix lead investor believe biotech sector have bottom month misery monday big pharma drugmaker offer tiny biotech share premium close price friday order acquire idenix portfolio early state hepatitis drug news spark rally biotech sector biotech etfs powershare dynamic biotechnology genome portfolio etf pbe jump monday advance week end june now have asset idenix spdr biotech etf xbi now idenix leap monday gain past day overall biotech sector etfs rise average past week big move then pullbacklast year biotech sector be best area market post bigger return february sector have undergo significant retrenchment first start flight risk sector many say be bubble territory timing be prescient next month string biotechs suddenly implode early march geron gern biotech product plunge regulator halter trial only experimental drug april cytokinetic cytk share lose more experimental treatment lou gehrig disease fail work better placebo clinical trial then first week see biotechs report failure lead drug candidate unexpected blowup overall flight risk hurt small cap biotech sector valuation say ron garren oncologist editor biotechinsight com online biotech stock newsletter carmel calif get decimate lose more half value course be overvalue begin late february ishare nasdaq biotechnology etf ibb track biotechs nasdaq pbe tumble xbi sank past month xbi climb year date return pbe be gain year ibb biggest biotech etf asset advanced last day return year date proshare ultra nasdaq biotechnology etf bib be leverage fund seek post daily return twice result nasdaq biotechnology index fall biotech correction gain past month year date bib be return past month be compare return average biotech etf opportunity see yield dividend stock begin dry risk stock look more attractive biotech beat think stock be great opportunity say garren have be incredible amount work immunotherapy cancer also be big opportunity involved fatal disease need therapy
1397,MRK,tyson food emerge winner bidding war hillshire brand offer share top pilgrim pride ppc offer series deal announce monday tyson food tsn largest meat processor sale complete deal hillshire brand hsh terminate
1398,MRK,british pharma giant astrazeneca azn announce new drug approval tuesday rolled strategy nearly double revenue next decade further quest convince shareholder not yield pfizer pfe takeover attempt shareholder do not seem excited however astrazeneca stock be fraction stock market today
1399,MRK,astra say fda have approve epanova treatment severe elevated level fat blood firm say adult suffer condition consensus estimate put annual sale less be fairly small potato world big pharma so separate press release conference call detail long term target company focuse bigger game
1400,MRK,astra project annual sale heart disease drug brilinta reach be ambitious target drug bring less last year analyst be estimate just sale
1401,MRK,also company expect diabetes respiratory franchise be make last year respiratory revenue totale diabetes business be more nascent astra take year company buy bristol myer squibb bmy portion joint venture
1402,MRK,astra also estimate risk adjust peak sale potential pipeline conference call company say medi immuno oncology drug currently phase testing lung cancer be ready approval filing analyst believe immuno oncology be big reason pfizer bid astrazeneca bristol merck mrk have already begin roll submission own immuno oncology drug pfizer have presence space
1403,MRK,such growth lie future however astra have be shrink major drug have go patent company affirm revenue be broadly line growth lift
1404,MRK,follow amy reeve twitter pharma giant astrazeneca azn announce new drug approval tuesday rolled strategy nearly double revenue next decade further quest convince shareholder not yield pfizer pfe takeover attempt shareholder do not seem excited however astrazeneca stock be fraction stock market today astra say fda have approve epanova treatment severe elevated level fat blood firm say adult suffer condition consensus estimate put annual sale less be fairly small potato world big pharma so separate press release conference call detail long term target company focuse bigger game astra project annual sale heart disease drug brilinta reach be ambitious target drug bring less last year analyst be estimate just sale also company expect diabetes respiratory franchise be make last year respiratory revenue totale diabetes business be more nascent astra take year company buy bristol myer squibb bmy portion joint venture astra also estimate risk adjust peak sale potential pipeline conference call company say medi immuno oncology drug currently phase testing lung cancer be ready approval filing analyst believe immuno oncology be big reason pfizer bid astrazeneca bristol merck mrk have already begin roll submission own immuno oncology drug pfizer have presence space such growth lie future however astra have be shrink major drug have go patent company affirm revenue be broadly line growth lift follow amy reeve twitter ibd_areeve
1405,MRK,earning season full force investor focus very best company elite ibd rank top rate growth stock factor strong relative price strength top fundamental ibd have several company report earning come week here be top due report earning wednesday social networking giant facebook fb
1406,MRK,pfizer pfe say be try acquire fellow big pharma astrazeneca confirm anonymously source report last week pfizer stock be astrazeneca morning trading stock market today pfizer bid astrazeneca jan offer share cash stock astrazeneca turn pfizer contact again
1407,MRK,stock future edge narrowly lower ahead tuesday open target read march trade balance
1408,MRK,dow future slip point fair market value nasdaq future be point future unwound point
1409,MRK,stock market today get start nasdaq snug bottom side day move average move level have capped index attempt uptrend past week be positive have hold day line sandwich level support april high
1410,MRK,day brief economic calendar show trade deficit narrow march commerce department also revise february deficit lower march number be line analyst expectation
1411,MRK,rumble massive international medical deal continue new jersey base merck mrk announce sell consumer care business germany bayer bayry unit include allergy medicine claritin decongestant afrin see sale last year north america statement bayer say deal make largest provider counter drug north america company expect deal close late year
1412,MRK,merck share rise fraction premarket trade bayer be flat
1413,MRK,action related earning report be generally mild tuesday open discovery communication disca mosaic mo wellcare health group wcg hold relatively steady report first quarter result
1414,MRK,tableau software datum pop ahead open maker business intelligence product report cent loss cent better analyst expectation leap revenue soar past estimate stock be february high year ipo price
1415,MRK,technology avgo add standard poor announce late monday singapore base chip designer be list index begin thursday stock have be shallow consolidation march high
1416,MRK,overseas hong kong hang seng index slump weak read april manufacturing shanghai composite end fraction higher tokyo nikkei tick lower
1417,MRK,europe major index carry mild loss midday trade
1418,MRK,euro rise week high vs dollar ahead janet yellen testimony schedule joint economic committee congress tomorrow policy decision european central bank thursday
1419,MRK,gold nose higher third day trading just ounce thursday settle oil continue bob barrel natural gas be steady stock future edge narrowly lower ahead tuesday open target read march trade balance dow future slip point fair market value nasdaq future be point future unwound point stock market today get start nasdaq snug bottom side day move average move level have capped index attempt uptrend past week be positive have hold day line sandwich level support april high day brief economic calendar show trade deficit narrow march commerce department also revise february deficit lower march number be line analyst expectation rumble massive international medical deal continue new jersey base merck mrk announce sell consumer care business germany bayer bayry unit include allergy medicine claritin decongestant afrin see sale last year north america statement bayer say deal make largest provider counter drug north america company expect deal close late year merck share rise fraction premarket trade bayer be flat action related earning report be generally mild tuesday open discovery communication disca mosaic mo wellcare health group wcg hold relatively steady report first quarter result tableau software datum pop ahead open maker business intelligence product report cent loss cent better analyst expectation leap revenue soar past estimate stock be february high year ipo price technology avgo add standard poor announce late monday singapore base chip designer be list index begin thursday stock have be shallow consolidation march high overseas hong kong hang seng index slump weak read april manufacturing shanghai composite end fraction higher tokyo nikkei tick lower europe major index carry mild loss midday trade euro rise week high vs dollar ahead janet yellen testimony schedule joint economic committee congress tomorrow policy decision european central bank thursday gold nose higher third day trading just ounce thursday settle oil continue bob barrel natural gas be steady
1420,MRK,merck agree sell consumer business german giant bayer tuesday continue big pharma recent flurry big deal merck stock fall close bayer stock dip company also announce global collaboration develop market bayer bayry line treatment pulmonary hypertension
1421,MRK,big pharmas novartis nvs glaxosmithkline gsk eli lilly lly announce massive exchange business unit tuesday morning set deal total value more novartis glaxo rise stock market today lilly slip fraction
1422,MRK,switzerland base novartis agree buy british glaxo oncology business milestone payment depend product pipeline pan turn glaxo pay novartis vaccine business novartis say selling flu vaccine business separately apparently hasn yet find buyer
1423,MRK,company also agree form joint venture consumer health care combine counter business novartis own jv hold seat board
1424,MRK,meanwhile novartis also sell animal health business lilly
1425,MRK,research note leerink analyst seamus fernandez write activity be not wall street be expect have be rumor go january novartis sell merck mrk animal health vaccine exchange merck counter business fernandez say like decision pursue oncology instead
1426,MRK,incremental focus oncology transaction bring nvs well opportunity possibly reconsider pursuit certain effort unapproved product be positive financial strategic move fernandez write
1427,MRK,go say glaxo be probably biggest surprise participant note glaxo now shift distribution business vaccine consumer exit increasingly fragmented crowd oncology market glaxo core business still depend respiratory product such advair fernandez add
1428,MRK,lilly meanwhile be follow commitment keep animal health business pressure street divest email client isi group analyst mark schoenebaum write novartis veterinary unit appear be lose money lilly say expect get ebit earning interest taxe margin combine business mid range
1429,MRK,suspect lly shareholder win be inspire lly decision buy animal health company shareholder always want big company buy biotech growth engine easier say do schoenebaum write however elanco lilly animal health unit have be story success lly so shareholder be likely give management benefit doubt deal
1430,MRK,novartis stock be morning trading tuesday earlier hit time high glaxo be lilly be
1431,MRK,follow amy reeve twitter ibd_areeve
1432,MRK,related hcv rivalry heat merck combo shine big pharmas novartis nvs glaxosmithkline gsk eli lilly lly announce massive exchange business unit tuesday morning set deal total value more novartis glaxo rise stock market today lilly slip fraction switzerland base novartis agree buy british glaxo oncology business milestone payment depend product pipeline pan turn glaxo pay novartis vaccine business novartis say selling flu vaccine business separately apparently hasn yet find buyer company also agree form joint venture consumer health care combine counter business novartis own jv hold seat board meanwhile novartis also sell animal health business lilly research note leerink analyst seamus fernandez write activity be not wall street be expect have be rumor go january novartis sell merck mrk animal health vaccine exchange merck counter business fernandez say like decision pursue oncology instead incremental focus oncology transaction bring nvs well opportunity possibly reconsider pursuit certain effort unapproved product be positive financial strategic move fernandez write go say glaxo be probably biggest surprise participant note glaxo now shift distribution business vaccine consumer exit increasingly fragmented crowd oncology market glaxo core business still depend respiratory product such advair fernandez add lilly meanwhile be follow commitment keep animal health business pressure street divest email client isi group analyst mark schoenebaum write novartis veterinary unit appear be lose money lilly say expect get ebit earning interest taxe margin combine business mid range suspect lly shareholder win be inspire lly decision buy animal health company shareholder always want big company buy biotech growth engine easier say do schoenebaum write however elanco lilly animal health unit have be story success lly so shareholder be likely give management benefit doubt deal novartis stock be morning trading tuesday earlier hit time high glaxo be lilly be follow amy reeve twitter hcv rivalry heat merck combo shine
1433,MRK,biotech endocyte ecyt get couple hefty price target increase analyst tuesday wake last week positive vynfinit news send stock morning trading stock market today
1434,MRK,wedbush analyst gregory wade lift target give room substantial upside even friday more intraday jump record high estimate peak annual sale combination vynfinit companion diagnostic agent be approve ovarian cancer eu seem likely friday endorsement advisory panel
1435,MRK,wade also write positive lung cancer result release same day risk ecyt small molecule drug conjugate technology platform suggest broader opportunity vynfinit ecyt tubulysin pipeline drug be be value street
1436,MRK,chardan capital market analyst ling wang also note eu approval expect come month trigger milestone payment big pharma partner merck mrk raise price target
1437,MRK,analyst also expect further lung cancer datum second half year be stock mover
1438,MRK,follow amy reeve twitter ibd_areeve biotech endocyte ecyt get couple hefty price target increase analyst tuesday wake last week positive vynfinit news send stock morning trading stock market today wedbush analyst gregory wade lift target give room substantial upside even friday more intraday jump record high estimate peak annual sale combination vynfinit companion diagnostic agent be approve ovarian cancer eu seem likely friday endorsement advisory panel wade also write positive lung cancer result release same day risk ecyt small molecule drug conjugate technology platform suggest broader opportunity vynfinit ecyt tubulysin pipeline drug be be value street chardan capital market analyst ling wang also note eu approval expect come month trigger milestone payment big pharma partner merck mrk raise price target analyst also expect further lung cancer datum second half year be stock mover follow amy reeve twitter ibd_areeve
1439,MRK,stock notch uneven early gain tuesday investor weigh solid new home sale mixed durable good datum potential deal greece eurozone creditor
1440,MRK,dow jone industrial average climb nasdaq add less split difference
1441,MRK,volume be mixed stock market today nasdaq lower nyse compare trade same time monday
1442,MRK,top line number commerce department durable good report show decline downward revision april number economist have forecast more mild slip bulk miss be apparently due sharp decline aircraft order month transportation durable good order rise line expectation so far year durable good order be run last year january period
1443,MRK,housing price improve steadily lift federal housing finance agency house price index increase be equal march increase just consensus forecast gain year year index be
1444,MRK,new home sale pop annualize rate accord commerce department be april upwardly revise pace well consensus expectation strongest number feb
1445,MRK,bit less rosy be preliminary june manufacturing estimate researcher markit purchasing manager manufacturing index be number forecast increase number point third month slow activity be gauge weakest gain month
1446,MRK,stock be good morning florida base company
1447,MRK,darden restaurant dri rise lead wide margin orlando base owner olive garden red lobster other chain report healthy fiscal fourth quarter result announce plan slice portion real estate asset separate real estate investment trust stock pop new high pare gain hold just cup base buy point
1448,MRK,citrix system ctxs peck gain best increase nasdaq stock fort lauderdale headquarter software developer be still buy range buy point cup handle base
1449,MRK,leader most ibd list post modest gain loss couple dramatic exception
1450,MRK,ambarella amba lead list rebound stock tumble monday follow short seller report friday question stock valuation stock remain extend mid rebound week support be well week move average
1451,MRK,bottom group burger joint sonic sonc dive massive trade fiscal third quarter sale profit meet consensus expectation full year earning guidance didn sell stop test stock week move average seriously damage effort shape month cup base stock notch uneven early gain tuesday investor weigh solid new home sale mixed durable good datum potential deal greece eurozone creditor dow jone industrial average climb nasdaq add less split difference volume be mixed stock market today nasdaq lower nyse compare trade same time monday top line number commerce department durable good report show decline downward revision april number economist have forecast more mild slip bulk miss be apparently due sharp decline aircraft order month transportation durable good order rise line expectation so far year durable good order be run last year january period housing price improve steadily lift federal housing finance agency house price index increase be equal march increase just consensus forecast gain year year index be new home sale pop annualize rate accord commerce department be april upwardly revise pace well consensus expectation strongest number feb bit less rosy be preliminary june manufacturing estimate researcher markit purchasing manager manufacturing index be number forecast increase number point third month slow activity be gauge weakest gain month stock be good morning florida base company darden restaurant dri rise lead wide margin orlando base owner olive garden red lobster other chain report healthy fiscal fourth quarter result announce plan slice portion real estate asset separate real estate investment trust stock pop new high pare gain hold just cup base buy point citrix system ctxs peck gain best increase nasdaq stock fort lauderdale headquarter software developer be still buy range buy point cup handle base leader most ibd list post modest gain loss couple dramatic exception ambarella amba lead list rebound stock tumble monday follow short seller report friday question stock valuation stock remain extend mid rebound week support be well week move average bottom group burger joint sonic sonc dive massive trade fiscal third quarter sale profit meet consensus expectation full year earning guidance didn sell stop test stock week move average seriously damage effort shape month cup base
1452,MRK,big pharmas report light mixed earning tuesday share go different direction stock market today wall street seem focus different detail report
1453,MRK,bristol myer squibb bmy say earning rise year earlier quarter cent share beating analyst consensus cent sale however fall miss consensus bristol add nickel low end previous ep guidance range now midpoint be analyst sale guidance be squarely line consensus represent modest decline last year
1454,MRK,hiv drug sustiva reyataz be largely responsible miss rheumatoid arthritis drug orencia other hand stroke preventer eliquis finally seem be find leg disappointing launch last year sale beating view diabetes also outperformed bristol sell business february astrazeneca azn still collect royalty
1455,MRK,bristol also announce begin roll fda submission process pd inhibitor nivolumab squamous nonsmall cell lung cancer base study expect complete year end nivolumab perform well disease phase trial present significant opportunity prognosis squamous patient today be poor bristol say report phase result meeting october
1456,MRK,company also acquire privately hold biotech ipierian develop treatment class neurogenerative disease call tauopathy
1457,MRK,bristol stock be midday trading
1458,MRK,merck mrk report similarly mixed quarter street be more impressed stock be profit climb year earlier quarter cent share beating estimate cent sale shrank miss consensus merck affirm previous guidance call ep sale
1459,MRK,isi group analyst mark schoenebaum most interesting thing result be beleaguered diabetes drug januvia beat expectation
1460,MRK,quantify price impact point note favorable year year price impact be good news mrk dpp category be plague new aggressive price competition write email client
1461,MRK,merck say leave pipeline update business review meeting next week also didn comment effort sell consumer business have reportedly draw interest reckitt benckiser procter gamble pg bayer bayry past few day
1462,MRK,sanofi sny report number euro sale converted constant exchange rate miss analyst consensus ep miss consensus cent rise constant exchange rate
1463,MRK,rbc capital market note sanofi moved expect filing timeline alirocumab cholesterol drug develop regeneron pharmaceutical regn previously expect file europe early next year somewhat later now expect eu filing late year
1464,MRK,product regeneron partnership dupilumab be be moved phase trial atopic dermatitis perhaps base encourage report regeneron stock be midday trading even sanofi stock be more
1465,MRK,sanofi be also news tuesday be report allergan agn have approach possible buyer allergan bid fend hostile bid valeant pharmaceutical vrx report be base anonymous source company refuse comment
1466,MRK,follow amy reeve twitter ibd_areeve big pharmas report light mixed earning tuesday share go different direction stock market today wall street seem focus different detail report bristol myer squibb bmy say earning rise year earlier quarter cent share beating analyst consensus cent sale however fall miss consensus bristol add nickel low end previous ep guidance range now midpoint be analyst sale guidance be squarely line consensus represent modest decline last year hiv drug sustiva reyataz be largely responsible miss rheumatoid arthritis drug orencia other hand stroke preventer eliquis finally seem be find leg disappointing launch last year sale beating view diabetes also outperformed bristol sell business february astrazeneca azn still collect royalty bristol also announce begin roll fda submission process pd inhibitor nivolumab squamous nonsmall cell lung cancer base study expect complete year end nivolumab perform well disease phase trial present significant opportunity prognosis squamous patient today be poor bristol say report phase result meeting october company also acquire privately hold biotech ipierian develop treatment class neurogenerative disease call tauopathy bristol stock be midday trading merck mrk report similarly mixed quarter street be more impressed stock be profit climb year earlier quarter cent share beating estimate cent sale shrank miss consensus merck affirm previous guidance call ep sale isi group analyst mark schoenebaum most interesting thing result be beleaguered diabetes drug januvia beat expectation quantify price impact point note favorable year year price impact be good news mrk dpp category be plague new aggressive price competition write email client merck say leave pipeline update business review meeting next week also didn comment effort sell consumer business have reportedly draw interest reckitt benckiser procter gamble pg bayer bayry past few day sanofi sny report number euro sale converted constant exchange rate miss analyst consensus ep miss consensus cent rise constant exchange rate rbc capital market note sanofi moved expect filing timeline alirocumab cholesterol drug develop regeneron pharmaceutical regn previously expect file europe early next year somewhat later now expect eu filing late year product regeneron partnership dupilumab be be moved phase trial atopic dermatitis perhaps base encourage report regeneron stock be midday trading even sanofi stock be more sanofi be also news tuesday be report allergan agn have approach possible buyer allergan bid fend hostile bid valeant pharmaceutical vrx report be base anonymous source company refuse comment follow amy reeve twitter ibd_areeve
1467,MRK,stock future show healthy gain early tuesday europe market rebound oil price re-cover lows economic news be fair positive
1468,MRK,dow future trade point fair market value point hour earlier nasdaq future add early gain be point future moved point even hour earlier level
1469,MRK,stock market today have eye wednesday afternoon federal open market committee member head day powwow expectation be high policy shift group announce decision wednesday et
1470,MRK,consumer price be flat november labor department report be gain october line economist expectation core price food energy rise equal october increase meeting consensus projection
1471,MRK,manufacturing activity new york region slow improve rate december accord new york federal reserve empire state manufacturing survey show performance vs show november be better read expect economist
1472,MRK,national association home builder release builder confidence index treasury department report long term treasury international capital flow october
1473,MRK,oil price take modest bounce early trade lift west texas intermediate less brent crude more still trading barrel respectively late day recovery market monday fed rebound european market lead index bounce week lows send dax frankfurt cac paris more midday
1474,MRK,stock miner steel market be rebound issue vale vale arcelor mittal mt ahead more dow diversify operator mmm old minnesota mining manufacturing co tank more lower earning guidance chevron cvx top index premarket trade gain
1475,MRK,also notch worst loss stock network ffiv take second hardest hit bit more
1476,MRK,chipmaker nvidia nvda newell rubbermaid nwl southwestern energy swn top list better
1477,MRK,flooring retailer lumber liquidator ll bolt higher news report detailed letter kase capital management manage partner whitney tilson declare have cover short position stock
1478,MRK,tilson have weigh company follow allegation flooring contain unsafe level formaldehyde tilson conclude management probably do not know problem accord bloomberg mean company be sloppy naive not evil tilson write stock end monday news investigation break february
1479,MRK,lead stock stick moderate move premarket action hawaiian top ibd list slightly more premarket trade dave buster play stake low end loss stock future show healthy gain early tuesday europe market rebound oil price re-cover lows economic news be fair positive dow future trade point fair market value point hour earlier nasdaq future add early gain be point future moved point even hour earlier level stock market today have eye wednesday afternoon federal open market committee member head day powwow expectation be high policy shift group announce decision wednesday et consumer price be flat november labor department report be gain october line economist expectation core price food energy rise equal october increase meeting consensus projection manufacturing activity new york region slow improve rate december accord new york federal reserve empire state manufacturing survey show performance vs show november be better read expect economist national association home builder release builder confidence index treasury department report long term treasury international capital flow october oil price take modest bounce early trade lift west texas intermediate less brent crude more still trading barrel respectively late day recovery market monday fed rebound european market lead index bounce week lows send dax frankfurt cac paris more midday stock miner steel market be rebound issue vale vale arcelor mittal mt ahead more dow diversify operator mmm old minnesota mining manufacturing co tank more lower earning guidance chevron cvx top index premarket trade gain also notch worst loss stock network ffiv take second hardest hit bit more chipmaker nvidia nvda newell rubbermaid nwl southwestern energy swn top list better flooring retailer lumber liquidator ll bolt higher news report detailed letter kase capital management manage partner whitney tilson declare have cover short position stock tilson have weigh company follow allegation flooring contain unsafe level formaldehyde tilson conclude management probably do not know problem accord bloomberg mean company be sloppy naive not evil tilson write stock end monday news investigation break february lead stock stick moderate move premarket action hawaiian top ibd list slightly more premarket trade dave buster play stake low end loss
1480,MRK,biotech endocyte ecyt big pharma partner merck mrk get double dose good news cancer drug vintafolide friday more double endocyte stock stock market today first european medicine agency advisory committee recommend conditional approval vintafolide brand vynfinit companion imaging agent treatment ovarian cancer imaging agent
1481,MRK,abbvie abbv throw gauntlet gilead science gild approval hepatitis drug further hammer gilead multibillion dollar franchise analyst say friday xlate thursday food drug administration approve abbvie drug dub mavyret coveted week label genotype hepatitis patient most hepatitis drug be take week period abbvie be pricing treatment week deeper discount prominent drug now be prescribe condition gilead harvoni epclusa leerink analyst geoffrey porge estimate mavyret be offer discount gilead see revenue prescribe course harvoni discount epclusa competitive dynamic now solidify fda agree forecast market share price erosion gilead modeled rebound abbvie hepatitis revenue begin porge write note client porge call gilead remain competitive patient harvoni be give week still lose share base contract payer population patient treat mavyret undergo treatment week other patient likely migrate mavyret base convenience week regimen predict gilead drug epclusa vosevi be dose week harvoni be prescribe week patient be treat week ibd take gilead make acquisition be linchpin send biotech sector higher industry observer say head ibd industry theme closer look company gilead be consider mavyret broad label give abbvie access vast majority hepatitis patient exception ve fail drug dow component merck mrk johnson johnson jnj drug bristol myer squibb bmy fda be not require genotype testing be big advantage gilead other participant market write mavyret do have black box warning label risk hepatitis reactivation patient infection patient undergo pretreatment testing hepatitis infection then monitoring be find have hepatitis hepatitis porge say isn significant burden most hepatitis patient have already be screen hepatitis abbvie likely focus early effort government segment mavyret wholesale price be line harvoni undercut epclusa conversely abbvie pricing mean revenue contribution mavyret be likely be limit largely consistent exist forecast say stock market today abbvie close flat gilead fall related gilead be make acquisition not thinkgilead hepatitis franchise topple again share abbvie hammer gilead hepatitis franchise
1482,MRK,regeneron pharmaceutical regn tank week low tuesday wake partner sanofi sny report lag sale dupixent spooking investor worry prescription eczema drug be slow xon stock market today regeneron dove share trade well day move average fall flat base begin form late june buy point regeneron be set report second quarter earning early thursday analyst poll zack investment research expect report adjust income share sale sanofi second quarter report be tell several key drug sanofi report dupixent sale miss view accord reuter sell side analyst see buy side analyst modeled credit suisse analyst althea young say early sign dupixent launch be encourage view key question be patient growth continue be bolus upfront write note client physician have written dupixent prescription thus far result quarter full year young see number grow prescription end third quarter year end call sanofi say prescriber target company have written prescription dupixent lion share prescription have be most severe patient meaning still room grow key question come month remain drive prescriber put more patient drug write be get more comfort reimbursement used drug ibd take biotechs have be hot streak recently be now rank fifth group track ibd slip spot last week merger acquisition send higher say industry observer head ibd industry theme breakdown leerink analyst geoffrey porge other hand say dupixent launch be indeed flatten still be patient moderate severe eczema meaning dupixent hasn yet hit ceiling sanofi also plan launch dupixent germany year regeneron sanofi be also look dupixent asthma sanofi say expect final result asthma phase trial future look bigger picture regeneron stand chance narrowing valuation gap sanofi come year duo be joined hip partnership feature regeneron research development sanofi wallet sanofi have say remain very very commit make praluent success praluent be pcsk inhibitor aim lower bad cholesterol currently lock patent battle amgen amgn also have psck inhibitor know repatha be also finishing registration trial pd inhibitor form skin cancer plan file food drug administration early next year drug possibly rival similar cancer medicine dow merck mrk bristol myer squibb bmy regeneron sanofi be also look pd inhibitor advanced lung cancer second form skin cancer duo also plan combine pd inhibitor drug several trial related clovis regeneron be lead biotech deluge todayhow astrazeneca fail not once twice cancer drugsdow merck crushed keytruda sale view
1483,MRK,pfizer pfe be await clarification tax reform embark merger deal dow component say tuesday investor push acquisition second quarter sale decline again xinvestor have be clamore pfizer drugmaker market cap make more acquisition sale have fall past consecutive quarters early tuesday pfizer say second quarter revenue slip conference call follow report pfizer reaffirm be short term event marketplace such tax reform change asset value evercore analyst umer raffat say note client trump administration have make lofty promise regard tax reform include proposal cut corporate tax rate help domicile company render corporate inversion less desirable washington act tax reform business development acquisition be somewhat delay pfizer reportedly say need see tax reform absence tax reform then look business development activity ibd take president donald trump tax vision benefit biotechs drugmaker more other head ibd technology page breakdown look likely benefit most year pfizer chief method grow topline have be make big deal acquire medivation last year deal earlier year buy anacor pharmaceutical bind therapeutic bamboo therapeutic also walk away deal acquire allergan agn political controversy link allergan ireland tax domicile deal have let pfizer change tax domicile ireland thus pay less taxe legacy drug weigh pfizer quarter pneumonia drug prevnar see sale decline pristiq depression drug lose market exclusivity topple sale erectile dysfunction drug viagra fall meantime pfizer be putt effort further develop immuno oncology drug call bavencio approve treat form skin cancer bladder cancer drug be develop germany merck kgaa bavencio be pd inhibitor compete rival drug astrazeneca azn roche rhhby competitor space dow merck mrk bristol myer squibb bmy have pd inhibitor pfizer be look combine bavencio other drug pfizer acknowledge tuesday call astrazeneca recent failure combine immuno oncology drug imfinzi tremelimumab treat lung cancer doesn bode well similar combination trial indicate immuno oncology immuno oncology combination be more problematic term pfizer reportedly say pfizer note value have pd inhibitor purview still other be ahead stock market today pfizer fall share be yearlong consolidation buy point related generic chip away dow stock pfizer cancer unit be stabilize astrazeneca fail not once twice cancer drugswhy clovis regeneron be lead biotech deluge todayhow dow merck be benefit back astrazeneca bristol
1484,MRK,dow merck mrk beat analyst expectation star cancer drug keytruda deliver board beat second quarter prod share lift friday xinvestor have be laser focuse keytruda sale launch combination eli lilly lly chemotherapy alimta evercore analyst umer raffat say combo receive accelerate approval first treatment patient advanced lung cancer quarter keytruda sale grow merck credit growth oncology unit higher keytruda sale additional approval keytruda closely rival bristol myer squibb bmy opdivo hepatitis drug zepatier human papillomavirus drug gardasil also help drive topline beat bring respective sale investor likely didn give lot credence zepatier due struggle elsewhere hepatitis drug raffat say note leerink analyst seamus fernandez note sale diabetes drug januvia janumet be lower expect revenue drug decline year year overall sale grow beating analyst expectation adjust earning share grow year year crushed consensus view cent ibd take merck bristol myer squibb be square immuno oncology get latest battle ibd technology page merck also narrow full year guidance sale adjust earning share note cyberattack june disrupt global operation say product see temporary delay certain market stock market today merck advanced continue rebound wednesday month low share have be form flat base early march buy point related astrazeneca fail not once twice cancer drugswhy celgene gamble help small biotech moredeal help celgene rival dow merck bristol cancer drug
1485,MRK,stock drop start bell strong early economic news thursday disappointing earning report cisco system csco wal mart wmt compound market reaction wednesday release federal reserve minute concern development washington dow jone industrial average shed start trade nasdaq composite dump apple aapl fang stock post moderate loss market stall wednesday ahead release minute federal open market committee july meeting just news break trump administration have abandon key business council manned blue chip top executive decision once again stir concern washington commitment tax cut other key element president agenda not be soon come chief executive corning glw general electric ge unite technology utx johnson johnson jnj have decide leave council wednesday wall street journal report response president trump response event saturday charlottesville va head merck mrk armour ua have announce exit monday leader alliance american manufacturing afl cio resign group tuesday blackstone group bx chief executive stephen schwarzman inform white house member president strategic policy forum have decide dissolve group accord wall street journal minute later president tweet be eliminate manufacturing council well strategy policy forum dow wal mart cisco throw early anchor post decline quarterly result cisco fall earning revenue decline line expectation growth service recur revenue be lackluster loss drag share back week support stock attempt build floor month consolidation wal mart drag lower meeting analyst second quarter target provide guidance expectation comparable store sale rise top end guidance straight advance traffic growth be traffic gain report target tgt wednesday wal mart early decline send share back cup base buy point lead china base stock be mixed alibaba group hold baba elevated forecast jump earning revenue gain fiscal first quarter ibd stock report revenue cloud compute service soar annual active user china retail marketplace rise stock be extend second rebound support week move average february vipshop hold vip tumble second quarter report ibd stock momo momo jump open stock have be attempt retake cup base buy point datum storage gear maker netapp ntap slump more early trade report fiscal first quarter sale earning beat late wednesday second quarter guidance be line expectation decline cut stock week move average heavy tgrade send sell signal stop short decline buy point avoid automatic sell rule close apply material amat latam airline lfl gap gps ross store rost be company schedule report manufacturing slow less expect mid atlantic region august send philadelphia federal reserve manufacturing business outlook survey read july consensus forecast dip report point notable increase shipment new order continue expansion job growth month consecutive growth new york fed empire state survey wednesday surge past forecast highest mark year first time unemployment claim drop week end aug labor department report be prior week tally well consensus projection claim industrial production rise july accord federal reserve slower june expansion short estimate gain capacity utilization eke vs june line forecast conference board report lead economic indicator estimate july et afternoon dalla federal reserve bank president robert kaplan be schedule speak et minneapoli federal reserve bank president neel kashkari speak et related big picture stock stall do threaten market bounce techs be buy point classic bullish patternthese global retail giant deliver punch investing action planstock buy watch top ipos big small cap growth stock
1486,MRK,abbvie abbv be likely swipe significant hepatitis drug share gilead science gild week regimen week shorter triple pill treatment gilead analyst say wednesday food drug administration tuesday approve gilead combination sofosbuvir velpatasvir voxilaprevir week regimen patient genotype combo have be recommend approval week course europe be approve patient ve already try drug meanwhile abbvie combination glecaprevir pibrentasvir look likely gain approval week regimen genotype hepatitis patient ve never undergo treatment gilead harvoni be approve week regimen only subset patient label place gilead competitive disadvantage rival abbvie abbvie be likely get approval genotype week course leerink analyst geoffrey porge say note client approval genotype be uncertain note gilead be pricing triple pill be brand vosevi bottle bottle month run week price be less costly gilead harvoni sovaldi more expensive zepatier dow component merck mrk ibd take hepatitis drug franchise decline gilead have say be open acquisition cancer space biotech buy be better purchase say analyst visit ibd technology page closer look gilead buy most patient take vosevi fail respond harvoni zepatier abbvie drug combination abbvie drug other hand be likely grab approval regimen patient have never undergo treatment porge expect abbvie price pill drug viekira pak hepatitis combination go month abbvie aggressively market drug combo gilead harvoni epclusa say strategy be likely result significant market share abbvie give convenience excellent efficacy drug combination say note client porge forecast sale vosevi second half year expect see gradual decline outside expect vosevi pull annually same time porge model gilead harvoni epclusa lose market share abbvie call gilead hepatitis drug franchise represent just total sale fall half sale stock market today gilead share climb close abbvie pop finish related vertex hit record high result cystic fibrosis trialcould biotech stir takeover interest cancer drug approval star align biotechs crush earning consensus
1487,MRK,major market index slumber lower early trade tuesday tech heavy nasdaq decline dow jone industrial average hold more modest loss xamong dow industrial apple aapl quietly pace advancer stock market today gain iphone maker attempt add more momentum recent flat base downside medical name johnson johnson jnj merck mrk trade have be fight support day line hold flat base buy point merck be back day line fang member netflix nflx trade lower receive price target hike piperjaffray analyst firm bump target price premium monday close price video streamer have be trading well better expect earning report week cause surge share more chip stock receive more good news late monday chip designer inphi iphi report better expect earning result stock have be consolidate mid february jump attempt get back day line retailer be rise tuesday earning beat michael kor kor ralph lauren rl michael kor leap ralph lauren moved be midst recover multiyear lows be surge back day line today other analyst action tesla tsla be upgrade hold buy argus prompt share rise electric automaker be build cup shape base entry be still away entry ibd pra health science prah zebra technology zbra lead vanguard early trade tuesday move respectively report solid quarterly earning result pra health be breaking flat base entry zebra be attempt reclaim day line downside recent breakout grubhub grub essent group esnt decline food delivery service remain entry essent be trading right own flat base buy point related nvidia disney china stock lead monster week investing action plandisney base monster zone ahead earning investing action planchip stock watch semiconductor industry newsdow jone industrial average dow stock news stock news quote facebook amazon netflix google
1488,MRK,stock open tight loss tuesday biggest tech name majority dow industrial open red dow jone industrial average dip nasdaq composite sag start trade apple aapl fang stock open lower amazon com amzn lead decline third dow industrial name open lower merck mrk johnson johnson jnj hardest loss ibm ibm top index early gain biotech drug maker fibrogen fgen punch report second quarter result positive result clinical phase trial pamrevlumab treatment idiopathic pulmonary fibrosis fibrogen share be now year twilio twlo jetted ahead much stronger forecast second quarter revenue earning report monday close gain score past buy point cup handle base gap move open buy range valid chipmaker inphi iphi surge start gate investor react second quarter earning revenue narrowly top analyst target third quarter revenue guidance be consensus view gain boost inphi back week move average stock try start right side month deep consolidation valeant pharmaceutical vrx vault quebec base drug maker report smaller expect decline earning revenue slip line forecast management trim slightly full year revenue guidance stock be april low extend rebound support week move average downside tenet healthcare thc tumble revenue more triple fail meet expectation company significantly lower full year earning guidance avis budget group car dive more report big second quarter earning miss late monday revenue also miss view narrower margin management carved back full year ep guidance unicredit downgrade bond rating avis hertz global htz sell hertz share trade marriott international mar open lower hotel chain turn strong second quarter performance late monday include gain revenue third quarter earning guidance be just short consensus target decline send share week line support heavy trade sell signal job opening labor turnover survey be due labor department et overseas action be mixed china benchmark rise datum show sharp decline import export july japan tokyo nikkei drop work week very flat trade europe market turn lower afternoon trade frankfurt dax slip cac paris london ftse related apple chip supplier buy point china name surge stock likely benefit apple iphone upgrade big picture china name flourish dow make stock buy watch top ipos big small cap growth stocksdisney base monster zone ahead earning investing action plan
1489,MRK,biotechs lead alexion pharmaceutical alxn gilead science gild vertex pharmaceutical vrtx outperformed pharmaceutical brother june quarter analyst say earning season near close xleerink analyst geoffrey porge estimate large cap biotechs sale top wall street expectation average most impressive beat come alexion gilead vertex biogen biib alexion sale top consensus gilead hepatitis unit fall again quarter total revenue top vertex report sale beating biogen top sale comparison pharma company result be more tepid eli lilly lly merck mrk deliver significant revenue surprise otherwise fairly tepid result consist modest beat line result modest miss porge say note client last week dow component merck lilly top consensus respectively bristol myer squibb bmy glaxosmithkline gsk roche rhhby deliver modest beat novartis nvs astrazeneca azn nordisk nvo be line sanofi sny pfizer pfe johnson johnson jnj miss earning side performance be even more robust biotech porge say large cap biotechs beat average relative consensus bigger pharmas deliver earning top consensus average revenue growth vs year earlier quarter be biotechs drug firm average porge say board company report improve patient access drug well positive demand inventory currency effect ibd take biotech fever look chilly late july sector overcome challenge outlined ibd industry theme report
1490,MRK,quarter rare disease player biotech side do particularly well brad loncar chief executive loncar investment tell investor business daily biogen vertex sarepta therapeutic srpt positively surprised market spinraza treatment spinal muscular atrophy biogen ionis pharmaceutical ion nearly triple consensus model drug bring obliterate view analyst say sarepta absolutely crushed analyst expectation rise month high july key drug exondys treat duchenne muscular dystrophy bring more analyst have expect sarepta also cut loss expectation half think category drug investor have be expect payer pushback loncar say so far hasn show be ever group company be go boom more rare disease company sentiment have soured biotech sector hit month high late july loncar cite political uncertainty note lion share biotechs drugmaker revenue earn product beat expectation raise guidance fact re not trading indicate investor have already reset expectation year so maybe just hasn be quite impressive context say have big run come earning season play factor well uncertainty tax reform be keep most major player look make big deal porge say trump administration have yet offer further detail plan cut corporate tax rate make corporate inversion less desirable gilead have be gun buy something wake slow hepatitis sale didn comment second quarter call dow pfizer say putt deal pause await more tax situation washington loncar note pfizer call be really crystalize theme broader medtech sector have previously say big deal biotech really send stock higher look unlikely term mega deal be pause happen happen say pretty disappointing shouldn really affect call bolt deal mega deal seem be hold thing related gilead hepatitis franchise topple again share be beatwill pfizer cancer drug help grow merger biotech just blow past buy point sale beatastrazeneca beat stock dife drug failure more reportvertex sing late crush sale profit expectation
1491,MRK,large cap fund be set potential breakout stock market remain time high xfirst be ishare edge msci min vol usa usmv be just shy flat base buy point briefly clear prior flat base entry late april pull back buy point bounce day move average en route gain fund track msci usa minimum volatility index comprise domestic stock tend be less volatile broader equity market carry expense ratio usmv biggest sector weighting be health care july just asset information technology follow nearly consumer staple financial health care name account half top becton dickinson bdx johnson johnson jnj stryker syk unitedhealth group unh intuitive surgical isrg fund top name make less total asset usmv also help limit volatility keep hold less have relatively low annual turnover year date gain july be line accord morningstar inc etf outpaced benchmark index past year vs slightly underperform past year vs have dividend yield flexshare quality dividend index fund qdf track northern trust quality dividend index be buy point flat base fund launch december target stock sustainable yield lead profitable company have ability keep pay dividend top holding july include procter gamble pg boee ba pfizer pfe apple aapl merck mrk top stock account asset annual turnover be qdf have lag year past year annualize yield be well benchmark index average yield expense ratio be tuesday be good day many foreign etfs include international equity fund dwm ishare msci hong kong ewh dwm be still buy range entry ewh flat base buy point stock market pare early gain wednesday leave only dow jone industrial average positive territory earning fuel jump apple aapl spdr dow jone industrial average dium hold only gain spdr spy slip powershare qqq trust qqq edge lower stock sell board telecom retail real estate lead decline spdr telecom xtl fall slip day line first time week vaneck vector oil service oih reversed advance west texas intermediate crude price early reversed higher barrel few sector buck decline industrial select sector spdr xli rise utility select sector spdr xlu climb vaneck vector gold miner gdx be vaneck vector junior gold miner gdxj give powershare db gold fund dgl spdr gold trust gld ishare gold trust iau hold small gain related dow keep streak alive foreign play breaking dow hit new high techs give gain apple focusdow mark record high check solid play buy pointsfind happen stock market today
1492,MRK,index nasdaq composite dow jone industrial average hit record high week techs fuel selling start thursday afternoon federal reserve signale not worry stock price facebook fb dow boee ba verizon vz mcdonald other company be hailed strong earning alphabet googl amazon com amzn other have less ideal result tobacco stock such altrium mo crash friday fda say reduce nicotine level cigarette sub addictive level nasdaq composite index fall week week retreat thursday morning record high flood earning report dow industrial rise fuel boee verizon facebook leap earning amazon alphabet fall result oil price soar treasury yield rise dollar continue trend lower treasury yield rise week dollar continue trend lower boee ba swung profit take charge year quarter revenue decline miss view boee raise full year ep outlook analyst view aerospace giant say have talk customer new midmarket plane see demand aircraft northrop grumman noc general dynamic gd raytheon rtn also raise full year earning outlook report earning result estimate northrop say aerospace system sale climb higher manned aircraft demand include work advanced hawkeye aircraft raytheon see higher air defense missile smart bomb sale general dynamic revenue get support strong gulfstream defense product demand boee share soar week raytheon rise northrop be lower general dynamic tumble related boee put midrange demand plane stock hit sell signfacebook jump week hit record high earning revenue growth blow past expectation facebook exceed view various metric include user growth monthly active user twitter twtr earning beat view monthly active user be flat vs first quarter twitter share plunge snapchat operator snap fall hit record lows related facebook earning surge fang duo monopolize digital adsamazon earn cent share vs year earlier way view due heavy spending commerce giant operate income wasn great revenue be growth accelerate second straight quarter amazon web service revenue swell amazon share retreat friday close recent buy point undercut intraday related be winter come amazon shareholder big investment google parent alphabet stock retreat internet search giant earning fall short heighten expectation report higher expect traffic acquisition cost pay partner website google recognize nondeductible european union fine worry eu regulator crack more google say second quarter earning be share year revenue rise exclude time charge google say earn share related food drug administration announce fda aim require nicotine level cigarette sub addictive level roil tobacco stock friday altrium mo sell marlboro cigarette lose british american tobacco bti recently buy rest reynold american fall philip morris international pm sell marlboro cigarette overseas initially tumble close related fda act vs cigarette tobacco giant be hold federal reserve keep wall street prefer script wednesday leave key interest rate unchanged putt announcement begin unwinding balance sheet fed patience come economy be perform pretty well real gdp grow pace second quarter inflation wage gain have be more muted expect combination have be good stock market partly prospect low interest rate have weigh dollar be boon earning multinational second half year decision fed september announce shift reinvestment policy gradual pullback current stance reinvest principal mature mortgage treasury bond portfolio also send signal policymaker aren overly concern financial market be too exuberant next interest rate hike be expect december real uncertainty hinging inflation outlook be fed policy look flurry chip industry player post beat raise june quarter result include chipmaker advanced micro device amd cypress semiconductor cy intel intc texas instrument txn well chip gear supplier lam research lrcx teradyne ter amd earn adjust cent share sale analyst expect break even sale current quarter amd forecast sale rise vs wall street target cypress earn cent share ex item sale vs estimate cent cypress expect earn cent ex item sale vs view cent intel earn cent share ex item sale top view cent intel forecast adjust earning cent share sale analyst be look cent ti earn share ex item sale june quarter vs analyst expectation cent current quarter ti expect earn share sale vs wall street target lam earn adjust share sale june quarter analyst be expect september quarter lam expect earn share sale wall street be modele teradyne earn cent share ex item sale top expectation cent teradyne expect earn cent share ex item sale analyst have be expect cent paypal pypl earning rise year revenue rise slightly top consensus estimate digital payment processor member ibd raise full year outlook analyst view share rise record high pare gain crude future spiked barrel sign supply be fall revive shale boom be peter nigeria say ll eventually join rest opec curb production saudi arabia agree cut oil export crude inventory tumble barrel domestic production dip energy company trim capital spending plan month sub oil halliburton hal warn see exploration production company tap brake rig count plateau exxon mobil xom chevron cvx earning miss general motor gm report adjust profit grow beating view revenue drop view gm reaffirm full year ep guidance cut second half production swell inventory fall industry sale ford motor top view raise guidance largely lower tax rate gm fall further buy point ford fall back multiyear lows fiat chrysler fcau hold buy point adjust ep swell sale fall short maseratus luxury brand do well biogen biib obliterate sale expectation spinal muscular atrophy drug spinraza amgen amgn fall late tuesday boost ep ex item guide lag view gilead science gild report hepatitis drug franchise decline be partially offset growth hiv hepatitis drug sale vertex pharmaceutical vrtx say total cystic fibrosis sale gap celgene celg alexion alxn also beat view latter bust ep expectation cent astrazeneca azn crash thursday report mystic lung cancer trial immuno therapy combination fail drugmaker also announce deal merck mrk gain access latter blockbuster keytruda merck rise thursday bristol myer squibb bmy have have several setback drug opdivo slide concern mystic failure bode ill similar opdivo combo study wall street soured casino player mgm resort international mgm wynn resort wynn melco resort entertainment mlco sector overall put mixed result guidance concern mass market gaming macau weigh wynn result nonetheless beat estimate mgm offer weak revenue available room outlook also cite higher anticipate disruption monte carlo be be revamp park mgm challenge comparison la vegas strip la vegas sand lvs top result melco focuse boyd gaming byd penn national gaming penn be mixed share verizon communication vz soar telecom report better expect wireless result stiff competition narrow loss high spending postpaid phone subscriber verizon add more forecast say strategy packaging video wireless service be jell verizon say consumer be willing pay premium unlimited datum service high perform network comcast cmcsa report second quarter profit revenue top estimate nbcuniversal film entertainment business deliver strong box office result video subscriber loss be higher expect citigroup speculate comcast acquire verizon charter communication chtr miss earning sale share soar speculation be acquire well mcdonald mcd earning same store sale top estimate help cheap drink offering premium menu item chipotle cmg be testing queso face concern sale recovery have stumble follow food bear illness scare begin sale impact report customer fall ill july remain unclear domino pizza dpz crash part disappointing international comp lower margin ep help tax rate already high stock valuation starbucks sbux tumble fiscal same store sale revenue miss ep match view coffee chain say close teavana retail store several industrial dow giant rolled past estimate tuesday thank part improve global growth caterpillar cat surge week high company see ep revenue unite technology utx see earning climb share revenue rise share tumble lowest level raise full year ep revenue guidance dupont dd also beat top bottom line dow peer mmm be outlier overall miss share tank proofpoint pfpt report profit revenue top expectation forecast current quarter sale earning just consensus estimate sunnyvale calif base proofpoint specialize email datum loss protection corporate network cloud compute infrastructure proofpoint rise modestly friday morning fortinet ftnt post mixed result beat ep revenue billing growth disappoint outlook provider computer security software have yet improve recent ransomware attack fortinet share tumble tal education tal top earning sale estimate share profit cent revenue come ahead forecast cent current quarter china base education company see revenue view yahoo finance estimate meanwhile peer new oriental education edu also pull ahead forecast cent ep addition bump total student enrollment midpoint revenue guidance pull just ahead current view tal new oriental share rise respectively latter fail thursday mastercard report better expect second quarter earning revenue share reversed modestly lower record high remain buy range baidu bidu earning rise well view revenue climb line share chinese search giant rise friday electronic art ea report better expect quarterly earning video game publisher give cautious revenue guidance ea share rise friday briefly fall recent buy point
1493,MRK,stock jump thursday open surge big tech name drugmaker spur optimistic start nasdaq composite leap take new high facebook fb alexion pharmaceutical alxn paypal pypl lead long list tech name pull higher strong quarterly result add dow jone industrial average jump also seize new high earning news be front center factor premarket action thursday name include lendingtree tree netgear ntgr anheuser busch bud steep ascent quarterly report heavy lifter facebook thunder start trade open well new high report broad second quarter wednesday close ep gain increase revenue top analyst target company report daily active user surge ad revenue facebook ibd stock extend rebound support stock week move average more buy point january paypal jump more second quarter result earning rise revenue climb top analyst forecast management boost full year ep revenue guidance consensus target ibd stock be extend flat base buy point follow july apple aapl facebook other fang stock cohort gain ground open amazon amzn rise remain stock watch today exit buy range buy point ahead second quarter report due close not tech be cheery twitter twtr tank report revenue earning slip less expect quarter quarter growth monthly active user stall stock have muster rally april low wednesday close thursday loss send share crash back stock week move average facebook alexion lead stock alexion spiked strong second quarter performance see earning jump gain sale alexion share end trade wednesday late low back key level support dow merck mrk set high early bar vaulting more announce strategic collaboration astrazeneca azn develop immuno oncology cancer treatment lynparza drug company agree equally share development marketing cost well profit astrazeneca share skid drugmaker report stronger forecast result say lung cancer treatment mystic do not meet target phase clinical trial ibd list china base tal education tal chalk advance school tutor test preparation chain report solid fiscal first quarter beat include increase student enrollment guide revenue analyst target share be extend flat base buy point tal peer new oriental education technology edu slip send share back handle buy point network ffiv bristol myer bmy impede early progress dive mixed report bristol myer drop solid second quarter result concern lung cancer treatment follow mystic announcement astrazeneca durable good order surge june commerce department report blow past economist expectation increase decline order be revise most surge be aircraft other transportation item capital good transportation eke only month increase well view gain first time unemployment claim jump week end july labor department report be prior week outpace expectation advance claim oil price take breather surge day rally west texas intermediate inched trade asia market post strong gain thursday market europe slip mixed trade afternoon session related big earning miss thursday investing action planwhole food la vegas sand nutrisystem earning big picture sign new rotation
1494,MRK,donald trump discuss drug price biotech big pharma company celgene celg merck mrk amgen amgn health care ipo tabula rasa healthcare trhc be enter new buy zone provider datum drive technology help health care organization optimize medication regimen see ibd smartselect composite rating jump friday day new score mean company go public last september be now outperform stock term most important fundamental technical stock pick criterium history show top market performer tend have higher score launch major climb tabula rasa healthcare clear entry thursday close friday still buy range note thinly trade stock average daily dollar volume such stock show wider daily weekly fluctuation stock greater liquidity accumulation distribution rating show heavy buy institutional investor such mutual fund pension fund last week company post ep gain second straight quarter triple digit earning growth top line growth have range last report tabula rasa healthcare hold rank peer computer software medical industry group medidata solution mdso be top rank stock group related company be now outperform stock
1495,MRK,stock get weak launch thursday apple aapl microsoft msft general electric ge drag dow lbrand lb post worst decline dow jone industrial drop future dive nasdaq slump open trade apple fang stock trade lower start thursday session apple be tracking fourth week week move average dow stock general electric take hardest early hit european union accuse industrial conglomerate withhold information link recent merger ge also receive price target cut jpmorgan note cite uncertain outlook lag growth potential maintain stock underweight rating also dow merck mrk shed report late wednesday food drug administration have suspend series clinical trial merck blood cancer treatment keytruda victorium secret owner brand lb crumble weak read june same store sale lb lead downside tesla tsla retreat more early action follow tumble heavy trade trigger warning goldman sachs wednesday weaker expect delivery figure late monday tesla model do not receive highest iihs safety rating wednesday loss send share tumble week line support trip sell signal trimming gain buy point earning result report late wednesday send pricesmart psmt yum china yumc lower electrical component maker azz azz dive report broad first quarter miss early thursday china beigene bgne spiked open announce strategic partnership celgene celg develop immuno oncology compound target solid tumor deal provide beigene upfront license fee capital investment gain put thinly trade beigene february ipo price celgene share open lower mazor robotic mzor bolt higher late wednesday update second quarter revenue guidance company now see revenue prior guidance advance hoist share back week move average seventh week possible base layoff announce employer drop june job cut mark lowest level year accord monthly job cut report challenger gray christmas unemployment rate stand lowest level give company stronger incentive hold worker report say nonfarm private employer add new worker june accord national employment report adp be hiring well new job project economist consensus adp also revise estimate downward add worker first time unemployment claim rise week end july labor department estimate economist expectation steady go tally week move average edge higher commerce department trade deficit narrow april trade gap just miss consensus estimate pullback researcher markit june service purchasing manager index institute supply management service index be schedule energy information administration report weekly inventory estimate natural gas inventory oil et related big picture sloppy second half start stockschip stock jump industry see strongest growth yearsapple iphone demand soft analyst contendsq earning preview stock expect growth
1496,MRK,astrazeneca azn advanced lung cancer trial benefit rival bristol myer squibb bmy leave dow component merck mrk twirl wind analyst say thursday ahead key datum readout leerink analyst seamus fernandez only give astrazeneca trial chance hit grand slam instead likely trial result strikeout say report astrazeneca reveal result trial dub mystic later year wall street reaction fernandez assessment be fairly muted stock market today merck stock fall close astrazeneca bristol stock slip marginally respectively mystic trial be evaluate combination astrazeneca drug imfinzi tremelimumab vs chemotherapy patient advanced lung cancer trial be testing long standing theory couple immuno oncology drug offer better cancer defense imfinzi be know pd inhibitor work block interaction involve pd protein immune system tremelimumab be call ctla inhibitor work block different interaction body astrazeneca be testing patient more pd protein have stronger reaction combination drug fernandez see just chance combo work patient regardless many pd protein body have ibd take cancer focuse biotechs be ride high earlier month sectorwide boom meanwhile incyte incy stock have be consolidate mid march biotech rally lead head ibd datum story closer look however fall trial have implication bristol say separate trial bristol be testing drug opdivo yervoy advanced lung cancer yervoy be similar tremelimumab opdivo be know pd inhibitor have slightly different mechanism imfinzi mystic be clear binary event astrazeneca degree bristol well say bristol trial be also testing immuno oncology combination vs chemotherapy patient advanced lung cancer datum be expect later year grand slam be least likely scenario instance fernandez say astrazeneca bristol expect split advanced lung cancer market immuno oncology combo leave merck lead monotherapy market keytruda merck be testing keytruda combination chemotherapy also look combination keytruda incyte epacadostat be know ido inhibitor keytruda be similar opdivo also pd inhibitor roche rhhby meanwhile be look combination drug tecentriq avastin chemo tecentriq be also pd inhibitor astrazeneca imfinzi top line result trial be expect third quarter assume modest peak share roche yet be determine combo fernandez say immuno oncology chemo regimen anticipate merck dominate follow roche bristol note however mystic trial negatively influence potential merck roche immuno oncology chemo combo mystic trial isn successful fernandez see downside astrazeneca see upside be trial succeed slim chance astrazeneca combo work patient regardless protein expression set high competitive bar bristol combo related dow merck be still lead bristol roche immuno tesaro overcome clovis lead combo merck co biotech fly nearly strong trial be drug better
1497,MRK,gilead science gild fill hole portfolio acquire incyte incy analyst suggest friday offer caveat vertex pharmaceutical vrtx still be less risky bet gilead make play now incyte tune premium stock price biotech largely be bet commercial success incyte immuno oncology drug epacadostat meanwhile deal slump hepatitis drug sale unit much value acquisition depend achieve substantial sale more epacadostat highly competitive somewhat unpredictable world immuno oncology leerink analyst geoffrey porge write note client porge imagine gilead afford pay share acquire incyte earlier year gilead acknowledge be open deal particularly oncology analyst have suggest incyte tesaro tsro clovis oncology clvs kite pharma kite potential target incyte help fill gap gilead portfolio porge say flagship product jakafi be approve number blood disorder region incyte be also work immuno oncology drug trial dow merck mrk bristol myer squibb bmy ibd take cancer therapy be winning investor approval kite pharma sit top run streak check industry snapshot closer look company prove be strong bet premium incyte stock price deal generate accretion year say transaction create rate return gilead shareholder next year projection be dependent strong sale epacadostat used premium model gilead earning be dilutive internal rate return north vertex incyte deal be similar size vertex represent lower risk less strategic option gilead give limit still substantial application vertex product technology say incyte other hand offer high risk high reward epacadostat broader development portfolio write stock market today gilead fall cent incyte be vertex be cent related be gilead fortune change acquisition gilead vertex join don hold breath analystwhy biotech rally still tack upside
1498,MRK,key hepatitis drug gilead science gild top wall street expectation investor be tune company second quarter report july more hint potential activity analyst say friday gilead hepatitis sale slip month follow biotech say be open deal especially oncology analyst have be quick offer incyte incy tesaro tsro kite pharma kite clovis oncology clvs potential acquisition target other have say vertex pharmaceutical vrtx be smart buy help fend larger dip hepatitis franchise credit suisse analyst alethia young expect gilead harvoni key hepatitis drug beat analyst second quarter model period model gilead pull sale just north consensus adjust income share top broader forecast nickel expect beat harvoni sale still be year year young also expect gilead genvoya hiv medication top wall street view sale model period see total prescription grow quarter quarter vs consensus expectation just growth however don expect share react strongly beat think investor be look gilead do deal write note client ibd take big biotechs be likely struggle year investor focus turn smaller cancer rare disease focuse biotechs analyst say head industry snapshot closer look company be pique analyst interest biogen biib also be limelight investor look strategic update plan growth heighten competition multiple sclerosis arena drugmaker roche rhhby march gain approval drug ocrevus treat form multiple sclerosis young see biogen key ms drug tecfidera tysabri pull line sale long term number be street quarter young forecast line total sale see adjust profit miss view share consensus view biogen be schedule report result give strategic update july strategic update look biogen give insight collaboration eisai well newly seat chief executive michel vounatsos long term vision company investor also likely want update alzheimer drug aducanumab think investor be hope hear company give interim readout aducanumab phase trial next year say think make want own other want datum incyte beat top line strong jakafi sale investor focus likely be immuno oncology drug epacadostat strategic partnership dow merck mrk bristol myer squibb bmy incyte be set report earning aug more broadly young expect line quarter large cap biotechs see amgen amgn alexion pharmaceutical alxn vertex biomarin pharmaceutical bmrn report metric line consensus view related gilead acquire biotech vertex be still better analystare gilead fortune change acquisition biotech rally still tack upside
1499,MRK,republican senator dean heller nevada just knife trumpcare not recover heller relatively moderate republican state expand medicaid announce friday support bill unveil republican leadership day heller say win vote bill take insurance away ten million american hundred thousand nevadans republican only afford lose gop senator so heller strong condemnation bill leave party perch precipice already conservative senator have threaten oppose bill be face criticism right wing group conservative be win be now harder do support bill give way center surprise heller be re election voiced opposition even congressional budget office release analysis bill impact early next week most gop senator be keep low profile ahead report perhaps hold hope increase rank uninsured wouldn compare figure cbo attach trumpcare bill squeak house handful gop moderate senator have push slower phaseout medicaid expansion voice concern have be sen susan collin maine shelley moore capito west virginia lisa murkowski alaska rob portman ohio response come cbo report be influenced heller strong stand hard be first republican oppose bill be too far right other hand be decide vote doom trumpcare be even harder now be conservative opposition be safer moderate oppose bill thursday detail bill emerge wall street breathe sigh relief push broad range health care sector stock include insurer unitedhealth group unh hospital group hca healthcare hca drugmaker merck mrk unitedhealth merck be dow jone industrial average component share hca medicaid focuse insurer centene cnc push higher late friday session investor possibly begin price lower odd trumpcare passage apparent reason health care stock rise thursday be mizuho analyst sheryl skolnick put senate bill wasn bad house intermediate term slower phaseout obamacare medicaid expansion wall street have be think conservative critic senate trumpcare bill year medicaid cut never happen friday market didn react much news first moderate gop senator come bill back march trumpcare appear doom house market stumble wall street strategist mark expectation rest president trump agenda include tax cut infrastructure spending expectation have come way lot market strategist be still factor modest tax cut earning expectation mean trumpcare take center stage come week be volatility ahead related trumpcare almost everyone get hca merck rally senate trumpcare bill pare term cutstrumpcare life house pass obamacare repeal bill
1500,MRK,here big problem face new senate trumpcare bill almost everybody get deal grave fault bill pass house do address couple obamacare sore spot raise cutoff limit subsidy provide more support moderate income young adult crunch number senate plan surprising thing be hard be find anyone pay less trumpcare plan roughly equivalent obamacare bronze plan almost everyone least year old get deal almost everyone earn poverty level include get deal person earn more poverty level new subsidy cutoff single get deal be political actuarial problem political problem be republican have spend year criticize obamacare high premium huge deductible hit middle class gop make problem almost everyone reason peter suderman put senate gop new health care bill be just obamacare less impossible overstate determine republican be repeal obamacare least tax increase mandate actuarial problem be prove be bill undoing send gop back draw board keep rest president trump agenda hold investor initial reaction senate trumpcare bill be more less positive least health care sector share insurer unitedhealth group unh hospital operator hca healthcare hca drugmaker merck mrk rise bill be unveil thursday unitedhealth merck be member dow jone industrial average last thing wall street want be trumpcare turn quagmire exhaust narrow legislative window available corporate tax cut infrastructure spending ibd take find wall street breathe sigh relief republican senate leader disclose trumpcare bill analyst email advice client buy unh hca just big rewrite challenge gop face be clear congressional budget office release analysis senate officially name better care reconciliation act early next week reason think be pretty severe consider else equal subsidy year old earn poverty level owe bronze type plan year senate trumpcare bill subsidy almost exactly same cost obamacare year accord kaiser family foundation subsidy calculator yet same plan have cost only house gop american health care act include age rating change base ibd analysis here be big deal house plan only manage lower average premium cbo dramatically shift landscape favor relatively young moderate income adult slash support older adult average plan cost less young person be price market older person be price brooking institution researcher matthew fielder loren adler calculate underlie increase cost insurance house plan be be obscure demographic shift cover population other factor underlie premium hike be function expect adverse selection trigger republican kill obamacare individual mandate mandate relatively young healthy aren go be willing pay much insurance come roughly deductible likely trumpcare bottom line be senate bill do quite bit less price relatively young healthy market less price older low income household well show net increase premium wild card be cbo analysis senate trumpcare bill impact premium state opt waive certain obamacare rule let state increase allowable ratio premium older younger adult raise pocket limit eliminate mandatory benefit such maternity care substance abuse service senate bill stack obamacare come premium be killer trumpcare most glaring problem be make obamacare deductible look minuscule especially true low income individual benefit obamacare extra cost sharing subsidy limit pocket spending medical bill year old couple earn poverty level good news be premium only cost income same obamacare bad news be instead face maximum additional bill health spending ll have combine deductible roughly bill gut obamacare medicaid expansion million person earn poverty level even less have get coverage individual market problem isn so much ll have pay premium equal income ll have deductible equal more half income john grave assistant professor health policy vanderbilt school medicine tweet ahca house bill cause more uninsurance strong sense be bcra senate bill be more underinsurance other word possible cbo analysis predict much smaller increase uninsured see house bill lot more person sign high deductible coverage include influx displace medicaid beneficiary premium rise due adverse selection create problem senate bill implement automatic subsidy cut total individual market subsidy exceed gdp much lower cap obamacare related unitedhealth hca merck rally senate trumpcare bill pare term cutsibd rank insurer just give obamacare big hugtrumpcare life house pass obamacare repeal replace obamacare save social security
1501,MRK,ethical drug industry group have be see increase strength past week wednesday abbvie abbv be discuss ibd income investor column potential beneficiary merck mrk be strong candidate merck keytruda drug continue show substantial sale growth april vs prior month market share rise same
1502,MRK,future index nasdaq dow jone industrial average erased modest gain turn slightly negative european stock loss grow dow industrial stock be worth watch apple aapl jpmorgan chase jpm merck mrk home depot hd american express axp be base build mode several very close buy point dow stock pay decent dividend american express dividend yield apple jpmorgan home depot merck dow jone industrial average future retreat fall nearly fair value nasdaq future dip future be just break even apple be world most valuable company have strong show iphone maker technically be flat base buy point trading tightly several week apple plunge many lead techs june stock then fall again june close day move average then key support line have act resistance share edge thursday apple need retake day first step build right side consolidation related apple aapl stock quote company news chart chase be double bottom base buy point share moved back day line june jpmorgan chase edge thursday close federal reserve say jpmorgan other big financial pass annual stress test next week fed decide not approve bank plan dividend hike buyback jpmorgan rise premarket trading friday related jpmorgan bofa goldman citi pass stress test now pay biotechs have be soar week several breakout traditional drug stock be act well too merck rise thursday so far week dow drug giant be close buy point aggressive investor have see potential early entry point merck be benefit success immuno oncology drug keytruda have be winning approval more cancer rival treatment run problem home depot be few brick mortar retailer be act well home improvement giant have be build short flat base buy point stock dip briefly day line june rebound follow session share have pull back last session edge thursday lighter trade american express technically clear flat base buy point tuesday gain be small volume just average share have do little rise cent anemic trade thursday ideally want see stock power past buy point heavy volume solid gain brisk trade be encourage shouldn chase stock buy more buy point asian trading japan nikkei rise china shanghai composite gain european trading intraday ftse fall germany dax lose france cac dip related stock erase gain bull be run sectoribd datum table dividend leadersdow jone industrial average dow stock news analysis
1503,MRK,xtenet healthcare thc other hospital lead broad advance health care stock thursday senate republican unveil own version trumpcare short takeaway courtesy mizuho analyst sheryl skolnick be senate bill be lot less short term lot more long term comparison house version particular medicaid spending suffer smaller hit term face even bigger long term cut hospital group hca healthcare hca rise tenet healthcare jump universal health service uhs gain stock performance have even take management surprise politico publish letter tenet send employee ask rally opposition trumpcare investor have good reason focus more intermediate term always possible big year cut be interrupt delay democrat make comeback example other hand sharp eventual spending cut relative obamacare threaten support moderate gop senator nbc news be report gop senator plan voice opposition new legislation enough deny passage manage care company also be solidly higher thursday centene cnc molina moh big player obamacare exchange medicaid expansion be better performer centene climb molina anthem antm biggest obamacare exchange insurer rise anthem say wednesday pull obamacare marketplace indiana wisconsin centene be rare company make profit exchange medicaid be big profit driver industry include unitedhealth group unh dow jone industrial average component insurer stand benefit gop plan tax health insurance plan unitedhealth rise record high aetna aet gain humana hum advanced skolnick message investor buy unh hca prospect more modest health spending cut fear assume trumpcare even pass also lift share drugmaker biotechs dow component merck mrk rise pfizer pfe johnson johnson jnj notch record high johnson johnson also stand benefit repeal obamacare tax medical device merck have be rally good news immuno oncology treatment keytruda crossed aggressive entry near conventional buy point
1504,MRK,xmajor stock index show modest gain afternoon trading thursday wall street digest strong earning oracle orcl health care stock outperformed gop release new version obamacare repeal bill stock market today oracle orcl gap flat base entry rise strong earning be catalyst buy stock gap buy point important buy close open price possible oracle open share be recently trading nasdaq composite lead way rally dow jone industrial average picked small cap outperformed russell volume nyse nasdaq be tracking slightly lower wednesday level health care related industry group outperformed few retail group lag outperformer dow include unitedhealth unh johnson johnson jnj pfizer pfe merck mrk meanwhile china stock be pressured chinese regulator ask weibo wb stop audio video stream service share weibo lose be session lows chinese government have be step effort stop political speech social medium site sina sina alibaba baba have ownership stake weibo share sina be well session lows still fall alibaba ease american airline aal picked be well session high news qatar airline be consider stake company american be still buy range handle entry tesla tsla gain time high company reportedly reach agreement city shanghai explore build production facility related weibo ibd chinese internet stock be selling offunitedhealth hca merck rally senate trumpcare bill pare term cutstesla get closer big manufacturing expansion china
1505,MRK,merck mrk keytruda continue gain share immuno oncology drug bristol myer squibb bmy roche rhhby approval keytruda chemotherapy combination overall immuno oncology drug sale grow month month datum symphony health show merck keytruda be gain share expense bristol opdivo yervoy leerink analyst seamus fernandez say keytruda share increase percentage point opdivo yervoy share fall respectively combine end roche drug tecentriq remain steady share year market tecentriq differ keytruda opdivo target pd protein vs pd protein target merck bristol drug pfizer pfe bavencio astrazeneca azn imfinzi be also pd antibody bavencio imfinzi be newest market have achieve only nominal share third first month respectively follow approval fernandez write note client ibd take other immuno oncology news kite pharma kite bluebird bio blue stock have rocket month follow american society clinical oncology meeting chicago head industry snapshot deep dive fernandez expect keytruda keep gain share follow approval advanced lung cancer combination alimta eli lilly lly keytruda also receive recent approval bladder cancer tumor evercore analyst umer raffat say keytruda be tracking analyst projection sale second quarter june sale be month month keytruda be likely beat expectation raffat write note client stock market today merck component dow jone industrial average be close share bristol rise roche stock lift related tesaro overcome clovis lead combo merck co biotech fly nearly strong trial be drug better dow merck pause cancer trial investigate keytruda tie death
1506,MRK,tesaro tsro zejula likely outperform drug clovis oncology clvs astrazeneca azn combine treatment big name pharmaceutical company analyst suggest tuesday leerink analyst seamus fernandez suggest tesaro do better mixed drug dow merck mrk bristol myer squibb bmy roche rhhby suggestion come day clovis unveil strong datum drug rubraca ovarian cancer phase trial dub ariel signal clovis get broader label expect ovarian cancer tuesday wall street scramble differentiate drug astrazeneca clovis tesaro have be know parp inhibitor drug aim block family enzyme cancer cell use proliferate differentiate tesaro zejula clovis rubraca astrazeneca lynparza likely come well combine immuno oncology drug block interaction involve pd pd protein immune system zejula appear be only late stage parp inhibitor be combinable pd pd inhibitor cross blood brain barrier fernandez say note client tesaro drug appear be less toxic liver be important immuno oncology combo ability cross blood brain battier help tesaro get foothold breast lung cancer commonly spread brain fernandez cut price target tesaro stock still have market perform rating share see even split tesaro clovis ovarian cancer patient ve already undergo round prior therapy ibd take merck bristol roche be work immuno oncology space head ibd industry theme closer look perform american society clinical oncology meeting earlier month chicago fernandez janney analyst debjit chattopadhyay see astrazeneca benefit clovis trial show parp inhibitor be more similar dissimilar lynparza be approve treat ovarian cancer patient mutation brca gene parp inhibitor be thought work better patient brca genetic mutation clovis trial show response patient regardless genetic still doctor preference screening patient mutation benefit astrazeneca chattopadhyay keep neutral rating tesaro stock trim price target fernandez see tesaro have leg clovis immuno oncology combo note house pd antibody be far mature also upgrade clovis stock buy rating price target clovis stock fly monday follow trial meanwhile tesaro stock be still be buoy rumor mill chattopadhyay say gilead science gild be rumore potential acquirer credit suisse analyst alethia young too boost price target clovis stock keep outperform rating share top line success ariel trial show rubraca have meaningful market opportunity parp space say close stock market today clovis stock be tesaro stock dove astrazeneca stock lift less related cancer drug specialist be todaybiotech fly nearly strong trial be drug better astrazeneca keep clovis tesaro unveil blockbuster drug
1507,MRK,xstock trek lower tuesday give back only piece ground gain monday nasdaq take hardest hit fall drop dow jone industrial average drift preliminary datum show volume exchange come higher monday level west texas intermediate crude drop just barrel oil slough undercut low settle lowest point november move ve send oil related stock crowd lowest slot dow barely even register chevron cvx exxon mobil xom drop less oil stock post only day worst loss stock general electric ge be dow worst performer weak trade apple aapl tumble fang stock end lower price target increase netflix nflx medical drugmaker biotechs post strong session merck mrk pfizer pfe easily top dow industrial respectively ibd stock regeneron pharmaceutical regn alexion pharmaceutical alxn lead nasdaq biotechs drugmaker take day top gain nasdaq stock regeneron surge reach month high novartis nvs report rth macular degeneration drug have outperformed regeneron eylea head head clinical trial regeneron be clear month cup base novartis share rise tuesday alexion jump regulatory filing show ceo ludwig hanson make purchase company share worth ibd leaderboard stock floor decor fnd end higher back early high gain left share buy range buy point settle april ipo price retail be tuesday worst perform industry dd penney jcp drop ross store rost shed almost worst decline nasdaq stock several big name be schedule roll earning report close adobe system adbe fedex fdx red hat rht top list related biotechs be lead industry month highamazon get rating upgrade whole food buy be grubhub next
1508,MRK,clovis oncology clvs rubraca isn wildly different tesaro tsro zejula treat ovarian cancer analyst say monday even clovis stock rushed month high tesaro stock topple afternoon trading stock market today clovis stock fly close earlier hit high last see november meanwhile tesaro stock dove much pare loss share be close rubraca significantly improve progression free survival ovarian cancer patient clovis say early monday trial look patient specific genetic mutation tie ovarian cancer call brca hrd clovis success patient regardless genetic mutation likely bode well astrazeneca azn tesaro leerink analyst seamus fernandez say astrazeneca drug lynparza well drug clovis tesaro be know parp inhibitor believe trial add considerable weight argument parp inhibitor have similar activity likely increase probability fda grant lynparza broad label only be study brca mutate patient say clovis have broadest label parp inhibitor market rubraca grab fda approval maintenance treatment ovarian cancer patient ve already undergo least prior therapy maintenance treatment keep patient cancer remission rubraca be already approve ovarian cancer patient specific brca mutation ve undergo least prior round therapy approval bode well commercial uptake drug leerink analyst michael schmidt say note client ibd take other cancer news dow merck mrk bristol myer squibb bmy roche rhhby unveil datum american society clinical oncology conference earlier month head ibd industry theme look winner conference schmidt have outperform rating clovis stock expect clovis become prime takeout candidate strong trial result rubraca leerink fernandez have market perform rating tesaro stock fernandez see differentiation parp inhibitor astrazeneca clovis tesaro come tolerability convenience late stage trial fewer patient have serious adverse event consistent other trial tesaro zejula be dose once daily vs twice daily dose schedule rubraca clovis say plan submit application food drug administration rubraca maintenance treatment follow least prior therapy next month related cancer drug specialist be todaycan astrazeneca keep clovis tesaro unveil blockbuster drug be sanofi gilead bidding war small cap biotech
1509,MRK,wall street remain bullish tuesday merck mrk even dow drugmaker suspend enrollment pair cancer trial note more patient die group used keytruda medication other group merck say late monday pause enrollment trial keytruda immuno oncology drug combine corticosteroid dexamethasone pomalyst revlimid celgene celg chemotherapy trial treat multiple myeloma blood cancer merck be look patient have never be treat patient cancer have relapse hadn respond previous treatment independent committee recommend merck suspend enrollment trial discover more patient die used keytruda comparison group merck say collect more information close bell stock market today merck stock dip finish regular trading session earlier fall much share biggest rival bristol myer squibb bmy be marginally ibd take keep tab biotech pharma industry bookmarking ibd biotech stock watch pharma industry news page company watcher likely aren figure much multiple myeloma sale merck ub analyst marc goodman write note client estimate risk adjust sale keytruda multiple myeloma importantly merck indicated other study keytruda continue unchanged say do not expect issue multiple myeloma carry other study important keytruda chemo combo advanced lung cancer credit suisse analyst vamil divan say note client be inevitable least keytruda combination ongoing trial wouldn work expect doesn expect pause multiple myeloma have material impact merck date keytruda have have clean safety profile number study ongoing very sick patient population be reasonable assume certain combination indication yield negative safety result say divan keep outperform rating price target merck stock ub goodman have buy rating price target share merck evercore analyst umer raffat note prior patient trial keytruda dexamethasone celgene revlimid be very effective patient show reduction tumor size be hint safety issue prior study say bigger question be rival bristol be see similar issue immuno oncology drug opdivo merck combination be month ahead bristol raffat write note so far update bristol trial related dow host diabetes study lilly benefit mosthere be winner loser year biggest cancer meetingdow merck clearly win vs bristol roche cancer trial
1510,MRK,johnson johnson jnj diabetes drug invokana cut cardiovascular event long term study eli lilly lly stand benefit most doctor steer clear medication worry increase risk amputation study dub canvas be present late monday dow stock johnson johnson say invokana reduce risk cardiovascular death nonfatal heart attack nonfatal stroke vs drug placebo additional analysis show invokana lower risk hospitalization heart failure invokana also delay progression albuminurium presence specific chemical urine indicate kidney disease rbc analyst glenn novarro say canvas study be unlikely reverse negative trajectory invokana sale first quarter invokana invokamet sale drop year year novarro forecast dip sale eli lilly other hand benefit johnson johnson study merck mrk trail analyst say lilly jardiance be sglt inhibitor work help kidney lower blood glucose level merck januvia be dpp block glucagon release trigger insulin secretion validate cardiovascular benefit boost sglt class credit suisse analyst vamil divan write similar study lilly jardiance also show benefit cardiovascular outcome jardiance also cut risk cardiovascular death mortality even canvas study lilly be poise grab chunk invokana sale food drug administration require johnson johnson physician potential amputation associate invokana invokana double risk amputation recent study expert cite leerink analyst seamus fernandez say amputation worry be biggest differentiate factor physician decision prescribe jardiance invokana show similar cardiovascular benefit diabetes patient close stock market today johnson johnson stock tick finish regular trading session lilly stock add share diabetes drugmaker merck dip end day ibd take johnson johnson stock have ibd composite rating meaning outperform more quarters stock term key growth metric more ibd rating visit ibd stock checkup meanwhile dpp class diabetes drug include merck januvia face incremental pressure credit suisse divan say time however expect enthusiastic response canvas efficacy datum drive use sglt class earlier course treatment concurrently push dpp further back say note client merck pfizer pfe dow stock be jointly work sglt inhibitor call ertugliflozin regulator approve drug december win have datum cardiovascular outcome several year pfizer take chunk sale meaning shift januvia ertugliflozin be net negative merck related lilly grab diabetes share dow amputation woesabbvie expect rival chip away biggest drug franchisedow pfizer face challenge roche lilly loom
1511,MRK,strong start nasdaq composite fade early tuesday day fed meeting get underway index regroup be back high afternoon trading western digital wdc tesla tsla wynn resort wynn be best percentage gainer nasdaq gain nasdaq add dow jone industrial average picked volume exchange be tracking significantly lower monday level western digital gap aegis capital initiate coverage buy rating set price target share jump nearly stock show solid action week move average key support level separately japanese medium outlet report western digital raise bid toshiba chip unit broadcom avgo be interested bidder citigroup add even cfo john gerspach warn second quarter slump trading revenue other money center jpmorgan jpm bank america bac goldman sachs gs also issue similar warning stock market today couple high profile health care name make headline dow component merck mrk gap lose news company be stopping enrollment new patient late stage study testing immunotherapy drug keytruda multiple myeloma combination other therapy news be better johnson johnson jnj company present strong datum diabetes treatment invokana share be mostly unchanged news stock have be perform well late still buy range early flat base entry sierra wireless swir rebound vengeance straight decline share jump small cap be major player nascent internet thing market everyday device be connect internet sierra wireless be top buy range buy point market uptrend pressure new buy carry add risk ibd nutrisystem ntri ichor ichr lumentum lite be top percentage gainer gain range related rival tesla see western digital seagate start buyhere be latest bank trading revenuedow host diabetes study lilly benefit most
1512,MRK,alphabet googl microsoft msft other tech titan sell drive market lower jpmorgan chase jpm bank america bac break financial hike buyback dividend pass stress test walgreen boot alliance wba drop plan buy rite aid rad major market average retreat volatile week big tech lead sell off tuesday thursday surround wednesday rally nasdaq fall week drop day move average microsoft alphabet get big eu fine be many top techs join apple key level dow industrial index retreat respectively financial such jpmorgan jpm bank america bac citigroup rally announce big shareholder return plan follow second round annual stress test energy stock rise oil price climb hawkish comment european central bank chief mario draghi lift euro eurozone bond yield push treasury rate pressure stock market direction be downgrade uptrend pressure economy grow first quarter revise prior estimate commerce department report consumer spending rise rate revise economist expect growth just end second quarter result steady unimpressive rate first half year meanwhile federal reserve primary inflation gauge pce price index rise just year annual gain february core pce inflation strip food energy slip february undercut case term rate hike european central bank president mario draghi put investor notice day bond buy boost economy elevate asset price be wind stock price take tumble particularly technology stock draghi tuesday speech economist interpreted signal ecb begin taper bond purchase start meanwhile federal reserve chief janet yellen vice chairman stanley fischer talk fairly rich equity price central bank gear begin slowly unwinding financial crisis asset purchase later year takeaway less supportive central bank be headwind stock not hurricane long policymaker don move too fast related draghi drama undercut key stock market federal reserve jpmorgan citigroup other large bank move forward dividend buyback increase central bank release result part annual stress test most bank quickly announce big shareholder return send share higher capital financial cof need resubmit capital plan dec address weakness plan procedure comprehensive capital analysis review evaluate bank capital cushion risk management procedure payout plan bank clear first round test earlier june related jpmorgan bofa goldman citi pass stress test now pay european union say google parent skewer search result benefit own shopping search service vs rival alphabet end offend practice day face further penalty impact google product list ad pla revenue be not clear depend remedy internet search giant take eu be also probe google android operate system adsense online ad service google map wild card be trump administration reaction federal trade commission end investigation google business practice internet search giant agree voluntary change practice share car rental company jump monday report avis budget group car inked deal manage car fleet waymo self drive tech unit alphabet googl hertz htz get extra pop later day report say apple aapl be lease handful car test self drive technology not clear much financial boost rental car firm get walgreen boot alliance wba scrap bid acquire rite aid rad announce deal walgreen pay rite aid store roughly half total new deal be expect close month follow month attempt ease regulator concern merger not harm competition report merger prospect whiplash rite aid stock rite aid also pull deal fred fred pharmacy chain set receive hundred rite aid store merger agreement walgreen walgreen rise thursday investor fear rite aid fred be too small be competitive rite aid crash thursday worst level nearly year fred tumble related ftc pushback rite aid buyout walgreen split differenceolive garden parent darden restaurant dri logged ep gain sale growth best expectation overall same store sale grow include comp gain olive garden share hit record high tuesday darden continue outperform sit peer such cheesecake factory cake buffalo wild wing bwld chilli parent brinker international eat nike nke easily beat profit sale estimate ep growth cent revenue gain management confirm call be indeed go sell certain shoe apparel accessory directly amazon share soar top buy point intraday earlier week armour uaa name patrik frisk new coo revive suite position leadership shuffle related nike deal amazon send dow stock soaringmemory chip maker micron technology mu earn adjust share reverse year earlier loss cent fiscal third quarter end june sale rise analyst expect current quarter micron expect earn share exclude item reverse year earlier loss cent sale base midpoint guidance wall street be modele analyst hailed result guidance micron share fall friday drop buy point western digital wdc resubmit bid acquire memory chip business toshiba jointly run japan base toshiba want sell unit consortium include korea base sk hynix bain capital japan reportedly bid western digital gain stake operation sandisk acquisition say toshiba sell unit toshiba sue western digital western digital also raise earning guidance left revenue target intact initial public offer blue apron aprn fall flat share pricing low end downwardly revise range blue apron trade flat thursday debut fall friday blue apron be company schedule ipo past week most struggle top performer be dova pharmaceutical dova open gain jump nearly friday dow component merck mrk say tuesday cholesterol reduce drug anacetrapid be able reduce heart attack cardiac death need certain heart surgery patient already cholesterol lower statin anacetrapid build fat tissue similar study merck didn test effect anacetrapid reduce risk stroke esperion therapeutic espr stock break wednesday announce trial combine bempedoic acid anacetrapid lower bad cholesterol kb home kbh result beat analyst expectation earning cent revenue delivery rise home average selling price increase backlog value rise increase volume home adjust homebuilding operate margin widen basis point kb home soar year high mdc holding mdc break follow kb home result builder pull back broad market sell higher interest rate facebook fb have top monthly active user double base little more year general motor gm now see industrywide sale low range year prior estimate demand be equal last year record meanwhile other sign point softening demand high margin suvs store capital stor announce investment berkshire hathaway brkb unit monday equal stake reit stock surge news metal specialist arconic arnc halter sale type aluminum cladding panel be used london high rise build fire kill dozen person mid june arconic stock plunge stage recovery satellite radio broadcaster sirius xm siri shake management pandora medium take investment stake stream music service be ceo tim westergren president mike herring chief marketing officer nick bartle cfo chopra be name interim ceo jason hirschhorn joined board director
1513,MRK,dow component merck mrk say friday keytruda outperformed immuno oncological counterpart bristol myer squibb bmy year study patient advanced melanoma wasn enough move merck stock much stock market today share dow jone industrial average group stock rise close bristol myer stock advanced separate study show drug have promise cervical cancer merck say american society clinical oncology conference more patient treat keytruda be alive year begin treatment compare be treat bristol yervoy study look patient never be treat have undergo prior round therapy keytruda yervoy be immuno oncology drug aim block interaction immune system allow cancer cell hide have different method former block pd protein yervoy block ctla protein receptor keytruda be more similar bristol opdivo ibd take merck stock be just year many technical characteristic be mend share begin create flat base march buy point visit income investor closer look merck stock be near finding keytruda be associate improvement survival half patient treat keytruda be alive nearly year start treatment year mark yervoy patient be still alive merck drug also nearly double rate progression free survival month keytruda group patient be alive hadn see disease progress vs patient yervoy group related gilead hiv combo pass muster stand glaxo merck bristol incyte match beat dow merck combination trialshow biotechs fall cancer partnership bristol myer
1514,MRK,roche rhhby return right license immuno oncology drug back newlink genetic nlnk analyst say shouldn impact incyte incy have rival drug trial merck mrk bristol myer squibb bmy stock market today newlink stock pop much be incyte stock fall trail bristol stock be roche stock advanced newlink drug dub gdc be know ido inhibitor work block anything prevent immune response cancer cell be combine roche atezolizumab call pd inhibitor effectivness combination be low result weren robust similar combination merck keytruda incyte still unapproved epacadostat incyte be also combine epacadostat bristol opdivo bristol too be work own ido inhibitor ibd take incyte stock be prep share begin consolidate mid march buy point head ibd datum story closer look indication surround incyte share be not surprised roche return gdc ido inhibitor newlink see disappointing datum asco american society clinical oncology conference atezolizumab credit suisse analyst alethia young say young keep outperform rating price target incyte stock say doesn expect roche return newlink ido inhibitor have impact incyte related dow merck clearly win vs bristol roche cancer trialsbristol incyte match beat dow merck combination trial
1515,MRK,xtech stock once again set example late rally thursday haul dow industrial shallow loss positive finish nasdaq end higher enough notch new close high turn index positive week dow jone industrial average scratch only thinnest gain dow do manage jab briefly fresh high earlier session index remain week small cap run well ahead general market russell smallcap rally preliminary datum show volume sharply higher nyse nasdaq vs trading level wednesday stock dow industrial end half higher half lower jpmorgan jpm goldman sachs gs caterpillar cat bandy lead end more merck mrk narrow late loss newlink genetic nlnk announce genentech return right newlink navoximod follow disappointing result joint trial test genentech indoximod combination merck keytruda move left merck week testing support week move average low price newlink unraveled china alibaba group holding baba loft higher snap far past buy point week tight pattern online retail commerce giant also ibd leaderboard stock announce full year revenue guidance far consensus view investor day conference yahoo yhoo top nasdaq advance rise come partly yahoo stake alibaba news report verizon vz plan trim yahoo work force integration aol also have be factor gain send share past yahoo november peak chipmaker nvidia nvda hurtle ahead citigroup lift stock price target put ibd stock so far week extend well new high health saving manager healthequity hqy pop heavy trade strong quarterly report deliver late tuesday stock have surge be extend buy point europe be likely be factor early trade friday result come today parliamentary election late poll show prime minister theresa conservative party significant lead labour party hope snap election strengthen back parliament support negotiation britain withdrawal european union related amex head buy point rival sell investing action planecb take baby step draghi rush curb stimulus
1516,MRK,wall street be undervalue foundation dow component merck mrk be make cancer fight drug keytruda analyst say annual american society clinical oncology meeting conclude tuesday veritable star grow immuno oncology market keytruda be now approve treatment cancer accord merck have ongoing study help expand approval credit suisse analyst vamil divan say note client drug continue drive story company acknowledge base business be face pressure oncology pipeline be not robust prefer write hype keytruda isn merck biggest drug januvia janumet be sale diabetes drug fall year year first quarter keytruda revenue grow lead growth company keytruda recently grab food drug administration approval use conjunction eli lilly lly alimta first line defense advanced lung cancer ibd take incyte have be headline year mixed outlook biotech sector get insight company new america competitive datum like rival astrazeneca azn roche rhhby bristol myer squibb bmy be unlikely rock boat merck divan say believe person be underappreciat impact strong foundation merck be build space say merck closest rival bristol be also partner separately incyte incy test drug incyte epacadostat keytruda bristol opdivo work block interaction involve pd protein prevent immune system response cancer incyte epacadostat be know ido inhibitor work block interaction involve different protein ido inhibitor aren establish pd make headline conference bristol too be work similar drug totality epacadostat datum asco look compelling credit suisse analyst alethia young write separate note client datum support epacadostat multiple tumor response be see regardless genetic marker share incyte topple stock market today young blame company decision exclude patient datum effectiveness datum include safety effectiveness datum have october cutoff always see more datum think datum set present meeting give confidence probably shouldn expect significant variance unconfirmed patient write young model peak adjust sale peak unadjusted sale epacadostat meanwhile astrazeneca remain confident immuno oncology combo advanced lung cancer dampen enthusiasm investor specific match astrazeneca be pairing pd ctla inhibitor trial company also see drug lynparza get fda approval second line defense treatment ovarian cancer lynparza be know parp inhibitor block family enzyme cancer cell use proliferate sector astrazeneca rival clovis oncology clvs tesaro tsro related here be winner loser year biggest cancer meetingdow merck clearly win vs bristol roche cancer trial
1517,MRK,stock market close mixed thursday late wave selling erased much day work nasdaq have be close less higher wipe modest gain close fraction lower dow jone industrial average fall less medical company merck mrk johnson johnson jnj pfizer pfe unitedhealth unh be best dow component small cap perform better russell climb downward reversal certainly be not encourage volume be lower board accord preliminary datum suggest institutional investor do not sell massive quantity also negative reversal be not severe scale senate republican unveil own version legislation replace obamacare investor seem mean health care sector medical software drug wholesaler manage care several other medical sector industry group be day best perform rise healthsouth hls break base base pattern close buy point volume be average dampen otherwise bullish move share rise hologic holx break flat base rise past buy point also suffer weak volume relative strength line be new high back day company say win fda approval aptima herpes treatment bankrate rate have better volume break pattern buy point volume be average stock add downside taylor morrison home tmhc gap loss sec filing company say price offer share do not specify price also say filing average sale community month end be home month vs same period net sale order same month rise expect home closing quarter end june be related unitedhealth hca merck rally senate trumpcare bill pare term cut key stock index play buy range biotechs surge again
1518,MRK,biotechs software lead solid nasdaq advance dow jone industrial average index hit record high boee ba announce slew paris air show order oil price keep fall fed clear big bank annual stress test china crack weibo wb amazon amzn spook more retailer nasdaq rise week biotechs other medical soar ease fear price control also reaction senate gop health bill celgene celg be biotech breakout regeneron pharmaceutical regn soar buy range desktop software also be big winner oracle orcl breaking earning amazon fear intensified apparel sporting good story dow industrial index hit record high monday pare gain weakness oil retail stock dow finished fractionally higher rise biotech stock surge week concern president trump tamp drug price begin subside big winner rally include regeneron pharmaceutical regn celgene celg pop nearly respectively clovis oncology clvs spiked strong trial datum suggest much wider use ovarian cancer drug analyst call growth stock gain most see rally continue traditional drug giant also fared well novartis nvs breaking buy point merck mrk near entry boee ba beat airbus eadsy commercial jet order paris air show event typically win european aerospace giant boee say have incremental order commitment airplane value list price analyst say staggering boee order show weren firm airbus say book firm order plane value memorandum understand aircraft value analyst weren expect many deal paris order be double see last year show farnborough england boee share rise week hit new high airbus set record high monday pare weekly gain related boee paris air show order be staggering hybrid design new boee midrange jet hit sweet spotwhy lockheed move production india texasoracle orcl earning easily top view revenue advanced software giant overall cloud revenue shot vs year earlier oracle have be latecomer demand cloud software shift transition be full force now share surge breaking record high meanwhile other software database leader soar record high stronger expect earning adobe system adbe raise guidance report ep gain fiscal red hat rht ep climb fiscal revenue rise open source linux software provider also give bullish current quarter guidance adobe rise red hat climb crude oil price fall month lows week continue oversupply concern weekly crude stockpile fall barrel energy information administration say double be expect domestic crude production nudge barrel day meanwhile libyan oil production rise sharply dispute end german oil company export nigeria be expect hit bpd august vs bpd july accord reuter saudi arabia deputy crown prince moham bin salman be appoint heir kingdom throne be widely expect continue current oil policy be major force riyadh saudi vision reform initiative aim curb country reliance crude related oil reverse sharply lower supply fearsjpmorgan jpm bank america bac nation biggest global bank have enough capital continue lend economic meltdown first round federal reserve annual stress result show none bank test have key capital level minimum set fed bank stock generally edge lower friday wall street attention turn result second portion exam come wednesday portion determine bank give buyback dividend ultimately firm pass fail test quantitative qualitative ground jpmorgan bofa goldman citi well fargo pass fed stress testchina order weibo wb other online platform shut audiovisual stream presumably user content violate country political standard weibo tumble thursday majority owner sina corp sina lose alibaba baba own big minority stake twitter twtr weibo edge lower momo momo yy yy social medium firm lot stream video sell initially momo close yy pare loss sina momo yy be ibd stock related weibo crackdown spur selling not panic china internetsamazon strike fear more retail group slam many apparel sporting good chain commerce giant announce amazon prime wardrobe home try system let user have more item ship free try home then be charge keep hit macy jwn tjx tjx more meanwhile bloomberg source say nike nke sell footwear directly amazon brand registry program send share already reel dick sporting good dks foot locker fl other sharply lower finish line finl rebound friday mixed quarterly result meanwhile whole food market wfm push little further share takeover price amazon lead wonder bidder be ready emerge even bigger offer barclay say not be surprised be be bidding war jpmorgan analyst have peg wal mart wmt possible contender reuter report late friday wal mart be not plan whole food bid whole food close week hit friday afternoon related here latest group have amazon induced anxiety attackprime wardrobe be amazon kill macy fashion game uber technology founder travis kalanick resign chief executive officer follow shareholder revolt ride hail company have be expose have workplace culture include sexual harassment discrimination uber also have be lose market share lyft twitter twtr stock rise bullish research report say struggle company have improve video strategy execution report come same day twitter announce way person earn money stream live periscope video service snapchat operator snap snap be increase pressure instagram story feature facebook fb have grow user vs snapchat snap be trading close ipo price advanced micro device amd surge nearly week launch latest server processor datum center amd new epyc server chip compete processor industry leader intel intc join amd launch event austin texas be customer partner back epyc include microsoft msft azure baidu bidu dell technology dvmt hewlett packard enterprise hpe intel share fall low share fedex fdx rise week hit record high move buy range package delivery giant easily top expectation fiscal fourth quarter tuesday shake ep miss last quarters earning climb jump revenue investment modernize aircraft fleet expand ground operation paid fedex guide full year profit high rival up announce monday charge retailer extra fee holiday delivery fedex say consider shipping giant be challenged key customer amazon amzn expand own delivery service related fedex easily top earning revenue forecast guide profit highstrong suv truck sale help drive board beat wednesday used car superstore carmax kmx first quarter ep climb almost year year rise revenue total unit sale used vehicle jump even large medium suvs truck accounting bigger share mix average used vehicle price fall vs year earlier accelerate drop prior quarter flood lease car be hit pricing reason new car sale be slumping carmax rise week msci msci tuesday finally greenlighted inclusion mainland china stock key emerge market index wall street have be closely watch decision several fund include ishare emerge market etf eem track be benchmark index china weight benchmark jump upward current move surprised market msci have give red light mainland stock share previous try eqt corp eqt agree buy rice energy rice deal set close create largest natural gas producer strengthen eqt position marcellus utica shale region accenture acn report line fiscal profit report top line growth slightly view new digital cloud security product service reach revenue management commentary weakness health care market send share
1519,MRK,dow component merck mrk clearly win battle trial demonstrate cancer treatment weekend american society clinical oncology meeting analyst say monday investment bank leerink note combination datum incyte incy look strong merck keytruda incyte still unapproved epacadostat be combine treat array tumor type sign cancer disappear lung cancer patient already undergo prior round therapy epacadostat be know ido inhibitor keytruda be call pd inhibitor be immuno oncology drug work block specific interaction prevent immune response merck incyte be far alone immuno oncology scene annual meeting chicago bristol myer squibb bmy roche rhhby newlink genetic nlnk celgene celg exelixis exel be also look combine drug better cancer bust efficiency bristol opdivo yervoy be combine advanced lung cancer patient year datum show combo have little incremental benefit vs opdivo monotherapy yervoy be far dead leerink analyst say opdivo be similar merck keytruda yervoy work inhibit immune reaction involve ctla protein receptor patient be more susceptible pd inhibitor due genetic cancer disappear patient regardless gene roche be also combine tecentriq attack cancer cell camouflage pd protein newlink genetic ido inhibitor result look safe consistent epacadostat leerink analyst say overall patient have response datum be still new ibd take keep track biotech industry bookmarking ibd biotech pharma industry stock news page bristol be also work emerge immuno oncological target combination trial treat multiple tumor type include rival incyte epacadostat bristol be partner incyte several ongoing trial outside immuno oncology alone company tesaro tsro be combine be call parp inhibitor pd inhibitor merck keytruda evercore analyst say vein half ovarian cancer patient respond remainder reach disease stability afternoon trading stock market today ibd company biom biotech industry group be less ethical drug stock fall nearly related tesaro crash beating astrazeneca stronger clovis astrazeneca muddy potential deal tesarodow merck beat rival bristol melanoma study
1520,MRK,loxo oncology loxo stock defy broad biotech dip monday spiked record high show drug larotrectinib shrink tumor number different cancer share loxo end monday regular session catapult higher follow presentation saturday american society clinical oncology annual meeting chicago company eli lilly lly merck mrk bristol myer squibb bmy roche rhhby be attendance loxo drug belong class immuno oncology agent aim inhibit family protein loxo be now set begin phase trial larotrectinib adult colon cancer child tissue tumor respond treatment big cap name weren big winner wall street instead company bluebird bio blue surge bluebird stock get jump present strong datum drug dub bb treat multiple myeloma monday bluebird say patient trial bb respond treatment relapse therapy be well tolerate leerink analyst michael schmidt say report have outperform rating bluebird stock ibd take supernus pharmaceutical supn stock have ibd composite rating best possible base key growth metric lead ibd company biom biotech industry group keep tab industry leader ibd stock checkup puma biotechnology pbyi stock lift rival roche unveil result yearlong test drug specific group breast cancer patient result be low end investor expectation rbc analyst matthew eckler say bode well puma be work drug call neratinib address same group patient eckler say roche drug herceptin perjeta be test adjuvant treatment treatment be add decrease risk relapse now assume adoption neratinib be largely unencumbered adjuvant use herceptin perjeta eckler write note client keep sector perform rating puma stock boost price target however puma bio share close well intraday high highest november tg therapeutic tgtx stock also cut wide berth monday rise much give gain back close earlier day tg have positive result trial abbvie abbv johnson johnson jnj form leukemia related dow merck clearly win vs bristol roche cancer trialstesaro crash beating astrazeneca stronger datum
1521,MRK,bristol myer squibb bmy immuno oncology drug opdivo show promise early trial patient advanced cervical cancer drugmaker say friday american society clinical oncology conference chicago woman cervical vaginal vulvar cancer see reduction size tumor median progression free survival be month disease be controlled nearly patient partial complete response be only see cervical cancer patient respond treatment opdivo cancer type test opdivo present severe life threaten adverse response patient cancer test study be link human papillomavirus be tie cervical cancer vaginal cancer vulvar cancer bristol say news release hpv be spread sexual contact close bell stock market today bristol stock be ibd take bristol myer stock have ibd composite rating meaning outperform nearly third stock term key growth metric still lag drug leader zoetis zts have cr best possible head ibd stock checkup list top rate drugmaker first assessment opdivo activity woman advanced cervical vaginal vulvar cancer enrolled cohort study support further investigation especially patient have very limit option chemotherapy radiation fail say dr cheng statement typically patient type cancer be first treat chemotherapy alone combine radiation first year survival rate advanced cervical cancer be roughly stage patient stage patient bristol say earlier week bristol announce partnership small cap biotech advaxis adxs combination trial patient advanced cervical cancer opdivo be combine advaxis drug adxs dual immuno oncology drug related dow component merck beat rival bristol melanoma biotechs fall cancer partnership bristol myersbristol incyte match beat dow merck combination trial
1522,MRK,future index nasdaq dow jone industrial average be mixed early thursday software biotech stock have become key leader ongoing market rally oracle orcl surge overnight strong earning report regular session celgene celg roar buy zone amgen amgn regeneron regn biogen biib peer show bullish action investor pay attention sector rotation stock performance be closely tie broader industry stronger industry sector performance reflect improve business condition company be momentum shift market become more enamored disenchant group nasdaq future rise more fair value overnight high future dow industrial climb nearly index future turn slightly higher crude oil future have plunge week edge last session medical biom biotech group have be top performer ibd industry group soar amgen regeneron biogen celgene be more just week biogen regeneron more ibd take celgene be rate ibd biom biotech group best possible composite rating find be other top rate biotechs stack vs objective critera go ibd stock checkup several other drug group be big recent winner ethical drug group include dow stock merck mrk merck rise wednesday new approval immuno oncology treatment keytruda merck have conventional buy point aggressive entry meanwhile ibd software desktop group home oracle be fourth best industry past day dow microsoft msft adobe system adbe red hat rht be also member other software group include enterprise software medical software also have have big gain celgene leap blast past buy point hold just chase zone grow feel investor president trump not crack drug price various comment have make campaign regeneron rise further extend buy point trading best level begin amgen advanced build right side base biogen gain retake day move average day vaulting day recent biogen spinoff bioverativ bivv edge be hold buy zone monday bioverativ be leaderboard ibd premium service highlight select cull stock mostly growth play buy zone clovis oncology clvs have sky-rocket week report strong trial datum suggest ovarian cancer drug get much wider use gilead science gild rise day line hepatitis hiv biotech try break downtrend go back more year good way play biotech boom be etfs such spdr biotech xbi ishare nasdaq biotech ibb xbi ibb break consolidation week oracle report much stronger expect earning late wednesday revenue growth also edge past view share business software giant shot premarket trading stock market today be record high well buy point overnight trading doesn always carry regular session still oracle already top aggressive entry wednesday rise heavy volume addition desktop software name microsoft adobe red hat be long time time high several other business software stock have be breaking hit high recent month include cloud base payroll software player such workday wday paylocity pcty paycom payc well servicenow now salesforce com crm veeva system veev asian trading thursday japan nikkei dip china shanghai composite slide europe intraday ftse retreat germany dax be flat france cac fall related big picture biotechs lift nasdaq oil bloodbath breakout biogen spinoff bioverativ buy zoneoracle earning come ahead top bottom linesbiotech surge generalist return subside trump dow merck be still beating bristol roche immuno oncologyis medical cloud compute play set rebound crash
1523,MRK,xstock trade mixed wednesday apparently unaffected surprising reshuffle saudi arabia succession plan country king replace nephew son heir throne wednesday action come late sell tuesday send general market fall record high tech heavy nasdaq lead major market index rise edge slightly higher dow jone industrial average turn negative dow industrial nike nke set pace advance merck mrk follow rise downside chevron cvx fall be downgrade neutral macquarie crude oil price have fall bear market status high boee ba fall cowen raise price target airplane maker intel intc decline software company surge almost news report company go private merger deal bmc software private company other advancer include advanced micro device amd carmax kmx rise respectively downside retailer foot locker fl decline energy firm continue recent slide helmerich payne hp chesapeake energy chk fall respectively earning front red hat rht jump beating fiscal earning sale target late tuesday stock have be testing week line recent trading session extend buy point computer software company adobe system adbe trade higher exceed street estimate fiscal lead stock stock market today paypal pypl rally receive upgrade pacific crest security analyst raise stock overweight sector weight ibd recent ipo floor decor fnd look extend day winning streak rise share hover ipo base buy point other top performer include regeneron pharmaceutical regn paycom software payc regeneron rise gruhub moved downside regional bank east west bancorp ewbc fall china stock new oriental education edu decline transunion tru fall related earning calendar analyst estimate stock watchboeing adobe red hat price target hike chevron downgradeddow jone industrial average dow stock news analysisadobe crush wall street estimate guide higher
1524,MRK,nasdaq composite follow monday bullish gain lower volume decline higher volume late trading tuesday dow ease buoy strength merck mrk pfizer pfe lose hurt weakness oil gas name distribution day be take shape nasdaq stock market today volume be tracking quite bit higher monday level benchmark west texas intermediate crude oil hit multimonth low settle barrel big biotech rally lift share ibd name regeneron regn share pop well extend buy point other biotechs move include celgene celg share rise right side current base show nice accumulation higher volume gain celgene approach buy point contract research organization provide outsourced service biotech big pharma get lift parexel prxl agree be take private private equity firm share parexel rise tesla tsla be session lows still rise report release national safety transportation board find fault tesla automate pilot system involved highly publicize crash model driver be kill chipotle cmg tumble company offer lukewarm same store sale guidance also warn higher cost earning news lennar len jump nearly early fade share gain company report better expect earning third straight quarter accelerate earning growth financial be pressure year treasury yield ease basis point loss select sector spdr financial xlf be tame set nice base buy point many other financial have do good job hold gain recent breakout related netflix price target hike nvidia upgrade nike pt loweredlennar earning top view share eye buy pointthese biotechs be lead sector month high today
1525,MRK,xstock be broadly lower tuesday afternoon biotechs lead rally health care stock nasdaq be dow jone industrial average ease pharmaceutical merck mrk pfizer pfe lead dow drugmaker other health care stock lead market merck add pfizer climb add space conjoin day day move average small cap lag russell dow transport fared even volume be tracking higher board stock market today loser lead winner ratio nyse ratio nasdaq energy sector be weakest oil price sank month low barrel chipotle grill cmg plunge more time average volume share already have tumble day move average almost touch day line session low fast casual restaurant chain give update operation outlook cause investor doubt recovery be track teladoc tdoc fall big volume come record high stock remain sharp upward trend late monday company announce be acquire best doctor provider consultation patient complex medical condition cash teladoc stock analyst canaccord genuity praise deal call excellent transaction teladoc analyst say provide cross selling opportunity plethora medical subspecialty domestically abroad broaden company offer low volume high acuity case furthermore transaction differentiate teladoc peer analyst say nvidia nvda amazon com amzn see unusually heavy trading major stock climb pare gain nvidia hold small price increase left share new high pacific crest upgrade stock sector weight underweight amazon be fraction volume track increase average stock member ibd leaderboard be extend rise support day move average ulta beauty ulta also see big burst volume small price increase less yet cosmetic retailer be find support pull back day move average second time related tesaro overcome clovis lead combo merck co biotechs be lead sector month high todaybiotech breakout biogen spin bioverativ buy zone
1526,MRK,gilead science gild experimental hiv drug combination meet goal late stage trial biotech company say tuesday putt closer seek approval europe later year combination bictegravir emtricitabine tenofovir alafenamide ftc taf be just effective regimen glaxosmithkline gsk used drug dolutegravir ftc taf be already approve treat hiv gilead be hope add bictegravir make more effective base result phase study combination bictegravir ftc taf represent important advance triple therapy treatment broad range hiv patient norbert bischofberger gilead chief science officer say news release study look gilead combination gsk previously untreated patient fourth trial examine patient switch gilead regimen other hiv therapy case gilead regimen prove just effective other therapy datum show regimen be well tolerate patient discontinue treatment due kidney issue gilead say aim file application approval europe respectively second third quarters year ibd take healthcare reform change outlook biotechs pharmas analyst say head ibd technology page closer look gilead narrowly escap potential game changer failure trumpcare gilead be pin hope hiv drug light slowdown hepatitis franchise sale unit collapse high cure rate europe gilead first hiv drug viread be approve year hiv gilead be face britain gsk dow component merck mrk be used generic drug regimen use generic make gsk merck regimen less expensive meaning gilead struggle gain share analyst have say stock market today gilead stock fall cent share be year ibd company biom biotech industry group have rise so far slide nearly tuesday close day line first time month glaxosmithkline share rise related gilead topple consensus lag hepatitis drug sale plummetwill merck glaxo undercut gilead next mount everest drug bristol myer beat gilead merck key approval china europe
1527,MRK,biotech industry always highly technical conundrum investor currently even greater challenge offer even greater opportunity usual early industry innovator amgen amgn biogen biib gilead science gild currently find big trouble accord loncar investment chief executive brad loncar largely victim own success cancer
1528,MRK,array biopharma arry advaxis adxs topple nearly tuesday small cap biotechs announce partnership pharma leader bristol myer squibb bmy stock fall line broader market see ibd company biom biotech industry group collective tuesday close advaxis stock lose end day array stock dove bristol stock be flat hard understand day day stock price advaxis chief executive daniel connor tell investor business daily spdr biotech etf nbi be be tough day good group stock plunge follow announcement bristol myer team advaxis treatment advanced cervical cancer array biopharma colon cancer advaxis study be expect start end year result array study be expect second half array advaxis test immuno oncology drug bristol drug opdivo opdivo be call checkpoint aim block interaction pd protein immune system cell pd protein tumor cell most closely rival keytruda drug dow stock merck mrk advaxis drug know adxs dual target cancer associate human papillomavirus connor liken combination bristol opdivo highway system adxs dual put more immune system cell tumor path opdivo clear path say think car immune system cell highway toll booth checkpoint say opdivo give easy pass go right checkpoint advaxis drug put lot car highway end highway be tumor ibd take be biotech sector set visit ibd datum story scoop trial bristol opdivo adxs dual be study patient ve already undergo round chemo advaxis be also partner astrazeneca azn advanced cervical head neck cancer merck advanced prostate cancer amgen amgn several cancer array drug binimetinib aim block specific enzyme be test combination opdivo opdivo yervoy patient colon cancer yervoy be immuno oncology drug bristol target ctla protein receptor study be expect establish recommend dose regimen well explore tumor activity combine binimetinib bristol drug bristol say news release related bristol incyte match beat dow merck combination trialsincyte team dow merck trounce roche cancermerck immuno oncology star tack new bladder cancer approval
1529,MRK,dow jone industrial average rise modestly even big techs such undercut nasdaq federal reserve raise interest rate give surprisingly hawkish outlook weaker economic datum amazon amzn agree buy whole food wfm apple aapl confirm enter autonomous drive field video game industry giant show oil price crash continue global supply glut nasty reversal june lead techs such apple facebook fb continue push nasdaq lower partly due hawkish fed report president trump be be investigate nasdaq sank week find day support thursday dow industrial rise hit time high weakness tech component such apple microsoft msft index edge fraction loss techs energy stock grocery chain grocer tumble amazon deal buy whole food market warning gloomy news kroger kr sprout farmer market sfm treasury yield hit lows rebound somewhat amazon announce friday buy brick mortar natural food grocer deal change landscape grocery store amazon commerce retail overall news roil grocery store already reel food price deflation due wal mart wmt amazon kroger thursday issue full year profit warning vow not be beaten price kroger sprout farmer market sfm supervalu plunge week big grocery seller wal mart costco cost target tgt cvs health cvs dollar tree dltr also tumble friday related amazon be buy whole food roil federal reserve hike key interest rate wednesday expect unnerved wall street shift policy outlook more hawkish direction even core consumer price inflation hit year low ahead fed meeting market participant weren expect subsequent rate hike year fed policy committee member projection point more hike hike fed also tee plan begin unwinding financial crisis era asset purchase later year strike analyst fairly aggressive vs expectation fed stick economic model show low unemployment feed faster wage growth higher inflation even incoming datum be raise doubt model wall street related fed hike rate hawkish tone unnerve msft launch powerful xbox formerly know project scorpio unclear many unit sell holiday season give price tag meanwhile sony sne playstation debut number vr title nintendo ntdoy dominate buzz attendee goldman sachs gs see nvidia nvda benefit higher sale nintendo switch console facebook oculus wasn video game expo industry pro see virtual reality take breather year facebook demonstrated live stream capability ar filter related video game virtual reality entertainment newsceo tim cook finally confirm apple aapl be investing heavily technology self drive car year rumor unconfirmed medium report interview bloomberg decline say apple make own car just produce technology automaker cook call initiative mother ai project meanwhile general motor gm say be more triple self drive test fleet gm ceo mary barra say advanced chevrolet bolt car soon join exist lineup first gen electric vehicle be be test related apple finally confirm worst keep secretapple have make car succeed autonomous drivingmay consumer price inflation datum labor department show broad weakness price airline ticket apparel new used auto medical care overall cpi fall year year again moderate core price strip volatile food energy category rise annual gain backtrack lowest retail sale slide overall exclude stall auto sector defy expectation mild gain sale nonstore retailer lead amazon amzn continue be standout category rise year department store sale slide meanwhile industrial production be weak philly fed new york fed report stronger expect regional manufacturing activity june housing start unexpectedly fall putt further pressure housing stock have be move new high crude future fall barrel hit month lows more evidence global supply glut continue opec production cut international energy agency say crude stockpile jump barrel oecd country april push year average higher opec production deal november crude supply fall latest week energy information administration say less expect gasoline supply unexpectedly rise domestic production rise barrel day barrel eia predict see output major shale basin jump barrel day july biggest increase come permian basin also opec own production climb barrel increase libya nigeria iraq domestic production rise barrel day barrel general electric ge say health care chief john flannery take current ceo jeff immelt aug immelt pivot industrial conglomerate financial service back engineering root sharpen technology focus ge stock have fall roughly take general electric indicated digital push continue flannery dow component also announce more executive change later week include exit power unit veteran steve bolze spur talk potential brain drain similar exit lose ceo candidate immelt be name ceo replace jack welch ge share jump monday uber technology ceo travis kalanick take indefinite leave absence follow independent review allegation ride hail company harassment discrimination aggressive culture investigation eric holder former attorney general lead recommendation create board oversight committee staff meeting discuss uber plan transform director david bonderman make comment see offensive woman lead resignation share dow component johnson johnson jnj merck mrk diverged monday news stem trial study show diabetes medicine invokana also cut cardiovascular event rise week new high merck halter enrollment cancer trial see more death patient treat immuno oncology drug keytruda vs other combination merck stock fall hawaiian holding crash unite airline ual say add service hawaii later year stifel analyst joseph denardi downgrade stock sell say hawaiian airline parent perform well have also benefit very benign competitive environment cheesecake factory cake share nosedive sit restaurant chain cut same store sale guidance cite sign uncertainty part many consumer unfavorable weather reduce patio usage east midwest citigroup predict weaker second quarter trading revenue cite low volatility vs brexit election season citi forecast follow similar one trading jpmorgan jpm bank america bac other citi fall week hold buy zone
1530,MRK,stock jump early trade tuesday apple aapl amazon com amzn lead early tech rally investor turn attention federal reserve policy meeting nasdaq set early lead gain dow jone industrial average trkked enough knock new high also grab gain federal open market committee swing day meeting washington wrapped policy announcement press conference chairwoman janet yellen wednesday afternoon new york federal reserve bank president be schedule speak today et market also have eye gaming stock electronic entertainment expo convention get underway los angele tuesday electronic art ea microsoft msft make key product announcement ahead gathering electronic art leap microsoft trade open apple jump more then begin pare gain stock be look regain support week move average goldman sachs gs advanced nearly head dow industrial merck mrk drop low end list fang stock netflix amazon com amzn alphabet googl pop nearly apiece early trade nvidia nvda leap almost open ibd stock have advanced series tight weekly close big remain well week move average tableau software datum jump boost upgrade buy neutral goldman sachs datum analytic program developer be december low remain deep month correction datum storage leader western digital wdc rolled early advance seagate technology stx climb more aegis capital initiate coverage stock rating western digital buy price target seagate buy price target price paid producer remain flat labor department report just consensus expectation increase core price energy food tick ahead view advance oil price reversed west texas intermediate shedding early gain drop back barrel gold slip ounce dollar be mixed vs euro yen bond be flat year yield stock europe climb afternoon trade london ftse add frankfurt dax rally cac paris show gain related bank stock just buy point investing action planone company wreak havoc trump agenda week
1531,MRK,nasdaq composite index dow jone industrial average hit record high friday morning nasdaq reversed sharply close day week lower apple aapl unveil homepod smart speaker entry like amazon amzn echo google googl home alibaba baba see boom growth macy wo keep grow age amazon jwn go private oil price tumble stockpile major average be trading record high friday morning seemingly resilient shock election outcome ex fbi director james comey testimony congress regard president trump key fear gauge hit year low lead tech stock suddenly reversed big loss friday department store continue struggle citigroup break many financial rally energy stock fall crude price consumer electronic giant apple aapl announce smart wireless speaker siri voice control worldwide developer conference apple be pitch homepod more premium audio speaker personal home assistant device rival amazon amzn echo google googl home speaker analyst say ll be good companion product apple music subscription service also wwdc apple preview new version software platform io maco watcho tvos launch refreshed lineup mac notebook desktop computer well inch ipad pro apple unveil augment reality technology future iphone ipad related be late market doesn hurt apple chinese commerce giant expect revenue growth fiscal end next march far analyst expectation alibaba baba be benefit part new venture include cloud compute alibaba shot thursday pull back modestly friday commerce rival jd com jd hit record high thursday tumble friday related alibaba soar stunning growth forecastmacy warn full year gross margin come previously thought sink stock lowest share retailer penney jcp sear shld also sell retailer struggle amazon amzn price chain fast fashion jwn say founding family be consider go private deal youth apparel chain urban outfitter urbn meanwhile warn same store sale be trend well expectation related macy trigger new retail rout gross margin nearly half gain family explore go private latest amazon vs wal mart amazon be offer discount monthly prime membership government assistance move wal mart wmt turf customer valid ebt card be eligible qualify year time meanwhile wal mart be testing automate hour day grocery pickup kiosk online order related amazon new wal mart assault prime cut government aid recipientsu crude price fall wednesday energy information administration announce weekly crude stockpile rise defy analyst forecast separate tally american petroleum institute platt eia also note gasoline inventory increase crude production dip strong uptrend be intact saudi arabia many other gulf state cut diplomatic economic ty qatar tension didn lift crude price perhaps trader see higher risk opec production cut deal break tesla stock achieve string record high even broad swathe auto related company tumble prominent analyst slash outlook vehicle sale next year analyst warn wave optimism electric car maker wane once investor begin judge tesla product demand growth profit tesla do finally reversed record high friday ibd tipp economic optimism index hold steady june just level donald trump surprise election fuel short live surge spirit carry index year high february index hold neutral level signale optimism ninth straight month yet surface june poll reveal modest rise optimism term direction economy deeper pessimism direction federal policy dave buster play first quarter earning revenue beat expectation same store sale miss still arcade sport bar ratchete low end full year revenue outlook dave buster large amusement segment include game skee ball life size rock sock robot outperformed dine segment analyst see more opportunity chain move space once occupied struggle retailer dave buster share hit record high end week barely higher health saving account manager healthequity hqy top first quarter estimate however well fargo analyst peter costa note company ep be help lower expect tax rate due change accounting standard company expect higher service cost spending fraud prevention hit gross margin still management be optimistic plan acquisition benefitguard move hope help compete retirement business bluebird bio blue stock rocket day unveil strong datum drug dub bb american society clinical oncology monday chicago same conference see loxo oncology loxo stock launch monday follow strong datum drug larotrectinib shrink tumor number different cancer merck mrk incyte incy have success combination keytruda epacadostat lung cancer patient bristol myer squibb bmy report opdivo yervoy show little benefit opdivo monotherapy analyst see tesaro tsro have stronger datum breast cancer drug vs astrazeneca azn assurance boee ba air force think kc refueling tanker be delay again boee already push back delivery date march august late development issue lt gen arnold bunch military deputy air force acquisition say believe delivery be little right target commercial side lion air reportedly be boee max launch customer indian full service carrier jet airway also be reportedly talk purchase narrow body jet worth least be lean max max vs airbus eadsy neo accord bloomberg gigamon gimo hire goldman sachs explore strategic option few week activist investor elliott management take stake maker communication network appliance security gear gigamon draw interest hewlett packard enterprise hpe private equity firm analyst say software maker coupa coup report narrower fiscal loss revenue rise top consensus estimate current quarter coupa forecast share loss cent line estimate revenue slightly view snap snap fall report snapchat user growth have be slow second quarter okta okta report smaller expect loss forecast revenue growth identity security software stock first report come public april okta share rise nearly thursday hit record high breaking initial ipo base share reversed friday end week little change thor industry tho ep rise revenue climb beating maker rvs mobile home rise general motor gm shareholder overwhelmingly reject activist investor call create share class focuse growth dividend also re elect board member reject nominee put forward greenlight capital david einhorn gm share be less week iii giii own donna karan bass other apparel brand shot week clothing manufacturer distributor swung loss cent beat view cent share loss revenue gain easily top
1532,MRK,bristol myer squibb bmy grab pair major win friday china approve hepatitis regimen europe bless immuno oncology drug opdivo treat head neck cancer spokesperson tell investor business daily daklinza sunvepra be approve treat hepatitis patient genotype common malady china daklinza be also approve combination other agent include gilead science gild sovaldi genotype pending approval sovaldi china chief commercial officer murdo gordon doesn expect bristol see gilead decline sale cure rate daklinza sunvepra combination gilead sale hepatitis drug sovaldi harvoni fall high cure rate picture be different china gilead hasn yet get approval drug be north person live hepatitis china gordon say put perspective be estimate hepatitis patient number be staggering think number infected person china hepatitis say think infrastructure chinese market care go need scale gordon wouldn comment bristol plan launch combination pricing say still negotiation be do daklinza sunvepra combination be also approve japan bristol likely win seek approval combination company discontinue effort gordon say competitive window have come go europe be primarily mature market hepatitis say ibd take gilead sale hepatitis drug topple biotech giant be count hiv drug bictegravir be major player visit ibd technology page closer look gilead plan leverage asset company hasn give forecast sale daklinza sunvepra daklinza sovaldi china gordon say daklinza be approve combination sovaldi cost wholesale week regimen due market size china gordon say ll be awhile chinese market become mature begin see widespread eradication dynamic china be different term long take get patient treat effectively point re actually eradicate disease say think duration be go take number year get point sale decline gordon expect competition china say be multiple product review emphasize speed chinese government approve combination year start finish call significant event china think important highlight be great story chinese fda innovative industry bristol myer squibb particular add help patient ve be wait innovation hit market other news gordon say europe approve application opdivo squamous cell head neck cancer second line treatment platinum base therapy opdivo target pd protein help immune system identify camouflage cancer cell compete most directly keytruda dow stock merck mrk stock market today bristol stock rise drug approval announcement follow strong first quarter earning report bristol sale profit top wall street expectation opdivo sale grow quarter bristol share rise week retake day move average approach day related vertex big winner biopharma abbvie astrazeneca dipastrazeneca wallop profit view topple sale eye key trialabbvie flip buy point earning sale top
1533,MRK,gold emerge market etfs gain friday retail small cap lag stock market key dow jone industrial average etf dip new high apple emerge market etfs show continue strength direxion daily emerge market bull share edc add ishare msci emerge market eem climb small cap underperform ishare core small cap ijr ishare russell iwm give respective etfs have slip back flat basis find support day line spdr dow jone industrial average etf dium edge lower trading tightly top flat base buy point general electric ge merck mrk be biggest loser blue chip index apple aapl lead upside gain bank america lynch hike price target iphone maker maintain buy rating deutsche bank lower ge sell hold cut price target spdr retail xrt extend thursday loss slide friday test support day move average jwn penney jcp sank respectively department store chain same store sale fall more expect macy dd kohl kss suffer sharp drop thursday gold play outperformed again gold future rise ounce vaneck vector junior gold miner gdxj vaneck vector gold miner gdx add respective etfs remain well week high gdx regain day move average spdr gold trust gld ishare gold trust iau track price precious metal climb less apiece related find happen today stock market actionj penney hit time low weak sale retail wo continueapple price target hike well fargo cut ge downgrade
1534,MRK,emerge market exchange trade fund show strength tuesday ishare msci emerge market eem rise week high direxion daily emerge market bull edc add more stock market today clear base base buy point etf rally breaking prior base stock market be modestly higher dow jone industrial average nasdaq composite be barely positive spdr dow jone industrial average dium edge higher ahead apple aapl earning close dow component iphone maker share be pare gain early spike analyst expect apple report best ep sale growth year other blue chip intel intc visa advanced more intel gain rival advanced micro device amd plunge slight quarterly sale miss powershare qqq trust qqq spdr etf trust spy be also slightly higher spy be top flat base entry rise previous flat base buy point clear february small cap lag ishare russell iwm dip slip back flat base entry sector play vaneck vector gold miner gdx be share be still week high gold future dip ounce tuesday health care select sector spdr xlv be big pharma giant merck mrk hold gain pfizer pfe be sharply pare early loss drugmaker report quarterly result related pfizer earning top sale come shortdow merck top view raise outlook key drug lag
1535,MRK,list exchange trade fund score gain government avert shutdown weekend gainer include proshare ultrapro tqqq powershare qqq trust qqq respectively tech heavy etfs be new high ground tqqq have asset management seek triple qqq performance gain day qqq top holding include apple aapl microsoft msft amazon amzn facebook fb apple rise new high monday direxion daily emerge market bull share edc also rally near buy point short flat base form base base pattern follow advance edc have aum sector exchange trade fund technology select sector spdr xlk financial select sector spdr xlf be lead xlk recent bounce week move average be trading highest level more year tech etf aum have rally flat base late last year xlf be year high financial etf be build flat base potential entry follow gain mid february prior flat base score advance november earning lurk corner big drug name good time check health related etfs health care select sector spdr xlv have shape week flat base buy point less entry etf have post small gain cup handle just start current pattern dow industrial average component merck mrk pfizer pfe report quarterly result tuesday biotech gilead gild earning be also tap tomorrow merck pfizer be xlv top holding april gilead make top broader market be mixed tech heavy nasdaq composite dow jone industrial average west texas intermediate crude price slide barrel spdr oil gas exploration production xop aum be etf have be pressure lately be december high gold price dip ounce weigh gold fund vaneck vector gold miner gdx have nearly aum fall week high spdr gold share gld edge lower related stock market do now
1536,MRK,be just year formula seem right biogen biib fourth largest company industry mix biotechnology megamerger biogen multiple sclerosis franchise lineup drug include tecfidera tysabri be grow tecfidera biogen most important drug bring further hemophilia sale small grow just brand name drug eloctate alprolix spinraza spinal muscular atrophy drug grab fda approval just day christmas plot thicken biogen chief executive george scango resign july leave company susceptible takeout like merck mrk allergan agn eli lilly lly pfizer pfe takeout rumor abound biogen stock end make cheaper asset buy thought last year be really time happen leerink analyst geoffrey porge say biogen offer last year be relatively stable ms business be still grow robust cash flow scheme opportunity spinraza hemophilia franchise so acquirer say get fast forward today picture be entirely different biogen be see increase competition ms market payer be balk spinraza price company have already take hemophilia drug equation now only wall street see biogen potential takeout candidate accord mizuho survey porge say biogen probably have see deal roll ever think have become significantly less likely porge say so happened incredibly successful multiple sclerosis include launch zinbryta abbvie abbv biogen ms unit be face loom competition like roche rhhby celgene celg porge tell investor business daily note client april porge call roche ocrevus game changer ocrevus be approve late march treat relapse remit primary progressive form ms separate pack be only approve relapse remit form ms physician patient community have be eagerly await ocrevus launch porge say drug high efficacy reasonable safety profile convenient month dose schedule be major factor drug positive reception spell trouble biogen tecfidera have comprise total product sale well ms unit biogen be actually partner roche ocrevus royalty win be enough offset erosion own ms franchise analyst say porge expect ocrevus get primary progressive ms market year relapse remit ms market porge see erosion tysabri erosion tecfidera novartis nvs gilenya sale meanwhile celgene be work ms drug call ozanimod phase testing function ozanimod be closest novartis gilenya also rival tecfidera sanofi sny aubagio tecfidera gilenya aubagio respectively lead ms market term sale celgene want buy sale force have something overnight help sell ozanimod biogen be company porge tell ibd biogen likely suffer erosion roche competition ms look less probable silver line biogen win patent interference case forward pharma fwp tecfidera be settlement fee forward stock topple decision now lose major royalty biogen spinraza have different set trouble develop ionis pharmaceutical ion spinraza be first only drug approve rare neurological disorder cause muscle weakness wasting infant child wall street largely thought spinraza slam dunk have profound efficacy august study infant child drug be so effective biogen ionis end study early ionis chief executive stanley crooke tell ibd december spinraza be approve dec fairly broad label approve use child adult spinal muscular atrophy remain only drug approve disease crooke call catastrophic drug thing be rapidly adopt widely reimburse porge say have happened be appear be good fortune label have turn liability payer become concern too many patient start drug so restrict access mizuho analyst salim sy call largely spinraza story biogen be set report first quarter earning april be particularly tell follow launch spinraza earlier year analyst say payer be push back hard reimbursement drug insurer anthem antm humana hum be only reimburse patient spinraza most severe form disease type unitedhealth group unh have broader policy cover type patient be spinraza cost treatment first year subsequent year make pricey drug consensus be project first quarter spinraza sale sy say porge lower expectation spinraza sale result first quarter be especially tell tell ibd north patient drug be pretty good long re see continue start then biogen hemophilia drug lineup february biogen spun hemophilia franchise bioverativ bivv then bioverativ share be be great bioverativ company consider biogen takeover think again unit porge say ibd take bioverativ isn standard biotech startup head new america find bioverativ have yet announce quarterly result have only be public early february company be set release first quarter earning result last full quarter biogen hemophilia unit bring year year now porge say be smart biogen also spin multiple sclerosis unit turn focus alzheimer alzheimer biogen be follow eli lilly merck have notable failure december february biogen alzheimer play be strongest sector analyst say march rbc analyst michael yee tell ibd pfizer merck be likeliest player make bid biogen be interested more brand drug particularly alzheimer pipeline biogen be work class alzheimer drug work remove plaque buildup brain associate alzheimer call bace inhibitor eisai bace inhibitor aim prevent plaque buildup porge say biogen likely have see renew takeover interest biogen be expect release result phase trial aducanumab bace inhibitor elenbecestat be also phase trial result expect september eli lilly solanezumab work theory remove plaque buildup call beta amyloid brain merck verubecestat be bace inhibitor fail be only handful potential alzheimer drug development now meanwhile axovant science axon be work different theory treatment doesn involve beta amyloid expect have phase datum drug intepirdine later year too change alzheimer landscape potentially further dent biogen chance merger still biogen board place high premium alzheimer pipeline ever come acquisition table porge say everything else have fail development cost aducanumab elenbecestat have head billion dollar porge say re willing take risk alzheimer still make sense acquisition ve hear person industry be re struggle bridge gap say board want be paid alzheimer go work related roche game changer drug chip away biogen novartisbiogen dife takeover buzz fade drug hit small cap biotech take gilead celgene biogen alzheimer
1537,MRK,stock index be little change friday surprisingly muted response smaller expect job growth attack syrium nasdaq dow jone industrial average be trade narrow price band dow component merck mrk be fda reject application research diabetes drug potential cardiovascular benefit volume wall street be tracking lower headline normally spawn rush trading stock open slightly lower government report employer add job march well forecast unemployment rate fall lowest april economist have expect hold steady suggest job market continue improve wall street also wasn much bother news thursday warship attack syrian air base retaliation chemical gas attack aerospace defense industry climb nearly raytheon rtn maker tomahawk cruise missile strike syrium be back day move average boee ba be form solid flat base buy point deserve look ep rise past quarters company turn profit metal heavy construction stock lead market metal distributor steel producer be best performance ibd industry group cement aggregate industry martin marietta mlm moved back day move average chipmaker be continue be brighter area market cypress semiconductor cy chipmaker turn weak quarters earning find support pullback day move average leave stock follow buy area analyst expect continue recovery ep growth skywork solution swks hit highest level july be extend jan energy sector lag oil price new york rise cent barrel drill exploration oilfield service stock be lower other be flat international exploration company be group retail have be bounce earlier week be lose side today stock market department store discount chain leisure type store be broadly lower retail sector have largest job loss friday job report march many retail stock remain depress week lows related jobless rate fall year low keep pressure feddow component merck pare loss fda reject diabetes label raytheon lockheed lead defense stock attack assadgold surge syrium strike job defense stock buoy
1538,MRK,bristol myer squibb bmy roche rhhby merck mrk tend grab immuno oncology headline american association cancer research annual meeting highlighted slew potential competitor wait wing earlier year analyst estimate be more clinical drug trial be examine different target immuno oncology branch cancer treatment aim immune system identify cancer cell aacr annual congress washington prove point leerink analyst michael schmidt say wednesday note client fda approve immuno oncology drug target specific protein enzyme many effective checkpoint be still be develop prior year aacr remain conference focuse earlier stage cancer program development write emerge immuno oncology target feature prominently preclinical early clinical work outside usual name bristol roche incyte incy merck astrazeneca azn company newlink genetic nlnk corvus pharmaceutical crvs prime therapeutic fprx calithera bioscience cala oncomed pharmaceutical omed be jump trend ibd take want breakdown immuno oncology sector include competitor worth head ibd technology page immuno oncology drug be also call checkpoint inhibitor immune system cell check pass cell right protein enzyme match cell pass unmolested cancer cell camouflage specific protein enzyme hide expert say block interaction allow immune system see cancer cell newlink incyte bristol roche be aim target ido enzyme prevent tumor cell hoodwink immune system newlink be research ido pathway inhibitor merck keytruda newlink drug indoximod show overall response rate melanoma patient phase trial detectable tumor disappear patient vs response combination keytruda incyte epacadostat corvus disappoint drug know cpi show low response rate just patient receive single drug cpi combination roche tecentriq cpi be know receptor antagonist other vein have be discontinue poor efficacy past prime calithera be look combine drug other drug calithera be aim combination drug work inhibit glutaminase enzyme bristol opdivo work inhibit pd protein oncomed datum support mechanism yet checkpoint inhibitor used immune receptor call tigit phase trial be now open leerink schmidt say follow talk management oncomed prime incyte also have preclinical poster second generation drug several next generation immune agonist aim overcome hurdle encounter first generation agent schmidt write second generation agonist be now phase generate significant interest conference attendee related bristol keep merck cancer incyte be true winner analystbristol afford lose dow stock merck immuno bristol prove longtime theory cancer defense
1539,MRK,many part president trump federal government have yet take shape leaner meaner food drug administration seem almost certain way agency watcher see trump blueprint nation pharmaceutical gatekeeper point funding cut budget outline also suggest user fee charge industry process approval much double yet trump also want speedier fda push more generic drug boost competition have deride astronomical outrageous drug price call competitive fair drug approval process drugmaker analyst say re re just not sure leaner fda accomplish support fda get more funding so approve generic drug faster ll bring drug cost say john maraganore ceo alnylam pharmaceutical alny alnylam make expensive specialty drug treat hemophilia other rare ailment acknowledge more competition generic market help tug rise drug price competitive marketplace base way do preserve market base time limit award really need innovation maraganore tell investor business daily irina koffler analyst mizuho agree fda now face drug backlog generic application tell ibd make dent backlog agency need more funding more staff legislation clear thicket law legal decision slow drug approval koffler say generic submission be sit languish be not enough competition koffler say situation ll have supply monopoly company be only manufacturing certain generic drug therefore charge lot biotech drug stock be touchy come trump march tweet president promising more drug competition send ibd company generic drug industry group generic drug company actually favor more competition say chip davis chief executive association accessible medicine advocate maker generic drug maker generic be know biosimilar drug experience constant price deflation say backlog generic application mean drug provide new revenue stream stay stick hold await fda review action only way time company be financially successful be be able get approval new generic help offset continue deflation see year year current mature portfolio tell ibd fully recognize more competition create downward pressure pricing prescription drug price rise re project jump year active employee early retiree american workforce accord advisory firm segal consult retiree age older price be expect rise slowdown likely take congressional push speed fda approval most recent iteration american health care act gop bill seek replace obamacare didn touch pharmaceutical trump pledge march kentucky rally work legislation bring pricing ibd take swearing trump have continue call drugmaker lower price do biotech drug stock read ibd industry theme trump budget blueprint hint package administrative action design achieve regulatory efficiency speed development safe effective medical product trump be same page alnylam maraganore imagine system fda incentive approve generic quickly congress enact legislation fda be incentivize approve second third manufacturer generic drug faster maraganore say imagine help speed lower drug price fda have prioritize second third drug approval other generic drug action trump not do be reduce drug testing safety effectiveness mizuho koffler say recall thalidomide crisis thalidomide be first market germany counter medication nausea pregnant woman ensue year child worldwide be born phocomelium malformed limb half survive be turn point drug approval process koffler say thalidomide wasn well test be sell vulnerable population pregnant woman result unexpected side effect newborn fda strengthen drug review process drug re take have assume terrible thing happen child take pregnant woman take person have bad kidney bad heart take say so have test drug more realistic representative population patient trump pick fda commissioner dr scott gottlieb have talk overhaul fda process generic complex drug have allow brand drug create monopoly perpetuity generic complex drug have more complex active ingredient formulation route delivery drug device combination typical generic gottlieb be industry insider formerly hold position fda center medicare medicaid service nomination have draw support aisle trump gottlieb support more competition generic market cut brand monopoly march article forbe gottlieb note older generic drug be sell cheaply be sometimes very costly prime example be turing pharmaceutical purchase decade old hiv medicine company spiked price pill overnight be often result failure way fda be regulate generic medicine say agency long costly approach regulate generic drug be reduce competition generic market increase cost manufacturing generic medicine maraganore identify more brand side aisle draw distinction generic groundbreaking treatment fda approve brand drug rare disease biogen biib spinraza spinal muscular atrophy even new treatment come now actually cure cancer drug receive patent protection number year generic make copy period maraganore call market base time limit award need innovation generic market be be greatest amount competition say address challenge system drug price drug approval process need be careful reform look good sound good be fact good preserve innovation engine have country january trump tell exec celgene celg eli lilly lly johnson johnson jnj novartis nvs merck mrk cut regulation fda approval process accord regulatory affair professional society trump pledge streamline process so standpoint actually have drug actually get approve instead wait many many year mizuho koffler note least law be revise drug price competition patent term restoration act stay generic drug application month allow patent holder time litigate generic filer protect patent month clock be place regardless dire need be drug legislate stay away mandatory month help expedite litigation process brand generic company create lot more competition say davis generic drug maker advocacy group argue congress tackle decade old law require maker fda take additional safety measure drug have risky side effect not properly administer brand company be take advantage risk evaluation mitigation strategy law prevent generic purchasing sample drug say davis contend company have used risk evaluation program create limit distribution program doesn allow generic company legally purchase sample drug need do clinical testing so submit application fda compete originator product say need be legislation make sure risk evaluation only be used intend purpose not delay competition generic biosimilar go forward say bill house now just study matter reality be everyone have know year be problem trump budget blueprint offer clearest view yet want run fda doesn clear away smoke trump argue industry benefit fda approval pay share constrain budget environment proposal doesn detail specific budget figure fda fda budget grow year fda have ask increase industry be brace potential cut agency funding indicated propose jump user fee law fda collect fee drugmaker brand generic biosimilar fund drug approval process trump blueprint propose boost fee agree user fee industry fda isn publicly available say davis so difficult know mesh trump blueprint deal be form month month dialogue generic biosimilar come away satisfied say trump blueprint likely include brand generic biosimilar be set pay fee year unclear trump plan include other type user fee fda user fee amount alliance stronger fda coalition consumer patient group health professional trade association call trump user fee jump neither wise realistic march statement not wise fda core responsibility safe effective medical product safe food need be support large measure public be primary beneficiary group say not realistic drug device industry have recently complete user fee agreement negotiation fda
1540,MRK,drugmaker pfizer pfe boost value takeover bristol myer squibb bmy analyst say monday acknowledge bristol specific macro uncertainty limit likelihood still be common question give challenge bristol myer squibb be face activist involvement name credit suisse analyst vamil divan say question takeout center next month say note client pfizer commentary recent meeting management other investor conference make think be certainly look possibility come business development write overall credit suisse see bristol have positive impact pfizer return capital cash deal assume pfizer pay premium extract synergy lead value creation cent share pfizer opt cash stock deal dilution issue undervalue share offset initial value creation analyst write deal partially finance stock issuance be break even pfizer shareholder ibd take bristol myer have immuno oncology drug approve meaning compete other fda approve treatment roche merck head ibd technology page breakdown drug sector close bell stock market today bristol be fractionally pfizer tick share bristol have be pressure year be january activist investor carl icahn reportedly take stake bristol myer february icahn be know investment company paypal pypl xerox xrx allergan agn jana partner activist investor buy stake bristol fourth quarter compound add pressure like merck mrk roche rhhby be add macro uncertainty bristol myer february bristol lose share immuno oncology market merck roche remain flat month month basis related bristol myer partner hit month high immuno oncology dealmerck be near rival keytruda approvalincyte spike record high rumor gilead acquire
1541,MRK,handful drug approve food drug administration define new market immuno oncology drug harness body immune system fight cancer early entrant market include bristol myer squibb bmy merck mrk roche hold rhhby here list treatment fda approve used be approve glaxosmithkline stock rise stock market trading friday close novartis share rise bristol myer rise merck rise small fraction roche inched cent medical ethical drug industry currently rank month stock price performance industry group track investor business daily politician health activist have slam industry price increase related merck bristol incyte race cure marketbristol myer topple guidance cut merck say drugmaker be get away murder
1542,MRK,bristol myer squibb bmy ono pharmaceutical benefit meaningful royalty stream merck mrk keytruda follow settlement announce friday credit suisse analyst vamil divan say monday stock market today merck bristol myer stock split difference merck stock dip bristol myer stock lift be reversal friday merck rise bristol myer plunge more year low merck make bristol myer time payment settle patent infringement litigation related keytruda merck also pay royalty keytruda sale january december rate drop follow year bristol myer get royalty japan ono get remainder bristol myer ono develop opdivo used pd antibody target cancer europe australia japan duo say merck keytruda infringe patent ibd take merck tie biogen eli lilly most drug approval apiece be slowest year year fda read ibd industry theme deeper analysis keytruda also target cancer programme cell death receptor pd keytruda be approve monotherapy metastatic melanoma head neck squamous cell carcinoma late last year get indication small cell lung cancer patient high expression pd gene now merck be testing keytruda immuno oncology drug combination eli lilly alimta chemotherapy meanwhile bristol myer be look combine opdivo yervoy drug nsclc bristol myer isn look accelerate approval combo divan estimate keytruda garner sale year rise royalty sale be quite meaningful write research report still divan have outperform rating merck stock neutral rating bristol myer stock settlement provide upside bristol myer remove economic contribution be currently assume merck write overall still prefer merck give impact expect keytruda have merck sale earning growth related bristol myer threaten merck head start lung cancer analystmerck lung cancer drug get large patient populationmerck carry incyte keytruda coattail hot tumor leerink
1543,MRK,roche rhhby tecentriq be modestly trail merck mrk keytruda continue chip away bristol myer squibb bmy share second line lung cancer market barclay analyst geoff meacham say tuesday overall immuno oncology drug have swipe total lung cancer market high range see previous quarters meacham say research report drug be most popular second line small cell lung cancer melanoma share respectively bristol myer be struggle second line nsclc set meacham say opdivo see high share market fall tecentriq gain mid single digit sequentially tecentriq be now modestly trail keytruda say investor be seemingly disappoint bristol myer isn seek accelerate approval opdivo yervoy combination first line nsclc combo be widely suspect be more potent combine chemo merck be testing latter keytruda eli lilly lly alimta keytruda already be approve monotherapy first line nscls patient high expression pd gene metastatic melanoma head neck squamous cell carcinoma food drug administration recently grant priority review chemo combination ibd take merck biogen eli lilly tie drug approval apiece lead broader biotech industry trail get more ibd industry theme combo open merck broader patient population only patient fall category have high expression pd gene half patient be be test meacham say have gene regardless expression chemotherapy be dominant first line nsclc have share keytruda still momentum look good keytruda meacham say sentiment be more negative bristol myer follow decision accelerate regulatory route opdivo yervoy bristol recent decision not pursue accelerate first line pathway have little impact term estimate increasingly negative sentiment make premium group harder sustain absent convince pivotal datum write research report meacham trim price target bristol myer stock rating overall biotech industry be positive bristol myer stock fall tuesday come penny more year low merck fall related fda track record bode well merck keytruda chemo merck meaningful keytruda royalty give bristol myer leg bristol myer dife opdivo setback get keytruda royalty
1544,MRK,complexity be actually kill company ability innovate adapt simplicity be fast become competitive advantage time lisa bodell author simple win escape complexity trap get work matter bodell be also founder ceo futurethink assist organization embrace change innovate learn eliminate redundancy communicate clarity make simplification habit individual company recognize activity be time suck create last value do thing matter say tip make simple pay implement new perspective leader have obligation make work simple possible colleague bodell state add new golden rule recommend use other time just want time used smart leader know successful simplification be enable employee do more work re excited complete bodell add set example complicate organization tend be overload person claim get thing do need more time analysis bodell have find say department hasn sign team hasn send specification etc leader operate simplicity mindset short circuit complaint say make decision quickly cleanly inspire do same leader have power set tone entire organization behavior embrace simplification re affirm use time be important part success reduce meeting amount sprint do bodell say several business unit take inventory meeting do year cut also be selective accept invite make person think really need time provide good reason get say yes manage email discourage scroll email possible keep short bodell advise encourage use nntr need respond subject line email avoid unnecessary response add pharmaceutical giant merck mrk do cut budget downside too many vital resource cost be undermine urgency foster complacency say scott sonenshein author stretch unlock power less achieve more ever imagined also business consultant professor management rice university actively choose create boundary constraint shift focus deliver outstanding result spark more creative engagement project say make do budget not supply most often company individual accomplish goal far less think need sonenshein say leader create culture promote ask do have reject distraction come be miss get act be one deliver outstanding result add adapt comfort plan everything sonenshein say research show rather modest relationship long range strategic plan company performance simple explanation say plan quickly become outdated best company learn quickly process real time information develop capability improvise ironically today speed beat scale bodell add assume best consider hear colleague someone be difficult re likely treat way fulfill expectation sonenshein say psychological level expect more person ll contribute help be more simple efficient stay commit sonenshein say yahoo yhoo president ceo marissa mayer be google now part alphabet googl be know post powerful simple message outside office read revenue solve problem say bodell complexity be kill ability perform simplification have become new operate system simplification be skill available yet very few leader use more secret success know spend time be stingy itto stay top keep reach highervanquish self defeat habit
1545,MRK,caterpillar cat csx csx biogen biib costco cost target tgt wal mart wmt be analyst microscope tuesday barclay upgrade stock overweight equal weight raise price target late last month construction equipment maker turn mixed fourth quarter result cut full year revenue outlook strength dollar share rise finish trading day related caterpillar trim outlook strong dollar stock buy pointjp morgan up price target railroad stock last week news surface former canadian pacific railway cp chief hunter harrison be talk potentially lead company activist investor mantle ridge have ask more seat csx board share advanced stock market today related rail vet know improve profit soon head drugmaker get upgrade buy neutral citigroup just late last week leerink analyst say biogen trail merck mrk astrazeneca azn eli lilly lly introduce bace inhibitor treat alzheimer share climb intraday related biogen trail merck lilly alzheimer hemophilia spinoff begin tradingbiogen sidestep sale miss strong ex hemophilia guidebernstein initiate coverage number retailer include membership warehouse costco big box store wal mart target costco wal mart be handed market perform rating price target respectively target be outperform bernstein eye price goal wal mart say tuesday be drop version amazon amzn prime offer free day shipping minimum order match commerce giant meanwhile costco share jump thursday report best monthly same store sale year contrast lackluster result retail peer costco add wal mart tick target inched bernstein also initiate coverage best buy bby home depot hd lowe low best buy lose lowe be home depot tick higher related costco soar biggest comparable sale gain yearswal mart offer free day shipping drop amazon prime rival
1546,MRK,biotech industry have mixed outlook few new drug come market year midcap incyte incy be few company potential blockbuster pipeline incyte close start major development first come late last year company discover jakafi drug win be face competition gilead gild previously expect jakafi be used treat malady myelofibrosis bone marrow disorder polycythemia vera type blood cancer gilead rival drug jakafi now know momelotinib fail phase study previously untreated myelofibrosis patient november left incyte primary revenue driver free competition foreseeable future accord ian somaiya biotech analyst bmo capital market rare see drug generate sale face competition say jakafi peak sale potential most recent earning report incyte official say jakafi account net product revenue third quarter year company raise full year net sale outlook drug earlier outlook morgan stanley analyst say note client tuesday see drug revenue grow year then earlier month incyte announce immuno oncology drug epacadostat merck mrk keytruda be used phase study year include treatment small lung cancer well renal bladder head neck cancer opportunity solid tumor be earning multiplier epacadostat somaiya say drug pass trial receive food drug administration approval analyst expect peak sale accord recent goldman sachs note morgan stanley analyst say note expect key datum study prompt company start phase trial be disclose american society clinical oncology conference chicago june epacadostat have potential least be biggest pipeline drug say eric schmidt biotechnology analyst cowen be active so many tumor type finally jan fda extend review period baricitinib investigational rheumatoid arthritis drug jointly develop incyte eli lilly lly morgan stanley take bullish sign fda didn ask new study see imminent approval still analyst lower sale estimate drug delay yet see peak sale management have play key role incyte success recent year incyte chief executive herve hoppenot take helm be previously president oncology novartis nvs many scientist oncology side follow hoppenot incyte always make incyte unique be expertise biology somaiya say management change have expertise develop drug conduct larger trial bring drug market independently market analyst question much longer company remain independent incyte be largest midsize company oncology space potential buyout target endgame most biotechs be be buy larger pharmaceutical firm have less fruitful pipeline accord michael schmidt senior biotech analyst leerink partner be relation cowen eric schmidt ibd take incyte be rank second ibd medical biom biotech group have composite rating share jump buy range flat base buy point jan company announce drug trail epacadostat oncology pipeline be very interesting standpoint scarcity company have good pipeline michael schmidt say wouldn speculate company be interested incyte september poll evercore isi investment bank analyst vote gilead most likely buy incyte next month president donald trump call drug industry disastrous drug price merger activity heat year trump administration be change tax code well possible boost foreign cash increase stock valuation accord reuter report incyte be poise successful biotech world isn risk traditional drug development risk be always regulatory risk michael schmidt say oncology be obviously competitive space particularly immuno oncology cowen eric schmidt say not worry competition oncology sector be too much unmet need too many patient be die say add valuation be prime risk biggest risk be be fair bit good news price incyte say so something go wrong valuation come correct lot share incyte seem ready hit third straight day gain meet resistance cross mark friday share end monday session marginally related fda track record bode well merck keytruda chemo leerinkamgen plan robust alzheimer migraine oncology ceo exclusive
1547,MRK,drugmaker roche rhhby merck mrk pfizer pfe likely disappoint guidance abbvie abbv stock remain top pick jeffery analyst jeffrey holford say friday research report rundown ahead earning stock market today abbvie stock fall ibd company medical ethical drug industry group fall fall day move average week abbvie be face pressure amgen amgn biotech market cap prep deploy humira biosimilar abbvie humira world top selling drug be used treat array disease include rheumatoid arthritis psoriatic arthritis crohn disease ulcerative colitis abbvie patent protect dose scheme humira be set be deliberate court feb patent administer milligram antibody day be set expire june patent likely be upheld bar entrant first filer amgen holford say ibd take low holford totem pole merck step eli lilly biogen deliver new drug approval else curry fda support head ibd industry theme more see patent block patent potential humira biosimilar give be assume biosimilar be develop be dose same concentration frequency write worst case scenario amgen launch humira biosimilar mid assume first filer doesn launch risk holford see share downside humira biosimilar launch give consensus expectation launch abbvie holford list novartis nvs bristol myer squibb bmy astrazeneca azn strong pick pfizer merck nordisk sanofi sny be opposite end holford list expect disappointing guidance nearly big cap drugmaker expect disappointing guidance majority eu large cap pharma roche novartis pfizer astrazeneca likely disappointing revenue guidance pfizer astrazeneca merck roche also expect disappoint earning share guidance write upcoming catalyst include datum roche aphinity trial examine perjeta regimen positive breast cancer holford lean positive outcome sense high degree uncertainty write merck keytruda combination eli lilly lly alimta be also pique investor interest combination immunotherapy chemotherapy be grant priority review first line small cell lung cancer month holford note fda accept application small datum set therefore combo be unlikely see wide use also see consensus too bullish combo undervalue immunotherapy combination like bristol myer astrazeneca first line small cell lung cancer related gilead outlook hamstrung hep rbc bullish amgen biogenbristol myer dife opdivo setback get keytruda royaltiesfda track record bode well merck keytruda chemo leerinktrump disastrous pharma view doesn rattle jpmorgan drug conference
1548,MRK,stock open higher friday strongest start week barack obama prepared step donald trump be schedule be swear president et nasdaq climb stock market today dow jone industrial average add nasdaq start trade friday so far holiday shorten week tack first slip week be week lean second straight weekly decline dow open deficit pull back test support day move average week have be much harder small cap russell smallcap start friday american express axp drop general electric ge nearly follow quarterly result drug giant bristol myer squibb bmy dive open company announce late thursday not seek accelerate approval immunotherapy drug opdivo lung cancer leave merck mrk significant head start market merck share rise open emerge energy service emes spiked goldman sachs up supplier sand used hydraulic fracture operation buy neutral stock end thursday buy point cup handle base procter gamble pg step report fiscal second quarter earning revenue analyst consensus target share have be contend resistance merged week move average mid december form base skywork solution swks bolt breaking base chipmaker fiscal first quarter sale earning top view second quarter revenue guidance be expectation company also launch share buyback initiative stock have be form flat base standard buy point be slightly more aggressive entry oil price rise west texas intermediate nearly barrel fraction higher week gold inched ounce half percent last friday end price dollar gain ground second day bond yield also continue higher year yield single basis point weekly rig count report baker hughe bhi come et philadelphia federal reserve bank president patrick harker be due speak et president john william san francisco federal reserve bank deliver comment et china market post mixed finish hong kong exchange shanghai datum show stronger expect fourth quarter gdp growth japan tokyo nikkei add end week recover mid week lows europe market manage narrow gain afternoon trade london ftse trade flat frankfurt dax add cac paris keep gain related bristol myer win seek accelerate fda approval lung cancer drug
1549,MRK,stock close modestly higher friday follow donald trump inauguration speech trump continue series ceremoney be swear president today dozen be arrest sometimes violent protest washington dow jone industrial average lead key index thank big gain merck mrk ibm ibm procter gamble pg dow close gain nasdaq add volume be mixed higher nyse lower nasdaq accord preliminary datum dow nasdaq shed week dip less small cap russell post weekly loss chipmaker department store oil stock be top gainer stock market today west texas intermediate crude price surge barrel gold stock advanced too gold future climb ounce medical fiber optic defense issue underperform merck lead dow gap healthy trade share work right side flat base potential buy point be bristol myer bmy say win pursue accelerate approval opdivo lung cancer drug potential rival merck keytruda bristol share gap plunge hit worst level late procter gamble add ibm general electric fall breach day move average fast turnover industrial giant report mixed result ibm be try clear resistance intel intc climb broad chip rally work handle cup base buy point mizuho security wednesday report name intel nvidia several chip stock benefit artificial intelligence deep learn rate stock buy chipmaker rise more friday apple aapl pare early gain close iphone maker share have yet show strong follow jan past buy point stock rs rating be soft too macquarie research friday reiterate outperform rating raise price target cite apple service business drugstore stock fall sharply walgreen boot alliance wba rite aid rad sank respectively report federal trade commission isn happy propose offer gain approval merger stock undercut day day line heavy volume bank stock lead upside ibd financial wtfc bank ozark ozrk gain more stock test week move average re recent high respectively take breather big postelection advance chip stock microsemi mscc broadcom avgo outperformed too microsemi be jam high continue ride day line broadcom be time high now extend past buy point clear december nvidia nvda sit chip stock rally volume be well average stock continue digest big gain graphic chip designer display climax top action late december pullback thus far have raise alarm related walgreen fall rite aid dife ftc reportedly oppose merger offerdid miss nvidia big last year don miss next onebristol myer dife year low opdivo lung cancer setback merck jump
1550,MRK,stock open solidly higher early friday ahead donald trump inauguration nation president merck mrk procter gamble pg be early leader dow jone industrial average dow nasdaq composite show gain volume be heavy early go due option expiration apple aapl add be get resistance recent buy point stock so far have be unfazed president elect trump tough trade talk china most think full blow trade war china be unlikely china state run global time have warn target apple other company big presence trump follow threat big tariff chinese import apple total revenue come china wall street also weigh news china gdp rise procter gamble clear recent upside resistance level rise nearly investor like look fiscal earning report other news share bristol myer squibb bmy dive company say win pursue accelerate approval lung cancer combination treatment bad news bristol myer be good news merck share rise merck jump last week regulator agree accelerate review combination lung cancer treatment combine immune system boost drug keytruda chemotherapy earning news oilfield service provider schlumberger slb give back more report result open adjust earning share fall year sale fall many other oil gas name schlumberger be potential turnaround story several quarters row earning sale decline annual earning be see rise year schlumberger be still buy range buy point heavy volume gainer include leaderboard name broadcom avgo share jump more now extend prior buy point ibd take broadcom be several top rate name ibd chip designer group see other leader be ibd stock checkup elsewhere domino pizza dpz gap keybanc upgrade share overweight sector weight domino have be longtime market leader formerly part ibd leaderboard midcap consumer play be set new base daily chart show cup handle buy point related schlumberger earning line revenue beatsbristol myer dife opdivo lung cancer setback merck jumpsapple gm boee be china top hostage trump trade invest case trump era secular bull invest stock sector lead past presidency reagan
1551,MRK,strong start general market give back early gain stock market today follow donald trump inauguration speech nasdaq hobble higher dow inched merck mrk lead dow higher move bristol myer squibb bmy decline seek accelerate approval combination approve lung cancer treatment bristol myer plunge last week merck be grant priority review keytruda chemotherapy first line treatment advanced lung cancer general electric ge lag blue chip index fall almost report revenue miss analyst estimate skywork swks soar more report better expect result apple chip supplier also announce new stock buyback program stock be gapping week consolidation quarterly earning only grow vs same quarter prior year facebook fb edge lower stock attempt add handle recently form cup shape base pacific crest initiate facebook overweight rating lead growth stock be mostly positive head afternoon trading financial stock rally several day top stock ibd be financial wtfc bank ozark ozrk citizen financial cfg rise ozark citizen financial tack stock have recently find support respective week line other ibd stock broadcom leaderboard member add stock have rally lows day line last trading day downside healthequity hqy drop lead hsa provider be back buy range stock break flat base entry surge volume related merck biogen lilly top drug approval fda slumpge ceo say obamacare repeal make customer cautious mixedskywork sky month high earning beat apple linefacebook still early stage growth massive size
1552,MRK,incyte incy oncology program grow merck mrk partnership tie keytruda epacadostat hot tumor leerink analyst michael schmidt say friday boost price target incyte stock schmidt have outperform rating incyte stock up price target reflect epacadostat opportunity stock market today incyte stock lift fraction earlier share rise much near month high achieve tuesday announcement be make monday annual jpmorgan healthcare conference san francisco merck incyte have test combo type tumor datum msi high colorectal cancer diffuse large cell lymphoma be not yet available keytruda epacadostat win advance ovarian cancer triple negative breast cancer duo continue work melanoma bladder kidney lung head neck cancer accord company announcement monday ibd take donald trump refer pharma industry disastrous accuse get away murder comment overlap annual jpmorgan healthcare conference san francisco tone be see cautiously optimistic
1553,MRK,schmidt be bullish incyte epacadostat opportunity phase trial keytruda be likely begin later year thus far datum have be unambiguous researcher company be comfortable move forward epacadostat belong class drug inhibit ido gene ido molecule be thought allow tumor cell escape detection immune system researcher be testing inhibit gene assist battle certain cancer question remain extent partnership schmidt say be unclear merck opt co fund plan trial period exclusivity be grant merck incyte initiate additional phase trial potentially overlapping indication pd inhibitor write note merck be also work eli lilly lly combine keytruda chemotherapy alimta treat small cell lung cancer opportunity epacadostat be nsclc depend development strategy competition schmidt say merck be well position market likely beat rival bristol myer squibb bmy astrazeneca azn market immuno oncology chemo treatment analyst note bristol myer creep merck io io combo merck stock rise fraction friday rise week related eli lilly rebound chemo drug patent vs generic teva
1554,MRK,fda track record oncology hit accelerate approval program bode well merck mrk keytruda chemo combo leerink analyst seamus fernandez say tuesday suggest administrator have access early datum merck keytruda immunotherapy combination eli lilly lly alimta chemotherapy be be test first line treatment squamous small cell lung cancer nsclc patient have high expression pdl gene last week fda grant combo priority review supplemental biologic license agreement bla base small cohort fernandez say surprise move be better explain fda have access ongoing phase datum thus better visibility efficacy view be controversial interview richard pazdur act director fda oncology center excellence cancer letter suggest agency have access clinical trial datum risk unbind study fernandez write research report ibd take drug stock momentarily tank last week president elect donald trump again pledge curb rise drug price make good promise mean drug biotech pick read ibd industry theme deeper dive accelerate approval last year have already have positive confirmatory phase datum have receive full approval fernandez say only approval take more month review merck case datum keytruda alimta combo be due september approve combo open merck patient population currently approve indication be only patient have high expression pdl gene patient drugmaker be face rival bristol myer squibb bmy be testing combination opdivo yervoy immunotherapy analyst have suggest combine immunotherapy be more potent add chemo immunotherapy merck approach astrazeneca azn too be creep merck tuesday astrazeneca outlined strategy trial test durvalumab monotherapy combination tremelimumab be immunotherapy durvalumab target pdl gene tremelimumab aim ctla gene mystic trial astrazeneca examine progression free survival pfs overall survival os high express pdl patient pfs os be examine comer regardless pdl status combo arm neptune trial be expand patient china be used regulatory filing country fernandez say neptune test combo durvalumab tremelimumab trial recruit asia pearl test durvalumab first line treatment vs chemotherapy datum be expect meaning merck still have month head start fernandez say stock market today merck stock fall lilly stock slip share astrazeneca fall bristol myer squibb edge cent related merck carry incyte keytruda coattail hot tumor leerinkeli lilly rebound chemo drug patent vs generic teva
1555,MRK,barclay analyst geoff meacham thursday say expect gilead science gild outlook be hinder limit hepatitis sale also see merck mrk alexion pharmaceutical alxn issue sluggish view be more bullish biogen biib johnson johnson jnj rbc capital wednesday say much same gilead also be more bullish biogen well amgen amgn hepatitis drug prescription dip quarter quarter accord market tracker im gilead make sovaldi harvoni combat hepatitis merck alexion meanwhile guide decline metric heavier spending new management respectively meacham predict argue be widely anticipate meacham say research report see biogen offer upside guidance spinraza launch ionis pharmaceutical ion johnson leverage cost control offer better view ibd take hepatitis sale fall gilead go check ibd industry theme full scoop biotech biggest be expect do ahead pharma earning season start next week report company such stryker syk intuitive surgical isrg meacham boost price target incyte incy stock note company phase tumor effort merck duo be testing immunotherapy keytruda epacadostat tumor meacham expect incyte earning conference call give color jakafi trial graft vs host disease well tumor effort merck bump price target incyte stock incycte hasn yet set date earning report incyte stock last week touch month high just shy rally close stock market today consensus analyst poll thomson reuter expect incyte report sale cent earning share third respectively vs year earlier quarter merck spending be likely ramp keytruda be grant priority review last week combination eli lilly lly chemotherapy alimta treat squamous small cell lung cancer nsclc patient high expression pdl gene keytruda alimta be phase testing datum be strong merck open larger patient population vs patient pdl expression keytruda be already approve monotherapy high express pdl patient nsclc related merck biogen lilly top approval fda slumptrump disastrous pharma view doesn rattle jpmorgan drug trump break republican push major drug reform
1556,MRK,rise consecutive year fda drug approval rate plunge year low biogen biib merck mrk eli lilly lly add new drug bailiwick accord swiss biotech hbm partner food drug administration approve new molecular entity year marked decade high approval nmes say hbm have not be fewer nmes approve fda give blessing just half nmes be not fully develop house be acquire be license hbm write new drug be first class drug therapeutic area cancer lead nmes new drug project industry lead peak sale be oncology hbm find ibd take ease fda approval process be part donald trump health care initiative president elect really break republican enact major drug reform trend past year oncology drug see major increase fda approval list new cancer drug be approve rise nmes cancer fda have increase appetite drug treat diabetes respiratory disease viral other infection interest cardiovascular genetic immunology drug increase moderately year also see fewer central nervous system drug then merck roche rhhby have have more drug approve other company add johnson johnson jnj pfizer pfe follow closely apiece gilead science gild novartis nvs glaxosmithkline gsk sanofi sny lilly have add new drug ibd company medical biom biotech industry group close stock market today group rank be tumble lawmaker debate issue drug steeply rise price related lilly regain key migraine drug colucid acquisitionfda track record bode well merck keytruda chemo leerinktrump disastrous pharma view doesn rattle jpmorgan drug conference
1557,MRK,dow jone industrial average give start week president trump immigration policy other move worry investor moved back level friday job report apple aapl boom return earning growth investor didn care facebook fb amazon amzn result guidance unite parcel service up be struggle commerce boom charle schwab schw launch new stock trading pricing war dow jone industrial average fall back key level regain friday january job report trump move ease dodd frank other financial regulation dow fall week nasdaq rise end week record high trump immigration order create conflict tech firm trading partner earning be mixed bag cboe volatility index vix rally extreme level not much related dow component apple earn share sale quarter end dec be better expect marked return growth straight quarters year year decline apple current quarter guidance be conservative usual apple say iphone demand outstripped supply service revenue apple share rise nearly week hit month high related advanced micro device amd report smaller expect loss forecast sale bullish outlook share shot nearly hit year high nvidia nvda compete amd graphic other market jump ahead earning come week apple chip supplier cirrus logic crus qorvo qrvo top quarterly view give bearish guidance stock sell thursday related facebook ep soar revenue rise easily beating view decelerate second straight quarter mobile ad account ad revenue facebook reiterate ad revenue growth rate come meaningfully deliberate move avoid ad saturation now see heavy expense growth step hire facebook fall week snap parent snapchat file publicly upcoming ipo snap report soar revenue growth also slow user growth facebook instagram imitate key snapchat feature snap use ticker snap win sell voting share related amazon top earning forecast revenue revenue outlook be lower expect amazon web service cloud compute unit generate most commerce giant profit report revenue gain forecast aw be feel pressure rival cloud effort alphabet googl microsoft msft amazon share fall nearly friday undercut recent buy point related amazon result miss revenue beat ep stock fallsunited parcel service up report modest earning revenue growth holiday fourth quarter fall short forecast up also guide profit target lower cite impact strong dollar up see significant shift mix lower revenue product residential delivery accounting total package volume up ceo say result indicate up quicken pace investment network shift handle increase commerce meanwhile amazon announce set air hub cincinnatus northern kentucky international airport seek lessen dependence up fedex fdx up share plunge fedex lose related mastercard edge past earning view revenue be light share have be buy zone pull back nearly even regain day friday larger rival visa late thursday report better expect quarterly result strong payment growth visa rise friday push dow stock past buy point record high related federal reserve left interest rate alone give indication policymaker be hurry raise rate add strong job january well estimate slim wage gain ease fear economy be overheat ism manufacturing index rise fresh year high january related exxon mobil xom report adjust ep view oil major plan boost capital spending activity heat royal dutch shell rdsa say cut spending year report ep view conocophillip cop say plan raise spending energy information administration say crude stockpile rise barrel analyst expect russia opec seem be comply promise output cut accord reuter datum related auto sale decline december longtime high even automaker offer hefty incentive general motor gm ford fiat chrysler fcau report year year decline only gm miss forecast datum offer new evidence auto demand have peaked related charle schwab schw cut stock etf commission trade lower fidelity td ameritrade amtd trade etfc schwab fall thursday td ameritrade trade rely more stock trade schwab tumble interactive broker ibkr charge cent share trade sank related president trump meeting tuesday ceo exec celgene celg eli lilly lly johnson johnson jnj merck mrk novartis nvs say drug price be astronomical reiterate aim bring drug price also urge drugmaker manufacture also promise deregulate industry cut taxe drug stock pop day response related drugmaker eli lilly pfizer pfe disappoint tuesday earning lag consensus sale top meet respectively roche rhhby sale be light revenue earning rise mid single digit merck follow thursday line sale earning include time defer revenue amgen amgn late thursday report better expect earning say ldl cholesterol fighter reduce cardiovascular risk study related miss merger deadline expire walgreen boot alliance wba rite aid rad extend agreement end date july walgreen cut takeover price share share depend many rite aid store have be divest order new term get regulatory walgreen fall rite aid fall concern ftc win approve deal fred have agreement buy rite aid store edge lower related armour uaa miss estimate top bottom ep fall penny cent sale rise revenue guidance be light athletic apparel brand cfo be step personal reason share tumble year low related
1558,MRK,stock market moved lower head final hour trading nasdaq fall dow jone industrial average drift lower volume be trend lower nyse nasdaq vs same time wednesday merck mrk try keep dow afloat stock gain revenue miss earning release stock be breaking resistance price area approach flat base entry caterpillar cat be biggest laggard blue chip index fall stock be trading cup handle buy point follow surge earning beat tuesday apple aapl trade quietly move lower netflix nflx trade be still hover high recent day have come relatively light volume indication fund be hold share alphabet googl look snap day lose streak move lose streak stock fall more way back day stock be trading just cup handle entry blow past expectation yesterday release facebook fb drop be buy point ibd screen lead growth stock be mostly negative stock market today be positive sign upside chip stock look recover recent loss advanced energy industry aeis moved higher be attempt shrug downside reversal day tuesday follow earning announcement downside financial stock continue struggle wednesday dovish fed announcement bottom perform ibd stock be member finance sector charle schwab schw fall day reduce trading commission main online broker competitor trade financial td ameritrade amtd fall more sympathy amazon amzn be set report much await report bell today dominant commerce platform be expect report ep revenue stock rise remain buy range cup handle entry notable earning reporter be visa ep be estimate rise cent share rise revenue stock be trading just cup handle buy point related facebook stock inch higher strong earning revenue beatamazon visa chipotle amgen earning due closeapple facebook amazon earning put focus fang stock takeaway apple outstanding report
1559,MRK,stock market moved lower reach new intraday lows head midday trading market weakness persist nasdaq fall respectively dow jone industrial average drop call recent market rally question volume be lighter nyse nasdaq vs same time monday medical sector bolster dow merck mrk pfizer pfe be few blue chip gainer midpoint pfizer full year revenue outlook come street expectation president trump continue call drugmaker manufacture curb rise price intel intc be big loser fall stock be trading cup handle buy point financial continue pullback stock market today goldman sachs gs break day line rise volume stock fall today action be sell signal share close level financial service company be big beneficiary rise interest rate have be lead stock stock be unable recover negative price action portend more weakness financial sector come week charle schwab schw fall stock remain well day line close eye shift apple aapl report quarterly earning close today stock edge lower remain cup handle entry tesla tsla re-cover monday sell gain electric car manufacturer be add handle long cup shape base amazon amzn facebook fb continue trade lower ahead earning release later week amazon commerce giant be trading just cup handle buy point report earning thursday market close social medium company be less cup handle entry facebook report earning wednesday close bell armour ua plunge follow earning miss open bell news cfo depart company kevin plank ceo armour say numerous challenge disruption north american retail temper fourth quarter result ibd list lead growth stock continue show weakness early trading monday sell bottom perform ibd stock be member chip sector advanced energy industry aeis have particularly notable price action surpass earning sale estimate late monday stock gap open now stock be bearish downside reversal related armour earning sale miss cfo exit stock diveswhat look facebook report earningspfizer report lag ep rebound trump lilly merck sit trump call manufacture
1560,MRK,share incyte incy pop buy zone monday drugmaker partner merck mrk announce advance phase clinical program look combine incyte drug merck therapy treat more type tumor company say plan initiate pivotal study combine fight small cell lung cancer renal cell carcinoma bladder cancer squamous cell carcinoma head neck be combine incyte epacadostat merck keytruda pd therapy have be work together treatment melanoma keytruda be approve treat certain type small cell lung cancer bristol myer squibb bmy be company develop compete treatment nsclc ibd take earning season begin earnest next week stock be worth watch ibd provide plenty source help include rise profit estimate list incyte merck announcement say expect make presentation latest datum upcoming medical meeting didn say just meeting incyte stock jump stock market today touch buy point flat base share earlier touch month high stock fall rbc capital market recently say incyte be takeover target success jakafi treatment type blood cancer call pv polycythemia vera merck stock rise monday regain day move average merck stock hit year high nov related bristol myer astrazeneca roche pressure merck lung cancerincycte be play strong jakafi sale rbc
1561,MRK,eli lilly lly stock bound thursday federal appellate court upheld patent chemotherapy alimta vs generic drugmaker teva pharmaceutical teva third court year do so court appeal rule early thursday propose generic teva parenteral medicine subsidiary generic drugmaker same name infringe eli lilly patent alimta leerink analyst seamus fernandez say decision remove overhang lilly stock stock close still outperformed broader industry ibd company medical ethical drug industry group plunge last year lilly stock rise stock market today again rise day move average support line be also important benefit lilly long term sale guidance least particularly wake merck mrk surprise bla biologic license agreement keytruda combination alimta small cell lung cancer ibd take drug stock tank wednesday president elect donald trump comment first post election news conference view drug industry disastrous vow create new bidding procedure grab ibd industry theme deep dive fernandez model alimta sale immuno oncology combo be test now bristol myer squibb bmy competitively pressure lilly merck io chemo combination note analyst broadly expect bristol myer io io combo hit shelve give lilly merck several month advantage io chemo combo also potentially be expand larger range patient meanwhile alimta patent litigation be ongoing europe lilly hasn fared well trial end judge ruling generic chemotherapy wouldn infringe lilly alimta patent france spain italy patent case be still unfold germany fernandez estimate alimta sale be risk europe keep outperform rating lilly stock midday trading stock market today lilly stock lift related lilly near fda nod arthritis drug chemo med stick courtlilly spike guidance claw back alzheimer flop
1562,MRK,here weekly investing action plan need know investor come week tech darling facebook fb apple aapl amazon amzn report earning federal reserve policymaker mull interest rate again fresh job datum provide new clue much inflationary pressure economy be see oil major exxon mobil xom royal
1563,MRK,merck mrk have several month head start bristol myer squibb bmy astrazeneca azn morgan stanley analyst david risinger say thursday fda unexpectedly approve priority review keytruda combo lung cancer wall street be question merck hold lead immuno oncology io drug include merck keytruda patient immune system fight cancer merck be combine keytruda chemo first line treatment small cell lung cancer keytruda be already approve nsclc patient highly express pd protein firm be trial patient expression protein successful open merck nsclc market risinger say research report thursday guggenheim analyst tony butler meanwhile say combine io therapy be key bristol myer have lead butler remove bristol myer best idea lieu merck thursday see former take share long run bristol myer opdivo yervoy io io combination trial checkmate have be guide read first half write research note believe see datum fully enrolled pd cohort sometime then perhaps mid ibd take drug stock tank wednesday commentary president elect donald trump tackle rise drug price ibd industry theme delve trump disastrous view industry do combat datum be positive bristol myer file receive approval early write even best case scenario high expresser population only represent total patient population merck have capture other piper jaffray analyst richard purkiss see merck grab market share expect erode bristol myer likely come market io combo see merck share drop purkiss have overweight rating price target merck stock guggenheim butler agree likelihood io io therapy have better response longer duration possibly better overall survival chemotherapy io direct evidence hasn yet be proven trial note butler upgrade merck stock buy neutral have price target morgan stanley risinger upgrade merck stock overweight raise price target stock market today merck stock lift nearly rise wednesday trading nearly month high buy point bristol myer stock fall thursday astrazeneca rise fraction related bristol myer gain lung cancer square vs merck jefferiesbiogen takeout still possible internal promotion ceo rbc
1564,MRK,general market retreat early thursday trading weekly jobless claim come less expect nasdaq faltered putt day winning streak jeopardy fall dow industrial give back blue chip index merck mrk be overwhelming leader be upgrade overweight morgan stanley ms raise buy guggenheim wednesday fda accept supplemental filing allow merck lung cancer treatment drug be offer larger patient population thus increase potential market sale news prompt guggenheim call drug company new best idea stock be form flat base entry dow laggard stock market today be disney medium company moved lower be cut sell pivotal research set new price target pivotal say cost capital be core price target change disney break saucer handle base entry price several week stock be entry amazon amzn buck market trend move commerce company retook day line last week be build right side potential base clear entry have be establish delta dal share be mostly unchanged company report earning cent share meet expectation sale top street view airline have be uptrending industry group currently rank month alaska airline alk southwest airline luv recently hit new high initial claim rise seasonally adjust less estimate claim number be associate healthy labor market big rally wednesday crude oil price jump today rise barrel be number fed speaker today capped federal reserve chair janet yellen speech et atlanta fed president dennis lockhart speak et st loui fed president james bullard speak et lead growth stock be mostly negative just open bell gatx gatx veeva system veev be laggard gatx fall be downgrade sell stifel nicolaus stock be now testing week support level veeva be rally day line stock be process build new base related delta air line lift unit revenue view see cost pressureairline take new high stryker preliminary sale beat streetis stock market close martin luther king jr day merck lung cancer drug get large patient population
1565,MRK,drugmaker merck mrk open broader lung cancer market food drug administration accept supplemental filing immunotherapy keytruda chemotherapy prompt share rocket wednesday merck stock rocket more nearly month high early trading stock market today finished trading session wednesday drug stock general fall late morning trading donald trump first press conference be elect president reiterate believe issue escalate drug price be address share merck rival bristol myer squibb bmy astrazeneca azn tumble wednesday close merck keytruda announcement late tuesday coincide presentation jpmorgan healthcare conference san francisco drug industry major annual event ibd take event such trump press conference move stock so keep date latest action ibd stock move keytruda chemo now have prescription drug free user agreement pdufa date follow fda acceptance merck supplemental biologic license agreement bla accelerate approval keytruda be currently approve first line small cell lung cancer patient have high expression pd protein cover nsclc patient population merck be run trial patient expression pd open rest nsclc market merck be unlikely durably penetrate entire population especially multiple compete regimen horizon approval give significant first mover advantage complement combination cheap chemotherapy agent broader patient population evercore isi analyst john scottus write research note bristol myer astrazeneca also be work combination therapy accelerate approval put merck combo market other pending confirmatory trial likely second half year scottus write leerink analyst seamus fernandez estimate merck combo address patient population have market perform rating merck stock scottus fernandez note first mover advantage merck grab fda ultimately approve combo add combine immunotherapy drug likely be more durable treatment early broad accelerate approval immuno oncology chemo combo further establish keytruda pd choice first line set least other agent be approve set write research report related merck partner incycte advance key trial
1566,MRK,nasdaq composite session streak be jeopardy late afternoon trading wednesday weigh weakness biotech stock dow jone industrial average rise add nasdaq be flat volume nasdaq nyse be tracking higher tuesday level stock market today biotechs take heat president elect donald trump take aim pharmaceutical industry first press conference say new bidding procedure be need drug price meanwhile lockheed martin lmt give day move average trump vow increase competition fighter jet bring cost alexion alxn incyte incy mylan myl biogen biib celgene celg be top decliner nasdaq fall anywhere ishare nasdaq biotechnology ibb give merck mrk be high still bright spot dow rise fda be consider immunotherapy drug keytruda chemotherapy treat advanced lung cancer decision be expect merck be work new base buy point small cap barracuda network cuda rebound tuesday reversal high solid earning share rise nearly still buy range double bottom entry ibd take security software group have be lag market recent month group be home intriguing name solid fundamental see be ibd stock checkup ibd chipmaker microchip technology mchp add work tight flat base buy point sale growth have accelerate straight quarters market cap firm new york mercantile exchange february west texas intermediate crude oil future settle barrel nearly related trump say drugmaker get away murder cite ford fiateconomic optimism hit new year high trump rally continuestrump vow fighter jet competition big thing lockheed
1567,MRK,general market tread water ahead president elect donald trump news conference conference be schedule et nasdaq be unchanged rise dow industrial lead way rise back merck mrk rise company announce morning fda have grant speedy review lung cancer treatment apple aapl trade line general market essentially unchanged stock market today apple be still buy point cup handle parsley energy pe fall company announce secondary offer stock have have trouble gain traction flat base entry be upgrade tuesday netease nte be initiate underperform bernstein analyst set price target chinese gaming stock share trade alibaba baba just add leaderboard watch list tack stock be build right side base clear entry have emerge lead growth stock be mostly calm shadowing market index upside rank middleby gain stock successfully find support day line cup handle stall downside rank healthequity hqy fall stock break flat base entry tuesday remain buy zone rank nvidia nvda fall stock have be consolidate exhibit sign climactic action also breaking upper channel line trigger upside sell signal related trump press conference celgene gw pharma lead investing action plan
1568,MRK,experimental ebola vaccine manufacture merck mrk have be find be highly protective deadly virus show promise fight future outbreak earlier epidemic kill thousand highlighted shortage weapon battle disease vaccine be study trial involve more person guinea receive shot final stage trial ebola case be record day incubation period accord study publish medical journal lancet outbreak ebola trigger public health crisis west africa result more death primarily liberium sierra leone guinea also expose hole global infectious disease preparedness infected traveler reach far away texas compelling result come too late lose life west africa ebola epidemic show next ebola outbreak hit not be defenseless marie paule kieny assistant director general health system innovation world health organization study lead author say statement trial call ebola a suffit french ebola enough be lead guinea ministry health medecin san frontiere norwegian institute public health well other international partner vaccine be call rvsv zebov manufacture merck sharp dohme subsidiary drugmaker merck year receive breakthrough therapy designation shot food drug administration enable faster regulatory review vaccine once be submit accord statement thursday finding reconfirm july study vaccine be potent weapon future disease spread vaccine be initially engineer support public health agency canada be eventually license merck sign agreement january gavi world biggest funder vaccine develop country submit experimental ebola vaccine regulatory approval end gavi bring together fund government company unite nation agency philanthropic group bill melinda gate foundation commit development vaccine july study publish lancet medical journal report merck vaccine be effective be test more person be close contact ebola patient guinea last outbreak vaccine maker rushed ready shot have never be test human disease spread have unexpectedly spirale control especially first few month public health official initially struggle curb infection share merck be fractionally midday trading friday
1569,MRK,stock pare loss early afternoon trading thursday ahead fed chief janet yellen speech et disney apple aapl weigh dow merck mrk advanced nasdaq trim loss dow jone industrial average be volume be tracking lower board stock market today vs same time wednesday steel financial build related stock be top decliner telecom medical gold miner lead upside dow stock be lower disney microsoft msft shedding volume be light however neither stock show alarm action disney remain buy range buy point clear jan jpmorgan reiterate buy rating entertainment giant lift price target pivotal research cut stock sell lower price target microsoft be still extend flat base entry be hold day move average apple stage upside reversal wednesday give nearly average trade share be buy zone buy point break past monday iphone maker aim add original script tv show apple music end year accord wall street journal already secure right carpool concert video ibd take several big cap techs break start new year re struggle hold apple netflix google be testing buy point thursday nvidia nvda dip more track extend slide third straight session stock be dec peak have find support level pause be likely overdue follow more gain march accelerate climb december graphic chip designer introduce self drive car brain ce last week be expect report ep jump upside merck lead dow rise nearly robust trade work flat base entry share gain wednesday food drug administration accept supplemental filing drugmaker keytruda chemotherapy healthequity hqy mark record high be only gainer ibd share be now extend flat base buy point clear tuesday fast turnover financial be biggest ibd loser bofi hold bofi sterling bancorp stl svb financial group sivb bank ozark ozrk shed more economic news jobless claim climb week end jan projection rise related ibm get price target hike skywork downgrade boee start lowapple talk bulk apple music original videomerck lung cancer drug get large patient population
1570,MRK,nasdaq suffer first loss major average close session high money flow bond gold year treasury yield fall basis point rebound test day line spdr gold share gld enjoy gain session year treasury yield have drop basis point past month so nasdaq composite dow jone industrial average lose slip small cap underpeformed russell volume nyse nasdaq be tracking slightly lower wednesday level telecom health care name mining stock outperformed steel stock lag merck mrk mcdonald mcd outperformed dow rise disney lag fall nearly hurt downgrade pivotal research sell hold thursday weakness be widely attribute disappointment president elect donald trump press conference wednesday fail give more detail plan lower taxe fiscal stimulus other thing also be market be show chink armor now distribution day count nasdaq have remain stubbornly high week russell nasdaq have show divergence recently bullishness newsletter writer have be week row cause least concern accord investor intelligence excessive bullishness have be see several market top past stock market today cheesecake factory cake continue show support action week move average first time late october share rise nearly ibd take cheesecake factory have healthy chart rank stock restaurant group see leader be ibd stock checkup amazon amzn be few bright spot technology sector share reclaim level rise nearly earlier today ceo jeff bezos say company expect add new job fiat chrysler fcau re-cover bit hit intraday low share still lose epa accuse automaker used software cheat diesel emission growth stock underperform many name ibd fall more related amazon plant re hire sign reach new jobsapple talk bulk apple music original videoepa charge fiat chrysler diesel emission cheating stock dife
1571,MRK,stock open lower thursday currency commodity international market recalculate follow president elect donald trump press conference wednesday dow industrial nasdaq fall lose late morning event trump specifically mentioned pricing drugmaker area target reform praise automaker ford fiat chrysler fcau plan investment drugmaker be mixed ford be flat fiat be open thursday investor generally cinch exposure risk send dollar sharply lower gold ounce bond advanced trimming year yield basis point most major international market trade lower tokyo nikkei lead decline diving investor crowd safe haven yen st loui federal reserve president james bullard set motion fed pronounce speaking offensive schedule thursday tell cnbc squawk box market be look trump congress deliver growth promise drugmaker merck mrk plow ahead dow morgan stanley upgrade stock overweight equal rate bestow price target gold mining stock be active premarket trade anglogold ashanti randgold resource gold rise respectively stock have be climb federal reserve vote increase interest rate december remain deep month correction newmont mining nem rise open stock uptrend start mid december newmont have be unable break resistance day move average taiwan semiconductor tsm slip chipmaker report consensus fourth quarter result revenue guidance first quarter be expectation stock be form flat base buy point delta air line dal open higher fourth quarter earning barely meet earning forecast revenue decrease less predict management say airline keep capacity check revenue trend firm operate margin return level stock have be find support week move average fifth week shallow consolidation import price rise december labor department report short consensus target gain export price improve view increase november import price decline export price slip unemployment claim increase week end jan claim prior week well expectation post holiday surge week move average edge lower third straight decline treasury department release december budget et philadelphia fed president patrick harker keynote bb annual economic forecast breakfast malvern pa begin et chicago federal reserve bank president charle evan speech american council life insurer executive roundtable naple fla be set start et atlanta fed president dennis lockhart be set retire feb speak speech st loui fed president james bullard be schedule et also et fed chairwoman janet yellen talk educator nationwide washington oil price climb nearly gain almost wednesday west texas intermediate trade barrel natural gas rise more related delta taiwan semi top investing action plan
1572,MRK,major index still show mixed action afternoon trading monday strength biotech semiconductor name help boost nasdaq decent gain nasdaq composite fresh robust gain last week begin new trading year rise nearly nasdaq gain gain counter loss dow jone industrial russell slip almost popular small cap gauge lag nasdaq last week lift volume be run sharply higher nasdaq pm et vs same time friday touch higher nyse hospital medical service pace field industry group gain respectively growth investor pay attention incyte incy developer tiny molecule drug research lesser know large cap play bolt good week high entry nearly week flat base pattern flat base also be see part long deep bottom base pattern incyte drop multiyear high low set february company show choppy fundamental wilmington del firm lose money year quarterly basis incyte profit be see fall cent share follow quarters row solid earning however annual basis wall street see earning ramp cent share cent rocket share amgen amgn be huge winner early thank success develop therapy treat anemia cancer patient amgen share more last week heavy turnover add nearly megacap market value be try form new base share be stock market today incyte say monday team big pharma play merck mrk develop new therapy treat variety disease include small cell lung bladder renal head neck cancer incyte have market cap share outstanding come public november eye care expert glaukos gkos base laguna hill calif rolled more higher volume be run nearly quadruple day average share small cap medical leader approach time high pioneer minimally invasive treatment serious eye disease glaucoma be add ibd leaderboard potential market leader friday break past buy point month cup handle glaukos sport just ep rating relative young public company have debut june analyst see outstanding profit growth earning re estimate rise cent share related be bottom base pattern help investor make moneythe bottom base pattern part ii apple form invest wall street trading tip stock market masteribd technology news incyte merck move forward phase clinical trial
1573,MRK,stock continue search direction early afternoon trade wednesday president elect donald trump send biotechs lockheed martin lmt nasdaq lag apple aapl nvidia nvda pull back nasdaq shed fall dow jone industrial average be flat volume be tracking higher board vs same time tuesday solar oil metal stock lead upside stock market today west texas intermediate oil future surge barrel biotechs other drugmaker get hammer president elect donald trump sharply criticize drug price blue chip drug giant pfizer pfe be dow biggest loser slide lose day move average fast trade merck mrk buck selloff healthy volume lead dow winner pare gain earlier pop share be build flat base buy point food drug administration accept supplemental filing merck immunotherapy keytruda be used chemotherapy treat advanced lung cancer apple meantime backed weak trade stock have so far be unable follow monday past entry cup handle remain buy range nvidia too be hesitate attempt recoup drop late december early january point recent stock market today column stock be due correction heady run march hold well day line overall trend be higher canaccord genuity jeffery raise price target graphic chip maker tuesday monday respectively tesla tlsa announce have hire apple executive include year veteran chris lattner lead electric car maker autopilot software effort tesla share dip stock be shape right side cup base lockheed martin lmt fall breach day line trump vow increase competition fighter jet bring cost share have be consolidate flat base try recover tough december trump blast cost twitter ibd biotechs unite therapeutic uthr celgene celg sank respective heavy volume unite remain extend buy point celgene slip day line be still build flat base related trump say drugmaker get away murder cite ford fiatmusk go tesla graveyard hire away apple exec trump vow fighter jet competition big thing lockheed nvidia stock get price target hike valuation concern
1574,MRK,stock be nearly flat open wednesday investor digest quarterly report look late morning press conference president elect donald trump dow industrial rise nasdaq be fraction merck mrk hammer gain open drugmaker announce expand immuno oncology partnership eli lilly lly clinical trial lilly lartruvo merck keytruda lilly share rise biotechs make early outsized move include achaogen akao signal genetic sgnl agricultural product leader daniel adm fall premarket trade chicago base company announce end tuesday session acquire pet food maker crosswind industry term deal be not disclose stock have generally trend higher past month msc industrial direct msm climb more fiscal first quarter earning top analyst expectation revenue meet estimate management lift industrial maintenance supply distributor second quarter revenue guidance consensus view stock end trade tuesday late october low pull back test support week move average signet jeweler sig shed warning investor fourth quarter earning comparable store sale miss consensus expectation wide margin owner kay jared retail chain have slip past week kill recovery attempt begin september company report result march grocery chain supervalu svu drop more fiscal third quarter result stop well short analyst target ibd stock healthequity hqy fall olin oln rise stage breakout flat basis tuesday healthequity be buy point olin be buy point stock market today have eye president elect trump hold first press conference july et new york oil price also be closely watch crude oil inventory expect energy information administration et otherwise economic calendar take break busy schedule datum report federal reserve speech thursday friday oil price improve diving more tuesday west texas intermediate add barrel gold rise ounce dollar climb bond inched pare basis point year yield overseas market trend narrow gain asia benchmark tokyo hong kong rise shanghai composite slip market europe be also mixed index london frankfurt more paris post narrow loss afternoon trade related trump press conference celgene lead investing action plan
1575,MRK,stock market push time high close tuesday broad base rally capped lead rise russell nasdaq rally reach new time high dow jone industrial average follow gain move blue chip index striking distance volume be tracking much higher nyse nasdaq accord preliminary figure dupont dd lead industrial higher report earning beat monday market close miss revenue estimate stock gain reach new week high downside verizon communication vz drop follow quarterly earning release alibaba baba gain be much premarket hour chinese commerce giant report blowout earning sale earlier morning stock be build right side base miner construction stock be act particularly well stock market today freeport mcmoran fcx leaderboard member soar gapping cup handle buy point see daily chart copper mining company report quarterly earning wednesday market open mastec mtz surge nearly reclaim day line have be fight support last several week stock be now away short cup shape base entry meanwhile lag sector be medical merck mrk pfizer pfe johnson johnson jnj fall johnson johnson provide cautious outlook earning revenue fall short street estimate lead growth stock ibd be very positive close only stock red broadcom avgo continue recent dominance be lead stock ibd tack recent gain stock be now extend flat base entry downside healthequity hqy be volatile close minor change lead health saving account provider be now top buy range stock break flat base entry surge volume stock be initiate overweight rating keybanc monday close hawaiian holding steel dynamic stld other report quarterly result close hawaiian holding parent hawaiian airline meet quarterly earning estimate be ep surpass revenue estimate share fall almost hour steel dynamic steel producer have not announce be estimate report ep cent intuitive surgical isrg top earning sale estimate share rise texas instrument txn beat expectation top bottom line estimate share edge lower seagate stx quarterly earning exceed street view earning sale figure share gain additional rise regular market hour related alibaba crush earning estimate raise guidancej hcv dip virtually mirror gilead view air steel dynamic texas instrument report closeseagate easily beat bottom line sale also top estimate
1576,MRK,president elect donald trump slam high cost drug once again pressure related stock general motor gm amazon amzn consumer small business be bullish apple aapl hit buy point jpmorgan chase jpm other bank stock report earning donald trump continue go company industry didn talk much tax cut other stimulus major average hold well nasdaq rise time high dow jone industrial average fall drug biotech stock tumble trump pledge go high price apple break base join alphabet googl netflix nflx bank stock rise modestly friday jpmorgan bofa well fargo report earning treasury yield rebound president elect trump double criticism high drug price say wednesday industry be get away murder say new bidding procedure be need suggest support legislation traditionally favore democrat not republican drug biotech stock sell hard comment trump also return attack costly lockheed martin fighter jet say ll save billion dollar push more competition lockheed have say be reduce jet cost year overrun delay say promise aggressively reduce expense lockheed ceo meet trump friday second such meeting election lockheed rise modestly friday fall week related trump say drugmaker get away murder cite ford fiattrump vow fighter jet competition big thing lockheed banking giant kick earning season sector friday differ result jpmorgan chase beat earning revenue bank america bac top earning fall short revenue well fargo wfc still deal fallout false account scandal miss top bottom line rise modestly friday related jpmorgan beat bank america result mixed well fargo missesthe ibd tipp economic optimism index rise point january fresh year high soar point december american have become much more upbeat presidential election stock market have soar hope donald trump cut taxe regulation ramp infrastructure spending boost economic growth meanwhile nfib small business optimism index spiked december year best net small firm see business condition improve vs october related economic optimism hit new year high trump rally continuestrump bump small business optimism soar year highgeneral motor see ep target analyst have expect then decline year gm recently report surprisingly strong gain sale december also add stock buyback program ford meanwhile add cent share regular quarterly dividend ford see earning fall year heavy investment improve profitability gm share rise week hit best level nearly year ford fall epa accuse fiat chrysler fcau cheating diesel emission standard recent truck suvs fiat chrysler deny wrongdoing share fall thursday hit record high earlier day earlier week volkswagen vlkay plead guilty relation diesel emission testing agree pay fine prosecutor charge vw official live germany tesla motor tsla hire apple exec head automaker autopilot software effort ceo elon musk once mock apple have own unconfirmed project titan electric car initiative tesla graveyard tesla also sketch charge fee used supercharger fee only driver order jan tesla share rise month high related general motor soar bullish earning forecast ford look federal trade commission be expect approve drugstore merger walgreen boot alliance wba rite aid rad obama administration end jan new york post report cite source walgreen announce share deal back october share walgreen rise rite aid climb smaller rival fred fred be buy rite aid store part effort ease antitrust concern fall related walgreen rite aid merger see trump take officefresh strong holiday season commerce giant amazon say expand full time full benefit base workforce mid last year amazon workforce be amazon be add position engineer software developer seek entry level position job training amazon gain be likely come expense traditional brick mortar retailer other rival amazon rise week close time high related amazon plant re hire sign reach new holiday be rough retailer not name amazon com amzn online shopping subdue store traffic hung heavy wasn bad morgan stanley analyst call lululemon lulu lift low end guidance holiday standout follow appearance annual icr conference francesca fran genesco gco now expect result upper end previously announce guidance ollie bargain outlet olli raise outlook well fargo analyst lululemon price retailer such tjx co tjx say say retail sector be generally almost uninvestable retail sale rise december slightly view just exclude auto nonstore sale include amazon lead way department store struggle oil price fall hard early week then bounce back somewhat trader try balance current future production gain opec output curb crude future close barrel biggest drop early november north american oil company spending exploration production rise year fall prior year higher oilfield service cost account increase accord barclay analyst hess corp hes parsley energy pe say boost spending year eia say crude stockpile increase barrel well barrel increase analyst expect production rise barrel day biggest increase month total production level hit month high russia kazakhstan be cut back output saudi arabia have reduce delivery asia part opec deal iraq be reportedly try boost export even further related oil company unleash spending cost rise toooil price floor iraqi export raise opec deal doubtsu crude stockpile production soar price rise opec cutsopec china lift oil price producer ready pouncedelta forecast flat unit revenue growth first quarter cheap fuel heighten competition sank metric year company say margin pressure higher fuel labor cost be likely peak margin begin expand second half year delta also say donald trump victory have already boost demand hope trump administration bring opportunity tax regulatory reform infrastructure improvement greater consideration case middle east rival big airline say carrier have expand government dime accusation carrier have deny meanwhile american airline aal unite airline ual southwest luv also lift unit revenue forecast related delta air line see market share pressure atlanticshare apply optoelectronic aaoi soar thursday record high maker optical communication device preannounce result revenue ep exceed expectation internet firm be upgrading datum center gigabit second technology analyst say apply optoelectronic have be boost demand amazon microsoft msft facebook fb demand china have also be drive revenue growth fiber optic component maker be speculation demand have softened oclaro stock rise say business china have be strong normal needham co conference share acacia communication acia fall more cautious comment related apply optoelectronic boom facebook amazon datum center buildsat annual jpmorgan healthcare conference merck mrk immunotherapy drug keytruda be accept priority review combination chemotherapy treat lung cancer celgene raise earning guidance ariad pharmaceutical aria takeout japanese takeda pharmaceutical share medicine co mdco announce strong interim datum ldl buster different enough avoid patent battle biotech amgen amgn trump harsh rhetoric vs drug industry price chill optimism chipotle grill cmg forecast fourth quarter ep revenue wall street expectation however improvement same store sale trend help lift share week jack box jack say icr conference late night delivery customer san francisco have burger chain food deliver partnership doordash be more forgive food quality burger fry tend not hold well takeout container taco jack best selling item pizza other restaurant be assess takeout service grubhub grub doordash uber eat other fit business gaming sport bar chain dave buster play say provide experience be duplicate home domino pizza dpz tout digital order platform international growth potential related chipotle warn stock jump same store sale trendjack box find forgive late night delivery customerchip foundry taiwan semiconductor manufacturing co tsm earn cent american depositary receipt year year sale nearly analyst expect cent tsmc current tsmc see revenue midpoint guidance do not give earning target wall street have be modele tsmc earn cent adr year year sale march quarter cfo lora see weaker demand part due seasonal supply chain inventory end related taiwan semiconductor dip cautious guidance
1577,MRK,key market index hit new time high friday stock hold moderate gain head last hour trading dow jone industrial average rise nasdaq add volume be lower board vs same time thursday oil drugstore food related issue lead upside stock market today west texas intermediate crude price rise barrel gold future fall nearly ounce gold miner steel department store retailer underperform pfizer pfe coca cola ko merck mrk be biggest dow winner gain more also blue chip apple aapl advanced retook day move average first time month share iphone maker be work flat base buy point microsoft msft climb new time high be now slightly extend flat base entry clear oct fast turnover software consumer product giant be expect benefit information technology spending increase accord recent pacific crest security report most ibd stock be lower only dozen advance afternoon chipmaker macom technology solution mtsi slump average trade remain extend cup handle buy point other ibd chip stock take hit include advanced energy industry aeis apply material amat none decline be alarm stock backed high light volume economic news university michigan preliminary consumer confidence index rise december well expectation read related fang apple alphabet regain key support facebook be lag boost technology budget benefit amazon microsoft salesforce
1578,MRK,eli lilly lly say wednesday alzheimer treatment solanezumab fail deliver statistically meaningful result stage clinical trial send drugmaker share sharply lower lilly say alzheimer patient mild dementia do not experience statistically significant slow cognitive decline compare patient treat placebo lilly say solanezumab result be directionally favorable be not enough justify seek regulatory approval result solanezumab expedition trial be not have hope be disappoint million person wait potential disease modify treatment alzheimer disease say eli lilly chairman ceo john lechleiter statement evaluate impact result development plan solanezumab other alzheimer pipeline asset investor hope eli lilly alzheimer drug have be high lilly share dive early afternoon trade stock market today trading earlier year low alzheimer be potentially enormous profitable field drugmaker have struggle achieve notable success treat underlie progression disease ibd take donald trump election suggest fewer regulatory hurdle takeover amgen biogen celgene gilead look replenish drug pipeline biogen biib have show promise early stage trial treatment aducanumab fda grant fast track status biogen treatment stock fall trading low merck mrk be move stage trial verubecestat safely lower amyloid beta protein link alzheimer patient unclear reduce cognitive decline merck share slide intraday lilly say provide more datum trial dec clinical trial alzheimer disease lilly take charge related trial update financial result offer guidance dec related health care etfs fall eli lilly juno add trouble sector woesjuno stock plummet patient die rival kite recover
1579,MRK,blue chip lead major index friday oil driller take hardest hit day nasdaq grip gain dow jone industrial average rise also volume stock market today be run sharply lower be likely end way market be schedule close et small cap russell have be lead market edge price west texas intermediate crude oil drop loss be blame uncertainty saudi arabia say not be attend monday talk opec producer discuss supply cut ibd list comprise stock top fundamental technical loser lead winner ratio computer networking company gigamon gimo hold biggest gain score new high china base gaming internet company netease nte suffer biggest dent crumple brisk volume blue chip dow medical related stock notch good gain johnson johnson jnj pop higher merck mrk echo gain johnson johnson confirm friday have hold talk actelion pharmaceutical potential transaction actelion be switzerland base biotech company nasdaq beaten stock peg better gain first solar fslr rise stock remain high solar stock be expect rise hillary clinton win presidential election clinton have pledge spend billion help solar industry economic news purchasing manager index service flash november come october read be second strongest past month related black friday score so far target wal mart macy apple mobile
1580,MRK,market wrapped week positive note ahead week likely be dominate federal open market committee day policy meeting meeting end policy announcement wednesday afternoon expect include increase interest rate nasdaq push rally day end session gain week also add sixth day rise friday weekly gain dow tick notch weekly gain index end week fresh high volume be lower accord preliminary figure small cap have rally past week smallcap rise stock market today bolt higher week russell inched friday climb week index roll easily new high dow pfizer pfe coca cola ko merck mrk lead session gain better apiece caterpillar cat lag index decline drill contractor diamond offshore do ensco esv lead respectively broadcom avgo be close end session ahead more ride chorus bullish analyst comment follow chipmaker strong fiscal fourth quarter result report late thursday stock end session buy range buy point emergent biosolution ebs lead gain company report late thursday have sign follow agreement supply center disease control prevention worth biothrax anthrax vaccine positive november consumer sentiment news university michigan be early session investor appear somewhat optimistic discussion schedule weekend organization petroleum export country official opec member regard production limit optimism offset sixth straight increase number rig drill still oil price end more friday leave west texas intermediate fraction lower week first slip week rally gold dip week dollar strengthen week bond slip putt year yield basis point week odd collection industry rise more week steel alloy consumer electronic retailer solar energy consumer lender friday fastest rise industry be canadian oil gas producer meat producer drug wholesaler nonalcoholic drink maker related show opec meeting add doubt output deal broadcom spike record high beat
1581,MRK,stock open lower wednesday surprise jump october durable good order dow industrial be fraction be nasdaq deere reap premarket gain fiscal fourth quarter earning revenue fall much less expect management say company performance have improve global farm construction market downturn project annual saving efficiency initiative deere share top previous high set june eli lilly lly unraveled announce stage trial result alzheimer treatment solanezumab fail show meaningful result investor apply selling pressure other drugmaker closely watch trial send biogen biib merck mrk hewlett packard company divide year slip report result late tuesday hewlett packard enterprise hpe be cloud service corporate networking business hp inc hpq be focuse pc printing product hp drop open report line fiscal earning better forecast revenue guide earning estimate hewlett packard enterprise slip less report mixed result also offer weak guidance ibd stock veeva system veev surge provider cloud base sale marketing software report earning jump fiscal fourth quarter far analyst target company biggest jump last year june quarter revenue jump also easily clear estimate management raise fiscal first quarter guidance consensus view veeva end tuesday session less buy point week cup base stock market today receive heavy dose datum open commerce department report durable good order surge october sharply reversed september decline clobber economist expectation increase transportation order rise vs prior month increase consensus view gain initial jobless claim jump nearly week end nov accord labor department wasn far consensus estimate increase week average ease second straight decline federal housing finance agency housing price index rise show home price gain steady september increase be just shade august rise well consensus view gain next london base researcher markit preliminary november manufacturing purchasing manager index arrive et october new home sale datum commerce department be due et final estimate november consumer sentiment university michigan be expect et weekly oil inventory report energy information administration roll et last far least minute federal open market committee nov meeting be schedule release et crude future dip west texas intermediate barrel trading higher week gold price be more ounce even week dollar gain ground bond drop lift year yield basis point international front china market post very narrow loss japan tokyo stock exchange be close day holiday trade europe remain turn lower afternoon action ftse london fall dax frankfurt be cac paris show loss major global market remain open week aside tokyo closure today market be close thursday re open short session friday stock market close et bond market shut shop related eli lilly alzheimer drug fail key trial
1582,MRK,stock be mildly lower late afternoon trading friday ahead shorten week trading next week due thanksgiving holiday dow jone industrial average nasdaq composite show loss new york small cap buck trend russell add soar last week popular small cap index be week volume nasdaq be tracking lower thursday level nyse volume be pace be slightly higher stock market today chevron cvx outperformed dow rise merck mrk procter gamble pg lag loss respectively addition chevron other oil gas producer outperformed devon energy dvn jump current consolidation show buy point ross store rost lead nasdaq rise nearly late thursday company report second straight quarter accelerate earning sale growth still buy range buy point nasdaq component western digital wdc wasn far rise be show support action week move average recent buy point soft start apply material amat be late trading strong earning chip equipment maker be poise sixth straight gain be still buy range buy point chip designer cirrus logic crus gain top second stage flat base buy point prior base form spring june year be long enough reset base count however stock have also gain lot ground rise past initial past january sucampo pharmaceutical scmp outperformed ibd rise stock be extend gapping day move average nov sucampo briefly spend time past week ibd sector leader screen potential big winner december wti crude oil future gain barrel year treasury yield add basis point dollar index be straight session related salesforce ross apply material guide gap guide lowoil rig see biggest jump july permian case trump era secular bull market
1583,MRK,eli lilly lly have giant albatross hang neck rbc analyst michael yee call clinical trial alzheimer disease conference next month san diego most important event biotech eli lilly deliver strong result phase trial alzheimer drug solanezumab stoke industry say biotechs spiked higher donald trump election trump be see less likely tackle mount drug price have propose incentive company bring more cash stateside spark more small cap biotechs intraday stock market today ibd company medical biom biotech industry group be fraction still day move average key level support group close higher past straight trading day rank ibd industry group ibd take alzheimer isn only area opportunity biotech biogen ionis be partner spinal muscular atrophy drug have interesting result delve ibd industry theme idea success do stock outside trump effect analyst have seize eli lilly solanezumab key driver industry include rival biogen biib have similar alzheimer drug line solanezumab be antibody act neuroprotector patient alzheimer disease believe event ctad be important term driver potentially rally biotech higher really take leg bring more generalist space yee say research note tuesday eli lilly presentation be still just tentative be slate present dec lilly have also say instead present datum expedition phase solanezumab trial medical meeting positive datum give strong credence lilly theory alzheimer be result plaque buildup brain yee write see chance positive statistically significant datum expedition trial result investor get more bullish alzheimer innovation biotech biogen be slate dec report phase result month titration study attempt reduce aria amyloid related imaging abnormality patient specific type allele alternative form gene also present month extension examine safety efficacy biogen stock be consolidate have possible buy point tick close tuesday lilly stock inched just day support line novartis nvs be partner amgen amgn discuss effort pairing alzheimer patient trial base part genetic amgen bace inhibitor act block buildup beta amyloid have be propose drug study lilly merck mrk biogen also have bace inhibitor roche rhhby partner genentech be expect have poster phase trial crenezumab look higher dose response prodromal mild patient axovant also offer analysis phase study intepirdine related biotech lilly upgrade alzheimer drug potentialcan small cap biotech take gilead celgene biogen alzheimer biogen top alzheimer datum vs eli lilly positive
1584,MRK,stock trade mixed monday bond take steep drop merger news give premarket action stir dow industrial climb hit fresh time high rise nasdaq fall fraction last week rally shift market more bullish foot leave nasdaq less so far fourth quarter initiate healthier buy environment investor earning report continue roll transdigm tdg india tata motor ttm china athm motion early report news several merger continue adjustment change political environment drive heaviest portion trade harman international har crank gain monday south korean smart phone maker samsung confirm monday have agree pay cash stamford conn base company harman be lead audio component automotive infotainment system maker harman end friday session buy point flat base digi international dgii spiked early action cable maker belden bdc announce saturday bid acquire maker electronic connectivity component digi confirm monday reject offer say undervalue company digi surge last week takeover speculation stock have be corral range more decade belden share be nearly mentor graphic ment vault design automation software developer confirm be acquire germany siemens siegy cash deal siemens expect earning interest taxe year project close second quarter next year siemens share be flat pfizer pfe fall less drugmaker soar broadly last week rebound investor recalculate positive donald trump presidency vs hillary clinton be expect target drugmaker tighter regulatory control ibd list gigamon gimo add premarket trade network performance gear maker be eyee new high be extend second rebound support level june other lead stock akamai technology akam edge fraction stock be extend cup handle buy point week busy economic calendar get slow start monday significant datum set release tuesday dalla federal reserve bank president robert kaplan speak et follow jeffrey lacker richmond federal reserve bank san francisco fed bank john william close week be jam packed federal reserve commentary include chairwoman janet yellen testimony congress thursday oil future lose ground west texas intermediate trading more barrel oil price be now trading day move average threaten undercut low gold dip fraction ounce copper jump more continue rally begin late october dollar climb bond drop hard market reopen friday break veteran day send year yield basis point
1585,MRK,stock market appear embrace donald trump improbable presidential victory send main index broadly higher stock have be act prefer hillary clinton victory monday tuesday future do plummet overnight result come index shake loss marched higher trading session high late afternoon index come session high remain higher dow jone industrial average lead gain pharmaceutical component pfizer pfe merck mrk be election remove fear crackdown drug price climb nasdaq small cap russell vault indication investor be willing take greater risk volume be tracking sharply higher winner lead loser board banking be sector lead market superregional bank industry group nearly today trading few regional bank break basis northern trust ntrs clear lopsided pattern rise buy point ease unite community bank ucbi top buy point undefined pattern thinly trade beneficial bancorp bncl top buy point flat base breakout sprout other sector market give day gain add fuel wagework wage employee benefit management firm break past buy point cup handle heavy duty truck manufacturer oshkosh osk rise past buy point flat base time more volume usual hospital solar energy stock loser trump administration sell solar energy industry group plunge nearly sank deeper ibd industry ranking hospital founder tenet healthcare thc slide lowest level year defensive group such utility food alcoholic beverage real estate investment trust be day worst perform too related solar stock plunge coal champion trump surprise wingold stock rise trump stunning raytheon launch buy range trump defense stock rally
1586,MRK,stock continue advance record high territory shopper kick shopping season even black friday fade somewhat importance oil future rise opec optimism output cut talk ahead nov deadline joined other major average record territory dow nasdaq rise more week apple aapl retook buy point fang stock gain ground laggard facebook fb move back day move average retail restaurant earning be generally positive urban outfitter urbn be big exception bad clinical trial news hit drug stock shopper once again rushed store deal day thanksgiving unofficial kickoff holiday shopping season black friday store importance have fade more sale be make online deal be spread november december still online black friday sale be expect top adobe predict wal mart wmt kick cyber monday sale friday amazon amzn predict record black friday not surprise target tgt hailed strong sale discount apple aapl product star war toy hasbro have other well smart speaker alphabet googl unit google amazon amzn likely be popular gift black friday score so far target wal mart macy apple mobileurban outfitter urbn miss earning sale send share tumble wednesday back buy point dollar tree dltr top earning forecast revenue fall short same store sale narrowly top forecast specialty discounter see solid holiday sale price retailer burlington store more double earning crush view sale just edge view signet jeweler sig parent jared zale kay jeweler luxury watchmaker movado mov report lower earning sale top view share company rally related burlington store stock near buy zone earning crush viewsdollar tree see strong holiday quarter sale mixed signet movado share shine earning holidayseli lilly lly say wednesday alzheimer treatment solanezumab fail deliver statistically significant slow cognitive decline stage clinical trial lilly not seek regulatory approval share tumble year low other drugmaker work alzheimer treatment also be hurt include biogen biib merck mrk meanwhile juno therapeutic juno halter trial new patient death latest setback immunotherapy treatment juno share fall sharply immunotherapy peer kite pharma kite initially tumble bounce back related eli lilly alzheimer drug fail key trial lilly biogen divejuno stock plummet patient dieu crude price initially rise oil cartel sound optimistic reach deal curb production nov deadline oil price tumble friday erase nearly week gain plan monday meeting opec member participation be scrap russia have say willing freeze not cut output opec still detailed agreement member tend quota libya nigeria reportedly be exempt iraq say join cut have give mixed signal iran also be question mark meanwhile crude supply fall modestly latest week domestic production rise related oil extend loss doubt grow opec output cut dealjack box jack earning shot cracker barrel cbrl ep rise easily top view restaurant report sale growth be slightly view jack box run jack box burger location qdoba eat also guide low jack share break base new high cracker barrel continue rapid postelection run analyst argue consumer confidence rally area countryside theme chain operate related cracker barrel beat profit raise guidance see trump effect china internet leader see stock jump report better expect earning show trend more chinese consumer go online remain strong weibo wb call twitter twtr china web portal company sina sina own weibo wb beat top bottom line so do social networking firm yy yy palo alto network panw stock tumble cybersecurity firm report fiscal revenue billing miss lower expectation forecast current quarter sale view palo alto network blame miss partly large deal do not close quarter palo alto have forecast pickup security spending latter half ibd company computer software security industry group take hit fall day support line proofpoint other stock fall pc printer firm hp inc hpq earn cent share exclude item year year match view sale rise top analyst estimate current hp see adjust ep cent vs view cent hp share tumble enterprise information technology firm hewlett packard enterprise hpe other half former hewlett packard earn cent share ex item sale analyst project cent current quarter hpe forecast profit cent midpoint vs consensus cent hpe share near buy point related cisco hpe view overseas cash trump cautious outlooksstrong notebook pc sale give hp lift ep guide missesdurable good order jump october best gain year core capital good order business investment proxy rise modestly meanwhile october exist home sale reflect actual closing picked fastest pace february new home sale reflect more recent contract signing fall last month downwardly revise september mortgage rate rise october spiking election borrow cost housing cloud base life science software maker ep rise revenue climb beating view veeva system veev also give bullish guidance veeva share break new high clear buy point meanwhile medtronic mdt fall month low sale guidance lag estimate latest medical device product maker give weak result outlook recent week related veeva system hit buy point outlook beat expand dife month low sluggish diabetes valve farm equipment giant report decline earning sale be better expect ep slide cent analyst have expect just cent deere say equipment sale fall see only drop fiscal share leap record high package food giant hormel hrl be upbeat full year forecast campbell soup cpb beat bottom line tyson food tsn hurt part lower beef price investment business jump feed cost deliver weak result company have face more competition fresher fare have become more popular related hormel upbeat fiscal profit campbell soup beatstyson weak profit outlook sink share other meat producer
1587,MRK,pfizer pfe stock pop thursday report drugmaker be consider selling consumer care business less month firm opted long rumore corporate breakup evercore analyst john scottus expect potential transaction garner cent earning share midpoint forecast assume tax proceed sale be used share buyback potential sale make sense scottus write research report thursday pfizer reassess future pfizer walk away merger ireland base allergan agn april lawmaker look crack tax inversion deal company be set headquarters lower tax region such ireland pfizer also have long mulled corporate breakup splitting innovative essential health division scrap idea september johnson johnson jnj buy pfizer then consumer care business pfizer build unit back acquisition wyeth later pfizer sell nutrition business nestle spun animal health business zoetis zts thus sale current portfolio consumer product appear be logical next step allow pfizer focus core competency develop selling innovative drug scottus write ibd take trump presidency affect drug biotech stock get full skinny ibd industry theme reuter first report potential customer care sale late wednesday cite anonymous source unit pull sale annually scottus liken bayer acquisition merck mrk consumer care business annual unit stock market today pfizer stock climb day line ramp second consecutive day follow election president elect donald trump share rise wednesday drug biotech stock have rebound trump election trump be see less likely challenge drug price vs democrat hillary clinton unveil plan last year cut spiraling price tag drug trump have promise tackle affordable care act obamacare investment bank rbc say tuesday cause dip biotech stock uncertainty new not yet outlined national health care editor note correct fourth graph show zoetis be spinoff related pfizer likely overpay post allergan breakup flop twist pfizer scraps breakup follow dead allergan merger
1588,MRK,donald trump stunning drug biotech stock rally wednesday investor sector cheer hillary clinton have be see far more likely crack drug price takeover activity gilead science gild rise stock market today pfizer pfe shot amgen amgn merck mrk mylan lab myl fire epipen price hike leap mylan late wednesday posted earning fall short top bottom line share be fraction clinton have say go excessive drug price hike also likely have favore change government negotiate lower price drugmaker meanwhile republican retain control house congress also ease regular concern drugmaker aren clear be still populist anger price new old treatment trump time signale also go drug price meanwhile justice department reportedly be close filing charge vs mylan other generic drug maker price collusion related stock future well lows trump win white house
1589,MRK,stock moved worst level morning dow jone industrial average rise stock market today fresh time high nasdaq fall decline eli lilly lly experimental late stage drug fail slow memory loss patient alzheimer disease company longer seek regulatory approval drug solanezumab share tank biogen biib merck mrk share be also impact lilly trial result fall respectively deere gain indicate better performance lie ahead earning sale still decline vs last year figure company say revenue continue fall less wall street expect share be trading time high ibd stock veeva system veev race past earning sale estimate tuesday bell life science software company report adjust ep cent vs forecast cent revenue increase top consensus additionally veeva operate margin increase significantly consensus veeva vault platform have become main driver total booking first time represent subscription revenue vault be cloud base system streamline pharmaceutical regulatory compliance stock be be breaking cup base entry point relative strength line hit new high today gap be particularly bullish indicator oil price drop dollar index soar new year high better expect durable good order october durable good order increase beating estimate september figure be also revise upwards gold price also fall conjunction rise dollar be weekly initial jobless claim come vs expect new home sale fall october downwardly revise september september housing price index rise vs markit preliminary november manufacturing purchasing manager index be vs expect still come weekly oil inventory report eia et minute federal reserve november meeting et eli lilly alzheimer drug fail key trial lilly biogen diveveeva beat guide high urban outfitter miss hpe hp inc mixeddeere stock soar earning crush estimate
1590,MRK,stock turn mixed soft start wednesday wall street digest news trump plunge more point overnight dow jone industrial average be mostly unchanged nasdaq lose ease early leader dow include pfizer pfe caterpillar cat merck mrk jpmorgan jpm goldman sachs gs also outperformed ibd take election result be describe shocking upset ibd tipp presidential tracking poll ultimately have right year treasury yield soar basis point december gold rally ounce drugmaker campaign target democrat hillary clinton due pricing trade generally higher pfizer industry group mallinckrodt mnk shire shpg allergan agn lead gain more hospital operator stand lose president elect trump act promise repeal affordable care act dove deeper early loss tenet healthcare thc topple hca holding hca skid universal health service uhs drop coal mining stock soar consol energy csx arch coal arch add cement construction aggregate supplier surge possibly early commitment infrastructure other large scale project trump vulcan material vmc martin marietta mlm higher martin marietta gap cup shape base buy point vulcan gap cup shape base buy point stock be still buy range early trading early gainer ibd include healthequity hqy eagle material exp gain pra health science prah morgan stanley ms add related clinton vs trump ibd tipp presidential election tracking pollafter initial fall stock rally trump victory agenda
1591,MRK,bristol myer squibb bmy celgene celg stock rocket thursday biotechs report metric wall street expectation up earning guidance bristol myer stock rise close stock market today celgene stock jump follow announcement fellow biotech alexion alxn also report thursday surge almost bristol myer report sale cent earning share ex item respective vs year earlier period consensus analyst poll factset have expect cent sale drive bristol myer quarter grow year year vs growth worldwide revenue drug cancer med opdivo lead bristol myer pipeline sale more triple year figure opdivo treat nonsmall cell lung cancer nsclc compete merck mrk keytruda european regulator recently approve opdivo treat adult relapse refractory hodgkin lymphoma bristol myer be look use opdivo treat unresectable metastatic urothelial carcinoma bristol myer also boost guidance ep ex item expect worldwide revenue grow high teen percentage introduce guidance ep ex item help alleviate nervousness go evercore analyst john scottus write research note ibd take political angst have draw biotechs ibd company medical biom biotech industry group fall group track just week keep eye ibd etfs fund section potentially hot sector celgene report ep ex item sale top consensus analyst poll thomson reuter year year basis metric grow chemotherapy drug revlimid drive lion share celgene sale bring revenue vs year earlier quarter revlimid sale top consensus expectation be drive new patient gain scottus write separate report revlimid be be examine maintenance treatment newly diagnosed multiple myeloma patient ve already receive autologous stem cell transplant european regulator be due make decision review revlimid ndmm first half growth be stoutest otezla celgene drug treat psoriasis other inflammatory disease otezla bring grow year year otezla growth be drive market share gain increase prescriber adoption company say otezla beat sale expectation be almost completely offset internationally sale miss broad analyst view scottus write celgene also update guidance sale include contribution revlimid ep item celgene see sale revlimid top ep item related alexion crush expectation stock bound drug trial planscelgene pit gilead biogen crohn drug battlecan top biotechs climb wall worry rbc call rallymerck crush expectation follow lung cancer drug winmerck topple bristol myer lung cancer drug
1592,MRK,stock market remain lower thursday jump interest rate cause real estate sector tumble nasdaq reversed lower loss be fraction dow jone industrial average be fraction dupont dd climb medical firm johnson johnson jnj merck mrk add volume be tracking higher board retail fiber optic stock be weakest day trading acacia communication acia plunge nearly big volume biggest customer chinese telecom equipment maker zte report revenue estimate acacia be hottest stock hot fiber optic industry august break day move average oct stock have be sink group remain real estate development mortgage provider real estate investment trust be broadly lower ibd mortgage industry group skid real estate development operation be yield benchmark year treasury note jump basis point month high yield other major global market also rise trader appear be embrace grow chance interest rate hike federal reserve december real estate select sector spdr fund xlre track new real estate sector slide lowest level march sell real estate stock follow weakness home improvement stock week weak outlook quarterly result whirlpool whr be just series gloomy report industry wednesday jpmorgan wedbush downgrade lowe low energy stock be mainly higher crude price rise cent barrel exploration production integrate oil gas industry group be few breakout be worth note vmware vmw break past buy point flat base heavy trading share soon dip back entry cloud compute company beat profit sale expectation bluecora bcor climb past buy point cup type base high volume also fade back pattern clear entry internet content company business include taxact tax preparation software post loss cent share still beat expectation network ffiv soar breaking past double bottom buy point datum center equipment company late wednesday beat quarterly expectation wall street firm hike price target upgrade stock response related acacia communication hammer customer zte sale missf network upgrade price target hike fiscal beat amazon alphabet lumentum gigamon earning expect hour
1593,MRK,major stock index capped week solid gain friday help news robust job growth july merck mrk be best percentage gainer dow jone industrial average rise follow financial jpmorgan jpm american express axp goldman sachs gs show gain better nasdaq composite rise record close also marked time close high dow picked preliminary datum show volume nasdaq come slightly higher thursday level volume nyse be slightly lower merck be beneficiary bad news bristol myer squibb bmy latter crash blockbuster drug opdivo already approve treat form cancer do not meet primary endpoint merck compete drug keytruda succeed similar trial recently ibd super regional bank group be day top performer rise more big gainer include svb financial sivb keycorp key region financial rf utility lag board meanwhile economy add job july second straight month robust job growth strong datum fed fund future trader still aren optimistic rate hike september accord cme group fedwatch tool odd september hike be currently rise december meeting gold slump treasury yield jump job datum gold december delivery settle ounce year treasury yield rise basis point earning news priceline pcln have make several attempt recent month avail come fruition friday heel strong earning report gap buy point rise leaderboard member monster beverage mnst add earning share report late thursday miss expectation sale growth accelerate nicely prior quarter rise monster be buy range buy point ahead result stock be slightly extend now ibd take stock monster industry group beverage alcoholic have higher composite rating monster see be ibd stock checkup
1594,MRK,major equity average edge higher early wednesday busy day headline flow goldman sachs gs walt disney apple aapl outperformed dow gain more nasdaq barely rise dow jone industrial average climb suffer third distribution day trading session tuesday raise count nasdaq composite currently show ibd take increase sign distribution higher volume decline index cause cause problem market uptrend learn more institutional selling impact market check lesson ibd university economic news private sector job be add july accord adp national employment report datum come ahead friday official job report economist expect july nonfarm payroll rise unemployment tick lower stock market today time warner twx buck trend rise nearly company report earning announce be take stake stream service hulu electronic art ea have be show support action week move average ahead earning rise adjust earning cent share fall year earlier handily top consensus estimate loss cent sale rise result be help strength digital download elsewhere biogen biib fall surge tuesday report merck mrk allergan agn be potential suitor ibd strong earning raise sale guidance late tuesday help cause paycom payc share rise almost provider workforce management software also get upgrade buy price target hike west texas intermediate crude oil september delivery rise barrel briefly top energy information administration say crude supply rise barrel last week gasoline inventory fall barrel crude production also fall close tesla motor tsla herbalife hlf be quarterly result tesla be flat fall prior day wake deal buy solarcity scty herbalife stock lose ahead earning stock have be volatile surge nearly week end july still hold buy point
1595,MRK,stock claw back morning loss trade higher go close fuel rebound bank stock such jpmorgan chase jpm deutsche bank db citgroup ease brexit fear nasdaq rise fall morning dow jone industrial average gain be stock market today small cap russell remain lower volume be tracking higher same time wednesday nyse nasdaq exchange brexit campaigning halter thursday shocking murder lawmaker jo cox thursday pro eu labour member jpmorgan deutsche bank citigroup turn fractionally higher fall significantly earlier session only notable be acacia communication acia emerge ipo base buy point soar company make high speed interconnect module cloud compute operator ep be forecast grow year next year do acacia communication stack other lead stock merck mrk rally nearly company announce successful phase trial cancer drug keytruda compare survival rate chemotherapy best perform industry group day be defensive food beverage utility worst performer be oil chipmaker west texas intermediate future july delivery fall drop barrel benchmark future market have fall straight day june intraday high year treasury yield fall well morning lows still trading not far bottom
1596,MRK,big biotech gilead science gild get downgrade several price target cut friday report miss expectation send stock tumble maxim group analyst jason kolbert downgrade gilead hold buy note record breaking launch hepatitis drug sovaldi harvoni be come competition tough year year comparison new patient number increase product margin patient be lower result increase hcv price competition merck mrk zepatier increase discount rate higher expect rebate claim kolbert write research note management believe hcv product have stabilize market share be be not so sure leerink analyst geoffrey porge lower price target gilead maintain outperform rating note company still have huge reserve cash write hcv franchise be erode earlier then expect be presume decline few year anyway result ep estimate fall only write research note ub analyst marc goodman also keep buy rating lower price target writing willing have little patience hcv category still have year ahead stable patient goodman write issue remain next valuation try remain patient gilead stock be afternoon trading stock market today positive side gilead company say friday eu committee medicinal product human use advise europe equivalent fda have endorse approve odefsey company newest drug combo pill hiv combo include taf know wall street son viread represent upgrade version gilead legacy blockbuster viread be due go patent future
1597,MRK,abbvie abbv say year pass begin accrete earning purchase stemcentrx abbvie stock reversed early loss be early thursday afternoon company announce acquisition abbvie stock fall much early stock market today be fraction afternoon trading record high set july south san francisco calif base stemcentrx lead late stage asset be call rovalpituzumab tesirine rova already registrational trial small cell lung cancer sclc abbvie say pay purchase price cash rest stock stemcentrx also receive cash milestone payment abbvie expect transaction be approximately cent dilutive ongoing earning share accretion begin company say announcement lower ep guidance abbvie say execute accelerate share repurchase program soon completion purchase be expect quarter meanwhile abbvie early thursday report earning beat wall street estimate fall tad short revenue abbvie say earn share item cent better analyst expect sale analyst poll thomson reuter have expect global humira sale rise exclude foreign exchange impact abbvie say humira be abbvie best seller generate total revenue treat immunological disorder primarily rheumatoid arthritis psoriasis thursday research note investor evercore isi analyst mark schoenebaum cite approximately beat humira sale largely offset miss global viekira revenue primarily drive miss possibly due competition merck mrk well abbvie put total humira sale sale viekira treat hepatitis be abbvie drug generate globally total sale abbvie say abbvie ceo richard gonzalez say purchase stemcentrx be mark abbvie innovation oncology critical component long term growth area significant need million patient worldwide stemcentrx trial drug rova have be submit fda breakthrough therapy designation too be investigation third line treatment sclc have approve therapy abbvie say rova be first predictive biomarker base therapy associate drug efficacy small cell lung cancer be big deal difficult disease charle rudin chief thoracic oncology memorial sloan ketter cancer center say abbvie announcement stemcentrx also have novel compound clinical trial triple negative breast cancer ovarian cancer small cell lung cancer other compound advance clinical trial proprietary technology platform leverage stem cell biology identify screen potential target live tumor tissue more predictably advance discovery development new asset abbvie say brian slingerland be privately hold stemcentrx co founder ceo scott dylla be co founder chief scientific officer
1598,MRK,ligand pharmaceutical lgnd be already diversify biotech year now make new claim technology base alter genetic ratsit seem distasteful not very profitable prove be turn point january early stage biotech company acquire omt firm develop technology omt stand open monoclonal technology be used rodent dna human antibody therapeutic use move give ligand avenue growth venture forth hottest area medicine say larry solow analyst cjs security also use animal antibody develop drug human used model solow tell investor business daily rat model lead human drug top selling drug humira remicade mabthera rituxan avastin herceptin used human antibody development omt be believe be only company world offer transgenic animal platform know name omnirat omnimouse omniflic ligand acquire omt drug company have license technology emergent biosolution ebs tizona therapeutic abba therapeutic swiss biotech come top licensee omt have previously line include biopharma giant merck mrk pfizer pfe celgene celg name few typical licensing partnership provide royalty milestone payment omt partner have be pay access technology eventually pay milestone payment royalty too ligand have expect omt add revenue year next year total more be addition emergent tizona abba client list deal ligand likely update guidance next earning report set omt deal positive news other ligand license drug haven diminish investor sentiment share have rise roughly year early april european commission approve expand use european version ligand top license drug promacta use pediatric patient rare blood disorder drug be sell partner novartis nvs mid march licensee spectrum pharmaceutical sppi win food drug administration approval evomela use treat certain case multiple myeloma form blood cancer drug earn ligand higher normal royalty positive clinical datum year other ligand license drug also bode well future revenue growth analyst say anticipate current revenue stream partner product broad development portfolio be poise drive significant growth longer term write analyst joseph pantginis recent research note roth capital partner addition royalty ligand already generate significant revenue proprietary formulation technology call captisol sugar molecule help absorb drug body especially helpful harmful side effect captisol other material sale vary quarter quarter depend be need clinical trial commercial use fourth quarter lower material sale vs year earlier cause overall revenue decline last year still revenue full year rise top growth royalty revenue rise more lumpy material sale related quarterly decline do not concern solow say expect royalty revenue grow year analyst poll thomson reuter see total revenue rise year go next year earning rise prior year cent share analyst expect flat ep growth year then increase next year share nearly half ligand drug partnership be base captisol technology solow say include top seller kyproli used treat multiple myeloma kyproli promacta oral drug boost platelet blood generate sale more last year solow say figure ligand last year receive royalty promacta sale vs kyproli roughly promacta be sell novartis krypoli amgen amgn kyproli ultimately have bigger commercial potential royalty be higher promacta so more important drug solow say ligand have dozen other early stage drug have find partner take next stage target multitude disease such hepatitis diabetes cancer anemia alzheimer kidney disease other ligand have more partner program different company ligand essentially pass heavy lift need bring drug market enjoy royalty milestone relatively little investment cost ligand cash operate expense last year totale partner spend research development say solow show power business model say note company overhead be relatively low yield commercial drug get royalty ligand partner be expect spend close add half growth come omt more shot goal partner program ligand have numerous avenue growth write analyst draw jone stephen initiation report mid april rate stock overweight jone expect promacta kyproli generate more royalty ligand next few year compare addition estimate several company next biggest program provide potential royalty move expect ligand management team continue shrewd capital deployment strategy technology focuse acquisition note
1599,MRK,biotech stock fall deepest crater history start last summer rumbling recovery be sound year bull run more quadruple value peak last july ibd medical biom biotech industry group plunge early february hurt backlash high drug price merger seek lower corporate taxe group have gain feb low lead stock have do better biotech stock buoy potential blockbuster drugsbiomarin pharmaceutical bmrn be feb low incyte incy have gain low point same week ligand pharmaceutical lgnd have climb medivation mdvn boost buyout talk be group be even more take hit past week negative earning news several industry player fund manager tell ibd rebound be here say spate bad news have already be factor stock price more see climate favore rejuvenate hot drug new product pipeline pricing power innovate product bottom line positive factor drive runup never go away say just get drown noise very key point be group be very high beta group particularly small midcap stock don have sale don have earning say tom vandeventer portfolio manager tocqueville asset management history group be elevated macro uncertainty definitely hit vandeventer say own opinion be group trade more sentiment fundamental time period vandeventer point trouble china emblematic macroeconomic concern hit biotech stock sentiment drive factor be politic many candidate presidential race have bash drugmaker high price have propose way clamp wall street have dismiss idea impossible ineffective seem be generate most concern be democrat proposal let medicare medicaid negotiate drug price be not allow do now already center medicare medicaid service have show tooth announce pilot program change reimbursement medicare part cover drug administer hospital clinic part reimbursement scheme be long criticize encourage use expensive drug reimburse health care provider entire cost drug top propose scheme reduce premium add flat fee unrelated price drug theory encourage doctor choose cheaper option front treasury department last month issue new guideline tax inversion deal derail have be drug industry biggest ever merger pfizer pfe allergan agn tax inversion have become popular way drugmaker boost bottom line get access cash allergan earlier merger be base ireland have low taxe think tax regulation call inversion bottom bad press associate health care industry create bottom mind say robert bombace senior portfolio manager frost investment advisor lot bad news have already be baked company fact number industry insider say breakup pfizer allergan merger turn be good biotech stock make acquisition target company allergan have long history acquisitiveness pfizer be think splitting innovative drug business other product evercore isi analyst mark schoenebaum say pfizer want bulk innovative business make valuable standalone pipeline be modest compare big pharma competitor schoenebaum have also say biotech board be balk buyout offer much valuation have drop so ve be unwilling sell market price suspect lead hostile takeover deal big player be willing do partly come fruition late april sanofi sny make unsolicited bid medivation rumor swirl astrazeneca azn pfizer be also interested medivation response reflect attitude schoenebaum speak market be underprice stock sanofi time proposal come period significant market dislocation several important term event company be design seize sanofi value rightly belong stockholder medivation founder ceo david hung say statement reject offer bombace however say biotechs reluctance be show think just bargaining chip say reality be most company have partner anyway larger pharma biotech name reach point pipeline be so dry force hand bombace see lot exciting biotechnology science go fill pipeline put re go model stage space shuttle stage decline name specific company point work biomarker include pd inhibitor such bristol myer squibb bmy opdivo merck mrk keytruda also cite work genetic mutation focus many rare disease firm such biomarin bluebird bio blue discovery be keep money flow biotechnology say leonard yaffe manage health care hedge fund kessef capital management tell ibd specialty drug largely biologic drug prescribe specialist opposed primary care doctor contribute only prescription last year dollar spend drug year earlier thing think drive biotech stock be look drug introduce last year revenue derive drug be biological yaffe say so most attractive sector pharmaceutical area also most publicly trade biotech stock don have earning have successfully launch drug remain highly profitable top biotechs market cap gilead science gild amgen amgn celgene celg biogen biib regeneron pharmaceutical regn have ibd ep rank range putt top stock ep growth regeneron have ep rank number however reflect pricing power biologic drug be precisely political attack day vandeventer say price uncertainty be biggest risk bull thesis group right now also point democratic presidential front runner hillary clinton attempt previous overhaul health care system back mid depress drug stock short term be follow late boom boom be drive first wave biotech innovation company amgen roche rhhby genentech prove biotechnology produce blockbuster vandeventer say innovation remain key maintain pricing power even political pressure point gilead portfolio hepatitis drug start late launch sovaldi much political criticism sovaldi high price stop drug be so superior anything else market company have do research ll continue get price increase say company be particularly rare disease orphan disease arena oncology space company have drug era target medicine have higher efficacy rather shotgun try hit disease be go have pricing power promise such drug still make small stock explode celator pharmaceutical cpxx have surge march favorable late stage trial result acute myeloid leukemia treatment company also see hedge fund take position stock attract favorable initial coverage analyst be sign even generalist investor think biotech stock have get cheap say yaffe first quarter common lament be biotech stock get punish bad news good news get reward biogen issue mixed earning report draw mostly negative reaction wall street april stock rise more biogen have fall even harder other big cap biotechs drop march high feb low so be ready bounce say yaffe overview comment be sector have correct point get level stock be very attractive say
1600,MRK,medical stock have be increase presence ibd majority aren company make drug rather most be more scene player provide drug development service make medical equipment pra health science prah provide outsourced clinical development service biotech pharmaceutical industry raleigh base company have work pharmaceutical company more
1601,MRK,stock market show tiny loss early afternoon trading monday major index trade tight range nasdaq dow jone industrial average fall volume nyse nasdaq be tracking slightly lower friday level stock market today generic drugmaker biotechs outperformed gold miner homebuilder lag new york mercantile exchange wte crude oil delivery fall nearly barrel apple aapl merck mrk pfizer pfe outperformed dow gain trio ibd name make nice move edward lifescience ew soar company announce positive trial sapien sapien xrt aortic valve replacement share be now extend cup base buy point mortgage lend service provider lendingtree tree climb nearly rise bring stock back buy point first stage cup handle base michael kor kor give back early gain still rise close recent high share be recently trading hit intraday high elsewhere tesla motor tsla jump ceo elon musk say pre order model electric car reach saturday night virgin america va meanwhile surge alaska air alk agree buy deal value image provide shutterstock
1602,MRK,stock open sharply lower tuesday follow lead overseas market slip nasdaq lose dow jone industrial average give stock market today appear pull premarket cue europe stock be pressure raft unexpectedly soft economic datum cac paris frankfurt dax trade more ftse london show loss afternoon trading market receive dose service sector datum later morning london base researcher markit release march service purchasing manager index et institute supply management deliver march index labor department report job opening labor turnover survey february early report show trade gap widen slightly february upwardly revise january commerce department report economist consensus have forecast milder uptick oil price dip slightly left west texas intermediate bob barrel natural gas jump more gain last week monday gold future climb more ounce dollar be mixed bond blipped higher send year yield basis point dow stock slide almost unanimously lower cisco system csco lead downside fall early outperformer include pfizer pfe procter gamble pg johnson johnson jnj pfizer report positive result psoriatic arthritis treatment phase clinical trial federal regulator announce pending rule change affect potential inversion merger rule directly affect pfizer allergan deal set close later year share ireland base allergan agn crumble tesla motor tsla lag nasdaq fall late monday company give delivery count mentioned model part shortage nearly ibd stock be flat start regular trade edward lifescience ew backed suggest well earn pause monday price spike wesson swhc show sign life sell monday japan tokyo nikkei dive week low yen continue gain strength disappointing industry forecast send iron steel issue tumble china market end mixed shanghai composite hong kong hang seng index stock india skid lower reserve bank india cut interest rate basis point line consensus expectation market have already price react cue global market bloomberg report send mumbai benchmark sensex index image provide shutterstock
1603,MRK,big pharma merck mrk report stellar result phase hepatitis hcv drug trial thursday spark debate analyst potential take market share leader gilead science
1604,MRK,international liver congress london merck report cure rate patient hepatitis genotype take combination drug candidate mk mk
1605,MRK,potentially combine pill take once day pairing rival convenience effectiveness gilead gild combo sofosbuvir ledipasvir be currently await fda approval expect october
1606,MRK,gilead launch sofosbuvir alone sovaldi december be still recommend be combine interferon genotype account hcv infection be already enjoy biggest launch drug history
1607,MRK,now however wall street attention be turn rival
1608,MRK,face competiton
1609,MRK,isi group analyst mark schoenebaum write email client consensus peak sale estimate merck regimen almost certainly go current nonetheless write rise present real danger gilead
1610,MRK,most analyst include have assume gild capture perhaps genotype share peak write open question however have be company grab other market propose perhaps mrk be now lead contender position
1611,MRK,merck still have way go clinical trial file approval win have first compete regimen expect be abbvie abbv enanta enta cocktail also expect launch late year
1612,MRK,however research note thursday nomura analyst ian somaiya write symposium hepatologist stefan zeuzam bring gilead higher efficacy abbvie certain patient well risk drug interaction patient also have hiv
1613,MRK,zeuzam also raise issue higher alanine level small percentage patient merck regimen point acute liver injury motivate many physician avoid regimen somaiya raise estimate gilead total hcv franchise year next year
1614,MRK,defense
1615,MRK,well fargo financial adviser brian abraham rise abbvie defense
1616,MRK,thesis regard hep competitive dynamic be abbvie regimen be competitor gild give efficacy multiple patient type clean safety still have disadvantage versus gild merck regimen be hyped potential competitive threat write research note thursday
1617,MRK,gilead share tumble more thursday lowest close mid october biotechs other growth stock lead sharp market sell abbvie lose even merck initially rise year intraday high close
1618,MRK,gilead worry express script esrx officer say pharmacy benefit manager try drive sovaldi price goldman sachs analyst terence flynn wednesday trim gilead price target physician survey imply hcv market be price sensitive big pharma merck mrk report stellar result phase hepatitis hcv drug trial thursday spark debate analyst potential take market share leader gilead science international liver congress london merck report cure rate patient hepatitis genotype take combination drug candidate mk mk potentially combine pill take once day pairing rival convenience effectiveness gilead gild combo sofosbuvir ledipasvir be currently await fda approval expect october gilead launch sofosbuvir alone sovaldi december be still recommend be combine interferon genotype account hcv infection be already enjoy biggest launch drug history now however wall street attention be turn rival face competitonisi group analyst mark schoenebaum write email client consensus peak sale estimate merck regimen almost certainly go current nonetheless write rise present real danger gilead most analyst include have assume gild capture perhaps genotype share peak write open question however have be company grab other market propose perhaps mrk be now lead contender position merck still have way go clinical trial file approval win have first compete regimen expect be abbvie abbv enanta enta cocktail also expect launch late year however research note thursday nomura analyst ian somaiya write symposium hepatologist stefan zeuzam bring gilead higher efficacy abbvie certain patient well risk drug interaction patient also have hiv zeuzam also raise issue higher alanine level small percentage patient merck regimen point acute liver injury motivate many physician avoid regimen somaiya raise estimate gilead total hcv franchise year next year defensewell fargo financial adviser brian abraham rise abbvie defense thesis regard hep competitive dynamic be abbvie regimen be competitor gild give efficacy multiple patient type clean safety still have disadvantage versus gild merck regimen be hyped potential competitive threat write research note thursday gilead share tumble more thursday lowest close mid october biotechs other growth stock lead sharp market sell abbvie lose even merck initially rise year intraday high close gilead worry express script esrx officer say pharmacy benefit manager try drive sovaldi price goldman sachs analyst terence flynn wednesday trim gilead price target physician survey imply hcv market be price sensitive
1619,MRK,analyst be singing praise life science giant gilead science gild illumina ilmn wednesday morning surge estimate late tuesday share company be stock market today
1620,MRK,gilead sale new hepatitis drug sovaldi be call most impressive beat biopharma history piper jaffray joshua schimmer increase price target only dollar gilead be morning trading wednesday
1621,MRK,rbc capital market analyst michael yee lift sale estimate previous add full year ep estimate now expect sovaldi sale hit next year ep reach
1622,MRK,nomura ian somaiya lift price target write gilead position hcv market be sustainable say sovaldi new sovaldi base combo pill expect launch later year be superior compete product abbvie abbv merck mrk
1623,MRK,cowen phil nadeau be also impressed note lengthy discussion payor pushback tuesday earning call provide probably not nearly enough resolution satisfy investor pharmacy benefit manager express script esrx insurer unite health unh have criticize sovaldi price
1624,MRK,gilead do discuss argument support price sovaldi such value cure health care system cost treat patient end stage liver disease yr nadeau write find gilead discussion datapoint encourage suspect investor concern payor ability limit access sovaldi shuttle patient compete regimen linger abbv pricing strategy be know presumably approval payor strategy be defined early
1625,MRK,meanwhile gene testing company illumina be wednesday morning beat estimate raise guidance sale rise year earlier quarter nearly consensus earning climb cent share top estimate cent
1626,MRK,company now expect full year sale growth ep range be consensus
1627,MRK,leerink analyst dan leonard write note tuesday report exceed even have consider best case scenario face multiple new instrument launch lift price target write launch new hiseq miseq gene sequence system do not appear be cannibalize older version add order hiseq system illumina announce january fanfare due claim sequence genome apiece be double initial target
1628,MRK,isi group ross muken note demand be illumina entire sequence portfolio raise price target reflect increase ep forecast however maintain neutral rating stock say current price already reflect annual revenue growth
1629,MRK,follow amy reeve twitter be singing praise life science giant gilead science gild illumina ilmn wednesday morning surge estimate late tuesday share company be stock market today gilead sale new hepatitis drug sovaldi be call most impressive beat biopharma history piper jaffray joshua schimmer increase price target only dollar gilead be morning trading wednesday rbc capital market analyst michael yee lift sale estimate previous add full year ep estimate now expect sovaldi sale hit next year ep reach nomura ian somaiya lift price target write gilead position hcv market be sustainable say sovaldi new sovaldi base combo pill expect launch later year be superior compete product abbvie abbv merck mrk cowen phil nadeau be also impressed note lengthy discussion payor pushback tuesday earning call provide probably not nearly enough resolution satisfy investor pharmacy benefit manager express script esrx insurer unite health unh have criticize sovaldi price gilead do discuss argument support price sovaldi such value cure health care system cost treat patient end stage liver disease yr nadeau write find gilead discussion datapoint encourage suspect investor concern payor ability limit access sovaldi shuttle patient compete regimen linger abbv pricing strategy be know presumably approval payor strategy be defined early meanwhile gene testing company illumina be wednesday morning beat estimate raise guidance sale rise year earlier quarter nearly consensus earning climb cent share top estimate cent company now expect full year sale growth ep range be consensus leerink analyst dan leonard write note tuesday report exceed even have consider best case scenario face multiple new instrument launch lift price target write launch new hiseq miseq gene sequence system do not appear be cannibalize older version add order hiseq system illumina announce january fanfare due claim sequence genome apiece be double initial target isi group ross muken note demand be illumina entire sequence portfolio raise price target reflect increase ep forecast however maintain neutral rating stock say current price already reflect annual revenue growth follow amy reeve twitter ibd_areeve
1630,MRK,big pharmas pfizer pfe astrazeneca azn be early trading stock market today word get sunday pfizer have offer buy rival
1631,MRK,cite unnamed source sunday time say have be talk astrazeneca have resist offer company decline comment
1632,MRK,report set wall street abuzz speculation astrazeneca rival be still fall patent cliff earning be expect keep decline lead many industry observer see buyout target most other big pharmas have be pare mode last couple year include pfizer have be reorganize division intention spin selling separate company
1633,MRK,nonetheless merger make sense accord isi group analyst mark schoenebaum
1634,MRK,opinion pfe have be signale last summer theory company not be opposed larger deal number make sense write email client sunday pfe have not get smaller ceo ian read just sake get smaller rather company have be clear have divest certain business thought be more valuable better run separate entity
1635,MRK,schoenebaum go point buy astrazeneca get pfizer immuno oncology game have be heating rival bristol myer squibb bmy roche rhhby merck mrk have be develop drug pd form cancer astrazeneca have own pd drug work earlier stage development other
1636,MRK,citigroup analyst andrew baum agree buy astrazeneca probably be good deal pfizer thought astrazeneca be flirt third party avoid pfizer buyout other hand analyst corporate research firm bernstein research didn think pfizer be actually serious such deal
1637,MRK,astrazeneca stock be more monday morning trading pfizer be more
1638,MRK,follow amy reeve twitter ibd_areeve big pharmas pfizer pfe astrazeneca azn be early trading stock market today word get sunday pfizer have offer buy rival cite unnamed source sunday time say have be talk astrazeneca have resist offer company decline comment report set wall street abuzz speculation astrazeneca rival be still fall patent cliff earning be expect keep decline lead many industry observer see buyout target most other big pharmas have be pare mode last couple year include pfizer have be reorganize division intention spin selling separate company nonetheless merger make sense accord isi group analyst mark schoenebaum opinion pfe have be signale last summer theory company not be opposed larger deal number make sense write email client sunday pfe have not get smaller ceo ian read just sake get smaller rather company have be clear have divest certain business thought be more valuable better run separate entity schoenebaum go point buy astrazeneca get pfizer immuno oncology game have be heating rival bristol myer squibb bmy roche rhhby merck mrk have be develop drug pd form cancer astrazeneca have own pd drug work earlier stage development other citigroup analyst andrew baum agree buy astrazeneca probably be good deal pfizer thought astrazeneca be flirt third party avoid pfizer buyout other hand analyst corporate research firm bernstein research didn think pfizer be actually serious such deal astrazeneca stock be more monday morning trading pfizer be more follow amy reeve twitter ibd_areeve
1639,MRK,stock slip mixed trade go noon hour tuesday trader continue handicap upcoming earning report nasdaq be dow jone industrial average rise smidgen stock market today volume run higher same time monday nyse nasdaq exchange
1640,MRK,hawaiian holding parent hawaiian airline be only claw way back loss morning stock report earning beat estimate close monday sidoti co downgrade stock neutral cowen raise price maintain market perform rating
1641,MRK,amazon amzn fall tuesday morning report consumer intelligence research partner say amazon prime have customer spend average year site triple size year research organization say
1642,MRK,amazon report earning close thursday analyst forecast loss cent share
1643,MRK,facebook fb have carved similar pattern amazon be slightly touch new intraday high stock be find resistance century mark open jeffery lift price target facebook
1644,MRK,ibd company be higher be lower best performer be bank ozark ozrk nearly break cup handle base late monday announce have buy atlanta base community southern holding stock
1645,MRK,worst performer be egg producer cal maine food calm fall pull back hit new high monday
1646,MRK,follow ken hoover twitter ibd_khoover stock slip mixed trade go noon hour tuesday trader continue handicap upcoming earning report nasdaq be dow jone industrial average rise smidgen stock market today volume run higher same time monday nyse nasdaq exchange hawaiian holding parent hawaiian airline be only claw way back loss morning stock report earning beat estimate close monday sidoti co downgrade stock neutral cowen raise price maintain market perform rating amazon amzn fall tuesday morning report consumer intelligence research partner say amazon prime have customer spend average year site triple size year research organization say amazon report earning close thursday analyst forecast loss cent share facebook fb have carved similar pattern amazon be slightly touch new intraday high stock be find resistance century mark open jeffery lift price target facebook ibd company be higher be lower best performer be bank ozark ozrk nearly break cup handle base late monday announce have buy atlanta base community southern holding stock worst performer be egg producer cal maine food calm fall pull back hit new high monday follow ken hoover twitter ibd_khoover
1647,MRK,last month democrat congress send now famous letter gilead science gild question price new blockbuster hepatitis medicine sovaldi reason raise suspicion price didn need be high speed sovaldi be approve food drug administration gilead file receive
1648,MRK,big pharma pfizer pfe say monday vaccine prevenar prevent pneumonia giant study elderly subject potentially greatly expand sale product pfizer be study particular variety call community acquire pneumoccal pneumonia cap press release call significant cause illness death adult world subject participate
1649,MRK,major average extend winning streak session monday show stall action give benchmark index first distribution day market uptrend be confirm seller come market just et fedspeak didn amount much index trade relatively tight
1650,MRK,recent decade high cholesterol have be big pharma gravy train statin oral drug lower bad cholesterol turn best selling drug history pfizer lipitor peak nearly sale
1651,MRK,now however statin have go patent be so pfizer pfe passel other company lead amgen amgn regeneron regn regeneron partner sanofi sny be turn new class cholesterol buster call pcsk inhibitor
1652,MRK,american cardiology conference acc washington saturday monday investor get chance see new drug be do clinical trial
1653,MRK,pcsk be short proprotein convertase subtilisin kexin type enzyme bound liver receptor ldl bad cholesterol target degredation block pcsk company aim boost liver ability eliminate ldl cholesterol blood thus reduce chance heart disease
1654,MRK,pcsk inhibitor mid late stage testing be monoclonal antibody biotechnology already be used best selling cancer immunology drug
1655,MRK,monthly injection
1656,MRK,drug also have be inject once twice month make somewhat more unpleasant take statin partly reason drugmaker be gun subgroup high cholesterol sufferer statin aren adequate
1657,MRK,majority patient program be treat statin normally highest tolerable dose say jay edelberg head sanofi pcsk development launch unit be primarily patient be familial genetic disorder ve have cardiovascular event be diabetic be high risk cardiovascular disease
1658,MRK,then be patient tolerate statin
1659,MRK,morningstar analyst stefan quenneville estimate description cover person expect grow roughly equivalent number potential patient also live abroad estimate
1660,MRK,regeneron sanofi drug alirocumab take most stage time acc meeting presentation detail datum clinical trial be conduct product include study patient genetic high cholesterol patient be take merck mrk zetia abbvie abbv tricor aren well comparison patient zetia alone vs alirocumab alone
1661,MRK,company expect file approval alirocumab early so do amgen be also conduct different late stage clinical trial candidate evolocumab
1662,MRK,amgen be give presentation evolocumab compare zetia statin well effectiveness statin intolerant subject patient kind genetic heterozygous march report study homozygous patient have meet endpoint didn say further detail be reveal
1663,MRK,pfizer be bit regeneron amgen bococizumab just launch phase program october schedule present dose range study patient statin acc
1664,MRK,analyst have be pleased trial result drug so far haven converge favorite way do recent hepatitis race instance hasn be much datum differentiate other say quenneville
1665,MRK,look safety issue
1666,MRK,think trial present acc be go be interesting point drug have be pretty similar quenneville tell ibd look more difference efficacy be anything do safety
1667,MRK,think go be major concern safety signal appear didn see smaller trial waylay specific drug even entire class drug
1668,MRK,safety pcsk come particular scrutiny earlier month word get twitter food drug administration have become aware neurocognitive adverse event pcsk inhibitor class have ask sanofi regeneron make assessment potential neurocognitive adverse event global development program alirocumab especially longer term study accord sanofi annual report
1669,MRK,turn other pcsk player have get same letter deny have find significant safety issue
1670,MRK,analyst however seem have settle evolocumab culprit member cohort osler trial include person report memory impairment amnesia
1671,MRK,isi group analyst mark schoenebaum however point most patient be also statin memory loss have be connect statin so not clear evolocumab be blame
1672,MRK,safety turn be problem quenneville estimate pcsk drug collectively sell more assume alirocumab evolocumab split most market due be first say pfizer yet have something sleeve
1673,MRK,pfizer have imply conference call have more potent pcsk phase discontinue patient person have dramatic lower say ll see not really enough datum tease point recent decade high cholesterol have be big pharma gravy train statin oral drug lower bad cholesterol turn best selling drug history pfizer lipitor peak nearly sale now however statin have go patent be so pfizer pfe passel other company lead amgen amgn regeneron regn regeneron partner sanofi sny be turn new class cholesterol buster call pcsk inhibitor american cardiology conference acc washington saturday monday investor get chance see new drug be do clinical trial pcsk be short proprotein convertase subtilisin kexin type enzyme bound liver receptor ldl bad cholesterol target degredation block pcsk company aim boost liver ability eliminate ldl cholesterol blood thus reduce chance heart disease pcsk inhibitor mid late stage testing be monoclonal antibody biotechnology already be used best selling cancer immunology drug monthly injectionsall drug also have be inject once twice month make somewhat more unpleasant take statin partly reason drugmaker be gun subgroup high cholesterol sufferer statin aren adequate majority patient program be treat statin normally highest tolerable dose say jay edelberg head sanofi pcsk development launch unit be primarily patient be familial genetic disorder ve have cardiovascular event be diabetic be high risk cardiovascular disease then be patient tolerate statin morningstar analyst stefan quenneville estimate description cover person expect grow roughly equivalent number potential patient also live abroad estimate regeneron sanofi drug alirocumab take most stage time acc meeting presentation detail datum clinical trial be conduct product include study patient genetic high cholesterol patient be take merck mrk zetia abbvie abbv tricor aren well comparison patient zetia alone vs alirocumab alone company expect file approval alirocumab early so do amgen be also conduct different late stage clinical trial candidate evolocumab amgen be give presentation evolocumab compare zetia statin well effectiveness statin intolerant subject patient kind genetic heterozygous march report study homozygous patient have meet endpoint didn say further detail be reveal pfizer be bit regeneron amgen bococizumab just launch phase program october schedule present dose range study patient statin acc analyst have be pleased trial result drug so far haven converge favorite way do recent hepatitis race instance hasn be much datum differentiate other say quenneville look safety issue think trial present acc be go be interesting point drug have be pretty similar quenneville tell ibd look more difference efficacy be anything do safety think go be major concern safety signal appear didn see smaller trial waylay specific drug even entire class drug safety pcsk come particular scrutiny earlier month word get twitter food drug administration have become aware neurocognitive adverse event pcsk inhibitor class have ask sanofi regeneron make assessment potential neurocognitive adverse event global development program alirocumab especially longer term study accord sanofi annual report turn other pcsk player have get same letter deny have find significant safety issue analyst however seem have settle evolocumab culprit member cohort osler trial include person report memory impairment amnesia isi group analyst mark schoenebaum however point most patient be also statin memory loss have be connect statin so not clear evolocumab be blame safety turn be problem quenneville estimate pcsk drug collectively sell more assume alirocumab evolocumab split most market due be first say pfizer yet have something sleeve pfizer have imply conference call have more potent pcsk phase discontinue patient person have dramatic lower say ll see not really enough datum tease point
1674,MRK,stock rebound mildly tuesday lighter trade market defensiveness meanwhile grow more evident few blue chip firm history go back far year show rare stock muscle nasdaq composite edge less higher fraction drop suffer prior session only
1675,MRK,british drug giant astrazeneca azn issue mixed report guidance thursday morning knock stock wall street take notice fact advance alzheimer disease candidate phase testing
1676,MRK,company say revenue drop year earlier quarter miss analyst consensus core ep share beat estimate penny be prior year
1677,MRK,peer astrazeneca be still tumble patent cliff blockbuster such heartburn drug nexium cholesterol buster crestor be expect face generic competition next few year company therefore guide continue shrinkage come year sale low mid single digit range ep fall teen constant currency basis say revenue be same imply upturn growth then
1678,MRK,product hope fuel longer term growth be azd experimental treatment alzheimer disease company say thursday have moved late stage clinical testing alzheimer be common disease currently real treatment lead analyst think company make breakthrough have megablockbuster hand
1679,MRK,azd be bace inhibitor target amyloid plaque form brain cell alzheimer sufferer merck mrk have similar product work start phase testing december isi group analyst mark schoenebaum write email client street be cautious product give drug industry long history failure alzheimer field so far least astra merck drug haven show toxicity problem competitor
1680,MRK,astra stock have high relative strength rating problem be late morning trade stock market today
1681,MRK,follow amy reeve twitter ibd_areeve british drug giant astrazeneca azn issue mixed report guidance thursday morning knock stock wall street take notice fact advance alzheimer disease candidate phase testing company say revenue drop year earlier quarter miss analyst consensus core ep share beat estimate penny be prior year peer astrazeneca be still tumble patent cliff blockbuster such heartburn drug nexium cholesterol buster crestor be expect face generic competition next few year company therefore guide continue shrinkage come year sale low mid single digit range ep fall teen constant currency basis say revenue be same imply upturn growth then product hope fuel longer term growth be azd experimental treatment alzheimer disease company say thursday have moved late stage clinical testing alzheimer be common disease currently real treatment lead analyst think company make breakthrough have megablockbuster hand azd be bace inhibitor target amyloid plaque form brain cell alzheimer sufferer merck mrk have similar product work start phase testing december isi group analyst mark schoenebaum write email client street be cautious product give drug industry long history failure alzheimer field so far least astra merck drug haven show toxicity problem competitor astra stock have high relative strength rating problem be late morning trade stock market today follow amy reeve twitter ibd_areeve
1682,MRK,still early day dec approval gilead science hepatitis drug sovaldi be enjoy most massive drug launch time current consensus call sale year whisper number be run even higher
1683,MRK,doesn surprise wall street sovaldi provide faster safer stronger alternative punish yearlong regimen interferon analyst obsessively watch weekly prescription number grow re also eyee datum sovaldi potential challenger market estimate year grow
1684,MRK,bristol myer squibb bmy daclatasvir grab headline last april phase trial combine sovaldi score cure rate
1685,MRK,gilead gild elect not pursue combo further instead study sovaldi combination similar drug ledipasvir so co formulate single pill not share market
1686,MRK,bristol however file european union approval daclatasvir use combination other agent include sofosbuvir generic name sovaldi be grant accelerate review early january firm plan submit similar filing food drug administration soon
1687,MRK,sovaldi set new standard
1688,MRK,october bristol file approve combo daclatasvir drug asunaprevir japan have unusually high rate hepatitis virus hcv infection due formerly taint blood supply
1689,MRK,dougla manion bristol vice president development virology japan say dual regimen score good result week duration be look yesterday news now sovaldi have set week standard hope be resolve triple therapy involve daclatasvir asunaprevir drug dub bms co formulate pill be take twice day now phase testing
1690,MRK,ultimately however do not expect single regimen conquer other not patient be same
1691,MRK,treat toughest patient
1692,MRK,daclatasvir have be study so many different drug used genotype hepatitis virus patient population especially toughest treat population manion say be go be liver transplant patient genotype patient patient cirrhosis ultimately patient decompensation
1693,MRK,decompensate cirrhosis worst form liver damage result hcv usually result liver transplant death
1694,MRK,decompensate group be population not include abbvie abbv phase trial regimen combine antiviral agent abbvie also stick most common genotype genotype do very well trial cure rate range company plan file second quarter hit market late year
1695,MRK,respect have nearly catch gilead current fda guideline sovaldi recommend be used interferon genotype patient tolerate interferon gilead be banking sofosbuvir ledipasvir combo be first official interferon free genotype treatment also expect launch later year feb filing
1696,MRK,barry bernstein abbvie vice president infectious disease development tout strong safety profile fact cure upward patient compensate cirrhosis
1697,MRK,believe regimen provide option genotype infected patient bernstein tell ibd
1698,MRK,abbvie bristol myer gilead be expect report final study detail international liver congress meeting london april company official be keep mum study be present abstract go online march late breaking abstract appear right conference often have hottest datum
1699,MRK,next generation regime
1700,MRK,further road even more drug be way
1701,MRK,abbvie partner enanta pharmaceutical enta be already work next generation regime treat more genotype also be simpler take common criticism be more complicate gilead promise pill day routine
1702,MRK,earlier month merck mrk also report very strong phase result drug combo genotype patient be co infected hiv johnson johnson jnj last october acquire hcv drug glaxosmithkline gsk hope combine already approve olysio oral regimen
1703,MRK,sovaldi meanwhile have lately be pressure pill price tag concern sustainability outcome find curative drug be patient population eventually shrink
1704,MRK,still morningstar analyst damien conover say gilead have first mover advantage such strong trial datum likely be biggest player indefinite future
1705,MRK,think ll have gilead represent hep market tell ibd abbvie take lion share remain still early day dec approval gilead science hepatitis drug sovaldi be enjoy most massive drug launch time current consensus call sale year whisper number be run even higher doesn surprise wall street sovaldi provide faster safer stronger alternative punish yearlong regimen interferon analyst obsessively watch weekly prescription number grow re also eyee datum sovaldi potential challenger market estimate year grow bristol myer squibb bmy daclatasvir grab headline last april phase trial combine sovaldi score cure rate gilead gild elect not pursue combo further instead study sovaldi combination similar drug ledipasvir so co formulate single pill not share market bristol however file european union approval daclatasvir use combination other agent include sofosbuvir generic name sovaldi be grant accelerate review early january firm plan submit similar filing food drug administration soon sovaldi set new standardin october bristol file approve combo daclatasvir drug asunaprevir japan have unusually high rate hepatitis virus hcv infection due formerly taint blood supply dougla manion bristol vice president development virology japan say dual regimen score good result week duration be look yesterday news now sovaldi have set week standard hope be resolve triple therapy involve daclatasvir asunaprevir drug dub bms co formulate pill be take twice day now phase testing ultimately however do not expect single regimen conquer other not patient be same treat toughest patient daclatasvir have be study so many different drug used genotype hepatitis virus patient population especially toughest treat population manion say be go be liver transplant patient genotype patient patient cirrhosis ultimately patient decompensation decompensate cirrhosis worst form liver damage result hcv usually result liver transplant death decompensate group be population not include abbvie abbv phase trial regimen combine antiviral agent abbvie also stick most common genotype genotype do very well trial cure rate range company plan file second quarter hit market late year respect have nearly catch gilead current fda guideline sovaldi recommend be used interferon genotype patient tolerate interferon gilead be banking sofosbuvir ledipasvir combo be first official interferon free genotype treatment also expect launch later year feb filing barry bernstein abbvie vice president infectious disease development tout strong safety profile fact cure upward patient compensate cirrhosis believe regimen provide option genotype infected patient bernstein tell ibd abbvie bristol myer gilead be expect report final study detail international liver congress meeting london april company official be keep mum study be present abstract go online march late breaking abstract appear right conference often have hottest datum next generation regimesfurther road even more drug be way abbvie partner enanta pharmaceutical enta be already work next generation regime treat more genotype also be simpler take common criticism be more complicate gilead promise pill day routine earlier month merck mrk also report very strong phase result drug combo genotype patient be co infected hiv johnson johnson jnj last october acquire hcv drug glaxosmithkline gsk hope combine already approve olysio oral regimen sovaldi meanwhile have lately be pressure pill price tag concern sustainability outcome find curative drug be patient population eventually shrink still morningstar analyst damien conover say gilead have first mover advantage such strong trial datum likely be biggest player indefinite future think ll have gilead represent hep market tell ibd abbvie take lion share remain
1706,MRK,still early day dec approval gilead science hepatitis drug sovaldi be enjoy most massive drug launch time current consensus call sale year whisper number be run even higher
1707,MRK,doesn surprise wall street sovaldi provide faster safer stronger alternative punish yearlong regimen interferon analyst obsessively watch weekly prescription number grow re also eyee datum sovaldi potential challenger market estimate year grow
1708,MRK,bristol myer squibb bmy daclatasvir grab headline last april phase trial combine sovaldi score cure rate
1709,MRK,gilead gild elect not pursue combo further instead study sovaldi combination similar drug ledipasvir so co formulate single pill not share market
1710,MRK,bristol however file european union approval daclatasvir use combination other agent include sofosbuvir generic name sovaldi be grant accelerate review early january firm plan submit similar filing food drug administration soon
1711,MRK,sovaldi set new standard
1712,MRK,october bristol file approve combo daclatasvir drug asunaprevir japan have unusually high rate hepatitis virus hcv infection due formerly taint blood supply
1713,MRK,dougla manion bristol vice president development virology japan say dual regimen score good result week duration be look yesterday news now sovaldi have set week standard hope be resolve triple therapy involve daclatasvir asunaprevir drug dub bms co formulate pill be take twice day now phase testing
1714,MRK,ultimately however do not expect single regimen conquer other not patient be same
1715,MRK,treat toughest patient
1716,MRK,daclatasvir have be study so many different drug used genotype hepatitis virus patient population especially toughest treat population manion say be go be liver transplant patient genotype patient patient cirrhosis ultimately patient decompensation
1717,MRK,decompensate cirrhosis worst form liver damage result hcv usually result liver transplant death
1718,MRK,decompensate group be population not include abbvie abbv phase trial regimen combine antiviral agent abbvie also stick most common genotype genotype do very well trial cure rate range company plan file second quarter hit market late year
1719,MRK,respect have nearly catch gilead current fda guideline sovaldi recommend be used interferon genotype patient tolerate interferon gilead be banking sofosbuvir ledipasvir combo be first official interferon free genotype treatment also expect launch later year feb filing
1720,MRK,barry bernstein abbvie vice president infectious disease development tout strong safety profile fact cure upward patient compensate cirrhosis
1721,MRK,believe regimen provide option genotype infected patient bernstein tell ibd
1722,MRK,abbvie bristol myer gilead be expect report final study detail international liver congress meeting london april company official be keep mum study be present abstract go online march late breaking abstract appear right conference often have hottest datum
1723,MRK,next generation regime
1724,MRK,further road even more drug be way
1725,MRK,abbvie partner enanta pharmaceutical enta be already work next generation regime treat more genotype also be simpler take common criticism be more complicate gilead promise pill day routine
1726,MRK,earlier month merck mrk also report very strong phase result drug combo genotype patient be co infected hiv johnson johnson jnj last october acquire hcv drug glaxosmithkline gsk hope combine already approve olysio oral regimen
1727,MRK,sovaldi meanwhile have lately be pressure pill price tag concern sustainability outcome find curative drug be patient population eventually shrink
1728,MRK,still morningstar analyst damien conover say gilead have first mover advantage such strong trial datum likely be biggest player indefinite future
1729,MRK,think ll have gilead represent hep market tell ibd abbvie take lion share remain still early day dec approval gilead science hepatitis drug sovaldi be enjoy most massive drug launch time current consensus call sale year whisper number be run even higher doesn surprise wall street sovaldi provide faster safer stronger alternative punish yearlong regimen interferon analyst obsessively watch weekly prescription number grow re also eyee datum sovaldi potential challenger market estimate year grow bristol myer squibb bmy daclatasvir grab headline last april phase trial combine sovaldi score cure rate gilead gild elect not pursue combo further instead study sovaldi combination similar drug ledipasvir so co formulate single pill not share market bristol however file european union approval daclatasvir use combination other agent include sofosbuvir generic name sovaldi be grant accelerate review early january firm plan submit similar filing food drug administration soon sovaldi set new standardin october bristol file approve combo daclatasvir drug asunaprevir japan have unusually high rate hepatitis virus hcv infection due formerly taint blood supply dougla manion bristol vice president development virology japan say dual regimen score good result week duration be look yesterday news now sovaldi have set week standard hope be resolve triple therapy involve daclatasvir asunaprevir drug dub bms co formulate pill be take twice day now phase testing ultimately however do not expect single regimen conquer other not patient be same treat toughest patient daclatasvir have be study so many different drug used genotype hepatitis virus patient population especially toughest treat population manion say be go be liver transplant patient genotype patient patient cirrhosis ultimately patient decompensation decompensate cirrhosis worst form liver damage result hcv usually result liver transplant death decompensate group be population not include abbvie abbv phase trial regimen combine antiviral agent abbvie also stick most common genotype genotype do very well trial cure rate range company plan file second quarter hit market late year respect have nearly catch gilead current fda guideline sovaldi recommend be used interferon genotype patient tolerate interferon gilead be banking sofosbuvir ledipasvir combo be first official interferon free genotype treatment also expect launch later year feb filing barry bernstein abbvie vice president infectious disease development tout strong safety profile fact cure upward patient compensate cirrhosis believe regimen provide option genotype infected patient bernstein tell ibd abbvie bristol myer gilead be expect report final study detail international liver congress meeting london april company official be keep mum study be present abstract go online march late breaking abstract appear right conference often have hottest datum next generation regimesfurther road even more drug be way abbvie partner enanta pharmaceutical enta be already work next generation regime treat more genotype also be simpler take common criticism be more complicate gilead promise pill day routine earlier month merck mrk also report very strong phase result drug combo genotype patient be co infected hiv johnson johnson jnj last october acquire hcv drug glaxosmithkline gsk hope combine already approve olysio oral regimen sovaldi meanwhile have lately be pressure pill price tag concern sustainability outcome find curative drug be patient population eventually shrink still morningstar analyst damien conover say gilead have first mover advantage such strong trial datum likely be biggest player indefinite future think ll have gilead represent hep market tell ibd abbvie take lion share remain
1730,MRK,executive bristol myer squibb bmy say tuesday company be plan phase trial drug nivolumab yervoy treat lung cancer company stock rise nearly news stock market today cowen co health care conference bristol senior vice president brian daniel respond question
1731,MRK,valeant pharmaceutical vrx beat analyst fourth quarter estimate thursday analyst be more interested canadian firm acquisition strategy quest become next drug giant
1732,MRK,cash ep rise vs year earlier cent consensus analyst poll thomson reuter sale rise line ep rise sale
1733,MRK,valeant share rise hit record intraday
1734,MRK,company executive maintain guidance issue early january call sale ep conference call analyst indicated be default guidance complete buyout precision dermatology admit foreign exchange head wind have build initial guidance
1735,MRK,cfo howard schiller say organic sale decline valeant feel maximum impact generic rival zovirax retin micro drug
1736,MRK,say growth return rest year overall sale be expect keep rise due company furious pace buyout especially massive acquisition bausch lomb august
1737,MRK,bausch business accelerate especially sale grow
1738,MRK,call ub analyst marc goodman say brand performance beat expectation category add didn know contact lens solution business ever grow fast
1739,MRK,schiller credit launch several product well general rebuild brand valeant buyout
1740,MRK,analyst also question ceo michael pearson firm acquisition strategy last month set formal goal valeant become world biggest health care company end mean least merger equal future
1741,MRK,pearson say be many candidate globally such merger include whole company major division big pharmas
1742,MRK,product be cash pay pearson say durable asset business salesforce relationship really make difference
1743,MRK,say business fit valeant profile be animal health be opportunity merck mrk be widely rumore be think shedding veterinary unit however pearson add everyone shouldn come away call think re buy animal health company
1744,MRK,actavis act recent agreement buy forest laboratory frx also spur few question pearson say forest be not type target interested doesn want get primary care actavis major interest forest analyst ask have specialty pharma rival size make acquisition more competitive pearson say didn think make difference
1745,MRK,aegis capital analyst ram selvaraju later lift price target writing further gross margin improvement be valeant grasp valeant pharmaceutical vrx beat analyst fourth quarter estimate thursday analyst be more interested canadian firm acquisition strategy quest become next drug giant cash ep rise vs year earlier cent consensus analyst poll thomson reuter sale rise line ep rise sale valeant share rise hit record intraday company executive maintain guidance issue early january call sale ep conference call analyst indicated be default guidance complete buyout precision dermatology admit foreign exchange head wind have build initial guidance cfo howard schiller say organic sale decline valeant feel maximum impact generic rival zovirax retin micro drug say growth return rest year overall sale be expect keep rise due company furious pace buyout especially massive acquisition bausch lomb august bausch business accelerate especially sale grow call ub analyst marc goodman say brand performance beat expectation category add didn know contact lens solution business ever grow fast schiller credit launch several product well general rebuild brand valeant buyout analyst also question ceo michael pearson firm acquisition strategy last month set formal goal valeant become world biggest health care company end mean least merger equal future pearson say be many candidate globally such merger include whole company major division big pharmas product be cash pay pearson say durable asset business salesforce relationship really make difference say business fit valeant profile be animal health be opportunity merck mrk be widely rumore be think shedding veterinary unit however pearson add everyone shouldn come away call think re buy animal health company actavis act recent agreement buy forest laboratory frx also spur few question pearson say forest be not type target interested doesn want get primary care actavis major interest forest analyst ask have specialty pharma rival size make acquisition more competitive pearson say didn think make difference aegis capital analyst ram selvaraju later lift price target writing further gross margin improvement be valeant grasp
1746,MRK,big pharma bristol myer squibb bmy stock be selling nearly heavy morning trading stock market today be news company possible reason be post new clinical trial nivolumab small cell lung cancer nsclc new trial study only patient pd biomarker do not
1747,MRK,annual meeting american association cancer research convene san diego april be view most drug industry watcher second tier medical conference physician investor be watch closely year pfizer report drug dramatically extend life patient breast cancer pfizer pfe
1748,MRK,merck mrk have bring new top scientist shake research development roger perlmutter former top scientist amgen amgn tell analyst late last year plan major surgery drugmaker research operation cut dead end project focuse laboratory biotech cancer medicine say too much red tape not enough risk take merck have be criticize be too cautious rival have moved biotech away primary care medicine merck top selling drug be januvia used treat diabetes top drug singulair treat asthma company have long history trace origin apothecary jacob friedrick merck acquire angel pharmacy darmstadt germany open branch year later open pharmacy manhattan become world renown world war branch company be seize government supply medical supply military war merck branch become independent company right now drugmaker be hot commodity wall street wednesday ibd medical ethical drug industry group be rank group most group action be drive smaller faster grow biotech company merck have be slow grower year annualize growth rate be just have earning stability factor scale low number correspond steady growth pay dividend cent share quarterly work annual yield year dividend growth rate be mean hasn be grow very much analyst expect ep slowdown additional slowdown
1749,MRK,biotech arrowhead research arwr stock price have already double year jump stock market today pair bullish analyst initiation report close tuesday michael yee rbc capital market launch coverage outperform price target move come day arrowhead receive fda permission launch
1750,MRK,likely biggest virtual real estate expansion year ve never hear massive growth internet land rush yesteryear have winner loser possibly unintended consequence
1751,MRK,generic top level domain gtld last portion internet address such com org edu gov be dramatically expand company already have line haggle bargain need be fight
1752,MRK,currently be roughly domain name worldwide com be most commonly used gtld accord internet corp assign name number nonprofit organization oversee various internet related task last year be gtld domain end roughly new domain be introduce internet icann say
1753,MRK,industry vertical ripe pick say erik ludwick chief executive box los angele base internet domain company say market potential domain be virtual know ll turn profit
1754,MRK,wading swamp
1755,MRK,bmw already have apply bmw vatican have request catholic apple aapl have dib namesake apple boston globe newspaper have apply boston new york london have own domain name google goog have send application amazon amzn have application own gtld include music book shop
1756,MRK,tech giant big city major automaker other company be get mix donut bellevue wash base company build purpose buy new domain name have be most aggressive bidder apply more domain range pet guru poker
1757,MRK,whole purpose program be bring new variety choice person need internet identity say mason cole vice president communication donut
1758,MRK,process expand internet domain name have be work several year get ground level have part cash application fee be proceed not go icann general fund instead be store icann larger internet domain business community decide do later money say cyrus namazi icann vice president
1759,MRK,dispute
1760,MRK,icann receive nearly application different entity roughly domain be be contest applicant name be decide auction other be decide bidding party negotiation icann take cent domain name sell charge other fee
1761,MRK,project enable provide new blank canvas allow business other domain holder have own distinct virtual identity namazi say
1762,MRK,participant domain name boom intend get depend want business donut box be hope profit venture other end buy domain simply block other person used dilute trademark
1763,MRK,internet have large stamp world wide web be indeed global national domain aren call gtld rather cctld country code top level domain germany be ireland be ie canada france fr even many domain name nation just use popular com sochi ru be plaster everywhere winter olympic
1764,MRK,key goal expand internet be expand latin character available use nation dominant language include arabic russian japanese farsi namazi say
1765,MRK,not wine cheese beer bratwurst business have specific brand find spending more defend trademark competitor say andrea calvaruso partner intellectual property lawyer kelley drye warren
1766,MRK,whole rollout be open kind can worm calvaruso say
1767,MRK,example merck co mrk new jersey base pharmaceutical giant merck kgaa german drug chemical maker have file merck domain
1768,MRK,competitive concern also exist critic question company be allow own certain domain such book search believe be open public be used hoard market share
1769,MRK,be thing particular company control get say get use be very problematic say john simpson director privacy project consumer watchdog santa monica calif base advocacy group
1770,MRK,nevertheless godaddy lead domain name retailer already have open name pre registration several new gtld include photography estate domain wholesaler such donut box receive percentage sale
1771,MRK,matter open opportunity source creativity innovation space say james cole global medium coordinator icann whole different ballpark now likely biggest virtual real estate expansion year ve never hear massive growth internet land rush yesteryear have winner loser possibly unintended consequence generic top level domain gtld last portion internet address such com org edu gov be dramatically expand company already have line haggle bargain need be fight currently be roughly domain name worldwide com be most commonly used gtld accord internet corp assign name number nonprofit organization oversee various internet related task last year be gtld domain end roughly new domain be introduce internet icann say industry vertical ripe pick say erik ludwick chief executive box los angele base internet domain company say market potential domain be virtual know ll turn profit wading swampbmw already have apply bmw vatican have request catholic apple aapl have dib namesake apple boston globe newspaper have apply boston new york london have own domain name google goog have send application amazon amzn have application own gtld include music book shop tech giant big city major automaker other company be get mix donut bellevue wash base company build purpose buy new domain name have be most aggressive bidder apply more domain range pet guru poker whole purpose program be bring new variety choice person need internet identity say mason cole vice president communication donut process expand internet domain name have be work several year get ground level have part cash application fee be proceed not go icann general fund instead be store icann larger internet domain business community decide do later money say cyrus namazi icann vice president disputeicann receive nearly application different entity roughly domain be be contest applicant name be decide auction other be decide bidding party negotiation icann take cent domain name sell charge other fee project enable provide new blank canvas allow business other domain holder have own distinct virtual identity namazi say participant domain name boom intend get depend want business donut box be hope profit venture other end buy domain simply block other person used dilute trademark internet have large stamp world wide web be indeed global national domain aren call gtld rather cctld country code top level domain germany be ireland be ie canada france fr even many domain name nation just use popular com sochi ru be plaster everywhere winter olympic key goal expand internet be expand latin character available use nation dominant language include arabic russian japanese farsi namazi say not wine cheese beer bratwurst business have specific brand find spending more defend trademark competitor say andrea calvaruso partner intellectual property lawyer kelley drye warren whole rollout be open kind can worm calvaruso say example merck co mrk new jersey base pharmaceutical giant merck kgaa german drug chemical maker have file merck domain competitive concern also exist critic question company be allow own certain domain such book search believe be open public be used hoard market share be thing particular company control get say get use be very problematic say john simpson director privacy project consumer watchdog santa monica calif base advocacy group nevertheless godaddy lead domain name retailer already have open name pre registration several new gtld include photography estate domain wholesaler such donut box receive percentage sale matter open opportunity source creativity innovation space say james cole global medium coordinator icann whole different ballpark now
1772,MRK,health care industry be rapidly change new advance medicine many most promising novel advancement be come smaller company be more nimble quicker change medicine health care related stock akorn akrx questcor pharmaceutical qcor parexel international prxl medidata solution mdso be highly rank company featured screen day
1773,MRK,specialty drugmaker akorn akrx tuesday report first quarter ep view revenue be light company also raise full year profit outlook lake forest ill base akorn say earn cent share month end march year earlier revenue also rise analyst have estimate profit
1774,MRK,megamerger be back major corporation appetite acquisition near pre recession peak especially tax friendly cross border deal global have reach year earlier accord datum compile thomson reuter mark strongest year deal make peak monday biggest announcement be hillshire brand hsh
1775,MRK,big pharma merck mrk miss sale estimate result guidance wednesday stock hit year high anyway announce new set deal cancer program merck say profit most recent quarter totale cent share year earlier quarter line analyst consensus
1776,MRK,danish drug giant nordisk miss sale estimate lower full year revenue forecast thursday loss support payer hurt stock fall nordisk nvo make cent share quarter year earlier quarter danish kroner penny analyst consensus sale increase
1777,MRK,big purse start spill open globe past week glaxosmithkline gsk novartis nvs eli lilly lly announce series business swap value astrazeneca azn straight arm offer pfizer pfe general electric ge offer france alstom britain reckitt benckiser group say monday be duel
1778,MRK,stock be session lows monday afternoon sell picked
1779,MRK,nasdaq widen loss slice day line fall fall further day line breach friday meanwhile dow jone industrial average fared better loss gain caterpillar cat merck mrk cushion blue chip index blow
1780,MRK,turnover be again run mixed stock market today nasdaq trade continue track slightly higher nyse turnover be tracking sharply lower
1781,MRK,open tal education group xrs say make minority investment provide online resource parent have now give gain past buy point flat base breach day line have be much round trip mark sell signal
1782,MRK,qiwi qiwi slump nearly month low provider online payment service have be pressure recently concern russia put new regulation cross border payment qiwi recently slide more buy point rare ascend base
1783,MRK,wynn resort wynn turn gain loss be poise stretch lose streak session still past buy point flat base
1784,MRK,only stock ibd sport gain stock be session lows monday afternoon sell picked nasdaq widen loss slice day line fall fall further day line breach friday meanwhile dow jone industrial average fared better loss gain caterpillar cat merck mrk cushion blue chip index blow turnover be again run mixed stock market today nasdaq trade continue track slightly higher nyse turnover be tracking sharply lower open tal education group xrs say make minority investment provide online resource parent have now give gain past buy point flat base breach day line have be much round trip mark sell signal qiwi qiwi slump nearly month low provider online payment service have be pressure recently concern russia put new regulation cross border payment qiwi recently slide more buy point rare ascend base wynn resort wynn turn gain loss be poise stretch lose streak session still past buy point flat base only stock ibd sport gain
1785,MRK,european exchange be high scorer world map tuesday investor return vigor day holiday
1786,MRK,germany frankfurt exchange lead pack dax index vaulting higher italy milano ftse mib punch cac paris surge london ftse post gain
1787,MRK,european market rally sign thursday agreement russia europe ease rise tension ukraine be falter tuesday ukraine order resumption terror operation
1788,MRK,massive complex deal swiss drug giant novartis nvs glaxosmithkline gsk be centerpiece session company effectively restructure single swap novartis buy glaxosmithkline oncology unit glaxosmithkline grab novartis vaccine business separate deal glaxo say receive indianapoli base eli lilly lly animal health business
1789,MRK,glaxo rise london exchange drugmaker bayer bayry merck mrk be day biggest mover frankfurt
1790,MRK,base astrazeneca azn climb london report new york base pfizer pfe have approach company last year takeover offer talk have reportedly end
1791,MRK,financial time quote mirabaud security steve clayton say crucial point underlie pfizer interest deal be avoid tax penalty company repatriate overseas cash acquisition have allow pfizer avoid hit secure new portion market
1792,MRK,addition ireland base drugmaker shire group shpg jazz pharmaceutical jazz rise heavy trade respectively jeffery report name possible takeover target allergan agn event california base company attempt fend hostile takeover attempt make public monday persh square capital management valeant pharmaceutical vrx
1793,MRK,market also receive assist euro hold week low vs dollar pledge european central bank intercede single currency show sign strength european exchange be high scorer world map tuesday investor return vigor day holiday germany frankfurt exchange lead pack dax index vaulting higher italy milano ftse mib punch cac paris surge london ftse post gain european market rally sign thursday agreement russia europe ease rise tension ukraine be falter tuesday ukraine order resumption terror operation massive complex deal swiss drug giant novartis nvs glaxosmithkline gsk be centerpiece session company effectively restructure single swap novartis buy glaxosmithkline oncology unit glaxosmithkline grab novartis vaccine business separate deal glaxo say receive indianapoli base eli lilly lly animal health business glaxo rise london exchange drugmaker bayer bayry merck mrk be day biggest mover frankfurt base astrazeneca azn climb london report new york base pfizer pfe have approach company last year takeover offer talk have reportedly end financial time quote mirabaud security steve clayton say crucial point underlie pfizer interest deal be avoid tax penalty company repatriate overseas cash acquisition have allow pfizer avoid hit secure new portion market addition ireland base drugmaker shire group shpg jazz pharmaceutical jazz rise heavy trade respectively jeffery report name possible takeover target allergan agn event california base company attempt fend hostile takeover attempt make public monday persh square capital management valeant pharmaceutical vrx market also receive assist euro hold week low vs dollar pledge european central bank intercede single currency show sign strength
1794,MRK,early akorn barely cling life series bad strategic decision left small specialty drug company vulnerable collapse new management lead rajat rai step save lake forest ill base firm thank renew focus research development introduction new product prudent acquisition akorn akrx have emerge healthier ever akorn ceo cfo understood various step have go embarked turnaround say kevin kedra analyst gabelli co rye step include grow series mostly small acquisition investing ensure have expand manufacturing capability rebound kedra call brink death akorn be amassing impressive drug portfolio focus ophthalmic medication injectable drug used hospital high barrier marketsakorn concentration ophthalmic market hospital injectable give strategic advantage keep press advantage nov company announce acquire merck mrk right brand ophthalmic product be ophthalmic market hospital injectable market kedra say be market high barrier entry limit competitor drug firm struggle manufacturing snafu food drug administration be tighten regulatory oversight akorn be well position pass muster fda have be raise bar quality control kedra say fda have manufacturing concern be crack akorn be bring online state art facility india akorn be well aware fda standard be not try take shortcut weathering sandypiper jaffray david amsellem tour akorn update ophthalmic manufacturing facility somerset come away impressed firm recently expand modernize somerset site support greater capacity everything see suggest well run operation say amsellem senior research analyst piper jaffray new york city superstorm sandy hit somerset hard late october knock akorn factory week amsellem laud company resilience product go offline week be disruptive say now production have return pre sandy level be situation be hand deck mentality get thing back normal be pain weather storm figuratively literally pretty well kedra amsellem praise akorn leader orchestrate successful turnaround also like communication style re straight shooter think re excellent senior management team amsellem say lot transparency re thorough careful bring healthy common sense table
1795,MRK,big money flow pharma tuesday novartis glaxosmithkline gsk eli lilly lly unveil giant swap business valeant pharmaceutical vrx bid roughly allergan novartis nvs agree buy glaxo oncology business milestone payment depend product pipeline fare turn
1796,MRK,corner stand dodge cox stock fund top rank heavyweight outperformed large cap stock fund least asset month end feb accord morningstar inc portfolio be morningstar category top large cap value peer be
1797,MRK,ligand pharmaceutical lgnd hasn turn profit year drug developer not only expect make money year lift guidance fourth quarter full year la jolla calif base company say last month now expect gaap earning cent share revenue vs
1798,MRK,new year turn investor physician patient alike be wait eagerly bristol myer squibb bmy report result latest trial drug candidate nivolumab trial study patient virulent disease call squamous small cell lung cancer be just phase trial normally require round company file
1799,MRK,biotech stock bounce back recently last month medical biom biotech group be rank ibd industry be dead last last week plunge partly reflect growth stock overall fall hard current market correction specific concern sky high drug price notably gilead science blockbuster hepatitis
1800,MRK,stock hit fresh session high late thursday be track fourth straight gain
1801,MRK,help internet computer hardware stock nasdaq rally dow jone industrial average be volume be tracking modestly higher major exchange stock market today
1802,MRK,tata motor ttm stretched gain earlier stock clear buy point double bottom base heavy trading indian carmaker have composite rating highest auto manufacturer group tata be mentioned international leader earlier month
1803,MRK,armour ua rally regain day line fast trade stock be flat base larger pattern telsey advisory group upgrade share outperform market perform wednesday
1804,MRK,downside microsemi mscc reversed fall ahead fiscal earning close chipmaker be expect earn cent share year mark second straight quarter accelerate growth microsemi be work potential base
1805,MRK,intuitive surgical isrg kla tencor klac skywork solution swks starbucks sbux also be report earning close stock hit fresh session high late thursday be track fourth straight gain help internet computer hardware stock nasdaq rally dow jone industrial average be volume be tracking modestly higher major exchange stock market todaytata motor ttm stretched gain earlier stock clear buy point double bottom base heavy trading indian carmaker have composite rating highest auto manufacturer group tata be mentioned international leader earlier month armour ua rally regain day line fast trade stock be flat base larger pattern telsey advisory group upgrade share outperform market perform wednesday downside microsemi mscc reversed fall ahead fiscal earning close chipmaker be expect earn cent share year mark second straight quarter accelerate growth microsemi be work potential base intuitive surgical isrg kla tencor klac skywork solution swks starbucks sbux also be report earning close
1806,MRK,go public march little biotech enanta pharmaceutical have be middle clash giant enanta enta be developer protease inhibitor antiviral agent abbvie abbv cocktail drug testing treat hepatitis virus hcv abbvie be consider be nearest contender
1807,MRK,stock dim slightly quietly mixed trade monday open
1808,MRK,nasdaq dow jone industrial average be steady loss early trade
1809,MRK,volume inched nasdaq nyse compare action early friday
1810,MRK,quiet start stock market today be ahead week heavy economic corporate quarterly report retail sale datum december be due tuesday housing price new home start datum set later week
1811,MRK,well fargo wfc jpmorgan jpm report result ahead tuesday open bank america bac goldman sachs gs citigroup report wednesday thursday
1812,MRK,leader start week well more ibd stock open higher nearly loss hold
1813,MRK,stock be top list
1814,MRK,qihoo qihu hammer gain early trade china base internet security software developer receive upgrade buy hold stifel note also hoist stock price target cite management comment advertiser company monetization efficiency improve substantially believe company be advertiser
1815,MRK,stock have see trading action tighten start wide loose consolidation october monday move punch share back week line support
1816,MRK,qiwi qiwi kiosk base online payment network russia pop open stock drop strong trade last week retest buy point ascend base monday gain put share almost entry
1817,MRK,medical stock be active investor turn ear jpmorgan healthcare conference get way san francisco
1818,MRK,merck mrk jump powerful trade lead dow drugmaker modify food drug administration submission mk melanoma treatment roll submission let reapply approval continue basis
1819,MRK,stock have be mild uptrend past month stock dim slightly quietly mixed trade monday open nasdaq dow jone industrial average be steady loss early trade volume inched nasdaq nyse compare action early friday quiet start stock market today be ahead week heavy economic corporate quarterly report retail sale datum december be due tuesday housing price new home start datum set later week well fargo wfc jpmorgan jpm report result ahead tuesday open bank america bac goldman sachs gs citigroup report wednesday thursday leader start week well more ibd stock open higher nearly loss hold stock be top list qihoo qihu hammer gain early trade china base internet security software developer receive upgrade buy hold stifel note also hoist stock price target cite management comment advertiser company monetization efficiency improve substantially believe company be advertiser stock have see trading action tighten start wide loose consolidation october monday move punch share back week line support qiwi qiwi kiosk base online payment network russia pop open stock drop strong trade last week retest buy point ascend base monday gain put share almost entry medical stock be active investor turn ear jpmorgan healthcare conference get way san francisco merck mrk jump powerful trade lead dow drugmaker modify food drug administration submission mk melanoma treatment roll submission let reapply approval continue basis stock have be mild uptrend past month
1820,MRK,share merck mrk be early trading tuesday big pharma update key clinical trial suggest thing be go well merck announce press release datum safety monitoring board recommend continue improve trial giant study aim prove cholesterol drug ezetimibe used zetia vytorin prevent
1821,MRK,acquisition have long be staple drug industry drive force investment decision big pharmas blockbuster drug have go patent ve filled pipeline buy smaller firm new drug smaller player buyout be usually investor chief hope healthy return investment little biotechs be
1822,MRK,food drug administration gilead science gild hepatitis pill sovaldi late friday expect still key step drug widely see mega blockbuster
1823,MRK,analyst foresee very rapid uptake sovaldi sale next year make world best selling drug
1824,MRK,gilead share edge higher late friday close
1825,MRK,drug end complicate label different regimen different patient group upshot be first time be treat inject pegylate interferon current standard treatment cause flu symptom
1826,MRK,fda still recommend take interferon sovaldi oral drug ribavirin week patient disease genotype type be most common patient ineligible interferon have liver cancer take just sovaldi ribavirin combo be recommend week patient genotype
1827,MRK,gilead be still testing other interferon combination therapy sovaldi ribavirin ledipasvir have notch cure rate patient group
1828,MRK,be hope sovaldi mark begin new era hepatitis treatment ceo john martin say statement
1829,MRK,gilead price sovaldi week expect week regimen cost estimate note isi group analyst mark schoenebaum
1830,MRK,sale estimate keep rise drug keep produce good trial result have hepatitis many don know re infected virus subsist decade symptom advanced case cause serious liver damage federal official have urge more american notably baby boomer get test
1831,MRK,abbvie abbv have oral hepatitis therapy late stage test launch see bristol myer bmy merck mrk johnson johnson jnj also have oral regimen pipeline food drug administration gilead science gild hepatitis pill sovaldi late friday expect still key step drug widely see mega blockbuster analyst foresee very rapid uptake sovaldi sale next year make world best selling drug gilead share edge higher late friday close drug end complicate label different regimen different patient group upshot be first time be treat inject pegylate interferon current standard treatment cause flu symptom fda still recommend take interferon sovaldi oral drug ribavirin week patient disease genotype type be most common patient ineligible interferon have liver cancer take just sovaldi ribavirin combo be recommend week patient genotype gilead be still testing other interferon combination therapy sovaldi ribavirin ledipasvir have notch cure rate patient group be hope sovaldi mark begin new era hepatitis treatment ceo john martin say statement gilead price sovaldi week expect week regimen cost estimate note isi group analyst mark schoenebaum sale estimate keep rise drug keep produce good trial result have hepatitis many don know re infected virus subsist decade symptom advanced case cause serious liver damage federal official have urge more american notably baby boomer get test abbvie abbv have oral hepatitis therapy late stage test launch see bristol myer bmy merck mrk johnson johnson jnj also have oral regimen pipeline
1832,MRK,big pharma merck mrk friday start suspend availability cholesterol drug tredaptive clinical trial report adverse event tredaptive be form niacin vitamin chemically modify reduce side effect normally associate take high dose niacin be approve europe same time reject
1833,MRK,drugmaker akorn akrx acquire right eye drop brand merck mrk division inspire pharmaceutical friday send akorn stock new high midday trading market akorn paid variant glaucoma treatment cosopt bacterial conjunctivitis move add akorn strategy become top player ophthalmology
1834,MRK,mutual fund investor score third straight month gain november stock scale epic high average diversify stock mutual fund return month be year date accord lipper inc back expectation continue monetary stimulus federal reserve stock market climb proverbial wall
1835,MRK,ibd revamp income investor column several month back introduce screen aim successful dividend investing be backbone column most company cover daily column today page be select screen screen seek stock solid grow dividend extremely stable annual earning other characteristic need maintain regular flow dividend relatively few stock make stringent list don look fast earning growth superb share price performance feature dividend return take precedent income investor here guide screen make best use screen broadest screen be dividend leader america best recognize company have be appear list thank history dependable dividend merck mrk microsoft msft home depot hd recently show screen utility leader second screen follow basically same selection criterium traditionally utility have be haven income focuse investor company tend have little growth steady reliable revenue stream make ideal dividend provider steady nature also give utility relative safety general market fall hard time growth stock be get trample reit leader look traditional fort income investor real estate investment trust be company create law let avoid pay corporate taxe long pass profit shareholder use dividend pass profit make reit surest bet income portfolio utility many reit have steady revenue stream example own specialize building medical technology company obtain regular lease proceed own apartment complex secure wealth rent payment slow economic condition hurt business tend be less volatile most other business datum column list most important be annualize dividend yield dividend growth rate study number compare investor gauge company research further use weekly chart story page learn fundamental technical detail
1836,MRK,gilead science gild hepatitis drug sofosbuvir win european advisory panel vote earlier wall street expect friday send stock more time high stock market today eu committee medicinal product human use chmp recommend approve sofosbuvir now brand sovaldi follow accelerate review procedure drug
1837,MRK,software maker veeva system veev get lot attention last month go public bolt gate stock more double ipo price few day
1838,MRK,now share have settle back early high excitement often surround ipo have subside investor focus firm product financial performance growth prospect nearly friday veeva trade open first day market
1839,MRK,tech company have lot go analyst say
1840,MRK,veeva provide cloud base software solution professional service life science industry software be design help drugmaker other kind customer improve sale marketing effort also operate more efficiently
1841,MRK,information manager
1842,MRK,veeva lineup include veeva crm customer relationship management solution let pharmaceutical sale rep account manager other manage track optimize interaction health care provider
1843,MRK,company also offer veeva vault cloud base content management collaboration solution help customer manage process such clinical trial quality management manufacturing sale marketing
1844,MRK,product veeva network be cloud base solution design help life science firm create maintain record health care professional organization interact
1845,MRK,cloud base solution customer operate more cheaply efficiently have run software house hardware system
1846,MRK,veeva cloud base application increase productivity compliance sale marketing personnel have be successful replace legacy premise solution life science industry deutsche bank analyst nandan amladi note report initiate coverage veeva
1847,MRK,kind solution be especially important life science industry have grow increasingly complex regulate
1848,MRK,recent interview ibd veeva ceo peter gassner say life science company have tremendous amount business process nature industry
1849,MRK,be deal human life government regulation so be perfect industry cloud software gassner say be stick legacy client server system be not able keep regulatory competitive environment change
1850,MRK,veeva have life science customer include lead drugmaker such merck mrk eli lilly lly gilead science gild bayer healthcare
1851,MRK,veeva revenue come north america come europe remain asia pacific
1852,MRK,demand veeva software be reflect company rapid financial growth annual revenue have more triple past year
1853,MRK,veeva be founder be also solidly profitable logged net income nearly first month current fiscal year
1854,MRK,analyst amladi reckon veeva have penetration core crm market less penetration broader market content management datum management product estimate total addressable market be year
1855,MRK,veeva industry cloud model enable deeper specialization achieve greater market share more time amladi note
1856,MRK,most veeva competition come privately hold firm such advanced health medium service stayinfront rival cegedim relationship management be publicly trade europe
1857,MRK,report earlier month initiate coverage veeva canaccord genuity analyst richard davis say veeva have almost venture capital backed competition
1858,MRK,combination cloud technology demand product strong financial growth limit competition high profile client help explain veeva stock price rise so rapidly first day trading oct
1859,MRK,ipo pricing share come expect range veeva raise sale share bank involved ipo include morgan stanley ms deutsche bank db well fargo wfc stifel nicolaus pacific crest security canaccord genuity
1860,MRK,stock market buzz
1861,MRK,veeva share close first day trading rumble higher next few day peak oct
1862,MRK,ipo generate level anticipation typically re-serve high profile name such twitter twtr splunk splk tableau datum workday wday say tom roderick analyst stifel nicolaus think enthusiasm be be warrant
1863,MRK,early volatility many analyst remain bullish veeva
1864,MRK,early cycle disruptive technology stock almost always work davis note add quite conservative estimate almost vc backed segment competition world class reference customer state art cloud technology don see many thing shake investor faith veeva
1865,MRK,veeva be schedule report result fiscal third quarter dec analyst expect earning cent share consensus analyst poll thomson reuter see revenue come year earlier full fiscal year revenue be expect rise software maker veeva system veev get lot attention last month go public bolt gate stock more double ipo price few day now share have settle back early high excitement often surround ipo have subside investor focus firm product financial performance growth prospect nearly friday veeva trade open first day market tech company have lot go analyst say veeva provide cloud base software solution professional service life science industry software be design help drugmaker other kind customer improve sale marketing effort also operate more efficiently information managerveeva lineup include veeva crm customer relationship management solution let pharmaceutical sale rep account manager other manage track optimize interaction health care provider company also offer veeva vault cloud base content management collaboration solution help customer manage process such clinical trial quality management manufacturing sale marketing product veeva network be cloud base solution design help life science firm create maintain record health care professional organization interact cloud base solution customer operate more cheaply efficiently have run software house hardware system veeva cloud base application increase productivity compliance sale marketing personnel have be successful replace legacy premise solution life science industry deutsche bank analyst nandan amladi note report initiate coverage veeva kind solution be especially important life science industry have grow increasingly complex regulate recent interview ibd veeva ceo peter gassner say life science company have tremendous amount business process nature industry be deal human life government regulation so be perfect industry cloud software gassner say be stick legacy client server system be not able keep regulatory competitive environment change veeva have life science customer include lead drugmaker such merck mrk eli lilly lly gilead science gild bayer healthcare veeva revenue come north america come europe remain asia pacific demand veeva software be reflect company rapid financial growth annual revenue have more triple past year veeva be founder be also solidly profitable logged net income nearly first month current fiscal year analyst amladi reckon veeva have penetration core crm market less penetration broader market content management datum management product estimate total addressable market be year veeva industry cloud model enable deeper specialization achieve greater market share more time amladi note most veeva competition come privately hold firm such advanced health medium service stayinfront rival cegedim relationship management be publicly trade europe report earlier month initiate coverage veeva canaccord genuity analyst richard davis say veeva have almost venture capital backed competition combination cloud technology demand product strong financial growth limit competition high profile client help explain veeva stock price rise so rapidly first day trading oct ipo pricing share come expect range veeva raise sale share bank involved ipo include morgan stanley ms deutsche bank db well fargo wfc stifel nicolaus pacific crest security canaccord genuity stock market buzzveeva share close first day trading rumble higher next few day peak oct ipo generate level anticipation typically re-serve high profile name such twitter twtr splunk splk tableau datum workday wday say tom roderick analyst stifel nicolaus think enthusiasm be be warrant early volatility many analyst remain bullish veeva early cycle disruptive technology stock almost always work davis note add quite conservative estimate almost vc backed segment competition world class reference customer state art cloud technology don see many thing shake investor faith veeva veeva be schedule report result fiscal third quarter dec analyst expect earning cent share consensus analyst poll thomson reuter see revenue come year earlier full fiscal year revenue be expect rise
1866,MRK,swiss giant pharma novartis nvs monday announce agree sell blood transfusion diagnostic unit spain grifol grfs send stock stock market grifol say deal complement core plasma business diagnostic technology also strengthen business production plant emeryville calif novartis
1867,MRK,sometimes best be save last earning season be wind leader qihoo technology qihu akorn akrx be tap be joined fellow ibd company wuxi pharmatech wx gentherm thrm be slate report earning come week ibd list company base superior earning strong price
1868,MRK,share merck mrk gap more year high early thursday big pharma say be submit bone drug approval early due good trial result
1869,MRK,late wednesday merck announce interim analysis phase trial osteoporosis candidate odanacatib show such good efficacy recommend study be close early not release exact detail yet more info become available submit drug approval europe japan first half next year
1870,MRK,news bring upgrade citi more double sale estimate drug analyst see potentially huge market good osteoporosis drug current standard treatment bisphosponate have safety issue quarter eligible patient tolerate
1871,MRK,related med stock react obamacare ruling share merck mrk gap more year high early thursday big pharma say be submit bone drug approval early due good trial result late wednesday merck announce interim analysis phase trial osteoporosis candidate odanacatib show such good efficacy recommend study be close early not release exact detail yet more info become available submit drug approval europe japan first half next year news bring upgrade citi more double sale estimate drug analyst see potentially huge market good osteoporosis drug current standard treatment bisphosponate have safety issue quarter eligible patient tolerate related med stock react obamacare ruling
1872,MRK,big pharma merck mrk miss first quarter sale expectation friday come slightly ahead profit affirm previous guidance revenue totale year analyst consensus be profit exclude certain item be cent share last year beating view penny company say
1873,MRK,big pharmas merck mrk pfizer pfe report basically line earning early tuesday have develop story pique investor interest merck revenue drop year earlier quarter slightly analyst consensus profit cent share beat estimate cent still earning fall last
1874,MRK,george merck passionately believe put customer first money follow case merck co mrk keep need ultimate shopper patient paramount produce financial windfall become president company have sale step be
1875,MRK,big pharmas merck mrk pfizer pfe report basically line earning early tuesday have develop story pique investor interest merck revenue drop year earlier quarter slightly analyst consensus profit cent share beat estimate cent still earning fall last
1876,MRK,george merck passionately believe put customer first money follow case merck co mrk keep need ultimate shopper patient paramount produce financial windfall become president company have sale step be
1877,MRK,pharmaceutical giant merck co mrk issue first quarter profit outlook wall street estimate follow trend set low guidance only beat drugmaker expect profit cent share analyst estimate merck also say unfavorable foreign currency exchange rate lower revenue quarter share be
1878,MRK,pharmaceutical giant merck co mrk issue first quarter profit outlook wall street estimate follow trend set low guidance only beat drugmaker expect profit cent share analyst estimate merck also say unfavorable foreign currency exchange rate lower revenue quarter share be
1879,MRK,major index gain ground pre market action thursday better expect datum initial jobless claim durable good order
1880,MRK,still nasdaq dow future continue trade lower ahead open bell
1881,MRK,labor department say weekly unemployment claim fall seasonally adjust last week result be slightly better estimate initial jobless claim
1882,MRK,meanwhile durable good order exclude auto transportation sank be smaller decline pullback project economist
1883,MRK,wednesday federal reserve policy statement weigh stock future earlier fed issue cautious tone pace economic recovery
1884,MRK,elsewhere merck mrk world second biggest drugmaker say expand business south africa partnership drugmaker adcock ingram major index gain ground pre market action thursday better expect datum initial jobless claim durable good order still nasdaq dow future continue trade lower ahead open bell labor department say weekly unemployment claim fall seasonally adjust last week result be slightly better estimate initial jobless claim meanwhile durable good order exclude auto transportation sank be smaller decline pullback project economist wednesday federal reserve policy statement weigh stock future earlier fed issue cautious tone pace economic recovery elsewhere merck mrk world second biggest drugmaker say expand business south africa partnership drugmaker adcock ingram
1885,MRK,veeva system veev stock pop ipo debut wednesday cloud software maker veeva stock be more midday trading stock market pricing late tuesday share expect range range have be raise earlier expectation veeva be several ipos year
1886,MRK,big biotech gilead science gild hit month high monday analyst deliver bullish outlook company sunday rbc capital market analyst michael yee lift ep estimate due stock buyback note several recent piece incremental good news cite late friday successful patent suit merck mrk ionis
1887,MRK,share biotech medivation mdvn tumble tuesday day congress attack pricing lead drug company hire new cfo late monday press picked letter representative senator include democratic presidential candidate bernard sander head national institutes health nih urge agency exercise march right lower price medivation prostate cancer drug xtandi bayh dole act give federal agency include nih authority license patent action be necessary alleviate health safety need be not reasonably satisfied invention be not available public reasonable term letter note price be clear barrier access consumer law be place year nih have never used broad powerful authority protect consumer excessive prescription drug price letter go say xtandi be sell medivation partner astella cost less third japan sweden canada letter urge nih hold public hearing xtandi pricing similar hearing lead abbott laboratory lower price aids drug norvir medicaid aids drug assistance program say nih do not actually use march authority however send letter advocate explain thought such move be inappropriate ub analyst matthew roden point only minority xtandi prescription be cover medicaid worst case dual eligible medicare medicaid be impact roden estimate xtandi sale be paid medicare perhaps be dual eligible letter represent latest salvo politician recent war high drug price something change focus recent attack valeant pharmaceutical vrx turing pharmaceutical focuse steep price increase old neglected generic drug xtandi be innovative product just launch price be not exceptionally high new cancer drug instance bristol myer squibb bmy opdivo merck mrk similar drug keytruda launch late be go year meanwhile medivation also say late monday have hire citigroup manager jennifer jarrett new cfo replace rick bierly retire july analyst roden write jarrett bring buyout expertise company turn dampen speculation medivation be buy morning trading stock market today medivation stock be growth xtandi have give company healthy ibd ep rank stock have be recover hit year low feb have weak relative strength rating just so stock have perform lowest stock past month
1888,MRK,drug stock take beating tuesday major average finished mixed again ahead fed monetary policy announcement wednesday dow jone industrial average eke gain nasdaq give respectively volume run higher nasdaq exchange bit lighter nyse vs monday accord preliminary number economic front february retail sale dip line view january datum be revise initial report gain drug stock get hurt stock market today valeant pharmaceutical vrx ibd lead downside stock plunge multiyear low canada base drugmaker report revenue top view earning miss valeant also slash ep revenue guidance other drugmaker endo international endp sank mallinckrodt mnk horizon pharma hznp pfizer pfe merck mrk underperform dow respective loss apple aapl outpeformed blue chip gapping rise volume apple be lighter usual share be december low april peak morgan stanley have overweight rating price target say note apple iphone demand be tracking ahead expectation apple be expect unveil new inch smartphone new apple watch band spring product launch event monday automaker food stock buck downtrend tesla tlsa add extend advance third straight session electric car maker stock have rev feb intraday low be now day line ibd ligand pharmaceutical lgnd shed slow turnover close converge day day line tal education group xrs lead upside gain economic datum slate wednesday include consumer price index housing start industrial production february fed policy statement be release et follow shortly thereafter fed chief janet yellen press conference
1889,MRK,share diabetes giant nordisk nvo jump friday company say drug victoza reduce heart attack stroke release few detail result study save next american diabetes association meeting june however do say be statistically significant reduction metric heart attack stroke death cardiovascular cause patient take diabetes drug year compare placebo group subject be age have cardiovascular disease multiple risk factor nordisk stock be afternoon trading stock market today highest rate stock low rate medical ethical drug group composite rating effect diabetes drug cardiovascular health have be subject several study lately notably eli lilly lly drug jardiance reduce death heart failure similar large long term study report last september other hand merck mrk januvia show effect good bad outcome trial report few month earlier similarly neutral result be report outcome trial sanofi sny drug lixisenatide be noteworthy lixisenatide be same class victoza be glucagon peptide glp analog similar bydureon astrazeneca azn lilly trulicity jardiance be sglt inhibitor same class invokana johnson johnson jnj farxiga astrazeneca merck januvia belong class call dpp inhibitor conference call analyst friday chief scientific officer mad thomsen say different result have come subtle difference drug think extend victoza plan successor semaglutide not only question be member give class glp agonist say thomsen also part kinetic dynamic distribution half life so get semaglutide have do rather detailed investigation be nothing animal pharmacology negate notion semaglutide do least well cardiovascular performance
1890,MRK,stock do not leap monday do convert thin open loss narrowly mixed trade start leap year trading session nasdaq reversed early loss be bit less dow show decline stock market today open february last trading session nasdaq re-cover sharply feb low still be third straight monthly decline open higher also re-cover sell early month economic news start sour note chicago purchasing manager index kingsbury international drop february be sharply january strong read well consensus expectation slip pending home sale drop full january accord national association realtor economist consensus have project slowdown growth dow jone industrial average stock open generally lower quickly begin trimming decline apple aapl exxon mobil xom chevron cvx pull ahead gain apiece merck mrk stake low ground signet jeweler sig rocked advance boost ep guidance well consensus view increase expectation synergy acquisition less jewelry retailer acquire competitor zale gain put signet share poise test resistance week move average stock have be consolidate october endo international endp tumble lower irish base drugmaker earning beat expectation revenue meet analyst consensus view however management full year revenue guidance be well forecast stock have be deepen consolidation april ibd list wesson swhc power heavy trade firearm maker be scaling right side deep cup base buy point pump maker graco ggg nose almost strong trade be enough move stock buy range buy point left just last week high ibd list stock be screen accord broad range factor fundamental technical strength
1891,MRK,investor seek high octane growth stock potential big fast gain other prefer slower steadier company offer dividend be hold longer term income investor column be almost tailor make slow steady crowd almost fast growth company be also featured column time time day income investor today ibd page highlight more company not only pay steady dividend also meet key fundamental technical criterium accompany dividend utility reit leader screen next column ibd offer plenty idea minichart list provide detail stock dividend leader broadest screen show name such merck mrk philip morris pm make screen lately thank steady earning track record dependable dividend other younger tech stock recently list include cisco system csco microchip technology mchp utility leader be often consider defensive play broader market be ailing growth stock be get hit utility tend hold well income investor also count steady dividend due utility reliable revenue stream utility have top ibd ranking industry group recent market volatility reit leader last screen also offer relative safe haven rocky market real estate investment trust be set such way avoid pay corporate taxe pass majority profit shareholder do so form dividend be many income investor also reit slow economy hurt business well reit also have fairly steady revenue stream collect rent payment lease proceed building other real asset own operate due tax structure pay most profit form cash dividend keep mind even utility reit stock sink rapidly stock market go deep decline exactly happened bear decline july march dow utility average fall so severe situation loss stock be cut short cash be raise screen provide annualize dividend yield long term dividend growth rate company last column list investor decide one research further most stock win look typical high growth company be set usually better be buy hold long term trend be have outperformed market recently telecom giant have rally year edge higher dow jone industrial average be slightly underwater last year year dividend aristocrat top dividend leader list yield well average payout
1892,MRK,share biotech intercept pharmaceutical icpt spiked early afternoon trading friday report company be explore sale reuter cite anonymous source report intercept have be work investment banker week receive interest other company reuter do not name suitor intercept have be perpetual source
1893,MRK,cybersecurity company palo alto network panw enjoy multiple price target hike early tuesday coverage be initiate networking giant cisco system csco buy rating gamestop gme be downgrade report disappointing quarter fbr capital stifel raise palo alto network price target follow strong quarterly report late monday suntrust robinson
1894,MRK,health care etfs pump big gain tuesday slew solid drugmaker earning technology focuse peer lag get boost tomorrow apple aapl stock advanced close better expect earning revenue sluggish day stock health etfs rise strong report pfizer pfe merck mrk bristol myer squibb bmy new york base pfizer gap earning beat new jersey peer merck rise more report profit jump latest quarter boost annual outlook medical equipment company edward lifescience ew grab gain beat top bottom line spdr health care xlv etf tracking sector rise stock market today spdr etf peer carve sector post loss tuesday energy stock lead decline xlv largest broad base health care etf allocate roughly asset combination stock pfizer merck bristol myer etf hold stock gilead science gild xlv third largest stock hold fall hour report robust profit raise full year outlook biotech giant have be rally straight week powershare dynamic pharmaceutical pjp pop drugmaker advanced etf hold stock allocate asset bristol myer pfizer merck pjp be top perform pharmaceutical etf year date rise vs xlv meanwhile alibaba baba leap china internet giant easily clear analyst expectation fiscal earning revenue mobile revenue surge gain fail give much boost etfs big stake stock kraneshare csi china internet kweb renaissance ipo ipo eke fractional gain tuesday alibaba be hold kweb asset hold ipo asset etfs hold safe haven asset such bond gold climb marginally tuesday listless stock market here look benchmark exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing bellwether etfs spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs ishare core aggregate bond agg rs powershare db dollar bullish uup rs follow aparna narayanan twitter ibd_anarayanan
1895,MRK,batter drug industry get blast good news tuesday morning big pharmas sizable biotech beat wall street expectation send stock
1896,MRK,unite therapeutic uthr be midday trading stock market today report revenue year earlier quarter beating analyst consensus more accord thomson reuter earning exclude time item rise share penny consensus usual do not provide guidance
1897,MRK,unite therapeutic have be lose investor confidence even recent drug stock sell recent launch drug orenitram oral version blockbuster lung drug remodulin initially go slower wall street have expect however orenitram sale rise beating consensus unite therapeutic other market drug beat consensus well unituxin new treatment rare childhood cancer call neuroblastoma come line expectation sale
1898,MRK,pfizer ep
1899,MRK,pharma giant pfizer pfe be midday tuesday report earning exclude time item cent share year earlier quarter beating consensus cent revenue shrank beat view
1900,MRK,pfizer add full year revenue guidance now vs last year ep guidance range be now dime previous guidance few cent last year number be current analyst consensus
1901,MRK,result include day business hospira generic drugmaker pfizer acquire bring revenue pfizer also note earning release exclude foreign exchange impact revenue rise company credit pneumonia vaccine prevnar be recently approve adult be enjoy increase demand preparation upcoming flu season accord press release ibrance breast cancer drug launch february take beating consensus
1902,MRK,good expense management also help quarterly performance slightly higher tax rate negatively impact net income write credit suisse analyst vamil divan research note add pfizer also beat expectation operate margin
1903,MRK,bristol lead pd battle
1904,MRK,bristol myer squibb bmy report earning cent share cent wall street average estimate revenue rise consensus exclude foreign exchange impact sale rise
1905,MRK,bristol myer add cent full year ep guidance range now be consensus flat modestly last year expect full year sale high side consensus slightly
1906,MRK,pd inhibitor opdivo launch melanoma late last year have be pick lung cancer indication then handily beat consensus sale bristol myer hepatitis franchise be overshadowed bigger drug gilead science gild abbvie abbv also trounce consensus sale
1907,MRK,big miss be yervoy ex vs consensus see last quarter appear consistent lumpiness bristol myer have say expect launch pd antibody write evercore isi analyst mark schoenebaum email client
1908,MRK,bristol myer stock be midday tuesday
1909,MRK,merck sale line
1910,MRK,bristol myer chief competitor pd business be merck mrk also report solid early tuesday merck earning rise year earlier quarter cent share exclude time item beating consensus cent revenue fall line estimate exclude forex impact sale rise
1911,MRK,merck raise lower end full year revenue guidance now last year also raise ep guidance beating wall street represent growth few percentage point last year
1912,MRK,merck compete drug opdivo keytruda totale capital iq analyst jeffrey loo write be lower expect see sale accelerate be approve additional indication next several year merck biggest selling drug januvia have also be competitive pressure lately rise modestly beating expectation
1913,MRK,merck stock be more midday trading
1914,MRK,follow amy reeve twitter ibd_areeve facebook batter drug industry get blast good news tuesday morning big pharmas sizable biotech beat wall street expectation send stock unite therapeutic uthr be midday trading stock market today report revenue year earlier quarter beating analyst consensus more accord thomson reuter earning exclude time item rise share penny consensus usual do not provide guidance unite therapeutic have be lose investor confidence even recent drug stock sell recent launch drug orenitram oral version blockbuster lung drug remodulin initially go slower wall street have expect however orenitram sale rise beating consensus unite therapeutic other market drug beat consensus well unituxin new treatment rare childhood cancer call neuroblastoma come line expectation sale pfizer ep pharma giant pfizer pfe be midday tuesday report earning exclude time item cent share year earlier quarter beating consensus cent revenue shrank beat view pfizer add full year revenue guidance now vs last year ep guidance range be now dime previous guidance few cent last year number be current analyst consensus result include day business hospira generic drugmaker pfizer acquire bring revenue pfizer also note earning release exclude foreign exchange impact revenue rise company credit pneumonia vaccine prevnar be recently approve adult be enjoy increase demand preparation upcoming flu season accord press release ibrance breast cancer drug launch february take beating consensus good expense management also help quarterly performance slightly higher tax rate negatively impact net income write credit suisse analyst vamil divan research note add pfizer also beat expectation operate margin bristol lead pd battlebristol myer squibb bmy report earning cent share cent wall street average estimate revenue rise consensus exclude foreign exchange impact sale rise bristol myer add cent full year ep guidance range now be consensus flat modestly last year expect full year sale high side consensus slightly pd inhibitor opdivo launch melanoma late last year have be pick lung cancer indication then handily beat consensus sale bristol myer hepatitis franchise be overshadowed bigger drug gilead science gild abbvie abbv also trounce consensus sale big miss be yervoy ex vs consensus see last quarter appear consistent lumpiness bristol myer have say expect launch pd antibody write evercore isi analyst mark schoenebaum email client bristol myer stock be midday tuesday merck sale linebristol myer chief competitor pd business be merck mrk also report solid early tuesday merck earning rise year earlier quarter cent share exclude time item beating consensus cent revenue fall line estimate exclude forex impact sale rise merck raise lower end full year revenue guidance now last year also raise ep guidance beating wall street represent growth few percentage point last year merck compete drug opdivo keytruda totale capital iq analyst jeffrey loo write be lower expect see sale accelerate be approve additional indication next several year merck biggest selling drug januvia have also be competitive pressure lately rise modestly beating expectation merck stock be more midday trading follow amy reeve twitter ibd_areeve facebook
1915,MRK,stock take moderate loss early action tuesday wave mixed earning report weak economic news drop dow jone industrial average nasdaq backed apiece
1916,MRK,volume be sharply mixed rise nyse fall nasdaq relative trade same time monday
1917,MRK,stock market today feel early drag commerce department weaker expect september durable good report
1918,MRK,case shiller city composite home price index be bit more positive rise august be slip july line expectation
1919,MRK,preliminary read october service sector activity researcher markit put purchasing manager index september disappointing forecast
1920,MRK,consumer sentiment also pull back october conference board consumer confidence index read vs revise tally september far estimate
1921,MRK,stock alibaba group baba broad jump join rank big tech name post solid earning beat china base diversify internet play report ep gain rise revenue fiscal easily top consensus forecast mobile revenue rise cloud compute internet infrastructure revenue rise
1922,MRK,company also announce security exchange commission give notice conclude inquiry enforcement action be recommend issue revolve interaction regulator china
1923,MRK,alibaba heavy volume gain send share back day move average month consolidation
1924,MRK,yahoo yhoo pop pull stake alibaba
1925,MRK,coach coh bag gain sneak past analyst consensus earning expectation meeting revenue forecast
1926,MRK,edward lifescience ew jump more top revenue earning expectation third quarter stock remain just buy point cup handle base
1927,MRK,pfizer pfe grab gain lead dow new york base drugmaker report earning gain vs expectation loss revenue fall less expect strong volume gain send share past buy point cup handle base pfizer peer merck mrk rank second dow gain nearly strong third quarter report
1928,MRK,coal miner consol energy cnx tank report adjust loss cent share vs expectation cent loss
1929,MRK,leader cadence design system cdns rise step early lead ibd stock developer automate circuit design software report earning revenue forecast give full year guidance consensus view gain massive trade trigger break past buy point cup handle base
1930,MRK,cal maine food calm take group largest loss almost send stock week move average heavy trade buy point trigger sell signal stock take moderate loss early action tuesday wave mixed earning report weak economic news drop dow jone industrial average nasdaq backed apiece volume be sharply mixed rise nyse fall nasdaq relative trade same time monday stock market today feel early drag commerce department weaker expect september durable good report case shiller city composite home price index be bit more positive rise august be slip july line expectation preliminary read october service sector activity researcher markit put purchasing manager index september disappointing forecast consumer sentiment also pull back october conference board consumer confidence index read vs revise tally september far estimate stock alibaba group baba broad jump join rank big tech name post solid earning beat china base diversify internet play report ep gain rise revenue fiscal easily top consensus forecast mobile revenue rise cloud compute internet infrastructure revenue rise company also announce security exchange commission give notice conclude inquiry enforcement action be recommend issue revolve interaction regulator china alibaba heavy volume gain send share back day move average month consolidation yahoo yhoo pop pull stake alibaba coach coh bag gain sneak past analyst consensus earning expectation meeting revenue forecast edward lifescience ew jump more top revenue earning expectation third quarter stock remain just buy point cup handle base pfizer pfe grab gain lead dow new york base drugmaker report earning gain vs expectation loss revenue fall less expect strong volume gain send share past buy point cup handle base pfizer peer merck mrk rank second dow gain nearly strong third quarter report coal miner consol energy cnx tank report adjust loss cent share vs expectation cent loss leader cadence design system cdns rise step early lead ibd stock developer automate circuit design software report earning revenue forecast give full year guidance consensus view gain massive trade trigger break past buy point cup handle base cal maine food calm take group largest loss almost send stock week move average heavy trade buy point trigger sell signal
1931,MRK,big pharma eli lilly lly beat earning expectation raise ep guidance early thursday company ceo defend industry drug pricing lilly revenue be more mixed bag firm continue struggle foreign exchange headwind stock be flat lilly lly make cent share exclude time item
1932,MRK,early investor facebook fb continue sell share social medium leader past week stock peaked apple aapl chief sell chunk iphone maker stock slump facebook director marc andreessen co founder venture capital firm andreessen horowitz disclose sale share nov nov total value oct nov andreessen sell nearly half holding facebook total value roughly prearrange plan transaction come facebook stock have hit series fresh time high lately early month facebook report earning revenue beat estimate strong growth mobile monthly active user facebook stock hit close high wednesday retreat afterward week share close nearly stock market trading apple ceo tim cook also continue sell share cook file monday sale share total cook nov disclose filing have sell share total value nov credit suisse say apple be cut order iphone supplier flagging demand asia new chinese datum also raise concern economic growth world largest consumer market credit suisse say still bullish apple share drop week gilead science gild president john milligan nov sell share value gilead chairman ceo john martin have be regular seller biotech share sell share earlier month gilead share share other drug stock have be pressure lately scrutiny pricing sale practice gilead have hold better many peer share decline skywork solution swks chairman ceo dave aldrich sell share nov nov however cfo donald palette buy share period share skywork apple chip supplier have come earth drop time high june week skywork slide first solar fslr ceo james hughe sell share nov cfo mark widmar sell share date earlier week first solar crushed third quarter estimate earning shot revenue spiked solar sector be slam weak sunedison sune result worry profitability solar yieldcos first solar share lose week illumina ilmn ceo jay flatley sell share nov gene sequence equipment giant have be upswing sync rise medical research equipment service group general illumina replace specialty chemical maker sigma aldrich index nov now merck mrk have buy sigma aldrich illumina share rise week constellation brand stz ceo robert sand sell share nov nov brother constellation chairman richard sand sell share period share rise less insider transaction don typically have major impact stock indicate major pending news rapid liquidation most insider holding however affect stock follow james detar twitter ibd_jdetar facebook
1933,MRK,big biotech gilead science gild get price target increase tuesday big pharma merck mrk release new datum hepatitis regimen be rival gilead blockbuster franchise oppenheimer analyst wendy lam lift price target gilead writing stock considerable sell june high investor be due revisit gilead strong fundamental acknowledge investor be nervous launch merck grazoprevir elbasvir doublet therapy hepatitis result price war similar abbvie abbv release own rival therapy late last year maintain positive outlook hep franchise term expect continue growth patient volume payer continue lift restriction treatment lam write research note tuesday merck threat believe merck entry be less disruptive thought suspect merck be less incentivize abbvie instigate pricing war expect gilead defend share aggressively already have be maintain vast majority payer contract merck testing hepatitis drug combomerck meanwhile be testing next generation combo doublet mk drug same class gilead blockbuster sovaldi tuesday american association study liver disease aasld release late breaking abstract presentation next month annual liver meeting show triple therapy have achieve cure rate genotype hepatitis virus week treatment similarly high rate genotype week treatment gilead harvoni be approve only genotype sovaldi be also approve type lower rate success typically longer treatment duration week however last month gilead announce new drug combo have succeed treat genotype so field remain hotly competitive datum abstract efficacy datum week triple combo therapy gt gt lesser extent gt appear encourage potentially feasible await further detail include baseline patient characteristic actual presentation evercore isi analyst mark schoenebaum write email client neither stock be help much news early afternoon stock market today gilead stock be nearly merck stock be similar amount follow amy reeve twitter ibd_areeve facebook
1934,MRK,fda approve bristol myer squibb bmy drug opdivo squamous lung cancer friday afternoon almost month ahead deadline boost bristol myer stock opdivo have already be approve melanoma squamous cell lung cancer represent minority lung cancer patient fda have jan decide allow patient
1935,MRK,big biotech gilead science handily beat analyst estimate raise full year guidance tuesday afternoon lead sale blockbuster hepatitis drug
1936,MRK,earning exclude time item rise year earlier quarter share beating analyst consensus cent accord thomson reuter revenue climb street number
1937,MRK,gilead gild duly add guidance product sale now do not forecast ep do trim guidance sg expense well tax rate evercore isi analyst mark schoenebaum calculate imply full year ep guidance number be more dollar earlier guidance line consensus
1938,MRK,share rise hour
1939,MRK,sale gilead hepatitis virus hcv drug harvoni sovaldi beat analyst consensus accord evercore isi harvoni pull even just launch october together make more half revenue
1940,MRK,prescription downtrend
1941,MRK,legacy hiv franchise also do better time drug board miss consensus due new competition glaxosmithkline gsk time beat expectation atripla come bit light
1942,MRK,monday rbc capital market analyst michael yee write investor be look closely gilead report get overall sense hcv market be relevant rival such abbvie abbv bristol myer squibb bmy expect future player such merck mrk achillion pharmaceutical achn
1943,MRK,other analyst have be able track prescription datum sovaldi harvoni im health im tracking service
1944,MRK,weekly trx total prescription have be decline hit impressive peak march yee write research note time gilead commentary call be total treat patient usa be high possible april july trx have be decline peak weekly july
1945,MRK,still early day market
1946,MRK,conference call analyst tuesday paul carter gilead head commercial operation acknowledge prescription do decline march peak however say believe market be still early day many patient have be restrict payer get hcv drug due high price run day
1947,MRK,carter say believe restriction loosen real world benefit drug become apparent fact be cure week rather standard week course further lower cost
1948,MRK,gilead be also promote effort increase awareness diagnosis hcv many victim be infected year symptom appear big biotech gilead science handily beat analyst estimate raise full year guidance tuesday afternoon lead sale blockbuster hepatitis drug earning exclude time item rise year earlier quarter share beating analyst consensus cent accord thomson reuter revenue climb street number gilead gild duly add guidance product sale now do not forecast ep do trim guidance sg expense well tax rate evercore isi analyst mark schoenebaum calculate imply full year ep guidance number be more dollar earlier guidance line consensus share rise hour sale gilead hepatitis virus hcv drug harvoni sovaldi beat analyst consensus accord evercore isi harvoni pull even just launch october together make more half revenue prescription legacy hiv franchise also do better time drug board miss consensus due new competition glaxosmithkline gsk time beat expectation atripla come bit light monday rbc capital market analyst michael yee write investor be look closely gilead report get overall sense hcv market be relevant rival such abbvie abbv bristol myer squibb bmy expect future player such merck mrk achillion pharmaceutical achn other analyst have be able track prescription datum sovaldi harvoni im health im tracking service weekly trx total prescription have be decline hit impressive peak march yee write research note time gilead commentary call be total treat patient usa be high possible april july trx have be decline peak weekly july still early day marketon conference call analyst tuesday paul carter gilead head commercial operation acknowledge prescription do decline march peak however say believe market be still early day many patient have be restrict payer get hcv drug due high price run day carter say believe restriction loosen real world benefit drug become apparent fact be cure week rather standard week course further lower cost gilead be also promote effort increase awareness diagnosis hcv many victim be infected year symptom appear
1949,MRK,stock rolled early gain wednesday china stock show strength oil price ease day rally
1950,MRK,nasdaq lead advance dow jone industrial average pop show gain volume be narrowly mixed nyse lower nasdaq compare trade same time tuesday
1951,MRK,stock market today be watch afternoon release minute federal open market committee march meeting seek sign pending action delay interest rate increase
1952,MRK,crude oil price dig bit deeper benchmark west texas intermediate more still hold barrel price come pressure late tuesday american petroleum institute estimate larger expect build weekly oil inventory energy information administration release weekly storage datum et
1953,MRK,stock mcdonald mcd merck mrk lead dow rise more
1954,MRK,china base stock be pound significant early gain buoy wednesday rally hong kong stock exchange yanzhou coal mining yzc spiked aluminum corp china leap
1955,MRK,noah holding noah pop punch seventh straight advance take new high move also break stock past buy point sloppy month base
1956,MRK,netflix nflx rise nearly very strong trade provider online movie rental original content gain prior session climb back day move average stock be mid february high
1957,MRK,lead stock open upsweep more ibd stock advance start trade
1958,MRK,mylan myl lead group rise more canonsburg pa base drugmaker be work fourth straight advance rebound test week support wednesday move lift share buy point flat base stock rolled early gain wednesday china stock show strength oil price ease day rally nasdaq lead advance dow jone industrial average pop show gain volume be narrowly mixed nyse lower nasdaq compare trade same time tuesday stock market today be watch afternoon release minute federal open market committee march meeting seek sign pending action delay interest rate increase crude oil price dig bit deeper benchmark west texas intermediate more still hold barrel price come pressure late tuesday american petroleum institute estimate larger expect build weekly oil inventory energy information administration release weekly storage datum et stock mcdonald mcd merck mrk lead dow rise more china base stock be pound significant early gain buoy wednesday rally hong kong stock exchange yanzhou coal mining yzc spiked aluminum corp china leap noah holding noah pop punch seventh straight advance take new high move also break stock past buy point sloppy month base netflix nflx rise nearly very strong trade provider online movie rental original content gain prior session climb back day move average stock be mid february high lead stock open upsweep more ibd stock advance start trade mylan myl lead group rise more canonsburg pa base drugmaker be work fourth straight advance rebound test week support wednesday move lift share buy point flat base
1959,MRK,share development stage pharmaceutical firm esperion therapeutic espr jump wednesday ub initiate coverage esperion stock buy rating praise cholesterol drug candidate analyst andrew peter write etc drug lower ldl cholesterol yielded positive phase trial result last month present further upside even stock already more double
1960,MRK,fda last month approve first biosimilar drug take first step lucrative potentially disruptive field medicine pfizer pfe be move big biosimilar hospira hsp acquisition have estimate global biosimilar sale hit year sale be just yearly now mainly european union march approval zarxio novartis nvs biosimilar version amgen amgn age blockbuster neupogen market crack open fda become more comfortable re go see biosimilar get lot more easily predict jitendra malik attorney alston bird specialize intellectual property drug approval issue first always hardest get fda be more cautious uncharted territory year biotech revolution not only bring life save new medicine also profit save protection competitor traditional pharmaceutical be assemble machine different chemical ingredient biologic drug be form biological process high tech version fermentation many process be trade secret patent have expiration date reverse engineeringas more company become familiar biotech manufacturing however be able reverse engineer process create biosimilar drug not identical original close enough novartis sandoz unit historically devote traditional generic drug have be pioneer field already selling biosimilar version neupogen sister drug epogen europe many other be line border own product hospira teva pharmaceutical teva have launch own version neupogen europe company be work biosimilar version abbvie abbv blockbuster immunology drug humira include sandoz hospira pfizer prior acquire hospira amgen german pharma giant boehringer ingelheim abbvie announce richly price acquisition pharmacyclic pcyc march analyst figured be drive need blockbuster face humira competitor key biologic face rivalsother drug biosimilar version late stage testing include biogen biib cancer drug rituxan roche rhhby breast cancer treatment herceptin johnson johnson jnj remicade merck mrk be develop biosimilar version sanofi sny popular diabetes drug lantus hospira biosimilar version remicade already have be approve europe be expect be february fda delay advisory panel meeting product due information request pending sponsor application analyst be closely watch biosimilar rollout europe remicade be approve variety ailment psoriasis inflammatory bowel disease ibd rheumatoid arthritis provide test case willing different specialist be use knockoff independent study iosimilar remicade be approve study account remicade sale write leerink analyst jason gerberry december research report specialist ve speak do not plan use remicade ibd indication clinical study report late europe biosimilar version neupogen have take market analyst generally expect same much depend drug be price generic pharmaceutical generally go fraction original drug price drive retail value so much original developer stop marketing product do keep manufacturing biosimilar be more difficult expensive develop so be fewer player less pricing competition novartis still hasn launch zarxio be keep mum price company spokeswoman geena wardaki tell investor business daily email biosimilar general typically expect discount be range reference biologic however depend therapeutic area market channel number competitor reimbursement situation cms vs fda biosimilarson tuesday center medicare medicaid service cms announce physician prescribe medicare part drug be reimburse biosimilar same way original drug average selling price pharmacy dispense part drug exclude original list prefer drug favor biosimilar wish so long provide transitional supply original patient already take imply cms be treat biosimilar effectively interchangeable original further muddy issue already unclear fda rule zarxio be used used approve neupogen boost blood cell various kind cancer patient not technically interchangeable mean doctor prescribe original drug pharmacy fill biosimilar doesn matter so much zarxio drug be administer hospital clinic rather retail pharmacy nonetheless drugmaker find worthwhile file separately approval likely involve study patient switch product say expert matter be deterrent second person come say malik show product be interchangeable doesn necessarily mean applicant road do same thing just piggybac lot case structure original drug be not perfectly know do have spend time convince person same yet question be aggressive payer pharmacy benefit manager pbms be push biosimilar ahead original drug save cost march report analyst gerberry write unnamed payer specialist have tell payer probably leave grace period month doctor get used biosimilar then start lean harder specialist expect policy grandfather stable patient receive tnf therapy remicade same reimbursement new patient new switch likely be require go prior authorization require patient use biosimilar first write gillian woollett senior vice president consult firm avalere health say issue be naming company develop new drug get generic also call nonproprietary name brand name generic name filgrastim case neupogen be used generic drugmaker patent expire name many biologic approve fda even have never be compare also share nonproprietary name be simply name active ingredient not name product biosimilar most other market share nonproprietary name reference product too first approval fda assign maker placeholder nonproprietary name case filgrastim sndz naming thing be important space watch woollett tell investor business daily think be go be brand product biosimilar most originator biologic have brand name again generic drug situation be totally different most generic do not have brand name
1961,MRK,name crop thursday sector leader first time least past few week be medical software maker veeva system veev pleasanton calif base company develop cloud base sale marketing customer relationship management software life science industry have licensing agreement salesforce com crm depend highly salesforce force com tool veeva
1962,MRK,stock hepatitis field be wednesday wake gilead science gild cautious forecast potential competitor merck hit fda setback gilead stock plunge more early trading multiple analyst cut price target wake guidance comment point high rate
1963,MRK,ibd medical biom biotech group be big gainer group be show sign let
1964,MRK,head thursday be rank group ibd database base month price performance
1965,MRK,thursday be top perform group abbvie abbv announce plan buy pharmacyclic pcyc cash stock
1966,MRK,look group be ready roll early february lose straight session find support day move average resume uptrend
1967,MRK,pharmacyclic be several biotechs have show big sale growth recent quarters blood cancer drug imbruvica be blockbuster food drug administration first approve imbruvica november treat mantle cell lymphoma drug have be approve other indication recent month
1968,MRK,stock biotech group recently have composite rating higher good bet group see more activity come month big player scoop smaller one compelling pipeline
1969,MRK,isis pharmaceutical isis isn profitable yet straight quarters accelerate sale growth solid mutual fund sponsorship market capitalization be worth note
1970,MRK,isis pipeline consist drug treat wide variety disease emphasis cardiovascular metabolic severe rare disease include neurological disorder cancer
1971,MRK,january company inked potentially lucrative licensing deal johnson johnson jnj janssen biotech unit agree pay front milestone payment develop drug autoimmune disorder tract used isis rna target platform
1972,MRK,last month isis receive milestone payment biogen idec biib isis be multiyear collaboration biogen advance treatment neurological disease
1973,MRK,isis be eighth week consolidation show buy point point thursday be only week high
1974,MRK,elsewhere group small cap newlink genetic nlnk have be busy partnership front newlink partner roche rhhby subsidiary genentech early stage cancer program newlink receive upfront payment genentech more potential milestone
1975,MRK,infectious disease newlink be work merck mrk ebola vaccine candidate
1976,MRK,newlink recently clear base buy point close time high
1977,MRK,meanwhile few large cap name group be back week move average consolidate gain include amgen amgn gilead science gild alexion alxn ibd medical biom biotech group be big gainer group be show sign let head thursday be rank group ibd database base month price performance thursday be top perform group abbvie abbv announce plan buy pharmacyclic pcyc cash stock look group be ready roll early february lose straight session find support day move average resume uptrend pharmacyclic be several biotechs have show big sale growth recent quarters blood cancer drug imbruvica be blockbuster food drug administration first approve imbruvica november treat mantle cell lymphoma drug have be approve other indication recent month stock biotech group recently have composite rating higher good bet group see more activity come month big player scoop smaller one compelling pipeline isis pharmaceutical isis isn profitable yet straight quarters accelerate sale growth solid mutual fund sponsorship market capitalization be worth note isis pipeline consist drug treat wide variety disease emphasis cardiovascular metabolic severe rare disease include neurological disorder cancer january company inked potentially lucrative licensing deal johnson johnson jnj janssen biotech unit agree pay front milestone payment develop drug autoimmune disorder tract used isis rna target platform last month isis receive milestone payment biogen idec biib isis be multiyear collaboration biogen advance treatment neurological disease isis be eighth week consolidation show buy point point thursday be only week high elsewhere group small cap newlink genetic nlnk have be busy partnership front newlink partner roche rhhby subsidiary genentech early stage cancer program newlink receive upfront payment genentech more potential milestone infectious disease newlink be work merck mrk ebola vaccine candidate newlink recently clear base buy point close time high meanwhile few large cap name group be back week move average consolidate gain include amgen amgn gilead science gild alexion alxn
1978,MRK,share bristol myer squibb bmy reach year high monday pharma giant say day earlier phase trial drug opdivo result superior overall survival lung cancer patient take result mark first time drug opdivo kind suggest survival advantage lung cancer patient company say
1979,MRK,stock show hesitation wednesday previous session strong price gain nasdaq slip dow jone industrial average ease respectively volume stock market today drop vs tuesday already average pace
1980,MRK,blue chip be mostly only handful stock dow rise tiny step downside chevron cvx carved slow turnover west texas intermediate crude oil fall chevron integrate oil company have rebound late august low remain july high
1981,MRK,integrate oil company be involved many facet business exploration production refine distribution late june crude oil begin fast price slide price oil be now explorer integrate refiner
1982,MRK,ibd list best stock fundamental technical mortgage software provider ellie mae elli take hardest hit drop more volume be average
1983,MRK,housing related stock get bad news november pending home sale drop unexpectedly
1984,MRK,however homebuilder horton dhi leaderboard stock shrug news horton be penny tepid volume stock show hesitation wednesday previous session strong price gain nasdaq slip dow jone industrial average ease respectively volume stock market today drop vs tuesday already average pace blue chip be mostly only handful stock dow rise tiny step downside chevron cvx carved slow turnover west texas intermediate crude oil fall chevron integrate oil company have rebound late august low remain july high integrate oil company be involved many facet business exploration production refine distribution late june crude oil begin fast price slide price oil be now explorer integrate refiner ibd list best stock fundamental technical mortgage software provider ellie mae elli take hardest hit drop more volume be average housing related stock get bad news november pending home sale drop unexpectedly however homebuilder horton dhi leaderboard stock shrug news horton be penny tepid volume
1985,MRK,stock show hesitation wednesday previous session strong price gain nasdaq slip dow jone industrial average ease respectively volume stock market today drop vs tuesday already average pace
1986,MRK,blue chip be mostly only handful stock dow rise tiny step downside chevron cvx carved slow turnover west texas intermediate crude oil fall chevron integrate oil company have rebound late august low remain july high
1987,MRK,integrate oil company be involved many facet business exploration production refine distribution late june crude oil begin fast price slide price oil be now explorer integrate refiner
1988,MRK,ibd list best stock fundamental technical mortgage software provider ellie mae elli take hardest hit drop more volume be average
1989,MRK,housing related stock get bad news november pending home sale drop unexpectedly
1990,MRK,however homebuilder horton dhi leaderboard stock shrug news horton be penny tepid volume stock show hesitation wednesday previous session strong price gain nasdaq slip dow jone industrial average ease respectively volume stock market today drop vs tuesday already average pace blue chip be mostly only handful stock dow rise tiny step downside chevron cvx carved slow turnover west texas intermediate crude oil fall chevron integrate oil company have rebound late august low remain july high integrate oil company be involved many facet business exploration production refine distribution late june crude oil begin fast price slide price oil be now explorer integrate refiner ibd list best stock fundamental technical mortgage software provider ellie mae elli take hardest hit drop more volume be average housing related stock get bad news november pending home sale drop unexpectedly however homebuilder horton dhi leaderboard stock shrug news horton be penny tepid volume
1991,MRK,clear buy point cup base october qualys qlys be bounce week move average
1992,MRK,rebound week line be generally used point add share investor still use setup start new position stock have retreat mostly tame volume have find support level
1993,MRK,demand gauge such stock accumulation distribution rating volume ratio remain level point strong buy fund ownership grow fourth quarter accord marketsmith year period
1994,MRK,qualys be thin issue average daily volume share daily dollar volume have double year
1995,MRK,redwood city calif base qualys provide cloud security compliance product more customer more country allergan agn best buy bby merck mrk be customer
1996,MRK,qualys be smaller company highly rank computer security software group have market cap symantec symc check point software technology chkp have market cap respectively
1997,MRK,smaller qualys have deliver much bigger earning gain compare industry giant recent quarters qualys profit grow latest quarters top line growth have accelerate straight period latest come new customer renewal upsell have help sale growth
1998,MRK,qualys report fourth quarter result feb market close analyst poll thomson reuter see earning surge cent share sale be expect year company full year profit be expect cent share earning be slate rise cent clear buy point cup base october qualys qlys be bounce week move average rebound week line be generally used point add share investor still use setup start new position stock have retreat mostly tame volume have find support level demand gauge such stock accumulation distribution rating volume ratio remain level point strong buy fund ownership grow fourth quarter accord marketsmith year period qualys be thin issue average daily volume share daily dollar volume have double year redwood city calif base qualys provide cloud security compliance product more customer more country allergan agn best buy bby merck mrk be customer qualys be smaller company highly rank computer security software group have market cap symantec symc check point software technology chkp have market cap respectively smaller qualys have deliver much bigger earning gain compare industry giant recent quarters qualys profit grow latest quarters top line growth have accelerate straight period latest come new customer renewal upsell have help sale growth qualys report fourth quarter result feb market close analyst poll thomson reuter see earning surge cent share sale be expect year company full year profit be expect cent share earning be slate rise cent
1999,MRK,biotech tetraphase pharmaceutical ttph jump new high thursday get volley price target increase report positive trial result antibiotic late wednesday
2000,MRK,trial find tetraphase eravacycline be noninferior merck mrk invanz treat complicate intra abdominal infection exact number be report scientific meeting next year
2001,MRK,noninferiority exist drug not sound much tetraphase note eravacycline cover broader range infection ivanz drug class call carbapenem include have develop resistance carbapenem make preferable therapy multidrug resistant infection tetraphase be also develop oral form drug particular trial used intravenously invanz
2002,MRK,be upgrade overwhelmingly buy rate stock number analyst deliver hefty price target increase seem be drive partly datum partly prospect buyout
2003,MRK,didn see surprise write baird analyst brian skorney research note raise price target
2004,MRK,add wake merck cubist cbst deal earlier month actavis act durata deal month cubist trius optimer deal last year believe antibiotic space be accelerate view eravacycline be significantly derisked ideal target
2005,MRK,model indicate acquirer pay upward share be npv net present value positive deal
2006,MRK,other analyst focuse eravacycline competitive position even absence buyout bmo capital market jim birchenough lift sale estimate drug say expect availability oral step therapy expect positive datum trial treat complicate urinary tract infection help differentiate competitor lift price target
2007,MRK,tetraphase be morning trading stock market today
2008,MRK,tetraphase debut march start lift early september result urinary tract trial lead highest possible ibd relative strength rating
2009,MRK,have product market so ep rank be just
2010,MRK,follow amy reeve twitter ibd_areeve
2011,MRK,related
2012,MRK,merck cubist deal be patent setback biotech tetraphase pharmaceutical ttph jump new high thursday get volley price target increase report positive trial result antibiotic late wednesday trial find tetraphase eravacycline be noninferior merck mrk invanz treat complicate intra abdominal infection exact number be report scientific meeting next year noninferiority exist drug not sound much tetraphase note eravacycline cover broader range infection ivanz drug class call carbapenem include have develop resistance carbapenem make preferable therapy multidrug resistant infection tetraphase be also develop oral form drug particular trial used intravenously invanz be upgrade overwhelmingly buy rate stock number analyst deliver hefty price target increase seem be drive partly datum partly prospect buyout didn see surprise write baird analyst brian skorney research note raise price target add wake merck cubist cbst deal earlier month actavis act durata deal month cubist trius optimer deal last year believe antibiotic space be accelerate view eravacycline be significantly derisked ideal target model indicate acquirer pay upward share be npv net present value positive deal other analyst focuse eravacycline competitive position even absence buyout bmo capital market jim birchenough lift sale estimate drug say expect availability oral step therapy expect positive datum trial treat complicate urinary tract infection help differentiate competitor lift price target tetraphase be morning trading stock market today tetraphase debut march start lift early september result urinary tract trial lead highest possible ibd relative strength rating have product market so ep rank be just follow amy reeve twitter ibd_areeve related merck cubist deal be patent setback
2013,MRK,stock get mixed start quickly turn positive shorten holiday week drugmaker show particular weakness monday open
2014,MRK,dow jone industrial average lead nasdaq backed early loss gain struggle hold fractional gain
2015,MRK,volume be sharply lower nasdaq nyse contrast friday heavy option expiration trading
2016,MRK,start last week stock market today feel little pressure overseas market oil price reversed early gain oil sector stock put damper early market action
2017,MRK,drugmaker be be hit hard market merck mrk post heaviest loss dow gilead science gild biogen idec biib regeneron pharmaceutical regn celgene celg hold low ground nasdaq stock energy issue hold worst loss
2018,MRK,leader leane generally higher gain be limit
2019,MRK,airline buck head list spirit airline save alaska air group alk ahead more spirit be recover harsh sell week end dec alaska have pull back test week support breaking double bottom base october
2020,MRK,drugmaker post list worst decline early trade
2021,MRK,gilead topple prescription benefit manager express script esrx announce support drug combination market abbvie abbv gilead sovaldi prefer treatment patient hepatitis express script rise abbvie share gain fraction
2022,MRK,celgene biogen also ibd list drop amgen amgn slip lower
2023,MRK,economic news exist home sale slip november annualize rate accord national association realtor be pace slight downward revision original estimate economist have forecast more moderate slowdown sale stock get mixed start quickly turn positive shorten holiday week drugmaker show particular weakness monday open dow jone industrial average lead nasdaq backed early loss gain struggle hold fractional gain volume be sharply lower nasdaq nyse contrast friday heavy option expiration trading start last week stock market today feel little pressure overseas market oil price reversed early gain oil sector stock put damper early market action drugmaker be be hit hard market merck mrk post heaviest loss dow gilead science gild biogen idec biib regeneron pharmaceutical regn celgene celg hold low ground nasdaq stock energy issue hold worst loss leader leane generally higher gain be limit airline buck head list spirit airline save alaska air group alk ahead more spirit be recover harsh sell week end dec alaska have pull back test week support breaking double bottom base october drugmaker post list worst decline early trade gilead topple prescription benefit manager express script esrx announce support drug combination market abbvie abbv gilead sovaldi prefer treatment patient hepatitis express script rise abbvie share gain fraction celgene biogen also ibd list drop amgen amgn slip lower economic news exist home sale slip november annualize rate accord national association realtor be pace slight downward revision original estimate economist have forecast more moderate slowdown sale
2024,MRK,eli lilly lly stock jump year high stock market today morgan stanley upgrade stock overweight underweight afternoon trading lilly stock be analyst david risinger raise expectation potential blockbuster pipeline cholesterol drug evacetrapib alzheimer disease treatment solanezumab only put
2025,MRK,big pharma merck mrk report wednesday recently approve melanoma drug keytruda show promise small early study patient particularly hard treat form breast cancer study give keytruda first new class drug call pd inhibitor patient advanced triple negative breast cancer triple negative mean cancer be not drive
2026,MRK,stock market be organism strive identify opportunity crisis hold true late summer early fall outbreak ebola virus west africa reach crisis proportion guinea liberium sierra leone first case be discover september liberian native return texas
2027,MRK,stock open broad breathtaking loss tuesday harsh selling overseas weaken energy price take bite investor confidence
2028,MRK,nasdaq tumble start bell dow jone industrial average fall
2029,MRK,stock market today open heavy trading volume more nyse nasdaq compare trading same time monday
2030,MRK,morning mild economic news be bulldoze prevailing influence energy price overseas trade
2031,MRK,number unfilled job position employer rise october accord labor department jolt report job opening labor turnover survey also revise september unfilled opening lower hire job separation layoff be steady month report say
2032,MRK,wholesale inventory expand steady rate grow october commerce department say be just expectation increase
2033,MRK,stock tesla motor tsla monster beverage mnst be drag nasdaq dow strained loss verizon vz merck mrk
2034,MRK,ibd list leader take even harder hit spirit airline save drilled loss start trade raymond james downgrade budget airline market perform outperform remove price target airline monday alter margin guidance base pressure see industry ticket price demand loss pull spirit away monday high send test week support buy point cup base
2035,MRK,ambarella amba loose drop point maker chip gopro gpro camera other device fourth straight decline stock have now drop last week high remain week line support extend october rebound
2036,MRK,oil natural gas remain stable diving respectively monday gold price jump more ounce
2037,MRK,stock list show resilience tuesday selling include generic drug maker akorn akrx rise heavy trade stock have be hold week support build base buy point
2038,MRK,san jose calif base chip designer cavium cavm also rise more powerful trade move hoist share past buy point cup base
2039,MRK,notable earning report schedule today close include krispy kreme doughnut kkd korn ferry international kfy healthequity hqy stock open broad breathtaking loss tuesday harsh selling overseas weaken energy price take bite investor confidence nasdaq tumble start bell dow jone industrial average fall stock market today open heavy trading volume more nyse nasdaq compare trading same time monday morning mild economic news be bulldoze prevailing influence energy price overseas trade number unfilled job position employer rise october accord labor department jolt report job opening labor turnover survey also revise september unfilled opening lower hire job separation layoff be steady month report say wholesale inventory expand steady rate grow october commerce department say be just expectation increase stock tesla motor tsla monster beverage mnst be drag nasdaq dow strained loss verizon vz merck mrk ibd list leader take even harder hit spirit airline save drilled loss start trade raymond james downgrade budget airline market perform outperform remove price target airline monday alter margin guidance base pressure see industry ticket price demand loss pull spirit away monday high send test week support buy point cup base ambarella amba loose drop point maker chip gopro gpro camera other device fourth straight decline stock have now drop last week high remain week line support extend october rebound oil natural gas remain stable diving respectively monday gold price jump more ounce stock list show resilience tuesday selling include generic drug maker akorn akrx rise heavy trade stock have be hold week support build base buy point san jose calif base chip designer cavium cavm also rise more powerful trade move hoist share past buy point cup base notable earning report schedule today close include krispy kreme doughnut kkd korn ferry international kfy healthequity hqy
2040,MRK,share gilead science gild hit new high stock market today biotech prepared deliver report close tuesday analyst note couple potential competitor seem be falter
2041,MRK,analyst poll thomson reuter expect company report earning share year earlier quarter sale be estimate just last year third quarter
2042,MRK,massive year year increase be due hepatitis drug sovaldi launch december analyst expect decline sale sequential basis doctor delay treat patient month launch harvoni gilead next generation hcv pill
2043,MRK,sovaldi fading harvoni just launch isn particular number analyst be champ bit see tuesday isi group analyst mark schoenebaum write earning prep pack client conference call question probably revolve harvoni launch dynamic hcv pipeline potential acquisition possible impact close double irish tax loophole effect gilead be still unclear
2044,MRK,also monday rbc capital market analyst michael yee note event bode well gilead longer term competitive position
2045,MRK,be johnson johnson jnj drug simeprevir call olysio sovriad elsewhere require label change japan patient used die earning report management comment firm plan stay competitive hcv even harvoni launch lead minor panic gilead investor fear price war yee write seem even less likely now
2046,MRK,jnj soon get fda label allow use olysio gild sovaldi write don expect much use combo anymore theoretical positive label update gild already have combo replace regimen price olysio make not feasible view
2047,MRK,give idea much price have be cut week round harvoni cost more round sovaldi alone
2048,MRK,yee also write merck mrk be sound less confident own hcv pipeline conference call discuss earning monday morning company confirm report trial week hcv therapy liver meeting next month commentary be less bullish previous conference call suggest datum help bookend various treatment duration be feasible week treatment be not necessarily relevant long regimen general be competitive
2049,MRK,merck earning modestly beat estimate top line come bit light be more late afternoon monday
2050,MRK,follow amy reeve twitter ibd_areeve share gilead science gild hit new high stock market today biotech prepared deliver report close tuesday analyst note couple potential competitor seem be falter analyst poll thomson reuter expect company report earning share year earlier quarter sale be estimate just last year third quarter massive year year increase be due hepatitis drug sovaldi launch december analyst expect decline sale sequential basis doctor delay treat patient month launch harvoni gilead next generation hcv pill sovaldi fading harvoni just launch isn particular number analyst be champ bit see tuesday isi group analyst mark schoenebaum write earning prep pack client conference call question probably revolve harvoni launch dynamic hcv pipeline potential acquisition possible impact close double irish tax loophole effect gilead be still unclear also monday rbc capital market analyst michael yee note event bode well gilead longer term competitive position be johnson johnson jnj drug simeprevir call olysio sovriad elsewhere require label change japan patient used die earning report management comment firm plan stay competitive hcv even harvoni launch lead minor panic gilead investor fear price war yee write seem even less likely now jnj soon get fda label allow use olysio gild sovaldi write don expect much use combo anymore theoretical positive label update gild already have combo replace regimen price olysio make not feasible view give idea much price have be cut week round harvoni cost more round sovaldi alone yee also write merck mrk be sound less confident own hcv pipeline conference call discuss earning monday morning company confirm report trial week hcv therapy liver meeting next month commentary be less bullish previous conference call suggest datum help bookend various treatment duration be feasible week treatment be not necessarily relevant long regimen general be competitive merck earning modestly beat estimate top line come bit light be more late afternoon monday follow amy reeve twitter ibd_areeve
2051,MRK,health care etfs be top performer year look most heavily trade group reveal slight difference affect performance health care select sector spdr arca xlv have broad coverage include health care equipment supply health care provider service biotechnology pharmaceutical industry fund draw holding
2052,MRK,big pharma bristol myer squibb bmy report quarter shrink sale earning still beat analyst expectation send share early afternoon trading stock market today bristol myer earning slip year earlier quarter cent share beating estimate cent sale drop bristol note
2053,MRK,major average never find foot monday end session lows sluggish open selling picked pace et close nasdaq lose give dow jone industrial average fall weak economic datum china be partly blame import shrank unexpectedly november
2054,MRK,stock future show moderate loss ahead monday open
2055,MRK,dow future be point fair market value drop nasdaq future be mild point future slip point
2056,MRK,stock market today open week fairly tame note regard quarterly earning report
2057,MRK,drug giant merck mrk be fraction deliver third quarter result
2058,MRK,allergan agn climb clear analyst earning revenue forecast third quarter guide fourth quarter earning consensus projection stock also have receive boost news report say valeant pharmaceutical vrx be prepared raise takeover offer nearly share prior offer
2059,MRK,allergan share end friday extend buy point quick pullback test support week move average
2060,MRK,chip equipment maker kla tencor klac pop premarket trade stock gain last week announce thursday borrow finance special dividend share
2061,MRK,brazil base stock be selling hard ahead open final presidential vote sunday re elect incumbent president dilma rousseff state own oil producer petrobra pbr tumble bank itau unibanco itub banco bradesco bbd be telecom tim participacoe tsu drop miner valevale fall
2062,MRK,elsewhere overseas china market close narrow loss tokyo nikkei bump europe news bank fail european central bank stress test exercise weekend help place european stock mild selling pressure midday failure do not broadly surprise analyst do not trigger new capitalization requirement
2063,MRK,dollar be vs euro yen commodity be oil hammer back just barrel
2064,MRK,national association realtor be schedule release september pending home sale datum et stock future show moderate loss ahead monday open dow future be point fair market value drop nasdaq future be mild point future slip point stock market today open week fairly tame note regard quarterly earning report drug giant merck mrk be fraction deliver third quarter result allergan agn climb clear analyst earning revenue forecast third quarter guide fourth quarter earning consensus projection stock also have receive boost news report say valeant pharmaceutical vrx be prepared raise takeover offer nearly share prior offer allergan share end friday extend buy point quick pullback test support week move average chip equipment maker kla tencor klac pop premarket trade stock gain last week announce thursday borrow finance special dividend share brazil base stock be selling hard ahead open final presidential vote sunday re elect incumbent president dilma rousseff state own oil producer petrobra pbr tumble bank itau unibanco itub banco bradesco bbd be telecom tim participacoe tsu drop miner valevale fall elsewhere overseas china market close narrow loss tokyo nikkei bump europe news bank fail european central bank stress test exercise weekend help place european stock mild selling pressure midday failure do not broadly surprise analyst do not trigger new capitalization requirement dollar be vs euro yen commodity be oil hammer back just barrel national association realtor be schedule release september pending home sale datum et
2065,MRK,merck mrk pembrolizumab win fda approval melanoma thursday afternoon make first drug much anticipate pd inhibitor class hit market pembrolizumab now brand keytruda be approve normal phase clinical trial be finished due breakthrough therapy designation monoclonal antibody attack mechanism let cancer
2066,MRK,big pharma merck mrk study hot new immunotherapy drug candidate combination rival pfizer currently approve xalkori treat metastatic lung cancer firm announce tuesday trial pembrolizumab xalkori expect start next year be just example willingness sponsor work together effort accelerate progress
2067,MRK,achillion pharmaceutical achn stock touch month high second straight trading day monday deutsche bank upgrade biotech startup boost price target positive news new hepatitis drug achillion stock be more afternoon trading stock market today rise friday achillion stock have
2068,MRK,big cap biotech gilead science gild rise stock market today hit new time high friday win dispute roche right blockbuster hepatitis drug separately be endorse cost benefit authority roche rhhby have claim right drug sovaldi last year due partnership
2069,MRK,big cap name lead way stock be higher noon hour approach friday dow jone industrial average hit time high
2070,MRK,volume swell quadruple witching simultaneous quarterly expiration single stock index future single stock index option
2071,MRK,dow be top performer major index rise nasdaq gain just year high
2072,MRK,stock market today dow stock merck mrk caterpillar cat be nearly dupont dd johnson johnson jnj exxonmobil xom be more
2073,MRK,ibd stock irish drugmaker shire shpg be top performer reject buyout offer abbvie abbv be little change volatile morning
2074,MRK,worst performer be emerge energy service emes announce secondary offer share discount thursday close price company mine silica hydraulic fracture used oil gas drill
2075,MRK,auto dealer carmax kmx vault report earning cent share increase year quarter analyst be forecasting cent big cap name lead way stock be higher noon hour approach friday dow jone industrial average hit time high volume swell quadruple witching simultaneous quarterly expiration single stock index future single stock index option dow be top performer major index rise nasdaq gain just year high stock market today dow stock merck mrk caterpillar cat be nearly dupont dd johnson johnson jnj exxonmobil xom be more ibd stock irish drugmaker shire shpg be top performer reject buyout offer abbvie abbv be little change volatile morning worst performer be emerge energy service emes announce secondary offer share discount thursday close price company mine silica hydraulic fracture used oil gas drill auto dealer carmax kmx vault report earning cent share increase year quarter analyst be forecasting cent
2076,MRK,johnson johnson jnj free report have most diverse revenue stream industry pharmaceutical division account almost half revenue company have several multus dollar drug cover broad range area such neuroscience cardiovascular metabolism immunology oncology pulmonary hypertension infectious disease vaccine however many peer be face generic competition pricing pressure product pharmaceutical segment stock have depreciate year so far compare unfavorably decline record industry pharma segment sale picked second half be soft first half be likely see positive impact trend second quarter result zack consensus estimate pharma segment sale be believe new product continue share gain key product label expansion drug imbruvica xarelto stelara darzalex meaningful contribution acquisition support top line continue share gain drive sale imbruvica cancer indication xarelto blood thinner zytiga prostate cancer stelara psoriasis please note market imbruvica partnership abbvie abbv free report zack consensus estimate total imbruvica sale be strong adoption witness newer indication crohn disease continue contribute stelara growth zytiga be approve first line set february contribute strong performance drug first quarter trend expect continue second quarter also strong adoption outside market accelerate adoption unite state line therapy be likely drive sale darzalex importantly darzalex be approve first line set add significantly sale second quarter positive offset loss sale drug invokana due higher manage care discounting market share decline due competitive pressure meanwhile biosimilar competition be expect hurt sale key arthritis drug remicade outside unite state please note market remicade partnership merck mrk free report zack consensus estimate total remicade sale be note inventory build seasonality issue hurt sale xarelto first quarter remain be see issue persist second quarter well regard newly launch tremfya say first quarter conference call uptake product have be strong drug record sale first quarter be expect be higher be report quarter meanwhile expect discuss initial sale number erleada newly approve next generation oral androgen receptor ar inhibitor prostate cancer second quarter conference call overall second quarter sale pharmaceutical segment be expect remain strong consumer medical device segment continue improve read more set pharma earning motion currently carry zack rank hold better rank large cap pharma stock be lundbeck hluyy free report sport zack rank strong buy see complete list today zack rank stock here share lundbeck have gain year so far earning estimate have go past day medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2077,MRK,bristol myer squibb company bmy free report announce fda grant approval combination blockbuster immuno oncology drug opdivo nivolumab mg kg low dose yervoy ipilimumab mg kg injection intravenous use treatment adult pediatric patient age year older microsatellite instability high msi mismatch repair deficient dmmr metastatic colorectal cancer mcrc have progressed follow treatment oxaliplatin irinotecan opdivo yervoy be first immune oncology combination therapy approve type colorectal cancer approval indication have be grant accelerate approval base overall response rate orr duration response dor approval be base positive datum cohort patient msi dmmr mcrc treat combination phase ii checkmate study cohort patient receive prior treatment oxaliplatin irinotecan patient overall response rate orr be responder be complete response crs partial response prs median duration response dor be not reach datum show responder have response greater month have response month share company decline year date compare industry decline note opdivo become first pd immune checkpoint inhibitor gain regulatory approval be currently approve several country include unite state eu japan several cancer indication opdivo yervoy combination be also approve other tumor type opdivo mg kg low dose yervoy mg kg combination be approve previously untreated patient intermediate poor risk advanced renal cell carcinoma opdivo mg kg yervoy mg kg be approve patient unresectable metastatic melanoma accelerate approval base progression free survival however opdivo face stiff competition merck mrk free report pd therapy keytruda be approve first line lung cancer set bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quotezack rank stock considerbristol myer currently have zack rank hold better rank stock same space be ionis pharmaceutical inc ion free report chemocentryx inc ccxi free report carry zack rank strong buy see complete list today zack rank stock here ionis loss share estimate have narrow cent cent past day earning estimate have moved cent cent past day company deliver positive earning surprise trail quarters average beat chemocentryx loss share estimate have narrow cent past day company deliver positive earning surprise trail quarters average beat stock have rally so far year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2078,MRK,biggest news week be pfizer pfe free report announcement plan re organize business new segment effective next year jnj free report be order st loui jury pay approximately nearly dozen woman lawsuit related talc base product merck mrk free report abbvie abbv free report bristol myer bmy free report provide update cancer drug pfizer re organize business unit pfizer be re organize business business segment separate consumer healthcare business standalone unit begin pfizer report new business unit innovative medicine establish medicine consumer healthcare presently pfizer have report segment namely innovative health essential health present innovative health unit be call innovative medicine unit now include biosimilar new hospital business unit infective sterile injectable be presently report essential health essential health unit now be rename establish medicine unit include pfizer legacy brand have lose lose market exclusivity read more pfizer reorganize business new unit pay talc lawsuit be order jury st loui court pay damage woman allege talc base product include baby powder contain asbestos cause develop ovarian cancer damage comprise compensatory damage punitive damage official statement say verdict be unfair appeal also say talc product neither contain asbestos cause cancer face more case talc product trump slam pfizer price hike pfizer defer increase tweet president donald trump slam pfizer raise price several prescription drug effective jul trump say pfizer other drugmaker be ashamed have raise drug price reason tweet also say raise drug price unite state drug company be offer bargain basement price overseas warn administration respond day tweet be publish pfizer issue statement say defer price increase president drug pricing blueprint go effect end year be earlier abbvie imbruvica lymphoma study fail abbvie announce late stage study evaluate cancer drug imbruvica first line treatment diffuse large cell lymphoma dlbcl fail meet primary endpoint study evaluate addition imbruvica chop combination rituximab doxorubicin vincristine prednisone be exist standard care dlbcl aggressive form hodgkin lymphoma nhl versus chop placebo however study datum show add imbruvica chop do not improve event free survival ef target patient population imbruvica be presently fda approve indication include cell blood cancer well chronic graft versus host disease drug abbvie market partnership record sale first quarter include sale international profit sharing abbvie also file supplemental new drug application snda fda label expansion venclexta venetoclax first line treatment acute myeloid leukemia aml abbvie be look get venclexta approve combination hypomethylating agent hma low dose cytarabine ldac aml patient be ineligible intensive chemotherapy read more abbvie imbruvica fail phase iii blood cancer study merck keytruda sbla get priority review merck supplemental biologic license application sbla look expand label keytruda previously treat patient advanced hepatocellular carcinoma hcc most common type liver cancer be grant priority review fda fda decision be expect nov sbla filing be base datum phase ii keynote study read more merck keytruda get fda priority review liver cancer bristol myer opdivo yervoy combo get fda nod colorectal cancer bristol myer announce accelerate approval combination immuno oncology drug opdivo yervoy type colorectal cancer combination be now approve previously treat patient dna mismatch repair deficient dmmr microsatellite instability high msi metastatic colorectal cancer opdivo yervoy combination be also approve other tumor type first line treatment intermediate poor risk advanced renal cell carcinoma unresectable metastatic melanoma read more bristol myer combo drug get fda nod colorectal cancer cti biopharma slump study failure share cti biopharma ctic free report slump monday pivotal study evaluate combination regimen cancer drug pixuvri hodgkin lymphoma fail improve progression free survival pixuvri have conditional approval europe monotherapy treatment multiply relapse refractory aggressive cell nhl however be yet receive approval unite state read more cti biopharma fall failure pivotal lymphoma study nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock record increase last week astrazeneca azn free report gain most past month glaxo have be biggest gainer jnj free report decline most see last pharma stock roundup here pharma stock roundup nvs divest eye care unit chmp give nod several drug next pharma world watch earning bigwig pharma world later month begin jul medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2079,MRK,index enjoy strong week gain boost expectation strong second quarter earning season strong economic datum such last friday job report also help investor ignore trade tension however trade war fear do make comeback wednesday president trump decision impose fresh tariff china temporarily halter market rally last week index gain last friday investor ignore trade conflict unite state china follow strong job addition june economy add farm job june outpace consensus estimate unemployment rate increase primarily due increase labor force participation rate index gain last week reverse straight weekly loss market close slightly higher monday initial decline owing uncertainty revolve president trump trade policy be reversed rally tech stock market close lower tuesday selloff tech stock pare earlier gain make energy stock trade war fear continue haunt investor feel jittery lead huge selloff however thursday market close higher follow rally tech stock dow index monday record biggest gain more month gain help blue chip index return positive territory moreover index also close day move average first time jun investor shrug trade war fear buoy strong economic datum primarily friday job report encourage datum trade deficit well strong consumer credit datum increase investor appetite riskier asset equity index gain tuesday post first day winning streak jun investor have pin high hope second quarter earning result evaporation trade war concern robust economy also boost investor confidence equity index lose wednesday once again enter negative territory year date president donald trump decision impose second round tariff worth chinese good halter day market rally new tariff undergo month review final decision be take energy stock plunge wednesday trade war concern positive news supply side index gain thursday boost rally tech major internet giant negate trade tension investor seem be focuse upcoming earning robust economic datum share microsoft corporation msft free report gain hit record high share cisco csco free report intel intc free report apple aapl free report gain respectively share caterpillar cat free report boee company ba free report gain respectively component move index boee recently announce program delivery commercial defense operation second quarter figure show rise commercial shipment decline defense shipment previous year zack rank hold boee report second quarter commercial delivery airplane year year primarily backed higher demand jet delivery single aisle jet increase second quarter year number defense space business boee delivery totale second quarter plunge dispatch year period boee total delivery be unit second quarter compare deliver year quarter read boee commercial delivery defense take hit merck co inc mrk free report announce fda have grant priority review supplemental new drug application sbla pd inhibitor keytruda latest filing zack rank merck be look get keytruda approve treatment advanced hepatocellular carcinoma hcc form liver cancer patient previously treat systemic therapy sorafenib fda be expect give verdict nov sbla be base positive datum phase ii study keynote outcome demonstrated treatment keytruda monotherapy lead overall response rate orr patient advanced hcc read merck keytruda get fda priority review liver cancer pfizer inc pfe free report announce be re organize business business segment separate consumer healthcare business standalone unit begin pfizer report new business unit innovative medicine establish medicine consumer healthcare presently zack rank pfizer have report segment innovative health essential health read pfizer reorganize business new unit separate development response president donald trump tweet monday pfizer say defer recent price increase several prescription drug maximum end year chief executive officer ian read announce decision follow extensive discussion president read pfizer defer price increase discussion trump chevron corporation cvx free report be set put many north sea oil gas asset sale bid streamline portfolio asset intend offload include britannia satellite alba captain elgin franklin erskine field move be part chevron strategic review global portfolio determine competitiveness project decision seem be prudent extract oil north sea be not so economical production cost be much higher return even other biggy bp plc bp free report royal dutch shell plc rd free report have jettison core asset region stock have zack rank strong buy see complete list today zack rank stock here microsoft be set introduce surface go tablet bid explore low price tablet market news come surprise development rumor have be do round follow bloomberg revelation microsoft have zack rank new surface go feature inch screen weigh pound lighter prevailing surface counterpart latest series be equip intel processor graphic chip different variant new tablet series come storage capacity gb gb gb gb gb ram few model also have feature connect lte cellular network price range accord specification read microsoft set launch surface go up ante edtech jpmorgan chase co jpm free report have initiate relocation plan several dozen employee office bid ensure business continuity brexit news be first report reuter memo also outlined plan expand bank presence other european city such paris madrid milan jpmorgan have zack rank most employee be relocate presently serve client face risk management related role company investment banking asset management division have be ask relocate brexit occur march now be expect bank move employee expand operation frankfurt luxembourg dublin already have banking license read jpmorgan relocate dozen personnel pre brexit performance top dow company table give show price movement largest component dow be price weight index last day last month last trading day dow have gain next week trump remain determine go ahead protectionist measure particularly china have make investor tad jittery have largely ignore such concern be fast become market best week recent time investor continue focus strong economic datum upcoming earning market notch more record week ahead medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2080,MRK,pfizer inc pfe free report announce be re organize business business segment separate consumer healthcare business standalone unit begin pfizer report new business unit innovative medicine establish medicine consumer healthcare presently pfizer have report segment innovative health essential health present innovative health unit be call innovative medicine other include current innovative health business unit innovative medicine include new hospital medicine business unit create sterile injectable infective medicine be presently record pfizer essential health unit also biosimilar now be include oncology inflammation immunology business segment innovative medicine unit essential health unit be rename establish medicine unit continue include pfizer legacy brand have lose lose market exclusivity include lyrica lipitor norvasc viagra certain generic medicine lipitor norvasc viagra have already lose patent exclusivity lyrica be expect lose same december year pfizer expect significant reduction impact patent protection loss post lyrica loss exclusivity last year pfizer have say loss exclusivity loe hurt sale negative impact go next year loe impact reduce further post go approximately not be more potentially lower loe impact pfizer be optimistic establish medicine unit generate sustainable modest revenue growth consumer healthcare unit be now part innovative health include pfizer counter drug pfizer be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction decision regard same be expect be make year pfizer ultimately opt retain business pfizer be have tough time find buyer consumer healthcare segment march british company reckitt benckiser group glaxo gsk free report pull discussion pfizer buy consumer health segment investor believe split make sale easier also speculate pfizer sell generic unit couple year news business re organization come day pfizer defer recent price increase several prescription drug be criticize trump be concern price hike company soon trigger market wide increase price drugmaker jnj free report merck mrk free report other year so far pfizer share have increase decrease industry pfizer currently carry zack rank buy see complete list today zack rank strong buy stock here hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2081,MRK,expect johnson johnson jnj free report healthcare bellwether beat expectation report second quarter result jul market open last report quarter company deliver positive earning surprise performance have be pretty impressive company exceed earning expectation trail quarters average positive earning surprise last quarters be johnson johnson price ep surprise johnson johnson price ep surprise johnson johnson stock have depreciate year so far compare unfavorably decline record industry factor considerj sale improve first quarter be pharmaceutical segment continue positive momentum see second half consumer segment sale improve positive sale trend be expect continue second quarter fact be quite confident pharma segment continue perform better market year impact biosimilar sale key arthritis drug remicade sale consumer medical device segment be expect improve believe new product segment successful label expansion cancer drug imbruvica darzalex contribution recent acquisition continue drive top line growth core product stelara zytiga simponi simponi aria invega sustenna be expect contribute growth however past quarters revenue pulmonary arterial hypertension pah product add june acquisition actelion decline sequentially due lower sale tracleer outside unite state due generic competition be less likely pah revenue improve second competition be expect hurt sale remicade outside unite state please note market remicade partnership merck mrk free report however do not expect biosimilar entrant zytiga prezista risperdal consta invega sustenna unite state however full year guidance include impact generic procrit tracleer well remicade biosimilar regard newly launch tremfya say first quarter conference call uptake product have be strong drug record sale first quarter be expect be higher be report quarter expect discuss initial sale number erleada newly approve prostate cancerdrug second quarter conference call medical device segment sale be expect rise consistently vision care cardiovascular unit diabetes care unit however continue remain weakin consumer segment beauty counter product be expect do well domestic baby care product sale likely remain weak recent acquisition well new product be likely provide support however higher investment new product launch continue hurt profit earning whispersour proven model show be likely beat estimate quarter have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold likely positive surprise zack esp earning esp be zack consensus estimate stand share uncover best stock buy sell re report earning esp filter zack rank have zack rank combination zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerhere be other large drug biotech stock also have right combination element beat earning time amgen inc amgn free report earning esp zack rank company be schedule release result jul see complete list today zack rank stock here abbvie inc abbv free report have earning esp zack rank company be slate release result jul hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2082,MRK,response president donald trump tweet monday pfizer inc pfe free report say defer recent price increase several prescription drug maximum end year chief executive officer ceo ian read announce decision follow extensive discussion president last week new york base company have announce increase list price several drug effective jul be second time year pfizer increase price medicine pfizer raise price medicine average be agree limit price rise year however price few drug xalatan viagra chanix have already increase double digit include january hike pfizer defend price rise state list price do not reflect actual price include discount also mentioned have hike price only tenth drug portfolio reduce price drug first tweet monday president criticize pfizer price increase trump warn administration act response pfizer other drugmaker be ashamed have raise drug price reason tweet also say raise drug price unite state drug company be offer bargain basement price overseas latest statement read say price medicine return pre jul level soon technically possible also say price be defer president drug pricing blueprint go effect end year be sooner meanwhile price cut company remain effect tweet tuesday president appreciate pfizer decision hope other follow suit incidentally pfizer announcement price hike come only few week trump claim pharma company soon take massive price cut voluntarily however have be sign such price cut pfizer face criticism price hike be concern price hike company soon trigger market wide increase price drugmaker jnj free report merck mrk free report lilly lly free report other year so far pfizer share have increase decrease industry pfizer currently carry zack rank buy see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2083,MRK,healthcare sector be spotlight again due exorbitant drug pricing president donald trump tweet monday criticize pharmaceutical giant pfizer inc pfe free report recent price increase several prescription drug last week new york base company announce increase list price several drug be second time year pfizer have increase price medicine pfizer raise price medicine average be agree limit price rise year however price few drug xalatan viagra chanix have already increase double digit include january hike pfizer defend price rise state list price do not reflect actual price include discount also mentioned have hike price only tenth drug portfolio reduce price drug pfizer announcement price hike come only few week trump claim pharma company soon take massive price cut voluntarily however have be sign such price cut pfizer face criticism price hike be concern price hike company soon trigger market wide increase drug price other pharma bigwig merck mrk free report other latest tweet trump warn administration act response pfizer other drugmaker be ashamed have raise drug price reason tweet also say raise drug price unite state drug company be offer bargain basement price overseas pricing controversy linger issue healthcare industry have always be spotlight high drug price sector previously wall street favorite be hit hard political rhetoric increase medium public focus high price drug drug pricing controversy have grab headline september several company be criticize overpricing drug include mylan myl free report increase price epipen valeant pharmaceutical international inc vrx free report strategy acquire company selling drug higher price trump election campaign have pledge take step lower prescription drug price ensure affordability high cost drug however concrete policy change have be announce decrease drug price trump take office industry have be constantly warn trump keep price drug affordable be probably not do anything part president take several step direction push faster generic cheaper copycat version brand drug approval be already do also ask discount rebate be disclose put limitation promotion advertisement drug mandate medicare negotiate drug price manufacturer be high time drug company take step provide relief consumer keep cost medicine affordable then drug pricing controversy remain overhang space pfizer share do take dip trump tweet close day green pfizer currently carry zack rank buy see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2084,MRK,merck co inc mrk free report announce fda have grant priority review supplemental new drug application sbla pd inhibitor keytruda latest filing merck be look get keytruda approve treatment advanced hepatocellular carcinoma hcc form liver cancer patient previously treat systemic therapy sorafenib fda be expect give verdict nov sbla be base positive datum phase ii study keynote outcome demonstrated treatment keytruda monotherapy lead overall response rate orr patient advanced hcc datum also show complete response rate partial response rate result treatment keytruda datum be recently produce american society clinical oncology asco cancer symposium san francisco notably keytruda be already market several cancer indication include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer drug be first pd therapy gain fda approval be now already approve use different setting involve different tumor type have already secure fda nod new indication include third line treatment adult well pediatric patient primary mediastinal cell lymphoma pmbcl type hodgkin lymphoma second line treatment recurrent metastatic cervical cancer drug be also be study more type cancer more trial include excess combination study merck be collaborate several company amgen amgn free report incyte glaxosmithkline gsk free report pfizer pfe free report separately evaluation keytruda combination other regimen keytruda be key top line driver merck logged sale first quarter sequentially year year sale continue be drive launch new indication globally company be carry keytruda development program be progress well several regulatory decision new indication unite state well europe expect label expansion approve widen patient population base further drive sale higher share merck have increase year date versus industry decline merck currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2085,MRK,biggest news week be novartis nvs free report announcement plan spin eye care division alcon new public company committee medicinal product human use chmp european medicine agency ema give positive recommendation grant marketing approval several drug week astrazeneca azn free report relatively new cancer drug lynparza imfinzi be grant marketing approval japan recap week most important storiesnovartis spin alcon novartis announce intention spin eye care division alcon separately trade standalone company novartis have acquire alcon novartis be conduct strategic review business long include retain business separation sale spin initial public offer decision spin alcon look prudent business be not perform management expectation alcon management believe create standalone company capital market exit create additional shareholder value divestiture unit also help novartis focus drug business novartis plan retain ophthalmic pharmaceutical part pharmaceutical portfolio concurrently company announce initiate share buyback program be execute end read more novartis spin alcon separate trading company chmp give positive opinion several drug bristol myer bmy free report pd inhibitor opdivo gain positive chmp opinion recommend expand approval adjuvant treatment adult patient melanoma chmp also give nod astrazeneca new formulation once weekly bydureon pre filled bcise device help improve glycaemic control new formulation be already approve unite state sanofi sny also gain positive chmp opinion cablivi caplacizumab treatment rare blood disorder call acquire thrombotic purpura cablivi be add sanofi portfolio latest acquisition ablynx novartis filing look label expansion car therapy kymriah cell malignancy be also give positive opinion chmp final decision european union product be expect come month astrazeneca gain japan approval new cancer drug astrazeneca parp inhibitor lynparza gain approval second indication japan lynparza olaparib tablet be already approve advanced ovarian cancer be now approve japan treatment patient unresectable recurrent brca mutate metastatic breast cancer patient have receive prior chemotherapy also astrazeneca new pd inhibitor be approve japanese regulatory authority locally advanced unresectable small cell lung cancer nsclc imfinzi be already approve unite state indication application eu be review decision expect second half read more astrazeneca new cancer drug get approval japan merck keytruda sbla get priority review merck mrk free report supplemental biologic license application sbla look expand label keytruda first line treatment metastatic squamous nsclc difficult treat lung cancer patient population be grant priority review fda fda decision be expect oct sbla filing be base datum keynote study remind investor datum present study steal limelight annual meeting american society clinical oncology earlier month datum study show combination keytruda chemotherapy lead significant improvement overall survival os progression free survival regardless pd expression read more merck keytruda get priority review difficult lung cancer bristol myer leukemia drug get eu nod expand indication bristol myer announce european commission have give marketing approval leukemia drug sprycel new patient population new formulation sprycel be now approve powder formulation administration pediatric patient philadelphia chromosome positive ph chronic myeloid leukemia cml chronic phase cp adamis get strong partner novartis adamis pharmaceutical admp free report announce exclusive distribution agreement novartis symjepi injection mg market emergency treatment acute allergic reaction include anaphylaxis deal novartis generic arm sandoz gain commercial right symjepi unite state exchange upfront fee potential performance base milestone payment company share profit equally meanwhile approval sandoz also get commercial right symjepi injection mg be presently fda review share adamis surge day partnership swiss pharma giant be announce read more adamis surge follow novartis deal symjepi nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr returnhere be major stock perform last trading session stock record increase last week glaxo gsk free report gain most past month too glaxo have be biggest gainer jnj free report decline most see last pharma stock roundup here pharma stock roundup ptct unveil promising datum rhhby acquire rest fmi next pharma world watch earning bigwig pharma world later month begin jul make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2086,MRK,bristol myer squibb company bmy free report announce european commission ec have approve label expansion oncology drug sprycel consequently drug be now approve treatment child adolescent age year year philadelphia chromosome positive ph chronic myeloid leukemia cml chronic phase cp also include powder oral suspension formulation approval be card european medicine agency committee medicinal product human use chmp have give positive opinion same april approval be base positive datum nct study evaluate safety efficacy sprycel pediatric patient newly diagnosed cp cml be resistant intolerant gleevec note sprycel be already approve unite state treatment adult philadelphia chromosome positive ph chronic myeloid leukemia cml chronic phase cp drug also receive fda approval adult ph acute lymphoblastic leukemia be resistant intolerant prior therapy fda also approve sprycel treatment pediatric patient ph cml cp november label expansion exist drug bode well bristol myer bristol myer share have decline year date compare industry decline blockbuster drug opdivo continue perform well label expansion drug further boost top line pricing concern stiff competition immuno oncology space be major cause concern particular merck mrk free report keytruda roche rhhby free report tecentriq stiff competition hence label expansion other drug company maintain top line momentum cancer portfolio also get major boost launch immuno oncology drug empliciti treatment multiple myeloma december bristol myer be co develop empliciti abbvie abbv free report zack rankbristol myer have zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2087,MRK,astrazeneca azn free report announce japanese regulatory authority have grant approval parp inhibitor lynparza tablet treatment patient unresectable recurrent brca mutate metastatic breast cancer patient have receive prior chemotherapy approval lynparza become first only parp inhibitor approve use ovarian cancer japan be second indication lynparza be now approve japan lynparza be approve first indication advanced ovarian cancer regardless brca mutation status country earlier year astrazeneca share have rise so far year contrast industry have decline unite state lynparza be approve breast cancer indication january lynparza be also presently market advanced ovarian cancer later setting lynparza be also different study range tumor type include breast prostate pancreatic cancer well earlier line setting ovarian cancer first quarter lynparza sale rise sale unite state surge gain recent label expansion approval ovarian cancer tablet breast cancer indication europe sale rise push higher number successful launch high brca testing rate encourage level reimbursement astrazeneca have joint development collaboration agreement merck mrk free report lynparza astrazeneca cancer drug imfinzi be also approve japan early stage lung cancer indication pd inhibitor be approve patient locally advanced unresectable stage iii small cell lung cancer nsclc disease have not progressed follow platinum base chemotherapy concurrent radiation therapy crt approval be base positive progression free survival datum phase iii pacific study imfinzi be already approve unite state canada switzerland india indication application eu be review decision expect second half meanwhile imfinzi durvalumab be be evaluate multiple cancer alone combination other regimen include late stage study combination tremelimumab hepatocellular carcinoma hcc liver cancer nsclc small cell lung cancer metastatic urothelial cancer head neck squamous cell carcinoma hnscc other imfinzi be launch unite state first indication second line advanced bladder cancer last year thereafter imfinzi be approve immediately launch early stage lung cancer unite state february year contribute significantly drug sale first quarter astrazeneca have zack rank sell better rank large cap pharma stock include pfizer inc pfe free report abbvie inc abbv free report zack rank buy see complete list today zack rank strong buy stock here pfizer stock have gain past year earning estimate well rise last day abbvie stock have rally past year earning estimate increase rise last day look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2088,MRK,eisai inc subsidiary japan base eisai co esaly free report partner merck mrk free report announce fda have extend review period supplemental new drug application snda cancer drug lenvatinib month aug currently company be look get lenvatinib approve first line treatment patient unresectable hepatocellular carcinoma hcc commonly know liver cancer fda have accept snda september last year regulatory body have now extend review period require additional time review application eisai be marketing authorization holder be work fda support continuation review process drug receive first approval indication japan march lenvima be approve single agent treat differentiate thyroid cancer combination novartis nvs free report chemo drug afinitor everolimus advanced renal cell carcinoma follow prior angiogenic therapy eisai share be so far year compare favorably increase register industry period snda include datum phase iii study compare lenvatinib bayer bayry free report chemo drug nexavar sorafenib candidate demonstrated inferiority overall survival treat liver cancer patient have not receive prior treatment drug also achieve statistically significant clinically meaningful improvement progression free survival time progression objective response rate eisai enter strategic collaboration merck march develop lenvatinib single agent combination merck pd therapy keytruda well eisai co price eisai co price eisai co quoteeisai currently carry zack rank buy see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2089,MRK,dow traverse holiday shorten week trading volume remain low rally tech share help index rebound monday initial hiccup trade tension however tech selloff reversed early gain lead loss index tuesday market be close wednesday fourth july holiday index advanced thursday boost tech stock post best performance more month last week index gain last friday last trading session first half year energy material stock help market friday see dow increase much point point bank stock perform well almost day fed announce second round stress test result lead major lender announce high dividend payout share buyback see bank share rally however late session selloff bank stock lead market shedding early gain index decline last week trade war fear dow also lose june trade tension raise market volatility significantly trade related concern index gain second quarter index decline first half fear trade war make investor jittery lead huge selloff tech stock have rally also take hit facebook inc fb free report get embroil datum misuse scandal cause major tech stock decline fear regulatory clampdown dow index increase monday gain point decline much nearly point earlier session initial decline owing uncertainty revolve president trump trade policy be reversed rally tech stock share facebook netflix inc nflx free report amazon com inc amzn free report increase respectively index decline tuesday selloff tech stock pare earlier gain make energy stock trade war fear continue haunt investor feel jittery lead huge selloff share boee ba free report caterpillar cat free report decline respectively apple aapl free report be biggest loser decline trading volume be lower market close et ahead fourth july holiday market be close wednesday fourth july holiday index gain thursday boost tech stock post best performance more month share intel intc boot wba free report gain respectively emerge strongest performer index report unite state european union eu plan withdraw auto tariff reinstate investor confidence extent however investor continue feel jittery unite state prepared slap tariff chinese import latest fed minute indicated country central bank be worry allow economy run too strong result significant economic slowdown central bank also acknowledge risk trade policy have intensified component move index merck co inc mrk free report gain priority review yet supplemental biologic license application sbla pd inhibitor keytruda latest application zack rank hold merck be look get keytruda approve combination chemotherapy first line treatment metastatic squamous small cell lung cancer nsclc be difficult treat lung cancer patient population fda grant priority review sbla decision schedule oct sbla filing be base datum keynote study recently conclude annual meeting american society clinical oncology datum presentation pivotal lung cancer study result merck emerge winner annual key cancer event read merck keytruda get priority review difficult lung cancer goldman sachs group inc gs free report be review equity capital market transaction australian branch be accuse mislead potential investor block trade transaction unit have undertake relation share healthscope limit november goldman sachs have zack rank buy australian security investment commission asic have put forth concern certain representation goldman sachs australia make investor minimum fix demand goldman sachs australia gs australia have be ask pay community fund sign enforceable undertaking require tighten control bookbuild messaging certain transaction read goldman sign undertaking asic block trade boee company ba free report bell helicopter joint venture jv bell boee recently secure modification contract relation aircraft term jv convert tiltrotor aircraft advance acquisition contract multiyear contract bell helicopter be unit textron inc txt free report value contract be award naval air system command patuxent river md agreement jv involve manufacture delivery cmv aircraft navy mv aircraft marine corps cv air force mv aircraft government japan majority work be execute fort worth amarillo tx ridley park pa rest be carry various location continental outside continental unite state stock have zack rank see complete list today zack rank strong buy stock here international business machine corporation ibm free report recently enter enterprise service deal france base cegid notably cegid offer cloud base management solution enhance performance financial accounting related process agreement zack rank ibm hybrid cloud architecture provide platform facilitate cegid service delivery read ibm cloud capability aid cegid expand europe presence separate development ibm recently enter infrastructure outsource deal denmark base kmd contract value be estimate notably ibm already offer mainframe service technology company current outsource contract read ibm sign deal worth strengthen ty kmd american express company axp free report announce increase quarterly dividend cent share begin third quarter also plan repurchase common share ccar comprehensive capital analysis review approval period third quarter second quarter american express have zack rank announcement come back objection nod receive company board governor federal reserve system capital plan submit recently plan submission be part ccar read amex dividend share buyback post stress test clearance performance top dow company table give show price movement largest component dow be price weight index last day last month last trading day dow have decline next week outlooka trade war unite state china seem have begin earnest imposition tariff chinese good start today tension be likely make presence feel trading session lie ahead investor now look crucial economic report line release next few day encouragement day ahead today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2090,MRK,merck co inc mrk free report gain priority review yet supplemental biologic license application sbla pd inhibitor keytruda latest application merck be look get keytruda approve combination chemotherapy first line treatment metastatic squamous small cell lung cancer nsclc be difficult treat lung cancer patient population fda grant priority review sbla decision schedule oct sbla filing be base datum keynote study recently conclude annual meeting american society clinical oncology datum presentation pivotal lung cancer study result merck emerge winner annual key cancer event datum study show combination keytruda chemotherapy lead significant improvement overall survival os progression free survival regardless pd expression pd be protein present surface cell risk death os be reduce compare chemotherapy alone pfs improvement say reduction risk progression death be nearly half patient keytruda combination group compare chemotherapy alone datum be term practice change cnbc change way doctor look prescribe drug cancer patient further cement merck position lung cancer market be most lucrative oncology sector year so far merck share have rise industry decline short span time keytruda have become merck largest product be already approve use different setting involve different tumor type year have already gain approval new indication include third line treatment adult well pediatric patient primary mediastinal cell lymphoma pmbcl type hodgkin lymphoma second line treatment recurrent metastatic cervical cancer label expansion approval drive sale keytruda future quarters treatment generate sale first quarter sequentially year year upside be drive global launch new indication further boost demand keytruda sale be gain particularly strong momentum first line lung cancer indication fact keytruda be only pd approve first line set certain lung cancer patient monotherapy well combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo keytruda be also be study more type cancer more study include excess combination study merck be collaborate several company include amgen amgn free report incyte incy free report glaxo pfizer separately evaluation keytruda combination other regimen merck have zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2091,MRK,gilead science inc gild free report announce european medicine agency ema committee medicinal product human use chmp have issue positive opinion company marketing authorization application maa car therapy axicabtagene ciloleucel treatment adult patient relapse refractory diffuse large cell lymphoma dlbcl primary mediastinal large cell lymphoma pmbcl more line systemic therapy axicabtagene ciloleucel chimeric antigen receptor cell car therapy modify patient own cell recognize attack cancer cell agency have earlier grant prime status axicabtagene ciloleucel tentative approval be card ema generally take chmp recommendation account review maa note axicabtagene ciloleucel be approve fda october yescarta approval europe boost growth prospect therapy give market potential information provide company be estimate patient dlbcl be refractory have relapse more line therapy be eligible car therapy europe concurrently novartis nvs free report also obtain positive opinion chmp car therapy kymriah cell malignancy cell acute lymphoblastic leukemia dlbcl gilead stock have gain year so far industry decline note gilead be look newer avenue help top line solidify presence gene therapy space initial uptake yescarta unite state be also encourage gilead be also intend foray nash market gilead hcv franchise be experience slowdown key market include unite state europe reflect lower sale harvoni sovaldi result competitive pricing pressure franchise see significant plunge sale due new competition fewer patient start note harvoni sovaldi epclusa face competition abbvie abbv free report viekira pak mayret merck mrk free report zepatier other nevertheless hiv franchise continue maintain momentum zack rankgilead currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2092,MRK,ever president trump imposition tariff steel aluminum import china market large have suffer dearly have be number meeting trade representative country vain further escalate trade war tension report have surface treasury department have be draft policy prohibit firm have more chinese ownership benefit emerge technology unite state such policy have negative ramification industry healthcare biotech pharmaceutical be tech heavy need acquire industrially efficient technology growth sustenance so trade war china turn be nightmare healthcare sector let have look trump protectionism dampen healthcare fortunesearly stage pharmaceutical startup biotech company have historically benefit increase access chinese investment resource intellectual property right protection be go hamper grow entrepreneurial spirit biotech space long run brunt be bear more relatively small scale startup american vcs focus more larger startup top notch university further china have not include medical product retaliatory tariff impose unite state be not likely do so future well however case such scenario occur not be too good healthcare industry norm china refrain used copy drug american biotech company expert fear china get violate patent right due escalation trade war start copy drug company have significant exposure asian country such circumstance company pharmaceutical drug industry have pay dearly such turn event also result dwindle global share healthcare industry market leader zack large cap pharmaceutical industry such abbvie abbv free report glaxosmithkline gsk free report eli lilly lly free report merck mrk free report pifzer pfe free report end be biggest loser such company not only have significant chinese exposure be highly vulnerable instance right infringement see complete list today zack rank stock here chinese investment be oxygen biotech pharma chinese venture capital fund have invest whopping biotech drug company period january march surpass investment chinese vcs whole part such increase be attribute china effort become leader healthcare investment globe china increasingly want make use manufacturing intensive nature economy reason typically increase investment biotech firm be china want access novel therapy make use high return such investment however restriction trump administration chinese involvement biotech spell doomsday industry big reason be be relatively cheaper drug pharmaceutical company perform clinical trial china china drug administration cda chinese fda take less third time take fda approve result consequently cost involved be also lower pharmaceutical industry have suffer recent past due rise cost associate raw material trump act tariff imposition china have prove be rather several industry large turn be nightmarish healthcare industry be know fact chinese investment breathe life small mid scale healthcare company america finally event china infringe drug patent right american company have significant operation chinese shore bloodbath healthcare industry be inevitable wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2093,MRK,equity market most closely watch index dow post biggest daily gain apr robust daily gain primarily be attribute strong performance tech sector lead apple inc aapl free report ease investor concern regard impending trade war stock market have remain mostly volatile so far strong first quarter earning result fail uplift investor sentiment due several reason include trade conflict inflationary expectation consequently major index dow be negative territory so far overall decline strong bunch total portfolio stock dow have provide positive return so far year investment stock favourable zack rank bode well investor volatility mark dow performance dow close gain point trading session be blue chip index biggest daily gain apr rise be mainly due report state legendary investor warren buffet be buy share tech behemoth apple first quarter exponential rise stock market continue momentum january however meltdown commence february persist next month result extreme market volatility however major stock market index witness marginal gain month april reverse overall negative trend last month strong first quarter earningsearning momentum remain robust first quarter buoy trump administration massive tax cut total earning member have already report result be same period last year higher revenue moreover expectation full year be impressive show total earning index expect be year earlier level drive higher revenue read more be earning picture really strong strong economyper bureau economic analysis gdp expand first quarter better consensus estimate first quarter gdp estimate generally remain weak due seasonality also commerce department report factory order month march grow indicate manufacturing sector constitute gdp be increase capital spending back massive tax overhaul deregulatory measure strong domestic global economy meanwhile personal consumption expenditure grow march first advance end notably personal consumption constitute gdp picksstock market momentum remain largely unhindered recent volatility steady economic activity business friendly policy adopt government pave way further stock market growth chart show price performance pick year date stage narrow search stock dow jone industrial average carry zack rank buy see complete list today zack rank strong buy stock here stock have strong growth potential provide strong return so far year boee co ba free report company generate positive earning surprise positive revenue surprise first quarter boee have expect earning growth current year zack consensus estimate current year have improve last day cisco system inc csco free report company generate positive earning surprise positive revenue surprise second quarter fiscal cisco have expect earning growth current year zack consensus estimate current year have improve last day merck co inc mrk free report company generate positive earning surprise positive revenue surprise negative fourth quarter fiscal merck have expect earning growth current year zack consensus estimate current year have improve last day more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2094,MRK,first quarter earning season have be relatively strong however stock market recent performance be yet reflect strength positive revision be see ahead start earning season estimate revision trend second quarter have be rather underwhelm member report result accord latest earning preview total earning index member increase year quarter improvement revenue beat ratio be earning revenue report first quarter earning company combine actual result have come estimate still come company be expect grow year year higher revenue please note broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning pharma bigwig report last week include pfizer pfe free report merck mrk free report allergan agn free report merck pfizer beat estimate earning miss same sale pfizer re affirm previously issue guidance merck raise outlook earning sale company witness relatively weaker top line performance quarter allergan beat estimate earning revenue first quarter raise guidance earning sale big biotechs celgene corporation beat estimate earning well sale raise earning expectation full year gilead earning sale miss estimate wider expect decline hcv franchise here have small biotech pharma company be set report first quarter result let see thing be shape announcement jazz pharmaceutical plc jazz free report jazz pharmaceutical be schedule announce result market close late company earning performance have be disappointing company surpass estimate only once last quarters miss same other average beat last quarter company deliver negative surprise however company have earning esp zack rank hold indicate likely positive surprise zack consensus estimate be peg share see complete list today zack rank strong buy stock here previous article show jazz be unlikely beat earning quarter however estimate change thereafter be now more confident likely positive surprise earning season call investor be keen know xyrem jazz lead product cataplexy excessive daytime sleepiness ed have perform also be keen know company pipeline progress business development plan be also expect draw notice read more jazz pharmaceutical earning store arena pharmaceutical inc arna free report arena be also expect report market closearena earning performance have be mixed bag trail quarters company surpass expectation last quarters miss same other occasion deliver average positive beat last report quarter company outpaced zack consensus estimate deliver positive earning surprise sale arena obesity treatment drug belviq only approve product arena portfolio be not expect be better arena have few pipeline candidate update same be expect first quarter conference call read more card arena earning season company have earning esp zack rank zack consensus estimate first quarter be peg loss cent share ligand pharmaceutical incorporate lgnd free report ligand be schedule announce result market close ligand stellar earning history show estimate beat last quarters company miss consensus mark only once also deliver average positive earning surprise last report quarter ligand pull positive surprise company have earning esp zack rank zack consensus estimate soon be report quarter be peg share first quarter conference call expect investor focus remain company update regard partnership well major pipeline asset read more lie ahead ligand earning season valeant pharmaceutical international inc vrx free report valeant be schedule release earning market open deliver negative earning surprise last quarter valeant earning performance have be decent earning miss expectation last quarters beating same remain bring average positive surprise quarter valeant have earning esp zack rank zack consensus estimate be peg cent share uncover best stock buy sell re report earning esp filter here be stock perform year so far more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2095,MRK,first quarter result pharma bigwig pfizer pfe free report merck mrk free report allergan agn free report steal limelight week other novartis nvs free report gain fda approval second indication car therapy kymriah abbvie abbv free report submit regulatory application eu psoriasis candidate risankizumab merck pd inhibitor keytruda gain fda priority review status yet label expansion application recap week most important storiesmixed result merck pfizer pharma giant beat estimate earning miss same sale pfizer re affirm previously issue guidance merck raise outlook earning sale company witness relatively weaker top line performance quarter merck strong sale keytruda gardasil bridion be partially offset lower sale other key therapy rotateq zepatier zostavax meanwhile loss market exclusivity several drug also hurt top line pfizer top line be hurt decline sale key drug lyrica prevnar prevenar enbrel loss exclusivity product viagra pristiq continue supply shortage legacy hospira product allergan beat estimate earning revenue first quarter raise guidance earning sale novartis kymriah get fda approval second indication novartis supplemental biologic license application sbla look get car therapy kymriah approve second indication be grant approval fda latest approval kymriah suspension have be approve intravenous infusion treatment adult patient relapse refractory diffuse large cell lymphoma more line systemic therapy include diffuse large cell lymphoma dlbcl high grade cell lymphoma dlbcl arise follicular lymphoma kymriah be first car therapy obtain fda approval august treatment patient year age cell precursor be refractory second later relapse separately novartis announce fda have give complete response letter bla propose biosimilar version roche cancer drug rituxan merck keytruda news merck supplemental biologic license application sbla look get overall survival datum phase iii keynote study include label pd inhibitor keytruda be grant priority review fda fda give decision sep study evaluate keytruda combination lilly alimta pemetrexed platinum chemotherapy cisplatin carboplatin first line treatment patient metastatic squamous nsclc regardless pd expression combination treatment improve overall survival regardless pd expression include patient tumor test negative pd notably combination therapy be grant accelerate approval fda aforementioned indication approval be base tumor response rate pfs datum keynote study hence positive readout keynote confirmatory study help company gain continue approval combo therapy support uptake sale merck also announce interim datum pivotal lung cancer study keytruda meet pre specify secondary endpoint overall response rate orr early cohort participant phase keynote study evaluate keytruda combination carboplatin paclitaxel nab paclitaxel first line treatment metastatic squamous nsclc abbvie submit application psoriasis candidate eu abbvie submit marketing application european regulatory authority investigational interleukin il inhibitor risankizumab treatment moderate severe plaque psoriasis marketing authorization application maa be support datum pivotal phase iii study datum study have show more half patient receive risankizumab achieve complete skin clearance year meanwhile abbvie also announce commencement self tender offer common stock price not less share not more share unite therapeutic acquire steadyme unite therapeutic corporation uthr free report announce definitive merger agreement steadyme ltd unite therapeutic acquire latter include contingent payment deal unite therapeutic add steadyme drug device pipeline product trevyent pulmonary arterial hypertension pah patient portfolio product have pose competition unite therapeutic remosynch implantable pump be review unite state trevyent be single use pre filled pump have be develop steadyme deliver day supply treprostinil subcutaneously used steadyme patchpump technology treat pah steadyme receive refuse file letter fda want further information steadyme intend resubmit nda end allergan ubrogepant succeed phase iii study allergan announce second pivotal phase iii study evaluate oral cgrp acute migraine treatment ubrogepant meet co primary endpoint phase iii datum show ubrogepant display strong efficacy clean side effect profile achieve ii study evaluate efficacy safety orally administer ubrogepant mg mg treat single migraine attack moderate severe headache intensity study datum demonstrated significant greater percentage patient treat ubrogepant dose be free pain hour initial dose compare treat placebo also statistically significant greater percentage ubrogepant patient take mg dose experience absence most bothersome migraine associate symptom photophobia phonophobia nausea hour initial dose compare treat placebo however mg dose fail demonstrate statistical significance endpoint seek label expansion pah drug jnj free report actelion submit supplemental new drug application snda fda seek approval label expansion pah drug opsumit macitentan include treatment patient chronic thromboembolic pulmonary hypertension cteph also announce definitive agreement acquire private biotech benevir biopharm benevir make oncolytic immunotherapy utilize proprietary stealth oncolytic virus platform have potential treatment solid nyse arca pharmaceutical index decline last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock decline last week astrazeneca rise pfizer decline most last month glaxo be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup nvs jnj sale earning top mrk bmy active aacr next pharma world watch pipeline regulatory update today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2096,MRK,aduro biotech inc adro free report incur first quarter loss cent share narrower zack consensus estimate loss cent year loss cent quarterly revenue soar substantially year year upside mainly be attribute receipt milestone payment merck mrk free report aduro worldwide licensing agreement company initiation phase study evaluate own cd antibody combination merck keytruda pembrolizumab treatment adult advanced solid tumor top line also surpass zack consensus estimate share aduro increase more hour trading follow earning release however stock have underperform industry year time have decline compare industry decrease research development expense slightly dip report quarter mainly owing lower contract manufacturing expense be primarily related company pipeline candidate bion currently development treat adult relapse refractory multiple myeloma however be offset increase cost related manufacturing select antibody company personalize neoantigen base immunotherapy general administrative expense be year year higher stock base compensation expense legal fee pipeline updateaduro have broad pipeline novel immunotherapy develop treat variety cancer company evaluate sting pathway activator adu combination novartis ag nvs free report pd checkpoint inhibitor pdr phase ib trial treat solid tumor lymphomas additionally candidate be be evaluate phase trial monotherapy patient cutaneous accessible metastatic solid tumor lymphomas top line datum program be expect soon meanwhile december aduro initiate phase ii dose escalation study examine pipeline candidate bion treatment adult relapse refractory multiple myeloma aduro biotech inc price consensus ep surprise aduro biotech inc price consensus ep surprise aduro biotech inc quote zack rank key picksaduro carry zack rank hold better rank stock health care sector be ligand pharmaceutical incorporate lgnd free report sport zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved north last day company deliver positive surprise trail quarters average beat share price company have surge year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2097,MRK,total earning total healthcare market capitalization be revenue growth growth rate seem unimpressive compare other sector earning revenue beat ratio respectively be also not great most notable player johnson johnson jnj free report be first major drug company report earning apr follow eli lilly company lly free report bristol myer squibb company bmy free report apr apr respectively other major drug company merck mrk free report pfizer pfe free report report industry bigwig come earning revenue beat earning focusjohnson world biggest maker healthcare product continue long streak earning beat earning share come cent ahead zack consensus estimate higher year quarter revenue grow year year edge past estimate johnson johnson raise revenue guidance maintain earning share outlook reflect growth read healthcare etfs focus johnson johnson earning drug giant surpass earning estimate lag revenue earning share cent come cent zack consensus estimate revenue fall shy estimate annual basis earning share revenue rise respectively pfizer expect revenue range earning share merckmerck also beat earning estimate miss revenue earning share come surpass zack consensus estimate cent improve year quarter revenue inched year year be estimate merck increase revenue guidance earning share guidance bristol myersbristol myer top estimate front report earning share cent cent zack consensus estimate ahead year earning cent revenue grow edge past zack consensus estimate company raise earning share guidance see healthcare etfs here eli lillyeli lilly also surpass earning revenue estimate earning outpaced zack consensus estimate cent come higher year quarter revenue grow beat estimate other drug maker eli lilly also raise revenue guidance earning guidance etf anglepharma etfs see terrible trading past month mediocre result fail boost confidence space push many fund week lows have highlighted detail fund have zack etf rank hold ishare pharmaceutical etf ihe free report etf provide exposure pharma stock tracking dow jone select pharmaceutical index focus firm be top holding basket accounting combine total asset suggest heavy concentration product have aum charge bps fee expense volume be light exchange share day fund have shed month spdr pharmaceutical etf xph free report fund provide exposure pharma company tracking pharmaceutical select industry index aum trade good volume share day charge bps fee year total product hold security focus firm take share product be same period read be spdr pharmaceutical etf xph free report hot etf right now vaneck vector pharmaceutical etf pph free report etf follow mvis list pharmaceutical index hold stock basket focus firm account more share product have amassed asset base trade moderate volume share day expense ratio come fund have lose month powershare dynamic pharmaceutical fund pjp free report be far most popular choice pharma space follow dynamic pharmaceutical intellidex index product have aum see lower volume share day fund charge bps fee expense hold stock fund invest least share bmy pfe lly etf have lose month first trust nasdaq pharmaceutical etf ftxh free report fund track nasdaq smart pharmaceutical index hold security basket pfizer johnson johnson account more share merck bristol myer eli lilly make more ftxh have lower level aum share average daily volume charge bps annual fee have shed same time frame want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2098,MRK,amgen inc amgn free report announce positive top line result late stage study evaluate safety efficacy abp biosimilar version jnj free report merck mrk free report remicade compare reference product treatment moderate severe rheumatoid arthritis ra abp be tnf monoclonal antibody datum phase iii study show abp be inferior compare remicade base primary endpoint be assessment acr week acr american college rheumatology criterium be used measure effectiveness various arthritis medicine clinical study acr score mean person ra have improve datum show be clinically meaningful difference abp remicade amgen share have gain so far year decrease register industry amgen have biosimilar product portfolio amgen biosimilar version abbvie abbv free report ra drug humira amjevita be approve fda september eu march same indication humira amjevita be first biosimilar version humira be approve fda well amgen first biosimilar medicine be approve amgen begin selling amjevita most country eu year unite state january amgen have collaborate allergan worldwide development oncology antibody biosimilar medicine biosimilar version roche avastin mvasi be already approve unite state eu biosimilar version herceptin kanjinti be review unite state eu biosimilar version rituxan abp be late stage development several amgen own drug be face biosimilar competition biosimilar be already have negative impact key product neupogen neulasta eu unite state neupogen be already face biosimilar competition other key drug neulasta epogen start face biosimilar competition year entry additional biosimilar unite state have negative impact company top line sensipar also lose patent exclusivity march generic be launch soon amgen currently carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2099,MRK,astrazeneca azn free report merck mrk free report cancer tablet lynparza demonstrated significant delay disease progression late stage study evaluate first line treatment advanced ovarian cancer phase iii solo study meet primary endpoint demonstrate first line treatment lynparza maintenance therapy lead statistically significant clinically meaningful improvement progression free survival pfs compare placebo woman brca mutate brcam advanced ovarian cancer meanwhile parp inhibitor demonstrated well characterize safety tolerability profile study full datum solo study be present future medical meeting company plan conduct discussion related submission get lynparza approve first line maintenance set regulatory authority approve expand use first line set sale lynparza improve future quarters lynparza be presently market advanced ovarian cancer later setting january lynparza become first parp inhibitor be approve breast cancer indication unite state lynparza be also different study range tumor type include breast prostate pancreatic cancer well earlier line setting ovarian cancer first quarter lynparza sale rise sale unite state surge gain recent label expansion approval ovarian cancer tablet breast cancer indication europe sale rise push higher number successful launch high brca testing rate encourage level reimbursement clovis oncology inc clvs free report rubraca tesaro inc tsro free report zejula be other parp inhibitor competition lynparza unite state astrazeneca share have rise so far year merck stock be contrast industry have decline astrazeneca merck have zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2100,MRK,merck co inc mrk free report announce fda have accept supplemental biologic license application sbla keytruda pd therapy review company be seek approval blockbuster drug adjuvant therapy treatment patient resect high risk stage iii melanoma decision be expect feb year so far merck share have outperformed industry share have rise period industry decline sbla include datum pivotal eortc keynote study demonstrated keytruda achieve significant increase recurrence free survival rfs surgery compare placebo patient population recurrence free survival be achieve patient treat keytruda year compare placebo drug also reduce risk disease recurrence death placebo merck have claim keytruda be first pd therapy achieve rfs benefit stage iiia iiib iiic melanoma patient drug have achieve rfs benefit patient irrespective braf mutation remind investor drug be already approve type cancer indication several setting include first line melanoma recently approve cervical cancer large cell lymphoma keytruda garner sale first quarter sequentially year year sale drug be particularly boost strong momentum first line lung cancer indication be only approve pd therapy monotherapy combination eli lilly lly free report cancer drug alimta pemetrexed carboplatin merck be focuse further develop successful drug other indication keytruda be be evaluate more study include excess combination study more type cancer company have collaborate several company include amgen amgn free report incyte glaxo pfizer pfe free report separately evaluation keytruda combination other regimen merck co inc price merck co inc price merck co inc quotemerck currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2101,MRK,gilead science inc gild free report announce european commission have grant marketing authorization hiv combination therapy biktarvy bictegravir mg emtricitabine mg tenofovir alafenamide mg bic ftc taf biktarvy be approve once daily single tablet regimen str treatment hiv infection adult present past evidence viral resistance integrase class emtricitabine tenofovir approval be support positive datum ongoing phase iii study namely study treatment nave hiv infected adult study virologically suppress adult approval bic ftc taf become gilead third ftc taf base str approve european union past year bic ftc taf meet primary objective week study regimen be earlier approve fda february approval europe further strengthen company hiv franchise gilead be dominant player hiv market impressive portfolio same hiv be primary area focus gilead company be work bring new hiv treatment market further boost sale franchise company be first bring market single tablet regimen str treatment hiv atripla taf base product genvoya odefsey descovy be perform well strong adoption unite state europe biktarvy combine novel unboosted integrase strand transfer inhibitor insti bictegravir demonstrated safety efficacy profile descovy ftc taf dual nucleoside reverse transcriptase inhibitor nrti backbone smallest insti base triple therapy str be produce approval new hiv therapy stiff competition glaxosmith gsk free report exist therapy tivicay triumeq meanwhile gilead be banking hiv franchise drive growth future give persistent decline hcv sale gilead stock have gain last month industry decline gilead hcv franchise be experience slowdown key market include unite state europe reflect lower sale harvoni sovaldi result competitive pricing pressure franchise see significant plunge sale due new competition fewer patient start pricing have largely stabilize market share stabilize mid patient start be expect decline further note harvoni sovaldi epclusa face competition abbvie abbv free report viekira pak mayret merck mrk free report zepatier other meanwhile gilead be look newer avenue help top line solidify presence gene therapy space initial uptake yescarta be also encourage gilead be also intend foray nash market pipeline candidate selonsertib filgotinib zack rankgilead currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2102,MRK,bristol myer squibb company bmy free report announce fda accept supplemental biologic license application sbla label expansion blockbuster immuno oncology drug opdivo indication first line advanced small cell lung cancer nsclc patient tumor mutational burden tmb mutation megabase mut mb fda set action date feb filing be base phase iii checkmate study evaluate opdivo base regimen versus platinum doublet chemotherapy patient first line advanced small cell lung cancer squamous squamous tumor histology be co primary endpoint part opdivo low dose yervoy versus chemotherapy overall survival os patient tumor express pd progression free survival pfs patient tmb mut mb pd spectrum primary endpoint part be os study be ongoing share company decline year date compare industry decline note opdivo become first pd immune checkpoint inhibitor gain regulatory approval be currently approve several country include unite state eu japan several cancer indication opdivo become first pd inhibitor be approve hematological malignancy classical hodgkin lymphoma unite state eu november drug have be perform impressively due demand result rapid commercial acceptance several indication include melanoma renal cell carcinoma second line nsclc small cell lung cancer occur patient lung cancer condition lead cause cancer death worldwide notably lung cancer be squamous cell carcinoma squamous nsclc account approximately lung cancer diagnosis moreover significant progress make space disease be associate low survival rate hence label expansion additional indication give product access higher patient population increase commercial potential drug significantly remind investor opdivo face stiff competition merck mrk free report pd therapy keytruda be approve first line lung cancer set also note march roche rhhby free report present datum tecentriq novel combination broad range tumor include lung cancer bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quotezack rank stock considerbristol myer have zack rank hold better rank stock same space be aeglea biotherapeutic inc agle free report carry zack rank buy see complete list today zack rank stock here aeglea loss share estimate have narrow past day company deliver positive earning surprise trail quarters average beat stock have rally so far year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2103,MRK,incyte corporation incy free report report net loss cent net income cent year quarter incyte have receive milestone payment year quarter boost bottom line zack consensus estimate be earning cent incyte corporation price consensus ep surprise incyte corporation price consensus ep surprise incyte corporation quotequarterly revenue be year year report figure however miss zack consensus estimate year year growth be drive higher sale jakafi incyte stock have lose past year compare industry decline follow disappointing result share be quarter detailjakafi sale grow year year drive strong patient demand net product revenue iclusig amount year quarter product royalty revenue novartis ag nvs free report jakafi ex market grow expense be year quarter sg expense amount year year company continue expect jakafi revenue range iclusig revenue be expect range expense be now expect range sg expense be now expect range earlier expectation pipeline phase ii trial reach trial evaluate jakafi patient steroid refractory acute graft versus host disease gvhd have complete enrolment result be expect first half incyte expect submit snda seek approval jakafi indication second half datum trial evaluate incb patient be expect second half however incyte suffer setback epacadostat external datum monitoring committee edmc review pivotal phase iii study echo evaluate epacadostat combination keytruda patient unresectable metastatic melanoma determine study do not meet primary endpoint improve progression free survival overall population compare pembrolizumab monotherapy phase iii trial echo be evaluate epacadostat merck mrk free report keytruda patient unresectable metastatic melanoma study second primary endpoint overall survival also be not expect reach statistical significance consequently base disappointing datum recommendation edmc incyte stop study enable patient physician consider alternative therapeutic option incyte be also significantly downsize epacadostat development program result incyte collaboration partner have decide pivotal trial epacadostat combination keytruda lung cancer echo echo be converted randomize phase ii trial enrollment be discontinue additional pivotal trial epacadostat combination pembrolizumab pivotal trial epacadostat combination bristol myer squibb bmy free report opdivo be amend enable patient physician consider alternative therapeutic option pivotal trial combination durvalumab stage lung cancer not be initiate however april fda convene arthritis advisory committee discuss resubmission baricitinib nda recommend approval mg dose baricitinib once daily oral medication treatment moderately severely active rheumatoid arthritis adult patient have have inadequate response intolerance methotrexate advisory committee unanimously support efficacy mg dose baricitinib do not recommend approval mg dose baricitinib propose indication base adequacy safety benefit risk profile fda action date baricitinib be june european commission have already approve baricitinib olumiant february treatment moderate severe active rheumatoid arthritis adult patient have respond inadequately be intolerant more disease modify rheumatic drug takeincyte performance first quarter be disappointing company suffer huge setback failure phase iii study echo evaluate epacadostat combination keytruda fail be most promising candidate incyte further approval mg dose baricitinib be also doubtful zack rankincyte currently carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2104,MRK,merck co inc mrk free report report first quarter adjust earning share beat zack consensus estimate cent earning rise year year attributable slightly higher sale lower cost quarter include charge related formation collaboration eisai first quarter earning share be cent compare earning cent share year quarter revenue quarter rise year year sale however slightly miss zack consensus estimate currency movement positively impact revenue exclude currency impact sale rise year year quarter pharmaceutical segment generate revenue exclude fx impact year year mainly strong sale pd inhibitor keytruda gardasil bridion offset lower sale other key therapy rotateq zepatier hepatitis zostavax prevention shingle previous quarters loss market exclusivity several drug also hurt top line keytruda largest product merck portfolio bring sale first quarter sequentially year year sale continue be drive launch new indication globally keytruda sale be gain particularly strong momentum indication first line lung cancer be only pd approve first line set keytruda be already approve many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer keytruda development program be also progress well several regulatory decision new indication unite state well europe pending year label expansion approve expand patient population drive sale higher zepatier bring sale year quarter due increase competition decline volume be expect continue bridion sugammadex injection generate sale quarter year year drive strong global demand meanwhile combine sale remicade lose exclusivity europe face stiff biosimilar competition region cancida lose exclusivity europe zetia lose market exclusivity unite state december vytorin lose exclusivity april decline almost quarter remicade sale decline quarter merck market brand version remicade outside unite state johnson johnson jnj free report market rheumatoid arthritis drug country cancida sale plunge quarter zetia vytorin franchise record sale due loss exclusivity zetia vytorin sale isentress decline quarter januvia janumet diabetes franchise sale rise higher international sale be partially offset lower sale due continue pricing pressure gardasil gardasil sale rise lower sale unite state be offset commercial launch china strong growth europe continue transition dose regimen impact volume unfavorably unite state zostavax sale decline quarter face strong competition glaxo gsk free report newly approve shingle vaccine shingrix merck animal health segment generate revenue exclude fx impact year quarter primarily drive higher sale companion animal product growth ruminant poultry business gross margin decline cost increase adjust gross margin come basis point bps year quarter marketing administrative expense be report quarter research development spend decrease quarter due lower licensing cost partially offset increase investment pipeline early drug development guidance raisedmerck raise outlook revenue range previously zack consensus estimate stand revenue guidance include approximately positive impact currency fluctuation company now expect adjust earning range raise previous guidance zack consensus estimate be peg share adjust earning guidance include approximately positive impact currency fluctuation adjust operate expense be still expect increase year year low mid single digit rate takemerck first quarter result be mixed company beat estimate earning miss same sale also raise guidance share be pre market trading so far year merck share have outperformed industry merck share have rise period decrease industry eye be performance keytruda be be tout key long term growth driver merck drug continue robust performance strong demand trend several label expansion slate year sale be expect increase further however significant decline sale zostavax zepatier due rise competitive pressure remain concern meanwhile generic competition several drug pricing pressure continue be overhang top line merck co inc price consensus ep surprise merck co inc price consensus ep surprise merck co inc quotezack rank key pickmerck carry zack rank buy ligand pharmaceutical incorporate lgnd free report be better rank stock health care sector sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate moved remain stable last day company deliver positive surprise trail quarters average beat share price company have increase year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2105,MRK,often lose sight thing once re thick earning season be now happen be job week automatic datum process adp free report private sector report come month april tomorrow important bureau labor statistic bls farm payroll report friday cnbc squawk box morning martin mucci paychex inc payx free report report small business job wage growth last month result be definitely interesting year year small business job growth be wage growth be lower see last summer indicate massive corporate tax cut see end have yet hit small business be indication not expect overall job number be notably affected tax cut arizona show best annual hourly earning growth be once again top city overall job growth phoenix top small business wage increase tennessee be state see largest gain small business employment overall manufacturing be month small business leisure hospitality come top hourly earning growth overall month wage growth small business be marginally far earning season go bell today expect result apple aapl free report snap snap free report many other morning see plenty result well ve only get time post couple pfizer pfe free report report cent beat bottom line cent share revenue miss anticipate company restate earlier guidance be accordance zack consensus number more pfe earning click here keep same industry well zack rank buy rate stock ahead earning result merck mrk free report also top earning estimate share versus cent miss marginally top line vs analyst be look also report line guidance current zack consensus estimate more mrk earning click here
2106,MRK,tuesday often lose sight thing once re thick earning season be now happen be job week automatic datum process adp free report private sector report come month april tomorrow important bureau labor statistic bls farm payroll report friday cnbc squawk box morning martin mucci paychex inc payx free report report small business job wage growth last month result be definitely interesting year year small business job growth be wage growth be lower see last summer indicate massive corporate tax cut see end have yet hit small business be indication not expect overall job number be notably affected tax cut arizona show best annual hourly earning growth be once again top city overall job growth phoenix top small business wage increase tennessee be state see largest gain small business employment overall manufacturing be month small business leisure hospitality come top hourly earning growth overall month wage growth small business be marginally far earning season go bell today expect result apple aapl free report snap snap free report many other morning see plenty result well ve only get time post couple pfizer pfe free report report cent beat bottom line cent share revenue miss anticipate company restate earlier guidance be accordance zack consensus number more pfe earning click here keep same industry well zack rank buy rate stock ahead earning result merck mrk free report also top earning estimate share versus cent miss marginally top line vs analyst be look also report line guidance current zack consensus estimate more mrk earning click here mark vickerysenior editorquestion comment article author click here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2107,MRK,pfizer inc pfe free report report first quarter adjust earning share cent beat zack consensus estimate cent earning rise year year lower tax rate share count due aggressive share repurchase quarter make weaker sale performance higher cost pharma heavyweight record revenue miss zack consensus estimate revenue however rise year quarter report basis due positive impact currency change currency movement benefit pfizer first quarter revenue however operational basis exclude impact currency revenue decline year year international revenue rise operational basis revenue decline segment report segment be pfizer innovative health ih pfizer essential health pfizer ih sale grow report basis operational basis year period ibrance eliquis do well quarter ih segment revenue be hurt lower sale enbrel lyrica prevnar prevenar meanwhile unfavorable customer buy pattern somewhat hurt sale ibrance xeljanz certain other product ibrance revenue rise quarter xeljanz sale rise lyrica sale decline eliquis alliance revenue direct sale rise chantix sale rise quarter revenue blockbuster prostate cancer drug xtandi add pfizer portfolio follow september medivation acquisition also contribute revenue xtandi record alliance revenue quarter compare previous quarter be partially offset continue decline revenue prevnar unite state lower revenue enbrel enbrel revenue decline key european market due biosimilar competition pfizer have exclusive right amgen inc amgn free report blockbuster rheumatoid arthritis ra drug enbrel outside unite state canada global prevnar prevenar revenue decline higher international sale make decline unite state prevnar revenue tank unite state due lower government purchase last year pediatric indication continue decline revenue adult indication however prevenar revenue rise international market revenue consumer healthcare segment pfizer be consider selling rise global oncology revenue increase global vaccine revenue decline internal medicine decline inflammation immunology franchise decline additionally portfolio rare disease rise pfizer segment sale decline operationally revenue be hurt loss exclusivity associate generic competition product primarily pristiq unite state lyrica europe lower revenue legacy hospira product due product shortage viagra sale decline due generic competition begin december however business biosimilar emerge market do well quarter biosimilar revenue rise operationally emerge market revenue grow operationally pfizer launch inflectra biosimilar version johnson johnson jnj free report merck mrk free report blockbuster ra drug remicade november last year inflectra record sale unite state globally other biosimilar bring sale outside market adjust selling informational administrative si expense decline operationally quarter adjust expense rise quarter pfizer buy back share worth include open market share repurchase accelerate share repurchase agreement execute march guidancerevenue be expect range adjust earning share be expect range mid point adjust ep be expect increase revenue be expect increase research development expense be likely be range si spending be project range adjust tax rate be expect be basis point less due expect advantage tax reform takepfizer first quarter result be mixed beat estimate earning miss same revenue meanwhile re affirm previously issue guidance share pfizer fall pre market trading lower expect sale quarter top line be hurt decline sale key drug lyrica prevnar prevenar enbrel also loss exclusivity product viagra continue supply shortage legacy hospira product hurt revenue year so far pfizer share have increase decrease industry pfizer face top line headwind form genericization key drug supply shortage legacy hospira product pricing pressure rise competition however believe new product ibrance contribution acquisition cost cut effort lower tax rate share buyback help company achieve guidance pfizer look well poise record profit growth pfizer also boast strong pipeline expect approximately drug approval next year include product have blockbuster potential pfizer carry zack rank buy see complete list today zack rank strong buy stock here pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotewall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2108,MRK,new jersey base merck co inc mrk free report be global research drive pharmaceutical product company well know product merck portfolio include remicade nasonex simponi vytorin zetia januvia janumet isentress emend keytruda cozaar hyzaar zocor proquad gardasil zostavax other however many peer merck be face headwind form generic competition several key product company sell consumer care business bayer october meanwhile merck acquire pulmonary fibrosis focuse company afferent pharmaceutical july rigontec acquisition october add early stage cancer candidate piepeline merck be also focuse immuno oncology merck performance have be pretty impressive company exceed earning expectation trail quarters average positive earning surprise last quarters be currently merck have zack rank buy definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning beat merck surpass earning expectation company report ep consensus call ep cent revenue miss revenue report quarter come slightly expectation merck post revenue consensus estimate outlook raise revenue be expect range previously zack consensus estimate stand company raise adjust earning expectation range zack consensus estimate stand share stock price impact share be pre market trading check back later full mrk earning report merck co inc price ep surprise merck co inc price ep surprise merck co inc quotewall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2109,MRK,incyte corporation incy free report announce phase ii trial reach evaluate lead drug jakafi combination corticosteroid treatment patient steroid refractory acute graft versus host disease gvhd meet primary endpoint datum study show jakafi demonstrated overall response rate orr day moreover number patient achieve response point time study be propel positive datum reach study incyte now plan file supplemental new drug application snda fda label expansion jakafi treatment steroid refractory acute gvhd third quarter incyte also plan present full detail study upcoming scientific meeting note jakafi first class jak jak inhibitor be already approve fda treatment person polycythemia vera pv have have inadequate response be intolerant hydroxyurea drug be also indicated treatment person intermediate high risk myelofibrosis mf include primary mf post polycythemia vera mf post essential thrombocythemia mf incyte have collaboration agreement novartis nvs free report jakafi jakafi be market incyte unite state be market novartis outside country jakafi performance have be impressive so far order expand patient population increase commercial potential drug company be work expand drug label further october fda approve label update drug include addition new patient report outcome pro datum comfort study well update warning related progressive multifocal potential label expansion gvhd further boost sale incyte stock have lose year so far compare industry decline meanwhile apart steroid refractory acute gvhd study reach trial program also include ongoing phase iii study steroid refractory acute gvhd reach steroid refractory chronic gvhd reach collaboration novartis datum study be expect incyte be also make effort develop other candidate reduce dependence jakafi fda have recently approve mg dose olumiant baricitinib once daily oral medication treatment adult moderately severely active rheumatoid arthritis ra have have inadequate response more tumor necrosis factor tnf inhibitor therapy incyte eli lilly lly free report have partnership olumiant however incyte suffer setback epacadostat external datum monitoring committee edmc review pivotal phase iii study echo evaluate epacadostat combination merck mrk free report keytruda patient unresectable metastatic melanoma determine study do not meet primary endpoint improve progression free survival overall population compare pembrolizumab monotherapy zack rankincyte currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2110,MRK,immunogen inc imgn free report announce fda have grant fast track designation lead candidate mirvetuximab soravtansine first class antibody drug conjugate target folate receptor fr alpha designation be development candidate platinum resistant ovarian cancer patient medium high fr alpha positive patient have receive least more prior systemic treatment regimen single agent chemotherapy be appropriate next line therapy fda grant fast track designation candidate development review be expect accelerate designation be grant candidate treat serious unmet medical condition designation candidate be expect be grant priority review once file new drug application immunogen share be almost include hour trading jun share company have rally compare industry rise so far year company be evaluate mirvetuximab soravtansine phase iii study forward treatment platinum resistant ovarian cancer express medium high level fr alpha single agent chemotherapy primary endpoint study be progression free survival enrollment study be complete ahead schedule april top line datum be expect first half phase ib ii forward ii study be evaluate candidate combination roche rhhby free report avastin merck mrk free report pd therapy keytruda platinum sensitive ovarian cancer express fr alpha study be also evaluate triplet combination mirvetuximab carboplatin avastin approve product portfolio progress lead candidate be drive stock investor remain focuse further update mirvetuximab immunogen inc price immunogen inc price immunogen inc quotezack rank stock currently carry zack rank hold aeglea biotherapeutic inc agle free report be better rank stock pharma sector carry zack rank buy see complete list today zack rank strong buy stock here aeglea loss estimate narrow last day company deliver positive earning surprise trail quarters average beat share price have increase so far year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2111,MRK,small cap take charge bull run february mega cap return forefront june be especially true blue chip dow jone index climb start june outpace gain russell notably dow jone surge last week biggest weekly gain march improve domestic international fundamental firm dollar compelling valuation lead outperformance recent raft economic datum point indicate robust growth first quarter slowdown american manufacturing be enjoy month winning streak average hourly wage have be rise year year growth unemployment have drop be lowest level consumer spending account more third economic activity surge most month april consumer confidence rebound year high most importantly trade deficit have be key reason ongoing tariff threat trade war concern drop second consecutive month april mark lowest level september shrink trade gap definitely benefit exporter lead surge mega cap stock first month export mexico canada european union have record double digit growth underscore unite state be expand strongly market fact trump be go fierce trade policy china key trading ally hurt export strong acceleration dollar basket currency have start start june weak dollar bode well blue chip company derive most revenue international market be weak dollar have make dollar denominate asset cheap foreign investor make multinational more competitive thereby lead increase profit such company have higher percentage international sale likely outperform add strength be compelling valuation month blue chip index have compel investor look bargain stock dow jone have ratio forward month compare russell give encourage mega cap trend investor stuff stock cheap outsized gain come week have used zack stock screener select stock market cap more zack rank lower dow jone top rank suggest rise earning estimate indicate optimistic view earning analyst hence higher chance outperformance finally arrived mega cap stock be cheap have potential deliver higher return toyota motor corporation tm free report ratio zack rank company produce sell lease repair passenger car truck bus boat airplane other product japan most foreign country earning estimate have go cent fiscal year end march month earning be expect decline toyota motor flaunt top vgm score market cap china petroleum chemical corporation snp free report ratio zack rank joint stock company be focuse core business petroleum petrochemical integrate upstream mid stream downstream operation complete marketing network stock have see solid earning estimate revision year past day expect growth rate have market cap vgm score see complete list today zack rank stock here merck co inc mrk free report ratio zack rank global company provide healthcare solution worldwide market cap stock see earning estimate revision year month have expect earning growth rate have vgm score hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2112,MRK,inc agen free report be expect report first quarter last report quarter company report negative earning surprise last quarters company deliver average positive earning surprise notably share have outperformed industry year stock have rally industry fall let see thing be shape company quarter factor playagenus collaboration agreement several company not only help procure fund form upfront milestone payment future royalty also validate proprietary product platform have collaborate merck mrk free report incyte develop multiple checkpoint antibody incyte collaboration be evaluate latter gitr checkpoint antibody incagn phase ii study ox agonist antibody incagn phase ii study ctla antibody agen phase ii study candidate be be evaluate treatment solid tumor january company announce launch combination phase ii study agen pd agen antibody have approve product portfolio only few candidate mid stage development include prophage series vaccine company be still few year away bring product market hiccup development process candidate weigh stock october establish separate business entity advance cell therapy program be design be self funded cell therapy company agentus focus discovery development breakthrough live drug advance cure cancer patient company take decision form smaller team entirely focus get product approve company expect combine value separate company exceed perceive value roof first quarter company focus pipeline candidate provide update model proven model do not show earning beat quarter be stock need have positive earning zack rank strong buy buy hold happen however be not case here see zack esp have earning esp be most accurate estimate zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank have zack rank sell decrease predictive power esp note caution stock zack rank strong sell go earning announcement stock warrant lookhere be biotech stock want consider model show have right combination element post earning beat quarter pfizer inc pfe free report be schedule release quarterly result company have earning esp zack rank see complete list today zack rank strong buy stock here gilead science inc gild free report be schedule release quarterly result company have earning esp zack rank inc price ep surprise inc price ep surprise inc hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2113,MRK,merck co inc mrk free report present new datum study evaluate type ii diabetes drug januvia sitagliptin treatment option type ii diabetes patient initiate insulin therapy mild renal impairment composit study show higher reduction blood glucose level patient initiate insulin dosage continue treatment januvia compare discontinue januvia composit trial evaluate subject mild renal impairment be not adequately controlled metformin datum study show treatment januvia result inferiority superiority reduce blood glucose level compare patient treat astrazeneca azn free report farxiga dapagliflozin datum be present american diabetes association meeting orlando fl share merck have gain year date versus industry decline combine sale januvia janumet decline due ongoing pricing pressure merck januvia franchise be face pricing pressure due higher discount rebate maintain good manage care coverage first quarter sale januvia janumet rise last april fda deny approval include cardiovascular outcome label januvia janumet death toll cardiovascular disease be significantly higher adult suffering diabetes comparison addition positive cardiovascular finding have help drive sale drug moreover eli lilly lly free report boehringer ingelheim include cardiovascular indication label sglt inhibitor jardiance dpp iv inhibitor januvia see patient switch sglt inhibitor latest addition merck diabetes franchise be steglatro ertugliflozin approve monotherapy well fix dose combination metformin januvia unite state last december eu march be important note merck market steglatro partnership pfizer inc pfe merck currently carry zack rank hold better rank stock same sector be lundbeck hluyy free report sporting zack rank strong buy see complete list today zack rank stock hereh lundbeck earning estimate have be revise upward past day stock have soar year date hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2114,MRK,latest earning preview earning season have already crossed half way mark be gain strength earning revenue growth track reach highest level year total earning member have already report result be same period last year higher revenue beating top line estimate beating revenue estimate proportion company beating earning revenue estimate be ongoing earning season seem have start solid note drug biotech sector major large cap player have report result bristol myer squibb bmy free report abbvie abbv free report beat zack consensus estimate earning well sale amgen inc amgn free report also surpass earning revenue expectation quarter higher demand be expect boost new product sale also innovation successful product line expansion positive clinical study result fda approval consistent performance key product grow demand drug especially rare treat disease agee population well increase healthcare expenditure be factor be expect keep sector growth trajectory also accord earning preview broader medical sector inclusive drug biotech well medical device company be likely record year year growth revenue witness rise earning quarter review pharma biotech giant be schedule report earning result let see thing be shape company upcoming release pfizer inc pfe free report be slate releaseresult market open company deliver positive earning surprise last report quarter company performance have be impressive recent past earning surpass expectation trail quarters average beat accord zack model company zack rank strong buy buy hold have good chance beating estimate also have positive earning esp combination company zack rank earning esp make reasonably confident earning beat zack consensus estimate company earning quarter review be peg cent share innovative health segment new product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain chantix smoking cessation eliquis blood thinner be expect drive top line essential health biosimilar emerge market be expect support sale bottom line be expect be drive cost saving share buyback read more pfizer earning beat estimate again pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quotemerck co inc mrk free report be slate report result open bell company deliver positive earning surprise last report quarter company track record be excellent have consistently top estimate last quarters average positive earning surprise model do not conclusively show merck beat estimate quarter be stockha earning esp zack rank zack consensus estimate quarterly earning be peg cent share see complete list today zack rank strong buy stock here merck new product cancer drug keytruda lynparza bridion injection be likely drive top line however loss market exclusivity several drug softness diabetes januvia janumet franchise lower sale key product zostavax zepatier due competitive pressure hurt sale read more card merck earning season merck co inc price ep surprise merck co inc price ep surprise merck co inc quotegilead science inc gild free report be slate report result market close company deliver positive earning surprise trail quarters average beat last report quarter gilead deliver positive earning surprise model show gilead be likely beat estimate quarter combination gilead zack rank earning esp make confident earning beat upcoming report consensus mark quarter be report be peg share company strong hiv performance other antiviral product sale be be drive continue uptake tenofovir alafenamide taf base product genvoya descovy odefsey expect trend continue first quarter well franchise receive further boost fda approval once daily single tablet regimen str biktarvy bictegravir mg emtricitabine mg tenofovir alafenamide mg bic ftc taf hiv infection february hence sale get further boost read more be beat card gilead earning gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quoteincyte corporation incy free report be slate report result market open incyte track record have be impressive so far company deliver positive earning surprise trail quarters average beat last report quarter incyte deliver positive earning surprise model show incyte be likely beat estimate quarter combination incyte zack rank earning esp make confident earning beat upcoming report consensus mark quarter be report be peg cent share uncover best stock buy sell re report earning esp filter incyte continue gain traction lead drug jakafi performance incyte jakafi performance be strong drive patient demand sale guidance be also impressive october fda approve label update drug include addition new patient report outcome datum comfort study well update warning related progressive multifocal pivotal reach trial evaluate jakafi patient steroid refractory acute graft versus host disease have complete enrollment result be expect first half assume successful result incyte expect submit snda seek approval jakafi indication jakafi sale be expect get boost update label read more jafaki help incyte beat earning estimate incyte corporation price ep surprise incyte corporation price ep surprise incyte corporation hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2115,MRK,biotech bigwig gilead science inc gild free report develop drug treatment human virus hiv liver disease such chronic hepatitis virus hcv infection chronic hepatitis virus hbv infection cardiovascular hematology oncology inflammation respiratory disease hcv franchise boast drug sovaldi harvoni recently launch epclusa however hcv franchise continue grapple competitive pricing pressure lead massive decline harvoni sovaldi sale harvoni sovaldi have be face competition abbvie abbv free report viekira pak merck mrk free report zepatier other gilead be dominant player hiv market impressive portfolio same company be first bring market single tablet regimen str treatment hiv atripla strs hiv market include complera eviplera stribild other newly launch tenofovir alafenamide taf base product genvoya odefsey descovy be perform well strong adoption unite state europe genvoya have already become most prescribe regimen treatment nave switch patient launch november also genvoya have be list prefer regimen several hiv treatment guideline taf base regimen now represent total gilead hiv prescription volume follow launch genvoya launch odefsey descovy zack consensus estimate sale genvoya be truvada use pre exposure prophylaxis set also put strong performance company see significant uptick prep usage approximately patient used truvada end note hiv be primary area focus gilead company be work bring new hiv treatment market further boost sale franchise company receive major boost fda approve company once daily str biktarvy bictegravir mg emtricitabine mg tenofovir alafenamide mg bic ftc taf hiv infection approval provide major boost gilead hiv franchise biktarvy combine novel unboosted integrase strand transfer inhibitor insti bictegravir demonstrated safety efficacy profile descovy ftc taf dual nucleoside reverse transcriptase inhibitor nrti backbone be smallest insti base triple therapy str available approval new hiv therapy stiff competition glaxosmith gsk free report exist therapy tivicay triumeq gilead stock have return last month compare industry loss gilead have decent track record company earning beating estimate last miss last report quarter company earning beat expectation overall company record average positive earning surprise expect strength hiv franchise offset hcv franchise weakness make highly likely company beat earning first quarter read more be beat card gilead earning zack rankgilead currently carry zack rank buy see complete list today zack strong buy rank stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2116,MRK,sanofi sny free report report first quarter earning cent american depositary share beat zack consensus estimate cent earning grow report basis constant currency rate cer earning grow first quarter net sale grow report basis almost sale however miss zack consensus estimate unfavorable exchange rate movement hurt sale cer sale dip year year sale decline cer unite state however sale rise emerge market europe decline rest world japan south korea canada australia new puerto rico sanofi announce successful completion acquisition bioverativ be consolidated company financial statement mar growth rate mentioned be year year basis cer segmental sale include emerge market dip however cer pharmaceutical sale fall sanofi report global business unit gbus sanofi genzyme specialty care diabetes cardiovascular general medicine emerge market consumer healthcare sanofi pasteur vaccine sanofi genzyme specialty care gbu sale include emerge market increase drive contribution new immunology drug dupixent kevzara higher sale multiple sclerosis rare disease drug sale ms drug aubagio rise sale lemtrada fall meanwhile sale rare disease drug myozyme lumizyme improve fabrazyme sale be cerdelga sale come cerezyme sale rise oncology sale decline jevtana sale be thymoglobulin record sale be taxotere sale fall eloxatin sale be sanofi regeneron regn free report rheumatoid arthritis drug kevzara sarilumab be launch unite state june unite kingdom netherlands germany europe second half kevzara record sale quarter compare previous quarter meanwhile dupixent dupilumab treat atopic dermatitis be launch unite state march approve eu september december sanofi launch dupixent germany dupixent generate sale first quarter compare previous quarter kevzara dupixent generate total immunology sale first quarter lower record previous quarter diabetes cardiovascular gbu include emerge market decline diabetes franchise include emerge market decline due lower sale key drug lantus toujeo unite state sale diabetes drug unite state decline due previously announce change coverage part business persistent decline average glargine net price sale diabetes drug emerge market be europe fall lantus sale decline quarter lantus sale decline unite state due lower average net price change coverage sanofi part business europe sale decline due biosimilar competition patient switch toujeo toujeo generate sale report quarter however sale be sequentially unite state soliqua once daily titratable fix ratio combination lantus lyxumia be launch unite state january european country trade name suliqua soliqua suliqua generate sale quarter compare flat sequentially cardiovascular franchise sanofi pcsk therapy praluent garner worldwide sale report quarter general medicine emerge market gbu sale come sale establish product be strong performance emerge market be offset lower sale europe generic competition renvela renagel unite state sale generic rise sustain emerge market sale consumer healthcare gbu sale be drive emerge market especially latin america first quarter consolidated sanofi pasteur vaccine sale fall vaccine sale reflect termination sanofi pasteur msd joint venture merck mrk free report europe december vaccine sale be be impact constrain supply pentaxim china low sale dengvaxia follow announce label update november cost risesel general administrative expense sg increase cer quarter reflect investment immunology additional expense china consolidation bioverativ operate expense expense be cer reflect increase spend immuno oncology program medical investment immunology franchise outlooksanofi reiterate guidance expect business earning grow cer share company announce share buyback program quarter be expect be complete mid takesanofi first quarter result beat earning miss sale expectation however sanofi outlook look upbeat expect return growth year back bioverativ ablynx deal strong pipeline lower tax rate new tax law company continue execute business priority position company new period growth be expect begin second half year date sanofi share have lose compare decline industry zack rank stock considersanofi carry zack rank hold top rank stock same space be ligand pharmaceutical lgnd free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat company share have rally year date sanofi price consensus ep surprise sanofi price consensus ep surprise sanofi quote look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2117,MRK,week be rule cancer datum presentation annual meeting american society clinical oncology asco chicago pharma bigwig bristol myer bmy free report merck mrk free report roche rhhby free report other jak inhibitor be news week lilly lly free report finally gain fda approval rheumatoid arthritis ra candidate olumiant baricitinib unite state abbvie abbv free report present positive top line datum fifth late stage study upadacitinib ra recap week most important storiesupdate asco merck steal show asco present datum several cancer study pd inhibitor keytruda key presentation be pivotal lung cancer trial keynote study evaluate keytruda monotherapy newly diagnosed lung cancer patient keynote study evaluate keytruda combination chemotherapy difficult treat squamous small cell lung cancer nsclc study show treatment keytruda lead improve survival particularly datum keynote study evaluate keytruda combination chemotherapy first line treatment metastatic squamous nsclc be consider practice change investor year follow datum present advanced melanoma study show treatment keytruda lead long term survival benefit interim datum cohort phase ii study keynote evaluate keytruda monotherapy patient previously treat advanced small cell lung cancer sclc demonstrated encourage response rate overall population sclc patient well patient tumor express pd keytruda also demonstrated encourage orr study evaluate lenvima keytruda combination different tumor type keytruda monotherapy first line treatment advanced clear cell rcc bristol myer nektar therapeutic nktr present preliminary datum mid stage study evaluate nktr combination bristol myer pd inhibitor opdivo several tumor type response rate melanoma kidney cancer patient do not impress investor result drop nektar stock monday read more nektar bristol myer present datum cancer study bristol myer also present datum opdivo asco late stage study evaluate opdivo versus yervoy broad range patient resect stage iii iv melanoma opdivo demonstrated sustain superior recurrence free survival versus yervoy study opdivo chemotherapy show improve pfs versus chemotherapy first line lung cancer patient pd expression novartis nvs announce positive datum combination study breast cancer drug kisqali long term leukemia study tasigna read more novartis announce positive datum kisqali tasigna roche present datum late stage study show tecentriq atezolizumab chemotherapy reduce risk disease worsening death pfs advanced squamous nsclc patient versus chemotherapy alone abbvie present early datum phase ii study evaluate combination cancer drug imbruvica venclexta venetoclax first line treatment patient chronic lymphocytic leukemia cll datum demonstrated high rate response such patient also interim datum late stage study evaluate imbruvica roche rituxan waldenstrm rare form hodgkin lymphoma show combination significantly reduce risk disease progression death compare placebo rituxan pfizer pfe free report astrazeneca also make cancer datum presentation meeting lilly get fda nod lower dose olumiant eli lilly partner incyte gain fda approval lower dose mg company jak inhibitor olumiant fda do not approve higher dose mg drug label be approve box warning state risk serious infection malignancy thrombosis olumiant be already market europe japan generate sale first quarter unite state lilly face significant trouble get fda nod olumiant april last year fda have issue complete response letter new drug application seek approval olumiant request additional information determine most appropriate dose year april fda advisory committee have recommend approval lower dose drug not recommend higher dose mg inadequate safety profile support approval relative benefit read more eli lilly olumiant get fda nod rheumatoid arthritis abbvie late stage upadacitinib study succeed abbvie oral jak selective inhibitor upadacitinib meet primary well secondary endpoint fifth phase iii study select program top line datum study show thata significantly higher proportion patient treat upadacitinib mg dose achieve superior response compare chemotherapy agent methotrexate abbvie plan submit regulatory application upadacitinib rheumatoid arthritis second half year read more abbvie upadacitinib fifth ra study datum positive allergan activist pressure split ceo chairman role allergan agn free report be pressure week hedge fund firm senator investment group appaloosa disclose letter urge company engage management board overhaul firm ask pharmaceutical company split chairman chief executive role presently hold brent saunder other management change appaloosa run david tepper senator investment group run dougla silverman suggest outsider be hire role letter come heel allergan strategic plan announce last week divest woman health infectious disease unit allergan respond say board have be refreshed addition member last month read more allergan request shareholder veto management change glaxo complete buyout novartis stake consumer healthcare jv glaxo announce have complete previously announce deal buy novartis stake consumer healthcare joint venture acquisition novartis stake glaxo now have ownership consumer healthcare unit include product such sensodyne flonase glaxo novartis create jv part part transaction company combine consumer division pfizer invest more venture capital arm pfizer plan invest venture capital arm pfizer venture be invest small biotechs other emerge growth company be earmark company involved promising early stage neuroscience research read more pfizer boost venture capital effort neuroscience focus meanwhile pfizer regulatory application orally available parp inhibitor talazoparib metastatic breast cancer patient inherited brca mutation be accept review fda european medicine agency unite state new drug application nda be grant priority review fda decision accept december year top line result talazoparib registrational study embraca germline brca mutate breast cancer present december demonstrated superiority talazoparib chemotherapy improve progression free survival roche haemophilium candidate get priority review roche sbla look label expansion drug hemlibra person haemophilium factor viii inhibitor be grant priority review fda hemlibra be presently market routine prophylaxis prevent reduce frequency bleed episode haemophilium patient factor viii inhibitor fda grant priority review decision be expect oct separately roche cancer drug rituxan gain fda approval new indication moderate severe pemphigus vulgaris pv potentially life threaten nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock be green last week astrazeneca decline merck rise most asco strength past month glaxo gsk have be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup zoetis buy abaxis nvs get fda nod migraine drug next pharma world watch fda decision many pipeline drug line extension market product month look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2118,MRK,dow enjoy week steady gain trade concern largely take backseat worry related trade be only evident tuesday mexico impose tariff wide range product spike yield boost financial wednesday tech stock continue make steady gain investor indulge profit take thursday last week dow gain last friday stronger expect job report shrug trade fear extent economy see job addition exceed consensus estimate moreover unemployment fall hit year low share goldman sachs gs free report surge index lose last week week be once again mar trade war fear trump impose fresh tariff import steel aluminum eu canada mexico also grow political turmoil eurozone country italy spain see market take hit however market re-cover slightly mid week energy stock rally oil price surge dow index gain monday investor confidence bounce back owing strong economic backdrop ease global trade war fear rally be lead tech consumer discretionary stock share walmart wmt free report target tgt free report surge respectively apple inc aapl free report unveil several tool aim popularize augment reality worldwide developer conference wwdc impressed investor see stock hit time high microsoft corporation msft free report also hit time high share rally news company acquire github software developer platform index decline less tuesday tension unite state few trade ally once again dent investor confidence investor panic mexico impose tariff wide range product include pork bourbon type cheese be see setback number package food company share general mill gis free report kellogg free report decline share goldman sachs take beating bond yield take toll bank other financial company gain rise interest index gain wednesday rally be lead financial stock boost rise benchmark year treasury yield partly support robust economic datum ease trade war fear wednesday ecb chief economist peter praet signale end bond buy program result bond price fall push yield higher year treasury note rise basis point highest lead rally financial stock dow gain thursday nearly third index component finished day gain investor sell tech stock indulge profit take trader remain wary even head group state meet summit canada treasury yield decline initially hover mark component move index company mmm free report recently announce sale substantial part communication market division corning incorporate notably corning be premier manufacturer glass ceramic related material industrial scientific application transaction worth be likely generate full year earning benefit cent share zack rank hold communication market division incorporate company optical copper passive connectivity solution such xdsl fttx structure cable solution sale remain system integration service business remain pending be likely be complete later read divest part communication market arm apple recently unveil new operate system apple watch watcho worldwide developer conference wwdc new operate system primarily aim provide improve health activity platform read apple unveil watcho look expand healthcare additionally zack rank apple ceo tim cook reveal number register developer app store have hit further apple witness almost visitor app store week due strong portfolio apps moreover app store be significantly lucrative developer have generate revenue apps store read apple app developer base hit competition intensify johnson johnson jnj free report announce fortive corporation ftv have offer acquire advanced sterilization product asp business unit surgical system instrument subsidiary ethicon fortive have propose bound offer aggregate value unit offer comprise cash retain net receivables zack rank have day offer plan consult various work council offer be accept transaction be expect close early read receive buyout offer sterilization product unit unitedhealth group incorporate unh free report recently announce propose increase quarterly dividend cent share shareholder record jun be expect get meatier dividend jun company current dividend yield be higher industry apart higher dividend diversify health well be company share repurchase program have also be renew lower share count boost bottom line company have be authorize buy back share approximately outstanding share stock have zack rank buy see complete list today zack rank strong buy stock here merck co inc mrk free report corner limelight annual meeting american society clinical oncology asco chicago present practice change lung cancer datum pd inhibitor keytruda drug giant present encourage datum study evaluate drug advanced melanoma small cell lung cancer sclc patient new analysis year datum phase iii keynote study show advanced melanoma patient remain progression free month complete year treatment keytruda read merck present positive melanoma datum keytruda asco microsoft put speculation rest confirm github acquisition hour trading yesterday transaction involve microsoft stock be value approximately jun bloomberg have report zack rank microsoft be advanced talk acquire open source software development platform giant github notably company be last value github offer open source platform coding enthusiast software developer platform bring developer together work project compromise other code founder social coding platform boast developer have host repository march read microsoft put rumor rest confirm github buyout unite technology corporation utx free report operate segment pratt whitney announce have be award contract lot propulsion system support variant lightning ii aircraft unite technology have zack rank latest contract intend reduce propulsion system price support program affordability initiative notably low rate initial production lrip contract deal engine apart cover area program management production support engineering support spare module well spare part read unite technology win deal propulsion system performance top dow company table give show price movement largest component dow be price weight index last day last month last trading day dow have gain next week outlookmarket be process come term trade worry president trump have trigger such fear recede begin week mexico decision impose retaliatory tariff have investor worry tuesday additionally fed be slate raise rate next week move be likely rattle market give backdrop only be natural investor turn economic report encouragement several key piece datum be line release next week include retail sale most be encourage nature stock soon return winning way look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2119,MRK,medical group have plenty great stock investor always be look company be outperform peer have merck co mrk free report be stock year let take closer look stock year date performance find merck co be individual stock medical sector collectively company sit zack sector rank zack sector rank consider different sector group average zack rank individual stock group be measure sector be list best worst zack rank be successful stock pick model emphasize earning estimate estimate revision system highlight number different stock be poise outperform broader market next month mrk be currently sporting zack rank buy past day zack consensus estimate mrk full year earning have moved higher signal analyst sentiment be improve stock earning outlook be more positive base most recent datum mrk have return so far year same time medical stock have gain average mean merck co be outperform sector whole year look more specifically mrk belong large cap pharmaceutical industry include individual stock currently sit zack industry rank stock group have lose so far year so mrk be perform better group term year date return mrk likely be look continue solid performance so investor interested medical stock continue pay close attention company
2120,MRK,gilead science gild free report enter research collaboration license agreement hookipa biotech ag agreement gilead own exclusive right hookipa therat vaxwave arenavirus vector base immunization technology major chronic infectious disease indication hepatitis virus hbv human virus hiv research work be carry hookipa manufacture arenavirus base vector clinical development gilead exchange gilead provide upfront payment addition hookipa be eligible receive payment total more base achievement specify development regulatory commercial milestone moreover gilead fund research development activity hookipa also be eligible receive tiered royalty net sale agreement further expand relationship hookipa gilead follow gilead participation hookipa series financing dec hookipa unique therapeutic vaccine technology demonstrated excellent safety immunogenicity phase study gilead be banking hiv franchise drive growth future give persistent decline hcv sale gilead stock have lose last month industry loss gilead hcv franchise witness slowdown key market include unite state europe reflect lower sale harvoni sovaldi result competitive pricing pressure franchise see significant plunge sale due new competition fewer patient start pricing have largely stabilize market share stabilize mid patient start be expect decline further note harvoni sovaldi epclusa face competition abbvie abbv free report viekira pak mayret merck mrk free report zepatier other meanwhile gilead be look newer avenue help top line solidify presence gene therapy space initial uptake yescarta be also encourage gilead be also intend foray nash market pipeline candidate selonsertib filgotinib first quarter gilead announce agreement sangamo therapeutic inc sgmo free report use sangamo zinc finger nuclease technology platform development next generation ex vivo cell therapy oncology zack rankgilead currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2121,MRK,tesaro inc tsro free report announce collaboration genentech subsidiary roche rhhby free report develop parp inhibitor zejula niraparib combination latter immuno oncology drug tecentriq atezolizumab mek inhibitor cotellic cobimetinib combination be evaluate ovarian cancer patient be sensitive platinum base chemotherapy zejula be already approve maintenance treatment patient ovarian cancer have achieve complete partial response platinum base chemotherapy drug have show potential commendable sale growth launch april first quarter sale grow sequentially however look tesaro share price movement so far year show company have underperform industry stock fall industry register gain tesaro be develop zejula monotherapy treatment ovarian cancer first line set phase iii study similar indication be currently enrolling patient company be also focuse develop drug ovarian cancer tesaro roche be plan develop zejula combination tecentriq pd antibody treatment metastatic bladder cancer phase ib ii study be expect be initiate end meanwhile phase ii study be evaluate zejula combination merck mrk free report pd monoclonal antibody keytruda pembrolizumab patient recurrent platinum resistant ovarian cancer triple negative breast cancer successful development zejula monotherapy combination other cancer drug boost prospect drug parp inhibitor segment compete astrazeneca azn free report lynparza clovis rubraca apart zejula tesaro be also evaluate own pd antibody tsr several early stage study multiple tumor type tesaro inc price tesaro inc price tesaro inc quotetesaro currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2122,MRK,bristol myer squibb company bmy free report announce encourage datum phase iii checkmate study opdivo checkmate study be ongoing study evaluate immuno oncology combination opdivo nivolumab low dose mg kg yervoy ipilimumab compare pfizer pfe free report sutent sunitinib intermediate poor risk patient advanced renal cell carcinoma rcc year follow period treatment opdivo low dose yervoy lead statistically significant difference patient report outcome baseline versus sunitinib year follow study demonstrated patient show significant benefit disease related symptom improvement cancer related quality life well be benefit occur early opdivo low dose yervoy combination therapy be largely maintain treatment period opdivo maintenance therapy checkmate study patient advanced renal cell carcinoma have earlier show efficacy benefit opdivo low dose yervoy number measure include overall survival objective response rate progression free survival however result present now show patient treat immuno oncology combination also report significant improvement disease related symptom well positive change physical emotional functional well be additional analysis show similar result significant benefit see opdivo low dose yervoy relative sunitinib change baseline pre plan week landmark bristol myer share have decline year date compare industry decline note opdivo become first pd immune checkpoint inhibitor gain regulatory approval july be currently approve several country include unite state eu japan several cancer indication opdivo become first pd inhibitor be approve hematological malignancy classical hodgkin lymphoma unite state eu november november opdivo gain fda approval treatment patient recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy meanwhile company continue evaluate opdivo alone combination therapy yervoy other cancer agent label expansion drug additional indication give product access higher patient population increase commercial potential significantly however opdivo be face competitive challenge unite state fda approve merck mrk free report keytruda first line treatment metastatic squamous small cell lung cancer nsclc company be expect suffer further loss market share separate release bristol myer announce fda lift partial clinical hold place checkmate phase iii study evaluate addition opdivo pomalidomide dexamethasone patient relapse refractory multiple myeloma decision follow consultation fda agreement amendment study protocol fda put clinical hold study evaluate opdivo base combination relapse refractory multiple myeloma september fda precaution follow risk identify trial study pd agent keytruda patient multiple myeloma stock warrant lookbristol myer carry zack rank hold better rank stock same space be illumina inc ilmn free report sporting zack rank strong buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year bristol myer squibb company price bristol myer squibb company price bristol myer squibb company hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2123,MRK,merck co inc mrk free report pd inhibitor keytruda rule annual meeting american society clinical oncology asco chicago drug giant present additional datum pivotal lung cancer study drug merck present additional datum pivotal keynote study patient locally advanced metastatic nonsquamous squamous small cell lung cancer nsclc tumor express pd protein level percent greater tps percent april merck have say such patient keytruda lead significant survival benefit compare platinum base chemotherapy latest release company say patient tps percent median overall survival os be month keytruda arm versus month chemotherapy arm pd tps percent patient population median os be month patient tps percent be month versus month month respectively chemotherapy alone also merck say risk progression death progression free survival pfs secondary endpoint be pd tps percent population time interim analysis be not statistically significant notably keytruda monotherapy be already market first line treatment patient metastatic nsclc tumor express pd protein level percent greater tps percent base datum keynote study os datum keynote study be approve be include keytruda label drug be prescribe treat expand lung cancer patient population further reinforce position lung cancer market later year merck file regulatory application get os datum study include label keytruda merck also announce datum second interim analysis pivotallung cancer study keytruda phase iii keynote study evaluate keytruda combination carboplatin paclitaxel nab paclitaxel chemotherapy first line treatment metastatic squamous nsclc datum study show combination keytruda chemotherapy lead significant improvement os pfs regardless pd expression risk death os be reduce compare chemotherapy alone median os be month keytruda combination group versus month chemotherapy arm pfs improvement be nearly half patient keytruda combination group compare chemotherapy alone median pfs be month keytruda combination group versus month chemotherapy arm regulatory application include datum study be submit fda same time company have present datum first interim analysis keynote study say study meet pre specify secondary endpoint overall response rate orr early cohort participant asco company say orr be keytruda arm compare chemotherapy alonemetastatic squamous nsclc be difficult treat population account lung cancer case keytruda combination be approve treat difficult treat population lung cancer sale drug improve further year so far merck share have outperformed industry share have rise period industry decline keytruda be second largest product merck portfolio be market many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma gastric cancer bladder cancer microsatellite instability high msi mismatch repair deficient cancer treatment fetch sale almost year year upside be drive global launch new indication further bolster demand keytruda sale be gain particularly strong momentum first line lung cancer indication fact keytruda be only pd approve first line set certain lung cancer patient monotherapy well combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo meanwhile keytruda be be evaluate several lung cancer study multiple setting stage disease monotherapy well combination therapy asco merck also present datum several combination study tyrosinekinase inhibitor lenvimaplus keytruda asco study evaluate lenvima keytruda combination different tumor type unresectable hepatocellular carcinoma hcc squamous cell carcinoma head neck scchn advanced renal cell carcinoma rcc advanced endometrial carcinoma ec demonstrated encourage orr well safety profile cancer combination remind investor march merck form deal japan eisai co develop commercialize lenvima monotherapy well combination keytruda several type cancer asco merck also present interim datum mid stage study keynote evaluate keytruda monotherapy first line treatment advanced clear cell rcc datum show keytruda arm orr primary endpoint be meanwhile sub group patient tumor expressed pd orr be keytruda be be study more type cancer more study include excess combination study merck be collaborate several company include amgen amgn free report incyte glaxo gsk free report pfizer separately evaluation keytruda combination other regimen merck currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2124,MRK,merck mrk free report have receive fda accelerate approval label expansion blockbuster pd therapy keytruda include advanced cervical cancer second line set company need evaluate drug confirmatory study indication gain continue approval eligible patient treatment cervical cancer be select base fda approve test pd expression tumor combine positive score cp approval come bit earlier expect date jun fda have grant priority review label expansion regulatory application march keytruda be most successful immuno oncology drug date approval several cancer indication include lucrative first line lung cancer be first pd therapy approve advanced cervical cancer first indication keytruda gynecologic cancer well year so far merck share have outperformed industry share have rise period industry decline latest fda approval be base datum single cohort multus cohort phase ii study keynote evaluate drug recurrent metastatic cervical cancer datum subset patient population express pd cp show keytruda achieve objective response rate moreover patient achieve complete response patient demonstrated partial response drug generate response cervical cancer patient pd expression tumor have cp merck be evaluate drug wide range cancer indication treatment setting more clinical study recently conclude annual meeting american society clinical oncology pd inhibitor steal limelight encourage datum multiple clinical study datum presentation garner attention physician investor be second interim analysis pivotal lung cancer study keytruda phase iii keynote study moreover merck have collaborate several pharma company include amgen amgn free report glaxo gsk free report pfizer pfe free report incyte evaluate keytruda combination other regimen drug generate worldwide sale almost first quarter year period line extension approval cervical cancer potential approval other indication review positive momentum drug be expect continue merck co inc price merck co inc price merck co inc quotemerck currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2125,MRK,eli lilly company lly free report swiss partner astrazeneca azn free report announce discontinuation late stage study alzheimer disease ad candidate lanabecestat recommendation independent datum monitoring committee idmc idmc say amaranth study evaluate lanabecestat early alzheimer disease daybreak alz study mild alzheimer disease dementia be unlikely meet primary endpoint completion lead decision discontinue study oral beta secretase cleave enzyme bace inhibitor company claim recommendation stop study be not base safety concern lilly do not expect incur significant cost related discontinuation maintain previously issue earning guidance meanwhile partnership lilly astrazeneca develop bace inhibitor remain intact lilly astrazeneca be also develop treatment alzheimer disease antibody target beta amyloid early stage study year date lilly share have rise industry decline be not first failure lilly alzheimer disease market november lilly amyloid candidate solanezumab fail meet primary endpoint late stage ad study lilly decide drop development solanezumab lilly also suffer major setback august have halt development phase iii alzheimer candidate semagacestat alzheimer disease market have attract lot attention several company however successful development therapy treatment alzheimer disease fatal illness cause progressive decline memory be challenge note several company have fail regard year jnj free report halter development atabecestat investigational bace inhibitor be be develop preclinical stage alzheimer disease due safety concern february year merck mrk free report discontinue second late stage study evaluate bace inhibitor verubecestat treatment prodromal alzheimer disease success be unlikely february last year merck discontinue late stage study evaluate verubecestat mild moderate alzheimer disease due lack efficacy late biogen alzheimer disease study ban fail show early positive result raise investor concern candidate chance success alzheimer disease market represent huge commercial potential successfully develop product generate billion dollar sale once launch lilly currently carry zack rank buy see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2126,MRK,merck co inc mrk free report share have perform well year so far contrast industry performance merck belong zack large cap pharmaceutical industry be stock group comprise largest drugmaker world zack large cap pharmaceutical industry have underperform well zack medical sector stock industry have collectively decline zack composite zack medical sector have rise year date respectively however merck share have rise year so far industry decline also earning estimate rise rise past day rally significant part merck outperformance year be drive strong performance positive regulatory update related pd inhibitor keytruda very short span time keytruda have become merck largest product be already approve use different setting involve different tumor type year have already gain approval new indication include third line treatment adult well pediatric patient primary mediastinal cell lymphoma pmbcl type hodgkin lymphoma second line treatment recurrent metastatic cervical cancer label expansion approval drive sale keytruda future quarters treatment generate sale first quarter sequentially year year upside be drive global launch indication further boost demand keytruda sale be gain particularly strong momentum first line lung cancer indication fact keytruda be only pd approve first line set certain lung cancer patient monotherapy well combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo recently conclude annual meeting american society clinical oncology pd inhibitor steal limelight encourage datum multiple clinical study datum presentation merck garner most attention physician investor be second interim analysis pivotal lung cancer study keytruda phase iii keynote study keytruda be also be study more type cancer more study include excess combination study merck be collaborate several company include amgen amgn free report incyte glaxo pfizer separately evaluation keytruda combination other regimen other year merck partner astrazeneca azn free report gain approval europe japan parp inhibitor lynparza advanced ovarian cancer unite state metastatic breast cancer merck also announce positive datum several late stage study mainly evaluate keytruda further line extension merck also sign deal japan eisai co ltd jointly develop commercialize latter tyrosine kinase inhibitor lenvima monotherapy well combination keytruda several type cancer also agree buy viralytic limit australian pharmaceutical company develop oncolytic immunotherapy range cancer strengthen oncology portfolio conclusionmerck carry zack rank hold have share challenge form generic competition several drug pricing pressure rise competitive pressure diabetes franchise product isentress hiv zepatier hcv zostavax vaccine nonetheless go forward new product keytruda lynparza bridion continue contribute meaningfully top line merck animal health unit be also strong remain core growth driver company meanwhile merck also continue focus cost cut initiative drive bottom line see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2127,MRK,tesaro inc tsro free report share rally jun rumor potential acquisition offer roche rhhby free report report intereconomia com article state roche announce offer soon roche be look strengthen oncology portfolio acquisition roche have recently offer buy remain stake molecular information company foundation medicine fmi free report help roche develop personalize cancer drug used foundation medicine genomic profile expertise roche be interested tesaro tesaro have long be consider attractive acquisition target investment community tesaro receive major boost approval parp inhibitor zejula unite state march last year drug be available maintenance therapy ovarian cancer treat platinum base chemotherapy drug have show potential commendable sale growth have gain majority share parp inhibitor segment drug be also approve europe november furthermore tesaro be develop zejula treatment ovarian cancer first line set company be also focuse develop drug monotherapy combination pd antibody ovarian cancer breast cancer small cell lung cancer bladder cancer company have collaboration roche merck mrk free report develop zejula combination tecentriq keytruda respectively moreover tesaro be also develop own pd antibody tsr several cancer indication performance zejula approve indication ongoing clinical study prospective indication make tesaro attractive acquisition target roche however several large pharma company now have ample cash hand follow tax overhaul increase probability other company rivale potential bid roche tesaro inc price tesaro inc price tesaro inc quotetesaro currently carry zack rank hold see complete list today zack rank strong buy stock here look tesaro share price movement so far year show company have underperform industry stock fall industry decline make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2128,MRK,myriad genetic inc mygn free report have moved step forward acquire fda approval company bracanalysis cdx test be used companion diagnostic pfizer pfe free report parp inhibitor talazoparib company note fda have accept supplementary premarket approval spma application bracanalysis cdx help identify best responder talazoparib be also encourage know talazoparib be currently hold status new drug application nda priority review fda target date set december myriad genetic pfizer submit respective spma nda proposal fda base result pfizer sponsored embraca trial evaluate talazoparib compare chemotherapy patient germline inherited brca mutate gbrcam negative locally advanced metastatic breast cancer mbc last december primary result study be present datum show patient gbrca locally advanced metastatic breast cancer mbc demonstrated superior progression free survival pfs treat talazoparib comparison have receive physician choice standard care chemotherapy recent development genetic have be leave stone unturned boost uptake bracanalysis cdx regard system get manufacturing marketing approval japanese ministry health labour welfare earlier april year system now be used companion diagnostic parp inhibitor lynparza notably january fda approve bracanalysis cdx test usage companion diagnostic astrazeneca azn free report merck mrk free report parp inhibitor lynparza olaparib patient negative metastatic breast cancer mbc germline brca mutation market potentialper myriad genetic patient metastatic disease be currently eligible bracanalysis testing japan moreover approximately new case negative breast cancer be diagnosed year promising datum indicate timely strategic role latest approval be likely play favor company share price performance myriad genetic have be gain investor confidence consistently positive result past month share company have significantly outperformed broader industry stock have surge broader industry fall myriad genetic currently carry zack rank hold look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2129,MRK,bristol myer squibb company bmy free report announce positive result phase ii study eloquent oncology drug empliciti study be evaluate addition empliciti pomalyst low dose dexamethasone epd patient relapse refractory multiple myeloma rrmm international study be evaluate pomalyst base triplet combination patient rrmm receive least prior therapy include revlimid proteasome inhibitor study achieve primary endpoint result show statistically significant clinically meaningful improvement progression free survival pfs patient treat epd compare only pomalyst dexamethasone pd datum be also present rd congress european hematology association datum study show patient randomize epd experience reduction risk disease progression compare patient randomize pd alone median pfs month compare month pd patient additionally pfs benefit experience patient randomize epd be consistent patient have receive prior line therapy more prior line therapy combination therapy approve provide important treatment option patient relapse refractory multiple myeloma disease have progressed treatment lenalidomide proteasome inhibitor bristol myer be co develop empliciti abbvie abbv free report bristol myer share have decline year date compare industry decline earlier company announce china national drug administration have approve blockbuster immuno oncology drug opdivo treatment locally advanced metastatic small cell lung cancer nsclc prior platinum base chemotherapy adult patient egfr alk genomic tumor aberration company be first only pd inhibitor approve china approval be base datum pivotal phase iii study checkmate trial patient enrolled be china note opdivo become first pd immune checkpoint inhibitor gain regulatory approval be currently approve several country include unite state eu japan several cancer indication opdivo become first pd inhibitor be approve hematological malignancy classical hodgkin lymphoma unite state eu november drug have be perform impressively due demand result rapid commercial acceptance several indication include melanoma renal cell carcinoma second line nsclc label expansion additional indication give product access higher patient population increase commercial potential drug significantly however opdivo face stiff competition merck mrk free report keytruda roche rhhby free report tecentriq limit market share gain zack rank stock considerbristol myer carry zack rank hold see complete list today zack strong buy rank stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2130,MRK,alzheimer candidate fail clinical study week independent datum monitoring committee idmc recommend lilly lly free report astrazeneca azn free report discontinue study lanabecestat share israel base small biotech galm pharmaceutical ltd glmd free report rise announce positive datum mid stage study nash candidate aramchol merck mrk free report gain fda approval new indication blockbuster pd therapy keytruda glaxo gsk free report late stage hiv study meet primary endpoint abbvie abbv free report roche rhhby free report astrazeneca gain regulatory nod label expansion key cancer drug recap week most important storieslilly astrazeneca alzheimer candidate fail lilly astrazeneca be discontinue late stage study alzheimer disease candidate lanabecestat recommendation idmc idmc say study early alzheimer disease other mild alzheimer disease dementia be unlikely meet primary endpoint completion lead decision discontinue study oral beta secretase cleave enzyme bace inhibitor latest setback add long list fail treatment option deadly brain disease read more lilly astrazeneca scrap study alzheimer candidate merck keytruda get fda nod new indication merck gain fda accelerate approval new indication blockbuster pd therapy keytruda week include third line treatment adult well pediatric patient primary mediastinal cell lymphoma pmbcl type hodgkin lymphoma second line treatment recurrent metastatic cervical cancer label expansion approval drive sale keytruda future quarters also merck regulatory application seek approval expand age indication hpv vaccine gardasil be grant priority review fda merck be look get gardasil approve woman man age hpv vaccine be presently approve man woman age read more merck keytruda get fda nod lymphoma indication glaxo gemini study drug hiv regimen succeed glaxo late stage study testing drug hiv regimen dolutegravir tivicay lamivudine show inferiority hiv control standard drug regimen regimen dolutegravir tenofovir alafenamide fumarate emtricitabine study be conduct treatment nave hiv infected adult have not receive prior antiviral therapy regulatory application get drug regimen dolutegravir lamivudine approve be expect be file later year positive news glaxo mylan generic version glaxo blockbuster respiratory drug advair be delay again second complete response letter fda galm share hit roof nash candidate succeed study galm announce positive top line result mid stage study lead candidate aramchol treatment alcoholic steatohepatitis nash study demonstrated aramchol be effective reach primary endpoint importantly reduction liver fat measure magnetic resonance spectroscopy be demonstrated patient have complete week treatment aramchol mg compare placebo result strongly support advancement aramchol pivotal phase iii study share company sky-rocket news be announce read more galm soar positive nash datum aramchol allergan cgrp drug meet goal study allergan announce second cgrp candidate atogepant meet primary endpoint mid stage study cgp md study evaluate dose atogepant prevention episodic migraine week atogepant achieve reduction statistical significance monthly migraine probable migraine mpm headache day baseline dose allergan oral cgrp acute migraine treatment ubrogepant have already show positive result phase iii study separately allergan announce positive top line datum phase iii study pipeline candidate bimatoprost sr investigational implant develop first sustain release drop free treatment option lower intraocular pressure iop patient open angle glaucoma ocular hypertension datum study show bimatoprost sr reduce iop approximately week primary efficacy period thereby demonstrate inferiority study comparator timolol eye drop abbvie roche cancer drug get fda nod combo use abbvie roche announce fda approval combination use cancer drug venclexta rituxan previously treat chronic lymphocytic leukemia cll fda approval be base positive datum phase iii murano study venclexta rituxan relapse refractory cll venclexta be jointly market abbvie roche subsidiary genentech unite state abbvie outside unite state separately roche announce fda approval cancer drug avastin combination chemotherapy carboplatin paclitaxel treatment woman advanced ovarian cancer follow initial surgery latest approval avastin be now approve different type cancer unite state tagrisso get eu approval first line set astrazeneca azn free report lung cancer drug tagrisso gain eu approval first line treatment adult patient metastatic nsclc tumor have egfr mutation similar label expansion application be approve unite state april now tagrisso be approve unite state european union japan china second line treatment option patient egfr mutation positive nsclc label expansion first line set drive sale tagrisso higher future quarters read more astrazeneca tagrisso win eu nod first line lung cancer accept offer sell diabetes unit formally accept bound offer receive march approximately private equity firm platinum equity lifescan diabetes device unit lifescan unit make blood glucose monitoring product generate revenue last year transaction be expect be close end year read more accept platinum equity offer lifescan unit nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session last week pfizer decline most glaxo generate highest return past month too glaxo have be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup mrk impress asco lly get fda nod olumiant next pharma world watch fda decision several pipeline drug line extension market product month wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2131,MRK,incyte corporation incy free report be schedule report first quarter result market open last report quarter company beat estimate incyte earning track record have be decent so far last quarters company earning surpass expectation thrice miss incyte deliver average positive earning surprise say time frame incyte stock have lose last month industry decline let see thing be shape quarter likely positive surprise proven model show incyte be likely beat earning quarter have right combination key ingredient stock need have positive earning esp favorable zack rank strong buy buy hold happen zack esp incyte have earning esp most accurate estimate be peg earning cent share zack consensus estimate stand earning cent positive esp hint earning surprise uncover best stock buy sell re report earning esp filter zack rank incyte have zack rank increase predictive power esp further combine positive esp chance earning beat be usually peg higher caution sell rate stock go earning announcement especially company be see negative estimate revision factor drive growthincyte lead drug jakafi ruxolitinib be first class jak jak inhibitor approve treatment patient polycythemia vera pv patient intermediate high risk myelofibrosis mf include primary mf post pv mf post essential thrombocythemia mf incyte market drug unite state be market novartis nvs free report jakavi outside country incyte continue gain traction jakafi performance incyte jakafi performance be strong drive patient demand sale guidance be also impressive october fda approve label update drug include addition new patient report outcome datum comfort study well update warning related progressive multifocal pivotal reach trial evaluate jakafi patient steroid refractory acute graft versus host disease gvhd have complete enrollment result be expect first half assume successful result incyte expect submit snda seek approval jakafi indication jakafi sale be expect get boost update label incyte expect jakafi revenue range more growth remind investor jakafi sale royalty be key component incyte revenue growth iclusig sale olumiant royalty be also contribute top line iclusig revenue be expect range expense be expect range sg expense be expect range also expect investor focus pipeline update incyte suffer few setback month incyte partner merck mrk free report announce failure combination therapy incyte epacadostat merck keytruda achieve improve progression free survival keytruda alone phase iii study echo keynote study be evaluate combination drug treatment unresectable metastatic melanoma external datum monitoring committee recommend termination study follow review datum pivotal study moreover fda arthritis advisory committee have recommend approval mg dose baricitinib once daily oral medication treatment moderately severely active rheumatoid arthritis adult patient have have inadequate response intolerance methotrexate however advisory committee do not recommend approval mg dose baricitinib propose indication base adequacy safety benefit risk profile fda be generally not require follow advisory committee recommendation consider same review nda baricitinib fda have earlier issue complete response letter same stock considerhere be other health care stock worth consider right combination element beat earning gw pharmaceutical plc gwph free report be expect report earning company have earning esp zack rank see see complete list today zack rank stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2132,MRK,glaxosmithkline plc gsk free report report core earning cent american depositary share first quarter miss zack consensus estimate cent however earning be constant exchange rate cer compare year figure share glaxo be almost apr hour trading due lower expect result report quarter moreover stock have lose year time industry growth quarterly revenue rise cer drive strong performance vaccine segment top line however marginally miss zack consensus estimate growth rate mentioned be year year basis cer quarterly highlightssale be unite state international market flip side sale europe be flat year year glaxo report financial figure segment pharmaceutical vaccine consumer healthcare pharmaceutical division register revenue growth drive hiv drug respiratory disease drug namely nucala ellipta portfolio upside be partly offset decline sale older respiratory product include seretide advair ventolin establish pharmaceutical hiv sale increase back growth unite state europe respectively international sale be also year year encourage number be drive continue market share growth triumeq sale tivicay sale however sale hiv drug epzicom kivexa tumble due more severe generic competition particularly affect european market notably company latest product hiv portfolio be juluca dolutegravir rilpivirine first drug regimen once daily single pill hiv drug be approve unite state last november generate first quarterly sale compare register previous quarter however last november gilead gild free report triple combination once daily single tablet regimen biktarvy bictegravir emtricitabine tenofovir alafenamide be approve fda hiv infection treatment nod regulatory agency competitive threat juluca future quarters respiratory sale be flat cer year year international market sale increase metric decline unite state europe respectively quarter review sale rise ellipta portfolio nucala be offset fall sale older product seretide advair ventolin sale new respiratory portfolio grow include first quarterly contribution newly launch trelegy ellipta trelegy ellipta only once daily single inhaler triple therapy copd yielded sale unite state eu first quarter notably april gsk announce trelegy ellipta gain fda approval expand indication new indication be long term once daily maintenance treatment airflow obstruction patient copd include chronic bronchitis emphysema ellipta product record surge sale drive market share gain global roll continue however upside be offset weak sale seretide advair ventolin sale drop year year immuno inflammation drug benlysta rise quarter discussion new grouping establish pharmaceutical comprise previous establish product cardiovascular metabolic urology other pharma product establish pharmaceutical sale decrease quarter review sale consumer healthcare segment nudge slowdown market condition power brand particularly pain relief oral health category see sturdy performance quarter sale vaccine segment be impressive have increase year year primarily drive sale newly launch shingrix vaccine prevention shingle unite state shingrix record sale report quarter drive favorable recommendation center disease control prevention advisory committee immunization practice merck mrk free report zostavax moreover company state be rapidly build coverage shingrix vaccine presently more patient have access vaccine medicare commercial channel be important note shingrix be approve eu well japan last month give indication unite state vaccine sale soar europe international market metric decrease respectively sale meningitis vaccine bexsero increase unite state europe market menveo unite state post higher sale same be offset soft performance establish vaccine thank fierce competitive pressure infanrix pediarix europe company continue expect ep growth cer advair generic be launch further year however probable event advair generic be introduce market mid glaxo anticipate adjust ep be flat year year cer company namely mylan myl free report hikma pharmaceutical novartis try bring generic version advair market have receive complete response letter crl fda mylan hikma get crl last year novartis be forward same year delay entry generic market glaxosmithkline plc price consensus ep surprise glaxosmithkline plc price consensus ep surprise glaxosmithkline plc quote zack rankglaxo carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2133,MRK,investor be keenly await earning result merck co inc mrk free report pfizer inc pfe free report main reason be merck kgaa consumer healthcare division be acquire procter gamble co pg free report last month follow acquisition focus shift pfizer procter gamble be expect acquire consumer healthcare business unit former meanwhile healthcare sector have jump past year become best perform sector sign sector well be become more evident last year nyse arca pharmaceutical index nasdaq biotechnology index gain respectively merck pfizer be schedule report be good time figure be better stock pharma giant carry zack rank buy see complete list today zack rank strong buy stock here other major earning schedule same day include apple inc aapl free report bp bp free report price have witness decline past year pfizer have advanced so pfizer be clear winner respect better return rival merck broader industry rise same period dividend yieldin year time merck pfizer have offer dividend yield respectively industry dividend yield be so pfizer have take lead here too compare merck broader industry net marginthe pharmaceutical industry enjoy higher profit margin several other sector be possibly reason critic sector continually draw attention allegedly exorbitant drug pricing help sector maintain steep margin net margin value pfizer perform better rival merck have net margin value comparison broader industry have net margin value debt equity debt equity ratio be good indicator financial health company be good proxy debt servicing capacity context capital intensive industry pharma be indicator company long term sustainability merck debt equity ratio be significantly high compare industry ratio comparatively lower ratio pfizer evidently have better leverage condition most appropriate ratio evaluate drug maker be perhaps ev ebitda metric be usually used compare stock same industry be superior other metric such be not affected different capital structure company come pharma major pfizer ev ebitda ratio be overvalue broader industry have ev ebitda value other hand ev ebitda ratio merck be underpriced pfizer industry earning history espconsider more comprehensive earning history merck have deliver positive surprise prior quarters average positive earning surprise comparison pfizer deliver average positive earning surprise prior quarters register earning beat time consider earning esp merck pfizer have esp value respectively imply pfizer be advantage respect moreover pfizer earning estimate current year have advanced last day slightly better merck increase conclusionour comparative analysis show merck hold edge pfizer consider only ev ebitda ratio previous earning performance however consider price performance leverage position net margin estimate revision pfizer hold advantage merck additionally pfizer have better dividend yield merck make clearly better stock clinch case favor pfizer point time be have positive better esp merck be lead indicator likely positive surprise be be better bet pfizer merck prepare report earning next week more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2134,MRK,expect pfizer inc pfe free report beat expectation report first quarter result market open last quarter company deliver positive earning surprise pharma giant have strong record earning surprise company earning surpass expectation last quarters deliver average positive surprise pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quotepfizer share have rise year so far decrease industry factor playin innovative health ih segment new product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain chantix smoking cessation eliquis blood thinner contribute top line meaningfully zack consensus estimate sale ibrance worldwide lyrica ih xeljanz chantix be respectively essential health biosimilar emerge market be expect support sale however loss exclusivity associate generic competition product primarily pristiq unite state continue hamper top line growth blockbuster drug enbrel sale continue decline quarter due biosimilar competition zack consensus estimate sale enbrel be prevnar prevenar vaccine franchise continue see lower sale unite state lower demand generic competition continue hurt sale viagra pfizer be face supply shortage product legacy hospira portfolio mainly due capacity constraint technical issue expect supply shortage continue hurt sale pfizer expect cut sterile injectable shortage new cancer drug bavencio avelumab besponsa inotuzumab ozogamicin mylotarg be likely contribute overall sale time xeljanz sutent bosulif be approve line extension fourth quarter new product line extension be boost sale bottom line be expect be drive cost saving share buyback also expect management provide update initial launch uptake pfizer partner merck mrk free report newly approve oral sglt inhibitor steglatro ertugliflozin tablet apart be approve monotherapy treat type ii diabetes steglatro have also be approve use combination metformin brand name segluromet januvia brand name steglujan model proven model show pfizer be likely beat earning have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate cent zack consensus estimate cent be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank pfizer have zack rank combination pfizer zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerhere be large health care stock worth consider model have right combination element beat earning time bristol myer squibb company bmy free report have earning esp zack rank company be schedule report first quarter earning apr see complete list today zack rank stock here celgene corporation celg free report be slate announce financial figure company have earning esp be zack rank stock investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2135,MRK,merck co inc mrk free report report first quarter result market open last quarter company deliver positive earning surprise merck performance have be pretty impressive company exceed earning expectation trail quarters average positive earning surprise last quarters be merck co inc price ep surprise merck co inc price ep surprise merck co inc quote merck share have rise year so far decrease industry let see thing be shape announcement factor considermerck new product cancer drug keytruda lynparza bridion injection be likely drive top line however loss market exclusivity several drug softness diabetes januvia janumet franchise lower sale key product zostavax zepatier due competitive pressure hurt sale keytruda sale be be drive launch new indication globally keytruda sale be gain particularly strong momentum indication first line lung cancer be only pd approve set keytruda development program also significantly advanced regulatory approval new indication unite state europe japan approval expand patient population drive sale higher second half momentum be expect be maintain well strong demand most market continue drive sale bridion sugammadex injection however rise competitive pressure have begin hurt sale relatively newer drug zepatier fourth quarter zepatier sale decline sequentially due reduction share volume due increase competition call merck have warn negative trend continue most market outside unite state start come pressure older product continue pricing pressure be hurt sale januvia lower demand due competition be hurt sale isentress vaccine zostavax sale continue be hurt strong competition glaxo gsk free report newly approve shingle vaccine shingrix gardasil gardasil sale be soft fourth quarter due lower sale unite state nonetheless fourth quarter call company have mentioned underlie growth increase coverage rate be still strong unite state remain be see gardasil sale improve soon be report quarter zack consensus estimate total sale vaccine segment be peg animal health franchise sale be likely remain strong zack consensus estimate animal health segment sale be earning whispersour proven model do not conclusively show merck beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be zack consensus estimate most accurate estimate be peg cent share uncover best stock buy sell re report earning esp filter zack rank merck zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considerhere be large cap health care stock worth consider model have right combination element beat earning time bristol myer squibb company bmy free report have earning esp zack rank company be schedule report first quarter earning apr see complete list today zack rank stock here pfizer inc pfe free report be also slate announce financial figure company have earning esp be zack rank stock investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2136,MRK,alzheimer fatal illness cause progressive decline memory have always be highly challenge area not much progress be make spite significant investment fund resource tuesday lilly lly free report swiss partner astrazeneca azn free report say be discontinue late stage study alzheimer disease candidate lanabecestat recommendation independent datum monitoring committee idmc idmc say study be unlikely meet primary goal completion prompt decision stall study oral beta secretase cleave enzyme bace inhibitor several company have fail develop safe effective treatment option deadly brain disease year jnj free report halter development atabecestat investigational bace inhibitor be be develop preclinical stage ad due safety concern february year merck mrk free report discontinue second late stage study evaluate bace inhibitor verubecestat treatment prodromal ad success be unlikely february last year merck discontinue late stage study evaluate verubecestat mild moderate ad due lack efficacy january pfizer pfe free report say end effort alzheimer parkinson disease area long back pfizer have shelved late stage ad candidate bapineuzumab iv fail phase iii study late biogen biib free report ad study ban fail show early positive result raise investor concern candidate chance success clinical stage company axovant science suffer major setback september investigational ad candidate fail meet co primary efficacy endpoint late stage study company decide discontinue development mg dose treatment ad lilly decide november not seek approval investigational ad treatment solanezumab follow disappointing result late stage study candidate be be evaluate see slow progression memory problem associate amyloid protein form plaque brain person alzheimer accord alzheimer association year drug be test alzheimer study register clinicaltrial gov only succeed go gain fda approval be somewhat underlie cause severe neurological ailment alzheimer not be clear disease cancer also alzheimer progress go unnoticed year time symptom ailment become evident significant function be already lose make develop drug treat disease difficult interest still alive setback several company continue invest heavily develop alzheimer disease treatment give high commercial potential market success area mean huge return consider more american be live alzheimer disease number expect triple datum alzheimer association be consider be biggest burden society be sixth lead cause death age unite state market have immense commercial potential company come new treatment rake billion dollar sale biogen novartis nvs free report eisai astrazeneca amgen be presently work alzheimer disease treatment biogen ad pipeline comprise mid well late stage candidate different mechanism action include tau candidate biib amyloid aducanumab candidate well bace inhibitor elenbecestat program candidate be be develop collaboration eisai meanwhile novartis amgen be collaborate bace inhibitor cnp have fast track status unite status roche be collaborate ac immune development alzheimer disease treatment lilly astrazeneca be also develop treatment alzheimer disease antibody target beta amyloid early stage study earlier year fda propose new guideline be aim lower clinical study goal alzheimer disease drug aim treat earlier stage patient have not yet display functional disability clinical abnormality strategy be part fda ongoing effort expand access safe effective treatment option many serious condition effort fda also reinvigorate research effort alzheimer drug repeat failure lilly merck carry zack rank buy see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2137,MRK,amgen amgn free report announce european commission ec have approve label expansion blockbuster drug prolium drug be now approve treatment bone loss associate long term systemic glucocorticoid therapy adult patient increase risk fracture be also call glucocorticoid induced osteoporosis be third approve indication prolium europe approval be backed increase bone mineral density bmd achieve drug phase iii study similar line extension application receive approval unite state last month prolium be presently market europe treatment man postmenopausal woman osteoporosis high risk fracture well increase bone mass man prostate cancer receive hormone ablation amgen share have increase year so far industry decline phase iii study evaluate prolium improvement bmd patient receive glucocorticoid treatment compare allergan agn free report actonel risedronate study comprise patient group patient sustain glucocorticoid treatment glucocorticoid continue arm second patient initiate glucocorticoid therapy glucocorticoid initiate arm arm prolium demonstrated greater improvement lumbar spine bmd patient year year compare actonel study primary endpoint glucocorticoid induced osteoporosis be most common form secondary osteoporosis press release patient receive glucocorticoid treatment long term have show vertebral fracture proportion eligible patient be small line extension be likely boost sale drug further prolium be major revenue source amgen be witness growth market share unite state internationally competition generic other drug approve osteoporosis first quarter drug generate sale almost half dollar year year drug face competition generic other brand drug include eli lilly lly free report evista alendronate merck mrk free report fosamax raloxifene novartis zometa zoledronate amgen inc price amgen inc price amgen inc quotezack rankamgen currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2138,MRK,dow traverse tough week suffering loss consecutive session initially investor be wary outcome fed ecb meeting outcome meeting president trump north korea kim jong be also eagerly await ultimately talk have little impact market proceedings comment ecb be also largely welcome investor however fed rate hike lead loss bourse last week dow gain last friday investor concern related global trade war summit fade away blue chip index post third straight positive trading session close highest level march notably procter gamble co pg free report be major advancer blue chip index gain index gain last week biggest weekly gain march dow post third straight weekly advance global trade war tariff related conflict however index end lower last tuesday trade tension dent investor confidence notably dow close best single day percentage gain apr last wednesday dow index gain merely point monday investor be apprehensive outcome meeting president donald trump north korean counterpart kim jong additionally market eagerly await outcome meeting major central bank index lose point tuesday gain consecutive session notably verizon communication inc vz free report be major decliner blue chip index loss nearly however movement index be modest direction investor be closely await outcome meeting fed ecb meanwhile investor concern regard trade war geopolitical conflict wane least time be president donald trump north korea leader kim jong inked agreement denuclearize korean peninsula stop war game index decline wednesday federal reserve announce second rate hike year indicated central bank raise rate more aggressively go forward be second rate hike be line market expectation fed official now expect rate hike year compare march meeting index lose thursday financial weigh index share jpmorgan chase co jpm free report lose be largest drag blue chip index however broader market moved higher strong retail sale jobless claim number investor also welcome ecb comment program bond purchase component move index boee company ba free report recently win modification contract provide full rate production lot aircraft navy contract be award naval air system command patuxent river boee have zack rank buy majority work be carry el segundo st loui mi rest be perform various location unite state work related deal be expect be complete june read boee win navy deal aircraft merck co inc mrk free report have receive fda accelerate approval label expansion blockbuster pd therapy keytruda include advanced cervical cancer second line set company need evaluate drug confirmatory study indication gain continue approval eligible patient treatment cervical cancer be select base fda approve test pd expression tumor combine positive score cp approval come bit earlier expect date jun fda have grant priority review label expansion regulatory application march read merck keytruda get fda approval cervical cancer separate development zack rank merck announce fda accelerate approval pd inhibitor keytruda third line treatment adult well pediatric patient primary mediastinal cell lymphoma pmbcl type hodgkin lymphoma read merck keytruda get fda nod lymphoma indication caterpillar inc cat free report report rise global retail sale month end deceleration rise witness april average sale growth note past month year separate development caterpillar announce board director have approve increase quarterly dividend cent share increase dividend be paid aug shareholder record jul stock have zack rank strong buy see complete list today zack rank stock here walt disney company free report avenger infinity war recently crossed gross collection globally day release debut apr only other movie avatar titanic star war force awaken have reach milestone avenger infinity war have collect jun make fifth highest gross movie domestically zack rank hold disney hold record biggest domestic debut ever open weekend internationally movie have collect notably avenger infinity war be third biggest western release ever china gross collection release country read disney avenger infinity war collect globally johnson johnson jnj free report have accept offer private equity firm platinum equity sale lifescan diabetes device unit company have announce receipt bound offer platinum equity march johnson johnson have zack rank lifescan unit make blood glucose monitoring product generate revenue last year move be line strategic plan diabetes business company have be plan streamline core asset last year part streamline effort have announce close operation corporation diabetes care unit last october read accept platinum equity offer lifescan unit exxon mobil corporation xom free report have accelerate development liza phase commence development drill offshore guyana development drill first well plan phase be initiate facilitate start production schedule liza prospect operated zack rank exxonmobil be locate mile kilometer offshore guyana stabroek block spread acre square kilometer exxonmobil co venturer have encounter estimate recoverable resource more oil equivalent barrel stabroek block read exxon mobil expedite liza phase development process performance top dow company table give show price movement largest component dow be price weight index last day last month last trading day dow have decline next week dow have endure difficult week thing seem be look investor geopolitical tension have be dial follow trump kim talk secondly ecb plan taper bond purchase have be welcome investor further even market moved lower fed rate hike move have be largely price meanwhile economic indicator continue remain encourage several key piece datum especially housing be line release next week most be encourage nature stock soon return winning way wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2139,MRK,world cancer research be change fast space be see huge development company be take great stride treat variety cancer cancer research be definitely exciting area investor keep close watch come year be disease be lead cause morbidity mortality world precede only heart disease day asco conference chicago be basically most important annual cancer research event conclude yesterday conference featured clinical update several company latest development treat disease merck mrk free report steal limelight asco present datum several cancer study pd inhibitor keytruda datum presentation merck garner most attention physician investor be second interim analysis pivotal lung cancer study keytruda phase iii keynote study study evaluate keytruda combination chemotherapy first line treatment metastatic squamous nsclc be difficult treat lung cancer patient population datum study show combination keytruda chemotherapy lead significant improvement overall survival os progression free survival regardless pd expression pd be protein present surface cell risk death os be reduce compare chemotherapy alone pfs improvement be nearly half patient keytruda combination group compare chemotherapy alone datum be term practice change cnbc change way doctor look prescribe drug cancer patient further cement merck position lung cancer market be most lucrative oncology sector context mention roche rhhby free report also present datum similar late stage study show tecentriq atezolizumab chemotherapy reduce risk disease worsening death pfs advanced squamous nsclc patient versus chemotherapy alone come back merck company also present datum pivotal lung cancer study keynote evaluate keytruda monotherapy first line nsclc patient pd expression least study also show treatment keytruda lead improve survival meanwhile year follow datum present advanced melanoma study show treatment keytruda lead long term survival benefit interim datum cohort phase ii study keynote evaluate keytruda monotherapy patient previously treat advanced small cell lung cancer sclc demonstrated encourage response rate overall population sclc patient well patient tumor express pd meanwhile keytruda also demonstrated encourage orr study evaluate lenvima keytruda combination different tumor type keytruda monotherapy first line treatment advanced clear cell rcc merck partner astrazeneca also present positive lynparza combo datum breast cancer share merck have go more friday jun asco strength nektar therapeutic nktr free report be biggest loser asco nektar partner bristol myer bmy free report present preliminary datum mid stage study evaluate nktr combination bristol myer pd inhibitor opdivo several tumor type response rate melanoma kidney cancer patient do not impress investor result fall nektar stock jun be probably worst performance index member last year read more nektar bristol myer present datum cancer study merck bristol myer nektar currently have zack rank hold see complete list today zack rank strong buy stock here bristol myer also present datum opdivo asco late stage study evaluate opdivo versus yervoy broad range patient resect stage iii iv melanoma opdivo demonstrated sustain superior recurrence free survival versus yervoy study opdivo chemotherapy show improve pfs versus chemotherapy first line lung cancer patient pd expression celgene celg free report partner bluebird bio present early stage datum car cell therapy bb patient late stage relapse refractory multiple myeloma study show median pfs month heavily pre treat patient population datum do not impress investor celgene also present datum car therapy liso ce jcar acquire acquisition juno earlier year datum show month patient relapse refractory aggressive cell hodgkin lymphoma nhl remain remission maintain complete response read more celgene present datum car therapy revlimid pomalyst novartis nvs free report announce positive datum combination study breast cancer drug kisqali long term leukemia study tasigna read more novartis announce positive datum kisqali tasigna abbvie abbv free report present early datum phase ii study evaluate combination cancer drug imbruvica venclexta venetoclax first line treatment patient chronic lymphocytic leukemia cll datum demonstrated high rate response such patient also interim datum late stage study evaluate imbruvica roche rituxan waldenstrm rare form hodgkin lymphoma show combination significantly reduce risk disease progression death compare placebo rituxan pfizer amgen astrazeneca also make cancer datum presentation meeting today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2140,MRK,merck co inc mrk free report be steal limelight annual meeting american society clinical oncology asco chicago present practice change lung cancer datum pd inhibitor keytruda drug giant present encourage datum study evaluate drug advanced melanoma small cell lung cancer sclc patient share merck be monday response positive news year so far merck share have outperformed industry share have rise period industry decline year follow datum present pivotal advanced melanoma study show treatment keytruda lead long term survival benefit new analysis year datum phase iii keynote study show advanced melanoma patient remain progression free month complete year treatment keytruda year datum melanoma cohort phase ib keynote study demonstrated significant survival benefit advanced melanoma patient year os rate secondary endpoint study be patient previously untreated metastatic melanoma patient interim datum cohort phase ii study keynote evaluate keytruda monotherapy patient previously treat advanced small cell lung cancer sclc demonstrated encourage response rate overall population sclc patient well patient tumor express pd overall population sclc patient overall response rate orr primary endpoint be patient tumor expressed pd orr be keytruda be be evaluate combination chemotherapy first line treatment patient extensive stage small cell lung cancer phase iii study keynote earlier asco merck present datum pivotal lung cancer trial keynote study evaluate keytruda monotherapy newly diagnosed lung cancer patient keynote study evaluate keytruda combination chemotherapy difficult treat squamous small cell lung cancer nsclc study show treatment keytruda lead improve survival further cement merck position lung cancer market be most lucrative oncology sector meanwhile keytruda also demonstrated encourage orr study evaluate lenvima keytruda combination different tumor type keytruda monotherapy first line treatment advanced clear cell rcc keytruda hold dominant position lung cancer be only pd approve first line set certain lung cancer patient monotherapy well combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo fact keytruda sale be gain particularly strong momentum first line lung cancer indication meanwhile keytruda be be evaluate several lung cancer study multiple setting stage disease monotherapy well combination therapy keytruda be be study more type cancer more study include excess combination study merck be collaborate several company include amgen amgn free report incyte glaxo gsk free report pfizer separately evaluation keytruda combination other regimen merck currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2141,MRK,nektar therapeutic nktr free report bristol myer squibb bmy free report announce preliminary datum ongoing pivot phase ii study american society clinical oncology asco annual meeting study be evaluate combination nektar lead immuno oncology candidate nktr bristol myer squibb opdivo nivolumab company present datum patient enrolled phase dose escalation stage study first patient consecutively enrolled select dose expansion cohort phase ii pivot study show pre specify efficacy criterium be achieve tumor type first line melanoma first line renal cell carcinoma type kidney cancer first line urothelial cancer company plan commence phase iii registrational study first line advanced melanoma patient third quarter pivotal study be also be design renal cell carcinoma urothelial cancer efficacy criterium recommend phase ii dose be meet first stage patient consecutively enrolled second stage patient consecutively enrolled combination regimen be advanced registrational trial tumor type result treatment nave patient stage iv metastatic melanoma show objective response rate orr first part study be treat subject response be observed patient stage study further datum show treatment nave patient stage iv metastatic renal cell carcinoma orr stage study be patient response be see patient second phase study finally result treatment nave patient stage iv metastatic urothelial carcinoma show orr first part study be patient same response rate pd negative patient pd positive tumour company add enrolment be also continue second stage pivot trial patient melanoma renal cell urothelial small cell lung triple negative breast cancer company add overall study week patient pd negative status baseline be converted pd positive status result show subject achieve stable disease partial response complete response share company be more response rate melanoma kindney cancer study be market expectation company believe nktr combination opdivo potentially expand treatment benefit bring patient cancer company add enrolment be also continue second stage pivot trial patient melanoma renal cell urothelial small cell lung triple negative breast cancer share nektar have decrease year date compare industry gain note opdivo become first pd immune checkpoint inhibitor gain regulatory approval july be currently approve several country include unite state eu japan several cancer indication opdivo become first pd inhibitor be approve hematological malignancy classical hodgkin lymphoma unite state eu november november opdivo gain fda approval treatment patient recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy also note february nektar inked agreement bristol myer squibb jointly develop commercialize nktr combination bristol myer squibb opdivo opdivo yervoy ipilimumab more indication tumor type nektar be also conduct phase ii propel study evaluate efficacy safety nktr combination roche rhhby free report tecentriq atezolizumab merck mrk free report keytruda pembrolizumab notably propel study complement company ongoing pivot trial stock warrant looknektar carry zack rank hold see complete list today zack rank stock here nektar therapeutic price nektar therapeutic price nektar therapeutic hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2142,MRK,dow traverse tough week suffering loss consecutive session initially investor be wary outcome fed ecb meeting outcome meeting president trump north korea kim jong be also eagerly await ultimately talk have little impact market proceedings comment ecb be also largely welcome investor however fed rate hike lead loss bourse last week dow gain last friday investor concern related global trade war summit fade away blue chip index post third straight positive trading session close highest level march notably procter gamble co pg free report be major advancer blue chip index gain index gain last week biggest weekly gain march dow post third straight weekly advance global trade war tariff related conflict however index end lower last tuesday trade tension dent investor confidence notably dow close best single day percentage gain apr last wednesday dow index gain merely point monday investor be apprehensive outcome meeting president donald trump north korean counterpart kim jong additionally market eagerly await outcome meeting major central bank index lose point tuesday gain consecutive session notably verizon communication inc vz free report be major decliner blue chip index loss nearly however movement index be modest direction investor be closely await outcome meeting fed ecb meanwhile investor concern regard trade war geopolitical conflict wane least time be president donald trump north korea leader kim jong inked agreement denuclearize korean peninsula stop war game index decline wednesday federal reserve announce second rate hike year indicated central bank raise rate more aggressively go forward be second rate hike be line market expectation fed official now expect rate hike year compare march meeting index lose thursday financial weigh index share jpmorgan chase co jpm free report lose be largest drag blue chip index however broader market moved higher strong retail sale jobless claim number investor also welcome ecb comment program bond purchase component move index boee company ba free report recently win modification contract provide full rate production lot aircraft navy contract be award naval air system command patuxent river boee have zack rank buy majority work be carry el segundo st loui mi rest be perform various location unite state work related deal be expect be complete june read boee win navy deal aircraft merck co inc mrk free report have receive fda accelerate approval label expansion blockbuster pd therapy keytruda include advanced cervical cancer second line set company need evaluate drug confirmatory study indication gain continue approval eligible patient treatment cervical cancer be select base fda approve test pd expression tumor combine positive score cp approval come bit earlier expect date jun fda have grant priority review label expansion regulatory application march read merck keytruda get fda approval cervical cancer separate development zack rank merck announce fda accelerate approval pd inhibitor keytruda third line treatment adult well pediatric patient primary mediastinal cell lymphoma pmbcl type hodgkin lymphoma read merck keytruda get fda nod lymphoma indication caterpillar inc cat free report report rise global retail sale month end deceleration rise witness april average sale growth note past month year separate development caterpillar announce board director have approve increase quarterly dividend cent share increase dividend be paid aug shareholder record jul stock have zack rank strong buy see complete list today zack rank stock here walt disney company free report avenger infinity war recently crossed gross collection globally day release debut apr only other movie avatar titanic star war force awaken have reach milestone avenger infinity war have collect jun make fifth highest gross movie domestically zack rank hold disney hold record biggest domestic debut ever open weekend internationally movie have collect notably avenger infinity war be third biggest western release ever china gross collection release country read disney avenger infinity war collect globally johnson johnson jnj free report have accept offer private equity firm platinum equity sale lifescan diabetes device unit company have announce receipt bound offer platinum equity march johnson johnson have zack rank lifescan unit make blood glucose monitoring product generate revenue last year move be line strategic plan diabetes business company have be plan streamline core asset last year part streamline effort have announce close operation corporation diabetes care unit last october read accept platinum equity offer lifescan unit exxon mobil corporation xom free report have accelerate development liza phase commence development drill offshore guyana development drill first well plan phase be initiate facilitate start production schedule liza prospect operated zack rank exxonmobil be locate mile kilometer offshore guyana stabroek block spread acre square kilometer exxonmobil co venturer have encounter estimate recoverable resource more oil equivalent barrel stabroek block read exxon mobil expedite liza phase development process performance top dow company table give show price movement largest component dow be price weight index last day last month last trading day dow have decline next week dow have endure difficult week thing seem be look investor geopolitical tension have be dial follow trump kim talk secondly ecb plan taper bond purchase have be welcome investor further even market moved lower fed rate hike move have be largely price meanwhile economic indicator continue remain encourage several key piece datum especially housing be line release next week most be encourage nature stock soon return winning way wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2143,MRK,merck co inc mrk free report announce fda accelerate approval pd inhibitor keytruda third line treatment adult well pediatric patient primary mediastinal cell lymphoma pmbcl type hodgkin lymphoma company need evaluate drug confirmatory study indication gain continue approval be second indication keytruda have gain fda approval week tuesday keytruda gain fda accelerate approval advanced cervical cancer second line set label expansion approval drive sale keytruda future quarters latest approval keytruda become first pd therapy approve pmbcl be also second indication keytruda hematologic malignancy first be refractory classical hodgkin lymphoma chl fda approval be receive march approval be base datum keynote study year so far merck share have outperformed industry share have rise period industry decline keytruda be largest product merck portfolio prior latest approval keytruda be approve use different setting involve different tumor type treatment generate sale first quarter sequentially year year upside be drive global launch indication further boost demand keytruda sale be gain particularly strong momentum first line lung cancer indication fact keytruda be only pd approve first line set certain lung cancer patient monotherapy well combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo recently conclude annual meeting american society clinical oncology pd inhibitor steal limelight encourage datum multiple clinical study datum presentation merck garner most attention physician investor be second interim analysis pivotal lung cancer study keytruda phase iii keynote study keytruda be be study more type cancer more study include excess combination study merck be collaborate several company include amgen amgn free report incyte glaxo gsk free report pfizer separately evaluation keytruda combination other regimen separate press release merck announce supplemental biologic license application sbla seek approval expand age indication hpv vaccine gardasil be grant priority review fda sbla be aim get gardasil approve woman man age prevention certain hpv related cancer disease vaccine be presently indicated man woman year age fda have set action date oct first quarter gardasil gardasil record sale year yearmerck currently carry zack rank buy see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2144,MRK,merck co inc mrk free report be look interesting pick technical perspective company be see favorable trend move average crossover front recently day move average mrk break day simple move average suggest short term bullish trend have already start take place stock have moved higher past week company currently have zack rank buy suggest now definitely be time candidate more bullishness especially be case investor consider have be happen mrk earning estimate revision front lately estimate have go lower past month compare higher consensus estimate have also moved higher too so give move estimate positive technical factor investor want watch candidate closely more gain future see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2145,MRK,eli lilly company lly free report report first quarter adjust earning share beat zack consensus estimate share earning rise year quarter backed robust volume drive growth new product sale lower operate cost tax rate include asset impairment restructure other special charge first quarter earning share be loss cent first quarter revenue detailquarterly revenue also beat zack consensus estimate sale grow year year backed strong performance new drug favorable currency movement make lower sale establish product strattera ciali forteo volume rise increase demand new product trulicity cyramza taltz basaglar jardiance lartruvo offset decline sale establish product however volume growth be softer previous quarter higher realize price several drug contribute sale growth quarter foreign exchange rate also have favorable impact revenue grow ex revenue rise pharmaceutical revenue rise quarter however decrease demand food animal product continue hurt sale lilly animal health segment establish product record growth quarter include humalog year year humulin trajenta sale other establish product decline quarter forteo sale decline due decrease volume unfavorable wholesale retail buy pattern unite state cymbalta sale decline erbitux sale decline alimta sale rise higher sale unite state offset sale decline international market ex market sale decline due competitive pressure loss exclusivity certain country however sale alimta increase unite state due increase volume higher realize price zyprexa sale decline due loss exclusivity japan ciali sale decline hurt lower demand unite state loss exclusivity europe strattera sale decline due loss exclusivity new product trulicity generate revenue year year revenue benefit growth glp market market share gain cyramza revenue be year year backed strong demand cyramza ex revenue increase benefit strong volume currency benefit partially offset lower realize price revenue increase drive increase volume higher realize price jardiance sale surge drive increase market share grow sglt class unite state increase volume outside unite state basaglar record revenue compare previous quarter generate revenue unite state improve sequentially drive increase demand drug gain medicare part formulary access taltz bring sale compare previous quarter higher ex revenue be offset lower sale be hurt unfavorable specialty pharmacy buy pattern lartruvo olaratumab generate revenue quarter compare previous quarter olumiant baricitinib have be launch select european country japan moderate severe rheumatoid arthritis drug generate sale quarter backed strong launch uptake germany compare previous quarter drug be review unite state lilly partner incyte corporation incy free report re submit nda baricitinib january setback company monday lilly inform fda advisory committee have recommend approval mg dose jak inhibitor not recommend higher dose mg ground safety profile be not adequate support approval relative benefit final decision fda be expect june year please note april last year fda have issue complete response letter crl new drug application nda baricitinib safety concern verzenio be launch unite state fourth quarter generate sale quarter compare previous quarter elanco animal health segment sale decline due decrease demand food animal product lilly be explore strategic alternative business include sale merger create separate company initial public offer decision regard same be expect be announce july lilly ultimately opt retain business gross margin operate income adjust gross margin quarter decrease basis point manufacturing efficiency higher realize price be offset negative product mix effect foreign exchange rate international inventory sell operate income increase year year due lower operate cost total operate expense include research development marketing selling administrative expense percent revenue decline basis point quarter due company cost save effort ep guidance uppedlilly raise previously issue outlook adjust earning well sale adjust earning share be now expect range higher expect previously reflect expect benefit higher operate profit lower tax rate revenue range be also slightly up expect previously gross margin be expect be approximately same previously expect adjust tax rate be expect be approximately previously approximately marketing selling administrative expense guidance be tighten range compare previously research development expense guidance be slightly increase range compare previously due increase funding requirement pipeline development takelilly first quarter result be impressive beat estimate earning sale also raise guidance metric share drug giant rise more pre market trading however year date lilly share have decline compare industry decline go forward lilly new product trulicity taltz basaglar cyramza jardiance lartruvo verzenio olumiant be expect continue drive revenue however competitive pressure lilly drug be expect rise year challenge remain company form loss patent exclusivity product ciali year impact generic competition strattera effient axiron latest baricitinib setback be disappointment lilly carry zack rank buy see complete list today zack rank strong buy stock here eli lilly company price consensus ep surprise eli lilly company price consensus ep surprise eli lilly company quotestock considerother top rank large cap pharma stock include merck mrk free report pfizer pfe free report carry zack rank merck share have rise year so far earning estimate increase respectively past day pfizer earning estimate rise respectively past day stock have go year so far make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2146,MRK,healthcare space have be tough journey year popular etf health care select sector spdr fund xlv free report have shed so farwhile vanguard health care etf vht free report fidelity msci health care index etf fhlc free report have gain least meanwhile ishare healthcare etf iyh free report have add mixed trend be likely continue head earning season big name pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc read healthy earning unitedhealth etfs watch let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stockspfizer have zack rank earning esp indicate higher chance beating estimate quarter stock have see positive earning estimate revision cent be report quarter deliver average positive earning surprise past quarters have vgm score pfizer be schedule report earning open bell merck be expect report result market open have zack rank earning esp stock deliver positive earning surprise last quarters average beat witness positive earning estimate revision cent past day be report quarter merck have vgm score amgen carry zack rank have earning esp indicate reasonable chance beating estimate time earning surprise track past quarters be strong average positive surprise addition amgen witness positive earning estimate revision cent past day quarter be report stock have solid vgm score amgen report earning apr market close read small cap biotech etfs be soar abbvie have zack rank earning esp company deliver positive earning surprise last quarters average beat see solid earning estimate revision cent past month be report quarter stock have solid vgm score company be schedule report apr open bell gilead be expect release earning market close have zack rank earning esp gilead deliver positive earning surprise last quarters see negative earning estimate revision penny past month be report quarter have vgm score bristol myer likely report earning apr open bell have zack rank earning esp stock deliver average positive earning surprise past quarter witness positive earning estimate revision cent be report quarter have vgm score sum earning surprise well card healthcare sector be expect witness earning growth first quarter suggest upside healthcare etfs particular etfs have zack etf rank see healthcare etfs here want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2147,MRK,glaxosmithkline plc gsk free report be schedule report first quarter result apr market open last quarter company deliver positive surprise share glaxo share have outperformed industry so far year stock have gain industry decline glaxo earning performance have be pretty impressive so far company bottom line surpass estimate thrice trail quarters meeting same remain overall company come average beat let see thing be shape quarter factor consider glaxo continue see strong sale pharmaceutical vaccine business segment company pharmaceutical segment be expect be drive solid sale new hiv product tivicay triumeq sale lately launch respiratory drug ellipta product nucala be likely offset decline sale older respiratory product namely seretide advair avodart fourth quarter conference call glaxo state inhaled respiratory product particularly older one be grapple persistent competitive pricing pressure expect continue meanwhile many glaxo key drug lovaza avodart be face sale decline due generic competition trend expect carry well be important note pricing dynamic rivalry wo be hurt sale company top selling drug advair unite state generic competition be hamper same europe vaccine segment be likely consistently benefit sustain uptake meningitis vaccine bexsero menveo acquire novartis ag nvs free report moreover glaxo shingrix vaccine prevention shingle approve unite state last october generate better expect initial sale previous quarter upcoming quarter expect significant contribution drug company sale sale gain favorable recommendation center disease control prevention advisory committee immunization practice merck zostavax moreover shingrix be approve eu well japan last month give indication fetch additional sale additionally glaxo receive approval other key new drug namely trelegy ellipta provide medicine single inhaler treat copd juluca dolutegravir rilpivirine first drug regimen once daily single pill hiv be also expect drive company top line last month glaxo announce have enter agreement novartis buy latter stake consumer healthcare joint venture acquisition glaxo now stake ownership claim consumer healthcare unit include product such sensodyne flonase expect management further discuss deal be report quarter importantly sale growth be wane consumer healthcare segment due generic competition transderm scop divestment well impact general sale tax india consumer healthcare segment be anticipate remain stress first quarter be not much predict push sale meanwhile cost saving restructure continue efficiency boost operate profit earning whispersour proven model do not conclusively show glaxo be likely beat earning quarter be stock need have positive earning esp favorable zack rank strong buy buy hold happen be not case here see zack esp glaxo have earning esp most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report ourearning esp filter zack rank glaxo carry zack rank increase predictive power esp however company esp make surprise prediction difficult caution sell rate stock go earning announcement especially company be see negative estimate revision glaxosmithkline plc price ep surprise glaxosmithkline plc price ep surprise glaxosmithkline plc quote stock considerhere be couple health care stock worth consider right combination element surpass estimate time pfizer inc pfe free report be schedule release result company have earning esp zack rank see complete list today zack rank stock here merck co inc mrk free report be schedule report earning company have earning esp zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2148,MRK,johnson johnson jnj free report kick pharma earning season strong note beating zack consensus estimate earning sale first quarter performance be drive continue positive momentum second half improvement consumer segment sale do perform earning share beat zack consensus estimate quarterly revenue be also beat consensus mark buoy strong performance company up previously issue sale outlook read more top earning estimate raise sale guidance pharmaceutical segment sale grow year year first quarter due strong sale domestic international market favorable currency impact sale market rise quarter international sale grow new product imbruvica cancer darzalex multiple myeloma continue perform well oncology sale increase quarter constitute almost quarter pharmaceutical sale core product xarelto stelara zytiga simponi simponi aria invega sustenna also contribute growth imbruvica sale rise drug be market partnership abbvie inc abbv free report edurant sale rise prezista sale increase however concerta sale continue decline due generic competition sale risperdal consta also fall sale invokana invokamet decline due higher manage care discounting blockbuster rheumatoid arthritis drug remicade market partnership merck co inc mrk free report fall pharma segment achieve clinical milestone quarter include fda approval prostate cancer drug erleada treatment man metastatic castration resistant prostate cancer line extension already market prostate cancer drug zytiga combination prednisone first line set certainly boost sale now expect revenue range higher expect previously overall expect pharmaceutical segment remain strong consumer medical device segment continue improve expect other company merck amgen inc amgn free report pfizer lilly follow suit novartis report encourage resultsnovartis ag nvs free report also report week swiss pharma giant beat earning revenue estimate drive strong performance key drug cosentyx entresto novartis report core earning share beating zack consensus estimate record year quarter revenue increase beating zack consensus estimate read more novartis beat earning revenue estimate sale innovative medicine division grow drive volume growth cosentyx entresto however entry generic gleevec unite state europe impact sale unfavorably cosentyx sale increase drive strong growth indication expand access entresto sale increase drive increase uptake oncology franchise exclude gleevec grow drive promacta revolade tafinlar mekinist jakavi recent launch however sale sandoz division be due price erosion unite state however year so far share have lose novartis share be decrease witness industry other pharma bigwig report solid result too pfizerpfizer top line be expect be favorably impact new product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain chantix smoking cessation eliquis blood thinner soon be report quarter moreover line extension xeljanz sutent bosulif receive fourth quarter be also expect bring more sale however loss exclusivity associate generic competition pristiq unite state lyrica europe product shortage legacy hospira likely affect sale negatively blockbuster drug enbrel sale continue decline quarter due biosimilar competition company sale be expect increase low single digit level zack consensus estimate sale earning be peg cent respectively zack consensus estimate sale currently stand represent year year growth pfizer carry zack rank buy merckmerck blockbuster drug keytruda lynparza bridion injection be expect boost revenue first quarter keytruda sale be gain momentum approval launch keytruda new indication especially first line lung cancer however rise competitive pricing pressure be expect hurt sale zostavax zepatier januvia isentress animal health franchise sale be likely remain strong first quarter merck carry zack rank see complete list today zack rank strong buy stock here zack consensus estimate sale earning be peg cent respectively zack consensus estimate sale be represent year year increase eli lilly lly sale lilly diabetes drug trulicity jardiance be expect grow drive market share gain other new drug such cyramza taltz lartruvo be also expect boost top line due continue strong demand verzenio be also expect generate higher sale first quarter however patent expiry country cymbalta strattera effient axiron zyprexa evista competitive pressure mainly immuno oncology agent alimta hurt sale drug expect strong uptake new product offset decline sale establish product quarter too zack consensus estimate sale earning be peg respectively zack consensus estimate sale stand represent rise year year lilly carry zack rank bristol myer squibb company bmy several label expansion bristol myer blockbuster cancer drug opdivo drive company sale last year be expect do so year well moreover cardiovascular drug eliquis also demonstrated strong performance expect trend continue quarter label expansion leukemia drug sprycel approve november bring more sale drug moreover continue strong performance yervoy orencia have favorable impact however genericization plavix avapro avalide baraclude unite state due loss exclusivity be significantly hurt company top line company also face stiff competition immuno oncology space hiv business continue face competitive pressure zack consensus estimate sale earning be peg cent respectively zack consensus estimate sale be peg represent rise year year bristol myer carry zack rank new product majority company be do well be expect offset decline sale legacy drug due loss exclusivity moreover most company boast deep promising pipeline also new tax law boost prospect strategic merger acquisition licensing deal collaboration smaller company strengthen company product portfolio wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2149,MRK,share astrazeneca plc azn free report have rise so far year large cap pharma industry decline drug sector be strong start have struggle thereafter probably market instability few negative update pipeline regulatory front only large cap drug stock have rise year include astrazeneca merck mrk free report abbvie inc abbv free report glaxo gsk free report factor drive astrazeneca announce quite few positive development regulatory pipeline front year lead share outperform industry astrazeneca record good progress oncology first quarter lynparza receive eu approval broad second line ovarian cancer indication tablet formulation breast cancer unite state tagrisso receive important approval first line egfr mutate small cell lung cancer nsclc pd inhibitor imfinzi be approve immediately launch second indication unite state early stage lung cancer drive sale higher first quarter hematology moxetumomab submission be accept fda grant priority review intend indication third line hairy cell leukemia cvrm astrazeneca receive eu approval lokelma treat hyperkalemia respiratory biologic medicine fasenra be approve eu japan january be however few negative pipeline update fasenra do not meet primary endpoint first copd trial galathea arctic trial imfinzi tremelimumab third line small cell lung cancer do not meet primary endpoint progression free survival pfs overall survival os meanwhile core product nexium crestor seroquel be face generic competition be hurt sale growth diabetes franchise also face stiff competition pricing pressure be hurt sale astrazeneca respiratory franchise nonetheless astrazeneca newer drug brilinta cardiovascular lynparza ovarian cancer farxiga forxiga type ii diabetes tagrisso lung cancer be do well brilinta farxiga achieve blockbuster status exceed sale imfinzi fasenra launch early be strong start give highly competitive clinical profile astrazeneca be also look further label expansion drug newer medicine register sale growth first quarter new drug keep contribute top line several launch be underway therapeutic area oncology cv metabolism respiratory astrazeneca be look return growth back newer drug meanwhile cost cut initiative drive bottom line positive development be likely keep stock momentum alive year astrazeneca currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2150,MRK,roche rhhby free report announce phase iii study impower immunotherapy tecentriq meet co primary endpoint overall survival os progression free survival pfs multicentre open label randomize study evaluate efficacy safety tecentriq combination carboplatin nab paclitaxel versus only chemotherapy chemotherapy nave patient stage iv squamous small cell lung cancer nsclc study result show combination tecentriq chemotherapy carboplatin abraxane albumin bound paclitaxel nab paclitaxel help patient live significantly longer compare chemotherapy alone first line treatment advanced squamous nsclc moreover tecentriq combination reduce risk disease worsening death progression free survival pfs compare chemotherapy alone note tecentriq be already approve unite state european union previously treat metastatic nsclc patient locally advanced metastatic urothelial cancer muc be not eligible cisplatin chemotherapy have have disease progression follow platinum contain therapy present roche have ongoing phase iii lung cancer study be evaluate tecentriq alone combination other drug be third phase iii study evaluate tecentriq alone combination demonstrate os benefit person nsclc have demonstrated positive result label expansion drug boost sale however competition be stiff nsclc market like merck mrk free report keytruda bristol myer squibb company bmy free report opdivo roche stock have lose year industry gain approval new drug potential label expansion exist drug bode well roche legacy drug herceptin mabthera be face competition biosimilar novartis nvs free report have already launch biosimilar version rituxan mabthera europe fda also approve biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer zack rankroche currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2151,MRK,dow endure volatile week marked key geopolitical development begin week treasury secretary make encourage remark progress trade negotiation china however later week president trump expressed dissatisfaction progress trade talk also cancel much await summit north korea leader kim jong result stock gain lose alternate session last week dow gain point last friday close session nearly unchanged trade negotiation unite state china continue weigh investor sentiment president donald trump say doubt negotiation have positive outcome also bond yield reach highest level last week index decline last week trade talk unite state china remain focus week continue weigh investor sentiment moreover high interest rate too push stock lower week year note yield crossed mark first time dent investor confidence see investor panic yield hit psychological level trigger fear equity become less appeal dow index gain nearly point monday dow also close mark first time march trade tension unite state china decline treasury secretary steve mnuchin sunday say be putt trade war hold industrial be biggest gainer stand benefit most trade war be avert share boee ba free report caterpillar cat free report unite technology utx free report jump respectively index decline tuesday erase early gain president trump say wasn satisfied progress unite state china trade talk moreover trump also say highly await summit unite state north korea not happen meanwhile white house say order get fresh nuclear deal unite state iran need stop enrich uranium withdraw support militant group middle east statement cause stock plummet further index gain wednesday lead lead rally share boee gain share mcdonald mcd surge stock gain minute fed meeting conclude earlier month hint policy maker aren worry inflation briefly run target level further such occurrence not result faster interest rate hike rate sensitive stock rally news broader market be able pare earlier loss result geopolitical tension close black index decline thursday president trump scrap summit north korea leader kim jong schedule next month have be maiden face face encounter north korean leader sit president energy stock emerge biggest loser day oil price decline follow unexpected increase domestic crude inventory share exxon mobil xom chevron cvx free report decline respectively lead blue chip index finish red component move index general electric company ge free report recently enter definitive agreement wabtec corporation wab free report lead manufacturer rail equipment agreement company merge operate segment ge transportation wabtec completion synergistic deal zack rank hold general electric obtain cash company shareholder own ownership interest combine company remain stake combine company be retain wabtec shareholder notably deal be likely close early latest move combine ge transportation digital solution railroad marine drill wind mining industry wabtec extensive range electronic solution result market capability be stronger add momentum development implementation innovative solution key market help improve safety efficiency productivity offering notably combine company have large global install base more locomotive create significant opportunity aftermarket service growth read general electric transportation unit merge wabtec johnson johnson inc jnj free report partner glaxosmithkline plc gsk free report announce european commission ec have grant marketing approval juluca make europe first drug hiv treatment johnson johnson have zack rank juluca combine approve hiv drug tivicay mg edurant mg single once daily pill treatment virologically suppress hiv infection juluca gain approval unite state november last year generate sale first quarter read glaxo drug hiv regimen juluca get eu approval merck co inc mrk free report announce pivotal study keynote evaluate keytruda chemotherapy combination first line metastatic squamous small cell lung cancer nsclc meet dual primary endpoint overall survival os progression free survival pfs drug combination chemotherapy demonstrated significantly longer os pfs versus chemotherapy alone merck supplemental biologic license application sbla seek continue approval keytruda combine eli lilly lly free report alimta platinum chemotherapy treat metastatic squamous nsclc be review unite state sbla be file base encourage datum phase iii study keynote company plan share datum keynote study fda expand sbla include patient squamous histology company present detailed datum keynote study upcoming annual meeting american society clinical oncology next month stock have zack rank see complete list today zack rank strong buy stock here pfizer inc pfe free report announce fda have grant breakthrough therapy designation rare disease candidate tafamidis candidate be be develop treatment transthyretin cardiomyopathy ttr cm designation fda be intend expedite development review drug early evidence substantial potential clinical benefit patient benefit patient current treatment option designation tafamadis be primarily base encourage top line datum phase iii attr act study demonstrated significant reduction combination cause mortality frequency cardiovascular related hospitalization ttr cm patient read pfizer tafamadis get breakthrough therapy designation separate development zack rank pfizer announce phase iii study evaluate epilepsy drug lyrica pregabalin pediatric patient meet primary endpoint read pfizer epilepsy drug lyrica succeed pediatric study microsoft corporation msft free report recently unveil new gamepad xbox adaptive controller be aim ensure gaming everyone controller price be personalize requirement gamer controller comprise big programmable button mm port round back connect blow tube pedal other accessory zack rank microsoft blog development story date back almost feature copilot release xbox witness creative use company imagination inspire developer bring inclusivity boost engagement consequently bolster user base go forward read microsoft unveil xbox controller specially able gamer performance top dow company table give show price movement largest component dow be price weight index last day last month last trading day dow have decline next week outlookcomment president trump have guide market lower more occasion week only nature fed minute have prove be encourage investor otherwise absence major earning report geopolitical event have weigh heavily investor sentiment give backdrop only be natural investor turn economic report encouragement several key piece datum be line release next week include important gdp report most be encourage nature stock soon return winning way look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2152,MRK,astrazeneca plc azn free report announce european commission have approve label expansion lung cancer drug tagrisso osimertinib latest development tagrisso be used first line treatment adult patient locally advanced metastatic small cell lung cancer nsclc tumor have egfr mutation tagrisso be hitherto approve unite state european union japan china second line treatment option patient egfr mutation positive nsclc earlier april fda give nod tagrisso osimertinib first line set eu approval be expect april committee medicinal product human use lend positive opinion recommend approval tagrisso first line set approval be base encourage datum phase iii flaura study compare tagrisso standard care egfr tyrosine kinase inhibitor therapy first line lung cancer set datum study show chance progression death risk be reduce more half tagrisso arm compare commonly used egfr inhibitor median progression free survival be month patient tagrisso compare month comparator arm tagrisso be well receive trial safety profile consistent previous study first quarter tagrisso record sale year year drive increase testing rate unite state japan approval first line set be likely boost sale tagrisso come quarters apart tagrisso astrazeneca market several cancer drug imfinzi lynparza other company market lynparza partnership merck co inc mrk free report oncology sale now comprise almost astrazeneca total product sale metric also rise share astrazeneca have gain year date versus industry decline astrazeneca currently carry zack rank hold see complete list today zack rank strong buy stock here better rank stock same sector include lundbeck hluyy free report eli lilly company lly free report lundbeck sport zack rank eli lilly carry zack rank buy lundbeck earning share estimate have be revise upward last day stock have substantially soar year date eli lilly company earning share estimate have rise last day stock have increase year date hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2153,MRK,spite strong start pharma biotech industry be struggle currently presumably due shift focus lower high drug price faster approval generic moreover quite few negative pipeline regulatory update announce year so far have probably have unfavorable impact industry however expect industry turn year progress demand drug be rise worldwide due increase ailing elderly population frequent approval new drug well line extension already market drug increase healthcare spending moreover reduction tax time low tax window cash repatriation have boost cash position large pharma company have lead increase merger acquisition activity boost innovation capital build biotech industry price tag propose acquisition shire plc shpg free report japanese firm takeda be biggest deal industry earlier year have see sanofi sny free report celgene corporation celg free report acquire smaller biotech company impax laboratory merged amneal other large pharma company be also lookout acquisition target large cap give current dampening mood focus large cap company lower portfolio risk putt money large cap company reduce risk due diversify portfolio large cash base moreover company stability dividend payment provide safety cushion portfolio moreover flat downtrend market be better focus specific stock large cap also give high return be less risky small mid cap however large cap pharma industry be so far year have rise large cap industry rank top half zack industry list mentioned stock have rise year so far outperform large cap pharma industry let discuss factor drive stock add portfolio astrazeneca azn free report share have gain so far year back several regulatory approval successful study result year company lynparza become first parp inhibitor be approve ovarian cancer fda approve label expansion metastatic breast cancer cancer drug imfinzi label be expand include advanced small cell lung cancer nsclc indication tagrisso eligible patient population be expand recently be now approve treat first line nsclc egfr mutation apart cancer drug astrazeneca asthma drug fasenra receive approval europe severe eosinophilic asthma moreover company add new drug portfolio approval lokelma formerly know zs triple combination therapy pt treatment chronic obstructive pulmonary disease copd significantly improve several lung function compare dual combination therapy datum late stage krono study approval new drug well line extension be likely boost company top line future quarters addition regulatory application seek label expansion forxiga oral adjunct treatment insulin adult type diabetes be accept review march europe thus expect stock momentum continue however negative regulatory update datum readout impact stock unfavorably key be final overall survival datum mystic study have already be delay merck co inc mrk free report stock have gain so far year backed encourage datum several clinical study evaluate keytruda well label expansion drug keytruda receive approval treat urothelial carcinoma japan moreover label expansion advanced cervical cancer be review unite state several other regulatory decision be pending unite state well europe drug have show encourage development clinical study keytruda significantly improve recurrence free survival rfs melanoma patient overall survival os nsclc patient monotherapy combination eli lilly alimta keytruda improve overall survival os progression free survival pfs first line nsclc positive datum readout increase probability keytruda label expansion moreover datum readout few clinical study evaluate keytruda include pivotal lung cancer study present annual meeting american society clinical oncology asco chicago be also encourage apart keytruda merck cancer drug lenvima be approve japan label expansion first line hepatocellular carcinoma hcc type liver cancer moreover label expansion astrazeneca lynparza breast cancer also boost merck revenue latter share development cost well sale astrazeneca meanwhile merck immunotherapy pipeline cancer treatment be expect get boost completion acquisition australian firm viralytic limit second quarter expect growth new drug continue offset loss sale certain product due loss market exclusivity drive company share higher go forward glaxosmithkline plc gsk free report influenza vaccine get approval label expansion infant month older unite state europe hiv treatment juluca be approve europe moreover company shingle vaccine near approval europe january committee medicinal product human use adopt positive opinion marketing authorization application fda approve label expansion asthma therapy arnuity ellipta maintenance treatment pediatric patient age year older moreover approval new product trelegy ellipta shingrix juluca quick succession unite state europe last year early year boost company top line drug uptake be encourage addition agreement acquire novartis nvs free report stake consumer healthcare jv be likely strengthen competitive position stock have rally so far year astrazeneca merck glaxo be zack rank hold stock see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2154,MRK,have be busy year fda so far agency approve drug key approval include novartis lutathera gilead science hiv regimen biktarvy vertex pharmaceutical symdeko tezacaftor ivacaftor ivacaftor treatment cystic fibrosis cf johnson johnson erleada prostate cancer amgen aimoviq treatment migraine biomarin palynziq treatment dova pharmaceutical doptelet other approval drug boost respective company top line few be struggle decline sale legacy drug meanwhile spotlight be right try law president trump recently sign bill enable drug regulator allow terminally ill patient access experimental drug law law patient life threaten condition now ask drugmaker drug have clear testing have not be approve fda yet drug development process be lengthy require lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst here be look few important regulatory event schedule month june new drug approval boost valeant valeant pharmaceutical vrx free report have few pdufa date remainder june be idp fda have accept new drug application nda idp halobetasol propionate tazarotene lotion experimental topical treatment plaque psoriasis november set pdufa action date jun valeant be banking approval new drug boost lag dermatology business company idp be first only topical lotion unique combination halobetasol propionate tazarotene formulation treatment plaque psoriasis adult patient thus extend duration use fda have earlier approve siliq psoriasis company also obtain fda approval vyzulta treatment option glaucoma fda also approve lumify counter eye drop low dose brimonidine treatment eye redness valeant currently carry zack rank hold see complete list today zack rank strong buy stock here valeant pharmaceutical international inc price valeant pharmaceutical international inc price valeant pharmaceutical international inc quotegwph epidiolex await fda nodgw pharmaceutical plc gwph free report complete roll submission nda investigational cannabidiol oral solution cbd also know epidiolex treatment seizure associate dravet syndrome lennox gastaut syndrome lgs fda oct agency set pdufa goal date jun fda approval be likely peripheral central nervous system drug advisory committee unanimously recommend approval nda approval be significant boost company assume approval epidiolex be first pharmaceutical formulation purify plant base cbd cannabinoid lack high associate marijuana first new category epileptic drug aed gw pharmaceutical plc price gw pharmaceutical plc price gw pharmaceutical plc quote keytruda label expansion cervical cancermerck mrk free report blockbuster drug keytruda supplemental biologic license application sbla treatment patient advanced cervical cancer disease progression chemotherapy be fda review agency decide same jun priority review basis merck blockbuster immuno oncology drug keytruda be already approve variety cancer metastatic small cell lung cancer nsclc recurrent metastatic head neck squamous cell carcinoma metastatic urothelial carcinoma gastric cancer other approval cervical cancer further boost sale drug merck co inc price merck co inc price merck co inc quotearray biopharma combo drug get approval array biopharma arry free report ndas support use experimental encorafenib binimetinib combination treatment patient braf mutant advanced unresectable metastatic melanoma be fda review agency have set target action date june company have previously announce treatment combination encorafenib mg daily binimetinib mg twice daily combo reduce risk death compare treatment vemurafenib mg daily patient braf mutant melanoma phase iii columbus trial array biopharma inc price array biopharma inc price array biopharma inc quoteapart fda also decide future few other drug alk free report nda aripiprazole lauroxil nanocrystal dispersion achaogen akao free report plazomicin other hence investor be expect keep close watch fda action month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2155,MRK,gilead science inc gild free report galapago nv glpg free report announce phase ii study equator pipeline candidate filgotinib achieve primary endpoint improvement sign symptom psoriatic arthritis week assessed american college rheumatology percent improvement score acr equator trial initiate galapago april be multicenter randomize double blind placebo controlled trial assess safety efficacy selective jak inhibitor filgotinib adult patient moderately severely active psoriatic arthritis datum study depict acr response filgotinib versus placebo additionally acr acr response week be also significantly higher filgotinib placebo filgotinib be generally well tolerate trial new safety signal be observed however be serious infection filgotinib group patient experience pneumonia fatal outcome other patient receive filgotinib develop herpes zoster company plan report detailed result equator trial future scientific conference concurrently gilead galapago also announce independent datum monitoring committee dmc conduct plan interim futility analysis phase iib iiii study selection filgotinib treatment ulcerative colitis analysis be conduct patient complete induction period phase iib portion study dmc recommend study go plan phase iii mg mg once daily dose level biologic experience biologic nave patient multicenter randomize double blind placebo controlled study assess safety efficacy selective jak inhibitor filgotinib adult patient moderately severely active ulcerative colitis be initiate gilead late consequently gilead pay galapago progression phase ii phase iii selection trial trial enroll total patient target be randomize receive filgotinib mg mg placebo once daily administer week primary objective selection be evaluate efficacy filgotinib compare placebo establish ebs endoscopy bleed stool remission week galapago gilead enter global collaboration development filgotinib inflammatory indication candidate be also be evaluate ongoing phase iii program finch rheumatoid arthritis phase iii trial diversity crohn disease also small bowel fistulizing crohn disease phase ii study other give persistent decline hcv sale gilead be look newer avenue help top line gilead stock have lose last month industry loss gilead hcv franchise witness slowdown key market include unite state europe reflect lower sale harvoni sovaldi result competitive pricing pressure franchise see significant plunge sale due new competition fewer patient start pricing have largely stabilize market share stabilize mid patient start be expect decline further note harvoni sovaldi epclusa face competition abbvie abbv free report viekira pak mayret merck mrk free report zepatier other gilead be look solidify presence gene therapy space initial uptake yescarta be also encourage gilead be also intend foray nash market pipeline candidate selonsertib filgotinib zack rankgilead currently carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2156,MRK,pfizer inc pfe free report announce fda grant breakthrough therapy designation lung cancer drug xalkori crizotinib new indication xalkori be already market treatment alk ro positive locally advanced metastatic small cell lung cancer nsclc fact be only fda approve treatment indicated alk positive ro positive metastatic nsclc fda grant breakthrough therapy designation xalkori treatment patient metastatic nsclc meet exon alteration disease progression platinum base chemotherapy designation indication be support result expansion cohort phase profile study xalkori show antitumor activity indication breakthrough therapy designation be grant xalkori be treatment patient relapse refractory systemic anaplastic large cell lymphoma alcl be alkpositive designation indication be support study study advl nct study nct study show compelling antitumor activity pediatric adult patient treat xalkori designation fda be intend expedite development review drug early evidence substantial potential clinical benefit patient share pfizer have decline year date compare industry decline nsclc be difficult treat disease accounting lung cancer case present lung cancer treatment market be highly crowd drug bristol myer squibb bmy free report opdivo merck mrk free report keytruda roche rhhby free report alecensa novartis zykadia taxotere other zack rankpfizer have zack rank hold see complete list today zack rank stock here pfizer inc price pfizer inc price pfizer inc quote today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2157,MRK,merck mrk free report share increase apr present full datum pivotal phase iii keynote study datum same show keytruda combine eli lilly lly free report alimta pemetrexed platinum chemotherapy cisplatin carboplatin significantly improve overall survival thereby reduce death risk half compare chemotherapy alone study evaluate combination therapy first line treatment patient metastatic squamous small cell lung cancer nsclc regardless pd expression combo treatment show progress overall survival irrespective pd expression include patient tumor testing negative pd meanwhile significant improvement progression free survival pfs be observed decrease death risk keytruda combination arm compare chemotherapy arm median pfs be month keytruda arm compare month chemotherapy pfs improvement be also observed patient tumor test negative pd result be present annual meeting american association cancer research notably january year merck have announce study meet primary endpoint pfs os well importantly keytruda be first pd inhibitor combination show os patient nsclc last combination therapy be grant accelerate approval fda aforementioned indication nod be base tumor response rate pfs datum keynote trial hence positive readout keynote confirmatory study help company gain continue approval combo therapy turn support uptake sale remind investor third quarter merck have mentioned be include overall survival os co primary endpoint keynote program defer readout study be then estimate evaluation be complete february however company release datum keynote study year earlier expect january merck share have gain so far year versus decline industry concurrently bristol myer bmy free report also report datum phase iii study blockbuster drug opdivo nsclc however merck keytruda combination demonstrated better overall survival compare opdivo zack rank key pickmerck carry zack rank hold better rank stock health care sector be ligand pharmaceutical incorporate lgnd free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved last day company deliver positive surprise trail quarters average beat share price company have soar year breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2158,MRK,eli lilly company lly free report announce deal buy early phase oncology asset ak aurka pharma inc venture capital firm establish tvm capital life science ak be aurora kinase inhibitor be study phase study multiple type solid tumor lilly make upfront payment acquire share aurka pharma addition aurka pharma shareholder be entitle potential regulatory sale milestone worth ak be originally discover lilly later sell tvm capital part former strategic review do tvm capital later form aurka part tvm life science venture vii fund investment model seek develop early stage pharmaceutical asset year date lilly share have decline compare industry decline lilly have well layer oncology strategy involve build key cancer treatment cyramza lartruvo verzenio foundational agent focuse develop new standard care change therapy combination regimen include immuno therapy meanwhile lilly be constantly lookout external innovation bolster growth oncology franchise aurka pharma acquisition add promising cancer compound target distinct cell cycle pathway further expand lilly oncology pipeline lilly latest acquisition deal come less week announce cash deal tobuy california base immuno oncology biotech armo bioscience inc share approximately acquisition add armo lead product candidate pegilodecakin lilly cancer pipeline pegilodecakin pegylate il be be study late stage study pancreatic cancer well early stage study lung renal cell cancer melanoma other solid tumor type armo bioscience go public january year transaction be expect close end second quarter armo bioscience acquisition add promising next generation immunotherapy pipeline asset lilly portfolio be also line lilly oncology strategy lilly currently carry zack rank buy see complete list today zack rank strong buy stock here other stock considerother top rank pharma biotech stock include ligand pharmaceutical incorporate lgnd free report merck mrk free report ligand have zack rank merck be rank stock ligand earning estimate rise past day stock have go year so far merck share have rise year so far earning estimate increase respectively past day more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2159,MRK,president donald trump friday unveil plan lower drug price keep promise make run presidential election pharmaceutical company broader industry have be anticipate trump come heavily have long criticize drugmaker get away murder charge way too much product however fear be dispel trump proposal actually not directly hamper profitability drug company instead reform be aim increase competition medicine cut list price reduce patient pocket cost pleasant surprise give stock pharmaceutical company boost long standing drug price be trump presidential campaign promise have commit take big drug company be also support trump democrat opponent hillary clinton then trump have time again criticize drug manufacture pharmaceutical company charge too much product have keep pharmaceutical company reel pressure quite time have fear trump pharma plan hurt profit broader pharma sector spdr pharmaceutical xph have decline year date industry have fear further loss apprehend harsh measure trump friday raise competition twist tale come trump stress increase competition medicine be highpoint speech friday frame plan most sweeping action history lower price prescription drug american person describe american patient first layer policy intend increase pharmaceutical competition power negotiation lower patient pocket cost trump policy also aim create incentive lower list price prescription drug reform certainly be ray hope american patient rise cost healthcare be nagging concern american patient first plan have immediate action well future opportunity lower pocket cost face patient reduce drug price interestingly trump refrain raise direct medicare price negotiation friday be agenda presidential campaign pharma stock rally trump reformsclearly trump american patient first plan doesn seem be threat pharmaceutical company profit fact be very much line financial interest drugmaker health insurer way hamper profit fear have often result share pharma company take hit last few month finally see bounce back friday sector decline initially friday stock start rally time trump have finished speech share regeneron pharmaceutical inc regn free report increase also share cvs health corporation cvs free report merck co inc mrk free report pfizer inc pfe free report walgreen boot alliance inc wba free report be respectively merck co have zack rank buy see complete list today zack rank strong buy stock here trump spare biggest reason rally be trump plan actually doesn hurt pharmaceutical company fact administration keep place few case extend role drug middleman have be often be blame spiking drug cost trump plan call drug company display price ad restrict gag clause pharmacist proposal come pharmacy pharmacy benefit manager pbm have contract donot allow pharmacist let patient know drug cash counter be cheaper be purchase insurance however trump splan give company new power medicare part program senior get drug coverage allow medicare change list cover drug midyear order push back price hike generic drugsthat donot actually have so much competition lead share healthcare service company mckesson corporation mck free report express script hold company esrx free report corporation abc free report cardinal health inc cah free report rise respectively sum uptrump american patient first come set reform have spark fear pharmaceutical company quite time however fear seem have subside somewhat new plan doesn hurt drugmaker profit see investor confidence finally get reinstate pharma biotech stock rally medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2160,MRK,inc agen free report report first quarter adjust loss cent share exclude loss early extinguishment debt cent share wider zack consensus estimate loss cent year loss cent higher net loss be due several time item well cash charge company do not generate revenue quarter zack consensus estimate be however company report revenue prior year period share company fall follow earning release so far year share have gain industry decline quarterly first quarter research development expense decline general administrative expense decrease pipeline updateagenus be progress well various pipeline candidate quarter review company launch combination trial ctla antibody agen pd target antibody agen include trial second line cervical cancer company have shift strategy first approval first line small cell lung cancerto second line cervical cancer reason strategy shift include increasingly crowd lung cancer opportunity merck mrk free report recent datum keytruda combination chemotherapy first line small cell lung cancer have set bar higher future approval company remainson track file investigational new drug ind additional ind first half be company next gen ctla design deplete cancer prone treg improve cell prime zack rank stock consideragenus have zack rank hold few better rank stock same space worth consider be ligand pharmaceutical lgnd free report protagonist therapeutic ptgx free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat company share have rally year date protagonist loss estimate narrow cent last day company deliver positive earning surprise trail quarters average beat inc price consensus ep surprise inc price consensus ep surprise inc quotelook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2161,MRK,look find strong medical stock be prudent search company group be outperform peer be merck co mrk free report stock right now take look stock year date performance comparison medical peer be able answer question merck co be individual stock medical sector collectively company sit zack sector rank zack sector rank include different group be list order best worst term average zack rank individual company sector zack rank be proven system emphasize earning estimate estimate revision highlight variety stock be display right characteristic beat market next month mrk be currently sporting zack rank buy past day zack consensus estimate mrk full year earning have moved higher mean analyst sentiment be stronger stock earning outlook be improve latest available datum show mrk have return start calendar year same time medical stock have lose average see merck co be perform better sector calendar year break thing more mrk belong large cap pharmaceutical industry group include individual company currently sit zack industry rank group have lose average so far year so mrk be perform better area investor interest medical stock continue track mrk stock be look continue solid performance
2162,MRK,immunogen inc imgn free report report adjust loss cent share first quarter wider zack consensus estimate loss cent moreover loss quarter be also wider year loss cent due higher operate cost immunogen share be presumably increase operate expense outlook however share immunogen have significantly outperformed industry so far year stock have soar versus industry decrease immunogen have approve product portfolio company earn revenue royalty license milestone payment research development support fee paid partner company report revenue beat zack consensus estimate quarter however sale decrease year figure immunogen record upfront fee takeda debiopharm respectively compare milestone payment year quarter however company also receive cash fee related license agreement cytomx last year research development expense increase year level mainly related accelerate completion time enrollment phase iii forward study selling general administrative sg expense be first quarter primarily attributable higher third party service fee stock base compensation immunogen cash cash equivalent end march be compare december company expect current cash estimate cash fund operation fourth quarter pipeline updateimmunogen have be progress well pipeline product mirvetuximab soravtansine candidate be currently phase iii study forward single agent therapy treat patient platinum resistant ovarian cancer tumor express high medium level fr alpha company have reach enrollment target month ahead schedule base datum interim analysis complete last month study continue top line datum expect first half notably combo therapy mirvetuximab soravtansine ovarian cancer be be evaluate phase ib ii forward ii study trial consist cohort assess mirvetuximab soravtansine combination roche rhhby free report avastin merck mrk free report keytruda quarter third cohort be add study evaluate triplet combination mirvetuximab paraplatin carboplatin avastin datum present march analysis mirvetuximab combination keytruda subset patient show combination achieve confirm overall response rate median progression free survival month base datum study enroll more patient apart mirvetuximab soravtansine immunogen be work develop couple other candidate early stage study include imgn relapse refractory adult acute myeloid leukemia imgn hematological malignancy include acute myeloid leukemia outlook company maintain revenue guidance range zack consensus estimate metric be peg company continue expect cash cash equivalent range however immunogen have increase operate expense guidance operate expense be now expect range compare expect previously immunogen inc price consensus ep surprise immunogen inc price consensus ep surprise immunogen inc quotezack rank stock currenrly carry zack rank hold enanta pharmaceutical inc enta free report be better rank stock drug sector sporting zack rank strong buy see complete list today zack rank stock here enanta earning share estimate significantly increase cent last day company come average beat trail quarters stock have surge so far year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2163,MRK,merck mrk free report announce pivotal study keynote evaluate keytruda chemotherapy combination first line metastatic squamous small cell lung cancer nsclc meet dual primary endpoint overall survival os progression free survival pfs drug combination chemotherapy demonstrated significantly longer os pfs versus chemotherapy alone merck supplemental biologic license application sbla seek continue approval keytruda combine eli lilly lly free report alimta platinum chemotherapy treat metastatic squamous nsclc be review unite state sbla be file base encourage datum phase iii study keynote company plan share datum keynote study fda expand sbla include patient squamous histology company present detailed datum keynote study upcoming annual meeting american society clinical oncology next month share merck be market trading news be announce year so far merck share have outperformed industry share have rise period industry decline notably keytruda be already approve monotherapy first line treatment patient metastatic nsclc tumor express pd protein level greater keytruda also have accelerate approval treat first line patient metastatic nsclc combination alimta chemotherapy merck remain focuse develop keytruda monotherapy combination therapy treatment lung cancer various mutation histology first line set bid further reinforce position segment lung cancer be attractive market be largest cause death cancer patient moreover keytruda be only immune oncology drug be approve treatment lung cancer first line set remind investor bristol myer bmy free report be also develop immune oncology drug opdivo first line lung cancer however keytruda early entry positive datum readout several phase iii study expand first line lung cancer patient bode well company top line note keytruda be market many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma gastric cancer bladder cancer microsatellite instability high msi mismatch repair deficient cancer meanwhile keytruda be be study more type cancer more study include excess combination study merck be collaborate several company include amgen amgn free report incyte glaxo pfizer separately evaluation keytruda combination other regimen merck co inc price merck co inc price merck co inc quotemerck currently carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2164,MRK,amgen inc amgn free report announce fda have approve supplemental biologic license application sbla seek label expansion prolium treatment glucocorticoid induced osteoporosis giop man woman high risk fracture have fail be intolerant other available osteoporosis therapy be fifth approve indication prolium approval be backed increase bone mineral density bmd achieve drug phase iii study drug be presently market unite state treatment postmenopausal woman osteoporosis high risk fracture well increase bone mass man osteoporosis high risk fracture share amgen be market trading follow news company share have rally year so far industry decline phase iii study evaluate prolium treatment giop patient man woman high risk fracture have fail be intolerant other available osteoporosis therapy compare allergan agn free report actonel risedronate study comprise patient group patient have receive glucocorticoid treatment less month prior study enrollment glucocorticoid initiate arm second patient have receive glucocorticoid treatment least month glucocorticoid continue arm arm glucocorticoid treatment be continue least month datum study show prolium increase lumbar spine bmd compare actonel glucocorticoid initiate arm lumbar spine bmd patient treat prolium glucocorticoid continue arm increase compare actonel glucocorticoid induced osteoporosis be most common form secondary osteoporosis serious condition be presently treat glucocorticoid treatment increase fracture risk first month treatment prolium now cater expand patient population drive sale higher prolium be key revenue generator amgen be witness market share gain unite state internationally competition generic other drug approve osteoporosis drug generate sale year year prolium face competition several drug especially generic version eli lilly lly free report evista alendronate merck mrk free report fosamax raloxifene novartis zometa zoledronate amgen inc price amgen inc price amgen inc quotezack rank amgen currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2165,MRK,johnson johnson jnj free report kick pharma earning strong note beating zack consensus estimate count first quarter drug consumer product giant up previously issue sale outlook share be pre market trading year so far share have decline compare unfavorably decline witness industry earning beatj first quarter earning come share beating zack consensus estimate increase year period adjust earning exclude amortization expense special item include item report first quarter earning share compare earning year period sale beat slightlysale come beating zack consensus estimate sale also increase year quarter reflect operational increase positive currency impact organically exclude impact acquisition divestiture sale increase operational basis better increase see be pharmaceutical segment continue positive momentum see second half consumer segment sale improve first quarter sale grow domestic market international market reflect operational growth positive currency impact sale segment sale rise year year reflect operational growth positive currency impact sale rise domestic international market sale domestic market rise international sale grow operational increase new product imbruvica cancer darzalex multiple myeloma continue perform well core product xarelto stelara zytiga simponi simponi aria invega sustenna also contribute growth please note market imbruvica partnership abbvie inc abbv free report organically exclude impact acquisition divestiture sale increase operational basis slightly less growth see previous quarter quarter record pulmonary arterial hypertension pah revenue less previous quarter acquisition swiss biotech actelion june last year diversify revenue pah category add sale growth first quarter however sale invokana invokamet decline due higher manage care discounting importantly sale blockbuster rheumatoid arthritis drug remicade market partnership merck co inc mrk free report be quarter sale decline however international sale rise biosimilar competition pharma segment achieve clinical milestone quarter include fda approval prostate cancer drug erleada treatment man metastatic castration resistant prostate cancer line extension already market prostate cancer drug zytiga combination prednisone first line set medical device segment sale come year period include operational increase positive currency movement domestic market sale rise year year international market sale increase operational increase year year consumer segment record revenue report quarter year year operational increase foreign currency movement positively impact sale segment sale domestic market rise year period meanwhile international segment record increase reflect operational increase positive currency impact outlook maintain previously issue earning guidance increase sale range still expect adjust earning share range reflect operational growth rate however now expect revenue range higher reflect operational constant currency sale growth rate range previously quite few key product portfolio remicade concerta face generic competition believe new product plaque psoriasis drug tremfya guselkumab cancer drug darzalex imbruvica zytiga currency tailwind contribution acquisition help deliver strong sale profit first quarter year lead raise sale outlook whole year fact be quite confident pharma segment continue perform better market year impact biosimilar remicade sale tell chief financial officer dominic caruso bloomberg meanwhile announce global supply chain initiative annually save approximately pre tax cost meanwhile alex gorsky chairman chief executive officer say company invest more capital investment unite state next year new tax law leave extra cash hand large pharma company allow invest innovation capital build zack rank stock considerj carry zack rank hold johnson johnson price consensus ep surprise johnson johnson price consensus ep surprise johnson johnson quotea better rank stock be pfizer inc pfe free report have zack rank buy see complete list today zack rank strong buy stock here share pfizer have gain year so far breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2166,MRK,hunt transport service inc jbht free report share increase announce first quarter revenue surpass zack consensus estimate millionshare eldorado resort inc eri free report rise company announce plan buy tropicana entertainment cashmerck co inc mrk free report share increase follow news cancer treatment drug keytruda reduce risk death trial combination chemotherapy instead used chemo aloneshare plc alk free report increase company announce food drug administration fda accept new drug application treatment depression
2167,MRK,bristol myer squibb company bmy free report announce result phase iii trial checkmate trial blockbuster drug opdivo number person majority be china late stage multinational randomize study compare opdivo docetaxel treatment patient stage iiib iv small cell lung cancer nsclc disease have progressed platinum base doublet chemotherapy result show opdivo demonstrated statistically significant benefit versus docetaxel primary endpoint overall survival os os benefit be observed regardless pd expression tumor histology opdivo reduce risk death versus chemotherapy additionally secondary endpoint objective response rate median duration response demonstrated durability opdivo compare docetaxel objective response rate quadruple opdivo versus docetaxel median duration response not reach opdivo versus month docetaxel result be update immuno oncology trial session american association cancer research aacr annual meeting chicago abstract ct remind investor china food drug administration accept company biologic license application opdivo propose indication previously treat nsclc november tentative approval further boost geographic reach drug efficacy safety opdivo predominantly chinese patient population advanced nsclc be consistent result global checkmate study share company have rally past year outperform industry gain opdivo become first pd immune checkpoint inhibitor gain regulatory approval july be currently approve several country include unite state eu japan several cancer indication opdivo become first pd inhibitor be approve hematological malignancy classical hodgkin lymphoma unite state eu november november opdivo gain fda approval treatment patient recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy opdivo continue be launch globally approval label expansion drug have be perform impressively due demand result rapid commercial acceptance several indication include melanoma renal cell carcinoma second line nsclc fda also approve opdivo intravenous use patient hepatocellular carcinoma hcc have be previously treat nexavar opdivo have rapidly penetrate second line hcc market label expansion additional indication give product access higher patient population increase commercial potential drug significantly earlier company stop phase iii combination study checkmate earlier expect meet co primary endpoint phase iii study evaluate opdivo yervoy patient previously untreated advanced metastatic renal cell carcinoma meet co primary endpoint study show superior os compare current standard care sunitinib intermediate poor risk patient fda accept company sbla same take decision apr however opdivo face stiff competition merck mrk free report keytruda roche rhhby free report tecentriq concurrently bristol myer announce collaboration illumina inc ilmn free report use latter next generation sequence technology develop globally commercialize diagnostic assay support bristol myer squibb oncology portfolio zack rankbristol myer carry zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company re already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2168,MRK,merck mrk free report announce encourage datum phase iii study eortc keynote evaluate pd therapy keytruda high risk stage iii melanoma patient adjuvant set datum study demonstrated adjuvant treatment keytruda significantly increase recurrence free survival rfs surgery compare placebo such patient drug reduce risk disease recurrence death placebo study rfs be achieve patient treat keytruda year compare placebo keytruda also significantly prolong rfs patient pd positive tumor reduce risk recurrence death placebo datum study be present american association cancer research aacr annual meeting be publish new england journal medicine share merck have outperformed industry so far year share have return industry decline say period study be be conduct collaboration european organisation research treatment cancer merck claim keytruda be first pd therapy achieve rfs benefit stage iiia iiib iiic melanoma patient drug have achieve rfs benefit patient irrespective braf mutation merck be evaluate keytruda broad clinical development program melanoma comprise clinical study setting stage disease separate press release merck astrazeneca azn free report announce final overall survival os datum phase iii olympiad study evaluate parp inhibitor lynparza metastatic breast cancer aacr annual meeting median os be month lynparza arm compare chemotherapy please note bristol myer bmy free report pd immune checkpoint inhibitor opdivo have receive approval intravenous administration melanoma patient adjuvant treatment december however keytruda have achieve rfs benefit higher proportion patient compare opdivo clinical study merck co inc price merck co inc price merck co inc quotezack rank stock considermerck carry zack rank hold eli lilly company lly free report be better rank stock pharma sector carry zack rank buy see complete list today zack rank strong buy stock here lilly earning estimate slightly increase last day company deliver positive earning surprise trail quarters average beat company be schedule report first quarter earning apr investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2169,MRK,seattle genetic inc sgen free report report loss cent share first quarter wider zack consensus estimate cent year quarter loss cent revenue come year year primarily drive strong sale adcetris revenue also beat zack consensus estimate however seattle genetic share have lose so far year compare industry decline same period quarter detailseattle genetic top line comprise product revenue collaboration license agreement revenue royalty company only market product adcetris generate product sale significant year year collaboration license agreement revenue increase almost mainly drive strong demand adcetris international market collaboration revenue include fee earn company agreement japan base takeda pharmaceutical adcetris other adc collaboration royalty revenue decrease year year due adoption new accounting standard revenue recognition research development expense be year year primarily attributable tucatinib development activity upfront cost related technology licensing pieris pharmamar also selling general administrative sg expense increase mainly due cost related acquisition cascadian therapeutic launch adcetris frontline hodgkin lymphoma outlook launch adcetris new indication company withdraw revenue expectation currently shire expect second quarter sale be range company increase outlook expense range sg expense be expect range previously rise likely be due increase investment development tisotumab vedotin ladiratuzumab vedotin company pipeline program pipeline updatedure quarter label expansion adcetris combination chemotherapy patient previously untreated stage iii iv classical hodgkin lymphoma be approve unite state january drug be approve treatment cutaneous cell lymphoma europe follow approval unite state november last year moreover top line datum echelon study frontline cd express mature cell lymphoma be separate study be also evaluate adcetris combination bristol myer squibb bmy free report opdivo relapse refractory classical hodgkin lymphoma addition company be enrolling patient pivotal study evaluate enfortumab vedotin patient metastatic urothelial cancer patient candidate be grant breakthrough therapy designation quarter moreover seattle genetic astella pharma be evaluate enfortumab vedotin phase ib study combination cpi therapy include merck mrk free report keytruda pembrolizumab patient locally advanced metastatic urothelial cancer first second line set company be plan initiate phase iii study seattle genetic germany base genmab be plan initiate phase ii study evaluate tisotumab vedotin recurrent metastatic cervical cancer metastatic cervical cancer treatment nave woman range other solid tumor type company be evaluate pipeline candidate polatuzumab vedotin diffuse large cell lymphoma study be be conduct collaboration genentech member roche hold ag rhhby free report other activitiesin bid boost pipeline company enter definitive merger agreement last month acquire cascadian therapeutic acquisition add pivotal stage positive metastatic breast cancer candidate tucatinib pipeline company have initiate pivotal study evaluate candidate metastatic breast cancer seattle genetic inc price consensus ep surprise seattle genetic inc price consensus ep surprise seattle genetic inc quoteseattle genetic carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2170,MRK,week be rule cancer datum presentation drug company annual meeting american association cancer research aacr chicago other jnj free report novartis nvs free report kick pharma earning strong note beating zack consensus estimate earning sale first quarter recap week most important storiesj beat earning raise sale guidance first quarter earning come share sale be number increase year year quite few key product portfolio remicade concerta face generic competition believe new product plaque psoriasis drug tremfya guselkumab cancer drug darzalex imbruvica zytiga currency tailwind contribution acquisition help deliver strong sale profit first quarter year lead raise sale outlook whole year read more top earning estimate raise sale guidance novartis first quarter earning come share beat zack consensus estimate revenue increase year year beat zack consensus estimate strong performance key drug cosentyx entresto lead impressive performance quarter novartis re iterated previously issue guidance read more novartis beat earning revenue estimate merck present successful keytruda datum aacr merck mrk free report present full datum pivotal keynote study evaluate keytruda combination alimta pemetrexed platinum chemotherapy cisplatin carboplatin first line treatment patient metastatic squamous nsclc regardless pd expression datum show keytruda combo significantly improve overall survival reduce risk death half compare chemotherapy alone january merck have announce study meet primary endpoint progression free survival pfs os co primary endpoint notably combination therapy be grant accelerate approval fda aforementioned indication approval be base tumor response rate pfs datum keynote study hence positive readout keynote confirmatory study help company gain continue approval combo therapy support uptake sale read more merck keytruda better survival lung cancer combo study merck also present update datum phase iii eortc keynote study evaluate keytruda monotherapy high risk stage iii melanoma patient adjuvant set datum study demonstrated adjuvant treatment keytruda increase recurrence free survival rfs reduce risk disease recurrence death placebo surgery such patient read more merck keytruda reduce death risk melanoma patient separately merck astrazeneca azn free report announce final overall survival os datum phase iii study evaluate parp inhibitor lynparza metastatic breast cancer aacr median os be month lynparza arm compare chemotherapy bristol myer opdivo focus bristol myer bmy free report present initial result phase iii study checkmate evaluate combination pd inhibitor opdivo yervoy first line treatment advanced nsclc patient high tumor mutational burden initial result show year pfs rate be more triple combination versus chemotherapy vs however result be encourage investor be disappoint merck keytruda seem have fared better opdivo yervoy combination read more bristol myer merck nsclc study fare better opdivo also demonstrated statistically significant overall survival primary endpoint benefit compare chemotherapy late stage study checkmate evaluate predominantly chinese population previously treat small cell lung cancer opdivo reduce risk death versus chemotherapy read more bristol myer report positive datum nsclc trial opdivo development opdivo be approve combination yervoy treatment intermediate poor risk advanced renal cell carcinoma previously untreated patient also bristol myer supplemental biologic license application sbla expand use opdivo monotherapy previously treat patient small cell lung cancer sclc be grant priority review fda fda be expect give decision aug separately bristol myer strike collaboration illumina inc develop commercialize companion diagnostic bristol myer oncology immunotherapy bristol myer also inked deal johnson johnson development bristol myer factor xia fxia inhibitor bms prevention treatment major thrombotic condition company be expect advance bms phase ii trial second half roche hemlibra get btd new indication swiss pharma giant roche rhhby free report haemophilium drug hemlibra be grant breakthrough therapy designation fda treatment haemophilium factor viii inhibitor base positive datum phase iii haven study hemlibra emicizumab be approve routine prophylaxis bleed episode person haemophilium factor viii inhibitor eu february unite state november last year have be successfully launch unite state read more roche hemophilia drug get breakthrough therapy designation shire agree sell oncology unit shire announce definitive agreement sell oncology business french company servier dublin ireland drug giant plan return proceed sale shareholder share buyback japan takeda consider take shire latter oncology business be key area interest takeda read more shire sell oncology unit ahead takeda potential offer shire however thursday reject takeda third offer pound share well say undervalue shire growth prospect pipeline meanwhile allergan agn free report issue press release same day say be early stage consider possible offer shire however later day issue press release say do not intend make offer shire bayer sell stake singapore temasek germany bayer have strike deal sell stake singapore investment company temasek total gross proceed euro latest purchase temasek own approximately bayer stock equity sale raise fund bayer upcoming merger seed maker company astrazeneca tagrisso get fda nod first line set astrazeneca lung cancer drug tagrisso gain fda approval first line treatment adult patient metastatic nsclc tumor have egfr mutation snda be base datum phase iii flaura study similar label expansion application be review eu now tagrisso be approve unite state european union japan china second line treatment option patient egfr mutation positive nsclc read more fda nod astrazeneca tagrisso first line nsclc nyse arca pharmaceutical index decline last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr returnhere be major stock perform last trading session merck be biggest gainer last week rise bristol myer decline last month astrazeneca have be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup nvs buy avexis pfe abbv drug succeed phase iii next pharma world watch first quarter earning result several drug giant other pipeline regulatory update wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2171,MRK,eli lilly company lly free report report first quarter result apr market open last quarter company deliver positive earning surprise lilly share have decline year so far underperform industry decrease lilly performance have be pretty impressive earning beating expectation last quarters bring average positive surprise eli lilly company price ep surprise eli lilly company price ep surprise eli lilly company quotelet see thing be shape quarter factor considerlike previous couple quarters strong uptake trend new product trulicity taltz basaglar cyramza jardiance lartruvo make decline sale establish product zyprexa alimta ciali strattera effient trulicity sale be be drive growth glp market market share gain jardiance sale be likely be drive increase market share grow sglt class positive trend be expect continue first quarter zack consensus estimate trulicity first quarter revenue be continue strong uptake outside unite state be likely drive sale cyramza strong launch uptake be expect drive sale taltz lartruvo loss exclusivity country cymbalta strattera effient axiron zyprexa evista continue hurt volume also lower demand unite state due competitive pressure mainly immuno oncology agent be hurt alimta sale country trend believe persist first quarter zack consensus estimate alimta sale first quarter be peg olumiant baricitinib be launch select european country japan generate sale year support strong launch uptake germany drug be review unite state lilly partner incyte corporation incy free report re submit nda baricitinib january verzenio be launch unite state fourth quarter generate sale expect new cancer drug generate higher sale first quarter also advanced breast cancer treatment gain fda approval first line set february have lead additional sale first quarter older product humulin forteo be expect do well other ciali be likely see weak sale due lower demand elanco animal health segment sale be hurt global competitive pressure trend have continue first quarter fourth quarter conference call management have say be slightly negative first half animal health revenue be expect improve second half support new product launch zack consensus estimate sale animal health segment be lilly be explore strategic alternative business include sale merger create separate company initial public offer decision regard same be expect be announce july lilly ultimately opt retain business investor look update first quarter conference call earning whispersour proven model do not conclusively show lilly beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be zack consensus estimate earning be share uncover best stock buy sell re report earning esp filter zack rank lilly zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considerhere be large cap health care stock worth consider model have right combination element beat earning time merck co inc mrk free report have earning esp zack rank company be schedule report first quarter earning see complete list today zack rank stock here pfizer inc pfe free report be also slate announce financial figure company have earning esp be also zack rank stock wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2172,MRK,bristol myer squibb company bmy free report announce fda have accept grant priority review designation supplemental biologic license application sbla label expansion opdivo nivolumab treat patient small cell lung cancer sclc disease have progressed more prior line therapy fda set action date aug submission be base safety efficacy datum sclc cohort phase ii checkmate trial evaluate opdivo monotherapy opdivo yervoy ipilimumab advanced metastatic solid tumor include sclc primary goal be ascertain objective response rate assessed blind independent central review secondary objective include safety overall survival progression free survival duration response share company have decline year underperform industry gain note opdivo become first pd immune checkpoint inhibitor gain regulatory approval july be currently approve several country include unite state eu japan several cancer indication opdivo become first pd inhibitor be approve hematological malignancy classical hodgkin lymphoma unite state eu november november opdivo gain fda approval treatment patient recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy opdivo continue be launch globally approval label expansion drug have be perform impressively due demand result rapid commercial acceptance several indication include melanoma renal cell carcinoma second line nsclc fda also approve opdivo intravenous use patient hepatocellular carcinoma hcc have be previously treat nexavar opdivo have rapidly penetrate second line hcc market label expansion additional indication give product access higher patient population increase commercial potential drug significantly however opdivo face stiff competition merck mrk free report keytruda roche rhhby free report tecentriq bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quotezack rank stock considerbristol myer carry zack rank hold top rank stock same space worth consider be ligand pharmaceutical lgnd free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved respectively last day company deliver positive earning surprise trail quarters average beat company share have rally year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2173,MRK,share bristol myer squibb company bmy free report fall investor be not much impressed company initial result phase iii study checkmate study be evaluate opdivo mg kg low dose yervoy mg kg combination first line advanced small cell lung cancer nsclc patient high tumor mutational burden tmb mutation megabase mut mb combination demonstrated superior benefit co primary endpoint progression free survival pfs versus chemotherapy initial result show year pfs rate be more triple combination versus chemotherapy vs overall response rate combination be chemotherapy arm responder have ongoing response year chemotherapy grade treatment related adverse event rate opdivo low dose yervoy combination be versus chemotherapy result be encourage investor be disappoint merck mrk free report keytruda seem have fared better opdivo yervoy combination merck announce result phase iii study keynote evaluate pd therapy keytruda combination pemetrexed alimta cisplatin carboplatin first line treatment metastatic nonsquamous nsclc result show keytruda pemetrexed platinum chemotherapy combination significantly improve overall survival os reduce risk death half compare chemotherapy alone consequently share bristol myer decline first line nsclc market competition be stiffening quite few company try capture additional market share share company have gain only past year underperform industry growth concurrently bristol myer announce obtain fda approval opdivo yervoy injection intravenous use first immuno oncology combination therapy previously untreated patient intermediate poor risk advanced renal cell carcinoma phase iii trial checkmate demonstrated significant unprecedented increase os abovemention combination patient population compare current standard care pfizer pfe free report sutent moreover opdivo demonstrated sustain os advantage standard care patient recurrent metastatic squamous cell carcinoma head neck checkmate patient treat opdivo experience reduction risk death year minimum follow note opdivo be currently approve several country include unite state eu japan several cancer indication opdivo continue be launch globally approval label expansion drug have be perform impressively due demand result rapid commercial acceptance several indication include melanoma renal cell carcinoma second line nsclc label expansion additional indication give product access higher patient population increase commercial potential drug significantly bristol myer announce worldwide collaboration johnson johnson jnj free report janssen pharmaceutical inc janssen factor xia fxia inhibitor program include development former factor xia fxia inhibitor bms note bms investigational anticoagulant compound be be evaluate prevention treatment major thrombotic condition company be expect advance bms phase ii trial second half study secondary stroke prevention zack rankbristol myer carry zack rank hold see complete list today zack rank strong buy stock here breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2174,MRK,astrazeneca plc azn free report miss zack consensus estimate earning sale first quarter hit decline sale cholesterol drug crestor swiss pharma giant maintain previously issue outlook stock decline more pre market trading friday year so far astrazeneca share have rise industry decline first quarter core earning be cent american depositary share ad miss zack consensus estimate cent core earning share cent decline year year constant exchange rate cer hurt lower revenue operate profit meanwhile lower other income due unfavorable timing divestment also hurt earning quarter total revenue decline cer report quarter due lower product sale well externalization revenue revenue also miss zack consensus estimate growth rate mentioned be year year basis cer product sale declineproduct sale decline cer quarter higher sale newer medicine strong performance china be offset rapid erosion sale crestor lower sale many other legacy medicine externalization revenue be quarter externalization revenue be revenue arise astrazeneca externalization agreement older productscrestor sale decline unite state accounting europe contribute cer europe sale be weak multiple generic version drug enter market seroquel xr sale decline due competition generic launch symbicort sale decline quarter due sale decline market symbicort sale unite state decline quarter due pricing pressure unfavorable timing government buy sale rise europe emerge market nexium record sale due decline sale unite state europe other key legacy product record sale decline quarter include zoladex arimidex casodex pulmicort daliresp daxas synagis very few older drug grow quarter include faslodex seloken toprol xl newer productsamong newer medicine lynparza sale rise quarter sale unite state surge gain recent label expansion approval europe sale rise push higher number successful launch high brca testing rate encourage level reimbursement first quarter lynparza gain approval japan ovarian cancer unite state breast cancer drive sale further please note astrazeneca have partnership agreement merck mrk free report lynparza brilinta brilique sale be report quarter year year brilinta maintain leadership position brand oral platelet market well number european market farxiga record sale quarter medicine continue lead market volume new respiratory product fasenra get strong start record sale quarter support strong launch uptake unite state germany fasenra be approve unite state november last year eu japan january year quarter onglyza sale decline reflect pressure dpp class increase competitive pressure class diabetes medicine label include cv benefit tagrisso record sale year year drive increase testing rate unite state japan last month astrazeneca secure fda approval tagrisso first line set advanced lung cancer drive sale higher future quarters other new medicine movantik moventig record sale quarter less previous quarter iressa sale decline bevespi lama laba pressurize meter dose inhaler launch commercially unite state january record sale quarter less previous quarter slower anticipate growth lama laba class pd inhibitor imfinzi generate sale first quarter compare fourth quarter february imfinzi be approve immediately launch second indication unite state early stage lung cancer nsclc drive sale first quarter imfinzi be launch unite state first indication second line advanced bladder cancer calquence be launch unite state october last year generate sale first quarter compare previous quarter regional performancein unite state product sale be flat higher sale newer product be offset lower symbicort sale unfavorable manage care pricing generic launch european market witness decline sale due weak crestor sale revenue emerge market be primarily back strong growth china sale decline ex china market due challenge condition healthcare market russia establish row market comprise japan canada other market sale decline profit core gross margin decline basis point bps core selling general administrative sg expense rise due investment new product launch quarter core research development expense decline drive efficiency saving operate margin decline bps quarter maintain previously issue earning sale outlook astrazeneca expect core ep range adr company expect product sale grow low single digit percentage however product sale growth be expect be weight second half year astrazeneca be hopeful effect crestor patent expiration europe japan recede materially second halfmanagement guide total externalization revenue other income be less currency movement be expect favorably impact product sale core earning share low single digit percentage adjust cost be expect be line decline low single digit percentage range level company anticipate sg cost increase low mid single digit percentage support product launch fasenra imfinzi adjust tax rate be expect be range compare astrazeneca currently carry zack rank hold see complete list today zack rank strong buy stock here better rank pharma biotech stock include ligand pharmaceutical incorporate lgnd free report eli lilly lly free report ligand have zack rank lilly be rank stock ligand earning estimate rise past day stock have gain year so far lilly earning estimate increase respectively past day more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2175,MRK,amazon amzn free report share jump past week let see drive optimism amazon stop buy google shopping adsmarketing firm merkle noticed late last month amazon ad stop appear alphabet googl free report google shopping platform amazon subsidiary zapoz however continue advertise platform google have say periodic adjustment ad campaign be not unheard person connect amazon have confirm condition anonymity company have fact stop advertising maybe be read too much amazon spend estimate year platform be worth analyze most obvious reason forward analyst be amazon be turn focus own advertising business so make money google try take share not make sense more amazon own comment earning call regard very strong growth advertising business support theory also be continuation escalation showdown company amazon earlier remove chromecast marketplace google remove youtube amazon device retaliation alexa build healthcare chopscnbc report accord internal document see reporter amazon be build healthcare division alexa obtain hipaa health insurance portability accountability act compliance particular focus diabetes management maternity pediatrics geriatric rachel jiang have varied experience company be lead effort missy krasner joined amazon last year help box attain hipaa compliance be responsible business development strategy other member team be larry ockene have work engineer amazon last year yvonne chou have take various role prime fashion retail healthcare market be complex highly regulate so amazon be rightly take step time past effort include collaboration merck mrk free report encourage developer make apps alexa skill diabetes management special team aw dedicate health pharmaceutical company joint initiative berkshire hathaway brk free report jpmorgan jpm free report improve patient outcome reduce cost insurer employer accord transparency market research digital health market be expect grow cagr reach end hipaa compliance facilitate sharing uploading patient datum alexa enabled device take amazon much closer take share market jeff bezos say success be go require talented expert beginner mind long term orientation so be go be amazon approach sure amazon experience centersamazon have tie home builder lennar convert model home company amazon experience center home customer have alexa operate thermostat light shade lock television simple voice command goal be showcase alexa operate so even aren buy lennar home buy amazon device convert home smart power alexa lennar community atlanta dalla los angele miami orlando san francisco seattle washington already have amazon experience center company haven say more location be add later lennar earlier have similar arrangement apple aapl free report siri likely didn go well have now go alexa amazon sear dealsear holding share soar announcement deal amazon see offer tire installation service order book amazon service extend brand not just own diehard brand service initially be available customer metropolitan area include atlanta chicago dalla los angele miami new york san francisco washington say want have tire ship sear auto center region service eventually be extend auto center relationship have be grow past year ever sear start selling kenmore brand home appliance amazon then later add diehard battery sear have see sharp decline sale past few year have be close large number store doubt company even be able continue go concern so deal be likely send customer store even be well satisfied amazon customer be something investor cheer just be en route selling entire business amazon know right share carry zack rank buy see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2176,MRK,roche hold ag rhhby free report announce encourage interim datum phase iii study impower evaluate tecentriq combination regimen first line treatment metastatic squamous small cell lung cancer nsclc datum show immuno oncology drug tecentriq combination blockbuster cancer drug avastin carboplatin paclitaxel significantly improve median overall survival os rate month compare avastin chemotherapy tecentriq combination regimen show survival benefit key lung cancer population such person egfr alk positive mutation liver metastase vary level pd expression november last year roche impower study meet co primary endpoint progression free survival pfs benefit march year roche announce study also meet primary endpoint median os however roche do not provide os number detailed datum study be present annual meeting american society clinical oncology asco early next month remind investor combination regimen be already priority review unite state indication first line set supplemental biologic license application be file base pfs os datum impower study decision be expect sep positive datum impower study be likely boost prospect favorable decision fda drug be approve nsclc second line set note merck mrk free report keytruda be only immuno oncology drug approve alone combination eli lilly lly free report alimta pemetrexed carboplatin treat nsclc patient first line set share roche have lose year date compare industry decline impower study consist cohort evaluate tecentriq combination avastin carboplatin paclitaxel tecentriq combination only carboplatin paclitaxel avastin carboplatin paclitaxel nsclc patient datum show tecentriq avastin arm achieve median os co primary endpoint month compare month avastin arm however tecentriq chemotherapy do not achieve statistically significant improvement os compare avastin chemotherapy roche be evaluate tecentriq monotherapy combination regimen late stage study include impower separate press release roche announce follow datum phase iii alex study compare alecensa pfizer pfe free report xalkori crizotinib treatment naive alk positive nsclc patient datum study demonstrated long term pfs benefit treat alecensa median pfs almost triple month compare month xalkori roche hold ag price roche hold ag price roche hold ag quotezack rankroche currently carry zack rank hold see complete list today zack rank stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2177,MRK,dow finished green seventh consecutive session post longest stretch gain nov do so blue chip index shrug recent fear rise inflation president trump proposal curb cost prescription drug also provide much need boost stock have be strong first quarter earning season index blue chip have not look attractive time now add strong performer portfolio help garner handsome profit month ahead inflationary fear decline fear gauge slideson soft datum consumer price inflation lead decline year treasury yield consumer price index cpi april increase come estimate level further core cpi increase only lower consensus estimate limit yearly growth lead reduction concern pace inflation be increase year yield increase remain mark have break earlier week be mostly reaction trump decision exit iran deal boost oil price meanwhile market fear gauge vix decline close mark seventh consecutive daily decline be lowest close level jan mark longest stretch decline year exceptional earning performancelook whole total earning be expect be same period last year higher revenue highest quarterly earning growth pace year earning growth be expect be double digit territory year earlier level zack sector read critical look earning season have receive result index member total earning index member have report result already be same period last year higher revenue beating ep estimate beating revenue estimate read retail stock maintain momentum dow recent run gain be product superlative first quarter earning performance most company several be blue chip likely also benefit strong economy additionally inflationary fear have recede reduce investor concern great degree investing select dow stock look smart option point have narrow search follow stock base good zack rank other relevant metric caterpillar inc cat free report deliver adjust earning share first quarter surpass zack consensus estimate margin revenue improve year year quarter surpass zack consensus estimate read caterpillar gain earning beat hike view caterpillar have zack rank strong buy company have expect earning growth current year zack consensus estimate current year have improve last day goldman sachs group inc gs free report report earning share comfortably beating zack consensus estimate net revenue be year year moreover revenue figure handily outpaced zack consensus estimate read goldman sachs earning impress improve trading goldman sachs have expect earning growth current year zack consensus estimate current year have improve last day stock have zack rank see complete list today zack rank stock here boee company ba free report report adjust earning share first quarter beating zack consensus estimate first quarter revenue amount quarter beating zack consensus estimate read boee beat earning hike ep view boee have zack rank buy company have expect earning growth current year zack consensus estimate current year have improve last day merck co inc mrk free report report first quarter adjust earning share beat zack consensus estimate cent revenue quarter rise year year merck have zack rank company have expect earning growth current year zack consensus estimate current year have improve last day medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2178,MRK,merck co inc mrk free report pfizer inc pfe free report report upbeat first quarter result fact pharma giant manage outpace earning estimate miss revenue front however company top bottom line rise year year merckha zack rank buy pfizer possess zack rank hold now let see stock be better position term fundamental post earning see complete list today zack rank strong buy stock here other major earning come other pharma giant abbott free report johnson johnson jnj free report earning performancein first quarter merck report adjust earning share surpass zack consensus estimate cent bottom line increase year period meanwhile company revenue fall short zack consensus estimate increase year year read more merck beat earning lag sale raise outlook pfizer post first quarter earning cent share beating zack consensus estimate only cent earning advanced year period due lower tax rate share count moreover revenue increase year year miss zack consensus estimate read more pfizer stock fall sale miss earning beat price have witness rise past month pfizer have advanced only so merck be clear winner respect better return rival merck broader industry decline same period most appropriate ratio evaluate drug maker be perhaps ev ebitda metric be usually used compare stock same industry be superior other metric such be not affected different capital structure company come pharma major pfizer ev ebitda ratio be overvalue broader industry have ev ebitda value other hand ev ebitda ratio merck be underpriced pfizer industry net marginthe pharmaceutical industry enjoy higher profit margin several other sector be possibly reason critic sector continually draw attention exorbitant drug pricing help sector maintain steep margin net margin value pfizer perform better rival merck have net margin value comparison broader industry have net margin value debt equity debt equity ratio be good indicator financial health company good proxy debt servicing capacity context capital intensive industry pharma be indicator company long term sustainability merck debt equity ratio be significantly high compare industry ratio comparatively lower ratio pfizer evidently have better leverage condition earning history estimate revisionsmerck deliver positive surprise last quarters average earning surprise comparison pfizer deliver earning beat trail quarters post average positive earning surprise consider estimate revision merck earning estimate current year have improve past day meanwhile pfizer earning estimate have decline same period conclusionin comparative analysis find pharma giant have certain positive pfizer hold better leverage position have higher net margin however term valuation merck be more underpriced pfizer further merck have comparatively higher price performance pfizer moreover merck also hold edge pfizer consider average positive earning surprise estimate revision clinch case favor merck point time be have better zack rank pfizer respect analysis clearly indicated merck be better position pfizer thus call investor attention post earning look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2179,MRK,horizon pharma plc hznp free report report lower expect result first quarter follow news company share go horizon pharma stock have decline year date compare industry fall company report first quarter adjust earning cent share miss zack consensus estimate cent be much lower cent report year quarter sale first quarter be year year miss zack consensus estimate quarter orphan unit record revenue year period growth net sale ravicti generate quarter year year be partially offset lower sale actimmune buphenyl quinsair additionally procysbi contribute performance net sale year year actimmune sale report quarter be year year procysbi lower sale growth quinsair decline sale be due divest marketing right europe middle east africa emea rheumatology unit generate sale year year also krystexxa sale quarter be strong come year year drive strong continue year year vial demand primary care garner revenue year year decline net sale be due greater anticipate seasonality impact accrual inventory sale channel report quarter net sale pennsaid duexix vimovo be respectively adjust research development expense be adjust selling general administrative expense be year year guidance pharma raise outlook now expect sale range previously mainly drive expect strong growth orphan rheumatology business unit especially krystexxa company expect krystexxa sale increase year year due year delay implementation government health resource service administration final rule drug ceiling price jul other updatesin february company file supplemental new drug application expand age range label raviciti month age older birth older january company announce program develop next generation biologic hzn pasylate uricase technology treatment uncontrolled gout currently horizon pharma be evaluate krystexxa combination commonly used different immunomodulator investigator initiate study recipe triple enhance response rate drug gout patient company be progress well phase iii study evaluation teprotumumab moderate severe active thyroid eye disease company expect complete enrollment study end meanwhile company be work expand actimmune label investigator initiate study moffitt cancer center be underway enrolling patient study be evaluate actimmune combination roche holding rhhby free report herceptin perjeta taxol certain advanced breast cancer patient phase study evaluate actimmune combination bristol myer squibb company bmy free report opdivo kidney bladder cancer actimmune be also be evaluate combination merck co mrk free report keytruda treat cutaneous cell lymphoma patient phase ii study new operate structurein line horizon pharma long term strategy management announce begin second quarter report result operate segment company separate strategic growth business orphan rheumatology primary care business company expect new structure help better allocation resource develop product unmet treatment need patient rare disease takehorizon pharma first quarter result be not impressive company miss top bottom line estimate however sale guidance be encourage expect krystexxa ravicti actimmune drive further growth company focus develop krystexxa actimmune be beneficial future expect study increase operate expense horizon pharma public limit company price consensus ep surprise horizon pharma public limit company price consensus ep surprise horizon pharma public limit company quotezack rankhorizon pharma currently have zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2180,MRK,last week senator tina expressed concern big pharma company plan use large corporate tax saving reward shareholder instead bring cost expensive drug benefit consumer senator question letter ceo big pharma company pfizer pfe free report merck mrk free report johnson johnson jnj free report abbvie abbv free report abbott lab free report plan use extra cash please note conference call hold earlier year most big pharma company discuss plan do extra cash save new tax bill company plan invest extra cash capital expenditure product pipeline licensing acquisition deal reward shareholder higher dividend share buyback not many talk take step lower prescription drug cost apart key announcement week include failure dermira inc derm free report acne candidate pivotal late stage study merck oncology collaboration japan eisai expansion jardiance clinical study eli lilly lly free report fda committee back pfizer xeljanz third indication recap week most important storiesdermira share sink acne candidate fail share dermira plunge announce acne candidate olumacostat glasaretil surprisingly fail meet primary endpoint pivotal phase iii study clareo clareo company say likely stop olumacostat glasaretil development follow failure read more dermira acne candidate fail pivotal trial share sink merck jointly develop eisai cancer drug lenvima similar last year profit sharing deal astrazeneca azn free report merck announce oncology collaboration japan eisai co ltd deal company jointly develop commercialize eisai tyrosine kinase inhibitor lenvima monotherapy combination merck pd therapy keytruda several type cancer deal merck give eisai upfront payment company share global development marketing cost well gross profit lenvima equally read more merck pay upfront co develop eisai cancer drug pfizer xeljanz snda get fda committee back pfizer supplemental new drug application include ulcerative colitis uc indication label receive back fda advisory committee fda drug advisory committee gidac vote unanimously favor jak inhibitor fda decision be expect june xeljanz be already approve treat rheumatoid arthritis active psoriatic arthritis record sale represent growth year year astrazeneca look forxiga eu approval type diabetes astrazeneca application look get sglt inhibitor forxiga approve new indication oral adjunct treatment insulin type diabetes patient be accept european medicine agency forxiga be presently approve monotherapy well combination therapy treat type diabetes approve forxiga become first sglt inhibitor approve europe treatment oral treatment adjunct insulin read more astrazeneca forxiga label expansion filing accept eu glaxo present asthma hiv datum glaxo gsk free report present datum osmo study new respiratory medicine nucala american academy allergy asthma immunology aaaai world allergy organization wao joint congress orlando datum study show patient asthma be uncontrolled xolair witness improve asthma control switch glaxo new respiratory medicine nucala glaxo also present interim datum phase iiib study inspiring investigational hiv candidate dolutegravir medical conference boston read more glaxo encourage asthma hiv datum medical meeting meanwhile glaxo gain approval expand european label once daily laba ics combination treatment relvar ellipta now relvar ellipta be used eu patient asthma be already adequately controlled ics laba label update doctor prescribe asthma patient switch once daily relvar ellipta current twice daily ics laba experience comparable benefit lung function safety profile lilly boehringer expand jardiance clinical study lilly partner boehringer ingelheim announce plan initiate phase iii emperial study evaluate effect lilly sglt inhibitor jardiance exercise ability heart failure symptom person chronic heart failure irrespective have type ii diabetes presently ongoing phase iii emperor outcome study be evaluate effect jardiance long term morbidity mortality outcome person heart failure emperial study investigate treatment jardiance help improve everyday life person live chronic heart failure read more lilly boehringer expand jardiance heart failure program nyse arca pharmaceutical index be last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session major stock rise largest gainer be glaxo lilly last month bristol myer bmy free report gain merck decline see last pharma stock roundup here azn imfinzi get fda nod mrk buy australian firm next pharma world watch regulatory pipeline news pharma stock don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
2181,MRK,astrazeneca azn free report announce european medicine agency have accept marketing authorization variation mav label expansion forxiga dapagliflozin forxiga selective sglt inhibitor be presently market monotherapy well combination therapy improve glycaemic controlin adult patient type diabetes mav astrazeneca be seek get forxiga approve oral adjunct treatment insulin adult type diabetes submission ema be base phase iii datum depict study show forxiga give oral adjunct adjustable insulin patient inadequately controlled lead significant clinically relevant reduction baseline blood sugar level hba weight total daily insulin dose week compare placebo mg mg dose year astrazeneca share have rally outperform industry gain remind investor december merck mrk free report pfizer inc pfe free report investigational oral sglt inhibitor steglatro ertugliflozin tablet steglujan ertugliflozin sitagliptin be approve fda adjunct diet exercise improve glycemic control patient type diabetes mellitus apart drug fda also approve segluromet ertugliflozin metformin same indication patient already treat steglatro glucophage metformin inadequately controlled type diabetes mellitus patient be already treat combination ertugliflozin metformin astrazeneca plc price astrazeneca plc price astrazeneca plc quote zack rank stock carry zack rank sell better rank stock same space be regeneron regn free report carry zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved respectively last day company pull positive earning surprise last quarters average beat wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2182,MRK,spite increase incidence alzheimer be recognize drug cure slow progress disease alzheimer association claim second american develop alzheimer person live alzheimer find extremely difficult carry daily function hence need be supervision round clock come other life threaten condition cnbc report death related alzheimer have sky-rocket follow heart disease have drop turn century detection year onset alzheimer sa blood test have be introduce detect alzheimer almost decade patient show noticeable symptom last year dr randall bateman washington university announce test be able detect accumulation amyloid beta brain buildup toxic protein be first sign deadly disease also january team researcher japan australia introduce blood test accuracy high detection disease dr bateman employ mass spectrometry testing identify protein accord email bateman cnbc scientist japan have develop identical mass spectrometry investigative procedure protein detection come similar result blood test speed drug trial drug delay start disease fail number time thank unavailability decent number qualify patient reveal dr jeff cumming cleveland clinic hence wider patient base higher be possibility meaningful clinical trial new blood test doctor be able detect patient early include clinical trial development effective preventive treatment also be proper utilization million dollar federal government funding preventive treatment importantly blood test be most efficient way detect alzheimer other alternative be quite expensive lumbar puncture early diagnosis be alternative collect cerebrospinal fluid process needle be insert lower back patient give rise need local anesthetic positron emission tomography be process cost least also accuracy pet scan be significantly lower blood test dr robert vassar northwestern university have also backed efficiency blood test other method diagnosis alzheimer meanwhile dr bateman add blood test be more demand once proper preventive measure have be establish stock gainpeople world likely gain access test come few year dr bateman however question loom large be be next course action find be risk develop alzheimer meanwhile launch blood test pave way advanced clinical trial more person be estimate be live disease unite state alzheimer association notably health organization expect number rise more time alzheimer be press concern be massive business potential space hence launch blood test help company focuse develop preventive treatment make billion base cambridge biogen inc biib free report have be pay particular attention step research work alzheimer company surpass zack consensus estimate last quarters average positive earning surprise be also expect company witness earning growth respectively have be almost year eli lilly company lly free report headquarter indianapoli be fight alzheimer company beat zack consensus estimate last quarters also expect company post earning growth respectively fact treat patient early alzheimer symptom astrazeneca plc azn free report eli lilly be jointly develop lanabecestat small molecule therapy candidate merck co inc mrk free report headquarter kenilworth nj have be focuse research treat alzheimer company be expect post earning growth respectively merck also manage beat zack consensus estimate last quarters biogen eli lilly merck carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2183,MRK,have be month last earning report merck company inc mrk free report share have lose time frame underperform market recent negative trend continue lead next earning release be mrk due dive investor analyst have react late let take quick look most recent earning report order get better handle important driver merck beat earning lag salesmerck report fourth quarter adjust earning cent share beat zack consensus estimate cent earning rise year year slightly higher sale lower taxe make higher cost quarter include provision related tax reform fourth quarter loss share be cent compare loss cent share fourth quarter revenue quarter rise year year sale however slightly miss zack consensus estimate currency movement positively impact revenue exclude currency impact sale rise year year strength keytruda bridion animal health offset headwind loss exclusivity product competitive pressure zostavax zepatier lose sale approximately market due network cyber attack june revenue quarter be also boost several time event sale terminate vaccine joint venture sanofi europe approximately favorable timing shipment japan approximately partial replenishment borrow dose gardasil gardasil center disease control prevention cdc contribute overall sale quarter pharmaceutical segment generate revenue exclude fx impact year year continue strong sale keytruda bridion offset lower sale key vaccine gardasil gardasil zostavax unite state previous quarters loss market exclusivity several drug also hurt top line keytruda second largest product merck portfolio bring sale fourth quarter sequentially year year sale continue be drive launch new indication globally keytruda sale be gain particularly strong momentum indication first line lung cancer be only pd approve first line set keytruda development program also significantly advanced regulatory approval new indication unite state europe japan approval expand patient population drive sale higher zepatier bring sale previous quarter due reduction share volume due increase competition management expect negative trend continue most market outside unite state also come pressure bridion sugammadex injection generate sale quarter year year drive strong demand meanwhile combine sale remicade lose exclusivity europe face stiff biosimilar competition region cancida lose exclusivity europe zetia lose market exclusivity unite state december vytorin lose exclusivity april decline quarter remicade sale decline quarter cancida sale plunge quarter zetia vytorin franchise record sale due loss exclusivity zetia vytorin sale isentress also decline januvia janumet diabetes franchise remain soft quarter isentress sale decline quarter lower volume demand due competitive pressure hurt sale isentress januvia janumet franchise record sale quarter year quarter higher global volume partially offset impact continue pricing pressure gardasil gardasil sale rise lower sale unite state be offset commercial launch china strong growth europe unfavorable timing public sector purchase adversely impact gardasil sale unite state nonetheless merck say underlie growth increase coverage rate remain strong unite state sale rise europe boost addition sale terminate vaccine joint venture sanofi zostavax sale decline quarter face strong competition glaxo newly approve shingle vaccine shingrix proquad ii varivax vaccine record combine sale flat year year merck animal health segment generate revenue exclude fx impact year quarter drive continue strength companion animal ruminant poultry business margin gross margin come basis point bps year quarter marketing administrative expense be flat report quarter research development spend increase quarter due increase clinical development spending timing business development expense resultsfull year sale miss zack consensus estimate revenue be guidance range sale rise year year adjust earning be share beat zack consensus estimate well guide range earning rise year year guidancerevenue be expect range revenue guidance include approximately positive impact currency fluctuation merck expect growth key product keytruda lynparza gardasil bridion make headwind loe softness diabetes franchise competitive pressure zepatier zostavax company expect adjust earning range adjust earning guidance include approximately negative impact currency fluctuation adjust operate expense be expect increase year year low mid single digit rate due higher cost adjust gross margin be expect decline slightly due unfavorable product mix adjust tax rate be expect be flat slight level due time benefit last year impact tax reformsmerck also say expectation improve cash position follow tax reform plan invest approximately next year capital expenditure approximately investment be make add manufacturing capacity unite state also company say have already make contribution merck foundation plan award eligible executive employee time long term incentive second quarter have estimate be move then analyst be quiet last month period none issue earning estimate revision merck company inc price consensus merck company inc price consensus merck company inc quotevgm scoresat time mrk have average growth score however momentum be do lot better stock be also allocate grade value side putt top investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested style score indicate stock be more suitable momentum value investor growth investor outlookmrk have zack rank hold expect line return stock next few month
2184,MRK,have be month last earning report merck company inc mrk free report share have lose time frame underperform market recent negative trend continue lead next earning release be mrk due dive investor analyst have react late let take quick look most recent earning report order get better handle important driver merck beat earning lag salesmerck report fourth quarter adjust earning cent share beat zack consensus estimate cent earning rise year year slightly higher sale lower taxe make higher cost quarter include provision related tax reform fourth quarter loss share be cent compare loss cent share fourth quarter revenue quarter rise year year sale however slightly miss zack consensus estimate currency movement positively impact revenue exclude currency impact sale rise year year strength keytruda bridion animal health offset headwind loss exclusivity product competitive pressure zostavax zepatier lose sale approximately market due network cyber attack june revenue quarter be also boost several time event sale terminate vaccine joint venture sanofi europe approximately favorable timing shipment japan approximately partial replenishment borrow dose gardasil gardasil center disease control prevention cdc contribute overall sale quarter pharmaceutical segment generate revenue exclude fx impact year year continue strong sale keytruda bridion offset lower sale key vaccine gardasil gardasil zostavax unite state previous quarters loss market exclusivity several drug also hurt top line keytruda second largest product merck portfolio bring sale fourth quarter sequentially year year sale continue be drive launch new indication globally keytruda sale be gain particularly strong momentum indication first line lung cancer be only pd approve first line set keytruda development program also significantly advanced regulatory approval new indication unite state europe japan approval expand patient population drive sale higher zepatier bring sale previous quarter due reduction share volume due increase competition management expect negative trend continue most market outside unite state also come pressure bridion sugammadex injection generate sale quarter year year drive strong demand meanwhile combine sale remicade lose exclusivity europe face stiff biosimilar competition region cancida lose exclusivity europe zetia lose market exclusivity unite state december vytorin lose exclusivity april decline quarter remicade sale decline quarter cancida sale plunge quarter zetia vytorin franchise record sale due loss exclusivity zetia vytorin sale isentress also decline januvia janumet diabetes franchise remain soft quarter isentress sale decline quarter lower volume demand due competitive pressure hurt sale isentress januvia janumet franchise record sale quarter year quarter higher global volume partially offset impact continue pricing pressure gardasil gardasil sale rise lower sale unite state be offset commercial launch china strong growth europe unfavorable timing public sector purchase adversely impact gardasil sale unite state nonetheless merck say underlie growth increase coverage rate remain strong unite state sale rise europe boost addition sale terminate vaccine joint venture sanofi zostavax sale decline quarter face strong competition glaxo newly approve shingle vaccine shingrix proquad ii varivax vaccine record combine sale flat year year merck animal health segment generate revenue exclude fx impact year quarter drive continue strength companion animal ruminant poultry business margin gross margin come basis point bps year quarter marketing administrative expense be flat report quarter research development spend increase quarter due increase clinical development spending timing business development expense resultsfull year sale miss zack consensus estimate revenue be guidance range sale rise year year adjust earning be share beat zack consensus estimate well guide range earning rise year year guidancerevenue be expect range revenue guidance include approximately positive impact currency fluctuation merck expect growth key product keytruda lynparza gardasil bridion make headwind loe softness diabetes franchise competitive pressure zepatier zostavax company expect adjust earning range adjust earning guidance include approximately negative impact currency fluctuation adjust operate expense be expect increase year year low mid single digit rate due higher cost adjust gross margin be expect decline slightly due unfavorable product mix adjust tax rate be expect be flat slight level due time benefit last year impact tax reformsmerck also say expectation improve cash position follow tax reform plan invest approximately next year capital expenditure approximately investment be make add manufacturing capacity unite state also company say have already make contribution merck foundation plan award eligible executive employee time long term incentive second quarter have estimate be move then analyst be quiet last month period none issue earning estimate revision merck company inc price consensus merck company inc price consensus merck company inc quotevgm scoresat time mrk have average growth score however momentum be do lot better stock be also allocate grade value side putt top investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested style score indicate stock be more suitable momentum value investor growth investor outlookmrk have zack rank hold expect line return stock next few month
2185,MRK,nektar therapeutic nktr free report report loss cent share fourth quarter substantially narrower zack consensus estimate loss cent year figure cent share nektar have significantly outperformed industry year time stock have sky-rocket industry have decrease quarterly revenue substantially soar year period upside mainly be attribute massive rise license collaboration revenue top line also significantly beat zack consensus estimate quarter top line comprise product sale royalty revenue cash royalty revenue license collaboration other revenue fourth quarter product sale tumble year however cash royalty revenue increase company report royalty revenue quarter review register huge improvement year uptrend be mainly back royalty revenue receive license agreement astrazeneca movantik shire plc adynovate license collaboration other revenue come compare prior year upside be mainly due receipt recur revenue related new sublicense agreement research development expense mount primarily due investment pipeline include key candidate nktr nktr nktr general administrative expense be report quarter resultsfull year sale jump year year sale outpaced consensus mark well previously guide range loss cent share be narrower zack consensus estimate cent year earlier figure cent pipeline most advanced candidate company portfolio be onzeald currently evaluation phase iii attain study treatment adult advanced breast cancer have brain metastase apart onzeald candidate company immuno oncology portfolio be nktr last year september nektar announce initiation phase ii propel study evaluate efficacy safety nktr combination roche rhhby free report tecentriq atezolizumab merck mrk free report keytruda pembrolizumab datum trial be expect second half phase ii study evaluate nktr potential combination treatment regimen bristol myer squibb bmy free report opdivo be also underway candidate be be examine tumor type include melanoma renal cell carcinoma small cell lung cancer bladder triple negative breast cancer combo therapy also be evaluate more potential indication candidate nktr be be evaluate phase iii program chronic pain management last july company report positive top line result oral human abuse potential study evaluate nktr assess opioid abuse potential compare oxycodone company be plan submit new drug application nda candidate april outlooknektar estimate revenue range exclude payment collaboration bristol myer enter last month agreement company jointly develop commercialize lead immuno oncology candidate nktr former combination latter opdivo opdivo yervoy ipilimumab nektar anticipate cash approximately year end include upfront payment collaboration bristol myer notably cash investment marketable security dec be comparison dec nektar therapeutic price consensus ep surprise nektar therapeutic price consensus ep surprise nektar therapeutic quotezack ranknektar carry zack rank hold see complete list today zack rank strong buy stock here don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
2186,MRK,pfizer inc pfe free report announce late stage study kidney cancer drug inlyta axitinib fail demonstrate clear improvement primary endpoint extend disease free survival dfs accordingly independent datum monitoring committee recommend study be stop plan interim analysis detailed datum study be present future medical meeting phase iii atla study be evaluate inlyta versus placebo adjuvant therapy patient high risk recurrent renal cell carcinoma rcc type kidney cancer follow surgical removal kidney share pfizer have rise so far year compare favorably decrease industry inlyta be presently market second line treatment patient advanced rcc atla study be successful then inlyta be able cater expand patient population kidney cancer patient be earlier stage disease inlyta generate sale decline meanwhile inlyta be be evaluate independent global phase iii study combination merck mrk free report pd inhibitor keytruda own pd inhibitor bavencio avelumab respectively compare sutent first line advanced rcc study continue be unmodified bavencio be currently approve metastatic mcc rare aggressive skin cancer unite state europe japan second line treatment locally advanced metastatic urothelial carcinoma accelerate approval unite state pfizer have develop bavencio partnership german company merck kgaa meanwhile avelumab be be develop different type cancer avelumab pd program have several study ongoing monotherapy combination other portfolio asset zack rank key pickpfizer carry zack rank buy see complete list today zack rank strong buy stock here top rank large cap pharma stock be glaxosmithkline gsk free report same zack rank pfizer share glaxo have return year so far estimate have increase respectively past day medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2187,MRK,dow enjoy week strong gain trade war syrium related fear recede president trump indicated trade dispute be resolve discussion meanwhile china president xi jinp pledge open china economy further trump also indicated military strike syrium be not imminent result investor choose focus upcoming bank earning financial gain last week dow decline last friday increase worry trade war brewing unite state china lead huge selloff moreover equity hit session lows final hour trading fed chairman jerome powell say central bank keep increase interest rate curb inflation dow tank last week escalate trade war related tension china volatile week start low china announce tariff good include pork apple dry fruit market gain traction white house give indication government not want enter trade war china notably thursday be also first day nyse march new week high outnumber week lows powell statement bank keep increase interest rate keep inflation control once again make investor jittery dow index gain monday trade war tension ease extent official president trump administration say trade dispute china be resolve discussion such comment help stock rally almost trading session however stock pare most day gain shortly market close news federal bureau investigation fbi raid office trump personal lawyer michael cohen index increase tuesday chinese president xi promise take measure open country economy cut import tariff investor confidence rebound fear trade war ease extent see stock rally almost trading session moreover share facebook inc fb free report too jump company ceo mark zuckerberg testify front congress follow news datum misuse scandal involve million user index decline wednesday follow president donald trump tweet warning russia possible military strike syrium escalate geopolitical tension unite state russia see investor take defensive stance stock tumble safe haven rally decline be lead bank stock such citigroup inc free report goldman sachs group inc gs free report morgan stanley ms free report however share facebook increase company ceo continue testimony front congress second day index gain thursday investor ignore geopolitical tension choose focus upcoming earning season investor concern recede trump tweet say military strike syrium be unlikely future financial be best performer day investor focuse upcoming bank earning component move index procter gamble company pg free report board director declare hike quarterly cash dividend cent share bid impress investor dividend be paid shareholder record apr new figure add annual dividend share zack rank sell be consider be dividend aristocrat index give consistent increase dividend year span operation more year business dividend yield more apr help attain position read procter gamble reward shareholder dividend hike apple aapl free report lure user unveil red iphone go sale apr be available store friday apr onward apple have zack rank reportedly company have labele device same price tag other regular model be iphone new device be expect offset weakness arise lackluster sale premium iphone iphone launch have be mainstay tech giant revenue however spurt revenue iphone last quarter be owing higher iphone average selling price total shipment witness decline lower expect sale iphone have be dampener company ever analyst have be slash sale estimate product read apple launch red iphone boost sale boee company ba free report recently secure contract deliver dreamliner aircraft american airline world largest airline term airline receive dreamliner boee expand modernize fleet deal be expect open new route american airline globe include europe asia pacific region deal be value more current list price make airline boee largest dreamliner customer western hemisphere stock have zack rank buy see complete list today zack rank strong buy stock here chevron corp cvx free report recently divest stake elk hill field california san joaquin basin upstream player california resource corp crc free report cash stock deal deal california resource secure full ownership historic elk hill field deal zack rank hold chevron have offloaded operated work interest field cash consideration issue share california resource divest region account production barrel oil equivalent day boe comprise oil natural gas natural gas liquid chevron read chevron sell stake elk hill field cash stock deal mcdonald corporation mcd free report be likely open restaurant nordic region next decade medium report bid attract customer meanwhile zack rank mcdonald seem be increasingly focuse delivery service order cater customer need better way be expect begin home delivery nordic region year sweden finland mcdonald start home delivery service onwards denmark norway latter half denmark sweden norway well finland company serve customer year have nearly restaurant region read mcdonald plan open restaurant nordic region merck co inc mrk free report announce datum phase iii study show treatment pd inhibitor keytruda monotherapy lead significantly improve overall survival os first line therapy certain lung cancer patient merck have zack rank pivotal keynote study evaluate patient locally advanced metastatic nonsquamous squamous small cell lung cancer nsclc tumor express pd protein level percent greater tps percent such patient keytruda show significant survival benefit compare platinum base chemotherapy os datum keynote study be approve be include keytruda label drug be prescribe treat expand lung cancer patient population further reinforce position lung cancer market read merck keytruda offer survival benefit lung cancer study performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have gain next week trade war syrium related fear recede background investor be able better focus upcoming earning bank earning be release first be widely expect higher rate lower taxe boost result meanwhile investor continue focus economic release schedule next week include crucial report industrial production retail sale make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2188,MRK,last week have be eventful pharma stock novartis nvs free report announce be acquire gene therapy company avexis merck mrk free report abbvie abbv free report announce successful study result other news pfizer pfe free report kidney cancer drug inlyta miss primary endpoint phase iii study recap week most important storiesnovartis buy avexis big news early week be novartis deal buy avexis lead product candidate avxs be time gene replacement therapy spinal muscular atrophy sma regulatory filing avxs unite state be expect second half year avxs have potential generate million dollar novartis approve company agree pay share avexis represent whooping premium avexis close price friday board company have approve deal buyout be anticipate close second half year read more novartis inks gene therapy deal buy avexis merck keytruda succeed key lung cancer study pivotal lung cancer study keynote merck blockbuster pd inhibitor keytruda meet primary endpoint keynote study evaluate patient locally advanced metastatic nonsquamous squamous small cell lung cancer nsclc tumor express pd protein level percent greater tps percent such patient keytruda show significant survival benefit compare platinum base chemotherapy notably keytruda monotherapy be already market first line treatment patient metastatic nsclc tumor express pd protein level percent greater tps percent os datum keynote study be approve be include keytruda label drug be prescribe treat expand lung cancer patient population further reinforce position lung cancer market read more merck keytruda offer survival benefit lung cancer study abbvie late stage upadacitinib study succeed abbvie oral jak selective inhibitor upadacitinib meet primary well secondary endpoint phase iii study select program phase iii study select compare evaluate candidate moderate severe rheumatoid arthritis patient be stable background methotrexate elicit inadequate response week treatment acr response first primary endpoint be achieve patient receive mg dose upadacitinib versus placebo second primary endpoint clinical remission be achieve patient upadacitinib arm versus only placebo arm read more abbvie ra candidate meet primary endpoint phase iii meanwhile fda have extend review period abbvie pipeline candidate elagolix month fda decision previously expect second quarter now come third quarter read more fda prolong review date abbvie endometriosis candidate pfizer inlyta miss primary endpoint phase iii study pfizer kidney cancer drug inlyta axitinib fail demonstrate clear improvement primary endpoint extend disease free survival dfs compare placebo phase iii atla study accordingly independent datum monitoring committee recommend study be stop plan interim analysis read more pfizer kidney cancer drug miss endpoint phase iii pfizer also announce initiation dose early stage study evaluate mini gene therapy candidate pf treatment boy duchenne muscular dystrophy dmd most common type muscular dystrophy early datum study be expect first half pacira exparel get fda nod expand label pacira pharmaceutical inc pcrx free report supplemental new drug application snda label expansion exparel nerve block set patient undergo upper extremity surgery get fda nod fda approval come surprise fda committee vote approval expand indication february read more fda okay label expansion pacira exparel stock exparel generate sale represent increase latest label expansion sale be expect go glaxo divest rare disease gene therapy drug private biotech glaxo gsk free report be divest rare disease gene therapy portfolio private biotech orchard therapeutic exchange stake company well seat board divesture be part strategic review glaxo announce july last year divest preclinical clinical program allocate capital priority program current area respiratory hiv infectious potential area oncology immuno inflammation read more glaxo sell rare disease gene therapy private biotech nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock record gain bristol myer bmy free report merck astrazeneca be biggest gainer rise respectively bristol myer decline last month astrazeneca have be biggest gainer merck decline most see last pharma stock roundup here pharma stock roundup lly cyramza shine cancer study pfe azn focus next pharma world watch novartis first quarter earning result other pipeline regulatory update make fortune shift electric carshere stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2189,MRK,johnson johnson jnj free report have most diverse revenue stream industry pharmaceutical division account almost half revenue company have several multus dollar drug cover broad range area such neuroscience cardiovascular metabolism immunology oncology pulmonary hypertension infectious disease vaccine however several product segment be face generic competition stock have depreciate year so far compare unfavorably decline record industry domestic pharma segment sale witness positive trend second half be soft first half year be likely see positive impact trend first quarter result zack consensus estimate pharmaceutical segment be last quarter segment sale beat consensus estimate believe new product continue share gain key product label expansion drug imbruvica xarelto stelara darzalex meaningful contribution swiss biotech actelion buy june support top line continue share gain drive sale imbruvica cancer indication xarelto blood thinner zytiga prostate cancer stelara psoriasis meanwhile strong adoption newer indication crohn disease continue contribute stelara growth also gain fda approval zytiga first line set february drive sale drug higher first quarter please note market imbruvica partnership abbvie inc abbv free report also strong adoption outside market accelerate adoption unite state line therapy drive sale darzalex positive likely offset loss sale drug invokana due higher manage care discounting meanwhile biosimilar competition be expect continue hurt key arthritis drug remicade sale outside unite state market remicade partnership merck mrk free report regard newly launch tremfya say fourth quarter conference call uptake product have be decent drug record sale last quarter be expect be higher be report quarter also discuss initial sale uptake juluca call first dual treatment hiv develop partnership glaxosmithkline gsk free report gain fda approval last november juluca be review eu meanwhile expect discuss plan erleada newly approve prostate cancer drug first quarter conference call overall expect pharmaceutical segment remain strong consumer medical device segment continue improve read more begin pharma earning store carry zack rank buy see complete list today zack rank strong buy stock here johnson johnson price ep surprise johnson johnson price ep surprise johnson johnson quotewill make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2190,MRK,nektar therapeutic nktr free report have announce initiation dose phase ii study evaluate combination novel immuno oncology agent nktr nktr patient advanced solid tumor nktr be toll receptor agonist design invite innate immune response fight cancer nktr be immuno stimulatory cd bias agonist share nektar have soar so far year substantially outperform industry decrease phase ii reveal study be open label multicenter dose escalation program design evaluate nktr nktr combination regimen administer initial intratumoral directly tumor injection nktr follow intravenous iv infusion nktr company believe combination therapy enable provide alternative treatment option patient moreover company also plan assess nktr nktr combination bristol myer bmy free report opdivo nivolumab give patient population remind investor september nektar enter clinical collaboration agreement bristol myer nektar nktr be examine combination latter opdivo tumor type include melanoma kidney colorectal bladder small cell lung cancer potential indication phase ii trial meanwhile september company announce initiation phase ii propel study evaluate efficacy safety nktr combination roche rhhby free report tecentriq atezolizumab merck mrk free report keytruda pembrolizumab be also important note nektar be develop several other candidate important therapeutic area include oncology pain infective immunology other company have make significant progress lead candidate onzeald formerly know nktr currently accelerate assessment eu treat adult advanced breast cancer well brain metastase response be anticipate first half couple other interesting candidate be nktr nktr nktr be be analyze phase iii program treatment chronic pain company initiate phase clinical study nktr treat wide range auto immune disease inflammatory disorder nektar therapeutic price nektar therapeutic price nektar therapeutic quote zack ranknektar carry zack rank sell see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2191,MRK,astrazeneca plc azn free report have announce final overall survival datum pivotal phase iii mystic study evaluate pd inhibitor imfinzi first line lung cancer be present second half delay first half expect previously mystic study evaluate imfinzi monotherapy combination tremelimumab treatment nave small cell lung cancer nsclc patient astrazeneca share have inched so far year compare unfavorably industry growth be second negative update astrazeneca relation mystic trial last july pharma company have report study failure meet primary endpoint progression free survival send company share tumble study show imfinzi combination tremelimumab not improve progression free survival pfs compare platinum base chemotherapy patient tumor express pd more cancer cell imfinzi monotherapy also fall short show benefit pfs however mystic study continue thereafter plan assess additional primary endpoint overall survival os monotherapy combination regimen final os datum primary endpoint be initially expect first half imfinzi be key drug london base astrazeneca immuno oncology io pipeline currently be evaluate multiple cancer alone combination other regimen include incyte incy free report epacadostat key phase iii trial combination tremelimumab hepatocellular carcinoma hcc liver cancer nsclc small cell lung cancer head neck squamous cell carcinoma hnscc other be way imfinzi be launch unite state first indication second line advanced bladder cancer be approve second indication unite state early stage lung cancer nsclc february drug generate sale last year talk pd inhibitor merck mrk free report keytruda bristol myer bmy free report opdivo have be notable successful launch keytruda fetch sale almost year year opdivo record revenue period astrazeneca carry zack rank sell see complete list today zack rank strong buy stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2192,MRK,aeglea biotherapeutic inc agle free report announce have initiate dose patient study evaluate lung cancer candidate pegzilarginase small cell lung cancer sclc cohort expansion phase study be evaluate pegzilarginase monotherapy sclc patient other be phase ii study evaluate candidate combination merck mrk free report pd therapy keytruda similar indication top line datum study be expect fourth quarter aeglea share have rise so far year industry loss period sclc expansion cohort be arm phase study be evaluate pegzilarginase cancer tumor stop produce certain amino acid arginine depletion arginine level tumor cause cell death promote tumor immune response phase ii study be evaluate combination pegzilarginase keytruda overall response rate patient extensive disease sclc disease have relapse progressed receive platinum base chemotherapy press release only sclc patient survive year treatment show significant unmet need several pharma company be develop therapy treat sclc astrazeneca azn free report be develop combination parp inhibitor lynparza chemotherapy temodar phase ii study abbvie abbv free report bristol myer have collaborate develop rovalpituzumab tesirine combination opdivo yervoy phase study therapeutic be also develop therapy combination chemotherapy sclc apart sclc aeglea be also develop pegzilarginase phase ii study patient deficiency rare genetic disease company report positive preliminary datum study earlier month aeglea biotherapeutic inc price aeglea biotherapeutic inc price aeglea biotherapeutic inc quotezack rankaeglea currently have zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2193,MRK,share immunogen inc imgn free report have shot year time massively outperform industry increase let analyze factor lead skyrocket rally immunogen rapid pipeline progress positive readout strategic collaboration consistently drive share price performance company make significant advancement regard lead pipeline candidate mirvetuximab soravtansine last month be be evaluate phase iii study forward single agent therapy treat patient platinum resistant ovarian cancer more site study enrolment third quarter aim complete middle readout primary endpoint be anticipate first half also candidate be be evaluate phase expansion cohort ovarian cancer patient fda nod mirvetuximab soravtansine be huge boost immunogen give immense commercial potential target market ovarian cancer cause maximum annual death gynecologic cancer majority patient diagnosed advanced stage meanwhile combination regimen mirvetuximab soravtansine ovarian cancer be also be examine phase ib ii forward ii study trial consist cohort assess mirvetuximab soravtansine combination roche rhhby free report avastin merck mrk free report keytruda immunogen have report initial result forward ii study show mirvetuximab soravtansine potential complement currently available therapy indication approval combo therapy significantly expand eligible patient population mirvetuximab soravtansine apart mirvetuximab soravtansine immunogen be work develop couple early stage candidate include imgn imgn december immunogen present positive finding ongoing phase study evaluate imgn patient relapse refractory adult acute myeloid leukemia aml annual meeting american society hematology moreover january company moved imgn phase study treat hematological malignancy include aml be also important note immunogen sign agreement several big healthcare player include amgen bayer eli lilly lly free report novartis roche sanofi takeda dint contract other company be allow use immunogen antibody drug conjugate adc technology provide fund form license milestone fee royalty clinical material revenue research development support fee platinum resistant ovarian cancer market offer immense commercial potential immunogen be notably set face intense competition approval however mirvetuximab soravtansine look promising juncture approval lend big boost company immunogen inc price immunogen inc price immunogen inc quote zack rankimmunogen carry zack rank hold seethe complete list today zack rank strong buy stock here hacker put money portfolio earlier year credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
2194,MRK,dow endure particularly tough week end marginal gain first time only thursday early half week strong earning result fail boost investor sentiment trade inflation related fear weigh investor most week fed refrain raise rate market watcher remain concern future action last week dow decrease last friday gain consecutive winning session strong earning result large cap technology internet boost investor sentiment mid day trading however market shed most gain soft gdp datum tepid earning report energy sector tumble stock blue chip index fall negative territory primarily due tepid earning result exxon mobil corporation xom free report dow lose last week investor remain concern iphone sale come expectation second quarter meanwhile caterpillar inc cat free report forecast economic growth decelerate later year also dampen investor sentiment spike treasury yield also weigh broader market dow index decline monday broad base decline push major index red slide healthcare industrial stock more offset gain several merger acquisition telecom mega deal moreover strong first quarter earning result also fail uplift investor sentiment dow gain month april strong earning result most large corporate fail encourage investor disappointing guidance taiwan semiconductor tsm free report largest contract chipmaker worldwide lead loss tech major rise bond yield also dent investor confidence index lose tuesday stock index close green trade red trading session blue chip index be once nearly touch lowest close april index decline wednesday market be early hour trading buoy fed decision keep monetary policy unchanged however broader market lose momentum later day news further escalation china trade conflict strong earning result apple also fail boost market sentiment investor remain concern inflationary pressure index gain thursday even investor remain uneasy ahead friday official job report earlier day dow be nearly point move day move average first such occurrence early april however re-cover subsequently post marginal gain fear related trade uncertainty fed future action weigh sentiment component move index apple inc aapl free report report second quarter fiscal earning share beat zack consensus estimate cent increase almost year year net sale increase year year surpass zack consensus estimate apple have zack rank hold total iphone unit sale miss zack consensus estimate increase year year back iphone iphone iphone third quarter fiscal revenue be project gross margin be expect operate expense be project read apple earning revenue top estimate chevron corporation cvx free report report first quarter earning share significantly ahead zack consensus estimate bottom line also improve significantly year profit chevron have zack rank quarterly revenue lag zack consensus estimate refine weakness be year year chevron total production crude oil natural gas increase compare last year corresponding period oil equivalent barrel day mboe chevron downstream segment achieve earning lower profit last year read chevron share gain post big earning beat dowdupont inc dwdp free report record profit report basis cent share first quarter compare cent share logged comparable quarter year bar time item earning come share quarter top zack consensus estimate zack rank dowdupont rake net sale report quarter comparable quarter year also surpass zack consensus estimate dowdupont expect net sale second quarter increase more operate ebitda rise more year year basis read dowdupont top earning revenue estimate merck co inc mrk free report report first quarter adjust earning share beat zack consensus estimate cent earning rise year year revenue quarter rise year year sale however slightly miss zack consensus estimate merck raise outlook revenue range previously zack consensus estimate stand company now expect adjust earning range raise previous guidance zack consensus estimate be peg share stock have zack rank buy see complete list today zack rank strong buy stock here mcdonald corporation mcd free report report first quarter adjust earning share outpaced consensus mark improve year quarter mcdonald have zack rank revenue outpaced consensus mark decline year year read mcdonald earning top comp continue impress pfizer inc pfe free report report first quarter adjust earning share cent beat zack consensus estimate cent earning rise year year revenue miss zack consensus estimate pfizer have zack rank revenue however rise year quarter report basis revenue be expect range adjust earning share be expect range read pfizer stock fall sale miss earning beat microsoft corporation msft free report deliver third quarter fiscal earning cent share beat zack consensus estimate dime figure rally year year basis microsoft have zack rank revenue increase almost year quarter constant currency cc further figure exceed zack consensus estimate read microsoft beat earning strong top line growth intel corp intc free report deliver first quarter gaap earning cent share beat zack consensus estimate cent figure surge year quarter decline sequentially intel have zack rank revenue totale year year quarter quarter figure surpass zack consensus estimate read intel beat earning robust datum centric growth exxon mobil report first quarter earning share miss zack consensus estimate however bottom line increase year quarter level cent exxon mobil have zack rank total revenue quarter rise year moreover top line surpass zack consensus estimate read exxon mobil fall earning miss beat sale performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have decline next week outlookmarket have endure difficult week weigh concern fed future action trade related tension china concern be unlikely disappear future fear spike inflation have also weigh investor sentiment economic report release recently have also be lackluster report gdp be particularly disappointing market now look crucial economic report such friday job report encouragement day ahead today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2195,MRK,exelixis inc exel free report deliver stellar first quarter earning revenue beat estimate strong performance cabometyx follow announcement result share exelixis gain market trading session exelixis share have lose year compare industry decline company report earning cent beating zack consensus estimate cent cent earn year quarter net revenue come year quarter report number surpass zack consensus estimate be report previous quarter exelixis inc price consensus exelixis inc price consensus exelixis inc quote quarter fda approve tablet formulation cabozantinib distinct capsule form brand name cabometyx april treatment advanced renal cell carcinoma rcc patient have receive prior angiogenic therapy net product revenue come year quarter upside be drive growth second later line advanced rcc business impact additional sale follow fda approval december expand indication cabometyx treatment previously untreated advanced rcc cabometyx generate net product revenue drive growth demand due expand indication demand be drive increase market share refill patient already therapy continue expansion prescriber base sequential increase cometriq cabozantinib capsule treatment medullary thyroid cancer generate net product revenue total collaboration revenue be compare earn year quarter company record revenue milestone payment due ipsen pharma sas ipsen second quarter potential approval cabozantinib first line treatment advanced rcc european commission report quarter research development expense increase stem higher personnel expense clinical trial cost consult outside service selling general administrative expense be significantly drive increase corporate give personnel expense marketing activity result primarily increase general administrative headcount support company commercial research development organization pipeline updatein march exelixis submit snda fda cabometyx treatment patient previously treat advanced hepatocellular carcinoma hcc base positive result celestial trial fda have previously grant orphan drug designation treatment advanced hcc exelixis european partner ipsen receive positive opinion chmp scientific committee ema cabometyx first line treatment adult intermediate poor risk advanced rcc ipsen also announce application variation cabometyx marketing authorization have be validate ema addition new indication patient previously treat advanced hcc exelixis be entitle receive milestone payment acceptance filing payment term collaboration agreement ipsen exelixis inked agreement bristol myer bmy free report roche hold rhhby free report develop cabozantinib combination immunotherapy agent january exelixis announce amendment protocol phase ib trial cabozantinib combination tecentriq patient locally advanced metastatic solid tumor amendment add new expansion cohort trial now include patient small cell lung cancer castration resistant prostate cancer addition previously include patient rcc urothelial carcinoma primary objective expansion stage trial remain determine objective response rate cohort meanwhile imspire trilogy trial evaluate combination cotellic tecentriq xelboraf first line braf mutation positive metastatic unresectable locally advanced melanoma have complete enrolment imspire trial evaluate combination cotellic tecentriq versus merck mrk free report keytruda first line braf wild type metastatic unresectable locally advanced melanoma be currently enrolling expect total cost operate expense range takeexelixis first quarter result be impressive earning sale beat estimate wide margin demand cabometyx grow approximately sequentially drive increase new patient start refill patient already therapy expect sale get further boost drug be now approve first line rcc increase eligible patient population caobometyx unite state approximately patient grab market share key drug sutent votrient first line rcc market however competition have further stiffen recent approval opdivo yervoy treatment poor intermediate risk first line rcc expect investor focus remain further label expansion cabozantinib cotellic potential label expansion advanced hcc further boost growth prospect company zack rankexelixis currently carry zack rank hold see complete list today zack strong buy rank stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2196,MRK,pfizer inc pfe free report share decrease report first quarter revenue lag zack consensus estimate billionmerck co inc mrk free report lose report first quarter revenue miss zack consensus estimate billiontenet healthcare corp thc free report share increase post first quarter adjust earning contrast zack consensus estimate loss shareshare bp plc bp free report increase report first quarter earning outpace zack consensus estimate
2197,MRK,gilead science inc gild free report report dismal result first quarter earning revenue miss expectation due wider expect decline hepatitis virus hcv franchise consequently stock decline market hour trading be expect open red give expectation further decline hcv franchise gilead stock have lose last month industry gain company first quarter earning share miss zack consensus estimate earning be also year quarter figure share gilead science inc price consensus ep surprise gilead science inc price consensus ep surprise gilead science inc quote moreover total revenue also miss zack consensus estimate further revenue decline year year harvoni sovaldi plunge furtherproduct sale come year year due accelerate decline hcv sale antiviral product sale include gilead hiv liver disease portfolio come quarter year quarter research development expense decline selling general administrative sg expense increase hcv product sale include harvoni sovaldi epclusa vosevi be report year quarter downside be mainly due lower sale harvoni sovaldi major market lower sale epclusa unite state result increase competition sale harvoni plunge year year quarter epclusa garner sale quarter year period figure meanwhile hiv hbv product sale come year year increase be primarily drive continuous strong uptake tenofoviral afenamide taf base product such genvoya generate sale year quarter descovy record sale odefsey register sale entry generic greater inventory drawdown prior year quarter somewhat impact sale however hiv treatment stribild complera eviplera sale decline respectively viread sale be atripla sale tank truvada sale fall other product letairis ranexa zydelig record sale respectively adjust product gross margin be compare year period guidance continue expect net product sale range adjust expense adjust sg expense be project range respectively adjust product gross margin be expect range company acquire kite pharma fda approval yescarta car therapy treatment adult patient relapse refractory large cell lymphoma more line systemic therapy gilead prospect company also acquire cell design lab expand further car space yescarta sale come quarter dividend share declare cash dividend cent share common stock second quarter dividend be payable jun stockholder record close business jun quarter company paid cash dividend repurchase share takegilead first quarter result be disappointing company earning sale miss estimate magnitude decline hcv sale be wider expect hcv franchise be tremendous pressure due lower patient start increase competition expect sale decline further go forward note harvoni sovaldi epclusa face competition abbvie abbv free report viekira pak viekira xr merck mrk free report zepatier pricing have largely stabilize market share stabilize mid patient start be expect decline further meanwhile hiv franchise maintain momentum drive rapid adoption descovy base regimen approval biktarvy feb fda have further widen portfolio biktarvy sale come quarter march biktarvy be add dhhs guideline use antiretroviral agent adult adolescent live hiv recommend initial regimen chmp have also adopt positive opinion marketing authorization application biktarvy eu gilead expect obtain approval same third quarter further solidify portfolio truvada use pre exposure prophylaxis set continue maintain momentum estimate patient used truvada end first quarter give persistent decline hcv sale company be look newer avenue help top line gilead be look solidify presence gene therapy space initial uptake yescarta be also encourage first quarter gilead announce agreement sangamo therapeutic inc sgmo free report use sangamo zinc finger nuclease technology platform development next generation ex vivo cell therapy oncology gilead be also intend foray nash market pipeline candidate selonsertib filgotinib candidate be be evaluate late stage study tentative approval diversify gilead portfolio zack rankgilead currently carry zack rank buy see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2198,MRK,share vtv therapeutic inc vtvt free report plummet significantly company announce dismal result part phase iii trial steadfast pipeline candidate azeliragon vtv therapeutic stock have plunge last month industry decline candidate be be evaluate patient suffering alzheimer disease result show candidate do not meet co primary efficacy endpoint patient take azeliragon versus placebo do not improve cognitive functional outcome measure thealzheimer disease assessment scale cognitive subscale ada cog clinical dementia rating scale sum box cdr sb study comprise independent identical randomize double blind placebo controlled phase iii trial part part azeliragon treat group part show point decline baseline ada cog point dip baseline cdr sb compare placebo fall respectively however difference be not statistically significant azeliragon be generally well tolerate withdrawal rate month be similar placebo treatment arm consequently vtv therapeutic discontinue ongoing study involve azeliragon include open label extension study part steadfast study nevertheless substantial portion patient part steadfast have complete month treatment study protocol failure late stage study be disappointing investor successful development subsequent candidate have significantly boost growth prospect give complexity drug late have be many failure drug be develop alzheimer february merck mrk free report announce stop phase iii study apecs be evaluate verubecestat mk investigational small molecule inhibitor beta site amyloid precursor protein cleave enzyme bace patient prodromal alzheimer disease decision be take external datum monitoring committee assessed overall benefit risk recent interim safety analysis conclude be unlikely positive benefit risk be possible january pfizer pfe free report announce plan end research effort new drug alzheimer parkinson disease eli lilly lly free report be major company have suffer many failure attempt develop drug alzheimer zack rankvtv therapeutic currently carry zack rank sell see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2199,MRK,merck co inc mrk free report announce datum phase iii study show treatment pd inhibitor keytruda monotherapy lead significantly improve overall survival os first line therapy certain lung cancer patient pivotal keynote study evaluate patient locally advanced metastatic nonsquamous squamous small cell lung cancer nsclc tumor express pd protein level percent greater tps percent such patient keytruda show significant survival benefit compare platinum base keytruda monotherapy be already market first line treatment patient metastatic nsclc tumor express pd protein level percent greater tps percent base datum keynote study os datum keynote study be approve be include keytruda label drug be prescribe treat expand lung cancer patient population further reinforce position lung cancer market study continue evaluate progression free survival pfs secondary endpoint base recommendation independent datum monitoring committee dmc later year merck present datum keynote study medical meeting also file regulatory application get os datum study include label keytruda share merck be more apr news be announce market open year so far merck share have outperformed industry share have rise period industry decline meanwhile keytruda be be evaluate several lung cancer study multiple setting stage disease monotherapy well combination therapy keytruda be second largest product merck portfolio be market many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma gastric cancer bladder cancer microsatellite instability high msi mismatch repair deficient cancer treatment fetch sale almost year year upside be drive global launch new indication further bolster demand keytruda sale be gain particularly strong momentum first line lung cancer indication fact keytruda be only pd approve first line set certain lung cancer patient monotherapy well combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo keytruda development program also significantly advanced several regulatory approval unite state europe japan new approval expand patient population drive sale last year positive momentum be expect sustain well meanwhile keytruda be be study more type cancer more study include excess combination study merck be collaborate several company include amgen amgn free report incyte glaxo gsk free report pfizer separately evaluation keytruda combination other regimen merck carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2200,MRK,share newlink genetic corp nlnk free report plunge announce conduct review study evaluate ido pathway inhibitor indoximod combination pd pd agent several cancer indication include melanoma share company have also decline year compare industry decline newlink decision come response incyte corp incy free report partner merck mrk free report announcement failure key melanoma combination study friday incyte merck say combination incyte epacadostat merck keutruda fail achieve improve progression free survival keytruda alone phase iii study echo keynote study be evaluate combination drug treatment unresectable metastatic melanoma external datum monitoring committee recommend termination study follow review datum pivotal study datum phase iii study demonstrated combination ido inhibitor pd antagonist not hold potential treatment melanoma obviously raise doubt potential success indoximod combination study pd pd agent newlink provide update review be complete newlinkclaims indoximod have differentiate mechanism action moa have demonstrated improve outcome patient cancer combination study result echo study also affected several company bristol myer squibb bmy free report be develop combination immunotherapy treatment cancer newlink genetic corporation price newlink genetic corporation price newlink genetic corporation quotezack rank newlink carry zack rank hold see complete list today zack rank stock here zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2201,MRK,incyte corporation incy free report partner merck mrk free report announce failure combination therapy incyte epacadostat merck keytruda achieve improve progression free survival keytruda alone phase iii study echo keynote study be evaluate combination drug treatment unresectable metastatic melanoma external datum monitoring committee recommend termination study follow review datum pivotal study datum phase iii study demonstrated combination ido inhibitor pd antagonist not hold potential treatment melanoma share company tumble nearly apr follow disappointing news incyte stock have be so far year compare industry loss period epacadostat ido inhibitor immunotherapy be late stage pipeline candidate incyte be be develop combination other immunotherapy include merck pd therapy keytruda bristol myer squibb bmy free report pd inhibitor opdivo ctla inhibitor yervoy incyte be develop combination therapy several other indication include small cell lung cancer renal cell carcinoma squamous cell carcinoma head neck bladder cancer epacadostat combination therapy have achieve improve response rate mid stage study however failure pivotal melanoma study larger patient population increase risk setback other late stage study other indication follow news failure share newlink genetic corporation nlnk free report small ia base biotech company sank nearly friday newlink be also develop ido pathway inhibitor indoximod combination pd pd agent several cancer indication include melanoma incyte corporation price incyte corporation price incyte corporation quotezack rankincyte currently carry zack rank hold see complete list today zack rank strong buy stock here zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2202,MRK,biogen inc biib free report partner samsung bioepis have announce resolution ongoing patent dispute abbvie abbv free report regard biogen biosimilar version imraldi abbvie blockbuster arthritis drug humira eu settlement agreement biogen samsung bioepis plan launch imraldi europe oct also unite state samsung bioepis enter settlement agreement abbvie allow former bring humira biosimilar market jan imraldi sb be used whole range indication include rheumatoid arthritis axial ankylose spondylitis plaque psoriasis psoriatic arthritis crohn disease ulcerative colitis polyarticular juvenile idiopathic arthritis active enthesitis related arthritis hidradenitis suppurativa infectious uveitis notably imraldi be second biosimilar version humira be launch eu biotechnology company amgen amgn be also expect launch biosimilar version humira eu come october year amjevita settlement abbvie notably amjevita be approve eu last march approve unite state september unite state settlement abbvie amjevita be likely be launch jan share biogen have underperform industry year so far stock have lose compare industry decrease remind investor biogen have joint venture samsung biologic biosimilar call samsung bioepis already market couple biosimilar eu namely flixabi biosimilar reference merck mrk free report remicade benepali biosimilar reference amgen pfizer pfe free report enbrel development turn make imraldi third tnf biosimilar biogen receive marketing authorization eu biogen be also work samsung biologic introduce new biosimilar market importantly biogen gross biosimilar revenue month period end december compare logged upside be primarily drive benepali record revenue compare year figure increase market share biogen inc price biogen inc price biogen inc quote zack rankbiogen carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2203,MRK,be happen week pharma stock key development week include new car deal pfizer pfe free report successful study result pfizer lilly lly free report allergan agn free report positive regulatory update astrazeneca azn free report recap week most important storiespfizer car deal tafamidis succeed late stage study pfizer announce alliance private biotech allogene therapeutic expedite development allogeneic car therapy pfizer own stake allogene also get representation latter board meanwhile cnbc report say pfizer be talk consumer giant procter gamble regard sale consumer healthcare segment last month glaxo gsk free report reckitt benckiser group pull discussion pfizer buy same unit read more pfizer inks new car deal talk unit sale pfizer pipeline candidate tafamidis develop treatment transthyretin cardiomyopathy ttr cm meet main goal late stage study attr act top line datum attr act study show treatment tafamidis lead statistically significant reduction combination cause mortality frequency cardiovascular related hospitalization primary endpoint compare placebo month read more pfizer rare disease candidate meet endpoint phase iii pfizer regulatory application pipeline candidate dacomitinib be accept priority review unite state response expect september company be look get drug approve first line treatment patient locally advanced metastatic small cell lung cancer nsclc egfr activate mutation read more pfizer lung cancer candidate get fda priority review lilly cyramza meet os endpoint liver cancer study lilly announce already approve cancer drug cyramza show overall survival benefit thereby meeting primary endpoint late stage study evaluate second line treatment liver cancer study also meet secondary endpoint progression free survival read more lilly cyramza show survival benefit liver cancer study astrazeneca provide regulatory update astrazeneca diabetes treatment bydureon gain fda approval add therapy insulin glargine also biologic license application bla seek approval astrazeneca cd recombinant immunotoxin candidate moxetumomab pasudotox second later line treatment hairy cell leukaemia hcl be grant priority review fda fda grant priority review decision be expect third quarter regulatory development astrazeneca partner merck mrk free report regulatory submission look expand label parp inhibitor lynparza include breast cancer indication be accept eu lynparza be already approve treat ovarian cancer eu latest filing astrazeneca look get lynparza approve brca mutate negative metastatic breast cancer eu unite state lynparza be approve same indication january read more astrazeneca bydureon get fda nod expand use allergan vraylar succeed label expansion study allergan partner gedeon richter say vraylar cariprazine meet primary endpoint late stage study adult major depressive episode associate bipolar disorder bipolar depression be third pivotal study conduct indication datum study be include company label expansion application company plan file second half read more allergan vraylar meet endpoint bipolar phase iii bio path mid stage study leukemia candidate show positive early datum bio path holding announce positive interim datum phase ii study bp lead pipeline candidate prexigebersen be be evaluate combination low dose cytarabine ldac treatment patient acute myeloid leukemia aml elect not be treat more intensive chemotherapy combination therapy demonstrated early leukemic activity nearly evaluable aml patient study total patient achieve form response combo treatment share bio path shot response read more bio path leukemia combo study show positive early datum fda approve sonoma skin gel sonoma pharmaceutical small solution maker skin condition advanced tissue care gain fda approval antimicrobial post treatment gel gel aim treat itch pain associate procedure include laser skin resurface post therapy chemical peel share sonoma shot more response nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock record gain bristol myer bmy free report glaxo be biggest gainer rise bristol myer decline last month astrazeneca have be biggest gainer merck decline most see last pharma stock roundup here pharma stock roundup abbv rova disappoint unit get buyout offer next pharma world watch regulatory pipeline news pharma stock make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2204,MRK,dow experience volatile holiday shorten week marked steep gain loss initially index increase tension possible trade war unite state china recede subsequently however tech stock drag broader market lower several major tech stock suffer severe beating disparate concern yield also plunge lead loss bank stock last week dow decrease last friday follow fear trade war unite state china take place trade related concern be heighten president trump impose hefty import tariff good worth billion dollar further technology stock have be drive market year well take massive hit facebook inc fb free report helm carnage fear possible trade war couple doubt regard fed ability protect economy slip recession normalizes monetary policy crisis era level also see cboe vix surge nearly index tank last week register biggest weekly loss january week date basis volatile week start low note follow concern facebook policy regard privacy user datum company allege datum misuse affect more user however market gain traction tuesday support rally energy share oil price settle highest level month only end week red follow quarter point rate hike fed trump decision imposition tariff china worth billion dollar dow index rally point monday increase represent biggest single day percentage gain august third best point gain history tension prospect trade war unite state china appear ease unite state request china slash tariff auto buy more semiconductor give firm more access chinese financial sector letter last week subsequently chinese premier li keqiang keqiang say china give equal treatment domestic foreign company also say win force foreign firm enter technology transfer agreement china also work strengthen intellectual property right keqiang add other hand facebook share initially decline news federal trade commission investigate company datum practice close higher index decline point tuesday re enter correction territory sharp decline be fuel selloff tech sector see major index suffering fourth decline session facebook share continue plummet even other major tech giant nvidia corporation nvda tesla inc tsla free report microsoft corporation msft free report apple inc aapl free report also take beating further financial stock too slump tuesday bank share witness heavy selloff government bond rally yield year treasury note decline index lose less wednesday follow selloff tech stock fail recover steep loss witness previous session amazon com inc amzn free report suffer most follow report president trump have indicated want rein commerce giant other tech stock such apple netflix inc nflx free report also take beating further tesla share plummet follow credit downgrade news official investigate fatal crash california component move index apple recently announce feature rich ipad cheaper third party stylus update iwork suite productivity apps new schoolwork application everyone create initiative zack rank apple focus quality be evident superior feature new ipad device help deliver immersive augment reality provide unmatched portability ease use day battery life notably apple new inch ipad support apple pencil ana fusion chip large retina display advanced camera sensor addition apple pencil support be significant earlier only higher price ipad pro model take advantage price new device start unchanged company entry level ipad however apple be try target school pricing lower read apple refocuse edtech bring feature rich ipad apps boee company ba free report recently win modification contract provide ea aircraft integrate product support equipment engineering service service be render navy government australia finland kuwait malaysia switzerland canada spain contract boee offer product support management design interface sustain engineering supply support maintenance plan provision technical datum update support equipment engineering well training software integration service deal be award naval air system command patuxent river stock have zack rank strong buy see complete list today zack rank stock here exxon mobil corporation xom free report total tot free report be expect jointly drill first well etzil structure locate block perdido fold belt offshore mexico october mexico national hydrocarbon commission cnh well be assign company late part hydrocarbon auction marked country energy reform cnh estimate oil major recover barrel oil equivalent boe structure be operated total zack rank exxon mobil total own stake project mexico auction well etzil structure be assume boast highest geological success rate read exxon total drill first well offshore mexico merck co mrk free report japanese partner eisai co ltd announce latter cancer drug lenvima have receive approval japan expand indication tyrosine kinase inhibitor lenvima have be approve japan first line treatment unresectable hepatocellular carcinoma hcc type liver cancer approval be base positive datum phase iii clinical study study reflect study show lenvima demonstrated statistically significant inferiority overall survival os month compare bayer ag bayry nexavar month follow approval japan eisai receive development milestone payment zack rank merck read merck eisai get japanese nod lenvima label expansion walmart inc wmt free report have clinch deal tencent holding limit tcehy free report latter pay mode payment accord report acceptance china popular pay method payment be likely enhance customer convenience strengthen walmart business subsequently supermarket giant discontinue alibaba alipay payment method store western part china include place sichuan yunnan gansu zack rank walmart start used china lead commerce player alipay back shake china retail space switch notably alipay pay be top payment method used chinese commerce shopper former currently ahead game source suggest drop alipay pick pay enhance tencent holding position payment war alibaba read walmart drop alipay pick pay here performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have lose next week outlooktension impending trade war unite state china have recede slump tech stock continue weigh market facebook recent trouble continue plague stock even larger counterpart such apple face new challenge be high unlikely market turmoil recede term eventful quarter investor surely look encourage economic datum boost spirit number key report line release early next month be likely play key role guide stock week ahead investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2205,MRK,investor be not much impressed exelixis inc exel free report fourth quarter performance company beat revenue earning be line estimate follow announcement result share exelixis fall market trading session exelixis share have rally year outperform industry decline company report earning cent line zack consensus estimate flat year year net revenue come year quarter however company suffer sequential decline generate third quarter increase overall demand be offset reduction approximately week wholesaler inventory build quarter revenue surpass zack consensus estimate exelixis inc price consensus exelixis inc price consensus exelixis inc quote quarter fda approve tablet formulation cabozantinib distinct capsule form brand name cabometyx april treatment advanced renal cell carcinoma rcc patient have receive prior angiogenic therapy december fda also approve cabometyx treatment previously untreated advanced rcc approximately month ahead assign prescription drug user fee act pdufa action date cabometyx generate net product revenue drive growth demand second line rcc demand be drive increase market share refill patient already therapy continue expansion prescriber base sequential increase cometriq cabozantinib capsule treatment medullary thyroid cancer generate net product revenue total collaboration revenue be compare earn year quarter fourth quarter research development expense increase stem increase personnel expense clinical trial cost consult outside service selling general administrative expense be significantly drive increase consult outside service support company marketing activity result primarily increase general administrative headcount support company commercial research development organization resultsrevenue come beat zack consensus estimate earning share come cent loss cent line zack consensus estimate cabometyx sale come year year pipeline updatein march fda grant cabozantinib orphan drug designation treatment advanced hepatocellular carcinoma hcc october exelixis announce celestial trial meet primary endpoint overall survival os cabozantinib provide statistically significant clinically meaningful improvement os compare placebo patient advanced hcc independent datum monitoring committee study recommend trial be stop efficacy follow review second plan interim analysis exelixis plan submit snda fda first quarter exelixis inked agreement bristol myer bmy free report roche hold rhhby free report develop cabozantinib combination immunotherapy agent exelixis bristol myer initiate phase iii trial checkmate july be evaluate combination checkpoint inhibition therapy combine cabozantinib compare sutent meanwhile update result ongoing phase trial cabozantinib combination opdivo yervoy patient refractory genitourinary tumor demonstrated acceptable tolerability profile high rate durable response previously treat metastatic uc metastatic rcc cohort january exelixis announce amendment protocol phase ib trial cabozantinib combination tecentriq patient locally advanced metastatic solid tumor amendment add new expansion cohort trial now include patient small cell lung cancer castration resistant prostate cancer addition previously include patient rcc urothelial carcinoma primary objective expansion stage trial remain determine objective response rate cohort imspire trilogy trial evaluate combination cotellic tecentriq xelboraf first line braf mutation positive metastatic unresectable locally advanced melanoma be underway imspire trial evaluate combination cotellic tecentriq versus merck mrk free report keytruda first line braf wild type metastatic unresectable locally advanced melanoma have enrolled first patient expect total cost operate expense range takeexelixis fourth quarter result be positive sale beat estimate earning come line expectation exelixis put strong performance drive gain market share cabometyx new patient market share second line set grow approximately end third quarter expect sale get further boost company launch drug first line rcc increase eligible patient population caobometyx unite state approximately patient grab market share key drug sutent votrient first line rcc market expect investor focus remain further label expansion cabozantinib cotellic potential label expansion advanced hcc further boost growth prospect company zack rankexelixis currently carry zack rank buy see complete list today zack strong buy rank stock here note be re issue article correct error original version publish earlier today tuesday february not be rely zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2206,MRK,investor be not much impressed exelixis inc exel free report fourth quarter performance company beat revenue earning be line estimate follow announcement result share exelixis fall market trading session exelixis share have rally year outperform industry decline company report earning cent line zack consensus estimate flat year year net revenue come year quarter however company suffer sequential decline generate third quarter increase overall demand be offset reduction approximately week wholesaler inventory build quarter revenue surpass zack consensus estimate exelixis inc price consensus exelixis inc price consensus exelixis inc quote quarter fda approve tablet formulation cabozantinib distinct capsule form brand name cabometyx april treatment advanced renal cell carcinoma rcc patient have receive prior angiogenic therapy december fda also approve cabometyx treatment previously untreated advanced rcc approximately month ahead assign prescription drug user fee act pdufa action date cabometyx generate net product revenue drive growth demand second line rcc demand be drive increase market share refill patient already therapy continue expansion prescriber base sequential increase cometriq cabozantinib capsule treatment medullary thyroid cancer generate net product revenue total collaboration revenue be compare earn year quarter fourth quarter research development expense increase stem increase personnel expense clinical trial cost consult outside service selling general administrative expense be significantly drive increase consult outside service support company marketing activity result primarily increase general administrative headcount support company commercial research development organization resultsrevenue come beat zack consensus estimate earning share come cent loss cent line zack consensus estimate cabometyx sale come year year pipeline updatein march fda grant cabozantinib orphan drug designation treatment advanced hepatocellular carcinoma hcc october exelixis announce celestial trial meet primary endpoint overall survival os cabozantinib provide statistically significant clinically meaningful improvement os compare placebo patient advanced hcc independent datum monitoring committee study recommend trial be stop efficacy follow review second plan interim analysis exelixis plan submit snda fda first quarter exelixis inked agreement bristol myer bmy free report roche hold rhhby free report develop cabozantinib combination immunotherapy agent exelixis bristol myer initiate phase iii trial checkmate july be evaluate combination checkpoint inhibition therapy combine cabozantinib compare sutent meanwhile update result ongoing phase trial cabozantinib combination opdivo yervoy patient refractory genitourinary tumor demonstrated acceptable tolerability profile high rate durable response previously treat metastatic uc metastatic rcc cohort january exelixis announce amendment protocol phase ib trial cabozantinib combination tecentriq patient locally advanced metastatic solid tumor amendment add new expansion cohort trial now include patient small cell lung cancer castration resistant prostate cancer addition previously include patient rcc urothelial carcinoma primary objective expansion stage trial remain determine objective response rate cohort imspire trilogy trial evaluate combination cotellic tecentriq xelboraf first line braf mutation positive metastatic unresectable locally advanced melanoma be underway imspire trial evaluate combination cotellic tecentriq versus merck mrk free report keytruda first line braf wild type metastatic unresectable locally advanced melanoma have enrolled first patient expect total cost operate expense range takeexelixis fourth quarter result be positive sale beat estimate earning come line expectation exelixis put strong performance drive gain market share cabometyx new patient market share second line set grow approximately end third quarter expect sale get further boost company launch drug first line rcc increase eligible patient population caobometyx unite state approximately patient grab market share key drug sutent votrient first line rcc market expect investor focus remain further label expansion cabozantinib cotellic potential label expansion advanced hcc further boost growth prospect company zack rankexelixis currently carry zack rank buy see complete list today zack strong buy rank stock here note be re issue article correct error original version publish earlier today tuesday february not be rely zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2207,MRK,dow experience volatile holiday shorten week suffering loss trading session investor continue remain concern rise inflation surge bond yield disappointing result key component also weigh index same time encourage job datum help index notch gain last week dow increase post sixth straight session gain however gain be curb special counsel robert mueller indict group russian national few entity country regard involvement presidential election meanwhile housing start surge highest level financial crisis also build permit rise month high index gain last week mark biggest weekly gain november president trump sign law bipartisan budget deal provide massive spending boost pentagon infrastructure turn have positive impact key index market manage rebound decline initially follow better expect consumer price report key inflation metric strong earning season steady economy lead key index shrug yearly decline close positive territory dow weekmarket remain close monday due observance president day index decrease tuesday follow decline share walmart inc wmt free report share walmart decline post fourth quarter result walmart snap quarter long trend post positive earning surprise also rate commerce sale growth decline sequentially quarter be walmart biggest percentage decline single day january hit highest level last week yield benchmark year treasury note surge monday further short term year yield linger year high such spike interest rate also weigh equity lead broad base loss market index lose point finish red wednesday follow release minute fed latest policy meeting bond rate surge year high follow release minute weigh heavily equity earlier session major benchmark have rally minute expressed concern lack broad base wage gain end federal open market committee fomc meeting fed official state most member have revise economic growth projection upward last meeting december moreover minute also state gradually increase interest rate help sustain economic growth index gain thursday follow encourage job datum help detract attention ongoing concern surround rise inflation spike bond yield initial claim week end feb decline second lowest level record end great recession metric also come well estimate level ultimately however stock slip session high healthcare financial enter negative zone afternoon session component move index walmart fourth quarter fiscal adjust earning share miss zack consensus estimate nonetheless adjust earning grow report year period total revenue advanced also surpass zack consensus estimate nearly segment record net sale growth quarter comparable store sale comp exclude fuel jump compare growth prior year quarter zack rank buy walmart earning fiscal come share year year however come consensus mark net revenue fiscal advanced cruise ahead consensus estimate notably comp fiscal climb walmart commerce sale soar fiscal company expect consolidated net sale constant currency basis increase range walmart commerce sale be project jump nearly read walmart earning miss hurt stock comp again chevron corporation cvx free report have recently recommence operation politically disturbed kurdistan region iraq reuter company restart operation sarta block kurdistan chevron have zack rank hold company have call operation region october due increase dispute january company reveal plan restart operation field take necessary step remobilize staff equipment region recommence operation dispute abate late market cap company start operation kurdistan region however be blacklist iraqi government july company sign contract kurdistan regional government acquire exploration block region read chevron kurdistan operation iraq back online exxonmobil corporation xom free report total sa tot free report have propose major expansion plan papua new guinea png liquefy natural gas lng plant partner oil search ltd exxonmobil have zack rank analyst expansion plan be aim increase gas export png lng plant fold ton cost plan include addition lng unit train be backed gas elk antelope field manage total unit be support exist field new nyang field manage exxonmobil subject approval png government partner intend commence engineering design work second half year preliminary cost build png lng plant be peg expansion cost be project range additional capacity ton annum mtpa ton read exxonmobil total expand capacity png lng plant traveler company inc trv free report recently unveil quantum home help company offer client much more efficient simplified way communication product introduce late enable property casualty insurer improve service also bring new business new offer be basically improve homeowner insurance product customize pricing more flexible coverage option interestingly product provide aforementioned service simpler policy document allow company client better understand insurance additionally insurer new product help agent seamlessly quote bind coverage product boast improve feature new discount client decrease deductible loss forgiveness option acknowledge customer loyalty stock have zack rank see complete list today zack rank strong buy stock here merck co inc mrk free report have propose buy viralytic limit australian pharmaceutical company develop oncolytic immunotherapy range cancer australian dollar deal make strategic sense strengthen zack rank merck presence fast grow immuno oncology market deal merck gain viralytic lead pipeline candidate cavatak oncolytic virus engage innate immune system attack cancer cell cavatak be be evaluate several phase ii cancer study include combination study merck pd inhibitor keytruda cavatak keytruda combination be be study melanoma prostate lung bladder cancer deal sign company november read merck buy australian firm boost immunotherapy pipeline goldman sachs group inc gs free report chairman chief executive officer ceo lloyd blankfein have receive hike total compensation package annual salary have be raise accord security exchange commission sec filing last week hike believe be well deserve keep mind blankfein contribution zack rank goldman take rein company have be instrumental boost pre tax earning moreover company report revenue improve year year challenge market make business environment read goldman ceo blankfein pay raise coca cola company ko free report fourth quarter comparable earning company be cent share surpass zack consensus estimate cent earning also improve year profit level cent help ongoing productivity effort coca cola have zack rank revenue quarter surpass zack consensus estimate however net revenue decline year year due negative impact structural item mark consecutive quarterly decline full year comparable earning come same year adjust profit level net revenue be organically revenue grow full year organic revenue be expect rise company expect adjust ep grow prior year comparable ep read coca cola share rally earning revenue beat performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have lose next week outlookinvestor be continue contend ongoing concern rise inflation accompany spike bond yield current impact factor be likely overstate possibly continue weigh stock week ahead give such backdrop investor look crucial economic report gdp durable order much need boost week ahead zack top stock addition stock discuss know finest ticker entirety wouldn be painstakingly hand picked company cover zack rank be primary pick buy hold be very first see
2208,MRK,key announcement week include fda approval second indication astrazeneca azn free report imfinzi acquisition offer merck mrk free report abbvie abbv free report present new datum pipeline candidate announce alzheimer deal small biotech recap week most important imfinzi gain fda nod second indication astrazeneca pd inhibitor imfinzi gain fda approval early stage lung cancer indication make drug second fda approval latest approval imfinzi now be prescribe treat unresectable stage iii small cell lung cancer nsclc patient disease have not progressed follow chemoradiation therapy imfinzi be launch unite state first indication second line advanced bladder cancer be also be develop several other cancer indication read more astrazeneca imfinzi get fda nod label expansion meanwhile astrazeneca license new antisense drug kidney disease ionis az rx ionis pharmaceutical inc ion free report go forward astrazeneca be responsible develop commercialize ionis az rx read more ionis license second candidate astrazeneca earn merck look buy innovative immuno oncology candidate merck propose buy australian oncolytic immunotherapy maker viralytic limit australian dollar believe deal get strengthen merck presence fast grow immuno oncology market deal merck gain viralytic lead pipeline candidate cavatak oncolytic virus engage innate immune system attack cancer cell transaction be expect be complete second quarter contingent viralytic shareholder approval read more merck buy australian firm boost immunotherapy pipeline abbvie report new mid stage datum upadacitinib abbvie announce new datum phase ii celest study evaluate multiple dose regimen jak inhibitor upadacitinib crohn disease week datum study show patient clinically respond upadacitinib treatment week induction phase maintain response week extension phase study please note result week induction phase celest study be previously announce last year read more abbvie present new datum upadacitinib crohn disease separately abbvie neurocrine bioscience first pivotal phase iii study pipeline candidate elagolix meet primary endpoint elaris uf study be evaluate elagolix reduce heavy menstrual bleed premenopausal woman uterine fibroid datum study demonstrated elagolix combination low dose add back therapy reduce heavy menstrual bleed compare placebo read more abbvie uterine fibrosis candidate meet goal study elagolix be already review unite state management endometriosis associate pain abbvie also announce global strategic collaboration small biotech voyager therapeutic inc vygr free report develop potential new treatment alzheimer disease other tau related disease nordisk oral ozempic succeed study nordisk nvo free report announce phase iii study pioneer evaluate tablet oral formulation newly approve diabetes treatment ozempic semaglutide achieve primary objective datum study show person type ii diabetes be treat once weekly oral semaglutide glp receptor agonist experience significant superior blood glucose control compare placebo dose mg evaluate meanwhile significant superior weight loss versus placebo be observed patient be give highest dose mg nordisk expect file approval oral formulation ozempic pending datum remain pioneer study ozempic semaglutide be approve last year december once daily pre filled pen improve glycaemic control type ii diabetes patient approval ozempic be base result phase iii sustain study fda accept acorda inbrija nda accorda therapeutic inc acor free report nda parkinson disease candidate inbrija be accept fda marked resubmission nda inbrija fda have issue refusal file letter inbrija august last year declare nda application be incomplete preliminary review fda be expect give decision candidate oct read more fda accept acorda nda parkinson disease candidate large cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session here be major stock perform last trading session major stock decline astrazeneca decline bristol myer squibb bmy free report go last month astrazeneca have gain merck decline see last pharma stock roundup here merck keytruda shine study priority review kymriah label expansion next pharma world watch regulatory pipeline news pharma stock zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2209,MRK,merck co inc mrk free report have propose buy viralytic limit australian pharmaceutical company develop oncolytic immunotherapy range cancer australian dollar believe deal make strategic sense strengthen merck presence fast grow immuno oncology market immuno oncology immunotherapy be new class cancer therapy utilize certain part immune system fight disease be do stimulating immune system attack cancer cell introduce immune system component body immuno oncology drug combination be great deal merck gain viralytic lead pipeline candidate cavatak oncolytic virus engage innate immune system attack cancer cell cavatak be be evaluate several phase ii cancer study include combination study merck pd inhibitor keytruda cavatak keytruda combination be be study melanoma prostate lung bladder cancer deal sign company november early clinical datum cavatak demonstrated robust potential wide variety tumor type monotherapy combination study past year merck share have underperform industry merck share have decline period increase industry merck have offer pay australian dollar share sydney base company represent premium viralytic average stock price past month merck acquire viralytic subsidiary transaction be expect be complete second quarter contingent viralytic shareholder approval importantly cavatak complement merck pipeline effort keytruda second largest drug keytruda be already market many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer be also be study more type cancer more study include more combination study latest offer merck be many merger acquisition expect year now tax reform be place new tax law cut corporate tax rate encourage company bring back huge cash hold overseas time tax rate be expect spur merger activity year biotech pharma activity have start gain steam sanofi sny free report celgene celg free report announce deal sanofi earlier year announce deal buy belgian biotech company ablynx haemophilium focuse biotech bioverativ celgene also announce deal buy juno therapeutic inc focus development car therapy impact biomedicine add late stage jak kinase inhibitor celgene pipeline merck carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2210,MRK,inc agen free report be expect report fourth quarter mar last quarter company earning meet estimate last quarters company deliver average positive earning surprise notably share have outperformed industry year stock have rally industry fall let see thing be shape company quarter factor playagenus collaboration agreement several company not only help procure fund form upfront milestone payment future royalty also validate proprietary product platform have collaborate merck mrk free report incyte develop multiple checkpoint antibody incyte collaboration be evaluate latter gitr checkpoint antibody incagn phase ii study ox agonist antibody incagn phase ii study ctla antibody agen phase study candidate be be evaluate treatment solid tumor january company announce launch combination phase ii study agen pd agen antibody october establish separate business entity advance cell therapy program be design be self funded cell therapy company agentus focus discovery development breakthrough live drug advance cure cancer patient company take decision form smaller team entirely focus get product approve company expect combine value separate company exceed perceive value roof october fda grant marketing authorization glaxosmithkline gsk herpes zoster vaccine shingrix contain proprietary immune adjuvant qs stimulon shingrix be indicated prevention herpes zoster also know shingle adult age year older same month health canada also grant marketing authorization shingrix approval canada mark first approval shingrix first approval vaccine contain qs stimulon be good news impact business positively have potential significantly increase market share shingrix fourth quarter company focus pipeline candidate provide update model proven model do not conclusively show earning beat quarter be stock need have positive earning esp zack rank strong buy buy hold happen however be not case here see zack esp agenusha earning esp be most accurate estimate zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank have zack rank increase predictive power esp however need have positive esp be confident earning beat note caution stock zack rank sell rate go earning announcement inc price ep surprise inc price ep surprise inc quote stock warrant lookhere be health care stock want consider model show have right combination element deliver earning beat quarter exelixis exel free report be schedule release fourth quarter result feb market close company have earning esp zack rank see complete list today zack rank stock here gemphire therapeutic gemp free report be expect releasefourth quarter result mar company have earning esp zack rank today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2211,MRK,horizon pharma plc hznp free report report better expect result fourth quarter follow news company share go however horizon pharma stock have decline year date industry fall company report fourth quarter earning cent share beat zack consensus estimate cent be cent year quarter sale fourth quarter be year year beat zack consensus estimate quarter orphan unit record revenue year period strong performance be backed solid net sale ravicti generate quarter year year drive continue conversion older generation nitrogen scavenger therapy well addition treatment nave patient due recent label expansion april ravicti label be expand include patient age month year older additionally procysbi contribute performance net sale year year actimmune sale report quarter be year year rheumatology unit generate sale year year also krystexxa sale quarter be strong come year year drive strong continue year year vial demand primary care garner revenue year year decline net sale be due implementation new contract model order secure broader inclusion company primary care medicine formulary report quarter net sale pennsaid duexix vimovo be respectively research development expense increase selling general administrative expense be year year full year be however company report earning share year year orphan unit record revenue year period drive growth sale procysbi procysbi be acquire october sale rheumatology unit also grow mainly drive sale krystexxa year year however primary care unit sale be full year expense increase selling general administrative expense be higher year year guidancehorizon pharma provide outlook expect sale range mainly drive expect strong growth continue orphan rheumatology business unit company continue invest expansion krystexxa nephrology indication expect sale growth more guidance include assumption lower net average net realize price begin second half primarily result government health resource service administration final rule drug ceiling price implementation schedule july horizon pharma be significantly increase investment key growth driver krystexxa expect net sale grow more company expect higher sg expense first half other updatesin february company file supplemental new drug application expand age range label raviciti month age older birth older december regulatory application seek label expansion procysbi include child year older live nephropathic cystinosis be file fda october company announce first patient be enrolled infuse phase iii confirmatory clinical trial evaluate teprotumumab treatment thyroid eye disease ted remind investor company acquire river vision earlier add biologic candidate teprotumumab pipeline meanwhile company be work expand actimmune label investigator initiate study moffitt cancer center be underway enrolling patient study be evaluate actimmune combination roche holding rhhby free report herceptin perjeta taxol certain advanced breast cancer patient phase study evaluate actimmune combination bristol myer squibb company bmy free report opdivo kidney bladder cancer actimmune be also be evaluate combination merck co mrk free report keytruda treat cutaneous cell lymphoma patient phase ii study company also have plan develop next generation uncontrolled gout development program maintain market leadership takehorizon pharma fourth quarter result be impressive company beating top bottom line estimate moreover sale guidance be encourage well expect krystexxa ravicti actimmune drive further growth acquisition teprotumumab have diversify company portfolio horizon pharma plc price consensus ep surprise horizon pharma plc price consensus ep surprise horizon pharma plc quotezack rankhorizon pharma currently have zack rank hold see complete list today zack rank strong buy stock here don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
2212,MRK,bayer ag bayry free report fourth quarter core earning share continue operation be cent american depository receipt adr top zack consensus estimate cent sep bayer perform adr ratio change new ratio bayer adrs correspond bayer ordinary share fourth quarter core earning share incorporate effect adr ratio change earning be year year cent adr total sale quarter be approximately year year company register growth sale earning pharmaceutical business decline consumer health crop science animal health improve well growth rate mentioned be year year basis adjust currency portfolio change fourth quarter full year bayer group lose facto control covestro group end september sep be report segment pharmaceutical consumer health crop science animal health such total figure life science segment longer be present separately revenue pharmaceutical segment decrease fourth quarter increase growth full year be backed persistently strong performance key product xarelto eylea xofigo stivarga adempas however division experience considerable decline kogenate sale mainly distribution partner place lower volume order active ingredient however consumer health sale be fourth quarter decline decline be due decline revenue north america particularly unite state owing challenge market environment further chinese authority unexpectedly change legal status bayer medicated skincare brand otc prescription lead sale decline fourth quarter however business expand slightly europe middle east africa sale latin america come prior year level report quarter crop science sale be year year sale full year decline sale agriculture business decline due situation brazilian crop protection business volume be hold back unexpectedly high inventory marketthe seed business environmental science register gain however be decline crop protection business sale animal health segment come fourth quarter increase sale improve positively region north america progress well asia pacific region development north american region be back price increase lower selling expense revenue generate cydectin product portfolio company acquire boehringer ingelheim vetmedica inc january resultscore earning share continue operation be share compare earning miss zack consensus estimate revenue be compare tjis miss zack consensus estimate discontinue operationsbayer take big step goal achieve full separation covestro medium term selling approximately interest company bayer cede facto control covestro deconsolidated company end september sync covestro cease be reportable segment third quarter be now present discontinue operation bayer direct interest covestro currently amount be hold bayer pension trust acquisition divestmenton oct bayer sign agreement sell select crop science business basf light plan acquisition company report brazilian antitrust authority approve acquisition company also commit divest entire vegetable seed business certain additional business activity bayer also be sell license transaction be subject regulatory approval well successful close bayer acquisition meanwhile bayer continue own operate maintain business close divestiture note bayer have make several acquisition enter number deal boost portfolio past few quarters september acquire merck mrk free report consumer care business category expansion addition merck consumer care business expand bayer geographic reach addition bayer have license collaboration agreement regeneron regn free report global development eylea ex market bayer expect sale be bayer expect sale increase low mid single digit percentage currency portfolio adjust basis expect acquisition second quarter bayer anticipate significant increase sale earning interest tax depreciation amortization ebitda special hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2213,MRK,pfizer inc pfe free report be repute name pharmaceutical sector not just medicine vaccine also consumer healthcare product new york base company be know product prevnar lyrica lipitor celebrex other pfizer share have outperformed large cap pharma industry past month stock have return timeframe compare industry gain pfizer outperformance be backed decent quarterly result positive news flow regulatory update here be reason invest stock year favorable rank earning surprise record pfizer have zack rank buy see complete list today zack rank strong buy stock here itha be consistently beating earning expectation earning surpass expectation last quarters average positive surprise company be expect record earning sale growth respectively meanwhile estimate be respectively past day strategic acquisition collaboration pfizer have be work strengthen product portfolio well pipeline acquisition licensing deal september takeover medivation strengthen pfizer cancer franchise add prostate cancer treatment xtandi portfolio xtandi be also be evaluate various other type cancer hold immense potential june anacor acquisition add eucrisa crisaborole topical ointment treat eczema pfizer pipeline pfizer estimate eucrisa peak sale potential be least hospira acquisition significantly expand sterile injectable biosimilar capability addition acquisition pfizer be look drive growth licensing deal collaborative agreement have strategic deal big name pharma sector merck co mrk free report lung cancer drug xalkori combination newly approve steglatro fix dose combination type ii diabetes bristol myer squibb company bmy free report eliquis glaxo gsk free report breast cancer drug ibrance combination deep pipeline pfizer have commit significant resource development treatment field oncology cardiology metabolic disorder neuroscience pain rare disease immunology inflammation vaccine immuno oncology most signify area company believe take lead position pfizer expect approximately drug approval next year include product have blockbuster potential include line extension xtandi ibrance xeljanz xr half potential blockbuster be expect receive approval pfizer have be work streamline effort have several late stage candidate pipeline include many immuno oncology candidate key candidate immuno oncology pipeline be bavencio avelumab be be evaluate different type cancer collaboration merck kgaa bavencio be already metastatic merkel cell carcinoma mcc advanced bladder cancer bavencio be be consider key long term growth driver pfizer explore world biosimilar pfizer market biosimilar version merck blockbuster medicine remicade unite state inflectra ixifi inflectra be first biosimilar monoclonal antibody available unite state other biosimilar late stage development include biosimilar version roche cancer drug rituxan avastin abbvie humira biosimilar version herceptin be review unite state eu meanwhile pfizer be evaluate biosimilar molecule various stage development aggressive cost cut initiative several product face slate face generic competition pfizer be look cost cut initiative drive bottom line growth company have be undertaking massive restructure cost cut measure past several year management be also look focus effort area have high potential oncology geographic region asia pfizer achieve cost reduction goal be announce end year earlier expect continue generate cost saving company also achieve target bring significant reduction annual spend end face share challenge form genericization key drug supply challenge legacy hospira portfolio pricing pressure rise competition however believe pfizer be able overcome headwind wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2214,MRK,astrazeneca azn free report announce fda have approve second indication pd inhibitor imfinzi be now approve unresectable stage iii small cell lung cancer nsclc drug be meant patient disease have not progressed follow concurrent platinum base chemotherapy radiation therapy astrazeneca share have return past year outperform industry gain period approval come back impressive progression free survival datum pfs patient treat imfinzi phase iii pacific study datum show imfinzi improve pfs more month comparison placebo concern patient population median pfs be month patient imfinzi compare month placebo imfinzi be launch unite state first indication second line advanced bladder cancer drug have bring sale press release globally nsclc patient have stage iii disease majority patient diagnosed unresectable tumor currently patient be treat chemotherapy radiation therapy follow active surveillance monitor progression imfinzi first immunotherapy approve indication be better treatment option patient represent better market opportunity astrazeneca astrazeneca be also develop imfinzi monotherapy well combination therapy treatment nsclc first line adjuvant set drug be also be develop several other cancer indication include head neck gastric pancreatic hepatocellular blood cancer however lung cancer be competitive segment attract several player due huge market opportunity novartis nvs free report roche receive approval respective drug zykadia alecensa treat metastatic nsclc first line set other immunotherapy treat various cancer indication include bristol myer squibb company bmy free report opdivo merck co mrk free report keytruda astrazeneca plc price astrazeneca plc price astrazeneca plc quotezack rankastrazeneca carry zack rank sell see complete list today zack rank strong buy stock here breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2215,MRK,nektar therapeutic nktr free report share increase more feb company announce global strategic collaboration agreement bristol myer squibb bmy free report agreement company jointly develop commercialize lead immuno oncology candidate nktr former combination latter opdivo nivolumab opdivo yervoy ipilimumab pursuant contract nektar be entitle receive upfront payment include payment cash equity investment nektar also get additional potential payment achievement certain developmental sale base milestone nektar bristol myer share profit respective ratio potential sale nktr worldwide positive note nektar not only retain ownership candidate also continue collaborate other company further development nektar jointly commercialize nktr opdivo combination unite state well major market eu japan bristol myer be entitle solely commercialize combination other global market remind investor nektar be already evaluate nktr opdivo phase ii pivot study tumor type melanoma kidney colorectal bladder small cell lung cancer potential indication latest deal bristol myer have be agree company evaluate nktr opdivo nktr opdivo yervoy combination more cancer indication tumor type november company report positive interim datum dose escalation part study evaluate safety efficacy combo therapy patient melanoma renal cell carcinoma small cell lung cancer nektar share have significantly outperformed industry year time stock have sky-rocket compare industry increase importantly nektar be also conduct phase ii propel study evaluate efficacy safety nktr combination roche rhhby free report tecentriq atezolizumab merck mrk free report keytruda pembrolizumab notably propel study complement company ongoing pivot trial additionally nektar have enter research collaboration takeda pharmaceutical explore combination nktr oncology compound takeda cancer portfolio nektar therapeutic price nektar therapeutic price nektar therapeutic quotenektar carry zack rank sell see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail be reissue article correct mistake original article issue thursday february longer be rely
2216,MRK,bristol myer squibb company bmy free report have announce supplemental biologic license application sbla pd immune checkpoint inhibitor opdivo nivolumab combination yervoy ipilimumab have be accept fda priority review company seek approval label expansion combination therapy address patient previously treat microsatellite instability high msi mismatch repair deficient dmmr metastatic colorectal cancer mcrc response regulatory body be await jul opdivo yervoy combo regimen have also be grant breakthrough therapy designation fda aforementioned indication notably opdivo acquire nod several country include unite state eu japan several cancer indication share company have rally past year outperform industry gain acceptance application be base positive datum phase ii checkmate study announce january evaluate combination therapy give indication result study show primary endpoint objective response rate investigator assessment be median follow month overall survival rate year be median os be not yet reach outcome show opdivo yervoy provide durable clinical relief patient dmmr msi metastatic colorectal cancer datum demonstrated statistically significant clinically meaningful improvement key patient report include symptom function quality life significantly combination procedure be also assessment phase iii checkmate trial first line treatment small cell lung cancer nsclc last month bristol myer announce positive datum program reflect superior progression free survival first line nsclc patient compare chemotherapy be first study examine combination regime immune oncology drug first line nsclc patient high tumor mutation burden company press release colorectal be most common cancer type third lead cause terminal disease related death unite state approximately new case crc be expect be diagnosed annually country moreover patient msi dmmr metastatic crc have mild possibility benefit conventional chemotherapy treatment hence approval combo treatment provide company access huge patient population base need alternative treatment option apprehend disease however bristol myer face fierce competitive pressure immuno oncology space fact opdivo battle stiff rivalry merck mrk free report pd immunotherapy keytruda roche tecentriq merck keytruda be also be analyze phase iii study crc hence label expansion opdivo yervoy combination lend company wider population base patient opdivo few approve drug treat patient crc be lilly lly free report cyramza roche rhhby free report avastin amgen vectibix bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quote zack rankbristol myer carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2217,MRK,roche hold ag rhhby free report subsidiary genentech announce phase iii study evaluate combination pd inhibitor tecentriq atezolizumab avastin bevacizumab carboplatin paclitaxel first line treatment advanced lung cancer meet co primary endpoint overall survival os impower study show patient advanced squamous small cell lung cancer nsclc be treat combination treatment live longer compare avastin carboplatin paclitaxel company plan submit additional datum global health authority well fda european medicine agency ema soon year share roche have decline industry growth december company have announce interim result impower study impower study show tecentriq avastin chemotherapy reduce risk disease worsening death compare be treat avastin chemotherapy november roche mentioned iii impower study meet co primary endpoint progression free survival tecentriq be approve treatment second line metastatic nsclc label expansion first line set boost drug sale further tecentriq be also approve treatment patient suffering locally advanced metastatic urothelial carcinoma muc be not eligible cisplatin chemotherapy drug record sale chf remind investor merck mrk free report pd inhibitor keytruda be approve fda monotherapy combination lilly lly free report alimta carboplatin first line treatment patient metastatic nonsquamous nsclc roche hold ag price roche hold ag price roche hold ag quote zack rank other stock considerroche carry zack rank buy top rank stock same space be regeneron pharmaceutical regn free report sporting zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved last day company pull positive earning surprise last quarters average beat medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2218,MRK,share immunogen inc imgn free report have be massively year so far outperform industry increase let analyze factor lead skyrocket rally immunogen rapid pipeline progress positive readout strategic collaboration have drive share price consistently company have make significant progress regard lead pipeline candidate mirvetuximab soravtansine year be be evaluate phase iii study forward single agent therapy treat patient platinum resistant ovarian cancer immunogenha activate more site study enrolment third quarter year aim complete middle readout primary endpoint be anticipate first half also candidate be be evaluate phase expansion cohort ovarian cancer patient company report positive datum trial demonstrated promising safety efficacy profile candidate meanwhile combination regimen mirvetuximab soravtansine ovarian cancer be also be examine phase ib ii forward ii study trial consist cohort assess mirvetuximab soravtansine combination roche rhhby free report avastin merck mrk free report keytruda immunogen have report initial result study show mirvetuximab soravtansine potential complement currently available therapy indication approval combo therapy significantly expand eligible patient population mirvetuximab soravtansine fda nod mirvetuximab soravtansine be huge boost immunogen give immense commercial potential target market ovarian cancer cause maximum annual death gynecologic cancer majority patient diagnosed advanced stage datum provide american cancer society approximately new case ovarian cancer be estimate be diagnosed unite state alone thereby take death toll more apart mirvetuximab soravtansine immunogen be work develop couple other clinical pre clinical candidate include imgn imgn notably imgn be be analyse phase study treat acute myeloid leukemia aml encourage datum report earlier month other hand company plan move imgn clinical development soon address hematological malignancy include aml company have sign agreement several big healthcare player include amgen bayer eli lilly lly free report novartis roche sanofi takeda dint contract other company be allow use immunogen adc technology provide fund form license milestone fee royalty clinical material revenue support fee notably august immunogen have announce strategic collaboration option agreement jazz pharmaceutical development candidate adc program namely imgn imgn pursuant deal immunogen be eligible receive milestone payment base certain pre decide condition platinum resistant ovarian cancer market offer immense commercial potential immunogen be notably set face intense competition approval however mirvetuximab soravtansine look promising juncture approval be big boost company immunogen inc price immunogen inc price immunogen inc quotezack rankimmunogen carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2219,MRK,dow experience holiday shorten eventful week notch gain successive day market be close monday christmas day holiday decline share key tech component push dow downward tuesday tech stock snap day lose streak wednesday boost index upward gain continue thursday index close yet record high last week dow decline last friday investor be reluctant participate intraday trading ahead christmas holiday lead unusually low volume day whole meanwhile trump sign tax bill well legislation pass senate keep government funded jan come economic datum new home sale november come unit more consensus estimate unit order durable good november come consensus estimate increase meanwhile personal saving rate november decline decade low index gain last week post fifth straight week gain senate republican finally pass tax overhaul bill development permanently slash corporate tax rate follow tax cut major bank telecom company pledge provide better pay employee turn boost investor sentiment moreover gdp increase third quarter post best growth pace more year dow weekmarket be close christmas day holiday monday index decrease point follow decline share apple inc aapl free report share iphone maker plummet worst decline august taiwan economic daily report tech giant be plan cut current quarter sale forecast new iphone unit initial unit meanwhile retail holiday sale unite state surge year high push sector stock higher further energy share rally crude future surge tuesday however benchmark end negative territory loss incur due apple not be offset encourage development index increase advance major tech player offset decline energy stock technology sector snap straight session lose streak end green buoy gain facebook inc fb free report microsoft corporation msft free report broader market largely continue winning run republican pass first tax reform year overall investor find few catalyst lowest volume week year trading volume fact remain lowest level year only average share be trade day year last year share be trade day index gain thursday register st record close year dow fail register intraday high fail achieve milestone only index advanced point largest contribution come unitedhealth group incorporate unh international business machine corp ibm free report financial emerge strongest gainer day technology select sector spdr xlk add second successive day gain share apple gain meanwhile material select sector spdr xlb gain follow increase price copper component move boee company ba free report business division defense space security recently secure foreign military sale fms contract worth term deal company procure new qa aircraft be provide qatar emiri air force contract be award air force life cycle management center patterson air force base be schedule be dec fms fund be utilize partially finance work be execute st loui mi read boee win deal supply jet qatar air force separate development zack rank hold boee recently secure modification contract manufacture delivery full rate production aircraft lot jet be provide navy government contract also offer lot segregable effort include unknown obsolescence class change assessment obsolescence monitoring value contract be award naval air system command patuxent river md majority work be carry seattle wa rest be execute various other location unite state cambridge boee utilize fiscal aircraft procurement navy foreign military sale fms fund complete task work related deal be schedule be december read boee secure deal manufacturing aircraft merck co inc mrk free report pfizer inc pfe free report announce fda have approve investigational oral sglt inhibitor steglatro ertugliflozin tablet steglujan ertugliflozin sitagliptin adjunct diet exercise improve glycemic control patient type diabetes mellitus merck have zack rank steglujan be fix combination steglatro januvia sitagliptin be approve patient be eligible treatment combination apart drug fda also approve segluromet ertugliflozin metformin same indication patient already treat steglatro glucophage metformin inadequately controlled type diabetes mellitus patient be already treat combination ertugliflozin metformin read merck diabetes drug get fda nod adjunct therapy unitedhealth recently announce wholly own subsidiary have sign definitive purchase agreement be set launch tender offer empresas banmdica initial step acquire chilean company deal value nearly enhance unitedhealth footprint south america transaction be expect close first quarter subject customary term condition zack rank unitedhealth already have presence south america backed acquisition amil participacoe sa make former operator hospital clinic brazil deal likely be beneficial unitedhealth give banmedica year expertise latin america largest private health group chile colombia peru further acquisition boost unitedhealth international operation stock have zack rank see complete list today zack rank strong buy stock here verizon communication inc vz free report ericsson eric free report qualcomm technology inc subsidiary qualcomm inc qcom free report have recently complete first successful fdd frequency division duplexing massive mimo multiple input multiple output trial fully compatible customer device verizon have zack rank trial be complete used ericsson latest massive mimo software hardware verizon wireless network mobile test device test device be power qualcomm snapdragon chipset be equip lte modem modem support transmission mode tm technology be compatible massive mimo test be conduct irvine read verizon qualcomm ericsson complete massive mimo trial general electric company ge free report recently land locomotive manufacturing order canadian national railway company cni free report undisclosed amount class railroad buy new locomotive manufacture ge transportation operate segment ge zack rank strong sell ge manufacture tier et tier es tier certify locomotive evolution series part order evolution series be best selling most successful freight locomotive history most class railroad north america have order tier locomotive company be well know produce significantly less particulate matter oxide nitrogen meet stringent environmental protection agency emission standard manufacturing locomotive be do fort worth tx facility ge manufacturing solution production delivery locomotive be expect be do next year begin read ge secure locomotive deal canadian national railway performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have gain next week have be year remember bourse dow nearly respectively year date even close thursday dow be course weekly gain do indeed occur index have post weekly gain last week year first time be little suggest gain not continue occur go forward projection fourth quarter earning remain strong fuel mainly recently conclude tax reform further economy continue remain robust international pressure be mostly absent give backdrop dow be likely go strength strength even herald more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2220,MRK,ligand pharmaceutical incorporate lgnd free report announce have inked worldwide license agreement global innovative pharmaceutical company glenmark pharmaceutical agreement glenmark be able use full omniab platform produce mono bispecific human therapeutic antibody ligand be entitle receive receive annual platform access payment development regulatory milestone payment tiered royalty product incorporating omniab antibody meanwhile glenmark be responsible cost related program latest deal glenmark also be able access technology include separate species single license notably be first new omniab deal include omnichicken addition omnirat omnimouse omniflic omniab include transgenic animal platform consist different technology omnirat omnimouse omniflic omnichicken produce mono bispecific human therapeutic antibody ligand share have gain year time compare industry growth remind investor omniab antibody generate platform become part ligand technology portfolio follow omt inc acquisition january ligand be focuse development licensing asset fact captisol formulation technology have allow company enter several licensing deal generate royalty captisol be well validate chemically modify cyclodextrin be design improve safety solubility stability bioavailability lessen volatility irritation smell taste drug other technology platform ligand include ltp technology selexis technology technology captisol omniab have create strong platform company seek new license partnership also ligand have partnership agreement lead healthcare company novartis nvs free report amgen merck mrk free report pfizer pfe free report celgene gilead lilly other ligand pharmaceutical incorporate price ligand pharmaceutical incorporate price ligand pharmaceutical incorporate quotezack rank ligand have zack rank strong sell see complete list today zack rank strong buy stock here zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2221,MRK,dow endure volatile week index hit fresh record high fall bank share lead loss index monday index slip tuesday follow positive news major component surge treasury yield lead loss index wednesday ultimately index surge record high thursday follow investor optimism economic growth last week dow gain last friday due optimism build implementation gop tax bill such broad base gain ensure improvement major benchmark negating effect dismal economic datum nonfarm payroll month december come lower consensus estimate job addition further trade deficit increase november settle be highest deficit january ism service index december decline point index add impressive point friday finish session milestone second straight day marked third straight record close last trading session best open week gain blue chip index be rather broad base last week index gain marked dow best weekly run dec period dow touch psychological level first time be index fastest point rise inception optimism strong market performance contribute gain favorable economic datum include upbeat manufacturing report record construction spending boost market dow index lose almost nearly point monday due fall bank share snap winning run marked end day streak gain blue chip index hit intraday record earlier session suffer broad base loss finish negative territory share major bank such goldman sachs group inc gs free report jpmorgan chase co jpm free report decline respectively weigh dow bank share decline analyst estimate be time charge fourth quarter earning bank suffer due implementation tax reform index increase tuesday follow report boee company ba free report have deliver record number airplane push dow record territory such event lead share boee gain contribute much point dow blue chip index amassed point finish record also contribute dow gain be increase share johnson johnson jnj free report gain add point dow index lose wednesday yield year benchmark note surge follow report china be consider halter purchase treasury market also suffer loss report canada surface government expect trump pull nafta soon meanwhile cost import good unite state surge year high index gain point thursday hit time high follow investor optimism economic growth share boee gain emerge largest contributor dow aircraft manufacturer likely be major beneficiary higher economic growth meanwhile ppi index decline move lower first time more year component move indexboee delivery show rise commercial shipment decline defense shipment year year basis company report commercial delivery jet higher delivery figure be company delivery guidance zack rank hold boee deliver model airplane follow delivery model boee deliver unit model compare unit year other delivery include compare unit respectively defense space business boee delivery be year total delivery consist apache helicopter new remanufacture chinook helicopter new renew read boee commercial defense jet delivery meanwhile boee defense space security unit recently secure modification contract worth production increment lot small diameter bomb sdb term deal company purchase additional quantity sdbs read boee win fms deal build small diameter bomb apple inc aapl free report announce be work feature provide increase parental control smartphone usage child announcement be make follow apprehension apple shareholder jana partner llc california state teacher retirement system regard role company shape child future bloomberg zack rank apple response criticism also mentioned iphone other apple product run io have be offer parent tool enable control child access company also offer ask buy feature require consent parent buy good service add bloomberg company be focuse make vigilance stricter new tool read apple develop tool increase parental control merck co inc mrk free report japanese partner easai co ltd announce fda have grant breakthrough therapy designation btd combination regimen zack rank merck pd therapy keytruda easai multiple receptor tyrosine kinase inhibitor lenvima company be develop combination potential treatment advanced metastatic renal cell carcinoma rcc kidney cancer be btd keytruda second lenvima designation aim expedite development review drug intend treat serious life threaten condition provide patient access soon possible read merck keytruda combo get breakthrough therapy status meanwhile merck announce phase iii study evaluate pd therapy keytruda monotherapy treatment high risk melanoma meet primary endpoint recurrence free survival rfs read merck keytruda succeed high risk melanoma study chevron corporation cvx free report effort divest stake south africa business china petroleum chemical corporation snp free report better know sinopec have be approve country competition commission notably sinopec acquire stake asset subsidiary soihl hong kong hold limit completion deal soihl manufacturer supplier petroleum petrochemical product enter south african petroleum market stock have zack rank strong buy see complete list today zack rank strong buy stock here pfizer inc pfe free report reportedly say statement end effort alzheimer parkinson disease area result layoff decision end neuroscience discovery program mainly affect employee facility andover cambridge groton ct zack rank pfizer however intend continue development pain candidate tanezumab be develop late stage study partnership eli lilly lly free report label expansion effort pain drug lyrica rare disease program read pfizer stall alzheimer parkinson cut job coca cola co ko free report affiliate chile local bottler brand enter agreement buy novaverde sa move be line strategy invest newer revenue generate platform company specialize juice canned fruit vegetable mainly brand guallarauco coca cola have zack rank embotelladora andina coca cola del valle new venture coca cola chile enter stock purchase agreement ownership novaverde share be transfer completion deal coca cola del valle new venture own share coca cola chile embotelladora andina own share respectively gain ownership share embotelladora andina direct indirect ownership novaverde be approximately be already shareholder coca cola del valle new venture deal be value accord reuter report read coca cola chilean arm buy novaverde diversify portfolio performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have gain next week outlookdespite recent hiccup market continue be fuel expectation strong economic growth bullish fourth quarter earning recently release datum manufacturing construction have also bear such sentiment several economic report be line release next few day release reveal critical insight retail sale industrial production housing most report be encourage nature market be likely maintain upward trajectory week ahead zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2222,MRK,rise demand immuno oncology drug combination merck co inc mrk free report pd therapy keytruda be fast become key top line driver pharma giant keytruda be market many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer have crossed mark sale third quarter keytruda become second largest product merck portfolio treatment fetch sale first month year year upside be drive global launch new indication further boost demand keytruda sale be gain particularly strong momentum indication first line lung cancer therapy be only pd approve first line set keytruda development program also significantly advanced regulatory approval secure new indication unite state europe japan key approval indication include advanced bladder cancer advanced microsatellite instability high cancer first approval combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo first line lung cancer new approval expand patient population drive sale third quarter momentum be maintain fourth quarter well meanwhile keytruda be be study more type cancer study include excess combination trial merck be collaborate several company include amgen inc amgn free report incyte glaxo pfizer inc pfe free report separately evaluation keytruda combination other regimen datum several program keytruda be present medical conference expect merck present datum several key keytruda study year include combination study incyte epacadostat first line metastatic melanoma also keytruda get approval relapse refractory primary mediastinal large cell lymphoma indication year fda action expect april conclusionmerck do witness setback regard keytruda pipeline program october company announce delay readout important lung cancer study postpone be due inclusion overall survival co primary endpoint keynote phase iii study keytruda first line lung cancer turn raise investor concern delay readout give competitor chance gain traction lung cancer market also combination study keytruda multiple myeloma be put clinical hold follow report death keytruda group last july also merck top line have be lately hurt generic competition several drug pricing pressure believe keytruda have immense commercial potential couple other newer drug ease impact genericization rivalry immuno oncology market have rise follow fda approval newer oncology treatment pfizer bavencio avelumab merkel cell carcinoma mcc bladder cancer indication astrazeneca imfinzi durvalumab bladder cancer believe keytruda give drug tough run money be ample scope growth immuno oncology space merck carry zack rank hold see complete list today zack rank strong buy stock here share merck have decline year industry rally zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2223,MRK,focus week be annual jpmorgan healthcare conference several biotech pharma company provide preliminary look result also provide pipeline update well outlook recap week most important storieskey takeaway jpmorgan healthcare conference several pharma company be present annual jpmorgan healthcare conference largest most informative healthcare investment symposium industry key update pfizer pfe free report say expect be rich datum delivery year bristol myer squibb company bmy free report also provide look pipeline include opportunity opdivo company also say business development remain important priority focus be deal make sense financial perspective asset technology be strategically align priority be potentially merck mrk free report be also lookout business development deal exercise financial discipline company say be look opportunity licensing deal bolt acquisition add drug technology address unmet medical need read more key takeaway pfizer other drug stock healthcare conference allergan be also present conference preliminary financial outlook read more allergan sale guidance lower expect glaxosmithkline gsk free report meanwhile be look strengthen pharma pipeline prioritize development capital focus core respiratory hiv infectious disease potential therapy immuno inflammation oncology area glaxo be zack rank buy stock see complete list today zack rank strong buy stock here nordisk go public ablynx proposal nordisk nvo free report confirm be look acquire belgium base biopharma company ablynx nordisk have initially propose acquire ablynx share cash however company come back revise offer ablynx reject first proposal nordisk latest offer include upfront cash payment share contingent value right cvr worth share total equity valuation approximately offer too have be reject ablynx company board announce proposal fundamentally undervalue ablynx growth prospect look ablynx pipeline show company well be position launch first product caplacizumab vwf acquire thrombotic purpura attp year caplacizumab be currently review eu regulatory application be file unite state first half estimate annual market opportunity attp life threaten blood clot disease be expect be company also have broad range partnership potential generate more milestone royalty other pipeline candidate also address significant market opportunity currently be rumor additional bidder eu approval caplacizumab well change scenario far nordisk be concern acquisition make sense caplacizumab be good fit company hematology portfolio deal also give boost nordisk pipeline especially give continue pricing pressure diabetes care particularly unite state read more nordisk confirm bid ablynx face rejection sanofi regeneron boost investment dupixent cemiplimab sanofi sny free report partner regeneron have decide boost investment development cemiplimab pd antibody oncology dupixent il il pathway block antibody type allergic disease base decision investment cemiplimab shoot least increase approximately initial agreement company contribute equally cemiplimab be be study monotherapy well combination other therapy wide range cancer include advanced skin cancer small cell lung cancer cervical cancer lymphomas regulatory application cemiplimab advanced cutaneous squamous cell carcinoma be schedule be submit european union unite state first quarter meanwhile dupixent currently approve eczema have potential be evaluate additional indication include chronic obstructive pulmonary disease peanut allergy grass allergy patient have multiple allergic condition be addition ongoing development pediatric atopic dermatitis pediatric asthma eosinophilic esophagitis nasal polyposis regeneron sanofi be currently seek fda approval dupixent uncontrolled persistent asthma patient least year old candidate benefit additional investment be regn il antibody potential atopic dermatitis asthma chronic obstructive pulmonary disease development update merck merck provide late stage datum pd therapy keytruda monotherapy surgically resect high risk melanoma keytruda meet primary endpoint recurrence free survival rfs merck also announce fda have accept regulatory application doravirine investigational nucleoside reverse transcriptase inhibitor nnrti treatment hiv infection adult response agency be expect oct fda also grant breakthrough therapy designation eisai lenvima lenvatinib combination keytruda treatment patient advanced metastatic renal cell carcinoma rcc breakthrough therapy designation help fasten development review drug be be evaluate treatment serious condition preliminary clinical evidence indicate drug be substantially better exist treatment clinically significant endpoint read more merck keytruda combo get breakthrough therapy status merck stock be last year compare rally industry belong cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session major stock johnson johnson jnj free report be pfizer decline last month bristol myer be glaxo decline see last pharma stock roundup here allergan announce job cut pfizer inks deal next pharma world watch usual pipeline regulatory update zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2224,MRK,alzheimer disease ad area be focus once again pfizer inc pfe free report say be drop plan develop treatment alzheimer parkinson disease accord news source pfizer expect decision result elimination position neuroscience discovery early development program expect additional detail be available company presentation annual jpmorgan healthcare conference today pfizer have have long association alzheimer disease research area company become part dementia discovery fund be form speed development new treatment neurological disease bring together major pharma company uk government alzheimer research uk fund be involved financing new early stage drug development project however alzheimer have always be highly challenge area not much progress be make investment lot fund resource fact pfizer have face major setback way back development effort alzheimer disease treatment company partner johnson johnson jnj free report decide discontinue development bapineuzumab iv follow late stage failure other company eli lilly company lly free report merck mrk free report have also stumble effort develop treatment alzheimer lilly decide november not seek approval investigational ad treatment solanezumab follow disappointing result late stage study candidate be be evaluate see slow progression memory problem associate amyloid protein form plaque brain person alzheimer meanwhile evaluation merck investigational alzheimer disease treatment verubecestat be halter phase ii iii study epoch february base interim analysis external datum monitoring committee edmc study fail study be ongoing result expect february biogen also suffer setback recently independent datum monitoring committee say ban do not meet criterium success base bayesian analysis month primary endpoint phase ii study failure show early positive result come major disappointment biogen be develop candidate association eisai clinical stage company axovant science axon free report suffer major setback september investigational alzheimer disease candidate fail meet co primary efficacy endpoint late stage study company decide discontinue development mg dose treatment alzheimer disease last year company share be compare decline industry belong accord alzheimer association year drug be test alzheimer study register clinicaltrial gov only succeed go gain fda approval road setback several company continue invest heavily develop alzheimer disease treatment give high commercial potential market success area mean huge return consider more american be live alzheimer disease number expect triple datum alzheimer association be consider be biggest burden society be sixth lead cause death age unite state market have immense commercial potential company come new treatment rake billion dollar sale company be currently work alzheimer disease treatment include biogen novartis nvs free report astrazeneca eisai amgen amgn free report biogen aducanumab be most important candidate company pipeline candidate currently couple late stage study biogen be also work elenbecestat bace inhibitor phase iii program candidate be be develop collaboration eisai lilly also have quite few alzheimer disease candidate pipeline include lanabecestat be be develop collaboration astrazeneca datum readout expect meanwhile novartis amgen be collaborate bace inhibitor cnp have fast track status unite status roche be also collaborate ac immune development alzheimer disease treatment company pfizer lilly merck be zack rank hold stock see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2225,MRK,have be hardly notable development first week market continue be holiday mood fact trump gift new year form tax reform be still keep market buoyant come development cancer space merck co inc mrk free report keytruda receive approval japan urothelial carcinoma seattle genetic inc sgen free report announce fda acceptance regulatory filing seek label expansion adcetris frontline treatment advanced classical hodgkin lymphoma fda grant breakthrough therapy designation btd novartis nvs free report breast cancer drug kisqali week merck seattle genetic carry zack rank hold novartis hold zack rank sell see complete list today zack rank strong buy stock here let discuss news detail merck announce keytruda approval japan merck pd therapy keytruda pembrolizumab have receive approval japan treatment previously treat patient urothelial carcinoma uc type bladder cancer approval keytruda be now approve indication japan remind investor keytruda be approve treat uc unite state europe first second line setting drug be approve several cancer indication include small cell lung cancer combination eli lilly lly alimta carboplatin read more merck keytruda get approve bladder cancer japan merck company inc price merck company inc price merck company inc quoteseattle genetic sbla adcetris grant priority review seattle genetic announce fda have accept sbla seek label expansion lymphoma drug adcetris also grant priority review sbla seek approval adcetris combination chemotherapy frontline treatment patient advanced classical hodgkin lymphoma fda have also set action date read more seattle genetic adcetris sbla get fda priority review seattle genetic inc price seattle genetic inc price seattle genetic inc quotenovartis kisqali get second breakthrough designation novartis announce fdagrant btd kisqali initial endocrine base treatment hr advanced metastatic breast cancer pre peri menopausal woman company be develop drug combination tamoxifen inhibitor indication drug be grant btd same cancer indication postmenopausal woman read more novartis get second breakthrough designation kisqali novartis ag price novartis ag price novartis ag quoteapart development inovio pharmaceutical inc ino free report announce amendment agreement chinese partner apollobio corporation related development dna immunotherapy product vgx greater china amend agreement apollobio make upfront payment higher previously agree also exclude apollobio right purchase inovio stock candidate be currently be evaluate phase iii study treatment human papillomavirus hpv related cervical pre cancer meanwhile exelixis inc exel free report amend protocol phase ib study cabozantinib combination roche holding rhhby free report tecentriq patient locally advanced metastatic solid tumor study addfour new expansion cohort include patient nsclc crpc rcc uc celsion corporation clsn free report announce fda have accept design phase ii study ovation ii ovarian cancer clear initiation study evaluate dna base immunotherapy gen localize treatment stage iii iv ovarian cancer newly diagnosed patient zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2226,MRK,dow start year strong note gain successive session expectation strong market performance boost broader market consequently index first trading day third day holiday shorten week index finished green ride strong employment datum moreover economic report china eurozone be also bullish last week dow lose final trading session follow broad base sell additionally report highlighted north korea be have receive fuel supply russia several occasion last few month senior western european security source turn raise concern possible geopolitical tension come day turn contribute friday late sell month december dow increase register straight month gain first time last year index climb post best yearly increase dow also notch st record close highest number record year dow weekmarket be close monday owing new year holiday index gain tuesday optimism market performance remain strong contribute gain government rally major oil exporter opec member recent crude supply cut russia opec country have positive impact oil price bullish sentiment oil price be reflect wti brent crude price day early tuesday wti crude price reach highest intraday settlement june moreover brent crude price settle intraday high best index gain wednesday due continue optimism strong market performance additionally gain chipmaker energy stock have positive impact investor sentiment ism manufacturing index rise november december reach highest settlement last year census bureau department commerce report construction spending november downwardly revise october figure be highest level record index gain thursday follow solid job addition private sector significant rise business activity china europe private employer add job december higher analyst expectation job accord automatic datum process inc adp free report china caixin china general service business activity advanced november december reach highest level august moreover ihs markit survey datum purchasing manager index measure business activity eurozone increase november december settle best level feb also expectation better earning season have positive impact investor sentiment component move index company mmm free report have recently file patent infringement suit lead global supplier touchscreen solution elo touch solution inc latest lawsuit file federal district court wilmington zack rank buy allege elo touch violate patent register unite state infringe patent relate metal mesh conductor technology be widely used touch system display base proprietary ultrafine metal mesh design technology enable developer integrator transform piece glass exciting multus touch real multus user customer experience read file lawsuit elo touch patent infringement apple inc aapl free report be have splendid be reveal software update be slow iphone older battery be currently face least lawsuit various federal court regard issue iphone maker recently issue letter apologize lack transparency relate handle iphone performance older battery however company deny have ever do anything intentionally shorten life product moreover company announce certain step pacify aggrieve customer company lower price warranty battery replacement anyone iphone later offer be available late january december also issue io software update new feature give user more visibility health iphone battery read apple apologize iphone issue older model still hit meanwhile apple recently acquire vancouver canada base mobile iteration platform buddybuild undisclosed amount move be expect simplify app development coder buddybuild be integrate apple suite software development tool call xcode stock have zack rank see complete list today zack rank strong buy stock here walt disney company free report star war last jedi be fly high box office worldwide collection cross mark movie record second largest open ever have already become eighth highest gross movie domestically further film be likely overtake seventh place movie star war rogue come day read disney last jedi smash record cross mark be dull year movie industry zack rank hold disney have once again emerge top grosser domestic box office collection medium report disney garner ticket sale north america be more total domestic market share blockbuster performance disney latest flick star war last jedi runaway hit beauty beast guardian galaxy vol be primary reason studio success read disney movie top chart beat time warner comcast general electric company ge free report intend increase ownership stake arcam ab approximately acquisition be do ge sweden holding ab subsidiary ge be swedish company ge aviation ge have zack rank strong sell share be acquire private investment management firm elliott management polygon investment group sek share transaction be slate be complete last work day year arcam develop cost effective metal base technology find commercial use orthopaedic aerospace automotive sector read ge own stake arcam market potential goldman sachs group gs free report fourth quarter result be likely reflect negative impact trigger new tax reform levy taxe overseas income also defer tax asset dta lose value due recent tax cut tax cut job act company base unite state be pay mandatory repatriation tax cash liquid asset illiquid asset irrespective earning be bring home immediately not zack rank goldman expect loss dta be much smaller part total time charge apart charge investment bank expect reform be beneficial long term also lower tax rate increase earning read goldman expect tax reform have time impact merck co inc mrk free report announce pd therapy keytruda pembrolizumab have be approve japan previously treat patient urothelial carcinoma type bladder cancer approval make keytruda eligible be indicated type cancer japan notably keytruda have already be approve unite state eu first second line treatment patient aforementioned indication apart bladder cancer keytruda be approve many malignant disease type treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma read merck keytruda get approve bladder cancer japan performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have gain next week outlookmarket seem be forge ahead point continue success enjoy potent combination economic datum bullish earning result be still fuel gain meanwhile recent tax cut be likely boost market future earning even higher give backdrop dow be likely go strength strength even head further zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2227,MRK,pfizer pfe free report have announce regulatory application pipeline candidate dacomitinib have be accept review unite state eu company be look get drug approve first line treatment locally advanced metastatic small cell lung cancer nsclc patient egfr activate mutation notably fda grant priority review dacomitinib response expect september regulatory submission dacomitinib be base positive datum global head head phase iii study evaluate dacomitinib versus astrazeneca azn free report lung cancer drug iressa gefitinib patient nsclc datum study demonstrated median progression free survival pfs month treatment dacomitinib compare month iressa reflect reduction risk disease progression however patient treat dacomitinib discontinue study due adverse event compare treat iressa company state final assessment overall survival study be present medical meeting later share pfizer be almost follow news however stock have gain past year underperform industry increase importantly pfizer regulatory application candidate have recently receive acceptance unite state be lorlatinib second line treatment patient nsclc response fda be await august small cell lung cancer occur patient lung cancer condition lead cause cancer death worldwide notably egfr mutation lead growth cancer cell occur nsclc tumor globally moreover significant progress make space disease be associate low survival rate hence approval candidate provide company access huge patient population base need additional treatment apprehend disease remind investor merck mrk free report pd therapy keytruda be approve first line lung cancer set also note last month roche rhhby free report have present datum tecentriq novel combination broad range tumor include lung cancer blockbuster drug bristol myer opdivo be approve treat nsclc other pfizer inc price pfizer inc price pfizer inc quote zack rankpfizer carry zack rank buy see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2228,MRK,astrazeneca azn free report announce fda have approve diabetes drug bydureon exenatide extend release injectable suspension adjunctive basal insulin approval allow use drug add therapy basal insulin treat type ii diabetes patient receive more antidiabetic medicine addition diet exercise inadequate glycemic control drug be originally approve treatment october fda approve extend release version bydureon bcise patient uncontrolled diabetes treat other oral agent astrazeneca share have return so far year industry decline approval be base datum duration study evaluate bydureon add therapy insulin glargine metformin drug achieve mean reduction hba level compare placebo patient mean baseline hba moreover patient bydureon arm reach hba level less patient placebo arm however bydureon compete several other diabetes drug include johnson johnson jnj free report invokamet xr have achieve better effectiveness reduce hba level clinical study separate press release astrazeneca announce fda have grant priority review regulatory application seek approval cd recombinant immunotoxin candidate moxetumomab pasudotox biologic license application bla be submit company seek approval candidate treatment hairy cell leukaemia hcl adult patient second later line set decision fda be expect third quarter bla be submit base datum phase iii study evaluate moxetumomab pasudotox patient relapse refractory hcl datum show candidate meet primary endpoint durable complete response study press release astrazeneca partner merck mrk free report announce european medicine agency have accept marketing authorization application maa parp inhibitor lynparza seek approval metastatic breast cancer drug be already approve treat ovarian cancer eu maa include datum phase olympiad study evaluate lynparza chemotherapy patient negative metastatic breast cancer harbore germline brca mutation drug achieve significant improvement progression free survival compare chemotherapy vs month lynparza also reduce risk disease progression death maa be likely get approval ema fda have already approve lynparza similar indication january base olympiad study datum approval certainly boost prospect drug give advantage other drug parp inhibitor segment unite state eu other parp inhibitor include clovis oncology inc clvs free report rubraca tesaro zejula be approve only ovarian cancer drug be also be develop breast cancer indication astrazeneca plc price astrazeneca plc price astrazeneca plc quotezack rankastrazeneca carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2229,MRK,fda have propose new guideline be aim lower clinical study goal alzheimer disease drug treat earlier stage patient have not yet display functional disability clinical abnormality strategy part fda ongoing effort expand access safe effective treatment option many serious condition suggest agency be open accelerate approval process such drug fda propose guideline come week major disappointment field be announce company develop drug treat deadly brain disease earlier week merck mrk free report announce be discontinue study evaluate verubecestat treatment prodromal alzheimer disease success be unlikely biogen biib free report also announce have decide increase number patient enrolment study be conduct crucial alzheimer disease candidate aducanumab raise concern regard chance success treatment december biogen alzheimer disease study candidate ban fail show early positive result raise investor concern candidate chance success alzheimer disease market have attract lot attention several company however successful development therapy treatment alzheimer disease be challenge be somewhat underlie cause severe neurological ailment alzheimer not be clear disease cancer also alzheimer progress go unnoticed year time symptom ailment become evident significant function already be lose make develop drug treat disease difficult note several company have fail regard last month pfizer pfe free report reportedly announce termination effort alzheimer parkinson disease area result layoff long back pfizer shelved late stage alzheimer candidate bapineuzumab iv fail phase iii study november lilly lly free report amyloid candidate solanezumab fail meet primary endpoint late stage ad study lilly decide drop development solanezumab lilly also suffer major setback august have halt development phase iii alzheimer candidate semagacestat alzheimer disease market represent huge commercial potential successfully develop product generate billion dollar sale once launch fda latest effort reinvigorate research effort alzheimer drug repeat failure wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2230,MRK,incyte corporation incy free report report net loss cent compare net income cent year quarter fourth quarter see significant surge expense exclude time charge stock base compensation expense earning share be zack consensus estimate be loss cent incyte corporation price consensus ep surprise incyte corporation price consensus ep surprise incyte corporation quotequarterly revenue be year year beat zack consensus estimate top line be drive higher sale jakafi unite state iclusig europe well royalty sale jakavi olumiant outside unite state incyte stock lose past year compare industry decline quarter detailjakafi sale grow year year drive strong patient demand indication net product revenue iclusig amount year quarter product royalty revenue novartis ag nvs free report jakafi ex market grow expense be year quarter sg expense amount year year company expect jakafi revenue range iclusig revenue be expect range expense be expect range sg expense be still expect range pipeline phase ii trial reach trial evaluate jakafi patient steroid refractory acute graft versus host disease gvhd have complete enrolment result be expect first half assume success trial incyte expect submit snda seek approval jakafi indication phase iii trial echo evaluate epacadostat keytruda patient unresectable metastatic melanoma be now fully recruit initial datum be expect first half incyte have also open new pivotal trial epacadostat pd antagonist collaboration merck co mrk free report bristol myer squibb bmy free report december new drug application nda baricitinib be resubmit fda be classify class ii resubmission begin new month review cycle pivotal trial baricitinib patient moderate severe atopic dermatitis have also be initiate european commission have already approve baricitinib olumiant february treatment moderate severe active rheumatoid arthritis adult patient have respond inadequately be intolerant more disease modify rheumatic drug takeincyte beat sale fourth quarter strong jakafi performance jakafi sale be drive patient demand sale guidance be also impressive label expansion jakafi gvhd further boost sale meanwhile nda olumiant be resubmit potential approval further boost top line zack rankincyte currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2231,MRK,nektar therapeutic nktr free report share increase more feb company announce global strategic collaboration agreement bristol myer squibb bmy free report agreement company jointly develop commercialize lead immuno oncology candidate nktr former combination latter opdivo nivolumab opdivo yervoy ipilimumab pursuant contract nektar be entitle receive upfront payment include payment cash equity investment nektar also get additional potential payment achievement certain developmental sale base milestone nektar bristol myer share profit respective ratio potential sale nktr worldwide positive note nektar not only retain ownership candidate also continue collaborate other company further development nektar jointly commercialize nktr opdivo combination unite state well major market eu japan bristol myer be entitle solely commercialize combination other global market remind investor nektar be already evaluate nktr opdivo phase ii pivot study tumor type melanoma kidney colorectal bladder small cell lung cancer potential indication latest deal bristol myer have be agree company evaluate nktr opdivo nktr opdivo yervoy combination more cancer indication tumor type november company report positive interim datum dose escalation part study evaluate safety efficacy combo therapy patient melanoma renal cell carcinoma small cell lung cancer nektar share have significantly outperformed industry year time stock have sky-rocket compare industry increase importantly nektar be also conduct phase ii propel study evaluate efficacy safety nktr combination roche rhhby free report tecentriq atezolizumab merck mrk free report keytruda pembrolizumab notably propel study complement company ongoing pivot trial additionally nektar have enter research collaboration takeda pharmaceutical explore combination nktr oncology compound takeda cancer portfolio nektar therapeutic price nektar therapeutic price nektar therapeutic quote zack ranknektar carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2232,MRK,february issue update report immunogen inc imgn free report immunogen report fourth quarter result feb company post wider expect loss report quarter revenue miss estimate however loss be significantly narrower year figure sale show massive increase period top line improvement be mainly drive substantially higher license milestone fee related divestment company core cell asset imgn november debiopharm international fourth quarter conference call focus be mainly progress related company pipeline development share immunogen have significantly outperformed industry year time stock have soar industry decline immunogen have significantly progressed respect lead pipeline candidate mirvetuximab soravtansine candidate be evaluation phase iii study forward single agent therapy treat patient platinum resistant ovarian cancer tumor express high medium level fr alpha notably combo therapy mirvetuximab soravtansine ovarian cancer be be evaluate phase ib ii forward ii study study consist cohort assess mirvetuximab soravtansine combination roche rhhby free report avastin merck mrk free report keytruda initial datum study demonstrated candidate have potential complement available therapy indication update datum program be expect first half notably mirvetuximab soravtansine enjoy orphan drug status unite state eu treatment ovarian cancer apart mirvetuximab soravtansine immunogen work develop couple other candidate include imgn imgn december immunogen release positive finding ongoing phase study evaluate imgn patient relapse refractory adult acute myeloid leukemia aml earlier january company initiate phase program analyze imgn treat hematological malignancy include aml immunogen have agreement several big healthcare company include amgen amgn free report bayer eli lilly novartis roche sanofi takeda contract turn allow other company use immunogen adc technology provide fund form license milestone fee royalty clinical material revenue research development support fee zack rankimmunogen carry zack rank hold see complete list today zack rank strong buy stock here don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
2233,MRK,merck co inc mrk free report announce be discontinue study evaluate verubecestat treatment prodromal alzheimer disease success be unlikely apecs be phase iii study evaluate efficacy safety verubecestat oral amyloid precursor protein site cleave enzyme bace inhibitor versus placebo study be stop recommendation external datum monitoring committee assessed study overall benefit risk recent interim safety analysis committee say chance observe positive risk benefit profile study continue be slim share merck decline almost tuesday past year merck share have underperform industry merck share have decline period increase industry february last year merck have discontinue study epoch phase ii iii verubecestat be evaluate mild moderate alzheimer disease due lack efficacy time committee have recommend apecs study continue unchanged alzheimer disease market have attract lot attention several company however successful development therapy treatment alzheimer disease be challenge note several company have fail regard last month pfizer pfe free report reportedly say statement end effort alzheimer parkinson disease area result layoff long back pfizer shelved late stage alzheimer candidate bapineuzumab iv fail phase iii study december biogen biib free report announce alzheimer disease study ban fail show early positive result raise investor concern candidate chance success november lilly lly free report amyloid candidate solanezumab fail meet primary endpoint late stage ad study lilly decide drop development solanezumab lilly also suffer major setback august have halt development phase iii alzheimer candidate semagacestat alzheimer disease market represent huge commercial potential successfully develop product generate billion dollar sale once launch merck carry zack rank hold see complete list today zack rank strong buy stock here don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
2234,MRK,new drug application nda pfizer pfe free report anaplastic lymphoma kinase alk tyrosine kinase inhibitor tki candidate lorlatinib have be accept fda nda seek approval lorlatinib treatment patient alk positive metastatic small cell lung cancer nsclc have receive prior treatment more alk tkis nda have also be grant priority review decision be expect august similar application seek marketing authorization europe japan have also be accept regulatory agency respective country share pfizer be almost follow news stock have return past year underperform industry gain period pfizer submit regulatory application base positive datum phase ii portion phase ii study evaluate lorlatinib several cohort base prior therapy small cell lung cancer occur patient have lung cancer lead cause cancer death worldwide lung cancer be attractive avenue pharmaceutical company due widespread occurrence disease however be also most competitive space due presence large number player several large small company be develop have approve therapy treatment various form lung cancer remind investor last month merck mrk free report announce encourage result phase iii study evaluate pd therapy keytruda combination eli lilly lly free report alimta carboplatin nsclc also note roche rhhby free report recently present datum tecentriq novel combination broad range tumor include lung cancer blockbuster drug bristol myer opdivo be approve treat nsclc other pfizer inc price pfizer inc price pfizer inc quotezack rankpfizer carry zack rank buy see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2235,MRK,immunogen inc imgn free report report adjust loss cent share fourth quarter wider zack consensus estimate loss cent however loss be significantly narrower year figure loss cent share immunogen have significantly outperformed industry year time stock have soar versus industry decrease immunogen have approve product portfolio company earn revenue royalty license milestone payment research development support fee paid partner company report revenue miss zack consensus estimate quarter however sale increase significantly compare year figure upside be mainly drive substantially higher license milestone fee related divestment core cell asset imgn november last year debiopharm international research development expense increase year level mainly related cost incur advance company lead pipeline candidate mirvetuximab soravtansine combination trial selling general administrative sg expense rise fourth quarter compare year number immunogen cash cash equivalent end december be compare december company expect current cash estimate cash fund operation fourth quarter pipeline updateimmunogen have be progress well pipeline product mirvetuximab soravtansine candidate be currently phase iii study forward single agent therapy treat patient platinum resistant ovarian cancer tumor express high medium level fr alpha notably combo therapy mirvetuximab soravtansine ovarian cancer be phase ib ii forward ii study trial consist cohort assess mirvetuximab soravtansine combination roche rhhby free report avastin merck mrk free report keytruda initial datum study demonstrated candidate have potential complement available therapy indication update datum program be expect first half apart mirvetuximab soravtansine immunogen be work develop couple other candidate include imgn imgn december immunogen release positive finding ongoing phase study evaluate imgn patient relapse refractory adult acute myeloid leukemia aml annual meeting american society hematology earlier january company moved imgn clinical development treat hematological malignancy include aml resultsfull year sale jump year year revenue growth be line previous expectation company report loss cent share narrower year tally share company expect revenue range zack consensus estimate metric be peg year operate expense be project band period moreover company anticipate cash cash equivalent stand range end immunogen inc price consensus ep surprise immunogen inc price consensus ep surprise immunogen inc quote zack rank key pickimmunogen carry zack rank buy top rank stock health care sector be xoma corporation xoma free report carry zack rank see complete list today zack rank strong buy stock here xoma loss share estimate have narrow cent cent last day company come average beat stock have sky-rocket last month wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2236,MRK,merck kgaa announce japanese ministry health labour welfare mhlw have grant sakigake fast track designation pipeline candidate tepotinib company be develop candidate treatment advanced small cell lung cancer nsclc sakigake designation be grant expedite candidate development review japan focus new unmet area regenerative medicine merck kgaa share have underperform industry so far year stock have lose compare industry decline period designation be grant tepotinib base datum phase ii study evaluate nsclc patient meet exon skip mutation be approve treatment indication datum study be present future medical congress apart tepotinib merck kgaa oncology pipeline include be bifunctional immunotherapy simultaneously block immuno inhibitory pathway be commonly used cancer cell company be evaluate candidate several tumor however most advanced candidate oncology pipeline avelumab be be develop collaboration pfizer pfe free report several indication include lung gastric ovarian kidney cancer press release lung cancer be most common cancer globally nsclc occur lung cancer patient however tepotinib target only nsclc patient have meet exon skip mutation however several big pharma company be already marketing drug treat nsclc include merck mrk free report pd therapy keytruda pfizer xalkori bristol myer bmy free report pd immune checkpoint inhibitor opdivo merck kgaa price merck kgaa price merck kgaa quotewill make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2237,MRK,merck co mrk free report japanese partner eisai co ltd announce latter cancer drug lenvima have receive approval japan expand indication tyrosine kinase inhibitor lenvima have be approve japan first line treatment unresectable hepatocellular carcinoma hcc type liver cancer approval be base positive datum phase iii clinical study study reflect study show lenvima demonstrated statistically significant inferiority overall survival os month compare bayer ag bayry free report nexavar month study also show lenvima demonstrated highly statistically significant clinically meaningful improvement compare nexavar secondary endpoint progression free survival regulatory application seek approval lenvima hcc be also unite state eu follow approval japan eisai receive development milestone payment merck past year merck share have decline industry gain be first approval lenvima company strike global strategic collaboration last month jointly develop commercialize drug monotherapy well combination merck pd therapy keytruda several type cancer lenvima develop eisai be presently approve treatment thyroid cancer monotherapy second line treatment renal cell carcinoma rcc type kidney cancer combination novartis nvs free report afinitor everolimus also late stage study be already ongoing evaluate lenvima separate combination study keytruda afinitor rcc meanwhile keytruda lenvima combination enjoy breakthrough therapy designation fda rcc merck eisai plan jointly develop lenvima cancer type potential indication company share global development marketing cost well gross profit lenvima equally however eisai book lenvima worldwide product sale monotherapy combination meanwhile keytruda be be study more type cancer exceed study include excess combination study merck be collaborate company amgen inc amgn free report incyte glaxo pfizer separately evaluation keytruda combination other regimen merck co inc price merck co inc price merck co inc quotezack rank merck carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2238,MRK,merck co inc mrk free report announce pd therapy keytruda pembrolizumab have be approve japan previously treat patient urothelial carcinoma type bladder cancer approval make keytruda eligible be indicated type cancer japan notably keytruda have already be approve unite state eu first second line treatment patient aforementioned indication apart bladder cancer keytruda be approve many malignant disease type treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma be also approve combination therapy eli lilly lly free report lung cancer drug alimta pemetrexed carboplatin pem carbo merck share have lose last year compare unfavorably increase industry approval be base positive datum phase iii keynote study trial outcome show clinically meaningful improve overall survival os benefit keytruda compare chemotherapy patient give indication program keytruda demonstrated reduction death risk compare chemotherapy moreover median os be month keytruda arm comparison chemotherapy significantly merck commercialize keytruda japan collaboration taiho pharmaceutical company company press release incidence bladder cancer japan be anticipate increase time approximately patient be detected bladder cancer country new case diagnosed hence market opportunity keytruda be fairly wide country keytruda fetch global sale first month year year sale continue be drive launch new indication globally keytruda sale unite state gain particularly strong momentum new indication first line therapy lung cancer outside unite state keytruda sale be primarily drive melanoma indication remind investor keytruda be first pd therapy gain fda approval be be study more type cancer study include combination trial merck company inc price merck company inc price merck company inc quote zack rank key picksmerck carry zack rank hold better rank stock health care sector be sucampo pharmaceutical inc acelrx pharmaceutical inc acrx free report carry zack rank buy see complete list today zack rank strong buy stock here sucampo earning share estimate have moved north current year last day company deliver positive earning surprise trail quarters average beat share price company have surge year date acelrx stock have see zack consensus estimate current year loss share be narrow cent last day investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2239,MRK,seattle genetic inc sgen free report announce today fda have accept filing supplemental biologic license application sbla label expansion lymphoma drugadcetris brentuximab vedotin grant priority review sbla be file adcetris combination chemotherapy frontline treatment patient advanced classical hodgkin lymphoma fda also set action date generally priority review designation fda be grant drug have potential provide significant improvement safety effectiveness treatment prevention diagnosis serious disease adcetris be only market product seattle genetic drug be approve relapse hodgkin lymphoma relapse systemic anaplastic large cell lymphoma salcl suffering classical hodgkin lymphoma be high risk relapse progression post autologous hematopoietic stem cell transplantation auto hsct consolidation share seattle genetic have increase compare industry gain submission sbla be base positive result phase ii study call echelon june company have announce positive top line datum echelon study demonstrated adcetris achieve improvement modify progression free survival statistical significance compare standard care chemotherapy fact echelon study evaluate adcetris addition adriamycin vinblastine dacarbazine patient advanced classical hodgkin lymphoma prior treatment november fda approve expand indication lymphoma drug seattle fda have approve adcetris treatment primary cutaneous anaplastic large cell lymphoma pcalcl cd express mycosis fungoide mf have receive prior systemic therapy notably approval be receive month action date set fda dec furthermore seattle genetic be develop adcetris more clinical study key study include evaluation cell lymphomas hodgkin lymphoma phase iii study be also evaluate adcetris frontline mature cell lymphomas drug be be study combination bristol myer squibb company bmy free report opdivo relapse refractory hodgkin lymphoma well however adcetris face competition other drug include merck co inc mrk free report keytruda be approve lymphoma indication march seattle genetic inc price seattle genetic inc price seattle genetic inc quotezack rank stock considerseattle genetic carry zack rank hold better rank health care stock be sucampo pharmaceutical carry zack rank buy see complete list today zack rank strong buy stock here sucampo earning share estimate have moved cent last day company deliver positive earning surprise last quarters average beat share price company have surge investor alert breakthrough pending medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2240,MRK,hampton nj base celldex therapeutic inc cldx free report be company develop immunotherapy technology other cancer target biologic company be still development stage do not have market product portfolio company be develop most advanced candidate glembatumumab vedotin triple negative breast cancer metastatic melanoma stock carry zack rank buy look good investment now see complete list today zack rank strong buy stock here let see reason stock prove be valuable addition portfolio favorable share price movement share celldex have rise past month industry register loss moreover company be trading cheaper price book ratio compare industry company be also better position pay obligation current ratio be rise estimate fact celldex earning performance have be pretty impressive company exceed expectation past quarters meeting same once average positive earning surprise last quarters be moreover loss estimate have narrow past day revenue be expect grow pipeline progress celldex most advanced pipeline candidate glembatumumab vedotin be be investigate phase iib study triple negative breast cancer separate phase ii study metastatic melanoma datum breast cancer study be expect second quarter moreover celldex be also evaluate glembatumumab combination varlilumab checkpoint inhibitor arm include bristol myer squibb company bmy free report opdivo merck co inc mrk free report keytruda melanoma study glembatumumab perform well single agent set apart glembatumumab vedotin celldex have several promising candidate pipeline include varlilumab be evaluate phase ii combination opdivo various cancer cdx cdx phase ii multiple solid tumor collaboration citn cdx phase advanced renal cell carcinoma other acquisition collaboration celldex have collaboration agreement bristol myer provide company strong partner expertise field immuno oncology strong financial also acquisition privately hold development stage company kolltan pharmaceutical strengthen immuno oncology pipeline add unique platform antibody target receptor tyrosine kinase celldex be develop candidate several cancer indication oncology market be highly competitive immuno oncology attract lot interest company juno therapeutic inc bluebird other be involved development immuno oncology treatment zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2241,MRK,recent fda approval exelixis inc exel free report cabometyx treatment previously untreated advanced renal cell carcinoma have put spotlight space rcc be most common form kidney cancer adult statistic approximately patient unite state world need first line treatment advanced kidney cancer many patient need same annually unite state approval come month ahead schedule note cabometyx cabozantinib tyrosine kinase inhibitor tki be already approve treatment rcc patient have already receive angiogenic therapy cabozantinib inhibit activity tyrosine kinase include meet axl vegf receptor ret approval come back result randomize phase ii trial cabosun result demonstrated statistically significant clinically meaningful improvement progression free survival pfs versus current standard care pfizer inc pfe free report sutent importantly cabometyx demonstrated clinically meaningful statistically significant reduction rate disease progression death median pfs cabometyx be month versus month sutent corresponding month improvement sutent be widely used first line treatment rcc novartis ag nvs free report votrient however fda approval cabometyx excellent rate pfs weigh sutent go forward pfizer too be strive hard retain drug leadership november fda approve label expansion sutent drug be approve adjuvant treatment adult patient high risk recurrent rcc follow nephrectomy surgical removal cancerous kidney approval be base result trac trial demonstrated significant reduction risk disease free survival event defined interval randomization tumor recurrence secondary primary cancer death cause patient high risk rcc recurrence receive sutent compare placebo adjuvant set meanwhile pfizer drug inlyta tki be also approve rcc bavencio avelumab monoclonal antibody inhibit pd combination inlyta be be develop first line treatment advanced rcc collaboration merck kgaa sector total return sector total return quoteon other hand immunotherapy be gear too place space september bristol myer squibb company bmy free report announce phase iii study be evaluate opdivo yervoy combination patient previously untreated advanced metastatic rcc meet co primary endpoint combination demonstrated superior overall survival os compare sutent intermediate poor risk patient combination also meet secondary endpoint improve os versus sutent randomize patient consequently independent datum monitoring committee have recommend trial be stop early base plan interim analysis last week fda accept bristol myer supplemental biologic license application priority review opdivo yervoy ipilimumab treat intermediate poor risk patient advanced rcc action date april fda have previously grant breakthrough therapy designation application expedite review additionally variety combination therapy be develop rcc include roche rhhby free report avastin tecentriq earlier month roche announce phase iii immotion study meet co primary endpoint investigator assessed pfs demonstrated combination tecentriq avastin provide statistically significant clinically meaningful reduction risk disease worsening death patient disease expressed pd programme death ligand expression protein compare sutent first line treatment person have advanced metastatic renal cell carcinoma mrcc top line result co primary endpoint os be not mature eisai inc merck mrk free report be also evaluate combination former lenvima multiple receptor tyrosine kinase inhibitor include fibroblast growth factor receptor fgfr combination latter pd therapy keytruda treatment nave previously treat patient metastatic clear cell rcc combination be be evaluate first line use combination ongoing phase iii study clear combination report encourage interim result september hence expect investor keep focus space give stiff competition brewing zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
2242,MRK,bristol myer squibb company bmy free report announce committee medicinal product human use chmp european medicine agency have recommend approval yervoy pediatric patient year older unresectable metastatic melanoma note european commission take chmp recommendation account consider application be not bound fda have approve drug same indication july remind investor yervoy mg kg monotherapy be approve so far year bristol myer share have rally compare industry gain last week company announce fda have accept supplemental biologic license application priority review opdivo yervoy treatment intermediate poor risk patient advanced renal cell carcinoma rcc application be base datum phase iii study checkmate study be stop ahead schedule base recommendation independent datum monitoring committee follow plan interim analysis overall survival study evaluate combination opdivo yervoy versus sutent previously untreated advanced metastatic rcc fda make decision apr meanwhile company continue evaluate blockbuster immune oncology drug opdivo alone combination therapy yervoy other cancer agent label expansion combination additional indication give product access higher patient population increase commercial potential however opdivo be face competitive challenge unite state fda approve merck mrk free report keytruda first line treatment metastatic squamous nsclc company be expect suffer further loss market share virology business be also pressure company be also look counter generic threat key drug deal acquisition company recently enter deal abbvie inc abbv free report halozyme therapeutic inc halo free report zack rank bristol myer currently carry zack rank hold see complete list today zack rank strong buy stock here zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2243,MRK,bristol myer squibb company bmy free report announce late stage study evaluate opdivo versus docetaxel be stop earlier expect meet primary endpoint checkmate study be be conduct mainly chinese patient be previously treat advanced metastatic small cell lung cancer nsclc study show patient receive opdivo nivolumab demonstrated superior overall survival benefit os compare receive standard care treatment docetaxel base top line result bristol myer submit biologic license application bla chinese regulatory authority seek approval opdivo previously treat lung cancer patient approve opdivo become first immuno oncology treatment approve previously treat lung cancer patient china so far year bristol myer share have rally compare industry gain note opdivo be already approve number indication include classical hodgkin lymphoma recurrent metastatic squamous cell carcinoma head neck scchn disease progression platinum base therapy additionally be approve monotherapy treatment squamous cell carcinoma head neck scchn adult progress platinum base therapy opdivo be also approve intravenous use patient hepatocellular carcinoma hcc have be previously treat nexavar drug receive approval liver colorectal cancer well meanwhile company continue evaluate opdivo alone combination therapy yervoy other cancer agent label expansion drug additional indication give product access higher patient population increase commercial potential significantly however opdivo be face competitive challenge unite state fda approve merck mrk free report keytruda first line treatment metastatic squamous nsclc company be expect suffer further loss market share zack rank stock considerbristol myer carry zack rank hold better rank health care stock same space be sucampo pharmaceutical therapeutic inc cort free report sucampo sport zack rank strong buy hold zack rank buy see complete list today zack rank stock here sucampo earning share estimate have moved cent last day company deliver positive earning surprise trail quarters average beat earning share estimate have moved cent cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2244,MRK,total earning total healthcare market capitalization be revenue growth not only be growth rate impressive earning revenue beat ratio respectively be great too robust number have push healthcare stock higher average gain response earning announcement most notable player johnson johnson jnj free report be first major drug company report earning jan follow pfizer pfe free report eli lilly company lly free report jan jan respectively other major drug company merck mrk free report bristol myer squibb company bmy free report report feb feb respectively industry prime post solid result earning revenue beat johnson johnson earning world biggest maker healthcare product continue long streak earning beat earning share come couple cent ahead zack consensus estimate higher year quarter revenue grow year year fall shy zack consensus estimate johnson johnson issue outlook earning share revenue read healthcare etfs focus post jnj result pfizer earning drug giant come earning revenue beat earning share cent come cent zack consensus estimate revenue be also ahead estimate annual basis earning share revenue rise respectively pfizer guide revenue range earning share merck earning focusmerck beat earning estimate miss revenue earning share come cent surpass zack consensus estimate cent improve year quarter revenue inched year year be zack consensus estimate merck issue revenue guidance earning share guidance bristol myer earning focusbristol myer top estimate front report earning share cent penny zack consensus estimate year earning cent revenue grow edge past zack consensus estimate company provide earning share guidance see healthcare etfs here eli lilly earning focuseli lilly also surpass earning revenue estimate earning outpaced zack consensus estimate cent come higher year quarter revenue grow beat estimate other drug maker eli lilly raise earning guidance maintain revenue outlook range etf pharma etfs see terrible trading past month latest global market rout string earning beat bolster confidence space compelling investor cash beaten price have highlighted detail fund have zack etf rank hold suggest room upside day ahead read inverse equity etfs bet historic selloff powershare dynamic pharmaceutical fund pjp free report be far most popular choice pharma space follow dynamic pharmaceutical intellidex index product have aum see lower volume share day fund charge bps fee expense hold stock fund invest more share bmy pfe jnj lly etf have lose month ishare pharmaceutical etf ihe free report etf provide exposure pharma stock tracking dow jone select pharmaceutical index focus firm be top holding basket accounting combine total asset suggest heavy concentration product have aum charge bps fee expense volume be light exchange share day fund have shed month spdr pharmaceutical etf xph free report fund provide exposure pharma company tracking pharmaceutical select industry index aum trade good volume share day charge bps fee year total product hold security focus firm take share product be same period vaneck vector pharmaceutical etf pph free report etf follow mvis list pharmaceutical index hold stock basket focus firm account least share product have amassed asset base trade moderate volume share day expense ratio come fund have lose month read new pharma etf pill investor need know first trust nasdaq pharmaceutical etf ftxh free report fund track nasdaq smart pharmaceutical index hold security basket pfizer johnson johnson account more share merck bristol myer eli lilly makeup more ftxh have lower level aum share averaged daily volume charge bps annual fee have shed same time frame want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2245,MRK,glaxosmithkline plc gsk free report report core earning cent american depositary share fourth quarter surpass zack consensus estimate cent bottom line be constant exchange rate cer compare year figure glaxo share have lose year time industry increase quarterly revenue rise cer drive strong segmental performance consumer healthcare pharmaceutical vaccine top line also outpaced zack consensus estimate growth rate mentioned be year year basis cer quarterly highlightssale be unite state international market flip side sale europe be flat year year sale new pharmaceutical vaccine product surge drive hiv drug tivicay triumeq respiratory drug ellipta product nucala meningitis preventive vaccine bexsero menveo glaxo report financial figure segment pharmaceutical vaccine consumer healthcare pharmaceutical division register revenue growth drive hiv drug tivicay triumeq respiratory disease drug relvar breo nucala upside be partly offset impact recent divestment sale decrease older respiratory product include seretide advair establish pharmaceutical hiv sale increase back growth unite state international sale respectively europe sale be also year year encourage number be drive continue market share growth triumeq sale tivicay sale however sale hiv drug epzicom kivexa tumble due increase generic competition particularly affect european market notably company latest product hiv portfolio be juluca dolutegravir rilpivirine first drug regimen once daily single pill hiv be approve unite state november drug generate initial sale quarter however week gilead science gild free report have announce fda approval triple combination once daily single tablet regimen biktarvy bictegravir emtricitabine tenofovir alafenamide hiv infection treatment approval competitive threat juluca come quarters respiratory sale be cer eu international market sale increase respectively however unite state metric be flat year year sale improvement be mainly drive new respiratory product sale growth partially offset sale decline older product seretide advair flovent ventolin notably recently launch respiratory product trelegy ellipta only once daily single inhaler triple therapy copd have generate initial sale unite state eu report quarter ellipta product record surge sale drive market share gain global roll continue however upside be offset lower sale seretide advair flixotide flovent ventolin sale decrease respectively immuno inflammation drug include benlysta rise quarter new grouping establish pharmaceutical comprise previous establish product cardiovascular metabolic urology cvmu other pharma product establish pharmaceutical sale decline quarter review sale consumer healthcare segment climb slowdown market condition power brand particularly pain relief oral health category see sturdy performance quarter sale vaccine segment be impressive have increase year year geographically unite state europe international market increase respectively meningitis vaccine bexsero decrease unite state same increase europe market menveo unite state post higher sale same be offset weak performance establish vaccine due increase competitive pressure infanrix pediarix unite state europe be important note october fda grant approval glaxo shingle vaccine shingrix later same month center disease control prevention advisory committee immunization practice vote favor recommendation use shingrix vaccine be prefer merck mrk free report zostavax owing favorable recommendation shingrix generate initial sale unite state period discussion resultsfull year sale gain year year however metric marginally miss zack consensus estimate earning share be line zack consensus estimate full year bottom line reflect growth compare year figure moreover report earning match previously announce guidance company state ep growth be uncertain due timing entry advair generic market hence issue set guidance company expect ep growth cer advair generic be launch further year however probable event introduce advair generic market mid glaxo anticipate adjust ep be flat year year cer company mylan myl free report hikma pharmaceutical novartis be try bring generic version advair market receive complete response letter crl fda mylan hikma receive crl last year novartis receive same week delay entry generic market long term company project ep witness cagr mid high single digit range vaccine segment be estimate register mid high single digit growth competition pediatric flu vaccine consumer healthcare segment be expect deliver low mid single digit top line cagr glaxosmithkline plc price consensus ep surprise glaxosmithkline plc price consensus ep surprise glaxosmithkline plc quote zack rankglaxo carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2246,MRK,nordisk nvo free report announce committee medicinal product human use chmp european medicine agency ema have give positive opinion recommend marketing authorisation ozempic semaglutide treatment adult type ii diabetes mellitus semaglutide be once daily pre filled pen improve glycaemic control type ii diabetes patient indication also refer specific section label study result respect combination other diabetes medication effect glycaemic control cardiovascular event population study label also demonstrate person type ii diabetes be treat once weekly semaglutide experience statistically significant sustain blood glucose control compare merck mrk free report januvia sitagliptin astrazeneca azn free report once weekly bydureon exenatide extend release sanofi sny free report lantus insulin glargine placebo nordisk plan conduct post approval safety study include long term diabetic retinopathy outcome study order get semaglutide approve europe also company expect receive final marketing authorization european commission first quarter remind investor december fda approve semaglutide once daily pre filled pen improve glycaemic control type ii diabetes patient share company have rally compare industry gain year date basis additionally nordisk be make effort develop new treatment diabetes be core area expertise september company receive approval fast act insulin aspart fiasp other semaglutide nordisk key pipeline candidate include nonacog beta pegol glp market include lilly trulicity astrazeneca plc once weekly bydureon be tough competition nordisk semaglutide nordisk price nordisk price nordisk quotezack ranknovo nordisk carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2247,MRK,merck mrk free report announce disappointing result pivotal phase iii keynote study evaluate pd therapy keytruda pembrolizumab second line treatment patient advanced gastric junction gej adenocarcinoma notably keytruda be already approve unite state monotherapy third line treatment advanced gastric gej additionally be approve many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer share merck have lose year so far compare unfavorably industry increase phase iii study fail meet primary endpoint overall survival os notably progression free survival pfs show statistical significance pd positive patient population however company say continue evaluate keytruda other phase iii study monotherapy well combination chemotherapy first line treatment patient gej remind investor keytruda be key top line driver merck bring sale third quarter sequentially year year sale continue be drive launch new indication globally significantly keytruda sale unite state have gain particularly strong momentum new indication first line lung cancer drug sale be primarily drive melanoma outside unite state meanwhile keytruda development program also significantly advanced year regulatory approval new indication unite state additional disease europe important approval include nod advanced bladder cancer unite state eu advanced microsatellite instability high cancer first sanction combination therapy eli lilly company lly free report cancer drug alimta pemetrexed carboplatin pem carbo commonly used chemo regimen lung cancer keytruda be continuously grow expand new indication market globally be trial more type cancer study include excess combination study merck be collaborate separately several company namely amgen inc amgn free report incyte glaxo pfizer inc pfe free report evaluation keytruda combination other regimen merck company inc price merck company inc price merck company inc quotezack rankmerck carry zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2248,MRK,bristol myer squibb company bmy free report announce fda have accept supplemental biologic license application sbla priority review opdivo yervoy ipilimumab treatment intermediate poor risk patient advanced renal cell carcinoma rcc note fda have grant breakthrough therapy designation application expedite development review same fda make decision apr application be base datum phase iii study checkmate study study be stop ahead schedule base recommendation independent datum monitoring committee follow plan interim analysis overall survival study evaluate combination opdivo yervoy versus sutent previously untreated advanced metastatic rcc study meet co primary endpoint improve overall survival objective response rate compare sutent intermediate poor risk patient combination demonstrated improvement progression free survival relative sutent co primary endpoint do not reach statistical significance so far year bristol myer share have rally compare industry gain note opdivo be already approve number indication include classical hodgkin lymphoma recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy additionally be approve monotherapy treatment squamous cell carcinoma head neck adult progress platinum base therapy opdivo be also approve intravenous use patient hepatocellular carcinoma have be previously treat nexavar drug receive approval liver colorectal cancer meanwhile company continue evaluate opdivo alone combination therapy yervoy other cancer agent label expansion drug additional indication give product access higher patient population increase commercial potential however opdivo be face competitive challenge unite state fda approve merck mrk free report keytruda first line treatment metastatic squamous nsclc company be expect suffer further loss market share virology business be also pressure company be also look counter generic threat key drug deal acquisition company recently enter deal abbvie inc abbv free report halozyme therapeutic inc halo free report zack rank stock considerbristol myer currently carry zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2249,MRK,merck mrk free report announce fda have grant priority review supplemental biologic license application sbla look label expansion market drug keytruda pembrolizumab rare lymphoma indication snda be look expand keytruda label treatment adult pediatric patient refractory primary mediastinal cell lymphoma pmbcl type hodgkin lymphoma nhl fda grant priority review response be expect apr finally approve be second nod keytruda regulatory body treat hematologic malignancy indication march april keytruda be approve unite state well eu refractory classical hodgkin lymphoma first keytruda approval hematologic malignancy indication merck share have decline year so far underperform industry rally sbla be accept fda base encourage datum ongoing phase ii keynote phase ib keynote study trial be evaluate safety tolerability efficacy keytruda monotherapy patient various blood cancer same press release company release outcome keynote study datum study demonstrated patient relapse refractory pmbcl achieve overall response rate additionally patient achieve complete response rate partial response rate median follow month drug be however unable achieve median duration response find study be present annual meeting american society hematology notably keytruda be grant breakthrough therapy designation fda january aforementioned indication company press release pmbcl account almost nhl unite state hence approval drug expand indication provide company access wider patient population pmbcl remind investor keytruda be first pd therapy gain fda approval be be study more type cancer study include combination trial key recent approval drug have be give indication include advanced bladder cancer advanced microsatellite instability high cancer first approval combination therapy be grant eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo lung cancer merck company inc price merck company inc price merck company inc quotezack rank key picksmerck carry zack rank hold better rank stock health care sector be therapeutic inc cort free report achillion pharmaceutical inc achn free report carry zack rank buy see complete list today zack rank strong buy stock here earning share estimate have moved cent cent last day company deliver positive earning surprise trail quarters average beat share price company have sky-rocket year date achillion loss share estimate have narrow cent cent cent cent last day company come positive earning surprise last quarters average beat more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2250,MRK,quite few pharmaceutical industry merger be card propose tax reform be finally approve senate pass amend tax reform bill last week thereby successfully pass second stage bill now be present conference committee representative house senate come together draft final bill tax reform propose cut tax rate corporate boost profit large drug biotech company meanwhile change tax code also allow company bring back huge cash hold overseas time tax rate change definitely leave more cash hand drug biotech company cash be invest merger acquisition have be few compare contrary expectation increase pharma biotech merger acquisition focus be mostly small bolt acquisition licensing deal agreement gilead gild free report nearly acquisition kite pharma johnson johnson jnj free report acquisition swiss biotech actelion be only noteworthy deal year rise investor expectation trump action drug price not be onerous previously fear be lot chatter possible increase meanwhile major drug biotech player struggle organic growth need infusion new growth driver pipeline product portfolio internal development buy asset strategic licensing deal be therefore inevitable innovation starve drug biotech company look growth highly competitive global marketplace drug biotech company have regularly try merge acquire competitor mega merger deal achieve critical mass sale marketing meanwhile smaller biotech research firm investigate new therapy interesting pipeline candidate have also attract attention larger counterpart last few year focus drug pricing take backseat possibility repatriation fund hope be high activity pick company pfizer pfe free report merck mrk free report be expect take lead support robust cash flow balance sheet wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2251,MRK,year world aids day be celebrate dec raise public awareness acquire immuno deficiency syndrome popularly know aids day be observed make person aware proper cure prevention disease regard year theme day year be right health day also commemorate have die aids related illness world aids day be official global public health campaign marked world health organization accord globally person be suffering hiv aids end total be child less year old aids be pandemic disease cause due infection human virus hiv virus weaken immune system destroy cell fight disease infection eventually lead aids medicine treatment hiv be call antiretroviral therapy art slow put check progression virus currently company be investigate new medicine treat prevent ultimately cure hiv scientist also be explore new treatment paradigm drug regimen make therapy drug drug improve long term safety profile new mechanism action improve medical understand hiv significant effort make lead government medical body prevent treat hiv aids disease still have limit treatment option person die aids related illness totale start epidemic base statistic be not surprising several healthcare company be investing significant amount expenditure develop treatment device hiv aids stock watch world aids day here be key pharma company hiv market investor rely glaxosmithkline gsk free report have long standing commitment hiv aids company have develop widely used antibiotic amoxycillin year be first medicine approve treat hiv sale older hiv product epzicom selzentry have be decline however newer hiv drug triumeq tivicay be witness consistent increase sale gain market share meanwhile significant portion expenditure be be used develop hiv medicine treat prevent hiv last week glaxo partner johnson johnson announce fda approval juluca combination glaxo edurant dolutegravir tivicay rilpivirine single tablet treatment hiv most medicine hiv treatment be make more antiretroviral drug juluca be first drug regimen be approve reduce number medicine hiv patient take compromise efficacy conventional drug regimen week viiv healthcare hiv company majorly own glaxo pfizer pfe free report announce start large late stage african study evaluate long act prevention hiv sexually active woman approve cabotegravir injection be administer month opposed presently available oral retroviral medication need be take day already viiv healthcare have start conduct hptn study cabotegravirin hiv uninfected man transgender woman have sex man co funding national institute allergy infectious disease niaid meanwhile cabotegraviris also be evaluate late stage study drug regimen withedurant third study initiation announce earlier week furthermore glaxo be develop drug regimen ofdolutegravir lamivudine gilead gild free report be dominant player hiv market impressive portfolio fact gilead hiv franchise be major contributor sale approve drug genvoya truvada atripla stribild descovy odefsey complera company be first introduce single tablet regimen str treatment hiv atripla gilead other strs hiv include complera eviplera stribild taf base product genvoya happen be bestseller surpass truvada atripla fourth quarter currently gilead bictegravir single table regimen str hiv treatment be priority review unite state fda be expect announce decision february str be fix dose combination bictegravir insti emtricitabine tenofovir alafenamide ftc taf dual nrti backbone combination be also review eu company work develop hiv drug be johnson johnson jnj free report company partner glaxo recently receive fda approval first drug regimen juluca discuss further company bill melinda gate foundation national institutes health be conduct efficacy study investigational mosaic hiv preventive vaccine study evaluate vaccine be safe be able reduce incidence hiv infection woman sub saharan africa hiv have significant unmet need woman girl account person live hiv eastern southern africa otherssome other popular market hiv drug be abbvie abbv free report kaletra merck mrk free report isentress mylan myl free report also recently receive tentative fda approval combination tablet comprise efavirenz lamivudine tenofovir disoproxil fumarate meanwhile merck be develop investigational nucleoside reverse transcriptase inhibitor doravirine single entity tablet combination fix dose tablet other antiretroviral agent lamivudine tenofovir disoproxil fumarate tdf company plan file regulatory application same end conclusionaid hiv be life threaten disease have limit medical cure however be numerous company be develop drug treatment care person suffering hiv be risk become infected hiv thereby make space competitive johnson johnson sport zack rank strong buy glaxo gilead carry zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pending medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2252,MRK,glaxosmithkline plc gsk free report share have decline year so far underperform increase witness industry british pharma consumer giant stock be rise trajectory announcement third quarter result oct call glaxo expressed interest purchase pfizer pfe free report consumer healthcare business latter plan put sale however glaxo interest buy pfizer unit raise investor concern acquirer possibly sacrifice portion dividend payment due potential buyout share decline sharply thereafter earning release share glaxo have decline earning estimate also witness decline past day meanwhile persistent challenge stiff competition genericization pricing pressure slow growth emerge market have be hurt sale pricing pressure competitive dynamic be hurt sale glaxo respiratory franchise particularly older product meanwhile top selling product advair be also expect face generic competition unite state next year further hurt sale mylan myl free report hikma pharmaceutical be look bring generic version advair unite staressale advair be already be adversely impact pricing competitive pressure unite state generic competition europe slowdown sale consumer healthcare segment year due slowdown global growth key consumer category be also concern however not everything be go wrong glaxo newer respiratory hiv drug vaccine be do well continue boost revenue new product generate glaxo pharmaceutical vaccine sale first month go ahead glaxo expect new pharmaceutical vaccine product include contribution shingrix deliver sale annum meanwhile glaxo have make significant progress late stage pipeline think glaxo possess stronger late stage pipeline large cap pharma company be focuse oncology immuno inflammation hiv respiratory therapeutic area company plan terminate partner divest pre clinical clinical program instead allocate capital priority program current area respiratory hiv infectious potential area oncology immuno inflammation recent back back approval new product trelegy ellipta only once daily single inhaler triple therapy copd shingrix vaccine prevention shingle juluca first dual treatment hiv have strengthen glaxo competitive position see glaxo strong pipeline consistent outperformance new hiv drug vaccine new product cost cut bring back track next year glaxo have zack rank hold see complete list today zack rank strong buy stock here large cap pharma stock have decline year be merck co inc mrk free report due several notable pipeline setback year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2253,MRK,investor merck co inc mrk free report need pay close attention stock base move option market lately be dec call have highest imply volatility equity option today be imply volatility imply volatility show much movement market be expect future option high level imply volatility suggest investor underlie stock be expect big move direction other also mean be event come soon cause big rally huge sell however imply volatility be only piece puzzle putt together option trading strategy do analyst think clearly option trader be pricing big move merck co share be fundamental picture company currently merck co be zack rank hold large cap pharmaceutical industry rank top zack industry rank last day analyst have increase earning estimate current quarter analyst have drop estimate net effect have take zack consensus estimate current quarter cent share cent period give way analyst feel merck co right now huge imply volatility mean trade develop often time option trader look option high level imply volatility sell premium be strategy many seasoned trader use capture decay expiration hope trader be underlie stock do not move much originally expect look trade option week very own dave bartosiak give top option trade check recent live analysis option trade nflx earning report completely free see here bartosiak trading netflix nflx earning option check embed video more detail
2254,MRK,gilead science inc gild free report report fourth quarter result earning revenue surpass expectation however management issue bleak view consequently stock decline market hour trading be expect open red give expectation further decline hepatitis virus hcv franchise nevertheless gilead stock have gain last month industry decline company fourth quarter earning share beat zack consensus estimate however earning be year quarter figure share moreover total revenue top zack consensus estimate however revenue decline year year gilead science inc price consensus gilead science inc price consensus gilead science inc quote harvoni sovaldi plunge furtherproduct sale come year year decline be due lower hcv sale partially offset higher sale hiv other therapeutic area antiviral product sale include gilead hiv liver disease portfolio come quarter hcv product sale include harvoni sovaldi epclusa vosevi be report year quarter downside be mainly attribute lower sale harvoni sovaldi major market sale harvoni decline year year quarter further sovaldi sale record steep year year decline epclusa garner sale quarter year figure meanwhile hiv hbv product sale come year year increase be primarily drive continuous strong uptake tenofoviral afenamide taf base product such genvoya generate sale year quarter descovy record sale odefsey register sale hiv treatment stribild complera eviplera sale decline respectively viread sale be atripla sale tank truvada sale fall other product letairis ranexa zydelig record sale respectively research development expense decline due impact ongoing milestone payment selling general administrative sg expense decrease adjust product gross margin be compare year period resultsrevenue come surpass zack consensus estimate earning share come beat zack consensus estimate guidancegilead now expect net product sale range adjust expense adjust sg expense be project range respectively adjust product gross margin be expect range company acquire kite pharma fda approval yescarta car therapy treatment adult patient relapse refractory large cell lymphoma more line systemic therapy gilead prospect company recently acquire cell design lab expand further car space dividend share gilead declare cash dividend cent share common stock first quarter increase dividend be payable mar stockholder record close business mar company paid cash dividend repurchase share company top earning revenue estimate fourth quarter magnitude decline hcv sale be larger expect hcv franchise be tremendous pressure due lower patient start increase competition expect sale decline further go forward note harvoni sovaldi epclusa face competition abbvie abbv free report viekira pak viekira xr bristol myer bmy free report merck mrk free report zepatier pricing market share be expect stabilize mid patient start be expect decline further meanwhile hiv franchise maintain momentum drive rapid adoption taf base regimen unite state eu taf base regimen now represent total gilead hiv prescription volume follow launch genvoya launch odefsey descovy truvada use pre exposure prophylaxis set also put strong performance company see significant uptick prep usage estimate patient used truvada end approval yescarta also bode well gilead expect decline hcv franchise offset positive momentum hiv franchise gilead be also intend foray nash market pipeline candidate selonsertib filgotinib zack rankgilead currently carry zack rank sell see complete list today zack rank strong buy stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2255,MRK,johnson johnson jnj free report present new datum large canvas outcome program type ii diabetes drug invokana sglt inhibitor demonstrate improve renal outcome datum be present annual meeting american heart association scientific session california publish circulation so far year johnson johnson share price have increase compare favorably rally industry belong new analysis canvas show reduction risk composite renal endpoint patient group history cv disease secondary prevention only risk factor cv disease primary prevention also invokana demonstrated reduction risk hospitalization due heart failure hhf patient group new adverse event be report additional analysis remind investor june company report datum canvas program demonstrated invokana be successful reduce risk cardiovascular cv outcome type ii diabetes patient have establish cardiovascular cv disease be risk cv disease invokana reduce major adverse cv event mace compare placebo mace be composite endpoint cv death fatal myocardial infarction fatal stroke however study also show drug increase risk amputation last month submit supplemental new drug application snda fda label expansion invokana include cardiovascular indication base datum canvas program many pharma company be work hard get label diabetes medicine update include cardiovascular benefit death cardiovascular disease be significantly higher adult diabetes compare addition positive cv outcome label diabetes drug give sale shot arm eli lilly company lly free report receive fda eu approval last year include cv risk reduction datum empa reg outcome study label jardiance additionally august nordisk nvo free report victoza liraglutide be approve fda new indication reduce risk major adverse cardiovascular cv event adult type ii diabetes establish cv disease however merck co inc mrk free report be deny approval fda include cardiovascular outcome datum tecos trial label dpp iv inhibitor januvia sitagliptin other medicine contain januvia astrazeneca bydureon also fail reduce cardiovascular risk phase iiib iv cardiovascular outcome study exscel johnson johnson price johnson johnson price johnson johnson quotezack rankjohnson johnson carry zack rank buy see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2256,MRK,world diabetes day be celebrate year november theme year be woman diabetes right healthy future focus be emphasize importance provide woman diabetic well risk be diagnosed diabetes affordable equitable access essential diabetes drug technology self management education information need achieve optimal diabetes outcome strengthen capacity prevent type ii diabetes ninth lead cause death woman world diabetes account death year accord information provide international diabetes foundation idf more woman have diabetes figure expect rise more woman be reproductive age birth be affected gestational diabetes gestational diabetes be associate higher risk type ii diabetes mother well child moreover many person type ii diabetes remain unaware condition long period time lead diabetes related complication time disease be diagnosed woman type ii diabetes be consider be time more likely suffer heart disease compare woman condition other diabetes related complication include blindness lower limb amputation kidney failure give statistic complication be not surprising several healthcare company devote significant amount dollar develop treatment device diabetes diabetes management diabetes market be highly crowd company come innovative treatment promising higher efficacy lower side effect currently available diabetes drug include different class treatment dpp inhibitor januvia onglyza trajenta glp receptor agonist victoza sglt invokana farxiga apart metformin insulin addition drug diabetes care market include glucose monitoring system insulin delivery system well insulin pump stock watch world diabetes world diabetes day here be look key pharma company diabetes market denmark base nordisk nvo free report be key player global diabetes market company diabetes portfolio comprise product tresiba once daily new generation insulin xultophy once daily single injection combination tresiba victoza ryzodeg soluble formulation tresiba novolog fiasp fast act mealtime insulin new formulation novolog victoza glp recent development include victoza tresiba label update victoza label now reflect prevention cardiovascular event tresiba eu label reflect significant reduction risk severe hypoglycemia well positive fda advisory panel vote semaglutide approval come later quarter however pricing pressure unite state remain major challenge diabetes care market intense competition globe also remain headwind share nordisk have gain year date significantly outperform industry rally nordisk be zack rank hold stock see complete list today zack strong buy rank stock here french drugmaker sanofi sny free report be key player diabetes market however company diabetes franchise be pressure key product lantus face increase competitive pressure payor level biosimilar competition several european market toujeo apidra amaryl lyxumia soliqua be other diabetes product company portfolio sanofi expect global diabetes sale decline annually constant exchange rate timeframe pricing pressure increase competition formulary exclusion continue impact segment challenge diabetes market sanofi continue work expand strengthen diabetes portfolio currently have diabetes candidate pipeline include sar glp gipr dual agonist phase type ii diabetes sar glp gcgr dual agonist phase ii type ii diabetes sotagliflozin oral sglt inhibitor phase iii type type ii diabetes sar rapid act insulin phase iii type ii diabetes efpeglenatide long act glp receptor agonist phase iii type ii diabetes schedule commence quarter late stage combination study sotagliflozin type ii diabetes be schedule commence quarter share sanofi be year date compare industry rally diabetes new cardiovascular metabolic disease be growth platform astrazeneca plc azn free report key product astrazeneca diabetes portfolio include farxiga onglyza bydureon other recent approval include improve device bydureon bydureon bcise combination farxiga bydureon type ii diabetes astrazeneca diabetes franchise sale unite state be also feel impact intense pricing pressure competition share astrazeneca zack rank stock be year date compare industry rally eli lilly company lly free report be well know player diabetes market lilly have strong portfolio diabetes treatment include trulicity glp jardiance sglt trajenta humulin basaglar humalog glyxambi company have diabetes alliance boehringer ingelheim several product lilly also have strong diabetes pipeline company expect pricing pressure continue diabetes market exclusion jardiance cvs health formulary also impact company diabetes franchise sale share lilly be year date compare industry rally lilly be also zack rank stock merck co inc mrk free report diabetes franchise account third quarter pharma segment sale consist product januvia janumet however peer merck diabetes segment sale continue be affected pricing pressure merck partner pfizer pfe free report be currently seek fda approval ertugliflozin fix dose combination product ertugliflozin januvia ertugliflozin metformin response fda expect december merck be also zack rank stock company share have decline year date compare industry rally diabetes market be currently face intense pricing pressure competition market remain lucrative consider grow prevalence disease demand new better treatment today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2257,MRK,inc agen free report have incur fourth quarter loss cent share wider zack consensus estimate loss cent year loss cent revenue miss zack consensus estimate however top line be prior year period so far year share have surge industry decline quarterly fourth quarter research development expense be general administrative expense be slightly pipeline updateagenus be progress well various candidate pipeline quarter review company commence phase ii combination trial ctla antibody agen combination merck mrk free report pd antibody keytruda patient first line small cell lung cancer nsclc have already complete dose escalation clinical trial ctla pd compound also launch phase ii combination study pd proprietary agent second line cervical cancer combo regimen assessment also support bla filing soon company make significant advancement novel immuno oncology antibody discover develop expect file investigational new drug ind application least antibody fact first ind filing be next generation ctla design deplete cancer prone treg improve cell prime company also report safety immunogenicity first synthetic neoantigen vaccine autosynvax asv combination study asv company own checkpoint antibody be plan company report loss narrower loss figure be however wider zack consensus estimate loss revenue come year year however top line miss zack consensus estimate inc price consensus ep surprise inc price consensus ep surprise inc quotezack rank key picksagenus have zack rank hold better rank stock same space be regeneron regn free report ligand pharmaceutical lgnd free report regeneron sport zack rank strong buy ligand carry zack rank buy see complete list today zack rank stock here regeneron earning share estimate have moved last day company pull positive earning surprise last quarters average beat be ligand earning share estimate rise respectively last day company deliver positive surprise trail quarters average beat share price company have soar year time hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2258,MRK,value investing be easily most popular way find great stock market environment wouldn want find stock be fly radar be compelling buy offer tantalize discount compare fair value way find company be look several key metric financial ratio many be crucial value stock selection process let put merck co inc mrk free report stock equation find be good choice value oriented investor right now investor subscribe methodology look elsewhere top pick pe ratioa key metric value investor always look be price earning ratio pe short show much investor be willing pay dollar earning give stock be easily most popular financial ratio world best use pe ratio be compare stock current pe ratio ratio have be past compare average industry sector compare market whole front merck co have trail month pe ratio see chart level actually compare pretty favorably market large pe stand focus long term pe trend merck co current pe level put midpoint past year moreover current level be fairly high stock suggest be good entry point further stock pe also compare favorably industry trail month pe ratio stand very least indicate stock be relatively undervalue right now compare peer also point merck co have forward pe ratio price relative year earning just so be fair say slightly more value oriented path be ahead merck co stock term too ratioanother key metric note be price sale ratio approach compare give stock price total sale lower read be generally consider better person metric more other value focuse one look sale something be far harder manipulate accounting trick earning right now merck co have ratio be marginally higher average come right now nonetheless see chart be well high stock particular past few year anything mrk be lower end range time period metric suggest level undervalue trading least compare historical norm broad value outlookin aggregate merck co currently have zack value style score putt top stock cover look make merck co solid choice value investor other key metric make pretty clear too example cf ratio great indicator value come be far better industry average clearly mrk be solid choice value front multiple angle stock overall merck co be good choice value investor be plenty other factor consider investing name particular be worth note company have growth grade momentum score give mrk zack vgm score overarch fundamental grade read more zack style score here meanwhile company recent earning estimate have be encourage current quarter have see estimate revision past day full year estimate have see upward downward revision same time period result current quarter consensus estimate have rise past month full year estimate have increase see consensus estimate trend recent price action stock chart merck company inc price consensus merck company inc price consensus merck company inc quoteeven merck co have better estimate trend stock have just zack rank hold be be look line performance company term bottom linemerck co be inspire choice value investor be hard beat incredible lineup statistic front furthermore robust industry rank top boost investor confidence however past year industry have underperform broader market see poor past performance industry good industry rank signal stock be likely benefit favorable broader factor immediate future add positive estimate revision robust value metric believe have strong value contender merck co hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2259,MRK,drug pricing issue cripple performance last year drug biotech industry small correction recently have witness turnaround year stock large market cap have do particularly well decline last year large cap pharma industry have rise year so far number thing go favor strong quarterly result new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval continue strong performance legacy product play pivotal role bring large cap drug sector back track year most drug company larger market cap have see share price rise year astrazeneca azn free report nordisk nvo free report novartis nvs free report johnson johnson jnj free report have even outperformed industry however couple large cap pharma company have witness downside year discuss merck co inc mrk free report merck be very few company share be last year notwithstanding industry decline other way round year share merck have decline year so far merck have suffer notable pipeline setback year october merck decide not seek approval cetp inhibitor anacetrapib cholesterol management clinical profile be not strong enough support regulatory filing last month company also announce delay readout important lung cancer study be due inclusion overall survival co primary endpoint keynote phase iii study keytruda first line lung cancer raise investor concern delay readout give competitor chance gain strength lung cancer market october merck also withdraw regulatory application europe be look get keytruda approve first line combination therapy lung cancer september merck discontinue development hcv combination program mk mk say hcv market be become extremely crowd also combination study keytruda multiple myeloma be place clinical hold follow report death keytruda group july keytruda be see key long term growth driver merck such setback do not bode well company remain be see strong performance new drug particularly keytruda strong vaccine animal health business cost save effort help merck pick here glaxosmithkline plc gsk free report share glaxo be year so far stock be rise trajectory announcement third quarter resultson oct third quarter conference call glaxo expressed interest purchase pfizer pfe free report consumer healthcare business latter plan put sale however glaxo interest buy pfizer unit raise investor concern acquirer possibly sacrifice portion dividend payment due potential buyout share decline sharply thereafter meanwhile persistent challenge stiff competition genericization pricing pressure slow growth emerge market have be hurt sale pricing pressure competitive dynamic be hurt sale glaxo respiratory franchise particularly older product meanwhile top selling product advair be also expect face generic competition unite state next year further hurt sale slowdown sale consumer healthcare segment year be also concern see glaxo strong pipeline consistent outperformance new hiv drug vaccine new product trelegy ellipta shingrix juluca have boost portfolio lately cost cut bring back track next year merck glaxo have zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2260,MRK,share immunogen inc imgn free report have be massively year so far outperform industry register increase let analyze factor lead rally immunogen rapid pipeline progress positive readout strategic collaboration have push share price consistently immunogen have make significant progress regard lead pipeline candidate mirvetuximab soravtansine year candidate be be evaluate phase iii study forward single agent therapy treat patient platinum resistant ovarian cancer company have presently activate site enrolment trial aim complete middle also candidate be be evaluate phase expansion cohort ovarian cancer patient company report positive datum study demonstrated promising safety efficacy profile candidate meanwhile combination regimen mirvetuximab soravtansine ovarian cancer be also be evaluate phase ib ii forward ii study forward ii trial consist cohort assess mirvetuximab soravtansine combination roche rhhby free report avastin merck mrk free report keytruda immunogen have report initial datum study show mirvetuximab soravtansine potential complement currently available therapy indication approval combination regime significantly expand eligible patient population mirvetuximab soravtansine approval mirvetuximab soravtansine be huge boost immunogen give immense commercial potential target market ovarian cancer result maximum annual death gynecologic cancer majority patient diagnosed advanced stage datum provide american cancer society approximately new case ovarian cancer be diagnosed unite state result more death apart mirvetuximab soravtansine immunogen be work develop couple other clinical pre clinical candidate include imgn imgn notably imgn be be evaluate phase study treat acute myeloid leukemia aml datum expect later year other hand company plan move imgn clinical development year end treat hematological malignancy include aml immunogen have agreement several big healthcare company include amgen bayer eli lilly lly free report novartis roche sanofi takeda contract allow other company use immunogen adc technology provide fund form license milestone fee royalty clinical material revenue support fee notably august immunogen have announce strategic collaboration option agreement jazz pharmaceutical development candidate adc program imgn imgn pursuant deal immunogen be eligible receive milestone payment base certain pre decide condition platinum resistant ovarian cancer market offer immense commercial potential immunogen be notably set face intense competition approval however mirvetuximab soravtansine look promising juncture approval be big lift company immunogen carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2261,MRK,seattle genetic inc sgen free report report loss cent share fourth quarter narrower zack consensus estimate cent wider year quarter loss cent share revenue come year year primarily back strong sale adcetris revenue also beat zack consensus estimate however seattle genetic share have lose past year compare industry decline same period quarter detailseattle genetic top line comprise product revenue collaboration license agreement revenue royalty company only market product adcetris generate product sale significant year year collaboration license agreement revenue increase almost mainly drive strong demand adcetris international market collaboration revenue include fee earn company agreement japan base takeda pharmaceutical adcetris other adc collaboration royalty revenue increase almost year year attributable higher international sale adcetris takeda pharmaceutical co research development expense be year year also selling general administrative sg expense increase cost be high primarily due investment development adcetris other indication company provide outlook total revenue range expect collaboration license agreement revenue be range royalty be expect range net sale adcetris be expect range company have not include impact potential line extension drug frontline advanced classical hodgkin lymphoma approval be expect company anticipate expense be sg expense be expect range rise sg likely be due inclusion expand commercial activity related potential line extension adcetris pipeline updateseattle genetic continue work expand adcetris label further phase iii study november fda approve expansion adcetris label include cutaneous cell lymphoma january drugwa also approve similar indication europe moreover fda have grant priority review supplemental biologic license application sbla seek approval include frontline advanced classical hodgkin lymphoma label sbla be file base datum phase iii study echelon show adcetris achieve statistically significant improvement modify progression free survival decision be expect moreover top line datum echelon study frontline cd express mature cell lymphoma be separate study be also evaluate adcetris combination bristol myer squibb bmy free report opdivo relapse refractory classical hodgkin lymphoma addition company be evaluate enfortumab vedotin pivotal phase ii study patient metastatic urothelial cancer patient moreover november seattle genetic astella pharma initiate phase ib study evaluate candidate combination cpi therapy include merck mrk free report keytruda pembrolizumab patient locally advanced metastatic urothelial cancer first second line set company be plan initiate phase iii study seattle genetic germany base genmab be plan initiate phase ii study evaluate tisotumab vedotin recurrent metastatic cervical cancer metastatic cervical cancer treatment nave woman range other solid tumor type company be evaluate pipeline candidate polatuzumab vedotin diffuse large cell lymphoma study be be conduct collaboration genentech member roche hold ag rhhby free report other activitiesin bid boost pipeline company enter definitive merger agreement last month acquire cascadian therapeutic acquisition add pivotal stage positive metastatic breast cancer candidate tucatinib pipeline company fourth quarter loss be narrower estimate sale also beat expectation give positive development adcetris investor focus update label expansion approval hodgkin lymphoma indication year boost sale further datum clinical study other pipeline candidate be also expect year seattle genetic inc price consensus ep surprise seattle genetic inc price consensus ep surprise seattle genetic inc quoteseattle genetic carry zack rank sell see complete list today zack rank strong buy stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2262,MRK,sanofi sny free report report fourth quarter earning cent american depositary share miss zack consensus estimate cent earning decline report basis constant currency rate cer earning decline fourth quarter net sale decline report basis almost sale also miss zack consensus estimate unfavorable exchange rate movement hurt sale cer sale rise year year january french drug maker swap merial animal health business boehringer ingelheim consumer healthcare chc business reflect exchange full consolidation sanofi european vaccine operation sale decline constant structure cs cer basis sale decline cer unite state however sale rise emerge market europe rest world japan south korea canada australia new puerto rico growth rate mentioned be year year basis cer segmental sale include emerge market decline however cs cer pharmaceutical sale rise sanofi report global business unit gbus sanofi genzyme specialty care diabetes cardiovascular general medicine emerge market consumer healthcare sanofi pasteur vaccine sanofi genzyme specialty care gbu sale include emerge market increase drive contribution new immunology drug dupixent kevzara higher sale multiple sclerosis ms rare disease drug sale ms drug aubagio rise sale lemtrada go meanwhile sale rare disease drug myozyme lumizyme improve fabrazyme sale be cerdelga sale come cerezyme sale rise oncology sale rise jevtana sale be thymoglobulin record sale flat year year taxotere sale be also flat eloxatine sale be sanofi regeneron pharmaceutical inc regn free report rheumatoid arthritis ra drug kevzara sarilumab be launch unite state june unite kingdom netherlands germany europe second half kevzara record sale quarter compare previous quarter meanwhile dupixent dupilumab treat atopic dermatitis be launch unite state march approve eu september december sanofi launch dupixent germany dupixent generate sale fourth quarter compare previous quarter kevzara dupixent generate total immunology sale fourth quarter much higher previous quarter diabetes cardiovascular gbu include emerge market decline diabetes franchise include emerge market decline due lower sale key drug lantus sale diabetes drug unite state decline due tough payer environment difficult year year comparison sale diabetes drug emerge market be europe rise lantus sale decline quarter lantus sale decline unite state due lower average net price exclusion cvs unite health formulary plan europe sale decline due biosimilar competition patient switch toujeo toujeo generate sale report quarter year year basis due difficult year comparison rise sequentially soliqua once daily titratable fix ratio combination lantus lyxumia be launch unite state january european country trade name suliqua soliqua suliqua generate sale quarter compare previous quarter cardiovascular franchise sanofi pcsk therapy praluent garner worldwide sale report quarter compare previous quarter general medicine emerge market gbu sale come sale establish product be strong performance emerge market be offset lower sale europe generic competition plavix japan renvela renagel unite state sale generic decline due lower sale europe emerge market consumer healthcare gbu sale be sale be exclude acquisition boehringer ingelheim consumer healthcare business drive higher sale europe unite state offset slight decline emerge market fourth quarter consolidated sanofi pasteur vaccine sale increase vaccine sale reflect termination sanofi pasteur msd joint venture merck mrk free report europe december vaccine segment lower sale emerge market unite state offset sale growth europe emerge market vaccine sale decline due phase effect hexaxim pediatric vaccine sale buyback unused dose sanofi dengue vaccine dengvaxia follow unfavorable label update announce november sanofi be face issue dengvaxia due safety concern november sanofi have reveal person have never be infected dengue virus vaccination dengvaxia subsequent dengue infection increase risk severe disease response december philippine fda ask company suspend sale distribution marketing dengvaxia withdraw market pending compliance directive agency unite state lower sale pediatric booster vaccine result decline cost risesel general administrative expense sg increase cer quarter reflect launch cost dupixent kevzara additional cost china expense be cer reflect higher pipeline development cost oncology isatixumab pd sotagliflozin full year resultsfull year earning american depositary share also miss zack consensus estimate share earning decline report basis cer earning decline be almost line sanofi expectation remain more less flat cer basisnet sale rise report basis cer almost sale however miss zack consensus estimate outlooksanofi expect business earning grow cer anticipate negative currency impact range business earning however guidance include impact recently announce pending acquisition belgian nanobody maker ablynx small biotech focuse make therapy hemophilia bioverativ inc acquisition strengthen sanofi position rare blood disorder market takesanofi fourth quarter result be expectation miss estimate earning sale higher sale multiple sclerosis rare disease drug significant contribution dupixent strong performance europe be offset continue weakness diabetes franchise lower vaccine sale emerge market unite state share sanofi be more pre market trading past year sanofi share have return underperform increase industry however sanofi outlook look upbeat expect return growth year back bioverativ ablynx deal strong pipeline lower tax rate new tax law sanofi carry zack rank hold see complete list today zack rank strong buy stock here sanofi price consensus ep surprise sanofi price consensus ep surprise sanofi quotezack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2263,MRK,dow traverse difficult week decline consecutive trading session investor remain concern prospect trade war follow president trump decision impose tariff steel aluminum import trump decision dismiss secretary state rex tillerson add investor jitter ultimately investor look pick blue chip stock dip help index finish green thursday last week dow increase last friday move past mark first time feb upbeat job datum lower wage growth subdue inflationary concern curb rate hike fear economy add job february exceed consensus estimate job addition however average hourly wage rise only february lower january increase index gain last week president trump sign tariff plan law fresh levy steel import aluminum import be impose however plan exclude country canada mexico offer trump chance renegotiate term nafta country also unite state want discuss national security issue country dow index decline monday investor remain concern prospect trade war follow trump decision impose tariff steel aluminum fear nature drag industrial lower session decline weigh broader market dow component sector unite technology corporation utx free report company mmm free report boee company ba free report decline respectively index lose tuesday trump administration dismiss secretary state rex tillerson additionally trump order broadcom inc avgo free report abandon plan takeover qualcomm incorporate qcom free report follow share qualcomm decline weigh broader market meanwhile consumer price index cpi increase february line consensus estimate figure be lower january increase development significantly reduce rate hike fear index decrease wednesday end red third consecutive trading day follow concern possible trade war china hostile move china jeopardize boee performance be share fall weigh dow register day decline point share decline index rebound thursday increase special counsel robert mueller reportedly subpoena trump organization trump business related document factor trade war fear weigh investor sentiment however dow manage post day rise point investor indulge bargain hunting seek blue chip stock dip dow component unitedhealth group incorporate unh free report increase be biggest contributor blue chip index gain day component move index apple inc aapl free report be likely come new version io maco annual worldwide developer conference wwdc set begin jun company announce session involve technical design focuse session present zack rank hold apple engineer help build next generation apps used newly announce apple technology apart software announcement company well make big announcement related hardware apple keep sale be now rumore launch variant iphone notably company be also rumore be work new high end noise cancele ear headphone upgrade version airpod advanced siri integration next generation smart speaker homepod face id technology read apple announce wwdc date expectation rise boee lockheed martin corp lmt free report joint venture unite launch alliance ula subsidiary have secure contract satellite launch service term unite launch service llc ul subsidiary deliver afspc afspc satellite intend orbit award contract division launch system enterprise directorate space missile system center los angele air force base be value modification contract ul carry launch vehicle production mission integration launch operation spaceflight certification afspc afspc mission operation be complete march deliver afspc satellite afspc satellite be deliver post completion operation june stock have zack rank strong buy see complete list today zack rank strong buy stock here chevron corporation cvx free report phillip psx free report joint venture jv chevron phillip chemical company lp recently announce be ready put new ethane cracker locate cedar facility baytown tx work get delay due hurricane harvey chevron have zack rank company launch feedstock start operation new cracker be primarily schedule come online end company new facility most energy efficient cracker have production capacity metric ton annum new ethane cracker construction be start completion mark finishing final phase company gulf coast petrochemical project facility be expect increase company ethylene polyethylene production capacity read chevron phillip bring new ethane cracker texas online merck co inc mrk free report announce supplemental biologic license application sbla pd therapy keytruda have be accept priority review fda latest application zack rank merck be look expand label keytruda treatment advanced cervical cancer disease progression chemotherapy fda grant priority review decision be expect jun be first time fda have accept filing pd therapy cervical cancer meanwhile be fourteenth regulatory submission keytruda accept fda sbla be base part datum phase ii keynote study read merck keytruda get priority review cervical cancer pfizer inc pfe free report announce positive outcome fda drug advisory committee gidac meeting discuss company supplemental new drug application snda look label expansion xeljanz tofacitinib zack rank buy pfizer be seek get xeljanz approve treatment adult patient moderately severely active ulcerative colitis uc xeljanz janus kinase jak inhibitor be already approve treat rheumatoid arthritis active psoriatic arthritis supplemental new drug application snda xeljanz be currently review fda read pfizer get fda panel back new indication xeljanz walmart inc wmt have expand online grocery delivery service more metro region unite state announcement follow recent launch various kitchen product meal kit expansion strategy enable zack rank walmart reach nearly nation household end year currently service be available market initiative be expect provide consumer more accessibility walmart flourishing online grocery delivery service read walmart strengthen grocery delivery plan expansion performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have lose next week outlookmarket be pass difficult time primarily due development related trump administration president trump have fire several key official recently add atmosphere uncertainty instability meanwhile decision impose tariff pronouncement china have weigh big industrial name give backdrop investor look likely look key economic release such gdp report comfort next week more stock news company verge apple run do miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
2264,MRK,merck co inc mrk free report announce supplemental biologic license application sbla pd therapy keytruda have be accept priority review fda latest application merck be look expand label keytruda treatment advanced cervical cancer disease progression chemotherapy fda grant priority review decision be expect jun be first time fda have accept filing pd therapy cervical cancer meanwhile be fourteenth regulatory submission keytruda accept fda sbla be base part datum phase ii keynote study year so far merck share have underperform industry merck share have decline period increase industry keytruda be second largest product merck portfolio be market many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma gastric cancer bladder cancer microsatellite instability high msi mismatch repair deficient cancer treatment fetch sale almost year year upside be drive global launch new indication further boost demand keytruda sale be gain particularly strong momentum first line lung cancer indication be only pd approve first line set monotherapy well combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo keytruda development program also significantly advanced several regulatory approval unite state europe japan new approval expand patient population drive sale last year positive momentum be expect continue well meanwhile keytruda be be study more type cancer more study include excess combination study merck be collaborate several company include amgen amgn free report incyte glaxo gsk free report pfizer separately evaluation keytruda combination other regimen merck carry zack rank hold see complete list today zack rank strong buy stock here breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2265,MRK,bristol myer squibb company bmy free report announce pd immune checkpoint inhibitor opdivo combination yervoy demonstrated superiority improve progression free survival pfs phase iii lung cancer study positive datum again show blockbuster potential opdivo be already approve multiple indication be also be evaluate several other share company have return past year outperform industry gain period phase iii study checkmate be evaluate opdivo monotherapy combination regimen squamous squamous advanced small cell lung cancer nsclc first line set study be be conduct part datum be announce part study evaluate combination regimen overall survival os patient tumor express pd pfs patient high tumor mutation burden tmb regardless pd expression datum show regimen significantly improve pfs patient compare chemotherapy however datum monitoring committee have recommend continue study overall survival endpoint base interim analysis be first study evaluate combination regimen immune oncology drug first line nsclc patient high tmb part study be evaluate opdivo combination chemotherapy broad patient population remind investor combination regimen have achieve durable clinical benefit phase ii study patient dna mismatch repair deficient microsatellite instability high metastatic colorectal cancer please note merck mrk free report pd immunotherapy keytruda be approve first line nsclc datum announce late stage study january show keytruda combination eli lilly company lly free report alimta result significantly improve os pfs metastatic squamous nsclc patient bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quotezack rank stock considerbristol myer carry zack rank hold exelixis inc exel free report be better rank stock pharma sector carry zack rank buy see complete list today zack rank strong buy stock here exelixis earning estimate increase cent cent last day company deliver positive earning surprise trail quarters average beat stock be past year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2266,MRK,merck co inc mrk free report report fourth quarter adjust earning cent share beat zack consensus estimate cent earning rise year year slightly higher sale lower taxe higher other income make higher cost quarter include provision related tax reform fourth quarter loss share be cent compare loss cent share fourth quarter revenue quarter rise year year sale however slightly miss zack consensus estimate currency movement positively impact revenue exclude currency impact sale rise year year lose sale market due network cyber attack june hurt top line however sale quarter be boost addition sale terminate december vaccine joint venture sanofi sny free report europe approximately quarter pharmaceutical segment generate revenue exclude fx impact year year continue strong sale pd inhibitor keytruda bridion offset lower sale key vaccine hpv vaccine gardasil gardasil unite state zostavax prevention shingle previous quarters loss market exclusivity several drug also hurt top line keytruda second largest product merck portfolio bring sale fourth quarter sequentially year year sale continue be drive launch new indication globally keytruda sale be gain particularly strong momentum indication first line lung cancer be only pd approve first line set keytruda be already approve many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer keytruda development program also significantly advanced regulatory approval new indication unite state europe japan approval expand patient population drive sale higher zepatier bring sale previous quarter bridion sugammadex injection generate sale quarter year year drive strong demand meanwhile combine sale remicade lose exclusivity europe face stiff biosimilar competition region cancida lose exclusivity europe zetia lose market exclusivity unite state december vytorin lose exclusivity april decline quarter remicade sale decline quarter merck market brand version remicade outside unite state johnson johnson jnj free report market rheumatoid arthritis drug country cancida sale plunge quarter zetia vytorin franchise record sale due loss exclusivity zetia vytorin sale isentress also decline quarter januvia janumet diabetes franchise remain soft quarter januvia janumet franchise record sale quarter year quarter higher global volume partially offset impact continue pricing pressure isentress sale decline quarter lower volume demand due competitive pressure hurt sale isentress gardasil gardasil sale rise lower sale unite state be offset commercial launch china strong growth europe unfavorable timing public sector purchasing partial replenishment borrow dose gardasil gardasil center disease control prevention cdc adversely impact gardasil sale unite state however sale rise europe be boost addition sale terminate vaccine joint venture sanofi zostavax sale decline quarter face strong competition glaxo gsk free report newly approve shingle vaccine shingrix merck animal health segment generate revenue exclude fx impact year quarter primarily drive higher sale companion animal product primarily bravecto companion animal vaccine growth ruminant business gross margin decline cost increase adjust gross margin come basis point bps year quarter marketing administrative expense be flat report quarter research development spend increase quarter due increase investment pipeline early drug development higher business development expense also raise cost quarter resultsfull year sale miss zack consensus estimate revenue be guidance range sale rise year year adjust earning be share beat zack consensus estimate share well guidance range earning rise year year guidancerevenue be expect range zack consensus estimate stand revenue guidance include approximately positive impact currency fluctuation company expect adjust earning range zack consensus estimate be peg share adjust earning guidance include approximately negative impact currency fluctuation adjust operate expense be expect increase year year low mid single digit rate merck also say expectation improve cash position follow tax reform plan invest approximately next year capital expenditure approximately investment be make unite state takemerck fourth quarter result be mixed company beat estimate earning miss same sale also issue line guidance share be slightly pre market trading past year merck share have underperform industry merck share have decline period compare unfavorably increase industry eye be performance keytruda be be tout key long term growth driver merck drug continue robust performance strong demand trend however significant decline sale zostavax due rise competitive pressure be concern meanwhile generic competition several drug pricing pressure continue be overhang top line merck carry zack rank hold see complete list today zack rank strong buy stock here breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2267,MRK,happy groundhog day see first friday almost month new farm payroll bureau labor statistic bls have be release open bell come conjunction tonnage new earning report yesterday market close today open headline be better expect not huge surprise new job create january unemployment rate remain steady number be higher analyst consensus roughly analyst month have be expect new job be adp adp free report payroll report release wednesday morning show new job just private sector alone typically however adp bls number do tend align future revision initially be often far apart pre market trading have be deep red ahead bls announcement claw back point dow only plummet back point follow news time last minute so market have again work climb early hole meanwhile year bill race past follow release job datum not be anything particularly grieve today job report construction post biggest improvement sector compare year new job aka real unemployment fall lowest ve see quite time otherwise figure come much expect aside predict unemployment rate average hourly earning be again positive tepid year year consistent labor force participation rate finally december bls total be revise upward be slightly offset november revision originally announce earning roundupfollow yesterday afternoon modest beat apple aapl free report amazon amzn free report biggest profit history alphabet googl free report earning miss tax adjustment today bell bring full load earning report exxonmobil xom free report miss top bottom line estimate bring cent share zack consensus revenue expect zack rank hold company have now miss earning estimate last quarters more xom earning click here phillip psx free report downstream oil gas play easily top expectation quarter share outpaced cent anticipate far ahead zack consensus more psx earning click here estee lauder el free report also surpass expectation share revenue beating share be look quarter be assist double digit growth skincare makeup fragrance category more el earning click here merck mrk free report top estimate cent cent share come short revenue estimate opposed expect generic competition have affected big pharma dow component quarter more mrk earning click here merck competitor astrazeneca azn free report also face generic competition top selling drug manage top earning revenue expectation cent share outperformed cent sale easily beat anticipate more azn earning click here
2268,MRK,discourage result phase ii study evaluate abbvie abbv free report promising cancer candidate rovalpituzumab tesirine rova third line later small cell lung cancer sclc grab headline week other news include purchase offer jnj free report diabetes device unit successful study result announce heron therapeutic hrtx free report roche rhhby free report recap week most important storiesabbvie rova fall short key lung cancer study abbvie promising cancer candidate rovalpituzumab tesirine rova fall short expectation phase ii trinity study evaluate third line later small cell lung cancer sclc abbvie say not seek accelerate approval rova third line set consult fda rova be add abbvie portfolio follow acquisition stemcentrx june abbvie have significant confidence rova potential failure trinity have raise skepticism rova potential have bring question viability stemcentrx deal read more abbvie stock fall weak lung cancer study outcome get offer lifescan unit say have receive bound offer private equity firm platinum equity lifescan diabetes device unit have time jun offer fail expire have be evaluate potential strategic option diabetes care unit specifically lifescan corporation calibra medical early last year read more get offer lifescan diabetes device unit pfizer get fda priority review expand label xtandi pfizer pfe free report japanese partner astella gain fda priority review regulatory filing be look expand label prostate cancer drug xtandi include early stage patient population regulatory application add metastatic castration resistant prostate cancer crpc indication drug label be base result prosper study xtandi fda grant priority review decision be expect july read more pfizer xtandi label expansion filing get priority review meanwhile british company reckitt benckiser group pull discussion pfizer buy latter consumer health segment last october pfizer have say be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction decision regard same be expect be make year ultimately opt retain business glaxo also say have withdraw race buy pfizer unit heron htx succeed phase iii heron therapeutic pipeline candidate htx meet primary endpoint pivotal phase iii study evaluate post operative pain control follow bunionectomy hernia repair respectively top line datum study show treatment htx lead statistically significant reduction pain intensity opoid use hour follow surgery candidate be also superior bupivacaine solution be current standard care local anesthetic postoperative pain control read more heron pain candidate meet endpoint pivotal studiesroche tecentriq succeed lung cancer combo study roche tecentriq meet co primary endpoint progression free survival phase iii study evaluate pd inhibitor combination chemotherapy carboplatin abraxane first line treatment advanced squamous small cell lung cancer nsclc tecentriq be already market treatment second line metastatic nsclc label expansion first line set boost drug sale further however roche await overall survival datum study continue read more roche tecentriq phase iii combo study meet primary endpoint novartis tasigna get fda nod label expansion novartis nvs free report leukemia drug tasigna be grant fda approval use pediatric year age older population first second line treatment philadelphia chromosome positive chronic myeloid leukemia chronic phase ph cml cp glaxo begin new combo study benlysta glaxo gsk free report have initiate late stage study bliss believe evaluate systemic lupus erythematosus medicine benlysta combination roche rituxan benlysta previous late stage study have demonstrated consistent efficacy reduce disease activity sle aim new combination study be achieve clinical remission sle patient apart demonstrate low disease activity read more glaxosmithkline initiate phase iii combo study nyse arca pharmaceutical index decline last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr returnhere be major stock perform week astrazeneca azn free report be only stock record gain last trading session decline bristol myer bmy free report be last month astrazeneca be biggest gainer merck mrk free report be biggest loser decline see last pharma stock roundup here abbv elagolix meet study goal mrk keytruda focus next pharma world watch regulatory pipeline news pharma stock look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2269,MRK,merck co inc mrk free report announce committee medicinal product veterinary use cvmp have recommend marketing authorization europe bravecto spot combination topical solution fluralaner moxidectin cat bravecto be part company animal health unit company share be so far year industry gain period veterinary medicinal product approval be used treatment internal external parasite infestation tick flea heartworm roundworm hookworm cat drug start kill activity tick flea immediately continue week prevent heartworm disease week bravecto be first approve chewable tablet formulation dog spot version be launch topical solution dog cat unite state bravecto be major growth driver animal health unit due rise demand formulation bravecto be ultimately approve eu sale product increase further however product company animal health unit face competition product other company zoetis inc zts free report eli lilly company lly free report elanco generic product merck co inc price merck co inc price merck co inc quotezack rank stock considermerck currently carry zack rank hold pfizer inc pfe free report be better rank stock pharma sector carry zack rank buy see complete list today zack rank strong buy stock here pfizer earning estimate increase last day company deliver positive earning surprise trail quarters average beat hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
2270,MRK,seattle genetic inc sgen free report announce fda have approve supplemental biologic license application seek label expansion adcetris include treatment treatment naive stage iii iv classical hodgkin lymphoma chl combination chemotherapy decision come more month earlier expect fda also approve conversion accelerate approval adcetris regular approval treatment systemic anaplastic large cell lymphoma salcl patient have fail least multus agent chemotherapy regimen therapy approval come basis head head study echelon adcetris chemotherapy compare current standard care seattle genetic share have return so far year industry decline period phase iii echelon study evaluate adcetris combination chemotherapy regimen avd adriamycin vinblastine dacarbazine abvd adriamycin bleomycin vinblastine dacarbazine current standard care chemotherapy regimen treatment newly diagnosed advanced chl datum study show adcetris combination therapy achieve statistically significant improvement progression free survival pfs compare abvd combination therapy reduce risk progression death need additional anticancer therapy patient do not achieve complete remission overall survival os rate be favorable adcetris regimen however do not show significant difference complete remission be achieve patient treat adcetris regimen compare abvd therapy american cancer society approximately half newly diagnosed patient hodgkin lymphoma unite state have stage iii iv disease adcetris be already approve indication include second later line treatment chl drug be only market drug company major revenue generator label expansion certainly boost prospect go forward however drug have several competitor include bristol myer squibb bmy free report opdivo merck mrk free report keytruda be approve relapse refractory chl seattle genetic inc price seattle genetic inc price seattle genetic inc quotezack rank stock considerseattle genetic currently carry zack rank sell horizon pharma public limit company hznp free report be better rank stock pharma sector carry zack rank buy see complete list today zack rank strong buy stock here horizon pharma earning estimate increase last day company deliver positive earning surprise trail quarters average beat make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2271,MRK,roche hold ag rhhby free report subsidiary genentech announce phase iii study evaluate combination pd inhibitor tecentriqplus chemotherapy carboplatin abraxane first line treatment advanced lung cancer meet co primary endpoint progression free survival pfs impower study show combination reduce risk disease worsening death pfs compare chemotherapy alone initial treatment patient advanced squamous small cell lung cancer nsclc however result do not show statistically significant overall survival os benefit hence study be continue interim datum be present upcoming oncology congress year share roche have decline industry growth tecentriq be market treatment second line metastatic nsclc label expansion first line set boost drug sale further tecentriq be also approve treatment patient suffering locally advanced metastatic urothelial carcinoma muc be not eligible cisplatin chemotherapy drug recore sale chf february roche announce positive result phase iii immotion study tecentriq combination oncology drug avastin bevacizumab first line treatment advanced metastatic renal cell carcinoma study meet co primary endpoint investigator assessed pfs patient disease expressed pd protein result show patient receive tecentriq avastin have reduce risk disease worsening death pfs compare person treat sutent remind investor merck mrk free report pd inhibitor keytruda be approve fda monotherapy combination lilly lly free report alimta carboplatin first line treatment patient metastatic nonsquamous nsclc roche hold ag price roche hold ag price roche hold ag quote zack rank stock considerroche carry zack rank buy top rank stock same space be regeneron pharmaceutical regn free report sporting zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved last day company pull positive earning surprise last quarters average beat today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2272,MRK,issue update report immune design corp imdz free report mar company be currently develop several candidate field immuno oncology base zvex glaas platform company key pipeline candidate be cmb cmb be be evaluate soft tissue sarcoma patient monotherapy phase combination roche rhhby free report pdl cancer immunotherapy tecentriq phase ii company have favorable meeting fda regard cmb have plan initiate pivotal phase iii trial evaluate cmb monotherapy synovial sarcoma patient mid patient be randomize co primary endpoint progression free survival pfs overall survival pfs endpoint be meet company intend file biologic license application seek approval cmb treatment synovial sarcoma be be evaluate multiple clinical trial include monotherapy local radiation complete phase study patient mcc ongoing investigator sponsored trial patient sarcoma be also be develop monotherapy combination therapy patient follicular hodgkin lymphoma randomize phase ib ii study monotherapy phase ib portion trial be evaluate local radiation randomize phase ii portion trial be evaluate local radiation combination pd agent keytruda pursuant collaboration merck mrk free report potential approval pipeline candidate be boost company immune design share have underperform industry year stock decline industry gain company have strategic agreement company sanofi sny free report roche merck not only validate glaas platform also provide company fund form collaboration license revenue such collaboration boost pipeline development dependence other company generate revenue increase concern immune design corp price immune design corp price immune design corp quote zack rank immune design carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2273,MRK,week be relatively light far development pharma sector be concern key highlight be priority review merck mrk free report keytruda advanced cervical cancer delay final datum astrazeneca azn free report key lung cancer study success abbvie abbv free report late stage study breakthrough therapy designation jnj free report cancer candidate recap week most important delay final datum mystic study final overall survival datum astrazeneca pivotal phase iii mystic study imfinzi first line lung cancer indication have be delay second half year datum be previously expect be present first half july last year study fail meet primary endpoint progression free survival read more astrazeneca final datum key lung cancer study delay merck keytruda get priority review indication merck supplemental filing look expand label pd therapy keytruda treat advanced cervical cancer have be accept priority review fda decision be expect jun be regulatory submission keytruda accept fda read more merck keytruda get priority review cervical cancer abbvie second late stage study elagolix meet endpoint abbvie neurocrine bioscience second pivotal phase iii study pipeline candidate elagolix meet primary endpoint elaris uf ii study be evaluate elagolix reduce heavy menstrual bleed premenopausal woman uterine fibroid datum study demonstrated elagolix combination low dose add back therapy reduce heavy menstrual bleed woman uterine fibroid compare placebo month read more abbvie uterine fibroid candidate succeed phase iii top line datum first study elagolix uterine fibroid be announce february study also meet primary endpoint read more abbvie uterine fibrosis candidate meet goal study cancer candidate get breakthrough therapy designation late stage pipeline candidate erdafitinib gain breakthrough therapy designation fda treatment urothelial cancer type bladder cancer read more erdafitinib get breakthrough therapy status nyse arca pharmaceutical index be marginal last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr returnhere be major stock perform merck emerge biggest gainer last trading session glaxo gsk free report share decline most last month astrazeneca have gain merck decline see last pharma stock roundup here mrk sign new cancer deal derm acne candidate fail next pharma world watch regulatory pipeline news pharma stock hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2274,MRK,pass new tax bill corporate tax rate have come be likely boost profit margin moreover cash repatriation window allow bill help company bring cash stash foreign location time tax rate leave company extra spending power most big pharma company discuss plan use extra cash save new tax bill fourth quarter conference call extra cash mostly be invest capital expenditure product pipeline licensing acquisition deal reward shareholder higher dividend share buyback however majority company do not mention effort regard lower prescription drug cost last week senator tina letter big pharma company expressed concern big pharma company plan used billion dollar save tax cut offer tax bill pass december be concern fact company be favore investor instead used saving bring prescription drug cost major life save drug be protected patent be steeply price thus make drug affordable help consumer lower medical cost senator have send letter ceo pfizer inc pfe free report merck co inc mrk free report johnson johnson jnj free report abbvie inc abbv free report abbott laboratory free report provide detail intend utilize major saving tax overhaul price major prescription drug have sky-rocket past year pinch hard citizen medical bill have soar moreover government also have pay higher cost drug be cover medicare concern senator be thus justified move restrict use tax saving boost shareholder be welcome move consumer moreover large player other industry have similar plan have undercut president donald trump plan create job boost wage senator be also work make cheaper generic drug available market faster introduce new legislation report kdal large cap pharmaceutical industry yr return large cap pharmaceutical industry yr returndon even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
2275,MRK,merck co inc mrk free report announce oncology collaboration japan eisai co ltd jointly develop commercialize latter tyrosine kinase inhibitor lenvima monotherapy well combination merck pd therapy keytruda several type cancer deal merck pay eisai upfront amount lenvima develop eisai be presently approve treatment thyroid cancer monotherapy second line treatment renal cell carcinoma rcc type kidney cancer combination novartis nvs free report afinitor everolimus meanwhile lenvima monotherapy be review unite state eu japan hepatocellular carcinoma type liver cancer also late stage study be already ongoing evaluate lenvima separate combination study keytruda afinitor rcc meanwhile keytruda lenvima combination enjoy breakthrough therapy designation fda rcc merck eisai plan jointly develop lenvima cancer type potential indication company share global development marketing cost well gross profit lenvima equally however eisai book lenvima worldwide product sale monotherapy combination other upfront payment merck also pay certain option right well reimbursement cost other eisai be entitle regulatory sale milestone payment so far year merck share have underperform industry merck share have decline period compare decrease industry keytruda be second largest product merck portfolio be market many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma gastric cancer bladder cancer microsatellite instability high msi mismatch repair deficient cancer treatment fetch sale almost year year upside be drive global launch new indication further boost demand keytruda sale be gain particularly strong momentum indication first line lung cancer be only pd approve first line set monotherapy well combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo keytruda development program also significantly advanced several regulatory approval unite state europe japan new approval expand patient population drive sale last year positive momentum be expect continue well meanwhile keytruda be be study more type cancer exceed study include excess combination study merck be collaborate several company include amgen inc amgn free report incyte glaxo pfizer separately evaluation keytruda combination other regimen expect merck present datum several key keytruda study year include combination study incyte epacadostat first line metastatic melanoma also keytruda get approval relapse refractory primary mediastinal large cell lymphoma indication year fda action expect april merck carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2276,MRK,earning remain focus week company astrazeneca azn free report report third quarter result meanwhile company roche rhhby free report merck co inc mrk free report be news due regulatory update recap week most important storiesmixed result astrazeneca astrazeneca third quarter result be mixed company miss earning beating revenue company have several pipeline event line come quarters include datum cancer drug lynparza imfinzi well regulatory submission moxetumomab pasudotox leukemia selumetinib thyroid cancer other read more astrazeneca miss earning tweak ep view fda nod merck cmv drug merck gain fda approval prevymis letermovir prevention cytomegalovirus cmv infection disease adult allogeneic hematopoietic stem cell transplant hsct patient common potentially serious viral infection allogeneic hsct recipient level cmv infection be associate increase mortality hsct patient merck say prevymis be first new cmv medicine be approve unite state year merck intend launch drug december list price day tablet injection merck be zack rank hold stock see complete list today zack rank strong buy stock here sanofi sign ms deal worth sanofi sny free report have enter agreement principia biopharma inc latter clinical stage blood brain barrier cross oral btk inhibitor prn have potential be develop treatment multiple sclerosis ms other central nervous system cns disease sanofi be willing shell include upfront payment balance be payable achievement milestone principia also earn royalty product sale moreover company have option co fund late stage development cost exchange higher royalty global sale profit loss sharing arrangement unite state sanofi already have presence ms market form lemtrada aubagio glaxo file nucala label expansion unite state glaxosmithkline plc gsk free report be look expand label il antagonist nucala mepolizumab be currently approve fda add maintenance treatment patient severe asthma age year older eosinophilic phenotype glaxo be now seek fda approval drug be used add maintenance treatment patient have chronic obstructive pulmonary disease copd eosinophilic phenotype accord information provide company copd be estimate affect person world be currently fourth lead cause death world however give prevalence become third lead cause death glaxo have also file fda approval nucala treatment adult patient eosinophilic granulomatosis polyangiitis egpa roche lung cancer drug get fda nod first line set roche gain fda approval lung cancer drug alecensa alectinib first line treatment person specific type lung cancer label expansion be base phase iii datum show alecensa significantly extend time person live disease worsening compare xalkori crizotinib risk cancer spread grow brain central nervous system be also significantly lower alecensa arm approval expand patient population alecensa significantly treatment previously be approve second line set roche also gain fda approval melanoma drug zelboraf treatment erdheim chester disease ecd rare blood disease roche have gain year date compare rally industry belong cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline marginally week major stock eli lilly lly free report be astrazeneca be last month johnson johnson jnj free report be glaxo decline see last pharma stock roundup here pfizer teva earning novartis seek new indication kymriah next pharma world third quarter earning season almost watch regulatory pipeline news pharma stock more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2277,MRK,total earning total healthcare market capitalization be revenue growth earning growth appear solid compare many other sector earning revenue beat ratio respectively look disappointing most notable player johnson johnson jnj free report be first major drug company report earning oct follow eli lilly company lly free report bristol myer squibb company bmy free report oct oct respectively other major drug company merck mrk free report pfizer pfe free report report oct oct respectively industry prime post solid result earning revenue beat johnson johnson earning world biggest maker healthcare product continue long streak earning beat earning share come cent ahead zack consensus estimate higher year quarter revenue grow year year edge past zack consensus estimate johnson johnson raise full year earning share guidance revenue guidance read healthcare etfs focus johnson johnson earning pfizer earning drug giant come earning beat line revenue earning share cent come couple cent zack consensus estimate revenue be line estimate year year basis earning share revenue rise respectively pfizer narrow revenue guidance range raise earning share guidance range merck earning focusmerck beat earning estimate miss revenue earning share come surpass zack consensus estimate improve year quarter revenue decline year year be zack consensus estimate merck raise revenue guidance earning share guidance year bristol myer earning focusbristol myer miss earning beat revenue report earning share cent couple cent estimate revenue grow edge past zack consensus estimate company raise earning share guidance see healthcare etfs here eli lilly earning focuseli lilly top zack consensus estimate front earning outpaced zack consensus estimate couple cent come higher year quarter revenue grow beat estimate other drug maker eli lilly also raise revenue earning guidance now expect revenue range compare previous expectation earning share range versus expect previously etf string earning beat fail boost pharma etfs see rough trading past month have highlighted detail fund have zack etf rank hold high risk outlook powershare dynamic pharmaceutical fund pjp free report be far most popular choice pharma space follow dynamic pharmaceutical intellidex index product have aum see lower volume share day fund charge bps fee expense hold stock fund invest share focus firm etf have lose month ishare pharmaceutical etf ihe free report etf provide exposure pharma stock tracking dow jone select pharmaceutical index focus firm be top holding basket accounting combine total asset suggest heavy concentration product have aum charge bps fee expense volume be light exchange share day fund have shed month read lie store pharma etfs spdr pharmaceutical etf xph free report fund provide exposure pharma company tracking pharmaceutical select industry index aum trade good volume share day charge bps fee year total product hold security focus firm take nearly share product be same period vaneck vector pharmaceutical etf pph free report etf follow mvis list pharmaceutical index hold stock basket johnson johnson pfizer bristol myer eli lilly account least share merck make asset product have amassed asset base trade moderate volume share day expense ratio come fund have lose month want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2278,MRK,weak performance due drug pricing issue pharma industry have bounce back year minor correction recently merck co inc mrk free report be very few company share be last year notwithstanding industry decline other way round year share merck have decline year increase large cap pharma industry let discuss merck have suffer notable pipeline setback year october merck decide not seek approval cetp inhibitor anacetrapib cholesterol management clinical profile be not strong enough support regulatory filing last month company also announce delay readout important lung cancer study say be include overall survival co primary endpoint keynote phase iii study keytruda first line lung cancer delay readout study raise investor concern delay readout give competitor chance gain strength lung cancer market october merck also withdraw regulatory application europe be look get keytruda approve first line combination therapy lung cancer please note october share merck be result back back pipeline setback september merck discontinue development hcv combination program mk mk say hcv market be become extremely crowd also combination study keytruda multiple myeloma be place clinical hold follow report death keytruda group july keytruda be see key long term growth driver merck such setback do not bode well company remain be see strong performance new drug particularly keytruda strong vaccine animal health business cost save effort help merck pick here merck carry zack rank hold see complete list today zack rank strong buy stock heremost other large cap pharma stock include astrazeneca azn free report jnj free report eli lilly lly free report bristol myer be year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2279,MRK,pipeline regulatory update be focus week fda approve first drug hiv treatment unite state european commission ec grant approval johnson johnson jnj free report tremfya expand label novartis nvs free report tasigna recap week most important storiesj glaxo hiv drug get fda nod glaxosmithkline gsk free report gain fda approval first drug hiv treatment unite state juluca combine approve hiv drug tivicay mg edurant mg single once daily pill maintenance treatment virologically suppress hiv infection company expect make drug available pharmacy december juluca mark begin new era hiv treatment other company gilead also work bring better treatment market read more glaxo get fda approval first drug hiv regimen eu nod psoriasis drug janssen cilag international nv company gain eu approval psoriasis drug tremfya use adult moderate severe plaque psoriasis be candidate systemic therapy approval be expect consider committee medicinal product human use chmp have adopt positive opinion september drug be approve unite state earlier year july psoriasis market be pretty crowd person world be estimate suffer psoriasis include european case be consider moderate severe tremfya be currently late stage development treatment psoriatic arthritis johnson johnson be zack rank buy stock see complete list today zack rank strong buy stock here roche present datum hemophilia cancer drug roche rhhby free report present positive datum recently approve hemophilia drug hemlibra late stage study haven adult adolescent age year older hemophilia inhibitor factor viii study meet primary endpoint well key secondary endpoint hemlibra significantly reduce bleed roche also present positive datum combination cancer drug tecentriq avastin patient type advanced lung cancer drug chemotherapy be find significantly cut risk disease worsening death first line treatment patient roche intend submit datum fda well other regulatory agency datum be not fully mature roche say initial observation show encourage overall survival os datum next os analysis be schedule first half read more roche report positive datum tecentriq combination study label expansion novartis cancer drug ec have expand label novartis tyrosine kinase inhibitor tki tasigna nilotinib so be used treatment pediatric patient newly diagnosed philadelphia chromosome positive chronic myeloid leukemia chronic phase ph cml cp pediatric patient ph cml cp resistance intolerance prior therapy include gleevec imatinib approval indication be expect give positive chmp opinion issue september treatment option be limit child cml be significant unmet need patient population read more novartis receive ec nod tasigna label expansion seek label expansion darzalex janssen cilag international nv be look expand label immunotherapy darzalex so be used combination velcade bortezomib melphalan prednisone treatment adult patient newly diagnosed multiple myeloma be ineligible autologous stem cell transplant approval expand patient population significantly regulatory application have be submit unite state well eu fda approval make fifth indication darzalex unite state first frontline set read more seek darzalex label expansion first line set have gain year date compare rally industry belong cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session major stock astrazeneca azn free report be merck mrk free report decline last month bristol myer bmy free report be glaxo decline see last pharma stock roundup here fda nod astrazeneca severe asthma drug bayer sign deal loxo next pharma world watch regulatory pipeline news pharma stock more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2280,MRK,tesaro inc tsro free report announce european commission have grant marketing authorization parp inhibitor zejula monotherapy maintenance treatment woman recurrent ovarian cancer drug be first approve parp inhibitor europe do not require brca mutation other biomarker testing marketing approval eu have boost prospect zejula be already market unite state approval eu be expect drug be recommend committee medicinal product human use september look tesaro share price movement so far year show company have underperform industry stock fall industry register gain approval be base datum international phase iii study engot ov nova show clinically meaningful increase progression free survival study evaluate drug recurrent ovarian cancer patient have achieve partial response complete response most recent platinum base chemotherapy tesaro be plan launch drug germany uk end year other european country next year parp inhibitor have bright prospect give tremendous demand however zejula face competition other approve parp inhibitor include astrazeneca azn free report merck mrk free report lynparza clovis oncology inc clvs free report rubraca however rubraca be review europe tesaro claim zejula be most frequently prescribe parp inhibitor treat ovarian cancer launch unite state sale number show better performance zejula zejula have generate sale more first month launch unite state lynparza sale be period also rubraca sale be similar adoption drug europe aid company approximately woman be diagnosed ovarian cancer year europe more woman be diagnosed annually europe ovarian cancer be sixth most common form cancer fifth most frequent cause cancer death however lynparza recent approval second line set hurt zejula sale tesaro inc price tesaro inc price tesaro inc quotetesaro carry zack rank hold see complete list today zack rank strong buy stock here zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
2281,MRK,celldex therapeutic inc cldx free report announce initiation phase ii study human monoclonal antibody cdx patient advanced head neck squamous cell carcinoma hnscc approve product portfolio investor focus remain progress celldex pipeline candidate share company be more friday follow news however celldex share be so far year underperform industry gain period phase ii study evaluate cdx combination eli lilly lly free report erbitux patient advanced hnscc be erbitux resistant previously treat pd checkpoint company believe patient population be evaluate study have limit availability treatment option particularly poor prognosis study continue treatment progression disease start patient become intolerant combination therapy primary objective study be achieve objective response rate stage study enroll patient first stage initiate second stage achieve partial complete response least patient remind investor complete phase ib study combination therapy have show promising tumor activity hsncc patient include durable complete response single patient disease have progressed erbitux monotherapy celldex be also progress well lead pipeline candidate glembatumumab vedotin be be evaluate phase iib study patient triple negative breast cancer phase ii study melanoma patient company be also evaluate candidate combination bristol myer bmy free report opdivo merck mrk free report keytruda separate cohort melanoma study celldex therapeutic inc price celldex therapeutic inc price celldex therapeutic inc quotecelldex currently hold zack rank buy see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2282,MRK,busy earning season almost come end impressive run be again focuse latest cancer update happen week week go see cancer drug receive fda approval new indication roche hold ag rhhby free report gazyva pfizer inc pfe free report sutent astrazeneca plc azn free report faslodex however interesting product development be cancer vaccine moderna therapeutic merck mrk free report be work merck have provide fund develop vaccine combination pd therapy keytruda return right half potential sale vaccine be personalize moderna have just develop first enrolled patient top line datum be expect september aveo pharmaceutical inc aveo free report also announce launch first drug fotivda be approve europe treat kidney cancer august recap week most important faslodex approve combination use fda approve new indication breast cancer drug faslodex nov label faslodex now be expand include combination use eli lilly lly new cdk inhibitor verzenio treat woman hr advanced metastatic breast cancer disease have progressed endocrine therapy read more astrazeneca faslodex get fda nod use verzenio astrazeneca plc price consensus astrazeneca plc price consensus astrazeneca plc quotepfizer sutent approve adjuvant treatment kidney cancer fda approve label expansion cancer drug sutent sunitinib malate latest fda approval sutent label have be expand include adjuvant treatment adult patient high risk recurrent renal cell carcinoma rcc approval mark first only adjuvant treatment recurrent rcc sutent be presently market first line treatment advanced rcc have be standard care indication approval decade application use same patient population be also review eu pfizer inc price consensus pfizer inc price consensus pfizer inc quoteroche gazyva approve first line set blood cancer roche obtain fda approval gazyva combination chemotherapy previously untreated advanced follicular lymphoma stage ii bulky iii iv patient respond combination therapy continue be treat gazyva alone approval be base superior progression free survival achieve drug compare rituxan phase iii gallium study drug be already approve use combination chlorambucil treat chronic lymphocytic leukemia cll adult have not have previous cll treatment roche hold ag price consensus roche hold ag price consensus roche hold ag quoteaveo add first drug commercial portfolio aveo partner eusa pharma announce launch kidney cancer drug fotivda european union company expect initiate selling europe start germany drug receive approval august first line treatment advanced rcc adult patient drug be also approve patient be not treat vegfr mtor pathway inhibitor therapy follow disease progression cytokine base therapy approval launch be major milestone aveo fotivda be first only market drug company portfolio acceptance drug be yet be see cut aveo dependence fund collaboration extent aveo pharmaceutical inc price consensus aveo pharmaceutical inc price consensus aveo pharmaceutical inc quoteapart label expansion drug launch buzzword immuno oncology segment car therapy grab headline major boost celgene corporation celg free report bluebird bio inc blue free report fda grant breakthrough therapy designation car therapy candidate bb candidate also receive access priority medicine europe bb be be develop previously treat patient multiple myeloma regulatory designation development be expect expedite meanwhile bayer sign collaboration agreement small base company loxo oncology give access latter pipeline candidate loxo bayer get entry field cancer treatment drug attack cancer base genetic rather attack organ origin moreover celsion submit phase ii clinical study protocol fda evaluate dna base immunotherapy gen localize treatment ovarian cancer look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2283,MRK,dow traverse tense week suffering loss consecutive day key component cut dividend significantly add index wo be linger concern trump administration ability push much vaunted tax cut ultimately dow rebound penultimate trading day week buoy once again encourage earning number last week dow lose point end red last friday market watcher speculate likely outcome delay tax reform propose last thursday senate finance committee share intel corporation intc free report merck co inc mrk free report decline respectively weigh heavily dow however share walt disney company free report advanced pare loss blue chip index index decline last week snap week winning streak senate finance committee release tax plan aim reduce corporate tax rate not contrast deadline propose house republican investor turn jittery follow concern tax cut be delay market curtailed part decline house way committee pass bill reframe tax reform meanwhile apple inc aapl free report market value jump first time ever finally benchmark touch new high last monday follow news possible merger broadcom qualcomm mark trading day time high be achieve key index be highest number record high achieve single year dow index gain little less monday tax wo continue worry investor gain be capped further share general electric company ge free report plummet year low release weak ep guidance however gain boee company ba free report mattel inc mat free report boost market meanwhile investor closely follow trump visit asia speaking manila trump comment make important announcement regard trade wednesday washington index shed point tuesday end negative territory share general electric decline second straight day hit lowest level moreover oil price decline international energy agency slash global crude demand forecast factor also weigh broader market further linger tax reform wo also dampen investor sentiment meanwhile elizabeth warren comment republican tax plan eventually lead economic slowdown index decline wednesday energy share tank follow decline oil price also marked dow worst day drop sep additionally worry center possible delay tax reform also lead market lower meanwhile senate finance committee announce major amendment version tax bill proposal abolish individual mandate obamacare increase child tax credit dow rebound day loss thursday gain more point strong earning performance wal mart store inc wmt free report cisco system inc csco free report help propel index higher share wal mart cisco gain respectively additionally house pass republican lead tax legislation boost investor sentiment further component move index general electric share be mid morning trading nov company announce have slash dividend half well other strategic business decision ge have zack rank strong sell dividend cut mark only ge second great depression company say shareholder payout now be cent share cent share cut become effective december ge only other dividend cut be back great recession ge also unveil annual profit projection be well wall street expectation company say be reset year anticipate profit range share analyst be expect share additionally ge be expect weak free cash flow roughly half company normal level read general electric share be fall today here home depot inc hd free report post fiscal third quarter earning share escalate record year quarter figure also beat zack consensus estimate net sale grow year quarter moreover top line surpass zack consensus estimate company overall comparable store sale comp increase comp unite state grow home depot now expect now expect sale growth nearly increase comp earlier company project net sale growth comp increase moreover management now anticipate earning share be nearly fiscal compare previous guidance growth stock have zack rank buy see complete list today zack rank strong buy stock here cisco report first quarter fiscal gaap earning cent share beating zack consensus estimate penny however figure remain unchanged year year basis cisco have zack rank hold revenue decline year year be almost line zack consensus estimate acquisition contribute basis point bps revenue growth quarter security application revenue increase quarter second quarter fiscal revenue be expect rise year year basis gaap earning be anticipate cent share zack consensus estimate earning be peg cent revenue be read cisco beat earning estimate outlook positive wal mart post third quarter fiscal adjust earning share exceed zack consensus estimate cent grow cent report year period earning also exceed higher end guide range cent share total revenue come include membership other income advanced year year surpass zack consensus estimate upside be drive strength business fourth quarter fiscal zack rank wal mart expect comp exclude fuel sam club comp exclude fuel increase range week period end jan company raise bottom line view fiscal now envision adjust earning range share compare prior expectation gaap earning be expect range share read walmart stock gain solid earning raise view boee recently seal deal deliver dreamliner emirate largest airline middle east notably aircraft giant receive order very first day dubai delivery twin aisle jet be schedule commence jet lot be expect be deliver purchase order addition jet come equipment related fleet total value current list price read boee deliver jet emirate separate development boee have inked deal flydubai max airplane value current list price order be award dubai air show mark largest ever single aisle jet order middle east carrier read boee flydubai ink deal max airplane performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have lose tickerlast day performance month performancemmm gs ibm hd ba unh mcd trv jnj aapl next week outlookfollow development thursday night market be finally witness definite progress tax cut front ge also seem have re-cover recent debacle stock remain pressure time however earning have continue be strong overall key component index go forward be little prevent stock notch further gain day ahead look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2284,MRK,astrazeneca plc azn free report report third quarter core earning cent american depositary share ad miss zack consensus estimate cent core earning decline year year constant exchange rate cer lower product sale gross margin higher sg cost hurt profit quarter total revenue rise cer report quarter revenue also beat zack consensus estimate revenue however gain mainly payment merck mrk free report oncology collaboration company announce july jointly commercialize develop lynparza selumetinib meanwhile product sale decline quarter due generic competition face legacy product key growth platform represent total revenue be quarter cer key growth platform emerge market new cardiovascular metabolic disease cvmd new oncology japan perform well quarter however respiratory sale decline report quarter growth rate mentioned be year year basis cer product sale declineproduct sale decline quarter due lower sale unite state well europe offset strong performance emerge market china crestor sale decline sale unite state europe due entry multiple generic version drug market seroquel xr sale decline due competition generic launch quarter onglyza sale decline due competitive pressure dpp class symbicort sale be quarter due lower sale unite state europe sale decline due continue pricing pressure manage care access ics laba class also competition other class lama laba combination medicine nexium record sale however legacy product record growth quarter include farxiga forxiga daliresp daxas faslodex iressa pulmicort newer medicine lynparza sale rise sale unite state gain label expansion approval august treatment second line ovarian cancer europe sale be push higher number successful launch brilinta brilique sale be report quarter year year sequentially brilinta maintain leadership position brand oral platelet market unite state europe china brilinta continue display impressive performance tagrisso launch record sale sequentially new medicine movantik moventig record sale quarter less previous quarter bevespi lama laba pressurize meter dose inhaler launch commercially unite state january record sale quarter less second quarter lama laba class grow more slowly anticipate pd inhibitor imfinzi launch second line bladder cancer unite state do not generate sale third quarter second quarter regulatory application seek label expansion imfinzi treat earlier stage lung cancer be grant priority review fda last month imfinzi be key candidate company immuno oncology pipeline be beingevaluat multiple cancer alone combination other regimen last month astrazeneca expand clinical trial collaboration incyte incy free report evaluate incyte investigational selective ido enzyme inhibitor epacadostat combination imfinzi compare imfinzi alone early lung cancer regional sale decline primarily due generic competition crestor seroquel xr pricing pressure symbicort unite state european market witness decline sale revenue emerge market be primarily back strong growth china establish row market sale be flat other core gross margin decline basis point bps core selling general administrative sg expense rise quarter core research development expense be flat outlookwhile astrazeneca retain previously issue sale outlook slightly refine core earning guidance astrazeneca continue expect total revenue decline low mid single digit percentage range however core earning be expect favorable end previously issue guidance decline low mid percentage base average exchange rate first half currency movement be still expect adversely impact top line low single digit percentage minimally impact core ep astrazeneca third quarter performance be mixed share rise pre market trading thursday company brighten earning outlook moreover company have announce quite few positive development regulatory pipeline front so far year latest such development be accelerate approval calquence treatment mantle cell lymphoma aggressive form blood cancer last month backed positive news flow so far year astrazeneca share have gain compare favorably industry growth astrazeneca plc price consensus ep surprise astrazeneca plc price consensus ep surprise astrazeneca plc currently carry zack rank hold see complete list today zack rank strong buy stock here better rank company large cap pharma industry be johnson johnson jnj free report carry zack rank buy share be earning estimate have go past day today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2285,MRK,nektar therapeutic nktr free report share increase more nov report better expect third quarter result earning sale surpass estimate quarterly earning cent beat zack consensus estimate cent notably company report loss cent year quarter nektar share have significantly outperformed industry so far year stock have sky-rocket industry have register increase quarterly revenue substantially rise year quarter upside mainly be attribute massive increase license collaboration revenue top line also beat zack consensus estimate quarter top line comprise product sale royalty revenue cash royalty revenue license collaboration other revenue third quarter product sale tumble year however cash royalty revenue increase company report royalty revenue thereby register huge improvement third quarter compare year quarter uptrend be mainly back royalty revenue receive license agreement astrazeneca movantik shire plc adynovate license collaboration other revenue come compare year quarter nektar receive upfront payment eli lilly company development nktr amount have be recognize time research development expense climb primarily due investment pipeline include key candidate nktr nktr nktr general administrative expense be quarter review pipeline most advanced candidate company portfolio be onzeald currently accelerate assessment eu treatment adult advanced breast cancer have brain metastase nektar also initiate randomize phase iii confirmatory study attain onzeald compare single agent chemotherapy physician choice patient advanced breast cancer have brain metastase shortly positive result study support regulatory filing unite state apart onzeald candidate company immuno oncology portfolio be nktr september nektar announce initiation phase ii propel study evaluate efficacy safety nktr combination roche rhhby free report tecentriq atezolizumab merck mrk free report keytruda pembrolizumab phase ii study evaluate nktr potential combination treatment regimen bristol myer squibb bmy free report opdivo be also underway candidate be be examine tumor type melanoma kidney colorectal bladder small cell lung cancer potential indication candidate nktr be be evaluate phase iii study treatment chronic pain july company report positive top line result oral human abuse potential hap study evaluate nktr assess opioid abuse potential compare oxycodone company be plan submit new drug application nda candidate april outlook updatednektar raise revenue outlook account upfront payment receive eli lilly company report quarter company now estimate revenue range compare project previously cash investment marketable security sep be comparison dec nektar continue expect cash year end approximately nektar therapeutic price consensus ep surprise nektar therapeutic price consensus ep surprise nektar therapeutic quotezack ranknektar carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2286,MRK,celldex therapeutic inc cldx free report incur third quarter loss adjust time item cent share be narrower zack consensus estimate loss cent well year loss cent share lower cost higher revenue lead narrower loss quarter total revenue quarter rise year year beating zack consensus estimate manufacturing service agreement international aids vaccine initiative lead higher revenue quarter share biotech company rise hour trading tuesday however stock have not do too well year so far have decline year date increase register industry research development expense decline year period due lower varlilumab contract manufacturing clinical study expense general administrative spend decline due lower commercial plan cost stock base compensation expense sep celldex have cash cash equivalent marketable security compare jun celldex expect cash net proceed raise sale common stock month agreement cantor be enough fund work capital requirement plan operation pipeline updatecelldex most advanced pipeline candidate be antibody drug conjugate glembatumumab vedotin currently be evaluate treatment triple negative breast cancer phase iib metric study metastatic melanoma phase ii enrolment key metric study close august datum expect second quarter melanoma study celldex add new cohort glembatumumab varlilumab arm glembatumumab checkpoint inhibitor arm include bristol myer bmy free report opdivo merck mrk free report keytruda apart glembatumumab vedotin other promising candidate pipeline include varlilumab cdx phase advanced renal cell carcinoma other varlilumab be be evaluate combination opdivo phase ii study include cohort indication colorectal cancer ovarian cancer head neck squamous cell carcinoma renal cell carcinoma glioblastoma celldex plan complete enrolment cohort phase ii portion study first quarter earning release celldex announce datum phase ii study evaluate combination glembatumumab vedotin varlilumab melanoma patient have progressed checkpoint inhibitor eligible patient only have confirm partial response patient have partial response single timepoint median progression free survival be month patient have stable disease week more full datum set be present society immunotherapy cancer sitc annual meeting week kolltan acquisition nov celldex gain right kolltan cancer pipeline candidate cdx cdx cdx be be evaluate phase study refractory stromal tumor gist other kit positive tumor phase ii study cdx patient recurrent metastatic head neck squamous cell cancer be refractory eli lilly lly free report bristol myer erbitux be expect be initiate year end celldex carry zack rank hold see complete list today zack rank strong buy stock here celldex therapeutic inc price consensus ep surprise celldex therapeutic inc price consensus ep surprise celldex therapeutic inc quotewall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2287,MRK,horizon pharma plc hznp free report report better expect result third quarter company also raise annual sale guidance follow news company share go however horizon pharma stock have decline year date industry gain company report third quarter earning cent share beat zack consensus estimate cent be cent year quarter sale third quarter be year year beat zack consensus estimate horizon pharma plc price consensus horizon pharma plc price consensus horizon pharma plc quote quarter orphan unit record revenue year period strong performance be backed solid net sale ravicti generate sale quarter year year drive continue conversion older generation nitrogen scavenger therapy well addition treatment nave patient due recent label expansion remind investor fda approve supplemental new drug application ravicti expand age range chronic management urea cycle disorder patient month older year older additionally procysbi contribute performance net sale actimmune sale report quarter be year year drive continue effort establish role actimmune broader range chronic granulomatous disease patient rheumatology unit generate sale year year also krystexxa sale quarter be strong come year year drive continue strong year year vial demand primary care garner revenue year year decline net sale be due implementation new contract model order secure broader inclusion company primary care medicine formulary sale also decline sequentially result lower average net realize price net sale pennsaid duexix vimovo be respectively report quarter company raise outlook now expect sale range compare earlier estimate company continue invest expansion krystexxa nephrology indication expect sale growth more guidance include assumption lower net average net realize price begin second half primarily result government health resource service administration final rule drug ceiling price implementation schedule july horizon pharma be significantly increase investment key growth driver krystexxa expect net sale krystexxa more drive higher demand company expect continue double digi net sale growth ravicti room additional uptake due recent label expansion sale procysbi decline divestiture european right sale actimmune be project grow other company announce first patient be enroled infuse phase iii confirmatory clinical trial evaluate teprotumumab treatment thyroid eye disease ted remind investor company acquire river vision earlier add biologic candidate teprotumumab pipeline june horizon pharma sell marketing right procysbi quinsair europe middle east africa region chiesi farmaceutici company focus higher return business meanwhile company be work expand actimmune label investigator initiate study moffitt cancer center be underway enrolling patient study be evaluate actimmune combination roche holding rhhby free report herceptin perjeta taxol aim determine optimal dose treatment combination certain advanced breast cancer patient company have collaborate fox chase cancer center evaluate actimmune combination bristol myer squibb company bmy free report opdivo phase dose study treatment kidney bladder cancer study continue enroll fourth cohort patient expect have dose level result end year national cancer institute have plan evaluate actimmune combination merck co mrk free report keytruda treat cutaneous cell lymphoma patient phase ii study remain track begin company remain track submit supplemental new drug application first quarter expand age range chronic management urea cycle disorder ucds birth older takehorizon pharma third quarter result be impressive company beating top bottom line estimate moreover increase sale guidance be encourage well expect krystexxa ravicti actimmune drive further growth acquisition teprotumumab have further diversify company portfolio zack rankhorizon pharma currently have zack rank sell see complete list today zack rank strong buy stock here zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
2288,MRK,third quarter earning season draw close focus be back deal regulatory approval pipeline update week company astrazeneca azn free report bayer bayry free report be news former announce fda approval severe asthma drug bayer sign cancer focuse deal loxo oncology recap week most important storiesfda approval astrazeneca severe asthma drug astrazeneca continue deliver pipeline company score couple fda nod week regulatory body grant approval company respiratory biologic fasenra benralizumab add maintenance treatment severe asthma patient age year disease be drive eosinophilic inflammation read more astrazeneca asthma drug benralizumab approve fda moreover astrazeneca get positive opinion committee medicinal product human use chmp european medicine agency ema fasenra read more astrazeneca get positive chmp opinion asthma candidate astrazeneca also gain fda approval use cancer drug faslodex expand patient population faslodex now be used combination eli lilly lly free report cdk inhibitor verzenio abemaciclib woman hr advanced metastatic breast cancer mbc disease have progressed endocrine therapy study result have show month progression free survival pfs combination treatment mark second fda approval faslodex cdk inhibitor treatment be already approve use combination pfizer cdk inhibitor ibrance palbociclib fda advisory panel meeting pacira exparel snda specialty pharma company pacira pharmaceutical inc pcrx free report announce supplemental new drug application snda exparel use nerve block regional analgesia be discuss fda anesthetic analgesic drug product advisory committee aadpac meeting be schedule be hold feb final response fda regard approval snda be expect apr read more pacira exparel snda be review fda advisory committee bayer oncology deal loxo bayer enter collaboration agreement loxo company focuse development highly selective medicine patient genetically defined cancer deal see bayer shell see company collaborate global development loxo highly selective trk inhibitor larotrectinib loxo patient trk fusion cancer agreement term include upfront payment loxo receive achievement certain regulatory commercial milestone additional milestone related loxo development cost be split equally company company co promote unite state loxo receive tiered double digit royalty net sale sale milestone totale ex territory larotrectinib be schedule be file fda approval late early janssen biotech licensing deal zymework janssen biotech johnson johnson jnj free report company have enter licensing agreement zymework development next generation bispecific antibody therapeutic deal janssen get worldwide royalty bearing license research develop commercialize bispecific antibody used zymework azymetric efect platform zymework be entitle upfront payment development milestone commercial milestone payment well tiered royalty potential sale janssen also have option add more bispecific program deal mean additional money zymework johnson johnson be zack rank buy stock see complete list today zack rank strong buy stock here chmp positive merck drug merck mrk free report get positive opinion chmp prevymis recently gain approval unite state merck be seek eu approval prevymis prevention cytomegalovirus cmv reactivation disease adult cmv seropositive recipient allogeneic hematopoietic stem cell transplant hsct chmp give positive opinion chance gain approval look high decision regard eu approval be expect month read more merck get chmp nod infection candidate prevymis update datum bristol myer immuno oncology combination bristol myer squibb bmy free report announce update result combination opdivo bms selective once daily oral ido inhibitor ongoing phase iia dose escalation expansion study study show maximum tolerate dose combination be mg mg dose be determine be recommend dose base safety pharmacodynamic datum moreover company say encourage response be observed heavily pre treat patient advanced cancer objective response rate orr disease control rate dcr be respectively bladder cancer cohort orr dcr be respectively cervical cancer cohort bristol myer also announce expansion label blockbuster drug sprycel now be used treatment child ph chronic phase cp chronic myeloid leukemia cml bristol myer have gain year date compare rally industry belong cap pharmaceutical industry yr returnlarge cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock astrazeneca be merck decline last month bristol myer be glaxo decline see last pharma stock roundup here astrazeneca earning roche merck drug get fda nod next pharma world watch regulatory pipeline news pharma stock zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
2289,MRK,cancer oncology space have always be keenly watch investor interested pharma biotech sector be disease be lead cause morbidity mortality world precede only heart disease major player field include pfizer pfe free report bristol myer bmy free report novartis nvs free report astrazeneca azn free report merck mrk free report roche rhhby free report cancer drug be most important revenue driver bigwig well smaller counterpart clovis oncology tesaro puma biotechnology othersevolution cancer spacea lot progress have be make area last few year company be aim bring newer better treatment immunotherapy gene therapy target therapy other novel therapy fact focus area have increase fda approval car therapy novartis kymriah gilead gild free report yescarta last year path breaking immunocellular therapy be time treatment used patient own cell fight cancer acquisition kite gilead juno celgene have lead renew interest area interest parp inhibitor have also increase considerably well be next major class therapeutic oncology accord imsquintile new cancer drug be approve indication worldwide cost cancer therapeutic supportive care drug shot unite state accounting cost more molecule be late stage development majority be target therapy attack specific feature target cancer cell new cancer drugsnew oncology brand include bristol myer opdivo merck keytruda pfizer ibrance abbvie imbruvica be fast catch give tough competition category stalwart such avastin herceptin rituxan new cancer drug approve last year include pfizer merck kgaa bavencio bladder cancer eli lilly verzenio novartis kisqali puma biotechnology nerlynx breast cancer tesaro zejula ovarian cancer most common indication new drug be small cell lung cancer nsclc hodgkin lymphoma melanoma breast cancer be patient population benefit go say new drug bring million buck company be sell huge amount money however be do enough cure patient help live longer better be relieve pain fatigue consider fact come premium fda have approve number oncology drug recent year also lower bar clinical study goal cancer candidate disease still remain top cause death many population here probably few drug have be successful allow patient limit life expectancy live year however efficacy several other be be question have lead only marginal benefit not much improvement survival quality life many drug be be approve base progression free survival amount time patient live tumor grow larger evidence benefit survival quality life be specially case drug aim treat terminal cancer few treatment option however overall survival os datum once available sometimes show drug do not help person live longer also drug do offer survival benefit gain be often marginal risk long term side effect drug have also be underestimated overall cancer survival have barely change past decade raise concern push get more drug approve instead get effective drug approve large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2290,MRK,merck co inc mrk free report announce committee medicinal product human use chmp european medicine agency ema have give positive opinion recommend marketing approval prevymis letermovir merck be look get prevymis approve eu prevention cytomegalovirus cmv reactivation disease adult cmv seropositive recipient allogeneic hematopoietic stem cell transplant hsct merck expect decision european commission month remind investor only last week prevymis receive approval fda prevention cmv infection common potentially serious viral infection allogeneic hsct recipient cmv infection be associate increase mortality hsct patient merck say prevymis be first new cmv medicine be approve unite state year merck intend launch drug unite state next month list price day tablet injection merck share have decline year increase industry other key pipeline candidate merck include doravirine hiv new drug application nda filing expect end year mk be be develop phase ii study refractory chronic cough idiopathic pulmonary fibrosis ipf cough merck pfizer pfe free report have develop diabetes candidate ertugliflozin regulatory application be review unite state eu company have file separate ndas ertugliflozin monotherapy twoforfixed dose combination metformin januvia sitagliptin respectively decision fda be expect next month merck carry zack rank hold see complete list today zack rank strong buy stock here better rank stock industry be johnson johnson jnj free report ligand pharmaceutical incorporate lgnd free report zack rank buy share be earning estimate have go past day share ligand pharmaceutical have rise year so far earning estimate have increase past day today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2291,MRK,nektar therapeutic nktr free report partner bristol myer squibb bmy free report announce positive interim datum dose escalation part phase ii study evaluate safety efficacy combination lead candidate nktr bristol myer opdivo nivolumab combination therapy be be evaluate treatment patient melanoma renal cell carcinoma small cell lung cancer nsclc datum study be present annual meeting society immunotherapy cancer sitc notably september last year nektar have enter clinical collaboration agreement bristol myer evaluate opdivo nktr combination therapy tumor type melanoma kidney colorectal bladder small cell lung cancer potential indication phase ii study company share cost combination study equally nektar retain global commercial right nktr nektar share have significantly outperformed industry so far year stock have sky-rocket industry have increase pivot phase ii study be conduct total patient number dose cohort datum trial demonstrated positive response rate tumor type pd positive pd negative patient company report treatment discontinuation due adverse event importantly nktr be cd bias agonist opdivo be pd immune checkpoint inhibitor different complementary mechanism comprise combination regimen provide new treatment option cancer patient remind investor nektar be also conduct phase ii propel study evaluate efficacy safety nktr combination roche rhhby free report tecentriq atezolizumab merck mrk free report keytruda pembrolizumab propel study complement nektar ongoing pivot trial earlier nektar have enter research collaboration takeda pharmaceutical explore combination nktr oncology compound takeda cancer portfolio nektar therapeutic price nektar therapeutic price nektar therapeutic quotezack ranknektar carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2292,MRK,market finished red friday market watcher speculate likely outcome delay tax reform propose last thursday senate finance committee meanwhile speech pacific rim summit trump comment not indulge multilateral trade be unfair unite state benchmark post weekly loss follow likelihood delay tax reform dow jone industrial average djia decrease close index inx fall close tech laden nasdaq composite index ixic close lose less decliner outnumber advancer nyse ratio nasdaq ratio favore advance issue cboe vix increase close do benchmark fare dow decline point end red such performance blue chip index put end week winning streak share intel intc free report merck mrk free report decline weigh heavily dow however share disney free report advanced pare loss blue chip index lose point also finish negative territory ensure also end week winning run major segment end red healthcare energy sector lead decliner health care select sector spdr etf xlv energy select sector spdr etf xle decline respectively share johnson control international plc jci free report plummet be biggest drag meanwhile nasdaq manage meager gain rise only fraction point finish positive territory such nominal gain be fuelled recovery semiconductor stock tax wo weigh broader marketson thursday version tax plan be release senate finance committee senate version differ house panel several way house republican tax proposal focus reduce corporate tax rate senate version support similar tax cut only also house republican top individual tax rate be senate version put ceiling rate worry possible delay tax cut plan weigh investor sentiment version tax bill be scrutinize debate reach conclusion such confused state affair dampen investor sentiment moreover market watcher speculate formal decision be likely tax bill thanksgiving even speculate likelihood such decision occur only christmas such fear weigh heavily broader market trump say future multilateral dealsin speech friday pacific rim summit vietnam president trump make heated speech bid defend economic nationalism say unite state not enter multilateral trade order protect commercial right speaking business leader country asia pacific economic cooperation forum trump comment global trading system world trade organization have be unfair unite state also add not let unite state be take advantage anymore trump make very clear only engage trade indo pacific country abide norm ensure fair reciprocal trade also mentioned unite state longer get agreement tie hand surrender sovereignty make meaningful enforcement practically impossible such comment trump place trade delegation directly other member attend economic forum economic datum front index consumer sentiment month november come october read come consensus estimate weekly week dow nasdaq decline respectively dow snap week winning streak nasdaq post weekly loss first time week meanwhile russell index rut post weekly decline biggest weekly loss august such loss be incur likely delay tax reform senate finance committee release tax plan aim reduce corporate tax rate not contrast deadline propose house republican investor turn jittery follow concern tax cut be delay market curtailed day decline house way committee pass bill reframe tax reform meanwhile apple aapl free report market value jump first time ever finally benchmark touch new high last monday follow news possible merger broadcom qualcomm mark trading day time high be achieve key index be highest number record high achieve single year stock make secure new epci contract arabian gulfenergy focuse engineering construction company mcdermott international inc mdr free report recently announce have receive engineering procurement construction installation epci contract customer middle east read more make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2293,MRK,friday february happy groundhog day see first friday almost month new farm payroll bureau labor statistic bls have be release open bell come conjunction tonnage new earning report yesterday market close today open headline be better expect not huge surprise new job create january unemployment rate remain steady number be higher analyst consensus roughly analyst month have be expect new job be adp adp free report payroll report release wednesday morning show new job just private sector alone typically however adp bls number do tend align future revision initially be often far apart pre market trading have be deep red ahead bls announcement claw back point dow only plummet back point follow news time last minute so market have again work climb early hole meanwhile year bill race past follow release job datum not be anything particularly grieve today job report construction post biggest improvement sector compare year new job aka real unemployment fall lowest ve see quite time otherwise figure come much expect aside predict unemployment rate average hourly earning be again positive tepid year year consistent labor force participation rate finally december bls total be revise upward be slightly offset november revision originally announce earning roundupfollow yesterday afternoon modest beat apple aapl free report amazon amzn free report biggest profit history alphabet googl free report earning miss tax adjustment today bell bring full load earning report exxonmobil xom free report miss top bottom line estimate bring cent share zack consensus revenue expect zack rank hold company have now miss earning estimate last quarters more xom earning click here phillip psx free report downstream oil gas play easily top expectation quarter share outpaced cent anticipate far ahead zack consensus more psx earning click here estee lauder el free report also surpass expectation share revenue beating share be look quarter be assist double digit growth skincare makeup fragrance category more el earning click here merck mrk free report top estimate cent cent share come short revenue estimate opposed expect generic competition have affected big pharma dow component quarter more mrk earning click here merck competitor astrazeneca azn free report also face generic competition top selling drug manage top earning revenue expectation cent share outperformed cent sale easily beat anticipate more azn earning click here mark vickerysenior editorquestion comment article author click here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
2294,MRK,astrazeneca plc azn free report report fourth quarter core earning cent american depositary share ad beat zack consensus estimate cent core earning rise year year constant exchange rate cer higher product sale boost profit quarter total revenue rise cer report quarter revenue also beat zack consensus estimate revenue growth however be partially offset decrease externalization revenue meanwhile product sale rise cer quarter due better performance new product partially offset lower sale legacy product key growth platform represent total revenue be quarter cer key growth platform emerge market new cardiovascular metabolic disease cvmd new oncology japan perform well quarter growth rate mentioned be year year basis cer product sale impresscrestor sale decline sale europe due entry multiple generic version drug market negative impact be expect continue europe seroquel xr sale decline due competition generic launch quarter onglyza sale rise drive growth emerge market symbicort sale remain flat quarter higher sale emerge market be offset lower sale unite state sale decline due continue pricing pressure manage care access ics laba class also competition other class lama laba combination medicine nexium record sale other crestor seroquel xr other legacy product record decline quarter include zoladex seloken toprol xl casodex however older drug grow quarter include iressa pulmicort faslodex daliresp daxas newer medicine lynparza sale rise sale unite state gain label expansion approval august treatment second line ovarian cancer europe sale be push higher number successful launch please note astrazeneca share lynparza development cost profit equally merck co inc mrk free report brilinta brilique sale be report quarter year year brilinta maintain leadership position brand oral platelet market unite state europe china brilinta continue display impressive performance tagrisso launch record sale year year new medicine movantik moventig record sale quarter bevespi lama laba pressurize meter dose inhaler launch commercially unite state january record sale quarter higher third quarter slower anticipate growth lama laba class pd inhibitor imfinzi launch second line bladder cancer unite state generate sale fourth quarter regulatory application seek label expansion imfinzi treat earlier stage lung cancer be grant priority review fda imfinzi be key candidate company immuno oncology pipeline candidate be be evaluate multiple cancer alone combination other regimen october astrazeneca expand clinical trial collaboration incyte incy free report evaluate latter investigational selective ido enzyme inhibitor epacadostat combination imfinzi compare imfinzi alone early lung cancer sale decline primarily due generic competition crestor seroquel xr pricing pressure symbicort unite state european market witness decline sale revenue emerge market be primarily back strong growth china establish row market sale be flat other core gross margin decline basis point bps core selling general administrative sg expense rise quarter core research development expense decline provide ep guidance be expect range adr zack consensus estimate stand adr company also expect revenue grow low single digit percentage base average exchange rate january currency movement be expect favorably impact top line low single digit percentage minimally impact core ep takeastrazeneca fourth quarter performance be impressive beat estimate earning sale also provide encourage outlook revenue improve company expect trend continue astrazeneca announce quite few positive development regulatory pipeline front past year several readout be expect backed positive news flow past year astrazeneca share have gain compare favorably industry growth astrazeneca carry zack rank hold see complete list today zack rank strong buy stock here astrazeneca plc price consensus ep surprise astrazeneca plc price consensus ep surprise astrazeneca plc quotea better rank company large cap pharma industry be abbvie inc abbv free report carry zack rank share abbvie be earning estimate have go past day breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2295,MRK,new jersey base merck co inc mrk free report be global research drive pharmaceutical product company well know product merck portfolio include remicade nasonex simponi vytorin zetia januvia janumet isentress emend keytruda cozaar hyzaar zocor proquad gardasil zostavax other however many peer merck be face headwind form generic competition several key product company sell consumer care business bayer oct meanwhile merck acquire hepatitis virus focuse company idenix pharmaceutical aug cubist pharmaceutical merck be also focuse immuno oncology merck performance have be pretty impressive company exceed earning expectation trail quarters average positive earning surprise last quarters be currently merck have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning beat merck surpass earning expectation company report ep cent consensus call ep cent revenue miss revenue report quarter come slightly expectation merck post revenue consensus estimate outlook revenue be expect range be line zack consensus estimate company expect adjust earning range zack consensus estimate stand share stock price impact share be pre market trading check back later full mrk earning report merck company inc price consensus merck company inc price consensus merck company inc quotebreaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2296,MRK,major pharma company pfizer pfe free report teva pharmaceutical industry limit teva free report sanofi read more sanofi earning line sale lag diabetes weak allergan read more allergan top earning estimate tweak view nordisk read more nordisk top earning estimate lag sale report third quarter result last week recap week most important storieswhy do teva share plunge earning teva share plunge follow release third quarter result company miss earning revenue be line expectation however key reason stock poor performance be lower outlook company face huge revenue erosion key brand drug copaxone face generic competition mg formulation well development alone be expect hit earning cent share meanwhile generic business continue face headwind price erosion remain major challenge read more teva stock plunge earning miss view cut key takeaway pfizer conference call pfizer third quarter earning surpass expectation result company raise earning outlook year read more pfizer beat earning raise ep view company say key brand include ibrance eliquis globally xtandi lyrica xeljanz chantix unite state continue perform well however company be face supply shortage product legacy hospira portfolio mainly due capacity constraint technical issue time acquire hospira complete september pfizer have expect take couple year integrate manufacturing plant resolve majority supply chain issue third quarter call company say expect make substantial progress cut sterile injectable shortage regard inflectra pfizer biosimilar version remicade company say penetration unite state continue be slower expect due exclusionary contract remicade remind investor pfizer have file lawsuit district court related provide patient physician access lower cost biosimilar read more pfizer sue accuse prevent inflectra uptake pfizer also provide insight expect impact loss exclusivity loe next few year loe be expect affect revenue next year go approximately not be more far term pipeline regulatory update be concern pfizer expect decision fda type ii diabetes drug ertugliflozin december meanwhile top line result parp inhibitor talazoparib phase iii embraca study read year end study be evaluate talazoparib versus standard care chemotherapy patient germline brca positive metastatic breast cancer datum pd inhibitor bavencio pfizer bb agent patient have not be previously treat immune checkpoint inhibitor be also due later year pfizer be also look submit application fda lorlatinib next generation alk inhibitor treatment alk positive metastatic small cell lung cancer year end pfizer have gain year date compare rally industry belong novartis seek label expansion kymriah novartis nvs free report be look expand label kymriah first car therapy gain fda approval company be seek fda approval use kymriah treatment adult patient relapse refractory diffuse large cell lymphoma dlbcl be ineligible autologous stem cell transplant asct novartis have breakthrough therapy designation dlbcl dlbcl be most common form hodgkin lymphoma nhl dlbcl be highly aggressive difficult treat hodgkin lymphoma be fatal almost patient due relapse refractory disease kymriah be currently approve patient year age cell precursor acute lymphoblastic leukemia be refractory have relapse least twice approval dlbcl indication expand patient population kymriah gilead already have presence area car therapy yescarta be approve treatment adult patient certain type large cell lymphoma have not respond have relapse least other kind treatment novartis also announce intention acquire advanced accelerator application strengthen presence oncology read more novartis buy french company fda approve astrazeneca blood cancer drug astrazeneca azn free report gain accelerate fda approval btk inhibitor calquence acalabrutinib adult patient previously treat mantle cell lymphoma aggressive type blood cancer be usually diagnosed advanced stage associate high relapse rate note abbvie imbruvica be also approve patient population astrazeneca also expand clinical trial collaboration incyte company evaluate efficacy safety incyte investigational selective ido enzyme inhibitor epacadostat combination astrazeneca pd inhibitor imfinzi compare imfinzi alone early lung cancer meanwhile astrazeneca say il human monoclonal antibody tralokinumab fail achieve primary endpoint late stage study severe uncontrolled asthma top line result late stage study show tralokinumab fail achieve statistically significant reduction oral corticosteroid ocs use primary endpoint add standard care patient dependent ocs fda nod drug label expansion fda also grant approval new dosage mg once daily johnson johnson xarelto mg formulation be approve use reduce continue risk recurrent venous thromboembolism vte completion least month initial anticoagulation therapy johnson johnson be zack rank buy stock see complete list today zack rank strong buy stock here valeant get fda nod vyzulta pdufa date idp valeant pharmaceutical international inc vrx free report vyzulta latanoprostene bunod ophthalmic solution also gain fda approval reduction intraocular pressure iop patient open angle glaucoma ocular hypertension company also announce fda have accept regulatory application idp halobetasol propionate tazarotene lotion investigational topical treatment plaque psoriasis response fda regard approval status treatment be expect jun cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline marginally week major stock bristol myer squibb bmy free report be merck mrk free report be last month be merck decline see last pharma stock roundup here lilly top front mixed result bristol myer next pharma world quite few small mid cap pharma company be yet report result moreover bristol myer get response fda regard label expansion blockbuster drug sprycel use treatment child ph chronic phase cp chronic myeloid leukemia cml company be also seek approval powder oral suspension pfos formulation sprycel response agency be expect november wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2297,MRK,dow continue notch gain week marked key legislative development initially investor be concern news house be consider gradual phase corporate tax rate however market receive boost fed choose not hike interest rate month investor sentiment be buoy further house republican finally reveal detailed framework new tax policy subsequently dow hit record close year last week dow increase last friday such gain be power surge tech stock share microsoft corporation msft free report intel corporation intc free report contribute most gain however blue chip index pare gain due loss chevron corp cvx free report merck co mrk free report share decline respectively broader market be also boost third quarter gdp estimate economy come consensus estimate index increase last week register seventh straight weekly gain be also longest streak weekly gain dow december last year broader market gain market watcher remain hopeful new tax code be sign policy soon moreover house representative clear budget blueprint majority republican voting favor move further ecb announce plan extend quantitative ease program dow index lose monday follow report bloomberg house be consider gradual phase corporate tax rate hurt investor sentiment cause broad base loss market investor also eagerly await announcement next fed chief name president trump be expect reveal thursday meanwhile market also suffer paul manafort be convict russian meddle case index increase tuesday follow gain share apple inc aapl free report meanwhile consumer confidence index logged best read many year last month dow gain post seventh straight month gain moreover be also dow longest streak gain april index gain wednesday fed choose not hike interest rate month moreover fed offer positive view economy say have be improve solid rate such comment boost gain broader market meanwhile investor eagerly wait president trump announce name next fed chief ism manufacturing index come october september meanwhile construction spending increase september august index increase thursday house republican finally reveal detailed framework new tax policy subsequently dow hit record close year meanwhile president trump nominated jerome powell post fed chief lead broad base gain market component move index chevron report third quarter earning share higher zack consensus estimate cent year profit cent quarterly revenue surpass zack consensus estimate be year year zack rank hold chevron total production crude oil natural gas increase compare last year corresponding period oil equivalent barrel day mboe chevron downstream segment achieve earning massive higher profit last year read refine higher oil power chevron earning beat exxonmobil corporation xom free report post third quarter report earning cent share surpass zack consensus estimate cent also bottom line improve year quarter level cent total revenue quarter increase year quarter moreover top line surpass zack consensus estimate quarterly earning upstream segment be show improvement year quarter downstream segment record profit report figure be higher july september quarter stock have zack rank strong buy see complete list today zack rank stock here apple report fiscal fourth quarter result earning share revenue easily beat zack consensus estimate respectively year year basis metric grow respectively apple have zack rank steady iphone sale higher average selling price be big factor spurt service segment resurgent macs ipad business backed impressive result fiscal first quarter gross margin be expect operate expense be project other income expense be likely be tax rate be expect be read apple earning impress iphone service lead merck report third quarter adjust earning share beat zack consensus estimate earning rise year year other item adjust earning exclude charge related new oncology collaboration britain astrazeneca azn revenue quarter decline year year sale also miss zack consensus estimate currency movement positively impact revenue exclude currency impact sale decline year year zack rank merck raise previously issue adjust earning guidance raise sale guidance marginally second time year company expect adjust earning range compare expect earlier revenue be expect range compare earlier forecast include negative currency impact less versus approximately previously read merck earning top sale lag keytruda stay strong pfizer inc pfe free report report third quarter adjust earning share cent beat zack consensus estimate cent earning also rise year year drive slightly higher sale lower cost share count pharma heavyweight deliver revenue be line zack consensus estimate revenue rise year quarter report well operational basis zack rank pfizer raise adjust earning guidance tighten revenue expectation year revenue be expect range compare expect previously zack consensus estimate be peg adjust earning share be expect range compare expect previously zack consensus estimate be peg share read pfizer beat earning raise ep view performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have gain tickerlast day performance month performancemmm gs ibm hd ba unh mcd trv jnj aapl next week outlookin recent week market have be buoy record third quarter earning season encourage news legislative front most economic datum release last month have also be encourage nature have few worry front early day ongoing month be likely be only aberration give current state affair market continue notch new record week ahead look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2298,MRK,exelixis inc exel free report report impressive result third quarter back increase cabometyx sale company post third quarter earning cent beating zack consensus estimate cent notably company report loss cent share year quarter exelixis inc price ep surprise exelixis inc price ep surprise exelixis inc quotenet revenue come significantly year quarter revenue also surpass zack consensus estimate millionrevenue be boost increase cabometyx sale fda approve tablet formulation cabozantinib distinct capsule form brand name cabometyx april treatment advanced renal cell carcinoma rcc patient have receive prior angiogenic therapy exelixis share price have increase year date compare industry gain quarter detailtotal product revenue be year quarter cabometyx generate net product revenue sequentially drive growth demand be attributable new patient start refill patient already therapy continue expansion prescriber base cometriq cabozantinib capsule treatment medullary thyroid cancer generate net product revenue total collaboration revenue be compare year quarter report quarter research development expense increase primarily result increase personnel expense clinical trial cost consult outside service selling general administrative expense be drive increase consult outside service support company marketing activity result primarily increase general administrative headcount support company commercial research development organization pipeline company continue focus cabometyx unite state exelixis file supplemental new drug application snda cabozantinib treatment previously untreated patient advanced rcc august fda have accept snda grant priority review assign prescription drug user fee act pdufa action date feb march fda grant cabozantinib orphan drug designation treatment advanced hepatocellular carcinoma hcc october exelixis announce celestial trial meet primary endpoint overall survival os cabozantinib provide statistically significant clinically meaningful improvement os compare placebo patient advanced hcc independent datum monitoring committee study recommend trial be stop efficacy follow review second plan interim analysis exelixis plan submit snda fda first quarter first quarter exelixis inked agreement bristol myer squibb company bmy free report roche hold ag rhhby free report develope cabozantinib combination immunotherapy agent exelixis bristol myer initiate phase iii trial checkmate july meanwhile exelixis roche have agree revise revenue cost sharing arrangement other drug former portfolio cotellic unite sate imspire trilogy trial evaluate combination cotellic tecentriq xelboraf first line braf mutation positive metastatic unresectable locally advanced melanoma be underway imspire trial evaluate combination cotellic tecentriq versus merck co inc mrk free report keytruda first line braf wild type metastatic unresectable locally advanced melanoma be open enrolment expect total cost operate expense range takeexelixis third quarter result be strong earning sale beat estimate drive solid cabometyx sale sequential increase cabometyx sale be positive company thereby underlie increase demand drug new patient market share second line set increase go forward expect investor focus remain further label expansion cabozantinib cotellic potential label expansion first line rcc advanced hcc significantly boost growth prospect company zack rank key pickexelixis currently carry zack rank buy see complete list today zack strong buy rank stock here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
2299,MRK,sanofi sny free report report third quarter earning american depositary share be line zack consensus estimate earning decline report basis however constant currency rate cer earning rise third quarter net sale rise report basis cer almost sale however miss zack consensus estimate unfavorable exchange rate movement hurt sale january french drug maker swap merial animal health business boehringer ingelheim consumer healthcare chc business reflect exchange full consolidation sanofi european vaccine operation sale decline constant structure cs cer sale decline cer unite state however sale rise emerge market europe rest world japan south korea canada australia new puerto rico growth rate mentioned be year year basis cer segmental sale include emerge market increase however cs cer pharmaceutical sale decline double digit growth multiple sclerosis drug vaccine franchise robust growth emerge market be offset decline diabetes establish product generic sale sanofi report global business unit gbus sanofi genzyme specialty care diabetes cardiovascular general medicine emerge market consumer healthcare sanofi pasteur vaccine sanofi genzyme specialty care gbu sale include emerge market increase drive strong launch dupixent higher sale multiple sclerosis ms drug sale ms drug aubagio rise sale lemtrada go however sale drug decline sequentially quarter meanwhile sale rare disease drug myozyme lumizyme improve fabrazyme sale be cerdelga sale come cerezyme sale rise oncology sale rise drive mainly higher sale jevtana thymoglobulin jevtana sale be thymoglobulin record sale taxotere sale rise eloxatine sale be sanofi regeneron pharmaceutical inc regn free report rheumatoid arthritis ra drug kevzara sarilumab be launch unite state june netherlands germany europe third quarter kevzara record sale third quarter compare previous quarter meanwhile dupixent dupilumab treat atopic dermatitis be launch unite state march dupixent generate sale third quarter compare previous quarter management be pleased drug uptake say unite state drug have be prescribe physician meanwhile dupixent be approve eu september be expect be launch germany end year kevzara dupixent generate total immunology sale third quarter diabetes cardiovascular gbu include emerge market decline diabetes franchise include emerge market decline due lower sale key drug lantus sale diabetes drug unite state decline due tough payer environment sale diabetes drug emerge market be europe decline lantus sale decline quarter lantus sale decline unite state due lower average net price exclusion cvs unite health formulary plan europe sale decline due biosimilar competition patient switch toujeo toujeo generate sale report quarter year year basis decline sequentially soliqua once daily titratable fix ratio combination lantus lyxumia be launch unite state january netherlands trade name suliqua recently soliqua suliqua generate sale quarter compare previous quarter management warn diabetes franchise sale decline accelerate rate fourth quarter due cvs unite health formulary exclusion plan difficult comparison last year consider recent market trend sanofi now expect global diabetes sale decline range cagr timeframe previously sanofi have guide sale decline range cardiovascular franchise sanofi pcsk therapy praluent garner worldwide sale report quarter flat sequentially incidentally amgen amgn free report report last week also do not report very significant sequential improvement sale pcsk inhibitor repatha uptake drug have not be very encourage so far due pricing re imbursement issue payer restriction general medicine emerge market gbu sale come sale establish product be strong performance emerge market be offset lower sale europe generic competition plavix japan renvela renagel unite state sale generic decline due lower sale europe consumer healthcare gbu sale be however sale be only exclude acquisition boehringer ingelheim consumer healthcare business due increase competition develop market third quarter consolidated sanofi pasteur vaccine sale increase due strong performance pediatric combination booster vaccine menactra vaccine sale reflect termination sanofi pasteur msd joint venture merck mrk free report europe december cost risesel general administrative expense sg increase cer quarter reflect launch cost dupixent kevzara expense be cer reflect higher pipeline development cost oncology isatixumab pd sotagliflozin outlooksanofi maintain previously issue financial outlook sanofi expect business earning be broadly flat cer anticipate negative currency impact range business earning compare unfavorably prior expectation positive currency impact takesanofi third quarter result mixed report line earning miss sale expectation strong performance multiple sclerosis vaccine franchise successful launch dupixent robust emerge market sale not make weak performance diabetes cardiovascular unit share sanofi be slightly more pre market trading so far year sanofi share price have rise slightly increase industry however greater previously expect headwind currency company maintain earning forecast be encourage be encourage strong performance ms drug aubagio lemtrada be also optimistic sale prospect dupixent prove be important growth driver company however headwind include bleak outlook diabetes franchise generic competition many drug slower expect uptake new product praluent sanofi price consensus ep surprise sanofi price consensus ep surprise sanofi quotesanofi currently carry zack rank sell see complete list today zack rank strong buy stock here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
2300,MRK,aduro biotech inc adro free report report third quarter loss cent share line zack consensus estimate narrower year loss cent share quarterly revenue fall year year top line also miss zack consensus estimate july company recognize milestone payment merck co mrk free report related development aduro cd antibody aduro share have underperform industry so far year stock have decline industry register increase research development expense show substantial increase quarter mainly due increase cost related manufacturing select antibody higher facility related cost general administrative expense be year year due lower consult professional fee pipeline updateaduro have broad pipeline novel immunotherapy development treatment variety cancer company initiate phase study september evaluate personalize live attenuate double delete pladd base immunotherapy immunotherapy used patient specific antigen be study patient microsatellite stable metastatic colorectal cancer aduro most advanced ladd candidate crs be be evaluate combination bristol myer squibb company bmy free report opdivo separate phase ii study gastric cancer mesothelioma datum mesothelioma study be expect end year meanwhile company initiate phase ib study evaluate sting pathway activator adu combination novartis ag nvs free report pd checkpoint inhibitor pdr treat solid tumor lymphomas quarter aduro announce fda have clear investigational new drug application ind april antibody bion company expect initiate phase study aduro biotech inc price consensus ep surprise aduro biotech inc price consensus ep surprise aduro biotech inc quotezack rankaduro currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2301,MRK,benchmark end red monday follow report bloomberg house be consider gradual phase corporate tax rate hurt investor sentiment cause broad base loss market market watcher also await announcement next fed chief name president trump be expect reveal thursday meanwhile market also suffer paul manafort be convict russian meddle case dow jone industrial average djia close lose index inx decrease close meanwhile nasdaq composite index ixic close decrease decline issue outnumber advancer nyse nasdaq decliner outnumber advancer cboe vix increase close benchmark post lossesthe dow decline point end session loss blue chip index be weigh decline share merck co mrk free report verizon communication vz free report share decline respectively merck suffer biggest day decline follow report have withdraw application seek approval usage cancer immunotherapy drug europe major sector end red healthcare stock lead decliner health care select sector spdr etf xlv dip monday post worst day dip aug moreover decline share advanced micro device inc amd free report general motor gm free report lead lower share amd decline analyst morgan stanley ms free report comment demand cryptocurrency mining chip be reduce almost share gm plunge analyst goldman sachs gs free report downgrade stock sell house propose gradual phase corporate taxesreport bloomberg surface monday legislator house be involved formulation new tax code be consider possible phase corporate tax rate cut effectively reduce current rate corporate tax however house way mean chairman kevin brady comment procedure be still review have not be formal decision guideline proposal state tax rate be slash percentage point year begin economist have clearly state such framework be adopt not only become less effective also delay economic effect president trump aide aim achieve however white house press secretary sarah huckabee sander press meeting comment trump want immediately slash tax rate such news lead loss russell index decline post worst single day decline aug investor sentiment be also hurt trump former campaign manager paul manafort be charge conspiracy unite state allege russian meddle presidential election meanwhile investor also eagerly know trump choose next fed chief trump be expect announce decision thursday economic dataon economic datum front personal income month september increase august consensus estimate period be also other hand consumer spending surge more zack consensus estimate mark highest level almost year such rally be attribute fact resident hurricane ravage texas florida replace flood damage automobile economist believe have only short term effect consumer spending meanwhile core pce inflation september increase line consensus estimate stock make headlinesunder armour earning top stock tank view cutunder armour inc uaa free report report mixed quarterly number third quarter earning come ahead zack consensus estimate revenue lag same read more daniel adm free report topple earning sale missarcher daniel company adm free report report dismal third quarter top bottom line lag estimate decline year year read more wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2302,MRK,gilead science inc gild free report announce health canada have grant notice compliance noc update label hepatitis virus drug epclusa drug label have be expand extend drug use patient co infected hiv drug be approve canada july treatment adult genotype chronic hcv infection cirrhosis compensate cirrhosis decompensate cirrhosis combination ribavirin expect drug sale increase label expansion hcv co infection remain major cause morbidity hiv infected individual last month health canada grant noc single tablet regimen vosevi sofosbuvir mg velpatasvir mg voxilaprevir mg chronic hcv infection gilead be know presence hcv market courtesy blockbuster hcv drug sovaldi harvoni hcv portfolio receive huge boost epclusa gain approval unite state june eu july become first only oral pan genotypic str consist sovaldi velpatasvir ns inhibitor treatment adult genotype chronic hcv infection approval vosevi be expect boost gilead strong hcv portfolio further however hcv franchise be pressure due competition pricing issue note harvoni sovaldi epclusa face competition abbvie inc abbv free report viekira pak viekira xr other competition well pricing pressure intensified further launch merck co inc mrk free report zepatier gilead stock have gain year date industry gilead recently announce plan acquire kite pharma inc foray emerge field cell therapy kite be pioneer cell therapy have develop engineer cell therapy express chimeric antigen receptor car engineer cell receptor tcr depend type cancer acquisition diversify gilead portfolio poise company dominant position cellular therapy space note investor be expect gilead announce acquisition term give decline once lucrative hcv market due competitive pressure zack rankgilead currently carry zack rank hold see complete list today zack rank strong buy stock here trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2303,MRK,pfizer inc pfe free report german partner merck kgaa announce pd monoclonal antibody bavencio avelumab have be grant marketing authorization eu monotherapy treat adult patient metastatic merkel cell carcinoma mmcc rare aggressive skin cancer company expect make drug commercially available eu germany next month notably approval drug now be market country eu include norway liechtenstein iceland be first approve immunotherapy eu give indication bavencio receive fda approval mmcc march approval drug become first immunotherapy option say cancer treatment bavencio receive fda approval second indication drug be approve urothelial carcinoma aggressive disease high rate recurrence also earlier month drug be grant approval switzerland treatment mmcc pfizer share be so far year compare unfavorably rally industry period approval be support positive datum phase ii study javelin merkel remind investor approval follow positive opinion adopt committee medicinal product human use chmp european medicine agency ema recommend approval bavencio mmcc july pfizer focus bavencio continuously grow expand new indication market globally also bavencio be be evaluate collaboration merck kgaa different type cancer include late stage study renal cell carcinoma lung cancer ovarian cancer head neck cancer pfizer be major player immunotherapy be several other big small company look develop introduce immunotherapy treatment market matter fact merck co inc mrk free report be conduct numerous study evaluate pd therapy keytruda more type cancer more study include more combination study astrazeneca plc azn free report recently approve immuno oncology drug imfinzi durvalumab be be assessed multiple cancer alone combination other regimen have bright long term prospect smaller biotechs be also work bring innovative immuno oncology treatment market kite pharma lead drug axicabtagene ciloleucel be currently priority review unite state treat aggressive hodgkin lymphoma nhl fda decision expect nov however believe bavencio give drug tough run money be ample scope growth immuno oncology space pfizer inc price pfizer inc price pfizer inc quotezack rankpfizer currently carry zack rank hold see complete list today zack rank strong buy stock here trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2304,MRK,dow mop gain week buoy announcement federal reserve decline tension unite state north korea lead gain index monday index moved higher tuesday speculation fed declare be trimming balance sheet actual announcement lead further gain wednesday ultimately index snap day stretch gain thursday stock lose luster follow fed announcement last week dow gain last friday mark sixth consecutive session gain stock be buoy rally bank stock even investor digest missile launch japan north korea bank share surge follow strong inflation number come expectation raise speculation rate hike fed retail sale drop august biggest decline month index gain last week investor sentiment improve impact hurricane irma be weaker expect dow also post biggest day percentage gain mar speaking investment conference treasury secretary state trump administration expect tax reform materialize year end also north korea threaten raze japan unite state nuclear weapon issue fresh sanction country dow index gain hit fresh record high north korea fear ebb follow secretary treasury rex tillerson announcement unite state be look peaceful solution problem country further investor focuse federal open market committee fomc day meeting give rise speculation fed start unwinding balance sheet boost treasury yield lead broad base gain financial sector index increase tuesday day fomc meeting kick meanwhile president donald trump make debut speech unite nation general assembly urge member state combat rogue nation north korea iran index gain wednesday federal reserve announce begin trimming balance sheet october fed also decide keep benchmark interest rate unchanged indicated rate hike be likely december such statement lead gain financial share benefit bank index lose thursday bring end successive day gain period index experience average increase point stock lose luster fed hint rate hike unwinding balance sheet be offing end year share apple inc aapl free report procter gamble co pg free report lose respectively contribute primarily day loss index component move index apple little snafu stage demonstrate new facial recognition feature mega edition iphone not only result wave troll meme social medium also give competitor opportunity take potshot tech giant report facebook fb free report ad post huawei take jab used clown iphone facial recognition state fail often person real artificial intelligence ai phone come oct refer upcoming device mate apple mega event sep company suffer major embarrassment phone craig federighi be used demonstrate face id feature do not unlock software chief be force use backup work be require read apple mock huawei take iphone mate development zack rank hold apple have acknowledge latest apple watch os series have issue cellular connectivity assured engineer be work problem fix be soon available future software release apple comment come several prominent reviewer lambaste watch repeat failure connect lte apple have tout build cellular usp watch read apple say watch have connectivity issue fix offing boee co ba free report have win modification contract worth provide new preliminary design activity requirement presidential aircraft par program contract be award air force life cycle management center patterson air force base contract boee complete preliminary design work modification aircraft replace age vc boee used presidential support aircraft work be schedule be complete dec be execute seattle wa read boee win air force contract par program additionally boee announce have secure contract air force provide support service minuteman iii weapon system contract company provide operation maintenance testing technical datum delivery support minuteman iii stock have zack rank buy see complete list today zack rank strong buy stock here johnson johnson jnj free report announce european medicine agency ema committee medicinal product human use chmp have grant positive opinion recommend approval pipeline candidate guselkumab treatment moderate severe plaque psoriasis eu johnson johnson have zack rank sell drug be approve unite state july year be market trade name tremfya treatment immune system related skin disorder decision european commission ec be expect later year read psoriasis drug guselkumab get chmp nod eu jpmorgan chase co jpm free report recently make undisclosed investment bill com largest business business payment network unite state move be part company effort enable business client do away paper check instead make receive payment electronically bill com technology be likely be integrate zack rank jpmorgan digital system early association benefit bank customer allow have access bill com network comprise almost user read jpmorgan partner bill com eradicate paper payment pfizer inc pfe free report announce fda advisory committee give mixed opinion regard regulatory application be file expand label cancer drug sutent sutent be presently market first line treatment advanced renal cell carcinoma rcc latest supplemental new drug application snda be accept fda year pfizer be look get label extend include use patient high risk rcc recurrence read pfizer sutent label expansion get mixed fda committee view meanwhile pfizer have file lawsuit district court allege johnson johnson be resort unfair practice prevent sale inflectra pfizer biosimilar version merck co inc mrk free report blockbuster rheumatoid arthritis drug remicade pfizer biosimilar version be available wholesale acquisition cost wac be lower reference product read pfizer sue accuse prevent inflectra uptake performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have gain tickerlast day performance month performancemmm gs ibm hd ba unh mcd trv jnj aapl next week outlookdespite gain make prior announcement fed hawkish stance have ultimately rob stock much luster have end long stretch gain such narrative be unlikely continue much longer next week feature release several crucial economic report include important gdp datum positive sign front be enough help stock return winning way trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2305,MRK,last week be eventful european society medical oncology esmo congress take place week see approval pfizer inc pfe free report bavencio europe hand tesaro inc tsro free report zejula receive positive chmp opinion eu other pfizer sutent get mixed view fda advisory committee label expansion application setback roche rhhby free report early stage study tecentriq be put partial hold smaller biotech company karyopharm therapeutic inc kpti free report announce oral selective inhibitor selinexor be superior placebo reduce risk progression death liposarcoma patient recap week most important storiestesaro zejula near approval europe ovarian cancer tesaro announce committee medicinal product human use chmp have recommend marketing approval zejula company be seek approval zejula monotherapy maintenance treatment woman suffering recurrent epithelial ovarian fallopian tube primary peritoneal cancer be complete partial response cr pr platinum base chemotherapy drug be approve unite state march read more tesaro drug zejula get positive chmp opinion tesaro inc price consensus tesaro inc price consensus tesaro inc quotepfizer bavencio approve europe mixed view sutent pfizer bavencio receive boost approval europe treat metastatic merkel cell carcinoma approval bavencio become first immunotherapy available europe indication launch be expect october drug be already approve unite state however label expansion application sutent adjuvant treatment recurrent renal cell carcinoma rcc receive mixed opinion fda advisory committee decision fda be expect january drug be currently approve first line treatment rcc read more pfizer sutent label expansion get mixed fda committee view pfizer inc price consensus pfizer inc price consensus pfizer inc continue roche last week approval amgen biosimilar roche cancer drug avastin fda week put partial hold early stage study latter tecentriq be evaluate drug multiple myeloma follicular lymphoma patient partial hold be implement due safety issue find study evaluate merck co mrk free report keytruda combination celgene revlimid pomalyst blood cancer meanwhile datum announce phase iii murano study conduct roche show venclexta combination rituxan achieve statistically significant improvement progression free survival chronic lymphocytic leukemia patient compare teva pharmaceutical industry limit teva free report treanda rituxan read more roche announce positive datum leukemia drug roche hold ag price consensus roche hold ag price consensus roche hold ag quote trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2306,MRK,pfizer inc pfe free report have file lawsuit district court allege johnson johnson jnj free report be resort unfair practice prevent sale inflectra pfizer biosimilar version merck co inc mrk free report blockbuster rheumatoid arthritis drug remicade pfizer biosimilar version be available wholesale acquisition cost wac be lower reference product pfizer share be wednesday share be however pfizer share have underperform industry year so far stock have return period compare unfavorably increase industry pfizer allege complaint file district court eastern district pennsylvania have enter biosimilar exclusion contract insurer contract encourage insurer not cover inflectra thereby make easily accessible patient protect reference product pfizer also claim anticompetitive contract be be offer hospital encourage discount purchase remicade condition do not buy biosimilar version pfizer claim unfair practice benefit sale reference product be key revenue generator latter remind investor second quarter conference call hold august pfizer have say inflectra penetration unite state have be slower expect be experience access challenge national commercial payer other hand have say second quarter conference call hold july rate penetration inflectramay be modest latest lawsuit suggest be responsible slow sale inflectra please note april year samsung bioepis biosimilar version remicade also receive fda approval pfizer have launch inflectra unite state november last year biosimilar be also market ex market inflectra generate sale unite state globally second quarter biosimilar be essentially cheaper version expensive biologic drug be complex make traditional generic drug biosimilar have be available eu quite be regulatory pathway biosimilar unite state long time however change pass biologic price competition innovation act bpci act part affordable care act president obama sign law march several pharma well biotech company be involved development biosimilar first biosimilar gain approval unite state be sandoz zarxio biosimilar version amgen inc amgn free report neupogen zarxio be launch unite state september inflectra be second biosimilar gain approval other approve biosimilar country include sandoz erelzi biosimilar amgen enbrel amgen amjevita biosimilar version abbvie humira however have not be launch yet due ongoing litigation earlier month fda approve first cancer biosimilar amgen allergan mvasi biosimilar version roche blockbuster cancer drug avastin biosimilar be expect reduce health care cost provide large number patient access much need biologic treatment however so far biosimilar have not see much commercial success be yet make significant dent reference product sale unite state fight drug giant be likely aid effort lower drug price increase biosimilar availability pfizer carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2307,MRK,roche holding ag rhhby free report announce positive result phase iii study murano study evaluate venclexta combination rituxan patient suffering relapse refractory chronic lymphocytic leukemia cll datum show study meet primary endpoint result depict statistically significant improvement time patient live disease progress progression free survival pfs treat venclexta rituxan compare treanda rituxan note roche be develop venclexta collaboration abbvie inc abbv free report company be commercialize drug unite state abbvie commercialize outside country remind investor fda approve venclexta april treatment person cll have receive least prior therapy deletion detected fda approve test fda also grant breakthrough therapy designation venclexta combination rituxan treatment relapse refractory cll base promising result phase ib study company be conduct murano study convert current accelerate approval venclexta full approval datum study be present upcoming medical meeting submit global health authority estimate be more new case cll diagnosed unite state cll be most common type adult leukemia hence potential approval indication boost sale potential roche hematology portfolio include approve drug mabthera rituxan gazyva tecentriq venclexta pipeline candidate polatuzumab vedotin rg small molecule antagonist mdm idasanutlin rg last week fda place partial clinical hold phase ib phase ii trial evaluate immuno oncology drug tecentriq due safety issue partial hold be put due emerge safety datum clinical trial evaluate merck co mrk free report keytruda combination celgene corp celg free report revlimid pomalyst note fda have put hold several trial fusion program celgene roche stock have gain compare industry gain year so far roche have strong presence oncology market company dominate breast cancer space due strong demand franchise drug herceptin perjeta kadcyla however sale avastin tarceva continue decline generic competition xeloda continue hurt sale competition biosimilar loom large roche key drug herceptin avastin rituxan zack rankroche currently carry zack rank hold see complete list today zack rank stock here promising stock pick keep eye news story computer hacking identity theft become increasingly commonplace cybersecurity industry look promising investment opportunity stock buy zack just release cybersecurity investor guide locking profit help answer question new special report give information need make well inform investment choice space more importantly also highlight cybersecurity pick strong profit potential get new investing guide now
2308,MRK,roche holding ag rhhby free report announce fda have put partial clinical hold phase ib phase ii trial evaluate tecentriq due safety issue partial hold be put due emerge safety datum clinical trial evaluate merck co mrk free report keytruda combination celgene corporation celg free report revlimid pomalyst note fda have put hold several trial fusion program celgene fda be currently evaluate ongoing blood cancer trial investigate pd pdl drug combination drug order determine be class wide pd pdl concern multiple myeloma blood cancer specific concern certain combination drug study include cohort evaluate tecentriq combination medicine imid relapse refractory multiple myeloma relapse refractory follicular lymphoma result partial clinical hold patient be currently enroled trial be derive clinical benefit continue receive treatment additional patient be enroled note fda grant accelerate approval immuno oncology drug tecentriq treatment patient suffering locally advanced metastatic urothelial carcinoma initial uptake drug have be encourage october tecentriq become first only pdl cancer immunotherapy be approve fda treatment metastatic nsclc fda recently grant accelerate approval tecentriq treatment patient suffering locally advanced metastatic urothelial carcinoma muc be not eligible cisplatin chemotherapy drug be previously approve patient suffering locally advanced muc have disease progression follow platinum contain chemotherapy month receive chemotherapy surgery neoadjuvant surgery adjuvant news come disappointment label expansion drug boost sale roche stock have gain industry gain year so far earlier fda also put partial clinical hold bristol myer squibb company bmy free report clinical trial checkmate checkmate same reason trial be investigate opdivo base combination patient relapse refractory multiple myeloma zack rankroche currently carry zack rank hold see complete list today zack rank stock here new report investor guide have become more frequent destructive ever fact re expect cause year damage cybersecurity industry be expand quickly response threat fact project year be spend protect consumer corporate asset zack have just release cybersecurity investor guide locking profit reveal promising investment candidate download new report now
2309,MRK,cancer capable striking fear even strongest heart be malignancy characterize uncontrolled growth abnormal cell not treat lead death accord american cancer society be more type cancer deadliest be breast cancer skin cancer lung cancer colon cancer prostate cancer blood cancer presentation european society medical oncology esmo congress hold sep madrid spain dominate headline cancer space week major presentation include bristol myer squibb company bmy free report astrazeneca plc azn free report positive result ongoing phase iii study melanoma lung cancer patient respectively pfizer inc pfe free report disappointing datum lung cancer candidate recap week most important imfinzi positive phase iii lung cancer study astrazeneca announce promising lung cancer datum late stage study new cancer drug imfinzi interim datum phase iii study pacific demonstrated imfinzi achieve improvement month progression free survival standard care patient locally advanced unresectable small cell lung cancer nsclc have not progressed follow chemoradiation datum separate phase iii flaura study lung cancer drug tagrisso show drug reduce risk progression death more half compare other commonly used egfr inhibitor read more astrazeneca lung cancer study datum promising bristol myer opdivo superior yervoy melanoma patient bristol myer announce datum phase iii study checkmate compare opdivo yervoy treat patient stage iiib stage iv melanoma have undergo complete resection interim datum study show opdivo be superior yervoy opdivo achieve statistically significant improvement recurrence free survival compare yervoy read more bristol myer report positive result melanoma study pfizer xalkori fail lung cancer study xtandi positive prostate cancer study pfizer ongoing phase iii study profile evaluate xalkori first line treatment alk positive nsclc do not meet secondary endpoint significant improvement overall survival os rate median follow month median os patient treat xalkori be month be month patient randomize chemotherapy however pfizer prostate cancer candidate xtandi achieve statistically significant improvement metastasis free survival drug be be evaluate combination androgen deprivation therapy phase iii study prosper potential label expansion include early stage prostate cancer patient read more pfizer lung cancer drug overall survival datum unfavorable disappointing week roche fda accept sandoz generic arm novartis biologic license application biosimilar version roche rhhby free report leukemia treatment rituxan rituximab novartis have receive approval rituxan biosimilar europe june rituxan have record sale almost first half setback fda approve amgen allergan biosimilar version key drug avastin treat multiple cancer indication include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer biosimilar be market trade name mvasi read more novartis bla biosimilar rituxan accept fda other updatesapart abovemention news be few other update cancer space fda accept new drug application ndas array biopharma seek approval combination binimetinib encorafenib treat patient braf mutant advanced unresectable metastatic melanoma regulatory body also accept supplemental nda teva pharmaceutical industry ltd teva free report trisenox seek label expansion drug include treatment nave acute promyelocytic leukemia patient nektar therapeutic announce initiation dose phase ii study evaluate efficacy safety lead immuno oncology candidate nktr combination roche tecentriq merck mrk free report keytruda look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2310,MRK,bristol myer squibb company bmy free report recently enter collaboration license agreement halozyme therapeutic inc halo free report agreement bristol myer use halozyme enhanze drug delivery technology facilitate subcutaneous administration bristol myer immuno oncology drug enhanze technology be base proprietary recombinant human hyaluronidase enzyme rhuph temporarily degrade hyaluronan chain natural sugar body enable dispersion absorption other inject therapeutic drug term agreement bristol myer pay initial use enhanze technology company have also designate multiple immuno oncology target include programme death pd have option select additional target year effective date collaboration extend maximum target halozyme be entitle milestone payment nominated collaboration target additional milestone payment combination product moreover bristol myer be also require pay halozyme royalty drug used enhanze technology develop collaboration bristol myer transaction be expect have dilutive impact bottom line approximately cent cent addition halozyme license enhanze technology roche holding ag rhhby free report exclusive development undisclosed therapeutic target term deal halozyme receive initially potential earn milestone payment subject achievement specify development regulatory sale base milestone halozyme also receive tiered mid single digit royalty sale commercialize product concurrent deal company raise sale guidance share halozyme be follow news meanwhile news bode well bristol myer too note bristol myer opdivo become first pd inhibitor be approve hematological malignancy classic hodgkin lymphoma unite state eu november label expansion additional indication give product access higher patient population increase commercial potential drug company have earlier suffer setback january decide not pursue accelerate regulatory pathway regimen opdivo yervoy first line lung cancer unite state base review available datum currently opdivo be face competitive challenge unite state fda approve merck co mrk free report keytruda first line treatment metastatic nonsquamous nsclc company be expect suffer further loss market share hence access larger population improve sale share price movement bristol myer stock have gain year date compare industry gain zack rankbristol myer currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2311,MRK,biosimilar space remain spotlight number regulatory decision be pending generic drug be follow version chemically synthesize molecule biosimilar contain version active substance already approve original biological drug development biosimilar be technically challenge development generic drug former require clinical study patient be engineer match reference drug quality safety efficacy due complex nature product development regulatory pathway biosimilar differ significantly generic biosimilar be usually less expensive brand drug thus market same remain highly lucrative acceleration approval biosimilar market have thus attract lot player be witness rapid growth here be few latest development space lead biosimilar space be novartis ag nvs free report generic arm sandoz be strong player biosimilar market market biosimilar omnitrope human growth hormone binocrit erythropoiesis stimulating agent used treat anemia filgrastim neutropenia brand name zarzio outside unite state zarxio unite state company plan launch major oncology immunology biosimilar include biosimilar version rituxan rituximab be approve european commission june market rixathon recently fda accept biologic license application bla propose biosimilar version rituxan august sandoz erelzi biosimilar version amgen inc amgn free report blockbuster drug enbrel gain approval unite state indication erelzi be also approve european commission european medicine agency also accept company marketing authorization application biosimilar version humira adalimumab remicade infliximab review novartis currently carry zack rank hold see complete list today zack rank strong buy stock here generic leader mylan nv myl free report be also explore world biosimilar market have potential grow fda recently notified mylan partner biocon target action date biosimilar version herceptin trastuzumab have be extend dec decision fda be expect sep fda extend review period due review clarificatory information submit agency part application review process note biocon partnership include biosimilar program such biosimilar version herceptin neulasta humira avastin enbrel neupogen insulin analog lantus humalog novolog mylan have collaboration agreement momenta pharmaceutical inc mnta free report develop manufacture commercialize momenta current biosimilar candidate include momenta biosimilar candidate orencia mylan currently carry zack rank strong sell meanwhile amgen allergan plc agn free report have also submit bla fda abp biosimilar candidate herceptin jul note company be collaborate oncology biosimilar include abp be second be submit fda approval company have also submit marketing authorization application european medicine agency candidate earlier note amgen have total biosimilar pipeline have be approve fda march european commission grant marketing authorization amgevita biosimilar version humira available indication company have important event line fda be expect give decision approval abp biosimilar version avastin shortly amgen currently carry zack rank hold last month biotech major biogen inc biib free report announce european commission grant marketing authorization imraldi biosimilar version humira be third tnf biosimilar biogen receive marketing authorization european union follow approval benepali biosimilar enbrel flixabi infliximab biosimilar version remicade biogen currently carry zack rank hold july merck co inc mrk free report launch reneflexis biosimilar version remicade unite state be approve fda april fda also grant tentative approval lusduna nexvue biosimilar version lantus basal insulin pre filled dose device merck currently carry zack rank hold medical sector yr return medical sector yr give fact so much be happen space expect investor focus upcoming approval date trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2312,MRK,nektar therapeutic nktr free report announce initiation phase ii propel study evaluate efficacy safety lead immuno oncology candidate nktr combination roche rhhby free report tecentriq atezolizumab merck mrk free report keytruda pembrolizumab notably checkpoint inhibitor tecentriq be approve treatment metastatic urothelial carcinoma unite state keytruda be recently approve refractory classical hodgkin lymphoma chl unite state eu nektar share have significantly outperformed industry so far year stock have surge much broader industry increase propel study complement nektar ongoing pivot trial nktr be be evaluate combination bristol myer bmy free report opdivo nivolumab tumor type melanoma kidney colorectal bladder small cell lung cancer potential indication phase ii study propel study be aim establish synergy nktr combine tecentriqor keytruda study be conduct separate arm patient first arm evaluate combination nktr tecentriq dose regimen week patient adhere approve treatment setting tecentriq include patient small cell lung cancer bladder cancer other hand second arm assess dose regimen nktr combination keytruda week approve treatment setting keytruda include patient melanoma small cell lung cancer bladder cancer company combination therapy provide cancer patient suffering multiple tumor type new treatment option combine approve checkpoint inhibitor therapy apart nktr interesting candidate company portfolio be onzeald currently accelerate assessment eu treat adult advanced breast cancer have brain metastase however july nektar file request re examination negative opinion adopt chmp same meanwhile nektar initiate randomize phase iii confirmatory study attain onzeald compare single agent chemotherapy physician choice patient advanced breast cancer have brain metastase shortly positive result study support regulatory filing unite state other pipeline candidate company portfolio include nktr mu opioid analgesic candidate chronic pain condition phase iii nktr autoimmune disease phase successful development candidate boost company top line consider lucrative market be target nektar therapeutic price nektar therapeutic price nektar therapeutic quotezack ranknektar currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2313,MRK,bristol myer squibb company bmy free report announce encourage result phase iii study checkmate opdivo checkmate be ongoing phase iii randomize double blind study opdivo versus yervoy patient have undergo complete resection stage iiib stage iv melanoma result study show opdivo mg kg lead significant improvement recurrence free survival rfs compare yervoy ipilimumab mg kg patient stage iiib stage iv melanoma follow complete surgical resection result plan interim analysis show opdivo meet primary endpoint statistically significant improvement rfs compare yervoy july company report positive result same study last week company report positive result phase iii study evaluate opdivo yervoy patient previously untreated advanced metastatic renal cell carcinoma rcc meet co primary endpoint study show superior overall survival compare current standard care pfizer inc pfe free report sutent intermediate poor risk patient base plan interim analysis independent datum monitoring committee recommend study be stop early note opdivo become first pd inhibitor be approve hematological malignancy classic hodgkin lymphoma unite state eu november november opdivo gain fda approval treatment patient recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy label expansion additional indication give product access higher patient population increase commercial potential drug however bristol myer suffer setback january decide not pursue accelerate regulatory pathway regimen opdivo yervoy first line lung cancer unite state base review available datum currently opdivo be face competitive challenge unite state fda approve merck co mrk free report keytruda first line treatment metastatic nonsquamous nsclc company be expect suffer further loss market share meanwhile fda put partial clinical hold clinical trial checkmate checkmate trial be investigate opdivo base combination patient relapse refractory multiple myeloma bristol myer stock have gain year date industry gain fda put study hold due risk identify keytruda pd agent patient multiple myeloma addition concern astrazeneca plc azn free report fail study lung cancer drug imfinzi loom large company checkmate study opdivo zack rankbristol myer currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2314,MRK,biotech bigwig gilead science inc gild free report develop drug treatment human virus hiv liver disease such chronic hepatitis virus hcv infection chronic hepatitis virus hbv infection cardiovascular hematology oncology inflammation respiratory disease apart blockbuster hcv drug sovaldi harvoni recently launch epclusa primary product gilead include stribild viread atripla complera eviplera emtriva other tenofovir alafenamide taf base product genvoya odefsey descovy newly approve hbv drug vemlidy gilead have solid presence hcv market however hcv franchise continue grapple competitive pricing pressure lead massive decline harvoni sovaldi sale harvoni sovaldi have be face competition abbvie abbv free report viekira pak viekira xr merck mrk free report zepatier nevertheless hcv portfolio receive major boost epclusa gain approval fda also approve vosevi tablet single tablet regimen str re treatment chronic hcv infection adult sovaldi recently obtain approval china approval new drug somewhat offset decline legacy drug gilead stock have gain last month compare industry gain company suffer decline hcv sale third quarter same be expect fourth quarter well hcv product sale be report year quarter downside be mainly attribute lower sale harvoni sovaldi major market partially offset higher sale epclusa launch sale vosevi approve unite state europe july patient start have exceed expectation competition have start erode gilead hcv market share net pricing company see impact third quarter most be due be experience fourth quarter hence expect older hcv product continue witness decline sale company expect hcv product sale zack consensus estimate sale lead hcv drug sovaldi harvoni be respectively fourth quarter hence weakness hcv franchise adversely impact gilead performance fourth quarter gilead have mixed track record company beating estimate last miss earning beat look highly unlikely fourth quarter give competitive pressure read more gilead disappoint investor earning zack rank key pickgilead currently carry zack rank sell see complete list today zack strong buy rank stock here better rank stock healthcare sector be exelixis exel free report zack rank strong buy exelixis earning share estimate have moved cent cent last day company deliver positive earning surprise last quarters average beat breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2315,MRK,fourth quarter earning result be pour focus be back healthcare sector high president trump agenda be attempt repeal replace affordable care act less year trump administration achieve primary objective tax cut new healthcare legislation tax cut job act new law effectively repeal individual mandate be essential proper function obamacare read more however upbeat quarterly result rise demand new product sale successful innovation fda approval product line expansion strong clinical study result well continue strong performance legacy product propel large cap drug sector new high tailwind be expect drive sector growth even read more healthcare sector jump past year better rally sign sector success become more evident last month nyse arca pharmaceutical index nasdaq biotechnology index gain respectively broader industry grow same time period merck co inc mrk free report sanofi sny free report schedule report feb feb respectively be good time figure be better stock stock carry zack rank hold see complete list today zack rank strong buy stock here other major pharma earning schedule period include bristol myer squibb company bmy free report astrazeneca plc azn free report price have see gain past month sanofi have decline so merck be clear winner respect better return rival sanofi broader industry rise same period most appropriate ratio evaluate drug maker be perhaps ev ebitda metric be usually used compare stock same industry be superior other metric such be not affected different capital structure company come pharma major merck sanofi be undervalue relative broader industry have ev ebitda value however sanofi hold edge here lower ev ebitda value compare merck value dividend yieldover last year merck sanofi offer dividend yield respectively industry return dividend yield so merck have take lead here too respect sanofi broader industry net marginthe pharmaceutical industry enjoy higher profit margin several other sector be possibly reason critic sector continually draw attention allegedly exorbitant drug pricing help sector maintain steep margin net margin value sanofi underperform rival merck have net margin value comparison broader industry have net margin value return equityreturn equity roe be key financial ratio pharma company entity employ huge amount capital bring product market respect used roe help evaluate company ability generate ample profit equity capital pharma company merck sanofi have comparatively lower roe respectively broader industry value however compare individual performance merck hold edge sanofi earning history espconsider more comprehensive earning history merck have deliver positive surprise prior quarters average earning surprise comparison sanofi deliver average positive earning surprise trail quarters merck manage post earning beat trail quarters meanwhile sanofi register earning beat only first quarter result be line estimate next consider earning esp merck be once again clear winner esp sanofi be disadvantage merck esp be conclusionour comparative analysis show sanofi hold edge merck consider only ev ebitda ratio however consider price performance roe net margin merck be advantage sanofi additionally merck also sport better dividend yield sanofi more comprehensive look previous earning performance merck be clearly better stock clinch case favorof merck point time be have positive esp be lead indicator likely positive surprise be be better bet merck sanofi prepare report earning next few day wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2316,MRK,investor be always look stock be poise beat earning season merck co inc mrk free report be such company firm have earning come pretty soon event be shape quite nicely report be merckis see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface mrk report fact most accurate estimate current quarter be currently cent share mrk compare broader zack consensus estimate cent share suggest analyst have very recently bump estimate mrk give stock zack earning esp head earning season merck company inc price ep surprise merck company inc price ep surprise merck company inc quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give mrk have zack rank esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead merck beat be card upcoming report wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2317,MRK,expect bristol myer squibb company bmy free report beat expectation report fourth quarter result feb market open bristol myer share have increase past year industry record increase bristol myer track record have be mixed so far company deliver positive earning surprise last quarters miss expectation twice average positive earning surprise last quarters be last report quarter bristol myer deliver negative surprise let see thing be shape quarter factor playbristol myer blockbuster immuno oncology drug opdivo be expect continue primary sale driver fourth quarter drug be already approve multiple cancer indication past quarters drug receive approval line extension be expect boost sale moreover december opdivo label be expand adjuvant therapy completely resect melanoma fda approval merck mrk free report keytruda first line treatment metastatic squamous nsclc have lower expect impact third quarter sale zack consensus estimate fourth quarter keytruda sale be peg flat year actual figure january european commission approve label expansion yervoy injection pediatric patient year age older unresectable metastatic melanoma fda have approve drug indication july zack consensus estimate drug sale fourth quarter be november bristol myer announce fda have approve line extension orencia pediatric patient ph chronic myeloid leukemia chronic phase label expansion include psoriatic arthritis july new administration option approve june be expect fuel growth drug register growth previous quarter zack consensus estimate orencia sale be other hand decline hepatitis franchise be expect continue due intense competition multiple drug include epclusa label be expand include hiv co infection august moreover hiv business continue face competitive pressure recent launch other company same space be expect further impact sustiva franchise zack consensus estimate hepatitis franchise sale be peg quarter year quarter actual figure company be develop key drug opdivo monotherapy well combination therapy several tumor type multiple study label expansion application review unite state expect investor focus update related opdivo conference call likely positive surprise proven model indicate bristol myer be likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate zack consensus estimate stand be lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank bristol myer have zack rank combination positive earning esp favorable zack rank make reasonably confident earning beat conversely caution sell rate stock go earning announcement especially company be see negative estimate revision bristol myer squibb company price consensus bristol myer squibb company price consensus bristol myer squibb company quoteother stock considerhere be biotech stock also want consider model show have right combination element post earning beat quarter alexion pharmaceutical inc alxn free report be schedule release result feb company have earning esp zack rank see complete list today zack rank stock here anthera pharmaceutical inc anth free report be expect release result feb company have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2318,MRK,benchmark finished negative territory tuesday follow slump healthcare energy stock blue chip amazon berkshire jpmorgan announce together form healthcare company order cut related cost employee turn weigh healthcare sector additionally recent increase shale production lead energy stock downward moreover rise bond yield have broad base negative impact key index experience worst day performance august dow witness biggest day drop last benchmark fared dow jone industrial average dji decrease point close fall close tech laden nasdaq composite index close lose fear gauge cboe volatility index vix increase close highest level august total share be trade tuesday higher last session average share decliner outnumber advancer nyse ratio nasdaq ratio favore decline issue moved benchmark tuesday commerce giant amazon com amzn free report make announcement together berkshire hathaway inc brk free report jpmorgan chase jpm free report healthcare company be build order cut cost employee improve worker satisfaction goal partnership be create company sole intention provide healthcare workforce future entity not aim make profit read more follow development health care select sector spdr xlv fall become worst perform sector session sector witness highest day drop last october dow component unitedhealth group incorporate unh free report merck co inc mrk free report decrease respectively additionally earning front pfizer inc pfe free report report fourth quarter adjust earning share revenue beat respective zack consensus estimate however share pfizer fall pharma heavyweight expect adjust tax rate be higher investor anticipate read more oil price dip weigh energy stocksoil price fall tuesday shale production recently come barrel day highest level jan eia wti brent crude price decrease settle barrel barrel respectively decrease oil price have adverse impact energy select sector spdr xle slump become second worst perform sector key component include chevron corporation cvx free report exxon mobil corporation xom free report decline respectively energy giant possess zack rank hold see complete list today zack rank strong buy stock here separately higher rate environment optimism steady economic growth higher inflation weigh bond price lower bond price support year treasury yield increase tuesday reach highest settlement almost year higher treasury yield also weigh broader equity market stock make headlinesc robinson surpass earning revenue robinson worldwide inc chrw free report fourth quarter earning share revenue beat respective zack consensus estimate read more robert half earning sale top estimate yrobert half international inc rhi free report come solid fourth quarter result top bottom line come ahead zack consensus estimate read more hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2319,MRK,pfizer inc pfe free report report fourth quarter adjust earning share cent beat zack consensus estimate cent earning also rise year year drive higher international sale lower cost share count pharma heavyweight deliver revenue also beat zack consensus estimate revenue rise year quarter report basis operational basis revenue be flat year year sale detailcurrency movement benefit pfizer fourth quarter revenue february pfizer divest hospira infusion system business icu medical exclude currency headwind revenue prior year quarter sale rise operationally strong performance newer product ibrance breast cancer xtandi prostate cancer xeljanz rheumatoid arthritis somewhat offset lower sale enbrel viagra loss exclusivity product supply shortage legacy hospira product international revenue rise operational basis meanwhile revenue decline segment report segment be pfizer innovative health ih pfizer essential health pfizer ih sale grow report basis operational basis year period pfizer ih revenue be drive persistently strong momentum eliquis globally xeljanz lyrica ibrance chantix champix primarily unite state ibrance revenue rise quarter drive strong revenue however ibrance sale be softer prior quarter time price adjustment hurt international sale xeljanz sale rise lyrica sale rise eliquis alliance revenue direct sale rise chantix sale rise quarter revenue blockbuster prostate cancer drug xtandi add pfizer portfolio follow september medivation acquisition also contribute revenue xtandi record alliance revenue quarter compare third quarter be partially offset continue decline revenue prevnar unite state lower revenue enbrel viagra enbrel revenue decline key european market due biosimilar competition pfizer have exclusive right amgen inc amgn free report blockbuster rheumatoid arthritis ra drug enbrel outside unite state canada total viagra ih sale decline due generic competition begin december global prevnar prevenar revenue rise higher international sale make decline unite state prevnar revenue tank unite state due continue decline revenue eligible adult patient population however prevenar revenue rise international market due favorable timing government purchase emerge market pediatric indication consumer healthcare revenue decline global oncology revenue increase global vaccine revenue rise internal medicine rise inflammation immunology franchise rise additionally portfolio rare disease decline pfizer be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction decision be expect year also be retain business pfizer segment sale record decline operationally exclude revenue sale decline revenue be hurt loss exclusivity associate generic competition product primarily pristiq unite state lyrica europe lower revenue legacy hospira product due product shortage divesture however business biosimilar emerge market do well quarter biosimilar revenue rise operationally emerge market revenue grow operationally pfizer launch inflectra biosimilar version johnson johnson jnj free report merck mrk free report blockbuster ra drug remicade november last year inflectra record sale unite state globally other biosimilar bring sale outside market adjust selling informational administrative si expense decline operationally quarter adjust expense also decline resultsfull year sale be flat year year operational basis sale marginally beat zack consensus estimate be line guidance range adjust earning share full year exceed zack consensus estimate well guide range earning rise year year guidancerevenue be expect range zack consensus estimate be peg adjust earning share be expect range zack consensus estimate share mid point adjust ep be expect increase revenue be expect increase research development expense be expect range si spending be project range adjust tax rate be expect be takepfizer fourth quarter result be expectation beat estimate earning revenue meanwhile issue upbeat guidance also pfizer say plan invest approximately capital project unite state next year increase access foreign cash follow tax reform however initial gain share pfizer fall premarket trading believe lower sale unite state sequentially softer performance ibrance quarter hurt investor sentiment past year pfizer share have increase compare unfavorably increase industry top line headwind form genericization key drug supply shortage legacy hospira product pricing pressure rise competition pfizer achieve adjust earning growth new product ibrance contribution acquisition cost cut effort lower tax rate share buyback help company achieve guidance meanwhile pfizer look well poise record profit growth pfizer carry zack rank hold see complete list today zack rank strong buy stock here don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
2320,MRK,astrazeneca plc azn free report announce datum late stage study imfinzi show new cancer drug lead superior progression free survival standard care lung cancer patient share astrazeneca inched more friday well pre market trading monday so far year astrazeneca share have moved compare favorably industry increase interim datum phase iii pacific trial study show treatment imfinzi improve pfs more month comparison standard care patient locally advanced unresectable small cell lung cancer nsclc have not progressed follow chemoradiation median pfs be month patient imfinzi compare month comparator arm present european society medical oncology congress esmo madrid datum be also publish online new england journal medicine remind investor earlier july breakthrough therapy designation be grant imfinzi indication astrazeneca claim imfinzi be first medicine have demonstrated superior pfs concern patient population be now left unattended want proper treatment option pacific study continue evaluate other primary endpoint overall survival os separate press release astrazeneca announce full result phase iii flaura study evaluate lung cancer drug tagrisso first line set disclose datum show treatment tagrisso reduce risk progression death more half compare other commonly used egfr inhibitor first line treatment patient egfr mutation positive nsclc median pfs be month patient tagrisso compare month comparator arm good news be consistent benefit be observed subgroup include patient brain metastase significant datum be also present esmo notably positive lung cancer find come huge relief post failure thepivotal first line lung cancer study mystic imfinzi july astrazeneca share price plunge sharply announce mystic study imfinzi fail show benefit progression free survival failure show pfs benefit bring question mystic ability show os benefit final os datum mysticare expect first half imfinzi durvalumab be presently market indication second line advanced bladder cancer year meanwhile imfinzi be be evaluate multiple cancer alone combination other regimen include phase iii trial first line urothelial cancer nsclc small cell lung cancer head neck squamous cell carcinoma hnscc other astrazeneca be work strengthen oncology product portfolio have several candidate pipeline immuno oncology therapeutic area be presently attract lot interest represent huge commercial potential other phase iii oncology candidate astrazeneca pipeline include acalabrutinib blood cancer priority review moxetumomab pasudotox leukaemia selumetinib thyroid cancer savolitinib kidney cancer lynparza presently market advanced ovarian cancerin partnership merck co inc mrk free report be also different study range tumor type include breast prostate pancreatic cancer well earlier line setting ovarian cancer tagrisso be also be evaluate earlier line setting lung cancer astrazeneca currently carry zack rank hold see complete list today zack rank strong buy stock herebetter rank biotech stock include alexion pharmaceutical inc alxn free report regeneron pharmaceutical inc regn free report zack rank strong buy see complete list today zack rank stock here share alexion be year date estimate have rise respectively past day regeneron share year so far estimate have rise have go past day more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2321,MRK,effort enhance shareholder value merck mrk free report declare hike quarterly dividend cent cent share paid last quarter increase dividend be paid jan shareholder record dec raise dividend rate bring merck annual dividend share imply yield be better industry average concurrently board director merck also sanction new stock buyback plan notably first month company complete purchase equity merck financial strength enable continue repurchase program initiate dividend payout sep company cash cash equivalent be increase repurchase authorization new dividend payout be expect boost investor confidence stock merck strategy return wealth shareholder demonstrate growth potential stable liquidity position meanwhile merck have global restructure program progress aim reduce cost structure increase company efficiency intend decrease number manufacturing site include animal health consolidate other facility instead company expect annual saving once restructure program be complete merck have also divest segment consumer care business so focus core area expertise however merck share have decline year so far underperform industry rally company have also suffer notable pipeline setback year hurt share price performance october merck decide not seek approval cetp inhibitor anacetrapib cholesterol management clinical profile be not strong enough support regulatory filing last month company also postpone readout important lung cancer study be due inclusion overall survival co primary endpoint keynote phase iii study keytruda first line lung cancer raise investor concern delay readout give competitor chance gain strength lung cancer market october merck also withdraw regulatory application europe be look get keytruda approve first line combination therapy lung cancer september merck discontinue development hcv combination program mk mk cite hcv market be extremely crowd also combination study keytruda multiple myeloma be place clinical hold follow report death keytruda group july drug be see key long term growth driver merck such setback do not bode well company remain be see strong performance company new drug particularly keytruda strong vaccine animal health business cost save effort help merck pick here merck company inc price merck company inc price merck company inc quotezack rank key picksmerck carry zack rank hold better rank stock health care sector be johnson johnson jnj free report ligand pharmaceutical inc lgnd free report achillion pharmaceutical inc achn free report carry zack rank buy see complete list today zack rank strong buy stock here johnson johnson earning share estimate have moved last day company come positive earning surprise trail quarters average beat share price company have surge year date ligand earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have surge year date achillion loss share estimate have narrow cent cent cent cent last day company come positive earning surprise trail quarters average beat investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2322,MRK,expect merck co inc mrk free report beat expectation report fourth quarter full year result feb market open last quarter company deliver positive earning surprise merck performance have be pretty impressive company exceed earning expectation trail quarters average positive earning surprise last quarters be merck company inc price ep surprise merck company inc price ep surprise merck company inc quote merck share have decline past year increase industry factor considermerck new product keytruda cancer bridion sugammadex injection be likely drive top line quarter however loss market exclusivity several drug lower sale key product januvia gardasil gardasil hurt sale keytruda sale be be drive launch new indication globally keytruda sale be gain particularly strong momentum first line lung cancer indication therapy be only pd approve first line set keytruda development program also significantly advanced regulatory approval new indication unite state europe japan approval expand patient population drive sale third quarter momentum be likely drive fourth quarter well result strong demand most market be drive sale bridion sugammadex injection meanwhile rise competitive pressure be hurt sale relatively newer drug zostavax zepatier third quarter earning call merck management have warn zepatier uptake fourth quarter be impact evolve marketplace competitive landscape continue pricing pressure be hurt sale older product januvia lower demand due competitive pressure be dampening sale isentress importantly call company have say pricing pressure continue hurt sale januvia janumet volume improve future quarters especially outside unite state animal health franchise also boost sale quarter call investor be keen find vaccine segment have re-cover product shutdown issue related last year cyber attack finally higher investment ongoing launch remediation expense related cyber attack well additional cost associate new oncology collaboration astrazeneca azn free report raise cost hurt profit earning whispersour proven model show merck be likely beat estimate quarter have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold likely positive surprise zack esp earning esp represent difference most accurate estimate cent share zack consensus estimate cent share be uncover best stock buy sell re report earning esp filter zack rank merck have zack rank combination merck zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerhere be other drug biotech stock have right combination element beat earning time alexion pharmaceutical inc alxn free report earning esp zack rank company be schedule release result feb see complete list today zack rank stock here nordisk nvo free report have earning esp zack rank company be schedule release result feb don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
2323,MRK,expect eli lilly company lly free report beat expectation report fourth quarter full year result jan market open last quarter company deliver positive earning surprise lilly share have rise past year industry record increase lilly earning performance have be modest earning miss expectation last quarters beating same remain bring average positive surprise eli lilly company price ep surprise eli lilly company price ep surprise eli lilly company quotelet see thing be shape quarter factor considerlike previous couple quarters strong uptake new product trulicity taltz basaglar cyramza jardiance lartruvo be likely make decline sale establish product zyprexa alimta ciali strattera effient trulicity sale be likely benefit growth glp market share gain jardiance sale be expect be drive increase market share grow sglt class continue strong uptake outside unite state continue drive sale cyramza strong launch uptake be likely drive sale basaglar taltz lartruvo please note taltz be approve new indication active psoriatic arthritis psa december bring additional sale fourth quarter meanwhile loss exclusivity alimta cymbalta strattera effient axiron zyprexa evista continue hurt volume also lower demand unite state due competitive pressure mainly immuno oncology agent be hurt alimta sale country trend be likely be reflect fourth quarter result new drug olumiant baricitinib be launch select european country japan last year be review unite state third quarter strong launch uptake germany lead better sale drug trend be likely be reflect soon be report quarter result lilly partner incyte corporation incy free report plan re submit new drug application nda olumiant unite state month older product humalog trajenta forteo be also expect do well animal segment sale be hurt global competitive pressure first quarters trend be likely see time well third quarter conference call management have say be explore strategic alternative business include sale merger create separate company initial public offer decision regard same be expect be make later middle year company then say lilly ultimately opt retain business investor look update related same conference call earning whispersour proven model show lilly be likely beat earning have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate zack consensus estimate be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank lilly have zack rank combination lilly zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerhere be other large cap health care stock worth consider model have right combination element beat earning time merck co inc mrk free report have earning esp zack rank company be schedule report fourth quarter earning feb see complete list today zack rank stock here astrazeneca plc azn free report be slate announce financial figure feb company have earning esp be zack rank stock zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2324,MRK,seattle genetic inc sgen free report be company focuse development therapy target treatment cancer company have only market product adcetris approve several indication past year seattle genetic share price have be trading industry stock have lose increase broader industry adcetris have be perform well begin prompt company raise guidance drug sale year moreover prospect drug receive boost line extension primary cutaneous anaplastic large cell lymphoma pcalcl cd express mycosis fungoide mf november moreover collaboration takeda pharmaceutical global development adcetris be also encourage seattle genetic earn royalty payment be entitle milestone payment june company announce encourage datum phase iii study echelon evaluate adcetris front line classical hodgkin lymphoma datum study show adcetris achieve statistically significant improvement modify progression free survival versus standard care supplemental biologic license application be submit fda base datum november phase iii study echelon be evaluate drug front line cd express mature cell lymphoma datum be expect study year apart adcetris company have adc candidate novel immuno oncology candidate be be evaluate early mid stage study phase ib study be evaluate pipeline candidate enfortumab vedotin combination bristol myer bmy free report opdivo roche hold ag rhhby free report tecentriq however dependence single product be concern company decline sale unfavorable response label expansion study affect stock moreover label expansion merck co inc mrk free report keytruda lymphoma indication march have increase competition adcetris wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2325,MRK,third quarter report cycle be witness revenue acceleration positive revision trend result half member be already oct total earning member be same period last year higher revenue surpass earning revenue estimate respectively accord earning preview company account index total market capitalization report total earning company be expect grow year year higher revenue please note broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning biotech pharma bigwig merck co inc mrk free report celgene corporation celg free report abbvie inc bristol myer squibb company bmy free report gilead science inc gild free report report third quarter result last week merck celgene abbvie outpaced zack consensus estimate earning lag same revenue however bristol myer gilead surpass expectation earning revenue notably bristol myer gilead raise earning outlook well merck raise previously issue adjust earning guidance up sale guidance marginally abbvie celgene also tighten earning guidance here have biotech pharma company be set report third quarter result oct let see thing be shape quarter pfizer inc pfe free report pfizer be schedule release earning market open deliver positive earning surprise last quarter company earning performance have be mixed bottom line miss last quarters beating same other bring average surprise negative quarter pfizer have earning esp zack rank hold zack consensus estimate be peg cent share uncover best stock buy sell re report earning esp filter new product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain eliquis blood thinner contribute top line meaningfully meanwhile sale blockbuster drug enbrel continue decline quarter due biosimilar competition lower sale trend prevnar prevenar vaccine franchise be likely continue well sale viagra be expect be affected lower demand read more be beat likely pfizer earning season previous article show pfizer be likely beat earning quarter however estimate change thereafter be not certain beat earning season pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quoteincyte corporation incy free report incyte be schedule release earning market open witness negative earning surprise last quarter company earning performance have be mixed so far have deliver positive surprise last quarters miss estimate unavailable average earning surprise last quarters be negative company have earning esp zack rank indicate likely positive surprise zack consensus estimate be peg cent share see complete list today zack rank strong buy stock here company key growth driver jakafi have be perform well expect trend continue be report quarter well incyte corporation price ep surprise incyte corporation price ep surprise incyte corporation quoteacorda therapeutic inc acor free report acorda be schedule release earning market open witness negative earning surprise last quarter company earning performance have be disappointing so far company have incur negative surprise last quarters average earning surprise last quarters be negative company have earning esp zack rank strong sell make surprise prediction difficult zack consensus estimate be peg cent share be caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision expect investor focus refusal file rtf relief late stage pipeline candidate inbrija be develop treatment patient be suffering parkinson disease acorda therapeutic inc price ep surprise acorda therapeutic inc price ep surprise acorda therapeutic inc quotezack best private investment idea be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor
2326,MRK,nasdaq notch record close follow splendid quarterly earning major tech stock meanwhile dow pare gain due loss chevron merck broader market be also boost third quarter gdp estimate economy come consensus estimate further benchmark post strong weekly gain dow jone industrial average djia close gain index inx increase close meanwhile nasdaq composite index ixic close increase advance issue outnumber decliner nyse ratio nasdaq advancer outnumber decliner ratio cboe vix decrease close impressive tech earning propel broader market third quarter earning tech heavyweight such microsoft corp msft free report alphabet inc googl free report amazon com inc amzn free report intel corp intc free report boost gain broader market friday help nasdaq notch record close share microsoft surge post first quarter fiscal result late thursday company post earning cent share revenue msft be share trading shortly earning report be release read more meanwhile share alphabet gain post third quarter earning company report third quarter diluted gaap earning exceed zack consensus estimate also earning increase sequentially year year internet powerhouse report decent top line number read more further share amazon rally report third quarter earning online retailer deliver massive beat third quarter result earning share cent beat zack consensus estimate cent be sequentially earning be however flat year year read more lastly intel rise report third quarter earning late thursday tech giant post gaap earning share beat zack consensus estimate cent figure surge year quarter sequentially strong earning growth be drive better expect top line performance operate margin expansion read more such splendid result lead gain well nasdaq major sector end positive territory technology lead advancer technology select sector spdr etf xlk surge end meanwhile nasdaq amassed point post best percentage gain nov last year dow pare dow add point end positive territory well such gain be buoy surge tech stock share microsoft intel contribute most gain however blue chip index pare gain due loss chevron corp cvx free report merck co mrk free report share decline respectively stronger economy accord latest report commerce department economy improve impressive annual rate come consensus estimate however second quarter figure also marked first time economy expand annual pace consecutive quarters report do not specify much impact do hurricane harvey irma growth economy economist comment primary factor such growth be increase consumer spending backed broadly encourage economic condition strong government outlay moreover business investment increase inventory rise trade sector gain weekly week dow nasdaq increase respectively marked seventh consecutive streak weekly gain dow fifth week gain nasdaq be longest streak weekly gain dow december last year have notch longest streak weekly gain late general electric ge free report suffer biggest day dip more year weigh heavily broader market meanwhile broader market gain market watcher remain hopeful new tax code be sign policy soon moreover house representative clear budget blueprint majority republican voting favor move further ecb announce plan extend quantitative ease program stock make headlinesaaron stock fall earning miss revenue beataaron inc aan free report incur negative earning surprise third quarter consecutive quarters earning beat zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
2327,MRK,merck co inc mrk free report report third quarter adjust earning share beat zack consensus estimate earning rise year year other item adjust earning exclude charge related new oncology collaboration britain astrazeneca azn free report revenue quarter decline year year sale also miss zack consensus estimate currency movement positively impact revenue exclude currency impact sale decline year year lose sale market due network cyber attack june hurt top line quarter meanwhile unfavorable comparison third quarter last year hurt sale quarter pharmaceutical segment generate revenue exclude fx impact year year continue strong sale pd inhibitor keytruda be offset lower sale key product diabetes drug januvia hpv vaccine gardasil gardasil previous quarters loss market exclusivity several drug also hurt top line keytruda bring sale third quarter sequentially year year sale continue be drive launch new indication globally keytruda sale be gain particularly strong momentum indication first line lung cancer keytruda be already approve many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer meanwhile keytruda development program significantly advanced first half regulatory approval new indication unite state additional indication europe key recent approval include advanced bladder cancer advanced microsatellite instability high cancer first approval combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo lung cancer new approval have expand patient population believe drive sale third quarter zepatier bring sale previous quarter bridion sugammadex injection generate sale quarter year year drive strong uptake follow launch unite state meanwhile combine sale remicade lose exclusivity europe face stiff biosimilar competition region cubicin lose patent protection unite state june zetia lose market exclusivity unite state december vytorin lose exclusivity april decline quarter remicade sale decline quarter merck market brand version remicade outside unite state johnson johnson jnj free report market rheumatoid arthritis drug country cubicin sale plunge quarter zetia vytorin franchise record sale due loss exclusivity zetia vytorin sale isentress januvia janumet diabetes franchise also decline quarter januvia janumet franchise record sale quarter year quarter due continue pricing pressure isentress sale decline quarter lower volume demand due competitive pressure hurt sale isentress gardasil gardasil sale decline production shutdown follow cyber attack result supply constraint adversely impact sale unite state however sale rise europe boost addition sale terminate vaccine joint venture sanofi sny free report asia pacific backed strong demand merck animal health segment generate revenue exclude fx impact year quarter primarily drive higher sale companion animal product primarily bravecto companion animal vaccine contribution valle acquisition gross margin cost rise adjust gross margin come basis point bps year quarter attributable favorable effect product mix offset cost related cyber attack marketing administrative expense increase report quarter research development spend increase quarter guidancemerck raise previously issue adjust earning guidance raise sale guidance marginally second time year company expect adjust earning range compare expect earlier adjust earning guidance include less negative impact currency fluctuation compare favorably approximately previously revenue be expect range compare earlier forecast include negative currency impact less versus approximately previously operate expense be still expect increase year year mid single digit rate increase cost be attributable increase investment ongoing launch remediation expense related cyber attack well additional cost associate new oncology collaboration astrazeneca takemerck third quarter result be mixed company beat estimate earning miss same sale relatively weaker sale performance merck raise previously issue adjust earning guidance also up sale guidance marginally share be pre market trading response lower sale merck multiple medicine year so far merck share have underperform industry merck share have rise year compare unfavorably increase industry eye be performance keytruda be be tout key long term growth driver merck drug continue strong performance sale cross mark quarter however company have suffer notable pipeline setback year earlier month merck decide not seek approval cetp inhibitor anacetrapib cholesterol management clinical profile be not strong enough support regulatory filing last month merck discontinue development hcv program say hcv market be become extremely crowd also combination study keytruda multiple myeloma be place clinical hold follow report death keytruda group julymerck carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2328,MRK,attempt get arm deluge earning report ahead final open bell trading week get first look gdp consensus estimate second consecutive handle follow final read mark first time economy have gdp number particularly noteworthy number be do see negative impact gdp quarter hurricane harvey irma marium most notably consumer spending have ratchete previous quarter time gdp take basis point hit still reach illustrate economic strength power consumer inventory be be normal come do ahead holiday season perhaps surprisingly federal government spend more maybe most importantly zack chief strategist john blank point last week major economy world be currently experience recession growth be now global synchronize be very rare occurrence see geopolitical headwind americas europe asia pacific earning roll onaside big blowout beat yesterday close amazon amzn free report alphabet googl free report microsoft msft free report have already add additional market see more earning tonnage generally oil gas pharma bio sector exxonmobil xom free report share be modestly today pre market follow result surpass estimate top bottom line earning cent share top zack consensus cent revenue really outperformed expectation far exceed have be look mark fourth beat past quarters largest oil gas supermajor energy sector have struggle xom look be improve chevron cvx free report also beat estimate earning sale morning share surpass cent consensus revenue ahead expect outgoing ceo john watson retire early next year cite continue improvement earning cash flow supermajor refine company phillip psx free report post mixed today pre market earning share beating consensus estimate cent revenue fall short estimate company refine business more triple quarter offset quarter quarter midstream chemical marketing pharmaceutical major merck co mrk free report post share ahead zack consensus estimate however quarterly sale be short have be expect say merck up fiscal year earning guidance share last time morning follow initial bump pre market share be now trading more ahead bell also biopharma firm abbvie abbv free report have branch abbott lab beat earning estimate cent share revenue come basically line estimate lymphoma treatment imbruvica rise year year rheumatoid arthritis drug humira improve year quarter
2329,MRK,friday october attempt get arm deluge earning report ahead final open bell trading week get first look gdp consensus estimate second consecutive handle follow final read mark first time economy have gdp number back back quarters particularly noteworthy number be do see negative impact gdp quarter hurricane harvey irma marium most notably consumer spending have ratchete previous quarter time gdp take basis point hit still reach illustrate economic strength power consumer inventory be be normal come do ahead holiday season perhaps surprisingly federal government spend more maybe most importantly zack chief strategist john blank point last week major economy world be currently experience recession growth be now global synchronize be very rare occurrence see geopolitical headwind americas europe asia pacific earning roll onaside big blowout beat yesterday close amazon amzn free report alphabet googl free report microsoft msft free report have already add additional market see more earning tonnage generally oil gas pharma bio sector exxonmobil xom free report share be modestly today pre market follow result surpass estimate top bottom line earning cent share top zack consensus cent revenue really outperformed expectation far exceed have be look mark fourth beat past quarters largest oil gas supermajor energy sector have struggle xom look be improve chevron cvx free report also beat estimate earning sale morning share surpass cent consensus revenue ahead expect outgoing ceo john watson retire early next year cite continue improvement earning cash flow supermajor refine company phillip psx free report post mixed today pre market earning share beating consensus estimate cent revenue fall short estimate company refine business more triple quarter offset quarter quarter midstream chemical marketing pharmaceutical major merck co mrk free report post share ahead zack consensus estimate however quarterly sale be short have be expect say merck up fiscal year earning guidance share last time morning follow initial bump pre market share be now trading more ahead bell also biopharma firm abbvie abbv free report have branch abbott lab beat earning estimate cent share revenue come basically line estimate lymphoma treatment imbruvica rise year year rheumatoid arthritis drug humira improve year quarter mark vickerysenior editorquestion comment article author click here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2330,MRK,share nektar therapeutic nktr free report have be almost year so far substantially outperform industry increase period let analyze factor lead massive rally nektar rapid progress robust pipeline year include several study initiation strategic collaboration have push share price consistently company pegylation technology have facilitate development several approve product unite state eu partnership healthcare company namely astrazeneca azn free report movantik ucb cimzia amgen amgn free report neulasta other notably randomize phase iii confirmatory study attain begin company lead candidate onzeald late last year trial compare onzeald single agent chemotherapy physician choice patient advanced breast cancer have brain metastase shortly positive result program support regulatory filing unite state apart onzeald nektar be work develop other candidate september company announce initiation phase ii propel study evaluate efficacy safety nktr combination roche tecentriq atezolizumab merck mrk free report keytruda pembrolizumab phase ii study evaluate nktr potential combination treatment regimen bristol myer squibb opdivo be also underway candidate be be examine tumor type melanoma kidney colorectal bladder small cell lung cancer potential indication notably company enter research collaboration takeda pharmaceutical explore combination nktr oncology compound takeda cancer portfolio candidate nktr be be examine phase iii study treatment chronic pain july company report positive top line result oral human abuse potential hap study evaluate nktr assess opioid abuse potential compare oxycodone company be plan submit new drug application nda candidate april meanwhile march company initiate phase clinical study evaluate nktr treat wide range auto immune disease inflammatory disorder subsequently july nektar enter co development deal elly lilly company nktr pursuant agreement company be responsible complete ongoing phase study candidate company share phase ii development cost lilly capture lion share total cost successful development candidate boost company top line consider lucrative market be target nektar carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2331,MRK,johnson johnson jnj free report partner glaxosmithkline gsk free report recently announce fda approval juluca combination glaxo tivicay rilpivirine edurant dolutegravir single tablet treatment hiv most medicine hiv treatment be make more antiretroviral drug juluca be first drug regimen reduce number medicine hiv patient take compromise efficacy conventional drug regimen approval juluca have shift investor focus hiv disease space let see company be try tap huge market note hivhiv stand human virus weaken immune system destroy cell fight disease infection eventually lead aids acquire syndrome medicine treatment hiv be call antiretroviral therapy art slow put check progression virus globally person be live hiv aids end total be child less year old improve medical understand hiv prevention treatment well significant effort make lead government medical body hiv aids still have cure notably person die aids related illness reach total number start epidemic company develop hiv drugsmarkete therapy hivseveral pharmaceutical company be marketing drug therapy treat hiv gilead gild free report be dominant player hiv market impressive portfolio company be first introduce single tablet regimen str treatment hiv atripla gilead other strs hiv include complera eviplera stribild taf base product genvoya be bestseller surpass truvada atripla fourth quarter company glaxosmithkline have long standing commitment hiv infectious disease company have develop widely used antibiotic amoxycillin year develop first medicine approve treat hiv azt company other market hiv drug include triumeq tivicay other popular market hiv drug be abbvie abbv free report kaletra merck mrk free report isentress pharmaceutical company mylan myl free report have receive tentative approval fda combination tablet comprise efavirenz lamivudine tenofovir disoproxil fumarate treat hiv pipeline company be work develop new drug treat prevent possibly cure hiv scientist be explore new treatment paradigm drug regimen make therapy drug improve safety profile new mechanism action gilead str bictegravir hiv treatment be priority review unite state fda be expect announce decision next february str be fix dose combination bictegravir insti emtricitabine tenofovir alafenamide ftc taf dual nrti backbone merck be develop investigational nucleoside reverse transcriptase inhibitor mk doravirine hiv infection plan tofile regulatory application fix dose combination same single entity tablet fix dose combination tabletconsist fix dose combination doravirine dor lamivudine tc tenofovir disoproxil fumarate tdf late glaxo be also develop drug regimen be dolutegravir cabotegravir rilpivirine increase number company be develop drug treat life threaten disease competition have intensified manifold space meanwhile be be see juluca fare market be reissue article correct mistake original article issue tuesday nov longer be rely
2332,MRK,be not much activity cancer space week however see drug get regulatory nod european commission ec zejula receive approval monotherapy maintenance treatment recurrent ovarian cancer patient be set give astrazeneca azn free report merck mrk free report lynparza run money parp inhibitor space europe other hand novartis nvs free report tasigna receive approval label expansion first line set paediatric patient chronic myeloid leukemia meanwhile johnson johnson jnj free report submit regulatory application label expansion darzalex first line therapy multiple myeloma unite state europe moreover roche hold rhhby free report announce encourage result phase iii study evaluate tecentriq combination chemotherapy stage iv squamous small cell lung cancer nsclc recap week most important storiestesaro zejula approve europe european commission have grant marketing authorization zejula maintenance treatment woman recurrent ovarian cancer be first parp inhibitor receive approval europe do not require brca mutation other biomarker testing drug be already market unite state same indication zejula now compete lynparza be already approve europe however zejula have edge lynparza require brca mutation status europe zejula have perform well unite state launch similar adoption drug europe aid company read more tesaro ovarian cancer drug zejula get approval eu tesaro inc price tesaro inc price tesaro inc quotenovartis tasigna get label expansion europe ec approve label expansion tasigna include paediatric patient newly diagnosed philadelphia chromosome positive chronic myeloid leukemia chronic phase ph cml cp label also include ph cml cp resistance intolerance prior therapy include imatinib gleevec tasigna be already approve adult similar indication accelerate phase cml second later line set read more novartis receive ec nod tasigna label expansion novartis ag price novartis ag price novartis ag quotej seek darzalex label expansion submit regulatory application unite state europe seek label expansion darzalex first line set treat multiple myeloma mm drug approve be used combination proteasome inhibitor mm drug velcade bortezomib melphalan prednisone treatment nave patient have autologous stem cell transplantation bone marrow darzalex contribute almost sixth total oncology sale potential label expansion approval geography further boost prospect read more seek darzalex label expansion first line set johnson johnson price johnson johnson price johnson johnson quoteroche tecentriq impress phase iii combination study roche announce encourage result phase iii impower study evaluate tecentriq nsclc patient study be evaluate efficacy safety tecentriq combination chemotherapy carboplatin paclitaxel avastin combination tecentriq avastin chemotherapy achieve statistically significant clinically meaningful reduction risk disease worsening death compare avastin chemotherapy person stage iv nsclc study be conduct patient do not receive prior therapy read more roche report positive datum tecentriq combination study roche hold ag price roche hold ag price roche hold ag quoteapart celldex therapeutic inc cldx free report announce initiation phase ii study pipeline candidate cdx combination eli lilly lly free report erbitux study evaluate candidate patient advanced head neck squamous cell carcinoma more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2333,MRK,very few option be available treat ovarian cancer primarily include chemotherapy radiation surgery effective treatment have many side effect chemotherapy destroy patient immune system radiation kill normal cell cancerous cell surgical process be ineffective cancer spread approval astrazeneca azn free report merck mrk free report lynparza december new target therapy treat ovarian cancer come market drug inhibit enzyme cell parp help repair dna cell thus destroy cell other parp inhibitor be approve fda tesaro inc tsro free report zejula clovis oncology inc clvs free report rubraca parp inhibitor have show more tolerability effectiveness clinical study however none market parp inhibitor rubraca zejula lynparza have be approve first line set date be many other company develop parp inhibitor include pfizer inc pfe free report abbvie inc abbv free report other let see market drug be perform have better prospect lynparza recent label expansion august be indicated maintenance treatment patient suffering platinum sensitive recurrent psr ovarian cancer regardless brca mutation status be also approve brca mutate ovarian cancer third line set drug be available capsule tablet formulation drug record sale first month grow annually drug be also be develop first line maintenance treatment brca mutate ovarian cancer astrazeneca merck expect file label expansion mid however lynparza sale have fall lately unite state launch zejula april year label expansion august include ovarian cancer patient regardless brca mutation have bring par zejula moreover potential approval first line set next year give edge other drug also astrazeneca have collaborate merck co develop lynparza combination immunotherapy successful development be boon patient rubraca receive accelerate approval fda late last year monotherapy advanced ovarian cancer patient deleterious brca mutation treat more chemotherapy clovis be conduct confirmatory study convert approval full approval meanwhile company file supplemental new drug application last month seek label expansion maintenance treatment patient psr ovarian cancer rubraca be review eu drug report sale first month however drug lag other drug be approve treat ovarian cancer irrespective brca mutation meanwhile clovis be evaluate drug phase iii study combination bristol myer bmy free report opdivo first line maintenance therapy stage iii iv high grade ovarian cancer patient be treat platinum base chemotherapy zejula be first parp inhibitor be approve maintenance treatment recurrent ovarian cancer regardless brca mutation be launch april drug be used patient do not have brca mutation be prescribe broader patient population moreover also remove requirement diagnosis brca mutation thereby reduce treatment cost time due competitive advantage zejula have register impressive growth launch have also encroach lynparza rubraca market share drug have generate sale launch company have also claim be most frequently prescribe parp inhibitor ovarian cancer further boost prospect drug european commission grant marketing authorization earlier week tesaro be also develop zejula combination merck pd drug keytruda patient platinum resistant ovarian cancer discussion be evident zejula have edge due requirement brca mutation status have fared better thus far however expand label lynparza be set get back lose share believe rubraca be relatively weaker position drug be uncertainty perform europe lynparza zejula be already approve however have end see actual performance drug few label expansion be expect next year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2334,MRK,gilead science inc gild free report report third quarter result earning revenue surpass expectation however stock be expect open red give decline hepatitis virus hcv franchise nevertheless gilead stock have gain year date industry decline company third quarter earning include impact stock base compensation expense share beat zack consensus estimate however earning be year quarter figure moreover total revenue top zack consensus estimate however revenue decline year year hiv impress yet again harvoni sovaldi plungesproduct sale come year year decline be due lower hepatitis virus hcv sale partially offset higher sale hiv other therapeutic area antiviral product sale include gilead hiv liver disease portfolio come report quarter hcv product sale include harvoni sovaldi epclusa vosevi be report year quarter downside be mainly attribute lower sale harvoni sovaldi major market partially offset sale epclusa launch sale vosevi approve unite state europe july sale harvoni decline year year report quarter further sovaldi sale record steep year year decline epclusa garner sale report quarter year figure note epclusa be launch europe june jul respectively meanwhile hiv hbv product sale come year year increase be primarily drive continuous strong uptake tenofoviral afenamide taf base product such genvoya generate sale year quarter descovy record sale odefsey register sale hiv treatment stribild complera eviplera sale decline respectively viread sale be atripla sale tank truvada sale fall other product letairis ranexa zydelig record sale respectively research development expense decline other hand selling general administrative sg expense increase adjust product gross margin be compare year period guidance updatedgilead now expect net product sale range provide earlier hcv product sale be project earlier projection hcv product sale be project earlier projection adjust expense adjust sg expense be now project range respectively adjust product gross margin be expect range earning share be now project earlier projection cent kite company recently acquire kite pharma last week company receive fda approval yescarta car therapy treatment adult patient relapse refractory large cell lymphoma more line systemic therapy dividend share gilead declare cash dividend cent share common stock fourth quarter dividend be payable dec stockholder record close business dec quarter company paid cash dividend repurchase share company top earning revenue estimate third quarter witness decline hcv sale hcv franchise be tremendous pressure due lower patient start increase competition expect sale decline further go forward note harvoni sovaldi epclusa face competition abbvie inc abbv free report viekira pak viekira xr bristol myer squibb company bmy free report daklinza other competition well pricing pressure have intensified further launch merck co inc mrk free report zepatier only patient begin treatment gilead regimen quarter prior quarter meanwhile hiv franchise maintain momentum drive rapid adoption taf base regimen unite state eu taf base regimen now represent total gilead hiv prescription volume follow launch genvoya launch odefsey descovy genvoya be now company bestselling hiv product treatment nave patient share strong uptake truvada use pre exposure prophylaxis set further boost sale company see significant uptick prep usage estimate patient used truvada end third quarter approval yescarta also bode well gilead however gilead have lose exclusivity viread truva further impact performance expect decline hcv franchise offset positive momentum hiv franchise zack rank gilead currently carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2335,MRK,major pharma company eli lilly lly free report bristol myer squibb bmy free report glaxosmithkline plc gsk free report novartis read more novartis earning sale top new drug strength report third quarter result week be beat raise quarter lilly bristol myer result be mixed recap week most important storieslilly top expectation mull option animal health segment lilly third quarter result be better expect company beating top bottom line raise outlook year reflect uptake trend new pharmaceutical product company also announce be explore strategic alternative animal health business elanco animal health update expect mid company be weigh option initial public offer merger sale retention business segment bring revenue so far read more lilly beat earning explore sale elanco lilly be zack rank buy stock see complete list today zack rank strong buy stock here mixed quarter bmy be mixed quarter bristol myer company miss earning surpass revenue expectation opdivo performance remain strong presence increase competition sale grow eliquis also perform well company say business development remain top priority expect buy back share worth additional year end read more bristol myer miss earning opdivo focus company have gain year date compare rally industry belong sanofi file patent infringement lawsuit mylan lantus french drugmaker sanofi sny free report have file patent infringement suit mylan myl free report lantus lantus solostar lawsuit file unite state district court district new jersey allege infringement patent sanofi diabetes product sale be immense pressure lantus franchise remain major contributor top line earlier year august sanofi have file patent infringement suit merck allege infringement patent related lantus product interest increase pfizer consumer healthcare business ever pfizer pfe free report announce be explore strategic option consumer healthcare business include full partial separation spin sale quite few company have be rumore be interested striking deal week british pharma major glaxo be ask third quarter call interest acquire pfizer consumer healthcare business glaxo own consumer segment have be witness material slowdown global growth key category factor pricing pressure increase competition tougher emerge market weigh performance read more glaxo earning beat revenue line share meanwhile accord reuter article pfizer expect start auction process consumer healthcare business november accord source possible bidder apart glaxo reckitt benckiser include name procter gamble sanofi johnson johnson nestle nyse arca pharmaceutical index decline week major stock glaxo decline mainly reflect concern company dividend payout especially strike deal pfizer consumer healthcare business last month be see last pharma stock roundup here beat raise quarter allergan hit restasis ruling next pharma world watch earning result company merck mrk free report pfizer wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2336,MRK,expect pfizer inc pfe free report beat expectation report fourth quarter full year result jan market open last quarter company deliver positive earning surprise pharma giant have fairly decent record earning surprise company earning surpass expectation last quarters miss result average positive surprise pfizer share have rise past year compare unfavorably increase industry factor playnew product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain chantix smoking cessation eliquis blood thinner be likely contribute meaningfully top line however loss exclusivity associate generic competition product primarily pristiq unite state vfend lyrica develop europe supply shortage legacy hospira product divesture hospira infusion system unit continue hamper top line growth blockbuster drug enbrel sale continue decline quarter due biosimilar competition prevnar prevenar vaccine franchise be likely see lower sale lower demand be expect hurt sale viagra third quarter call pfizer say be face supply shortage product legacy hospira portfolio mainly due capacity constraint technical issue time acquire hospira september pfizer have estimate take couple year integrate manufacturing plant resolve majority supply chain issue company also state remediation business have take longer expect expect supply shortage hurt sale fourth quarter meanwhile bottom line be likely be drive cost saving share buyback leukemia treatment besponsa inotuzumab ozogamicin approve eu june unite state august relapse refractory acute lymphoblastic leukemia mylotarg newly diagnosed cd positive acute myeloid leukemia aml be approve third quarter xeljanz sutent bosulif be approve line extension fourth quarter ixifi pfizer second biosimilar version johnson johnson jnj free report blockbuster drug remicade be also launch december new product line extension bring additional sale fourth quarter also expect management update plan new approve oral sglt inhibitor steglatro ertugliflozin tablet conference call apart be approve monotherapy treat type ii diabetes steglatro have also be approve use combination metformin brand name segluromet januvia brand name steglujan model proven model show pfizer be likely beat earning have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate zack consensus estimate be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank pfizer have zack rank combination pfizer zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerhere be other health care stock worth consider model have right combination element beat earning time abbvie inc abbv free report be schedule release result jan company have earning esp zack rank see complete list today zack rank stock here merck co inc mrk free report have earning esp zack rank company be schedule report earning feb pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotetoday stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2337,MRK,pfizer inc pfe free report announce positive top line result phase iii comparative study evaluate pf company biosimilar version roche rhhby free report blockbuster leukemia drug rituxan mabthera rituximab notably rituxan be approve treat blood cancer include hodgkin lymphoma follicular lymphoma diffuse large cell lymphoma chronic lymphocytic leukemia well immunological disease rheumatoid arthritis share pfizer have gain year time underperform industry rally phase iii reflection study be design compare efficacy safety pharmacokinetic immunogenicity pf compare rituxan study meet primary endpoint demonstrate equivalence overall response rate first line treatment patient cd positive low tumor burden follicular lymphoma mark pfizer fifth propose biosimilar monoclonal antibody mab show positive trial result significantly pfizer biosimilar capability be substantially boost acquisition hospira december company launch ixifi second biosimilar version johnson johnson jnj free report merck co inc mrk free report blockbuster drug remicade unite state remind investor pfizer be evaluate biosimilar molecule various developmental stage incidentally biosimilar product late stage development include biosimilar version roche avastin abbvie humira also herceptin biosimilar version be review unite state well eu importantly novartis teva file regulatory application last year unite state biosimilar version rituxan september june respectively pfizer inc price pfizer inc price pfizer inc quote zack rankpfizer carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2338,MRK,expect abbvie inc abbv free report beat expectation report fourth quarter result jan market open last quarter company deliver positive earning surprise abbvie share have soar year time ahead industry rally notably abbvie earning history be quite impressive pharmaceutical company outpace estimate last quarters meeting same overall abbvie have average beat let see thing be shape company quarter factor considerabbvie expect fourth quarter earning range share revenue be estimate grow approximately operational basis foreign exchange be anticipate have favorable impact sale period be report company key drug humira be likely remain growth driver fourth quarter backed strong demand trend drug abbvie expect humira full year sale growth mid high teen range internationally metric be project mid single digit range operational basis zack consensus estimate humira be be report quarter significantly fourth quarter conference call investor focus also be performance label expansion update abbvie cancer drug imbruvica drug have be record strong sale past few quarters trend expect continue even quarter be report zack consensus estimate imbruvica be period other drug duopa creon be also likely continue perform well soon be report quarter however abbvie hepatitis virus hcv treatment viekira continue see decline sale impact intense pricing competitive pressure hcv market notably abbvie week pan genotypic ribavirin free once daily hcv treatment mavyret gain approval unite state eu canada japan third quarter mavyret record global sale quarter initial uptake drug have be impressive expect higher sale fourth quarter earning whispersour proven model show stock be likely beat earning quarter have right combination key ingredient positive earning esp favorable zack rank strong buy buy hold happen zack esp abbvieha earning esp represent difference most accurate estimate share zack consensus estimate moreover positive esp indicate likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank abbvie have zack rank increase predictive power esp together positive esp chance beating estimate stock upcoming release be always peg higher caution sell rate stock go earning announcement especially company be see negative estimate revision abbvie inc price ep surprise abbvie inc price ep surprise abbvie inc quote other stock warrant lookhere be other health care stock worth consider model comprise right combination element beat earning time pfizer inc pfe free report be schedule release result jan company have earning esp zack rank see complete list today zack rank stock here merck co inc mrk free report have earning esp zack rank company be schedule report earning number feb astrazeneca plc azn free report be slate announce financial figure feb company have earning esp be zack rank player hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2339,MRK,fourth quarter earning season be full swing trend so far appear impressive notably company have post result jan earning revenue growth latest earning preview also company top earning revenue focuse attention large cap pharma sector be yet witness main show space only company have report quarterly result now so far large cap pharma sub industry carry zack industry rank place first zack industry back testing show top zack rank industry outperform bottom half factor more remind investor drug stock have prolific run courtesy slew fda approval regulatory body approve novel drug last year easily surpass total tally particularly large cap player industry rake stellar return last month upbeat quarterly result rise demand new product sale successful innovation product line expansion strong clinical study result well continue strong performance legacy product propel large cap drug sector scale new high moreover tailwind be expect drive sector growth meanwhile jubilant republican pass tax overhaul bill first time year tax bill be sign law president donald trump only last month dec corporate tax rate have be slash now boost profit large drug biotech company meanwhile change tax code also allow company bring back huge cash stash overseas time tax rate also tax cut be expect prevent earlier inversion rampant drug industry importantly outlook upcoming fourth quarter result look bright earning preview broader medical sector inclusive drug biotech well medical device company be expect record year year growth revenue rise earning time pick likely winnersgiven enormity healthcare space task select stock potential beat estimate appear quite daunting proprietary methodology make job fairly simple way taper list choice earning season be look stock combination favorable zack rank zack rank strong buy buy hold positive earning esp more often not positive earning surprise deliver company lead stock price appreciation well research quantitative model earning esp be used identify stock higher chance deliver positive surprise upcoming earning announcement show percentage difference most accurate estimate zack consensus estimate uncover best stock buy sell re report earning esp filter investing stock large market cap be much more reliable investment same control large portion respective industry also company larger market cap have evidently perform well here be large cap pharma stock poise surpass estimate fourth quarter accord methodology first pick be abbvie inc abbv free report north chicago il base company have earning esp zack rank see complete list today zack rank stock here stock have see zack consensus estimate fourth quarter earning be peg share company boast positive earning surprise record have exceed expectation last quarters average beat abbvie be schedule report result jan next choice be merck co inc mrk free report stock have earning esp zack rank consensus mark fourth quarter earning stand cent share base kenilworth nj merck have encourage positive earning surprise history company average beat trail quarters be merck be slate announce result feb astrazeneca plc azn free report too have please earning profile company have consistently outpaced earning expectation last quarters average beat look perfectly poise repeat winning streak fourth quarter well london uk base company be zack rank player have earning esp zack consensus estimate be peg cent share astrazeneca be schedule release earning performance feb wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2340,MRK,seattle genetic inc sgen free report partner takeda pharmaceutical company limit announce european commission have extend current conditional marketing authorization expand indication lymphoma drug adcetris brentuximab vedotin marketing authorization be extend treatment adult patient cd positive cutaneous cell lymphoma least prior systemic therapy decision be base positive opinion issue committee medicinal product human use nov note adcetris be only market product seattle genetic drug be approve relapse hodgkin lymphoma relapse systemic anaplastic large cell lymphoma patient suffering classical hodgkin lymphoma be high risk relapse progression post autologous hematopoietic stem cell transplantation auto hsct consolidation year share seattle genetic have decline industry gain marketing aurthorization be mainly base positive datum phase iii trial alcanza study patient cutaneous cell lymphoma ctcl interestingly alcanza study achieve primary secondary endpoint study show ctcl patient treat adcetris have superior outcome primary secondary endpoint compare patient control arm be treat methotrexate bexarotene standard care agent marketing authorization adcetris be valid country european union november fda have approve adcetris treatment primary cutaneous anaplastic large cell lymphoma cd express mycosis fungoide have receive prior systemic therapy approval be be base positive datum phase iii trial alcanza phase ii investigator sponsored trial patient ctcl label expansion be expect boost sale drug further evidently sale drug third quarter grow year year furthermore seattle genetic be develop drug more clinical study key study include evaluation cell lymphomas hodgkin lymphoma phase iii study be also evaluate adcetris frontline mature cell lymphomas again drug be be study combination bristol myer squibb company bmy free report opdivo relapse refractory hodgkin lymphoma however adcetris face competition other drug include merck co inc mrk free report keytruda be also approve lymphoma indication seattle genetic inc price seattle genetic inc price seattle genetic inc quote zack rank stock considerseattle genetic carry zack rank hold better rank stock health care space be exelixis inc exel free report carriy zack rank strong buy see complete list today zack rank stock here exelixis earning share estimate have moved cent cent last day company deliver positive earning surprise last quarters average share price company surge past year wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2341,MRK,johnson johnson jnj free report report mixed fourth quarter result beating zack consensus estimate earning slightly miss same sale drug consumer product giant issue decent outlook share be pre market trading fact past year share have return compare favorably increase witness industry earning beatj fourth quarter earning come share beating zack consensus estimate increase year period adjust earning exclude amortization expense special item include charge related recent tax law change include item report fourth quarter net loss share versus earning share year period sale miss slightlysale come slightly miss zack consensus estimate nonetheless sale increase year quarter reflect operational increase positive currency impact organically exclude impact acquisition divestiture sale increase operational basis better see third quarter first half pharmaceutical segment continue positive momentum see third quarter fourth quarter sale grow domestic market international market reflect operational growth positive currency impact sale segment sale rise year year reflect operational growth positive currency impact sale rise domestic international market sale domestic market rise international sale grow new product imbruvica cancer darzalex multiple myeloma continue perform well other growth driver be core product xarelto stelara zytiga invega sustenna please note market imbruvica partnership abbvie inc abbv free report quarter record pulmonary arterial hypertension pah revenue acquisition swiss biotech actelion june last year diversify revenue pah category add sale growth however sale invokana invokamet decline due higher manage care discounting importantly sale blockbuster rheumatoid arthritis drug remicade market partnership merck co inc mrk free report decline quarter sale decline international sale decline due biosimilar competition pharma segment achieve clinical milestone quarter include approval tremfya guselkumab eu november plaque psoriasis juluca dolutegravir rilpivirine first dual treatment hiv unite state please note juluca have be develop partnership glaxosmithkline gsk free report juluca be review eu tremfya be approve unite state july last year quarter also gain fda approval several line extension lower dose xarelto new indication simponi aria psoriatic arthritis ankylose spondylitis use adolescent stelara medical device segment sale come year period include operational increase positive currency movement domestic market sale rise year year international market sale increase operational increase year year consumer segment record revenue report quarter year year operational increase foreign currency movement positively impact sale segment sale domestic market decline year period meanwhile international segment record increase reflect operational increase positive currency impact resultsfull year sale rise fall slightly short zack consensus estimate adjust earning be share zack consensus estimate year year earning be higher end guidance range share outlook issuedj issue decent guidance earning range be consensus estimate sale fall slightly short same expect adjust earning share range reflect operational growth rate company guidance exceed thezack consensus estimate share expect revenue range reflect operational constant currency sale growth rate range however sale guidance fall slightly short zack consensus estimate acceleration underlie sale growth see third quarter continue fourth quarter quite few key product portfolio remicade concerta face generic competition believe new product segment label expansion drug imbruvica darzalex contribution actelion lead better sale trend second half compare first half profit outlook be also quite upbeat carry zack rank hold see complete list today zack rank strong buy stock here johnson johnson price consensus ep surprise johnson johnson price consensus ep surprise johnson johnson quotewall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2342,MRK,healthcare be perform well start new year thank encourage industry trend favorable policy environment notably popular etfs health care select sector spdr fund xlv free report vanguard health care etf vht free report ishare healthcare etf iyh free report fidelity msci health care index etf fhlc free report have gain nearly so far bullish trend be likely continue head earning season big name johnson johnson jnj free report pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc read tax bill etf investor need know let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stocksjnj have zack rank earning esp indicate lower chance beating estimate quarter stock have see earning estimate revision yet be report quarter deliver average negative earning surprise past quarters have impressive momentum style score value growth style score johnson johnson be slate release earning jan open bell see healthcare etfs here pfizer have zack rank earning esp indicate reasonable chance beating estimate quarter stock have see positive earning estimate revision penny be report quarter deliver average negative earning surprise past quarters have impressive growth value momentum style score respectively pfizer be schedule report earning jan open bell merck be expect report result feb market open have zack rank earning esp stock deliver positive earning surprise last quarters average beat witness negative earning estimate revision couple cent past day be report quarter merck have value growth momentum style score respectively amgen carry zack rank have earning esp indicate less chance beating estimate quarter earning surprise track past quarters be robust average positive surprise amgen witness negative earning estimate revision cent past day quarter be report stock have solid value style score growth momentum style score look dull amgen report earning feb market close read wave push biotech etfs higher abbvie have zack rank earning esp company deliver positive earning surprise last quarters average beat see earning estimate revision past month be report quarter stock have solid value growth style score momentum style score be unimpressive company be schedule report jan open bell gilead be expect release earning feb market close have zack rank earning esp gilead deliver positive earning surprise last quarters see negative earning estimate revision cent past month be report quarter have solid value style score growth momentum style score look ugly bristol myer likely report earning feb open bell have zack rank earning esp stock deliver average positive earning surprise past quarter witness positive earning estimate revision cent be report quarter have solid momentum growth style score respectively unfavorable value style score sum earning surprise well card healthcare sector be expect witness earning growth fourth quarter suggest upside healthcare etfs particular etfs have zack etf rank want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2343,MRK,new jersey base merck co inc mrk free report be global research drive pharmaceutical product company well know product merck portfolio include remicade nasonex simponi vytorin zetia januvia janumet isentress emend keytruda cozaar hyzaar zocor proquad gardasil zostavax other however many peer merck be face headwind form generic competition several key product company sell consumer care business bayer oct meanwhile merck acquire hepatitis virus focuse company idenix pharmaceutical aug cubist pharmaceutical merck be also focuse immuno oncology merck performance have be pretty impressive company exceed earning expectation trail quarters average positive earning surprise last quarters be estimate movement have be mostly static past day currently merck have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning beat merck surpass earning expectation company report ep consensus call ep revenue miss revenue report quarter come expectation merck post revenue consensus estimate lose sale product market due network cyber attack june hurt top line quarter outlook merck raise previously issue adjust earning guidance raise sale guidance marginally second time year adjust earning be expect range versus previously revenue be expect range compare earlier forecast stock price impact share be pre market trading check back later full mrk earning report wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2344,MRK,glaxosmithkline plc gsk free report report core earning cent american depositary share third quarter surpass zack consensus estimate cent bottom line be however flat constant exchange rate cer glaxo share drop more hour trading third quarter conference call glaxo show interest purchase pfizer pfe free report consumer healthcare business latter plan put sale however glaxo interest buy pfizer unit raise investor concern acquirer possibly sacrifice portion dividend payment due potential buyout so far year stock have lose industry increase quarterly revenue be cer back strong performance mainly pharmaceutical segment however revenue be line zack consensus estimate growth rate mentioned be year year basis cer quarterly highlightssale be unite state international market other hand sale europe register decrease sale new pharmaceutical vaccine product surge drive hiv drug tivicay triumeq respiratory drug ellipta product nucala vaccine prevent meningitis bexsero menveo glaxo report result segment pharmaceutical vaccine consumer healthcare pharmaceutical division register revenue growth drive hiv drug tivicay triumeq respiratory disease drug relvar breo nucala upside be partly offset impact recent divestment hiv sale rally back growth unite state international sale europe sale be however year year otherwise encourage number come back continue market share growth triumeq sale tivicay sale however sale hiv drug epzicom kivexa tumble due increase generic competition particularly affect european market respiratory sale be flat cer unite state europe sale dip however international market same increase downside be mainly due continue transition newer product portfolio sale new respiratory product relvar breo ellipta anoro ellipta arnuity ellipta nucala be offset lower sale seretide advair sale flixotide flovent ventolin sale decrease respectively ellipta product record surge sale drive market share gain global roll continue immuno inflammation drug include benlysta rise quarter new grouping establish pharmaceutical include previous establish product cardiovascular metabolic urology cvmu other pharma product establish pharmaceutical sale decline quarter sale consumer healthcare segment go slowdown market condition power brand particularly pain relief oral health category see strong performance quarter sale vaccine segment be flat cer geographically unite state europe be international market drop meningitis vaccine bexsero unite state europe menveo unite state see higher sale same be offset weak performance establish vaccine drive increase competitive pressure infanrix pediarix unite state europe notably october glaxo announce fda have grant approval vaccine shingrix prevention shingle herpes zoster subsequently same month center disease control prevention advisory committee immunization practice acip vote favor recommendation use shingrix vaccine be prefer merck mrk free report zostavax company expect face generic competition advair unite state next year affect top line however be uncertainty regard timing launch generic version drug generic version advair expect be unveil company continue expect core earning growth range cer remind investor mylan myl free report effort bring generic version advair market suffer blow fda issue complete response letter abbreviated new drug application anda advair april thereby delay entry generic hikma pharmaceutical plc generic version advair be also deny approval fda drug generic version be therefore not likely be approve year glaxosmithkline plc price consensus ep surprise glaxosmithkline plc price consensus ep surprise glaxosmithkline plc quotezack rankglaxo currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2345,MRK,celgene corporation celg free report report mixed result third quarter earning beat expectation sale fail meet estimate company report adjust earning share beat zack consensus estimate year quarter total revenue grow quarter miss zack consensus estimate revenue be boost consistent performance company key growth driver revlimid however sale otezla unite state be weak celgene stock have fall last month industry gain share company be pre market trading due revenue miss third quarter stock be hit earlier phase iii trial revolve cd pipeline candidate ged crohn disease extension trial sustain cd be discontinue revlimid continue shinenet product sale increase year year net sale revlimid come reflect year year growth drug perform well unite state growth report quarter be drive increase volume result increase duration treatment market share net sale cancer drug abraxane increase sale grow unite state international market sale oncology drug pomalyst imnovid come sale be drive increase volume duration gain otezla report sale report quarter sale unite state be impact increase gross net adjustment contract implement january slow overall category growth due more challenge market access environment other product sale include istodax thalomid vidaza authorize generic version vidaza unite state totale report quarter year quarter adjust research development expense increase due increase spending related drug discovery clinical trial activity adjust selling general administrative expense decrease last month celgene announce fda put hold several trial fusion program partial clinical hold have be put trial full clinical hold trial trial be evaluate imfinzi pd antibody combination chemotherapy agent blood cancer such multiple myeloma chronic lymphocytic leukemia lymphoma celgene enter strategic collaboration astrazeneca plc azn free report medimmune april develop commercialize imfinzi hematologic malignancy combination revlimid pomalyst vidaza other fda place hold trial due risk identify other trial pd antibody merck co mrk free report keytruda patient multiple myeloma combination agent celgene corporation price ep surprise celgene corporation price ep surprise celgene corporation quote outlook updatedcelgene update guidance company anticipate earning range compare previous guidance share zack consensus estimate earning be share revenue be now project compare earlier projection revlimid sale be project abraxane sale be estimate be pomalyst revenue be project however otezla sale be now project previous projection takecelgene third quarter result be mixed company beating earning miss sale estimate revlimid sale be impressive yet again otezla sale unite state be weak lead management reduce annual guidance drug consequently company update annual guidance august company obtain fda approval idhifa enasidenib treatment relapse refractory acute myeloid leukemia aml isocitrate dehydrogenase idh mutation drug be develop partnership agio pharmaceutical inc agio free report go forward expect approval new drug boost top line zack rank celgene be zack rank hold stock see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2346,MRK,third quarter report cycle be witness revenue acceleration positive revision trend result third company member be already revenue beat ratio company be slightly precede quarter be unusually high compare historically total earning member have report already be same period last year higher revenue beating ep estimate accord latest earning preview report company account index total market capitalization report total earning company be expect grow year year higher revenue biotech pharma bigwig eli lilly company lly free report biogen inc biib free report amgen inc amgn free report have report third quarter result week company beat expectation earning sale lilly also raise earning sale outlook amgen slightly raise lower end previously issue sale outlook raise earning guidance back effective cost management however share biogen amgen decline follow result announcement concern regard biogen multiple sclerosis franchise sale well sale recently launch spinal muscular atrophy sma treatment spinraza hurt investor sentiment amgen year year decline sale lead share price fall here have large pharma company be set report third quarter result oct let see thing be shape quarter abbvie inc abbv free report abbvie be schedule release earning market open have deliver positive earning surprise last quarter lilly earning performance have be mixed earning breaking even last quarters beating same other bring average surprise quarter abbvie have earning esp almost zack rank hold zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter company key drug humira be likely remain main growth driver backed higher demand quarter abbvie expect humira sale rise high teen range internationally same be estimate increase mid single digit range operational basis other drug duopa creon be also expect continue perform well soon be report quarter read more abbvie spring surprise earning season abbvie inc price consensus abbvie inc price consensus abbvie inc quotemerck co inc mrk free report merck be schedule release earning market open merckhad deliver positive earning surprise last quarter company earning performance have be pretty impressive so far have deliver positive surprise last quarters average earning beat last quarters be company also have earning esp almost zack rank zack consensus estimate be peg share see complete list today zack rank strong buy stock here merck new product keytruda cancer zepatier hcv bridion sugammadex injection be likely drive top line quarter keytruda sale unite state be gain particularly back strong momentum new indication first line lung cancer read more merck keep earning streak alive previous article show merck be likely beat earning quarter however estimate change thereafter be not certain beat earning season merck company inc price consensus merck company inc price consensus merck company inc quotelook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2347,MRK,share bristol myer squibb company bmy free report gain company end phase iii combination study checkmate earlier expect meet co primary endpoint phase iii study evaluate opdivo yervoy patient previously untreated advanced metastatic renal cell carcinoma rcc meet co primary endpoint study show superior overall survival os compare current standard care sunitinib market sutent pfizer pfe free report intermediate poor risk patient fact combination opdivo yervoy also meet secondary endpoint improve overall survival randomize patient base plan interim analysis independent datum monitoring committee dmc recommend study be stop early safety tolerability combination treatment observed study be consistent previous report dose schedule similar subgroup august bristol myer announce top line result checkmate study study meet co primary endpoint objective response rate orr markedly co primary endpoint progression free survival favore combination opdivo yervoy versus sunitinib do not reach statistical significance bristol myer share have underperform industry year date stock have be compare industry gain same time frame note opdivo become first pd inhibitor be approve hematological malignancy classic hodgkin lymphoma unite state eu november november opdivo gain fda approval treatment patient recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy fact renal cell carcinoma be most common type kidney cancer adult have huge unmet medical need thus label expansion additional indication give product access higher patient population increase commercial potential drug additionally company enter collaboration agreement seattle genetic inc sgen free report june deal bristol myer evaluate combination opdivo seattle genetic antibody drug conjugate adc adcetris phase iii trial potential treatment option patient relapse refractory transplant ineligible advanced classical hodgkin lymphoma hl however bristol myer suffer setback january decide not pursue accelerate regulatory pathway regimen opdivo yervoy first line lung cancer unite state base review available datum currently opdivo be face competitive challenge unite state fda approve merck mrk free report keytruda first line treatment metastatic nonsquamous nsclc company be expect suffer further loss market share bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quotezack rankbristol myer currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2348,MRK,dow endure significant loss holiday shorten trading week market be close monday labor day holiday index endure worst day loss several week tuesday follow rise tension north korea index rebound wednesday president donald trump conclude agreement congress debt ceiling issue however loss key component drag index lower thursday last week index gain last friday market watcher play chance possible rate hike fed follow desultory nonfarm payroll datum august total job be add economy august significantly lower consensus estimate job addition payroll addition be lower expect unemployment rate increase reach meanwhile ism manufacturing index hit year high month august index gain last week period hurricane harvey pummeled houston force major oil refinery area shut moreover north korea test fire ballistic missile japan raise geopolitical tension unite state meanwhile speaking cnbc secretary state steven mnuchin say trump administration have present detailed tax plan congress expect sign law year end dow weekmarket be close monday labor day holiday dow suffer loss more point tuesday register worst day drop aug end day winning streak such loss be incur investor rotate relatively riskier asset due escalate tension pyongyang washington likelihood fallout hurricane name irma coast florida send home insurer lower index gain wednesday president trump reach agreement key member congress extend debt ceiling deadline be do aid relief funding victim hurricane harvey however category hurricane irma gain momentum be slate land fall coast florida weekend news irma come send timeshare vacation stock lower meanwhile fed vice chairman announce plan retire mid october cite personal reason index lose thursday drag share walt disney company free report goldman sachs group inc gs free report disney share lose ceo bob iger announce company earning guidance full year be be revise downward share goldman sachs also decline weigh heavily dow broader market close marginally lower investor rotate financial seek telecom consumer discretionary stock component move index unite technology corporation utx free report recently inked definitive agreement acquire iowa base avionic firm rockwell collin inc col free report strategic transaction be likely create industry behemoth unrivaled competitive advantage be largest aircraft equipment manufacturer world individual capacity zack rank hold unite technology acquire rockwell collin share combination cash stock term agreement rockwell collin shareholder be entitle receive share cash balance amount unite technology share equate purchase price include rockwell collin net debt company expect fund transaction secondary debt offer available cash maintain solid investment grade credit rating transaction be likely close third quarter subject mandatory approval other customary close condition read unite technology inks accretive rockwell merger deal boee co ba free report recently announce be company receive aerospace system air platform technology research program contract unite state air force have ceiling value notably boee be final company receive award pentagon contract company be responsible provide quality research affordable revolutionary capability warfighter be award air force research laboratory patterson air force base boee expect complete task aug work be carry company hazelwood ms facility utilize fiscal research development fund finish task stock have zack rank buy see complete list today zack rank stock here johnson johnson jnj free report announce fda have approve label expansion oral pulmonary arterial hypertension pah medicine tracleer johnson johnson have zack rank consequently mg tablet tracleer be now approve use pediatric patient age year older idiopathic congenital pah improve pulmonary vascular resistance pvr be expect result improvement exercise ability approval tracleer have become first medicine unite state be approve use pediatric patient mg oral suspension formulation pediatric use be expect be available fourth quarter year presently tracleer be market mg dosage adult patient still be available read pah drug label expand pediatric use merck co inc mrk free report announce pd therapy keytruda have receive approval european commission first second line treatment certain patient locally advanced metastatic urothelial carcinoma type bladder cancer keytruda have be approve first line therapy patient receive standard care chemotherapy contain cisplatin keytruda be also approve second line treatment patient have be previously treat platinum contain chemotherapy read merck keytruda get eu approval bladder cancer separate development zack rank merck announce acquire germany base rigontec privately hold immuno oncology focuse biotech upfront cash payment almost euro rigontec be leader retinoic acid inducible gene rig target therapeutic be novel immuno oncology treatment approach deal completion date be not yet disclose subject certain close condition apart upfront payment base achievement certain milestone merck also make additional contingent payment worth approximately euro read merck opt buy german immuno oncology biotech pfizer inc pfe free report announce fda have grant approval mylotarg adult patient newly diagnosed cd positive acute myeloid leukemia aml drug also receive approval treat relapse refractory cd positive aml adult well child year older pfizer have zack rank approval be expect fda oncologic drug advisory committee have vote favor mylotarg approval july however be note label drug include box warning hepatotoxicity include severe fatal hepatic veno occlusive disease approval be grant base datum multiple investigator lead clinical trial include alfa aml mylofrance alfa phase iii study evaluate mylotarg combination chemotherapy newly diagnosed aml patient drug show significant improvement event free survival ef achieve month compare month chemotherapy read pfizer acute leukemia drug mylotarg approve fda performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have decline tickerlast day performance month performancemmm gs ibm hd ba unh mcd trv jnj aapl next week investor seem be weigh several concern domestic foreign origin tension north korea continue simmer hurricane be likely make landfall weekend such crisis occur even texas recover effect hurricane harvey give such backdrop only encourage economic datum help market return winning way week ahead more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2349,MRK,celgene corporation celg free report announce fda put hold several trial fusion program partial clinical hold have be put trial full clinical hold trial trial be evaluate imfinzi durvalumab pd antibody combination chemotherapy agent blood cancer such multiple myeloma chronic lymphocytic leukemia lymphoma fda have place hold trial due risk identify other trial pd antibody merck co mrk free report keytruda patient multiple myeloma combination agent result new patient be enroled trial nevertheless patient enroled trial partial hold receive clinical benefit same determine investigator remain treatment patient enroled trial full clinical hold be discontinue treatment remind investor celgene enter strategic collaboration astrazeneca plc azn free report medimmune april develop commercialize imfinzi hematologic malignancy combination revlimid pomalyst vidaza other trial place partial clinical hold be medi mm medi mm medi mm medi nhl medi dlbcl trial place full hold include medi mm earlier week fda also put partial clinical hold bristol myer squibb company bmy clinical trial checkmate checkmate same reason note july fda place clinical hold keynote keynote keynote combination study keytruda multiple myeloma decision be take follow review datum datum monitoring committee higher death be report keytruda arm keynote keynote lead halt enrolment news come major setback label expansion drug have boost celgene top line celgene stock have moved year date compare industry gain share be pre market trading news regain ground thereafter meanwhile celgene revlimid continue outperform drive market share increase newly diagnosed myeloma treatment duration zack rank key pickcelgene currently carry zack rank hold better rank stock healthcare sector be aduro biotech inc adro free report carry zack rank buy see complete list today zack rank strong buy stock here aduro biotech loss share estimate narrow last day company have top estimate trail quarters average more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2350,MRK,be quite few important development week eli lilly company lly free report announce be streamline operation cut workforce focus develop new medicine improve cost structure meanwhile novartis nvs free report announce ceo be step recap week most important storieslilly streamline operation cut job lilly announce restructure plan see company streamline operation so focus develop new medicine improve cost structure company be cut job most reduction expect voluntary early retirement program lilly also be close certain site move production larchwood ia animal health manufacturing facility exist plant fort dodge ia research development office bridgewater nj lilly china research development center shanghai china also shut lilly expect generate annualize saving be used improve cost structure new product launch label expansion study streamline program result company incur pre tax charge post tax charge cent share be recognize third fourth quarters cut report earning guidance adjust earning outlook remain unchanged lilly also say streamline effort now expect achieve opex revenue ratio less indicate improvement previous forecast merck buy rigontec immuno oncology focuse deal immune oncology space continue attract interest big pharma player merck mrk free report announce intention acquire rigontec deal worth include upfront payment rigontec expertise lie access retinoic acid inducible gene rig pathway be part innate immune system goal induce immediate long term tumor immunity acquisition add rigontec lead candidate rgt merck pipeline rgt be currently early stage development patient various tumor also read merck opt buy german immuno oncology biotech merck also announce european commission have expand label pd therapy keytruda treatment certain patient locally advanced metastatic urothelial carcinoma type bladder cancer also read merck keytruda get eu approval bladder cancer bmy opdivo impress rcc study bristol myer squibb company bmy free report have mixed news pd immune checkpoint inhibitor opdivo company say late stage study checkmate evaluate opdivo yervoy be stop early show overall survival os benefit patient previously untreated advanced metastatic renal cell carcinoma rcc follow plan interim analysis independent datum monitoring committee dmc recommend study be stop early combination provide rcc patient new first line treatment option approval indication boost sale significantly be significant unmet need area rcc be most common type kidney cancer adult year survival rate advanced metastatic stage be second set opdivo related news be not so encourage company say partial clinical hold have be place fda opdivo base combination study multiple myeloma fda decide place study partial hold follow identification risk identify combination study evaluate merck keytruda multiple myeloma mylan face month delay herceptin biosimilar decision mylan nv myl free report partner biocon have bit longer get response fda biosimilar version roche blockbuster drug herceptin trastuzumab fda inform mylan be extend target action date month so review clarificatory information submit part application review process result regulatory body now issue response regard approval status biosimilar dec biosimilar version have receive favorable vote july fda oncologic drug advisory committee odac herceptin be approve wide range indication include breast cancer metastatic adjuvant setting novartis ceo retire replacement announce novartis ceo joseph jimenez be step position board director have appoint vasant vas global head drug development chief medical officer successor effective feb also read replace jimenez novartis ceo novartis stock have gain year date outperform rally industry belong novartis be zack rank hold stock see complete list today zack rank strong buy stock here fda issue warning letter pfizer pfizer get warning letter fda regard manufacturing facility meridian medical technology inc brentwood mo letter mention significant violation current good manufacturing practice cgmp requirement combination product company have be accuse fail thoroughly investigate several serious component product failure epipen product manufacture behalf mylan include failure associate patient death severe illness earlier year march meridian medical technology have announce voluntary recall epipen product follow receipt previously disclose report outside unite state failure activate device due potential defect supplier component cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session most major stock record gain astrazeneca azn free report rise bristol myer be last month bristol myer be merck decline see last pharma stock roundup here novartis car drug get fda nod lilly give baricitinib update next pharma world watch usual pipeline regulatory update safety effectiveness glaxosmithkline plc gsk free report shingle vaccine shingrix be review fda vaccine related biological product committee vrbpac sep more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2351,MRK,bristol myer squibb company bmy free report announce fda put partial clinical hold clinical trial checkmate checkmate trial be investigate opdivo base combination patient relapse refractory multiple myeloma fda put study hold due risk identify merck co mrk free report keytruda pd agent patient multiple myeloma fda maintain datum obtain opdivo study indicate risk pd pd treatment pomalyst revlimid possibly pd pd treatment alone other combination outweigh potential benefit patient multiple myeloma consequently new patient be enroled study patient be currently enroled checkmate checkmate experience clinical benefit continue treatment company be work tandem fda address issue note july fda place clinical hold keynote keynote keynote combination study keytruda multiple myeloma decision be take follow review datum datum monitoring committee higher death be report keytruda arm keynote keynote lead halt enrolment news come disappointment investor earlier company suffer setback january decide not pursue accelerate regulatory pathway regimen opdivo yervoy first line lung cancer unite state base review available datum bristol myer stock have gain year date industry gain note opdivo become first pd inhibitor be approve hematological malignancy classic hodgkin lymphoma unite state eu november november opdivo gain fda approval treatment patient recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy label expansion additional indication give product access higher patient population increase commercial potential drug moreover opdivo be face competitive challenge unite state addition concern astrazeneca azn free report fail study lung cancer drug imfinzi loom large company checkmate study opdivo zack rank key pickbristol myer currently carry zack rank hold better rank stock healthcare sector be aduro biotech inc adro free report carry zack rank buy see complete list today zack rank strong buy stock here aduro biotech loss share estimate narrow last day company have top estimate trail quarters average more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2352,MRK,merck mrk free report announce acquire germany base rigontec privately hold immuno oncology focuse biotech upfront cash payment almost euro rigontec be leader retinoic acid inducible gene rig target therapeutic be novel immuno oncology treatment approach deal completion date be not yet disclose subject certain close condition apart upfront payment base achievement certain milestone merck also make additional contingent payment worth approximately euro share merck have underperform industry year date stock have gain compare industry rally period acquisition complement merck current immuno oncology pipeline keytruda label expansion study wind buyout merck add rigontec lead candidate rgt portfolio notably rgt be currently evaluation phase study treatment patient various tumor significantly merck be actively pursue deal order build long term portfolio company enter several licensing deal past few year target achieve more future remind investor july merck announce oncology collaboration astrazeneca azn free report jointly commercialize develop latter parp inhibitor lynparza mek inhibitor selumetinib oncology candidate astrazeneca monotherapy combination study multiple cancer type merck make upfront payment astrazeneca presently market advanced ovarian cancer lynparza be different study range tumor type include breast prostate pancreatic cancer merck astrazeneca independently develop combination medicine lynpraza selumetinib respective pd pd inhibitor imfinzi keytruda merck company inc price merck company inc price merck company inc quotezack rank stock considermerck currently carry zack rank hold better rank stock pharma sector be aduro biotech inc adro free report acadium pharmaceutical inc acad free report carry zack rank buy see complete list today zack rank strong buy stock here aduro biotech loss share estimate reduce last day company deliver positive earning surprise trail quarters average beat acadium loss share estimate narrow last day company post positive earning surprise last quarters average beat simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
2353,MRK,merck co inc mrk free report announce pd therapy keytruda have receive approval european commission ec first second line treatment certain patient locally advanced metastatic urothelial carcinoma type bladder cancer keytruda have be approve first line therapy patient receive standard care chemotherapy contain cisplatin keytruda be also approve second line treatment patient have be previously treat platinum contain approval be expect july committee medicinal product human use chmp european medicine agency ema have grant positive opinion recommend approval keytruda unite state keytruda receive accelerate approval advanced bladder cancer indication year approval be base datum phase ii keynote trial phase iii keynote trial datum study have show clinically meaningful improve overall survival benefit keytruda versus chemotherapy difficult treat population keytruda be presently approve many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer keytruda bring sale second quarter sequentially year year sale continue be drive launch new indication globally keytruda sale gain particularly strong momentum new indication first line lung cancer outside keytruda sale be primarily drive melanoma indication meanwhile keytruda development program also significantly advanced first half regulatory approval new indication additional indication europe important approval include advanced bladder cancer advanced microsatellite instability high cancer first approval combination therapy eli lilly company lly free report cancer drug alimta pemetrexed carboplatin pem carbo commonly used chemo regimen lung cancer further keytruda datum readout be pending second half keytruda be continuously grow expand new indication market globally keytruda be be study more type cancer more study include more combination study merck be collaborate several company include amgen inc amgn free report incyte glaxo pfizer inc pfe free report separately evaluation keytruda combination other regimen merck share have rise year so far increase industry merck carry zack rank hold see complete list today zack rank strong buy stock here surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
2354,MRK,cancer be second most common cause death precede only heart disease traditional cancer treatment include surgery radiation chemotherapy however immunotherapy gene therapy other new novel therapy be be develop improve supplement replace traditional cancer treatment target reduce remove cancerous growth accord report american cancer society almost new cancer case be expect be diagnosed create significant need effective cancer medication go say big pharma company be gear develop bring innovative cancer treatment market well expand label market oncology drug pharma biotech giant have significant financial resource disposal have even collaborate pool resource technology here discuss pharma giant possess industry strongest oncology pipeline portfolio astrazeneca azn free report astrazeneca be work strengthen oncology product portfolio have several candidate pipeline company target be launch least new oncology medicine include lynparza tagrisso imfinzi be already approve market interesting candidate company immuno oncology pipeline be imfinzi durvalumab be evaluate multiple cancer alone combination other regimen include phase iii trial combination tremelimumab first line urothelial cancer nsclc small cell lung cancer head neck squamous cell carcinoma hnscc other imfinzi be launch first indication second line advanced bladder cancer other phase iii oncology candidate astrazeneca pipeline include acalabrutinib blood cancer moxetumomab pasudotox leukaemia selumetinib thyroid cancer savolitinib kidney cancer lynparza presently market advanced ovarian cancer be also different study range tumor type include breast prostate pancreatic cancer well earlier line setting ovarian cancer tagrisso be also be evaluate earlier line setting lung cancer astrazeneca carry zack rank hold see complete list today zack rank strong buy stock here so far year astrazeneca share have moved compare unfavorably increase large cap pharma industry pfizer pfe free report pfizer newly approve immunotherapy bavencio be be consider significant top line driver new york base pharma giant bavencio avelumab receive fda approval metastatic merkel cell carcinoma mcc march advanced bladder cancer bavencio be review eu mcc decision expect third quarter pfizer be focuse continuously grow expand bavencio new indication market globally pfizer have also initiate avelumab double triple combination study chemotherapy target therapy have avelumab combination therapy immuno oncology agent development pfizer other oncology candidate have also be approve fda recently besponsa relapse refractory acute lymphoblastic leukemia august mylotarg new relapse cd positive acute myeloid leukemia september other cancer candidate pfizer pipeline include talazoparib advanced breast cancer dacomitinib advanced nsclc egfr activate mutation pfizer be also aggressively work expand label approve cancer drug ibrance xalkori pfizer also carry zack rank hold so far year pfizer share have moved abbvie abbv free report abbvie be work expand accelerate presence oncology build grow position hematological oncologyabbvie imbruvica currently approve several cancer indication have multus dollar potential abbvie be explore potential expand imbruvica label solid tumor autoimmune disease abbvie be position imbruvica pipeline molecule treatment be several company sponsored study acquisition cancer drugmaker stemcentrx abbvie gain late stage candidate rovalpituzumab tesirine rova additional early stage compound solid tumor indication significant portfolio pre clinical asset rova be currently registrational study small cell lung cancer sclc phase arm basket study rova neuroendocrine tumor be also ongoing accord abbvie candidate have blockbuster potential be launch abbvie intend study candidate additional indication estimate peak sale close abbvie be also study market cancer drug venclyxto venclexta expand label address broader relapse refractory cll patient population expand earlier line therapy broaden other hematologic malignancy abbvie also carry zack rank so far year abbvie share have moved bristol myer bmy free report bristol myer pd inhibitor opdivo have be perform impressively bristol myer be work expand label opdivo further alone combination therapy yervoy other cancer agent further bristol myer cancer portfolio include multiple myeloma drug empliciti leukemia drug sprycel contribute top line addition bristol myer be evaluate other immune system pathway treatment cancer pathway help company bring market potentially immunotherapy combination monotherapy help fight different type cancer bristol myer also carry zack rank so far year bristol myer share have moved other not far behindmerck mrk free report be also conduct numerous study evaluate highly successful pd therapy keytruda more type cancer more study include more combination study roche rhhby free report dominate breast cancer space strong demand franchise drug herceptin perjeta kadcyla apart strong breast cancer franchise roche oncology portfolio also boast lung cancer drug avastin tarceva immuno oncology drug tecentriq newly approve multiple sclerosis drug ocrevus label expansion effort be ongoing cancer drug swiss drugmaker novartis nvs free report also boast many experimental cancer drug pipeline include couple biosimilar version popular cancer drug novartis cancer pipeline be bolster deal buy most glaxo gsk free report oncology portfolio lilly lly free report also layer oncology strategy call hold july involve build key treatment cyramza lartruvo abemaciclib foundational agent focuse develop new standard care change therapy combination regimen include immuno therapy cancer market be fierce not pipeline candidate be successful however pharma biggy have enough late stage cancer program portfolio be chance quite few rollout come year surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
2355,MRK,be relatively good year pharmaceutical stock give have catch eye investor greater part occasional comment drug pricing time president trump pharma company have be largely spare close scrutiny front such scheme thing be far cry hillary clinton comment issue run last presidential election additionally trump commitment deregulation have gladden sector leader meanwhile be other factor continue have positive impact pharma biotech stock be new product sale ramp success innovation strong result higher number fda approval continue strong performance legacy product read pharma biotech stock be big winner earning sign sector success be more evident nyse arca pharmaceutical index nasdaq biotechnology index have gain respectively year date merck co inc mrk free report pfizer inc pfe free report schedule report oct oct respectively be good time consider be better stock stock carry zack rank hold rating see complete list today zack rank strong buy stock here other major earning schedule period include aetna inc aet free report electronic art inc ea free report price pharma sector recovery fortune be more evident price performance broader industry be year date pfizer merck be underperformer respect broader industry however pfizer be better performer count have gain year date versus merck gain most appropriate ratio evaluate drug maker be perhaps ev ebitda metric be usually used compare stock same industry be superior other metric such be not affected different capital structure company come pharma major merck pfizer be undervalue relative broader industry have ev ebitda value however pfizer hold edge here lower ev ebitda value compare merck value dividend yieldboth pfizer merck have offer superior dividend yield last year period compare broader industry have return period however dividend yield pfizer be ahead merck count only merck have offer dividend yield same period gross marginthe pharmaceutical industry enjoy higher profit margin several other sector be possibly reason critic sector continually draw attention allegedly exorbitant drug pricing likely help sector maintain stiff margin gross margin ttm value merck underperform rival pfizer count other hand pfizer sport gross margin ttm value outperform merck well broader industry have gross margin ttm value earning history esp estimate more comprehensive earning history merck have deliver positive surprise prior quarters average earning surprise comparison pfizer deliver earning beat trail quarters average positive earning surprise consider earning esp merck be once again clear winner esp pfizer be disadvantage merck hold value additionally merck zack consensus estimate current year have increase last day pfizer have remain unchanged conclusionour comparative analysis show pfizer hold edge merck consider price performance ev ebitda ratio gross margin also sport marginally superior dividend yield however consider estimate revision more comprehensive look previous earning performance merck be clearly better stock clinch case favor merck point time be sport superior esp value compare pfizer dismal read be be better bet merck pfizer prepare report earning next few day look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2356,MRK,inc agen free report be expect report third quarter oct last report quarter company deliver positive earning surprise trail quarter average notably share have underperform industry year date stock have be industry gain let see thing be shape company quarter earning whispersour proven model show be likely beat earning quarter have right combination key ingredient positive earning esp zack rank strong buy buy hold have significantly higher chance beating earning zack esp have earning esp be most accurate estimate loss cent come lower zack consensus estimate loss cent uncover best stock buy sell re report earning esp filter zack rank zack rank combine positive esp make reasonably confident earning beat note caution stock zack rank sell rate go earning announcement factor playagenus be immuno oncology company focuse discovery development checkpoint modulator vaccine adjuvant treatment cancer earn revenue only fee receive collaboration license agreement currently company be evaluate agen phase study incagn phase ii study treatment solid tumor fact have initiate phase study ox agonist antibody incagn phase ii study collaboration incyte expect begin combination study agen agen second half third quarter conference call investor be likely remain focuse company update initiation combination study antibody be expect focus advancement additional checkpoint modulator antibody vaccine clinic come quarters january enter clinical trial collaboration national cancer institute nci evaluate prophage hsppc conjunction merck co inc mrk free report pd therapy keytruda phase ii study evaluate effect prophage conjunction keytruda overall survival rate patient newly diagnosed glioblastoma ndgbm recently announce fda grant marketing authorization glaxosmithkline herpes zoster vaccine shingrix contain proprietary immune adjuvant qs stimulon shingrix be indicated prevention herpes zoster also know shingle adult age year older be positive impact business inc price ep surprise inc price ep surprise inc quotestock warrant lookhere be health care stock want consider model show have right combination element post earning beat quarter seattle genetic inc sgen free report have earning esp zack rank company be schedule release result oct see complete list today zack rank stock here gilead science inc gild free report have earning esp zack rank company be schedule release result oct zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
2357,MRK,expect pfizer inc pfe free report beat expectation report third quarter result oct market open last quarter company deliver positive earning surprise pharma giant have mixed record earning surprise company earning surpass expectation last quarters miss other result average negative surprise pfizer share have rise year so far compare unfavorably increase zack classify industry factor playnew product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain eliquis blood thinner contribute top line meaningfully however loss exclusivity associate generic competition product pristiq vfend zyvox celebrex expiration few co promotion agreement continue hamper top line growth sale blockbuster drug enbrel continue decline quarter due biosimilar competition lower sale trend prevnar prevenar vaccine franchise be likely continue sale viagra be also likely be affected lower demand zack consensus estimate prevnar enbrel be respectively call management say penetration inflectra pfizer biosimilar version jnj free report blockbuster rheumatoid arthritis drug remicade unite state have be slower expect be experience access challenge national commercial payer fact september pfizer file lawsuit district court allege wasresorting unfair practice prevent sale inflectra do not discuss much inflectra impact brand drug sale lawsuit call expect update pfizer upcoming investor call meanwhile bottom line be likely be drive cost saving share buyback however new product launch expense investment be expect hurt profit pfizer acute lymphoblastic leukemia candidate bavencio avelumab receive fda approval metastatic merkel cell carcinoma mcc march advanced bladder cancer bavencio be also approve eu japan september leukemia treatment besponsa inotuzumab ozogamicin relapse refractory acute lymphoblastic leukemia mylotarg newly diagnosed cd positive acute myeloid leukemia aml be also approve fda third quarter besponsa be also approve eu june expect management record sale new cancer drug quarter earlier month pfizer say be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction update matter be expect investor call model proven model show pfizer be likely beat earning have right combination key ingredient stock need have positive earning zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate cent share zack consensus estimate cent share be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank pfizer have zack rank combination pfizer zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quoteother stock considera couple stock pharmaceutical sector also have positive earning esp favorable zack rank be merck co inc mrk free report schedule release result oct have earning esp zack rank see complete list today zack rank stock here bristol myer squibb company bmy free report schedule release result oct have earning esp zack rank zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
2358,MRK,merck co inc mrk free report announce datum phase ii keynote study evaluate use pd therapy keytruda patient advanced hepatocellular carcinoma hcc form liver cancer be previously treat systemic therapy sorafenib datum show treatment keytruda monotherapy lead overall response rate orr datum also show complete response rate partial response rate treatment datum also include month overall survival os progression free survival pfs rate median pfs keytruda arm be month month pfs rate percent however datum show median os be not reach time analysis month os rate be datum be present present american society clinical oncology asco gi cancer symposium san francisco notably keytruda be already market several cancer indication include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer last week merck announce keytruda combination lilly lly free report alimta pemetrexed acisplatin carboplatin meet dual primary endpoint phase iii keynote study combination be evaluate first line treatment patient metastatic squamous nsclc study meet primary endpoint progression free survival pfs os co primary endpoint remind investor third quarter call merck have mentioned be include overall survival os co primary endpoint keynote study defer readout study be then estimate study complete february therefore year earlier expect positive read keynote study be big boost company share merck have lose past year compare unfavorably industry increase remind investor keytruda be key top line driver merck bring sale third quarter sequentially year year sale continue be drive launch new indication globally significantly keytruda sale unite state have gain particularly strong momentum new indication first line lung cancer meanwhile keytruda development program also significantly advanced regulatory approval new indication unite state additional disease europe keytruda be continuously grow expand new indication market globally be trial more type cancer study include excess combination study merck be collaborate separately several company namely amgen inc amgn free report incyte glaxo pfizer inc pfe free report evaluation keytruda combination other regimen merck company inc price merck company inc price merck company inc quotezack rankmerck carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2359,MRK,fda approve novel drug last year have give approval drug so far include august key approval year include gilead vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other drug have blockbuster potential recent landmark approval be novartis kymriah make first gene therapy unite state mark begin new era treatment cancer other serious life threaten disease drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst here be look few important regulatory event schedule month september fda follow advisory panel vote mylan herceptin biosimilar mylan nv myl free report hear fda soon approval status biosimilar version roche blockbuster drug herceptin trastuzumab company partner biocon ltd get favorable vote fda oncologic drug advisory committee odac july biosimilar herceptin be approve wide range indication include breast cancer metastatic adjuvant setting earlier year mylan have enter global settlement agreement roche genentech hoffmann la roche ltd herceptin trastuzumab mylan get global license exclude japan brazil mexico trastuzumab product mylan well be first launch biosimilar version herceptin unite state approval boost investor sentiment company have lose year date versus decline industry fda advisory panel discuss glaxo pfizer ptc therapeutic few fda advisory panel meeting be schedule month fda vaccine related biological product committee vrbpac be meeting sep discuss safety effectiveness glaxosmithkline plc gsk free report shingrix glaxo be look get live recombinant vaccine approve prevention herpes zoster shingle person be year old shingle common potentially serious condition cause last pain other complication such scarring visual impairment then sep fda odac be meeting discuss supplemental new drug application snda submit pfizer pfe free report cancer drug sutent pfizer be look expand sutent label adjuvant treatment adult patient high risk recurrent renal cell carcinoma rcc follow nephrectomy surgical removal cancer contain kidney fda be expect render final decision regard label expansion jan sutent bring sale first half later month sep fda peripheral central nervous system drug advisory committee discuss ptc therapeutic ptct free report new drug application nda translarna ataluren treatment patient due nonsense mutation gene translarna be already approve outside unite state fda be expect give response regard approval status drug oct fda grant approval amgen allergan avastin biosimilar amgen amgn free report allergan be also expect decision fda biosimilar version roche cancer drug avastin bevacizumab company get favorable vote fda advisory panel odac recently chance gain approval fda action date sep look good share amgen have gain year date significantly outperform industry rally merck bristol myer seek label expansionmerck mrk free report be look expand label pd therapy keytruda use treatment recurrent advanced gastric junction adenocarcinoma keytruda be priority review indication response expect sep keytruda bring sale first half be key product merck portfolio be be evaluate wide range indication merck have gain year date versus growth industry bristol myer squibb company bmy free report be also look expand label pd inhibitor opdivo opdivo be priority review use patient hepatocellular carcinoma hcc prior treatment nexavar sorafenib fda be expect give response sep opdivo prioritize brand bristol myer portfolio bring sale first half bristol myer have gain year date versus growth industry fda approve plivensia johnson johnson investigational rheumatoid arthritis ra treatment plivensia sirukumab il inhibitor be fda review response expect sep however early august plivensia fail get support fda arthritis advisory committee safety concern be look get plivensia approve treatment adult patient moderately severely active ra have have inadequate response be intolerant more disease modify rheumatic drug dmard ra be common chronic life long autoimmune disease affect person unite state fda be not require do so usually follow advice advisory panel consider safety concern raise panel quite likely agency ask additional information grant approval share have gain year date outperform industry rally neos therapeutic be also await decision month nt amphetamine xr liquid suspension product candidate attention deficit hyperactive disorder adhd approval sep allow company go ahead plan launch product jan zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
2360,MRK,incyte corporation incy free report announce european society medical oncology esmo publish abstract contain new update datum ongoing phase ii echo trial epacadostat echo study nct be evaluate safety efficacy incyte selective ido enzyme inhibitor epacadostat combination merck co mrk free report keytruda patient advanced melanoma datum study reveal robust durable response patient advanced melanoma treat combination epacadostat keytruda efficacy evaluable advanced melanoma patient median progression free survival pfs be month pfs rate month month month respectively median pfs be not reach patient be treatment nave advanced disease landmark pfs rate month month month respectively echo clinical trial program be be conduct investigate efficacy safety epacadostat core component combination therapy oncology incyte be evaluate epacadostat combination pd pd inhibitor broad range solid tumor type well hematological malignancy echo nct phase iii randomize double blind placebo controlled study be investigate keytruda combination epacadostat placebo treatment unresectable metastatic melanoma be also ongoing fully recruit meawnhile incyte have extend collaboration bristol myer squibb company bmy free report evaluate epacadostat combination opdivo pivotal study tumor type plan initiation end incyte sign clinical trial collaboration agreement merck bristol myer roche hold ag rhhby free report other evaluate epacadostat respective pd pd agent phase ii study incyte stock gain year so far compare industry gain believe agreement not only validate company research approach also enhance company financial position incyte stand earn revenue form milestone payment royalty successful development however june incyte roche decide end echo trial epacadostat tecentriq further enrolment slow study recruitment zack rankincyte currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2361,MRK,bristol myer squibb company bmy free report announce new datum cohort phase ii checkmate study opdivo checkmate study be ongoing study evaluate opdivo nivolumab yervoy ipilimumab previously treat patient dna mismatch repair deficient dmmr microsatellite instability high msi metastatic colorectal cancer result study show primary endpoint objective response rate investigator assessment be median follow month overall survival rate year be median os be not yet reach result show opdivo yervoy provide durable clinical benefit patient dmmr msi metastatic colorectal cancer datum show statistically significant clinically meaningful improvement key patient report outcome include symptom function quality life bristol myer share have rally past year compare industry gain note opdivo be already approve number indication include classical hodgkin lymphoma recurrent metastatic squamous cell carcinoma head neck scchn disease progression platinum base therapy additionally be approve monotherapy treatment scchn adult progress platinum base therapy opdivo be also approve intravenous use patient hepatocellular carcinoma have be previously treat nexavar drug receive approval liver colorectal cancer well meanwhile company continue evaluate opdivo alone combination therapy yervoy other cancer agent label expansion drug additional indication give product access higher patient population increase commercial potential significantly however opdivo be face competitive challenge unite state fda approve merck mrk free report keytruda first line treatment metastatic squamous small cell lung cancer nsclc company be expect suffer further loss market share bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quote zack rank stock considerbristol myer carry zack rank hold few better rank stock health care space be exelixis inc exel free report xoma corporation xoma free report xoma sport zack rank strong buy exelixis carry zack rank buy see complete list today zack rank stock here exelixis earning share estimate have moved cent cent last day company deliver positive earning surprise last quarters average share price company surge xoma loss share estimate have narrow cent cent last day company post positive earning surprise last quarters average beat share price company sky-rocket hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2362,MRK,be historic week not just novartis nvs free report also medical community patient fda give nod first gene therapy unite state novartis kymriah mark begin new era treatment cancer other serious life threaten disease recap week most important storiesnovartis get head start car market kymriah approval novartis get huge boost fda approve company car cell therapy kymriah child young adult cell acute lymphoblastic leukemia be refractory have relapse least twice make kymriah first car cell treatment be approve unite state path breaking immunocellular therapy be time treatment used patient own cell fight cancer cancer bone marrow blood progress quickly be most common childhood cancer unite state accord national cancer institute patient year younger be diagnosed year kymriah not only provide patient new treatment option have also show promising remission survival rate study novartis intend seek label expansion kymriah later year additional indication include treatment adult patient diffuse large cell lymphoma also read novartis car therapy kymriah receive fda approval share novartis have gain year date outperform industry rally novartis be zack rank hold stock see complete list today zack rank strong buy stock here allergan settlement agreement famy care restasis allergan agn free report enter settlement agreement famy care be look bring generic version allergan eye drug restasis market patent infringement lawsuit be settle famy care get license market generic version unite state feb earlier certain circumstance patent be schedule expire aug teva austedo nabs fda approval second indication teva pharmaceutical industry teva free report get good news finally company gain fda approval second indication austedo austedo have gain fda approval apr treatment chorea associate huntington disease be now approve treatment dyskinesia adult well dyskinesia debilitating often irreversible movement disorder be estimate affect person unite state also read teva austedo get fda nod label expansion dyskinesia teva be currently go tough time company performance be impact generic pricing erosion teva have many challenge ahead pay debt divest core business increase focus core area generate cash hire permanent ceo deliver pipeline get generic business back track lilly provide baricitinib regulatory update eli lilly company lly free report partner incyte provide update regard resubmission regulatory application unite state experimental rheumatoid arthritis ra treatment baricitinib company have previously say expect delay least month resubmission regulatory application baricitinib announce be resubmit regulatory application jan new safety efficacy datum be include resubmission also read lilly incyte re file baricitinib nda faster expect bayer hemophilia drug submit fda approval bayer ag bayry free report have submit biologic license application bla unite state long act site specifically pegylate recombinant human factor viii bay treatment hemophilia bayer portfolio already include hemophilia product form kogenate approve bay provide patient less frequent dose option astrazeneca inks deal takeda astrazeneca azn free report have sign takeda pharmaceutical joint development medi alpha synuclein antibody be develop parkinson disease pd investigational treatment be schedule enter early stage development later year phase development be conduct astrazeneca future clinical development activity be handled takeda future development cost well future revenue be share company deal term include astrazeneca include initial revenue development sale milestone thereafter parkinson disease second most common disease be estimate affect person world also read astrazeneca takeda ink deal develop parkinson drug cap pharmaceutical industry yr returnlarge cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session major stock record gain bristol myer squibb rise lilly be baricitinib update last month be merck mrk free report decline see last pharma stock roundup here roche drug get priority review eu nod novartis drug next pharma world watch usual pipeline regulatory update company astrazeneca be present european society medical oncology esmo congress datum presentation approve pipeline candidate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2363,MRK,merck co inc mrk free report announce detailed datum large phase iii cardiovascular outcome study reveal evaluate anacetrapib cholesteryl ester transfer protein cetp inhibitor patient cardiovascular disease datum phase iii study show anacetrapib statin reduce risk major coronary event composite coronary death myocardial infarction coronary relative placebo patient atherosclerotic vascular disease be already receive effective cholesterol treatment anacetrapib reduce risk same be patient placebo statin however significant benefit be observed reduce risk ischemic stroke detailed datum be publish new england journal medicine present european society cardiology congress merck share have rise year so far compare unfavorably increase industry top line datum study be announce june company say study have meet primary endpoint also say cetp inhibitorled significant reduction major coronary eventsversus placebo patient high risk cardiovascular event be already receive effective cholesterol treatment however detail have only be mentioned now company funded reveal study be conduct more patient be take atorvastatin common medicine lower bad cholesterol ldl median duration least year be also say anacetrapib safety profile be line observed previous study most significant side effect be accumulation anacetrapib fat tissue year take drug announce june merck be not sure datum be strong enough seek approval plan review result external expert company then consider file regulatory application fda other agency remind investor previous experimental cetp inhibitor have fail respective study cetp inhibitor be design raise hdl cholesterol level be know good cholesterol eli lilly company lly free report terminate development late stage cetp inhibitor evacetrapib base recommendation independent datum monitoring committee suggest chance meeting primary endpoint be low back pfizer inc pfe free report have suspend late stage development cetp inhibitor torceptrapib due safety issue roche rhhby free report discontinue development cetp inhibitor dalcetrapib due lack efficacy however uncertainty regard not company actually file datum regulator remain be apprehend accumulation anacetrapib fat tissue get way regulatory approval merck carry zack rank hold see complete list today zack rank strong buy stock here surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
2364,MRK,abbvie inc abbv free report be schedule release third quarter earning oct open bell abbvie share have soar so far year industry have record increase last quarter company deliver positive surprise notably abbvie earning history be mixed bag pharmaceutical company beat estimate last quarters record line earning other quarter average beat be abbvie inc price ep surprise abbvie inc price ep surprise abbvie inc quotelet see thing be shape company quarter factor considerabbvie expect third quarter earning range share revenue be estimate grow approximately operational basis foreign exchange be not expect impact sale third quarter company key drug humira be likely remain main growth driver third quarter backed higher demand quarter abbvie expect humira sale rise high teen range internationally sale be estimate increase mid single digit range operational basis zack consensus estimate humira be third quarter significantly cancer drug imbruvica record strong sale past few quarters trend expect continue quarter be report imbruvica be approve fda treat adult patient chronic graft versus host disease cgvhd disease failure more line systemic therapy imbruvica expand label also contribute sale growth company expect drug sale growth approach third quarter zack consensus estimate imbruvica be quarter other drug duopa creon be also expect continue perform well soon be report quarter however abbvie hepatitis virus hcv treatment viekira continue be adversely impact intense pricing competitive pressure hcv market notably abbvie week pan genotypic ribavirin free once daily hcv treatment mavyret maviret gain approval unite state eu canada earlier july august company believe maviret have potential rejuvenate growth hcv franchisea compare competitive dynamic hcv market expect management update plan maviret conference call maviret be expect contribute considerably revenue only onward company have make significant progress pipeline quarter be focus investor keep tab abbvie partner roche rhhby free report announce positive datum phase iii murano study venclexta rituxan september expand label address broader relapse refractory cll chronic lymphocytic leukemia patient population label expansion indication increase patient population venclexta significantly boost commercial potential also same month company announce oral jak selective inhibitor upadacitinib meet primary endpoint phase iii study treatment ra rheumatoid arthritis additionally abbvie partner neurocrine bioscience announce new drug application nda elagolix have be submit fda september abbvie be look get elagolix approve oral medicine pain management associate endometriosis earning whispersour proven model do not conclusively show abbvie be likely beat earning quarter be stock need have positive earning esp bullish zack rank strong buy buy hold happen be not case here see zack esp abbvie have earning esp most accurate estimate zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter zack rank abbvie zack rank increase predictive power esp earning esp make surprise prediction difficult caution sell rate stock go earning announcement especially company be see negative estimate revision stock warrant lookhere be health care stock want consider model have right combination element beat earning quarter merck company inc mrk free report be schedule release result oct zack rank company have earning esp see complete list today zack rank stock here pfizer inc pfe free report be schedule release result oct company have earning esp also carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2365,MRK,thank encourage industry trend hope favorable policy environment healthcare be top perform sector year notably popular etfs health care select sector spdr fund xlv free report vanguard health care etf vht free report ishare healthcare etf iyh free report fidelity msci health care index etf fhlc free report have gain least so far read healthcare etf hit new week high bullish trend be likely continue head earning season big name pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stockspfizer have zack rank earning esp indicate reasonable chance beating estimate quarter stock have see earning estimate revision yet be report quarter deliver average negative earning surprise past quarters have impressive value style score growth momentum style score respectively look disappointing pfizer be schedule report earning oct open bell pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotemerck be expect report result oct market open have zack rank earning esp stock deliver positive earning surprise last quarters average beat witness negative earning estimate revision cent past day be report quarter merck have strong momentum style score value growth style score merck company inc price consensus ep surprise merck company inc price consensus ep surprise merck company inc quoteamgen carry zack rank have earning esp indicate less chance beating estimate quarter earning surprise track past quarters be robust average positive surprise amgen witness negative earning estimate revision cent past day yet be report quarter stock have solid value momentum style score respectively growth style score look dull amgen report earning oct market close read keep portfolio healthy biotech etfs amgen inc price consensus ep surprise amgen inc price consensus ep surprise amgen inc quoteabbvie have zack rank earning esp company deliver positive earning surprise last quarters average beat see negative earning estimate revision couple cent past month be report quarter stock have solid value style score growth momentum style score respectively be unimpressive company be schedule report oct open bell abbvie inc price consensus ep surprise abbvie inc price consensus ep surprise abbvie inc quotegilead be expect release earning oct market close have zack rank earning esp indicate reasonable chance beating estimate gilead deliver positive earning surprise last quarters average beat see earning estimate revision nickel past month be report quarter have solid value style score growth momentum style score respectively look ugly see healthcare etfs here gilead science inc price consensus ep surprise gilead science inc price consensus ep surprise gilead science inc quotebristol myer likely report earning oct open bell have zack rank earning esp stock deliver positive earning surprise past quarters average beat witness positive earning estimate revision couple cent be report quarter have solid growth style score unfavorable value momentum style score respectively bristol myer squibb company price consensus ep surprise bristol myer squibb company price consensus ep surprise bristol myer squibb company quotesum earning surprise well card healthcare sector be expect witness earning growth third quarter have strong zack rank top suggest further upside healthcare etfs particular etfs have zack etf rank read top rank healthcare etfs long term investor want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2366,MRK,expect merck co inc mrk free report beat expectation report third quarter result oct market open last quarter company deliver positive earning surprise merck performance have be pretty impressive company exceed earning expectation trail quarters average positive earning surprise last quarters be merck share have rise year so far compare unfavorably increase industry factor considermerck new product keytruda cancer zepatier hcv bridion sugammadex injection be likely drive top line quarter keytruda sale unite state be gain particularly back strong momentum new indication first line lung cancer keytruda development program significantly advanced first half regulatory approval new indication unite state additional indication europe key recent approval include advanced bladder cancer advanced microsatellite instability high cancer first approval combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo lung cancer new approval have expand patient population be expect drive sale third quarter however call management warn zepatier uptake be impact ongoing decline overall patient volume many market increase competition previously strong underlie demand trend unite state europe japan have support zepatier sale company also face headwind form genericization well increase competition negative impact currency exchange sale remicade lose exclusivity europe face stiff biosimilar competition region cubicin lose patent protection unite state june zetia lose market exclusivity unite state december vytorin lose exclusivity april be likely decline quarter sluggish growth integrase class continue competitor dynamic unite state europe continue affect isentress sale zack consensus estimate isentress sale be third quarter investor also be focuse performance merck dpp inhibitor januvia pricing pressure hurt sale januvia janumet franchise first half vaccine animal health franchise be expect boost sale quarter zack consensus estimate vaccine total animal health segment be respectively call merck mentioned network cyber attack june disrupt global operation include manufacturing research sale time merck have say full recovery cyber attack take time result temporary delay fulfill order product not keytruda zepatier januvia certain market expect update upcoming conference call remediation expense related cyber attack increase investment ongoing launch additional cost associate new oncology collaboration astrazeneca be expect result higher operate cost quarter earning whispersour proven model show merck be likely beat estimate quarter have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold likely positive surprise zack esp earning esp represent difference most accurate estimate share zack consensus estimate share be uncover best stock buy sell re report earning esp filter zack rank merck have zack rank combination merck zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision merck company inc price ep surprise merck company inc price ep surprise merck company inc quoteother stock considerother large cap pharma stock have positive esp favorable zack rank include bristol myer squibb company bmy free report schedule release result oct have earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report have earning esp zack rank company be schedule release result oct today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2367,MRK,expect bristol myer squibb company bmy free report beat expectation report third quarter result oct market open year date bristol myer share have increase industry have record increase bristol myer track record have be positive so far company deliver positive earning surprise last quarters miss expectation average positive earning surprise last quarters be last report quarter bristol myer come positive surprise let see thing be shape quarter factor playbristol myer high profile immuno oncology drug opdivo be expect be primary sale driver third quarter drug be already approve multiple cancer indication quarter fda approve drug additional indication hepatocellular carcinoma metastatic colorectal cancer patient have receive prior treatment label expansion be not expect have much impact top line combine label expansion second quarter certainly boost sale second quarter see stability second line lung cancer set fda approval merck mrk free report keytruda first line treatment metastatic nonsquamous nsclc increase competition impact sale unfavorably zack consensus estimate indicate drug sale increase year quarter july fda also approve label expansion yervoy injection pediatric patient year age older unresectable metastatic melanoma zack consensus estimate drug quarter be meanwhile rheumatoid arthritis drug orencia receive approval treat psoriatic arthritis unite state well europe july moreover june bristol myer announce availability subcutaneous administration option orencia patient moderately severely active polyarticular juvenile idiopathic arthritis label expansion new administration option be expect fuel growth drug drug register growth previous quarter be expect generate sale quarter zack consensus estimate other hand decline hepatitis franchise be expect continue due intense competition multiple drug include epclusa label be expand include hiv co infection august moreover hiv business continue face competitive pressure recent launch other company same space be expect further impact sustiva franchise zack consensus estimate hepatitis franchise sale be peg quarter year quarter company be develop key drug opdivo monotherapy well combination therapy several tumor type multiple study label expansion application review unite state expect investor focus update related opdivo conference call likely positive surprise proven model indicate bristol myer be likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate earning cent zack consensus estimate earning cent stand be lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank bristol myer currently have zack rank combination positive earning esp favorable zack rank make reasonably confident earning beat conversely caution sell rate stock go earning announcement especially company be see negative estimate revision bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quoteother stock warrant lookhere be biotech stock also want consider model show have right combination element post earning beat quarter clovis oncology inc clvs free report be expect release result nov company have earning esp zack rank see complete list today zack rank stock here celgene corp celg free report be schedule release result oct company have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2368,MRK,roche hold ag rhhby free report report sale chf first month year period roche stock have gain year date compare industry gain company report result division pharmaceutical diagnostic growth rate mentioned be year year basis constant exchange rate sale pharmaceutical division increase drive strong growth tecentriq ocrevus alecensa perjeta be partially offset lower sale tarceva tamiflu avastin diagnostic division sale climb primarily back strong business result detailherceptin sale improve due increase demand unite state brazil additional reimbursement approval broader use china perjeta sale grow follow increase demand neoadjuvant metastatic setting europe unite state brazil sale kadcyla be drive increase demand international market meanwhile sale avastin decrease due increase use cancer immunotherapy medicine lung cancer sale rituxan mabthera be drive growth oncology well immunology segment growth gazyva gazyvaro be strong increase competition chronic lymphocytic leukemia recently launch drug tecentriq bladder cancer alecensa lung cancer be strong start tecentriq ocrevus alecensa contribute chf new sale performance immunology franchise be drive increase sale actemra roactemra strong uptake esbriet xolair increase use actemra roactemra single agent subcutaneous formulation be key growth driver however sale tarceva decline due grow use other therapeutic option sale xeloda continue be hit generic competition sale tamiflu also decline revenue diagnostic division climb back solid performance centralised point care solution unit be turn propel tissue diagnostic molecular diagnostic also perform impressively however diabetes care sale decline sale continue be impact challenge market condition particularly north america outlook reiteratedroche now expect sale grow mid single digit company expect core earning grow tandem sale company intend further increase dividend local currency pipeline progressroche continue expand cancer immunotherapy drug tecentriq label tecentriq be approve unite state monotherapy treatment patient suffering locally advanced metastatic bladder cancer have be previously treat platinum contain chemotherapy be consider ineligible cisplatin chemotherapy regardless pd status arthritis drug roactemra be approve treatment giant cell arteritis gazyvaro combination chemotherapy be approve previously untreated advanced follicular lymphoma fda also approve actemra intravenous injection treatment chimeric antigen receptor car cell induced severe life threaten cytokine release syndrome patient year age older takeroche performance first month be strong drive contribution newly launch drug label expansion key drug further drive growth however sale avastin tarceva continue decline generic competition xeloda also continue hurt sale note competition biosimilar loom large roche key drug herceptin avastin rituxan first biosimilar mabthera be already market company expect biosimilar herceptin end early note novartis ag nvs free report have already launch bisomilar version rituxan mabthera europe moreover roche be face stiff competition like merck co inc mrk free report keytruda bristol myer squibb company bmy free report opdivo immuno oncology space zack rankroche currently carry zack rank hold see complete list today zack strong buy rank stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2369,MRK,share celgene corporation celg free report decline company announce phase iii trial revolve cd pipeline candidate ged crohn disease extension trial sustain cd be discontinue celgene stock have moved year date compare industry gain decision discontinue trial come follow recommendation datum monitoring committee assessed overall benefit risk recent interim futility analysis consequently phase iii trial define cd crohn disease not be initiate meanwhile celgene be wait review full dataset phase ii trial ulcerative colitis determine next step news come disappointment candidate be late stage development celgene inflammatory bowel disease portfolio currently consist ozanimod phase iii otezla phase ii ongoing uc pending positive result phase iii trial be initiate otezla be approve patient suffering moderate severe plaque psoriasis be candidate phototherapy systemic therapy drug be also approve treatment adult patient active psoriatic arthritis celgene be currently work label expansion drug pomalyst imnovid abraxane otezla other meanwhile celgene revlimid continue outperform drive further market share increase newly diagnosed myeloma continue increase treatment duration recent approval idhifa unite state relapse refractory acute myeloid leukemia have further boost company portfolio however celgene be highly dependent revlimid foreign exchange headwind be expect continue abraxane sale be competitive pressure last month celgene aannounce fda put hold several trial fusion program partial clinical hold have be put trial full clinical hold trial trial be evaluate imfinzi pd antibody combination chemotherapy agent blood cancer such multiple myeloma chronic lymphocytic leukemia lymphoma celgene enter strategic collaboration astrazeneca plc azn free report medimmune april develop commercialize imfinzi hematologic malignancy combination revlimid pomalyst vidaza other fda have place hold trial due risk identify other trial pd antibody merck co mrk free report keytruda patient multiple myeloma combination agent zack rank key pick celgene currently carry zack rank hold better rank stock healthcare sector be aduro biotech inc adro free report currently carry zack rank buy see complete list today zack rank strong buy stock here aduro biotech loss share estimate narrow last day company have top estimate trail quarters average wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2370,MRK,approval gilead science inc gild free report yescarta week see approval second car therapy treat cancer be regard most advanced immune oncology treatment option moreover fda have grant priority review label expansion application major cancer drug include astrazeneca plc azn free report lynparza advanced breast cancer imfinzi earlier stage lung cancer bristol myer squibb company bmy free report opdivo melanoma patient high risk recurrence exelixis inc exel free report cabometyx advanced renal cell carcinoma rcc meanwhile ipsen partner exelixis announce positive result phase iii study hepatocellular carcinoma candidate moreover abbvie abbv free report enter immuno oncology research collaboration harpoon therapeutic focuse novel cell recruit biologic therapy abbvie use harpoon tri specific cell activate construct platform develop immuno oncology pipeline let see news detail key newsgilead acquisition kite pharma nearly have finally paid approval yescarta axicabtagene ciloleucel latter chimeric antigen receptor cell car therapy candidate fda approve therapy treat relapse refractory large cell lymphoma rlbcl adult have receive more line systemic therapy various form rlbcl yescarta be approve include diffuse large cell lymphoma dlbcl primary mediastinal large cell lymphoma pmbcl high grade cell lymphoma be second gene therapy be approve unite state novartis ag nvs free report kymriah receive approval august acute lymphoblastic leukemia car therapy be most advanced form treat cancer be do modify patient cell part body immune system fight cancerous cell therapy be manufacture specifically single patient gilead science inc price consensus gilead science inc price consensus gilead science inc partner merck mrk free report market advanced ovarian cancer drug lynparza receive priority review supplemental new drug application snda seek approval previously treat chemotherapy patient negative metastatic breast cancer fda be expect give decision first quarter lynparza be different study range tumor type include breast prostate pancreatic cancer well earlier line setting ovarian cancer meanwhile fda have also grant priority review astrazeneca snda key cancer drug imfinzi unresectable small cell lung cancer read more astrazeneca snda cancer drug get priority review astrazeneca plc price consensus astrazeneca plc price consensus astrazeneca plc quotebristol myer announce fda have grant priority review supplemental biologic license application sbla label expansion opdivo company be look get drug approve treat patient melanoma be high risk disease recurrence follow complete surgical resection drug be already approve treatment patient braf mutation positive unresectable metastatic melanoma moreover company announce opdivo alone combination yervoy achieve encourage result previously treat small cell lung cancer patient phase ii checkmate study opdivo monotherapy combo therapy achieve objective response rate respectively read more bristol myer get priority review opdivo label expansion bristol myer squibb company price consensus bristol myer squibb company price consensus bristol myer squibb company quoteother newsexelixis renal carcinoma drug cabometyx be also grant priority review fda snda snda seek approval cabometyx patient treatment naive advanced rcc fda deem snda be sufficiently complete decision expect feb moreover company advanced hepatocellular carcinoma candidate cabozantinib achieve statistically significant clinically meaningful improvement median overall survival rate placebo phase iii celestial study exelixis be develop candidate partnership ipsen meanwhile inovio pharmaceutical inc ino free report initiate phase ib ii study evaluate combination ino cell activate immunotherapy ino immune activator roche pdl inhibitor tecentriq advanced bladder cancer immune design also initiate pivotal phase iii study support regulatory application cmb treat patient synovial sarcoma wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2371,MRK,biolinerx ltd blrx free report announce partner genentech member roche hold ag rhhby free report have initiate phase ib ii study evaluate lead pipeline candidate bl combination roche tecentriq atezolizumab treat patient gastric cancer share biolinerx have outperformed industry so far year stock have gain versus broader industry increase phase ib ii multicenter randomize controlled open label combo therapy trial be design evaluate safety tolerability multiple pharmacodynamic parameter combination therapy study be conduct approximately patient study patient be administer bl injection prime monotherapy thereafter receive bl tecentriq injection continue multiple treatment cycle year disease progression remind investor september biolinerx have enter collaboration agreement genentech support several phase ib study be investigate biolinerx bl combine tecentriq be marked third trial commence biolinerx collaboration genentech significant note joint endeavor be part roche novel cancer immunotherapy development platform morpheus phase ib ii adaptive platform assess efficacy safety combination cancer immunotherapy significantly bl be biolinerx lead therapeutic candidate have successfully complete phase iia study relapse refractory aml acute myeloid leukemia be midst phase iib program aml consolidation treatment be expect initiate phase iii study stem cell mobilization autologous transplantation earlier biolinerx have announce have submit regulatory filing commence phase iii study importantly july biolinerx have announce genentech have initiate phase ib ii trial assess bl combination tecentriq cure patient metastatic pancreatic ductal adenocarcinoma biolinerx have announce begin first phase iia combat study evaluate efficacy bl combination merck mrk free report keytruda patient pancreatic cancer back september subsequently earlier january biolinerx have announce onset second phase iia study give combination biolinerx ltd price biolinerx ltd price biolinerx ltd quotezack rank key picksbiolinerx currently carry zack rank hold better rank stock healthcare sector be ionis pharmaceutical inc ion free report sporting zack rank strong buy see complete list today zack rank stock here ionis loss share estimate fall cent cent cent cent last day company deliver positive earning surprise trail quarters average beat ionis share have rally so far year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2372,MRK,nordisk nvo free report share gain friday announce fda have approve label expansion victoza drug be now approve treatment reduce risk major adverse cardiovascular cv event include heart attack stroke cv death adult type ii diabetes establish cv disease victoza be once daily human glucagon peptide glp analogue approve treatment type ii diabetes adult drug be main revenue contributor company sale first half nordisk share have outperformed industry year date stock rally compare industry gain same time frame note fda approval be base datum pivotal leader study cv outcome evaluate drug more person type ii diabetes high risk major cv event study evaluate drug combination standard care period year datum study demonstrated victoza significantly reduce risk cv death drug lower risk fatal heart attack fatal stroke compare placebo show absolute risk reduction study cv disease be lead cause death diabetic patient addition new indication label victoza be expect bring more revenue now be prescribe diabetes medication also reduce patient cv risk however last year fda approve eli lilly company lly free report label expansion diabetes drug jardiance include cv risk reduction datum drug update label have already be launch january increase competition victoza moreover other company merck co inc mrk free report astrazeneca plc azn free report be also develop drug same indication notably merck be deny approval fda april include cv outcome datum tecos study label januvia also astrazeneca bydureon fail reduce cv risk phase iiib iv cv outcome study exscel nordisk price consensus nordisk price consensus nordisk quotenovo nordisk currently have zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2373,MRK,biogen inc biib free report announce biosimilar version abbvie inc abbv free report top selling blockbuster drug humira have be approve european commission biosimilar be market trade name imraldi imraldi sb be used whole range indication include rheumatoid arthritis axial ankylose spondylitis plaque psoriasis psoriatic arthritis crohn disease ulcerative colitis polyarticular juvenile idiopathic arthritis active enthesitis related arthritis hidradenitis suppurativa infectious uveitis remind investor biosimilar be grant positive opinion committee medicinal product human use chmp june year biogen have joint venture samsung biologic biosimilar samsung bioepis joint venture company already marketsa couple biosimilar eu flixabi biosimilar reference merck co inc mrk free report remicade benepali biosimilar reference amgen pfizer enbrel make imraldi third tnf biosimilar biogen receive marketing authorization eu benepali be do quite well generate sale first half flixabi record sale same period note earlier year amgen inc amgn free report gain eu approval amgevita biosimilar version humira biogen share have rise year so far industry record increase biogen carry zack rank hold see complete list today zack rank strong buy stock here surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
2374,MRK,key news week include priority review roche rhhby free report experimental hemophilia drug eu approval novartis nvs free report advanced breast cancer drug meanwhile deal involve company astrazeneca plc azn free report eli lilly company lly free report be also announce week recap week most important storiespriority review roche hemophilia drug roche investigational hemophilia treatment emicizumab get priority review fda agency expect give decision feb roche be look get emicizumab prophylaxis preventative approve once weekly subcutaneous treatment adult adolescent child hemophilia factor viii inhibitor accord information provide company person hemophilia develop inhibitor standard factor viii replacement therapy result treatment option be limit be increase risk life threaten well repeat bleed also read roche hemophilia drug grant priority review lilly inks multus year deal topas lilly have enter multus year research option agreement focuse immune tolerance germany base biotechnology company topas therapeutic initial focus be external antigen thought induce inflammation autoimmune disease pre clinical proof principle study be conduct topas receive funding lilly lilly have option license develop candidate produce collaboration deal signify lilly focus immunology immune tolerance have be attract interest quite few large player celgene signing exclusive global research collaboration anokion privately hold company develop novel tolerance induce therapeutic autoimmune disease earlier year astrazeneca mrna focuse deal ethris astrazeneca enter strategic deal germany base ethris development mrna therapy respiratory disease year strategic research deal be focuse use ethris proprietary snim rna technology new stabilize immunogenic mrna therapy respiratory disease astrazeneca make upfront payment upfront provide research funding well other payment include research development milestone payment sale related royalty astrazeneca have option take exclusive worldwide license target collaboration be not first time astrazeneca have sign mrna focuse deal company be collaborate moderna therapeutic mrna therapeutic candidate treatment range cancer cardiovascular metabolic renal disease well meanwhile astrazeneca also announce result new sub analysis datum phase iii pegasus timi study show risk reduction cardiovascular cv death treatment brilinta compare placebo patient take low dose aspirin still high risk event major cause acute coronary syndrome cv death astrazeneca be zack rank hold stock see complete list today zack rank strong buy stock here cardiome brinavess regulatory update cardiome pharma share be news fda have inform company datum package resubmission regulatory application antiarrhythmic drug brinavess not be sufficient company be look resubmit new drug application nda brinavess base original file year accumulate safety datum brinavess sale country well interim result more patient enrolled spectrum study prospective post authorization eu safety study pre clinical datum subsequent study complete company fda request eu nod novartis advanced breast cancer drug novartis cdk inhibitor kisqali gain approval eu use combination inhibitor first line treatment postmenopausal woman hr locally advanced metastatic breast cancer approval be largely expect consider positive committee medicinal product human use chmp opinion earlier year june accord information provide company woman be diagnosed advanced breast cancer year world third patient early stage breast cancer eventually develop advanced disease kisqali be approve mar novartis be work launch full commercial campaign gain formulary coverage share novartis have gain year date outperform industry cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index gain last trading session major stock bristol myer squibb bmy free report be lose last month be merck co mrk free report decline see last pharma stock roundup here multiple sclerosis drug price focus mixed datum bmy opdivo next pharma world watch usual pipeline regulatory update surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
2375,MRK,celldex therapeutic inc cldx free report announce completion enrollment phase iib study metric evaluate lead pipeline candidate glembatumumab vedotin treat patient metastatic triple negative breast cancer share celldex have underperform industry year date stock have massively plunge versus industry gain period metric be randomize phase iib study enrolled total patient give indication patient trial be randomize glembatumumab vedotin roche hold ag rhhby free report breast cancer drug xeloda capecitabine primary endpoint study be progression free survival pfs top line datum study be expect second quarter remind investor phase ii study glembatumumab vedotin be currently underway patient metastatic melanoma single agent datum study be present june annual meeting american society clinical oncology asco glembatumumab vedotin perform well single agent set response rate disease control rate median duration response month patient have fail prior line therapy study also include new cohort glembatumumab varlilumab arm glembatumumab checkpoint inhibitor arm include bristol myer squibb company bmy free report opdivo merck co inc mrk free report keytruda glembatumumab vedotin celldex pipeline comprise important candidate varlilumab be be evaluate several phase ii combination study multiple type cancer celldex therapeutic inc pricecelldex therapeutic inc price celldex therapeutic inc quotezack rankcelldex currently carry zack rank hold see complete list today zack rank strong buy stock here simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
2376,MRK,sanofi inc sny free report perform quite well first half look well poise carry momentum second half earning share beat zack consensus estimate first quarter meet same second earning rise report basis first half constant currency rate cer year year basis first halfnet sale rise report basis cer jan sanofi swap merial animal health business boehringer ingelheim consumer healthcare chc business reflect exchange full consolidation sanofi european vaccine operation sale rise constant structure cer remind investor sanofi terminate sanofi pasteur msd joint venture merck co inc mrk free report europe december last year strong performance genzyme specialty care genzyme vaccine unit be make accelerate decline diabetes franchise support top line fact second quarter conference call sanofi raise previously issue profit outlookbacked better expect performance first half cost discipline tough payer environment hurt sale thediabetesunit sanofi expect business earning be broadly flat cer outlook compare favorably previous expectation flat cer so work sanofi favor second half continue strong performance genzyme unit especially multiple sclerosis drug aubagio lemtrada rare disease drug myozyme fabrazyme be positive vaccine unit be also expect perform well sale include emerge market rise cer genzyme unit cer vaccine unit first half meanwhile sanofi second quarter conference call sound quite optimistic sale prospect newly launch drug dupixent treat atopic dermatitis drug be launch march generate sale second quarter backed strong demand management waspleas drug uptake be optimistic sale prospect dupixent prove be important growth driver company other dupixent other new drug kevzara launch june soliqua once daily titratable fix ratio combination lantus lyxumia launch january also bring higher sale back half year however management expect diabetes franchise sale decline faster second half due impact formulary exclusion cvs health corporation cvs free report unitedhealth group difficult comparison last year diabetes sale decline first half sanofi diabetes franchise be significant pressure key product lantus face increase competitive pressure payor level biosimilar competition several european market japan cardiovascular franchise also remain be see sale trend sanofi pcsk therapy praluent improve second half uptake pcsk inhibitor praluent amgen inc amgn free report repatha have be slower expect due significant payer utilization management restriction limit market access europe praluent uptake remain limit guideline support broader use treatment be issue phase iii cardiovascular outcome study datum be also generic competition continue hurt sale many key drug sanofi portfolio include blockbuster drug plavix challenge believe new drug approval solid pipeline aggressive saving pave way growth second half do number say so far year sanofi share price have rise better increase industry strong quarterly result back back product approval year have lead uptick estimate well sanofi earning estimate go moved past day sanofi earning performance have also be pretty impressive company report positive surprise consistently average earning beat last quarters be sanofi carry zack rank hold seethe complete list today zack rank strong buy stock here simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
2377,MRK,biolinerx ltd blrx free report announce regulatory submission commencement phase iii study evaluate lead pipeline candidate bl cxcr antagonist combination granulocyte colony stimulating factor csf notably bl be short peptide indicated mobilize hematopoietic stem cell autologous transplantation patient multiple myeloma biolinerx share have significantly outperformed industry so far year stock have rally versus broader industry decrease randomize controlled phase iii genesis study be design evaluate safety tolerability efficacy combination therapy compare combination placebo csf study be conduct part first part study evaluate efficacy safety treatment bl csf be conduct patient part be follow randomize placebo controlled multus center study be conduct approximately patient remind investor september biolinerx have enter collaboration agreement genentech member roche hold ag rhhby free report support several phase ib study investigate biolinerx bl combine tecentriq atezolizumab significant note collaboration be part roche novel cancer immunotherapy development platform morpheus phase ib ii adaptive platform assess efficacy safety combination cancer immunotherapy importantly bl be biolinerx lead therapeutic candidate have successfully complete phase iia study relapse refractory aml be phase iib study aml consolidation treatment july biolinerx have announce partner genentech have initiate phase ib ii trial evaluate bl combination roche tecentriq treatment patient metastatic pancreatic ductal adenocarcinoma september biolinerx have announce initiation first phase iia combat study evaluate efficacy bl combination merck mrk free report keytruda patient pancreatic cancer subsequently january biolinerx announce onset second phase iia study give combination american cancer society provide datum more patient be diagnosed pancreatic cancer unite state pancreatic cancer account cancer country cancer death pancreatic adenocarcinoma accounting case indicate huge market potential combination therapy biolinerx ltd pricebiolinerx ltd price biolinerx ltd quotezack rank key picksbiolinerx currently carry zack rank hold better rank stock pharma sector be aduro biotech inc adro free report carry zack rank buy see complete list today zack rank strong buy stock here aduro biotech loss share estimate narrow last day company deliver positive surprise trail quarters average beat zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
2378,MRK,issue update report zoetis inc zts free report aug zoetis boast robust diversify product portfolio company business be divide category infective vaccine parasiticide medicated feed additive other pharmaceutical zoetis market offering primarily core species cattle swine poultry sheep fish collectively livestock dog cat horse collectively companion animal zoetis derive majority revenue diversify product portfolio medicine vaccine be used treat protect livestock companion animal company continue strengthen diverse portfolio product lifecycle innovation strong customer relationship access new market technology apoquel other product launch continue drive growth companion animal portfolio company expect witness stronger growth companion animal portfolio drive dermatology portfolio apoquel cytopoint further penetration simparica ongoing uptake new vaccine latest datum show dog dermatology problem be treat apoquel cytopoint first quarter addition new approval further boost portfolio zoetis receive approval clavamox chewable cytopoint european union april canada march zoetis stock have moved year so far compare industry loss however disease outbreak animal be concern zoetis livestock product such outbreak hurt regional global sale particular animal derive food product result reduce export same due heighten export restriction import prohibition turn dampening demand livestock product moreover zoetis face stiff competition other animal health medicine vaccine company merck animal health animal health division merck co mrk free report elanco animal health division eli lilly co lly free report bayer animal health animal health division bayer ag bayry free report boehringer ingelheim animal health animal health division boehringer ingelheim zack rank zoetis currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2379,MRK,astrazeneca azn free report partner merck mrk free report announce japanese ministry health labour welfare have grant approval parp inhibitor lynparza maintenance therapy relapse ovarian cancer irrespective brca mutation status patient have respond last platinum base chemotherapy lynparza become first parp inhibitor approve indication japan remind investor lynparza prospect get boost line expansion breast cancer earlier month unite state expansion label geography certainly boost sale drug meanwhile label expansion application include breast cancer be review europe astrazeneca share have increase last year share merck be period meanwhile industry moved same time period approval be grant base encourage datum phase ii study study phase iii study solo study evaluate lynparza monotherapy maintenance set placebo datum solo study show lynparza improve median progression free survival pfs month compare month placebo similarly datum study trial demonstrated drug achieve pfs month versus month placebo drug also achieve median overall survival os month month placebo median os be yet be reach solo study clovis oncology inc clvs free report rubraca tesaro inc tsro free report zejula be other parp inhibitor give competition lynparza unite state separate press release astrazeneca announce fasenra benralizumab be also grant approval add treatment bronchial asthma japan drug be approve patient continue experience asthma exacerbation receive treatment high dose inhaled corticosteroid other asthma controller approval be base datum program include phase iii study sirocco calima zonda datum sirocco calima show fasenra achieve significant reduction exacerbation improvement lung function meanwhile datum zonda study show fasenra alone combination standard care glucocorticoid lead statistically significant clinically relevant reduction daily maintenance oral corticosteroid ocs compare placebo other severe asthma candidate astrazeneca portfolio be tralokinumab tezepelumab partnership amgen astrazeneca plc price astrazeneca plc price astrazeneca plc quotezack rankastrazeneca carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2380,MRK,global market largely echo wall street fortune last week stock europe be buoy notable earning performance strong economic datum meanwhile asia nikkei linger year high encourage growth number buoy china stock bullish economic outlook help stock brazil scale new high period stoxx gain strong economic datum earningsvolumes remain low europe last monday market take breather week notable gain stoxx re-cover partially close lower even most sector close red ftse cac dax decline respectively only italy benchmark ftse mib add news british construction firm carillion have declare bankrupt weigh sentiment help boost other stock sector utility also notch considerable gain stoxx advanced last tuesday even most major sector finished green however fall commodity price dampen investor sentiment even foreign market register strong gain ftse lose cac dax gain respectively stock oil company lose follow significant decline crude price strong performance wall street fail lift europe stock last wednesday corporate development dominate proceedings stoxx lose ftse cac dax lose most sector close red medium stock decline stoxx advanced last thursday buoy strong show wall street nearly index sector close black tech stock gain boost encourage earning number similarly strong economic datum trigger gain region stock last friday stoxx add touch highest point aug basic resource stock be major gainer session fuel encourage demand datum china strong gdp boost china stock nikkei linger year highstock asia end higher last monday follow record gain wall street nikkei add defy rise yen meanwhile kospi asx increase respectively australia material gold mining stock emerge day best performer however hang seng close red disappointing last hour trading shanghai composite shenzhen composite decline respectively market asia close higher last tuesday follow dollar overnight loss nikkei gain breach year record earlier session kospi overcome early loss end higher meanwhile asx lose shanghai composite shenzhen composite advanced respectively stock asia close red last wednesday follow loss wall street nikkei moved touch year high precede session kospi lose asx decline shenzhen composite csi decline respectively only shanghai composite index defy prevailing trend finish higher nikkei slip new year high last thursday finished session lower market region end mixed investor receive key economic datum china official datum show china economy have record annual growth rate exceed target rate additionally industrial production number also exceed estimate kospi inched asx end red meanwhile shanghai composite shenzhen composite csi add respectively asia stock largely finished green last friday nikkei add even financial stock register strong gain kospi gain asx decline shanghai composite increase add record gain logged thursday however shenzhen composite lose early gain end lower bovespa surge economic outlook chile stock scale new bovespa gain last monday follow expectation president trump likely moderate stance nafta renegotiation last tuesday brazil stock inched fresh time high bovespa gain move mark point session optimism country economic prospect fuel day gain meanwhile mexico bmv ipc stock index gain more bovespa gain last wednesday move mark follow strong foreign capital inflow corporate development also help boost stock occasion share petrobra pbr free report gain government set be create committee deal long standing dispute oil right last thursday bovespa gain even chile stock touch intraday high meanwhile argentina benchmark merval index also hit new time high gain more brazil stock continue linger record level last friday bovespa gain create new intraday record meanwhile merval slip record achieve previous session lose stock newstaiwan semiconductor manufacturing co tsm free report report fourth quarter earning cent adr exceed zack consensus estimate further increase sequentially year year moreover revenue increase year year sequentially increase be primarily drive major mobile product launch strong sale cryptocurrency mining boom north america account total revenue asia pacific china emea europe middle east africa japan account total revenue respectively first quarter taiwan semiconductor expect revenue be range zack consensus estimate be peg read taiwan semi earning beat strong product ramp toyota motor corporation tm free report have announce produce vehicle north american vehicle assembly plant primary drive force production be robust demand sport utility vehicle suvs truck sustain economic stability low price fuel however production volume be nearly lower vehicle produce north america zack rank hold toyota total vehicle production have reach nearly japanese auto giant add manufacturing plant jv mazda huntsville alabama also vehicle manufacturer announce make large amount investment different manufacturing facility read toyota produce nearly vehicle north america ericsson eric free report be undertaking colossal writedown book charge roughly amount whopping impairment testing swedish equipment maker have decide asset worth sek sek cash charge be book due recent tax reform zack rank strong sell ericsson say charge not impact cash flow affect operate profit upcoming fourth quarter result writedown primarily affect business digital service cloud compute medium unit read ericsson book charge restructure royal dutch shell plc rd free report have recently inked deal acquire stake silicon ranch corporation partner group deal help shell leverage position top wholesale power seller unite state boost new energy division silicon ranch be lead solar energy company unite state deal make shell largest stakeholder deal company continue operate exist management retain brand transaction be value cash contingent silicon ranch performance subject regulatory approval satisfactory close condition deal be schedule completion first quarter stock have zack rank strong buy see complete list today zack rank strong buy stock here teva pharmaceutical industry ltd teva free report announce fda have approve label expansion trisenox injection include first line treatment acute promyelocytic leukemia apl patient combination tretinoin teva have zack rank sell eligible apl patient have translocation pml rar alpha gene expression trisenox be currently approve similar indication patient be refractory relapse retinoid anthracycline chemotherapy drug be already approve eu first line second line treatment indication read teva trisenox get fda approval first line treatment atla copco ab atlky free report recently announce acquire australia base hy performance fluid power pty ltd financial consideration buyout be not disclose hy performance fluid primarily provide service remanufacture repair servicing hydraulic component customer mining infrastructure end market buyout hy performance fluid strengthen zack rank atla copco product line customer mining infrastructure market be integrate company exist mining rock excavation technique business read atla copco buyout spree acquire hy performance fluid astrazeneca plc azn free report partner merck mrk free report announce fda have approve supplemental new drug application snda lynparza seek approval label expansion metastatic breast cancer lynparza be presently market advanced ovarian cancer astrazeneca have zack rank latest fda approval lynparza now be used treat previously treat chemotherapy patient negative metastatic breast cancer harbore germline brca mutation moreover drug be also approve patient hr breast cancer be treat endocrine therapy be ineligible same read astrazeneca lynparza label now include breast cancer performance lead foreign table give show price movement largest stock list index worldwide last day last month next week outlookstock have largely be guide economic datum earning number week be most evident china stock be buoy strong growth number meanwhile strong economic outlook brazil boost country stock only impediment point seem be government shutdown event be threaten spoil market party early resolution crisis go long way ensure longevity market gain day ahead hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2381,MRK,be good year pharma biotech stock sector witness positive development lead much await recovery key reason sector improve performance be willingness investor look drug pricing controversy focus more fundamental instead drug pricing controversy be major overhang remain headline risk investor seem more comfortable issue moreover significantly higher number fda approval have restore investor confidence sector approval first gene cell therapy last year be major breakthrough sector hope more merger acquisition have also go tax reform place big player lookout company innovative pipeline technology have already be quite bit buzz year potential deal celgene rumore be interested buy juno biogen biib free report acorda sanofi sny free report bioverativ meanwhile nordisk recently confirm be look acquire belgium base biopharma company ablynx ablynx reject nordisk offer look forward new product sale ramp success innovation continue strong performance key product more activity grow demand drug especially rare treat disease age population increase health care spending be factor keep momentum headwind include drug pricing scrutiny pricing pressure increase competition grow presence biosimilar generic competition slowdown growth legacy product concern regard amazon interest enter healthcare arena major pipeline setback biotech pharma stock keep eye earning seasonaccording zack earning trend article medical sector have be better perform sector last several quarters be expect record earning growth revenue growth fourth quarter give scenario medical sector earning round corner make sense look pharma biotech stock be expect report positive earning surprise quarter investing such stock prove beneficial investor earning beat usually lead significant share price appreciation help zack stock screener have zero pharma biotech stock sport zack rank strong buy buy hold have positive earning esp earning esp be very valuable tool investor look stock be most likely beat earning estimate moreover add zack rank have produce positive surprise time see complete list today zack rank stock here uncover best stock buy sell re report earning esp filter alexion pharmaceutical inc alxn free report alexion have strong presence rare disease market market drug include soliris treatment patient paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus acetylcholine receptor achr antibody positive generalized myasthenia gravis gmg strensiq enzyme replacement therapy patient hpp kanuma enzyme replacement therapy patient lysosomal acid lipase deficiency lal alexion be focuse grow maximize presence rare disease business core area focus include hematology nephrology neurology metabolic disorder alexion have consistently surpass earning expectation last quarters average surprise zack rank stock report fourth quarter result february have earning esp quarter soliris revenue be expect range metabolic revenue be expect range celgene corporation celg free report celgene be focuse discovery development treatment cancer inflammatory disease next generation solution protein homeostasis immuno oncology epigenetic immunology neuro inflammation earlier month company announce preliminary result fourth quarter revenue expect be earning be approximately share celgene have surpass earning last quarters average surprise zack rank stock be report fourth quarter result january have earning esp abbvie abbv free report abbvie be know blockbuster drug humira be focuse development treatment primary therapeutic area immunology oncology virology neuroscience earning be expect be share revenue growth approximately humira be expect remain key growth driver sale expect cross abbvie be report fourth quarter result january company have decent track record have surpass earning expectation last quarters average surprise zack rank stock have earning esp fourth quarter abbvie share be last year significantly surpass rally industry belong merck mrk free report merck be report fourth quarter result february company have strong earning track record be expect deliver surprise fourth quarter growth driver include keytruda gardasil few hospital specialty product animal health division help offset impact genericization zetia vytorin merck be also zack rank stock hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2382,MRK,couple quiet week cancer space witness activity fda action label expansion positive datum readout major drug several company meanwhile biosimilar blockbuster cancer drug receive approval europe new drug be also grant approval treatment leukemia amgen inc amgn free report multiple myeloma drug kyproli receive fda nod include overall survival os datum head head endeavor study label first car therapy receive approval novartis ag nvs free report kymriah get boost fda accept supplemental biologic license application sbla seek label expansion diffuse large cell lymphoma dlbcl moreover astrazeneca azn free report lynparza get fda nod label expansion metastatic breast cancer teva pharmaceutical also announce approval label expansion acute promyelocytic leukemia drug trisenox injection first line set combination tretinoin moreover amgen partner allergan agn free report announce approval mvasi biosimilar version roche rhhby free report blockbuster cancer drug avastin europe datum readout include encourage datum merck mrk free report keytruda confirmatory phase iii lung cancer study exelixis inc exel free report cabometyx phase iii hepatocellular carcinoma study apart biolinerx ltd blrx free report also announce encourage partial result phase iia combat study pancreatic cancer lead pipeline candidate bl partial datum study show bl monotherapy be safe well tolerate patient give indication let see news detail amgen kyproli get label update avastin biosimilar approve fda approve regulatory application include os datum endeavor study label kyproli fda decision come much earlier expect be initially expect april similar application be review europe read more amgen get fda nod add endeavor datum kyproli label amgen inc price amgen inc price amgen inc quotenovartis car therapy sbla accept fda novartis announce fda have accept grant priority review sbla seek label expansion car therapy kymriah potential approval expand drug access patient relapse refractory dlbcl be ineligible relapse autologous stem cell transplant read more novartis sbla car therapy kymriah accept fda novartis ag price novartis ag price novartis ag announce label expansion lynparza breast cancer astrazeneca parp inhibit ovarian cancer treatment lynparza be grant label expansion unite state include metastatic breast cancer indication lynparza become first parp inhibitor approve treat metastatic breast cancer expand label certainly boost drug prospect give advantage other parp inhibitor be only approve ovarian cancer read more astrazeneca lynparza label now include breast cancer astrazeneca plc price astrazeneca plc price astrazeneca plc quotemerck keytruda impressive phase iii lung cancer study merck share get boost jan follow announcement keytruda combination lilly alimta carboplatin achieve dual primary endpoint confirmatory phase iii keynote study study be evaluate combination treatment metastatic squamous small cell lung cancer nsclc first line set datum be report much earlier anticipate february combination be grant accelerate approval aforementioned indication read more merck strong confirmatory phase iii lung cancer study merck company inc price merck company inc price merck company inc quoteexelixis cabometyx positive phase iii carcinoma study exelixis partner ipsen announce datum pivotal phase iii celestial study cabometyx datum study evaluate drug advanced hepatocellular carcinoma show achieve significant os benefit patient have receive prior treatment median os achieve drug be month versus month placebo read more exelixis ipsen report positive result lead cancer drug exelixis inc price exelixis inc price exelixis inc quoteapart gilead announce week have enter collaboration agreement pfizer develop car therapy yesacrta combination latter utomilumab patient refractory large cell lymphoma make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2383,MRK,johnson johnson jnj free report kick third quarter earning season pharmaceutical sector strong note company beating earning revenue focus remain strong earning result company allergan agn free report be also news regard patent litigation recap week most important storiesj result impress raise outlook earning result be strong company beating earning revenue segment consumer medical device pharmaceutical do well oncology record robust growth result include contribution pulmonary hypertension product become part company portfolio follow acquisition actelion base solid third quarter result raise outlook year well read more beat earning actelion buyout drife sale company have gain year date compare rally industry belong sanofi dupixent top allergic inflammatory disease study sanofi partner regeneron pharmaceutical announce positive phase ii result dupixent dupilumab adult active moderate severe eosinophilic esophagitis chronic allergic inflammatory disease patient receive dupixent weekly report significant improvement ability swallow versus placebo read more sanofi regeneron dupixent succeed phase ii study market be huge dupixent gain timely approval give lack fda approve treatment dupixent have orphan drug status unite state indication dupixent have blockbuster potential be currently approve eczema be be evaluate additional indication apart eosinophilic esophagitis fact last month company have announce positive top line datum late stage study dupixent uncontrolled persistent asthma regeneron sanofi be also collaborate aimmune therapeutic clinical stage company focuse development treatment potentially life threaten food allergy clinical collaboration aimmune ar be evaluate adjunctive dupixent peanut allergic patient mid stage study be schedule commence next year study be sponsored regeneron aimmune provide clinical supply ar food challenge material datum merck keytruda priority review lynparza snda merck mrk free report present update overall survival os datum pd therapy keytruda first line treatment patient suffering metastatic small cell lung cancer high level pd company say additional month available datum continue show reduction risk death keytruda compare chemotherapy keytruda more double median os compare chemotherapy year follow keytruda be key product merck portfolio drug bring sale first half merck partner astrazeneca also announce have be grant priority review fda supplemental new drug application snda use parp inhibitor lynparza tablet patient gbrca negative metastatic breast cancer mbc have be previously treat chemotherapy neoadjuvant adjuvant metastatic setting response agency be expect first quarter nordisk diabetes drug get fda panel support nordisk nvo free report get boost fda advisory panel endocrinologic metabolic drug advisory committee voting unanimously favor approve once weekly semaglutide use type ii diabetes patient give favorable vote chance gain fda approval look pretty high second quarter call nordisk have say expect decision fda year end semaglutide approval be major positive company drug expect be key growth driver nordisk be zack rank buy stock see complete list today zack rank strong buy stock here priority review bmy drug label expansion bristol myer squibb company bmy free report immuno oncology therapy opdivo have be grant priority review fda label expansion treatment melanoma patient be high risk disease recurrence follow complete surgical resection opdivo prioritize brand bristol myer portfolio bring sale first half read more bristol myer get priority review opdivo label expansion adverse ruling allergan restasis patent litigation allergan continue make headline related blockbuster eye drug restasis time round company announce have receive adverse ruling district court eastern district texas regard patent cover drug court find patent be invalid allergan intend appeal ruling say fda be yet approve generic version drug however ophthalmology focuse company imprimis pharmaceutical announce be work make lower cost alternative restasis available company say initial prescription be cent month supply refill start month include shipping accord allergan restasis patent be schedule expire aug allergan enter settlement agreement generic challenger recently innopharma have be adopt different way protect restasis generic competition company come fire enter agreement saint regis mohawk tribe lawmaker question unconventional move adopt company protect drug generic competition restasis be allergan second best selling drug bring sale almost lawmaker point sovereign status native american tribe make patent challenge lengthy complex tribe be immune legal claim make generic drug maker challenge patent deal have basically raise concern curb generic competition pharmaceutical industry discourage generic drugmaker make cheaper copy cat version expensive drug impax combine amneal specialty pharma company impax laboratory be merge privately hold generic company amneal pharmaceutical stock transaction merger combine company have high value generic product pipeline grow specialty business deal be expect boost impax stand alone earning share first month generate double digit revenue earning share growth year follow close transaction annual cost synergy be expect be achieve year merger be expect go first half read more impax laboratory amneal pharmaceutical agree merge cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be week sector react positively result major stock be bristol myer decline last month bristol myer be see last pharma stock roundup here pfizer mull option consumer healthcare lly pipeline setback next pharma world watch earning result company novartis eli lilly lly free report bristol myer other come week wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2384,MRK,abbvie inc abbv free report announce pan genotypic regimen glecaprevir pibrentasvir mavyret have be approve canada treat chronic hepatitis virus hcv infection major genotype gt be important note ribavirin free mavyret recently gain approval unite state eu combination medicine be priority review japan same indication abbvie share have marginally outperformed industry so far year stock have rally compare broader industry increase approval canada be backed datum registration study abbvie clinical development program clinical trial be conduct more patient major hcv genotype datum study show week treatment achieve cure rate major genotype chronic hcv significantly glecaprevir gle be potent protease inhibitor pibrentasvir pib be new ns inhibitor glecaprevir be discover collaboration agreement enanta pharmaceutical enta free report hcv protease inhibitor company press release canadian be chronically infected hcv more new case hepatitis be report approximately patient estimate be unaware disease also gt be most common genotype canada gt be most difficult treat cure hence drug approval be expect provide company access market huge potential remind investor gilead science inc gild free report launch epclusa first oral pan genotypic single tablet regimen treat adult genotype hcv infection unite state eu last year lend strong competition mavyret not inform merck co inc mrk free report be also evaluate oral triple combination therapy mk mix mk grazoprevir ruzasvir treatment chronic hcv genotype gt infection pricing pressure hcv market be increase company say experience market share loss price erosion due competitive dynamic hcv arena downturn continue year viekira hcv treatment sale expect decline abbvie inc priceabbvie inc price abbvie inc quotezack rankabbvie currently carry zack rank hold see complete list today zack rank strong buy stock here surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
2385,MRK,gilead science inc gild free report announce health canada have grant notice compliance single tablet regimen vosevi sofosbuvir mg velpatasvir mg voxilaprevir mg treatment chronic hepatitis virus hcv infection vosevi have be approve treatment hcv infection adult genotype previously treat ns inhibitor contain regimen genotype previously treat sofosbuvir contain regimen ns inhibitor drug be already approve gilead be know presence hcv market blockbuster hcv drug sovaldi harvoni hcv portfolio receive huge boost epclusa gain approval jun eu jul become first only oral pan genotypic str consist sovaldi velpatasvir ns inhibitor treatment adult genotype chronic hcv infection approval voseviwill further boost gilead strong hcv portfolio however hcv franchise be pressure result competition pricing issue note harvoni sovaldi epclusa face competition abbvie abbv free report viekira pak viekira xr bristol myer bmy free report daklinza other competition well pricing pressure intensified further launch merck mrk free report zepatier gilead stock have moved year so far compare industry gain meanwhile hiv franchise maintain momentum drive rapid adoption taf base regimen eu now represent total prescription volume genvoya be now company bestselling hiv product treatment nave patient share strong uptake truvada use pre exposure prophylaxis set be expect further boost sale however gilead lose exclusivity viread country outside impact sale zack rank gilead currently carry zack rank buy see complete list today zack rank strong buy stock here surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
2386,MRK,astrazeneca plc azn free report partner merck co inc mrk free report announce fda have approve new tablet formulation ovarian cancer drug lynparza also broaden label astrazeneca share be so far year compare unfavorably increase industry fda have approve expansion lynparza tablet label include maintenance treatment patient suffering platinum sensitive recurrent ovarian cancer regardless brca mutation status meanwhile fda also approve new tablet formulation tablet twice daily parp inhibitor opposed capsule capsule twice daily improve patient convenience lynparza accelerate approval brca mutate ovarian cancer third line set be also converted regular approval remind investor lynparza be first approve fda accelerate approval basis dec capsule formulation label expansion strengthen lynparza position parp inhibitor market competition have become fierce clovis oncology inc clvs free report rubraca launch dec tesaro inc tsro free report zejula niraparib available apr share small biotechs be thursday follow news lynparza be also be evaluate different study range tumor type include breast prostate pancreatic cancer well earlier line setting ovarian cancer astrazeneca announce oncology collaboration merck last month commercialize develop lynparza monotherapy combination study multiple cancer type company share development marketing cost equally also profit lynparza astrazeneca carry zack rank hold see complete list today zack rank strong buy stock here surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
2387,MRK,pharmaceutical stock be limelight week merck mrk free report ceo ken frazier resign president donald trump manufacturing council sector be also news investigation be launch rise price multiple sclerosis ms drug recap week most important storiesbayer novartis teva other face ms drug price probe drug pricing be back news investigation skyrocket price ms drug be launch rep elijah cumming rep peter welch letter have be send company include biogen teva roche novartis nvs free report merck kgaa bayer sanofi request information pricing strategy ms drug letter have also raise issue shadow pricing expensive new drug be launch price exist drug be raise other company follow suit increase price match higher price accord american academy neurology study annual sale ms drug double almost meanwhile information provide national multiple sclerosis society show average wholesale price ms disease modify therapy be shot mylan pay doj settlement mylan myl free report announce agreement have be sign department justice doj relator regard medicaid drug rebate settlement move claim relate classification mylan epipen auto injector epipen jr auto injector purpose medicaid drug rebate program have be resolve epipen be list innovator drug be reclassify mylan say also enter corporate integrity agreement office inspector general department health human service also read do mylan stock surge today broader label astrazeneca merck parp inhibitor fda expand label astrazeneca azn free report merck parp inhibitor lynparza ovarian cancer new tablet formulation be also approve maintenance treatment woman platinum sensitive recurrent ovarian cancer regardless brca mutation status well use third line set brca mutate ovarian cancer approval tablet formulation provide patient convenient dose option take tablet twice daily instead capsule twice daily astrazeneca merck be zack rank hold stock see complete list today zack rank strong buy stock here pfizer get fda nod target cancer drug pfizer pfe free report gain fda approval besponsa provide new treatment option adult patient relapse refractory cell precursor acute lymphoblastic leukemia aggressive type blood cancer poor prognosis adult accord information provide pfizer year overall survival rate patient relapse refractory adult be less besponsa approval path include breakthrough therapy designation priority review label come black box warning hepatotoxicity not impact uptake give poor survival rate patient population eu approval besponsa come earlier year june bristol myer opdivo combination disappoint kidney cancer study bristol myer squibb bmy free report opdivo fail meet co primary endpoint late stage study evaluate pd immune checkpoint inhibitor yervoy versus sutent sunitinib intermediate poor risk patient previously untreated advanced metastatic renal cell cancer opdivo yervoy combination meet objective response rate co primary endpoint versus fail show statistical significance progression free survival third co primary endpoint overall survival be yet mature opdivo be approve second line renal cell carcinoma positive datum study have help support label expansion first line set study ongoing overall survival datum hit co primary endpoint support label expansion also read bristol myer opdivo fail kidney cancer trial checkmate bristol myer stock have lose value year date versus gain industry cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock glaxo gsk free report be lilly lose last month be merck decline see last pharma stock roundup here mylan miss perrigo top zynerba plunge study failure next pharmaceutical world watch usual pipeline regulatory update surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
2388,MRK,astrazeneca plc azn free report partner merck mrk free report announce fda have grant priority review supplemental new drug application snda lynparza snda astrazeneca merck be look expand label lynparza presently market advanced ovarian cancer advanced breast cancer indication snda look get drug approve previously treat chemotherapy patient negative metastatic breast cancer harbore germline brca brca mutation be base datum phase iii olympiad study fda grant priority review fda be expect give decision first quarter snda be also first regulatory application parp inhibitor ovarian cancerlynparza be different study range tumor type include breast prostate pancreatic cancer well earlier line setting ovarian cancer competition parp inhibitor market have become fierce clovis oncology inc clvs free report rubraca launch december do well tesaro inc tsro free report launch zejula niraparib april separate press release astrazeneca announce fda have also grant priority review snda key cancer drug imfinzi earlier stage lung cancer disease snda be base datum phase iii pacific study interim datum study present september show imfinzi lead superior progression free survival compare standard care patient locally advanced unresectable small cell lung cancer nsclc have not progressed follow chemoradiation imfinzi be launch unite state first indication second line advanced bladder cancer imfinzi be be evaluate multiple cancer alone combination other regimen include phase iii trial combination tremelimumab first line urothelial cancer nsclc small cell lung cancer head neck squamous cell carcinoma hnscc other today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2389,MRK,johnson johnson jnj free report be first large cap pharma stock report earning result season oct beat zack consensus estimate earning revenue third quarter also raise sale profit outlook share be more tuesday sale growth accelerate third quarter lead company post first positive sale surprise almost year higher sale pharmaceutical segment well positive contribution actelion deal pull top line quarter acquire swiss biotech actelion june year overall pharma sector have witness great turnaround year drug pricing issue cripple performance last year decline last year large cap pharma industry have rise year so far outpace gain same time frame new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval new drug approve alone continue strong performance legacy product have play pivotal role bring sector track year factor be likely drive sector rest year probably next challenge rise competition pipeline setback slowdown growth mature product generic competition certain key drug better expect result especially strong performance pharmaceutical segment have raise optimism strong quarterly performance pharma sector mainly large cap company let have closer look expect big pharma stock report month early next month company be expect deliver earning beat quarter pfizer inc pfe free report pfizer be schedule announce third quarter result oct market open zack rank hold earning esp chance stock beating zack consensus estimate third quarter be high uncover best stock buy sell re report earning esp filter new product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain eliquis blood thinner be expect contribute pfizer top line meaningfully however loss exclusivity associate generic competition product pristiq vfend zyvox celebrex expiration few co promotion agreement continue hamper top line growth blockbuster drug enbrel sale continue be soft quarter due biosimilar competition pfizer surpass zack consensus estimate trail quarters show chart pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quotebristol myer squibb company bmy free report bristol myer be schedule release result oct market open similar pfizer quantitative model indicate earning beat bristol myer zack rank stock have earning esp see complete list today zack rank strong buy stock here bristol myer high profile immuno oncology drug opdivo be likely drive company top line be report quarter opdivo sale be drive melanoma second line small cell lung cancer renal cell carcinoma indication recent label expansion classical hodgkin lymphoma head neck cancer indication also boost drug sale bristol myer outpaced zack consensus estimate trail quarters reflect chart bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quotemerck company inc mrk free report merck be schedule release result oct market open zack rank earning esp chance stock beating zack consensus estimate third quarter be high merck new product keytruda cancer zepatier hcv bridion sugammadex injection likely drive revenue quarter well keytruda sale unite state be gain particularly strong momentum new indication first line lung cancer keytruda development program significantly advanced first half regulatory approval new indication unite state additional indication europe new approval expand patient population be expect drive sale further however genericization increase competition likely remain overhang merck outpaced zack consensus estimate trail quarters reflect chart merck company inc price ep surprise merck company inc price ep surprise merck company inc plc gsk free report brentford uk base glaxosmithkline be expect report result oct glaxosmithkline be also expect outperform third quarter due zack rank buy earning esp glaxo pharmaceutical vaccine business segment be expect perform well glaxo pharmaceutical segment be expect continue be drive strong sale new hiv product tivicay triumeq however many glaxo key drug lovaza avodart be face decline sale due generic competition moreover sluggish sale growth consumer healthcare segment due slowdown market condition impact divesture negatively impact top line third quarter notably company surpass zack consensus estimate trail quarters show chart glaxosmithkline plc price ep surprise glaxosmithkline plc price ep surprise glaxosmithkline plc quoteeli lilly company lly free report eli lillyis slate announce third quarter result oct market open zack rank earning esp chance earning beat be report quarter be high continue trend past few quarters new product trulicity cyramza taltz jardiance be likely support top line report quarter however sluggish performance alimta cymbalta zyprexa be expect continue third quarter due loss exclusivity notably eli lilly surpass zack consensus estimate trail quarters show chart eli lilly company price ep surprise eli lilly company price ep surprise eli lilly company quotenovartis ag nvs free report swiss company novartis be schedule report result oct market open novartis be not expect beat estimate third quarter due zack rank earning esp recent approval kymriah acute lymphoblastic leukemia be major boost novartis give potential car therapy space moreover new product cosentyx entresto be expect boost top line cosentyx have be strong company have grab market share rival abbvie humira amgen enbrel cosentyx achieve blockbuster status however weak alcon business generic competition several key drug be expect hurt revenue quarter notably novartis outpaced zack consensus estimate trail quarters reflect chart novartis ag price ep surprise novartis ag price ep surprise novartis ag hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2390,MRK,demand immuno oncology drug combination rise pfizer inc pfe free report newly approve immunotherapy bavencio be be consider significant top line driver new york base pharma giant pfizer share be so far year compare unfavorably increase industry bavencio previously avelumab receive fda approval metastatic merkel cell carcinoma mcc rare aggressive skin cancer mar fda approval bavencio become first immunotherapy option treatment metastatic mcc bavencio receive fda approval second indication drug be approve urothelial carcinoma aggressive disease high rate recurrence meanwhile bavencio be review eu mcc decision expect third quarter last month committee medicinal product human use chmp european medicine agency ema grant positive opinion recommend approval bavencio mcc pfizer focus continuously grow expand bavencio new indication market globally meanwhile bavencio be be study different type cancer include late stage study renal cell carcinoma lung cancer ovarian cancer head neck cancer collaboration merck kgaa pfizer have also initiate avelumab double triple combination study chemotherapy target therapy have avelumab combination therapy immuno oncology agent development immuno oncology immunotherapy be new class cancer therapy utilize certain part immune system fight disease be do stimulating immune system attack cancer cell introduce immune system component body immuno oncology drug combination be great pfizer be major player immunotherapy be several other company big well small look develop bring immunotherapy treatment market merck co inc mrk free report be conduct numerous study evaluate pd therapy keytruda more type cancer more study include more combination study astrazeneca plc azn free report recently approve immuno oncology drug imfinzi durvalumab be be evaluate multiple cancer alone combination other regimen have bright long term prospect meanwhile smaller biotechs be also work bring innovative immuno oncology treatment market kite pharma lead drug axicabtagene ciloleucel be currently priority review treat aggressive hodgkin lymphoma nhl fda decision expect nov juno therapeutic novartis ag nvs free report be develop jcar ctl respectively utilize car cell technology however believe bavencio give drug tough run be ample scope growth immuno oncology space pfizer carry zack rank hold see complete list today zack rank strong buy stock here simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
2391,MRK,bristol myer squibb company bmy free report announce disappointing top line result checkmate trial study investigate immuno oncology drug opdivo nivolumab combination yervoy ipilimumab versus pfizer inc pfe sutent intermediate poor risk patient previously untreated advanced metastatic renal cell carcinoma combination show improvement progression free survival pfs do not reach statistical significance median pfs be month opdivo yervoy combination versus month sutent hence trial do not meet primary endpoint nevertheless combination meet co primary endpoint objective response rate orr achieve orr versus sutent however company have decide continue study plan allow third co primary endpoint overall survival mature tolerability profile observed checkmate be consistent observed previously report study dose schedule note renal cell carcinoma rcc be most common type kidney cancer adult account more death worldwide year clear cell rcc be most prevalent type rcc constitute case thereby underlie demand same bristol myer receive huge boost high profile immuno oncology drug opdivo become first pd immune checkpoint inhibitor gain regulatory approval anywhere world jul be currently approve several country include eu japan several cancer indication however company have have share pipeline regulatory setback oct bristol myer announce final primary analysis checkmate phase iii study evaluate use opdivo monotherapy first line treatment patient advanced small cell lung cancer nsclc tumor expressed pd greater equal jan company announce not pursue accelerate regulatory pathway regimen opdivo yervoy first line lung cancer unite state base review available datum bristol myer fail effort expand opdivo label include first line treatment lung cancer adversely impact share bristol myer stock have decline year so far industry gain opdivo face stiff competition merck co mrk free report keytruda roche hold rhhby free report tecentriq recent fda approval merck keytruda first line treatment metastatic nonsquamous nsclc further impact sale moreover failure astrazeneca azn free report mystic study imfinzi nsclc investor be worry outcome checkmate study opdivo first line nsclc give similarity trial management have play uncertainty regard trial concern remain zack rank bristol myer currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2392,MRK,johnson johnson jnj free report report better expect third quarter result beating zack consensus estimate earning sale drug consumer product giant raise sale profit outlook send share pre market trading fact year so far share price be be almost line increase witness industry earning beatj third quarter earning come share beating zack consensus estimate increase year period include amortization expense special item report third quarter earning share year period sale beatsale come beating zack consensus estimate sale increase year quarter reflect operational increase positive currency impact organically exclude impact acquisition divestiture sale increase operational basis third quarter sale grow domestic market international market reflect operational growth positive currency impact sale segment sale rise year year reflect operational growth positive currency impact sale rise domestic international market sale domestic market rise international sale grow organically exclude impact acquisition divestiture sale increase operational basis new product imbruvica cancer darzalex multiple myeloma continue perform well other growth driver be core product xarelto stelara invega sustenna sale concerta zytiga improve quarter quarter record pulmonary arterial hypertension pah revenue acquisition swiss biotech actelion june diversify revenue pah category however sale invokana invokamet decline due higher manage care discounting importantly sale blockbuster rheumatoid arthritis drug remicade market partnership merck co inc mrk free report decline quarter sale decline international sale decline due biosimilar competition regard mention pfizer inc pfe free report file lawsuit district court recently lawsuit pfizer allege resort unfair practice prevent sale inflectra pfizer biosimilar version remicade be launch unite state november last year pharma segment achieve clinical milestone quarter include label expansion unite state pulmonary arterial hypertension pah drug tracleer pediatric use imbruvica chronic graft versus host disease gvhd drug first indication outside cancer market imbruvica partnership abbvie inc abbv free report call company also mentioned not file global regulatory application rheumatoid arthritis candidate sirukumab remind investor last month receive complete response letter crl fda sirukumab want additional safety datum medical device segment sale come year period include operational increase positive currency movement sale gain mainly inclusion abbott medical optic acquisition add operational sale growth exclude impact acquisition divestiture operational basis worldwide sale increase domestic market sale rise year year international market sale increase operational increase year year operational growth be drive wound closure product general surgery business product cardiovascular business acuvue contact lense vision care business make weaker sale performance diabetes care consumer segment record revenue report quarter year year operational increase foreign currency movement positively impact sale segment sale domestic market decline year period slower growth baby care product due competitive pressure be partially offset growth beauty counter product international smoking cessation aids meanwhile international segment record increase reflect operational increase positive currency impact guidance raisedj raise adjust earning sale outlook year expect adjust earning share range compare expect previously revenue guidance be raise range compare expect previouslyour takea indicated last quarter sale growth accelerate third quarter lead company post first positive sale surprise almost year higher sale pharmaceutical segment well positive contribution actelion deal pull top line quarter actelion acquisition add impressive operational sale growth quarter quite few key product portfolio remicade concerta be face generic competition believe new product segment label expansion drug imbruvica darzalex contribution actelion lead better sale trend go forward carry zack rank hold see complete list today zack rank strong buy stock here johnson johnson price consensus ep surprise johnson johnson price consensus ep surprise johnson johnson quotelook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2393,MRK,bristol myer squibb company bmy free report announce fda have grant priority review supplemental biologic license application sbla label expansion opdivo company be look get drug approve treat patient melanoma be high risk disease recurrence follow complete surgical resection however drug be already approve treatment patient braf mutation positive unresectable metastatic melanoma generally priority review designation fda be grant drug have potential provide significant improvement safety effectiveness treatment prevention diagnosis serious disease fda also previously grant breakthrough therapy designation application be seventh indication opdivo have receive designation supplemental biologic license application be base datum ongoing phase iii checkmate study bristol myer announce encourage result checkmate study opdivo checkmate be randomize double blind study opdivo versus yervoy patient have undergo complete resection stage iiib stage iv melanoma result study show opdivo mg kg lead significant improvement recurrence free survival rfs compare yervoy mg kg patient stage iiib stage iv melanoma follow complete surgical resection result plan interim analysis show opdivo meet primary endpoint statistically significant improvement rfs compare yervoy july company report positive result same study so far year bristol myer stock have rally compare industry gain fact opdivo become first pd immune checkpoint inhibitor gain regulatory approval anywhere world july notably drug become first pd inhibitor be approve hematological malignancy classic hodgkin lymphoma unite state eu november november opdivo gain fda approval treatment patient recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy opdivo continue be launch globally approval label expansion also receive approval several indication include melanoma head neck lung kidney blood cancer fact opdivo yervoy regimen be approve multiple market treatment melanoma drug have be perform impressively due demand result rapid commercial acceptance several indication opdivo generate revenue second quarter year period meanwhile fda have put partial clinical hold clinical trial checkmate checkmate trial be investigate opdivo base combination patient relapse refractory multiple myeloma also concern astrazeneca azn free report fail study lung cancer drug imfinzi loom large company checkmate study opdivo currently opdivo be face competitive challenge unite state fda approve merck co mrk free report keytruda first line treatment metastatic nonsquamous nsclc bristol myer be expect suffer further loss market share bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quotezack rank stock considerbristol myer carry zack rank hold better rank stock health care sector include nordisk nvo free report hold zack rank buy see complete list today zack rank strong buy stock here nordisk earning share estimate have moved company pull positive earning surprise trail quarters average beat share price company have increase year date look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2394,MRK,johnson johnson jnj free report have most diverse revenue stream industry pharmaceutical division account almost half revenue company have several multus dollar drug cover broad range area such neuroscience cardiovascular metabolism immunology oncology pulmonary hypertension infectious disease vaccine however several product segment be face generic competition share have gain past year outperform increase witness industry belong domestic pharma segment sale decelerate first half however sale growth accelerate third quarter be likely see continuation positive trend fourth quarter probably zack consensus estimate pharmaceutical segment be last quarter segment sale beat consensus estimate believe new product segment label expansion drug imbruvica xarelto stelara darzalex meaningful contribution swiss biotech actelion buy june support top line pharma segment also continue benefit easier comp second half compare first continue share gain be likely drive sale imbruvica cancer indication stelara psoriasis strong adoption newer indication crohn disease be expect contribute stelara growth also strong adoption outside market accelerate adoption unite state line therapy be likely drive sale multiple myeloma product darzalex positive offset loss sale drug invokana due higher manage care discounting also gain fda approval several line extension second third quarters lower dose xarelto new indication simponi aria use adolescent stelara combination use darzalex celgene celg free report multiple myeloma drug pomalyst sixth indication imbruvica other line extension expand eligible patient population drug drive sale fourth quarter new drug be approve last year include tremfya guselkumab unite state july well eu november plaque psoriasis first dual treatment hiv juluca dolutegravir rilpivirine partnership glaxosmithkline gsk free report unite state november juluca be review eu regard tremfya say third quarter conference call have be well receive physician patient drug be likely contribute sale soon be report quarter expect update plan juluca fourth quarter conference call however biosimilar competition be expect hurt sale key arthritis drug remicade outside unite state please note market remicade partnership merck mrk free report overall strong performance pharmaceutical segment well positive contribution acquisition actelion abbott medical optic pull top line quarter meanwhile higher investment product launch continue hurt profit have be case third quarter read more set pharma earning motion carry zack rank hold see complete list today zack rank stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2395,MRK,share nektar therapeutic nktr free report have increase massive year time substantially outperform industry gain let analyze factor lead massive rally nektar rapid progress robust pipeline year accompany several study initiation positive readout strategic collaboration have drive share price consistently company pegylation technology also facilitate development several approve product unite state eu partnership healthcare company namely astrazeneca azn free report movantik ucb cimzia amgen amgn free report neulasta other furthermore have robust pipeline early late stage candidate nektar have make significant progress lead candidate onzeald formerly know nktr be currently accelerate assessment eu treat adult advanced breast cancer well brain metastase response be anticipate first half meanwhile randomize phase iii confirmatory study attain begin onzeald late last year study compare onzeald single agent chemotherapy physician choice patient advanced breast cancer have brain metastase late positive result program be likely support regulatory filing unite state apart onzeald nektar be work develop other candidate september company announce initiation phase ii propel study evaluate efficacy safety immuno oncology candidate nktr combination roche tecentriq atezolizumab merck mrk free report keytruda pembrolizumab phase ii pivot study evaluate nktr potential combination treatment regimen bristol myer squibb opdivo be also underway tumor type melanoma kidney colorectal bladder small cell lung cancer potential indication november company announce positive datum pivot study treat patient melanoma renal cell carcinoma small cell lung cancer also nektar enter research collaboration takeda pharmaceutical explore combination nktr oncology compound takeda cancer portfolio candidate nktr be be examine phase iii program treatment chronic pain july company report positive top line finding oral human abuse potential study analyse nktr assess opioid abuse potential compare oxycodone be plan submit new drug application candidate april march company initiate phase clinical study evaluate nktr treat wide range auto immune disease inflammatory disorder subsequently july nektar seal co development deal elly lilly company nktr pursuant agreement company own responsibility complete ongoing phase study candidate company share phase ii development cost lilly acquire lion share total expense year look extremely favorable stock several update line expect approval onzeald eu breast cancer submission nda nktr act catalyst further drive stock nektar therapeutic price nektar therapeutic price nektar therapeutic quotezack ranknektar carry zack rank sell see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2396,MRK,president donald trump power polarize continue weekend tragic event charlottesville va subsequent remark cause president become further isolate member business community tuesday scott paul president alliance american manufacturing step president trump american manufacturing council tuesday paul be latest member group chief executive biggest company manufacturing base business resign council grow president early manufacturing job initiative paul take twitter twtr free report tuesday morning officially announce move resign manufacturing job initiative right thing do scott paul scottpaulaam august head alliance american manufacturing resignation president trump council promote american manufacturing job be hardly president have hope paul follow recent wave high profile ceo separated president weekend deadly white supremacist rally many include ceo left council cite president trump seemingly noncommittal rebuke white supremacist merckmerck mrk free report ceo kenneth frazier few african american ceo fortune be first major council member step monday america leader honor fundamental value clearly reject expression hatred bigotry group supremacy run counter american ideal person be create equal frazier say pic twitter com pnqzism merck merck august intel intc free report ceo brian armour uaa free report ceo kevin plank also step council monday intel earlier today tender resignation american manufacturing council say blog post resign call attention serious harm divide political climate be cause critical issue include serious need address decline american manufacturing politic political agenda have sideline important mission rebuild america manufacturing base tweet follow just hour official resignation be post be hesitation condemn hate speech white supremacy name intel ask country leadership do same brian bkrunner august armour kevin plank have catch flack ua athlete include stephen curry initial support president trump council also take twitter post reason leave be appreciative opportunity have serve have decide step council plank say love country company continue focus effort inspiring person do anything power sport promote unity diversity inclusion love country company be step council focus inspiring unite power sport ceo kevin plank pic twitter com yvndjmjj armour underarmour august trump response president trump be quick respond twitter recent resignation now ken frazier merck pharma have resign president manufacturing council have more time lower ripoff drug price donald trump realdonaldtrump august merck pharma be leader higher higher drug price same time take job bring job back lower price donald trump realdonaldtrump august ceo drop manufacturing council have many take place grandstander not have go job donald trump realdonaldtrump august poor performance armour stock take big hit tuesday share struggle sportswear company sank afternoon trading touch new week low share earlier dick sporting good dks free report see stock price crash today armour have large exposure chain share intel be year also dip tuesday merck stock have rise so far year much less dow industrial average share merck hover flat see marginal loss company be left recent resignation chief executive currently comprise american manufacturing council include dow general electric ge free report boee ba free report other big name original company be ask join president trump manufacturing council have now step first major executive part way be tesla tsla free report elon musk left council earlier year president trump announce withdraw paris climate agreement other executive part way council left be longer position list include former ford free report ceo mark field zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
2397,MRK,high profile retailer continue report result final leg earning season specialty retailer home depot hd free report coach dick sporting good dks free report post july quarter number ahead today open bell retail sale last month also hit tape finally more ceo have resign president trump american manufacturing council morning follow merck mrk free report ceo ken frazier departure yesterday wake trump initial response white supremacist rally weekend claim life several injury july retail sale come hotter expect morning rise expect perhaps even more tell june revision swung disappointing negative decent positive initial read revision morning headline ex auto ex auto gas be strong control number indicate real retail sale growth not time anomaly make way headline number figure also satisfy economist ve be scratch head late try figure robust labor market surge consumer confidence other growth metric point higher retail sale continue lag now growth more full percentage point past month look keep folk tear model despair home depot outperformed expectation morning beating bottom line cent share year year quarterly sale reach easily outpace zack consensus year year zack rank buy rank home improvement giant crank guidance sale earning even still hd share be trading slightly today pre market potentially sell news scenario company be year date specialty handbag retailer coach beat earning sale estimate fiscal guidance be so be stock pre market trading earning cent share beat expectation penny revenue surpass be look yet coach lower full year earning nearly dime share previous estimate company expect kate spade purchase yield end fiscal year zack rank sell rate dick sporting good be selling big league morning follow earning release bottom line be expect cent share expect sale be smudge zack consensus guidance sale earning full year have also be ratchete dick share be selling already have tumble more year ceo intel intc free report underarmour have give seat president trump american manufacturing council early today intel brian ua kevin plank cite tacit support white house separatist rally attack protestor charlottesville va saturday reason forfeit post president trump have state publicly racism be evil include kkk neo nazis white supremacist be unclear corporate leader attempt be replace point president have not yet tweet anything disparage ceo
2398,MRK,aug issue update report ligand pharmaceutical incorporate lgnd free report ligand captisol formulation technology platform have allow enter partnership several lead drug company novartis ag nvs free report merck co inc mrk free report amgen inc amgn free report provide fund form milestone royalty payment royalty depend sale key partner asset novartis kyproli amgen promacta ligand receive royalty milestone payment several fda approve product used captisol technology latest product approval include spectrum evomela lundbeck carnexiv melinta therapeutic baxdela apart several other candidate be late stage development be expect bring royalty company once commercialize july company announce have enter commercial license supply agreement amgen grant right use captisol formulation cd cd bite bispecific antibody amg agreement term ligand be entitle potential milestone payment royalty revenue future sale amg regard company internal pipeline various candidate be be develop indication diabetes most advanced candidate be lgd presently undergo phase ii study treatment type ii diabetes datum trial be await second half potential bring future licensing opportunity nonetheless ligand entry medical device segment acquisition multiple program own cormatrix be also encourage however ligand obtain captisol single supplier hovione major global supplier active pharmaceutical ingredient drug product intermediate locate portugal interruption captisol supply hit company result zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
2399,MRK,tuesday august high profile retailer continue report result final leg earning season specialty retailer home depot hd free report coach dick sporting good dks free report post july quarter number ahead today open bell retail sale last month also hit tape finally more ceo have resign president trump american manufacturing council morning follow merck mrk free report ceo ken frazier departure yesterday wake trump initial response white supremacist rally weekend claim life several injury july retail sale come hotter expect morning rise expect perhaps even more tell june revision swung disappointing negative decent positive initial read revision morning headline ex auto ex auto gas be strong control number indicate real retail sale growth not time anomaly make way headline number figure also satisfy economist ve be scratch head late try figure robust labor market surge consumer confidence other growth metric point higher retail sale continue lag now growth more full percentage point past month look keep folk tear model despair earning rounduphome depot outperformed expectation morning beating bottom line cent share year year quarterly sale reach easily outpace zack consensus year year zack rank buy rank home improvement giant crank guidance sale earning even still hd share be trading slightly today pre market potentially sell news scenario company be year date specialty handbag retailer coach beat earning sale estimate fiscal guidance be so be stock pre market trading earning cent share beat expectation penny revenue surpass be look yet coach lower full year earning nearly dime share previous estimate company expect kate spade purchase yield end fiscal year zack rank sell rate dick sporting good be selling big league morning follow earning release bottom line be expect cent share expect sale be smudge zack consensus guidance sale earning full year have also be ratchete dick share be selling already have tumble more year incredible shrink manufacturing councilceo intel intc free report underarmour have give seat president trump american manufacturing council early today intel brian ua kevin plank cite tacit support white house separatist rally attack protestor charlottesville va saturday reason forfeit post president trump have state publicly racism be evil include kkk neo nazis white supremacist be unclear corporate leader attempt be replace point president have not yet tweet anything disparage ceo mark vickerysenior editorquestion comment article author click here
2400,MRK,think way back week so market be enjoy multus week gain time high be late term bull market look be just pick new steam appear be nothing earning season overall economic metric be position stifle such historic positive seem long time now doesn be see future initial pre market session new week not say mood be same be last monday plenty question mark float market today form economic datum other actionable information be release week well threat nuclear conflict north korea even leadership identity unite state instance just morning merck mrk free report ceo ken frazier have announce be step president trump american manufacturing council reaction president statement regard deadly tragedy charlottesville va weekend standoff white nationalist and protest white nationalist end tragic death protestor other injured be result hatred bigotry violence many side provoke frazier say honor fundamental value reject hatred feel responsibility take stand intolerance extremism frazier statement read statement result new twitter attack frazier company be not really surprise be fairly true form president trump rather get deeper discussion here suffice say be yet arena see thorn barb weren weren visible time last week july retail sale come tomorrow expectation growth look be third straight month retail sale consumer confidence be apparently consumer aren spending exactly be disconnect here question mark be partially answer earning report due wednesday walmart wmt free report target tgt free report also wednesday look answer minute release most recent federal reserve meeting be advancement language articulating wind fed balance sheet even chance new rate hike september be close nil point work massive debt be postpone stall way now inflation metric have yet find way economy expect time question question everywhere
2401,MRK,monday august think way back week so market be enjoy multus week gain time high be late term bull market look be just pick new steam appear be nothing earning season overall economic metric be position stifle such historic positive seem long time now doesn be see future initial pre market session new week not say mood be same be last monday plenty question mark float market today form economic datum other actionable information be release week well threat nuclear conflict north korea even leadership identity unite state instance just morning merck mrk free report ceo ken frazier have announce be step president trump american manufacturing council reaction president statement regard deadly tragedy charlottesville va weekend standoff white nationalist and protest white nationalist end tragic death protestor other injured be result hatred bigotry violence many side provoke frazier say honor fundamental value reject hatred feel responsibility take stand intolerance extremism frazier statement read statement result new twitter attack frazier company be not really surprise be fairly true form president trump rather get deeper discussion here suffice say be yet arena see thorn barb weren weren visible time last week july retail sale come tomorrow expectation growth look be third straight month retail sale consumer confidence be apparently consumer aren spending exactly be disconnect here question mark be partially answer earning report due wednesday walmart wmt free report target tgt free report also wednesday look answer minute release most recent federal reserve meeting be advancement language articulating wind fed balance sheet even chance new rate hike september be close nil point work massive debt be postpone stall way now inflation metric have yet find way economy expect time question question everywhere mark vickerysenior editorquestion comment article author click here
2402,MRK,gilead science inc gild free report announce fda have grant priority review company new drug application nda investigational fix dose combination bictegravir mg bic novel investigational integrase strand transfer inhibitor insti emtricitabine tenofovir alafenamide mg ftc taf dual nrti backbone treatment hiv infection nda be file jun fda have set target action date prescription drug user fee act pdufa feb marketing application bic ftc taf be also review european union be validate european medicine agency ema july potential approval be expect toboost gilead hiv gilead be dominant player hiv market impressive portfolio same newly launch taf base product genvoya odefsey descovy be perform well strong adoption eu genvoya have already become most prescribe regimen treatment nave switch patient launch nov taf base regimen now represent total gilead hiv prescription volume follow launch genvoya odefsey descovy genvoya be now company bestselling hiv product surpass truvada atripla fourth quarter genvoya be now company bestselling hiv product treatment nave patient share gilead expect use truvada pre exposure prophylaxis prep continue boost sale hiv franchise go forward particularly strong uptake truvada use pre exposure prophylaxis set also boost sale company see significant uptick prep usage estimate patient used truvada end second quarter meanwhile gilead stock have gain only year so far industry gain uptake hiv franchise help company combat persistent decline hcv franchise due competitive pressure hcv business see improvement second quarter hcv franchise be boost fda approval vosevi hcv patient start first half be better expectation see gradual decline second half due increase competition harvoni sovaldi epclusa have be face competition abbvie abbv free report viekira pak viekira xr bristol myer squibb company bmy free report daklinza competition well pricing pressure intensified further launch merck mrk free report zepatier zack rank gilead currently carry zack rank buy see complete list today zack rank strong buy stock here trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2403,MRK,impax laboratory inc share have rise almost announce robust result aug company report second quarter adjust earning cent share beating zack consensus estimate cent however earning be cent year period due higher cost total revenue increase year year growth generic division sale revenue also surpass zack consensus estimate report quarter fact year date impax share be industry decline quarter detaildure report quarter impax generic division revenue increase year quarter increase revenue be due higher sale epinephrine auto injector oxymorphone product acquire teva pharmaceutical industry ltd teva free report launch generic version merck co inc mrk free report vytorin quarter impax specialty pharma division record revenue year year largely due higher sale rytary however zomig sale be adjust research development expense grow report quarter adjust selling general administrative expense sg increase other quarter july company receive approval generic version focalin xr mg concerta mg fda approval generic focalin xr complement portfolio generic focalin xr include mg capsule be already market april impax announce have receive final fda approval generic version vytorin ezetimibe simvastatin tablet mg immediately initiate activity first market opportunity end march company have announce district court district delaware rule favor astrazeneca plc azn free report patent infringement case regard generic version zomig outlook company expect full year adjust earning be range cent cent share company expect adjust gross margin range adjust research development expense include patent litigation expense generic brand division be forecast be range previously adjust selling general administrative expense be expect be range takein first quarter release impax have discuss cost save initiative include several process improve efficiency margin focus growth opportunity saving annualize cost tune be expect limit saving projection save total end however headwind generic segment be likely continue impact top line upcoming quarters impax laboratory inc price consensus ep surprise impax laboratory inc price consensus ep surprise impax laboratory inc quotezack rankimpax currently carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2404,MRK,second quarter earning season be draw close most major company have report result week company endo mylan myl free report nordisk perrigo prgo free report present second quarter result recap week most important storiesa look earning result mylan second quarter result be disappointing company miss earning revenue cut outlook also read mylan miss earning sale lower view mylan have push back major product launch reflect ongoing challenge uncertain regulatory environment product launch include generic version advair copaxone escalate price erosion generic market remain major challenge meanwhile mylan get subpoena department justice doj late jul seek information relate opioid manufacture market sell company jan dec mylan have lose value year date versus decline industry perrigo second quarter result be better expect company raise outlook also read perrigo earning sale top view raise nordisk also top earning estimate raise outlook meanwhile endo top earning revenue estimate lower outlook also read endo beat earning sale guidance lower endo stock have lose value year date versus decline industry perrigo be zack rank hold stock see complete list today zack rank strong buy stock here esperion positive mid stage datum esperion espr free report share be positive top line datum study evaluate company bempedoic acid zetia ezetimibe combination lipitor versus placebo patient mid stage triplet oral therapy study meet primary endpoint greater ldl lower compare placebo company intend conduct additional study next year expect file fda approval combination first quarter zynerba plunge star fail shine zynerba see share plunge disappointing mid stage datum company experimental cannabinoid treatment zyn result double blind placebo controlled star study adult epilepsy patient focal seizure show dose zyn fail meet endpoint compare placebo focus have now shift couple more study be conduct zyn osteoarthritis top line datum expect aug fragile syndrome top line datum expect sep valeant get crl eye drop valeant vrx free report report second quarter result week also read valeant beat earning sale line trim view get complete response letter crl fda new drug application nda vyzulta latanoprostene bunod ophthalmic solution company be look gain approval use intraocular pressure lower single agent eye drop patient open angle glaucoma ocular hypertension safety efficacy concern be raise fda crl refer current good manufacturing practice cgmp inspection bausch lomb manufacturing facility tampa fl valeant be work resolve manufacturing quality issue tampa plant be work agency determine path forward cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock bristol myer bmy free report be glaxo lose last month be merck mrk free report decline see last pharma stock roundup here mixed result pfizer bristol myer announce io deal next pharma world watch usual pipeline regulatory update make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2405,MRK,dow end record run win suffer dramatic decline end week stellar earning performance help index register record close monday tuesday tide have turn index close red trump sound strong warning errant north korea such saber rattle ultimately lead significant loss blue chip index well broader market thursday last week blue chip index register record finish threshold yet again last friday index gain end green ninth straight trading day be highest number gain record february goldman sachs group inc gs contribute most gain index stellar performance session such gain be primarily attributable astounding number job addition month july total new job be create unite state past month alone total new job have be add economy index gain last week mark second straight weekly increase dow have finished positive territory now past week dow surpass milestone ride high performance jp morgan jpm free report mmm free report goldman sachs also boee company ba free report have add point blue chip index february help cross psychological milestone dow index increase monday register record close end psychological mark yet again index also increase tenth straight trading day highest february blue chip index rise february boee goldman sachs contribute majority gain index lose tuesday end session record run win year tuesday tumble trump sound fresh warning north korea president trump announce north korea be dealt fire fury world have never see rogue country continue threaten blue chip index be lead lower primarily drop share merck mrk free report dupont nike nke index decline wednesday briefly slip milestone pare loss finish psychological level decline dow be primarily due loss make share walt disney company free report medium behemoth announce plan end distribution deal netflix inc nflx free report index lose thursday even benchmark endure most dismal trading day middle third successive session benchmark have suffer loss mark first such reverse middle april broader market be weigh heighten tension north korea dow be weigh primarily apple inc aapl free report goldman sachs lose respectively only dow component manage close day gain component move index disney post better expect earning third straight quarter report third quarter fiscal result company earning report quarter come share beating zack consensus estimate decrease year year meanwhile revenue come almost flat year year miss zack consensus estimate concurrently zack rank hold rate disney state terminate distribution agreement netflix subscription stream new movie start instead company have own stream service disney pixar brand espn follower read disney earning top unveil stream service boee have finalize order deliver max airplane air lease corporation al detail contract have be reveal recently order be announce paris air show deal comprise order max max also include new order dreamliner read boee secure max jet order air lease additionally zack rank rate boee have clinch contract next generation thermal power control ngt pac program work related deal be schedule be jul value contract have be award air force research laboratory patterson air force base read boee win air force deal ngt pac program cisco system inc csco free report win temporary victory long run patent infringement case international trade commission itc close rival arista network anet free report notably zack rank rate cisco file complaint investigation itc late allege arista infringe patent itc issue limit exclusion order cease desist order find arista ethernet switch product violate patent recent filing arista follow disapproval unite state trade representative itc final determination case be now bar import selling aforesaid ethernet switch product however victory be short live cisco accord filing patent trial appeal board ptab have issue final written decision invalidate claim related mentioned patent arista be find infringe itc read cisco win temporary victory arista product face itc ban intel corporation intc have become latest tech company announce plan build self drive car try stay ahead competition qualcomm qcom free report nvidia nvda zack rank buy rate intel plan build car test self drive technology car be level vehicle mean be able handle most drive situation be test israel europe new car include technology israeli tech company mobileye mbly be world largest supplier system used automotive collision detection system aug intel have officially complete acquisition mobileye read intel announce plan build self drive car dupont dow chemical say have receive require regulatory approval clearance plan mega merger company expect merger equal complete market close aug share company cease trading close nyse aug moreover share new combine entity dowdupont start trading nyse ticker symbol dwdp sep follow completion merger combine entity eventually break independent company tax free spin off plan breakup be still expect take place month completion deal stock have zack rank see complete list today zack rank strong buy stock here goldman sachs have agree sell remain stake rothesay life plc exist shareholder blackstone group lp bx massachusett mutual life insurance co gic pte singapore sovereign wealth fund transaction be expect be complete end bloomberg article deal have be value execution deal company shareholder acquire portion zack rank sell rate goldman sachs stake blackstone gic hold highest percentage read goldman sachs divest remain stake rothesay life performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have decline tickerlast day performance month performancemmm gs ibm hd ba unh mcd trv jnj aapl next week outlookinvestor focus have squarely shift earning broader economic theme rise geopolitical tension north korea market watcher believe be unlikely actual conflict break same time short breather actually be beneficial stock give gain have continue record period remain be see extent north korea centric tension weigh market day ahead make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2406,MRK,celldex therapeutic inc cldx free report incur second quarter loss cent share be narrower zack consensus estimate loss cent well year loss cent share lower cost higher revenue lead narrower loss quarter total revenue quarter rise year year beating zack consensus estimate manufacturing service agreement international aids vaccine initiative lead higher revenue quarter share biotech company rise hour trading tuesday however stock have not do too well year so far have decline year date increase register industry research development expense decline year period general administrative spend decline jun celldex have cash cash equivalent marketable security compare mar celldex expect cash anticipate proceed future sale common stock agreement cantor be enough fund work capital requirement plan operation however guidance assume celldex pay future kolltan contingent milestone stock not cash pipeline updatecelldex most advanced pipeline candidate be glembatumumab vedotin currently be evaluate treatment triple negative breast cancer phase iib metric study metastatic melanoma phase ii enrolment metric study be expect be complete september year top line datum expect second quarter datum phase ii metastatic melanoma study glemba single agent be present june annual meeting american society clinical oncology asco glemba perform well single agent set response rate disease control rate median duration response month patient have fail prior line therapy study also include new cohort glembatumumab varlilumab arm datum expect year end glembatumumab checkpoint inhibitor arm include bristol myer squibb company bmy free report opdivo merck co inc mrk free report keytruda apart glembatumumab vedotin celldex have several promising candidate pipeline include varlilumab cdx phase advanced renal cell carcinoma other varlilumab be be evaluate combination bristol myer opdivo phase ii study include cohort indication colorectal cancer ovarian cancer head neck squamous cell carcinoma renal cell carcinoma glioblastoma celldex plan complete enrolment cohort phase ii portion study first quarter meanwhile company present datum phase potion varlilumab opdivo combination study asco june datum show combination be well tolerate test dose level increase autoimmunity inappropriate immune activation kolltan acquisition nov celldex gain right kolltan cancer pipeline candidate cdx cdx cdx be be evaluate phase study refractory stromal tumor gist other kit positive tumor datum expect year end phase ii study cdx patient recurrent metastatic head neck squamous cell cancer be refractory eli lilly company lly free report bristol myer erbitux be expect be initiate fourth quartercelldex therapeutic inc price consensus ep surprise celldex therapeutic inc price consensus ep surprise celldex therapeutic inc quotecelldex carry zack rank sell see complete list today zack rank strong buy stock here more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2407,MRK,horizon pharma plc hznp free report top earning sale estimate second quarter company also raise sale guidance company share moved better expect second quarter result increase guidance however horizon pharma stock be year date industry gain company report second quarter earning cent share beat zack consensus estimate cent include stock base compensation expense exclude time item be cent year quarter exclude stock base compensation expense company report ep cent sale second quarter be year year fuel solid growth orphan rheumatology business unit report sale also beat zack consensus estimate horizon pharma plc price consensus ep surprise horizon pharma plc price consensus ep surprise horizon pharma plc quotequarter orphan unit record revenue year period strong performance be backed solid net sale ravicti generate sale quarter year year drive continue conversion older generation nitrogen scavenger therapy well addition treatment nave patient due recent label expansion apr fda approve supplemental new drug application ravicti expand age range chronic management urea cycle disorder patient month older year older additionally procysbi contribute performance net sale actimmune sale report quarter be year year rheumatology unit generate sale year year also krystexxa sale quarter be strong come year year drive continue strong year year vial demand primary care garner revenue year year decline net sale be due implementation new contract model order secure broader inclusion company primary care medicine formulary net sale pennsaid duexix vimovo be respectively report quarter company raise outlook now expect sale range compare earlier estimate horizon pharma be significantly increase investment key growth driver krystexxa expect net sale krystexxa drive higher demand guidance include assumption lower net average net realize price begin second half primarily result government health resource service administration final rule drug ceiling price implementation schedule oct company expect continue double digit net sale growth ravicti room additional uptake due recent label expansion drug be also expect be launch europe second half sale procysbi decline divestiture european right sale actimmune be project grow low single digit drive year year growth second half other updatesdure quarter company acquire river vision thereby add biologic candidate teprotumumab late stage development thyroid eye disease confirmatory phase iii trial be slate be year end company expect annual net sale teprotumumab exceed jun horizon pharma sell marketing right procysbi quinsair europe middle east africa region chiesi farmaceutici company focus higher return business meanwhile company be work expand actimmune label company have collaborate fox chase cancer center evaluate actimmune combination bristol myer squibb company bmy free report opdivo phase dose study treatment kidney bladder cancer national cancer institute have plan evaluate actimmune combination merck co mrk free report keytruda treat cutaneous cell lymphoma patient phase ii study remain track begin later year takehorizon pharma second quarter result be impressive company beating top bottom line estimate moreover increase sale guidance be encourage well net sale rare disease drug increase expect krystexxa ravicti actimmune drive growth second half acquisition teprotumumab have further diversify company portfolio however key drug duexis vimovo face competition pfizer inc pfe free report celebrex generic other brand steroidal inflammatory drug nsaid cheaper generic version nsaid zack rankhorizon pharma currently have zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2408,MRK,week company novartis nvs free report merck mrk free report johnson johnson jnj free report be news merck provide datum keytruda novartis be news gain priority review status label expansion car therapy kymriah recap week most important storiesmerck keytruda shine st line lung cancer study merck score week pd therapy keytruda combination alimta pemetrexed cisplatin carboplatin meeting primary endpoint overall survival os progression free survival pfs late stage study first line treatment patient metastatic squamous small cell lung cancer nsclc interim analysis conduct independent datum monitoring committee show keytruda combination result significantly longer os pfs compare alimta platinum chemotherapy alone read more merck strong confirmatory phase iii lung cancer study priority review label expansion novartis kymriah novartis first company gain fda approval car therapy kymriah say agency have grant priority review company regulatory application seek expand label product novartis be look get kymriah approve treatment adult patient relapse refractory diffuse large cell lymphoma dlbcl be ineligible relapse autologous stem cell transplant asct kymriah also get accelerate assessment status european medicine agency ema treatment child young adult cell acute lymphoblastic leukemia adult patient dlbcl be ineligible asct read more novartis sbla car therapy kymriah accept fda unfavorable ipr decision suffer setback week patent trademark office pto issue final written decision parte review ipr related sole unexpired patent list cover company prostate cancer therapy zytiga abiraterone acetate fda orange book generic drug company argentum pharmaceutical have challenged claim patent be due expire aug issue statement regard pto decision say be evaluate option rehearing appeal court appeal federal circuit zytiga bring sale first month novartis sandoz global partnership biocon biosimilar sandoz novartis division be enter global partnership biocon development manufacture multiple biosimilar immunology oncology company share responsibility end end development manufacturing global regulatory approval number product have cost profit share arrangement responsibility be divide partnership allow company address next wave biosimilar opportunity globally sandoz biocon have have success biosimilar space sandoz portfolio include biosimilar market various country world company be currently seek fda approval biosimilar version abbvie blockbuster immunology drug humira regulatory application biosimilar be recently accept review fda pfizer gilead clinical trial collaboration pfizer pfe free report have enter clinical trial collaboration kite gilead gild free report company safety efficacy kite car cell therapy yescarta axicabtagene ciloleucel be evaluate combination pfizer utomilumab fully humanize bb agonist monoclonal antibody patient refractory large cell lymphoma phase ii study be expect commence year pfizer be zack rank buy stock see complete list today zack rank strong buy stock here company stock be last year compare rally industry belong cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session major stock merck be bristol myer squibb bmy free report decline last month bristol myer be glaxosmithkline gsk free report decline see last pharma stock roundup here nordisk reveal bid acquire ablynx pfizer other healthcare conference next pharma world watch usual pipeline regulatory update well fourth quarter earning announcement january make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2409,MRK,major news cancer segment week be failure eli lilly company lly free report newly approve breast cancer drug verzenio pivotal lung cancer study latest failure lilly join list large pharma company have fail respective lung cancer pivotal study recent past however verzenio be grant priority review status first line treatment breast cancer meanwhile fda grant breakthrough therapy designation astrazeneca plc azn free report tagrisso egfr mutation positive small cell lung cancer nsclc well astella leukemia candidate gilteritinib also abbvie seattle genetic announce collaboration agreement strengthen oncology pipeline let see news detail key newseli lilly company face yet pipeline setback phase iii juniper study fail meet primary endpoint overall survival study be compare verzenio roche astella pharma tarceva patient stage iv nsclc have kra mutation lilly announce fda have grant priority review new drug application nda seek approval first line treatment advanced breast cancer verzenio be approve treat metastatic breast cancer last month patient disease progressed platinum base chemotherapy read more verzenio fail phase iii lung cancer study eli lilly company price consensus eli lilly company price consensus eli lilly company tagrisso be grant breakthrough therapy designation first line treatment metastatic nsclc egfr mutation week company be develop drug phase iii study flaura compare standard care soc egfr tyrosine kinase inhibitor tki therapy datum study be present earlier astrazeneca also announce european medicine agency have accept marketing authorization application maa imfinzi treatment locally advanced unresectable small cell lung cancer astrazeneca plc price consensus astrazeneca plc price consensus astrazeneca plc quoteseattle genetic inc sgen free report partner astella pharma initiate phase ii study enfortumab vedotinin locally advanced metastatic urothelial cancer meanwhile seattle genetic announce clinical collaboration evaluate sgn liv triple negative breast cancer tnbc study evaluate sgn liv combination merck co mrk free report keytruda other study evaluate candidate combination standard chemotherapy neoadjuvant treatment read more seattle genetic inks clinical collaboration cancer drug seattle genetic inc price consensus seattle genetic inc price consensus seattle genetic inc quoteother week also see application submit clovis oncology clvs free report label expansion rubracaas maintenance treatment patient platinum sensitive recurrent ovarian cancer fda also grant fast track designation expedite development astella pharma gilteritinib adult patient relapse refractory acute myeloid leukemia be flt mutation positive meanwhile abbvie abbv free report enter research option license agreement turnstone biologic gain right latter next generation oncolytic viral immunotherapy deal be expect boost abbvie immuno oncology potential stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
2410,MRK,company pfizer pfe free report merck mrk free report eli lilly lly free report be news week pfizer be mull strategic option consumer healthcare business merck say not file cetp inhibitor recap week most important storiespfizer divest consumer healthcare segment pfizer be currently review different strategic option consumer healthcare business include full partial separation spin sale company also ultimately decide retain business be not first time pfizer have decide spin sell core business segment strategic step take pfizer include sale hospira infusion system business icu medical february spin animal health business lead creation zoetis well divestment nutrition business nestle pfizer have sell capsugel business affiliate kohlberg kravis robert co divestment consumer healthcare business help pfizer focus innovative health segment also bring fund company use return value shareholder form share buyback dividend read more pfizer consider sale spin consumer healthcare unit pfizer be zack rank hold stock see complete list today zack rank strong buy stock here company have gain year date compare rally industry belong merck collaborate kalvista clinical stage pharma company kalvista pharmaceutical see share shoot collaboration agreement merck kvd future oral diabetic macular edema dme compound base plasma kallikrein inhibition kvd investigational intravitreal ivt injection be schedule move phase ii proof concept study later year merck have option acquire right candidate follow completion study merck have similar option certain other dme candidate kalvista receive refundable upfront payment well payment associate exercise option merck achievement milestone program add company also stand receive tiered royalty net sale candidate commercialize deal merck also acquire ownership stake kalvista worth pipeline setback lilly lilly suffer setback recently approve breast cancer drug verzenio fail meet primary endpoint late stage study kra mutate advanced small cell lung cancer cdk inhibitor fail meet primary endpoint overall survival os analysis secondary endpoint progression free survival pfs overall response rate orr show evidence monotherapy activity read more lilly verzenio fail phase iii lung cancer study meanwhile verzenio have be grant priority review fda use initial treatment advanced breast cancer mean response agency be month receive regulatory application instead usual timeframe month seek fda nod new prostate cancer treatment johnson johnson janssen biotech be seek fda approval apalutamide investigational next generation oral androgen receptor ar inhibitor man metastatic castration resistant prostate cancer crpc be significant unmet need patient population give absence fda approve treatment patient prostate cancer most common cancer american man be expect be diagnosed more man american cancer society apalutamide become part pipeline follow acquisition privately hold aragon pharmaceutical apalutamide approval strengthen expand presence prostate cancer market company currently sell zytiga be approve use combination prednisone treatment patient metastatic castration resistant prostate cancer mcrpc be look expand zytiga label earlier stage metastatic prostate cancer allergan settle restasis litigation innopharma allergan agn free report enter settlement agreement innopharma related litigation regard restasis patent challenged patent be list orange book be schedule expire aug settlement agreement innopharma start selling generic version eye drug unite state feb earlier certain circumstance moreover certain circumstance innopharma be allow launch authorize generic version restasis aug allergan be adopt different way protect restasis generic competition company recently come fire enter agreement saint regis mohawk tribe lawmaker question unconventional move adopt company protect blockbuster eye drug generic competition restasis be allergan second best selling drug bring sale almost lawmaker point sovereign status native american tribe make patent challenge lengthy complex tribe be immune legal claim make generic drug maker challenge patent fact tribe be filing dismiss ongoing parte review ipr restasis patent base sovereign immunity ipr challenge deal tribe have basically raise concern curb generic competition pharmaceutical industry discourage generic drugmaker make cheaper copy cat version expensive drug allergan have be ask committee oversight government reform provide certain document information deal oct merck not file anacetrapib merck have decide not seek regulatory approval investigational cetp inhibitor anacetrapib company decision be base thorough review clinical profile drug note merck be not first company drop cetp inhibitor plan company lilly roche pfizer have have high profile setback cetp inhibitor class be more less written read more merck not seek approval cetp inhibitor anacetrapib crl acelrx acelrx pharmaceutical acrx free report share plunge company get complete response letter crl fda sufentanil sublingual tablet fda say approve regulatory application current form have ask additional safety datum agency have also ask company make certain change direction use ensure proper administration tablet acelrx have be ask validate same human factor study acelrx be look get approve reduction moderate severe acute pain dose error associate iv administration invasive single dose applicator sda medically supervised setting cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index gain week major stock be lilly decline last month bristol myer squibb bmy free report be see last pharma stock roundup here mylan teva copaxone news lawmaker question allergan deal next pharma world aerie pharmaceutical aeri free report rhopressa be evaluate fda advisory panel treatment patient open angle glaucoma ocular hypertension october company share be favorable briefing document be report earning october read more kickstart pharma earning store stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
2411,MRK,total earning total healthcare market capitalization be revenue growth earning growth be weak compare many other sector earning revenue beat ratio respectively be particularly encourage fact healthcare be fourth sector surprised investor most earning trail aerospace technology material most notable player johnson johnson jnj free report be first major drug company report earning july follow eli lilly company lly free report bristol myer squibb company bmy free report july july respectively other major drug company merck mrk free report pfizer pfe free report report july august respectively industry prime post solid result earning beat few lag revenue front johnson johnson earning world biggest maker healthcare product continue long streak earning beat narrowly miss top line estimate earning share come cent ahead zack consensus estimate higher year quarter revenue grow year year fall shy zack consensus estimate johnson johnson raise full year earning share guidance revenue guidance zack consensus estimate be peg earning share revenue time earning release jnj have gain date earning announcement read brighten outlook healthcare etfs focus pfizer earning drug giant beat earning miss revenue earning share cent come couple cent zack consensus estimate revenue fall shy estimate annual basis earning share rise revenue decline pfizer expect revenue range raise lower end earning share guidance zack consensus estimate be correctly peg revenue earning share share pfe be earning announcement merck earning focusearning share come surpass zack consensus estimate cent improve year quarter revenue inched year year be zack consensus estimate merck raise revenue guidance reiterate earning share projection year zack consensus estimate be currently peg revenue earning share stock have lose follow earning announcement bristol myer earning focusbristol myer report earning share cent penny ahead estimate increase year quarter revenue grow edge past zack consensus estimate company raise low end earning share guidance year zack consensus estimate time earning announcement be peg share bmy be date earning announcement see healthcare etfs here eli lilly earning focusearning eli lilly outpaced zack consensus estimate cent come higher year quarter revenue grow beat estimate other drug maker eli lilly also raise revenue earning guidance now expect revenue range compare previous expectation earning share range versus expect previously zack consensus estimate time earning release be peg revenue earning share share lly have lose earning release etf string earning beat fail boost pharma etfs see rough trading past day have highlighted detail powershare dynamic pharmaceutical fund pjp be far most popular choice pharma space follow dynamic pharmaceutical intellidex index product have aum see moderate volume share day fund charge bps fee expense hold stock fund invest share focus firm etf have lose past day have zack etf rank hold rating high risk outlook read lie ahead pharma etfs second half ishare pharmaceutical etf ihe free report etf provide exposure pharma stock tracking dow jone select pharmaceutical index focus firm be top hold basket accounting combine total asset suggest heavy concentration product have aum charge bps fee expense volume be light exchange share day fund have shed past day have zack etf rank buy rating high risk outlook spdr pharmaceutical etf xph free report fund provide exposure pharma company tracking pharmaceutical select industry index aum trade good volume share day charge bps fee year total product hold security focus firm take share product be same period have zack etf rank high risk outlook vaneck vector pharmaceutical etf etf follow mvis list pharmaceutical index hold stock basket johnson johnson take top spot basket asset pfizer bristol myer merck eli lilly collectively account asset product have amassed asset base trade moderate volume share day expense ratio come fund have lose past day have zack etf rank medium risk outlook read etfs buy avoid healthcare bill failure want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2412,MRK,exelixis inc exel free report report impressive result second quarter back increase cabometyx sale company post second quarter earning cent beating zack consensus estimate cent notably company have report loss cent share year quarter exelixis inc price ep surprise exelixis inc price ep surprise exelixis inc quotenet revenue come significantly year quarter revenue also surpass zack consensus estimate revenue be boost fda approval tablet formulation cabozantinib distinct capsule form brand name cabometyx apr treatment advanced renal cell carcinoma rcc patient have receive prior angiogenic therapy exelixis share price have increase year date compare industry gain quarter detailtotal product revenue be year quarter cabometyx generate net product revenue sequentially drive growth demand be attributable new patient start refill patient already therapy continue expansion prescriber base cometriq cabozantinib capsule treatment medullary thyroid cancer generate net product revenue total collaboration revenue be compare year quarter report quarter research development expense decline primarily result increase clinical trial cost cost related cabosun start cost associate checkmate phase ib trial cabozantinib tecentriq locally advanced metastatic solid tumor be partially offset decrease cost related meteor personnel expense selling general administrative expense be drive increase headcount connect build support commercial organization increase legal cost increase consult outside service support marketing activity pipeline company continue focus cabometyx exelixis plan file supplemental new drug application snda cabozantinib treatment previously untreated patient advanced rcc third quarter base positive datum randomize phase ii trial cabosun independent radiology review committee have confirm primary efficacy endpoint result investigator assessed progression free survival pfs cabosun trial analysis committee cabometyx demonstrated clinically meaningful statistically significant reduction rate disease progression death measure pfs first quarter exelixis inked agreement bristol myer squibb company bmy free report roche hold ag rhhby free report collaborate development cabozantinib combination immunotherapy agent exelixis bristol myer initiate phase iii trial checkmate jul exelixis have also initiate dose escalation stage phase ib trial cabozantinib combination tecentriq drug be evaluate patient suffering locally advanced metastatic urothelial carcinoma uc rcc mar fda grant cabozantinib orphan drug designation treatment hcc phase iii trial celestial be currently ongoing patient advanced hcc company now expect complete second intermin analysis event second half meanwhile exelixis roche have agree revise revenue cost sharing arrangement other drug former portfolio cotellic roche also announce imspire trilogy evaluate combination cotellic tecentriq xelboraf first line braf mutation positive metastatic unresectable locally advanced melanoma enrolled first patient jan imspire trial evaluate combination cotellic tecentriq versus merck co inc mrk free report keytruda first line braf wild type metastatic unresectable locally advanced melanoma be likely enroll first patient third quarter year expect total cost operate expense range guidance include cash cost expense related primarily stock base compensation expense expense be project increase second half due initiation combination study takeexelixis second quarter result be impressive earning sale beat estimate sequential increase cabometyx sale be positive company thereby underlie increase demand drug go forward expect investor further label expansion cabozantinib cotellic potential label expansion first line rcc significantly boost growth prospect zack rank key pickexelixis currently carry zack rank buy see complete list today zack strong buy rank stock here more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2413,MRK,aduro biotech inc adro free report report second quarter loss cent share narrower zack consensus estimate loss cent however company report earning cent share year quarterly revenue plunge year year top line deterioration be mainly due recognition milestone payment second quarter pursuant agreement novartis nvs free report development adu combination pd checkpoint inhibitor however decrease be partially offset recognition milestone payment collaboration merck co mrk free report view investigate crs combine merck pd therapy keytruda treat gastric cancer revenue surpass zack consensus estimate aduro share have outperformed industry so far year share company have rally industry have register increase research development expense show substantial decline quarter mainly due decrease expense related manufacturing gvax pancreas pancreatic cancer clinical study expense incur second quarter general administrative expense be year year due lower consult professional fee pipeline updateaduro have broad pipeline novel immunotherapy development treatment variety cancer most advanced program ladd platform be combination crs aduro ladd live attenuate double delete base immunotherapy gvax pancreas bristol myer squibb company bmy free report opdivo pd checkpoint inhibitor be currently evaluation phase ii stellar study patient metastatic pancreatic cancer aduro have also complete enrollment initial cohort phase ib study evaluate combination crs standard care chemotherapy patient unresectable malignant pleural mesothelioma jun aduro biotech announce initiation phase ii study evaluate combination therapy crs merck keytruda treat patient previously nurse malignant pleural mesothelioma mpm same month aduro announce fda have clear investigational new drug application ind adu miw combine novartis investigational pd checkpoint inhibitor pdr candidate be develop treat advanced metastatic solid tumor lymphomas aduro biotech inc price consensus ep surpriseaduro biotech inc price consensus ep surprise aduro biotech inc quotezack rankaduro currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2414,MRK,immunogen inc imgn free report report loss cent share third quarter wider zack consensus estimate loss cent company report year loss cent exclude restructure charge be important note effective jan immunogen have transition fiscal year end dec share immunogen have gain more nov company raise cash guidance full year stock have significantly outperformed industry year date company share have soar industry have increase immunogen have approve product portfolio yet company earn revenue royalty license milestone payment well research development support fee paid partner company report revenue significantly miss zack consensus estimate quarter however top line increase compare year figure upside be mainly drive substantially higher clinical material revenue compare year research development expense decrease year level downside be primarily due workforce reduction lower third party cost selling general administrative sg expense decline due decrease personnel expense third quarter immunogen cash cash equivalent end sep be compare dec company expect use current cash estimate cash amount fund operation fourth quarter pipeline updateimmunogen be progress well pipeline product mirvetuximab soravtansine candidate be currently phase iii study forward single agent therapy treat patient platinum resistant ovarian cancer tumor express high medium level fr alpha notably combination regimen mirvetuximab soravtansine ovarian cancer be phase ib ii forward ii study trial consist cohort assess mirvetuximab soravtansine combination roche rhhby free report avastin merck mrk free report keytruda immunogen report initial datum forward ii study demonstrate candidate have potential complement currently available therapy indication apart mirvetuximab soravtansine immunogen be work develop couple other candidate include imgn imgn notably imgn be be evaluate phase study treat acute myeloid leukemia aml datum expect later year other hand company plan move imgn clinical development year end treat hematological malignancy include aml company maintain revenue guidance range however have significantly raise cash guidance due execution agreement jazz third quarter development early stage antibody drug conjugate adc imgn imgn company now expect cash cash equivalent range compare expect previously operate expense be now expect range compare expect previously immunogen inc price consensus ep surprise immunogen inc price consensus ep surprise immunogen inc quotezack rank other key pickimmunogen currently carry zack rank buy top rank stock health care sector be ligand pharmaceutical inc lgnd free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have surge year date wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2415,MRK,biolinerx ltd blrx free report announce encourage partial result monotherapy portion phase iia combat study evaluate lead pipeline candidate bl cxcr antagonist treatment patient pancreatic cancer share biolinerx have outperformed industry year time stock have rally better industry increase monotherapy portion open label multicenter single arm combat study be design evaluate multiple pharmacodynamic parameter bl difficult treat patient population partial datum study show bl monotherapy be safe well tolerate patient give indication additionally result show increase number cell know attack tumor cancer cell patient metastatic pancreatic cancer only day monotherapy bl company say outcome trial be present jan asco american society clinical oncology cancer symposium san francisco notably bl be also be evaluate combination merck mrk free report pd therapy keytruda combat study treatment patient pancreatic cancer notably program be conduct biolinerx collaboration sign merck early apart merck biolinerx have collaboration agreement roche hold rhhby free report genentech evaluation bl combination latter tecentriq atezolizumab multiple solid tumor indication remind investor october biolinerx roche have initiate phase ib ii study evaluate bl combination roche tecentriq treat patient gastric cancer datum provide american cancer society approximately patient be diagnosed pancreatic cancer unite state disease various type be seventh most common cause cancer death accounting cancer further indicate huge market potential combination therapy biolinerx ltd price biolinerx ltd price biolinerx ltd quote zack rank key pickbiolinerx carry zack rank sell better rank stock health care sector be exelixis inc exel free report carry zack rank buy see complete list today zack rank strong buy stock here exelixis earning share estimate have be revise upward cent cent last day company deliver positive earning surprise trail quarters average beat share price company have soar year time zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2416,MRK,johnson johnson jnj free report healthcare bellwether report fourth quarter result jan open bell last quarter company report positive earning surprise share have gain past year outperform increase witness industry belong earning beat expectation last quarters average positive surprise let see thing be shape announcement factor considerwe believe strong performance pharmaceutical segment well positive contribution acquisition actelion abbott medical optic pull top line fourth quarter however higher investment product launch put pressure profit third quarter domestic pharma segment sale decelerate first half however sale growth accelerate third quarter be likely see continuation positive trend fourth quarter probably believe new product segment label expansion drug imbruvica xarelto darzalex meaningful contribution swiss biotech actelion buy june support top line however biosimilar competition be expect hurt sale key arthritis drug remicade outside unite state new drug be approve last year include tremfya guselkumab unite state july well eu november plaque psoriasis first dual treatment hiv juluca dolutegravir rilpivirine partnership glaxosmithkline gsk free report unite state november juluca be review eu regard tremfya say third quarter conference call have be well receive physician patient drug be likely contribute sale soon be report quarter expect update plan juluca fourth quarter conference call medical device segment sale continue gain mainly inclusion abbott medical optic acquisition diabetes care unit be however expect remain weak hurricane texas florida puerto rico hurt sale growth last report quarter due lose surgery day third quarter call company have say supply disruption be not anticipate be not clear time surgical procedure miss third quarter be re-cover fourth pricing issue india system outage europe also hurt sale extent remain be see issue be resolve time consumer segment global consumer category slowdown many company market continue hurt sale however recent acquisition well new product be likely provide support model proven model do not conclusively show be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be uncover best stock buy sell re report earning esp filter zack rank zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considera couple stock large cap pharma sector have positive earning esp favorable zack rank be merck co inc mrk free report earning esp zack rank company be schedule release result feb pfizer inc pfe free report be schedule release result jan company have earning esp zack rank see complete list today zack rank stock here johnson johnson price ep surprise johnson johnson price ep surprise johnson johnson quotezack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2417,MRK,merck mrk free report share gain more jan company announce pd therapy keytruda combination eli lilly lly free report alimta pemetrexed carboplatin pem carbo meet dual primary endpoint confirmatory phase iii keynote study combination be evaluate first line treatment patient metastatic squamous small cell lung cancer nsclc notably combination therapy be grant accelerate approval fda aforementioned indication hence positive readout phase iii confirmatory study help company gain continue approval combo therapy remind investor third quarter company mentioned be include overall survival os co primary endpoint keynote study keytruda first line nsclc defer readout study therefore datum now release come much earlier investor expectation be big boost company merck share have inched year time compare unfavorably rally industry study be design evaluate combination therapy compare chemotherapy alone study meet primary endpoint progression free survival pfs os co primary endpoint datum study demonstrated significant improvement os pfs nsclc patient receive keytruda combo therapy compare receive chemotherapy alone be base interim analysis conduct independent datum monitoring committee be important note keytruda be first pd inhibitor combination show os patient nsclc company say datum trial be present upcoming medical meeting submit regulatory authority significantly october last year merck also announce have withdraw european regulatory application seek approval combination keytruda alimta carboplatin nsclc application be base positive datum cohort keynote trial however new positive readout possibility drug get nod eu increase note roche rhhby free report recently present datum tecentriq novel combination broad range tumor include lung cancer remind investor keytruda be first pd therapy gain fda approval be be study more type cancer study include combination trial keytruda fetch global sale first month year year merck company inc price merck company inc price merck company inc quote zack rank key pickmerck carry zack rank hold better rank stock health care sector be exelixis inc exel free report sporting zack rank strong buy see complete list today zack rank stock here exelixis earning share estimate have be revise upward cent cent last day company pull positive earning surprise trail quarters average beat share price company have surge year time more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2418,MRK,merck co inc mrk free report be big mover last session company see share rise nearly day move come solid volume too far more share change hand normal session stock picked sharply flat trend past month time frame move come company announce positive result phase study lung cancer drug company have see estimate revision past few week zack consensus estimate current quarter remain unchanged recent price action be encourage so make sure keep close watch firm future merck currently have zack rank hold earning esp be positive merck company inc price merck company inc price merck company inc quotea better rank stock large cap pharmaceutical industry be bayer ag bayry free report currently carry zack rank buy see complete list today zack rank strong buy stock here be mrk go predict see other think stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2419,MRK,merck co inc mrk free report announce be not go ahead filing regulatory application seek approval anacetrapib cholesteryl ester transfer protein cetp inhibitor have develop cholesterol management stock be more wednesday merck share have rise year so far compare increase industry detailed datum large phase iii cardiovascular outcome study reveal announce august show anacetrapib statin reduce risk major coronary event composite coronary death myocardial infarction coronary relative placebo patient atherosclerotic vascular disease be already receive effective cholesterol treatment anacetrapib reduce risk same be patient placebo statin however significant benefit be observed reduce risk ischemic stroke top line datum study be announce june company say study have meet primary endpoint be also say anacetrapib safety profile be line observed previous study most significant side effect be accumulation anacetrapib fat tissue year take drug merck have clearly say then be not sure datum be strong enough seek approval merck say consider file regulatory application fda other agency review result external expert be apprehend investor accumulation anacetrapib fat tissue get way regulatory approval follow thorough evaluation datum discussion external expert merck decide not seek approval anacetrapib clinical profile do not support regulatory filing remind investor previous experimental cetp inhibitor have fail respective study cetp inhibitor be design raise hdl cholesterol level be know good cholesterol eli lilly lly free report terminate development late stage cetp inhibitor evacetrapib base recommendation independent datum monitoring committee suggest chance meeting primary endpoint be low back pfizer pfe free report suspend late stage development cetp inhibitor torceptrapib due safety issue roche rhhby free report discontinue development cetp inhibitor dalcetrapib due lack efficacy merck carry zack rank sell see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2420,MRK,seattle genetic inc sgen free report announce clinical collaboration evaluate sgn liv triple negative breast cancer tnbc sgn liv be antibody drug conjugate adc be develop treatment metastatic breast cancer patient tumor express liv protein seattle genetic share have outperformed industry year date stock have be industry gain company test sgn liv combination merck co mrk free report keytruda phase ib ii study first line treatment locally advanced metastatic tnbc study be expect enroll patient agreement seattle genetic retain global development right sgn liv hold investigational new drug ind study additionally sgn liv be evaluate combination standard chemotherapy neoadjuvant treatment phase ii spy study newly diagnosed stage human epidermal growth factor receptor negative breast cancer study be sponsored quantum leap health care collaborative quantum leap be expect enroll patient sgn liv treatment arm fact study be design way so screen potential treatment specific patient subgroup base molecular characteristic furthermore clinical study be plan sgn liv breast cancer focus tnbc apart sgn liv monotherapy be be evaluate ongoing phase trial patient metastatic breast cancer include patient heavily pre treat tnbc fact breast cancer be most common form cancer woman tnbc also be very aggressive form associate poor patient outcome therefore lot company be develop product space last month infinity pharmaceutical inc infi free report expand exist clinical collaboration bristol myer squibb bmy free report evaluate ipi combination latter checkpoint inhibitor opdivo collaboration include patient tnbc have not be previously expose pd pd therapy notably very few patient triple negative breast cancer respond checkpoint inhibitor alone so be left very limit therapeutic option turn expand collaboration include patient tnbc have not be previously expose pd pd therapy turn enable infinity test ipi combination opdivo increase number patient respond checkpoint inhibition seattle genetic inc price seattle genetic inc price seattle genetic inc quotezack rankseattle genetic carry zack rank buy see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2421,MRK,series setback continue eli lilly company lly free report company announce phase iii juniper study fail meet primary endpoint study be evaluate verzenio advanced small lung cancer nsclc kra mutation share fall tuesday announcement verzenio receive approval treat metastatic breast cancer last month patient disease progressed platinum base chemotherapy lilly share be so far year slightly underperform industry gain period juniper study compare verzenio roche astella pharma tarceva stage iv lung cancer patient have progressed platinum base chemotherapy have receive additional systemic therapy study do not meet primary endpoint overall survival however show improvement secondary endpoint progression free survival patient overall response rate successful completion study have give verzenio edge pfizer inc pfe free report ibrance novartis ag nvs free report kisqali be only approve breast cancer lilly be currently evaluate verzenio multiple study nsclc include combination therapy merck mrk free report keytruda pd therapy remind investor lilly face major setback past year include complete response letter fda rheumatoid arthritis candidate baricitinib april fail study alzheimer candidate solanezumab november last year meanwhile lilly be also face generic competition due loss exclusivity several key drug include zyprexa cymbalta moreover alimta be face competition immuno oncology agent unite state give recent setback generic competition absence drug near approval lilly struggle maintain growth pace have show so far year eli lilly company price consensus eli lilly company price consensus eli lilly company quotelilly carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2422,MRK,seattle genetic inc sgen free report astella pharma inc announce initiation phase ii study ev enfortumab vedotin study evaluate patient locally advanced metastatic urothelial cancer have be previously treat checkpoint inhibitor cpi therapy enfortumab vedotin be investigational antibody drug conjugate adc target nectin cell adhesion molecule be expressed many solid tumor seattle genetic share have underperform industry year date stock have surge compare industry gain study evaluate antitumor activity safety enfortumab vedotin order get approval fda study enroll patient enfortumab vedotin be administer week duration treatment primary endpoint study be confirm objective response rate orr independent review secondary endpoint include assessment overall survival progression free survival safety tolerability company move ahead ev study base result ongoing phase study ongoing phase study be assess safety tumor activity enfortumab vedotin escalate dose milligram kilogram mg kg weekly week cycle company june announce update datum patient be diagnosed muc median age year patient be previously treat checkpoint inhibitor cpis have undergo treatment platinum base chemotherapy result show positive antitumor activity well tolerate safety profile patient heavily pretreat metastatic urothelial cancer treatment option metastatic urothelial cancer be limit patient do not respond chemotherapy checkpoint inhibitor be therapy approve fda patient progress follow cpi treatment thus see be number company evaluate candidate treatment locally advanced metastatic urothelial cancer last month merck co inc mrk free report announce pd therapy keytruda receive approval european commission ec first second line treatment certain patient locally advanced metastatic urothelial carcinoma type bladder cancer keytruda have be approve first line therapy patient receive standard care chemotherapy contain cisplatin keytruda be also approve second line treatment patient have be previously treat platinum contain chemotherapy eli lilly company lly free report also announce positive result phase iii study range evaluate oncology drug cyramza ramucirumab expand use combination docetaxel patient locally advanced unresectable metastatic urothelial carcinoma study meet primary end point demonstrated improve progression free survival pfs patient give indication seattle genetic inc price seattle genetic inc price seattle genetic inc quotezack rank stock seattle genetic carry zack rank buy top rank stock health care sector include bayer bayry free report see complete list today zack rank strong buy stock here bayer earning share estimate have moved last day company pull positive earning surprise trail quarters average beat be share price company have increase year date wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2423,MRK,share barracuda network inc gain post second quarter revenue surpass zack consensus estimate millionmerck co inc mrk free report share gain company purchase stake kalvista pharmaceutical inc kalv free report price shareanaptysbio inc anab free report share rally company announce positive result proof concept datum phase trial drug anb used treatment atopic dermatitisshare hudson technology inc hdsn free report decline company lower third quarter earning guidance share share earlier
2424,MRK,pharma biotech stock start strong note part market remain favor year progress so far year nasdaq biotechnology index nyse arca pharmaceutical index be respectively investor be more comfortable drug pricing scenario focus have shift fundamental sector drug pricing issue remain headwind expectation be step take trump administration drive drug price not be draconian previously expect deregulation increase competition seem be way be used control drug price fda be work lower healthcare cost speeding development next generation treatment especially rare disease target cancer therapy be also work clear backlog orphan drug application fda have approve far more drug year do whole key approval year include novartis nvs free report kymriah first gene therapy unite state lilly verzenio advanced metastatic breast cancer gilead gild free report vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other quite few drug have blockbuster potential meanwhile other factor continue have positive impact pharma biotech stock be new product sale ramp success innovation strong result higher number fda approval continue strong performance legacy product accord zack earning trend report medical sector have be better perform sector last several quarters be expect record earning growth revenue growth third quarter give scenario medical sector earning round corner make sense look pharma biotech stock be expect report positive earning surprise quarter investing such stock prove beneficial investor earning beat usually lead significant share price appreciation drug stock keep eye earning help zack stock screener have zero pharma biotech stock sport zack rank strong buy buy hold have positive earning esp earning esp be very valuable tool investor look stock be most likely beat earning estimate moreover add zack rank have produce positive surprise time see complete list today zack rank stock here uncover best stock buy sell re report earning esp filter pfizer inc pfe free report pfizer be focuse development wide range medicine vaccine well consumer health care product company have surpass earning expectation first quarters key revenue driver include ibrance eliquis xeljanz pfizer expect revenue be affected due loss exclusivity loe be work bring new product market make lose sale company have potential blockbuster line next year half potentially focus also remain grow new product ibrance eliquis xeljanz meanwhile impact loe continue decline come year well less pfizer zack rank stock carry vgm score vgm score be useful tool allow investor gain insight stock strength weakness research show stock vgm score combine zack rank offer best upside potential company be report third quarter result october have earning esp eli lilly company lly free report lilly have strong presence pharmaceutical well animal health segment be slate report third quarter result october zack rank stock have earning esp third quarter lilly surpass earning expectation first quarters company be face challenge include generic competition new product drive result lilly have several important pipeline catalyst line come quarters well estimate earning growth current year be lilly have gain year date compare rally industry belong vertex pharmaceutical vrtx free report vertex key player cystic fibrosis cf market surpass earning expectation last quarters average surprise company hold strong position cf market product orkambi kalydeco portfolio early august vertex have say expect cf franchise deliver revenue include orkambi revenue company be work expand cf portfolio be currently seek fda ema approval tezacaftor ivacaftor combination fda grant priority review response be feb vertex zack rank stock have gain year date substantially outperform rally industry belong company be expect report third quarter result october have earning esp quarter biogen inc biib free report biogen be key name multiple sclerosis ms market several approve product tecfidera tysabri avonex portfolio company also have spinal muscular atrophy product spinraza portfolio be work develop treatment disease alzheimer parkinson amyotrophic lateral sclerosis biogen earning track record be good company surpass earning expectation last quarters average surprise company be schedule report third quarter result october have earning esp last day stock have see zack consensus estimate third quarter current year earning be revise respectively biogen zack rank stock have gain year date outperform rally industry belong merck mrk free report merck zack rank stock have consistently surpass earning expectation last quarters average surprise company be report earning october earning esp be company do have challenge form generic competition well safety issue related study be conduct keytruda new product keytruda strong performance base business provide support merck also have deep pipeline bode well long term growth today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2425,MRK,hepatitis be infectious disease cause hepatitis virus hcv primarily affect liver gilead science inc gild free report market blockbuster hcv drug sovaldi harvoni other well know name market be abbvie inc abbv free report viekira pak bristol myer bmy free report daklinza johnson johnson jnj free report olysio accord center disease control prevention cdc person unite state be live chronic hepatitis infection many remain unaware be infected be new hepatitis case year unite state many go unreported consider number be not surprise quite few pharma biotech company be work bring new improve shorter duration hcv treatment market market be thus get crowd see increase pricing pressure lot have happened hcv space late september gilead science sovaldi receive approval china component combination antiviral treatment regimen be first gilead hcv drug be approve china meanwhile gilead single tablet regimen str sovaldi velpatasvir voxilaprevir vosevi receive approval unite state eu canada july august vosevi become first once daily str available salvage therapy patient infected hcv genotype have fail prior treatment daa regimen include ns inhibitor gilead share have outperformed industry year date stock have rally compare industry gain same time frame stock carry zack rank hold see complete list today zack rank strong buy stock here meanwhile abbvie week pan genotypic ribavirin free once daily hcv treatment mavyret maviret gain approval unite state eu canada past couple month mavyret abbvie next generation hcv program be combination glecaprevir potent protease inhibitor pibrentasvir ns inhibitor maviret have potential rejuvenate growth hcv franchise accord abbvie mavyret be used hcv patient depend stage liver disease prior treatment history abbvie share have outperformed industry year date stock have rally compare industry gain same time frame stock carry zack rank however last week pharmaceutical giant merck mrk free report announce be discontinue further development next generation hepatitis hcv program mk grazoprevir ruzasvir uprifosbuvir mk ruzasvir uprifosbuvir company make decision base review available phase ii efficacy datum heavily crowd hcv market merck share have underperform industry year date stock have gain compare industry gain same time frame stock carry zack rank merck giant johnson johnson also discontinue development investigational hcv treatment regimen jnj combination direct act antiviral al odalasvir simeprevir company take decision consider be several highly effective therapy available indication johnson johnson share have underperform industry year date stock have gain compare industry gain same time frame stock carry zack rank be believe discontinuation merck combination hcv regimen act favor gilead abbvie gilead abbvie benefit lack additional competition enter market least term however company continue face challenge form decline patient volume intense pricing pressure lack additional entrant market also slow rate decline sale do zack investment idea come be welcome download full minute list zack rank strong buy stock free charge be better place start own stock search access full list avoid zack rank strong sell other private research see stock free
2426,MRK,pharmaceutical sector have be grab investor attention late nyse arca pharmaceutical index gain large cap pharmaceutical industry year date outpace gain new drug approval tax reform be expect provide further impetus stock however factor drug pricing competition biosimilar continue act major deterrent other hand company eli lilly company lly free report be resort workforce reduction leaner cost structure front apart johnson johnson jnj free report acquisition actelion ltd june nothing much have happened space merck co mrk free report recently announce acquire germany base rigontec privately hold immuno oncology focuse biotech boost immune oncology pipeline nevertheless propose tax reform be expect boost cash balance company turn be used merger acquisition here have picked largest drug company look well poise growth be prudent choice add portfolio base switzerland novartis ag nvs free report be leader health care solution wide array drug service novartis have presence field oncology neuroscience ophthalmology generic novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu improve formulation exjade recent fda approval kisqali advanced metastatic breast cancer breakthrough gene transfer treatment kymriah suspension acute lymphoblastic leukemia have further boost portfolio approval be major boost novartis give potential car therapy space growth driver cosentyx entresto more offset impact generic erosion mainly due glivec cosentyx achieve blockbuster status believe approval new drug label expansion exist one boost top line go forward novartis currently carry zack rank buy see complete list today zack rank strong buy stock here novartis stock have gain year date strength oncology drug approval first car therapy continue boost performance pfizer inc pfe free report lead pharmaceutical company unite state focus development wide range product include human animal biologic well small molecule medicine vaccine consumer health care product pfizer be look drive growth licensing deal collaborative agreement company be look expand label approve drug ibrance xeljanz xalkori eliquis pfizer also boast strong pipeline moreover pfizer be evaluate various biosimilar molecule several stage development give potential market share company have moved last month compare favorably industry gain pfizer presently carry zack rank earning estimate company have be static past day bagsvrd denmark base nordisk nvo free report be global leader diabetes market company be also key player hemophilia care growth hormone therapy hormone replacement therapy obesity company portfolio include drug levemir novorapid victoza novomix novomix novomix novoseven norditropin additionally obesity drug saxenda liraglutide mg be launch unite state uptake have be encourage victoza be currently market leader glp segment expect victoza continue be significant contributor company top line august fda approve new indication victoza reduce risk major adverse cardiovascular cv event adult type ii diabetes establish cv disease believe label expansion drug further boost top line company currently carry zack rank company share have rally year date company earning estimate have moved last day headquarter leverkusen germany bayer ag bayry free report be life science company core competency area health care agriculture bayer have be consistently make effort transform pure life science company drug launch last few quarters be expect continue drive top line bayer be look label expansion oncology drug stivarga be approve treatment metastatic colorectal cancer metastatic stromal tumor company have inked several strategic deal undertake meaningful acquisition recent past bayer be look acquire cash transaction combine business be expect boost bayer crop science business provide accretion bottom line bayer currently carry zack rank buy company share have gain year date earning estimate company have moved north last day bottom line challenge form pricing pressure competition remain healthcare sector nevertheless pick outperformer space backed solid zack rank positive price movement lead investor gain earning season stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
2427,MRK,merck mrk free report unitedhealth unh free report coca cola ko free report help lift dow jone industrial average tuesday mark fastest climb point barrier index year history gain ibm ibm free report goldman sachs gs free report also help dow surge tuesday morning index end close threshold early gain sunk red afternoon dow close day still small downturn tuesday have already be strong year index broader market take dow only day trading soar year date dow have climb fact dow gain point last week mark second week row gain more point last time dow experience run be march last week dow have sky-rocket more now question have start fly massive bull market end point length current bull market sign enough bear day be horizon other side thing person point strength technology firm such amazon amzn apple appl ability make more profit reason be optimistic run continue couple recent gop tax overhaul see corporate tax rate fall investor hope bull market still have leg today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2428,MRK,immune design corp imdz free report incur second quarter loss cent share narrower zack consensus estimate loss cent also year loss cent immune design share price have increase year date compare zack classify industry gain quarter detailimmune design total revenue second quarter be year quarter revenue be primarily due collaboration revenue receive partner sanofi sny free report hsv therapeutic vaccine quarterly revenue be zack consensus estimate research development expense be quarter decrease be due timing difference manufacturing activity be offset increase clinical cost attributable continue advancement immune design phase phase ii study increase personnel related expense be need support company pipeline general administrative expense also decrease pipeline updateimmune design be develop multiple candidate used discovery platform zvex glaas field immuno oncology key pipeline candidate include cmb presently cmb be be evaluate soft tissue sarcoma st patient monotherapy combination pd antibody company present cmb monotherapy datum pat asco st patient recurrent disease datum show observed median overall survival mo have not yet be reach patient overall survival rate month respectively sep company present early datum phase ii study compare cmb roche hold ag rhhby free report tecentriq tecentriq alone furthermore be develop glaas platform be be evaluate ongoing phase dose escalation randomize phase ii study patient low grade follicular hodgkin lymphoma nhl datum phase dose escalation monotherapy study present asco demonstrated disease control rate dcr third patient achieve partial response pr used criterium least tumor reduction prs dose level test evaluable patient experience shrinkage untreated distal abscopal lesion association presence cell infiltrate notably immune design complete patient enrolment phase ii study compare low dose radiation xrt versus xrt systemic administration merck co inc mrk free report pd agent keytruda company intend submit datum patient randomize phase ii study compare xrt versus xrt pembrolizumab dec furthermore also plan submit follow datum patient treat monotherapy phase dose escalation portion study outlookimmune design continue anticipate cash fund operation second half immune design corp price consensus ep surprise immune design corp price consensus ep surprise immune design corp quotezack rankimmune design currently hold zack rank buy see complete list today zack rank strong buy stock here more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2429,MRK,share incyte corporation incy free report be company report loss second quarter incyte report loss cent penny wider zack consensus estimate loss cent incyte have report earning cent share year quarter quarterly revenue be year year beat zack consensus estimate top line be drive higher sale jakafi iclusig europe well royalty ex sale jakavi olumiant incyte share have moved year so far compare industry gain quarter detailjakafi sale grow year year net product revenue iclusig amount product royalty revenue novartis ag nvs free report jakafi ex market grow research development expense be year quarter increase be primarily due expansion portfolio well upfront milestone expense related collaboration license agreement selling general administration sg expense amount year year outlook company now expect jakafi revenue range iclusig revenue be expect range expense be now expect range earlier forecast due acceleration phase iii plan epacadostat sg expense be still expect range incyte corporation price consensus ep surprise incyte corporation price consensus ep surprise incyte corporation quotepipeline updatea phase iii trial reach evaluate jakafi treatment patient steroid refractory chronic graft versus host disease gvhd be expect be initiate jun pivotal program reset evaluate jakafi versus anagrelide patient essential thrombocythemia be now open enrolment first patient be dose come week phase iii trial gravita itacitinib patient treatment nave acute gvhd be initiate july earlier incyte extend collaboration merck co inc mrk free report pivotal program study epacadostat combination keytruda total tumor type incyte merck advance additional tumor type melanoma small cell lung cancer bladder renal head neck cancer phase iii trial trial be expect begin additionally incyte extend collaboration bristol myer squibb company bmy free report evaluate epacadostat combination opdivo pivotal study tumor type plan initiation end european commission approve olumiant feb treatment moderate severe active rheumatoid arthritis adult patient have respond inadequately be intolerant more disease modify rheumatic drug drug be approve japan too however company suffer setback fda issue complete response letter olumiant fda indicated additional clinical datum be need determine most appropriate dose fda further state additional datum be necessary further characterize safety concern treatment arm jul lilly incyte announce resubmission new drug application nda olumiant be delay period anticipate be minimum month company be further evaluate future plan agency analyse option resubmission include potential additional clinical study request fda takeincyte report wider expect loss second quarter nevertheless revenue beat be impressive jakafi sale be drive patient demand be expect boost revenue increase sale guidance be also encourage most demand be due larger establish patient base myelofibrosis be also expect be major long term driver jakafi growth be owing larger potential patient population possibility longer duration treatment jakafi be include recommend treatment patient myelofibrosis patient latest national comprehensive cancer network nccn clinical practice guideline oncology neoplasms mpns jul be likely boost demand further however delay nda submission olumiant be disappointing zack rankincyte currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2430,MRK,pfizer inc pfe free report report second quarter adjust earning share cent beat zack consensus estimate cent earning also rise year year other hand revenue miss expectation pharma heavyweight deliver revenue fall short zack consensus estimate again revenue decline year period due currency headwind divestiture hospira infusion system business feb pfizer divest hospira infusion system business icu medical sale detailcurrency movement impact pfizer second quarter revenue sale growth be flat operational basis exclude revenue sale rise operational basis lower sale enbrel prevnar prevenar vaccine franchise loss exclusivity product offset strong performance key product ibrance breast cancer xtandi prostate cancer xeljanz rheumatoid arthritis international revenue decline flat operational basis meanwhile revenue be flat segment second quarter pfizer reorganize report segment pfizer innovative health ih pfizer essential health pfizer ih sale grow operationally year period pfizer ih revenue be drive persistently strong momentum ibrance eliquis globally growth lyrica xeljanz primarily ibrance revenue rise quarter xeljanz rise lyrica sale rise eliquis alliance revenue direct sale rise revenue blockbuster prostate cancer drug xtandi add pfizer portfolio follow sep medivation acquisition also propel revenue xtandi record alliance revenue quarter compare first quarter be partially offset continue decline revenue prevnar lower revenue enbrel viagra enbrel revenue decline key european market due biosimilar competition pfizer have exclusive right amgen inc amgn free report blockbuster rheumatoid arthritis ra drug enbrel outside canada viagra sale decline due lower sale international market due reduce demand global prevnar prevenar revenue decline prevnar revenue tank due high initial capture rate eligible adult patient population follow successful launch result smaller remain catch opportunity second quarter compare year quarter unfavorable timing government purchase pediatric indication also hurt sale eucrisa crisaborole topical ointment treatment atopic dermatitis eczema be buy part jun anacor acquisition be launch first quarter ointment record sale second quarter consumer healthcare revenue rise global oncology revenue surge drive ibrance global vaccine revenue decline internal medicine rise inflammation immunology franchise decline additionally portfolio rare disease decline pfizer segment sale record decline operationally exclude revenue sale decline revenue be hurt loss exclusivity associate generic competition product pristiq generic version launch mar vfend zyvox celebrex lyrica lower revenue legacy hospira product divesture however business biosimilar do well quarter pfizer launch inflectra biosimilar version johnson johnson jnj free report merck co inc mrk free report blockbuster ra drug remicade november last year inflectra record sale globally other biosimilar bring sale outside market adjust selling informational administrative si expense be flat operationally quarter adjust expense rise guidance pfizer raise lower end adjust earning guidance retain revenue expectation year revenue be expect range adjust earning share be expect range compare expect previously higher previously anticipate royalty income certain product lower interest cost lead increase lower end profit outlook mid point revenue be expect be slightly level adjust ep be expect increase previously research development expense be still expect range si spending be project range key drug key pipeline candidate bavencio avelumab receive accelerate fda approval metastatic merkel cell carcinoma mcc mar advanced bladder cancer candidate be be study different type cancer include several combination therapy other immuno oncology agent pipeline candidate besponsa inotuzumab ozogamicin be approve eu june monotherapy relapse refractory cd positive cell precursor acute lymphoblastic leukemia candidate be review fda decision expect later month takepfizer second quarter result be mixed beat earning estimate miss same sale share decline slightly pre market trading company continue struggle sale performance pfizer share be so far year compare unfavorably increase industry pfizer continue face headwind form genericization key drug lose alliance revenue pricing pressure rise competition be hurt top line product viagra lyrica chantix lose exclusivity couple year nonetheless believe new product ibrance contribution acquisition cost cut effort share buyback help company achieve guidance pfizer also boast strong pipeline expect approximately drug approval next year include product have blockbuster potential bavencio be be consider key long term growth driver pfizer pfizer carry zack rank hold see complete list today zack rank strong buy stock here pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotewill make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2431,MRK,sanofi sny free report report second quarter earning cent american depositary share be line zack consensus estimate earning rise report basis constant currency rate cer second quarter net sale rise report basis cer almost sale however miss zack consensus estimate sale benefit favorable exchange rate movement jan french drug maker swap merial animal health business boehringer ingelheim consumer healthcare chc business reflect exchange full consolidation sanofi european vaccine operation sale rise constant structure cer sale decline cer strong performance multiple sclerosis drug vaccine not make weak diabetes performance sale rise emerge market europe rest world japan south korea canada australia new puerto rico market growth rate mentioned be year year basis cer segmental sale include emerge market increase drive growth multiple sclerosis consumer healthcare franchise offset decline diabetes generic sale sanofi report global business unit gbus sanofi genzyme specialty care diabetes cardiovascular general medicine emerge market consumer healthcare sanofi pasteur vaccine sanofi genzyme specialty care gbu sale include emerge market increase drive mainly strong uptake multiple sclerosis drug aubagio lemtrada meanwhile sale rare disease drug myozyme lumizyme improve fabrazyme sale be cerdelga sale come however cerezyme sale decline quarter due difficult year comparison oncology sale rise drive mainly higher sale jevtana thymoglobulin jevtana sale be thymoglobulin record sale taxotere sale decline due generic competition japan eloxatin sale be flat sanofi regeneron pharmaceutical inc regn free report rheumatoid arthritis ra drug kevzara sarilumab be launch june approve canada feb eu jun kevzara record sale second quarter meanwhile dupixent launch march treat atopic dermatitis generate sale second quarter management be pleased drug uptake say drug have be prescribe physician dupixent be review eu receive positive recommendation european medicine agency panel earlier month drug generate total immunology sale second quarter diabetes cardiovascular gbu include emerge market decline diabetes franchise include emerge market decline due lower sale key drug lantus sale diabetes drug decline due tough payer environment sale diabetes drug emerge market be europe decline lantus sale decline quarter lantus sale decline due lower average net price cvs unite health formulary exclusion europe sale decline due biosimilar competition patient switch toujeo toujeo generate sale sequentially report quarter management warn diabetes franchise sale decline faster second half due exclusion cvs unite health formulary plan difficult comparison last year soliqua once daily titratable fix ratio combination lantus lyxumia launch jan generate sale second quarter compare previous quarter cardiovascular franchise sanofi pcsk therapy praluent garner worldwide sale report quarter sequentially incidentally amgen inc amgn free report report earlier week also report sequential increase sale pcsk inhibitor repatha uptake drug have not be very encourage so far due pricing re imbursement issue payer restriction general medicine emerge market gbu sale come sale establish product be strong performance emerge market be offset generic competition plavix japan plavix lose exclusivity japan lower sale europe sale generic decline sale decline europe well emerge market consumer healthcare gbu sale be however sale be flat exclude acquisition boehringer ingelheim consumer healthcare business lower sale europe due early cough cold season first quarter be partially offset higher sale drive pain allergy portfolio higher sale emerge market due sale recovery russia second quarter consolidated sanofi pasteur vaccine sale increase due strong performance pediatric combination menactra vaccine sale reflect termination sanofi pasteur msd joint venture merck co inc mrk free report europe dec cost risesel general administrative expense sg increase cer quarter reflect launch cost dupixent kevzara xyzal expense be cer reflect higher pipeline development cost oncology isatixumab pd sotagliflozin outlooksanofi raise previously issue financial outlook sanofi expect business earning be broadly flat cer outlook compare favorably previous expectation flat cer anticipate positive currency impact range business earning takesanofi second quarter result be not great report line earning miss sale expectation slight margin however share rise more pre market trading response raise earning forecast optimism surround dupixent launch fact so far year sanofi share price have rise better increase industry be encourage strong performance ms drug aubagio lemtrada be also optimistic sale prospect dupixent prove be important growth driver company however headwind include bleak outlook diabetes franchise generic competition many drug slower expect uptake new product praluent sanofi currently carry zack rank buy see complete list today zack rank strong buy stock here sanofi price consensus ep surprise sanofi price consensus ep surprise sanofi quotemore stock news company verge apple rundid miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
2432,MRK,like merck mrk free report unitedhealth unh free report have help lift dow new height early gain amazon amzn free report just have signale tech sector be track outstanding year however investor begin review investment landscape much talk social medium firm not be bad place start use importance advertiser be set expand year company stand benefit greater social medium usage be sometimes malign twitter twtr free report recent market research firm emarketer note recent report social medium use be expect climb new height be positive sign twitter use boost daily monthly active user category get year social medium user base be expect hit be just shy entire adult television audience account total population social medium use also reportedly fall just user short total digital video audience twitter have also recently receive few notable upgrade mid december morgan jpm upgrade twitter hold overweight up price target share morgan analyst doug anmuth call social medium company top small mid cap pick believe twtr story financial result strengthen next year company continue build differentiate value proposition user return revenue growth anmuth write note client tuesday aegis capital analyst upgrade twitter buy firm note mark inflection point social medium company aegis say expect twitter become gaap profitable spark sustain double digit growth daily active user current fundamental third quarter twitter grow dau base year year marked fourth consecutive quarter double digit growth category twitter be also able grow monthly active user base social medium company now boast maus company also begin tout first real foray live stream last quarter twitter note stream live event reach global audience twitter also note sign new live deal twitter be currently zack rank buy sport grade growth momentum style score system help company earn overall vgm score look ahead fourth quarter twitter be expect see revenue earning dip base current zack consensus estimate however be analyst project twitter be set finally break time red twitter full fiscal company bottom line be expect hit share full year revenue be project reach mark year year jump projection term long term earning growth potential twitter be expect expand ep figure annualize rate next year alone figure help investor regain confidence twitter investor be even more excited pair ep growth projection expectation social medium use grow rapidly share twitter have sky-rocket last week alone blow away internet software industry average however spite massive run share twitter rest week high tuesday close mean investor buy share somewhat discount price ahead many predict be stellar twitter company be set report fourth quarter full year result open bell feb today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2433,MRK,biotech industry be expect witness continuation last year favorable trend last year industry benefit number fda approval new product sale ramp success innovation strong clinical study result continue strength legacy product be first time approval innovative game change treatment option noteworthy be approval novartis nvs free report kymriah first cell base gene therapy know car therapy be innovative treatment option cancer be follow car approval kite pharma yescarta spark therapeutic luxturna first gene therapy treat rare inherited form childhood blindness be also approve last year nasdaq biotechnology index gain moreover medical biom genetic industry increase same time frame pricing pressure rise competition pipeline setback slowdown growth mature product generic competition certain key drug be headwind mentioned factor continue contribute sector growth december tax overhaul be sign law slash corporate tax rate boost profit large drug biotech company meanwhile change tax code also allow company bring back huge cash hold overseas time tax rate also tax cut be expect prevent inversion be rampant drug industry change definitely leave more cash hand drug biotech company cash be invest merger acquisition have be few bullish outlook sector look biotech stock have see share price rise more year so far look well position rest stock have witness upward estimate revision have favorable zack rank zack rank strong buy buy plc alk free report be focuse development marketing treatment central nervous system cns disease year be expect be year development pipeline key event line year include fda review alk new drug application nda treatment major depressive disorder phase iii datum readout alk schizophrenia nda filing alk first half be be evaluate treatment multiple sclerosis company also gain fda approval new initiation product aristada aripiprazole lauroxil nanocrystal dispersion treatment schizophrenia jun zack rank stock have see share gain year date compare rally industry belong see complete list today zack rank stock here company have see zack consensus estimate earning be revise upward last day vertex pharmaceutical inc vrtx free report vertexsport zack rank earning share estimate have moved last day company deliver positive earning surprise last quarters average beat share price company have increase year date year be tremendous year vertex positive datum read out regulatory approval lead increase eligible patient population cystic fibrosis cf product kalydeco orkambi trend continue orkambi get eu approval pediatric use consistent expansion patient population vertex cf product revenue increase company be optimistic positive trend cf sale continue additional reimbursement approval orkambi ex market approval launch tezacaftor vx ivacaftor combination medicine vertex cf pipeline be also quite strong broad portfolio next generation cf corrector vertex also make decent clinical progress multiple cf study have meaningful pipeline catalyst investor focus be triple combination cf regimen be crucial long term growth have potential treat cf patient vertex plan initiatepivotal phase iii study triple combination regimen first half inc agen free report agenuscarry zack rank loss estimate company narrow last day share price company have increase year date have form collaboration merck mrk free report incyte develop multiple checkpoint antibody october fda grant marketing authorization glaxosmithkline gsk free report herpes zoster vaccine shingrix contain proprietary immune adjuvant qs stimulon be good news shingrix have blockbuster potential increase sale impact business positively earlier month company announce dilutive royalty financing transaction healthcare royalty partner hcr significantly boost cash position use part proceed redeem royalty bond fund pivotal pipeline program company also announce new leadership appointment enhance team advance ongoing pivotal program ctla pd support plan bla filing second half today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2434,MRK,astrazeneca plc azn free report partner merck mrk free report announce fda have approve supplemental new drug application snda lynparza seek approval label expansion metastatic breast cancer lynparza be presently market advanced ovarian cancer latest fda approval lynparza now be used treat previously treat chemotherapy patient negative metastatic breast cancer harbore germline brca mutation moreover drug be also approve patient hr breast cancer be treat endocrine therapy be ineligible same approval make lynparza first approve parp inhibitor treat metastatic breast cancer also first time parp inhibitor have be approve ovarian share have increase last year share merck be period meanwhile industry moved same time period fda approve label expansion base datum phase iii olympiad study evaluate lynparza chemotherapy drug achieve significant improvement progression free survival pfs compare chemotherapy vs month lynparza also reduce risk disease progression death achieve objective response rate orr double compare chemotherapy patient be select base myriad genetic inc mygn free report fda approve companion diagnostic test be cure metastatic breast cancer lynparza offer new treatment option lengthen duration disease progression press release be patient unite state metastatic breast cancer have inherited brca mutation lynparza register sale first month grow year year label expansion certainly boost prospect drug give advantage other drug parp inhibitor segment include clovis oncology inc clvs free report rubraca tesaro zejula rubraca zejula be approve only ovarian cancer drug be also be develop breast cancer zack rankastrazeneca carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2435,MRK,be eventful year pharma biotech stock industry face challenge drug pricing scrutiny pricing pressure increase competition concern regard amazon interest enter healthcare arena fewer expect acquisition deal major pipeline setback be positive development well be significant surge fda approval investor appear more comfortable drug pricing controversy innovation win day fda grant approval gene therapy cancer well rare form blindness tax reform be also expect work sector favor merger acquisition expect pick come quarters keep mind here be look key takeaway presentation make major pharma biotech stock annual morgan healthcare conference largest most informative healthcare investment symposium industry pfizer inc pfe free report pharmaceutical giant pfizer expect be rich datum delivery year company focus be therapeutic area include oncology inflammation immunology vaccine rare disease internal medicine immuno oncology portfolio focus remain mainly drug combination bavencio variety pfizer target agent first half year company present late stage datum bavencio second line small cell lung cancer vyndaqel cardiomyopathy regulatory submission be expect xtandi metastatic castration resistant prostate cancer parp inhibitor talazoparib breast cancer second half year see company present phase iii datum rivipansel sickle cell tanezumab pain company also have couple pdufa date xeljanz ulcerative colitis first indication outside rheumatology lorlatinib second line small cell lung cancer pfizer be zack rank hold stock company share be last year compare gain record industry belong celgene corporation celg free report biotech company celgene announce preliminary result well outlook healthcare conference celgene also be present significant amount datum year include revlimid rituxan relapse refractory follicular lymphoma otezla scalp psoriasis several study initiation be also expect year moreover company expect submit supplemental new drug application snda fda revlimid combination bortezomib dexamethasone rvd patient newly diagnosed multiple myeloma ndmm new drug application nda fedratinib myelofibrosis snda otezla behet disease meanwhile fda decision be expect year ozanimod relapse multiple sclerosis rm once daily formulation otezla company say continue invest business development celgene be zack rank stock company share be last year compare gain record industry belong bristol myer squibb company bmy free report bristol myer pipeline represent several opportunity long term growth company provide update blockbuster drug opdivo be expect drive mid term growth small cell lung cancer renal cell carcinoma rcc hepatocellular carcinoma gastric cancer be area represent commercial potential excess be disease area high prevalence high unmet medical need low survival rate bristol myer have several datum readout opdivo plan company immuno oncology portfolio have several early stage candidate late stage asset relatlimab lag bms bms ido company say business development remain important priority focus be deal make sense financial perspective asset technology be strategically align priority be potentially bristol myer be zack rank hold stock company share be last year merck mrk free report merck too business development remain key priority company say be look opportunity licensing deal bolt acquisition add drug technology address unmet medical need merck provide outlook february company say headwind remain form competitive pressure drug zostavax zepatier zetia vytorin still feel impact generic competition however keytruda represent significant growth opportunity drug be several study label expansion combination use moreover company pipeline oncology asset novel vaccine select hospital specialty product also provide scope long term growth merck be also zack rank stock see complete list today zack rank strong buy stock here company share be last year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2436,MRK,johnson johnson jnj free report announce have submit supplemental new drug application snda fda label expansion diabetes drug invokana include cardiovascular indication base datum large canvas outcome program application include indication risk reduction cardiovascular event type ii diabetes patient also apply invokana fix dose combination invokamet invokamet xr filing be base datum canvas program evaluate invokana sglt inhibitor compare placebo cv event type ii diabetes patient have establish cardiovascular cv disease be risk cv disease primary endpoint study be defined major adverse cardiovascular event mace include cv death nonfatal myocardial infarction nonfatal stroke study show invokana be successful reduce risk heart attack stroke canvas program comprise nearly identical large outcome study call canvas canvas however study also show drug increase risk amputation so far year johnson johnson share price have increase compare unfavorably gain record industry belong many pharma company be work hard get label diabetes medicine update include cardiovascular benefit death cardiovascular disease be significantly higher adult diabetes compare diabetes addition positive cv outcome label diabetes drug give sale shot arm eli lilly company lly free report receive fda approval last year include cv risk reduction datum empa reg outcome study label jardiance update label include cardiovascular indication be launch jan american diabetes association ada have also update diabetes treatment guideline european commission also approve jardiance label update cardiovascular indication august nordisk nvo free report victoza liraglutide be approve fda new indication reduce risk major adverse cardiovascular cv event adult type ii diabetes establish cv disease fda decision be base result landmark leader trial demonstrated victoza statistically significantly reduce risk cardiovascular death fatal heart attack fatal stroke versus placebo add standard care absolute risk reduction however merck co inc mrk free report be deny approval fda include cardiovascular outcome datum tecos study label dpp iv inhibitor januvia sitagliptin other medicine contain januvia astrazeneca bydureon also fail reduce cardiovascular risk phase iiib iv cardiovascular outcome study exscel johnson johnson price johnson johnson price johnson johnson quotejohnson johnson carry zack rank sell see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2437,MRK,seattle genetic inc sgen free report announce fda have grant breakthrough therapy designation status lymphoma drug adcetris frontline treatment advanced classical hodgkin lymphoma company recently complete phase iii study echelon drug indication remind investor adcetris be currently approve second third line treatment classical hodgkin lymphoma systemic anaplastic large cell lymphoma least fail multus agent chemotherapy regimen unite state well europe breakthrough therapy designation be grant speed development review drug target serious life threaten condition company share close higher monday follow news share seattle genetic have rise so far year underperform industry gain period june company announce positive top line datum echelon study demonstrated adcetris achieve improvement modify progression free survival statistical significance compare standard care chemotherapy echelon study evaluate adcetris addition adriamycin vinblastine dacarbazine patient advanced classical hodgkin lymphoma prior treatment designation be grant base datum company expect submit supplemental biologic license application sbla end seattle genetic be develop drug more clinical study key study include evaluation cell lymphomas hodgkin lymphoma company have complete alcanza phase iii study submit sbla last month expand label include cutaneous cell lymphoma decision be expect december phase iii study be currently evaluate adcetris frontline mature cell lymphomas recently initiate study be evaluate drug combination bristol myer squibb company bmy free report opdivo relapse refractory hodgkin lymphoma adcetris be only market product seattle genetic generate sale first half almost year period further label expansion new indication boost sale number however adcetris face competition other drug include merck co inc mrk free report keytruda be recently approve lymphoma indication seattle genetic inc price consensus seattle genetic inc price consensus seattle genetic inc quotezack rank stock considerseattle genetic carry zack rank hold regeneron pharmaceutical inc regn free report be better rank stock health care sector sporting zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have increase last day company pull positive earning surprise trail quarters average beat share price company have increase year date make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2438,MRK,late last week merck mrk free report announce decision discontinue development couple candidate hepatitis virus hcv program mk grazoprevir ruzasvir uprifosbuvir mk ruzasvir uprifosbuvir company decision be base review available phase ii efficacy datum grow competition hcv market merck have market product hcv market form zepatier elbasvir grazoprevir bring sale first month include favorable adjustment rebate accrual due mix business merck continue work expand zepatier utilization world uptake be impact ongoing decline overall patient volume many market increase competition gilead abbvie hcv spotlightmerck announcement have now put spotlight firmly gilead science gild free report abbvie abbv free report key player market gilead be undisputed leader hcv market hcv product bring sale first half company revolutionize treatment paradigm hcv market introduction sovaldi cut duration treatment few week instead prior standard care week moreover need peg interferon injection come several side effect be reduce eliminate completely gilead launch harvoni next first once daily single tablet regimen treatment most prevalent hcv genotype unite state be follow launch epclusa first oral pan genotypic single tablet regimen treatment adult genotype chronic hcv infection year gilead gain approval yet hcv treatment vosevi gilead rule hcv market quite few year sale be decline give intense pricing pressure grow competition pricing scrutiny decline patient population approval newer hcv product have result rapid increase number patient be treat cure follow decline number patient seek care be able access hcv treatment gilead expect hcv net product sale range announce result represent quite drop last year hcv product sale meanwhile abbvie hcv product include mavyret glecaprevir pibrentasivr viekira pak ombitasvir paritaprevir ritonavir tablet co package dasabuvir tablet viekira xr dasabuvir ombitasvir paritaprevir ritonavir mavyret be approve recently viekira sale be first half mavyret company next generation hcv offer be meaningful contributor sale other hcv drug include bristol myer squibb company bmy free report daklinza daclastavir janssen therapeutic olysio simeprevir remind investor merck be not only company have take decision halt development hcv candidate last month johnson johnson jnj free report have announce decision terminate collaboration agreement achillion pharmaceutical achn free report hcv janssen pharmaceutical say be discontinue development investigational hcv treatment regimen jnj combination direct act antiviral al odalasvir simeprevir merck drop investigational hcv treatment gilead abbvie benefit lack additional competition enter market least term company continue face challenge decline patient volume intense pricing pressure lack additional entrant market slow rate decline sale gilead have be work expand hcv market encourage baby boomer get test accord company have be increase hcv antibody screening baby boomer start initiative increase testing have lead increase diagnosis person be newly diagnosed hcv represent significant opportunity exist player hcv market gilead abbvie be zack rank hold stock see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2439,MRK,merck co inc mrk free report announce be discontinue further development next generation hepatitis hcv program mk mk market be become extremely crowd mk be oral triple combination regimen uprifosbuvir combination grazoprevir ruzasvir develop treatment chronic hcv infection mk be combination ruzasvir uprifosbuvir merck share have rise year so far compare increase industry company now focus grow sale key hcv drug market zeptier be approve use ribavirin treat chronic hcv genotype infection zepatier once daily fix dose combination tablet contain ns inhibitor elbasvir ns protease inhibitor grazoprevir be gradually become key top line driver merck cancer drug keytruda medicine record sale second quarter much higher first quarter attributable strong underlie demand trend unite state europe japan company continue launch zepatier globally however remind investor second quarter conference call management have warn zepatier uptake go forward be impact ongoing decline overall patient volume many market increase competition hcv market be get crowd be thus see increase pricing pressure gilead science inc gild free report market blockbuster hcv drug sovaldi harvoni other well know name market be abbvie inc abbv free report viekira pak bristol myer daklinza johnson johnson jnj free report olysio moreover other company be also look bring new improve shorter duration hcv treatment market abbvie pan genotypic shorter duration hcv regimen glecaprevir pibrentasvir mavyret receive approval unite state canada eu july august meanwhile gilead already market epclusa oral pan genotypic single tablet hcv regimen meanwhile gilead single tablet regimen str sovaldi velpatasvir voxilaprevir vosevi receive approval unite state eu canada july august vosevi become first once daily str available salvage therapy patient infected hcv genotype have fail prior treatment daa regimen include ns inhibitor merck carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2440,MRK,have already crossed halfway mark second quarter report cycle earn season have show broad base growth record earning quarter jul member accounting index total market capitalization report result accord earning preview company beat count compare first quarter total earning index member be year quarter improvement revenue beat ratio be earning revenue medical segment have also perform well so far earning increase revenue report total earning company second quarter be expect grow year year higher revenue plenty result still come actual earning growth quarter exceed mark follow earning growth first quarter increase revenue highest almost year johnson johnson jnj free report begin earning season pharma sector mixed second quarter result performance novartis nvs free report lilly lly free report biogen inc biib free report be encourage company beat earning revenue estimate lilly biogen also raise earning revenue estimate other pharma bigwig report last week abbvie inc abbv free report report better expect result earning sale surpass expectation lymphoma drug imbruvica record record growth merck co inc mrk free report also beat estimate earning sale second quarter mainly backed strong sale pd inhibitor keytruda let take look pharma biotech company be set report second quarter result aug let see thing be shape quarter pfizer inc pfe free report pfizer be schedule release earning open bell deliver positive earning surprise last quarter pfizer earning performance have be mixed earning miss expectation last quarters beating same twice result average negative surprise quarter pfizer have earning esp zack rank hold indicate likely beat zack consensus estimate be peg cent share uncover best stock buy sell re report earning esp filter pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quotenew product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain eliquis blood thinner be likely contribute top line meaningfully read more be beat card pfizer earning aerie pharmaceutical inc aeri free report aerie pharma be schedule announce result close bell aerie pharma have miss estimate past quarters have average negative earning surprise company have earning esp zack rank buy see complete list today zack rank strong buy stock here aerie pharmaceutical inc price ep surprise aerie pharmaceutical inc price ep surprise aerie pharmaceutical inc approve product portfolio aerie depend heavily late stage candidate rhopressa roclatan aerie have submit regulatory application rhopressa expect submit same eu second half hence expect investor focus remain pipeline update read more card aerie earning season incyte corporation incy free report company be expect report market open incyte deliver earning surprise last quarter incyte performance have be pretty impressive company report positive surprise consistently average earning beat last quarters be company have earning esp zack rank zack consensus estimate be peg loss cent share incyte corporation price ep surprise incyte corporation price ep surprise incyte corporation quotemore stock news company verge apple rundid miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
2441,MRK,share expedia inc expe free report rise report second quarter adjust earning cent share surpass zack consensus estimate cent share merck co inc mrk free report rise post second quarter earning share beat zack consensus estimate share align technology inc algn free report surge revenue grow year year quarter surpass zack consensus estimate mattel inc mat free report post loss share second quarter be wider zack consensus estimate loss
2442,MRK,last week several pharma major report second quarter result meanwhile important study datum be release merck mrk free report astrazeneca azn free report recap week most important storiesa look earning result big pharma company merck lilly lly free report glaxo roche bristol myer bmy free report astrazeneca report second quarter result last week bristol myer lilly merck beat expectation merck maintain outlook year read more merck beat earning sale keep view bristol myer update same read more bristol myer beat earning tweak view lilly be hit baricitinib update report beat raise quarter read more key takeaway lilly call baricitinib cancer pipeline meanwhile astrazeneca result be shadow disappointing mystic datum imfinzi treatment nave small cell lung cancer nsclc patient company share fall read more astrazeneca beat earning fall fail study british drugmaker glaxo set new priority company company decide allocate capital priority asset current respiratory hiv infectious disease potential oncology immuno inflammation therapy area glaxo also say more pre clinical clinical program be stop read more glaxosmithkline beat earning lower guidance lilly merck be zack rank buy stock see complete list today zack rank strong buy stock here merck keytruda miss endpoint hnscc study be lot update merck last week addition earning result company be hit disappointing result late stage study evaluate pd therapy keytruda monotherapy patient previously treat recurrent metastatic head neck squamous cell carcinoma hnscc study fail meet pre specify primary endpoint overall survival os be latest keytruda related setback merck earlier month company have announce fda have place clinical hold combination study keynote keynote keynote be conduct keytruda multiple myeloma mm meanwhile look merck second quarter result show keytruda remain strong lung cancer set keytruda be currently more study include more combination study merck astrazeneca sign oncology collaboration merck astrazeneca be collaborate global development merck keytruda astrazeneca parp inhibitor lynparza different type cancer lynparza currently approve brca mutate ovarian cancer multiple line treatment be different study range tumor type include breast prostate pancreatic cancer deal cover evaluation parp mek inhibitor pd pd inhibitor astrazeneca stand receive include upfront payment certain license option additional achievement regulatory sale milestone merck stock have gain year date ytd lag rally industry belong astrazeneca have gain ytd janssen inks deal bavarian nordic johnson johnson janssen pharmaceutical company denmark base biotech company bavarian nordic enter additional worldwide exclusive license collaboration agreement janssen get exclusive right bavarian nordic mva bn technology additional program target vaccine hepatitis virus hbv hiv make upfront payment equity investment worth bavarian nordic also be eligible receive milestone payment worth tiered royalty future sale deal company be now collaborate program combine bavarian nordic mva bn technology janssen advac technology platform pfizer astella xtandi breast cancer program drop astella report result last week provide update pipeline show company partner pfizer pfe free report have decide drop development xtandi breast cancer development program include phase iii study triple negative breast cancer phase ii study pr positive positive breast cancer astella say decision be base discussion pfizer change competitive landscape need further diagnostic development new phase ii datum ongoing program xtandi include metastatic castration resistant prostate cancer phase iii prostate cancer patient metastatic biochemical recurrence phase iii metastatic hormone sensitive prostate cancer phase iii hepatocellular cancer phase ii cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock merck be astrazeneca lose last month be bristol myer gain see last pharma stock roundup here nvs earning merck drug get tentative fda nod next pharma world watch second quarter earning result company pfizer shire shpg free report allergan agn free report other moreover fda arthritis advisory committee be meeting aug discuss regulatory application investigational rheumatoid arthritis treatment plivensia sirukumab more stock news company verge apple rundid miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
2443,MRK,dow enjoy strong week gain ride stellar earning result index decline monday due spike bond yield dim attraction such safe haven stock telecom utility index close green successive day close thursday record level fed decision refrain raise rate end day policy meeting also lift investor sentiment last week dow lose last friday general electric company ge post decline second quarter earning revenue furthermore decline oil price adversely affected energy share turn weigh broader market petro logistic opec be expect increase crude production barrel day bpd month such expectation increase production level oversupply concern drag oil price lower index decline last week dismal performance ibm ibm free report goldman sachs gs weigh dow again amazon sear deal adversely affected home depot hd free report turn weigh dow other benchmark end week gain dow dow decline monday largely due fact bond yield increase lead investor exit utility telecom stock also share johnson johnson jnj free report fall drag blue chip index be largely due fact merck co mrk free report together south korean partner samsung bioepis co ltd have start selling renflexis less expensive alternative version johnson johnson rheumatoid arthritis drug remicade unite state index gain tuesday follow stellar earn result mcdonald corp mcd caterpillar inc cat oil price rise follow saudi decision curb oil export be broad gain technology stock tech rally continue index increase wednesday boost strong earning result fed decision not raise rate end day meeting splendid second quarter earning boee company ba free report help close dow record high dow outperformed other benchmark close record high thursday ride rally share boee company verizon communication inc vz free report blue chip index gain however technology stock take batter share apple inc aapl free report swoon due now familiar speculation overvaluation tech stock component move index company mmm free report report strong second quarter result healthy year year increase earning revenue gaap earning report quarter be share compare share year earlier quarter however report earning miss zack consensus estimate penny net sale quarter be year quarter miss zack consensus estimate zack rank hold rate raise earlier guidance read slightly miss earning organic growth caterpillar deliver upbeat quarter adjust earning share second quarter logging improvement year year also ahead zack consensus estimate revenue improve year year quarter surpass zack consensus estimate give upbeat first half performance improve order activity discipline cost control zack rank buy rate caterpillar have hike revenue guidance range prior range read caterpillar top earning revenue raise view coca cola company ko free report report second quarter adjust earning cent share surpass zack consensus estimate cent net revenue decline year year due currency headwind negative impact structural item zack rank buy rate coca cola expect organic revenue rise company expect adjust ep decline prior year comparable ep read coca cola healthy drive help earning beat boee report adjust earning share second quarter beating zack consensus estimate gaap basis boee report earning share loss cent share year quarter company revenue amount report quarter miss zack consensus estimate report figure also decline year year stock have zack rank buy see complete list today zack rank strong buy stock here dupont record adjust earning share second quarter share year result top zack consensus estimate zack rank rate dupont logged net sale roughly year year higher volume also surpass zack consensus estimate read dupont earning revenue trounce estimate mcdonald post robust result second quarter bottom top line outpaced zack consensus estimate adjust earning share ep surpass zack consensus estimate improve year quarter mcdonald have zack rank revenue decline year year mainly due impact company strategic refranchise initiative constant currency figure decline however same surpass zack consensus estimate nearly nearly read mcdonald top earning solid comp growth general electric report second quarter earning cent share beat zack consensus estimate cent total consolidated revenue report quarter decrease year year surpass zack consensus estimate ge have zack rank strong sell general electric reaffirm guidance company continue anticipate operate earning be organic growth read ge excel earning revenue estimate affirm view procter gamble company pg fiscal fourth quarter core earning cent share beat zack consensus estimate cent bottom line also increase prior year quarter report net sale surpass zack consensus estimate top line however remain unchanged compare year level procter gamble have zack rank cincinnatus base company expect organic sale growth range fiscal core earning share growth be project compare fiscal core earning share read procter gamble top earning revenue estimate unite technology corporation utx free report report second quarter earning share beating zack consensus estimate bottom line also come higher year tally net sale report quarter come outpace zack consensus estimate addition top line come higher prior year figure zack rank rate unite technology raise lower end full year earning guidance adjust earning be currently anticipate lie share range previously estimate range read unite technology top earning lift view verizon post second quarter adjust earning cent share line zack consensus estimate total revenue increase year year beating zack consensus estimate verizon have zack rank total operate expense second quarter be year year operate income come compare year quarter read verizon earning line revenue beat estimate visa inc report third quarter fiscal end jun earning cent share beating zack consensus estimate cent also bottom line improve year year net operate revenue surpass zack consensus estimate also revenue climb year year visa have zack rank fiscal visa largely reaffirm guidance adjust earning share growth be project be normal dollar basis read visa beat earning revenue tweak view microsoft corporation msft free report report fourth quarter fiscal earning cent share beat zack consensus estimate cent earning share ep increase constant currency cc year year basis sequential basis revenue adjust window deferral impairment restructure charge increase sequentially year quarter cc further exceed zack consensus estimate read azure office help microsoft top earning performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have gain tickerlast day performance month performancemmm gs ibm hd ba unh mcd trv jnj aapl next week outlookmost dow component earning have be bullish nature keep tone rest second quarter earning result bunch key earning way shift turn somewhat economic datum follow release gdp datum today come better expect market be likely focus economic fundamental give growth be slate pick second half year stock be likely receive further catalyst gain day ahead hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionary still leave plenty money regular investor make right trade early see zack best stock play trend
2444,MRK,astrazeneca plc azn free report report second quarter core earning cent american depositary share comfortably beat zack consensus estimate cent core earning also increase year year constant currency rate cer share astrazeneca be almost thursday reflect disappointing result phase iii study evaluate imfinzi combination therapy first line lung cancer however astrazeneca share have gain so far year compare unfavorably industry increase concurrent earning release company announce initial result phase iii mystic study study show imfinzi combination tremelimumab do not improve progression free survival pfs first line small cell lung cancer nsclc compare platinum base chemotherapy core earning increase due continue focus cost control higher other income expense total revenue decline cer report quarter revenue be line zack consensus estimate key growth platform represent total revenue emerge market new cardiovascular metabolic disease cvmd new oncology japan perform well quarter however respiratory sale decline report quarter revenue detailproduct sale decline quarter externalization revenue fall loss exclusivity crestor seroquel xr lower symbicort sale hurt product sale quarter product sale plummet primarily due entry generic version crestor seroquel xr pricing pressure symbicort european market witness decline sale revenue emerge market be however report quarter primarily back strong growth china performance key drugssymbicort sale be quarter due pricing headwind competitive dynamic europe nexium record sale contribute europe accounting however crestor sale decline accounting europe contribute europe sale decline sharply quarter multiple generic version drug enter market product record growth quarter include farxiga forxiga daliresp daxas faslodex iressa lynparza concurrent earning release company announce agreement merck co inc mrk free report jul develop lynparza keytruda tagrisso launch record sale sequentially upside be drive strong japan sale due strong patient demand trend successful commercial launch multiple market company also announce same day datum phase iii flaura study evaluate tagrisso demonstrated statistically significant improvement inpfs nsclc patient new medicine movantik moventig record higher sale quarter reach brilinta brilique sale be report quarter year year brilinta maintain leadership position brand oral platelet market europe china brilinta continue display impressive performance recently launch drug imfinzi bladder cancer bevespi copd record sale respectively report quarter other core gross margin increase basis point bps core selling general administrative sg expense decrease due integration share service outsource activity quarter core research development expense decrease outlook continue expect total revenue decline low mid single digit percentage range company also maintain guidance core earning be expect decline low mid percentage base average exchange rate year currency movement be expect adversely impact top line low single digit percentage minimally impact core earning share adjust cost be expect be broadly line level company anticipate further reduction sg cost owing evolve structure business astrazeneca plc price consensus ep surprise astrazeneca plc price consensus ep surprise astrazeneca plc quotezack rank key currently carry zack rank hold couple better rank stock health care sector be arena pharmaceutical inc arna free report aduro biotech inc adro free report stock carry zack rank buy see complete list today zack rank strong buy stock here arena pharma loss share estimate narrow last day company deliver positive surprise trail quarters average beat company be expect report aug aduro loss share estimate narrow last day company deliver positive earning surprise trail quarters average beat company be expect report aug hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2445,MRK,merck co inc mrk free report report second quarter earning share easily beat zack consensus estimate cent earning also rise year period revenue quarter increase year year beating zack consensus estimate currency movement negatively impact revenue exclude currency impact sale rise year year quarter pharmaceutical segment post revenue exclude fx impact year year mainly backed strong sale pd inhibitor keytruda keytruda bring sale second quarter sequentially year year sale continue be drive launch new indication globally keytruda sale gain particularly strong momentum new indication first line lung cancer approve oct last month be series regulatory approval label expansion keytruda drive sale go forward important approval include advanced bladder cancer advanced microsatellite instability high cancer first approval combination therapy eli lilly company lly free report cancer drug alimta pemetrexed carboplatin pem carbo lung cancer however earlier month pivotal phase iii study keytruda head neck squamous cell carcinoma fail meet primary endpoint overall survival also combination study keytruda multiple myeloma be place clinical hold month follow report death keytruda group meanwhile competition immuno oncology market be rise follow recent fda approval pfizer inc pfe free report bavencio avelumab merkel cell carcinoma mcc bladder cancer astrazeneca plc azn free report imfinzi durvalumab bladder cancer zepatier bring sale previous quarter attributable ongoing launch globally bridion sugammadex injection generate sale quarter year year drive strong uptake launch meanwhile combine sale remicade lose exclusivity europe face stiff biosimilar competition region cubicin lose patent protection jun zetia lose market exclusivity dec vytorin lose exclusivity apr decline quarter sale isentress januvia janumet diabetes franchise also decline quarter remicade sale decline quarter merck market brand version remicade outside johnson johnson jnj market rheumatoid arthritis drug week merck launch renflexis biosimilar version remicade cubicin sale plunge quarter zetia vytorin franchise record sale due loss exclusivity zetia vytorin januvia janumet franchise record sale quarter year quarter due lower sale due pricing pressure lower customer inventory level isentress sale decline quarter lower volume demand due competitive pressure be hurt sale isentress vaccine sale be primarily drive increase gardasil pneumovax vaccine vaccine sale be also boost addition approximately gardasil sale terminate vaccine joint venture sanofi gardasil gardasil sale climb drive strong demand asia pacific favorable timing sale brazil merck animal health segment post revenue exclude fx impact year quarter primarily drive higher sale companion animal product margin gross margin come basis point bps quarter attributable favorable effect product mix lower inventory offsmarketing administrative expense increase report quarter research development spend increase quarter guidancedespite lower expectation negative impact currency exchange rate company maintain previously adjust earning guidance raise sale guidance marginally company expect adjust earning range include approximately negative foreign exchange impact versus previously revenue be expect range compare earlier forecast include negative currency impact approximately versus previously operate expense be expect increase year year mid single digit rate compare low single digit rate expect previously takemerck second quarter earning be encourage company beat sale earning strong performance new product keytruda bridion zepatier higher sale vaccine animal health franchise offset lower sale diabetes franchise loss market exclusivity many drug merck share have rise year so far compare unfavorably increase industry merck also announce cancer collaboration astrazeneca jointly commercialize develop latter parp inhibitor lynparza monotherapy combination study multiple cancer type lynparzais presently market advanced ovarian cancer meanwhile merck independently develop combination medicine lynpraza keytruda deal merck pay total consideration include upfront payment merck also say network cyber attack june disrupt global operation result temporary delay fulfill order product merck company inc price consensus ep surprise merck company inc price consensus ep surprise merck company inc quotemerck carry zack rank buy see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2446,MRK,first look gross domestic product gdp growth perhaps main signifier grow economy ratchete putt economy pretty much exactly expect growth averaged number consumer spending rise business spending go part be equipment sale grow employment cost index fall housing be government be inventory positive also revision show year higher originally report be lower first thought basically be glean quick glance be expectation be line expectation mean be small business confidence base election president trump last november have hold market haven moved much latest gdp announcement have go dow nasdaq earning wrap maker merck mrk free report post better expect earning report share opposed cent anticipate zack consensus estimate revenue also top expectation ahead have be look high growth melanoma treatment keytruda outperformed estimate quarter mark growth sequentially year year zack rank buy company american airline aal free report also top expectation bottom line report share compare expect be currently zack rank strong buy stock revenue also beat zack consensus bring represent growth year year share buyback cent dividend increase help put cap successful aal exxon mobil xom free report miss expectation earning report cent share opposed cent expect revenue beat zack consensus however report opposed zack consensus be call overall production be line year figure natural gas production be zack rank sell company tesla model wayfinally first delivery tesla tsla free report model car company first affordable electric only automobile occur today satisfying roughly individual have put reserve place line first model regard author sale business widely spread energy conscious company model look bring tesla brand garage neighborhood america elsewhere
2447,MRK,roche hold ag rhhby free report report sale chf first half year period core earning come chf share first half share roche have perform better zack classify industry year so far fact stock gain time frame compare gain industry company report result division pharmaceutical diagnostic growth rate mentioned be year year basis constant exchange rate sale pharmaceutical division increase drive strong growth tecentriq ocrevus perjeta be partially offset lower sale tarceva tamiflu pegasys diagnostic division sale climb primarily back strong business first half detailherceptin sale improve due increase demand brazil additional reimbursement approval broader use china perjeta sale grow follow increase demand neoadjuvant metastatic setting europe international market sale kadcyla be drive increase demand international market meanwhile sale avastin be strong international region especially china sale grow due broader market penetration lung colorectal cancer set however sale drop due increase use new immunotherapy agent lung cancer set overall sale decline sale rituxan mabthera contribute top line growth oncology well immunology segment growth gazyva gazyvaro be witness europe increase competition chronic lymphocytic leukemia recently launch drug tecentriq bladder cancer alecensa lung cancer be encourage start initial uptake have be strong tecentriq ocrevus alecensa contribute chf new sale contribute half division growth performance immunology franchise be drive increase sale actemra roactemra strong uptake esbriet xolair increase use actemra roactemra single agent subcutaneous formulation be key growth driver globally however sale tarceva decline due grow use other therapeutic option sale xeloda continue be hit generic competition sale tamiflu also decline revenue diagnostic division climb back solid performance centralised point care solution unit be turn propel tissue diagnostic molecular diagnostic also perform impressively however diabetes care sale decline sale continue be impact challenge market condition particularly north america outlook raisedroche now expect sale grow mid single digit prior guidance low mid single digit company expect core earning grow tandem sale company intend further increase dividend local currency roche hold ag revenue ttm roche hold ag revenue ttm roche hold ag quotepipeline progressroche continue expand cancer immunotherapy drug tecentriq bladder lung cancer label tecentriq receive accelerate approval fda treatment person locally advanced metastatic urothelial carcinoma be not eligible cisplatin chemotherapy apr lucentis be approve fda monthly treatment form diabetic retinopathy actemra roactemra subcutaneous injection be approve fda treatment giant cell arteritis fda further approve rituxan hycela rituximab hyaluronidase human subcutaneous injection treatment adult specific form blood cancer other hand new tablet formulation esbriet be approve european commission treatment mild moderate idiopathic pulmonary fibrosis ipf fda have already approve same early roche also present positive result emicizumab patient suffering haemophilium phase iii study haven meanwhile study show roche ocrevus significantly reduce risk relapse primary progressive multiple sclerosis rm ppms patient require mobility aids versus comparator however phase iii study imvigor evaluate tecentriq patient locally advanced metastatic urothelial cancer disease progressed treatment platinum base chemotherapy previously treat do not meet primary endpoint overall survival compare chemotherapy takeroche result first half be impressive sale be boost new product launch tecentriq ocrevus sale tecentriq be mainly drive strong uptake metastatic bladder cancer metastatic small cell lung cancer nsclc label expansion drug be expect boost sale further successful launch ocrevus treatment form multiple sclerosis have also boost topline base strong performance first half company also raise sale guidance however sale avastin tarceva continue decline generic competition xeloda also continue hurt sale note competition biosimilar loom large roche key drug herceptin avastin rituxan first biosimilar mabthera be already market company expect biosimilar herceptin end early note novartis ag nvs free report have already launch bisomilar version rituxan mabthera europe moreover roche be face stiff competition like merck co inc mrk free report keytruda bristol myer squibb company bmy free report opdivo immuno oncology space zack rankroche currently carry zack rank hold see complete list today zack strong buy rank stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionary still leave plenty money regular investor make right trade early see zack best stock play trend
2448,MRK,equity market be go turbulent time be lot volatility uncertainty owing rise geopolitical risk political uncertainty have increase appeal dividend investing geopolitical risk have be rise north korea conduct seventh nuclear test continental ballistic missile fly japan sep kim jong action have create huge unrest number asian economy unite state response continuous missile test president donald trump maiden general assembly speech threaten completely destroy north korea prompt north korean leader kim jong unite state highest level hard line countermeasure history moreover north korea foreign minister state trump comment indicate unite state have declare war north korea declare war country have right make countermeasure include right shoot bomber even be not yet airspace border country foreign minister ri yong say however white house have reject accusation latest development make investor flock safe haven investment lead decline tech stock read safe haven currency etfs gain latest north korea threat trump actionsthere be increase uncertainty regard trump ability pass promise legislation relate tax reform deregulation economic fundamental have be strong be renew doubt capability trump administration trump introduce new travel ban restriction citizen nation be muslim majority start oct citizen chad iran libya syrium venezuela yeman somalia north korea be ban travele unite state however person hold permanent residency visa be exempt ban renew visa once expire moreover trump administration be be highly criticize separate development adviser trump have be find be used personal email address official government purpose be ironical give trump stance investigation hillary clinton use personal server prior presidential election read trump widen north korea sanction etfs focus such scenario dividend pay security provide consistent income investor uniqueness security be increase political uncertainty weigh market more so apart high dividend security exhibit less volatility be stable mature company let now discuss few etfs focuse provide exposure equity relatively high dividend yield flexshare quality dividend index fund qdf free report fund seek provide exposure company provide high dividend maintain quality factor utilize constraint minimize risk have aum charge fee basis point year sector look fund have high exposure information technology financial industrial allocation respectively jun fund top holding be merck co inc mrk free report well fargo co wfc free report boee co ba free report allocation respectively sep fund have return year year date sep quality dividend growth fund dgrw free report fund seek provide exposure large establish company provide high dividend apply quality screen have aum charge fee basis point year sector look fund have high exposure information technology health care industrial allocation respectively sep fund top holding be johnson johnson jnj free report apple inc aapl free report microsoft corporation msft free report allocation respectively sep fund have return year year date sep have dividend yield currently have zack etf rank buy medium risk outlook schwab dividend equity etf schd free report fund seek provide cheap exposure company provide high dividend have aum charge fee basis point year sector look fund have high exposure consumer staple information technology industrial allocation respectively jun fund top holding be verizon communication inc vz free report pfizer inc pfe free report intel corp intc free report allocation respectively sep fund have return year year date sep currently have zack etf rank hold medium risk outlook want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2449,MRK,sep issue update report ligand pharmaceutical incorporate lgnd free report ligand lead captisol formulation technology platform have allow enter partnership several lead drug company novartis ag nvs free report merck co inc mrk free report amgen inc amgn free report thus turn provide fund form milestone royalty payment ligand receive royalty milestone payment several fda approve product use captisol technology ligand major royalty revenue come sale key partner asset novartis kyproli amgen promacta other latest product approval include spectrum evomela lundbeck carnexiv melinta therapeutic baxdela apart several candidate be late stage development expect bring royalty company once commercialize regard company internal pipeline various candidate be observation development indication diabetes such extremely advanced candidate be lgd presently undergo phase ii study treat type ii diabetes month company report positive top line result study further expect lgd bring future licensing opportunity nonetheless ligand entry medical device segment acquisition multiple program own cormatrix be also encourage however ligand obtain captisol single supplier hovione major global supplier active pharmaceutical ingredient drug product intermediate locate portugal interruption captisol supply hit company result make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2450,MRK,issue update research sanofi inc sny free report sep sanofi perform quite well first half earning rise report basis first half constant currency rate cer year year basis first halfnet sale rise report basis cer january sanofi swap merial animal health business boehringer ingelheim consumer healthcare chc business reflect exchange full consolidation sanofi european vaccine operation sale rise constant structure cer remind investor sanofi terminate sanofi pasteur msd joint venture merck co inc mrk free report europe december last year strong performance genzyme specialty care genzyme vaccine unit be make accelerate decline diabetes franchise support top line fact second quarter conference call sanofi raise previously issue profit outlook backed better expect performance first half cost discipline however tough payer environment hurt sale thediabetesunit continue strong performance genzyme unit especially multiple sclerosis drug aubagio lemtrada rare disease drug myozyme fabrazyme be positive vaccine unit be also expect perform well sale include emerge market rise cer genzyme unit cer vaccine unit first half meanwhile sanofi be quite optimistic sale prospect newly launch drug dupixent treat atopic dermatitis drug be launch unite state march generate sale second quarter backed strong demand management be pleased drug uptake be optimistic sale prospect dupixent prove be important growth driver company other dupixent other new drug kevzara launch june soliqua once daily titratable fix ratio combination lantus lyxumia launch unite state january also bring higher sale back half year however management expect diabetes franchise sale decline faster second half due impact formulary exclusion cvs health corporation cvs free report unitedhealth group difficult comparison last year diabetes sale decline first half sanofi diabetes franchise be significant pressure key product lantus face increase competitive pressure payor level biosimilar competition several european market japan cardiovascular franchise also remain be see sale trend sanofi pcsk therapy praluent improve second half uptake pcsk inhibitor praluent amgen inc amgn free report repatha have be slower expect due significant payer utilization management restriction unite state limit market access europe praluent uptake remain limit guideline support broader use treatment be issue phase iii cardiovascular outcome study datum be also generic competition continue hurt sale many key drug sanofi portfolio include blockbuster drug plavix challenge believe new drug approval solid pipeline aggressive saving pave way growth sanofi more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2451,MRK,quite few pharmaceutical industry merger include large deal be card now tax reform be place tax bill be sign law president donald trump december last tax rate corporate now go boost profit large drug biotech company meanwhile change tax code also allow company bring back huge cash hold overseas time tax rate also tax cut be expect prevent inversion be rampant drug industry change definitely leave more cash hand drug biotech company cash be invest merger acquisition have be few compare gilead gild free report nearly acquisition kite pharma johnson johnson jnj free report acquisition swiss biotech actelion be only noteworthy deal week senior executive largest pharmaceutical biotech company discuss impact tax reform merger acquisition plan use excess cash jp morgan healthcare conference ceo say brent saunder chief executive officer ceo allergan agn free report say first half year be likely see smaller deal such celgene celg free report bigger high profile merger large pharmaceutical biotech company probably happen latter half year next year last week celgene announce have offer buy small cancer drug developer impact biomedicine read more celgene acquire impact biomedicine boost pipeline lilly lly free report ceo dave rick chief financial officer dominic caruso say tax cut american company compete better foreign counterpart operate better tax environment caruso say new tax law provide more flexibility ease analysis term get transaction do same line merck mrk free report ceo meg tirrell say have access overseas cash give more financial flexibility think different way go transaction tirrell however confidently say even new tax law be implement company have enough power balance sheet make bolt acquisition want do michel vounatsos biogen biib free report ceo smartly argue tax overhaul spur activity rationale activity not be cash available go say be look set potential target gilead ceo john milligan say tax reform be good company allow plan long term fda approval process be quite lengthy meanwhile maintain goal investing replenish pipeline also say excess cash allow clean balance sheet repay debt conclusion overall be quite clear drug industry be optimistic tax reform fuel greater activity be major drug biotech player struggle organic growth need infusion new growth driver pipeline product portfolio internal development buyout strategic licensing deal be therefore inevitable innovation starve drug biotech company look growth highly competitive global marketplace give take several year million dollar develop new therapeutic scratch large pharmaceutical company sit huge pile cash prefer buy innovative small mid cap biotech company build pipeline matter company look buy drug biotech stock be current sale performance latter drug product prospect sale growth quality pipeline wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2452,MRK,dog dow strategy have history outperform dow jone industrial average long term lag return just compare gain blue chip index dog have generate outsized return previous year miss only dog dow represent highest yielding blue chip company dow jone industrial average be favor market thus have higher dividend yield due depress stock price high dividend yield suggest stock be oversold territory rebound faster other stock fundamental change such strategy combine element dividend value investing give hone stock be cheaper peer unlikely cut dividend generate market return lead juicy yield fact new tax legislation act biggest catalyst stock lead dividend hike thereby result higher shareholder return read sector etfs stock set explode higher tax cut let meet year dog dow dog dog dow verizon vz free report international business machine ibm free report pfizer pfe free report exxon mobil xom chevron cvx merck mrk free report coca cola ko free report cisco system csco free report be list astounding performance boee ba free report caterpillar cat lead departure have be replace procter gamble pg general electric ge free report investor note ge be unusual inclusion dog give cut dividend late read steer clear ge bet industrial etfs instead dog dow lead year give recovery oil natural gas price spur outperformance integrate oil giant xom cvx be respectively start year additionally general electric biggest laggard last year have turn hottest stock start year stock logged biggest weekly percentage gain nov first week new year however performance dow dog differ bull bear market great caution need be exercise investing company still look invest stock do so basket form etfs lower risk have highlighted etfs heavy exposure dog dow look exciting etf betselement dj high yield select etn dod free report be etn option provide investor pure play highest dividend yielding security dow jone industrial average equal proportion track dow jone high yield select total return index charge bps annual fee note have only aum trade light volume share average daily basis dod shed start new year alp sector dividend dog etf sdog free report fund apply dog dow theory sector sector basis used be easily do select highest yielding security gic sector equally weigh higher yielding stock appreciate order bring yield line market potentially lead outsized gain approach result portfolio stock security accounting more total asset fund have accumulate asset base trade good volume more share charge bps annual fee have gain first few trading session guggenheim dow jone industrial average dividend etf fund offer alternative strategic beta approach dow jone industrial average weighting security dividend yield rather price follow dow jone industrial average yield weight index hold dow stock basket dog account portfolio product charge bps annual fee investor have amassed asset base trade paltry volume share day average have add so far year read dow etfs more upside ahead ishare core high dividend etf hdv free report product provide exposure dividend stock tracking morningstar dividend yield focus index dog dow account portfolio suggest dog dominate return fund hdv be largest most popular etfs large cap space aum average trading volume share charge bps fee year have add first few trading session first trust morningstar dividend leader index fund fdl free report aum fund follow morningstar dividend leader index total hold stock have show dividend consistency sustainability dog dow collectively accounting asset volume be good exchange nearly share day average expense ratio come fund be so far year read dividend etfs least yield gain want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2453,MRK,nordisk nvo free report announce health canada have approve ozempic semaglutide injection improve glycemic control adult type ii diabetes mellitus metformin be not tolerate contraindicate ozempic once weekly glucagon peptide glp receptor agonist also be used together other antidiabetic drug diet exercise do not achieve adequate glycemic control share company have rally compare industry gain past year approval ozempic be base result phase iii sustain study result show person type ii diabetes be treat once weekly semaglutide experience statistically significant sustain blood glucose control compare merck mrk free report januvia sitagliptin astrazeneca azn free report once weekly bydureon exenatide extend release sanofi sny free report lantus insulin glargine placebo december fda approve ozempic once daily pre filled pen improve glycaemic control type ii diabetes patient european regulatory authority also adopt positive opinion recommend marketing authorization ozempicon dec additionally nordisk be make effort develop new treatment diabetes be core area expertise september company receive approval fast act insulin aspart fiasp other semaglutide key pipeline candidate include nonacog beta pegol approval drug give boost company revenue nordisk price nordisk price nordisk quotezack ranknovo nordisk carry zack rank buy see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2454,MRK,friday july first look gross domestic product gdp growth perhaps main signifier grow economy ratchete putt economy pretty much exactly expect growth averaged number consumer spending rise business spending go part be equipment sale grow employment cost index fall housing be government be inventory positive also revision show year higher originally report be lower first thought basically be glean quick glance be expectation be line expectation mean be small business confidence base election president trump last november have hold market haven moved much latest gdp announcement have go dow nasdaq earning wrap maker merck mrk free report post better expect earning report share opposed cent anticipate zack consensus estimate revenue also top expectation ahead have be look high growth melanoma treatment keytruda outperformed estimate quarter mark growth sequentially year year zack rank buy company american airline aal free report also top expectation bottom line report share compare expect be currently zack rank strong buy stock revenue also beat zack consensus bring represent growth year year share buyback cent dividend increase help put cap successful aal exxon mobil xom free report miss expectation earning report cent share opposed cent expect revenue beat zack consensus however report opposed zack consensus be call overall production be line year figure natural gas production be zack rank sell company tesla model wayfinally first delivery tesla tsla free report model car company first affordable electric only automobile occur today satisfying roughly individual have put reserve place line first model regard author sale business widely spread energy conscious company model look bring tesla brand garage neighborhood america elsewhere mark vickerysenior editorquestion comment article author click here
2455,MRK,year jul world hepatitis day whd be observed raise awareness viral hepatitis lead cause death world accord world health organization viral hepatitis cause death world many person remain unaware be infected same be type hepatitis hepatitis be main killer person live hepatitis person live hepatitis person live hepatitis live hepatitis be unaware status hepatitis together account liver cancer case world consider number be not surprise quite few pharma biotech company be work bring innovative treatment area market however challenge hepatitis virus hcv market exist form intense competition pricing pressure stock focushere be look key player hepatitis market biotech major gilead science inc gild free report be perhaps most well know name hcv market hcv drug include harvoni sovaldi epclusa recently approve vosevi hbv offering include viread vemlidy however foster city base company have see lot up down market gilead hcv franchise be major revenue contributor bring multus dollar sale increase competition pricing pressure result significant decline hcv product sale even gilead recently raise guidance hcv franchise sale be nevertheless expect witness significant decline gilead launch educational campaign encourage baby boomer get test accord company have be increase hcv antibody screening baby boomer campaign start result increase diagnosis well company estimate person be newly diagnosed hcv gilead be conduct additional study harvoni well vemlidy have early stage hbv candidate pipeline gs tlr agonist gilead be zack rank buy stock year date ytd company stock be lag rally industry belong see complete list today zack rank strong buy stock here large cap pharma company merck co inc mrk free report be big name hcv market accord information provide merck person have chronic hcv infection merck hcv portfolio comprise zepatier be launch last year pegintron victreli however company hcv franchise be not major revenue generator earlier year merck take major impairment charge related hcv candidate become part pipeline follow acquisition idenix decision be take base change product profile well change company expectation pricing market opportunity merck be zack rank stock ytd company stock be lag rally industry belong abbvie inc abbv free report also have major presence hcv market company hcv product include viekira pak technivie abbvie be currently seek approval maviret investigational pan genotypic regimen glecaprevir pibrentasvir once daily ribavirin free treatment have potential provide faster path virologic cure major hcv genotype gt maviret represent blockbuster potential help abbvie gain major market share once approve launch abbvie be zack rank hold stock abbvie stock have gain ytd perform better industry belong watertown base enanta pharmaceutical inc enta free report have collaboration abbvie protease inhibitor paritaprevir glecaprevir paritaprevir be key compound abbvie direct act antiviral daa regimen viekira pak other daa daa treatment regimen currently market hcv glecaprevir combination pibrentasvir maviret be currently regulatory review enanta earn royalty abbvie product sale meanwhile enanta be also work develop hbv pipeline focus be currently core inhibitor clinical candidate identification plan enanta be zack rank stock ytd enanta stock have gain outperform rally industry belong bottom linethe hcv market continue face challenge more treatment enter market result increase competition additional pricing pressure fact hcv drug have face immense scrutiny due high price say market nevertheless represent significant commercial opportunity information provide enanta market hcv therapy be worth hcv patient start usually witness surge follow introduction new drug market major part hcv infected person remain undiagnosed remain significant opportunity market awareness increase newly diagnosed patient seek treatment hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2456,MRK,new jersey base merck co inc mrk free report be research drive pharmaceutical product company well know product merck portfolio include remicade nasonex simponi vytorin zetia januvia janumet isentress pegintron maxalt cosopt trusopt temodar emend keytruda cozaar hyzaar zocor proscar proquad gardasil rotateq zostavax nuvaring however many peer merck be face headwind form generic competition several key product company sell consumer care business bayer oct meanwhile merck acquire hepatitis virus focuse company idenix pharmaceutical aug cubist pharmaceutical merck be also focuse immuno oncology merck have pretty good earning track record company deliver positive earning surprise last quarters average surprise estimate movement have be static past day currently merck have zack rank buy definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning beat merck surpass earning expectation company report ep consensus call ep cent revenue beat revenue report quarter also come expectation merck post revenue consensus estimate keytruda bring sale second quarter sequentially year year outlook merck maintain adjust earning guidance raise sale outlook marginally company expect adjust earning range include approximately negative foreign exchange impact versus previously revenue be expect range compare earlier forecast include negative currency impact approximately versus previously stock price impact share be pre market trading merck company inc price ep surprise merck company inc price ep surprise merck company inc quotecheck back later full mrk earning report hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionary still leave plenty money regular investor make right trade earlyee zack best stock play trend
2457,MRK,earning season be mean countless publicly trade company continue release quarterly earning report update investor company financial result provide insight economy have perform past quarter however insane amount press release earning season make easy investor become lose ocean report fortunately zack earning calendar list company be expect report earning give calendar date make useful organizational tool investor say let break few most important upcoming report check major company release earning report friday july exxon mobil corporation xom free report friday july market opencrude oil giant exxon mobil release quarterly earning report tomorrow morning market open zack consensus estimate call revenue represent year year growth additionally company be project report earning share constitute year year growth whopping exxon have collaborate russia explore potential commercial reserve country yet tension unite state russia lead sanction country thwart attempt exxon make capitalize oil reserve russia also exxon feature dividend yield be lowest major energy firm sit industry average fact zack rank sell turn head wrong reason company prepare release earning report chevron corporation cvx free report friday july market openenergy behemoth chevron be expect post quarterly earning report market open july zack consensus estimate call chevron real revenue report earning share constitute strong year year growth respectively however first quarter chevron generate just operate cash flow deal dividend capital expenditure trend be detrimental company continue next few quarters company be rely asset sale debt fill deficit also chevron mass production violence prone region nigeria pose additional risk investor chevron currently hold zack rank sell provide gloomy financial outlook move forward merck company inc mrk free report friday july market openmerck company be large global research drive pharmaceutical company discover develop manufacture vaccine medicine address unmet medical need more importantly company be expect release quarterly earning report tomorrow morning accord latest zack consensus estimate merck company be project report sale earning share merck feature impressive product portfolio pipeline include many candidate advanced stage development target multiple disease such atherosclerosis cancer diabetes cardiovascular disease company have continue prioritize pipeline so candidate highest potential get require support investor feel sense optimism merck currently sport zack rank buy have beaten earning estimate past operational quarters date back abbvie inc abbv free report friday july market openabbvie be global research base company focus develop marketing advanced therapy address world most complex disease accord zack consensus estimate abbvie be project report revenue earning share constitute year year growth respectively abbvie flagship product humira continue drive revenue inflammatory product have witness sale increase company expect humira real total sale more fact abbvie have defeat earning projection past operational quarters date back couple adequate zack rank hold instill confidence investor approach report more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2458,MRK,second quarter report cycle be full swing quarter undoubtedly be strong start jul member accounting index total market capitalization report result accord earning preview total earning index member be year quarter improvement revenue beat ratio be earning revenue earning momentum be expect continue season report total earning company second quarter be expect grow year year higher revenue follow earning growth first quarter increase revenue highest almost year pharma bigwig eli lilly company lly free report biogen inc biib free report release second quarter result week company beat earning revenue estimate raise sale earning expectation full year moreover vertex pharmaceutical incorporate vrtx free report amgen inc amgn free report report encourage second quarter result jul beating estimate count however glaxosmithkline plc gsk free report report mixed second quarter result same day beating earning miss sale let take look large cap pharma company be set report second quarter result jul abbvie inc abbv free report abbvie be schedule release earning market open have deliver positive earning surprise last quarter abbvie earning performance have be mixed earning beating expectation last quarters meeting same remain result average positive surprise quarter abbvie have earning esp zack rank hold do not conclusively show abbvieis likely beat estimate quarter zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter abbvie inc price ep surprise abbvie inc price ep surprise abbvie inc quoteabbvie key drug humira be perform well be expect continue do well second quarter imbruvica have be record strong sale past few quarters expect trend continue however hcv franchise continue be pricing pressure read more abbvie earning disappointment store merck co inc mrk free report merck be also schedule announce result open bell merck have beaten estimate last quarters result average positive surprise last report quarter merck deliver positive surprise merck company inc price ep surprise merck company inc price ep surprise merck company inc company have earning esp zack rank buy thus do not look poise deliver beat time see complete list today zack rank strong buy stock here merck new product keytruda cancer zepatier hcv bridion sugammadex injection drive top line quarter however company be expect face headwind form genericization increase competition negative impact currency exchange read more merck pull surprise earning season more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2459,MRK,second quarter earning season be strong start july approximately company index total membership have report result deep look result show earning company report so far be year year higher revenue have top earning estimate have beat revenue estimate however pace growth be first quarter line quarter average have improve quarter average go forward estimate third quarter be go estimate growth be start quarter pharma sector have more less combat overall decline financial market maintain momentum last week industry bellwether johnson johnson jnj free report report mixed second quarter result beating earning miss sale swiss major novartis ag nvs free report report encourage second quarter result meanwhile biotech giant biogen inc biib free report surpass expectation earning sale second quarter raise annual guidance let take look biotech company be set report second quarter result jul bristol myer squibb company bmy free report be schedule report open bell last quarter company beat earning estimate bristol myer have decent track record so far company earning beat estimate trail quarters average positive surprise currently company have zack rank hold earning esp current rank increase predictive power esp esp make unlikely stock beat quarter uncover best stock buy sell re report earning esp filter bristol myer high profile immuno oncology drug opdivo be expect continue drive company top line be report quarter first quarter see stability second line lung cancer recent fda approval merck co inc mrk free report keytruda first line treatment metastatic nonsquamous nsclc impact sale read more offing bristol myer earning bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quotecelgene corporation celg free report be schedule report open bell last quarter company beat expectation celgene key product revlimid be expect continue be main growth driver first quarter drive share gain important market longer treatment duration newly diagnosed multiple myeloma mm other key product pomalyst imnovid abraxane otezla continue perform well second quarter call investor be expect remain focuse company performance label expansion effort update pipeline front celgene have submit new drug application fda idhifa relapse refractory aml nda idhifa be grant priority review prescription drug user fee act pdufa action date aug celgene track record have be pretty decent company toppingearning estimate thrice trail quarters overall company have deliver average positive surprise currently company carry zack rank earning esp indicate likely earning beat quarter read more be celgene poise beat earning season celgene corporation price ep surprise celgene corporation price ep surprise celgene corporation quotealexion pharmaceutical inc alxn free report be schedule report result open bell last report quarter company earning surpass zack consensus estimate alexion blockbuster drug soliris continue perform well label expansion drug additional indication be expect boost revenue new product strensiq be do well kanuma lag expectation management be reassess strategy drug go forward alexion track record be excellent company have consistently top expectation last quarters average positive earning surprise currently company carry zack rank earning esp indicate be likely beat estimate quarter read more be beat store alexion earning season alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2460,MRK,yesterday big pharma player eli lilly company lly free report report better expect second quarter result raise outlook year however share be investor focuse company update regard investigational rheumatoid arthritis ra treatment baricitinib here be look few key takeaway lilly conference call do key drug perform lilly second quarter revenue increase year quarter top zack consensus estimate new product trulicity taltz basaglar jardiance lartruvo cyramza perform well drive volume growth late life cycle product ciali forteo drive price growth alimta continue face significant competitive headwind zyprexa cymbalta evista strattera axiron be impact loss exclusivity ciali be also affected lower volume reflect decline overall erectile disorder ed market well presence generic animal health revenue decline quarter reflect market access pressure competitive pressure cattle swine read more lilly earning top baricitinib re filing delay baricitinib face significant delaylilly announce be delay least month resubmission regulatory application baricitinib be be develop collaboration incyte incy free report mean resubmission not take place year fda have issue complete response letter crl baricitinib earlier year april time agency have tell company be unable approve baricitinib once daily oral medication treatment moderate severe ra current form fda have ask additional clinical datum determine most appropriate dose well further characterize safety concern treatment arm lilly disagree fda conclusion believe comprehensive clinical datum support positive benefit risk profile company enter discussion fda determine kind study need better define benefit risk profile baricitinib meanwhile lilly incyte have plan explore baricitinib other indication late stage study psoriatic arthritis slate commence next year study atopic dermatitis lupus continue phase ii atopic dermatitis datum be present scientific forum year end note baricitinib be approve eu trade name olumiant feb european medicine agency ema committee medicinal product human use chmp recently agree label be update include precaution patient have risk factor deep venous thrombosis dvt pulmonary embolism pe oncology strategylilly provide depth look oncology strategy company strategy involve build key treatment cyramza lartruvo abemaciclib foundational agent focus develop new standard care change therapy clear very high bar span variety mechanism include immune oncology now lilly focus candidate priority internal development additional candidate mab csf mab merestinib study datum pending rest molecule pipeline be partner molecule have make lilly priority development list include abemaciclib be already fda review tim mab pd mab erk inhibitor tgfb ri ki pi mtor inhibitor prexasertib molecule be earmark external partner development asset be own third party lilly be look partner remain fgfr adc ralimetinib fgfr inhibitor notch inhibitor galunisertib cxcr peptide antagonist emibetuzumab bottom lilly deliver beat raise quarter company result get overshadowed baricitinib update investor be disappoint delay resubmission baricitinib regulatory filing company say be minimum delay month several product face generic competition competitive pressure increase lilly need focus bring new product market company decision prioritize oncology pipeline make sense lilly be zack rank buy stock see complete list today zack rank strong buy stock here year date lilly share have gain just top industry rally watch earning report other large cap pharma company merck co inc mrk free report pfizer inc pfe free report merck zack rank stock have pretty good earning track record have surpass expectation last quarters average surprise merck be report result jul pfizer track record be mixed company top expectation last quarters pfizer be report aug have positive earning esp second quarter hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2461,MRK,benchmark turn mixed performance monday be largely due fact bond yield increase lead investor exit utility telecom stock also sale johnson johnson fall release new drug renflexis merck co also weigh dow other hand nasdaq end green tech rally continue ahead major earning sector slate week dow jone industrial average djia decline point close index inx fall slide point close apart nasdaq composite index ixic close add point total share be trade monday lower last session average share decline issue outnumber advancer nyse ratio nasdaq ratio favore advancer bond yield go utility yield year treasury note increase have negative ramification safe haven such utility telecom selloff bond be responsible surge rate lead investor offload utility telecom stock favor safer fix income counterpart result weigh index johnson johnson disappoint share price tankshare johnson johnson jnj free report fall monday be largely due fact merck co mrk free report together south korean partner samsung bioepis co ltd have start selling renflexis less expensive alternative version johnson johnson rheumatoid arthritis drug remicade unite state drug sell astounding discount list price remicade move be tout bring price widely sell medicine general trend price generic medicine show once multiple biosimilar drug become accessible price drop rapidly due stiff competition rival furthermore come jolt healthcare heavyweight pfizer inc launch inflectra late last year percent discount list price later drop discount tech stock show stellar close record high monday primarily due splendid performance broad base gain technology stock come just earning release faang stock such amazon com inc amzn free report facebook fb free report be due later week year facebook apple inc aapl free report amazon netflix inc nflx free report alphabet inc googl free report have gain primary reason nasdaq recent gain have be splendid performance netflix share jump add subscriber july exist home sale exist home sale have take hit due acute shortage property time demand be high house be sale market last month skid year median house price have also increase year time additionally national association realtor announce monday exist home sale drop unit last month stock make headlinescore laboratory earning top estimate sale lagcore laboratory clb free report report second quarter adjust diluted earning share surpass zack consensus estimate read more hibbett dim view eclipse entry ecommerce stock fallshibbett sport inc hibb free report announce comparable store sale comp second quarter fiscal fall much read more more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2462,MRK,inc agen free report be expect report second quarter jul last report quarter deliver positive earning surprise moreover trail quarter average surprise be notably share price have increase year date outperform industry rally let see thing be shape company quarter earning whispersour proven model show be likely beat earning quarter have right combination key ingredient positive earning esp zack rank strong buy buy hold have significantly higher chance beating earning zack esp have earning esp most accurate estimate be loss cent zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank currently carry zack rank combine positive esp make reasonably confident earning beat note caution stock zack rank sell rate go earning announcement factor playagenus be immuno oncology company focuse discovery development checkpoint modulator vaccine adjuvant treatment cancer earn revenue only fee receive collaboration license agreement currently company be evaluate agen phase study incagn phase ii study treatment solid tumor fact have initiate phase study ox agonist antibody incagn phase ii study collaboration incyte expect begin combination study agen agen second half second quarter conference call investor be likely remain focuse company update initiation combination study antibody be expect focus advancement additional checkpoint modulator antibody vaccine clinic come quarters january enter clinical trial collaboration national cancer institute nci evaluate prophage hsppc conjunction merck co inc mrk free report pd therapy keytruda phase ii study evaluate effect prophage conjunction keytruda overall survival rate patient newly diagnosed glioblastoma ndgbm march company restructure operation decision be take order cut cost sharpen focus develop key product candidate company plan close basel site consolidate key function cambridge lexington term move be anticipate result elimination position next month furthermore transition consolidate certain key management position objective streamline leadership reduce cost inc price ep surprise inc price ep surprise inc quotestock warrant lookhere be health care stock want consider model show have right combination element post earning beat quarter intercept pharmaceutical inc icpt free report have earning esp zack rank company be expect release result aug see complete list today zack rank stock here gilead science inc gild free report have earning esp zack rank company be schedule release result jul more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2463,MRK,hurdle trump plan repeal replace obamacare healthcare be second best perform sector year lag technology optimism come especially encourage industry trend hope favorable policy environment trump administration plan focus ease regulatory hurdle rather lower drug price expedite new drug approval additionally shift investor sentiment defensive sector healthcare generally outperform period low moderate growth rise geopolitical uncertainty have lead rally healthcare stock read top rank healthcare etfs long term investor such popular fund health care select sector spdr fund xlv free report vanguard health care etf vht free report ishare healthcare etf iyh free report fidelity msci health care index etf fhlc free report have gain least so far year trend be likely continue head earning season big name pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stockspfizer have zack rank earning esp indicate reasonable chance beating estimate quarter stock see earning estimate revision yet be report quarter deliver negative earning surprise past quarters additionally have impressive growth momentum style score respectively value style score be favorable pfizer be schedule report earning august open bell read build winning etf portfolio second half pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotemerck be expect report result july market open have zack rank earning esp make surprise prediction difficult stock witness positive earning estimate revision penny past day be report quarter deliver positive earning surprise last quarters average beat merck have strong value momentum style score unfavorable growth style score merck company inc price consensus ep surprise merck company inc price consensus ep surprise merck company inc quoteamgen have zack rank earning esp indicate less chance beating estimate quarter earning surprise track past quarters be robust average positive surprise amgen witness negative earning estimate revision couple cent past day yet be report quarter stock have solid value momentum style score respectively growth style score look dull amgen report earning july market close amgen inc price consensus ep surprise amgen inc price consensus ep surprise amgen inc quoteabbvie have zack rank earning esp indicate less chance beating estimate quarter company deliver positive earning surprise last quarters average beat see positive earning estimate revision couple cent past month be report quarter stock have solid value style score growth momentum style score respectively be unimpressive company be schedule report july open bell read brighten outlook healthcare etfs focus abbvie inc price consensus ep surprise abbvie inc price consensus ep surprise abbvie inc quotegilead be expect release earning july market close have zack rank earning esp indicate reasonable chance beating estimate gilead deliver positive earning surprise last quarters average beat see earning estimate revision past month be report quarter have solid value momentum style score respectively growth style score look ugly gilead science inc price consensus ep surprise gilead science inc price consensus ep surprise gilead science inc quotebristol myer likely report earning july open bell have zack rank earning esp make surprise prediction difficult stock deliver positive earning surprise past quarters average beat witness positive earning estimate revision cent be report quarter have unfavorable value growth momentum style score respectively see healthcare etfs here bristol myer squibb company price consensus ep surprise bristol myer squibb company price consensus ep surprise bristol myer squibb company quotesum healthcare sector be expect post earning decline second quarter have dismal zack rank bottom surprise well be card suggest upside healthcare etfs particular xlv vht iyh have zack etf rank fhlc have zack etf rank want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2464,MRK,merck mrk free report japanese partner easai co ltd announce fda have grant breakthrough therapy designation btd combination regimen merck pd therapy keytruda easai multiple receptor tyrosine kinase inhibitor lenvima company be develop combination potential treatment advanced metastatic renal cell carcinoma rcc kidney cancer be btd keytruda second lenvima designation aim expedite development review drug intend treat serious life threaten condition provide patient access soon possible merck share have decrease past year underperform industry gain period fda grant btd combination regimen base datum rcc arm open label phase ib ii study study be currently evaluate keytruda lenvima cancer indication keytruda be merck blockbuster immunotherapy drug approve several cancer indication easai lenvima be approve single agent treat differentiate thyroid cancer combination novartis nvs free report chemo drug afinitor everolimus advanced rcc follow prior angiogenic therapy apart lenvima merck have collaborate several company include amgen inc amgn free report incyte glaxo pfizer inc pfe free report separately evaluation keytruda combination other regimen merck company inc price merck company inc price merck company inc quotemerck carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2465,MRK,amgen amgn free report partner ucb announce marketing authorization application maa seek approval evenity treat osteoporosis have be accept european medicine agency ema amgen be look get evenity approve treatment osteoporosis postmenopausal woman man increase risk fracture europe share company have increase past year outperform industry decline period maa include datum pivotal phase iii study frame arch bridge postmenopausal woman osteoporosis postmenopausal woman osteoporosisat high risk fracture man have osteoporosis evenity treat osteoporosis increase bone formation reduce bone resorption simultaneously increase bone mineral density bmd reduce risk fracture arch study evenity show statistically significant superior fracture risk reduction postmenopausal woman compare current standard care osteoporosis merck co inc mrk free report fosamax ema review potential evenity increase bmr well reduce risk fracture also cardiovascular safety signal arch study remind investor biologic license application bla seek approval evenity same indication unite state be issue complete response letter crl fda july crl be issue due cardiovascular side effect observed arch study bla include datum only frame study fda have request resubmission application additional datum arch bridge study separate press release amgen report mechelen belgium base biocartis group have sign development agreement amgen develop former idylla tm cdx biomarker test analyze novel oncology compound be used treatment certain solid tumor amgen inc price amgen inc price amgen inc quotezack rank stock consideramgen currently carry zack rank hold couple better rank stock pharma sector include celldex therapeutic inc cldx free report catabasis pharmaceutical inc catb free report stock carry zack rank buy see complete list today zack rank strong buy stock here celldex loss estimate remain stable cent cent last day company deliver positive earning surprise trail quarters average beat catabasis loss estimate narrow cent last day company deliver positive earning surprise trail quarters average beat zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
2466,MRK,merck co inc mrk free report announce phase iii study evaluate pd therapy keytruda monotherapy treatment high risk melanoma meet primary endpoint recurrence free survival rfs keytruda be already approve many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer interim datum keynote study show treatment keytruda adjuvant therapy surgically resect high risk melanoma patient lead significantly improve rfs compare placebo other word keytruda show potential extend duration disease recur high risk melanoma patient study continue evaluate other key endpoint include overall survival result study be submit regulatory authority also be present future medical meeting merck be conduct study collaboration european organisation research treatment cancer eortc share merck have decline past year industry surge keytruda second largest product merck portfolio be key top line driver merck fact keytruda be continuously grow expand new indication market globally keytruda development program also significantly advanced several key regulatory approval further drive sale keytruda be be study more type cancer more study include combination study merck be collaborate several company include amgen inc amgn free report incyte glaxo gsk free report pfizer inc pfe free report separately evaluation keytruda combination other regimen press release merck announce fda have accept new drug application nda investigational candidate doravirine nucleoside reverse transcriptase inhibitor nnrti treatment hiv infection merck be look get doravirine approve once daily single tablet combination other antiretroviral agent also once daily fix dose combination regimen contain doravirine lamivudine tc tenofovir disoproxil fumarate tdf dor tc tdf fda be expect give decision application oct merck carry zack rank hold see complete list today zack rank strong buy stock here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
2467,MRK,biosimilar space be focus key fda approval biosimilar contain version active substance already approve original biological drug development biosimilar be technically more challenge development generic drug former require clinical study patient be engineer match reference drug quality safety efficacy due complex nature product development regulatory pathway biosimilar differ significantly generic biosimilar be usually less expensive brand drug thus market same be highly lucrative acceleration approval biosimilar market have thus attract lot many player be witness rapid growth here go progress report merck co inc mrk free report launch reneflexis biosimilar version remicade infliximab unite state july approval april fda also grant tentative approval lusduna nexvue biosimilar version lantus basal insulin pre filled dose device merck currently carry zack rank hold see complete list today zack rank strong buy stock here remicade have be see intense competition biosimilar space late note pfizer inc pfe free report supply inflectra biosimilar version remicade pfizer be strong player biosimilar market december pfizer get fda approval remicade biosimilar ixifi treatment rheumatoid arthritis crohn disease pediatric crohn disease ulcerative colitis ankylose spondylitis psoriatic arthritis plaque psoriasis company have portfolio market biosimilar medicine outside unite state include inflectra retacrit epoetin zeta nivestim filgrastim strong pipeline distinct biosimilar molecule various stage development pfizer currently carry zack rank generic leader mylan nv myl free report be also explore biosimilar market have potential grow early last december mylan partner biocon ltd announce fda approval ogivri trastuzumab dkst biosimilar version herceptin trastuzumab ogivri have be approve indication include label reference product herceptin include treatment overexpressing breast cancer metastatic stomach cancer ogivri be first fda approve biosimilar herceptin first biosimilar mylan biocon joint portfolio mylan currently carry zack rank meanwhile amgen inc amgn free report allergan plc agn free report win fda approval biosimilar version avastin september treatment multiple type cancer note mvasi be first biosimilar approve unite state treatment cancer amgen biosimilar version humir amjevita be already approve fda be launch unite state jan company resolve litigation abbvie inc abbv free report company have also submit bla fda abp biosimilar candidate herceptin july note company be collaborate oncology biosimilar include abp be second be submit fda approval company also submit marketing authorization application european medicine agency candidate note amgen have total biosimilar pipeline have be approve fda amgen currently carry zack rank boehringer ingelheim cyltezo adalimumab adbm biosimilar humira be also approve fda august medical generic drug industry yr return medical generic drug industry yr slew fda approval expect investor remain focuse space future zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2468,MRK,merck mrk free report announce fda have grant tentative approval lusduna nexvue company biosimilar version sanofi sny free report lantus insulin glargine treatment person type type ii diabetes lusduna nexvue deliver insulin pre filled dose device note candidate be formerly know mk fda have grant provisional approval trade name lusduna nexvue be used once product be make available merck share have underperform industry so far year stock have gain compare broader industry increase lusduna meet regulatory safety efficacy standard approval be tentative due ongoing litigation sanofi final approval lusduna be subject resolution sanofi litigation september last year sanofi sue merck patent infringement lantus litigation automatically invoked stay final fda approval lusduna month event court rule favor merck be sooner notably lantus have be major contributor sanofi top line have account total sale however company consider conditional approval significant milestone be advance candidate step closer market remind investor merck be develop lusduna collaboration samsung bioepis agreement term merck be responsible clinical development manufacturing bioepis be partially funding development currently application regulatory approval lusduna treatment patient type type ii diabetes be review eu remind investor eli lilly company lly free report be already marketing follow insulin glargine product basalgar dec separate press release merck announce collaboration pfizer pfe free report modernization pharmaceutical packaging introduction corning valor glass enhance storage delivery drug formulation merck company inc pricemerck company inc price merck company inc quotezack rankmerck currently carry zack rank buy see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2469,MRK,bristol myer squibb company bmy free report be schedule report first quarter result jul open bell last quarter company beat earning estimate bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quotebristol myer stock have lose past year underperform industry remain flat period bristol myer have decent track record so far company earning beat estimate trail quarters average positive surprise bristol myer surpass expectation time well let see thing be shape quarter factor impact quarterbristol myer high profile immuno oncology drug opdivo continue drive company top line be report quarter opdivo sale be drive melanoma second line small cell lung cancer renal cell carcinoma indication recent label expansion classical hodgkin lymphoma head neck cancer indication boost drug sale however lung cancer market become more competitive due entry tecentriq bristol myer expect second line lung cancer business be competitive pressure result sale drug market be project be flat first quarter see stability second line lung cancer recent fda approval merck mrk free report keytruda first line treatment metastatic nonsquamous nsclc further impact sale other hand virology business be expect decline significantly due competition epclusa hiv business continue face competitive pressure recent launch other company same space be expect further impact sustiva franchise bristol myer be also look diversify portfolio development bms nash positive note bristol myer raise earning expectation concurrent first quarter result company now project earning range share old guidance revenue be expect grow mid single digit range due strong trend business particularly key product opdivo eliquis yervoy gross margin be project decline year progress be estimate range expense be expect increase low double digit range second quarter earning call investor be expect focus company performance label expansion effort opdivo update business development activity earning whispersour proven model do not conclusively show bristol myer be likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen unfortunately be not case here elaborate zack esp earning esp bristol myer be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank bristol myer currently carry zack rank increase predictive power esp however esp make unlikely stock beat earning quarter be caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock warrant lookhere be health care stock want consider model show have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report have earning esp carry zack rank company be schedule release result jul see complete list today zack rank stock here gilead science inc gild free report have earning esp carry zack rank company be schedule release result jul make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2470,MRK,merck co inc mrk free report be report second quarter earning jul market open last quarter company deliver positive earning surprise merck performance have be pretty impressive company exceed earning expectation consistently average positive earning surprise last quarters be merck share rise year so far compare unfavourably increase industry factor considermerck new product keytruda cancer zepatier hcv bridion sugammadex injection drive top line quarter believe keytruda sale likely be drive strong uptake launch new country expansion additional indication especially first line nsclc mar apr keytruda receive fda eu approval refractory classical hodgkin lymphoma chl first keytruda approval hematologic malignancy indication keytruda be approve first line combination therapy lung cancer first fda approval combination therapy expand indication especially combination therapy add keytruda sale quarter apart continue strength melanoma indication rapid penetration head neck cancer indication boost keytruda sale last couple month be series regulatory approval label expansion keytruda advanced bladder cancer expect update management plan same conference call first quarter conference call management have say be work secure reimbursement keytruda first well second line nsclc indication outside lung cancer sale become much larger contributor outside country year progress expect update conference call meanwhile ongoing launch globally be likely support zepatier sale however company continue face headwind form genericization increase competition negative impact currency exchange sale remicade lose exclusivity europe face stiff biosimilar competition region nasonex generic version launch mar cubicin lose patent protection jun zetia lose market exclusivity dec likely decline quarter sluggish growth integrase class continue competitor dynamic europe continue affect isentress sale investor focus remain performance merck dpp inhibitor januvia pricing pressure hurt sale januvia janumet franchise first quarter remain be see trend improve second quarter vaccine animal health franchise also boost sale quarter earning whispersour proven model do not conclusively show merck be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be most accurate estimate well zack consensus estimate stand cent uncover best stock buy sell re report earning esp filter zack rank merck zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision merck company inc price ep surprise merck company inc price ep surprise merck company inc quotestock considerstock pharmaceutical sector also have positive earning esp favorable zack rank be nordisk nvo free report schedule release result aug have earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report have earning esp zack rank company be schedule release result aug vertex pharmaceutical incorporate vrtx free report have earning esp zack rank company be schedule release result jul make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2471,MRK,second quarter earning season pharma sector kick week industry bellwether johnson johnson jnj free report swiss pharma giant novartis nvs free report report result meanwhile merck mrk free report gain tentative approval fda follow biologic basal insulin company launch immediately due ongoing patent infringement case recap week most important storiesa look novartis result industry bellwether swiss pharma giant novartis report second quarter result earlier week surpass earning expectation revenue fall short company raise outlook year operational sale growth expect accelerate second half factor help include earlier launch tremfya more moderate erosion remicade business compare previous expectation well continue strong performance key drug contribution new product medical device segment be also expect pick back half year strong growth vision care segment expect continue consumer segment however continue be impact weaker macroeconomic dynamic read more beat earning lag sale up view novartis second quarter result be better expect company beating earning revenue entresto cosentyx continue perform well sandoz sale decline reflect pricing pressure meanwhile alcon performance improve encourage company raise alcon sale outlook low single digit growth read more novartis top earning sandoz face pricing pressure novartis stock have gain year date outperform rally industry belong tentative approval merck follow basal insulin merck get tentative approval fda biosimilar version sanofi sny free report blockbuster diabetes drug lantus lusduna nexvue insulin glargine injection technically follow biologic basal insulin have be develop merck funding samsung bioepis however merck have launch product due automatic month stay result patent infringement lawsuit initiate sanofi sep merck launch product expiry stay period favorable court ruling occur first note biosimilar version lantus be already market form lilly lly free report boehringer ingelheim basaglar enter market mid dec lantus sale decline first quarter include decline reflect lower average net price patient switch toujeo impact formulary exclusion pricing pressure increase once merck product enter market sanofi merck be zack rank buy stock see complete list today zack rank strong buy stock here sanofi nanobody deal ablynx sanofi have enter research collaboration global exclusive licensing agreement belgian company ablynx focuse development nanobody base therapeutic treatment various immune mediate inflammatory disease deal sanofi gain access certain nanobody ablynx exist portfolio well ablynx scientist proprietary nanobody platform sanofi make upfront payment other financial detail include milestone payment well tiered royalty collaboration sanofi be look expand drug discovery pipeline immunology eu nod astrazeneca kyntheum astrazeneca azn free report psoriasis treatment kyntheum gain approval eu iceland liechtenstein norway company say partner leo pharma gain approval use biologic medicine treatment moderate severe plaque psoriasis adult be candidate systemic therapy kyntheum be approve trade name siliq feb black box warning regard risk patient suicidal thought behavior cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index gain last trading session major stock astrazeneca be gain last month astrazeneca be gain see last pharma stock roundup here fda panel vote novartis car drug sny buy vaccine co next pharma world watch second quarter earning result company lilly bristol myer bmy free report astrazeneca other make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2472,MRK,issue update research report inc agen free report sep notably be immuno oncology company focuse discovery development checkpoint modulator vaccine adjuvant treatment cancer fact company have collaboration agreement number company not only provide fund form upfront milestone payment future royalty also validate company proprietary product platform have form collaboration merck co inc mrk free report incyte corporation incy free report develop multiple checkpoint antibody february agneus incyte amend agreement amend agreement convert ongoing gitr ox antibody program co funded development profit sharing arrangement royalty bearing program agreement incyte be responsible funding conduct global development candidate program be approve be entitle receive royalty global net sale approve product follow amend agreement receive accelerate milestone payment incyte related clinical development incagn gitr agonist incagn ox agonist program collaboration be eligible receive total future potential development regulatory commercial milestone company collaboration agreement player incyte merck not only validate technology platform also provide company fund fact note company qs stimulon adjuvant be partner glaxosmithkline gsk free report be key component multiple gsk vaccine program target prophylactic therapeutic impact variety infectious disease cancer moreover effort develop prophage vaccine glioblastoma multiforme be encourage be also explore different option advance prophage vaccine phase iii study newly diagnosed gbm alone collaboration third party also company be look partner fund study plan retain right unite state company announce strategic decision spin cell therapy business separate unit also have make decision so make smaller team entirely focus get product approve expect combine value separate company far exceed perceive value roof go forward however have approve product portfolio only few candidate mid stage development include prophage series vaccine number qs stimulon contain vaccine candidate company be still few year away bring product market hiccup development process candidate weigh heavily stock be highly dependent partner development candidate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2473,MRK,gilead science inc gild free report announce blockbuster hepatitis virus hcv infection drug sovaldi have now be approve china food drug administration cfda also drug be approve treatment adult adolescent age year infected hcv genotype component combination antiviral treatment regimen note sovaldi be first gilead hcv drug approve china note hcv be fourth most commonly report infectious disease china approximately patient hence approval country hold promise growth note sovaldi be approve unite state europe drug be currently approve country addition gilead be evaluate hcv single tablet regimen harvoni epclusa clinical trial site china gilead be know presence hcv market thank blockbuster hcv drug sovaldi harvoni hcv portfolio receive huge boost approval epclusa unite state june eu july become first only oral pan genotypic str consist sovaldi velpatasvir ns inhibitor treatment adult genotype chronic hcv infection fda approval vosevi sovaldi velpatasvir mg voxilaprevir mg tablet also boost company portfolio drug be single tablet regimen str re treatment chronic hepatitis virus infection adult genotype previously treat ns inhibitor contain regimen genotype previously treat sovaldi contain regimen ns inhibitor however hcv franchise be pressure due competition pricing issue note harvoni sovaldi epclusa face competition abbvie inc abbv free report viekira pak viekira xr other competition well pricing pressure intensified further launch merck co inc mrk free report zepatier gilead recently announce plan acquire kite pharma inc foray emerge field cell therapy kite be pioneer cell therapy have develop engineer cell therapy express chimeric antigen receptor car engineer cell receptor tcr depend type cancer acquisition diversify gilead portfolio poise company dominant position cellular therapy space note investor be expect gilead announce acquisition term give decline once lucrative hcv market due competitive pressure more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2474,MRK,agilent technology free report recently receive approval food drug administration fda cancer diagnostic name pd ihc pharmdx test be used case urothelial carcinoma uc squamous cell carcinoma head neck scchn be new step company effort expand grow cancer diagnostic market pdl ihc pharmdx test have already be approve melanoma well squamous small cell lung cancer nsclc now have be approve uc scchn patient too test enable physician unite state identify uc scchn patient still have disease progression platinum base chemotherapy be most likely benefit treatment opdivo opdivo be immunotherapy develop bristol myer squibb bms pd ihc pharmdx be develop collaboration opdivo maker bms currently test have lot more utility other pd assay market agilent role healthcare sector be witness revolution personalize medicine be take center stage provide improve patient care better manage cost administer most appropriate treatment individual have be find not treatment be suitable suffering specific disease require more specialize test advancement have far reach effect entire healthcare system personalize medicine considerably improve patient care reduce medical bill agilent have sign several collaborative agreement pharma biotech company include pfizer pfe free report astrazeneca azn free report bristol myerssquibb merck co mrk free report amgen eli lilly develop diagnostic used genomic base technology better treatment cancer bottom lineagilent be original equipment manufacturer oem broad base portfolio test measurement product serve multiple end market remain positive agilent broad base portfolio increase focus segment higher growth potential further company continue introduce high margin product accord report com worldwide cancer diagnostic market reach drive several technological advancement diagnostic platform moreover market have see advent hybrid imaging instrument enhance accuracy such pet ct spect ct advancement have take cancer diagnostic market new height believe new assay help agilent cash fast grow healthcare cancer diagnostic segment stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
2475,MRK,sep issue update research report impax laboratory inc impaxis company focuse development obesity treatment be base hayward impax anaphylaxis treatment epinephrine auto injector have show notable growth sale opioid analgesic oxymorphone boost growth prospect note impax have acquire certain generic product teva pharmaceutical industry ltd teva free report last year meanwhile launch generic version merck co inc mrk free report cardiovascular drug vytorin april be expect further boost impax revenue drug register sale first month approval generic version johnson johnson jnj free report concerta july also help sale growth end june company have abbreviated new drug application anda pending fda approval anda generic pipeline impax likely be able take advantage upcoming patent expiration pharma industry effort save cost impax initiate several process improve efficiency margin focus growth opportunity company have start consolidate stopping manufacturing pack facility company be also modify generic portfolio so eliminate low value product streamline operation company expect action save annualize cost tune end however generic industry be face pricing pressure have negatively impact revenue company marketing generic drug impax have lower earning guidance anticipation dampen revenue stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
2476,MRK,tuesday share company axovant science ltd axon free report have crash stock be currently share late morning trading say experimental alzheimer drug fail key late stage trial drug call intepirdine be be test patient suffer mild moderate alzheimer do not respond initial treatment late stage trial be highly anticipate intepirdine fail improve cognitive ability daily activity be also compare placebo be deeply disappoint trial result also be saddened million patient family impact alzheimer disease axovant ceo david hung say however believe fight alzheimer other important area unmet need neurology be too important be derail setback alzheimer be type dementia cause problem memory think behavior symptom develop slowly worsen time become severe enough interfere daily life alzheimer affect more american be sixth lead cause death be current cure alzheimer be treatment available symptom only drug have be approve treat symptom most recent drug approval axovant setback follow other company eli lilly lly free report merck mrk free report denmark lundbeck suffer fail alzheimer drug trial similar lundbeck drug idalopirdine intepirdine be so call ht antagonist work block ht receptor release acetylcholine be need normal cognition axovant isn give completely company be now testing intepirdine patient suffer condition know lewy body dementia disease symptom similar alzheimer parkinson trial result be expect end year company also test drug patient dementia be affect balance gait share axovant be year date stock experience nice rally back april dr hung come chief executive company have other drug development currently sit hold zack rank hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
2477,MRK,world heart day be observed year september raise awareness world cardiovascular cv disease cv disease more commonly know heart disease stroke be basically disease heart blood vessel accord world heart federation cv disease be biggest killer world accounting death year number expect cross factor contribute number include uncontrolled hypertension high cholesterol level obesity smoking diabetes sedentary lifestyle theme world heart day be share power focus inspiring person world be heart healthy focus be create heart healthy environment help reduce cardiovascular risk be work home simple change lifestyle include healthy eating exercise lower alcohol consumption give smoking be way cut even prevent risk cv disease accord fda person die cardiovascular disease day unite state add american year give statistic be not surprising several healthcare company devote significant amount dollar develop treatment device cardiovascular other disease increase risk heart issue accord gbi research report more product be active development cv disease focus be main indication hypertension heart failure dyslipidemia thrombosis importantly be not just healthcare company be involved fitness segment many cv disease be preventable address behavioral risk factor food consumption smoking lack exercise person be become more conscious health have lead tech company come fitness tracker help keep track heart rate calory burn sleep pattern help management lifestyle disease diabetes obesity world heart day come let take look well position stock segment market biotelemetry inc beat free report malvern pa base biotelemetry be wireless medical technology company provide health information aim improve quality life reduce cost care company provide cardiac monitoring service original equipment manufacturing primary focus cardiac monitoring device centralize core laboratory service zack rank buy stock have strong earning track record have surpass expectation last quarters recent acquisition lifewatch have position company largest provider remote healthcare service world biotelemetry look well position rapidly evolve connect health market expect serve more patient share biotelemetry have gain year date significantly outperform industry rally edward lifescience corp ew free report edward lifescience hold lead position patient focuse innovation structural heart disease critical care monitoring company portfolio include product annuloplasty ring catheter heart valf enable treatment patient cardiovascular disease edward lifescience be focuse develop structural heart therapy estimate global transcatheter aortic valve replacement tavr opportunity cross drive increase awareness expand indication improve technology share zack rank strong buy stock hold strong position approximately global surgical heart valve segment be year date compare industry rally company have consistently surpass earning expectation last quarters novartis ag nvs free report swiss drugmaker novartis have be news lately gain approval first car cell treatment unite state company be also key player heart failure segment zack rank stock have approve drug form entresto treatment heart failure reduce ejection fraction heart failure debilitating life threaten condition be estimate affect more person world heart failure patient suffer reduce ejection fraction novartis be work generate more datum entresto heart failure more active plan study novartis also have good earning track record earning surpass expectation last quarters share zack rank stock be year date compare industry rally addition stock be several other company involved therapeutic area include company merck mrk free report nordisk nvo free report eli lilly lly free report other company be key player diabetes market accord information provide american heart association adult diabetes be time more likely die heart disease adult diabetes merck lilly be zack rank hold stock nordisk be zack rank stock see complete list today zack rank stock here hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
2478,MRK,share merck mrk free report decline large cap pharma industry surge industry rally be backed strong quarterly result new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval continue strong performance legacy product play pivotal role bring large cap drug sector back track last year pharma giant astrazeneca azn free report nordisk nvo free report johnson johnson jnj free report lead front outperformed industry however merck miss opportunity suffer notable pipeline setback october merck decide not seek approval cetp inhibitor anacetrapib cholesterol management clinical profile be not strong enough support regulatory filing october company also announce delay readout important lung cancer study be due inclusion overall survival co primary endpoint keynote phase iii study keytruda first line lung cancer raise investor concern delay readout give competitor chance gain strength lung cancer market october merck also withdraw regulatory application europe be look get keytruda approve first line combination therapy lung cancer september merck discontinue development hcv combination program mk mk say hcv market be become extremely crowd also combination study keytruda multiple myeloma be place clinical hold follow report death keytruda group july keytruda be see key long term growth driver merck such setback do not bode well company remain be see strong performance new drug particularly keytruda strong vaccine animal health business cost save effort help merck pick keytruda second largest product merck portfolio be gain strong momentum new indication first line lung cancer fact keytruda be continuously grow expand new indication market globally keytruda development program also significantly advanced several key regulatory approval further drive sale merck global restructure program aim reduce cost structure increase efficiency intend reduce number manufacturing site include animal health site consolidate other facility company expect annual saving once restructure program be complete merck carry zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2479,MRK,merck mrk free report pfizer inc pfe free report announce fda have approve investigational oral sglt inhibitor steglatro ertugliflozin tablet steglujan ertugliflozin sitagliptin adjunct diet exercise improve glycemic control patient type diabetes mellitus steglujan be fix combination steglatro januvia sitagliptin be approve patient be eligible treatment combination apart drug fda also approve segluromet ertugliflozin metformin same indication patient already treat steglatro glucophage metformin inadequately controlled type diabetes mellitus patient be already treat combination ertugliflozin metformin so far year share merck have lose compare industry growth fda approve drug base datum phase iii study evaluate steglatro monotherapy combination januvia bristol myer squibb company bmy free report glucophage study also evaluate steglatro combination insulin sulfonylurea datum study show steglatro single agent combination januvia significantly reduce level measure blood glucose compare placebo steglatro also significantly reduce body weight patient be already receive combination januvia glucophage versus placebo drug also achieve significant reduction systolic blood pressure approval new drug boost merck diabetes portfolio comprise januvia janumet market drug have see volume growth first month have generate sale however merck receive complete response letter fda supplemental new drug application crl seek label expansion januvia janumet janumet xr april company be discussion fda resolve issue crl moreover merck also receive setback earlier month key immune oncology drug keytruda fail phase iii gastric cancer study merck company inc price merck company inc price merck company inc quotezack rank stock considermerck carry zack rank hold therapeutic incorporate cort free report be better rank health care stock carry zack rank buy see complete list today zack rank strong buy stock here earning share estimate have increase cent cent last day company deliver positive earning surprise trail quarters average beat company stock be so far year zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2480,MRK,have be banner year stock market trend be likely continue next year tax reform act major drive factor stock couple strong corporate earning accelerate economic growth many part world christmas tree symbolize good tiding let build similar tree stock loving investor rake big gain start base most valuable portion tree technology sector seem be perfect fit here be place top broad zack sector industry classification semiconductor general be expect outperform be cyclical sector tend move higher market rally new area such autonomous car cloud compute gaming wearable vr headset drone virtual reality device internet thing iot artificial intelligence continue fuel exceptional growth intel intc have zack rank strong buy seem excellent pick stock see solid earning estimate revision cent next year past day fall industry have zack rank top see complete list today zack rank stock here stock form leave tree be westlake chemical corporation wlk free report basic material sector acco brand corporation acco industrial product sector sector be expect benefit trump pro growth policy especially big spending infrastructure thus carry sector rank top westlake chemical have zack rank be part industry rank top have see solid earning estimate revision next year past day expect growth rate other hand acco brand see positive earning estimate cent next year past day expect earning estimate have zack rank buy industry rank top look best stock be first see top stock portfolio here top layer have select energy sector be expect be largest contributor earning growth hollyfrontier corporation hfc seem intriguing pick sector have rank top stock see solid earning estimate revision cent next year past day expect earning growth rate have zack rank industry rank top very top be star stock zack rank xoma corporation xoma have soar nearly year so far room more upside next year zack consensus estimate have moved loss loss cent rise earning estimate indicate analyst optimistic view earning indicate higher chance outperformance additionally stock boast solid industry rank top now be do tree structure time decorate bell candy light chocolate concentrate area expect benefit most tax reform bell candy be company be poise benefit tax policy bring offshore cash home reduce tax top hoarder be tech sector apple aapl microsoft msft free report cisco csco free report alphabet googl free report oracle orcl free report hold money overseas accord moody drug maker amgen inc amgn gilead science gild pfizer pfe free report merck co mrk free report also stash huge cash offshore be likely gain tax repatriation policy stock have zack rank hold banking stock be fairy light tree light dual tailwind rise rate tax cut accord keefe bruyette wood tax cut add median bank earning ab bernstein see earning share jump large bank mid cap bank be several choice bank new york mellon corporation bk free report currently have zack rank industry rank top company be expect generate double digit earning growth next year small cap stock pay highest effective tax rate be sweet treat be biggest beneficiary corporate tax cut accord thompson reuter datum company russell pay median effective tax rate larger multinational pay mega cap stock dow jone industrial average pay additionally tend outperform rise rate environment give spread top rank stock double digit earning growth potential include upland software inc upld free report farmer merchant bancorp inc fmao free report geopark ltd gprk petm express inc pet free report stock double year voila tree be bring bountiful return investor jingle santa bell look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2481,MRK,dow traverse choppy week marked gain loss even much vaunted tax legislation finally gain legislative approval index increase monday tax cut hope dip tuesday follow concern change adversely impact future monetary stimulus decline come wednesday follow pullback occur investor have already price impact tax cut ultimately index notch gain thursday bank telecom company pledge provide better pay employee last week dow increase last friday hit new time high follow optimism much await republican tax bill have garner sufficient support policymaker enable be pass follow week support senator bob corker marco rubio raise expectation tax related legislation not face further obstacle passage index gain last week follow optimism passage tax cut bill higher rate environment federal reserve finally increase benchmark interest rate quarter percentage point new rate interest hover further central bank official reiterate earlier projection possible rate hike dow index gain monday follow rise optimism much await republican tax bill be likely be pass week development be expect reduce corporate tax rate dow notch record close advanced more point first time year additionally number corporate deal also help boost investor sentiment index lose tuesday optimism passage republican tax bill be outweighed likely impact future monetary stimulus further investor widely expect much await tax cut legislation be pass week turn result stock sell however house fail comply senate rule tuesday follow house re vote tax bill again wednesday housing start rise november upwardly revise october well analyst estimate moreover build permit increase year year settle index decline wednesday investor remain indifferent even congress pass much await republican tax bill day key index reach record high level initially finished lower follow pullback market have already trade higher previous session optimism passage tax cut bill witness sell house actually pass bill index gain thursday follow gain bank energy stock follow passage legislation related tax cut major bank telecom company pledge provide better pay employee turn boost investor sentiment additionally energy sector rally upward wti oil price hit second highest level so far moreover gdp increase third quarter post best growth pace more year further support yesterday gain component move indexnike inc nke free report post second quarter fiscal earning share beat zack consensus estimate revenue come also exceed zack consensus estimate nike have zack rank hold total revenue be year year basis revenue nike brand be revenue converse be earning be year period nike cite decline gross margin higher selling administrative expense reason earning slump read nike post earning beat praise direct consumer effort pfizer inc pfe free report board director announce hike pharma giant quarterly dividend also authorize new share repurchase program quarterly dividend be raise cent cent add annual dividend share amount annual dividend yield increase dividend first quarter be payable mar shareholder record close business feb read pfizer hike dividend announce share buyback plan separate development zack rank pfizer announce fda have approve leukemia drug bosulif first line set drug be now approve first line treatment patient suffering chronic phase ph cml please note pfizer have partnership avillion bosulif read pfizer leukemia drug get fda nod first line set wal mart store inc wmt free report soon be brand walmart officially seem be leave stone unturned counter amazon amzn free report rise dominance supermarket giant have forayed meal kit space card already play earlier year amazon well source reveal wal mart start selling meal kit online begin month give competition other meal kit player blue apron aprn free report hellofresh plait big box retailer be offer kit alliance home chef takeout kit be responsible fulfillment delivery order takeout kit offer wide range global option home chef offering be more classic side takeout kit home chef conduct entire selling process walmart receive small commission well referral fee company meal kit price range kit serve roughly person medium source wal mart begin new venture approximately kit already have option sell stock have zack rank buy see complete list today zack rank strong buy stock here merck co inc mrk free report announce disappointing result pivotal phase iii keynote study evaluate pd therapy keytruda pembrolizumab second line treatment patient advanced gastric junction gej adenocarcinoma phase iii study fail meet primary endpoint overall survival os notably progression free survival pfs show statistical significance pd positive patient population however zack rank merck say continue evaluate keytruda other phase iii study monotherapy well combination chemotherapy first line treatment patient gej read merck keytruda miss primary end point gastric cancer procter gamble company pg free report have appoint activist investor co founder trian fund management nelson peltz board effective mar prolong proxy battle latest announcement come procter gamble reveal last month peltz be lead ernesto zedillo share company nearly diluted share outstanding however latest sec filing company say result ernesto zedillo nelson peltz be extremely close peltz receive almost share vote zack rank procter gamble announce zedillo other be re elect company agree add peltz board director have garner so much shareholder support election result be so close large number shareholder vote nelson peltz be director board have engage numerous discussion mr peltz regard board seat company say read procter gamble appoint peltz board proxy battle exxonmobil corporation xom free report be likely end decade old marketing joint venture bhp billiton ltd bhp free report due concern raise australian competition consumer commission accc relate gas supply rise price accc expressed alarm company market gippsland basin biggest producer country southern state joint venture be biggest producer gippsland basin be rumore zack rank exxonmobil bhp billiton be compel end joint venture sell gas separately company argue joint venture bolster economy termination make new investment supply gippsland basin more complex primary concern be big gas buyer be receive not more offer multus year deal be possible only exxonmobil bhp billiton start marketing gas separately consequently accc announce company sell gas separately gippsland basin legal action be take partner fail comply decision read exxonmobil bhp billiton terminate marketing jv performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have gain next week outlookinvestor have heaved sigh relief tax cut legislation finally gain approval house senate bring end long run political struggle be likely boost market day ahead evidence such trend be visible thursday promise higher pay major company boost stock moreover gdp datum have exceed expectation wide margin most other economic indicator have also be largely bullish be little stop market notch further record day ahead look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2482,MRK,share nektar therapeutic nktr free report have sky-rocket almost year so far substantially outperform industry increase let analyze factor lead massive rally nektar rapid progress robust pipeline year include several study initiation positive readout strategic collaboration have drive share price consistently company pegylation technology have facilitate development several approve product unite state eu partnership healthcare company namely astrazeneca azn free report movantik ucb cimzia amgen amgn free report neulasta other notably randomize phase iii confirmatory study attain begin company lead candidate onzeald late last year trial compare onzeald single agent chemotherapy physician choice patient advanced breast cancer have brain metastase shortly positive result program support regulatory filing unite state apart onzeald nektar be work develop other candidate september company announce initiation phase ii propel study evaluate efficacy safety nktr combination roche tecentriq atezolizumab merck mrk free report keytruda pembrolizumab phase ii trial evaluate nktr potential combination treatment regimen bristol myer squibb opdivo be also underway candidate be be examine tumor type melanoma kidney colorectal bladder small cell lung cancer potential indication november company announce positive datum study treat patient melanoma renal cell carcinoma small cell lung cancer significantly company enter research collaboration takeda pharmaceutical explore combination nktr oncology compound takeda cancer portfolio candidate nktr be be examine phase iii program treatment chronic pain july company report positive top line finding oral human abuse potential study analyse nktr assess opioid abuse potential compare oxycodone company be plan submit new drug application candidate april meanwhile march company initiate phase clinical study evaluate nktr treat wide range auto immune disease inflammatory disorder subsequently july nektar seal co development deal elly lilly company nktr pursuant agreement company own responsibility complete ongoing phase study candidate company share phase ii development cost lilly acquire lion share total expense successful development undertrial candidate boost company top line consider lucrative market be target nektar carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2483,MRK,key announcement week include fda approval eye disease drug well diabetes treatment label expansion exist product regulatory pipeline update be also provide company astrazeneca azn free report johnson johnson jnj free report recap week most important storiesaerie rhopressa gain fda approval aerie pharmaceutical aeri free report get boost earlier expect fda approval rhopressa lower elevated intraocular pressure iop patient open angle glaucoma ocular hypertension approval be expect consider favorable advisory panel vote october approval come couple month ahead feb pdufa prescription drug user fee act goal date rhopressa be first product aerie portfolio company expect launch product mid second quarter read more aerie get early fda approval lead drug rhopressa merck pfizer diabetes drug get fda nod sglt inhibitor steglatro ertugliflozin have be develop merck mrk free report pfizer pfe free report gain fda approval treatment type ii diabetes steglatro be enter highly crowd diabetes market already have other sglt inhibitor form invokana farxiga jardiance steglatro have also be approve use combination metformin brand name segluromet januvia brand name steglujan priority review astrazeneca tagrisso label expansion astrazeneca supplemental new drug application snda use tagrisso osimertinib first line treatment patient metastatic small cell lung cancer nsclc tumor have egfr mutation have be grant priority review fda approval indication expand patient population significantly read more astrazeneca tagrisso label expansion filing accept fda janssen car deal priority review apalutamide janssen biotech have inked worldwide collaboration license agreement legend biotech usa inc legend biotech ireland limit subsidiary genscript biotech corporation development manufacture chimeric antigen receptor car cell drug candidate lcar lcar specifically target cell maturation antigen bcma be currently regulatory review china multiple myeloma mm meanwhile clinical study be be plan unite state term deal global net trade sale exclude greater china area be record janssen company split cost profit equally greater china janssen legend have cost sharing profit split arrangement deal term also include upfront payment janssen additional payment achievement development regulatory sale milestone be latest agreement field car have be attract lot interest recent quarters janssen also announce get priority review status fda new drug application nda apalutamide company investigational next generation oral androgen receptor ar inhibitor treatment man metastatic castration resistant prostate cancer crpc fda grant priority review response be april give be fda approve treatment currently available patient population timely approval be boost company cancer portfolio have gain year date compare rally industry belong allergan provide update vraylar seysara allergan agn free report provide couple update pipeline front company partner gedeon richter say vraylar cariprazine meet primary endpoint late stage adult major depressive episode associate bipolar disorder bipolar depression company plan seek label expansion indication second half read more allergan vraylar positive bipolar disease phase iii allergan also announce nda seysara have be accept review allergan partner paratek pharmaceutical be look get antibiotic approve treatment moderate severe acne vulgaris patient year age older approval come second half fda expand label pfizer bosulif grant btd bavencio fda have give nod label expansion pfizer bosulif use newly diagnosed chronic phase ph chronic myelogenous leukemia ph cml patient bosulif initial approval be use patient chronic accelerate blast phase ph cml resistance intolerance prior therapy expand indication increase addressable patient population significantly accord american cancer society new cml case be diagnosed unite state pfizer also announce fda have grant breakthrough therapy designation btd bavencio avelumab use combination inlyta treatment nave patient advanced renal cell carcinoma rcc avelumab be partner merck kgaa breakthrough therapy designation help fasten development review drug be be evaluate treatment serious condition preliminary clinical evidence indicate drug be substantially better exist treatment clinically significant endpoint be second time bavencio have receive btd hard treat cancer first time be treatment patient metastatic merkel cell carcinoma mmcc disease have progressed least previous chemotherapy regimen label expansion clinical trial collaboration bmy opdivo bristol myer squibb bmy free report pd immune checkpoint inhibitor opdivo gain fda approval yet indication regulatory agency grant approval opdivo intravenous use adjuvant treatment patient completely resect melanoma lymph node involvement metastatic disease opdivo be already approve wide range indication alone well combination other agent be currently several study well fact company also announce clinical trial collaboration taris biomedical evaluation safety tolerability preliminary efficacy taris tar gemris combination opdivo phase ib study evaluate combination patient muscle invasive bladder cancer mibc be schedule radical cystectomy opdivo be prioritize brand bristol myer portfolio product bring sale first month bristol myer be zack rank hold stock see complete list today zack rank strong buy stock here cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be slightly last trading session major stock merck be lilly bristol myer decline last month bristol myer be glaxo decline see last pharma stock roundup here teva announce major job cut lilly provide outlook next pharma world watch regulatory pipeline news pharma stock look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2484,MRK,roche hold ag rhhby free report announce fda have approve perjeta pertuzumab combination herceptin chemotherapy perjeta base regimen adjuvant surgery treatment positive early breast cancer ebc high risk recurrence patient receive adjuvant perjeta base regimen year cycle perjeta combination herceptin docetaxel be already approve use patient have positive breast cancer have spread different part body metastatic have not receive therapy chemotherapy metastatic breast cancer come back release approval indication be base result phase iii aphinity study study show perjeta herceptin chemotherapy significantly reduce risk invasive breast cancer recurrence death compare herceptin chemotherapy alone combination wasalso grant priority review fda october invasive disease free survival dfs serve primary endpoint secondary endpoint include overall cardiac safety dfs health related quality life addition fda grant full approval use same regimen neoadjuvant treatment positive locally advanced inflammatory early stage breast cancer now neoadjuvant indication have be allow accelerate approval roche stock have rally year date compare industry gain company have strong presence oncology market dominate breast cancer space strong demand franchise drug herceptin perjeta kadcyla herceptin growth be drive improve demand unite state europe due longer treatment duration moreover subcutaneous formulation herceptin be be increasingly adopt europe meanwhile sale perjeta have be strong europe largely due uptake neo adjuvant set persistent growth metastatic set kadcyla sale be be drive increase demand europe internationally apart strong breast cancer franchise roche oncology portfolio also boast drug avastin tarceva lung cancer however note roche be face stiff competition like merck co inc mrk free report keytruda bristol myer squibb company bmy free report opdivo immuno oncology space roche hold ag price roche hold ag price roche hold ag quotezack rank stock considerroche carry zack rank sell better rank stock same space be sucampo pharmaceutical carry zack rank buy see complete list today zack rank strong buy stock here sucampo earning share estimate have moved cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date zack best private investment idea be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
2485,MRK,key highlight pharma sector include complete response letter crl fda johnson johnson jnj free report investigational rheumatoid arthritis ra treatment fda approval merck mrk free report bristol myer squibb bmy free report cancer drug recap week most important storiescrl ra drug janssen biotech get crl fda sirukumab treatment moderately severely active ra agency have ask additional datum safety sirukumab do not come surprise consider investigational treatment fail get support fda advisory panel last month give safety concern raise panel request additional datum be more less expect intend meet agency determine requirement gain approval il inhibitor meanwhile company have submit new drug application nda first darunavir base single tablet regimen treatment hiv approval make combination only complete regimen potential deliver advantage single table regimen high genetic barrier resistance darunavir demonstrated safety profile taf fda nod merck keytruda merck pd therapy keytruda have gain fda approval yet indication cancer therapy be already available wide range indication now be used previously treat patient recurrent locally advanced metastatic gastric junction gej adenocarcinoma tumor express pd mark tenth new indication keytruda year period keytruda be key product merck portfolio drug bring sale first half company be work expand label drug be currently more study cover wide range cancer treatment setting read more merck keytruda get fda nod advanced gastric cancer merck be zack rank hold stock see complete list today zack rank strong buy stock here allergan announce share buy back cfo departure allergan agn free report continue work return capital shareholder company announce intention buy back share worth come shortly company complete share buyback program allergan also reaffirm commitment increase cash dividend year reiterate commitment maintain investment grade credit rating pay debt company also announce departure tessa hilado executive vice president chief financial officer cfo be retire company once successor be appoint bristol myer opdivo get approval bristol myer also gain approval indication immune oncology therapy opdivo latest approval opdivo now be used treatment hepatocellular carcinoma patient previously treat nexavar sorafenib make opdivo first only immuno oncology agent be approve patient population read more bristol myer opdivo get approval liver cancer company also gain approval japan use opdivo treatment unresectable advanced recurrent gastric cancer have progressed chemotherapy gastric cancer be highly prevalent asian country be second most commonly diagnosed cancer japan bristol myer also enter clinical trial collaboration abbvie combination opdivo abbvie investigational antibody drug conjugate abbv be evaluate meet overexpressing small cell lung cancer nsclc bristol myer stock have gain year date compare rally industry belong priority review aradigm drug aradigm get priority review linhaliq treatment cystic fibrosis bronchiectasis ncfbe patient chronic infection pseudomona aeruginosa aeruginosa response agency regard approval status drug be jan ncfbe severe chronic rare disease affect more person unite state person europe drug currently approve treatment condition be significant unmet need aradigm share be news cap pharmaceutical industry yr returnlarge cap pharmaceutical industry yr nyse arca pharmaceutical index be so far week major stock lilly lly free report be pfizer pfe free report be last month bristol myer be glaxo gsk free report decline see last pharma stock roundup here pfizer file suit supernus hit study update next pharma world watch usual pipeline regulatory update hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
2486,MRK,roche hold ag rhhby free report announce european commission ec have approve immunotherapy drug tecentriq monotherapy treatment patient locally advanced metastatic small cell lung cancer have be previously treat chemotherapy regardless pd status ec also grant marketing authorisation drug monotherapy treatment person locally advanced metastatic urothelial carcinoma have be previously treat platinum contain chemotherapy be consider ineligible cisplatin chemotherapy regardless pd status note drug be already approve unite state indication approval other geography further boost sale estimate patient die year due lung cancer earlier month fda have put partial clinical hold phase ib phase ii trial evaluate tecentriq due safety issue partial hold be put due emerge safety datum clinical trial evaluate merck co mrk free report keytruda combination celgene corporation celg free report revlimid pomalyst roche also announce ec have approve label expansion gazyvaro drug have be approve combination chemotherapy follow gazyvaro maintenance patient achieve response new treatment previously untreated advanced follicular lymphoma approval be base result phase iii gallium study show show superior progression free survival mabthera note drug be approve combination chlorambucil patient previously untreated chronic lymphocytic leukaemia comorbidity make unsuitable full dose fludarabine base therapy gazyvaro be also approve combination bendamustine follow gazyvaro maintenance patient follicular lymphoma do not respond progressed month treatment mabthera mabthera contain regimen addition ec approve actemra roactemra tocilizumab treatment giant cell arteritis gca make first therapy approve treatment gca europe roche drug be also approve unite state indication actemra be approve treatment adult patient moderate severe active rheumatoid arthritis roche stock have gain year date compare industry gain roche have strong presence oncology market company dominate breast cancer space due strong demand franchise drug herceptin perjeta kadcyla however sale avastin tarceva continue decline generic competition xeloda continue hurt sale competition biosimilar loom large roche key drug herceptin avastin rituxan fda have accept novartis ag nvs free report biologic license application propose biosimilar version rituxan hence approval new drug label expansion exist drug bode well roche zack rankroche currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2487,MRK,ligand pharmaceutical incorporate lgnd free report announce have sign commercial license supply agreement amgen inc amgn free report deal amgen be grant exclusive worldwide right use ligand captisol technology development pipeline candidate amg wide variety therapeutic indication captisol be well validate chemically modify cyclodextrin be design improve safety solubility stability bioavailability lessen volatility irritation smell taste drug amgen be develop early stage candidate amg cd cd bite bispecific antibody treatment acute myeloid leukemia share ligand have outperformed zack classify medical biom genetic industry so far year stock have rally compare broader industry increase company already have agreement amgen used captisol develop amg preclinical early clinical study term recent agreement amgen be liable pay undisclosed upfront payment potential milestone payment royalty revenue future sale amg formulate used captisol ligand captisol formulation technology platform have allow enter partnership several lead drug company novartis ag nvs free report merck co inc mrk free report provide fund form milestone royalty payment ligand also derive revenue selling captisol material partner have license company captisol enabled drug have license captisol internal program ligand pharmaceutical incorporate price consensus ligand pharmaceutical incorporate price consensus ligand pharmaceutical incorporate quotezack rankligand currently carry zack rank hold see complete list today zack rank strong buy stock here trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2488,MRK,johnson johnson jnj free report report mixed second quarter result earning beat expectation sale miss same however drug consumer product giant raise sale profit outlook send share more pre market trading year so far share price be compare favorably increase witness zack classify large cap pharma industry earning beatj second quarter earning come share beating zack consensus estimate increase year period include time item report second quarter earning share year period sale miss againsale come miss zack consensus estimate sale increase year quarter reflect operational increase negative currency impact organically exclude impact acquisition divestiture sale increase operational basis second quarter sale grow domestic market international market reflect operational growth partially offset negative currency impact sale segment sale decline year year reflect operational growth negative currency impact higher sale international market offset weaker performance sale domestic market decline international sale grow new product imbruvica cancer darzalex multiple myeloma continue perform well other growth driver be xarelto stelara invega sustenna however sale invokana invokamet decline also concerta decline zytiga sale fall importantly sale blockbuster rheumatoid arthritis drug remicade market partnership merck co inc mrk free report decline quarter sale decline international sale decline due biosimilar competition regard mention pfizer inc pfe free report launch inflectra injection biosimilar version remicade late last november do not have significant impact remicade sale past quarters management be expect comment impact biosimilar second quarter sale conference call pharma segment achieve clinical milestone quarter include fda approval darzalex be used combination celgene corporation celg free report pomalyst pomalidomide dexamethasone third line treatment multiple myeloma importantly last week announce fda approval pipeline candidate guselkumab treatment moderate severe plaque psoriasis drug be market trade name tremfya meanwhile last month complete previously announce acquisition swiss biotech actelion diversify revenuesto pulmonary arterial hypertension pah category actelion pah drug add top line quarter medical device segment sale come year period include operational increase negative currency movement sale gain mainly inclusion abbott medical optic acquisition exclude impact acquisition divestiture operational basis worldwide sale increase sale domestic market rise year year international market sale increase operational increase year year operational growth be drive advanced surgery business product cardiovascular business acuvue contact lense vision care business make weaker sale performance diabetes care consumer segment record revenue report quarter year year operational increase foreign currency movement negatively impact sale segment sale domestic market grow year period slower growth baby care product be partially offset growth counter product meanwhile international segment record decline reflect operational decline negative currency impact guidance raisedj raise earning guidance increase lower end sale outlook expect adjust earning share range include currency impact compare expect previously revenue guidance be range compare expect previouslyour takedespite third consecutive sale miss look optimistic better sale performance second half chief executive officer alex gorsky say sale growth accelerate second half year importantly sale medical device segment be pick make lower sale international consumer pharmaceutical segment quarter sale domestic pharma segment have decelerate year key growth driver have slow due competition quite few product portfolio remicade concerta be face generic competition however believe new product tremfya label expansion drug imbruvica darzalex contribution actelion lead better sale trend remain half year carry zack rank hold see complete list today zack rank strong buy stock here johnson johnson price consensus ep surprise johnson johnson price consensus ep surprise johnson johnson quote trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2489,MRK,amgen inc amgn free report partner ucb sa announce fda have issue complete response letter crl biologic license application bla evenity romosozumab amgen be look get evenity approve treatment postmenopausal woman osteoporosis original bla include datum pivotal frame study however fda now require safety efficacy datum other pivotal phase iii study arch bridge be include application agency have ask resubmission bla be consider extension current review remind investor amgen have present datum arch fracture study romosozumab compare merck co inc mrk free report fosamax alendronate postmenopausal woman osteoporosis datum study show evenity romosozumab lead statistically significant superior fracture risk reduction fosamax alendronate be current standard care osteoporosis however cardiovascular side effect be observed study company then say safety datum arch datum now be consider regulatory review agree fda follow heart related safety issue emerge otherwise successful arch result amgen warn do not expect evenity be approve year crl thus do not come surprise so far year amgen share be better increase register zack categorize biom genetic industry frame study evaluate effectiveness evenity reduce risk new vertebral fracture month also compare effectiveness month evenity administration follow month xgeva placebo follow xgeva administration bridge study evaluate evenity older man osteoporosis history fragility fracture vertebral fracture study evaluate effectiveness evenity increase bone mineral density bmd lumbar spine effect bmd femoral neck total hip company be work fda be process re submit bla request datum separate press release amgen announce submission supplemental new drug application snda fda variation marketing application european medicine agency ema myeloma drug kyproli submission regulatory application be do expand drug label include overall survival os datum phase iii endeavor study remind investor kyproli twice weekly be already approve use combination dexamethasone celgene corporation celg free report revlimid lenalidomide dexamethasone base primary analysis progression free survival pfs datum aspire study submission include datum pivotal endeavor study compare kyproli velcade combination dexamethasone patient relapse refractory multiple myeloma datum demonstrated kyproli reduce risk death compare velcade increase median os month month vs month kyproli be first only therapy achieve superior os head head comparison current standard care velcade last week amgen announce os datum aspire study overall survival datum study show patient relapse refractory multiple myeloma live month longer treat kyproli revlimid dexamethasone krd compare treat revlimid dexamethasone rd median os month krd versus median os month rd kyproli be also be evaluate couple other study potential label expansion amgen be evaluate weekly dose regimen kyproli phase iii study arrow relapse refractory multiple myeloma patient datum be expect be amgen inc price consensus amgen inc price consensus amgen inc quotezack rankamgen currently have zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2490,MRK,gilead science inc gild free report announce company marketing authorization application maa once daily single tablet regimen contain bictegravir mg bic emtricitabine tenofovir alafenamide mg ftc taf treatment hiv infection adult have be fully validate european medicine agency ema currently application be review ema regimen be novel experimental integrase strand transfer inhibitor be be evaluate treatment hiv infection adult share gilead have underperform zack classify medical biomedical genetic industry last year stock lose period industry gain maa bic ftc taf be base datum phase iii study regimen meet primary objective inferiority week ongoing study be design explore efficacy safety bic ftc taf compare triple therapy regimen contain glaxosmithkline gsk free report tivicay dolutegravir mg dtg treatment nave patient virologically suppress patient switch exist antiretroviral regimen datum study show bic ftc taf demonstrated high rate virologic suppression treatment emergent resistance week fourth study be be conduct virologically suppress patient compare switch bic ftc taf versus suppressive regimen nucleoside nucleotide reverse transcriptase inhibitor boost protease inhibitor additionally gilead submit new drug application nda bic ftc taf jun company present week datum phase iii study evaluate bic ftc taf compare regimen contain tivicay mg dtg treatment nave adult patient international aids society conference hiv science ias july paris note gilead be dominant player hiv market impressive portfolio newly launch taf base product genvoya odefsey descovy be perform well strong adoption eu genvoya have already become most prescribe regimen treatment nave switch patient launch nov uptake hiv franchise help company combat persistent decline hcv franchise due competitive pressure competition well pricing pressure have intensified further launch merck mrk free report zepatier gilead science inc price consensus gilead science inc price consensus gilead science inc quotezack rank key pickgilead currently carry zack rank hold better rank health care stock same space be enzo inc sport zack rank strong buy see complete list today zack rank stock here enzo loss share estimate narrow cent cent cent cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2491,MRK,gilead science inc gild free report announce company marketing authorization application maa once daily single tablet regimen contain bictegravir mg bic emtricitabine tenofovir alafenamide mg ftc taf treatment hiv infection adult have be fully validate european medicine agency ema currently application be review ema regimen be novel experimental integrase strand transfer inhibitor be be evaluate treatment hiv infection adult share gilead have underperform zack classify medical biomedical genetic industry last year stock lose period industry gain maa bic ftc taf be base datum phase iii study regimen meet primary objective inferiority week ongoing study be design explore efficacy safety bic ftc taf compare triple therapy regimen contain glaxosmithkline gsk free report tivicay dolutegravir mg dtg treatment nave patient virologically suppress patient switch exist antiretroviral regimen datum study show bic ftc taf demonstrated high rate virologic suppression treatment emergent resistance week fourth study be be conduct virologically suppress patient compare switch bic ftc taf versus suppressive regimen nucleoside nucleotide reverse transcriptase inhibitor boost protease inhibitor additionally gilead submit new drug application nda bic ftc taf jun company present week datum phase iii study evaluate bic ftc taf compare regimen contain tivicay mg dtg treatment nave adult patient international aids society conference hiv science ias july paris note gilead be dominant player hiv market impressive portfolio newly launch taf base product genvoya odefsey descovy be perform well strong adoption eu genvoya have already become most prescribe regimen treatment nave switch patient launch nov uptake hiv franchise help company combat persistent decline hcv franchise due competitive pressure competition well pricing pressure have intensified further launch merck mrk free report zepatier gilead science inc price consensus gilead science inc price consensus gilead science inc quotezack rank key pickgilead currently carry zack rank hold better rank health care stock same space be enzo inc sport zack rank strong buy see complete list today zack rank stock here enzo loss share estimate narrow cent cent cent cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2492,MRK,merck co inc mrk free report announce fda have approve pd therapy keytruda monotherapy third line treatment advanced gastric junction adenocarcinoma keytruda be already approve many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer drug label have now be expand include treatment heavily pre treat patient recurrent locally advanced metastatic gastric junction cancer tumor express pd determine fda approve test however approval tenth new indication keytruda come accelerate basis continue approval dependent further benefit demonstrated clinical study fda approval be base datum keynote study keytruda be key top line driver merck bring sale second quarter sequentially year year sale continue be drive launch new indication globally keytruda sale gain particularly strong momentum new indication first line lung cancer outside keytruda sale be primarily drive melanoma indication meanwhile keytruda development program also significantly advanced year regulatory approval new indication additional indication europe important approval include advanced bladder cancer unite state eu advanced microsatellite instability high cancer first approval combination therapy eli lilly company lly free report cancer drug alimta pemetrexed carboplatin pem carbo commonly used chemo regimen lung cancer further keytruda datum readout be pending year keytruda be continuously grow expand new indication market globally keytruda be be study more type cancer more study include more combination study merck be collaborate several company include amgen inc amgn free report incyte glaxo pfizer inc pfe free report separately evaluation keytruda combination other regimen merck carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2493,MRK,key announcement week be teva pharmaceutical industry ltd teva free report restructure plan eli lilly company lly free report outlook focus also remain datum presentation annual conference american society hematology ash company roche rhhby free report bristol myer squibb bmy free report merck mrk free report be present recap week most important storiesash highlight several company be ash datum approve pipeline drug roche present phase ii datum show polatuzumab vedotin bendamustine mabthera rituxan br increase complete response rate compare br alone previously treat aggressive lymphoma complete response rate increase addition polatuzumab vedotin br patient treat combination live longer compare patient br alone month versus month roche also present datum tecentriq avastin combination certain person advanced kidney cancer read more roche report positive datum tecentriq combination study venclexta venclyxto mabthera rituxan combination previously treat chronic lymphocytic leukemia read more roche abbvie report positive phase iii result venclexta bristol myer be also present ash datum sprycel dasatinib add standard chemotherapy show year survival benefit pediatric patient newly diagnosed ph acute lymphoblastic leukemia read more bristol myer report positive datum leukemia drug company partner seattle genetic also present interim result phase ii study combination adcetris opdivo relapse refractory hodgkin lymphoma combination datum show objective response rate complete response rate lilly provide outlook lilly provide outlook say expect recently launch product trulicity taltz basaglar jardiance verzenio cyramza olumiant lartruvo drive low single digit revenue growth company expect earning share revenue however challenge remain company form loss patent exclusivity product ciali impact generic competition strattera effient axiron pricing access pressure also remain headwind meanwhile company continue expect earning share revenue lilly raise quarterly dividend well company also reaffirm guidance average annual revenue growth least say expect operate margin least pipeline front lilly expect regulatory action unite state baricitinib treatment rheumatoid arthritis galcanezumab migraine treatment new indication verzenio breast cancer launch new indication taltz psoriatic arthritis read more lilly issue guidance new drug drive top line stock have gain year date compare rally industry belong teva share restructure plan week speculation teva be cut workforce company announce restructure plan see job cut more company global workforce next year majority expect new ceo goal be reduce cost base simplify organization improve business performance profitability cash flow generation productivity company expect cut cost base estimate end plan also call optimization global generic portfolio especially unite state price adjustment product discontinuation several manufacturing plant unite state europe israel growth market well facility headquarters other office location geography be shut divest far pipeline be concern program be review so core project be identify other project be terminate immediately company also suspend dividend payment annual bonus say continue look opportunity divest core asset step come time teva be face several challenge company have significant financial obligation come year environment remain challenge company largest generic market unite state teva also expect fewer generic product launch unite state teva share be restructure announcement investor cheer step take company execution remain key priority review bristol myer opdivo yervoy combination fda have grant priority review bristol myer supplemental biologic license application sbla label expansion opdivo use combination yervoy treatment intermediate poor risk patient advanced renal cell carcinoma rcc regulatory agency grant priority review response be apr update sanofi sanofi sny free report provide update pipeline project include new molecular entity novel vaccine analyst meeting week company say expect start least late stage study least pivotal phase iii study be expect start next month period sanofi expect file regulatory approval investigational cancer drug cemiplimab isatuximab type diabetes treatment sotagliflozin potential treatment uncontrolled persistent asthma dupilumab fact sanofi partner regeneron announce positive topline result pivotal mid stage study cemiplimab patient advanced cutaneous squamous cell carcinoma cscc second deadliest skin cancer melanoma overall response rate orr be observed study company have start submit roll biologic license application bla pd antibody submission expect complete first quarter read more regeneron sanofi report positive top line skin cancer datum meanwhile sanofi gain fda approval admelog insulin lispro injection rapid act insulin similar lilly humalog management blood sugar level mealtime admelog be approve eu earlier year july read more sanofi win fda approval biosimilar lilly humalog update merck keytruda merck provide couple update related pd therapy keytruda week company say sbla seek label expansion use keytruda treatment relapse refractory primary mediastinal large cell lymphoma pmbcl have be grant priority review fda company also present datum ash show use keytruda result overall response rate difficult treat patient population fda grant priority review response agency be apr approval make second blood cancer indication keytruda earlier indication be use certain patient classical hodgkin lymphoma read more merck keytruda get fda priority review rare lymphoma however keytruda fail meet primary endpoint overall survival pivotal study second line treatment patient advanced gastric junction gej adenocarcinoma progression free survival pd positive population also fail show statistical significance merck be zack rank hold stock see complete list today zack rank strong buy stock here cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock astrazeneca be merck gain last month bristol myer be glaxosmithkline gsk free report decline see last pharma stock roundup here fda nod nvo ozempic second indication lilly taltz next pharma world watch regulatory pipeline news pharma stock investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2494,MRK,last week issue article mentioned merger acquisition be quite lean pick significantly propose tax reform be finally approve reform aim cut corporate tax rate boost profit large drug biotech company change tax code also allow company bring back huge cash hold overseas time tax rate change definitely leave more cash hand drug biotech company also focus drug pricing take backseat large drug biotech company struggle organic growth be lot chatter possible increase large give take several year million dollar develop new therapeutic scratch large pharmaceutical company sit huge pile cash prefer buy innovative small mid cap biotech company build pipeline article discuss mid large cap name be logical acquisition target next year company pfizer pfe free report merck mrk free report johnson johnson jnj free report other matter buy drug biotech stock be current sale performance drug product prospect future sale growth quality pipeline company discuss have most factor go favor acquisition small cap drug biotech company be very difficult predict quite frequent hence have be exclude discussion biomarin pharmaceutical inc bmrn free report company product pipeline portfolio include rare disease drug be great demand be less competitive space expensive treatment bring huge profit biomarin be such drug developer market cap be biomarin key orphan disease drug vimizim kuvan continue do well backed strong underlie patient demand trend biomarin expect sustain growth drug brineura earlier expect approval year treatment child cln disease form batten disease be also huge boost biomarin impressive rare disease pipeline be also progress well approval pegvaliase treatment expect pipeline believe late stage candidate vosoritide achondroplasia most common form dwarfism bmn hemophilia have blockbuster potential biomarin have already be target takeover speculation company gilead gild amgen amgn roche be interested buy biomarin vertex pharmaceutical inc vrtx free report vertex so far have be tremendous year positive datum read out regulatory approval lead increase eligible patient population approve cystic fibrosis cf kalydeco orkambi cf be vertex main area focus consistent expansion patient population vertex cf product revenue have increase quarter quarter company be optimistic positive trend cf sale continue gain additional reimbursement approval orkambi ex market get approval launch tezacaftor vx ivacaftor combination medicine meanwhile company have also make decent clinical progress multiple cf study year have meaningful pipeline catalyst market cap vertex be incyte corporation incy free report incyte strong oncology portfolio make lucrative target company gilead amgen bristol myer market cap incyte be more primary reason incyte be ripe buyout be product market jakafi iclusig jakafi jak inhibitor be first only product be approve polycythemia vera pv myelofibrosis mf rare blood cancer jakafi be see strong sale performance drive strong patient demand indication order expand patient population increase commercial potential drug company be work expand label further iclusig be approve chronic myeloid leukemia acute lymphoblastic leukemia meanwhile incyte pipeline boast candidate immune therapy epacadostat be study combination pd agent merck bristol myer other olumiant rheumatoid arthritis approve europe regulatory application be file unite state january alexion pharmaceutical inc alxn free report biomarin alexion be also focuse development life transform drug treatment patient ultra rare disorder key drug be soliris approve severe ultra rare disorder paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus have be consistently do well meanwhile alexion be work expand drug label include additional indication approve boost further sale growth have other drug rare disease call strensiq kanuma be emerge growth driver alexion also have robust pipeline several candidate development include soliris follow candidate alxn roche pfizer novartis be interested buy alexion market cap alexion be more today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2495,MRK,nordisk nvo free report announce fda have approve semaglutide once daily pre filled pen improve glycaemic control type ii diabetes patient glp receptor agonist be market trade name ozempic approval ozempic be base result phase iii sustain study result show person type ii diabetes be treat once weekly semaglutide experience statistically significant sustain blood glucose control compare merck mrk free report januvia sitagliptin astrazeneca azn free report once weekly bydureon exenatide extend release sanofi sny free report lantus insulin glargine placebo also positive recommendation fda advisory committee meeting october support approval nordisk expect launch ozempic unite state begin part post approval requirement company conduct paediatric trial patient year meanwhile ozempic be review several regulatory agency include european medicine agency japanese pharmaceutical medical device agency share company have rally compare industry gain year date basis additionally nordisk be make effort develop new treatment diabetes be core area expertise september company receive approval fast act insulin aspart fiasp other semaglutide key pipeline candidate include nonacog beta pegol september company receive approval fast act insulin aspart fiasp glp market include lilly trulicity astrazeneca plc once weekly bydureon give tough competition nordisk semaglutide zack ranknovo nordisk carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2496,MRK,pfizer inc pfe free report supplemental new drug application snda xeljanz have be accept review fda xeljanz mg twice daily jak inhibitor be presently approve second line treatment moderate severely active rheumatoid arthritis ra patient have have inadequate response tolerate methotrexate drug be approve europe china march year ra latest application company be look get drug label expand include treatment adult patient suffering moderate severe active ulcerative colitis uc response fda be expect march next year pfizer share be so far year compare unfavorably zack classify large cap pharma industry gain acceptance snda be base datum pivotal study octave global clinical development program constitute octave induction octave induction octave sustain also include datum open label extension study xeljanz evaluate long term effect patient have complete treatment have failure octave sustain do not respond treatment octave datum study demonstrated xeljanz be more effective placebo induce maintain remission patient datum show patient be remission compare placebo octave patient be remission versus placebo octave week octave sustain evaluate different administration achieve remission mg mg patient compare placebo week octave induction study evaluate induction remission twice daily mg oral administration drug patient uc octave sustain evaluate xeljanz mg mg maintenance therapy patient include achieve least clinical response octave induction be encourage pfizer label expansion effort xeljanz sale be year year first quarter label expansion drug boost sale further meanwhile snda xeljanz be review psoriatic arthritis be file year response agency be expect dec pfizer inc price consensus pfizer inc price consensus pfizer inc quotezack rank stock considerpfizer currently have zack rank hold better rank stock healthcare sector include astrazeneca plc azn free report sanofi sny free report merck company inc mrk free report astrazeneca sport zack rank strong buy sanofi merck carry zack rank buy see complete list today zack rank stock here astrazeneca earning estimate have increase last day company come positive earning surprise last quarters average beat share price company be so far year merck earning estimate have moved last day company come positive earning surprise last quarters average beat share price company be so far year sanofi earning estimate have moved last day company come positive earning surprise last quarters average beat share price company be so far year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2497,MRK,world aids day take place year december person world come together fight hiv support live hiv commemorate have die aids related disease everybody slogan world aids day be everybody count goal be ensure access affordable high quality care service person hiv strong health care system well integration hiv tuberculosis hepatitis service accord information provide world health organization more person have lose life due hiv so far person die last year hiv related cause end approximately person be live hiv number newly infected hiv patient be currently available treatmentswhile be cure hiv present virus be controlled use effective antiretroviral arv drug accord adult child hiv be currently lifelong arv person live hiv be receive antiretroviral therapy art combination art combine more atv drug have be find be effective suppress viral replication person body thereby allow immune system strengthen regain capacity fight infection hiv drug landscape have evolved year drug vary mechanism action be approve year include multus class combination product atripla complera stribild nucleoside reverse transcriptase inhibitor nrtis combivir epivir truvada viread nucleoside reverse transcriptase inhibitor nnrtis edurant sustiva protease inhibitor pis prezista reyataz norvir hiv integrase strand transfer inhibitor insti isentress tivicay well fusion inhibitor entry inhibitor ccr co receptor antagonist accord new hiv infection fall hiv related death decline third art save life however only hiv infected person be aware status remain significant need spread awareness disease availability rapid diagnostic test rdts detect presence absence hiv antibody accord globaldata hiv market unite state france germany italy spain uk japan brazil china be expect grow be significant need new alternative arv treatment option come better tolerability higher efficacy lower rate treatment discontinuation here be look few key player hiv market drug stock focusjohnson johnson jnj free report be key player hiv market company introduce several medicine therapeutic area last year company partner glaxosmithkline plc gsk free report recently gain fda approval juluca first complete single pill drug regimen treatment hiv infection certain adult live disease be virologically suppress once daily antiretroviral be combination tivicay insti edurant nnrti maintain safety efficacy traditional drug regimen nrti simpler treatment regimen make compliance easier hiv patient need stay consistent treatment regimen order keep viral count low company be currently seek fda approval partner gilead science inc gild free report darunavir base single tablet regimen str once daily regimen comprise darunavir mg cobicistat mg emtricitabine mg tenofovir alafenamide mg taf be also work hiv vaccine company bill melinda gate foundation national institutes health be conduct efficacy study investigational mosaic hiv preventive vaccine be significant unmet need vaccine hiv lot progress have be make treat manage disease almost person become infected year develop vaccine hiv have prove be challenge due unique property virus include ability mutate rapidly moreover genetic diversity multiple strain subtype prevalent different part world be additional hurdle be zack rank buy stock see complete list today zack rank strong buy stock here stock have gain year date compare rally industry belong gilead science inc hiv be primary area focus gilead company hiv portfolio include drug genvoya truvada atripla descovy odefsey complera stribild contribute approximately total sale first month gilead taf base product genvoya descovy odefsey remain key growth driver gilead be currently seek fda approval investigational fix dose combination bic ftc taf fda expect respond feb meanwhile company expect complete mg cohort phase study gs tlr agonist hiv cure year end late stage study evaluate descovy pre exposure prophylaxis prep be schedule complete third quarter company hepatitis virus hcv franchise see decline sale gilead be focuse hiv franchise growth company hcv product be expect generate sale however competition market be intense moreover company be face competition generic product well gilead be zack rank hold stock stock have gain year date compare rally industry belong glaxosmithkline glaxo be majority stakeholder viiv healthcare global specialist hiv company be set partnership pfizer inc pfe free report now have shionogi shareholder well key product hiv portfolio include triumeq tivicay glaxo be work bring new growth driver hiv business juluca be recent addition glaxo be explore new treatment paradigm drug regimen new modality long act injectable new mechanism action include maturation inhibitor broadly neutralising antibody company be work dolutegravir lamivudine combination also be naive patient long act cabotegravir rilpivirine combination viiv have commence late stage study long act cabotegravir prevention hiv infection sexually active woman study compare cabotegravir injection give month daily oral pre exposure prophylaxis prep emtricitabine tenofovir disoproxil fumarate glaxo zack rank stock have decline year date compare rally industry belong merck mrk free report merck have presence hiv market form isentress isentress hd hiv integrase inhibitor use combination other antiretroviral agent company hiv franchise bring sale first month year period mainly due lower demand unite state due competitive pressure merck hiv pipeline have couple late stage candidate mk doravirine nnrti mk doravirine lamivudine tenofovir disoproxil fumarate dor tc tdf company expect file regulatory approval doravirine single entity tablet fix dose combination tablet dor tc tdf year end merck zack rank stock have decline year date compare rally industry belong medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2498,MRK,bristol myer squibb company bmy free report announce fda have approve immuno oncology drug opdivo intravenous use patient hepatocellular carcinoma hcc have be previously treat nexavar approval indication be grant accelerate approval base tumor response rate durability response however continue approval indication be contingent verification description clinical benefit confirmatory trial estimate hcc be most common type liver cancer fastest grow cause cancer death note opdivo become first pd inhibitor be approve hematological malignancy classic hodgkin lymphoma unite state eu november november opdivo gain fda approval treatment patient recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy bristol myer stock have rally year date compare industry gain label expansion additional indication give product access more patient increase commercial potential drug additionally company enter collaboration agreement seattle genetic inc sgen free report june deal bristol myer evaluate combination opdivo seattle genetic antibody drug conjugate adc adcetris phase iii trial potential treatment option patient relapse refractory transplant ineligible advanced classical hodgkin lymphoma hl however bristol myer suffer setback january decide not pursue accelerate regulatory pathway regimen opdivo yervoy first line lung cancer unite state base review available datum currently opdivo be face competitive challenge unite state fda approve merck co mrk free report keytruda first line treatment metastatic nonsquamous nsclc company be expect suffer further loss market share meanwhile fda put partial clinical hold clinical trial checkmate checkmate trial be investigate opdivo base combination patient relapse refractory multiple myeloma addition concern astrazeneca azn free report fail study lung cancer drug imfinzi loom large company checkmate study opdivo zack rankbristol myer currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2499,MRK,seattle genetic inc sgen free report announce fda approve expand indication lymphoma drug adcetris brentuximab vedotin company announce fda have approve adcetris treatment primary cutaneous anaplastic large cell lymphoma pcalcl cd express mycosis fungoide mf have receive prior systemic therapy notably approval be receive month action date set fda dec august fda grant priority review supplemental biologic license application bla file get adcetris approve primary cutaneous alcl mf be most common subtype cutaneous cell lymphoma ctcl be blood cancer skinadcetris be only market product seattle genetic drug be approve relapse hodgkin lymphoma relapse systemic anaplastic large cell lymphoma salcl patient suffering classical hodgkin lymphoma be high risk relapse progression post autologous hematopoietic stem cell transplantation auto hsct consolidation so far year share seattle genetic have increase compare industry gain latest approval be mainly base positive datum phase iii trial alcanza phase ii investigator sponsored trial patient cutaneous cell lymphoma ctcl interestingly alcanza study achieve primary secondary endpoint study show ctcl patient treat adcetris have superior outcome primary secondary endpoint compare patient control arm be treat methotrexate bexarotene standard care agent go forward expand label further boost sale drug evidently sale drug third quarter grow year year furthermore seattle genetic be develop drug more clinical study key study include evaluation cell lymphomas hodgkin lymphoma phase iii study be also evaluate adcetris frontline mature cell lymphomas again drug be be study combination bristol myer squibb company bmy free report opdivo relapse refractory hodgkin lymphoma however adcetris face competition other drug include merck co inc mrk free report keytruda be recently approve lymphoma indication zack rank stock considerseattle genetic carry zack rank hold better rank health care stock same space be ligand pharmaceutical incorporate lgnd free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved last day company pull positive earning surprise trail quarters average beat share price company have increase year date make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
